[Bio] / FigKernelPackages / Prot_reps_drug_resistance.pm Repository:
ViewVC logotype

View of /FigKernelPackages/Prot_reps_drug_resistance.pm

Parent Directory Parent Directory | Revision Log Revision Log


Revision 1.2 - (download) (as text) (annotate)
Fri Dec 13 01:08:22 2013 UTC (6 years, 3 months ago) by golsen
Branch: MAIN
CVS Tags: rast_rel_2014_0729, rast_rel_2014_0912, HEAD
Changes since 1.1: +9 -9 lines
Fixed spelling of $max_exptrapolate to be $max_extrapolate.
The value is exported, so it should be reasonably correct.

#
#  Prot_reps_drug_resistance.pm
#
package Prot_reps;
use strict;
use gjoseqlib;

our @prot_reps       = gjoseqlib::read_fasta( \*DATA );
our $assignment      = 'Protein matching drug resistance reference sequences';
our $feature_type    = 'protein';
our $max_expect      = 1e-10;
our $max_extrapolate = 10;
our $max_rep_sim     = 0.87;    # identity below which a new rep is needed
our $min_coverage    = 0.70;
our $min_identity    = 0.30;
our $tag             = 'drug_resistance';

1;

__DATA__
>fig|100226.1.peg.751 Ribosome protection-type tetracycline resistance related proteins
MRTLNIGILAHVDAGKTSLTERLLFDHGAVDRLGSVDAGDTRTDDGGIERRRGITIRSAV
AAFTVGDTRVNLIDTPGHSDFVAEVERALEVLDGAVLLLSAVEGVQARTRVLMRALRRLR
LPTIVFVNKIDRAGARTDGLLGDVRRLLTPHVAPLNEVADAGTPRARVTRRPPDGRTAQA
LAEVDTEVLAALVDGPEPTGEDVARALAARTADGSFHPLYHGSALGGQGVAELVEGLLGL
IPAATPGTSGGTEPRGTVFAVRPGPAGERTAYLRLYGGEVHPRRRLTFLRRESDGRTTEV
SGRVTRLDVVGGDATLTAGNIAALTVPGGLRVGDRLGGPTDRAPQFAPPTLQTLVRARHP
EQAAPLRSALLALADQDPLLHARPAASGATALLLYGEVQMEVLAATLAEDFGIEAEFTPG
RVRFLERPAGTGEAAEEMPWLDRTRYFATIGLRVEPGPRGSGGAFGYETELGALPRAFHQ
AVEETVHDTLRTGLTGAAVTDYRVTLIRSGFSSPLSTAADFRGLTPLVLRRALARAGTVL
HEPYQAFEAEVPADTLAAVTALLASLGADFTGTTGGDPAWIVTGELPARRVREAELRLPG
LTRGEAVWSSRPCEDRPLKPGNSGPGTGVGGHSGE
>fig|100226.1.peg.770 Oxetanocin A resistance protein
MREHTADRTRTRARAELRGDCASCFGLCCAALPFARSADFAIDKDAGTPCPNLRTDHRCG
IHATLRERGFTGCTVYDCFGAGQRVSQLTFGGRDWRAGPPEQRRRMFDVFPVVRQLHELL
WYLTEALTLPAARPVHADLRGALADTERLAGGTPEELAGLDVAAHRQRVNVLLLRTSELV
RAGTRGRKKNRRNADLMGARLKGADLAGADLRGAYLIAADLTGADLRGADLIGADLRDAD
LTDADLTGAFFLTQPQVNAARGGPGTGLPDSVTRPVHWTAGR
>fig|100226.1.peg.1326 Permease of the drug/metabolite transporter (DMT) superfamily
MSSVPSPSAPSPARRVLDWRLRFGLLSLVWGFSFLFMKVGTESFAPFQVTLGRLAFGTAV
VAAAMAVKRERLPRGAWTWLHLTVAGFLLNALPFSLFAFSELTIPSSLAGICNATSPLWG
MALSLVALSEDRPTRRRVAGLGIGFLGVLTVLGVWQGFHGLDVTGTALALLASFSYPVGW
IYVRRTLAGSSHSHLSLTGAQLGLATLQLAVVTPLFTSVPTSFPVLPLLAVAALGVLGTG
LAFLIQYDLVAEVGPTTAQMVTYFTPVIATAAGVALLGESLSWSTPVGAAVVLAGAALTQ
SRPRADRAAPAPAPAPAPETPGTTGVRQGSRV
>fig|100226.1.peg.1534 Multidrug resistance efflux pump
MNRTLQPAHPTEAVKRPGRWLALSVLVLAVLLVAVDATVLGLATPYISEDLAPSGTQLLW
IGDVYSFVIAGLLVSMGSLGDRIGRKRILLIGATAFGAISVLNAYAHTPEVMIFARALLG
VAGATLMPATLALIRNLFHDPRERSLAVGIWGAAASAGAAVGPVVGGFLLEHFWWGSVFL
INLPVMVVLVVVGVKMLPESRNPNPGPWDLLSVVLSLVGMVGVVYAVKETAAHGFAWATL
AAGLLGAAALYGFVRRQLTMPVPLLDMRLFRNRGFSGAVLADLLTILGLSGLVFFLSQYL
QLVQGRRPFEAGLAELPAAVGAVVAGLIAGRAARRFSVRAVVAGGLAAVGLALAALTVIG
QHTGYPLLGAALLVVGLGAGFAFTVTADVILSSVPGEQAGAASAVSETAYELGAALGIAV
LGSIVTGVYRDFTGPAGTPDAAHESLGGAVEAAAHLPGPAGEALLDSARQAFVDGLTLAA
GVGAAVLLAAAAASWYLLRGQRLEDGVEHP
>fig|100226.1.peg.1555 Permease of the drug/metabolite transporter (DMT) superfamily
MRAQSSATASPRIAVDATGADAGGASFGTVQAALGVVAFSLTFPATAWGLEGFGPWSLIA
VRSVLAAAVAGSCLVVVGVPPRERSRAWGRVAPPERRHWLGLAVVGAGVVLGFPLLTTLA
LQTSTTAHAAVVVGLLPLTTALLSALRVGTRPSRTFWIAALAGAAAVIAFTVQQSGGALT
SADAYLFAALLVCAAGYTEGGRLARVMPGWQVIGWALVLCLPLTVPMAAIALSLEPVRLT
AHAVTGLLWVAIGSQFLGLVVWYRGMAAIGIPKASQLQLAQPLLTLVWSVLLLGEHLPVA
APLTAAAVLVCIAVTQRARG
>fig|100226.1.peg.1671 Permease of the drug/metabolite transporter (DMT) superfamily
MMTTARTSPPAPWHRRPDLLAAGAATVTVVLWASAFVSIRSAGEAYSPGALALGRLLSGV
LTLGAIWLLRREGLPPRAAWRGIAISGLLWFGFYMVVLNWGEQQVDAGTAALVVNVGPIL
IALLGARLLGDALPPRLLTGMAVSFAGAVTVGLSMSGEGGSSLFGVVLCLLAAVAYAGGV
VAQKPALAHASALQVTTFGCLVGAVLCLPFAGQLVHEAAGAPVSATLNMVYLGVFPTALA
FTTWAYALARTTAGRMGATTYAVPALVVLMSWLALGEVPGLLTLAGGALCLAGVAVSRSR
RRPAAVPDRAAPTAEPRREDAGRA
>fig|100226.1.peg.2258 Permease of the drug/metabolite transporter (DMT) superfamily
MTARGWFLFSLMGVVWGVPYLMIKVAVDEVSPSGVVFARCALGAALLLPFALRKGDLLGT
VRRRWKPMLAFAVIEIIGPWWTLTDAERHLSSSTAGLLIAGVPIVAVLLARFFGAEERVG
ARRITGLGLGLAGVAVLTVPHLTGGDARSLAEVLVTVVGYATAPLIAARHLKDVPTLQLI
TPCLTLAAVVYAPAAFLTRPATLPSGEALAALAGLGLVCTAIAFVAFLELIKEVGPTRAG
VITYVNPAVAVAAGALLLDEELTLGIGVAFTLILAGSVLATAAAGPGREARRVPWSTRQT
SRAGGRVESLTGLPEERPGSTGQGDG
>fig|100226.1.peg.2309 Multidrug resistance protein B
MAGDVREATESEPDPARPAAPGEREQVSSGVLVSIGALLLGMLLAALDQTIVSTALPTIV
SDLGGLEHLSWVVTAYLLAATAATPLWGKLGDQYGRKKLFQLAIGIFLVGSALCGIAQGM
GQLIAFRALQGLGGGGLMVLSMAIVGDLVPPRERGRYQGLFGAVFGATSVLGPLLGGVFT
EHLSWRWVFYINLPIGVVALAVIAAVLHIPRRTTRHVIDYLGTLLIASVATSLVLVASLG
GTTWAWSSPQIIGLAVLAVVLAVLFVAVERRAAEPVLPLKLFRVRTFALSAVISFVIGFA
MFGAMTYLPTFLQVVRGVTPTMSGVYMLPMVFGLLLSSTVSGQIVSRTGRWKVFPVAGTA
VTTLGLLLLHQLDENSATAEMGAYFFVFGLGLGLVMQVLVLIVQNAVAYEDLGVATSGAT
FFRSIGASFGVAIFGTIFASRLGDQLTDAFRGAALPPGVSVDTLKADPRGIGALPPALRP
EAIHAYASSITDVFLYAAPVALLAFLLAWLLKEDRLRGSVTAPDATQTLASNPVERSSHD
EVCRALSVLGTREGRREIYRRITARAGYDLLPASSWMLLRVRKYGRVEPAQLAERSPVPL
ATVMAAARQVEERHLAVREGPDLVLTRQGREVAERLALAREESLAELLGDWWGPDRPTDL
VRLVRELTGELCGSERERPHEGRTPARAG
>fig|100226.1.peg.2611 Permease of the drug/metabolite transporter (DMT) superfamily
MAATRPAVIALTALAPVSWGSTYAVTTEFLPPDRPLFTGLMRALPAGLLLLALARVLPRG
AWWGKAAVLGVLNIGAFFPLLFLAAYRMPGGMAAVVGSVGPLLVVGLSALLLGQRPTTRS
VLTGVAAASGVSLVVLEAAGALDPLGVLAALAATASMSTGTVLAGRWGRPEGVGPLALTG
WQLTAGGLLLAPLALLVEGAPPALDGPAVGGYLYLALANTALAYWLWFRGIGRLSATQVT
FLGPLSPLTAAVIGWAALGEALGPVQLAGTALAFGATLVGQTVPSAPRTPPVAAGAGPFS
SASRNGRKDSMDLTGAALRR
>fig|100226.1.peg.2860 Quaternary ammonium compound-resistance protein SugE
MAWVLLFVAGLLEVGWSIGMKYTDGFTRLWPSVFTGAGIVASMMLLSYAARTLPIGTAYG
VWVGIGAAGAAVLGMVVLGEPATAARIFFICLLLVAVVGLKATSGH
>fig|100226.1.peg.5165 Quaternary ammonium compound-resistance protein SugE
MAWLLVIVAGVLETGFAVCLKLSHGFTRLWPTIAFCAFALGSFGLLTMSLKKLDVGPAYA
VWTGIGAAGTAIYGMIFLGDLVSTLKIVSISFVIIGVIGLQLSGSAH
>fig|100226.1.peg.7457 Chloramphenicol resistance protein
MPLAVYILGLSVFALGTSEFMLSGLLPPIADDMDVSIPRAGLLISAFAIGMVVGAPLLAV
ATLRLPRKTTLVALISVFGVGQVAGALATSYEVLFVSRVVSALACAGFWAVGAAAAIAMV
PVTARARAMAVMIGGLSIANVLGVPAGAFLGEHLGWRSAFWAVGGASAVALVGVVTLIPR
IPLPERRPRLRGELAIYRDRQVWLSIVVTALAAGGVFCAFSYLAPLLTDVAGLADGWVPT
VLALFGVGALIGTTIGGRVADAHLFGVLLSGITASTVLLAALALFASSPAVVIVLSLLLG
VSAFYTAPALNARMFNVAGAAPTLAGATTTAAFNLGNTGGPWLGGTVIDADLGYEATAWA
GGAMTLVAIAFVAVSLRLHTRSRVVTGGGPASETASLERAQRV
>fig|100226.1.peg.7593 Chloramphenicol resistance protein
MPLPLYLLAVAVCAMGTSEFMLAGLVPDIASDLGVTVGTAGTLTSAFATGMIVGAPLVAA
LARTWPRRSSLLGFILAFAAAHAVGAGTTSFPVLVACRVVAALANAGFLAVALTTAAALV
PADKKGRALAVLLSGTTVATVAGVPGGSLLGTWLGWRATFWAVAVCCLPAAFGVLKAIPA
GRATAAATGGPPLRVELAALKTPRLLLAMLLGALVNAATFASFTFLAPVVTDTAGLGDLW
ISVALVLFGAGSFAGVTVAGRLSDRRPAQVLAVAGPLLLVGWPALAMLADRPVALLTLVF
VQGALSFALGSTLITRVLYEAAGAPTMAGSYATAALNVGAAAGPLVAATTLGHTTGNLGP
LWASGLLVAVALLVAFPFRTVITTAAPADATR
>fig|100226.1.peg.8006 Methylenomycin A resistance protein, Mmr
MTTVRTGGAQTAEVPAGGRRDVPSGVKITALATGFVMATLDVTVVNVAGATIQESLDTTL
TQLTWIVDGYVLTFASLLMLAGGLANRIGAKTVYLWGMGVFFLASLACALAPTAETLIAA
RLVQGAGAALFMPSSLSLLVFSFPEKRQRTRMLGLWSAIVATSSGLGPTVGGLMVSAFGW
ESIFLLNLPIGAIGMAMTYRYIAATESRATRLAVPGHLLWIVALAAVSFALIEGPQLGWT
AGPVLTAYAVAVTAAALLALREHRVTNPVMPWQLFRGPGFTGANLVGFLFNFALFGSTFM
LGLYFQHARGATPFQAGLELLPMTIFFPVANIVYARISARFSNGTLLTAFLLLAGAASLS
MVTITASTPYWVVAVAVGVANIGAGIISPGMTAALVDAAGPENANVAGSVLNANRQIGSL
VGIAAMGVVLHSTSDWDHGAAISFLAVGLAYLLGGLSAWRLIARPERRSAVTAAT
>fig|1002809.3.peg.669 Permease of the drug/metabolite transporter (DMT) superfamily
MKFPPQLLLILATLLWGGNFVIGRAVSGDIPPITLAFLRWIVAFLVFFPIAYNRTKKEWP
ALKQHWGAVIILAITGVAAFNTLVYIGLHDTTSINASLMNSSTPIIIYILSFIFLKERLT
KFQMIGTLLSLAGVLFIISGGSLQSLLSFSFNKGDLIVLIAVVCWSFYSLLIKKYAGKLP
GYSTFLVTIAIGAIMLLPFAVYELLTTSQAIVWNASTIGAIFYVGIIASIVAFLSWNNGV
VSLGANKAGIYLNFIPLFATIFAVLFLNEQLLIAQVIGGIAVITGVFISSIK
>fig|1002809.3.peg.790 Drug resistance transporter, EmrB/QacA family
MEAPIFNVKSPKGMAAVLMISTFVGLFGETALNMALTNIMDDFGVSAASAAWLTTGYLLV
LAVLVPLSSYLVRWFTTRQLVVAAVVFAVIGSLLGALAPNFAVLLAGRFVQALATGIILP
LMFSVVMLIFPVQKRGAVMGIVGIILTAGPALGPSIAGLIVSSLSWRYIFWIMVVVYAVV
IVLAFSKVDNVSNVTRPKIDLLSLIASTFGFGGVVFALATLAEQSITKPIVWVPLVVGFV
LLVVFGIRQTKMDEPMIDLSVFKSPMFSLGVALMVATMFMILSVAILVPMFLKTVLGFAA
LTAGLCMLPGNILNIIMSPIVGTNFDKVGAKIFTRIGFTLILVSMIVFLTTISATTATWI
IIVNLCVFFVGVSMTIMPAQTNAMNSLAPHKFADGSAALNTLTQIAGASGTAIAITMFTI
GQQNYIEKFSNALPAEFLAHGVHSAFIVVTVVAVLGLVGSFFVKNSKPVGN
>fig|1002809.3.peg.843 Permease of the drug/metabolite transporter (DMT) superfamily
MFKKSTVALIALILIWGASWPINKLAVPYSPPLLYAGQRALLGGILLTVIIWKTRKAINW
RENWQKYCIGAFFNTILFFGLQTAGLLYLPSGLFSVLVYFQPILLGLFAWLLLGEDLSPV
KILGLFLGFVGVAVVSVDGLMVHISAIGVTLGLLTAVSWAFGVIYVKKISKEVDAYWMVA
LQCIIGGVFLLGTGSVFESWSAIEWNRNYLSGLGFGATIGIPLAYILYYNLVNAGEASKV
GSYTFLIPIVAVLLGVLFLGETVTYSLVIGMLLVAISIYFVNFQYKTKNKSISKD
>fig|1002809.3.peg.961 Multidrug resistance protein
MKAQRAVIIALYVVAMFMVSIDGTIVNVLLPTIAVEFGVTPGATNGINIGYLVSIAVALP
AAGYLSNRYGVKRMYVLSVSLFTLASLLCGWAGSLQALILARVLQGLAGGIITPVSMTLL
FRTFSPPERQNLSRSLVLPIAFAPAIGPLVGGLFSEYLSWNWAFFINIPFGIIIVLIGLF
ALTEFEIFKAPFDTKGYMLIALGLPLLMLTLSLIASDGVSITVVFCAIVGVFLLRRFYVY
ERKIKEPLLDVRLYEQPLFLSSSLVAMCSMGALMGMLYLFPLMYQYAYSASALESSLITF
TEALGLMVASKLLPRTSKRFGMLHTVRLGLIGTVMIFCCIAIIGPSANPWLLRGLMFAVG
ICLGHSVIGSQLSAFHHVAKSQMSKATTLYNMLNRVGAAVGIALVATTLTVSGRYFSEIL
SYQYALVATVVLLLAGLGCSLFAKEQETILKGEKA
>fig|1002809.3.peg.1102 Permease of the drug/metabolite transporter (DMT) superfamily
MEKPPIHPYIPIIIGVISVSLSAIFVKLSSADAGVIAFYRMLFSIMIMLPWFLIKYKNEI
KVLSKRDWIFSSIAGVFLSFHFILWFESLNYTSVASSTVLVTMQPLFAFIGTYLFFKEKI
TLQTFIAGGIAILGSVLISWGDFKISGTALYGDILALIACALITGYLLFGQDVRKRLSLV
TYTMVVYSVSTVTLFFYIIVKGESFGPYPAIDWMWFILLAIIPNLLGHNLFNWVLKWTST
NVISIAILFEPVGAALLAMFIFNEYLTVSQIVGGLVVILGIMLFVIDLKKFFRKKA
>fig|1002809.3.peg.1127 Multidrug resistance protein B
MPKQVWLLIIGTFVNTVGNSFLWPLNSIYIHDHLGKSLTTAGIVLMLNSLAGVFGNLVGG
YLFDKLGGYKAILIGVVFNLLSITLLTIWHDWPQYIIFLTMMGFSGGIVYPAIYAIAGSA
WPEGGRRAFNSIFLANNVGVAIGPALAGIVADIKFDYVFSANLFFYAVFFVLVITTYKRF
DMKGLTTKPFSGNETKRRNRGPIVALSILSISLIVCWLSYSQWSATISSYTQGLGMSLSE
YSLLWTINGFMIVAVQPIIRPLVTRWENKIKHQLVLGLILMSLSYIVVYFAQDFKMFAAA
MVILTFGEVFFTPVIPMIANKLAPHGQEGFYQGLVNSASTIGRMIGPVFGGLMVDLYGMQ
ILMLILSVLIIVAIIPCLVFDRTLGKEQT
>fig|1002809.3.peg.1256 Drug resistance transporter, EmrB/QacA family
MEQTKDVKTFQKPPYLMIAVLFVGAFVAFLNNTLLNVALPSIMTAFDIKDYSTVQWLATG
YMLVSGVLVPTSAYLITKFRTRPLFILSMAIFVIGTALASFAPSFSFLLAGRMIQAAGAA
TMAPILMNVMLISFPVEKRGQAMGMFGLVMVLAPAIGPTLSGWIVEHYDWSVLFKMILPI
AVLSLLLAVWKLEDVLPNRDAKIDILSIVLSTIGFGGLLYGFSTASSAGWSAVEVWGTIT
VGAIGLAWFIIRQFRLEQPLLDLRIYTYPSYALASVVSMVLSVAMFSGMILTPAYVQSVR
GIEPFEAGLMMLPGAIVMGIMSPITGKLFDRFGPRILAVVGLTITTLATIGLGYLEVDST
YLFIISVYTIRMLGISMVMMPIMTNGLNALPNRLNPHGTAMNNTAQQVAGAIGTAVLVTV
FNSHTKTRAAEIAADMQANASSAVQPTAEQIAQAQAQVMQQAMLDGITYSFFVAAAVTVV
ALILALFIKRVDITKREDFTGAVQEKK
>fig|1002809.3.peg.1709 Vancomycin B-type resistance protein VanW
MKTNFIYLVLFGLCLLGCEKASYSGTSETDGVKEHQIEASTSSPLSEREAIVGEYPLIYP
AVITLIDPRTMEIVKSFTPQLLGYGTDRELYEANIKKVARELARGSKERTGYDQTMVLHK
IGENGEIIEGNPGIVLKESELVEKILAASPKGDHIFLPLYILESNLEIDIPSLDDVTVAS
FTTYFNGAESGRSENIELSAKAIHNILVGDGDYFSFNTMVGERTVEKGYQPAPEIINKEL
VMGIGGGICQTSSTLFNAVDQLGIRITERHHHSLNIGYVPTGRDATVSYGSLDFKFQNTS
GAPFLIKTYYSKGSLTIALTTSHQYKDLLKK
>fig|1002809.3.peg.1784 Drug resistance transporter, EmrB/QacA family
MSDIYGRRQILIIGILVILVSEMITPLMVSNIYHLMIFRAIQGLGGALAAVVGLIVISDI
FDLANRAKFLGFYGALNAITAIVAPTLGGIFVQYMSWHWVFYSIAPIGVIGLYLVVKYMP
NIPRTENAKLDYKGISILSAAILVFVAITTFGGSRIPWLSVPMFVLVTVFVLSIFGFITS
QKKVAHPIVPLRLFKYRVFVVCMLSVFAVMFAATGLIFLLPMFLQNLFGFTPTETGLFMT
FRGTTSFIFAAMSGFLVVKLKDFKLVAIIAMVIFASMIFTLTFFTTSASTLALTIICLIW
GTSSGVLISIFHTGIQMNLPDKDISVAMSVIQLAVAVSSLLATSFLGLFLRLPNLSQGLS
YLLFACLGAVVLALGIFVITLQKRNLKIEEEEPAAEQLV
>fig|1002809.3.peg.1926 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
METLQQDLMNKPVKKLFFHFFFPAVFGMLLMSVNLLLDGIFVGHGVGEVGLAGVNLAAPI
FTIILAISLWIGIGGATNFSMAMGEEMADEARSSFTLALAIFTAILGVISIVGYLNLQTV
AGWLGANEETLAPTTDYLGVLFALGWVLGLQQLLSIFIRNDGRPMLGMVSLGLTSVVNIL
LNYVFIFVLDMGVYGAALATILGGVVGVLVFVPHFFNKKVVLNKWRFNWSLPLGRRILAI
GFPSLLAESGAFVLVVGYNLSVVAALGTEGVTAFSVINYLHGFMFLAFFGIETAMQPMVS
YYHGSKKKAQLKETLALAEKTALILGVTLFVIGYLLAPQLVQLFGVDDPAIVQLAVEGIR
LFFIGYLFIGLSFVYMTYFQSVGKVWSATLIIVMRSYIVFLIYLFVLPKVFGVNGIWLTM
PIAEMTMAIVIVMFVRKRVKQTLI
>fig|1002809.3.peg.1980 Permease of the drug/metabolite transporter (DMT) superfamily
MKNKRMIGFLLVVSGSFFWGIGGTMAQQLFSLGIEVSWLVSTRLVIAGILLLIAQAIFKD
QGQIFKIWRERRDAFRLLVFAIVGMLGVQYTYMASIKEGNAAVATLLQYLAPVMIIIWVT
VRGLSKFTKKDAVTIVLALSGSFFLLTNGSLSAFAVPLPAILWGLLSGVTLAFYTLYVIP
LLKRFDSLVVVGWAMLLAGLTISFVQPPWDVDVSVLTGATLVYLVIVIIFGTMLAFWFYI
ESLQTLTAKETSLLGNIEPLTAVLATVLWLKEPFGGFQWLGTSLILVMMIYIALKADRQK
DEDLDKVEDAIVEDN
>fig|1002809.3.peg.2185 Tetracycline resistance protein
MVQKTRVESSEEQTATLKSYILYPEKQKALYKRTLFVVSVSQIFGGAGLAAGVTVGALLA
QQMLGTEAYAGLPSALFTLGSAGAALLVGRLSQASGRRIGLATGFMIGGLGAIGVIIAAI
INSVLLLFLSLLVYGSGTATNLQARYAGTDLANNKQRATAISLTMVFTTFGAVAGPNLVN
VMGDIALSIGVPALAGPFILAAAAYILAGIVLFVMLRPDPLLIARSIEASNNEKHAKTHS
AITEQVENRRGIIVGATIMVLTQIVMVAIMTMTPVHMRHHGHSIGEVGIVIGYHIGAMYL
PSLVTGFLVDKLGRTAMAIASGITLLLAGLTAAFAPGDSMVFLVIALSLLGLGWNFGLIS
GTALIVDSTTTSTRAKTQGTLDVFVALSGAAGGALSGVIMAGSSYLTLSFIGGILSLLLI
PVMLWSRSAKN
>fig|1002809.3.peg.2231 Membrane component of multidrug resistance system
MQNELSEQTRKILLIVMIAGCFFSTLNQTLLNVALSDLMNTFSVSPTTIQWLATGFMLVN
GILVPITAFLIKRFSTRQLFISAMLFLLAGSVVAACAMNFGMLLTGRMIQAVGAGIILPL
MMTVIVYLFPEERRGAIMGKVGFAIIFAPAIAPTLAGFIIDYLSWRWLFISLIPFIVIII
VLAYKYLMNVNEGAKLKIDLISLIYSTFGFGLLLFGFSSAGSRGWDDGVILTTIGAGLII
IFLFCQRQLSSQDPLLNLSVFRYKMYSMTTIINVAITIIMYADLILLPMYLQDGRGFSAL
DAGLLLLPGAIINAFLSPVTGKLFDKYGAKPLFIFGLVLVALSMWLVIDLSSTTSYVYIL
VRTIILRIGLAFITMPLNTAALNAIPRELASHGSAVNNTIRQLAGAIGTAVIVTVYTLQL
TGTSVQVNESYATAASSTYFYMFLLAIVAFIVVLFVPKHKRTMPAQETN
>fig|1002809.3.peg.2236 Permease of the drug/metabolite transporter (DMT) superfamily
MQKYKGELLMLITAVMWGSGFVGMAKGLEHWTVFQLMAGRFLLASIILSFIFYKKLKLIS
KAVIWKGAILGAILFIAFTLQTMGLEYTTPSKNAFLTAINVIIVPIIAYVIYKRRIDRFE
FIAAGVAVVGIGFLSLQDSMTINFGDFLSILCAVGFAFDIFYTNVFVKTEDALALTIVQF
YTATVLSVISVVMLGEVPTTYTSEGLGIIVYLAIFCTAVAYVCQNIGMQYANPTKSAIIL
STESLFGTMFSVLILNEILTGRMLVGCVLIFFAILFAEVKPTFRRKKSYI
>fig|1002809.3.peg.2366 Transporter, drug/metabolite exporter family protein
MERLKGIAMIIVGSIFWGATGPMMEWLLQQTAMTAEFMLAVRLMIAGILILGIAAMQKKS
IFSIWKNRNYSVQLLIFSVIGMVGLQFTFVKSIEVSNAIIATLLQFLAPIFIVIYTSVVG
KVLPPRSQLIGIFGTLVGLFLLLTNGSVSGLLVSNEALVWGLLLGFTYAFYTLYPARLMA
EVGVIIIIGWGMIIGGLMFSVAGQLWKTEQWLLLLDPVNVFLIIATGIFGSFAYILFLTS
LKYISPVETSILSSFEPLTAMVISVVWLGATLYSWQYVGILLMLVFVVYLSIAGSKKATL
RMSK
>fig|1002809.3.peg.2467 Ribosome protection-type tetracycline resistance related proteins, group 2
MHTTIGVVAHVDSGKTTFCEQLLYHTNAIKKRGRVDHQDAFLDNHAIERQRGITIFAEQG
RIDYNGQAYTLIDTPGHIDFAPEMERAIHVMDAAIVIISAVDGIEGHTETVWHLLREHHV
PTFIFINKVDREGADVAAVMSAIKKDLSPNALLFNDGFDTTVKEWLAERDEQLMEKYFAD
NLAENDCLESLKHAINHEQAFVCMSGSALKDEGVLAFFETIAQLMETKFDVNGPFEGKVY
KIRHDHQQRLTFMKALSGVLKVRDEFTFGETTEKVTEIRLYNGNSFTTVPQVQAGDIFAV
KGLAMPLIGDVIGATETNPAQFDMIPTLQAKVIYEGALHIKELHRVFREIEAEEPSLRVV
WNEKFQEISVHVMGTIQLEVLTELVKERFGIEVQFGKPQILYKETIAAPAIGYGHFEPLK
HYAEVHLKMELNNRGAGITFSNRCHADDLSVGHQRLIEKHLFERDHHGLLTGFPVTDIHL
TLLTGRAHNKHTDGGDFREASFRALRQGLEQVKNVLLEPYYRFKMKASSDHIGRMMSDIQ
QASGSFEAPNLTEDTVTLYGRAPVATFMDYSTQFAAYTNGKGALTLQFEGYDVCHNSDEI
IEQIGYNKNADPEYTSSSIFCAKGKGYSVPWNKAKAAMHCEVHEID
>fig|1002809.3.peg.2582 Permease of the drug/metabolite transporter (DMT) superfamily
MEFSMKKGMLLGFIGIVCFSFTLPATSIAVPYFGETIVGLGRTVIAAIIVGTVFIVKKQP
LPSISQFKSLLIVAVGAVLAFPLLTTYAMKSLPVSHGAIELALLPLATAGFAMWRGGERP
SKRYWIASATGAVTVIIYAIYLGLGQLHKGDFALIAAVILLGLSYAEGGKLSKEVGSWQV
IAWAILIGAPFFIIPVGLGLSDRMLDAPIEAWISLFYLGIVSQFLAYVAWYGGMSLGGIA
RVGQIQYLQPFLMIGFSVLFLGESITWITIVLAMIVVLCVIVGKNADDKQSLELK
>fig|1002809.3.peg.2591 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MENSTKELSLFKLTWPLFLELFLFMLMGLADTFMLSAVSDDAVAGVGTANQYIQIAILLL
GVIGTGASIVVSQYLGSRLIAEASQIAALSVTLNLLVGLVISGLFILFSDVLMKMMNLQG
AVLEAAQSYLVIVGGFIFVQALITSMSSIIRVQGWTKQTMYVSLAMNIVHVVLNYILIFG
KFGMPELGVEGAAISSVVSRVLASVVFFWLLYQALEVRIEWADYYRLSKNYISKILKIGI
PSALEQVLYQTNQIVLLYYVTFIGAEALSARQYAVNISMFTYLFAMAIGMATAILVGRYV
GAGEKELAYSKVWFGVKSALIFTLSMVAIIILFREPFMRIFTDNEEIIQIGASVLLLSIL
LETGRTINITIINSLRASGDAAYPVRIGFISMIVIGLSLGYLFVFVLDLGLVGVWLAIAC
DEWIRAVLVIFRWRSRKWERYAIVSSDK
>fig|1002809.3.peg.2609 Permease of the drug/metabolite transporter (DMT) superfamily
MNVRSMLKLTISMAIFGSIGFFTTQTGLPAVELVFVRCICATIFLGGLWLITGGHKTEDW
NRSEVMKTIVCGIFLVLNWVFLFKAFEVMSISVAISIYNLAPIFVLILGSVFLAEKMGIR
SICATAICFFGSILIIGIESFTSVSQFMNSGFIWALLSAICYALTMFTSKTIHGMSSYAL
TYIQTITGIILLLPFCDFAAFEGLTNTNWLYILGTGLIHTGFVYYLFFDSVRDLPTVIVS
VLVFVDPVVAILLDALLLSFRPDLLQVLGIVLIFGSILYTVFYPKQTINKVKTSSSQ
>fig|1002809.3.peg.2621 Permease of the drug/metabolite transporter (DMT) superfamily
MSLQGKANILMVIVTMFWGLSYTFMVMGLESLEAFNVVALRCLIAFIIAGLIFLPKMLRV
NIKTILYASIQGFLLFTIFALSLLGLKTTSAGNAGFILSLTVVLVPIMTSFIEKRLPSRA
VSFAVVATMIGITVLTLKESLTFQTGDLLVAIAAVCYSIYLILNSKFTKNVESISYGVYQ
LGIAGLFGAVFTMMFESPMFPSNSSSWIAVLGLGIICTAFCFIAQAVVQQYTSPTHTGLI
FSLEPIFAALFAMIFLGEGLTAQLVIGGSFILIGNTVAQLEQFIAMKKIPAPTHSETTL
>fig|1002809.3.peg.2625 Probable multidrug resistance transporter, MFS superfamily
MELQEQTNKIFTKRFISLFFTNMSIFLVFYGLITTLPLYAIGELGKSDDDSGLLVTVFLI
SAIIVRPFSGKLLDLFGKKRLLILSLVLYFACTVLYLFFKPFLLLLALRFFQGIWFSIAT
TASGSLAADIIPKRRKGAGLGYFAMSTNLAVVFGPFIGLLIIQYLGFDMLFIVLSVLVAI
GGLLALTIQTKDLPKPVVTDRSFKFSFNDLFERSALPLAALASLIAFSYASVLSFLSLYA
EQKDLLSVASYFFAVFAVAMISVRPFTGRIYDTIGAKFVIIPSFFIFALGLIILGNADQE
IPFLLSAIFIGAGYGTLTTSFQSLCIQSTSIQRSGYATATYFTLFDIGIAIGSYLLGMVA
VKLGYEFVYYIAAFIIIVVFALYMLVLNRQKHKIEQ
>fig|1002809.3.peg.3228 Teicoplanin resistance protein vanZ
MIHSFLLSMIAYCTVSFPIYCILRMFYMKNKTSSARRELVMLLFFFYSISIFSQTIIPSF
QISNGQIIFDTSSAYVRSNFTPLQTIMLYYDQLNGPLANIAFYNLAGNIVLFIPFGFFIP
LLWKKFRGWRIMHIVAFAIPLFIESTQYFIGRSIDVDDVLLNAIAIVIGFVLFKIFRRLR
KMSAPK
>fig|1002809.3.peg.3521 Drug/metabolite transporter (DMT) superfamily protein
MKINKGVFFVLLGAGCFGFTPVFAKLGFGHGYSLGQINLVQMVISFLLLWSIAFLKGDGT
KGLTKKNIIPIMITGCFIGLTSIFYYGAMQYLPASLAIILMFQFVWIGILFEWVFNKIKP
APITIFSIVLILVGVFFASNILNGDMQGLPIKGFVMGILSAFTYAAFIFFSGKVAVDVNP
LTRTSLMVTGSTILVFILFMKDIPTVFPLEGSLVTSAAGVSLFGAVLPPLFYAVGAPLIS
GGLANILTSVELPVAILSASIILAETVKAVQWLGIVLILVAIVLNEIGPNIIRMKKRSKR
TILHQHNKN
>fig|1002809.3.peg.3555 Quaternary ammonium compound-resistance protein SugE
MGWIFVILAAILETIGVIGLKKFSTSKKPKDLVTLVAGFGSAFYFLYASFEYLQVSIAYA
VWIGLGTTAAVIINMLFFGESRSIGRMVAVFVIVIGVSGLKYVS
>fig|1002809.3.peg.3556 Broad-specificity multidrug efflux pump YkkC
MKKSWIYVGLTSLCELLWIYGFNVASASWHWAIIIPLITVDFYFLAKACEGLPTGTVYAI
FAAIGTIGTALMDVYLFGESFTTLKIVFISIIVIGVMMLNIADTLSERKVEKGAL
>fig|1002809.3.peg.3635 Permease of the drug/metabolite transporter (DMT) superfamily
MNILPYLFVLMAAMLWGTVGTTQTFLTEGISSFAVACVRSGIGGGVLLLAVLAMRKISFR
NWSWKWTILAAIAIALFQSLFFTSVRFTGVAVGTVVTIGSAPVFAGFIEWIFWKVRPTLV
WAIATVLAIVGCLLLFMNQGETAINPLGIGLALAAGSMFALYTNVSKQLMKREETLPAVA
MTFSICALFLLPLAAKDGFGWLTEGVNIWPILFMALAATSLAYILFLGGLKKISSSAAVT
LSLAEPLTAALLGVFLVGEHLTFVSWIGVSLLLGGIIVLTFGTKKAAS
>fig|1002809.3.peg.3691 Multidrug resistance protein B
MKDYKITLGLLLLNLFIAFLGIGLVIPVLPTLMNELQISGTVVGYLTAAFAIAQLIVSPL
AGKAVDKYGRKIMIVIGLFIFGISEFLFGLGKTIEVLFISRVLGGISAAFIMPAVTAFIA
DITTMETRPKALGYMSAAISTGFIIGPGIGGFLADFGTRVPFYFAGALGTTAAILSIILL
REPERNMVNVENAPVQTSGFKRILEPMYLIAFILIFVASFGLAAFESFFSLFVDHKFSFT
PTDIAIVITGGAIVGAIAQVALFDRLAQKWGEIKLIRYSLILSGVLVFLMTVVSSYFAIL
LVTCIVFVGFDLFRPAVTSYLSKIAGNEQGFVGGMNSMFTSLANIFGPILGGMLFDIDIN
YPYYFATVVIFFGILLTLIWKKPASYM
>fig|1002809.3.peg.3843 Multidrug resistance protein B
MSTTTVKQSNPVYPIMVSIGVCHLINDTMQAVIPAMFPLLERDLGLTFTQLGMISFVLNM
FASLLQPAVGFMTDKKPFPYALPLGMVSSFIGLTMLILAGEYWMILVSVLFLGLGSAIFH
PEGSRVSFMAAGNKRGLAQSIYQVGGNSGQALAPLLSAFIILPFGMYGVSVILIFTSIGI
FLLTKISMWYKRQLEAEKRSKIKKMLVSSLPPLTKKQVGMALLVLLFIIFARSFYVTNIT
SFYVFYLSEQYGMSVERGQLFIFIFMAVGVVGTFFGGPLSDRFGRKNVILLSVIAPIPFC
LALPFVPLPAVLVLLIIIGLLIMVSFTVTVVYAQELVPSKIGTMAGLTVGVAFGMGAIGS
IVIGMLIDKMGIHFTMNAVSVLTLLLLVAFLLPRDRVGD
>fig|1002809.3.peg.3851 Permease of the drug/metabolite transporter (DMT) superfamily
MKQNWIYPLLIVIAASSYGVLSTIVKVAMQHGYTSSEAVTSQYFVGFLLALVLFVVTQRT
LPKLSKKGAITLLLAGTCTAITGIVYGHSLNYLPASLAVVMLFQFTWIGLFMDCFLKRRL
PTRIELISLVFLFVGTILAAGVIDVDLSQIAWQGWALGLLAAFTFAAFMQFNAQPVEGVT
TIGRTFILSVVSLIIVFIFLSPEIVWNGQLTGGLWKFGLALGLFGIILPILLFSIAAPKV
GGALVPILSAMELPVAITVSVIVLNESLTLLQIFGIVFVLFGMVLPSYFASKKVRVIDQK
QQLP
>fig|1005048.3.peg.86 Glyoxalase/bleomycin resistance protein/dioxygenase
MIHIREIDHIVLRVTDLEQMLRFYCDALGCTVDRRLDNIGLVQLRAGSAMLDLVPVDGKL
GSVGGAAPGKEGRNLDHFCFRVEPFDEATIRAHLVAHGVAAGELESRNGAEGEGPSIYVT
DPEGNVVELKGPPYD
>fig|1005048.3.peg.789 Fosmidomycin resistance protein
MGSHDAEKTGFRVLGAISFAHFLNDMIQSLILSIYPLLKGNFNLSFAQIGLITLTYQITA
SILQPLVGLYTDKHPKPYSLALGMGFTLVGLLILSVAPSYGILLFAAALVGTGSSIFHPE
SSRVARMASGGRHGLAQSIFQVGGNAGSSMGPLLAAWIVIPHGQTSIAWFSAAALLAIVV
LWQIGNWYKRKRQEAKSKPAKAKQHHVALPRNKVLFSVGILLMLVFSKYFYMASLSSYFT
FYLIDKFQLSVQSAQLHLFVFLFAVAAGTVLGGPIGDKVGRKVVIWVSILGVAPFTLMLP
YANLFWTGVLTVVIGVILASAFSAILVFAQELVPGKVGTVSGLFFGFAFGMGGIGAAALG
QLADMTSIRFVYQVCSFLPLIGLLAAFLPNLEGHRRKAAG
>fig|1005048.3.peg.1085 Permease of the drug/metabolite transporter (DMT) superfamily
MSGKLQPGSRQIFLGGLAIAVAGAILFSAKAIVAKLIYRYPVDAVLLITFRMLFALPLFA
AVALWKARSEAPLSNQDRMRIVVLGLIGYYLSSFLDFLGLQYISAGLERLILFLTPSFVL
LMSFLFYRRRVTWLEWAALLISYLGTVLVFLHDVRLGGSNVGLGSALVLGAAISYALYLM
LSGELVSRVGAMRLVAYAMCVSCAACIVQFLLLRPWPILLQQPAAVYGLSVINAVFCTVL
PVFLTMVAVARIGPATAAQAGMVGPVSTLFLGALILAEPVTAIQLTGTGLVLAGIYLISK
KKS
>fig|1005048.3.peg.1277 Acriflavin resistance protein
MSISAAFIKRPIGTTLLAIAIFLIGAAVWPLLPVAPLPQVDFPTIQVSANLPGGNPETMA
SSVAQPLERQFSLIAGLSQMTSTSSLGSTQITLQFDLNRSIDAAALDVQAAITAASGQLP
ANLPSPPTFRKVNPADSPILVMSVQSDALPLIQVNDFADNILAQQISQIPGVGLVNIGGV
QKPSVRIQVDPTKLAAIGISLEDIRGVIASLTVNQPKGTVDGAKQSFTVYTNDQLLSAEP
WNDMVLAYKNGAPIRVRDVGVAVDAAENLKVAGWAYAGAAAPAGNTITNGRSIVLAITKQ
PGANVIETVDRIKAALPRLQAAIPPTVHVNTLIDRTQTIRASVSDVEFTLVLTIALVVLV
IFLFLRNVPATLIPSVTVPLALLGTAGIMFLLGFSLDNLSLMALTIAVGFVVDDAIVMLE
NIYRYVEEGMAPIEAAYKGAGEIGFTIISISVSLVAVFIPLLLMGGIVGRLFREFAITVT
LTIAVSVVISLTLTPMLCSRFLKSHTAESHGRMYQMFERGFDAMLNGYKRGLHVVLRHQF
ITLMVFFATMAATVVLFVIIPKGFFPQQDTGFVYGFAESAQDSSFASMNKRMLALADVVR
KDPDVTGFGMSGGGSTFNTGNFFISLKPKDEGRTASADEVIARLRPQLAKVQGVNLFLQA
GQDINVGGRLSRTQYQYTVTDSNLDELNVWAPKLLNRFRQLPQLTDVASDQQNAAAAANL
TIDRARASSFGITPALIDSTIYDAIGQRQVAQYFTQINSYHVILEVTPKLQEDPELFNKL
YLTSPVTGQQVPLSTFVTIDTNKTSYLSISHQGQFPAVTISFNLAPNVALGEAVDAIQKA
QSEMGVPATLTGAFQGTAKAFGDSLSSQPYLIAAALVAVYIVLGLLYESYIHPLTILSTL
PSAGVGALLILMMGGYDLSVIALIGIILLIGIVKKNGIMMIDFALTAERQHGMKPEEAIY
QACLLRFRPIMMTTMCALLSGLPLMLGHGAGSELRRPLGYAMVGGLVLSQALTLFTTPVV
YLYLDRAHYWYMRRKEARQARKAARKAAA
>fig|1005048.3.peg.1496 Permeases of the drug/metabolite transporter (DMT) superfamily
MTAGVIALVLCAALLHASWNAMLKSSGDRLWAITLMTIGSAVASIPIVLWAPLPALASWP
YILMSVVLHAGYNLFLVRAYRAGDFGQSYPIARGSSPLLVSLGAALFAGEQLGILTLAGV
VLISAGIISLAQIKFRRGSSVAGSRQWDAPLSAFTTGVFIAGYTIVDGLGSRLAGSAASY
AGWMFLLDGLPLLMIYLSMHGSLRIALRERATWNALGGGAMSLLAYGIVIWAITLAPMGP
VSALRETSVLFAALIARMFLGEALTLRRLLSCAVIALGAVMLGWSA
>fig|1005048.3.peg.1709 Inner membrane component of tripartite multidrug resistance system
MPSISSELPIKPLAGAQLIGAGLLLAAANFIAVLDTTIANVSVSTISGALGASSSQGTYV
ITSYAVAEAITVPLTGWLANRFGAVRVFITSMVMFGVFSALCGLANSLGLLIAFRIFQGL
AGGPLIPLSQTLLLRVFPKEKAPTAVGLWAMTTLIAPIAGPILGGVLCDQYSWPYIFYIN
VPVALICGYLGWKMFKRYESSLVKVPIDKVGMGLMIVWVAALQLMLDQGKEKDWFASPEI
MALALVATIGFIAFLIWELTERNPVVDLRVFRHRGYSASVITICLAFGAFFGATVLTPLW
LQGYMGYTATHSGQTTALSGILAVMTAPFVAKLSTKVDPRKLVCLGVLWLGSVTLLRSFN
STDMTTFQIGWPLLLQGIGMPLFFVPLTGLALSSVNFSETASAAGLMSFCRTMSGAIATS
LVNTSWENKAIYYHAELSGLVDQAGNASNTLVQSGLSAEQARLSIEQTVQSQSIMLSTNH
IFMMAALSFLLAATAVWFAPKPKRIADTSAAH
>fig|1005048.3.peg.1710 Membrane fusion component of tripartite multidrug resistance system
MSHSDSQAVQELASTEATLKAEQAATTKKRKKLFAILGGVVLLGGLSYATYWHFIGSRYI
STDNAYTAAEISQITPAINGIVADVKVVDTQYVKQGEVLVVIDNSDAKLALLQAEADLDR
SQRRVQAYFANDAGLAAQVLARDAEQSRAAAQVLSAQADLQRAELDLRRREALAKSGSVS
GEELTNARSALLTAQASMKVAEAGAIQAKSNRSAAIGAQQASTVLTANTTVATNPEVELA
RAKRDQAKLDLERTVLRAPVDGVVARRQVQVGQRVQAGTALMTVVPTQSMHVDANFKEGQ
LTQVQLGQPVTMSADIYGGSVEYHGTVVGLSGGTGSAFAMIPAQNATGNWIKVVQRLPVR
ISIDRKELIAKPLSVGLSMEVAIDTRGDKSAPAARM
>fig|1005048.3.peg.1711 Outer membrane component of tripartite multidrug resistance system
MPRPCFPPYAALSLCVLALSISGCAPFSEIGPRAVPKDISSYQAGQLAGNAVSWPDDNWW
TIYRDPQLDRLIAEGLKGAPSLAAAQARLLKAQGVAQQQGAALLPQVSANASADYMKQSY
NNGVPPEFVPPNYNVEGKATLNLSYEIDFWGKNRAALAAATSDLEAARADAAQARIALAT
SIAAAYAEFERLLSQHDTAQEALQVRIQTLDLFEQRRLNGLETLGSVKQVVARKASAEAD
LLSLDESIALQRNKLAALLGAGPDRGLSLQRPVLDLSKPFALPSQLPVNLLGRRPDVVAA
RLRAEAAAKQIKVAKAQFYPNVNLTAYLGFQSLGLGMLTKAGSDIGSIGPAISLPIFEGG
RLRGQYRQASASYDEAVANYDNAVTQALQDVADAAVSEKALSGRLGKVQEAVDAAAAAAQ
IAQNRYAGGLATYLDVLNAQDTLLTNQRDLSTLRSRMFALDVQLVRALGGGYRQAAI
>fig|1005048.3.peg.1912 Methylenomycin A resistance protein
MAPSGLLPLLTLAIGFVMAMLDVTAVNVALSDISLNLSVPLSGLVWVVDGYTLTFAALLL
VGGALADRYGAKTIYLSGLVVFMLGSLLCGAAPDGNTLIAARMLQGVGSALFMPSSLSLL
THAYEDDRVRARMLGTWSAIVAVAAAMGPLVGGVLVHGFGWRSVFLINVPVGLLGLLLAH
TVIPAAPRHWRPLPAASHALGITGLASLCFTLIEGPVYGWTSSPILATAALVVIALMLLV
RRERRGAEPLLPRALFATPRFAAANAIGFLINFGAFGQLFLLSLFLQQARGADALHTGLQ
LLPVMAVFSVGNLLSGRITARWGARLPMLGGLLLAALLAALLTGMRPHTSYLLFAMAAAI
ANWGVGIAVPAMTTTVMQVAGRIHANSAAAALNANRQIGALVGVAIIGSILHAAPDWDLR
IPLAFGAIAIAYGGAALLVWRFIKSPGKD
>fig|1005048.3.peg.1933 Permease of the drug/metabolite transporter (DMT) superfamily
MNIAELFLLAAIWGASFLFMRVGTPEFGPVPLIFLRVGIAALVLLPVLRSAAARSHLRSK
AWPMLVVGVTNSAIPFSLFAYSTLYVNAGFDAVLNATVPLWTGLIAFVWLKAPMSRAQVI
GMLVGMAGVVVLVWDKIGEGQAGVWLATAAVLLATLCYGFAINYSKTRLVGVPPFVVAGG
SQLAATLVLLPLAFWYWPTATVSATAWYAVLALGVVCTGLAYAIFYRLLDRVGSAYAASV
TFLIPIFGVIWGAIFLKEEVTPGMVLGCVIILLGTALATGKLNLSVFLRDKTAK
>fig|1005048.3.peg.2315 Outer membrane component of tripartite multidrug resistance system
MKPIMSYPFRKSLSCLGMAGLLAACAAGPDFQAPPAPVVPQYTAGVQPLATVSSAGAGGG
AQHFDPGMDIPAQWWTLFHSPQLDALVREALANSPSIVQAKAALRQASENLGGQIGATRY
PQVDLQVGGVRQQIDTAALGIPNVPQAGPFTLYNASLDVSYTVDVFGADTRMLEGLQAQV
DNQAAELQAARLTLAGNVVTAAIRHASLHAQIASTGQMLQLQRQQLGIMEQRLAAGGIAE
RDLKNQRTLVAQSEAALPALLQQQAQTSHQLAVYLGKAPAQADMPPLDLDSLTLPDRLPL
SLPSALARQRPDIRAAEATLHQASAQVGVASANLYPQLTLSGSVGTEQGRIADLADSLNV
WNIGLNLMQPLFHGGELRAKKRAAVAAYDAAAASYQQTVLQALQQVADSLRALENDAKVL
QARAQAAENAQGSLAITSRQYQAGGVSHLSLLDAQRQGLQTALDRTVAQAARYADTAALL
QALGGGWWNTVASDQP
>fig|1005048.3.peg.2525 Probable transmembrane drug efflux protein
MSDGKKTGFNLSRWALEHIPLTRYLMVVLVIGGILSYGRLGQDEDPPFTFRAMVVSAQWP
GATALQMADQVTDKLEKKLQETPHIDTIRSYSKPGETLIILTLQESAPPKETADAWYQVR
KKINDIKLTLPQGVVGPFFNDEFGETYGSIFAVSGDGFNYADVKDYADFVRQQLLTLPSV
AKVDLFGVQDEKIFIEFSQKKFSQLGITVRDIVNQLSAQNALQSTGVLATATDNLQIRVS
GALASPKDLENLQLRANNTTFRLGDFAVVKREYQDPPQTKMRFNGKEVIGLGVSMAKGGD
IISLGKDMERMTAQIKAKLPVGIDLERVSNQPKIVAESVNEFLKTLMEAVLIVLAVSFLS
LGFHTKPFRIDVRPGLVVALTIPLVLAVTFLFMSIFSIDLHKISLGALIIALGLLVDDAI
IAVEMMVRKMEEGLSRLEAATFAYTSTAMPMLTGTLITAAGFLPIGLAKSAAGEYTFSMF
SVNALALLISWLVAVLFTPYIGFLLLKVKPAAGADGHHELFNTPFYTRVRRTVNWCVEWR
KTTIALTLMVFALGVFGFKFIEEQFFPDSSRPELMIELWLPEGSSFAATEAEAKKFEAYI
HAAPELESMTTYVGSGSPRFYLPLDQILPQTNVAQLVLLTKDLASRDALRLRITEAFKHG
FPEVRGRVKLLPSGPPVPYAVQFRVSGTDAAKVRTIADQVKSVMNGNPNIIGLNDNWNES
VKVLRIDLDQDKLRTLGIGSQTVMQTVNTMLTGTTIGQYREHDRLIDIVVRQPLDERATI
DALNQANVPTASGKSVPLAQVATVKLVWEPGVVWREWRNWAITVQADVIDGVQGPTVTAQ
IDPQLDKIRAQLPPGYIIDVAGAAHDSGKAQDSIAANVPLVIFIIFTLLMLQLHSFSRSL
LVFLTGPLGVAGAAAALLLLHRPFGFVAQLGVIALFGMIIRNSVILIDQIEHDIANGVAP
WNAIVESAVRRCRPIMLTAAAAVLAMIPLSRSVFWGPMAVAIMGGLIVATGLTLLFLPAL
YAAWFRVKKPQPENAADNHG
>fig|1005048.3.peg.2543 Permease of the drug/metabolite transporter (DMT) superfamily
MNLTTFAFIISGVCLNAVAQLLLKAGTNAVGVISLTPQNWFATGIKLATQLPILGGLTCY
VISLIVWIIGLSRVDVTIAYPMLSLGYVISAVGAWYFLGEAVSAQRLVAIGVIIVGVVLL
TRS
>fig|1005048.3.peg.2545 Polymyxin resistance protein ArnC, glycosyl transferase (EC 2.4.-.-)
MKPELSVVIPVYNEESGLAKLFERLYPALDALGISYEILYVNDGSRDKSAAILAEQFRLR
PDVTRVVLFNGNFGQHMAILAGFEATRGDIVVTLDADLQNPPEEIGNLVAKMREGYDYVG
SIRRKRQDSAWRTVASKAMNLLREKITGIRMTDQGNMLRAYGRNVVDLINQCQEVNTFVP
ALAYTFARKETEIVVEHEERSAGESKYSLYSLIRLNFDLVTGFSIMPLQLFSLIGIVLSF
ASAALFFILVARRFLFGAEVQGVFTLFAFAFFLMGMILFGIGLVGEYVGRIYQQVRARPR
YVVQAMLEQSSAEDKQAS
>fig|1005048.3.peg.2548 Polymyxin resistance protein PmrJ, predicted deacetylase
MPNLVRLLSKYQARATFLFSLGHDHTGWALKQVFRPGFFQKVSRTSVVEHYGLKTLMYGV
LLPAPDIGKTCANYMQAVRDAGFECGVHTWDHRVWQDHVRQRGADWTSQQMQRSFDRFTQ
IFGQAPNTHGAAGWQMNPYAFEQLEKFGIAYASDGRAMLADDGALADQAAGPHRLQVNGK
TLACIQLPTTLPTLDELLGRSFGGVELTPANIAAHILALTATPRDHVFTLHAELEGQKLA
PIFEQLLQAWKAQGYDLVAMEDYYRQVKDQQLPTVPLAWAELPGRSGEMIMQASSS
>fig|1005048.3.peg.2558 Outer membrane component of tripartite multidrug resistance system
MISAAVLLLAACANFSGIHSTASTNNPDDYASASALPGQGGLWPAGSWVSTIGGSQLQQL
VDEALAGNPNLQAAAARIGAARAMVEAAGATSKPQVGASLSATRERFSENSIYPPPFGGM
YVTDYETALNFSYDLDFWGKHSAQLRSAISQSKAAEAEHYAARLALTAGISKAWLQLGRQ
YAQLDLTNQQLVLRDKLDKLTQQRFAAGLDTQSDNQQSRQQVAGLRAEQAQWQEAIALTR
NQIAALMGQGPDRGLKIAPPALPADAAIALPDQLPLGLLGRRPDVVAARWQVEAAQSDIK
VAKTEFYPDINLSAMAGFSSLSFSQFLNHSSKVVGIGPAIHLPIFEGGALRAQLKGRVAA
YDGAVATYNQALNDAFHEVADSVQSLQAAETQGKNQQAAVDAAERGMKLAEQRQQVGTAN
MLQVVSTQISWLAQRKLELDTRARRADLRVNLIKSLGGGFDASAEGLNPAEASTGTASPQ
ANAAN
>fig|1005048.3.peg.2559 Membrane fusion component of tripartite multidrug resistance system
MTTPNQTPENPSPAAAAPAPAAANGNGKRRSLLIGVTIALIIVLIAYGIWWFIYARHYEN
TDDAYVGGNVVQVTPQVGGTVLAINTDDTELVQAGKPLVELDKADAKVALDQAEAQLAQT
VRQVRTLFVNNNALVSNVTARTSELERARADLARRQQLISTGAVSKEELDHAKVAVQGAE
AALQATREQLASNRVLTDHTTVEQHPNVQNAAAQVRNAYINLARTTLLAPTTGYVAKRSV
QVGQRIAAGTPLLSIVPLNALWVDANFKEVQINNMRIGQPVTLKSDLYGSKIEYHGKVVG
LAAGTGSAFALLPAQNASGNWIKIVQRIPVRISLDAKDLETHPLRIGVSMDATVDIAQTE
GTSLTAGTARTTPAYTTDVFDKSGQEADARIASIIAANNNAAAAH
>fig|1005048.3.peg.2560 Inner membrane component of tripartite multidrug resistance system
MSSPKPAMPARPPSQPLPPLTGGKLVMGTVALSLAVFMNVLDSSIANVSIPAISGDLGVS
PQQGTWVITSFAVANAISVPLTGWLTQRFGQVRLFVTSIILFVLSSILCGLAPSMEVLIA
ARVLQGAVAGPMIPLSQSLLLSSYTPAKSGMALAFWGMTTLVAPVMGPLLGGWISDNYTW
PWIFYINIPVGVFAAWATWSIYHKRESAVYKLPIDKIGLALLVIWVGSLQIMLDKGKELD
WFNSSTIVILGAISLIAFIYFVIWELGDDHPVVDLTLFKGRNFSGGVIAISVGYGLMFGG
LVILPLWLQTTLGYTATLAGEVMAPVGIFAIILSPFIGKILPKVDARWVASTAFLIFAVV
FFLRAQFTENVDTFTLMIPTVIQGAAMAMFFIPLTSIILSGQPPEKMPSAAGLSNFVRIM
FGGMGTSITSTFWDRRTSLHHSQLTEFTGPHSPAFTEAVHNLTAQGMSEPAAWATIERLI
TVKAATQGATDIFWISAVLFLMLIALVWLTKPSRSSVPADAGGAH
>fig|1005048.3.peg.2622 Permease of the drug/metabolite transporter (DMT) superfamily
MTDESKGMWLGLVGVAVFSLTLPFTRMAVAELNPVFVALGRAVVAALCSMLLLWKLKAKL
PTAAQWKPLALTALGVVVGFPVFSSVAMRYVPAAHGAIVLGVLPLATALFGALRFGERPS
AGFWIAAVIGSLIVVVFALSQGGGGLQAADLALLAAVLAAAMGYAEGGRLSQTMGGQQVI
AWALLLSLPVLLPVTVWLGWHYGVSASPRAWLGFAYVSVFSMFIGFLFWYKGLALGGIAR
VGQVQLLQPFLTLLGAALLLGETLQAGNMLFALAVLVVVAFGRKMAVRRQAA
>fig|1005048.3.peg.2845 Permease of the drug/metabolite transporter (DMT) superfamily
MQPTHILLALLTVTIWGMNFVVIKIGLAGLPPLLFSALRFVFAALPLVFFIKRPAIPWRY
LAGFGLFQFALQFSLLFSGMQLGIGAGLASLVIQLQAFFTIGLAVLLLGERPLLTQLLGA
LVALAGIVLVATHLEAQATVIGFLLVIGAGLSWASANIVTKKIGKVNPLALMAWGSLMAA
PPLLLASAVLEGPAAWHVAFAHFGWTSAAAVFYQSYPNTIIGYGIWTILMRKYPAATVAP
FSLLVPLVGMLSAAVLLGESLQWWKIVAGVLVLGGLALNLFGGRLMLALKARA
>fig|1005048.3.peg.2931 Permease of the drug/metabolite transporter (DMT) superfamily
MTISSASRSPNSSAKGLWFADLLLLLVAIVWGTSYGVAKDALVFYPVLGFVAIRFCMTFF
LLLPSLRQLARPEGRAALRAGVPLGLILLAIFICETFGVALTQASNAAFLISLCVVFTPF
VEWLVMAQRPPISAFVVAFVSLLGTWLLTIGSNLTFNLGDGLMLAAALLRAFMMVMTKRL
TVDKDMSNLTLTAVQSGVVGFGCLLVASLFMQGGLPPLPSDPSFWVSTIYLVLFCTIFAF
FAQNYGLRRSNPTRVSLLMGSEPVFGALFASFWLGEKLGALSWVGGALIVGATLWATLPR
SMINFGAFFSTRNIKPENAPIIGAGIDSSQ
>fig|1005048.3.peg.2957 Permease of the drug/metabolite transporter (DMT) superfamily
MDKKVSGTVEMTAAMIISGTIGWFVVVSGQPVLDVVFWRCVFGAATLLAVCAAMGLLRGA
ITLRLLALAALGGVAIVINWLLLFISYSHASISISTAVYNTQPFMLVGLGAVFFSERLTL
NKLTWLAIAFGGMLLIVLAQPGAADGGSNYLAGILMALGAAFFYAVAAIIAKKLAGTPPH
LIALVQVCVGMLMLAPFAHLSALPSDIGTWSILVTVGVVHTGLMYILLYGAIQKLPTYLT
GSLSFIYPIVAIAVDFLAFGHRLQLSQLAGAAAILIAAAGMNLGWSLWKPKVQMQ
>fig|1005048.3.peg.2995 Glyoxalase/bleomycin resistance protein/dioxygenase
MISHVFVGVADFQRAFGFYSAIMEVLELQLKFCDADKPWAAWMASGKARPLFIIGAPYSG
AAAAGNGQMIALLAPTRTAVDKAYAAALRNGGSCEGAPGLRLEYHPDYYGAYFRDADGNK
LCVCCHDAVA
>fig|1005048.3.peg.3142 Permeases of the drug/metabolite transporter (DMT) superfamily
MHSASLPAAAPAHRLLAAMPMVFVLLWSTGFVVAKFGLPYAPPLTFLLLRFAGVLLVLLP
LVLLMRAPWPAGQVRHIALAGILLQGGYLAGVWCAIKLGMPAGVSALIVGMQPILTAFAA
PLIGESVRPRQWLGLLLGICGVGLVVAAKVSLIGLSWQSISLCLLALLSITLGTLYQKRN
CPQFDLRTGTIIQFAASIVVLLPFAIFYEHLGPSLDTVQWTPRFIGALLWSILALSIGAI
FLLFALIRKSAATRVTSLLYLTPPTTALMAWLMFGEVFNLLGMAGMAVAILGVVFVMKK
>fig|1005048.3.peg.3316 Quaternary ammonium compound-resistance protein SugE
MAWIILVLAGIAEVIWAVGLKYSEGFTRNLPSLITCVGMAISIWLLAIAMRTLPLGTAYA
VWTGIGAVGSFIAGIVLLGEAVSLARIASVSLIVLGLIGLKLSTAA
>fig|1005048.3.peg.3330 Glyoxalase/bleomycin resistance protein/dioxygenase
MPAIALNHYNLRAPRALLLQLKEFYCEVIGLQAGARPPFDNFGFWLYAGDQAVLHLSEAR
AGDIRHTDTATTFDHVAFSCVDPEQMEACLQAHALPYQVAFVPTMQQKQIFLRDPAGNGV
ELNFAHLS
>fig|1005048.3.peg.3470 Permease of the drug/metabolite transporter (DMT) superfamily
MRHTKSYAYLALAMMLVGANIGFGKAIIAVMPVLVFGLLRFVIAVVVMAPQFFKAAPRLE
RHEWLTLFGQAFFGTFLFTLCMLYGVQHTTATAAGVITSTLPAAVAILSRLILKERLQPR
TLASILLAIAGIAVLNLSKSDSGDGGQTPLIGNLFVMAAVLCEATYVVLSKRLTQTLSPM
RITAYSHLFGLLLMLPFGLTAALSYDFSQVTPGMWLLVFWYALAASVIAFWLWLTGTKHV
QANVAGIFTALMPLAAAFIGVVFLHESLSWAHFVALALVLTGIAVASWPQSMKTVQEV
>fig|1005048.3.peg.3779 Outer membrane component of tripartite multidrug resistance system
MLLLSACADFSGIDKQSRLTDGNSLSGGATLANLSQTAWPTGAWWQNYRDPQLDTLVQQA
VAGSPSLKIAQARIRQASSLAGVARAATLPKVGAEATSTRGLYSSEYIFPPPLGGSWNWD
NEITVKASYDLDLWDKDRSALESALDTVHVSAAEARSAQLNLEVAVVRGYLQLATQYALR
DIAVTTLAQQTLIASFAQRRLAAGLGTRLEVSQAETALPDARANIEKIDENIALLRNQIA
ALSGQGPGSGEAIQRPQLAARLVGADHSAPLAIGLPDNVPAHLVGRRPDVIAQRWRVEAM
DKNIDVAKAAFYPDINISAFVGLQALGFTNFLSASSAVRGAGPAISLPIFEGGRLRANLG
AQTAALDGAIESYNNTLVQALQSVADQIIRLKSQQQQRAQSEQALALSKQSYDLAMRGYQ
AGLTANINVIQTQLVLLQQQIRVAQIRASYLDSWAQLMQALGGGLGDDLPQPADAVAAEK
>fig|1005048.3.peg.3782 Fusaric acid resistance protein fusE
MKSSSIIKTLLQVAITLIVVLIAFLLVRALWDRYMNTPWTRDGRVRADVISVAADVSGIV
VAVPVVDNSYVHKGDLLMKIDPARYALALAQAEATVAERRIGLSTKQRDAARRAKLDGDV
ISNENRENSSADASAAQAQYQAALAARDSARLNLDRTEIRATVDGWITNLNVHAGDFAQA
GTPKLAVIDANSFWVYGYFEENKLPLMKVGDAVDMRLLGSEQLINGHIDSISRGITDRDN
ALGSYGLANVNPSFNWVRLAQRVPVRIHIDKVPDGITLAAGMTCTVIVKPGEPKPQK
>fig|1005048.3.peg.4401 Multidrug resistance transporter, Bcr/CflA family
MTNTPATSASEKLLPGWLLLLGALTAIGSLSIDMYLPSFPTIAQQFGVGSNLVQLTLASF
LVGLAVGQMFYGPLSDRFGRKPPLYVGMTLYLLGSLACMVSQDVVALILFRFLQGLGGCA
GMVIARAVIRDRLGTTGAARAFSLMMLVMGLAPILAPLIGGSVLKFWGWRVIFGGLAAFG
LFCLLAIHYTMQETLDRHKAEPLHLGRTLKQYGRLLLDRQFVAYSLVGGLIQGGMFAYIT
GSSFVLIELHGIKPEHFGFVFGTNAFGLIAASQINARLVGRYSLDTILGRALWLPALLSL
FIALLVACGVNNLPILLVGFFGYLACYGFISPNASAIALSQQGKQAGTASALMGTLQFTL
GITSGVGMSLWHDGTALPLMVVMATCGVGGLLLHRFVARPEHRRQLQTAAHS
>fig|1005048.3.peg.4452 Permease of the drug/metabolite transporter (DMT) superfamily
MAMSLMLILCLCWGLQQVAIKVAAPNISPILQNGLRSAVAAVLVSGLMWWRGSKFSLTDG
SFWPGLATGLLFAGEFLCVSIGLNYTTASHMSVFVYTAPIFTVLGLHWLVPGERFGLTQW
LGVIAAFAGVTVAFAGGFDAGAGFSRTLVGDALGVLAAVFWAATTIMIKRSVLTNTAPSM
TLWYQLAVAAVTLPLLALVTGQAEVVTPLTGIMWTSLVFQSLIVAFGSFLAWFWMLRRYL
ASRLTVFSFLTPLFGVSFGVLLLDDPIGLPFVFGAVLVLSGIVLVNWQRS
>fig|1005058.3.peg.80 Inner membrane component of tripartite multidrug resistance system
MNQTPIKGGALVMMTLGLALATFMQVLDSTIANVAIPTIAGDLGASSTQGTWVITSFGVA
NAIAIPITGWLARRFGEVKLFLVSVLIFVIASWLCGISHSLNMLIACRIIQGLAAGPIVP
LSQSLLLNNYPPQRRAMALAFWSMTVVVAPICGPILGGWLSDDFHWGWIFFINIPVGILV
ILFTQITLGDRETKTYQQPIDSIGLILLILGVGALQLMLDRGREEDWFNSTEIVVLAIVA
AVGLIALIIWELGEKHPIVDIALFQKRNFTVGCLCTSLAFLIYLGSVVLIPLLLQQVYGY
TATWAGLATAPIGLFPLLLSPIIGRFGHKVDMRLLVTVSFFVYALTFHWRAVTFEPEMDF
AAVALPQFIQGIAVACFFMPLTTITLSGLKPEETASASSLFNFLRTLAGSVGTSLTTFMW
YNREALHHGEMVENITPYNPASQQYFHAMAEKGLNETQTAASLANQITHQGLIIGANEIF
YISAIAFMLLFVIIWLAKPPFGARH
>fig|1005058.3.peg.884 Multiple antibiotic resistance protein MarC
MFDSFLVQFVVLWAVIDPIGSVPVYLTKTIGLSATDRKKIARNAVLIATGILFFFLITGQ
FLLEAMQIPLTAFQVAGGLVLLLFALTMVFSEGKAEQEMRLSSNINELAVYPLAVPSIAS
PGAMMAIVLLTDNHRFSFADQIVTAAIMALVLLITYLLLIAANRIQRLIGTTGAAIISRV
MGLILAAIAVNHILSGIKAFFIEVIPTVT
>fig|1005058.3.peg.1088 Permease of the drug/metabolite transporter (DMT) superfamily
MQNRLTLGIFLALSAAALNSTIGIFSKVLIEQGLTIEAISFIKTIIAFVLVSIVLFRQPQ
KEQQQSICPHYSSTVKLWGQIAFCAFLGVFVMFFFETLAYQYGQAANVVVVLMASAAVSA
LIGGWLLLAEPIVFSAIVGTLIAILGIFIISWSGSGTWQAVVNASLAGIGYGLFSVFIKR
FRLNGGLPLIKMLMFFGAIYLLFPFIQHFETINWSWSIALNLLALAVLPTLLGFYCTTKA
LVYLSAAKVQVTELSEPIFSMCLAWLFLSEIPTLYFFIGAVCIVLGIILINQLYKFAR
>fig|1005058.3.peg.1243 Permease of the drug/metabolite transporter (DMT) superfamily
MQKQKLAIPGILIGCVVFGLGSLIVAHVPVGAYAIAFWRLLIAAIIFFILAKLFKQPFPK
SKQTIRYGLLAGVFLAFDLGFWHESVYAVGPGISTLLNSLQIFFLAAIGFFYFKEKQSIV
QLFSLVLAVIGVYLITGSEFQHNDNALWGFVSGVVSSLLLALSMVYIRKTHEAEPCAIFP
LMLLVSVGGILALIIPSLLFNFDNLYPTTALDWFWVFVYGAVMQCFAWGMIAYSVPLLSL
AVTGLLLLSEPIAALVIDYSVLNKPINLIQWCGAAITMFAIYLGSVSSQPKKSKIRSLKG
QNKG
>fig|1005058.3.peg.1310 Modulator of drug activity B
MKFLLLNGGKAFGHSQGKLNTTLHNTAKETLLALGHEVQETIIDAGYDINQEIEKFLWMD
VVIWQMPGWWMGEPWIVKKYIDEVFTFGHGKLYQSDGRHRVNPTEGYGTGGLLQGRKHML
SLTWNAPIEAFEREGDFFEGKGVDGVYLHFRKANEFIGLSPLPTFICNDVIKNPNVEQHI
TEYKAHLNKLFAK
>fig|1005058.3.peg.1935 Tetracycline resistance protein C
MFLRLSRPHHHDTINILTVCYFKSIMENKNHQQENFKSTYQSLVNSARILFVEKGYQAVS
IDEISGKALVTKGAFYHHFKNKKQLLSACYKQQLIMIDAYITTKTDLTNGWSALESIFEH
YLDYIIDNNKNLIPIQEVMPIIGWNELEKISLEYITGKVNAIVSKLIQENQLKAYDDDVL
KNLLNGWFMHIAIHAKNLKELADKKGQFIAIYRGFLLSLKDK
>fig|1005058.3.peg.2037 Glyoxalase/bleomycin resistance protein/dioxygenase
MSPLIGFHHIALIVSNYEVSKHFYINILGAEVIAETYRQARQSYKLDLRFRDGSQIELFS
FPITPPRPTTPEACGLRHLAFKVDDLQQAIEYLNQHNVECEPVRIDELTGKQFTFFKDPD
GLPLELYQWEN
>fig|1006551.4.peg.91 Multidrug resistance protein A (ErmA)
MSANAESQTPQQPGSKKGKRKGALLLLTLLFIIVAVAYGIYWFLVLRHFEETDDAYVAGN
QVQIMAQVSGSVTKVWADNTDYVQKGDPLVTLDQTDAQQAFEKAQTQLAASVRQTRQQMI
NSKQLQASIDVKKTALSQAQTDLNRRIPLGAANLIGREELQHARDTVASAQAELDVAIQQ
YNANQAIVLGTKLEQQPAVLQAATEVRNAWLALQRTKIVSPISGYVSRRSVQPGAQITTT
TPLMAVVPATNLWIDANFKETQLAHMRIGQPATVISDIYGDDVKYTGKVVGLDMGTGSAF
SLLPAQNATGNWIKVVQRLPVRIELDEKQLAEHPLRIGLSTLVEVNTTDRGGEMLASQVR
SSPVYESNAREIGLEPVNKLINDIIQANAG
>fig|1006551.4.peg.382 Permease of the drug/metabolite transporter (DMT) superfamily
MAFVSRNLMVDLFLTALAPAIWGSTYIVTSQFLPPDRPFIAALLRVLPAGIALLIWSRRF
PLRAEWWKLIVTGILNIGAFQALLFIAAYRLPGGLAAVIGAIQPLLVMLLTWCVDRQRSP
WLAVLSALMGIAGMAMLLLSPQTTLEPLGIAAAFLGAMSMALGTWLSRRWAIALPVIALT
GWQLLVGGIVLAPIALLVDPPLHQVTLTQAAGYLWLCVAGAMLAYGLWFRGISRLSPVAV
SAMSLLSPVTAVLLGWVFLGQKIEGLALVGLVIVLFSVLSIQRALSNKSAVAGR
>fig|1006551.4.peg.389 Inner membrane component of tripartite multidrug resistance system
MTSSRSSVIRKKWPLLALVLAAIVALILVIWQLQTSPETNDAYVYADTIDVVPEVSGRIV
EMPIRDNQRVKKGDLLFRIDPRPYQAMLDDAKARLTTLDAQIMLTQRTIKAQEYNAQSVS
AAVERAKALVKQTTSSRIRLEPLVPQGFASQEDLDQARTAEKAARAELEATLLQAKQASA
AVTGVDAMVAQRAGILAQIALAELHLEFTEVRAPFNGVVVALKTTIGQYASALKPVFTLL
DDDHWYVVANFRETDLKNVRPGVPARITVMTNHSRAFEGVVDSVGTGVLPDGGSVIEGLP
VIQKSINWVHVSQRFPVKIAVKDPDPNLFRMGASASAVLQPQ
>fig|1006551.4.peg.390 Membrane fusion component of tripartite multidrug resistance system
MQSLWPFLTRELRDAPGRANYTLRLTLSCAVLIVLFMTLHIPFLAVALIVVFYVSQPNVL
MIKLVSVVFVVTVSVALGGVLLIIKWTYDYPLIRLVASVILFFCAIYLMRVLGKLGLAFF
VVALAVIYAQTFPSMTSQSEILVRLLLWLWVAINTAILVTLLVNACFQQAFPGYQFKARL
VVMLRQTARRLSQPDDGTPPPTVTEIAGQFNQLRSLYQQAARATPEIAASPQAWQSLMAA
ALSCSHLTALLLPGDDHPDARRRIASQLNALADNLPAAAEVQPLIVPRDGANSAILQEIA
EVLARLARGETIPLPQGEVEKAPLLLPDAWSNPAYLHFALKTLLATLLCYVFYTAADWQG
IHTIMLSCVIVAQPGLGATMQKTWLRIGGALLATLIALLLIVFVQPWTDSLSGLLAMTLP
VFALAAWIAAGSERIAYAGIQIGFTFALAFLSWFGPLSNLTELRDRVIGILLGVLVSSIV
HLYLWPDSEAPQLKARLAQLYRQLAQTLAARDDEVQQVPLFAALTESETLINRVAAEPLG
TYAHPWPEAKSWPARATFRQAEEILRLSEGYRLYAAPEDTFLARCARRLEAYASDIDAQQ
NTVERVQAPQPDPANPFGAPLVNALAALPTWPLASSVIPRQATRS
>fig|1006551.4.peg.391 Outer membrane component of tripartite multidrug resistance system
MTKTTPLPRVWRSLALAFALTQLAGCALIQDDPGQVPLVNPQQAELAKVIHLANSGWPTA
RWWESYQDPQLNMLVNRALQNSPTMQAARLRISQSQSTVELAQSAMGIQATAVAAQNRLR
VTNKQFTWPYSFSLPVDKNGPWYTLNTVGVGATLNIDLWGADRARVAAAIGEKNARQAET
AGIELDLASSVAQLYFAMQATFQKIELLNQLEAIARLSVQAHEHRTARGVEDSVDVANAQ
AELLAAQQQVITAQGTLTQYRETLRALIGADAHSMPEIHPVALPTLQETLPDSLSFELLA
RRPDLQALRGYVSASMSQVDAAKAAFYPHFDIKAFWGYNALSVGDLFKSSFQQINILPGL
YLPLFDGGRLNANLKSTRTASNILIKQYNQAVLDAVRDVAISSSQLNDLNQQAALQQQKV
TAAMVTTRSASAHHQRGLVSYYAAQEARRPAIAQQLLLLDIQAQRLSTDITLIKALGGDY
RGPAQSENAPSR
>fig|1006551.4.peg.406 Glyoxalase/bleomycin resistance protein/dioxygenase
MRELVNTIAHIGYQVSDLTRSLAFYEPLGFQRQQRFSKPSPQGAIEVAFLEMAGAVLELY
QLPEGTPFDAPRCGIDHLALEVSDLDAVQQRLAALGYPLDEGPIEEENVRFLLIRGPDGE
RLEFDAFKR
>fig|1006551.4.peg.747 Permease of the drug/metabolite transporter (DMT) superfamily
MKQQAGIGIILALTTAMCWGALPIAMKQVLEVMEPPTVVFYRFLMASFGLGAILAMKRKL
PPLRIFRKPRWLVLLVIATAGLFGNFILFSSSLQYLSPTASQVIGQLSPVGMMVASVFVL
KEKMRGTQVVGALMLVSGLVMFFNTSLIEIFTRLTDYTWGVIFGVGAATVWVCYGVAQKV
LLRRLASQQILFLLYTLCTISLLPLAKPSQVLALSDWQLACLVFCGLNTLVGYGALAEAM
ARWQAAQVSALITLTPLFTLLFSDLLSLAWPDVFARPLLNLMGYLGAFVVVAGAMYSAVG
HRLWGRWRKREAVVPLPRSGE
>fig|1006551.4.peg.806 Fusaric acid resistance protein fusE
MAIFRAWVYYTASPWTRDARFSADIVAIAPDVSGLISQVNIKDNQLVKKDQVLFVIDQPR
YQKALAEAEADVSYYQTLAQEKRVEAGRRNRLGVQAMSREEIDQANNVLQTVEHQLAKAT
ASRDLAKLDLERTVIRAPADGWVTNLNVYRGEFITRGSTAVALVKQNTFYVMAYLEETKL
EGVRPGFRAEITPLGSVHTLRGTVDSIAAGVTNASSSSDSKGLASIDSNLEWVRLAQRVP
VRIRLDQQQGNLWPAGTTATVVITGKEDRDTRQANFFQKLAMRLREFG
>fig|1006551.4.peg.1012 Polymyxin resistance protein PmrM
MGLIWALFSVGLASGAQLLLRSAMVELPPLTEIFTFLNHLLHLRAGTFGLAFGLMGYLLS
MVCWYFALHQLPLAKAYALLSLSYILVWAAAIWLPGWHEPFHWQSLLGVLLIVAGVLTIF
WPVKRLN
>fig|1006551.4.peg.1013 Polymyxin resistance protein PmrL, sucrose-6 phosphate hydrolase
MSVWICLVFASLLSCAGQLCQKQATRPSKSGRRGYHILGWLGLALLSLGCSMLLWLSVLQ
SIPVSIAYPMLSLNFVWVTLAAWGIWREPVARRHWLGVGLIVVGIVILGSRI
>fig|1006551.4.peg.1015 Polymyxin resistance protein PmrJ, predicted deacetylase
MKQVGLRIDVDTFRGTRDGVPRLLALLSQHGIQASFFFSVGPDNMGRHIWRLIKPKFLWK
MLRSKAASLYGWDILLAGTAWPGRRIGAGNEDVIRAAAQEHEVGLHAWDHYSWQAWSGVW
PQERLTLEVERGLLELERIIGRPVTCSAVAGWRADQRVIKAKEAFDFLYNSDCRGTGPFL
PQLGNGAPGTVQIPVTLPTWDEVVGNAVDSAGFNRYLLDCIHRDAGTPVYTIHAEVEGIA
FAEQFDELLTMAAQEEIRFCPLSQLLPADFSVLPRGKVVRGELAGREGWLGREQLLNSGV
>fig|1006551.4.peg.1017 Polymyxin resistance protein ArnC, glycosyl transferase (EC 2.4.-.-)
MFSYPPVKKVSVVIPVYNEQESLPELIRRTDTACATLGRQYEILLVDDGSSDDSARMLTE
AAEAEGSHVVAVLLNRNYGQHSAIMAGFSHVTGDLIITLDADLQNPPEEIPRLVEKADEG
YDVVGTVRQNRQDTFFRKSASKMINRLIQRTTGKAMGDYGCMLRAYRRHIIDAMLNCHER
STFIPILANTFARRAVEIPVMHAEREFGDSKYSFMRLINLMYDLVTCLTTTPLRLLSLFG
SVIALLGFAFGLMLVVLRLVFGPQWAAEGVFMLFAVLFMFIGAQFVGMGLLGEYIGRIYN
DVRARPRYFIQRVVRQPETASQEEDRS
>fig|1006551.4.peg.1154 Membrane fusion component of tripartite multidrug resistance system
MDLLIILTYVAIAWSIFKIFKIPVNKWTVPTAALGGVFIVSALILLMNYNHPYTFTAQKA
VISIPITPQVTGVVSSVTDKANQRVKKGEVLFTIDPVRYQARVDRLQADLVTALHSINTL
KAQLSEAQANTTRVSAERDRLYKDYQRYLKGSQARVNPFSESDIDNARQNYLAQDAMVKG
SVAEQAQIQSQLDSMINGEQSQVVSLRAQLAEAKYNLDQTTVRAPSDGYITQVLIRPGTY
AASLPLRPVMVFIPQQKRLIVAQFRQNSLLRLEKGDDAEAVFNALPGQVFRGKLVSILPV
VPGGTYQAQGTLQALTVTPGTDGVLATIELEPDAAVDALPDGIYAQVAVYSDHFTHVSVM
RKVLLRMTSWMHYLYLDH
>fig|1006551.4.peg.1247 Permease of the drug/metabolite transporter (DMT) superfamily
MTRQRQADLLLIAATVIAACGWIFSREAIAGMPVFAFLGLRFLFAALLLLPFCRGLRVER
QQWPRMIISGLWFALNLCLWIYSVSTTPSLGEGAFIMSLSMLFVPLTAWVMMKARPARAY
WECLPIAVVGLGLLSLHMPIAFHPSQGWFLLTALVQSIWFCYTSKSAREVPLIPLTTVQL
GITGIVGLGISAAVESWTQPFTLPTFGWLLASIVIATSLRFGLQMKGQKYAAVASAAIIM
VLEPLLTVIAAALWYGEQLPLQKIIGGLLILVAQLWFRWRMLKPLR
>fig|1006551.4.peg.1291 Multidrug resistance protein D
MKRHKNFNLLLMLVLLVAVGQMAQTIYIPAIADMAISLNVREGAVQSVMAAYLLTYGVSQ
LFYGPLSDRVGRRPVILVGMSIFMLATLVAITTHSLPVLIAASAMQGMGTGVGGVMARTL
PRDLYEGAQLRHANSLLNMGILVSPLLAPLIGGILDTLWNWRACFVFLLVLCAGVTFSMA
RWMPETRPTGAPRTRLITNYKTLFGTGAFNCYLLMLIGGLAGIAVFEACSGVLMGAVLGL
SSMSVSILFILPIPAAFFGAWFAGRPNKRFPTLMWQSVICCLLAGVLMWIPGLLGVMTVW
TLLVPAALFFFGAGMLFPLATSGAMEPFPFLAGTAGALVGGLQNIGSGVLAWLSAMMPQT
GQGSLGLLMMLMGLLILLCWLPLASRFHQHQQPV
>fig|1006551.4.peg.1974 Fosfomycin resistance protein FosA
MLSGLNHLTLAVSQLAPSVAFYQQLPGMTLRARWDNGAYFSCGDLWLCLSLDPQRRVISP
EESDYTHYAFSIAEADFALFAGRLNAAGVPVWKTNKSEGASHYFLDPDGHKLELHVGNLA
QRLAACRAKPYKGMVFFGEDEQAAGNP
>fig|1006551.4.peg.2389 Permease of the drug/metabolite transporter (DMT) superfamily
MRIADYLRLLLLAAIWGASFLFMRIAVPQFGAINTAFLRVFFGSTGLAVILFIFKSSFDF
KDKFKSSVMLGVINSGLPFLMYCLAAKWLPAGYSAILNATTPLMGAVIGFAFFAEKLTFR
KWAGMLLGIVGIIAIATIGEPLSAEKQIAVVIACLIATSCYATAGFLTRSWISNKGGLDP
KIVAFGSQIGASFFLLPFFIWSTHSGPTVNWLQQEAWISVIAAGAICTAFAYILYFRLIA
DIGPLRSLTVTFLIPPFGVLWGYMVLNETVNNGFVIGAIIIGIAVWMVVSPEKNN
>fig|1006551.4.peg.2576 Multidrug resistance-like ATP-binding protein mdlB
MRSFTELWPTLKRLLAYGSPWRKPLMIAVAIMWVAAVAEVSGPLLISYFIDNMVAKNSLP
LKLVCGLAAAYIGLQLLAAGLHYCQALLFNRAAVGVVQQLRSDVMDAALRQPLSEFDTQP
VGQLISRVTNDTEVIRDLYVTVVATVLRSAALIGAMLVAMFSLDWRMALVAIAIFPAVLI
VMMIYQRYSTPIVRRVRAWLADINDGFNEVINGMGVIQQFRQQARFGERMREASYAHYLA
RMQTLRLDGFLLRPLLSLFSSLILCGLLMLFGFSSSGTIEVGVLYAFISYLGRLNEPLIE
LTTQQSMLQQAVVAGERVFELMDKPRQAWGEDSEPLRSGAMSIDHVSFAYRDDSLVLQDI
NLDIPSRSFVALVGHTGSGKSTLASLMMGYYPLTQGEIRIDGRPLSSLSHSALRQGIAMV
QQDPVVLADTFYANVTLGRDISEEQVWEALEAVQLAALAREMENGIYTLLGEQGNNLSVG
QKQLLALARVLVDTPQVLILDEATANIDSGTEQAIQQALARVREHTTLVVIAHRLSTIVE
ADTILVLHRGQAVERGSHQQLLAARGRYWQMYQLQLAGEELAASAQEESLIA
>fig|1006551.4.peg.3295 Drug resistance transporter EmrB/QacA subfamily
MLWMQAAIITLGAFATMLSSTMLSAALPAMAAGLGVTDTAIQWIATAYLMALAAGVPLSA
WAARRFGATQLWLYGLILFAIFSAVCALSPHFEVLLAARVMQGLAGGLLVPAGQTILGLV
VGRERLGRVIGTIGVAIVIAPLLGTSLGAVLLESCGWRGLFWITVPFCLCACLAGWKLLP
RPTIKTDRPLSLDWLGLALVFCSLPMLMEGMKELSLNSGKYGRNVIMLSVGALFTCLFIY
RSLRIESPLLHLELFKHRGFTLSAVLMAIGGAVNFGGQFLLPLYFRDVCHVTLAEVGLLL
TPQLIGSAIGFPMAGYFSDKLGPRTVLIIGGLLAAFATLPLAMIDEGSRYTLVGGAIAVR
GFGLALATVPAMAAGLAMAGSRHVADAAPVLNILQRVGAMAGAALVTACYVRFAHTRGSL
AAFHHAGWLLTGGAVLLALCALFMVNHSTLTTQEE
>fig|1006551.4.peg.3310 Permease of the drug/metabolite transporter (DMT) superfamily
MPYLLLTLAALFWGGNYVVGHILVQGADPILMTEARWALTALLLVLLYQRQIRDSRPLFR
QNGATLLVLTLCGQVSFPLTLYIGLQSTSALNAAIYMSATPCMVLMINRLIFHDRVSARN
WWGVIFSTAGVLLLLLHGNLSNAEGLKGFSQGDLWAMGSALSWAVYCSLLRNKDRRIPAN
AFVAVSSLLGALILLPVVIFWLWLHPATSFAAYHDIAFLTGLAYLVIFPSWLAYLFWNKG
IAAIGATRGEIYTHIIPLSGGILSIVFLHTQPHLYHLLSSLLILTGIAICSFAKKAAAYS
>fig|1006551.4.peg.3936 Permease of the drug/metabolite transporter (DMT) superfamily
MNALLYGLVVVIWGTTWIAIFLQQGPVAAPVSIFWRFAVASVAMLTILLVTRRLRPLAAR
DHLFCLLQGCCVFCFNFWCFYTAAAYINTGLESVIFSMAVLFNAINSFLFYRQQPPGRFW
LAAALGLAGIVTLFWDDLWASGLNASLLLGIALSALGTFGFSLGNMLSIRHQRRGLETLT
TNSWAMLYGTLVMGAIALVRGDNFAPQWTLSYMGALLYLAVFGSVIAFGAYFTLVGRIGA
GKAAYSTLLFPLVALTISTFYEGYVWHSSAVAGLALILVGNLVMFARPEQWLLRRRLAWV
RSDRC
>fig|1006551.4.peg.4265 Multiple antibiotic resistance protein MarC
MMDLFKAIGLGLVVILPLANPLTTVALFLGLAGNMNNAERNRQSLMASVYVFAILMVAWY
AGQVVMNTFGISIPGLRIAGGLIVAFIGFRMLFPQQKAHDSMEAKLKSEELEDEPTANIA
FVPLAMPSTAGPGTIAMIISSASTVKHGASFPDWVVLVAPPIIFALVGIILWGCLRSSGA
IMRLVGKGGIEAISRLMGFLLVCMGVQFIINGVLEIISTYHA
>fig|1006551.4.peg.4266 Multiple antibiotic resistance protein marR
MVNQKKDRLLNDYLSPMDITSTQFRVLCSIRCEVCITPVELKTVLSVDPGAMTRMLDRLV
CKGWIERLPNPTDKRGVLVQLTPDGAALCEQCHQVVGQKLHQELTKNLSTDEVATLECLL
KKVLS
>fig|1006551.4.peg.4267 Multiple antibiotic resistance protein MarA
MSRRNNDAITIHSILSWIEDNLESPLSLEKVSERSGYSKWHLQRMFKKETGHSLGQYIRS
RKLTEIAQKLKQSNEPILYLAERYGFESQQTLTRTFKNYFDVPPHQYRITNVPGESRYLL
PLNNCC
>fig|1006551.4.peg.4268 Multiple antibiotic resistance protein MarB
MKLFASAAIVLLALVSSQSYAEQTSTPVRHNNRDAMIIPSEHNDSPFDFNHMASGSDKSD
ELGVPYYNQQSL
>fig|1006551.4.peg.4269 Permease of the drug/metabolite transporter (DMT) superfamily
MIYAADELFGSLILFAKIPITTEAGMTRKDGLLALLVVVVWGLNFVVIKVGLHNMPPLML
AGLRFLLVAFPALLFVARPKIPLSLLLGYGLTISFGQFAFLFCAISLGMPAGLASLVLQA
QAFFTIILGAFIFGERLQGKQLAGIALAIFGVLVLVEASLGGQHVPLVGFMLTLAAALSW
ACGNIFNKKIMSHASRPPIMSLVVWSALIPVLPFMLASWILDGPQVMAESLLHIDLLTIL
SLLYLAFIATIVGYGIWGALLGRYETWRVAPLSLLVPVVGMASAALLLGETLNSLQLLGA
VLIMAGLYINVFGLRIVRPGMARG
>fig|1006551.4.peg.4400 beta-lactam resistance protein
MENVFNRIVELIGWIVLGVSALLLVIAHHIDNYQSPPAVDAVQTKPLSK
>fig|1006551.4.peg.4422 Fusaric acid resistance protein fusE
MKKLKYLSTLLVAALAIIAAWLVWNYYTQSPWTRDGKVRAEQVGVTPQVSGSILQLNVRD
NQLVKAGDVLFRIDDTPYKIALLNARAQLAKAKAEVARAQAEQKKAASDASRRRHLSQNF
ISAEDLENANTALNTATTNLEAAKAVVGVAQATLDHAQWQLTQTEIKAPVDGWVTNLSTR
VGDYAAVGHPVFALVDSRSFYVVGYFEETKLRNIRPGDSAQIILYSSKQKLQGHVSSIGR
AIVDQSVESGGDLVANIKPNIPWVRLAQRVPVRIEFDHLPPDTILVSGTTCTVAIGAQ
>fig|1006551.4.peg.4441 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MQKYFIEARQLLALAIPVILAQVAQTAMGFVDTVMAGGYSATDMAAVAIGTSIWLPAILF
GHGLLLALTPVIAQLNGSGRRERIAHQVRQGFWLAGFVSLLVMVVLWNAGYIISSMHNID
PAMAEKAVGYLRALLWGAPGYLFFQVARNQCEGLAKTKPGMVMGFIGLLVNIPVNYIFIY
GHFGMPELGGIGCGVATASVYWVMFFSMLFWVRRARSMRDIHHTERFSKPDFAVIQRLVQ
LGLPIALALFFEVTLFAVVALLVSPLGIVDVAGHQIALNFSSLMFVLPLSLAAAVTIRVG
FRLGQGSTLEAQTSARTGVGVGVCMAVFTAVFTILMRKQIALLYNDNPEVVTLASQLMLL
AAIYQISDSIQVIGSGILRGYKDTRSIFFITFTAYWVLGLPSGYLLALTDIVVPRMGPAG
FWCGFIIGLTSAAVMMMLRMRFLQRQPSSVILQRAAR
>fig|1006551.4.peg.4656 Albicidin resistance protein
MLIQVGELAKRAGITVRTLHHYEQTGLLTPSARSAAGYRLYNLAAVQRLHMIKALAQAGL
ELATIKDYLDRDAFSLSDLLVKQIATLDRQLQTLSTLRQRLALLREELDCGDEPDLESWL
QTLELMKMYDRWFSQQELQVLPFAEQDAQRNQIWLELVGEAQQLMGERCPADEPRAIALA
TRWMAQLEQDTAGRPEFLTRLNEMHAAEPQMREQTGVTPEMIDFITRAFAESKLAIWARY
LNAEELAFTRQHYFDRLMEWPALVAELHRACREKREPASAEGQQLAQRWLALFQSYAGKD
PHTQQKFRYAMEREPHLMKGTWMTPEVLGWLQQAIGVMMRQAPGPAAG
>fig|1006551.4.peg.4700 Multidrug resistance protein D
MLGRAALVLVTALLMFPQIAETIYSPALTDISARFSVSAPQAALTLSVYFIGFAVGVLLW
GGFSDRYGRRPALLAGLGVYALGCLMALWATDFSLLLAARIVTAAGAATGSVVTQTVLRD
CYRGRQLAGIFSFIGLALAVSPAVGVYIGGGLTALWGMRGVFSALALLAAALLLGCLALM
PETRPQNLRRGPFLHVLRRMVGDTRVALAAILVAAFNVSLFSYYSLAPFLFARFDLDALT
FGYSGMALAAGSLLGALLNHRLLRRNVSLGRILAIACILHLAGGVAVYVLRESIWFVAPV
ALVTLAWAMAIPLVLGSALSAYGDCRGTAGAFFGLFYYVLIGAGLLAAGWGQSLGASLLA
CAGVSMLAGWRYIIVLNEG
>fig|1006551.4.peg.4856 Permease of the drug/metabolite transporter (DMT) superfamily
MSTRQLLPLIGALFALYIIWGSTYFAIAVGVASWPPLMMAGVRFLSAGAVLTAWLLATGH
KLPARKPLLNAALIGVLLLAVGNGFVTLAEHQHVPSGIAAVMVATVPLFTLCFSRFFGIA
TRKLEWLGIAIGLAGIVLLNSGGNLNGNPWGALLILIGSMSWAFGSVYGSRIELPTGMMA
GAIEMLAAGVVLMIASTLTGEKLTQMPSWSGIFAVAYLAIFGSLIAINAYMYLIRNVTPA
VATSYAYVNPVVAVLLGTGFAGESLSAVEWLALGIIIFAVVLVTLGKYLLPARREITSCR
AEK
>fig|1006551.4.peg.5200 MFS family multidrug transport protein, bicyclomycin resistance protein
MTAKQNSSLGIVFILGLLAMLMPLSIDMYLPALPVIAAQFNVPDGSAQMTLSTYILGFAL
GQLLYGPMADSMGRKPVILGGTLVFAAAAVACALSQTIDMLITMRFFHGLAAAAASVVIN
ALMRDIYPKEEFSRMMSFVMLVTTVAPLVAPMVGGAVLVWFSWHAIFWILAVAALLASAM
IAFFISETLPPERRQKFHIRTTLGNFATLFRHKRVLSYMLASGFSFAGMFSFLSAGPFVY
ININHVSPQHFGYYFALNVVFLFVMTMINSRFVRRVGALNMFRAGLWIQFAMAAWMVVCA
LFGVGFWALVFGVAAFIGCVSMVSSNAMAVILDEFPHMAGTASSLAGTFRFGIGAIVGAL
LSMATFTTAWPMLISIAFCASSSILFYLYASRRRKAAR
>fig|1007096.3.peg.517 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MPKSKSYEIDMCNGPVLSKMLLFALPLMCSGILQLLFNAADVIVVGRYAGDNSMAAVGSN
AALINLLTNLFIGLSVGANVLAARYFGAKREVELRATVHTAMLLALCSGVGLILAGMAGA
RQVLIWMQAPPAVLELAALYLRIYFLGMPAMMVYNFGAALLRAKGDTQRPLYFLLLAGVV
NVALNLLLVIVFHLGVAGVAIATVVSQCISAVLVVICLARETGGFRLELKALQIQKEPLK
GILRVGLPAGVQGVIFSLSNVVIQSSINSLGEVVMAGSAAAANIEGFVYAAMNAIYQATL
SFSSQNTGAGQLNRINRILLTGQGLVTVTGAVLSIGVWQAGRLLLGIYTDDPAVVEAGFV
RLGIVCAPYAICGMMDIMVGVLRGIGYSVMPMIVSLMGVCALRLVWIATVFQIPQYHTPE
CVYWSYPVSWVVTLFVHILCYLWAKRRTDLRFAAAMAERKAEKELSLFENTK
>fig|1007096.3.peg.623 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MEGRQEEKYIRMTTEPVGRLICELAVPCIISMLVTSIYNMADTYFVGKLDSNSATGAVGV
VFSLMAVIQAIGFFFGHGSGNYISRKLGEQDGAEARRMSSTGFTLALLAGAVLCVLGEIF
LTPLANLLGATPTILPYARDYMRIILIGAPWMTASLVLNNQLRFQGSAAYGMVGISAGAV
LNIALDPVFIFALKMGVAGAALATVLSQFASFCLLLWQCGRGGNLRPHLKDAQIKRFYCQ
EIARGGLPSLARQGLASLATICLNRSARGYGDTVIAAMAVVTRVMMFGGSALIGFGQGFQ
PVCGFNYGAKLYHRVRQGFWFCVKWGTAFLLVVCALGAVFAPELVALFRNDPEVIRVGAL
AMRCQCVGFALSGWVVISNMTLQTIGDTGPATFLAAARQGVFFIPAVLILPRLFNLWGVI
LAQPVSDILAFAVAVPLMLRALGKMRETGKN
>fig|1007096.3.peg.1015 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MRELRRGLQAAPLSNCHRAPLQSRRENERKRVFMEERSKKLTENKMGVMPVGKLVFNMSL
PIMISMLVQALYNVVDSIFVSRISENALTAVSLAFPMQALMIAVSTGTAVGINALLSRAL
GARDPKRAQSVALNGIFLAGLSVLAFILIGWLVSPVFFRSQTDVAEIVDGGITYLTICSC
VSFGLFFGITFERILQSTGRTLYTMFTQGLGAIINIILDPILIFGLFGLPRMGVAGAAVA
TVIGQICSMCLSLFFCLKKNPEVPLKFKGFRPNGEIIRDIYLIGVPSIIMQAIGSIMVYG
MNRILIPFTTTAATVFGAYFKLQSFIFMPVFGLNNGVIPIVAYNYGAQKKNRIMRAFKVS
LATAACIMVVGTLIFLLVPGWLLALFDASDEMLAIGAPALQIISLSFPMAAVGIVCSGVF
QALGNSVLSMIVSLARQLILLLPAAWLLSLSGNLDMVWWAFPIAEVVSLILTIVFFRWTY
HKHIVPLAGAQS
>fig|1007096.3.peg.1090 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MFSVLRQKPGFYSRLWRLALPIILQNLITTSLGFVDTFMVGLLGNEELSAVTAANTPIFL
VQVIIFGLMSGLTVLVCQYWGKGDAASINRVMGVAMYVGIAISGVAALLLFLFPEGVMAL
VTNNAQLIELGAPYVRIVGVSYVFNAVSSVYVSMQRSTENPGFGMLVFATSMLLNTFLNY
CLIFGNFGAPRLGITGAAAATLASRVVEFIIVLVYAICNKRVPLIPKALFCPGRAMLKSA
AVYAGPVILNETLWGLGTTVMTAIMGHMVISADMLAAYAIMGNIDKFSTVACFGVAGATA
VIVGKRIGERADKEEVYNLSCCLLLVSFLLGAVIALALLIVLPTVFIPYLYPLFSLTEKA
TEVAVTMCVVYIVMMPLKSYDISNITGVLRAGGDARMAAILDLCPLWLVSVPLTALTGLV
LDAPIWLVCFGIYSENTCKMPLGIIRLHSRKWINDVTIHEGE
>fig|1007096.3.peg.1163 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MGQSNQKIDIFERMPVKRAVLKQIAPAIAGQMITLIYSLADTYFVGMLNQSAATAAITVA
FPMFLMLTAISNLFGVGGASAIARALGKKDLEKARQIAGISFWSGLVAGILYSCVFLFLG
EPVLRLCGATERTFAIALGYARWVILIGGPFTILNTLLANLVRAEGSAMHASVGVSMGGI
LNTILDPIFVLPQFLGLGAVGAGVATAISNAAAMAYFICYAVKKKNATVVSLSPKNLRYT
GRHIKEILAVGFPSAVQFALTVVSISVQSKFVSRYATEAVAGLGIVKKLDQLPLYFTMGV
SNGLLPLLAYNYSVGNQERRKQAFHFGCTISLGFSVLCLICYEAFAPLLAGIFIEDPATI
QYASGFLRIMVTAMPMMSLCYPIIVQFQAMGKAKPALVCSVIRKGILDIPISFVMDALIP
LYGLMWVQPIVDTISLAVAGILYRKQNRRG
>fig|1007096.3.peg.1196 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MEQQGADLRSGKVGKLLFSLALPTVTSQIVNMLYNLVDRIYIGHIPGVGRAALTGVGVCL
PIIMLITAFSSLAGAGGAPRASIEEGKGNPEESERIMGNCLTLLLIASVVLTAFFVLFNR
PILLSFGASADTIDYAVAYMRIYALGTIFVQLTLGMNIFITAQGFSKVSMQTVLIGAGLN
TVLDPIFIFALNLGVQGAALATILSQAVSAVWVLRFLMGRKTKWRLKRQYLRPRAKVVLP
CVALGLSPFIMQATESVLAVCFNTSLLKYGGDIAVGAMTVLTSIMQFAMLPLQGLTQGAQ
PIISYNYGARLPQRVREAFRLLLRVCVIYSASLWALVELFPGIFVRMFNSDPELVAYAVP
ALRVYMAMCCIFGIQIACQQTFIALGNAKSSLFLAVLRKIILLIPLIYILPNFFENQAFA
VFLAEPVADTMAVLTTAIMFAVQFKKSMKRLEAPPWEK
>fig|1007096.3.peg.1378 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MTVGSPARHIFLFALPLLLGSFLQQLYNMVDSWVVGNYVGDAALAAVGVGFPVIFMFTSL
FMGIANGGTVVIAQYYGAGKLDRVRDAVDTIYTTFLVSAIPVTILALLLVKPLLFLLRVD
EAAYHEAWVYLMIVCAGLVGTIGYNTNAGILNGIGNSRTTLLFLAVAAGLNIALDLILVL
CAGMGVAGVALGTIISQTFSWLFGLLYINRKYPQIAIHPFCFRFDKTLFRQVLGIGLPAG
FQMSLVSIGVMTVMSKVNTFGTAYTAAYNVGNKLDSMAFLAVQALTNSVTAFVGQNVGAK
KPERVRQGVRMTVTATVVWCLLMTVVLLVWSDRLFHLFSPEAAVAEAGNYYIRAIMPPYA
LFGVMYILNGAMRGAGESVFPMTVTILSMIVLRVPAVYYLANHFGPAYMFYGFGIGWIGG
FVLCVTYYLSGRWKKRGSLADETS
>fig|1007096.3.peg.1426 Vancomycin B-type resistance protein VanW
MNTVEVQEQRKKHSKLPVVLLCVLGALTAGYMGLCAYAANSGAIWRGTEVLGQDLSGLTV
TQAARKLDSTLPKLKIGVYLYDGSLEEAPERADTPDAKIALADLGITADTSALAQSAYQK
NLKGNFLTLGWRYLTNHGVSCSAAGLISLDADKTASAAQAATDSLSYPKEDTSYEVADSA
LMVHMAKDGRSIDSEILAKHLAAGEWDTDLSLDVPYSTETAQTMSAQEIYDQVSGEMKNA
GYDPETRSIIPERTGAEFDVAVAQSTMDSAAPGSTVEISAAIEYPAVTAEELKPVLFRDE
LGSYTTHVGGSAARISNVKLSSAAVNGTVLNSGDIFDYNEVVGQRTSARGYQAAPAYVQG
ETVDEIGGGVCQPSSTLYLATLKSNLEIVERYAHRYVPAYIPKGMDATVSWGGPNYRFRN
NTNYPIKIQAVLSKGYLTMTLYGTKTDDVTVKMTNKVLSTTEYETIYEDDPTLPAGTQTV
KTTPYTGYKVETYRNLYDGNGKLISSSYEAGSDYKVRNKIIVKGPALPSVPTGGTSSEPV
PPETAPGTPPGTTPGTSPETGGVPSTTPVIPEETTTAPSSGETQQPEIDPNAVISPLPAA
>fig|1007096.3.peg.1790 Permease of the drug/metabolite transporter (DMT) superfamily
MQKTSFVRQNILPVLAAFIWGTSFVAQSVGADYVEPFTFNAARSAIAFIFLLALCAVFRF
RRKKDFEAQAKPRPHYRRDLVIGGLCCGAALTLGANLQQKGIETTTSGKAGFITALYIVI
VPILGIFLKKKVGKMVWGSVALAVGGLYCLCIQQGSSIAAGDFYIFLCSLCFSAHILIID
HFTQKVDGMELSCAQFFVAAVLSAVGMLATEQPTWEALRLCVGPLLFVGIFSSGVAYTLQ
ILAQRDSNPTVVSLLLSLESVFATVAGAVVLGDRMSGREYFGCFLMLTAVVLAQIPVKEK
QVAVVEVEEAEEEPLPPET
>fig|1007096.3.peg.2055 Vancomycin B-type resistance protein VanW
MLMQNSERPKKRSAARLRAGKLYYGALRRLLWIKMRNSFASARQEQLLPYTCFAHQTVLL
RKLKDVDMWMQENKIVNLKIAARRVNGILLRPGEIFSYWKLIGRPSRGKGYLPGMILRNG
SFQGGIGGGLCQLSNLIFWMTLHTPLTVLERHRHGYDVFPDSNRTQPFGSGATCFYPYGD
LMIRNDTQDIYQLLIRVGADDLEGEWRISEKPQDRFEIVERNHEFRSEYWGGYTRHNQLY
QQRFNLYGELLDERLAVENSAITMYAPFLSGDVPSTNVKQSNDTEGGYSC
>fig|1007096.3.peg.2064 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MKRLFLYPAFCFWEEKKMDLLYGNVKKVYFNYLSAAFGSALISSIYSTVDMAVVGQYQGP
AGTAALAIVSPIWNIVYSLGLLMGIGGSVLLGAAKGRGDEQQKNEWFTSALIGTIVLAVI
SWGVVALFDTQLLQLFGAEETLLPLAKEYLFPIKFIVPLFLFNQLFTAFLRNDNAPALAT
VAVLSGGIFNVFGDFFFVFTLDMGIFGAGLATAIGALISVLVMLTHFFTRKNTLKLVKPH
GIVGQLKRITVTGISTFFIDAAMGILTMLFNRQIVRYLGTDALAVYGIIVMISTVVQCCA
YSVGQAAQPIISINYGAESWTRIKETLKYALYAVCFFSLTWTALICAIPNGFVRVFMTPS
AEILRIAPFILRSYGISFLLLPLNIFSTYYFQALMKPVPSFAVSVARGLLISGSLILTLP
VVAGANALWYAMPITEAVVAVAVVGLMVKYTKQLAN
>fig|1007096.3.peg.2065 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MNETIYHKPLNFKNLLVFVIPTMLMTVIQSLYSMIDGVFISNLIGTDALSALTLIAPFFS
ILMAIAAMLASGGSAVVMKKMGEGKEQEAKEDFTMLILVNILIGIVLTLGGTAFVSQLSG
SFGASPVVTAYCQSYLSTYIAFIVPELLFSNVLMYVIAAGGSKLAMASSLFGGVFNIAFD
FIFIKLFGFGMMGAALASGLGMMIPCLIIMAYFFNKKRMLHFVRPKFRGCVLTRTLSNGV
SEFFSNLVSGVVMLLFNRSMLHYAGENGVAASTIIFYVFSFMNAVYMGYMLGTSPMFSYF
YGEQNREKLRKLKALSLKLIGALGIATTILTVLSSRQLIGIFTGPDNPAYAMALHGNRLF
SAALLIAGFNTFSSALFTALGNGLISAVISFSRTFVFLAGCILILPVFLGIDGLWLSVPI
AECMALVLSVCFVKKYETKYGY
>fig|1007096.3.peg.2259 Permease of the drug/metabolite transporter (DMT) superfamily
MNATKQTSLGYFFALFTVVVWGTTFVASKQLLAVYTPARIMLMRFVLAYLALWIIRPRPL
KLPWKTELRFLVLGVSGCSLYFLTENTALLYTTAANVSIIVSAAPIFTAILAHFMIDEKF
HRNTLFGFLVAFAGVVLVVCNGAFVLHLSPMGDLLALLAACCWAVYSVLLRRTAADLDPI
LVTRRTMLWGMITAIPMSIPGGAFTLSPLSSPLLAFDLLFLGLIGSALCYVLWAKAFTLL
GVVPTNNCIYLIPFVTIVAAHFTLKEPISAAAILGAGLITAGVVLAQRRKIDDGAPKAEL
SEET
>fig|1007096.3.peg.2912 Ribosome protection-type tetracycline resistance related proteins, group 2
MKKLAIGILAHVDAGKTTLTEGLLYTGGVLRKLGRVDHRDAFLDTFALERERGITIFSKQ
AVLPLDGLELTLLDTPGHADFSSEAERTLRVLDCAVLVVSGADGVQGHTLTLWRLLARYG
VPTFLFVNKMDQPGTDRSALLAELKSRLDGGCVDFSGPDAERGEEIALCGEAAMEEYLAC
GQLKDETIAALVGERKLFPCLFGAALRLGGVEELLDGLRRFAPSPVYGSAFGAMVYKISR
DPQGARLTHLKVTGGTLRVKDLLCGSRDGEDWQEKADQIRVYSGAKFRAVDAAEAGTVCA
VTGLTRTFCGEGLGEEEASAPPMLEPALTCQVLLPDRCDPHTALMQLRQIEEEDPQLHVS
WQERTGAINLQLMGTIQLEILQRLLKERFDLDVAFGPGAIVYRETIAAPVIGIGHFEPLR
HYAEVHLLLEPLERGAGLRFASACSEDVLALGWQRLVLSQLAGRSHPGVLTGSPVTDMKI
TLIAGRAHEKHTEGGDFRQAAWRALRQGLLSAQSVLLEPWYDFRLTLPTAQTGRAMADLQ
RMGGDFAPPETVGEEALFTGSAPASALRDYAAEVTAYTRGRGRLTCAPGGYRPCRNQEAV
VDAAGYDPERDLENPADSVFCAHGAGYNVKWDQVPAHAHVNSGVHLGARPLDEQSPPAAA
RSASYVGTVEQDKELQAIFERTYGPVKRRAFQKPVPASSARPEPAAAPRPAGPEYLLVDG
YNVIFAWDELKTVAAEHLDAARRELCDLMSNYQAFRRCKVIVVFDAYKVKGGIEKVEKYH
NIHVVYTKEAETADAYIERTTYQIGREHRVRVVSSDGAEQIIILGHGALRVSAAGFHEEM
LQTTGEIKKILEKNNLTGKVRPLREALTKALEKGSE
>fig|1007105.3.peg.140 Multidrug resistance ABC transporter ATP-binding and permease protein
MLRWFESLLNSFPPEEAPLPPRGLLPFLWACTRGSRRYLAALALLSASVSIYEAWLFAFL
GQIVDLLATWQAGAPASAHERRVLWTVGIVLVASIGLVALRTMVQHQALAINLPLRLRWD
FHRLMLRQSLSFFSDEFAGRVTTKVMQTALAVREVLFTFIEIVLGIGVYFVTIVALAGGF
DARLTLPFIGWIILFGLAMAYFVPRLGKVGQEQAHARSSMTGRVTDAYTNITTVKLFSHT
KREAHFARAAMEDFKDTGFRQMRLVSRFEIVNQALVAALIFSVGGYALWLWHSEQVGAGA
VAAVTAMALRVNGMSHWIMWQMASLFESIGTVQDGIATLSRGAKVQDAPGAPALRVMRGE
VEFDHVFFNYNGERQVLDGLSLTVRPGEKIGLVGRSGAGKSTLINLLLRFYDLDSGRIRI
DGQDIAQVTQESLRGAIGMVTQDTSLLHRSIHDNIAYGRPDASDAEIRAAAVHAQADDFI
QQLSDPQGRNGYDTTVGERGVKLSGGQRQRVAIARVMLKNAPILLLDEATSALDSEVEVA
IQESLNAMMEGKTVIAIAHRLSTIAAMDRLVVMDQGRIIEQGTHAELLAQNGTYARLWRH
QSGGFLAEETSELA
>fig|1007105.3.peg.147 Outer membrane component of tripartite multidrug resistance system
MIERLSLRFTSLAMALLLAGCAVGPDYQRPDVDVPNAFKEASLSPEAAKQWKMAQPADAL
ARGRWWAIFNDPILDGLEDQAMSANQDLKVAAARVKQARALRQNAEAGLLPSLDAGFGPT
RQRQSSAAQGLPEDTGSSAQTLWRAQAGISYEADLFGRIASDVDAATADAEQSAALFQSV
RLALQADVAQAYFRIRRLDAEQDLYRRTVDLRGKTLELVQQRYDEGEISELDLARAKSAL
SSASSQALGIKRERAVAEHALATLLGKTPAQFALAPEPLGRVSVDIPAGLPSSLLERRPD
IAAAERAMAAANARVGVAKAAFFPRLTLTGAFGYESSELGNLLEWSSRTFLLGPLVGTML
TLPIFDGGRREAGLERARALYEEDVAAYRQTVLSAFREVEDGLSSLRILKDQTQVQDAAV
QQASRAAELSQIQYREGSVSYLDVIDADRQVLVQQRASLALDGERAQTAVALIRAIGGGW
DIDRQLASR
>fig|1007105.3.peg.452 Permease of the drug/metabolite transporter (DMT) superfamily
MFAGMGACVKVAADYGASLPHVVLFRGIPSVLLLFIWTQLTHRSLVPNSWKLHIWRNLSG
VSSMWLGFFAISHLPLPTAISLNYTAPLFIACWMLGWGGTQRDPVRIVAVALGFLGVLAV
LRPSIAHEHLLAAALGLGAGALSAIAMMQIRSLGRVGEPEWRTVFIFSCFVCFTGSAGLL
VDGWRDISLSAWLALTGVGVFGLVGQLAMTRAFGMGSALLTAALQYTTIIFAALLGIIFW
DDVPDAIAWAGMGLIIASGLLSIWRTYTEDRIMRGQTVVQMQAATVDTAIEETRRV
>fig|1007105.3.peg.519 Outer membrane component of tripartite multidrug resistance system
MKSLLPIVFVAVLSGCAAIKPGEPAVVKTDAVRLGLQDSAIAWPTEQWWQRYGDPQLNQL
LGQALAGSPSLDAAQARLNLANAAVSSARAVRLPQANAGYQLTRERFSENYIYPPPYGGS
MQTDNSLRLDIGFDLDLWGRNRSHYAAAVSRQRAAEADAQMARNTLVSAVVQSYFNLQNA
LAQQQVLGQLVTQLENVLDITRQRVTAGLDTEVETNQADSAVSAARVQLSQAATNADLLR
HQIAALLGAGPQRGQEIQRAKLTQTPRGVPDSIPLSLLGRRPDIVAARLRVKASDSDISA
AKAEFYPNVNLSAFAGFMSLGLSNLLEGGSQTYGVGPAITLPIFHGGALNAQLDARQAER
DLAIADYNQTLLTAVREVADATSAIQALQQQTLDQAASLRAITSAYKIAVNRYKSGLGNF
VQVLQAQNEVQKQAILNTDMQTRAYKLDAQLATALGGGYDSPTATH
>fig|1007105.3.peg.817 Permease of the drug/metabolite transporter (DMT) superfamily
MGDNTGPPLFEFSMSFSSNQLKAYGCLALSMSLVGAYVALTKPLALVLPVFLLGWMRFGI
GAIAMLRWIRKPASEPTLSVQTRWLIFLESFLGNFLFTLCMIVGVSMTSAVSAGVIMSSI
PATVAVLSRVFLKEAISARVWAAIACGVLGIGLLSLTQTPGTGNALDLPGGDSSRQWLGN
LLIFGAVLCEGSYAVIGKKLTAVLGPKRISAVINLWGFVLMTPMGLYTALQFDFTAVDPS
MWLLLLFYGLAASVWTVWLWMVGLKSVPASQAGVFTVMLPISAALVGVLVLGENLGGMQL
LAFAIALAGLLLATLPSRGMKASH
>fig|1007105.3.peg.1609 Multidrug resistance protein
MISTAKPAGLWQQAREILRQAWPVLISSWASIIFGVMDTAMAGHASAADLQVMALAASIY
ITVFVGLMGVVHALIPIIAQHFGGQRYIEVGRTWGQGVWLALGLSLVGAAAMLFPGMWLS
LSGGVEPVVRDGITWYLRALVLALPATLVFRTIYALGTAVSRPKTVMVINLLSVGFKFFF
NWILIFGKFGMPALGAVGAGLSTAIVGWMTLLAGLWAIRHDPYYLRFKPAVGRPHWPSQK
ELLRLGIPMGGSYLIEVCAFTFMALLIAREGMFVTGGHQIMSNLAALSYMMPMAVGIATA
SLTAQAIGAGDLQRARLTGRAGIGIVLLGATVTATVLVVAKQPILRLYTDDMQVAIVAGA
LLQLLPWFHLFDATQCIGSYLLRAYKVAVVPLILQIVALTGLGLIGGWWLGFGPAADTLK
PVVTRIAPGAPMGAASMWLMALAGLALSASLLFAWYGHVVRSHMRAGRV
>fig|1007105.3.peg.1615 Multidrug resistance transporter, Bcr/CflA family
MHQMPPQQNTLTTIPSWLILMGLLTAIGPLAIDMYLPAFPAIAQGLGATHGDVERTLASY
LLGLALAQLFYGPLADRYGRKKPLMLGLAIYTVAAIACGYTNDIEHLGFWRVVQAFGGAA
GIVIPRAVIRDNFDTRDASKALSLLMLVMGVTPILAPILGGQVLVFASWRGIFAIMAACS
ALLLAAVALTMRETLQPEKVIPLGARVIARNYLALLGHKRFMCYTLAGGFGAAGMFSYIA
GSPRIFIDIYQVDPRYFGLLFGLNAAALIIAAQVSARLLSRHTPEKLLRPAQIILAGVTL
VAVALTLANAINLLSLMVCLMIFMASQGFVNPNSAALSLREQGHRLGAASAMMGALQMLC
GAGAGLAVSSWQSPTALPLTAILAFCACLSWFFGRMALRTAAKPLD
>fig|1007105.3.peg.2137 Multidrug resistance protein B
MPAESTVSPASTPLTPKDIRSIIIGLMLAILLGALDSTIISVALPKMAADLQGINLLAWV
MSGYLIAMAVATPIYGKLGDIYGRRSVLSSAIVLFLVASVACAMAPTMPVLVAARILQGL
GGGGLISVAQATIADVVSPRDRGRYQAYISGAFAVASVSGPVLGGVLTAYLSWRWVFWIN
LPLGLIALLISRRALAKLHVPQHKRSVDYLGAALLSLGLTAILLAITRAGQQNVPGLDHN
SLWMIVIAVVSLAAFGWHALRVPEPIVPLGLFRIRTVSICCLILFIAFVELVALTVLVPL
ELQMLTSVGADGAAWRLIPLSLGVPLGAYISGRLMTHWGTYKHIQLTGALLMPIAIFLLA
FADPASTFTMAVLLSLIGFSIGLQLPTSTVAVQNAVPHRHVGVATAASAFCRSLGSAIGI
ALLTAFLLIWLRAGAGAIGNGMNGADIINTLIGHSHTSIQDIDLSGLAPIARLSFQKVYM
LAAAIATVSILLSALLKNESLSEKPAAKSSKE
>fig|1007105.3.peg.2658 Polymyxin resistance protein ArnC, glycosyl transferase (EC 2.4.-.-)
MNALVENWRLDADHDSHVELSVVVPLYNEHEVITMMYQRLTTVLSGLAISYELVLVDDGS
HDGTPNVINLLAKSDPNVTAVFLSRNFGKEAALTAGIEHAAGAAVIIIDADLQDPPELIP
QMLAAWKDGVDVVCMRRRSRAGETWLKRCSAHHFYRLLNAISDVDIPPDAGDFRLLSRKA
VYALQQLNERNRYMKGLFAWIGLPTAIIEYDRMPRAAGATKWDYLGLLNLAFQGITSFST
APLRFAMGSGLLTALFGVLFTLWIVIKALVLGDPVQGYPSLISMITILGGVQLLSIGLLG
EYLGKTYYEAKQRPVYLVRDVMRRGKPVQEMATDKGRSSKVKEAYASFK
>fig|1007105.3.peg.3048 Permease of the drug/metabolite transporter (DMT) superfamily
MTSNAHEAGGDREASLAIRISLLTCLSMLAFAGNSILCRLALMERHIDPLSFTALRLASG
TLVLYALVYLSSHRAAARQTTPVRQSGSWAGAIALVLYAVAFSLAYVNMESGVGALILFG
SVQLSMLLYGMIKGERLGALSMVGLLASIAGLVFLLLPGSSAPPLAAAALMAIAGAAWGW
YSILGKGATNPLASTASNFGRAVPLSLLAALPLLATLHWDARGLSYAILSGTVTSGLGYV
VWYGVMKQLSVLKASTVQLSVPILTAVMGAALLGEALTLQLILSCILVLGGIGLVLVSKG
RSQA
>fig|1007105.3.peg.3142 Polymyxin resistance protein ArnC, glycosyl transferase (EC 2.4.-.-)
MTMKLSIVVPVYKSQSILPELVEQIKTSFEEQGLAGQFELILVNDCSPDHSWQVIGQLAK
INPFIRGISLRKNFGQHSATMAGLNHARGEVVIIMDDDLQHPPSEITNLMAAINNGADAC
YTRYIERQHALWKKIGSRFNDWVATVLLDKPQGLYLSSFKALSRELVQEVIKYDGPYAYL
DGLILEVTRSIAVVDIKHQARHDGEGNYNLRRSISLWLRMATSFSVFPLRVATFFGFCLA
AVSLIFVAVVIVQKLLDPSIAMGWTSLMATVLFVGGVQTFCVGLLGEYLGRTYLRINGKP
QFVVRETTWADKS
>fig|1007105.3.peg.3606 Permease of the drug/metabolite transporter (DMT) superfamily
MPTSQGTPLWLAAAPALFLLLWSFGFIFLKLGLAYADPFTFLALRYACVVAILAIPCLWL
RPPLPATPQVWMHLSIVGLLVQAGYFSFAYLSLKQGVSAGALAIITAQQPLLVGLLAPAI
ASERVGAIRWAGLLMGVVGAGIVIFAKSAVEVASTAGLLYGVLALLCMTGGTLWEKRYGT
EVHPISANMIQYTVGLAVAAPLAFLLEPMQVQWTIGLFASLAYLVVGNSIIAISLLLAMV
RRGEASRVSALFCLVPPTTALLAFPILGEAIPVLAWPGMVLAVAGIYLVMRKS
>fig|101510.15.peg.507 Glyoxalase/bleomycin resistance protein/dioxygenase
MEFTMSDLQHTVKGVDHVAYPTFDPAATVTFYRDVLGFPVVHSICAAGWGPEKHPDFIHF
FFDIGNDDRLAFFYYFGLEPFDGGPQGDSYSRFAEDVPIFFIRSRHLAIHVDSEDDLMEY
RRRLDHSAWPVEMQIQHETIESIYTHDPNGYMIEITRALRPVTPQEDLDANLTIDALVDV
VTGPDPSMAALLTRKAELITERAAAWHQEQESKEMVTR
>fig|101510.15.peg.1069 Glyoxalase/bleomycin resistance protein/dioxygenase
MADATIGSILLASTHPDRLRDWYTAAFSPKVERTPGEPGYDVLDFDGFYIMLDRRDDVGD
TNPEPGRILLNVEVTDARAAADRIDELGATWLSPLEDRDGSWFGTAVDPDGNYVQIIQLS
AQARAEMS
>fig|101510.15.peg.1550 Drug resistance transporter, Bcr-CflA family protein
MPSLLCCFMTETEERAAPTADRTTTRPSLRVILVLGAMVALGPFTIDMYLPALPDIGTDL
GASSSAVQLTITGTLLGLALGQLIVGPLADSLGRRRPLIAGIGVHVVASVLAVFAPTVAV
LGVLRVFQGIGAAAAAVVALAVVRDLFSGNTVAVVMSRLMLVLGVAPVLAPSIGGALLIA
VDWRGIFVVLAVIGTLTALIGVWGLTETLPPERRRKSNLRAVLSTYKSLLGDRAFMVLAL
VSSVAMGSLFSYVSGASFVFQDQYGLDEQQFALLFSSGAIALIGASQLNVRALARWSPLQ
ITVSALAFATVAGLALVTTAHFEFGGLVGFVVPLWFLLAGVGFVLPNAPALALGRHGEAA
GTAAALLGALQFGVGALIAPLVGVLGNTGVALAITMTACAGLGLVALAAAAKAEAH
>fig|101510.15.peg.1790 Glyoxalase/bleomycin resistance protein/dioxygenase
MSSFPGLTHVAITVSDLPASTAWYTALFESAPVLDEDEESGTFHHTVFALDGGMLFGLHT
HPDSGAPARFDERQVGLDHIAFQCSPDALPRWVERLDALGIEHGGIKTAHYGSGISFRDP
DNIALEFFAPPVSTS
>fig|101510.15.peg.1969 Multidrug resistance protein B
MTSPTAANAAPDKLDGTVLKIASVVVLGAIMSILDVTVVSVALPTFATEFDTTYATVAWT
MTAYTLALATVIPVTGWAADRFGTKRLYMTALVLFVLGSVLCSFAWDITSLIGFRVLQGL
GGGMLMPLGMTIMTKAAGPDRVGRVMAVLGIPMLLGPIGGPILGGWLIEAASWHWIFLIN
LPIGIIALAAAFIILPSDNASPSESFDFLGMLLLSPGLALFLFGVSSIPEVGTVASARVL
VPGAIGLALIVAFVVHALRKDHPLIDLHLFKNRQLSVAVITTSLFIVAFMGAGLLFPSYF
IQVGGHTTLAAGLLMAPQGIGAMLTMPVAGRLVDKIGPGKIVLTGLPLILIGLGVFTQVA
SDSPTWLLMGALFVMGMGMGCTMMPLMTAAIVTLSNEQVARGSTLMNIVQQTAGSIGTAV
MSVVLTNQLLDRGLDSQTVAMQHVPEVAAQEPPGMVDQVLSQAADAFGNTFLVATVLIAL
TLIPAFLLPRKKSVNPKLEAEGAPTVMMH
>fig|101510.15.peg.2208 Probable ABC multidrug resistance transporter, ATP-binding component
MDNLTFNVKPGMVTGFLGPNGAGKSTTMRMILGLDRPTAGSALIDGKPYSDLVQPLRTVG
ALLDAKWVHPNRSARAHLQWMAASNSLPKSRVDEVLHLVGLTEVAGKKAGGFSLGMSQRL
GLAATLLGDPKVLLFDEPVNGLDPEGIVWIRKFMQRLAAEGRTVLVSSHLLSEMALTAEH
LVVIGRGRLIADTTVSEFVSKSSESTVRVRSPQLDALRSALTSNGLTVREDGSDGQQALV
VVDSSTDVVGGIAGSQGIVLHELASQRGSLEDAFMKLTGDDVQYHAEGVEDVMRGAL
>fig|101510.15.peg.2629 Probable ABC drug resistance transporter, permease component
MISAPAHTLAEPAPADLRFHPLRDSATMLRRNLDHMLRYPSMTVTLVGMPVVFLLLFVYV
FGGTLGAGLGGVSGGRAEYVNYVVPAIILMTVTAAVQGTAISVAMDMTEGIIARFRTMHI
ARVSVLTGHVLGSVIQAMLSVAIVIGVALLVGFRPTAGVGAWLATAGFLVVVTFALVWLS
VALGQVSKTVEAASNVGMPLVLLPFLGSGFVPTDSMPAGLRWFAEYQPFTPIIETLRGLL
MGTPIGNNAWIALGWCAVIALGGYLWSKRLFNREYSR
>fig|101510.15.peg.3920 Glyoxalase/bleomycin resistance protein/dioxygenase
MGTTDEQERSQRFAEQRDRIRAEHLKPVAARPASSARGLHHTALISSDVERTVRFYQDLL
EFPLTELIENRDYAGSSHFFFDIGNGNLLAFFDFPGLDVGPYQEVLGGLHHIAISVEPDR
WEHLRTKLIDASVELVEHSEVSMYFRDPDGARLELIADPLGEMYGSHVL
>fig|101510.15.peg.4177 Glyoxalase/bleomycin resistance protein/dioxygenase
MLRGLITVSLFADDIPAAREWYCALLGITPYFERPDSENPAYIEYRIGDYQHELGIIDRR
YAPHGAADGPSGVVVFWHVDDVTAAVEKLLTMGAKEHEPRTERESGFVTASVVDPFGNIL
GVMYNPHYLDVLGSRGEA
>fig|101510.15.peg.4385 Drug-export protein
MNTAVGQAQSATAGDELGPGTSPALAALLAGTFVGTVSNNIVNVPLNAILTDFDAGLGSG
IFVVVGFLLTFAATMPLAGWIGDRFGRRRVYCAALLGTAVCSLGAALAPSLPVLVIWRSL
GGIAAAAFAPAVMGLIAWLFGPPRRARAVGAWAAVNGIGQAVGPSMGGIVSDWWGWRWAF
VPLVPVALIGFAATLRYIPRYPGKKMRLDVIGASTVTLGAVLLILGLTTVSMEQVPAWVS
IATIGGGVVVTAGFVLHCRRAANPFVPIDLVIESRFLRSALAAFTQMFALGALLLALPLY
LTGSGSSTTQAGLMLFVLPVVMTCVAPVVGRLVDRIGARVVMRTGLAVLISSQVALAITL
SADVRNPVAVGAVLLVAGVGIGMVQTPAAAGSTRSPAGAVGTGLGLFNLIRFGGSAVGAA
WVGVAAHLSADPYGLLFAVAALVVLAGLAGTFAGENPVAG
>fig|101510.15.peg.4565 Glyoxalase/bleomycin resistance protein/dioxygenase
MTGRIVHFEIPFDDGDRARAFYRDAFGWAIAEIPDMDYSMVTTGPVGESGMPDEPGYING
GMMQRGEVTTPVVTVDVESIESALERIESLGGKTVTGRTPVGNMGFAAYFTDSEGNVVGL
WETAR
>fig|101510.15.peg.4781 Quaternary ammonium compound-resistance protein SugE
MLSGILEAVWATALGRSEGFTKLGPSAVFGVALILSMAGLAFAMRSLPIGTSYAVWVGIG
AALTVGFAMVTGAESSSLVKILLILGIVGCVVGLKVLH
>fig|101510.15.peg.4836 ABC-type drug export system, ATP-binding protein
MMFRRAQTAARLRPAGGALELSHVTYSFGDYAAVKDLSLVIEAGECFGLLGPNGAGKTTT
IRLLNTLLPLQGGDVSIFGYDVRTQAMAVRRLLGYVPQQLSIEGALTARENVSWFARLYD
VPRPERRRRVDEVLEMVDLADVADRVASSFSGGMVRRLELAQALVNRPSLLVLDEPTVGL
DPVARDSVWTRVTEMQKQYGMTVLLTTHYMEEAEALCDRVALMHRGELRAVGSPSGLVAE
LGPDSTLDDVFRHFTGDSLTADEKGGLRDVRSARRTARRMG
>fig|101510.15.peg.5248 Vancomycin B-type resistance protein VanW
MNDEDGDKGSKAPERSTPDPSATAESVEPENVADPPAPEPDEVPAPDEAAAPENAPASDE
APAPDAPAEQPNADDAPTTQLNLGDLGERSEEQAPDAPLWVEPPANEDVTQVIPAIPPGP
VPGPTQAYTTPADEPTVVAPAAAAQIPPQPAPEPSAPAEPSAEPTKPARAPWVKIAAVTG
GVIALIGIAYAADLAVSSGKVPRGVTVAGVDVGGSSREEAEAILQAQVGPRADQPLTVTA
GDVSTQLVPSAAGLGVDWEATLDRADSQPLNPFTRLTSFFTTDEIGVVSTRNEAALASAV
DGLRTETDRASREGTVVFEGPTPVPVDPSTGQNLNGEGAEAALTEEWAFGRTVELPVDVV
PVTVTKEGVQRALAEVAVPAASADLVVTGRDGKVATAARQQIGAIVGFEPDGNGGLKPTY
NIEAAIGILAPQLVSTEIAPKDATITLDGGSPTVVPAVVGDLVQWPKTLETLPELLRGNG
SHTTAAVYGPVPPALTTEAAQALGVKEVIGEFTTGGFSAASGTNIRLAASEINGALVKPG
DTFSLNGYTGPRGTAQGYVESGIINNGRPDTAVGGGVSQVATTLYNAAYFAGMEDVAHTE
HSYYISRYPEAREATVFEGAIDLQFRNTGKTGVMIQAIGGASDLTIRFWGTKTVDVESIT
GNRTKPTEPDTVTLPAGDHCIASSGAPGFTASDTRVISDHATGQEISRDTRTVRYDPVPI
VKCEAPAPAPKPDERTPAASPAPSESPKPTTPKPNPNDGE
>fig|101510.15.peg.5259 Glyoxalase/bleomycin resistance protein/dioxygenase
MPDRPSLTGAPCWIDLTSSDPRQVIPFYTGLFGWRSDTNEDPQYGGYSIFSMNGKPIAGL
GPQQQGNPYGNVWTTYIASEDAEATAAKAAEAGGQVMMPAMVVGDQGTMAILGDPAGAVI
GVWQADQHGGFGLVDEPGAPVWHETLSRNYAAALPFYADVFGWTFRTLGDTDEFRYSQAN
LGDRTVAGVMDADSFLPEGVPSFWQFYIGVEDTDAAVAKVTELGGTVRRAPEDTPFGRLA
SVADPLGATFQITTLQS
>fig|101510.15.peg.5300 Probable drug/metabolite transporter, permease component
MTRNSTHVGATMALTSMLCVQSGLAISVGVSERVGAEGAAWLRLAWAGVLLAVIVRPRPK
AFTRSSLGACVLLGVVTAAVTLLFMAAVDRIPLGTASALEFLGPLGVAVLHGRGRLKWPA
LAAVGVLLLTQPWAGGVDPVGILFALGAAACWALYIVLTQRVGDEVAGLNGLAVSMPVAG
LVATAVGGPSMLGKMTPDLLMIGLGLAILLPVVPFTLEMLALRRLNTAAFGTLMSLEPAL
ALIIGLVVLHQIPDHAAVAGICFVVAAGIGAARAGARTTPDQGDVTESAAPLSAPT
>fig|101510.15.peg.5597 Glyoxalase/bleomycin resistance protein/dioxygenase
MSFQGELVSFVASTDLDVSEMFYVETLGLTLVSRDEFALALDCNGSLLRVTLVQAKADTG
YTVLGWKVGDLNKVVETLRSKGIEFTEYPGMDQDEHAAWRAPDGIRVAWFRDPHGNVLSL
FEDPN
>fig|101510.15.peg.5918 Multidrug resistance protein B
MPTVAAALSAGPAAQTWILSSMSVGLAAVLLTAGALADDYGRRRVFHWGAWLLALGAVVG
AVSQEPVLFIVGRLIQGVAGAALIAASLGAVAHAFTTPAARATASGIWGASVGAGIAVGP
VVAGLLDLAGWWRGLYWALAVASLVIGQVATRALAESRSAVPKRIDVPGAVTLCAAMVLV
LVALVEGRQGNIAATVLCGVGAAVFTLVFVAVERRRPFPMLDLTLFRRRDFLAATLAALA
TGAGIIGLMSFACTFLVKTMHVSTLAAAGVIALWSGTSVVASLLARTLPARLAGSPQLVI
GLAGVGLAMLTMTGLTPDSSLLRLVPGLLLAGVASGLLNAGLGRQAVASVPADQGGLGSG
ANNTARYLGSSIGVTVVSIIALDPAGTVDGMMLGWNSAAVTTGLISLVGAGVVGVLVRGT
AVRR
>fig|101510.15.peg.6259 Glyoxalase/bleomycin resistance protein/dioxygenase
MTISFNHTIVAAKNKQESATFFTTLFGLPDAVPAGHFLAVALDNGVSLDFAEPPVEFPPQ
HYAFLVGEDDFDRIYGLIVEWGLDHWADPRQTLPGTINTNDGGRGVYFLDPSGHYLEIIT
RPYGSGG
>fig|101510.15.peg.6691 Drug resistance transporter EmrB/QacA subfamily
MATLDNLVMTSALPVIQRDLGASVGQLQWFMNAYTLAFATLMLTLSALGDRLGRRRVFLW
GIVLFALASIASALSTTSEMLIAARAVQGVGAAAIMPLSLTLLAGAVPLAKRALAIGIWG
GVSGLGVALGPVVGGAVVDGVSWQAVFWINVPVAAVAIPLALYALGESKGKRQPLDPLGV
VLAGAAVFLGVWGIVHGNDDGWTSATVLGALVAAAVLLAAFVVRELRTPFPVMPLRLFRS
RQFSLANVIGLTFTLGMMGAVFLLSQYLQIVMGYSPFEAGLRTLPWTAAPMLVAPIAGLL
APRLGVRTLLVTGLVLQGLSLLWMASLIVPGATYGSMVPAFVMAGAGMGLTFAPNATAVL
ADMPEADHGTASSTNATLREIGVALGIALLTAVFLGAGGSLTPTGYIDALAPALYVGAGF
VAVAVVAAALMPGRSKAVLAST
>fig|101510.15.peg.7091 Daunorubicin resistance ABC transporter ATPase subunit
MNAPTVVVEDLHVAYNKTWALDGVDLEAAAGTTLGVLGHNGAGKTTLIRTLTTLVRPTIG
RVQIEGLDVVVHATEVRRRIGVTGQYAGLDEFLTARENLELIGRLTGLRRTARERADALI
DRLGLQEYASRRVGELSGGSRRRVDLAASLVGSPSVLFLDEPTTGLDPLARAGLWDVVDE
LTDAGTTVVLTTQYLEEADRLADHIVVLRRGRVAARGTPAELKRIVGGKVLSATIPAGQL
AALPFVPDTDPRVDGDRLRVSVTVGDAPAATALVADLHRGGIEVTDLDVTSPSLDDVFTH
LAHTGAHK
>fig|101510.15.peg.7139 Drug resistance transporter EmrB/QacA subfamily
MTEPTGLVNDEARADDRIERRHLQVIGVLLVASFVVILNETVMSIAIPVLQVELGVHPSV
GQWLTTAFMLTMAVIIPLTGYLIQRIPTRTLFVLAMSLFTAGTLIAFAAPGFGVLLFARI
VQASGTALMLPLLMTTIMTLVPPARRGAMMGNISIVIAVAPALGPTLSGFILDHFGWRWI
FGFVAPIALATLVLGARFVVSVSETTKAGIDILSIPLAVLGFGGLVYGLVSIGESAQKSP
TIPVWVPFLIGAAAMSGFLARQFRLQREDRALLDLRVFGYRQFSISVVAMLVGMATMMGT
FIIVPYFAQSVIHLDPFETGLITLPGGLLMGLAGPIVGRVYDRRGPLVLVIPGSILVSIG
VWMLTTLNTSTSLWWLLLSNMALCLGLAATFTPLMTSGLGSVAAHLYAHGSAVVGTFQQV
AGAAGTALFVTVMTVIASRSGHPHDSPDAIAEGVRMVFVVAGILSFVLIAACAFVRKPAD
PVEHAHPASVDAPALGT
>fig|101510.15.peg.7580 Major facilitator superfamily multidrug resistance protein
MSINEAPSEDGCPEGQTDGRIHGVRRQIAIVAVILLLCELNAMAVAMLVPGLRPMAAEFP
VEGLAWTITIVSLVGAMVMPLGGKLVDRFGQRPVVLTACAVFLVGSLISALSSSFALMIV
GRALQGTIAVMPVIAYRVFRDSLPPRVVPIALGALGTGFGVSGLLAPVIGGAFVDGLGYR
SIFWFFFAFTAVLAPLSVIVLPRTPRQRSAEVGRVDILGGLLLALGIGGILLGLGQGDKW
GWLAPLTLLVILGGFIALGMFVLVESRVEEPMIDLRVLRNPAVALTLTVGLVGFMACGMM
AIALPQMLQTPSSTGMMYAFGLSALMVGLAQIPFGITSMVFGPLGGLLTKRFNPRAIMIS
SMASFAIGSTLLALAHHSLVLVLVWLCVMGVGFGLFWAAQPNLMVEAVPRKYTGVSGGIQ
VCSVSISTAIASAIVGAVLSSNVADVGPEGPLYNDAAFTTIFLVGAGSAVIALIISMFMR
HGRQPATGGAATDLELDVEGATFARVGSADGQGLA
>fig|101510.15.peg.7935 Probable glyoxalase/bleomycin resistance protein, dioxygenase superfamily
MSAVTTNQPLGTPTWIDLGIPDLDRAMTFYGSVFGWEFDVGPEEYGRYTMCLLGGNKVAA
LMPNPDENATEFWWNVYLATDDLDATVARSAAAGGTLLMEPKDIADQGRMAMVRDPSGAQ
FGLWQGRAHVGCELVNEPNTLLRNDLVTPNPGPARDFYAAVFDFTLDGNDDLPGVDFTFL
RRPDGHEIGGIVGDPAASASSWGTLFQVVDTDAVVAAARANGGTADDPTDMPYGRTADVA
DPFGATFTVGSPLPGGQG
>fig|101510.15.peg.8990 Multidrug resistance transporter, Bcr/CflA family
MATGVYLPGLPSIASALGTSNIGVQLTLTTFMVGLGLGQLLAGALSDSWGRRRLLLGGSV
AFTVASAVCALAPTIGVLTVARLIAGFSGGIGVVLARAVISDRARGIEAARLFSVMMIIG
GVAPVIAPVLGGMLLGPIGWRGTFWVLTAIGGIMTFGVATAIPETLPPETRHTGGLLVLG
QNFRQVVGDRRFVGYAAAMAIGAGAMFSYIAASPFVVQKIFGFTPTQFSLVFAFNALSLV
TAMTINSRLVSRISVRRLLIFGVGVVWVSGLGLLAVSLFSPTTPWPLLALLLTMMFGMGL
TMGNAVALAQDQVPSVAGTGSAVIGAAQFAVAAIVSPLVGLGGESTSVPMAVSIAVCGTI
ALTALLTLTRDRPETRLPGFRFQKNAL
>fig|1026882.3.peg.117 Acriflavine resistance protein a precursor
MKISPSISRVIALSALLILTACQSDEQQQGAQQQESHVDVVTLAPQKVTLRSSLPARTTA
FRQAEVRPQVNGIIEKRLFEEGAQVKEGQQLYQIDAALYEAEVANAKAQLMRAKAALQTA
KSKEARYKNLLADNAISQQDYDDALATYQQTEADIKVQEATLKTAETNLNYTHVYAPISG
QIGKSNFTEGALVTAQQTAVLTTIYQLDPIYIDVSQPSKQLLDLRKRIIARQINKEKAPK
VTITLEDGTAYSETGTLQFAEANVDPTTGDVVLRAIMPNPDNLLLPGMFVKATIEEGQLD
NVILAPQKGITFDREGNATALVVNKENKVELRQLELDQAVNDNWIVKSGLNAGDQIIVEG
LQKVAPEASVKIDNNTLQTADSGA
>fig|1026882.3.peg.320 Acriflavin resistance protein
MLEAPIRNGKLLTVIVLIIMVLGIAAAKRIPVQMIPDLDVQTISVVTGWPGATPQDIEKE
ILIEQERYLRSVPNLARMESLADTGQATIELEFPFGVDVNETLIEVSNALSQVSNYPENV
DQPRLYSSSFSENAFMYFAVTPLPGNPLSLDMDMVTDFIDDDVRPRMERVPGVSEVQLRG
GAERQIQIHIDPAKLAQRGLSLTDVRDAIRERNRDTSAGDLDDGKRRYFIRTVGRFKDVE
SLRELTLAHRNNTDIKLKDVAEVRLDHYEVRGLSIVNDEAALTMAVKRETGSNVIDIKQA
MLKEIDEIRQDQLHPNGLTISLIGDDVRYVQASVEKVTQNLALGAILATLILYLFLRSGR
ATVIGLLGMPVCTIAAFIGLLAFDRTINVISLAGIAFAIGMTVDNTIVVLESIEQARRRG
LDRIQAAITGVKEVWTAVLASSMTTVLVFAPVLFVDEEAGQLYSDIAIAISTAILASMLF
AVAVVPAACARVGFGDDRDHGDDLKHPGPILKMVSWLNTSPLKRLLSIVIIFTSTMGAGW
YLLPPAEYLPEGEEPKAFSMMIAPPGYNIPEMRLLADDIRQHLSEALHADPQKFDNGEHR
LPALKYYFQRINPGSIWILSEPVRPQDLQAMMDALTSMFKEYPGMRGFSNRGSIISSNQG
GTRAVNLDISGADQESLYSTAEYAMRRAEKLFGNPQIESEPSALSLDQPLVEIRPNWDRL
AEIDMSADDFGYTVAALSDGAYVDEFFMNDDKIDMFIFSTAGQNQTLSSLANVPIMTPQG
TVLPLNALANIVDTVDSDQLRRVNGRRTVTLLIIPPREIALETAVNQVRTQMLPNMQAEG
EVAKGVSISISGAADQLDATRESLSGNLVIALILIYLLLVAIFSHWWYPLLILATVPLGI
AGGIVGLAAVNAAGPLLNLFGLPAIIQPFDMITMLGFVILLGTVVNNPILIVEQARRNLE
DKAVSVRDAVNQAVATRLRPILMSTATTVFGLAPLVFIPGAGTELYRGVGIVVLVGILCS
MIVTLTFLPSLLITVLNWAERFSVKKTEINEATTRM
>fig|1026882.3.peg.1124 Multidrug resistance efflux pump
MVKLKKFLLPVLIFGLTILIVVVLVATKPKATPKDAQQKAWLVNAVAAQMTTVSPQVTVY
GRIETPRDATLKAAVEADVEQVLVLEGETVTQGELLLQLDKTDVELVKQQRQADVDEIIA
SIANENVRYRRDLALLENQKQLVNLADKAVQRAKKLEQNKLTSQAALDESSAAYQQQELA
LKQLQNDIAEHPSRIAQLEASKKRAEALLKQSEVNLERTDIRAPFPSRVAKLNVAVGDRV
RPGDSLINVYDLNNLEVRAQIPGRYSQQIRQMMQRHQLIQATAMIDDERVKLELKRLSGE
VRLDSGGIDGLFRLVNHPNNLPLGTFVELQLQLSEQHNVIELPFSALYGLDRVYLIEDGH
LKAVTIERVGEVVGKDNQHRLLIRSDEIASGDLIVTTQLPNAITGLAVETKL
>fig|1026882.3.peg.1216 Quaternary ammonium compound-resistance protein SugE
MNWLILITAGLLEVGWAIGLKYTDGFTKPAASITTFLLMIVSLYMLSIALRSLPMGTAYA
IWVGVGMVGTVIVGALFFNEAFSLIKLVSLVLIITGIAGLKWSTS
>fig|1026882.3.peg.1502 Glyoxalase/bleomycin resistance protein/dioxygenase
MSENKLVRPGKTGGMRHIALFVDDLAACEFFYTELLGMHVEWRPDEQNVYLSSGNDNLAL
HQAAEPPAPSHQQKLDHIGFIIPSMDEVDAWFDFLSANNVEIRNPPRTHRDGARSFYCYD
PSGTVVQIIYHPPIS
>fig|1026882.3.peg.1791 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MDKAVLSGPIIPTFLRFAIPSILGLLAITTASIVDGIFVGQFVSAEGLAAINLLIPYLSL
IFGLALMLSIGGAVRAGYYLGQKRFAAASDVFSQCLIAIVVIGLSFMLLSWFFADSILGF
LGTPESLLTLIRPYFYIINAVLVVQISTMVMYYFIRQDNAQTLASSALISGALINIVLDA
LFIIVFDWGLKGAAAATAIAQVIQLIMLSRYFLRAEKTLSFSLTQQHWSEIKPAMFNGGS
EFINEISGGLVILVLNWLLVSRLGVEGIAAFAVINYLIFISLMLYYGISDALHLVVSQNH
GAQNVQRIRQFLLTALSCILLISISLTLCLVFFPEQISRLFLDETAEQTLLLSQQFIALL
WPLFLINGVNVIMSIYLTAIQKPIPSMVIALSRGLFLPVLLLLLFSWLLPEPEFLIALPL
SEWLTFIIAIVLFSWYRPSKQT
>fig|1026882.3.peg.1848 Multidrug resistance transporter, Bcr/CflA family
MNQTTTPTKALILLLAALTALTPLAIDAYLPAIPQMANDLITSIHDTEISLSLYLAGFAL
GQILGGPFSDHFGRRTATGSGLTIFCLGTIGIIFSQDIHSVWGFRVIQAIGGGVAVVNAA
AVIRDLSHGKDSARHLSNMAVIMMLAPLLAPLIGMLILHISGWRLIFVFLLVYGLTIGIA
LFFRLPETRKKTTERTSMLKRYGMVLSHRCALGFIFSQCFALAGMFAFITGSPSVYMGYF
EISETIYPFLFGLNVIGMMLANRLNIRLLHYYKPHFLLSLGQAAQILTSLILLSYVSVIA
QPQLWFVVSLLILFITAMGLIVSNATSGTVEFFPHNSATATALLGSIGFAAGALSGSLVG
LLGDGTPWPMVLIMFICSLLGPILRTLLQYGQQQPQTQP
>fig|1026882.3.peg.1994 Multidrug resistance efflux pump
MSEVSAASLENSPRLGHSLLLLITLFFICAFWWASVTELDEVTRGQGKVIPSSKVQVIQN
LEGGILSEVLVNEGDLVDKGDVLLRIDDTRFSSSFRETQLKYWELLARKARLTAEVEGKP
LELPEEIIKQQPSLAASERSLYQSRQLELQSSINVLEQQVKQREQELLENQAKLNKLSTS
YDLSRQELEMSEPLVSVGVISEVELLRLKRATNDLRGEMETTRLAIPRIRSTLNEAKQKI
KDTTLRFKSDAASQLSEVQSELAITKETTTSQQDRVRRTLVRSPVKGKIKQLKINTVGGV
IQPGMDLVEIVPVEDNLLIEANIRPSDIAFLSPGQQAMVKLTAYDFSIYGGLPATLERIS
ADTIINDEGESFYLIYLRTDKNYIDSSKGPLEIIPGMTVTVDILTGKKTVLDYLFKPILK
AKNEAMRER
>fig|1026882.3.peg.2089 Multiple antibiotic transporter
MLDYTEYTKFLVSLIAIVNPLGIIPIYISLTADYSSAERAKIARTVIIAATTILLVTAFL
GQWILEFFGISINSFRVGGGIMLLLMGIGMLHNTSKGLKQNHELAQQSGESIAVVPLAMP
LLAGPGAISTVIINAYKGHGVAHYSIIALDIILLGLLLWILLLLVPWIARRMSTNGINIA
TRIMGLILAAIAVEFIANGLKGLFPALAG
>fig|1026882.3.peg.2255 Permease of the drug/metabolite transporter (DMT) superfamily
MLMWALCYPLIKLSLPYAPVMITAFLRAVTAGSVLIAIALLINRRFPNTIRIWVYIAIIG
FSGTGLGLWGMFYAGKLLNPGFATVLTNTQPLIAGVLGWYVLNEKLGKIPLTGTVVGFIG
IIIISTNTLFDTGETVLQGILYVFLASTGVAISNVLLKKIAGQVDVFIAMGLQLLFGSIP
LAFLAFNTSHFSLLDWQLNYTLILLSLALVGTALPYVTWFWLMHRTSLYKLNVYNFLTPV
FGLYLGLNFFSETLTELQWLGAGLIIVAILLVTATNGGIKTES
>fig|1026882.3.peg.2493 Multidrug resistance protein A
MKWAKLGLLSICLVGIIVGLGLWWQHQKTYPSTDDAYVEANILTVSSQESGRVTELNATE
NAYVKAGDVLLKIDDSDLQSAVDEATSELEKTIQKHMMAGSDVSEAIANLNAVQATLRDA
ELEFERQQTLYERRIISKSTLDKTQANLDKIKADRDSARAALNTAQTQLGGKTDEDPAVR
AARATLKRAQIALSHAIIYAPADGWIANLTLRPGDVITAGQSLFSLVEKNDWWVTANFKE
TALSRIQPGQPASIEVDMYPDLKLTGKVASLGMGSGAIFSLLPPENATGNWVHVTQRFPV
RIHLDYQPSPDQQQRLRAGASVTATVDTTNLDKAND
>fig|1026882.3.peg.2696 Permeases of the drug/metabolite transporter (DMT) superfamily
MEVLVVLSRLLFSAFSNVFQKQLTHRGFDSLFIVFSAYIVLAVICLPLLFLFDPFSLTAT
FWINIFFAALLDMAGTVYLVISLSKTDLSVFGPLNAYKVVVSMILAMIFIGEIPNLQGFF
GVAVIVAGSYFLFPAKTAQQSRIWTLLKDKGVQYRFLSILLFSIGTLPLKTAVVNGGALA
TTVFWCLLGLPLAAMTQWFFIKGKLQENMTKAQANIQSFIYLGCLIFLMQYMTMLVFSQL
FVAYSLALFQLSMVLQVFLGYRIFNEQYIWRRLSACLVMVAGSLLVLNA
>fig|1026882.3.peg.2780 Acriflavin resistance protein
MTDIKPTLGISGRIAALFQDNALTPLMALLALLLGLFALMVTPREEEPQIDVTMADIFIA
YPGASAKEVESLIATPAEQVVSEISGLKHVYSVSKPELAIITAQFEVGENRTDAIVRLYN
KIYSNLDWLPKNLGVSQPIIKPKGIDDVPILTLTLWRQGQQDSNQLKQLAQSLEVELKRV
DGTRDIYTVGGADTVVNITLDPEAMAAYHIDSHRLSQALSAANQSAEAGTTVQNNQMTSV
QAGQFIVSADTLKSLIVGVFNDQPVYLTDVADIALGPEQPRQYVWFGTGPAASDKQIRAQ
GEYDAVTIAIAKQPGTNAADIADAVLQQVTALKGVMIADDVQVTVTRNYGETADQKADTL
IHKLIFVTVAVVLLVLFALGWREAIIVGVAVVITLLLMLFASWAWGFTLNRVSLFALIFS
IGILVDDAIVVVENIHRHIQQGKLTLKQAIPIAVDEVGQPTILATLAVIAALLPMAFVSG
LMGPYMSPIPINASMGMLLSLMVAYIVTPWMVLKMLSHSRSANHEKVAESQYNAVFQRIL
SPFLLHENAARRRKLLWGGLIMLVVVSVGLAAVKLVILKMLPFDNKSEVQIVIDMPEGSP
LEKTAAVTRALTDYLSTVADVTDYQAYVGTASPINFNGLVRQYYLREAWHQADIQINLRD
KHQRDEHSHALALKLREPLTAIAKKWDARIKVVEVPAGPPVLSPIVAELYGLNEQQRQNQ
ASQLVKVFEQTDGIVDIDSSIEAKADRQIINVDRNKASLFGLSQQQIVEAIQLALTGEDV
GYLHDDNVKYAIPLRLQWSIEDKANLDAVLNMKLINQQGELIRLSDVVNVVDGEHQQTLY
HKDLQAVTYVTADMAGKVDSPLYGMFSVYQQLENMPIQQYLVSVPSLALQDSLKWDGEWQ
ITYETFRDMGLAYAVGIILIYLLIVAQFRSYLLPLIIMVPIPLTVIGVMPGHALLGAPFT
ATSMIGMIAMAGIIVRNSILLVDFIRHAMAEGMTAEKAVIAAAATRAKPIILTALAAMVG
AVFILDDPIFNGLAIALLFGILVSTLLTLLVIPLLYYSYIKTR
>fig|1026882.3.peg.2913 Daunorubicin resistance ABC transporter ATP-binding subunit
MAYKNQYAILTKGLTKQYGQALAVNGLDLSIEPGQFYGLLGPNGAGKSTTIHMLTTMTSA
SSGEAWIAGREVKRYPVQTRALVGLVFQDSALDRMMTVDENLQFAAALYNLNKQQAEQRI
AELLSVFGLEKKRHQKLVALSGGQRRAVDIARGVLHKPQVLFLDEPTIGLDLPNRRSIWR
FIEQLRKDEGMTVFLTTHYLEEAEACDHVDFIQKGQLQKGGAPKKLIKNLAAYMLEIDCA
DTEVVSQQMRPQFGEPLWEDQHLTYRIQDKETDFYQLQKTLGNAVNAMQWRKPNLNDVYL
WTVCPPDYGVVT
>fig|1028307.3.peg.241 Multidrug resistance protein B
MSLVSSCSLDQGFEAPRRYLAAAAILIGVLMAALDSSIVNVALPSIASALRVDSASGIWI
TNGYQVASAATMLICASLGSRIGEKRFYTAGMVLFTLSSLGCSLAPTFGVLVTMRILQGV
SYAVMISVGLGLYRVIFPPCALGTIFGLNALAFAVGTAIGPALGGFIISSLSWPWLFYIN
ILPGGAAIVFSLISLGEDNEKEQGFDWAGAVSSAAALGLMVVAVDQIGRWEGRTLIYCAV
ASVALFAFFFIAQTRAKHPLLPLDIFRSRQYTLAVISSSSLFIAQGMALVGLPFVLQHTY
HYSVLESAFIFTPWPVAVAICAPLAGSLSNRFNPTQISTVGVVIFCLGLGSLALLPGAAT
VNDFLWRTAVCGVGYGLFLPPNNKEMFANVSANRTATASGVLSTARTTGLSIGAALVAMV
IALLNGLTGLAGAQFSVYVFGLACVIAAISSLASTLRLHR
>fig|1028307.3.peg.458 Transcriptional repressor of for multidrug resistance pump (MarR family) protein
MDKTHSSTPPESHESRFHKEEFPFFWVVNVYARYTQLMEIELKKIDIDLSRFRVLMLVHQ
YHRASISRITEYAVSKMPTVTKIVGRLRDDGLLTTHVSVSDGRVTEAELTAAGEAKVAEA
RALAETVFAKAFKGVTPAQEKKMNQVLALILHNLDD
>fig|1028307.3.peg.1880 Permease of the drug/metabolite transporter (DMT) superfamily
MDASFPTPSIFANKKVAYVCATLCCLLWGSSYPAIKNGYELLYIATDDVPSKIVFAGYRF
LFAGLLLLLFALAQRKPIARLNGRQCGQLAMLGLTQTAIQYAFFYVGLAFTTGVKGSIMN
ATGTFFSVLLAHFIYQNDRLSYNKTIGCVLGFIGVMLVNFNTSLGDFNFVWQGDGFVVLA
AFILSAATLYGKRISQTVDPTVMTGWQLAFGGLVLVAGGYLTGGELRMHSVTAAMILGYL
TLLSSVAFALWSVLLKHNRVSMIAPFNFVIPVAGTVLSAIFLGENIFEWKYAIALVLVCV
GIRWVNKNQAR
>fig|1028307.3.peg.2658 Multidrug resistance efflux pump
METLLLLCYAALCIVIFKVFRIPLNKWTVPTAVLGGVILIGMLILGMNYNFPYSEVGKQV
YRTVPIVSQTRGRVTSVPVKPNQMLHEGDILFTIDPTPFQAKVDDLTAQVKAASQDALSL
DAGLTSAQADLSKAVAERDRAQREYARFQAGHDKGAFSDQMVDTRRQNWKASQAAVDAAR
AKVAQARNDLNSVVHGENTKVASLLAQLREAQFKLDNTVVRAPSDGYVSTVGLRPGTMST
ALGLKPVMTFVPTDNANSREYVAAFRQNALQRLQKGEQAELLFPSIPGTVFKAQVAEVLP
AIGESQFQGQGTLLTANDLAARGRALVVLKVTDDRLANYQLPQGADVEAAVYSEHFEHLS
LIRKILIRMKSWESYLYLDH
>fig|1028307.3.peg.3201 Permease of the drug/metabolite transporter (DMT) superfamily
MSSLKLSITPQELILIVITMFWGGTFLAVQYAVNFSGPFFFVGLRFATAALAVALLSLRT
LRGLTWLEVKAGVAIGVAIALGYSLQTWGLQSISSSKSAFITAMYVPLVPLLQWLCLGRM
PGVMSCVGIVLAFIGLILLAGPENNLLALGIGEMITLASAVAIAAEIILISAWARQVDVR
RVTVVQLATASLVAFAAMAPAGESIPPMRPELLAVALGLGIFSAIIQVTMNWAQRSVSPT
RATLIYTGEPVWAGVFGRIAGERLPLLALVGCLFILAGVLVSELKWKKKSRPQIAAEEAP
ELAERREP
>fig|1028307.3.peg.3516 Glyoxalase/bleomycin resistance protein/dioxygenase
MKVAHIALWTRHLEQQARFWVEFFAGEINEKYRSKTNPGFESYFVKIGSDVAIELMTKPG
LHDSTHDNNHTGWVHLAIAVGGTEQVNALAKRAEMAGILVSAPRTTGDGYYEAVIKDPDG
NLVEIVA
>fig|103690.1.peg.3858 Permease of the drug/metabolite transporter (DMT) superfamily
MQLKLSASKFPIAPLLLIAPFFLWGTAMVAMKGVMPHTTPFFLAGVRLLPAGVLILIAAA
LSGRPQPNSWQAWLWISLFGLVDGTLFQGFLAEGLVRTSAGLGSVMIDSQPLAVALLSLW
LFQERIGLWGWLGLGLGVTGISLIGLPDEWIFSLLGTGAEVTIGNWQNLFASGEWLMLLA
ALSMAVGTVLIRFVTRYVDPVTATGWHMIIGGLPLWGISSVVESQQWENLVGSEWLALAY
ATVFGSAIAYGLFFYFASSGSLTSLSSLTFLTPIFALLFGHLLLSEVLSTLQWVGVFLTL
ISIYLINQRDNLAGQNKQSVMEEISAKSQPILAEATAKKLNPLTVKVRESEPETLP
>fig|1045004.4.peg.268 Multidrug resistance ABC transporter ATP-binding and permease protein
MVPLIVQRLIDSYERGIDYRQIIFLAAIFVMQLLFNALGLYLFALIGAIATKNYQQGTFN
QVLQHRVGWFEEQESTNLANKIYNNIDLLRTLFTNSLPEMISGVLTIVGIAVVLLSLNWA
LTIVTLFGVLLMVGVFGLLGAPLANRIADFQDQKSLFATHTSKFFRLVKMIKANAAEKIV
QKDDADDMKVLFESGRRLARINALINPLIGAVMMLIMLGIFGYGGYLLNNGSITNGVLIA
FLLYVIQIMVPLGSFSEFFHGYVGAKTAMNVLMQLRDNSQNERQGGCALPRDSQSDLVFK
DVNFAYDDAKTITLDDINMVFKPNTMTAIVGPSGAGKTTIVSLIEQFYAANSGVILSGTS
DITQFSLFSWRQSIGYISQKADLLGSSLRDYLSFGRKENYSDNQIKDVLGKVGLLEAFNG
HLDDKLLEDGNNISGGQLQRLAIAQAILKEAGIYIFDESTANLDADSEMKVKQIMEELAE
KHIVIAIAHRLSTIKSADNIYFLEDGTITGSGTHSQLLANHKTQLLANHKTYARYVAEQM
L
>fig|1045004.4.peg.636 Multidrug resistance ABC transporter ATP-binding and permease protein
MAKKSKQQKSGLTALFKYAEIKKSLLMTGLIFSVLSAALSLVFPLFIANLIDSFRKHFSL
PLVLAVIVTLLFSTLFSVLNSYTMGKASQTFIASIRKKASARLMNIPIKFFTDKQSGEIS
NHIANDTQSIDLLIRQNISSFISGVILVIGSIVILFLINWSLTLIVLLALIAVFLILSPI
SNIQNKTSASLQNELGHFSSRLNQVASEIRMIKSFNGQESQKEKLNDSVDRLYRFNMKVL
KINSLLDPIEYTILFSSIFFVLIIGGLMVSSSGMTIGALVSFFIYFLQIMTPISIIAQTI
NQFQSANGASKWLVALLQTGEETDNQQLVPAGTFASPLVFDQVSFAYNPKADVLSNLNFK
IPAGSVTAFVGPSGGGKSTIISLIEKFYLPSKGECPWLEKISKISACIIGVIMLPMCPSR
VQCLLGRCVII
>fig|1045004.4.peg.637 Multidrug resistance ABC transporter ATP-binding and permease protein
MLVGTLRDNLTIGLKKEVSDEQINQALKDASAFDFVEKLPKKLDTDLSERGANLSGGQLQ
RIMIARAFLKQADIYIFDEATASLDSQSEFFIQQAIDKIKAKATIIMIAHRLATVKNADQ
ILFLDHGQITGEGTHDELYKTHPLYRKYVQEQLLKQG
>fig|1045004.4.peg.703 ABC transporter ATP-binding/membrane spanning protein - multidrug resistance
MSKYLKEQWAWTLFCVFLIALMSGSKVAAALINTYLLNSLISFQRNRFLLLVGLAILTWV
IFAFLIYVVYSLRARLVQKMSLSLRHDISQQISGLPYSRFHAKNSDDYSSWLMNDVTMIE
NGGFSVFFDIISVSLDAIFSIIALLSFHWSLVVLTLLLSVVTIFAPQLMQKKLKKASVET
SQANENFAASVNDTLHGFDTLFAYNLTQRIINHVDKSGRLPQTKKVQLGRTQAAATSIGV
LANAGSQLITIAWTGALALARLTPIGSILSTGALASNVFNGLANLGPTLTSVKSLNPLFA
KYHLGVDTSLNTSNQSTKSLADATINLTNLSYRYQDKIALKPVSIKLPLNSKVIITGESG
AGKSTLLNILAGKLLNYSGSVKIAGQELKDLSSEQLRKTITYVDQIPYIFNGTIRDNLTL
GEKFSDDAIFQALKRSDLFDFVMAQKQGLDSSVGEKGQLFSGGQRQRLALARGLLRNPQI
LLVDEGTNSLKSESAIQVEKQFLSLQDMTVIFVTHQLHEEIRPEIDQLITLA
>fig|1045004.4.peg.766 Lincomycin-resistance
MANKQVRRPFVVILGILVVNFLGLFSETSLNIALPVLRETFSVSSAAIQWLVIAYMLMIG
LALPLSTLISHWFKTKDIIIFAIFIFALGSVIAACANSFTVLLIGRTIQGIATGLFIPLM
FTIATIIFPSNKFGSVMGVIGVVMGFAPVIGPTLSGIIIDSLSWRWIFWLFLPFLLLSLL
LTIFTMPNVIEQTHPRVDWLSVILSMLGFGLLVSSVGLISNLGIASPIVIILILLSLLIL
FIYIHRQLRINRPILNFKILTNSRYRNGTLIVIFNFGIVLAAMYLLPQMLQNGLGQKANT
TGWILLPAGVLNAVISVIAGRLSDRFGARYLVLTGTVIFIAGLIMMSIINLKSGIPYIIS
AQSMLLSGSAMLFPPAQSYSLRSLSAAHSSDGSTIMNTCQQIMGALSTSITNSLLVFGGT
LHPLQNTAARFMSASRFAFIFAFVLAVLILIVAFQIKGKDKTSRQTA
>fig|1045004.4.peg.1068 Permease of the drug/metabolite transporter (DMT) superfamily
MLGPFLWGLNGVVTQYLFDQVGMDVNWVLSIRLFFAGLALFIYVLVFDRQNLFNLIKDKS
VRWRLIVFMIFGDFMSQYSYIIAISESNAALATILTSLSLLFVIFFYVIVQHHLPQRIDL
LSLIVALAGTFLLVTHGRIGHLQLSSAGLFWGLFAALVYAFATIYPIKLVSKYGPLPVTA
LSLFVSGILFNCYRPFFEHVPKMSGVNWFLLIFFTIVSTAFGTAMWFLSLHLVGATTMSL
LSAVEPLTAAILSITLLHLAVQGIDVLGSGLILLMMCLQAFKHQRVR
>fig|1045004.4.peg.1647 Multidrug resistance ABC transporter ATP-binding and permease protein
MENKGNPNKNLGLKWVLAQLPVSLLILIIIFAIIASLEGVISGYAIGQITAIATTHVASP
ALFVLRFVLIYFAVYTGLYIFILLQNRAIKYLNVALKQAFMKNAFQTDYVHQDADKLLNQ
VTADAKQIEQRYFSNLVNLLLSVIAIITSSVFVIAINPMLGLIDVILSFSIMIPTLFDNK
KLDQYSSDWSMANQHYLGQVKEIFAGIDIIKNFRAEKTMLAANDAKLNESENRYLALNNR
QFFTQYFSWLMIIISFLGPVLIGLLFRQYQLFGVTISAIVTLALSGGNVATQVRTGIQYY
AGMKTTRALRQSVIPDPTPEENSAANLPDKPLLSVADVSFSYKNHPILKDVSLSLPYGGK
LLLSGDSGSGKSTFLNLLTNKLDVQTGSITLGGQQIHENDFAYITQTNWVFNDTVKENLT
LGQNFSNAALLASLKEVNLANELGDDPLNYQCGEGGKNLSGGQKQRIAIARALLRKRPLL
LLDEVTAALDEKNSEKLRDLIYRLPQTIIEIAHHYDTDQIQANHVQHLQLSAGKISPAN
>fig|1045004.4.peg.1746 Drug resistance transporter, EmrB/QacA family
MSAKSVDIHNKRYSRFMFVLVILFATFAGMLMQTSLGTALPTLMDDFHINLATAQEATTW
FLLANGIMIPVSAYLSTKFPTKKLYIFAFGLLLVGQFISYSAPVTNWTWFLIGRIIQAIS
VGITMPLMQVVLVYIFPAEKRGAAMGLSGLVIGMAPAIGPTLSGWILDSSHSFASFTLSN
SWRSIFLLPMAVIALTFLLSFIFLRDVIPNQPVHLDFRSLVQSTLGFGLFLWGLTNVANA
NYGGWTDMTHVIIPGAVGIFFIIIFLWHQLEMRHPFLDIRVFAVKQFSVTTVLISLSMMA
MIGIEMMLPTYLQQLRGLSPLSSGLTLLPGALLIGIMSPIAGAVYDRSGAKRLARVGFLI
LLIATIPFLFFGLNTPRDFITVFYSLRMFGIAMVMMPLTASAMSALPKEKAADGTASNNT
VRQVLTAMVVSLLSSVTQNIANTNAPVASLKQQNIFEFGQRTLDASLKGFHVSFAISLFF
ALLGLILAGMLHSGKVIEQDPDLLDEKGGN
>fig|1048339.3.peg.42 Vancomycin B-type resistance protein VanW
MTESTPVSSAGGSGGRRTALRVGIVAGGAVAAVGLLYGVAVATTGGNIPRNTEVLGIPIG
GKSVEDARMHLSVALPERLPDAMTVVAGDKRLSRPTGELGLDVDLEATAEKAREGWASPF
RAIKTLFGAGREVDPVPAVNTETLQTAVEEMNDEVSLGFVEGGLDFSTGVAKPIAPVPGR
GLDDEAVAAALTDAFLAGDSEVAAAIVDVQPEIDQAAVDRALAGIGAKAMSGPVTITVAK
NAVELTPAEFGPFLSTEPADGELRLVVDAEGLVDSLEDEVEDLGRPPRDAKFRFDEEEET
VEIIPSRAGIVLDARVLGDKLADVLIGDGPRTVDAGARTQAPEFSTADAEALGISDKLSS
FKTEYPYAAYRVTNIGRAAELINGSIVMPDEIWSLNKTVGERTVKNGFVRGYIIKNGQFI
EDLGGGVSQSATTTYNAAFFAGLKDIEHHPHSLYISRYPAGREATVAWGSKDLRFQNDSG
HPVYIQATHKVGSIEVSMWGTKVWDEIESISSPRRNIVSPKTVESEDPDCEEQSPVDGFD
ITITRVFIKDGEEVKRETYDTHYFPTDKIVCVEPGKGTKSPTPGSSSSPDPSPSRTPKPP
KSTPTPKPEPSPSATPTTTSSAPPLPVGSGDDDSGRD
>fig|1048339.3.peg.58 ABC drug efflux pump, inner membrane subunit, DrrB family
MMNPQITLSTARRVLIQLGRDHRTVAMLLVLPSALLGLMCWVYSDIPGRFDRVGPQLLGI
LPFVVMFVVTSVATLRERRAGTLERLLTTPMNKLDLLLGYGLAFGLVAIVQSGIAALLTM
TLYGVDAETKGGWALFLSAAVVGVFGAAAGLFASAFARTEFQAVQLLPAVVIPQLFLCGL
FVPRSQLDDVLNAVSDVLPLSYAVDAMNQAMQRGGLTGQVGRDLAIVGGSALLALAAGAA
TLRRQSA
>fig|1048339.3.peg.308 Probable antibiotic-resistance protein
MTRPKVIDAWIQPWTKEVVEGLPDRALHVFKQYGQASRLQDGISLEVMMEEMDAAQVDIS
LISGGPMVPMHLVLEAMERWPDRLRAVVWTDPTQTSIVRALADLEALVRNYPVCGFKMEA
FALWRDPTDRVFYPLYAKCAELGIALQTQVGGTGPLYPSRTGQPLLIDEIALDFPELKIV
CGHVGSPWVDEMIHVAWKHPNVFIDTSARLPKYFEPAFTKFLTSFGQDKCIYASDWPVLD
FQRPLGQVDSLGLSPEVREKFLVSNAITAFGLDDLRA
>fig|1048339.3.peg.2767 Probable multidrug resistance transporter, MFS superfamily
MGGDRRGWRRHAIDLSPLEHRDYRRLWAGNAIAFVGFQVTAVAVPVEIYDITGSSFWVGM
MGAVGLVPLIVFGLWGGAVADALDRRRVLLVGSVTMWLTTLGLLAHSLLDGDSVTVLLAL
VALQSAAFAVVGSTRGAIIPRVVPPEQIAAANTLGFTTSNVSMMAGPLLAALIITQVSLS
AAYALDAVLYLAALYAAVRLPSLPPLGEISAPGLRSVIDGLAFIATRPVLLVSFAVDIVA
MVFAMPRALFPARAEELGGDAAVGWLFAALAIGAVVAGATSGWVGRVQRQGVALVVAIVV
WGLAVAGAGLAGNLWLAVFLLAVGGAADLVSAVYRQTMLQTYAPDEMRGRMQGVFIVVVA
GGPRLGDVRAGTTAAAVGVQASWVGGGLLCAAVVLLALAVPVFRRYRAPTATDPRPSDDP
T
>fig|1048339.3.peg.3351 Vancomycin B-type resistance protein VanW
MSRFLARRITIVVVAAAALLGLGLYAAAYAAAGSDIKKGTTVLGIDIGGLSRAEAESKLA
AELPAVISKKVTVRAGEKSFELDTVKSGITVDAAATVAKAGERSLNPGVLFPVLFGAKDR
IDPVLAVDDKALTAAVTGIAKKVNQKVREGRVKFTAGEAVAVQPREGRSLLVPETAEALR
KAYETGAAEVTAALKTTPPVVGQAEVDRVMNSFAGPAMAGPITVKLDGQNVTLSTAKLDD
YLKITPSGPTLNWTVDTDRMVEDLAEENPKLVTPPKDARFTFERNKPKLVPGEDGEKIEA
VSFGEQMRAALVAPVPRTVEAQVVPAEPELTTEEAQNLGITEKISSFRTNYPIAPYRVNN
IGRAAELINESLVLPGEIWSLNKTVGERTEANGFVKGFIIDKGQFKEDLGGGVSQSATTV
FNAVFFAGLKDIEHHTHSLYISRYPAGREATVAWGAKDLRFQNDTPTGILVRATTQPGWI
RVTIWGTKYYDKIESVSSDRYNYKQPKTITSAAADCTPQSPVAGFDIDVTRVFYKDGKVV
KREKFFTRYIPTDRIICTNPRKD
>fig|1049789.4.peg.31 Acriflavine resistance protein
MIEKGQKILESRPVSTGMFLFGLILFGAISYVKNPISLFPNTTYPGLTVSIEYPGADVKD
LEEMITIPIEESISGVGGIEEIYSFTERGKTEINVEFEKESNLEFKSLEVRERIDIVAGN
FPREVHKPFIYSYDPDNRPTMILTLKSETFDFIELRTIADNEVKRYLENIEGISKISVTG
GKVREVLVSCDMQKLRAYGLDLSEIQRSIRENNTTSAVANLKKQGLSSKLLLLGRYKDLN
DLKTLPVFSTKEGRNILLEDLANVSFSYREEESSSRLNGKENVSLYIYKSSLGNTLSISK
EIHRKLDDLKISGVNFKLIYDQSETVKKSYLNLIACGGVGLILFFLLLYYHRNYKQVRIR
TTLLTQTILNFFLFQFVLYIFKLDFDIIIFSAFILGFAIWTLVSFLLLEKTPQDLSNLKQ
VSTLPEFSALISIVLFLSLPLYFLDREIGEASFKLGVFIVLFLVFSYFSFSPIKRFFNQI
RNRYFPSFISEPLQLELKFSLFQGLEPKITRKTILLIYVVVLLASIYRVVKIDKEFYYTI
ENKKILGYVELPSGTGFGFTNSITKRIEEKILALSEIEEVTSKVEGGHSFLIITLKDSAI
AGDTFLEKMKKQVGNTSPAFVYFSRESDASKFKEIVVDVLGEDTEKLDETVKLLAEKARK
IPGVEEVILRYKPPRDELSLVLDKYKTSHSNLSNLEIGTYLKLAIQGAVVSKFIEDSKEI
DIRVRLSEEYRNSEKSLENYFIKNSTGKYAPLTEISSPKESKSPIKIFRKNKKRVLSFAI
RTGKISHSKILSDLKSLGEELPDGYHLELGRSLEKTVETESKIYIVIGFAILFLFGILSS
YFESFILALKALVKLSLPSSISFLFLSYVFGAFTLSMYLGILILLSISSFLIIVSHKMEE
TKSLKSIFYAFLPVVCLFISEVLFASEGGKFLKEIEITILVGFFVFAALLPFINPKPKNN
TTE
>fig|1049789.4.peg.356 Acriflavin resistance protein
MNNTRETPLGFAGKIANLFINSRLTPVISIASILLGILAVTLTPKEEEPQISVPMVDIHI
SSPGFVAKETERKVVEPIERAVWGLEGVEYVYSASADHGAIITVRFKVGEPLEPSLVKIH
HSLMEIKSTLPPNVSEPTVRSYTIDDVPFLALTFSSETRDDYSLRSIVAPLARELSSTPD
VARMELLGGRKEAVRVIAEPEKMQVYGLSISDIANGIRANQGFMPSGKNWGKDFLYDIEI
GTPISNAKQVMLTPLVRRGGNVVRVSDVAEVHDGAEEKVRQSSILDKSLGPDHRNAVTIL
FSKRKGTDISKLSREILERSEFFTKDLPKDIAMTVLRDYGATAGDKSSELIEHLLIATFS
VSVLIAVWMGIRASFVVSISIPVTLSLTLALYYFLGYTLNRVTLFALIFSIGILVDDAIV
VVENIERHLKLKPGQGIVKTTLQAVSEVGNPTILATFTVIAAILPMAFVRGLMGPYMKPI
PVGASLAMILSLLVAFIVTPWASVRFLKLHSKVEKKSVKDSKLNLLYESFTAWLLYSRKN
AILFGLSIIILLLASFSLVALKFVKVKMLPFDDKEEFQVLIDYDPKTPLEKTTKYTRVLA
NSLIENSNIQKIQIFVGDPAPFSFSGMVKHSFLRNKEWQADLHIVLKNKNERNKKSHDII
ESLRPSITDFGKQNNAITKVLEIPPGPPVLATFVAEVYAPTEQEREDVAIEIKKSLSLQQ
GVVDIDSSLRAQRPSIVFPFDYVSAGNLGVQAVTIAQASNYVFQETSLSTLSETSRPEDI
AISLSLKDSIRASKTPFAKLNVTTLESGSIRADQVLDQPTIHENRIRNRKNLRSLEYVTA
EFSGAEESPVYGILNLSDKVTHPTFTSEIPSVLNQAVVKWDGEWFITYEVFRDLGISFAI
VMLIIYVLVLGWFQDYLVPLIIMAPIPISLIGILPGHWLLGAYFTATSMIGFIAGAGIIV
RNSIILVDFINTEISSGAPLRQAVINAGLVRFRPMLLTASAVVVGSSVMLFDPIFQGLAI
SLIFGEVAATLLSRFAIPAIYYWFLMNRGHISKKN
>fig|1049789.4.peg.582 Glyoxalase/Bleomycin resistance protein/Dioxygenase family protein
MNNMEDPKKQTDNSTSPAETTPKAIGIGGIFFFSDNLKETKEWYAKNLGLEINEWGSSSF
ESRNINKPDEINSLQWTPFKKGDEYFSPSKKEFMINYRVQNIEGLVNKLKENGVTVLDSI
ATYDFGKFVHIMDAEGNKIELWESVDNG
>fig|1049789.4.peg.802 Glyoxalase/bleomycin resistance protein/dioxygenase
MKKLLIAICILITGISFWWAITSSQSDYHKIDNIDFSYATLILNSPNPERLSEFYRNALG
AQRSKEEAVWSLDGSIKSVISLRTAGYDEQGPLLTILKSDKSNIESPLPNDLGYAHICFE
SDDIPGLIEQILKNGGKILSSFKDLEKVPAAYATDPDGNVFEIHLPFPAPVTPRTIYRSL
NSLVRISFKLAPAKVDAIRFLHVNINSTDWIKTMNFYTKALGTSATGFERNYRGEFIENL
TGINGAVVRGRHVELPGYSEGGPTFEIFTYNKSSSKKPRTMTEMGFVATGFQVQNLDTAI
KKIISEGGTLVSRRGSQSAILKDIDGNILILAPKNKFLRINR
>fig|1049789.4.peg.1100 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MIFFKIIQTLIAKVVWMEAIQKDTQLELERTSIWGELKKALTGTEADYTQISLGKAVFLL
SVPMVLELVMESAFAVVDIYFVGALGPSAVAAVGLTETYLFLLYSLAIGMSTAVTAIIAR
RIGEGDKEQAGIAAVQSVFLSILVSLPFAIFGVWFAKDLLLLMGGDPWVIEHGSRYTQWI
FGGNIVIMLLFGLNAVFRGAGDAAIAMRVLWISNGLNIILDPIFIFGFGPVPALGIEGAA
IATNIGRGVGVVFQVYLLLKGGKHIRVLGSQISVHWKIISDIVRTSLGGIGQTIIGMTSW
IFLVRIISDFGSEAVAGATITLRIMMFTLMPSWGMSNAVATLVGQNLGARRPDRAERSVW
IVGAWNMFFLIGVSICYFIFRESLVSIFTSDAKVISIGSEWLGIVSYSYFVYAWWMVSVQ
AFNGAGDTMTPTIINLVFFWIFQIPFAYVLAKVLSYGYSGVFWASMITETSVGLFTLWLF
RKGGWKTSKV
>fig|1049789.4.peg.1196 Acriflavin resistance protein
MRAIIESFIKNRLFFYLGTSFVFLAGIVSLLGLRRDTFPNVDMKQLVITTKFPGASPADV
ELRVTYPIEEKIKEIDGIDEIRSFSRNSASDIDVRVSLEEKDPEKILDEIRRAVDNAISE
FPPQVTEKPKIIERKSSSYPVLEFSVFGGKDEIELHTTAEFLERELEKISGVARVDVFGK
RDREWQILVNANRLKHYQLDLSDITTAIRNRNVNLPAGSVDSETAFDLRIDGEFRNPSDI
YKIPIRTNDLFSKVELGSLARVEDTFEYPRFLAIANGKQGLILSVVKKERADAIDVADHV
RKRLAELEKTAPPEIKTVMLSDEAKRTSKRLDIVSNNALIGFCIVFGILFLFLDFRTATI
TSLSLPISMLMTFAVLPFFDVSFNMISMMGLIIALGMLVDNSIVISENIYTYLGKNMDSF
TASVKGTLEMLVPIFGSYLTTVAAFLPMLFMSGVMGKFVWQIPLVVIVALTASLIESFLF
LPARITAFAKTPDQLKRTTGFRKTLDAFFHRMEERFSDFVAFTLRHKYSSFITILILILA
SFVALSRMKFILFPKEDIEIFTVKAEFPSSFRIYQTREKMKYMETIIKRIPPDELVSYSI
KIGVQQTDPEDPLSRYGENLGVILVYLTPESERKRKAGEILASLESDFRKTPSLVDVYME
EFGAAPPIGAPITVSILGKDYKDLTKVSAELQTFLKTIPGVHSVRDDYRYGRKQMQVRLD
EGLESFTGVSTFAAANMLRTAYDGERAGTVRKGRTKIYLRVMYDKDFRKNPDEIKHIPLR
NKAGNITHLSKISKMELVDSPELLSHREFERAITVNAEIKVDQITAHEANSKIIEVFKPL
IERQYPGISLAFGGEEKDTQRSMESLGKAGLLALFGIFAILALTMQNFWKPFLILSTIPL
GIMGIVLGFPLSGKSISFLAMIGIIGLAGVLVNASIVLVDCIDSIQKGSTDSMDEILLEA
SRRRFRPILLTTLTTVAGILPTAYGLGGTDPVLVPMTLALGWGLGFGTLGSLLYVPVTLS
VFHRFASKKKKVHH
>fig|1049789.4.peg.1424 Permease of the drug/metabolite transporter (DMT) superfamily
MQITSSVKFYILLVIAMISWGFAWPSAKSIVGLENPNVIIFWRFLATAISILPILLWRKE
SLRLPDIKSFFQVCVGGVLYTAYNQFFLLGLSSGFAGAGGVLVTTMNPIFTYILGHLLQK
QYPGKKDAFGLLLGLSGGLVLLHIWDKPTEGVFQSGNIFFLLCAFSWAILSMNSHSTGQK
ISPLVYSFYVFTIGTIFDFIFALPYGLSNVFSLDWMFWGQIFYLSVISTTFGTTVYFFAS
TKLGSRIASSFIFLVPATAVLGSWIFLGEVPSLTTLFGGSLAVSAVLILNGNRTKKTEIQ
AES
>fig|1049789.4.peg.1659 Tetracycline resistance protein
MRKQSFILVLTVFIDMMGFSLIFPIFPETLNHFLAQAGDPVLDLLAGWTSHLLDNSGGDW
KLFVALFGGIVASLYSVLQFLFAPIWGKLSDRTGRRPVLVFTCTGSFLGYLVWLASGSFS
LFVLSRILTGLMGGNISVATAAMADLTEEKDRAKGMGMIGAGIGLGFIAGPSIGGILAHT
DPSTLLPFFPWSKMTVFPSVALAASAAALVNLLFVLFRFRETLPITLRRKPEGRLHPILG
VLDIGSREVLFLSLLNFLFLFFFSGFEFSLNFYLDQFLNFKPIQIGYTFVYIGLIIVVVQ
GGIIRRISGKIPEKQIGLFACGLLTLGFLLLSFTNSHTQLFLALTLLAMGSAFLNPSISA
MVSLFSPPQDQGKNIGLLRSLGSLGRGISPIAFSLVYSQRGPQISFLVSAVLSAVFLILF
WFLRQPKKHHA
>fig|1049789.4.peg.1965 Acriflavine resistance protein homolog
MKTILEYFLSKSIFVNLLTFLIIMFGGLTAVLMNREAFPNINFDIVSISTLYPGASPQEV
EKLVTNPLEKAIKEVDGIKEYRSTSIEGRSGIVVTLDPDAKDSQKVVDDIKSAIDRVEDT
PEDAEDPIVTEITTARTPVIEVSVTLKNDDGSVESEKKLKAHAKIVEQSLLDISGVAKVV
RRGWRDTEMQVDLNPSGLNSRYLTGQDVINALRNRNVNVPGGNVTGSENEIILRTVGEFD
TPDEISRVHVRGNEIGYAIRVQDVSKVTEGLKEADYLENVNGKKTVALTVLKRQSSDAIK
VVDDVKNTVEKFRQSNKEFEYAFVNDLSKYIRRRLNVLISNAGFGMVLVTASLFFFLGWR
VALMTALGIPVSFGATFILMNYFGLTLNLISMFGLVLVVGILVDDAIIICENVYRYIEEG
LPPYEATLKGTLEVVSPVTATVTTTIAAFAPMLFMSGIFGKFVYSIPLVVIIALCASLSE
AFFILPNHLYDINKRHVKTGEIKGESGWFARFRNTKYIPVLKFSLAHPWAMTFGIVGLLI
VSFIVLANYPRFKLFPGSVDQFYVKITAKTGASLSETYRYLKVIEKEIAKIPPEDLENFA
TRVGIIQANPNDPFTKRGKHFGMTMAYLTAEENRKKCHKTDDIIRRLRKKTLWLLNDESR
KIEEGRIKKESADKKDECDVDEPAVIPEEFASLRGKLVALEYEKLSGGPPVGKPIAIEIR
GDEYDTLSKIAAEYKEVLGKVNGVTDIADDFNEGKDEVRIKVSESLASTAGVSVSRVAQA
INTAFQGTVATKIKRTDEEVEVKVRFPESYRQSVGSLNHVYVSNLQGKMIPVSRLITIQK
NPGFSNINHLDGKRVMTVSANLASGKNTNPSKANSESKKLADARKILEKYPGYTVRFGGE
NKDTDDSFKSLGLAFAAAFLIIYIILASLFGSLLQPLVVVSAIPFSFIGVILAFVSHGEY
FGFLAFLGIVGLSGVVVNDSIVLVDFANSLRKNNPNKDIIEVLLETGNLRLRAVILTTVT
TVLGLLPTAYGIGGFDPFLVPMALAFGWGLAFASLVTLVMVPVFYLHLYRYQTWFSGLSD
RIWSAKPKSITYSFESSPIPQKQKKKK
>fig|1049789.4.peg.1995 ABC-type drug export system, membrane protein
MINFINKTLIISELEIRKIIHDPSEIITRSVQPALWLLIFGQVFAKMPFLANRTDYLSFM
TPGILAQSVLFVSIFSGIAIIWERDLGLIQKMLSTPTPRTAMVLGKAISAGFRTLPIVVI
IYLLALILGVSIHWDIFKILGVLLFVFLGSIFFSTFSLIIACLVKTRERFMGIGQLLTMP
LFFASNAIYPIEIMPDWLKVVSHVNPLTYVIDALRSLMLDFPSNFGVLVDFGVLFIASLL
VVLIGGVLYKRVAV
>fig|1049789.4.peg.1996 ABC-type drug export system, ATP-binding protein
MNILELHDLSKSFGKLTVVSSLNLMVEEGEIFALIGPNGAGKTTTIKMLTTLLPPSSGEA
FIGGFNLKTQTDQIRRIIGYVPQMVSVDGNLTGYENLMLFAKLYDLPRKEQKERVKDALH
FMGLDSFGDVLIQKYSGGMVRRLEIAQATIHRPKLLFLDEPIVGLDPIGRNVVWEHILAL
RKKYATTIVMTTHLMDEAEKICTKIALMSRGKLAAIGSPAQLKESVGGSDKSLEEVFIHY
AREDLNESDGNFHSVNLERKTARRLG
>fig|1049789.4.peg.2121 Daunorubicin resistance ABC transporter, permease protein yadH
MNFREKFNAFSTIVRKETVRILRIWIQTLIPPGITISLYFLIFGKLVGSQIGDVGGHTYI
QFIVPGLVMMSVILNAYNNVVSSFYGAKFGKNIEELLVSPTPAYLIVLGYSIGGVIRGIL
VGIIVTVVSLFFTELRLYSPWIVIVTVALSALMFSMGGFLNALFAKKFDDVTIIPTFILT
PLTYLGGVFYSIQMLPEAWQIVSKFNPILYMVNAFRYGFLGVSDIDPGLAIGLLAVGTIL
LYSLSVFLLSRGIGTRT
>fig|1049789.4.peg.3055 Permease of the drug/metabolite transporter (DMT) superfamily
MDSKQETLLTRLSMGASEETKGFIYALLGTVLFSSKGVLVKLVYNYGVDSVTVLAFRMLF
AIPFFAVVLYRESSRSDAAPIASKDYLNVVALAFIGYYLASFFDFWGLEYLSASMERLVL
FTYPALVLLLSFLFLGKKAHSVELYAVALTYSGILLAFLPDAEANGQKSLVGAALVFLSA
LAYSVYLIGSGQMIPKLGSRRFTALLMLWSGGFVLLHFFLRKEVSSIFLQPLPVYAYGFA
LGFLTTVLPAFLTTAGIQRIGSNKASIAGSAGPIFTLFLSAILLNEKITWENLGGTTLVL
SGVLLLSRKKKIVV
>fig|1049789.4.peg.3666 Acriflavine resistance
MGVDLFPDVNIPIVSVTTIYPGAGPEEIEELISKPLEEELSSISGLKKISSRNQEGVSVV
FGEFTLSTDIKYAEQQFRDKVGLVRPKLPDGIKEPKVVRFDPADQPIVRLAVFADLGQAQ
LYDLAKETVKSKLEQITGVGSVKLVGGTRREIQIELDRNKLISYQMPMVVIAGRLKSAGL
NTPVGKFESGTKETSYRTLGRYESISQIENTIVSFGGDVGNSVLIKELGSVRDGTEDEET
LGYLWASKSDAVEEEDVALFAHPFIWTGQTFRKIKNLFSSKKKEAVEKEIKPALFIDVYK
QSGGNTVAVADEVLKRIDKLNADIKPLAGNPRIRLIRDGSRWIRYNVEDVTEAIVLGVLL
AVITVYFFLGNFRSTVITGLALPNSMLGAFILMWIMGFTINVMTLLALSLAVGLLVDDAI
VVRENIFRKLEEGHNVLEASEKGTMEVALAVVGTSLTVIAVFFPVGFLSGIVGQFFKQFG
LTVVFAMIISLFDGLFVAPMLSAYFAGKLDHSKRNKAVVAFDKFQTWLEKIYGITMKFAL
AHPGKVILLTFLIFVLSLVSCSFVKKTFLPANDQGEFLVTLDLPPGTSLQGTKEVADKVL
LDLQKFPEMDKIAVTIGKPDGGEPNSATLAIALVSSKKRKKTTVAIKDEIRDILKNYAFA
RPAVSDYSAVGGGVQYPFQLVIKGDNLAEMEAYSKKVIDRLKAIPDLADIDTDFRAGKPE
YQIALDNTRMQLVGVLPGVAGAELRYQIAGDTVSKFYDKGIEYDVRMRLHPDQRNLRAAY
GQTKVPNIANKLIPLNAIGSGKETVGPSRINRIDRARTIVINANLAPGGAIQSATEGATK
IMTTELPPPAGVRFNFQGQSEDFKELIVNILVAFGLALVFIYLVLSSLYESFITPVTILF
AIPPAISGAFFALFITGEMLNLFSMIGLILLMGLVAKNSILLVDYAMQAIRDRGITRDEA
IFEAGLVRLRPILMTSLAMIMGTVPIALGLGEAAKSRTAMGIAIIGGLILSTLVTLIVVP
SIFGGIDRFREWIESKFRPDMGATVSHTESTTAGGNNHRETADLSEWAKAVEEPVKKPTS
KKKK
>fig|1049789.4.peg.3964 Quaternary ammonium compound-resistance protein SugE
MNWILLITAGLFEVGFTTCMKLSDGFRDWKYAIGFLIFACLSFFFLNRSTQTISLGTAYA
VWTGIGAAGTVVIGIFFFGESAQAWRIFFLSTLIASVIGLKFVAIE
>fig|1049789.4.peg.4097 Glyoxalase/Bleomycin resistance protein/Dioxygenase family protein
MIIVEGIDYIVIPTGDLDSSVKFYSELFDFETIEERTGEFAIIGLDSVNIKLLHTNGTKG
ALSEAKSPVLSFVLDVDDFTEAIVELESKSVQIVRGPEARDGGEFLHFLDPSGNILEINY
KES
>fig|1049789.4.peg.4197 Multidrug resistance transporter, Bcr/CflA family
MYLPGLQSISRDFDTPISNVQLTLTSFFFGISFGQLVYGPLIDKFGRRTPMMAGLIIYTV
SSIGCSLSVSVWSLVFFRFLQSLGACAGMVVPRAVVRDVFSPHEGAKVFSQIILVMGIAP
IVAPTVGGLLLTYTNWRAIFVVLTLISIIVSIGAWLYLPETGKKDSSVSLKPGGVLKEYY
EVLCVPRFNAYVIASGLSAAVMFAYIAGSPFVFMGIFGLSESEYGWFFGSNAAGLILASQ
LNRLLLRKFEAESIVNAISIFYVPIGILLVLSATYHWGMISMIGLIFLLVSGFGFIVPNA
SALAMAPFTRNAGSASALMGAMQMVSAVVATASVSLLHDGTALPMTLVMSGAGILSLLSL
VILRPKSRLSIEE
>fig|1049789.4.peg.4757 Acriflavin resistance
MMMIGIILLGTIGFSRMGLSQMPDVDFPVVNVTLNLEGANASVMETDVVDPIEEVLLTVQ
GVVEVRSVSTDNSATITVELELKRDVDVAIQEIQTKIAQVQNKLPDALDPPILMKSNPDD
TPIIWISLTAVGRTDQEKMIFVKSHLKDKFQEISGVGEIILGGYVDRTINVFLDPIRLTR
AELTVNDITNTLTEQNIEVPSGRVENKSSEVSLRAVGDVPTVEQFSNIFINSRSGAAMFR
PVRLREVAHIEDGLDEIRRISRFNGISAVGLGIKKLKGANAVQVGDLIKKKIAELKPTLP
KGYDLSIANDNTTFIRDSVKELIFTLVLSALLTGFVCRLFLGSWSSTWNVLLAIPTSVMG
TFLILYFAGFTLNTFTLLGLSLAVGIVVDDAIMVLENISRHREMGKTWFQAALDGASEIR
FAALAATLAIIAIFLPVAFMSGIIGRYFLEFGVTVAVAVALSLFEALSFTPMRASRYREH
KLQEHKKRGGKATIRFPEPVSDPNRFEQTIAKFKAAVAPISFFKKMDPIIERFLQFSERI
YGKALDYVIAFPKIILILSTLLFVLSLGFLLLLKKEFIPPQDMGRFIIRAKMPIGSSIYR
TNEAMKKVEEYLLKKPEISKYMSNIGGMGGTESNGAMFFVSVKDMGQRPKSKKTGREITQ
NEIFGDLRKDLKALVPECKFSVQDLSQRGFSAGRGYPVELVLSGPDWANLAKVADEIRNR
LDQSGVLLDIDTDYVSGQPEVRILPNREAAALRGVSMANIGNTIGPLMGGKKVSRFTENG
RSYDVRVKINKEQGEKADIIPNISVRNTYGEFVRLKDVLVLQATNTLKNITRVNRDRTIK
IFGNPPVAVGQNKATEESIRIAKEVLPEGYSVDVTGSAKTAGESASSLLFALVMGIVMSY
MILASQFNSLKQPLYILLAMPFSFSGALIALYFTKQSFNMYSFIGLIMLLGLVKKNSILL
VEFVNHVRSQGKSIAESIREGCPVRLRPVLMTSFSSIAAAIPPALALGPGSETRVPMAIT
ILGGLVLSTLITFIVVPAAYFLMEKESNDKLSHNR
>fig|1049789.4.peg.4828 Permease of the drug/metabolite transporter (DMT) superfamily
MEQRFAMKQFKNEGALILCTLVWGGTFTATKLSLVSVSPSLFLGIRFAIASAVFLIYALL
QKPTKEFYGESKKPRLWFPILLGFWMFLGFACQTIGLKFTTATKSGFLTGTLVVITPILQ
TIFFRRIPNAGNLLGVIIVMLGLFFLSFDPEVGSGKLSFLFHWGDVITIAGAFFFSLYIL
LMDRVSREVSIQTLLLSQTLTTSILSFLLAFGLDYLGWETLMWHWETGVLPALVYNGLIS
SVGTTFLQTKYQKAVTPTRAGLIFSLEPVFSAVIAYYTLGERMQFVGLLGCGLVMTGVLF
AELFGSSKERVSKTGA
>fig|1051632.5.peg.49 Glyoxalase/bleomycin resistance protein
MSFHFVGIDHVQLAGPPQCEETARRFYGEILGWVELPKPEHLRRRGGLWFQCGAQQVHIG
IQKDFTPATKAHPAFYVRDIQALREHVIKNGLDPIEDEPLPGADRFYLTDPFGNRLEFLE
WL
>fig|1051632.5.peg.212 Multidrug resistance protein homolog
MKHFPSAVWATAFATFVAFMGIGVVDPLLPLIGRAMGATHAEVEWLFTSYIAVMALTMLV
SGVLGTRLGGKRTMLLGLGLVVVFATLSGKSPSIEFLAIVRGGWGLGNAFFTSTALSIIV
GLSTGGMGPAITLYEAALGLGIATGPLLGGFLGSYSWRDPFFGTATLMAIAFLATYFLVK
EPARRETPRTARDIFRALGYRPVLTNALIGLTYSFAFFTILAYSPLTLSHLSPVALGLTY
FAWGILVAFSSVVVVNWLIARWSPMTVLKVNLAVLIGVLVLMGFLPSQDLLGLVVATGFF
CGISNALFTTLAMEVSPFPRSIASGAYNFVRWAGAAIAPALAGWIGQRFGLTWPFFLAAG
VLFFGWVALMPATRLLEGALRQHGDHLAREVKTS
>fig|1051632.5.peg.329 Membrane component of multidrug resistance system
MATNPGQPRVAWGITLFVLIVGAFMSILDTSIVNIAIPKLESVFSVTTDQVQWVVTIYLL
ALGVVVPASSYLGDRFGYHRIYIFSLVLFTIGSALSGLSWNLTALIVFRVIQAIGGGLIM
PVTMAMIYRIVPRDRIGTAMGFWGLALIVAPAIGPTLGGYLVEYVNWRYIFYVNVPIGII
GVLLALRYVPPFPVIHRGDFDLPGFLMVAAGLFGLLLVFSEGQSWGWTSEASILVLMASL
WALVWFVVWELGRAHPLLDLRVFKYDSFTVANLLTVIITIGMYSGIFYVPLFLQTVAGFG
ALKTGLIMMPAALASAFMMPISGRLYDRIGARPLALVGLSLLAITTYLLHNLTINTPIPT
IILWLVLRGFGMGMSMMPITTGGMSAVPGHEVGSASAVNNILQRVGGSFGLAVMTALLTN
RQAVHAQAMAATITPTANGYAVWNQVHALFAQLGFGVVPTTQLTTTELYGLVQEQSFVLA
MGDIFVVAALVTAVGVFVALFLKTYRTHNGERAMSMGD
>fig|1051632.5.peg.447 Drug resistance transporter, EmrB/QacA subfamily
MNPAALRASRGVLLATFLGAMDSTVMGTIGPTVASRFHALVWEPWMITAFMLCTTLATPV
FGRLADTTDNRRLYAVALTVFAAGSAWTALSPSMDFLLIGRIIQGLGAGGLFTMGLILLG
RLFTGPTRATMQARQSAMWGIAAVLGPTLGGVAALGAGWRLLFAINVPLAWMAIRVMRAV
ELPPPDQQAPPLDRAGLALLTIVLVAVLALPTLWATGEPVKWLWAALGTALIGGSLLLAV
ERRIRDPLIPWALWRHPVVRRTTSLAILASALIYSLVTLVPLWTRQLWHADALTTGWVTL
PIPLGWAIGSIMVGRRLKSWGFRRMGLWGTGIFGLGIASLDIAPRFPLPLIIGAGGGLLA
GVGMGSVIMTGLLLVQSTASVDTLGAATGLYNFGRNLGNALGPGVLGGVAVGMATIGHPN
GLRASTAGWLHALNGTWLGIVALTLGVAILLMRFPQHVPNPDPSVDTWNPVSPS
>fig|1051632.5.peg.454 Permease of the drug/metabolite transporter (DMT) superfamily
MTHQLKQPSQRVSRRGVTDALLVLVAIIWGSSYITTKDVVNHVPVLFFLMVRFGIAAIGF
GLVGWQHLSRATATTWLTGISLGLFLTGIFVAETFGVKHTTAIAAGFLISLNVVLVPWVE
KWILHYPIHWALMVSMVIALGGTALVTSSHGGQFVVNLGDGLILLAASLRAIQMTVTKRW
VSEERIDIIALNVIQFMTVWIVCGGLTAITSNSLTIINALKSVSFWLVAGYLGLLGTVAA
FVIQMVSIRHTSAARAALLLGLEPAFSALFGVIGGERLSLSSAIGGGLIVAGTLWGQQAE
YRRRLEIENRT
>fig|1051632.5.peg.503 Drug resistance transporter EmrB/QacA subfamily
MRKWLVLGVVVLGLWMDLMDMTIVNVAIPAIQNDLGTSLQGVQYVVTSYLITIGVFEPIT
AYWADTQGMKRMYLASLAIFTVASALNGLAWSLPSLIAFRILQGIGGGMIMPLALSIVSV
TFAPEERALALGLMGLPLLAAPALGPTIGGWFVQFHTWRDVFWINVPIGIVAFIAALRAL
QEFPTTRKPLDLGGFVLAAIGFASLLVALSNGPTAGWGSLEIVLLLQIAIFSLALFGLWE
ARHPSPLFDLRILRLRWYSSANVVTFFTMMGLFGVLYLLPVFLETVGGLGPMDTGMTLIP
LVLSAAITIPLSGLLLPRLGAVGLTSLGLTVMGLGTAQLMHLGLSWDAGWLRLWVSVIGA
GLGLGIMPAITVAYGSLPPAWMNQGSAMLNLMRQVGSALGVALYTTIIQMREPVYWTQLA
STVTVTNFRAQARLAAWQQQGIAHGLSPAQAHVWALTMMAHQLQQTATLWAFHNAFGAAA
VAAVIGIGPALWLWGSRQVLRPPDARHTALGEPGGVT
>fig|1051632.5.peg.695 Permease of the drug/metabolite transporter (DMT) superfamily
MRRGFLFLISATLLWSGNYVAGRVLARQMDPLELNAIRWTISAVLLWGILRAGGKTLRWR
SHWAVYFLLGLLGMVLFSSLTYLGLARLPAVQAGLISGLNPVMIVLLSLWLLKETPDRST
WAGVLLAVLGVVILVETKRANWSAHLITGDVLLVLAAWAWAFYTVVGKRVAGDPLELTTG
AAVMSVIPNWLLSWVGSSPSGGHLSAVGWGALIYVSTGPSVVAYWLWNLGVRRVGASRSA
PTMNLLPLWTVVLGVGLLHEQLALNQIIGGVIVLAGAWLSGRPRPSAMGLAH
>fig|1051632.5.peg.796 Permease of the drug/metabolite transporter (DMT) superfamily
MKYCQLRIPRRLQGYLMVLLSATFWGVSGTAAQKLFVVGHVHPGWLVSIRMLGSGALLLL
GSVMRQASTSLRLLKRAAWGPLLAFAIVGLLGVQYTYFEAIHTGNAAMATLLQYMGPSFI
AVYGALTTRRWPSPVGFGALLLALGGTLLLVTGGHLAHLAVPATAIVWGLLSALFLAFYT
IYPVPLIRQWGSLPVVGWGMVIGGLVAAGLTRFPDGGPSRWTPSILGLVLFVVLIGTLLA
FFLYLASLTRLSPTEASIAGSAEPISAVLAATLWLHVRFTSMQMVGGMAIVAAVVVVAWL
RPFEQRSSASAGASGRGG
>fig|1051632.5.peg.1017 Vancomycin B-type resistance protein VanW
MRYWIMVVWLLLWPNVPLPTFLAPHGGRQWAQLEYVPSAPVVVVPGESAARAMKLPYLLA
RQTTNYNHASPSQAKNIELVAQRLNGTVVKPGQIFSYYARVGPYTAENGFGWGRMFVGDR
IVPSIGGGVCQGSSTLYAALLRTGLPIIERHHHGLTVPYLPPGEDATVASDYLDFRFKNN
RTTPILITAQAGQRHLTVAIWGATPGPEIVVKHQILAEYPFKILKRVDPKLKPGQEQVLA
PGQKGVSVKTWLEIKTPHGTETRDLGIDRYRPSPRIIAVGPKTPSADSTGP
>fig|1051632.5.peg.1018 Permeases of the drug/metabolite transporter (DMT) superfamily
MLVFWMIARVASLTGERIMFHAIGDGLDPWVTASSTYGGAALLLWLTAWTTGQAVWVPGA
WLPSVVYAGSFWLYIAALSRGPVSQVTPVANASLLVAFFVRPSWGVMSVLALVLFAVGLW
WLVPKTGRLSTAVWWMLLSDGGLVWGRLLDSRLAGGAPALAYAATLYSGVTLVFLAGTLI
RRQGVSLGRVWRQRGASLAGASFFNGFSYLTVVMLLGYLPPSGVEAVSAIAGITGTWMGA
LWFHEEHVGRRVLAAVFMTAGAFLLILHHVQNAPTADLPLDRRAFFR
>fig|1051632.5.peg.1268 Permease of the drug/metabolite transporter (DMT) superfamily
MIDPEIRDRSVSPRSGGPRRTWAGLLALALVTAIWGYSNVLIRQLEHQWDPLLLLWVRYA
LVGLVGIPWLVTQGLSWSSWLWGGLVGAILAVTTLAQAIAMESVSVDQMAFITALYVVLT
PLVMAFFRRRRPPRAVMAFALVSLTGVLLLVGHLTFTVAIGTLWSFAAAGLATLQIISTA
RFSRRLGAFELTFTGALGAAVILGLLLLIPGTHGPFHPVWSWRSLWRLLYLAGPGTLLAF
WLQIWGQSRLTATQAAFLFNVEPVWTAVFAWLVLGQTLSPGQGIGAGLILVSLLALSRDG
>fig|1051632.5.peg.1747 Permease of the drug/metabolite transporter (DMT) superfamily
MKGYDPAGRTGGSIIQRLGGMIALAAAATIWGGMYVVSKELLTAVSPVLLMWLRYGIASV
VMLGGLIARRQLQFDRDTLKWALRVGVMGYVLSIGAQFWGTALSTATLGSVITAATPAFM
VLFARLLYHEGMTAAKITAVGLATLGVLLVVPWQGAARITWGSGILVAAALTWALMSVWV
GYMPPTISTTRVTAYAIGIAWVLITPAAWVSLPTVSAGVWQSQAFWLGVLYVGVLSTALA
FWLWSYGLRQVDPATGGVFFFFQPLSGTILAALFLHEAVDPSLVIGGVLIVAGVIVSQWA
QKTPSPRPVGNRGDGEDSSVNP
>fig|1051632.5.peg.2023 Drug resistance transporter, EmrB/QacA subfamily
MMPRQTLIIVGSAAMCVGLSALDMSITTIAAPRIVASLRGPITQVALIFATYLGAAVLIL
PWSGVLADRWSSPGVLIGGLALFGVGSVGCLIAPNFLVFLLSRTVQGLGGGVLMVLPMTI
IGQRYAPNERPRWQGILAAAYGLATLVGPPLGGWITTVFGWRWIFGLNLPLTAIALVGGS
GIPSHRGSSGESPHWTNLVLFSGIVGFILLLTTRHWSAMEYGVFIVGLLILGVPFVQQVR
NRQSSLWPQELEESLIISRGFLLMFLIAASIEMGAVYSPLLFQRIFLITPQQTGIWLIPM
SLVAILASLWSGKWMTETGLYRRLLIGAQFIMVFGLMLATLSLVTHILGILEISTLLFGL
GLGLQQPILAVVIQAATPDTYIGRMSSLLPLVWNVGALVGILISSFALALFHGLWGWVTL
YLMASAILLLTVGIAIRLPYRSILDVTSHSENASGGYSV
>fig|1051632.5.peg.2526 Drug resistance transporter EmrB/QacA subfamily
MAVLNSTTLLIALPTLTRVLHMSTFLAIWVLLVYMVVQTALVLTVGRLSDVWGRKKLYVA
GFAIFTVAALLAGLAPNGLLLLVIRGIQAIGGAMVMGNSTAIVTDAFPRHELGLALGINS
IVIALGQVLGPILGGLLVTWFSWHWIFWFNVPIGIVGTLWAWKQLQDVVPPAREPALDYR
GNITYIVSLVALLMGVTAGGIMGWTQPLAVGALLMGALGAMLFIRLEKTAAYPLLSLSLF
ENRVFLLSNLANFFIAMVRGAVILLFVFYFQGARGDSPLEAGLLVIPLAAAMGVIGPISG
WLADHIGPRVPASLGALCVAIGFVGFGITLHRSTGYGLIAVWMILVGFGNGLFNSPNTST
IMGAVSPQSRGVAAGIRTMLFNTGGVFAIALVMALIASRLPSSVMMAVLAGETARISTSG
LENLLLALRSIFLILAIIALAAALFSWIPARRQDPTPTVSRLSHTRVS
>fig|1051632.5.peg.2528 Permease of the drug/metabolite transporter (DMT) superfamily
MTAEAIIYTILWASAAIATKFGLMAGPPLMLAGFRFTFAGVILLIIRRITRHPLIPPRRW
WRPLFILGALNTTVYLGASFVALTVMPAGLFNLFVATNPLMVLLVERFVLHRTITRNQWA
GLILATIGLALGAGQSIWQWHTPIWSLALIVLGQTAMAIGSIYFHVRRIDLPNMAVNMWQ
LLIGATLLWPIALGTERTVPIHWNAEWWGALVWLIGGVSIGAMLFWFHLLRHGGARQASF
WLLLTPVIGYILGWLLLHESFTWADLGATLLVIGGLILAQISIPAAPAETPSTNY
>fig|1051632.5.peg.2711 Multidrug resistance protein B
MDRKWVVALAFVAAMFMNIMDTTVVNTALPAIARQFHTTPAGADWVVIGYLLSLAVWILA
SGWLGDHWGTKRVFLAALAIFTGASWLAGLSQTLGQLVLSRLIQGIGGGIMAPVGQAMLY
RAFPPAERARASMILTIPMVMAPATGPVIGGFLVDHWSWHWVFYINLPIGLITWIFSFRW
LPEYRTFTQTRFDGSGFLLSALGLLLFVYSLSEGPLVGWAHPQIWLSGLLGVVLLIALLR
IERQRAHPLVAVAALDNHLFRTSLAIGFFGRAAFLGILYVMPQFLQEARLLSPLQSGLTT
FPEALGVILSTQVVGRLYPRIGPRRLMTAGLFGVALVIAAMTSLNLRSSLWEIRSLMFLL
GVGMAYMIMPLQTAAFAQISHELMGRAAALYNAQLQVSGAMGVALLTTMMTSFGNGSIHQ
VNPYHLAFELGAALALLGSLSALWIHDHDALNTMTIKSQAS
>fig|1051632.5.peg.2945 Drug resistance transporter, EmrB/QacA family
MLAMALAAMDSTIVATAIPTIVRDLGGFSLFPWVFSIYLLTQAAMVPIYGKLADLFGRKP
VLMAGTGIFIAGSVFSGLAWNMLALIVFRGFQGIGAAAIIPITSTIVGDLFTLEERAKMQ
GYLSSVWGLSAVIGPAIGGFFVQYASWRWVFYINLPIGLAALLMLGGYLHESVSRQAHRL
DYEGAFLLMAAIGCLITALLEGGVHWKWTSPASILLLAAGLVGLALFVGQERRAPEPVLP
LWVFRQRAISAANTASLGIGILTIGLSSYLPTFVQGVLERSPLVAGFALGMMSIGWPLAS
SLSGRLYLTVGFRATALIGSAVTILGSLGFVLLSPESSPWQAGLASFVMGCGLGLGSTSL
LVSIQSVVAWNRRGMVTGSNMFMRQLGSAIGVAGYGGLVNARLSAAFHHPPATVASRLPH
NLNAAGLALGRLASMPEAVSRYIRLALAGAIHRVFWGVFLVAAMTFLIEWALPQHLRKKR
VPDPDRLRP
>fig|1051632.5.peg.2963 Drug resistance transporter, EmrB/QacA subfamily
MSEKGVIESRPTVSRPSTALSGRALWLSFAAATTGTFMVNVDASVVNVALPVLQHQFQLP
ISTLQWVITGYLLIITALLPMAGYLADALGRREVFMGGVLVFTLGSLASALAPNFSGLVA
ARVLQGIGGATIMANVMAIIALIFPVHERGRALGLIGSVVAAGTLAGPPLGGLLTAWYGW
RSIFWINLPVGLWGLWGSWRYLPHFPPDPHASLQRFDWAGAGFFMATTSLLQFGLADLHH
WTGLAFLAADGLSLAAFIRIESRNDHPLIPLRLFRVRAFSFNMLAGMAYWVLMMFPAFLM
PFYLHTERHLPISWVGLSLVPQALAMIIVSPWGGRWADRRGIMGPGRTGLALFILADVLL
ASLPLSAPLWTIWLALAIIGVAAGLFSSPQNAAVLNSVTAHDTGLASSLLATQRNLGRAV
GVALGSGILSLVWLLIGAGPNPSHTDPHYIHWLLIGIRGVFWSGIGFALIGLWLLTDPAK
SPGSGGKA
>fig|1051632.5.peg.3316 Drug resistance transporter, EmrB/QacA family
MMTSRAKTWIVVSIMLAMMLTALDMTIVGTAMPSIVSDLHGVSIYSWVFSAYLLTSTTPI
PIYGKLADMLGRKRVFMVGTGLFMIGSALAGVSQSMPELILFRALQGLGAAGVLPVALTI
VGDIFTLEQRGRVQGLFSGVWALSAVIGPLTGAAIVEHVSWRWVFYINVPLGILVMLILW
LAFHEQVESHGHAIDYPGTVILTAGVTLVLLGLLDTGTTREILLGIALVTLVGFVFWEQH
FSEPVLPLSIFRHRMILLGNIMNFFGGIIMFGLISYMPLFVQGVQGQSPTVSGQAITPMM
IGWPLAALSIGSLIKKVGYRVLGILGGTLVMLGTAWLGLVGDRTTLVLVGSMLAIGAGLG
FSLTSLLIGVQNAVPWNLRGVVTGSTQFFRNIGGAIGVAILAAVFNEGLSRAISRAPRLH
GLNTASVTETLLVPRLRDRLAPTLHQLLLSTLNHGLAAVFLTIFGIGVLAFVTMLALPAK
PRAWDQEAETAPTEEVG
>fig|1051632.5.peg.3350 Drug resistance transporter, EmrB/QacA subfamily
MSSEAARAQGLRALWEALPSERFTTRPNYIWYVVGTVCIGAFMAAVDASIVNVAIPDLSR
YFSAPASIVGWVLISYLLTLATLLTLFGRLADMWGRRPLYTFGFLVFIIGSAACGAAPNL
LFLIVARVFQAAGAAMLQANSVAIITATVPANVRGRAIGFQGSAQAIGLSVGPAVGGALI
GLFGWRAIFYVNVPVGIIGTLMAAMILPKDKLTNTGTQFDWWGALLFSPFLVSLMLALTW
GPHLGWTSPTVLGLFLVSVILLVAFILREKGFRAPLVDINLFKLRVFTMGNLTGLMSYMV
MFGVLFLMPFYFEKVSGYVSAVVGLLLTAVPIGMTVVAPQAGGLADRYGSRLLTTAGMGV
TALGTLLLSVMMSLHADLPVLIVGLFLVGAGLGMFTPPNNSSVMGALPPTRLGVGGGILN
MARSLGMAMGTAVSSSLMAIFLGIFGSHLVRGSKLVWIPTMRYALLALAIVAAVAAVLSI
LKTTRENASPQEKIEVPMEF
>fig|1051632.5.peg.3475 Permease of the drug/metabolite transporter (DMT) superfamily
MTKAATQATGTSPGKLESLGVVYGLAGVLVFSLTLPASKAAVGSFGVLIVGPGRALIAAL
FAALTLWTRHERLPQKKYLPGFIIISVGAVFGFPLLTAWAMDRVPASHGAVELALLPLAT
AAVSALRNGERPSWFFWSCSAGGAATVVMYTWFAGLGRIHLADLALIGAVIVVAFAYAEG
GRMASELGGWQVIAWSVVFSVPALVVLLIADFSFVGVPDVWHATWTAWAGLLYLGIGSQF
FGFVAWYTGMGMGGVARVSQIQYLQPFFTIIFSWVWLGEQLTIKTLVAAIVVVLWVAVGK
RATVRRP
>fig|1051632.5.peg.3520 Drug resistance transporter EmrB/QacA subfamily
MQSRHTRKWWILSVVTLVAFVTNLDGTIVVVGLPRMIEGLHVSMTTGLWTLTSYIITSTV
FLLPAGRWSDLIGRKKIFLSGLLIFTGSTFLCGIAPTGSFLLAFRFVQGMGAALALATAT
PIIVSTFPPQQLGRALGINSTSWVMGSIVGPVAGGLLVGTLGWRWVFFVAIPFALIGVVG
SMIVLKDTASTPSVPTDWVGALTFGLGLLSLLLALSFGPKWGWFSTREVGLGLLTTLAFI
AFIEIERRLPHPLFNLGLLAHPHYRSGLLITLSYSIGFFATTFLLTLYVQGALHRSPVEA
GLLLVPLSAPQLVMGPLGGAWADRYGPSRLIALGIIGMAGGTFWLGHLSTAYRVWTIVLP
LLLISASNGLAWPSLTKAVMSAAPRDKSGSASGMFFSFRNVGMALSLTVALVVAAASLPP
ALASQIYVGTGHVLNSRLAASLVHATNTGFQVFVGFYALAFVALLPFFRRRSDAVRPSAP
PLP
>fig|1051632.5.peg.3714 Permease of the drug/metabolite transporter (DMT) superfamily
MSRLGAKIWLLGITLIWGATFTLTKGALTDVGVLPFLGARFGLAALGLAVLAWGRGADWS
WPGLLRGAGLGVLLFGGYLFQTWGLTTIQPAMSGFITGLNVVLVPLVARIWLKTPIRSNA
WGALGLAILGLAVLSGIHWQGWARGDGLTFVAAVFLAWQLVAVERWAASGATLSLAFVEI
AVVAVLSGLGSRLTGQPVWSPDMLKGPVLRALVVNGLLGTALAFWIQTLAQQVLPAFEAA
LIFMLEPVFAALVAAWIGHESFSWRTIVGGAMILAAMMIADPEWRQWWKVRHHLSNTST
>fig|106370.11.peg.719 Polymyxin resistance protein ArnC, glycosyl transferase (EC 2.4.-.-)
MHHRHGPAIGAGTTTSDRQDAGPGRRWAGTTTGSHTDVSVSAIHRPEHPQAGTPVQAASG
DGVAAVGPDAPYVTIVLPCYNEQDHVLLELERITAAMDASGYSYEVLAIDDKSTDNTLAV
LREVAPRFPRMRVMPFRRNGGSGTARRIGTQEARGKIVVWTDADMTYPNERIPEFVRYLD
DNLDVDQVVGARRTEEGTHKWARVPAKWFIRMIAQRLSGMKIPDLNSGLRAFRRDVSLPY
LRLLPPGFSCVTTITMSFLSNQHPVDYIPIDYAKRSGTSKFHPFRDARRYILQVLRMVMY
FDPIKVLMPVALWIMGLGFVKLIVDLIRYDFHVATSTLLAILVGFQIVVLALIGDLVARS
RSDT
>fig|106370.11.peg.1227 Drug resistance transporter EmrB/QacA subfamily
MAAQTQAPAAAGGGMTGGSGDRLDPALIRLAGIVLVGAVVVQLDATITSVAINTLARSFN
VGISTIQWVSTGYLLALAMVIPVTGWSAERFGAKRMWLLSLVLFLVGSALCGAAWSAGSL
IAFRIVQGLGGGLLLPLMQTIIAQAAGPERLGRLMAAVGVPALVTPVLGPVIGGLIVDDL
DWRWIFFINVPVCLIGLVLAWLGMPDVRTPGRHRFDALGFALLSPGLAAIVYGFSVAGRQ
GDFTGVRVIVPLALGAALLVLFTVHALRTAVEPIIDLRLFRSRAFAGSSGMMFLFGISLF
GAMFLLPLYEQQARGRSAAAAGLLLAPQGLGMMIALIVLGRVADRRSPRLFVLVGLLLSA
LGSVAYTQVAADTSEVLLGVSLTVRGIGLAMALIPVMSSAYHGLRREEIPRATSAGRIFQ
QIGGSLGTAILAVVLSHQITGRPAGTGPADPVALAGAFGTAFWWTLGSTVLAAPFAFLLP
GRPAGAEQPAPSGPPVELPRPAGAVPTRRRSGDHGELKSHETSPGRRAAVSGAEGNRHDG
REYRVPAPRGGRGGGQWRG
>fig|106370.11.peg.1834 Tunicamycin resistance
MLVCPCLTILRLVPTLIWINGPNAVGKTQVAHNLHRRLPGSFISDPEHLGFAMRRMLPKP
RRMDFRDVPLWRQAVSEMLHLALQGPEDPVIAPMTILDPGLLGELTASARAAGHRVEHVT
LLADRTTMIRRIHRRGETSRSFSARQLDRALDVLRAPEFARHLPTDTLSISAVADDVASH
TGFTLSPDTSGRLVRQGRQLAVQLRHIRLNA
>fig|106370.11.peg.2262 Drug resistance transporter, EmrB/QacA family
MDPGVRTSASRNTLMSLLAHERARPRAVRDLPGGWWLAVATVCFGAFMGQLDASIVTLAY
GPLCAQFHAPLAAVTWVSLAYLLTLVALLVPVGRLADAHGRKQFYLYGLLVFTATSAACG
LAPSLAALIGSRVAQAVGAAMLQANSVALVATSAPRPRMRAALGVQAAAQALGLALGPTL
GGALVTTLGWRWVFAINVPVGTIALIAGYYLLPRTRQRTDPAPFDWPGLALLATATTTLL
LAISAVSGLNLPSAATAILAILAPLAGYGLVQRERRAPAPLIDLRLLRIPALAGGLVGAL
CGYLVLFGPLVLVPVVLTDRGTSPLHAGLVLTALPGGFALAASGAGAVLPDRWSDRRRYA
LGAVTCTMALAAALAVPLSAPWLIPPMAMLGLGLGVYTPTNNTTIMSAIPAHASGTGGGL
VNMTRGLGTALGVAMVTLAVHLAAGATGPRLAIVGLTAASLLLFTPLLTPSRGMRNIGTE
NSARC
>fig|106370.11.peg.2344 Drug resistance transporter EmrB/QacA subfamily
MIEPGPAAVAGQLGQRQHGHREAQPEQCGKHRQEQHAAADAANSVSPGVELRFLAAEPAL
GLGDLHAFPGPHPQTRGAGGELLLPLGIFRDRNFALSNVAVAAAGAAVPAVLVPLYFYLE
SVRAMSGADAGLVVAPMAILAMVCVPIIGIFGDLIHPRVIPSAGFALFAVTLMIFAMFMT
PDSVIGCS
>fig|106370.11.peg.4107 Multidrug resistance protein B
MTRPEAHSGSADGPNPSNDLEQAGPSLVPLATTLIVGAFAALLDTTVVAVAIDTLGRDLQ
ADITVIQWVTTSYLLAMAAVIPVVGWLVDRFGARAIWSGALGLFLAGSVLSGLAWSAGAL
IAFRVLQGLGGGMILPLTQLVLARAAGPQHFGRVMGVVGLVGQLAPISGPVLGGLLIDTW
GWRWIFFVNVPIVVVSLLMTTRWFPREDPRTERSLDVVGLVLLPTGIVAMIYALSNVESG
STVVSAQVLVAALVGVALLAAFVLRPTTPGRPSLIDLRLFGDRSFRGGSVMLFVFGVTSW
GPMFVLPLYYQQLRGLSALDAGFALAPQSVGLGLAYLATGRYADRLAPRPLVAGGLVVAS
AGTLPFVFATADSNLTLLGISLFVRGIGFGAASLPASAAVYRTLRTADIPGATSASNVIQ
RVGAATGTAVMALILQADGFTPALTWMFVLTSGALAGTVFLPGQKPAPAPRDTVPTTTAT
GAQ
>fig|1069080.3.peg.215 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MFLQENQAIKAENHLMEPSDKEHTQLEIPISLINLLRFASPAIIMMLFIASYTIVDGIFV
ANYLGTEALAAVNIVFPFSSIIFSLAIMLSTGGSALVGIKLGSKAELQAKQYFTLLLVSA
AGAGICLSAGALIFREQILSFLGAEGATLAYAQTFFTITASFAPVVILQILFENFFITIG
KARVALGLTIVAGLVNAALDYLFLAVWGWGIEGAALATAAGSFFPVAYALYYFTNQQQLL
AFVKPIWEWAIIKQACFNGSSEMISQLSGGIIALLFNIILLKLFGIAGVAAVSIVLYSEF
LVLAIYSGFSMGIAPLLSYNYGGKERLKIKKLVRLALGIVLLLSSGIYVLLNFFTGNIVA
LFVPINSEVYILAKQGLTIFAVGYILAGVNIFAAAMFTAFGNGRISAILAILRTFVFIVL
GLYVWPKIISGIGVWLAVPCAELLTIIFTIYYLQTNRKRYSY
>fig|1069080.3.peg.352 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MKLSFAVASKRILQFMLPILLTMLTVAGMNAIDIIMSGHASTADLAGVSVGNSIWFPIYT
GFNGVIIALTTIIAHLLGQNKPQEVSTALKHGLYLAILTGAAIIFFINLIISNINYFITI
EPYVQEVAVGYIRAISWGVIPLCLCNTLRQFIEALNFARIISLVYLSALPLNALINYGLI
FGNWGLPKLGGIGAGYATSITYTIICLILLIIITQQQPFASYRIFQIIRLDYRIFFEQLR
LGLPIGFSIFLEMSIFSLTALIISKFGTVTIAANQAAFSAVTIIYMFLLSLSIALNIIIS
YELGANNPVTAKQFAHYGLKFSLFLSLAVIVLLFFTRAQVAALYSNDPTVQILIQDFLVY
VLFYQLADAILTPSQGILRAYKDVNMAFYIALISYWLVCFPIGYILDNYYNFGAVAYWNG
FVCGMSVGALISLYRINYLQKTSLPKI
>fig|1069080.3.peg.506 Permease of the drug/metabolite transporter (DMT) superfamily
MKPRDLFMALLIVTIWGANFTVIKLGLADIPPMLLAGLRYVFATLPAIFFIKRPNISWKY
LALYGLTVGIGQFSCLFYALKIGMPAGIASIVLQAQPFFTVIFSAFLFKESLYRLQILGF
AIAFTGLYLIGGDTSGVPLPLAAFLLTILAACFWSISNIVIRYSAIEATQKQEKLDMLAV
VIWSSLLLPVPFFLLALLFNSPQELLSVVTNLKPSSLAAVLYLALGATVFACGMWNILLS
KYSPTKIAPLSLLVPVTGLITANLVLGEQLSFWQTLGGIIIILALLVLNFKSLPWANAFK
AK
>fig|1069080.3.peg.597 Multidrug resistance ABC transporter ATP-binding and permease protein
MQVYGKYIKKYRVPAFGAMLCVTLEAGCDLLGPTLMAKIINEGIIAHSMAEVTKWGGMML
LITICGAFFAITRSILASTVSQRIGADLRYEVFKKILNFSEASADKIATGSLITRMTNDI
NQLTQFINGMMRIFIKAPLVCLGSIILATLLNPQLSIIIYGFVALVATVIAISLKLSYPL
YAKVQQAIDRVNSVVQEYLLGIRLVKALGTYNEETERFEQANKNLEQRSLASQMIFMVSG
PLIMLLFGTATTGVLYWGSSLFAKNLANPGEISAFIIYMTQMLIAIMMITSIFNVFVRTK
TSSERILEVLNSEEDFSNSGIEQKLQGSIEFSRVSFAYPNGSGLLALRDVSFKINAGENL
AIIGPTGSGKSTLAWLLLRFYQANQGKILLDGVELNSLAVHNLRSQIAIVPQKSLLFSGT
IEENLLWGNMQADKIQRQRALELARADFVQEFPAAEQTVLGSRGVNLSGGQRQRLSLARA
LLKQAKILILDDATSALDGVTEAKVLKNLQTVASNHTVIIITQRCSTAMAAGRILVLDEG
EKVGFGTHSELMQQCPTYQEIYKTQIESNKVS
>fig|1069080.3.peg.813 Vancomycin B-type resistance protein VanW
MQCGKRKFYGFVALITLVTIFFVASVSFDIGEQIVENIRIQNVAVGKLTRTQALQELKQQ
IRKPVLKLSYKNKNYYITPEDIAYGYDYQASIEQVYQVGRIPQENIYQRYVDIYYTRQYG
RSYQLVCTYDKELLHTKIQEIIREIQIQPQDAKLIGSTQQNNLQVEQIGVLVEAYGLYYQ
ILEALHKGQDCEIRIETLNFLPGRYAQDLVKFKKMLGRQSFSSDEADLALIDCLDGIVWK
KNTSISWQQQLNRIEKSTNYSIPKGNSQLMLEGFYQLSQQLQLFSERISLDEAGKLIVQK
GNLDLIIRNNSNQDIYISCYKERNKIYLEFWGEN
>fig|1069080.3.peg.1269 Permease of the drug/metabolite transporter (DMT) superfamily
MTHYHPFVCMAYIFIWGTILLLPLMLVFNAFQPLVFNFFQPPNFSLLGILVYLGIFSSVY
SYFIWYKAINTIGAVKTSVFMYLNPLISTITGAFFLSESLAITTMIGGACILCGVYLVNK
NK
>fig|1069080.3.peg.1287 Broad-specificity multidrug efflux pump YkkC
MLILSSFLLLIRAYKLIPVGIAYAVFVGIGTIGTYIVSIYFFNEKLSFVQFIFLFLLLIG
IIGLKITTQEVKK
>fig|1069080.3.peg.1340 Permease of the drug/metabolite transporter (DMT) superfamily
MQENQLAGHLSVFITILIWGTTFISTKVLLVDFTPLEILFFRFSMGLLALMLIYPQRLKV
TDNKQELYFAGAGLCGVTLYFLLENIALTYSMASNVGVISCIAPFFTALFSYCFLGGEKL
RANFLLGFGAALFGISLITFNSSTSFQLNPLGDFLAVLATIVWAAYSIFTKKISAYGYNT
IQMTRRIFAYGLVFMLPALFFLDFRVGLERFANPVNLFNIIFLGLGASAMCFVTWNFSVK
LLGVVKTSIYIYLVPVITVVTSVIVLKEQITLLAIVGSVLTVSGVFISDSQNGLKLLANL
VRKR
>fig|1069080.3.peg.1483 Permease of the drug/metabolite transporter (DMT) superfamily
MKNNISKSLATLLVLTASIAYGTLSTTIKLAYKAGFTVGEMVFGQIFLAFLFMFCFALIK
DYKFLGSIKPKTILILIGAGSISSLTTIFYNLCLQYISASLAIILLFQFTWIGILLDYIF
NKVKPSRLRIIALLIILLGTYFALNISYQALAVNPLGIIFGLASAFSYSFFIYFSGNLAT
NIPIIYKNSIMLSGSLIISLVFFPPIFLFTPSVIPISFYLYSSYLAVLGMVLPFYFFSKG
VPIIGTTSATLIGALELPTVLIGATLILGEKIVLHQIIGICLIILGIFISTRTKIST
>fig|1069080.3.peg.1765 Fosmidomycin resistance protein
MSVKYNLPILLLAIAHLVTDLTQGAVPILLPFLKEKFLLNYSQVGMIVLVQNLTSSVIQP
LFGYYTDKISIFWLLPASVLVATIGIVLTGYATSYSSLLFIVIITGVGVAAFHPQASRSA
MLLSSADSKGKNMGLFSVGGNLGFALGSIIMSVLIVLPGDLYNTVYFLIPGILVFAWLMQ
ARGQLDTYTKVGSKGEKIKPAAKVAQAYYYLLMLISFIFIRSTIQMGITTYLPLYYIENL
AGEPKYAANLISMFLVFGVLGTFLGASLSDKFGRKKIILASMVITLPLLILLPYSSGLST
IVLTAVLGFALVFSFATTVVLAQELLPNNIGMASGLTIGFSIGLGGVGVTALGFLADNFG
LEIVFKLLMFLPLLGLVLVSRLPNDQK
>fig|1069534.5.peg.148 Multidrug resistance protein B
MMNAALIDGSDLSDIDDFAKKYDGKVSAKEKYKYVGRTVKERVKNFKRDNTGFSCSTDYK
KGKLVWFSVPYDKGWDATLDGKKIEIIKSAGMMAVKVPKGEHNLVFKYHTPGFKLGIIVS
IISFIVFGIYTAILVFRKRIN
>fig|1069534.5.peg.616 Multidrug resistance protein B
MTTKKKWHVMPAVVSTTIMSFCGVLIETSMNVTFPTLMKQFGIDAGLIQWVTTANLLTVA
ISIPLSAYLIRNVSEKNLFVSSNLFFLLGVILDSIAGNFELLLAGRILQGIGTGLALPLA
MHIILEHVPLEKRGFMVGVATMTTCFAPAIGPTYGGIILHHFDWNKIFLFLVPILAISFV
VGIMSIPQRKIETKTGFNFGGYFFLALGLALLLVAIERFSLWLLLLSIMALLMFYFSNKK
KRLISLNVFSNHRFVWFMYGALVTQAIALGISFIFPNYLQIGLHQNTVTAGLFMLPGATF
VAFLAPVSGRLMDELGYFKPIVFGMTLASLGLAFLAFVLPNAGVKLLLCGDVATKIGMGL
ATSSLVATSLSQLEREESIDGNSVLNTLQQFSGALSTTVVSVIFGWAQKTMSNGSMVGSR
ISIVLILAITLIALGLVLKLKFEARS
>fig|1069534.5.peg.624 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MSILMSIMQLIVIPVNGITQGVQPIISCNYGAEDMLRVKETVVRLVSVCLLGTLILAGVA
IFCPGIYASMFTNDAELVALTCRIMPSFFLGIAIWVIRAACQATFLALGQANVSLFIATL
RKIILLIPLALILPKFSGVKGIYIAEPVSDVISVIVTVITLKRIFIEMEDKS
>fig|1069534.5.peg.639 Ribosome protection-type tetracycline resistance related proteins, group 2
MLNNLLCYNTFRQYERSDGTLFPQTTLKHIVTGIIAPVDSGKTTLTEALLYKAGELKKLG
RVDNGDAFLDFEELERKRGITIFSHQANLTWKNLQLTLLDTPGHVDFVSQTEQVLRVLDC
AIMVVSARNLITSHARTLWSLLDFYHVPTFVFVNKLDLSDLSKADIVQRLKQLDQGIMAF
DGTETEELAELDDALLEKYLENDSIDRTDVLALIKQRKAFPCFFGSALKLEGIDALLQGL
ADFAPELESRNEFSARVFKISHTEKNERLTWLRVFGGSLHPKDMILDDQKANELRVYDAK
RYGAAKEIVAGQICAIPNLNETFVGQGLGFLENDAASCMTPVLSYALNPNGCDLHACLVA
LKELEDEDEHLHVVWSKQLNELRVQLMGPIQLEVLQQILKDRYELDVSFEQGRTLYKETI
TQTIEGVGHFEPLRHYAEAHLIMEPGKPGSGLVFSSDCSLEELDKNWQNQILSCLKSKEH
LGVLIGAPLTDVKITLATGRASIKHTVGGDFRQASGRAVRQGLMMLKERHGLKLLEPWYR
FVLKVPEEKLGRAMNDIQQMSGTFSLDQASGTLSGLAPVSEMQSYAETVRTYTHGKGLLE
LSVDGYRQCHNEQEVVSNSSYDPLSDLENTPQSVFCAHGAGYTVDWSDVPKMAHVPYRSS
>fig|1069534.5.peg.1059 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MSDLRTFMNYVIPSVLSFALSGVYAIVDGFFVGNTMGDIGLSAINVAYPITAVILAVGTG
IGMGGAVQYSISSAQNKPKKAMNFVNGTLWLLIVSSIIITLSAGLFPEFFVSLLGAKGTL
LEMGTIYIRVIALGAFLQIGSTGLVPMIRNYGGAFFSMVAMISGFVTNIILDYLLVWVLN
LGMTGAGLATILGEGLTFLLAMIYLLKKSSISLKIPLSIIKKISGPVIRVGIAPFGMSLA
PNISLVIINWFSIKYGGDRAVATYACISYVICVIYLILQGVGDGSQPLMSRYYGAKNLHK
LKITRDMAYVFSLILALLGCFATFYAKGAIGALFGTSASVNAEIEKIIPIFLVSVPFVSI
SRIATASFYATEKTAFSYVLTFIEPVLMLILMLILPPLFGGQIMVWWSSVFARIISAILA
YALKLVVEKSEKTQLS
>fig|1069534.5.peg.1210 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MQRTIDTVQSMEKGSLFLASTSHLPQRKMKTLTKGNPIKLILLFAVPLLIGNLFQQLYSL
SDTIIVGQTLGVDALAAVGSTGSIQFLIIGFAQGLTAGLSILTAQYFGAGDYQKVRQSFV
TSIVITVIVTVLLTIFSLTFVGKILELMQTPAEIKNDAQTFISVIFASMVVLMAYNLLSN
IIRALGDSKTPLYFLIFATIVNVILELLFLLVFHWGIAGAGFATVLAQGISVVLCIVYII
RKLPLLQIEWKDFKTITKESLGKHLYVGLPMAFQMSIIAIGAVLLQSALNGLGTTAVAAS
TAGGKIDQLATLPMMSLGVAMSTFTAQNYGAKKCGRILQGVRQTIIVSITVAIIGAVLII
IFGKQLVTLFVGNQAPAVLKLSQTYFNITCTFYWVLGILFVIRYTLQGLGQSIVPTLAGI
AELVMRSSAALFLAKALGYAGACCANPMAWAGSCFVLIPSYVKSYKMLKQREKEQDNKSN
EESGTEF
>fig|1069534.5.peg.1436 Permease of the drug/metabolite transporter (DMT) superfamily
MTDKEQHKEIFKKKNLILLILFAVFGMVPSQLTFFLAIRYGNAATATILQFLGPVFIIVC
LAIQYRKLPRRIDVISLMIAVLGTILIVTNGKIGTLALSAAGIFWGIMAGVSQASYTLIP
RRLLEQFDARLVTGLGMVIGSVLFWPLILTTKIPSITPFTVGSFAYIIIFGTMASYLCYL
QSVKYIPASTTGMLSAFEPLTANVLSVIWFHETLGAFQTAGAVLILSTAFLQAMALKGK
>fig|1069534.5.peg.1438 Permease of the drug/metabolite transporter (DMT) superfamily
MSKRNQGIMLAIIGTMFWGISGPFAQALFAQNVKPLWLVGARLLLAGILLSQVLICV
>fig|1069534.5.peg.1912 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MKNDNAVMTEGSYKKKIVYFAIPIFFGSLFQQMYSTADSLIVGNFLGSSALAAVSSSGNL
IFLLIGFIQGLTIGCSVVIARFIGARDHKMTSLAVHTTVALGLVSSLVLTLVGIFLAPQI
LRLMSTPEEIMDQSVEFFRMYFLGSAGFVMYNTLVSILQASGDSKHPVYYLIIASIINIL
LDLLFIGVFRFGVGAAGVATSISQTISALLALHQLMTQSGSCRVDLRKIRFQPQILKMII
KFGLPSGLQNSIIGLSNVIIQSYINFYGKNAVAGIGSYCKVEGFAFLPVTCFTMALTTFV
AQNLGAKEYQRIRAGVRFGTICTLVLAEGLGILLFVFSPQLIGAFDSTPAVVSFGVARAH
VCGPFFFLVAFTHVMAAVMRGAGKAMIPMIIMMICWCAVRILTLYVVGMFYQTIQTTYWV
YPLTWMLSSLAFLLCYRRLDFTKL
>fig|1069534.5.peg.2097 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MIGIPASLTNLMQSYNMTIINRYLIDYGSKAVAAMGIAIKVNMIIMMIMVGFAFGAQPLI
GYSYGAKDNKRLQKIIRFDLLVEVGFSALAAVFIIIFAPHLIGSFMDDSAVVAYGTGMLR
WFTLTTPFCGIVLVLTTCFIAMGKAVPSFVLSISRQGVIFTVVILITAACFGYDGIICAQ
PVADFLTAVVGIFMYAAARKSDQTLRKED
>fig|1069534.5.peg.2098 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MENKQELFEKAPVWKAYFIISLPVVFSMLVTLIYNMVDTFFVSGTQNADLVAGVSQCTPL
FTLMLALGDIFGLGGSSIISRLFGQKDDATAKNVSGFCFYAAVISGLIVTGLMFLFQTPI
LKMLGATDSTVKYASQYYFFIAWGAPLIILSLTPSNIIRTEGLALQSMIASVAGSIVNIA
LDPLFIFTFKMGGLAVQRLQR
>fig|1073972.4.peg.245 Vancomycin B-type resistance protein VanW
MYKILKTYKNLRLEKSISSVIFTILIILSIVFPISFVNYRISSLVNSWEGKVYSGVTINN
VDVSGLSRSALKDFLVEKFSGSITNDIVEFRLNGKGIDIQSNELGITYDYDRAIDEAFSF
SDGLTYTQKVNQILNPQKIKDIKLNEIFDISDYQVESLYNKLSNRFNVDPINAEISIVDG
QPVIVKESYSSIEIDKESLISMISDTDPSSAFQNGMNLSAKSLNSKYTSDILGKINGKLS
SYSTSYKSSSSERATNVELSASFINGTILMPGESFSFNRIVGQRTRERGFKDAAIIVGNV
YESGLGGGICQTSSTLHQAVVRAGIIPTQRRNHSLPTSYMPLGFDAAVAWGSLDYVFKNT
YSFPILIDISTEGRNLTVSIYGDVTAVDKTYSTVAETQESIPYSTKYVNDNTLAKGTQVV
QKNGVNGSKVKVYLVSKDKKTGKVIEKKHVWNDYYAPQDKVVRVGTK
>fig|1073972.4.peg.380 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MGTIQLSDKFNYKKLLRFTFPSMIMMVFTSLYMVVDGFFVSNFVGKVPFAAVNFIMPVLI
ILASIGFMFGSGGSDLVSKILGEGDQDKARRLFSLIVYSTIICGIIIFIVSFIFIESIVS
FMGADGEMLENCIIYGKIILVALPFYMIQFEFQSFFITAGKPHMGLITTVVCGVTNMILD
ALFMAVFSWGIVGAAVATTISQILGATISVLYFCRPNAGVLRLTKTKMNAKALLKTCTNG
SSELMSNISLSIVSMLYNFQLMKYAGENGIAVYGVLMYVNMIFLSIFIGYSTGVAPVIGY
HYGAKNYSELKGLLRKSCIIICIFALIMFGLAESLAGTLASIFVGYDMELMGMTERAFKI
YSISFLFSGFAIYGSSFFTALNDGVTSALISFLRSLVFQIVAVIVLPLIFGIDGIWFSVI
AAEIVAVLITVLFIIGKRSKYRYL
>fig|1073972.4.peg.441 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MVKIFFKYSISSMIAMLVTSLYTIMDGIFVGRGIGDTGLAAVNMVLPITIMYFGLATMIA
VGGGSLVSKSFGENNEIKAQNIFGQTIRLIVLLSLFLSVIALFGCHKIMYLVGARDEILY
YSSEYLKYYSLFCSFNLIGIVINSFVRNDGNPKLGMIANIFGAITNIVLDYIFIFKFKWG
IQGAALATGIGQIMTIIILMNHFIFKKGALRFKRASFNSDVLKSIVMIGFPSFLAEITFS
MIIFFYNIALIFFVGSKALTAFSVINYINSNIYMVLLGMNFGVQPLISYSFGEKNGKDML
KFYGFSKRFGFSLTFIYVLICLIWGNNLIKIFTSDLEIIRIAYFGLNVSNLAFFILGINL
TTSIYYQAMEIPRYSNVICIFRSFIFLPISLLILSRLFGLTGIWMSLIFSEGLSLLFINF
VVRVKRITEKLIFN
>fig|1073972.4.peg.1181 Multidrug resistance protein B
MNKSNRQFTKIFLLNMIVYISLTMVHPITPKFINENNLPTFYFGLLQGCLNISTFISAPT
FGIICNIYGKKITMLISLIGYTIGQIIFGFFPNNVSVIIARIISGIFIAGYFVSSMAYVS
SITPVKLKLKKISYFNASNSIGVILGSLIGGILGINDYKLTFFTQISISLLSIILITILF
KDNTPKNKDSKFTLKILNFKDLSKIKKSNKFVYLILLIMILTFLAIQGYASTISYYVEDI
LNLPTSINGVILGSSGMFTLITNLIIIPIVGKKFNSKSLYMFSILLSGSSILIAMSVTNQ
YITVIALLIFIITHTLITPTIQTLLLENSTQNQGEILGIQNGFKAIGSFLGSILSGLLFN
VWFKLPFIVIGLSLILSFIILKSFKEKSPHH
>fig|1073972.4.peg.1328 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MKRMDLLNDDLKKIFIRYLIPGILSSLAISLYIFVDTMFVGIGVGRDGLTALNVTVPLFT
LFTSINLCIGIGGSNILSLNKASGGKDSNKIFTIAFLFTIMIGIIISVLGVVFTDQIGKV
LGATPDISYLFRDYFRILVGFTWAFLISGVLGCFIRNDGAPKLVMTATVVANITNVVLDY
IFIFEWNLGIKGAVIATVISPIVNILILSTYFFKKNSNIKLCKVRFDFRLLSRILNNGFG
TFLLEMSRGISIFIFNNILVRLGGNIYVASYGIILNVSYVIICIFSGIAQSIQPIVSMNY
GHNSIKRTKTVFRYGFITSIFIGVSSFLIALMFSENISSLFINNDFELLSITIYGMKIYF
IGCIFMAFNIVTIYFFQSINQSQKSILISLCSGILFIILGFLILIPILKINGVWFVYPFS
EFLGCIVCLLIIKRTNIENKKELIL
>fig|1078846.3.peg.1897 Permease of the drug/metabolite transporter (DMT) superfamily
MPSNQSPAEQRNQMTGFALVLLGAFGFSAKAILIKLAYAADVQIDAITLMALRMLFSLPF
FLVVAFWNNAASVAAPMTGRQWLLAIALGLTGYYIASYLDFLGLQTISAGLERVILFLYP
TFVVLLSALFHKRKISLRVGLALVLSYTGMLLVFMEQLSLASANILLGSALVLASAVTFA
IFTMGSGVMTHSIGSTRFTAYTMTVASMATLAHFGLRHGTEIKHLSTGVYVLALVMAVFS
TVLPSFFMNAGIRRIGASSASIISTTGPIATLALAFFILDEAITGTQLAGTFLVLAGVYV
VSKK
>fig|1078846.3.peg.2020 Permease of the drug/metabolite transporter (DMT) superfamily
METTQSICGTCLVLIKRAYFLAFLAMMAIAGNSLLCRLALKHAVMDAASFTTARIMASAL
MLISICLPRLGRYCCLAP
>fig|1078846.3.peg.2397 Acriflavin resistance protein
MHDSLVLLDSIREHEGSDKPITELIIEACTSRFRPILLAFLTNFAGFLPTLLETSPQAQF
LIPMTLSLSAGLLFGMAASLVLTPVCYAMMGEK
>fig|1078846.3.peg.2842 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MTIRSKQLVALTLPVALSAMLDNAYRVIDQHAVQWLGVEAQAAIASCTFILIAYYAIYSI
ISAGTLSLVARAVGAGQAAGQKQLMGNALAGSVLLGSMVLALSGLYAPVLTNLLGLSDSV
ADQASMYLRWHAVYCLPQAIMPTLNAILIAFGCTRTVLLLQIIATVLNILLNPVCIYQLG
YGIGGSAMATGLSQAVAAATGLVLLRRTTPFRWSDLGLGRPVLKIAKIGLPMCWGTMMFA
LVYGAMLHWVISPLGAPVNAALGIGFSALEGFTWPVFWGFSMGIASIVGRSLGAGNLNEA
KQAIRLAFKLLTMAGLAVSGIFFFGATLLCGLFTQDALVLGEAVRYAQILAFSQLFVAYE
SLAEGVLGGAGKTHSILYWSAPLNLLRIPFSWLFAVYFGYGAAAVWWVIGASTLLKAMGK
WWSVRSGAWQKV
>fig|1078846.3.peg.3002 Multiple antibiotic resistance protein MarC
MLNWNEYLQLLVGLLSVVNPIGIIPTFISLTTNRPPQERRHTAIVCAFSVAMVLFISLLA
GEPILHFFGIGLPAFRVSGGLLVMMMGISMLSANNDNIRHTPEEKAESYEKDSIAIVPLA
IPLLSGPGAISTTIVYAHGGQSLEHFLLVGSVILSVSVLVLAALLAAPKIADAMGRTGMN
VVTRVMGLFLTSIAVEFIAKGLGELFPVLVKIFP
>fig|1078846.3.peg.3097 Glyoxalase/bleomycin resistance protein/dioxygenase
MDISGINHINIVVTSAQLPDVVAFYEQIIGLRQGLRAVSKRNGAWLYCHDTAIIHLSVVE
QAPYTGKDTLFNHVALSCSGVTGWVSHLNRHAVHFDIDYRPSPEMTQLFLYDPVGIRIEL
NFAGERLEPSA
>fig|1078846.3.peg.3728 Membrane fusion component of tripartite multidrug resistance system
MMDTVKKSRHRFKNIANLLGDKAGGQLRQWRYRRNRRLLSVTLSAVLVGVVYWAYWQRHA
SHFVTTNDAYVIGNLVALKAQTSGTVVDVRVDTTQYAHKGEVLVRLDGLAAKVALEQAEA
NLAETVRQVETLSSTAERLRQKIAAQEAPLGRTRRDLLRYRSVAQEGAVSAQQIENTEFT
VRELEAGIRQTRAELGGAEALIHGVALEHNPKVLQAASALKQAYLDKVRQNIVAPVSGYI
AKRHIQPGEQVHPDTPLLAIVPLDYLWIEANFLEDELTEVQPGQAAEITVDLYGSEIVYH
GEVLGIGAGTGSVFGLLPPDNATGNYIHITERVPVRISLRPEELKAHPLRPGLSAVARID
TRQKGRSVLQPFTATPPESYRTDVYDTQLDGAEALVDKIVKGNRAMARAPV
>fig|1078846.3.peg.3730 Inner membrane component of tripartite multidrug resistance system
MSLDDDNTRAAWAPLTHDSLNAELAGKSSLGASQFVLLNFALLLGNVLVLFNTGAFASIS
LHATGELGVSPSHASWIQTYYFISLAIALPVSAWLAARFGEVRWYLIAMLAMALGSLLCS
LAHDLTWFLLGRALQGFFGGLTIPLSQTLLLREYPESKKAFGISLWSMAALSPFTLGPLL
GGWIADNLGWHWLFYLNVPLPLLSAALVWALLSDRVSVRSLRPFDTMGFVLLAIALACLQ
TALNQGQDEDWYNSAFIVSLAIAGVLALVYFIIWELGERYPLLNLRLFARRNFAIGTIGL
SVSFLLMYGLLSVLLVRLQSVSGYTSFLAGAVLVPLLFFAKPMAGFFHLIVHRYDARLLV
CLNMLSFALFCYMTSTYDFFQRNSWFTHTLWSQVLEGFCLGGLFVPMTTLFLSGLNAKRQ
TQAVELGGILRILGGSVASPLLGVLWERRTAFHQSHIVQTLGTYDALGREALTSLDTAGF
HGQLTIARLAQAANQHAAILGLDDAFRLSAWIFLGLATWVWFAYPVKPITKMGKKERLRE
NALESLVEEP
>fig|1078846.3.peg.3768 Permease of the drug/metabolite transporter (DMT) superfamily
MRAKVWAALLAVYVVWGSTYLMIRFVVETLPPFLSAGLRFLVSGVILLGWRCLAGDAVPT
LRQWRSAAIVGTLLLLGGNGLVCWAEQTVPSGVAALIIGTVPMFLVIADALRPNGTRPSL
RVLAGLVIGFLGIYLLVGPSAISNGMPLNGPGVAALLLASLLWAAGSIYSKNADLPETAL
MTTGAEMLCGGFALMTVSALSEEWGVFSFAQVSASSWLALAYLILFGSMIGFASYAWLLQ
NASIPLVATYAYVNPLVAVFLGNWFAQEPLTPRILSASAIIIGSVIFMNSSYRGKPAATQ
GAGK
>fig|1078846.3.peg.4001 Acriflavin resistance protein
MSIETKKDSLTVAIVRLFTTSHLSLLFLIISLLAGAAALFLTPREEDPQIIVPVMDVFVQ
VPGASAEEVEKQVTTPLETLLRQIQGVEYVYSASRPGESVVTVRYLVGENLENSVIKTRD
KVLANQDIIPPGVTNWLVKPVEIDDVPILMLSLSPQRSDMEATDLRRVADELVERLREVD
NVGKSWVVGSAPRRISIYPDPAKLQAGNITLLDIQQALAKNNVNLPVGTLTEQNKEIILE
AGPHYQTAEQIGGTVVKVVEGRLLTLRDVAQIIDGGADTDTYTRIGFGPAVAHMQTAGEV
AKLPAVGEERPLTTIAIAKRKGSNAVSVAEQVLTVTEQLKGTLIPDDVLITITRNYGETA
DHKVNELVMHLSIAILTIIVLLALSLGFKESLIVSLAVPMTFAVTLLCDYLFGYTINRVT
LFALILSLGLLVDDPIVDVENIHRHYKLRKEPPLQALLSAVDEIRPPTILATFAVIMSFV
PMFFITGMMGPYMAPMAFNVPVAMLMSLVIAFTVTPWASFKLLKGDYGKDHGEAFDLKTT
RGFKIYQAIVAPLLASKAKAWLFLLIVMIAFVASAMMAVTRIVPLKLLPFDNKNELQLIV
DMPKGSSLETTDEVAAALGHYLATVNEVSSYQSYVGLSSPMDFNGMVRHYYLRQGANVGD
IRIVLADKKHRDQPSHNIALRIRPEIERIAKQYGANIKIVEMPPGPPVLSTLVAEIYGPP
EASYADLLHVAKRVRGDIEKTAGVVDVDDFAEAEHGKLHYLVDHDKAALLGISTAQVAQT
LQLAIAGGSVGVLHIPQERQPLTIQLQLPRAARSSEADLLALSVQTSNGQLVRLSEIGSF
KHEQGERAIYHKNLQRVAYVTGEMAGRSPVEAILDLFGTFDEKPLPDGYKAEMAGEGEWK
ITVDVFRDLGLAFGAAMVMIYVLLVGQTGSLGVPLIMMIAIPLTVIGIMPGFWFINLFTE
PVGGYATPIYFTATAMIGMIALAGIVVRNSIILIDFIENIYRNNPLISLADAIVEAGATR
LNPIFLTAASAVLGSMMIVLDPIFSGLAWSFIFGIIASTLFSLVVIPVVYFLIKRNMPKQ
IIQEQ
>fig|1078846.3.peg.4649 Inner membrane component of tripartite multidrug resistance system
MENHQADPHVTSIKRRLLLGRIIGTLIVLGALMTGTLAWRINYQHPRTNDAMIRANIVGI
ASEVGGRIVELHVEDNQYVKKGELLYVIDPRPYLARLAQAKAELLLAEKEVDSRRASSGS
AELAIARLEHQRAAAEAEANRIEAEDEYLHNYLERIEPLAEKQYVTADQLKQARSKYAAS
RAELADARAKALSAQSAIEEAKSESRRAVSLIAQSGNVNARIEAAKAVVTAAELDVEYCS
VRAPFDAYVTNLNTREGEYTKAGAQLFALVDDRHWYAIANFKETYLQSIRPGQEAEVFLV
AYPGKRYRGVVTGIGWANSPDNIKQQGVLPEVQRTLNWVVLASRFPVRIEINERDPEHPL
RMGMTAFVTVLDRLAEIPKPLSAKEDIANTPPIPQ
>fig|1085623.3.peg.424 Acriflavin resistance protein
MSNVQNKSPWYTTFFRSGHLLVLSIIIILVAGLSAVSSLPRLEDPRIDLRNVLILTSYPG
ASPERVEALVSDVLEDELRELYEIKEIKSTSKAGFSSLLVELQDWVDDSSNQQIFSKIRD
SLENASAKLPVGASKPLLEDKRGATAFTMLISIDAANPDTTSLSVSGRLASELVDRVRNV
PGTELVRLYGHPIEEIVVALNPQALAAAGLSIAQVSDRIRSADSKLPAGVLRTDQKNIRV
QVAEPLENLDIVANIPLVAADGSYLRLADVATIEQSWQTPEREFAFVDGQRTIFMAARMQ
TTVRVDQWTEAVKSKIADFNTEFDGTSQANMVFEQNEYTQARLTELTENLLLGSLVVMLV
ILVFMGARASWIVGLALPLCAAFAIFSLSFFDQQIHQMSIFGIIIAIGLLIDNAIVITDE
IRLNLLDQNLTRLQALEKSVKHLFSPLLASTLTTVLGFMPIFLLTGNIGDFIGAIAISVV
MALLGSLAISLTIIAALAARYLPRDGGVGHAWYRRGWQMPAVSHQFSKLLGKLIKRPLLV
LPLISIFCLSGFVLSQQLPSVFFPSADRDQFEIYVWLPNGASIKQTKQVAQSIDVLIREK
QEVQQVTWLVGASTPSIYYNQVMSRDNSPEFANAVVTTNSIAGAAALIPKLQYELQDAYP
NAQIVVRPFGQGPPIPAPIEVDIFGPDINTLNALGEQVRLAMSKVPGITQTIASITTGEP
ELQYDVSENDSYIAQLSLTEIAKQLQLALAGTTGGSVLQGTEELPVRVRINDYQRGSMKE
LDALPLMNRELIQNGASIGVASLGEFTLVPSISGITRLDGERVNKVQAFLLQGVPAIDAS
EQLRELLENGDFVLPQGYRIKMAGDADEQQQALGQLATYAPVLLVLMITALILTFNSVRF
AAVIGMVAVLSVGLGMFSLWVSGLPIGFNPLLGSAGLIGVAINGSIVVIAAINGNAKAKS
GDTKAIVEETMSCSRHILSTTFTTVGGLIPLLLFSQGSFWPPLAVVLAGGVGFSVILSLF
FTPTIVAMMCRIRTSKLQKRAQRTANA
>fig|1085623.3.peg.511 Multiple antibiotic resistance protein MarC
MIEILSAATMLFLIMDPLGNLPIYMSVLKTIDPKRRRVVIIRELVIALVILMVFLHSGQA
LLDFLKIKQETVSIAGGIILFIIAIKMIFPRPGGIMGLPAGEEPFIVPLAVPMIAGPSTM
AALILLANQEPNKMTQWSVALFAAWLISAIILTMSNTFHRVLGEKGLNAIERLMGMILVM
IAIQMLLNGIGRYFQHQLS
>fig|1085623.3.peg.614 Glyoxalase/bleomycin resistance protein/dioxygenase
MPAPFHLAIPVTNLADAEAFYGTLMGCEQGRRSEHWIDWNFFGHQLVTHLVAEMPTAPAP
NQVDSKAVPVPHFGVVLNMEEWTVLAEKLSTAKQSFVIEPYIRFAGKVGEQGTFFLLDPA
GNALEFKGFADESQIFAK
>fig|1085623.3.peg.826 Acriflavin resistance protein
MIAWFAKNDVAANILLFVIMISGLYVATTQIPVDLFPEFEQRNVQVSMVLPGASPQEVEE
GITIKIEEAIQDLEGIRQITSQSREGSASVTVEVEEGYAVRDLLDEMKIRVDAVNNFPVE
AESLLVQVPQWRRDAIGVVLYGDYDSLTLRRFADGIRDELAALSSISQVEVSNVLPYEIS
IEIQEWSLRQYDISLEQVAAVLRQNSTDVSAGNLKTEGGDIFIRSLGQAYKADDFGDIPI
ITTQDGTMIRLRDIANIRDEFEETPLRTRFNGVSAIEVEVFRTGDESIIEVTSAVRDYID
AKQVDMPQGLSLDYWRDRSEPIKARLQTLSTSAWQGLLLVIALLALFLRPSVAFWVCLGI
PMSFMGAFLFMPLFDVTLNLMSLFAFILVLGIVVDDAIVTGENVYSHLQRGEDPLSAAIK
GTQEVAVPVTFGILTTAAAFLPLAFQTGRGSWYAAIPFVIIPVLLFSLIESKFILPAHLK
HVKARNDKNSSKLSMVQQKIANSLEVLIAKVYQPALAQAMRWRYATWMAMFAILIIIIGT
IAAGHTKFVFFPRVQSEVATATLVMPAGTAFESTDRIISSMTQHAKDLQKEYTDADTGES
VIRNIYSISGGRNSTTGRVQIDMIPPELRTVDVTTREVVNQWRERVGQVAGAEQLNYRAE
IGGWGGAPINIELKGRDTESLNELAEKLKQQLGQYAAVSDIEDSLSDGKEELQLALKPEA
RLLGLDLNTVARQVRQAVFGFEVQRVQRGRDEVRVMVRYPLESRQSIETLEQMMIRVGPN
REVPLWQIADVLPGLSPDSILRVDRQRTISVSADFDKQGGDLSLVQSEIREWLQQEVLTY
PSTNFEMGGEARDQEESSQGLLVGGIGLAILIYILLAIPFKSYLQPIIVMSVIPFGLVGA
VIGHWIMGMDLTLLSFMGMLALSGVVVNDSLVLVDYINQKRKEGVALKDAVYNAGGRRFR
PVLLTSLTTFAGLMPLLFEESTQAQFLIPMAISLGFGILFATVITLFIVPLNYLILEDIQ
RYFKRYGADMKGLVSSKAK
>fig|1085623.3.peg.915 Permease of the drug/metabolite transporter (DMT) superfamily
MENYHDNFKGVIAIVIASFLWGTTGTVASYSPDVSSLAIGAFSMGIGGVLLVVTAQKKLF
IDYKLMLEQPRILLFGGASVAIYPLAFYTSMRFSGVAIGTVVSIATAPFFAAILEHLISK
KHISQQWILSFVIGAIGIALLTLGRDQSNNTAYSINQQGLGILLGCIAGLTYAGYSWAAR
RLIESGVHSKASMSGLFGCAALLLLPSLWFTGDNLFSSSTNALVSLYMAIIPMFLGYLLF
GFGLNYIDASKATLITLIEPLVATILAVFIIGEKFKVIGWIGVALVSLCLLMQTIKPQNQ
LRLAFKST
>fig|1085623.3.peg.1029 Glyoxalase/bleomycin resistance protein/dioxygenase precursor
MVLGLLSISLKVADIAISKAFYEKLGFNQMAGHVDQKWVVMKDPNDQVIGLFEGMLEKNM
LTFNPGWDANAKHIDDYIDVRYLQKMLSDKGIDCGQMIGENNKGPANFMLTDPDGNPILI
DQHR
>fig|1085623.3.peg.1297 Acriflavin resistance protein
MTDLNADNDKKVAEEQTGIIAYFANNSVAANLLMGFIIIMGVISYITIPRQMFPTIERNY
INISVQYPGASPQEIEENIVLKIEEQLNDITEIKKSIGRSWRGGGRVTLEINLNEEVNEV
LDKVKARVDSIGTFPAAMEPVTISQQEFRQEVMQLTIVGDLSLDDLKPIAEQIEDEILQL
QNVQLANARSPDDEIAIEIKPEVLRKYNLSIEDVTQAIRRFSANFSAGQIRTESGMIAVR
VENQFYNGEEFRDIPVKIGPSGSKVLLKDVATIKDGFTEGERYFKYNGKNAISLEVSATK
AQSIIPVAESVKSYMEARNQTLPESVEIKVLVDMTYYLNGRLDMMLKNLVQGAILVFLML
ALFLRFKLAFWVMLGLPICFLGAMMLMPIFGMTINILSLFAFIMVLGIVVDDAIVIGESA
YTEVEANGGGVANVVRGAKRVATPATFGVLTTIAVFAPFTMGEGPQSDFFFNIAVVVIFC
LIFSLIESKLILPAHIAHTNFKPLKEDSWRQKFNTAYFGFVNGRYRRFITLCTEWRWPVL
GLFIAMLFISIGLINANYVRVVPNPKVPHDFPSIRIEMAETVSDTITIDALKTIEKVIQD
VDKQIVEEYGSPMVRDILVFNNSRTEGEVMVPLVAEDDRVMDTFELARRWREAVPNIAGM
KSFTVRDDVNGGGDGGEFAYLLFGADIETLNNAGRYLINLLQEEKGLFDVSSTIDPDSKE
VQMTLKAVAYDLGLDLTSIASQVGASFYGGEAQRVLRNGEEVKVMVRYPEFTRERFSELK
YAVIKTPSGQEVLLGDVVELTEKPGISYIRREGGYRSVYVWGSIDEQLVEPNEVTETVKE
KLLPQMKERFPSVKTELGGDIKEQQEQNSEQLMFFAAGLIMVYILLAVPLKSYAQPLIVM
SVIPFSFTGAVWGHYWLGLDMSLFSTFGLIAAAGVVINDSLVMTDFVNQRRKEGYSIREA
VIDAGCARFRAITLTSITTFAGVLPIMFETSLQAAFVIPMAVALGFAVMYATLVTLILVP
CLYIILLDLGRPFVAIKQRFFSSKVVLN
>fig|1085623.3.peg.1841 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MNQTITKQAFLTEMKTLLTLAWPLLIAQVTQTLMGVSDTIMAGRYSYTDMAAVAIGFSIT
MPVLMFIQGVTLGLSPIISRLQGSKQTNKVANALHQCIWLSLILSAFALLLIFVVVPLLE
NIEMEAAVRTITVDYIIYILLAAPGFALYQSLRNCCEGLSSTRPTMIIMFAGLLVNIPAN
YILINGLFGLPEMGGAGCGLATLLVIYVMAFVTLLYMMIAKKLKQYDLFTKFHWPKLDLQ
LSQLKIGLPIAFTIVFEVTLFGVVAVLLARFGAEVVASHQIALNFSSLMFMLPMSIGMAV
AIRIGYSVGNEDALNAKISVYCALVCSIVIALFTATMTVILSTEISALYTENQGVIMIAS
SLLFFAALFQFSDGIQVVSANALRGYKDTKAMLILSFVSYWLVGLPVGIILGLTDWFFPV
MAAKGFWIGFISGLSCAAVLMFWRVKVIQKRVAHDVKAYA
>fig|1085623.3.peg.1864 Acriflavin resistance protein
MSKQYEEEHIDTEKGIIAWFARNSVAANLLMFVIILGGIFGIIRVQKQVFPTFEVNVISV
QVPYLGAAPQEVEEGVILKLEEAIKDLEGIKKMTSTAREGVGSISIEVEDGYDVQNLLDE
VKVQVDAIPSFPGNTEKPVVYRIKFPQDVLWVSVYGETTERELKEYAQGIRDDIANLGGI
SDVSVVGSRDYEISVEISERKLQEYNLTFNELVTAIRQSSIDLPGGSIRSENGDILLRAN
GQAYNAWDFAKIVLVSREDGTRLLLGDIATINDGFIEDRQFALFDGKPAVSIRVRAVGDQ
NALQISKSVNSYLDEKRKTMPANLSADTWGDSSFYLADRLSMMLKNMGFGALLVFIVLSL
FLRVKLAFWVIVGLPVCFLGTLMFMPASQIDVSINMLSLFGFILVLGIVVDDAIIMGESA
YSEIDKKGHSTDAIIRGVKRVAMPATFGVLTTIAAFSPMLMVSGTFGVIWKTIGIVVIMC
LIFSLIESKLILPAHLVHMKLKPYDPSKATKFQKFRDIFSIGIKSFIENKYIPFLKKAVQ
YRYTTLASFIGLLIITIGLFASGLVRWQFFPTIPSDFMQASVELEPGSSLGQRDQAINAM
LDAMYKMDDEVADETGTKAVKHVIAFDNGTLGGSVFVELTKGETRELTDVQIQDIWREYL
PEIPGVKNFNIGSPGGPGGGNGLSFEFRSDNISQLENISKELRSYLGSYAGITEVNDSFS
GGSDEIKLALKPEAESLGLSLSQLAQQVRYGFYGAEAQRIQRDDEEIKVMVRYPKDERNS
IGNLETMRVRAPNGDDIPFSEVADIELGQGYANIIRVDGNRSVSVTAKVNADVVDTRDLL
IDVQTKVIPEMLERYPAVDFRLQGNSKDESEAIVSLAQGFLFALVAIYALMAIPLKSYSQ
PIIIMSVIPFGMVGAIVGHLILGQAVSVLSICGIIALAGVVVNDSLIMVDFVNRARAEGR
TLIEAVLKSGSERFRAIILTSLTTFMGLMPIVFERSLQAQVVIPMAISLAFGILFATVIT
LLLIPALYMILDDFKRVFKRKDKTMLTQPLPDNG
>fig|1085623.3.peg.2179 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MLNGDIAKTLKSMTIPMIVGMIMLMTFSIVDTFFVSMLGTEQLAAISFTFPVTFTVISLN
IGLGIGTSAIIGKYIGSGDTVHAKTIATGALMLSALLVGILAVVGVFSIEFIFSLMGADE
TLMPFIKAYMVPWYLAGIFLAIPMVGNSVLRAFGDTKTPSIIMAAGGAINAVLDPILIFG
WGPMPALGIQGAAIATAIAWAVCVVWILYLLAVKRQLIESRLLSLQEFIVASKGVLKIGL
PAAGANMLTPIAGGVMTAVVATYGAEAVAAWGVGNRLESMASIIVLALSMSLPPFISQNY
GANKLARIKTAFDMAAKFVMLWQLMVFVILVIFSGYIAQVFAEEASVKRDITLFLCIVPL
GYGLQGIIILVNSSFNAMHKPMSALVLSILRLFVFYVPIASLGSYLYGLIGLFWGCVIAN
VVTSVLAYIWFNRNLKNEMALQTFSPVLGSEK
>fig|1085623.3.peg.2439 Polymyxin resistance protein ArnC, glycosyl transferase (EC 2.4.-.-)
MSSKYISIVVPAKNEAENIDILVDEIITHLDSLYQFEIIYIDDGSSDSTAEKVLGLMRRY
PDQVRLIQHDSSVGQSTAIYTGVKQACGELIVTIDADGQNNPADMINLIKTAEAFPKGVD
FCVAGYRKKRKDTAWKRFQSRVANGVRATLLGDDTPDTGCGLKVIPRKTFLRLPYFNHMH
RYLPSLIKRLGGKIVVVEVGHRDRQHGESNYGMWGRLFAGLVDMLGVMWLQRRNKLPVVR
ELFPDD
>fig|1085623.3.peg.2586 Permease of the drug/metabolite transporter (DMT) superfamily
MSNPLLFLATVMIWGSTWIAINYQINVVDPAVSVAFRFSIAAAILGFWCWFRKLPLRMPL
ETHKKLILVGILFYTLDYSFLYAAQHHIISALLALLSSSVIYINVVLRRVLLGKPMRLEV
VIGATFGLIGIAMIFIPEFEAMSVNEGLTVGLLFAAASFLSAGVGNVVSEKILDVGTPVI
QMNFWAMSYSLIFTFGFAFISGASFTLPTVASYYYALLYLALFGSVLAFGAYMKLLQQIG
SDKAAYVVLVYPIIALAISTLFEGYQWTILSAIGVIVVLFGNAVAMGKIALFMRKNAVLN
T
>fig|1085623.3.peg.2618 Acriflavin resistance protein
MNLSDIGLSYNRLVMTVVLSLMVFGGVSYFSLPAQEDPSIKVREAVITTNFPGMPAEKIE
LLITKTVEEGVRNVDEVEEIRSISMQGTSVVYVDLYDRYFDLDQIWDKVRNELDKVRSEF
PEGTPPHFINDNFGDVAILTVALQADDGIFMGDMFDMAQHARDMIYTVDGTQSVSILGAQ
QENIVIEVSDVKAAQLGVSPSQLLDTLQQQNVIRSGGNVNLNGKSFSIVPSGDFTSIESI
KEVIFTLPNTNNSIRLEDIATVYRSIQTPEFQTAYFNGERAIVLAVAKNDRFSVTEYTPR
LEKMLRALEQQMPAGISLNVITRQADQVNAAVDGVSINVIQTLAIVLAVVILFLGVRIGL
IVGAIVPAVVLIVLAVLNFSGMALERMSLATLIISLGLLVDNGIVVAEDFKKRLENGEKR
REIVSDIGRTLAIPLLTSSVTTMLVFLPLMLAESSSGEYTRSVSIVIIYSLFTSWLLSLM
VTPYLCFLFIKDEAVKKKSGFQAKVANFFDLINPVYKSILRFVLKYRAFTMALTILLFLG
AGFAMSTVPVKFFPDSDRAQVLAYIDLPAGSSMRETEDVLEKVFDVLDDKERYPYVENYA
AYGGFGGPRFVLSLTPITPESSKAFVMLNLVDRQYQNETIKSLREDFANDFPKVNARVTK
MFLGPSDSNKIDVQIIGPDKDYIYNTALEIEEIFRNLEGTVEIKNDWENKITQIDVQIDQ
ARAKRAGVTSADVARSLETFFSGRVVSEFREGDDLIPIIIRGKAEDRYDISRIYGINVYS
ASRNVNVPLEQVADINFSPQYARIARENLFRTVTIEAKNLNMTAEDMVPILQPEFDKIRE
RLPPAHRLEFDGVVKDSKESQASLNANLPLCLAAVMLVLIAQFNSLRRAGIVILTVPLIL
IGAVIGLLSVQANFGFMVILGLYALAGIIVNNAIVLIDRIDIERKETEDQYEAIVEACMR
RLRPIIMSTVTTILGLLPLILSKDALFFGMASALAFGLAIGTLLTLGVVPVLYSLFFNIK
KQTAPE
>fig|1085623.3.peg.2762 Permease of the drug/metabolite transporter (DMT) superfamily
MNFRLIVGTVTAMLAFAGNSVLCRLASEQLTIDPASFTSIRLLSGAIVLTILLLSIPKLM
LAEQPLSADGDANSNDVYVNKCFRLLSLKQSSWLGGFSLFAYAAGFSFAYISLPTGTGAL
ILFAMVQITMLSYALVQGSRFSLAQWFGFAMALVGLVYLFLPGISAPPLLGATLMGIAGI
AWGVYSILGKRVVNPTQSTTENFIRASIITLLLSLIFINDISISSRGALLAIASGALTSG
IGYAIWYAVLPFLKAASSASLQLTVPVIATIGGVVWLGEEVSIRLALASISILGGVAIVV
LLPKRE
>fig|1085623.3.peg.2905 Permeases of the drug/metabolite transporter (DMT) superfamily
MDPVKKSLISLHITVMLLGGTALFSQLIPLGSIDITFARSVFACLLLFAVAKLSGDGLRL
NSNRDYFIAFGLGIIMAVHWVTYFMAMQLSSVSVGIIALFTFPVITVLIEPYFEKNRLLW
QDIASAVVVLAGIALIVPDASLENDVTLGVIVGIFSAFLYAMRNLLHRHYFSHYSGAKAM
AWQTLIVCPTLVFFVSDELVMIDLNTLWLLLALGTFFTAIPHAMIATTLQHLRAKTFSLV
ACMQPFYAILFAMILINEQPTWQTLVGGLLVISAAIYETINTHKENQKAKQCS
>fig|1085623.3.peg.2967 Glyoxalase/Bleomycin resistance /Dioxygenase superfamily protein
MLSYATIGVSDLNKSEAFYNELLAPLGAKTLIKMDRIIFIGKSMAEPMLAICIPYNEEPQ
HCGNGNMLAIAPGSKEKCDELYKKAISLGASCDGEPGQRIPDVFYGAYFRDLDGNKIVFN
HFG
>fig|1085623.3.peg.2985 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MTEASEKKEDKNSLVEGPVLPIISRLAMPMIFGIVAVFSISLVDTYFVGKLGTAQLAALS
FTFPVTMAIASLSSGLGAGASSVVSRAIGADNRSHAKRLSTDSLLLASLLVVLISAIGYF
TITPLFKLLGASGDVLKYIIQYMEIWYISMPFLVIPIVANAIIRSVGNALWPSIIMFFAA
AVNIALTPVLIFGFGPIPAMNIEGAAISTMIARIVTFILALYVAIYREEIIQVSKPEYQV
FIDSCKSVLKIALPAGAGSVINPIGIGIVTAIIAGYGDDTVAAFGVATRIESFACIPMLA
LSASIGPIAGQNWGAGNKHRVIQTLKYCYLICVLWSLVIIALFYGFADQFSSLLASSESV
AAKSTDYLYIVAVSLVGYGWIIVSSAAFNSLGKSVTGFNYYAVRTFALYVPLSLAASIWF
DEKWVYIAIAIANLVSGFLVAGYTLLWLKKAKQEDCHPDWTLNLLSS
>fig|1085623.3.peg.3262 Permease of the drug/metabolite transporter (DMT) superfamily
MKTSHLIELLVLGAIWGASFMLMKSTVPAFGVFALVEVRATLAALFLLPVVYFTRQWADL
SGNWAKLLFVGAINTAIPFSLFAYTSVHLDAGLTSILNATAPMFGAVIAYFYLQDRIGVH
GVIGTFLGFLGVVIISQDTQSASPVTLLPVLTALAATCCYGIAACFMKKHLSGVKPFAIA
AGSQVFAALLLFPFALYAWPDVNPDAGTWGAALVLALVCTGVAYIMYFDLIAKVGASQAM
TVGYLVPMFGILWGMVVLGEVLSNYAMIGGSLIIIGVMITTGILKRRRAKINL
>fig|1085623.3.peg.3273 Permease of the drug/metabolite transporter (DMT) superfamily
MHASINTLILVGKTLVLSILKPFYPVLFLLVWSAGYAMGKLALVYTEPLNLLAFRFAGAF
LALTPLVILLRLPIPNFRKSYALMGTGLFLHIGHFGSIYVGMKLGASASIMALFAASQPV
LVIIASALLARKIPAWNVWASLTLGLLGATLIIGVNMQGNEGYLLGAILGFTAVVGLSIG
QVIEKQRKLGVHPIVATWVQYAFASAISIPFAFAFEGLVFENALPFWGAMAFLIFGNSIV
GILLMFTMVRQGSIAKVASIMFMVPAVGALVAWLVADEVPKLIAIPGFILAMLGALWTNK
IANKSLTEPKKPRGQVS
>fig|1085623.3.peg.3354 Glyoxalase/bleomycin resistance protein/dioxygenase superfamily protein 9
MSLALWNKSDTPIQTLRATQRTRQNANSVLKLHHHAFKCKNAEETRVFYEDILKMPLVCA
IVEPSDPITGAETPYAHLYFELADGSWLAFFDFPSKYEELECGFDKTDVWTHHIALEVPD
EATLIAHRKNLDDHGIEYMNIDHEYCNSVYFFDPNGLVVEFTHNVDETERYFHDKARDVK
QDMEHWLKVRAEHYPEKA
>fig|1085623.3.peg.3417 Efflux pump antibiotic resistance protein
MSRFPVTTVALIAVCIGYLIAPMGMAAVNVAIPVLAEDLQASAIKVSWLPTLYILANVAF
MLPFGKLADNYGRKRVYAYGLLLNALSALMCAIGTDIDWILFWRFMQGAAGAMIFSTGVA
IITSVTPSHKRGAALGVLAACVYIGLTLAPAVGGWLTELLGWRAVFYFQIPLVIALLILM
KLKLHGEWKNEHHSRFDWIGSAIFITFACTLVYGLSKLPSLLGFALLLVSLLSLVGFIVH
QSRDRQPLIRVQMFRESRVFSLSLSTSFLMYGSNFAIIFLLSLYLQYIKGFSPAYAGQIL
LMQALCMAIVAPFAGKLADRFQPRIIATIGCSIVAVGFLFLIQISPDTTAFYIGGSLGLV
GLGFGLFSTPNNSAIMGAVKEQEVGVASASMNLSRTIGNLVGMSLVNLMMHYYIGDANFG
PESNPALMSTISLALLMSLSFVIIASVISAVRGKQ
>fig|1088868.3.peg.206 Membrane fusion component of tripartite multidrug resistance system
MADAGEVMDQQSVSANEETGKSKANPLKKFLIIGVCCLLVIGAGIYWWLTRDDIDTDDAF
TAGRIVYIAPHVNGYVTDLLINDNQFVHKGDLLLKIDSRDYEAAKKEAEGNLIRAQGQYI
ASQYMLEVAKKNYPGQLKVAQGQLGIAKAQAFKAKTEYVRQHSIVKAATTQQAIDNATAA
YEQAKAEIIKAEGNLLIAQPVEANIQTSNSQINEQKGALEAAEAKLRQAELNVGWTEVRA
PHDGWISKRNVEQGNYVTTGQSILAIVEPEVWVIANYKETQITNMRPGQKVKIEVDAYPF
LKLKGHIDSLQAGTGAVFSAFPPENATGNYVKIVQRVPVKILIDEGLDPKIPLALGLSVT
PTVYTK
>fig|1088868.3.peg.207 Inner membrane component of tripartite multidrug resistance system
MSEMVVADDGIDRSGWKPKYNPWLIAVVVTLAAFMEILDTTIVNVSLPHIAGSLSTTYDN
ATWALTSYLAANAVVLTISGWLGRVLGRKRYFIICILMFTVSSFLCGMAGSLGELIIFRL
MQGFFGGGLQPNQQSIILDIFPPEKRGAAFGLTAMATVVAPILGPSLGGWITDNYSWRWV
FYLNVPIGIFTVFAVLMLLEDPPWEKKRKERVDVIGLTLITMGLGCLEVMVDRGENADWF
GSFDIRLMGVFAFIGIVGAIFWLLKAKNPVVDLHVFKDRNFAVSSILMAGLGGCLYASAI
IVPQFSQQVVGYTAFLSGLVLTPGGIVIIFLLPIVGRIINVVPMRYVIAFGFFWMGSAMF
FSAHLTPTLDFDHLVLFRVAQTACLAFLFVPLSTIAFMTIPAKYNADAAALFSMVRNVLG
ALCISGATALVTQTRQADQARIVHTMSPLNQPFNEYLAHMKAVAQQAGYAAQDQASVAMR
YLYTDFQKQVAILAYNDVFMIIGFCAFLLVPICFLLDGYTAKKKKEK
>fig|1088868.3.peg.592 Permease of the drug/metabolite transporter (DMT) superfamily
MIYIIIAGIIWGLGGVVGQYVLQYKHLDAAWIISIRLWIPGVILLTLCYRKHKKAIFNPL
KTPRELMILLFFSVVGIMNSQLSYFLAIQYSNAATATILQYLYPVVIAIILAFYLKKRPS
FALIISIILALVGAFCLVTDGSIDKITLPPKAIIFGALCVVGSVAYTLSPIPLLQRYNTT
TIAGWGMLFGGIILNCFHPFWHISGIIDFASVISIIFIVLVTGMIAFLLYLIGVKLLGSS
KGSILATIEPLAAAFFSVVILHVDFNIVDWIGAACIIAMIVILAKNKV
>fig|1088868.3.peg.597 Permease of the drug/metabolite transporter (DMT) superfamily
MDFFILTILYKRVLPRMSTVQQVSNGKSKVLVATASGLLTILLWSSLAVTTTSLPNMPRF
QLLWFGFGEAFIIGSIILTLTGRVREMAQPFAPWFTAFCGIFFFHLFYFVGLDFAPPAKV
TLLSYLWPTMLVVCIALLSKKQFHIAYLLGALMGLIGTIFLMPADQGSVLTSGNLFGYLL
GVLCAIVWTIYSIVNRKYISVPTGMMIGVCGGISLVSMMIHFAFELTVMPNSWQEMLIIL
YVGCGPMGIAFLAWDYATKNANLSLMGSLSYLAPLLSTLWLVIAGRAPATMGLLIAVILI
VGGAVVATYPLKK
>fig|1088868.3.peg.881 Drug resistance transporter, EmrB/QacA family
MNAINQNKQNTLLPIVAAIAFFMASLDTTAVNTIIPYLATVFHSPLATTKNIIIFYMIAN
SLFIPLTGVLCQKYGCRIIFCAALCIFSVGSLLCGISGTLNELLIARVIQGIGGALMLPV
GRLAVIQTFPKDQLIKALSLVTIPGLTGPLIGPIVGGGIASYLDWPVIFFINLPFGIAGI
YFALKYFPTQKDENLRIDTWGYIIFAASIALITYALSLYSETKYYMTPTIIICVGTVFLA
AYWIRSLYHDYPLFAPKLFKIRSFSVGLLGNLVARLGCGAVPFMIPLMLQRLLGLSPVAC
GMAMLPLAISAMMAKPFVSKAIHIAGYRNFLFINTLILSASYMSYCLVNEHSGWVLISTL
MFITGFINSMQFTAMNTVTVLDLSAKRQASGSCLLSTVMQVSMASGVAVSAILLTLDETI
HLHALPATHFHFTWLYLGLITAVSAFIFVLLPNKRI
>fig|1088868.3.peg.1309 Permease of the drug/metabolite transporter (DMT) superfamily
MYIESPMPSQNHQFLGIIAVIIAAILWGTTGVSASFAPQVSPIAIGSMAMGVGGLLQAAI
ATNIIRSYRFNLYRQWPYVLCGALSVAIYPLVFYASMRMAGVTIGTVVSIGSAPLLSAVI
EAIMEKAKFSTKWIIGATLGIIGIALLSLSGQEHHADQTQHPHLILGIGLALLAGLTYAL
YSWIARYLMQQNIPSKAAMGSIFGIGGLLLMPVLFMTGSAFLASWSNAAVGIYMALVPMF
IGYICFGYGLARIAASTAITITLLEPIVAAFLAVIIIKESLSIMGWIGVILVFTCLVCVI
MPSRKK
>fig|1088868.3.peg.1516 Multiple antibiotic resistance (MarC)-related proteins
MHLTETFPLLHAFTSVSGSFLFALSALIPIADPLGSCLIFYQVTEEREDAERKLLARKIA
IYAFVILAFSIFIGEFVLRFFGISINAVRIAGGLVIAVRAWTLLNAPEQNADRKQKEAEQ
GGRTMALPNGLDAAFFPLTMPFTIGPGCIAVAIALSSVRPTGAGNGAAIFSFYNGLILAV
VVVCLTIFITYTFCDKIMKVLGKSRARILSRMAALILLCIGVQIVGTGIQGFLIPIFQQH
>fig|1088868.3.peg.2200 Outer membrane component of tripartite multidrug resistance system
MKYTFSFLSMVIVIPTLVGCAVGPDYHKEDVWTPSKWSKPTQNLQASVNSQVVMDKINPQ
WWDYFHDPVLSDLERRAVTANLDVQMATQRLIASRAQLMIAGSARFPSVNGSAGYQRNQY
SKKGFSRAIDKIRNREPALGNMVNPSDIDVPAFNQWDDALDTSWEVDLWGRVRRQYESAK
ALKQMSEEDRRGILIAQQAEVAQNYMTLRGLQAQLQIVKENEKIAQDILDLANQRFNGGL
VTELDVRSAEAQLEQTRADIPNLEQQIIEYINALGLLLGEPPRALSTELSTPKPIPPVPS
QVPIGFPSELAQRRPDIRQAEAKLHSATAEVGVAEADFYPKVTIDARLGFQSLSLRDLGF
WSSRAWSVGPSLSLPIFEGGKLKGQLTLKKAEQKEAALAYRKTVLQAWQEVDNALNAYQA
EQLRQVRLQDTVKSNQRSVYLAQAQYRQGLQTFINVLNAERRLLSSQQDLVNSNTQISIN
LVQLYKALGGGWESTYPDSSQIASTQPQTEVQTQGQTQTMSKKN
>fig|1112215.3.peg.838 Drug resistance transporter EmrB/QacA subfamily
MTTTNEPPVATTHTSTASDPAAKRSILLLFAGLMVTMLLSALDQTIFSTALPTIVGELDG
VNHMLWVTTAYILAATIMMPVYGKLGDLIGRKGLFVGAISIFMIGSVVGGLAPDMTWLIV
GRAVQGLGGGGLMILSQAIIADVVPARERGRYMGAIGGVFALASVAGPLLGGWFTESIGW
RWAFWMNLPLGALAILAAITLLKLPKHDNTRKPTIDIAGMILLAITSTAIVLVTTWGGTQ
YDWDSLIIIGLIALAVVGGFSFVMVERAAPEPIMPLHMFKERNFVLTTTSGLITGIAMFG
ALAYMPTYLQMVTGVNATQAGLLMIPMMGALLVSSVTAGQLVSRTGRYKWLPLTGSFIVA
IGLALLSTMTPDLPIWVLCSYLAVMGLGLGMSMQILVLIVQNTFPNSQVGTATSSNNYFR
QIGASIGTAVVGSLFVARLTELLGTRLPAAAASATGDTNSLTPAAVRDLPDAIREIIVGA
YNDSLTPVFLYMVPLVLVSAVLLMFIKEVPLATTIDRGDKSETLDGLGVEDGTDTEGATT
AADAESHELITVSDQTGATSIIRSQP
>fig|1112215.3.peg.1446 Permease of the drug/metabolite transporter (DMT) superfamily
MPLRSILAAVLVAVIWGLNFVVIDVGLEGMPPTLFLALRFMVVIVPAIFFVPRPKSRFRD
VVLIGSFMSLGQFGLLYTALAIGMPPGLASLVLQAQVVLTVVFAALALRETPTRSQLVGV
ALGAAGLVVVGSGRGVETPVLAFFVTLAAAASWAIGNVIARRVGRIGSTFSPLAGLSLTV
WSALVVPIPMLGLAFVINGADAVGFALTHLTVPQLLSTLYTAWLASLVGYGIWNTLLARH
AASAVVPFTMLVPPVGMTTAWLALGEVPTTIEIVGGVMLLLGVAITTGVLGRRRRQRHTP
SGEVAASADPVENPL
>fig|1112215.3.peg.1553 Permease of the drug/metabolite transporter (DMT) superfamily
MSAPVADAGRVEKHDSTSNLGTTLRFAAAGLVWGSSFLFIKIALDGVSFGQVAWSRAVLG
AIALVIVFTVSRRKLPRKPIVWAHFTVLAFLFAVFPYLLFAWAEQYVSSGLASIYNATTP
IMTAIFATLVFRVEKLTRSQIAGVTLGIFGVLVIIAPWQAGDISGSLLGQLACLGAALCY
GAAMSYQRKFVAPYKIAGVTSATMNIGIAAVIYILLTPLIAVGPVNLTLPVVASLLALGV
LGTGMAYVWNYRVLAEWGPTRTSTVTYITPVIGVILGFVILKETMSWHEPVGAVLVIIGV
LLAQGRLKWPRGAARTHAALK
>fig|1112215.3.peg.2590 Multidrug resistance transporter, Bcr/CflA family
MTTVVHPGDSLSARQRLVYVLVLGALTALGPFTVDLYLPAFPLIEADLETTAAVVQLTLT
ATTLGFALGQLIVGPLSDRFGRRLPLIVATSVHLIASLGVALAGDIEMLFVFRLVQGMGA
AAGAVVTMAIVRDLFGGLPLVRMLSRLALVQGLAPILAPLIGSQLLLITPWRGMFVFLAI
YGALVLLAAWFFIVETLPPARRRDLGHATARDRYKALFTDRVFVGTAIIAGMTFSGLFAY
LSSSPFLLQNVYGLDPQAFGLVFAANSVGVVVGVQASAFLMRYIGPQWILAGAGVGLLLS
ASTIVFLDVVNGDLFAVLIPLFFFVMFCGFSFPTTQVLALANHGGEAATAASVLGAVNFG
LAGLTSPIVGWFGITNAIPMGIVMACTATVSIIIMWTVVRPRTVPALSR
>fig|1112215.3.peg.2968 Multidrug resistance protein
MTTFLQILVNTAVANITTSYLWFALTFWVYLETRSVLATGIIGGAYMLLVAAFSMVFGTI
VDRHRKHVVMLFAGLVTLVAFGIAGTIYALFPESILLDLGGPMYWIFAGIILFGAVIENM
RNIALSTTVTLLVPQERHANANGLVGTVQGLSFLVTSVFSGLSIGLLGMGWTLVIAIVLS
AAALIHLTVLRIPEQKPEPEEGGRSPLVDLRGSITAVRAATGLFALSSSRHSTTSSAVCT
SH
>fig|1112215.3.peg.2969 Multidrug resistance protein
MDPYGLELFPVEVWGIVLGVSSSGFIIGGLLVAKFGLGRNPIRTMLFLVGLMGVLGAMFT
IRDWWWLYAGGILLYMTLVPAVEAAEQTVIQKIVPYRTQGRVFGFAQAFEAAAAPITAFA
IAPIAQFLIIPYMDSQNGQDAFRWLLGDGAARGIALVFLIAGLLMVVVAIVAFSTKSYRF
LSQQYAGTTASVPAAEPAENS
>fig|1117647.4.peg.21 Permease of the drug/metabolite transporter (DMT) superfamily
MSNRDLLIVVALMALWGLNFSAIQLGVDQINPLLLTAARFFCAVIPAILFVPRPAVAWRY
LVAYGLSFGVGIWGMMTLAMDMGLSPGMAGLLLQLNIVSGLALGWWLFGEVITAQKIAGA
GLALAGLLLTLLLTDGSVSWAGLGLAMIAAQCWSLMGVTVKKANTDKVFAFGVWGMAFAP
LPLVLLAWGWFGAEVFYQLPDRFNGRALFSILFQAWPTTLLGYWLWNRLNRRYPMSLVAP
FTLLVPLFGFLGSVVFYGEQLGPVKIAACVLILTGLAIGQGWVKLPVGRRQPV
>fig|1117647.4.peg.1038 Permease of the drug/metabolite transporter (DMT) superfamily
MLHSTRFALFMLVLVCAIWGVGFVVTEHALGKLSTQSLNALRFALAALSLLPLWYWSGNR
RAFAEHGKMLLGASAGLGFVLFLAFYTQTEGLRHTSVSNAGFITGMLVPLVPLLNWLLFR
QRIGKHVLIAVALSSLGLWLLTGGASALNKGDLLVLAGAVGYATHIVLTGHYARKLPVLA
LAMLQMVAVSVYSLLASAIFDADRSQTVFVLSVEHWANLLTPDIIGAFIWMAVLSTAFGF
WVQTHCQQMLEAHKVALVFALEPIFAHIAGAIWLDERLTLAGWLGAGAIIGAMLLAELGD
RKANAKLHPGDLAVAPDPGD
>fig|1117647.4.peg.1191 Acriflavin resistance protein
MTDNQPELIEQEDPTRRGIIAWFARNTVAANLLMVFILLGGLISAITMKQQMFPEIEIDW
LQVQVYYPGAAPKEVEEGITLKVEEALKSLQGLERVITYSRRGMSQAYIKVAKGFDPQEV
LDEVKGQVDSISSFPAGIERPRIERFKYRQEVMYLSLYGDLSPTQLKDLGRKIHEEIQSL
PSVSVSEYFSGLGYEIGVEVSKDRLREYNLTFQDIAQAIRNYSSNMSAGQIKAADGYISL
RVENQAYRGYQFEQIPLVNLRDGTQVKLGDVATISDGFEDGIQYQKFNGKNSVAFFIGAT
RDQNIMSVAQVVKNYVEKKEAQLPDGVHLETWVDMTYYLQGRLDMMKSNMWMGAALVFFL
LAIFLRVRLAFWVMLGLPISFLGAFMFMPLEWVNISINIASLFGFILVLGVVVDDAIVIG
ESAYNEIEEKGQSVENVIRGAQKVAMPATFGVLTTVAAFFPMLLADGPSKGFSIAIGGVV
ILCLLFSLVESKLILPAHLAHMKQRPHNPKNPFHWLRQHVDGGLRHFVENIYRPKLQSLL
NYRWAVLASFLAVLLISFGFFGSGLIRFIGTPKVPSDFPDINIEMQITASEQATLDAALA
VENMIYEVDKQLEAEFGQKMIRSLNVELRSRTSARIMSMLVDPEVRPVDTFELAARWREA
MPPLPGVKTLTIQDSLFGNDRDDGDISFRLESTNQEELYLAVQDLRDKLSTLKGVGDIND
SRRQQTHEVQFQLKPLAYSMGLTLADVARQVGYGFYGIEAQRILRNGEEIKVMVRYPEHQ
RNGVALVEDTVIRAPNGAEVPLSEVADFTMVMAPAEIRRENSKRSINVWASVDAQQAEPQ
KIAQDIRDNFLPAMLKNYPSVKSSISGRIQEEMDDQAKQMRNFLLSMIVVYALLAIPLRS
YTQPMMIMSVIPFGIIGSMIGHMIMGMDMSAMSVFGLIAVAGVVVNDSLVMVDYVNNARR
EGSPLIQAVVDAGCRRFRAIILTSLTTFIGVVPILLETSMQAKIVIPMAVSLAFGVLFAT
VITLLMIPCLYVAGNDIRGLFRRKQPSQDVAASPQSV
>fig|1117647.4.peg.1678 Acriflavin resistance protein
MNIAERSIKNSTITWVVTGILLVVGMIAFNNLSRLEDPEFTIKEAMIITPYPGASAREVE
IEVSDLVERATQEMGQLFYVESHSYRDKSIVKVRIKDQYDKDGLPQVWDELRRKVNDIQH
QLPPGAGPSLVNDDFGDVFGVYIALTGDGYTQKDLYEFAKFLRRELLLVQDVKKITFYGQ
PKEVIYVEMQRDKMTALGISPQDIYSALGAKNTAEQAGYMTVGNRRLAVSPTGEFHSEQQ
FAGLVINARNLQNQQVVLGDVATITRGLQDPPNNLLRFDGEPAIGLAISTTSGGNVVTMG
EGLYQKVEELKPQIPLGIQLNVVSMQSDSVVEAINNFLISLIEAVVIVVVVLLFFMGLRS
GLIIGTVLAVTITGTFIFMSILGITLERISLGALIIALGMLVDNAIVVTDGMRVRMEQGE
DALSAARKVVSQTAMPLLGATAVAIAAFAAIGTSQDATGEYTRSLFTVILISLTMSWVTA
VTTTPLLCKTFLKSGQLGSQGAPYQGVFYQRYRQFLTLAIQHRWVAIGITVALFAASLIG
FGYVKQSFFPDSTRPQFMVDLWLPEGTHIHETERRLAPFEEKLKGYSNVTKVTTQVGGSS
PRFLLTYQPEQPNSNFARLLVDVDDYRIINQFSQQVQNDLEFIDPDVNVNVRLFVLGPAT
GGKVQLRLSGPDHQELRRLGNEVLNVLRQHPNVKGIRNEWGEQVQVIKPVMSDVLASQLG
IGRPEIAQATAHTVEGVRAGVYRERDELIPIVARAPEHERRNLDNLDQLPIWSPTAQRMI
PLGQVVSHFDVDFENPHIWRQDRVSMLRIHFDQREGLSSELLADLKADVEKAINVDVAGY
LKLAADADIDHQSSTIPIKYRDRLPIAGKPGYYAAWGGENEDSDKGSTAIMGSIPVFFGL
MVFIVICLFNSLRKTAVIWLVVPLAIVGVTAGLLLFNQPFGFMALLGFMSLAGMLIKNAI
VLVDQIGEELSTGKNGVEAVIESGVSRLIPVAMAAATTILGMIPLLGDAFFIAMAVTIMF
GLGFATVLTLVVVPVLYATIFRFR
>fig|1117647.4.peg.1739 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MNRSMQPMLTEGPVSGHLREMAMPMVWGLLATMSFNAVDTFFVAMLGHEPLAAMSFTFPV
VMVLTSIAIGLGAGTSSTVARAIGSDNHHLAQRMATDAMSLTTIIALVVCGIGWFTIEPL
FKLLGAEDQLVPLIHDYMWIWYFSAPCLMVPMVGLASLRAMGLARIQGTLMIAAAALNLV
LDPILIFGLFGFPRLELEGAALATLITRALSLVVVLWVLHKRLGMLVNPFARFDEVWASW
RAILHVGVPAMVNNVIIPMASGVVVYLVASYGTVAVAGLGIAMRIEPIALIVFYALSGVV
GPFCGQNLGAQKFARLDETLRVVTRFCLGFGVVLALVLWLAGELLIRLFSDQQEVIDVAR
SYLLIVPFSYGAYGLVMSVNAAFNGIGQPMPGVAISFMRVLGFYLPLALMMQWLWGLTGL
FVATASCNFLVGLVAWLWLRQRFHTTATAATT
>fig|1117647.4.peg.2627 Acriflavin resistance protein
MRLREQKAQPDDAARKGTGEVWGALLASTATTVAIFLPVVFLKDVEGQLFSDLALTITIA
VSISLLVAVTIVPLLASRWLKEEGLTDHNIGLWQRITSLVMRITHTPKQRWSLIAGLITA
PLLATWLLLPELDYLPPVKRDAVDTWFRFPPATNIDTIEREIVDVINQRMAPYMKGEKEP
ALKNYYVLVWPGGGTMGARVQDQSRVDELLKIVREEITVNLPDTMAFSAQGNLFGGFGGD
RAIPVHIQASDARQLADVAEQAVGWVREALPEAQSRVDPGTADAEPELRLLPNDRALQEQ
GWTRRDLGAVVRMLGKGLWVGEHFDSVKRMDVILRAQAWDDPEALINLPLATPTGGMVPL
SQLVTLDRTVGPNQIRRIDRRRTLTLVVVPPETMSLEKALHALQTDVEPKIRAALPSDGN
IQYGGSADNLKQALGTMGENFLIALLILFLLMSVLFRSPKDSALVLLAMPLAMVGGVLAM
QILNLINFQPLDLLTMIGFVIMLGLVVNNAILLVHQTRSAEREGMNRHLAVEQALMLRLR
PIFMSTLTSIFGMLPLLLMPGAGSVIYRGLAAVIVGGMCVSTIFTLVLLPCFLRMGAKSQ
PKLADIPPHSELRRLKSVA
>fig|1117647.4.peg.2628 Acriflavin resistance protein
MNLTAATLRNPPAAIVAIVFAVAFGLFSLNKLPIQLFPDIESPVINISTGWRAASPKEME
SEIVEPIEEVLQGLPGVKEMAAGANAGFAWINLTFGMDTDMQKTLVDVISRMNRLKPLPR
DAMQPVITLGGWDGGTPALTWYFLQVLPENPNKVEDYFTFVEEVISPALESIPGVARAGI
GNGNGPMEELQIRFDPYRAAQLGVQLPMVAGLLGQSNDVSGGFVDIGRRQYTLRMAGRWE
PEQLGQMVIEWRDGKPILLGDIAEVKVSLPDRNNLATQNGNPAIGIRIDRESGANVLATL
NAVKEKIDELRAGPLKERNLTMVQSFDASVFIYRAINLVTSNIFLGVLPGCGNFVVVFAP
RPRHPDCRPHHSHFAVVHVHHAAVHRPHAERDFTRRPRLCRGHGIGCGYCGTGKCGALAR
TKSPTR
>fig|1117647.4.peg.2649 Acriflavin resistance protein
MNSLIKWFSANPIAANLLMILVLIAGAMSLNGTDKEVFPGALVNQIEISMAYPGAGPREV
EEQICIRIEEAVASLDGIKEITSVARQGTGSVVIEVASGYDTQRLLNNVKTKIDAINTFP
VDAERPLVNERLFTSELMSLAMYGDVDERLLKDTSQWVRDEISVLPGVSLVEVDATRTDE
VAVEIRENALRRYGLTFEQVVSAIQKTSVNLPAGVIKSSHGDIQIQARGQAYDGDAFGQT
VVLSRPDGAAVLLRDVATITDGFSETDVIARYNGLPAVFVELYVTENPNVLQTSESVRQY
LTGLPQRLPQGISVDISRDWSEVFSARLKLLSSNAVSGLLLVFVVLMLFLRPALAIWVCA
GITVAFAGAMWLMPALGVSFNMLSLFAFLLILGIVVDDAIIVSESIYTRQQKGATGIASA
QDGALKVAGPVFFAVVSTMIFFVPMLFIPNTLGDIVYPIPVIVISCLLFSLVESMLILPS
HLAHLKPERAPGSKPALWLSLARQRCAEGLQHAASHWYGPFIRRCLHDVRLPIAGFFALF
LVAMSIYGAGWIRQSFMPQVPSDFLHARIQLEEGVPFSRAQALLEKVEQAAAALKTDATL
IAAIDGNPAFIRSVESWASPQNVRVRLALMDAETRAVGSPQVARRWRELIGELPEAKEFD
VGFTINARDKAIRLRVGINENTLERQRQALDAVKAALAAYPGVNEVKDSLQSARDEIELT
LLPNAELLGLGLQDVARQVRQGFYGAEAQRVPRGKEDVRVMVRYPRAERESVDSLYDMRI
RTQSGDEVPFETVAQGEYVAGYTVINRVDRQRANSVTAELDSSDSGQAFAIVNAVLAEHG
DTWRREFPGFRLEVAGDMKAQNEFMQELVRDFFLSLLVIYALMAIAFRSYGQPLLIMSAI
PFGFMGAVFGHLLLGREISMLSMLGFLACAGVVVNDNLVLIDRINQLRARGMAVLEAVAQ
AGRDRFRAIVLTSLTTFIGLVPIMAETSVQARFLIPMVISLAFGVLLASTVTLVLVPCLY
VAGVNLKRRAQALLAR
>fig|1117647.4.peg.2795 Glyoxalase/bleomycin resistance protein/dioxygenase
MDLGAFSVSLAVKDIHASRQFYSALGFNEIAGDIAQNWLIMKNGQHVIGLFQGMFDNNIL
TFNPRWHQDCTENPDAPDIRDIQAALKAAGIALDSEVDPNSQGPASLTLTDPDGNTLLLD
QHC
>fig|1117647.4.peg.3126 Acriflavin resistance protein
MSHWLDRTVGSTLKGGLPLFIFIASLLTGVLALQFTAREEEPQIVVPMVDVLVQAPGLSA
RQTERQVTTPLEKLLAQIPGVEHVYSVSQTGQAAVTLRFYVGQDREEAILNTYNKLYSNQ
DRIPGVVSDWLVRPVEVDDVPIMVLSLWSSDPGRYTDFELRRFAEDISTGLQAIPQTSEV
KVVGGRPRTITLKVKPEALSARKITPAEIVSALGLSNQLQSAGLWTFNNEAIQLESGDFI
RTRAELEQLVVSVIDGVPVYLQDLVTINDGPEEARHYTWIDFAPGHPEFRSANDGYPMVA
ISVAKQRGSNAVTVADAVHQLIATLEQELLPPEIQVEVIRDYGQTANEKVNNLTSSLGFA
IITVVIFIGVFLGWRQALVVGLAVPICYGATLGLDMAFGYTINRVTLFALILSLGLLVDD
PITGVDNISRFLKEGSGSKAERIVGAISELKVPLVMSTLTIVLAFVPLAFITGMMGPYMA
PMAFNVPVSVIASTLVAFLVTPWLASKFLKADDYVAEPSANNESAYARMITPLLDNPRRA
KGVLWIMLALFIGAALLPMFRTVPLKLLPFDNKNEVQIVVDMPESASLEQTAAMARRISA
QVSQVPEVRAVAAFVGTPSPMDFNGMVRRYYQRTGNHMADLRLTLVDKTEREHQSHGVVL
RLRALLAPFNTGDINIKVVEVPPGPPVLSTLVAEIYGEGLTDYATQRDAARVLMDRLARE
AHVTEIDSTVEAHQSRQRFVLDKQKAALSGVATEDVNATLAMANGGYNAGFLQGYLHAER
ESAPLPVQLRLPVDERASLNDFLSLQVKGRPGIAQQSNPQGLETAPQPLVSLGELGGFVA
LDADRAIHHKDLQPVVYVMAELNGRTPAEIIADVNADQGAEPGAAQTEWQSRNFITSFFA
GPGDGWQLPAGTTLKWTGEGEWRITKDVFRDMGLAFAFALAAIFVVLRMQTASTALSLII
MSAIPLTIIGIMPGFWFLNQWGERVIAGSPEPVLFTATAMIGMIALAGIVVRNSLILVEF
ITQARAAGNSIRDALIAAGSVRMRPVLLTAGTTLLGNLVITLDPVFSGLALAIIFGIIAS
TLFTLIVVPVVYLLVFGNSEHAHD
>fig|1117647.4.peg.3637 Glyoxalase/bleomycin resistance protein/dioxygenase
MQFNHFNLEVPADQLDKVKQFYQQVFGWREGDRPAFSRPGYWLYEGDLPILHLVQHRGGQ
TAAGNGALNHLAFRTSQLAAFRNTLDKLNIPYRQVILADAGISQLFFHDPTGLKLEVNGP
AL
>fig|1117647.4.peg.3861 Multiple resistance and pH regulation protein F precursor
MFIAVTLAILVTIGLALARALAGPTTYDRIAAANMFGTKTVLLIAVLAFLSDRADLLDIA
LVYALINFIGVIAALKLVTRGNFHGSSDKDSGII
>fig|1120924.3.peg.1 Permease of the drug/metabolite transporter (DMT) superfamily
MLVQRVMKKSVMPQRHEWPRLMILSAMVCLGFYTTQTFAMQFVDSGLSAVLVFTMPIFIG
VLAHYFLNEYLTRQKIFGLILGTLGLIAILWPQLHHLGLNLSLVGQIMLIGSGLFWAMST
VYIKKYFATYDKIKLTIWQLLLGGVVVFIGALSFEPVDAKVWLNPLNESLLIYIAIIGTG
FAFALWNWIVSQVDTFVASISIMCIPILSLLFGALIWHEALTLNIVIGAAFICMGIVMSA
LTLTHQKTSMQYSRCPK
>fig|1120924.3.peg.34 Polymyxin resistance protein ArnC, glycosyl transferase (EC 2.4.-.-)
MQLTPFLSCVVPAYNEAENLKKFIPALAANLEQQQLSYEIIVVDDGSRDDTLHVLQSMVD
HYPLVVLELSRNFGKEAALSAGLDRVRGDITLLIDADFQHPLDAIPTMVNLWKNGYDMVY
GIRDRSSESWLKRILTNNYYKVLNMSSPIDIPENAGDFRLMDAKVVDAVRRLPEKNRYMK
GLYAWVGFKSIGIHFSEQQRQFGQSSFNGKALFRLAMSGLTGFTDLPLRLSIYLGALLAL
SAMGYGIWVLIETLIEGIRVPGWATLVIGLTLLGGIQLLFLGIVGEYIARIYAEVKNRPK
YIVSSEYSHVKAAHQLQDFDQHVSKP
>fig|1120924.3.peg.322 Multidrug resistance transporter, Bcr/CflA family
MSESRLNRQYSTAWIMLLALLTALGPLSIDMYLPALPQMAEDFGVSTAMVANTLPAYFLG
LAIGQLVYGPISDRIGRKKPLYVGLTLYVIASASCVLADNEWSLIFARIIQALGGCVGVV
IARAAIRDRLDVQGSAQAFSSMMIVMGIAPIAAPALGAFVLEFFHWQAIFWILALIGCIS
LVCIHFFFIETLVPEKRLRLSLNQVFTLYIAIFKDASFRFPMFAGCLTGGVLFSYISSAS
AVLMDQYGLSQQQFAYAFGFNALGIIILSSLNKKLVSRLSTLQRLKIGGFIQLTGALVVL
VSGLLIHAPIVMVMTGLFLAVSGLGMTGPNAMALAMSQQGSRAGTASAIMGSMQFACGLL
AGVLLNFLIWNALFNMGLMMLLFSGVGVIAIFVVARQLKLQTT
>fig|1120924.3.peg.367 Membrane fusion component of tripartite multidrug resistance system
MSDEQAPKVPPQAASNDNTQAQSNAQSTNSSTPTPYKPVQRVGKLIPTKKSTLFIMFFVL
LVGIGLIMWAWRIGPFHTMIEQTDNSYVKGKTTVLSSQINGYIKEVLVKDFDDVKQGQPL
LYIDATTYDQKVTQAESAVAQAQNTLANQTQTIAQREADIIAAQAQVDQAQAEYQLSLDQ
LRRYQQLGDSGAASKSEQDQIAATAKNNLAALKKAKANVKVANEALKTAQVAEVGLNAQV
TSAQAQLDQAKTTKNYSVITAPMDGQLGEVTPRIGQYVAAGSQLLYLIPNQTWVIANFKE
TQIAHMKIGQPATFTVDALDHQKFKGHIEQISPAAGSEFSVLKADNATGNFTKVVQRISV
RIAIDPNQDELKRLRPGMSVITSVDTSSR
>fig|1120924.3.peg.447 Bacteriocin resistance protein, putative
MHRESVLIKPAIEEQFRGIVRQAYDYSCGSAALTTLLNGYVGTKLTEQQTMNGLLRFGEY
QRIIERRSFSLLDMKRFVTALGLESGGYRGEFSDLVNQGQPAIVPISYAGFKHFVVYKGY
KDGRVYVADPALGNISFDEVRFKEIWENNTLFLIQVPEAQRQHMLALQESDMRHVEDTTI
NKYAFIDMQYPSFYMERIADRISTVRRAPDMDKNSYTYGQNIDTFMRLYYKRK
>fig|1120924.3.peg.538 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MTPKRSLITQQKLWKTFLIFLLPLIATNILQNLSGTINTVFVGQMMGVDAIAAVAVFFPI
LFCMMAFIIGLSAGSTVLIGQAWGAQNIEKVRCVVGSTLFMTIIGGCIIAALGVFFSREI
LTLLGTDASVMHLSLPYVQWMLAGSPLLFVYIIYTSILRGVGDSITPLIALGMTSLIGLV
ITPVLIAGYFGFPKLGIVAPAIATIIGYLSVLAFLAVYLNKKNHPLKPDLALLRHIRHHS
EISRLILRLGIPTGVQMITTSVAGLVIVGLVNRFGAHATAAYGAVNQVLNYIQFPALSIA
IAASIFGAQAIGMGKSDLLARVTRTALWMNIIITGTLVILAYLFSKYLMALFITDESVVQ
LGQELLFIVLWSILFFGAAAIFASIMRSSGTVTVPMLINIAAILFIEVPCAYWFSTLWGL
KGIWIGYALAFVCLCIMQAAYYQFVWKKKTIKALI
>fig|1120924.3.peg.660 Outer membrane component of tripartite multidrug resistance system
MHQFFSLQIRVKPSKLLSAFSLGVMGVLSGCQIVKPEPSAQLNIQAQFSQPAQYGLDAKK
WETEDWKIAVPSDQLPRGEWWQIFQDTQLNQLVEQLNRENASIAQYEAQYRQATALLNQA
TASTKPTVTGNTNVTRAKSGESATTANYNMGLNASWEPDFWGKVRQNIWVNQDKAQASEA
ELNSIRLSMQAQLTTSYLQWVILGFQLQSQQESLKNLQKFLQLTHNQYQAGIVASTTVDQ
AQSQYQTALANYTEMQLAQIQLQHAIAMLIGQPQDQLQLILPKTLPVLPQIPVNLPSSIL
QRRPDVAAAERTMAAANAQVGVAKLAVFPDFSLGGNLGYKSSKLSNLFSAPNFIWSVGPT
LAATLFDGGLRHAQTEQAKASYDASAAVYKQTVMSAIQNVEDNIAAQYLLSKEVAQEQQS
LAAATRAEQSTTNQYKAGIVGYLNVLTAQNNRLSAQNNVWSLTSKQYQTTVNLISAMGGS
F
>fig|1120924.3.peg.788 Permease of the drug/metabolite transporter (DMT) superfamily
MAISLAAETQPPAFKLYLCIAVTVFCWGYSPIGVHNALHSYTPQHIALLRFLIASFFLLL
LVMKKGIQPLKWKDAPALAVLGFFSVTLHHLLINTGQQYVSAVASSILSQSIPLFTFIIS
ALLFKEKIVFKQWLCILLGLGGAVLVVSGDHGFGVPSPYSLMIVLAAIAWGLYFNLYKKF
ALNYDALSMMCYIIWFGTIPLLFYSAHLPSEILHATWQANMSIVLLGIFPSAMAYVLWGY
VLKNMPLTIASNFLYCSPIVAMSLAVVFLNEKPSMIVLLGGVMIVGSLVWMNWGNRRTIK
>fig|1120924.3.peg.964 Permease of the drug/metabolite transporter (DMT) superfamily
MRFSFSPVQTGSLCAVSAAFLFSTKAIFIKQAYALSPLVDATLLMALRMISALPFFLLLC
WFNRHHNQAISAKDWLVLIFSGLLGYYFASWLDFMGLMLISASLERIILFLYPTLTVLAS
SFLYHQKLNIKTWFAIFLSYGGTVLVMLQEGKNAPSQGGFWLGASLVFASAVAFAVYLLL
TPALIKKFGSWNFTGLASSVACLGTIMHYLIATPAPLTVINELPLAVWGYGISLGFFVTV
IPTILLMQGIQRLGASQSAMIASIGPILTILLAVIFLNEQLNLWQWLGCVLNILGVLLIT
LSKTRLKH
>fig|1120924.3.peg.1482 Acriflavin resistance protein
MNIFALFVHRPVANILLGIAMTLLGILAFFRLPVAALPQVDIPTIVVRANLPGASPESMS
ATVATPLERAMMGVSGIKAINSSSSQNSTQVILHFDLDTDINEAAREVQAAINVAMSQLP
SGMPSPPEYFKVNPSQSPIFYLALSSRYLSAGKLYELASNQLKPNLAQTSGVGEVEIDGA
SMPAVRIILNPNALISQGISLEQVRDAVKKSNVVQSLGVIEHQNNRWQVALSTHIKDAAD
FSNLIVHQTAQGIVRLKDVAEVEDSVENRYVAGFHNGEPAVMIKISRQPNANTIATIEKI
KAKLPELNSMIPADAKLTTVMDGSEVIHTGLQEARETLLFSIFLVVVVVVLMLGRLRSAI
VPSIAMLVTLVGAISLIYLAGFSFNNLSIMAVIVAIGLVVDDAIVVLENIERHIEQGEHP
FSAAIQGVREVGFTLVAMNLALIIIFISVLFMGGVIERLFREFSLTLVFIVVVSVFVSLI
LTPSLSARCLQSINVQNRQPLYDYSQRMMHGLTRHYIHSLQWIIRHTYLVILLWLGAIIG
SVYVYQSLPKRILPEQDTGRIESFIRGDDGFSFQIMQPKIATFSQSLLKDPAIKDVIGTS
GGAGGTTNSFFMVSLKPKAEREGKTTREIAERIRQNAPWIAGAIFSARVQQDLELDDPFS
GNSGQDYLLLLQSDDVALLRKWAPKVAEAIQKLPELEEVETLGDEGAQHVTLDINREAAR
RLGVDVESISSVLNNSFSQRQISTIYDQTNQFHVVMEIDKRFTENPEALADIKVPNQNGE
YVPLTNFATWSYGITNDRVHRRNQYAAMGIGYVLKQGYTAEQAEYAIRSVLPQVMLPNQI
FVATDKDVEAESLQAGLSTPMLLVTVIALIYIVLGITYESMVHPLTILSTIPAIALGGLL
TLWLFNFEFTLIALLGMFLLIGIVVKNAILLIDFTLQQRRLGKTALESVVSAATLRFRPI
LMTNTAALLGAIPLALSTTEGSELRQPLGLVIVGGLALGQLLTLYTTPVMYLVLEKLAQI
FKKFKMSNAIGYRNR
>fig|1120924.3.peg.2380 Permease of the drug/metabolite transporter (DMT) superfamily
MPTKTNIMLTYIVLVFIWASTPLAIVWSVSDLNVLWAMVLRFFIALPLAVIILFVLRVKF
PTDKIAVHSYIAGSFSLIGSQVFTYIATQYLSSGIIALMFGLAPIIAGLIGCFAFGQQLN
RLQWLGMAIAITGLAVICVGGASQHIHPLGIGLMLISVFTYCCSIYWVKKVNADVQPIAQ
ATGSILISTLVSLCLLPFIWAHAPTHIPEIKSLMALLYTTIMASLIAMFCYFKLVKNIQP
TTLSLTNVMTPILALVIGALFNHERISLMVVIGAMIILSGLFLYFYRDIQANRRFSQHMK
QQLRQK
>fig|1120924.3.peg.2470 Permeases of the drug/metabolite transporter (DMT) superfamily
MQAWRNAFQKQLSTSVDIYGTTLARFLFSPIFAFSYLAFLYSQQPVTVHVSFSHKFWLYI
VIAGISQIYATALMVKLFQQKNYAIGVGLAKSEAILAALVGVLFLQEHLTAWGWVGVSIG
AVAVFLLSKGRQHSELSFKTLIIGLGSGLCFAITSLLVREASLELGMLPFLHRAAWVLCS
LISFQCVIMLLYLGLFSRHTLYHMWQRIGLTFKVSVCSFLASLGWFSAMSMQTVAIVKTL
GQVEILFSLLISAFFFKEKLAKTDHLGLWLVIVAAIMVIWA
>fig|1120924.3.peg.2725 Membrane fusion component of tripartite multidrug resistance system
MDELSQTDDRQEPNYTRRKKVAWIVLILLFLGILLGILYYWFVYRFYESTENAYVKSDLT
WIMPKVSGEVIELLAKENQYVEKDQPLVILDNRDLQARADQAKAMLALKQAGLSVQSENE
KSAQSTILEAQSARDAAQADVSRLSSDYRRYQQLLKEGVITRQRFEATQAEYLSAQAQLN
KAQAAIQAAQAQFSGVQAGRAQLYADLDNAKATVKLYDVDLGASEIQAPVAGKIGSLAVR
LGSRVSPQTRLMAIIPKNSLYVEANFKETQIEKMRVGQTVSLVLDAYPSLTYRGKVESFA
PASGATFSMMPPDNATGNFNKVVQRIPVRISILPHPQIDLIKPGMSVEAKVDLRSQSS
>fig|1120924.3.peg.2726 Multidrug resistance protein B
MTMSSASIEWQFSPRVAWLIFIAMIFGNFMAILDIQIVASSLNEIQAGMSASRYEVTWVQ
TVYLIAEIIAIPMSSVLSRILSTRIYYALCATGFTISSLLCALAWNLESLLVFRAFQGFM
GGGMIPTSMTALFLLFPEAKRAVPLVLFGMISTLGPAIGPTVGGWLTTSFSWHWMFLINI
IPGIIISVVIYASQAIDQANYKLLKELDWLSLIGMAMFLGGLEYFLDEGGRYDWFADFGV
RIAFLVSLLGAMIFFYRSYVQPKPLLDLSVFKNKNFTLSCMITFVIGMALYGLGYMIPVF
LGQVREMNSSQIGHIMMVTGIVMFFFAPVLAWLIPNFDARKTVFIGMLMAAFGVWLNAHL
TIQSDYDFMFWPQVYRGIGLMICLIVISHLAMSTLPEHKIADASGIYNLMRNIGGAVGLA
LINSRIDWLTAWHATELNSQLTPANWIFVERLAQLKAQYAELGDLSEQLAMQVIYRQVHY
QALAASFNDLLKLLAIIMLVVAFLTFFMDRGKKVSF
>fig|1120924.3.peg.2771 Permease of the drug/metabolite transporter (DMT) superfamily
MNQTTKVHGWAFLLPVIAVLIWSLNIAVTRYAVDLISPASISFYRWLIAFIVLTPFMLKS
VWRKRHLVRQHMGQLAILSAFGMVLYQGLAYTAAHYTTATNMGIVNAFIPVFTIFVSMLI
LKEIPNLFAILGSAISFFGLLYILSKGDLSQLAQMGGHWGDLLMMVAVFFYAFYGVFLKK
WQLQIPLLISLYVQIGFALIYHIPFLLYFGLDPINAQNAPSLFYAGIFPSLVAPLLWMLA
VQQIGPNRTSIFMNLVPVFTAIIASLWLAEQWTIEHSIGGIMILLGIIMAQKKAARVISQ
QAP
>fig|1120924.3.peg.3200 Permease of the drug/metabolite transporter (DMT) superfamily
MCIWGGFTIFSRLNAQWHISAWDIVAIRFAIAFCILMPILIYKKDLAFLWQREAVILALI
GGIGYCLTVYSAFLYAPAAHAAIFLNGCIPLCTAIAAYILFKQPFDGHTWLSFCIMLGAI
TLMSFLMMQRDHVSFGVGDLLFVMSAICWGVFTVLLKQWKLSAWHSMASVAIWSAVIYLP
VYLLFFPKHFTGVNPIHLMIQGVFHGVFVVIISTLAYIAAIERLGAFKTGSIVTLAPFIA
AVVAVPLLNEPLSASIICGLIGMGIGALQPWRWRLKDTLTIELEKQKQKSD
>fig|1120924.3.peg.3207 Fusaric acid resistance protein fusE
MSQVDLRKIVRPVVTLLMAIVAIAVIIHLWNYYNSAPWTRDGRVRGDVIQVSSDVSGLVT
EVLVQDNQTVKKGQVLFKIDVVRQQLDVEQARSDLAKAKAGLAQSQANLIAAKANLTKSE
ANTALAEKNAARYSSLLDGAISKQEQDQIYATRDQSRAEIAQMKAAIEQAEATIVQQKSL
IEVAQSNLNLALLNMQRSEVVAPADGTLSNFGLQVGNYVKTGDAVAALIDRHQLYVVGYF
EETKLNHIHIGDQATVQLMGDDQKIRGHVQGIASGIEDRERSSSSTLLANVNPTFTWVRL
AQRVPVKIVLDEAPKNSLAFVAGRTATVNIVQSNSQKN
>fig|1120961.3.peg.326 Permease of the drug/metabolite transporter (DMT) superfamily
MDKDSGDTHKNSATIIGFTAVLMWALLALFTDATGNIPPFQLAFMTFFIGTLIGIIWNIG
RKKPTNEEPIPLRVALAGGIALFAYHALYFGAVKNAPAVEASLIAYLWPLLIVVCSALLP
GEKLDWHHVLGAFAGFAGTILIVTGGKGFTIDPAAAFGYGLAFAAAFTWTAYSLVSRKFA
DVPTKSVIAYCAVTTVLALAAHLMFEETTLPSTTLQWLAIIGLGLLPVGAAFYTWDYGMK
RGDVQVIGASSYAAPLLSTIILIAFGRAIFSWSIVFACLLITFGAMLAAKNIIRRRKPDQ
L
>fig|1120961.3.peg.461 Permease of the drug/metabolite transporter (DMT) superfamily
MRRIYANLLLLFVGAVWGMGFVAQSTAMDAIEPIFFTGIRFLAAAIAVLPFAIWEQKRRA
RTMPESEPTLTRKNILNFAILGAILFSSLATQQIGLLTTSVTNSGFLTGIYVVMVPVLGL
LVLRQVPHTIIWPASALTLTGIFLLSGGSLTGLTTGDYWTILCAVLWACHVLFLGRVLTT
QRGGNTPFTLATIQFFTCAILGLVLASFFETVSWAILVAAAPEILFAGVVSGGVAFTLQA
VAQQYTTAPQAAIFMSSEALFAALFGAIILGERIGFSGYIGCLLIFTAMLAVEIIPMLRL
RGRTQIS
>fig|1120961.3.peg.560 Permease of the drug/metabolite transporter (DMT) superfamily
MSYARDIALTALAPAIWGSSYIVATEFLPLIDPLIVSLLRALPAGIILLIIVKELPKGWW
IAKIFLLGALNFSIFWTMLFIAAYRLPGGVAAVVGSLQPFIVIFAARLIIGTPIKLLSIV
AVMAGMLGVALLILTPKASLDLFGIGAALIGSASMALGTVMSKKWQPPVPPLTFTAWQLT
AGGILLLPTLLLVEGQWSDFSLTNFAGIAYLGLIGAAFTYLLWFRGIARLNPSSVAILGI
LSPLVATLLGWFILGESLSALQLFGVGIVLVSVIAGQYALRPNRVVLKPAMSK
>fig|1120961.3.peg.958 Permease of the drug/metabolite transporter (DMT) superfamily
MFIFEAAAMLAALTWAFTSILSADPAKHLGAIAFNRWRMTIVFVALIAWATLFGTWSSIT
GDAFWALFWSGFIGIFLGDTALFLTMNRLGPRRTAILFSMNAPISVLLGYLFLGEALALQ
TFLGVSITIIGVILAIIFGKRKTQLHKWESITGTLWVGILFGTLAALAQAIGALIARPIM
ETGVDPVAASALRVGTAAFGLWALMLLPHKNFKQANPGSVSIWTQVALSGLLGMGLGMTL
LLFALSGGKVGVITTLSATTPALLLPILWWRTKEAPAIGAWIGAILVILGSALIFNA
>fig|1120961.3.peg.1052 Permease of the drug/metabolite transporter (DMT) superfamily
MANGIKLETVAPALFVLLWSTGWIVAKYANDYAGPLTFLTWRFAIAALAFAVIAVIMSAK
WPTTRAGWLHAIISGLFLHAIYLGGVWWAIKQGVPASISGLLAALQPLMTAMIAFWIIKE
RLTMRQRMGIAVGLFGLLIAIGPRLLSLDTDALLTASLPLIINVIAMASVTFGTIYQKRF
LQEGDLIPVATLQYVGAFIFIAPAAMILEPSLVFDLNIHSILAMIWSVFGLSLGAILLLL
YLIRRGQVSRAASLIYLVPPAVGIEAWILFGETPTIPFIIGTLIVVAGVWLVNHKRPVQK
ST
>fig|1120961.3.peg.1173 Permease of the drug/metabolite transporter (DMT) superfamily
MQNNKNAYIFLFLTTLFWGGNAVAGKLAVGHVSPMMLTSIRWGVAVSLLLLIGGKQFWQD
RAIIKPHLPLLFIYGGLGFAVFNVTMYSALNHTSAINVAIEQAAVPAVIFIGNFILFRMR
VSALQIFGFSLSLIGVAVVASHGSLERLAALEINKGDMFMGIGVLAYAAYSVILRYKPDL
HWKSLMTTMAIAAFIVSLPFAYFELKGPNAILPDAQGWAIGFYTAIFPAIIAQVLWIKGI
DLIGANRAGVFINLVPIIGTILAVIILGEVFGLYHGIAMALVVGGIWIAESSGRKAHRNA
PDVPR
>fig|1120961.3.peg.1369 Glyoxalase/bleomycin resistance protein/dioxygenase
MPDKAKMLGTACVLLVRDFKKSVDYWENCLGFTAHIWGEPPNFAIMERDNIRIMLSHAPD
HTNKPNWEVGGGIWNSYFWVDDVQSIYQEFIANGAKIDYTLHEKPYGVLEFGIQDLDGHD
IAFGQDLN
>fig|1120961.3.peg.1700 Permease of the drug/metabolite transporter (DMT) superfamily
MLAVRFNWTIAVLLFLITALVMTAFAANSVLARAALLGPTIDPASFTTVRLISGAAMLAL
LLLTRKQTSIRGLIGGGNWHSAFWLFAYAVTLSFAYIGLDTGVGALILFALVQATMIGWS
VFKGDRPIVPEWAGLIIAFSAFVWLVSPGLEAPDPFSAFLMALSGIAWGAYSLRGRGATD
PLKATAGNFILAVPMAIAVSAICFSQNNASTYGILLGIASGAITSGIGYAIWYRVLPQLS
AMQGSIVQLTVPVIAGLGGLIWSGEPFTLRFVLGSVFILGGVALAIISKTKRV
>fig|1120961.3.peg.1879 Drug resistance transporter, Bcr/CflA subfamily
MTNFERVALYALLISITALSLDMLLPLLPTIAQEFKSSDSNQIYFVISAVIFGMIFGEII
FGPLADAIGRKPALIIGLAVFLFGTIIALTAHNLTWLLIGRAIQGIGVSGPKIATRALIR
DQFQAAQMARMMSMVFFMLIGVTMLAPILGQWLGNALGWRSIFYFYLIITFVAGGWLLLR
HKETLPRNARTPLLLKEMLKNLNLILKNGRVLSYTCIAGLVFGAQLTFLSVAQSIFDKTY
GRADSFVYWVAALSLCIGLSSLLNSYLVMRKPMDYLVGFALSGLGFIGAILFTFSQVSDT
YPPFIVFITATAFAFGCIGTVFGNINAMAMTYLGRVAGLGASVISSVSSLIAFALAAFMS
QIHDGTPFALSICFMIAGLGGLTALIMARQLDEISV
>fig|1120961.3.peg.1882 Permease of the drug/metabolite transporter (DMT) superfamily
MLLKQSESRMSKPTINSSMTTIEWVMLITLSVVFGGSFFFVGVIVQDMPPKTIVFFRVLI
AALALHLFMRVTGRKIPWTGTAWFAFFAMGLLNNVIPFSLIVWGQTQIASGVASILNATT
PLFTVMIAHALTTDEKLTITRVSGIVAGFIGVAIMIGGGAIADGAATALAQIACIGAAIS
YGFASVFGKRFKGMTISPYAVATGQVTASTIMMFPIMMIFDQPWTLSMPSTQSIFALLAL
GLISSAFAYILFFSILDGAGATNLSLVTFLVPVSAIFLGIVFLGEILLPRHLAGLGLIIV
GLILVDGRVLKRRVTA
>fig|1120961.3.peg.2118 Glyoxalase/bleomycin resistance protein/dioxygenase
MHITKLDHVNIRTTQLDVMVKWYCDVLGMKSGPRPDFPFPGAWIYAGDNAVVHLIGVEND
AGAGSETLLKLEHFALSATGLAAFEEKLKSRGEEYRRGELPDFKIVQINVYDPDGNHIHV
DFRTDEEVA
>fig|1120961.3.peg.2378 Glyoxalase/bleomycin resistance protein/dioxygenase
MIDHSGISAADISKAVSFYDQAFAPLSISMLAEVPIEFTDGKRVVGYGTHRPQFWLSEGE
AQKPPVHFAFAAPTRAAVDAFYEAALKAGGSDNGAPGIRAHYHENYYGAFVLDPEGNNIE
AVCHKAKT
>fig|1120961.3.peg.2478 Permeases of the drug/metabolite transporter (DMT) superfamily
MTPYQKGLLITGFGGLVLTIDIPLIRLGGGDAWSAQFTRSGLGLVIALLCWIFIRLRQGK
RVSLLPGRAGMVVAAFYGLSAIAFVAAVFNTTTANLVFILTSTTIFSALLGWVILRERPK
TATLITMAIMVFAVFLIVSESIQSGNYFGDLCAVAASFGLSMAIVFARLSGKDMGFAPMI
GGILPLILATGVLLSKGGVSAFHLDAAWWTIANGAIVIPIAFWCLATGPKYLSGPEVGMF
YLLETVLAPIWVWIIFSEAPTRNTMIGGTILIIALIGHSLWQLRSERKRRSAERNELATN
IG
>fig|1120961.3.peg.2542 Permease of the drug/metabolite transporter (DMT) superfamily
MNPIRKASPADLALLLFVAIIWAMAFIAIKIAVPEVGPLWLAAIRVGIGALVLAPYAIYR
GMALPSSSRMWTLIIAMAILNVVIPFFLISWAELTIDAGVTSLLMGVGPFLALVSGHFFT
NDDKINTRKAIGVLFGFVGVLTVVGADALSHMGDSNILGQLAALGGSLCYVTAGVLIRKI
DMPPTRLAFLALLIGTVILFPVALLFADPISAMPSSNAMMALIFLGVLPTGVAYIIRFYL
INKVGYSTFSMSINLIPVFGIFLGFLILGEPLRPQILIALALVLIGLFIAKSGGPKGEKI
DKEAVS
>fig|1120961.3.peg.2758 Permease of the drug/metabolite transporter (DMT) superfamily
MIAAPAFFSTNLIFGRYVAPETDPFILAFIRWACVAIILLPFAIKSGGAQMVRLIRTEWP
FFLFLSFLGMGISGSGVYLGLQSTTATNATLIYSTAPILIILLERVFAARKSSPGEGLGI
AVAFVGIVIIVAKGSFDTIAQFAFNPGDLLIALAALSWAGYSILYRSERFSGLSSVTLFG
IIAIFGAIINLPVATYAFYTGAQLPHSASAWSAVAGIIFISSLIAFSAYQYGVRALGASI
AGLFMYLMTPYGVLMAVIFLGEELLPFHIIGIICVMVGVTMATFPKSMLDKFKRKAA
>fig|1120961.3.peg.3118 Bicyclomycin resistance protein
MTISADIYQAAKPKIWILVVLAAVGPLAINIFVPSMPSIALDLDAPYATVQLGLSMYLLA
TAAISLFSGPLSDKYGRKPVLVGSLILFLVGSTICLLADNASSFLIGRIIQAASATGMVL
SRAIVRDVYPREKSASMIGYVVMGMAVAPMIGPAIGGYIDSVAGWRWSFGLLTSFGLIAL
LATLILLPETNTNIGQSASNQIQGYISLATMPIFWLFVGSASFTSAVFFSFLGGGPAVSS
LFFGQTPFEYGMYFSLCALGYAFGNGIAGRYSEAVGLEKMMSLGAIFSFIGPVVSLLLFY
LSAEPAAWMLFVPLSLIGLGNGMTLPNVTAATISVRPEAAGAASGLLGSLQIGGGGLASI
IGGIVVGETGSPYGLCALLVGFGLAALIITLMAARMSRRYEAN
>fig|1120961.3.peg.3214 Drug resistance transporter, Bcr/CflA family
MFRFAVILGLLSAVGPLAIDMYLPALPLIEAGLGADVTAVQASLTVYFIAFGVAQLFFGP
YSDQVGRKKPLYIGLAIFAIGSIGCALAPTIGWLLAGRFVQGIGGAVVMVVPRAIIRDQY
TGTQATRLMALIMMVISVSPMLAPLAGSVLMEVASWRGIFWALAVLTLASLALTLFALPE
TLAHDNKVPVNVTSLMRGCGILLRDKKFMGLTFIGGFGMASFFVFLANAAFVYTSEFGLS
PVQFSLAFAVNALGFFSSSQLAANLGEKFGMEKVVATATFGFLVFTGLLLGLVLAGFGTL
PVIVGVLFLANACLGLVVPSTMVMALDDHGDMAGLASSLGGTLQMVAGGLMVVLASPFFD
NTALPMVAAITVCAVVAFVLTRLVLNKSDIAVTPV
>fig|1120961.3.peg.3296 Permease of the drug/metabolite transporter (DMT) superfamily
MKYIIFILFTVATNAAAQLMLKQGMTTLSPSVLAQDNIILKLLMVVFSPWVFFGLATFVI
SMASHMFVLSKVDLSFAYPFLSLAYVLVAVLAWQLFGEELGTYKIAGIVFICIGTVLIAQ
SGSPTQETSISQTTTEEYNS
>fig|1121428.3.peg.571 Permease of the drug/metabolite transporter (DMT) superfamily
MNSMIGGALYLSLAAAIWGGMYVVSKFALATVPPFTLLFLRYLVAALLLVGILWRKQEKL
LPDTARGLILQVGLVGYFFSIAAQFIGTKLSSAHMGAVITTLSPVFLSAFAVVILKERLT
VKQAVAMAVALAGVLVVVGVPGRQGEPSALAGNLFLLGAALCWGYYSVISRKVSTVYSPL
QITTWGILIATLFTFPCLYFEYGQWSPADLLQLPIVLSVLYIGIISTALAFFSWNKGLAL
VPSHQAGLFFFLQPVVGTLLGWFFLDEHLSGSFFIGSLLIMAGVYYNMKQTAGSE
>fig|1121428.3.peg.634 Vancomycin B-type resistance protein VanW
MNKARLTFLVTLALGFQLLVCIGLSSTATVLYYRDTILPGTSVQGVDLGGLKAAAAEQAL
RRALPWPSPDSLLMLVDPEGQSTHIRYSDINYRADYQATVQEALKQSRQAAAWHNIGALF
GAIHQGHNMPLVKTFNQAAFSKILNQLADKYNVPARNAQFAFNGNNVILFAESKGRQLDI
PGTLKQLRELPPDQHRLALQFKTVEPEVVISDYNGINTRLAIFVTQFDSSNKARSHNIEL
ASKLINNLIVPPKQVFSLNKVLGPRSQDRGYLQAPVIINNKLTSDYGGGVCQVATTLYNA
VALAGLQVVERVPHSLPVPYAPPGQDATIAGDAIDFKFLNNTDYPILISSQVQHGKLLVS
IFGHRQGASARLIKIETERSITKPERKYVQEQNLAPGQVVVRRPGRDGYQLKTYEITMEN
DKEVDRRLLSQAIVEPEPEVIAVGPGISTKGQVKK
>fig|1121428.3.peg.727 Efflux pump antibiotic resistance protein
MEKDAALKKYTLLTACGASFLTPFMGSAVNLAIPSIGKEFNSSALLLSWVATSYILASAA
FLVPFGRLADIVGRKKIFMLGVLGFWLSSVLCGFARSVEALIAFRVIQGIGSAMIFGTGM
AILTSVFPPQERGKVLGINVATVYTGLSLGPVLGGVLNHHFGWPSIFYFTSLIALSVFFL
TVTKLSGEWAGAREERYDFLGAALYALGLVALMYGISAVATSPWAKYILLFGFVVLLVFV
RYELRVKHPVLNLSLFKHNTVFAFSNLAAFINYSATFAVGFLLSLYFQVVLGFNSQITGF
ILLSQPVIMALLSPFAGSLSDRKDPRIVSSWGMTLTTVGLFIFCFLDRNTPLWLIIMNLL
LLGTGFALFSSPNTNSVMGSVEKRFYGIASSALGTMRLTGQAVSMAIVTLLLALYVGNVK
LSQAPADLLVKGTKTTFIVFALLCFMGIFASLARGKKPAGLQKAPPYK
>fig|1121428.3.peg.746 Acriflavin resistance protein
MFLTNLSLKRPVFATVTVLALLAVGIISYIGLNINDYPEVEFPYVVVTVVQPGASPEQVE
SKIVSKLEEAIGQISGVKHIYATAREGVATVFAEFSLETSPEVAAQDVRDKIGTIRGELP
QDIEEPIIARFDPSAMPIASLAVTGSLSQRELTTVVEDLIKRRLETVNGVGAIDIYGDVK
REIHLQLDKYKLAAYGLTTAEVINSLRSENMEVPGGKVGNGDREMTLRTVGSINRVEEFA
NLPVARRDGVQLYVKDIATVVDGVEETDSLSRYQGKPAIGIDIIKQSGANTVEVADRIKA
VLAEVKQELPPGVQLEMVRDNSVYIRDAVKDVRNTLIEGSVLAVLTVFIFLRDWRSTLIG
ALAIPTSIIATFFAMKVLGFTLNFMSLMALSLAVGLLIDDAIVVIENIVRHLRLGKSPLE
AARDGTGELGLAVTATTLTVVAVFLPVGMMTGIVGQFFKQFGLTVVFSVLVSLFVAFTLV
PMLASRCLKEEEHLPGGPVGKFLKWFNRGFDKITAFYADFLKVVLRNRKKTLGIALLLFL
GSLMLIPLLGSTFVPSSDIGELYVVADLDAGLGMAAAGQVTAEMEKVLQGFPEVTKLYTT
VTNERANIFVKLVDKHHRDKTIDRLAMDMRHQLNAIPGVKVTVNQQAGMSDGAAIQFRLL
GDDLDQLQVYAEQAQKIMESIPGTVDVSGSYKPGKPEGQVQIKRDVAADLGVSTASVADT
LRTLFNGVVVSQYEEGEERFDVRVRLAEDHRRNLADLSNIYLPGAQGLVPLSQVSETVFA
TSPSQINRFDRTKEIVLSCNTDGSISMGEFNKIFKERVAKEMNLPPGYSFYEGGDAERMG
ETFTAMLLALVTAVLFIFFILAAQFESYIDPFSIMLSLPMAVVGAILALLTVGSDLSIMS
MIGIIMLMGLVTKNAILLIDFTKQERARGVERNEALRKAALTRLRPIVMTSTAMILGMLP
LALALGPGAEGRAPMAHAIIGGLITSTLLTLVVVPVIYTILDDLKAKTTALKHRFMQAGD
GA
>fig|1121428.3.peg.903 Permease of the drug/metabolite transporter (DMT) superfamily
MKPSIKGFFFLVGATFLWGVSGTVAKILFNHQVNPMHLVTIRLTLSFAVLLLYLAVWQPH
LLKVKKSQLPYLAVLGTAGVGLVQFSYLFTISQTNVATAVFLQYLAPALVAVYAFLRQRE
SKSPVKLLALLLTAGGGYLIVSGVPGGGLAVNWPGLASGLVSAASLAFYTLYGKKGLATM
NHWTMLLYCFGFGALVWNIFQPPWVAMVGHSLTEWYFFLYIAVFATVLPFGFYFCGLNCL
TPVITSLTSTMEPVVAAVVAFLALGETLYPLQLVGCSMILIGVIAIQCVPEQEKLPDKQS
VSQEG
>fig|1121428.3.peg.1465 Acriflavin resistance protein
MHITELSVKRPKMMTMVILVFVILGLYTYRQIGVELYPAVNTPFVSISVSYPGAGAEEIE
TQIVKPIEDAVSSLSRLKTVTSTASAGSANINLEFALSADADQAAIDVQKKMDALRRRLP
DGADDPVVIKRDINAAPVMLLALSGDSGRTELYDLANDVIKERLQRLAGVSEVAVFGGLR
REIRIEVDKNKLTGYGLSINQIVNRLKAENINDPSGRLDRPEAEYNVRVLGEFRSVQEIE
EIAIPTASGYAVPLKAVATVTDGYQEVRVHSRVNGQNAIGIQIYKQSDASMVAVGQAVKQ
ELAALQTQLPPGTSLKISRDNSDFVQRSVNGTRSNIIEGIITTGLVLFLFLRQWRASLIV
LLAIPTSLMATVMMMYFCGFTFNMMSLMGLALCIGILVDDSIVILENIHRHLHMGKTPWQ
AAIEGRREIGMAAIAITLSDVVVFAPLAFMNGMIGQFFRQFGLTIVFATLFSLFVSFTLT
PMLASRLYKEGDTAESARPTRKSLFDILWQHTVPLGQQIKSKYTNMLLWSLSNRKKVLVL
SALAFFLSLSLIPLKLIGTEFMPRTDEGGLTVSLEMPVGTPLEKTNEVLRRLEHYIGQIP
DVQYYNTMAGSGGRGGAGGANTGRIEVQLRPKQQRQKSAAQIAEEIRKQGMAVKDAKVFV
AESDSRGGGGGSAVRILVAGHDPEQINLLADQVKEKVAKVQGVTDARTDWSLGQPEIQIK
VDHNRAAHYGLSVQEVAGTARTAVNGQNAGVLRDGEQEVNITVKMANAQLQDIESLQNLL
INSNGIPVALGQVANLEYGSGPKSIRREDKQRVITVSAGIKERPLGDVMADIRKELAGIQ
LPAGCSIKFSGQDQSMRESFSELISALILSVVLVYMVLVMLYESFSTPLIRMLSLPLGIV
GALTALALTKNNINIFTLIGIIMLDGLVAKNGTLLIDYTHTLLERGRTLKDALTEAAVTR
LKPILMTTVTMVAGMLPTALSITEGAENRSGMAWVLIGGLLTSTVFTLFVIPVVYTIFDD
YKTKWRHRRFSSQVSQPAPEITA
>fig|1121428.3.peg.1501 Membrane component of multidrug resistance system
MGLHNQDNSSRRQNQPPPYAAEAKSIPWGALLILVIGAFMAILDSSIVNVALPRFMTLFG
SSADEIQWILTGYMLTSGVVVPITGYLGDRFGNKRMYIWSVAAFTLGSLLCGLAWSTQSL
TVFRVIQAIGGGMIIPVSMAMIYRIIPREKIGLALGIWGIAAIMAPAVGPTLGGYLVDNY
SWHWIFTINIPIGIVAIMLAIAYLEETPVQKNLKPDLVGILLSSAGCFALLLALSEGQDK
GWTSQYIVTLLVFSGFVLCLFALWELQVPNPLIDIRLLKNPVLSASLLATCLTTIGLFSA
VFLIPIYAQNLLGYTPMETGLLMMPMALVTGLMMPISGKLFDKFGAFWLGMIGMSLVVAV
TYYLHTLTLDTSYRHLQVILSLRAVGLGLATMPLTTAGMNTVPRFLVGRASALNNTVRQI
SGSMGIAYLTYVMLQRQAYHTAVLNESVSLTSPVASLAQAQIKGYLVGYGLNGEAARQGS
YSVISGLLARQSFMNAISDTFVVSAVIIALVLPLMFLLSKQRVEQERIKQQNLSQGRLPA
>fig|1121428.3.peg.2139 Permease of the drug/metabolite transporter (DMT) superfamily
MTKMKQLQADLALLAVTVVWGATFVVVQDALSGIGPYFFTGIRFAIAFALLGLIYFRRLA
NLDRATLRAGCLIGVILFAGYAFQTVGLKYTTASNAGFITGLAVVLVPVFTSLITKQLPA
PAVLLGVTGATLGLALLSLGDNLSVNYGDVLTFFCAVSYAGHILLVGRYAPRHDPVLLAI
LQIGTVAVISLLFGLCLETLPAQFSKPVWQGLIITAIPATALAFLIQNSVQRYTSPTHAA
IIFITEPVFAAATAWLVAGEVLTTRQWVGCLLILAGMLVAELKDYLFNVTKIKQARET
>fig|1121428.3.peg.2177 Vancomycin B-type resistance protein VanW
MAEQILKRVVPVVLPLLFLISLAVFLATQMSFAPADRILPGVYMLSINLSLLDYPQAVSA
LKKLEQDMQKPLTVKYQGKSWLLPMDRVGLKLNCQQEARRAINIGRSGPLWQRFCERRQA
YRGIRLEPEIIIDTGLLQQQVSQTAKDIILPPRDAGLIINNDDTVEISPAQSGREIDIQQ
LRQDIRERLLQQDTSPIELKPVEIPPARTTEEVQAMGVDTLLGMFSTQFDPNNVNRAYNI
SVAAAALDGLSIRPQEIVSFNEVVGPRSTEAGYKNAPIIINNELVDGLGGGVCQVSSTLY
NAVLLANLEVTERANHSLPVPYVPIGRDATVVFDAVDLKFKNNTDYWLYLQSFVTGGRLT
VKIFGNHRFKRDVVIRSWVEETYPPRTVVEKDYSLRLGDRVVKQKGAQGYRAASERIVMQ
DGKVIKVEKLPYSVYKARHQIISQGMAPPASLVKNPDPPGEAVEQDRGNPDVLP
>fig|1121428.3.peg.2372 Permease of the drug/metabolite transporter (DMT) superfamily
MVFLSYIKVRFQYFRLHEDDTVSIEFFLWGVFHHRIEIPVLMLRQKMAGFSLISRTELET
GQGDPGEIMSRENQITITGVQQLLDKLRKWLLWLQVVQEDVDFFLRHLVLEKFYWRISFG
TTDAAATGMLAGLAWSFAGLVTALFYHKIAPGRVQPVIKVEPDFKKAGFATSADCIFKIR
IGYIMVTGLKILKKKANKQGVNFLGRTSHRRSHENCHGKY
>fig|1121428.3.peg.2429 Vancomycin B-type resistance protein VanW
MPFLIGLLGLVALVAGVVSGFWIFQLNHAEAQCIPPGIFVEGIDLSNLDRRQAAAKLQQY
EQTLLSKQIQLSYQDQAWHMTLQELGFMAKSDEVLNLALQNNFSLLQQRLQAYFRPVRRD
YHVTIEINKEQMTKALESVVRSIERPARNAELVISDHGRVMIQPDQKGYQVNLEQVYKQL
LNTDIRQASIQVNLAVNELIADKTTADIEKLRINGKIAEFTTKFDANNVNRTVNIRTAAA
RINGVMLAPGQEFSFNKVVGERTGKAGYRPAAVIVANKFEEALGGGICQVSTTLYNAILL
AGLTPVERHNHSLAIGYVPLGRDAAVAWQQLDFKFKNTLPGHLYLRTVVTSDAITVQVFG
DTAAKKDIVVRSWVTETIMPDQVIKEYDPALPPGEEVTVAPAYAGFRAKAERIFKENGTV
VKREALPDSYYQPRPKIVKVGQKTEQTDPNLQAVETEF
>fig|1121428.3.peg.2764 Permease of the drug/metabolite transporter (DMT) superfamily
MISGSNMFSYAVLILATVSWGGAFVAAKMVVGEIPALVAAALRFWLAFLCLLPFMLVQEG
RKAKISSKDWPALVFLGFSGIFLYNILFFNGLRVSAAMDGSLLVACGPVLTALLSAFFLQ
EPLHWRQAAGFLVSLGGVVVIVTKGVPAALLSWDINHGDLMLTCSALTWSFYSVGGKVIM
KRLSPLTCSTYAMGIGAVMLTLAAVTQWQDNPFGRMTIVSVAGLTYLAVIASALSFVLWF
AGINRVGAGKAAIFQNLVPLSGAVFSVLLLGEQWQLFHAVGGGLILGGVYLVTKPAGTVL
PAGKVSRGI
>fig|1121451.3.peg.182 Acriflavin resistance protein
MNLARWCIENNRTAIALFLLVALGGAMTFVSIPKNEDPDFTIRTAVVMTVFPGASPQRVE
ELVTDKLEEKIREIDVIKNVKSQSMTGISIIEVEFLENIKDMDPVWQRLRNKVSDAVPTL
PSEAQAPIVNDEFGDVYGILVALTGDGFTYRELKDVADYTRDELLHVPGVGKVERWGLQD
ERIFIDFSNSRMAAAGISPFLLGQVIDHQNTIRPSGSAKVGPERIYIEPTGEFKSVDDIA
SLSMRVEGMKTSMKLSDVTDVSRGFADPPSVMARYNGKPAIMLAISMAEGNNIMELGEKV
TARLDELSADLYHGMEYNIVVYQPEYVETAVSDFMLNLLESFIFVVIVILAFAGFRTGLV
AGSLVPMAMLGCIGLMPYFDVGLQRISIASLIISLGILVDNGVVVSEAILVRLAAGEERM
NAVSNAVSELWMPLLAASMTTVFAFLPIPLAESTTGEYCFSLFVVVTLTLLCSWILSMSM
VPMLCYYVLKPKVVIQTFSSRMYRAYRAMLLCCLKHRTVFLAVVLAGCVVAFWGFKFVPK
MFFPPNERAQFTIDFWQPFGSDITTTAEEVGRLEQFLLADKDVVSVGTFIGHGGPRWYLP
LNLEQRNDNLSTFVVNTKSIDSVDALMTRTRQELKANFPDADFSLKKLMNGPPVGAPVQI
RISGPDQKTLYRLRDKIVAMLEARAGVSRVWDDWGQWTKKMVVEVDQDKAREAGLSSFDV
AASLQSGMSGYQASIFREGDTNIPIVLRSEDAFRNRLDKLESINIYSYQDGKSVPLNQIA
VSKLVWQPSDIRRRDQTRTMTVKADLFDGYFAMQILNSVRPEIEALTKTSQWPVGYSVAY
GGEFEKSEESQASINANMPLAMGLLVLVLIFQFNSFRRPLIILMTLPPMMCGITPGMILT
NSPFGFMPMLGMISLLGIIVNNAIMLIDRIEIQRKKGINLDDSIVLASLERARPIIMTAT
TTIIGMVPLSLQGGEMWRPMANCIMSGLMFATVLTLILCPVLYSVFFKQSYKGYNWNPAV
IEHGKDG
>fig|1121451.3.peg.751 Multiple antibiotic resistance (MarC)-related proteins
MLAIFFQTYLKLFFILTPFFAISAFLSLTQEMSPAERKRTAVKVTMAVIISSVLLYLYGR
YIFELFGITLDAFRIGAGAVLFLSALNMVGGGTKKFEAGNEDDDISVVPLAIPIIVGPGT
IGALLVMGSTVQGYKDMVLACTALVAAVLTVGVLLFLSSGFKRLLGKRGLNIMSRLTGLI
VASIAAQIFFTGLRNFMLN
>fig|1121451.3.peg.1051 Permease of the drug/metabolite transporter (DMT) superfamily
MTDRSLKADILLLITAIIWGAAFVAQRVGMDYMGPLTFNAVRFALGAVALLPLIYSLDRE
KKKDGTYRKVELGSFLKGSLIAGGALFLGATFQQWGMVYTTAGNAGFITGLYVVFVPVFG
LFFKQKTGLPTWIGALLAVTGMYLLSVNEEFHIEFGDLLVLCSAFFWAGHVIVISLLATR
VDPVKFAGGQFVACSIFSFMGAFIFENVSLAGIIDGAVPILYGGLMSVGVAYTLQVIAQQ
DAKPAHAAIILSLESVFAALAGYVLLGEMLTVQGMAGCALMLCGMIISQVKSS
>fig|1121451.3.peg.1414 Acriflavin resistance protein
MSVPANSENSQGLIASAVRFFLHSKLTIVLVIGALLLGVAAIQLTPREEEPQIVVPMADI
MVQAPGAGVEEVEKLITTPLERILWQIDGVEYVYSVSRRDASLVTVRFFVGEDREESLIK
LHNAIAKNTDIAPRIASGWVIKPVEIDDVPIVALTLFPAAGRNDISDFELRRVAEELSTR
LAEVEDLSRVSLVSGRSREVRVELLPERMAGFNISPVEIAAVLEGADQSAVAGAVLAGNR
EITVSANSFLDSASDVNNLIVGVSESRPVYLRDVAVVKDGPEEPSSYSRIGFSRLYMTLT
GQDVEESSRPAVTIALSKKKGTNAVKVAEAVLARMDRLKETVLPAGIEVEVVRDYGKTAD
SKVSDLLGSLGFAVFTVIILLAFTLGWREASVVALAVPISFSLALFVNYMLGYTINRVTL
FALILSLGLVVDDPITNVDNIQRHILMKKKKAAEATLDAVSEVLPPVIMSTLAIIVSFVP
LFFITGMMGPYMAPMAANVPLTVTFSTFCALTIVPWMAFRLLKNIQPQKVATDTGPGRIE
IFYSAVITPFLDSRFRRWMLVGVIVIGLIVSMALAGFRLVPLKMLPYDNKNEFQIIIDMD
EGTPLEQTDRVVRQFEEILRGVPEVTNFVTYAGEPSPMDFNGLVRHYYWRSGGHMADIRV
NLVDKSLRSEQSHAIVLRLRHELEAVAARNNACIKIVESPPGPPVISTITTEVYGAEDRP
YSALIEGAKQIVSVMKTESGVVDIDDSTAAERIMVDFVLDKEKAALHGVNAREVVATLQM
ALSGMVPATVHAEGERNPLPVKLILPFVRRADVASLSQLRVKTAAGKRVPLAELGELVEI
NQEQPIYHKNLKRVVYVFAEMAGRAPGEAILDMQGKLKKDPLPPFIWTDWAGEGEWQITL
DVFRDLGLAFGAALLGIYILLIVETGSFGMPLLIMSAIPLTLLGIMPGFWLLNLVSAEKV
QGLVGAGFVDPVFFTATGMIGMIALGGIVIRNSLVLIDFIRKSLAEGMELKAAIIKSGAV
RLRPIALTAATTALGAWPITLDPIFSGLAWALIFGLLASTLFTLVVIPVGYYAFEKNG
>fig|1121451.3.peg.1638 Multiple antibiotic resistance (MarC)-related proteins
MEIKSLSAIFEIAFPLFLIMDPLGNLPVCLSMLKEFSPAKQRKILLRELLFALGIIILFM
YLGAGLMKMLNIHQSTLRIAGGVILFIISMKMIFPKPEGSATEAEKDPFIVPIAVPLFAG
PSLLAAVMVYGSRGDADLTVLSGTMLAWGLTFIIMMAGPTLARILGKRGLRACERLMGLV
LILLAVQMLEDGVAFYINNVLGK
>fig|1121451.3.peg.1803 Acriflavin resistance protein
MAGNPVASNLLMFILLVGGLVMAFNIKQEVFPEFTMDTVTVSVVYSGASPEEVEQGIVLA
VEDAVMGLDGVKEVSSSASEGSGSVIVEAEEGYDLQRLSQDIKSEVDRITSFPEEAEDPK
VKIASRKRQVMTLMVHGDEEPLALRKLAEQVREELINTSGVTQVELSEVSGLQVTIEVPQ
DKLRAYGLTLSDVAAKLAQTSVELPGGGIKTEAGEILVRFKERKDYAREFARVPIVTGED
GTQVLLEDIADVKEDFQSDDYISSFNGDPAVRLNVYRVGTQTPISVSDAVHEKLEIINEG
LPDGVSVAVRNDSSDIFKQRMDLLLKNAYMGLGLVFIFLALFLEPRLAFWVAMGIPISFL
GAMLILAPAGASVNMVSMFAFIISLGIVVDDAIVTGENVFTMRQQGMSWYEAACEGAKRI
AMPVTFSVLTNIVAFMPMFFIPGVMGKIFKVIPLVVISVFFISLVESLFVLPAHLGHCRG
RKPGKIMGYILRHQQKISGGLLTFIHKVYRPFLDRAVTWKYLTVAIGFACLIVAFAYIKS
GRMGFTLFPKIESDYAYLTVDLPYGTAKEVTLRVQDKVLDAAEQVAQENGGEELVEGVYS
SIGGVGRRGSSGSHVLKVQVFLTDADSRPITTEEFVNQWRRNLGPIPGSESILFESDRGG
PGAGGSLEIELSHSNIEVLKRASADLAKALATYPKVKDIDSGYSPGKRQLDFELLPTGRS
LGLTSRSVANQIRSSYYGAEVLRQQRGRNEVKVMVRLPESERVSKYNFEEMMIRTPKGTD
VPLREVVKIKDGRAYTTIDRRNGRRVVSVSADVNPRKETSQIMSAVVADVLPQLKADYPG
LGYSLEGKQADLKESTDSLISGLLIAMMVIYALLAIPFKSYFQPIIVMICIPFGIVGAVV
GHILLGYSLSLMSLFGIVALSGVVVNDSLVFIDYVNIQRRKGHCAYDAVLEAGTARFRPI
LLTTLTTFGGLAPMILETSRQARFLIPMAISLGFGILFATAITLLLVPSFYLIFEDIRLG
LRKLFRRSDDDFRDDGITEHYPVKHCKHKSE
>fig|1121451.3.peg.2767 Permease of the drug/metabolite transporter (DMT) superfamily
MQQHDQKKAYIYGLSAVLIWSTVASAFKIALSHMEPLHLLFYAVIFSTLALLIILIIQKK
IGQITLMSKRELLKNALPGLLNPFLYYIILFEAYNLLPAQEAQPLNYTWAITLSLLSIPL
LGQKMTARELLAIFTSYLGVVVISTHGDLLDIKFSNGYGVFLALVSTIVWALYWIYNTKS
TADPLIGLFLNFCLGLPFVTAAMFIFSGPPPVNGPAILSAAYVGLFEMGITFALWLKALK
LTEKTARISNLIFLSPFLSLILIHLILGEEILPSTLVGLIFIVGGNIIQQMGKRTA
>fig|1121451.3.peg.3168 Permease of the drug/metabolite transporter (DMT) superfamily
MSSTTLLYFKLIGSVTFWGGTWIAGRILAEDLTPYSAAFLRFLFATIFMFFLVRRTTGRK
PECQLADILPLAFLGLTGVFLYNILFFTGLQTVTAGRAALIIAGTPTFIALGSALFFKEK
FTPGKIAGFLLAITGVATTIGDGNPISIITQGASYGDLCIVGCVFSWAAYSLAGKPVMKR
INPIESVYWSSLFGTIMLLGPALYHGLLNEILNASMTDYSCILYLALLGTGLGFSWYFEA
IREIGPSKTGIFINLVPVTAIILGAIILGEPVGLPLIIGGMLTISGVYITNRS
>fig|1121451.3.peg.3172 Permease of the drug/metabolite transporter (DMT) superfamily
MMSFFQSKYIAVVALLVAVFLWSSSFIALKVAMAVYDPMVVIFGRMILASLCFLFFIPSF
KKQAIQKGDLKWLAFMAFCEPCMYFIFESHALVYTSASQAGMIVATLPLLMAVSARFILK
EKLSKKTLSGFILAVIGGIWLSLSSSSTEASPAPMLGNFLEFLAMCCAVGYMTVLKKMTA
RYSALYLTAFQAFMGAIFYLPLLALPSTTLPTVFDPVAVWTIVYLGVCITLGAYGLYNFG
MSRLPANQTTAYVNLIPVFTLFMGWAILDETFTSMQFAAAGLVMSGVIMSQDRKMSS
>fig|1121451.3.peg.3285 5-nitroimidazole antibiotic resistance protein
MAGENKARKGQTKDKTIIDQYLSEGEILHLALKDRIGIFSVPVNYGFYGDKLYVHSSKQG
RKIQALREGGVIGFSIVVSHEVVGKDAPCKWGCSFKSIIGTGVPRILDDKEKAAALNLIM
KQYSGKEWEFNPAAIDAVDVVEIMITSVSARSVEKE
>fig|1121862.3.peg.305 Acriflavin resistance protein
MNIAEYSISHRVISWMFVVILLVGGAVSFFGLGQLEFPEFTIKQAMVITHYPGASPEQVE
EEATLPLEEAIQQLEYVKVIDSISSNGRSQIMVELKEQYPSSQLPQIWDELRRKINDAQS
SLPPGVYPSVVVDDFSDVFGMLFNITGDGYTSRDLENYADYLKRELVLVDGVKKVSIAGA
RQEQVVVEMSQAKLANLGIDPAWIFSLIQNQNVVSNAGNMLVDGRSIRIHPTGEFRNVRE
LEQLIISPPGSTQLVRLGDIASVRRSYDETPDTLYTSNSHPALSLGVSFASGVNVVDVGE
RVRNRLSELTSEQPVGIELTTVYDQPATVSESVNGFLINLAEAIVIVIVVLLLAMGVRAG
LLMGAVLLLTISGTFIVMKVLGIDLEMISLGALIIALGMLVDNAIVVTEGIQVGLQRGQT
RLEAAKRVVSQNQWPLLGATVIAIMAFAPIGLSDDATGEFCLSLFQVLLISLMLSWITAI
TLTPFFCNILFKKYEKATENQETFSVDPYQGALFTLYKQLLNFSLKHRPVTLGLTLLALV
LAILSFGFVKNVFFPPSNTPIFFVDFWMPEGSDIRATESELARFEQQVLSMPGVSNVTSV
IGMGAQRFILPYQPEKQYTSYGQLIIEAESLEAINTLIPPLEIVLDEQFSDVEYRIKLMQ
NGPAAPAEIEARFYGEDPEVLRSLAVQAMTVLRNEPTATNIRHGWRNQVSLVRPHLDEAS
ARRSGISKQALDDALLVNFTGRQVGIYREGSQLMPLIVRSPETERLNADSITDLQVWSAD
YNSYVPITQAISSFDTEWENPLIIRRDRKRMLSVMADPDLMSDETTDSVFRKVRTNIEAI
PLPEGYTLEWGGAYELSTDAQNATFASIPMGYLAMFLITVFLFNTIRQPLAIWATVPLAL
IGVVTGLLVLNTPFSFMGLLGLLSLSGMLIKNGIVLVEQIKLELEEGWEEHEAIFHASVS
RLRPVCMAALTTMLGMIPLLFDAFFKSMAVTIIFGLGFATVLTLVVLPVIYSLLYKINFK
GFDYRKIGHH
>fig|1121862.3.peg.417 Acriflavin resistance protein
MNITRATINNNRTALVLVIVLIIAGLQAYKNLPRAYDPGFVIRVAKVITHFPGASPERVE
QLITDKLEKVIQEIPELDFVKSTSRTGISIITVSIQESYTNMRPIWDNLRRKIESAAKDM
PDGVIGPEVNDEFGDVFGIVVTLTGPEFTYAELKDIADQARDEFLRVPEVAKVEIYGAQE
ERIFIEYNNARLSELGLSPTQLMQMLENRNIVVPGGAITLDMERIELEPSGNFESVDDIR
HTIVSIPGSNNVVYLEDIATVKRGYVDPASSKVHSSGQQALGLGLSMREGGNNIRMGEQV
QEVLNYLNQTYPIGIDFNVINFSPKEVEDKVNDFVSNLIQAVLVVAAVMLVALGPRTGLI
VASLIPMSMISAMLVMSFFDIGLDQISLAALIIALGMLVDNGIVMAESIMVQMNNGKKPV
EAAIDSASELRVPLLTSSLTTAAAFLPIYLAESAVGEFTASLFLVVTITLLCSWLLSMTL
IPLLCVQFLKPKKESTDYNRGFYQRYRELLTWVLKHRVISLAATAVLFAVVMSGFKYVPK
IFFPPSDRLYFKTELELPLGTAIERTEAIIKELEAFITEEMKINGARTEGVISWISHIGT
GGPRFVLQHSPEPASPNYAMMVINTTSSDAIGGMIDKLDSYAFDNFPDLQITSRRIESGV
SITNPVEIRLYGKETDQLFSLVEQLKAEMAQINGLKNISDDWGQRIKKLKVVINQSRALR
VGATSQDIAISLQSGLSGLELTQYREGEDAIPVLLRSVEADRQDIDKLETLSVYIQSTGE
SVTLKQVADIEVVWEPAQILRRDGLKTVSVGAQLTPGMTAAEGFAQLQPWLDEHSHRWPA
GYRYELGGEAESSGKANQSIGEKLPMAAFLILILLVAQFNSLRKPAIILATIPLGMIGVI
IGLLTAQSFFGFMTLLGVISLAGIVINNAIVLLERIKYEIDDNGLSAQEAIIVAAQRRLR
PILLTTATTVLGMIPLYLGGGEMWEPMAVAIIAGLLFSTILTLGLVPVLYSLFYRVKY
>fig|1121862.3.peg.768 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MQMLSSRFHHFIDESKALLGLSLPIIVTQLATNGMNFVDTSMAGQASARDLAAIAVGTSL
WLPASLLLRGILMMLTPVTAHHRGAGNNPGISKDLGQTLWIALLCSAALISYLNFSEDIL
VYMTVAPEIIPVGVGYLHALAFGLPGIALFYMLNSFLEGMGNTRAPMVISLLGLLVNIPV
NYVLIYGKFGLPELGAVGCGWATSIVYWMMSILIFLYIRTHHRYEHLLDLRATLPDFTRI
RELFRLGLPIGVSICVCGSIFAVIALLIGKLGANNIAAAQIALNFSSMTYMVPMSLSFGI
TIRVGHSLGKGLNDEARIQAICGILTAALIAVLSVLCILIFRQQIISLYTNDPLIVKGAS
VLLVCAAMYQISDAVQASASGALRGYKDTRVPMVLSCGAYWGIALPVGYAFAMTDIFGAP
MGTEGFWVGIISGLTLAAGLLLGRLVRLMKL
>fig|1121862.3.peg.904 Permease of the drug/metabolite transporter (DMT) superfamily
MKYALRNINTSRQGSIAVLLSALMWGTTGAAASFISDVNPMAVGAFSMGIGGILLALTAR
KKLIEECLLLSHSWRIILIGSLSLTVYPQAFYSSMHFAGVAVGNVISIASAPFMTVIIER
LLLNKKQITFRWLFSAVLGASGIVLLTLSDAYSTQAIIEDSSRQIGVLLGLLAALTYAGY
TCAAKKLMEQGAHSTSAMGSIFCCASLILLPTLLFTGEHLFSSIENTVAVWYLALVPMFL
GYLCFGFGLRFIPASKATLLTLFEPVVAVCLAVIIVKEVIALTGWFGMGLIMVCLIIQAS
EKDETRRGLLKEYSKAG
>fig|1121862.3.peg.1802 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MSVHTTDDKMTSGSTTVDFFRFVVPSILGLVALSSAGIVDGIFVGNYVGATALAAVNLVV
PLYSVFFGLCVMMLVGGAVVAGKALGAGDTRKASNIFTKSLTVIVIFALIVASLAFLFAG
NIAAFVGAEGEALPLTTEYIRIISPFMFFMGLAYTLSYFSRVDDAPNYALAGLVLTALTN
IALDALFIKVWGWGVSGAAFASGIAYTVGTAFLVIRFFGKQARIRLIKPYGSWFELFRAA
YNGFSEFINEMSGGLVMFVINWILMIEAGTTGVAAFTIVNYILWLSIMVAYGTAEALGPL
VSVNFGARKPERIASFMKLGVGLAIMVGITFATVLLVYPEELASVFIRSDEVATLALTMS
IIAVIWPAFLFNGINITLSGYFTGMHAATQSALIAMSRSLVLPLVLIILFWKTLGLEGAF
LALPVAEILTFALSVTLFYRATPKMMVSKDVAAGNNEIDSLGGVHN
>fig|1121862.3.peg.2003 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MASIDLRSDPIPSSFFYYLLPAVSGMLVKSLYVLVDSIMVGRGVGADALAALSLTVPFFA
LFLALALMIGVGGSALMSTQFGRGNYTEGQNIFFQSVLLTLVISGFLVSVGFIWLDEVVL
MTGASEALFTMTRDYLEIMLMFFMIYAVGWVLSCFVRNDGNPRLAMYSLVVSALTNVVLD
YVFIFVFPWGVKGAALATGLSQLVLFAGVITHFVRSKGVLRLKLPSSNVKWVGKIMSTGL
PTFFIESTIGVSTLIFNWVLIRHGGDLYVTAYSIVINVAVLVLFILMGVGQACQPIISFN
HGAKSVSRVRETLVLGVKTAVGVGIAALMLASLETDWLVGLFVVDYPVLFDLASLAMPLY
FMAFPCMAINLMIASFFQAVEKPMLATALSIVRGFGFVVLGLVVMPWLMPEYGIWLVVPF
AEMITLVFSLVLYHRHHVQSSGSSTVVLSA
>fig|1121862.3.peg.2130 Multidrug resistance protein A
MDNTAPHPVRRWLLTVAVLLLAFIAGYFYFEHQKNYPSTNDAYVHGNIIYIAPQIGGRIS
VVNVDNYEHVHTGEMLLQIDPSSYEAQLNKAKASYQVATEENEAASEGILAASTNISTAA
ANLRKVQLNFRRTMTLVSEGVLPQQEADTARAALATAQDSLTSARAHMAQLIAEQGAEGE
EAPAVQEAAAALMLATLNLSYTNIAAPADGELGKVNVHPGSVVSVGQALMPLVVAESFWI
QANFKEDDLGRIQPGMSARVQLDMYPDSSFSGKVESISPASGSAFSLLPPENATGNWVKI
TQRFPVSVRLADADNQRGKEPLRVGASATVTVDTIAADHEQ
>fig|1121862.3.peg.2131 Multidrug resistance protein B
MSNNISRQAITITIILSSLMVLIDMTVANVALPDMMGTLGATSEQITWVLTSFSMAEAIC
IPLAGFLTLRFGERQLLLYSIAGFIVMSAMCGQADSLMEMIFFRIFQGIFGAAVIPLSQS
VLMQVYPKEEQGRAMALFAIGVMVGPVLGPVIGGILTEHLNWRWVFYINLPVGGVCLLLI
FRNIQISNRGKSSVDWLLIITMALGIGLLQMVLSQGNEKNWFSSDFILLSTIISVLMITA
FIIRSFWTKGEIAPVWLLKDRNLAISCLIVSCFAVGTFGVLQLQPMLLQELLNYPVETSG
FIMAPRGVASAVVLIMAAPLMDKLDSRILIFVGLVFNAVGVWQMSLYSLEIDPFWIVLPS
IIQGAGLGLVFAPLSKIAFSTLDPAFITGGTAMFNLCRTIGSSIGIAVINTYFSYVKQLE
WQSLGGSLSPDNRLLQNYAEVAGQGITNTDFLEQIAALLKQQSSMLAFVYCFTLMVFIYL
FLILLLPIFRKKAPASSS
>fig|1121862.3.peg.2434 Multiple antibiotic resistance protein MarC
MELFFKDFIMLWSTIDPVGTLALFTGLTARLSKSQKRKVALKATTYAFVILLSALVLGQI
ILKAMSIQLISLQLAGGIILFLFGLQMIFSDPEEGTGSREPGHQLAVFPLAVPSIASPGA
IMAVIVLTDNNMKTFTQQAMTAGAMTSVLLITCGLMLIADRIFRVIGHNGSAIIIRVMGM
ILAALSVELVMTALGVQRWMS
>fig|1121862.3.peg.2447 Drug resistance transporter, Bcr/CflA subfamily
MMDSVLNRSRPGIGLLATLLALPQLSETIYTPVLPAIAQGFGVSESMAQLTMSIYFVGFA
LGVLTWGWLADRWGRRRAMLAGLLCYGMGAAGALFSSEFMLLLGARFLLAFGISVGSVVT
QTVIRDCYSGKALGKLFSTVGAVISLSLAIGPVLGSIGAIAGGYQTVFMMLGGTALLMTL
WVGLSLPETHPGHESVKSSKGSLLVRMIRDRKIRVYSIMVAGANLVLFGYFTLGPFLIKQ
IGFSASVFGVTGVLIALGSALGAMFNRQLLTRHSGGQLILRGCWLGVSGALLQLIITLFL
PSVPFVALLLVVAPMVLMVIAFGLIVPNLLSSALSEYKDELGTAGALFGLSYYLLIAAGL
ALISHHYVSFAGYMPAVFLVIFLLMLMIWFCYRQHILRR
>fig|1121862.3.peg.2679 Multidrug resistance protein D
MKQQGFFQVLFVIVVLTACGQLTNTIYVPTMSQMAADFGVVPGTVQAAIALYLIPYGISQ
FLYGPLSDRFGRKPLMLIGLVIFIAGSLIGSFAHSFEMLLLASFVQGMGTGVGGVMARTV
MRDLYSGLHLQRANSYISMALIFTPLMAPMLGGFLGTAFGWQASFWFLTGFGVLVWLLVL
GRFGETHKNVGKRSMGALASYRYVLSNVQFNGFMISLVATFAGIAVFEAAAGVLFGELMG
LDPRVISVLFVIPIPGYLFGSWLAGQMAKKHSLESIIGRGVVMLVIGSGSMLVAGLMGYL
NAWVILVPATLYFLGSGLLFPTATTAALEPFPENAGVAGAVLGGMQNLGGGLVTLVAASI
PMASQVPVAAILCVLTLLVVMTVRILLAPAAGRATV
>fig|1121862.3.peg.2698 Bicyclomycin resistance protein
MFHITSPNKTWNYPLARTLLLMVPFDLLASLGMDIYLPALPGMGEFFSASPFMVQLTLSL
YMLMLGCGQLIFGPLSDRYGRRPVLLFGCLLFVICSIGLTMTGSIELFIFFRLCQAAGGS
AALVATFATVRDVYGHKPESATLYALLGGMLAFVPALGPIVGSLLIGWFGWASVFWGLAV
SGSVAGVHALFSWPETHCSVGGGSIKHAFGRVITSPAFLLYTSGFTVAMGSFFVYFSIAP
GILIGKLGYSSLVFSLLFAMAAVAMIIVSRFAGSIARKFGISGTLKLGMAVILAGALLML
LGSTLQLPEAPVLLLPMMVIAVGISITCSVCATGALAEFKDIAGTGVALYYCLEAVLVCL
LGTAVVMLFPVGSLWPLIAFSGIGSLVVMASAAWINK
>fig|1121862.3.peg.2792 Multidrug resistance ABC transporter ATP-binding and permease protein
MKLLWKLRFILKDYWQQYLLAFICLQIVSALNLLPPWLIGHVVDGIKDKSLTNQELFNYV
AGIVVTGVAVYGFRYVWRAKLYGASIELIRKQRSRLFAHFTQLSPEFYQQHTTGDLMAHA
TNDLNAVEESVGVGIMTLVDSLIAGLTVLFAMVFLVSGKLTLLAMLPFPLLVWVTKRYGV
ALYSRFGRSQAAFSNLNEETRESITGIRAVKAHQLTDRQTQRFEQLSMEAVEANTSVARV
DALFGPSISLFFGLSFVLALVGGAWLISHGQLTVGLLTSFTLYLSQMLGPMLQFGWQFNV
FQRGSASWGRLEKLLSRKPKVSNAPDAQQAPDDTSLSINIQSFSYNAASDEKPVLQGIST
EIAAGAFIGITGRTGSGKSTLLRLILREFDLPEGSFIQMGNIPLQQLTVESLREKLAWVP
QEPMLFSGTIADNIRFSAPDASLEAVEKAAKLAAIDEEIMGFKDGYDTLLGENGINLSGG
QKQRLALARALLADAEILLLDDAFSALDMKTEARILKNLMAMKGKKTIILVTQRLPELIT
ADHILVLDRGRIIEQGNHDRLMASDQPEENTTEHWYAKIFRQQARTLLHPLEVKPDTVIK
RSDVA
>fig|1121862.3.peg.2793 Multidrug resistance ABC transporter ATP-binding and permease protein
MIANDEKKTSGYRGLARLVRYAKPYQWQFLGAFLILLLATSLEMLAPWLMKIILDEHIAP
GVNDTMGLAMMGSALFGTYLGSAILQYIQNVKFQENALKVVHDIRRMLFAHVLRLPMSYF
DSEPTGRLVSRITNDSEVLRQMFVGVIPAILQAFFRVVGIFIAMALLDVRLMFMTAMLIP
VMLLAIHLYQKISHPVIHGVRSQLANINTRVNESLNGMRIIQAMGQEAHLQQQFDKDNEE
WSQLKRKNINIDSLLLMPFTHLLNGIALAVVVGWFGYQSGFSLVEVGTLYAFINYLGRFF
EPFRQITMQMSSLQQSLVASERLFQVLNEETEDTQHGQSKNQTDSPEIHSGKLEFNNVTL
SYDSKNMALDNVSFTVEPGQFVAIVGHSGSGKSSVINLLMRFYQHQEGQILIDNQPLTSL
KEDTLRQGLGLVFQEPYIFSGTMAENISLNHDQITDEHVQAAARKVHADPFIQELDESYE
HKPGPGGKALSTGERQLLSFARTIAQNPKILLLDEATANIDGETEHHIKEALITLRENRT
TIAVAHRLSTIQDADQILVMDKGRIVQSGTHEELLLQEGHYRDLYLAQQTEEQLGTTQQP
GLTMAAANA
>fig|1121862.3.peg.2827 Permease of the drug/metabolite transporter (DMT) superfamily
MNTTIKADLVLLLVTLLAASGWLFSKFAIGGMPPIGYIGVRYIAAALLLLPFAARQLFQL
NKSQLFICVMVGLIQMAAMYLWIQAVDSSDRLGEGAFIMSLSMIMVPFMGRLLYGSRIDR
FTLFALPFAIAGIALLALKGSWEFEPAQGLYLMATLFIALHFVFTNRNAPGIPSMALTFI
LLLVPGVLGMAISVTTESWPEQIATDTWVWVAAAVLVATSLRYFLYTWALKHSEAGHAAL
IMVIEPVWTALMSAIWMGESMTSQKLLGCGLIFMALLVARWRSIFKPAIAESQLVRE
>fig|1121862.3.peg.2883 Acriflavin resistance protein
MSRLSDALINRGPIAWMARNSVTANLLMLFFIVGGLLTSFQIRKEVYPNYQLNSVKITVS
YSGATPDEMEMGIVLPIENAIRGIEGIKQVNSRALGGFANITAELVNNVNVDRVLGEIES
EVNRTNLPAGAEKPRVTRSAIQHESMELILYGDVDPVALRETTSLVRDTLLRSPYLTQVE
MHWASKYEVKVYVDKENLERYGLTLDSLSNSISRYAVTQSGGKLETAGGDILVEVDNRQE
WAKDFSSVPVVSTAQGGHIYLDEIATIEDGFADRKFSFFYNGKPSTSIKIYRVGDQTPIG
ISEAVHDMMPQLQALLPPGILLEIVNDDAILYEQRMALLLKNAFSGLVLVLVVLALFLDL
RLAFWVTMGIPTAFLGSLIFLPAMDVSINMISMFAFIIALGIVVDDAIIAGENVYDHMNQ
GMPFAQAAIIGVKDIAVPLTFSILTNIVAFIPIWFLPGTMGMMFQVIPLVVITVFAISWI
EALFILPAHLVHLKNDNPALIFRFATALQALFNRGLNRLIVHFYKPVMRVLLEFRYLVVA
LGIAMLMTSISYIAGGHMGFTTMPKVEAEFSVGRATLPVGTSLEDATAIRHRLERSAQKV
MDENGGKALVKGISSIQRNLDGEFIIIVRMFLQPSEVRTMSTKEVSRLWRESTGTIPGVE
GIRFSSAGSGPGSDVAGVTIEMRHHDNNMLEEASNELAMMLAGYAGVIDIENTFSSGSSK
LNLKLLPAGQSLGLNEKELAKQVRSAFNGVRSIRQQRGSEEVDIKVMLPDYQRASEFDLE
QLPVRVGNDYVPLGQVASITRDYSASVIQRREGRRRVIVSADITPSSEAMTLSQTLSEET
FPILKQSYPGLDIGFRGDQIEQKESMDSLFVNGIMVMLALYCLLAIPFRSYSQPFIIMAI
IPFGLIGSVLGHVALGYTMSVVSLLGVLALSGVVINDSLILVTEANERREKDMLGVHDAL
LEACHRRFRPIILTTLTTFGGLAPMILETSNQARFMIPMAISLGFGILFATFITLLLLPC
MYSVLEDIKGVFTNTAYEAEVPLKS
>fig|1121862.3.peg.3045 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MLFHNHCILREFRALLKLSLPLMGTYLVMSLAGFIDTLMAGQYSSVDLAGVAIAYTAWIP
VNVFLVGLLMGKTAFISQLYGARKLRDIVAMGQQGLLLATGSGIVGLALLSVFSELLIYV
DASNAVREIASGYLTFVALGMPGVALNQALRSYLEGQGYVRSVMVAQVLGLLINIPLNYA
LIYGRFGLPEMGGLGCGIATAVIMWLSPLFMVAYICFNKALKSTSPFCYALDLDLEKLKA
LVAIGLPIAVTLFCQFLVFMVITVLLASHGHVVVGAHQIVFNVSTLLMMVPSAIGGAVTI
RAAYYIGAGHSSMGGFVSLVGLSISFMVMCVLGVGGWWARFSIVRLYTQDLAVIELAASL
MGLVVIYLLLTVIQQLGAAALRAYRDAFSVMWIMLVSLWGIMLPLGYFLANMDFLGAPLG
VKGFWLAMVVAYFLAAIGTCCRCCLVVK
>fig|1121862.3.peg.3434 Permease of the drug/metabolite transporter (DMT) superfamily
MYSVKTKALRADLLLLMVSAIWGFAFVAQIKGMEHLGPFLFNACRFALGFLSLLPVYFLL
EAFSAKKNGKKESGVESVKKYDNHLLLKWGPITGIVLFLASSFQQVGLLYTTAGNSGFIT
GFYIILVPILGICFGHSTRPVTWLGGAIALAGLYFLTVNDGLSLNKGDLLTLGSALMYAI
QILLIGWLSRHVHPLRLSLTQFFMTALCSLLVALYLEPISLDAITQSVGPLLFAGVLSTG
VAFTIQIIAQQDAASSHAAIIMSLEAVFAVFGGWLLLDEQLGSRGVVGCALMMAGMLLSQ
LRRPRGRSTA
>fig|1121862.3.peg.3582 Permease of the drug/metabolite transporter (DMT) superfamily
MDASLISGVQKEDNNTFLYASYVVLLGSCFPIMRYASIHFDTVNNNAIRFLAGGILFLIM
VIAKYRNEVSKLLAEPVMIVKLLLIGVLMTVNMYFFMNGMQLTTALTGSIFSILGMPVAT
IMASIFFADERKKAANPRFIIGCLLSIAGSFLFIFNADTTGHSENFVLGSAFWVLAITIA
AMQNLLVKNLAKDLHPVVISAATATIAGLIYLFIATATGKIQELSTTPDSLIIFLIMAGM
FGMLVGMLMAFYIIRKSGVITFNMLQIMAPLSTAIIAYITLGETISTIQAFGAAIVVVGC
THSLKANRVN
>fig|1121862.3.peg.3870 Acriflavin resistance protein
MDIARYTIAKRTSVWVIIALTLIGGYISYLKLGRFEDPEFVIRQAVINTPYYGATAQEVS
DEVTDLIEGAVQSLQELKEVKSVSKQGMSEVTVEIQLEFAKSSADLQQVWDKLRRKISDV
QRQLPPGAGPSIVNDDFSDVYALFFAVTGEGFTDKQLQDYVDTLRRELVLVPGVAKTATL
AEQQETIFVEISSERMAKFGLSAEQVLQVLQKQNLVTVAGSIETNSMRIPVIPDASVHSF
DDLKNLQVGVGENSTVLRLGDIADLKRGYQEPASMLMRYNGERAIGFGISNVTGGNVVDM
GDAVKARIAELESQRPLGMELHVISMQSDSVRASVANFIDNLIAAVAIVFVVLLLFMGVR
SGVIIGFVLLLTVAGTLCIMLVEDIAMQRISLGALIIALGMLVDNAIVVTDGILVRLQKN
PDEDRAALASEIVKSTQWPLLGGTVVGICAFSAIGLSPSDMGEYAGSLFWVILYSMLLSW
VFAVTVTPMLCHDFLKVKAIAADQKPGRMVTAYKALLMWVLKHRLISSALLMGTLAVAIW
GVQFVPPGFMPDSQRPQFVVDVYLPQGSDITRTEAIIADVEQDVKAKEGITNIASFIGGG
GLRFMLTYSPEARNPSYGQLLIDIDDYTRIAPLIGELQSELASKYPDASIKVWKFMLGRG
GGKKIEAGFKGPDSQVLRQLAEQAKAIMLSDSNLIAVQDDWRQQVPVLRPVYSAEEAQRF
GLTTPEINQAIAQTLTGRNVGVYREGDDLIPIVVRAPEGERNHQRAIENTEVFSPKANTF
IPVSQLVESVDVVYQDAILRRIDRVPTILVQADPAPGVLTADAFNLLRSKIEAIEMPPGY
ELTWYGEFKASKDANEGLVISAPYGFAAMILSVIFMFNALRQPLVIWLTTPLALVGVAAG
LVIFQTPFEFMAILGFLSLIGMMVKNAIVLVDQADVEIRDGKPPYHAIIDAALSRARPVL
LGALTTILGVAPLLIDPFFKSMAVTIMFGLLFATILTLVVIPLFYAVFFRVKIEEA
>fig|1121862.3.peg.3905 Quaternary ammonium compound-resistance protein SugE
MAWVYLLLAGMFEIGWPVGLKMAQSPDTRWLGIFTAIICIGLSGYTMWLAQKEIPMGTVY
AVWTGLGAAGAFFVGIIFYGEAASLMRYMGVLLIIAGVVTLKLAY
>fig|1121862.3.peg.4015 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MRTNLSAFARYRAELRELLYLAGPIMGAQLATTGMTFVDTSMAGQYSAMDLAAIALGSSI
WMPVYLLIRGILMAITPTVAHLYGARQTGEIGGQVRQGLWVALLMSLLALVFIYKSDVVL
QWLQVEPEMAAKTLEYLKALAWGIPAICLFQALTCYCEGMGKTKPSMVFSFIALALNIPL
NYVLIYGKFGFPELGGVGCGYATAVCFWVMFLMMAGYTMLGQQHRKIGLFDHWDLPSLSI
ISSQLKLGVPIGLAIFFEASIFSVVALLIGKLGAIVVAGHQIALNFTSLAFMVPMSLAMG
LTIRVGQALGAGKTEQAAYSSYAGIATTLVSATVSASVMMFLPGVVTSIYTQNPEVAILA
AQLLVYAALFQYADGIQIAANGALRGYKDTRVPMAMILFACWGVALPLGYILGLTDWIVE
PMGPHGLWIGLVTALTMGAFLLTLRLRAIIRRNRMLASEIMPMPA
>fig|1121862.3.peg.4237 Acriflavin resistance protein
MKSLLPFFIARPKIVNLLVGCVFLAGFLLLDGLRYEYNPRVDMGTVNITTTRLGSGPEEI
ERSITMPIEEELLKVEGIEKIFSSSMDGMSVITARLDINYHDKTLLLSDIQKAVDRAYTR
LPQDLLDKPLIEEQSTQKTPVIEIHLVGNVSEEILRASARKVAEGLREVEGVSGEHRIGY
RRSEVKVFLSPEKLTQLGISIDEVRKAIVSRNVRDSGGSLSSFNAEKKVISVGQFQQPKD
IESVIIRAYEPGNVVRVSDVASVISGYGDWEVESRTDGRRSIILQVHKKPTSDELHTASN
VRNYIERMRAQMPAGIELIDVNDISRLTIQMLDVLVSNAALGLALVLVILYVTLSPRLAF
WVAMGLPFSIILTFLTIDALGISVNAINLVAIILMLGILVDDAVVVGESVQYQRELGLSG
PEAAIKGTQSVAKPVMFAVLTTILAFVPMLAMGGRDGAFMKDFPIAVLIVLTVSLFESQY
ILPTHLAHKSGSIEQKQSRFLSRWSSIYEKVISTLIRHSRKSTLAFIVVFIGVMAFGAST
INFQLYPAVDIDNVNVKIELPAGSRMTDTREVVSALETRARELIPASDLLNITSQIGHHD
TDFYGATEGRSESWALMIVQLKPLSQRTVKTHEMVELLRTELKKVSPVTHLVVEPQTDIP
VTDKPIQVEFISSEESRFPAAQKLLDYLEQHPAVTESWSSFKPGRDVVDLTFNYELLASR
GLTVREITDAVRVAMDGLIVDELQTLDERIYYRLQYPPSRESQLSTLENLSIINHRGEQI
FLNSLVEFNWRSGEADIKHYQGRRTTTVYAEMDTAVMSLEQLNQDVSDFIATQSWPQTHP
DLRVYQGGALVQQADSLGRMGDAFLICLLAIFIALVLLFNSYSQPALVLLCLPFGVMGVV
LGFGLQGIDMGYVALTGVLGLMGVLVNDSLVLLHTLNNQKTDRASLLSNSEIAAGAAMRF
RPIVITSLTTVAGLIPTAYGIAGTNSYITPMVMAMAWGVGFGMFVTLLLLPCLYTIDRDI
KAYFHRRSEAKKDLSWQNSEQV
>fig|1121862.3.peg.4262 Permease of the drug/metabolite transporter (DMT) superfamily
MQNILLFSLCSFVWGSTWYAITFQLGDVDPLWSISYRFLLAGLILMAVCFLQRAPVQFTV
RQHLRIFLQGICFCGISYWLVYLSELYINSAQSALVCTSMLYLNVIIGRFWLGNPVRLPV
VIGGVLGSLGIVMVFLPELASSLTTDLMKGIVMAFVGCIFFSIGSLICEINKKSGLPLLP
VVMTAMMYSSIFTAVFALSLGKLPSFQWSKPYVFSLLYLALFGSILAMTSYVALIGRIGA
DRTAYVDIIYPIIALFIATMFEGYQWTTLSLLGVLVVLAGNYIALGVNFDKAHIAK
>fig|1121862.3.peg.4881 Bicyclomycin resistance protein
MGAIAIIPMLPITLYIPILPHIASQFGYDTEIFQLTLPLFIISQVVAMPITAMLSDTGYR
LQALYWALMVFIIGTVLCIGWPSLWLFCTGRVLQAFSAATLMTVIPALINECYDTNSVAR
ILSYVTAIGFVIPIVGPELSTLASQHWSWYSVFVFMLAYSMTTFLICRRSIGKATPPANR
LTIEPLKKGLYHWKIMVQDKETQAFLVCHTGIAVVGQIYISNSAFLFLDYYQLTEISYSY
LISVLYVSRTAITLINGLLLKHIPYSKLIDLSLPVLMILALCMLLLDWFYGASLIPSLIL
VVAFFALSGLVVTNALTGVLKNHESWSMQASALLFIVFSGTASMLNIALIALHDGTPRVL
SMVSMLILILTYLLYQRIKSGS
>fig|1121862.3.peg.4984 Permease of the drug/metabolite transporter (DMT) superfamily
MLRNYLFLFGIGVIWGSQFIFQQMAVADISPVWVGAGRSLIGFLTLVIICQVMRIKSNGG
QWFKFSLIGLLEATIPFILVAWGQQYLDTAIAAILMGTIPFFTVILAPLVIKGARITFAG
IGSVLLGFSGLVMLFYPELMSGSSTTNLMAAGAIIVASACFSVALLLLKGVENEHPLIIA
RNVLGSASVQIILFAMLVAPVTEITPTASSLMAVTYLGTLCAGLVYFLYMMLIRDAGPVF
ASLNNYLVPMIGVLLGATINGEALSVHSWAALATIMMAVAFNQIFTGKSSKGSESSEPEE
ASAEGLLPAK
>fig|1121862.3.peg.4993 Glyoxalase/bleomycin resistance protein/dioxygenase
MIAENLFGPVRQWGFLVKDLDHAMSQWHDVMGVGPWWGYRNVPLETEVNGKAYEVRMDVG
LAFQNGVQIELIQQTNNVPSPYSDFFLHSDEKQVFHQIAFFAPDIELALEKARNAGLVEV
GLCKTPLQRFYYLNAPWLGNTVIELMEVNDSFVSGYEFCAREAASWDGSNPYRLISL
>fig|1121876.3.peg.163 Permease of the drug/metabolite transporter (DMT) superfamily
MNYLLLLLIGAIWGAQFVLIDASLIAFSPEQLALFRTFYAVVFLVLFCLILNIRRSNARS
LTDWVKVASIGVLEVVIPFTLVMWAQQFLTGSMASILMGTIPFFTLLLVMLTKVERASVS
KFVAMIVGFIGLLVLLAPDLLSSGLSGSVVPKLAILLGSLSFAGALIVIKSMPKENAFIL
SRDAFAFGTVIMFVINLAQGNLSDLHFPLIPVTTSVVLGVFCSGLVYVLYVYLIKRAGAG
FCSLSNYLVPLFGSVLGVLIMNDHITLRMVVACLLILLSIAVEPFLSYLKYIVKSRQGAK
SA
>fig|1121876.3.peg.368 Permease of the drug/metabolite transporter (DMT) superfamily
MSNGTKALLALMLTIIFWSSAFVGIRFIMENFSSGGLALSRYFVASIAMAIPFVFIRNKK
MPSVKEALQFLIMGCLGFFIYNVLLNEGEITVSAGIANFIVSQLPLFVIIFASIFYRERI
NRYGAFGIIISILGTLLILLSEHQGGSFVGVVFIYVATLSAAIYSTMQKKLLVKFHPIEV
ISYCIWAGTLMLLIFLPVTWKNLSHATSLDYMVIIYMGVFPGAIAYALWAYAFKHIKASI
ASSTLYVMPISSLFLAWLFLGEHAEMLTVMGGIIAVLGAVILSKFGVKK
>fig|1121876.3.peg.502 Multidrug resistance protein D
MEKTKTGESMQSNKSLVFYPMILMIAYWVITKAGLPFVDEMSQFFAVSHQRIQQILSLSL
IISSLSPLLWGPLIDYISLKRFAIIASVLSFVITILMLITTSVTIFTITYIIATSIIFSL
SVCSRSFPFIYFDQLEQKQKAIGITFMGVYFCSFMIPLFSGWIGFYLGWEFGYSLVLLWL
FIVFIAMYRLKSNTEPVAIEKVGFLKNAMMIFMHMRTKGFLRYALFVAILNGLAWTYIIA
LPFWLASIFTIGSKYLALYLFPLALPGLLCPIIVSFLERFMSKEAIMKLSVIIFLIAGVL
AIFLGVKLWDSAVIYIIPGVLLNLASAMAFAIASTKVFTHVKTAFNAASGLFSLIQYFAF
GVIVFVESYISIHHYYLEGVLVCIGGVFLLILQRGRAN
>fig|1121876.3.peg.549 Multidrug resistance transporter, Bcr/CflA family
MSKLTILMVLSVCIITPFANDIFIASFPSMQLAFHSDKITLIMTSFMLGLAISQLFYGPL
LDRFGRKVVLLGGLVIYCIASTFILFSGNILMLLILRFFQGVGVCSTIVSAMAIARDVYK
KEELVKAMATIMAIIGVCPVLAPLFGSFLQSSFGWRASFVLLLVLGIVYFFVVLFLYKES
IKEKNMHALKLSMLYKNYISLLQKKAFTGYILVSACSYGVLFSYAAASSILIIKHLHYSV
MSYGVLFALNASAIVLMSILTPRLSARYGISRMVIIGCIFILLGALFAILMGVLIGENIY
TLMLPMWIATIGIGMIRPSASAGAIALAEHKITGSAAALFNFSSFVGGSIATYLIANFTL
TVVNYGIFAFIIACIAICLSLYVYHAEFVHNFRCDGIKEA
>fig|1121876.3.peg.572 Permease of the drug/metabolite transporter (DMT) superfamily
MTIVIWSLLLFGVFLNACAQLFLKFGVDRIGEFSFTLQNLIPIGWKLATNYFVILGLLCY
VISVVVWLMVLSRIPVGIAYPMVSIGYIITAIAGYFLLGESLTVTRVIGILVIIIGVYLV
ARV
>fig|1121876.3.peg.640 Drug resistance transporter, Bcr/CflA family
MSVNRYFIAFFVNFTIPLGGMSTDIYLPSLPAMAKYFNTSSTEVQLTVTLFALGLAIGQV
LTGPISDALGRKKIYLLGIILQLASVLYILLSTTVLSLIIVRFIQGFGAALMMVPARAML
NDVFEGAALKKQYTYITAAFALGPIIAPFIGGYLQHYFNWHASFIFVLIYLVVLFIICLL
FVPETINSKKNFSLSHLTHSYHTVLTNKKFVTGALLLSFFFGYVATFNVAGPFIIQNLMG
KNAIFYGYIALLMGVAWFAGNMISRLFFRFKLKHKSYALLGLILLMSVIMFVINLSSLSV
PRFITPVFIITMSAGFLFPIYVGECLSLFRQEAASANGLLFAIIWVSFSLFSFIAANLKV
HSLMPLLSCYVIVSLILLLVYIMIVARHHS
>fig|1121876.3.peg.969 Permease of the drug/metabolite transporter (DMT) superfamily
MTQKPKQPKALYAISLLILLGALWGSGYTIARYCMTHGVHPLGYGFWQSLGPMIFLLLVI
IFARIPFSLKPNYIRYYIACGVLGIAIPNTVMYFAAAHIPSGILTVLINTVPILIFPLSI
LFALEHFSLKRFFVVLLGFLGILLTILSNLTLPTLHNIPWSIIALIAPLSFALCAVWIAA
FRPMPSNSLSLSLGMLIISSLCLVPLTLIMGAFHPISFPLQINDWLIILEIILSSLGYIV
LFVLIKLAGPIYYSLVGGMASVFGLLWGKLFYGESLNSSSWLGVFCIIGAIILLTLLLKK
EKEVAEN
>fig|1121876.3.peg.1223 Membrane fusion component of tripartite multidrug resistance system
MTSENETQGEQEVKKSKGWIKYATVLAVVVLCIIGFYIYVKYTEIYPSTEDAYVNANTVY
ISAQVTGKVDKIYVEDNQAVKKGQLLLTIEPQSFEYALQEAKANLALAEQQIQAIEDSIR
LEEAKLKEAEAQEFVARQKQKRISKLVAQNMSSKESGDEALGDYNVAVASVNAAKASISQ
QKRQLVLQASKIEAEKSQVETAKLNLSYTKIYAPTSGYITNFSLRPGSMINQNQSLFVLV
SNTGFWVDANYKETQMERMKAGQSAEVVLDMYPNVTLHGVVESISSGSGSVFSLLPPENA
SGNWVKVTQRFPVKVIIDPKEIKKVPQFRVGASASVTIDTRSK
>fig|1121876.3.peg.1336 Drug resistance transporter, Bcr/CflA family
MLEMQASKSAKAIFVTMILITSMLGIFVSDIYVPSLPSIGDEFGTNASILAFSVTFYFIV
FAFAQLIYGPLSERFGRRKIFLSGLAISIFGTCITLFSINFTMLIIGRTFEAIGMAAPMS
LGRVILRDVIPDKTSYARFMSFMGIGTLLAPVLAPIVGAFLAHVFHWRADFIFILLLSVS
CYVLCYYFLIETLLSPSKRLSAKLSIQTYIWVIKNKVFIKNTTISSCVMASIIAYLSLSA
FLFQQHFGLSEINYAIVFAIGEAFIMIGMFANGMALKYISIENSQRIGVILFLFSSILMI
IQAFIFPDNLVFIMIAVMIFNFSAGVIFPTSSALAIVTFKTRLGAVGSLYGCLSMLVAGL
VGGAAMLVPLSAIHLIAILFLITAIISFVFLFGVKND
>fig|1121876.3.peg.1407 Multidrug resistance protein D
MKTRYLGLIILFIFPIGQMSIDIYAPSLPAISHDFLASSTDVKLTVSLFVVTYAIAQLFY
GPLSDQFGRKKPLITAMLIYIIGTLLATFAAKLYVLYIARFLQGIGVAGIMVIVRAMISE
SFKGNMLKKISSYIALLFSGSAIISPWIGGLLQYISGWRSVFILLLIYGLISFILMLSLP
ETHHKRAQFNLLQFIQNSKEIVTHCTFLSAICFQSVVLSFFFVFALQGTFVIQKGLGMSA
SAFGELALIIGFGVLIGSLINKTYSTRIATLQLIKICFSLMLLTSIIFVIFSCLFPQSLY
LMVIASFIWALIATTAGPSFFSLFLSTFSMNAGLSNALSGFATYTLVGIITFIMSHFQQT
NLLPICIYTLFASIIAWGSYFAIKRPLREFS
>fig|1121876.3.peg.1540 Bcr/CflA family drug resistance transporter
MSNKLKAIATPSLFILVLMISVGPFGDTIYAPSLPSIAKAFNTAYHNVQLTITFYLFGYA
VSQILYGPFSDRYGRKPIMVIGAVAFLLGSIICLISTDITILIAGRFIQGFGACAGAVIS
SAAVRDAFSHKEQGKVFAKMNTAFAIAPGVGAIVGTFITWQMNFSILFALAIILLIAVII
LFPETLKKKNKGATRPRKLISNYFSLFRTQGYFVYLCILGLSIGMVYSCLVEAPALVIDT
LHLSKPWFIVIAAGIVLAFMVGSLICTMLCHRLKQNSILLVGMVISLIGSLLLLIFMSLE
IVNLISLLIPVVIVFTGIAFVIPIATAQALAPFEMTAGSASAMMGFFQMGMASAITAIVT
ALPLRDTMTLPVSFSLLSLVSIIILASYVIKHKRKSPAI
>fig|1121876.3.peg.1885 Multidrug resistance protein B
MSEKHHTISTAAKWLITITVMLSAMIEIIDTTIVNVALKDMAGSLGASTDEISWVVTSYI
VSAAICMPLTGFFVRIFGRKRLLLINIVGFLIFSMLCGLSTSLDQMVFFRIMQGIFGASL
VPLSQYVLRDTFPPKEQVKAMAVWGIGIMAAPVLGPTLGGYITDWMNWRWIFYINIPVCL
LAILMTLLFITETKREKVKIDWIGLALLVITISTLQIFLDRGNTDGWLSSHFILGLLLTW
IIAGIIFIVRGWITPRNILNLHLFQDRNYAASCILLVLYTAGIFGMMTVQPLIMQGYMNY
SASLSGELMAPRGIAAAIAMVFVTPLAKKIDLRLIILLGILITAYGNYLYAGVPLMSDPW
NLTYPGIVQGIGMGFFFVPVSTMALQTLAPAALAEGSGMFSFFRNLGTSVGTSVMVTVLT
QQAQVAWHSMIQKINTMNPDYHMWLQHMSWSAEDPHTLAEVVKLILPQANIIAFDDVSYL
SYLLLLVAIPFIFMLKKPKNTAVSMEH
>fig|1121876.3.peg.2120 Multidrug resistance protein D
MAQFDRNFYRILFLIIILTAAGQMTNTIYVPALSQMAEEFSVNAGRMQAVIACYLFPYGL
FQFAYGPLSDYFGRKPLILIGIALFTLGSLIALFATHFATLLLASFIQGSGIAVAGVMAR
TVMRDLYSGRALHSANSLMAIALILAPLLAPILGGFFTDLYSWRVIFLFLSAYGIALLII
QMLFFQETNLYKGIKGSFLQKYKIVLSNPNFMLNLILLIVANGGIAIFEVSSGAIFTSIL
QLSPATASFLFIIPLPFYMIGSFVAGKLARFYTLDRLLIIGCLVLITSGIFMVGFYYLIG
VELLAIILPGSIYFFGCGIIFPTATTKALEAFPNIAGTAGAVLGGTQNLGAGILTALSAL
IPLHSQLPLAVILSALAISALVAIRMLPANPQDNS
>fig|1121876.3.peg.2177 Membrane fusion component of tripartite multidrug resistance system
MPALWNLIKKSKVVITIIIILIIGYLIYFYVYFAKITDNAYVVANTRSVAAEVPGIIDQV
NVRNGEFVKKGALLFSLRSNLYQYRYEEAQAALNAAKAQLSETKQKIAILINDVNTSEKS
LALAKERYEGDKTLYEQNLSAKLVYHESRNQYYKAQNALDNAKEQLTAANIAKARSEFQL
DEASAAVKVAKHNLHATKVYAASNGVVNNLFLSPGSPVKAYEPLFAFVDTSTWWVQANFK
ETNLSGVHVGQKATIRLRMYLGEKVYHGVVVSTNWAVGRNETNPNNNLQSVPSENQWLLL
PQRFPVLIRINNIDPHYPLHMGASAYVSLD
>fig|1122132.3.peg.255 Permease of the drug/metabolite transporter (DMT) superfamily
MSLLSRAFSWLFNRPYLLLSLTFLFWAINIVLGRYVAGSIPPVALSQIRWLGASLIILPI
AWPHLKRDWPTIRSHLGLMVLLAAAGIGAYNTLAYYGLQYTEALNGLLMQSIAPLVIGVW
SLILFRDRMTSAQITGVGLSLCGVVLIICRGDPTVLLHLTLNVGDIIMLVAISCSGFYSA
LLKKAPRIHYWSMLGFIIPVGALTILPFFALEMASGKIIQATPLTFAVLAYVIVIPSVVA
YLFFNRGVALIGPNRAGPFFHLLPVFGSAIAIVFLGEQPRWYHGAGYALIIGGITIAQLS
LARIRAFGR
>fig|1122132.3.peg.325 Permease of the drug/metabolite transporter (DMT) superfamily
MAMGISPIFVRLTDVGPFASAFWRVGGALPVLLAWALYEARRAGISPGSVFRLDGPILAS
GLLFAGDLIFWHLAILRTSVANATFLATMAPVWVVLGSGFFIGEKVGRDVLAGLALCLIG
ATFLIGMSWQVRPDHLDGDLFGIVTSFFFGGYFLAVRAARRTSSAGKITFLSTLVTSLAL
LLMALATEPRILPASLDSAASLAGLAFISQAGGQGLLAFALGHLPAAFSALVIFLEAIAA
ALAGWLFLGEAVSAGQAIGGALILVGIFIARPQRPR
>fig|1122132.3.peg.435 Permeases of the drug/metabolite transporter (DMT) superfamily
MPTADAEASQRLRGIALYCLAMLCFAVLDASAKFAAQYVPVLSIVWVRFAIHALLAVALF
QPWRHWAVYRTRRPVLQILRALFLTGSTFFNFLAVHQLQLDQTMSIGFSAPFITAALAGP
ILGEWAGPRRWAAIIVGFIGVLIITMPGFGNLNPAIFLSLIAACCNACYILSTRMLTRSD
SSAGMLLYSAVVPLILLTPVAQPLEAMPPTILVALCLFLTGALGFVGHWFLIRAHHHTAV
PVLAPFMYTGLIWMILLGYFVFGDVPEPRTLVGASIIIASGLYLLYRERVRAPGGD
>fig|1122132.3.peg.888 Phosphotransferase (aminonucleoside antibiotic resistance)
MSKPRLVIITGAMAAGKSTVAQAVAEALPKSVHLRGDVFRKMIVGGAAVMGPVLDEEALA
QLKLRHDLACDVARRYHAAGFSVVYQDILIGRYLTDVAARLADLDPQIVVLAPDAATLAR
RDRDRGKTGYSASFPPEILADALVRETPRTGLWIDSSQMSVTDVVARILAG
>fig|1122132.3.peg.1080 Acriflavin resistance protein
MSGINLSAWSLNHRSFVVYWMIAVMVAGIASFIGLGRNEDPPITIKTMIVHAVWPGATIE
DTLNQVTERLERKIQEIPEVDDVRSSTSAGSTTLFVNLRQDVTSAEVPDVWYEVRKGIGD
IRQTLPSGVLGPFFNDSFGDTFGIIYGFTADGFTHRDLRDYVEAARSRLLQVPDVSQIEI
IGAQDERIYVEFSTKQLAGMGIDRTALLNALRAQNVVSPAGVLETGEERISLRVSGAFET
EQDLLDINFVANGQLVRLRDIAQIHRGYASPPQPQFRVDGKPAIGLGIAMRDGGDILALG
ENIRKAMAEITADLPLGIQPTLVADQAVVVDEAIGDFTTSLWQAIAIIAVVSFVSLGIRA
GTVVALAIPISLAMVFAVMNIVGIDLQRISLGALIIALSLLVDDAMTTVDSMTSRLAAGE
SKEDAAANTFKTLALAMLTGTLVTAAGFVPIGFAQSSAGEYTFSIFAVVGIALVVSWLGA
VIFSPLIGAVLLKSPKQKPDPNKVSIVVRVFRAILLTAMRMRWITIALTLAAFVGALLLL
PHVPRQFFPASDRTELMVDLRLPQNASIYQSGDVSARFDAIMRDDPDVERWSTYIGRGAI
RFYLPLNVELPNEFFAQAVVIAKDVDARLRLEKRLETVLAEQFPDSVSRVAPLELGPPVG
WPVQYRVSGPDVDQVRDISLRLAQIVSANPDTKRVNFDWMEPARMVRVKIDQDQARLLGL
SSQALAAALNAVVTGTTVTQVRDDIYLVDVIARATDEQRVSLANLQTLQVPLPNGRTVPL
SQFATFEHGQEYPLIWRRDRVPTLTVQSDVRAGGSPEAVVAELTDEVEALRATLPRGYDI
AVGGVVEESAQSLQSVMAVVPIMLFLMVSFLMAQLQSFGRLFLVLCVVPMGLIGVVGALF
LFNRPLGFVAILGILSLLGLIAKNAVILIEQIEAERKRGLPIWDAVVEATVSRFRPIMLT
AISTVLGMIPIAATIFWGPMAFAIMGGLLVATILTLVFLPTLYVTFYRGREGEAAPAAAT
PAPVASAAT
>fig|1122132.3.peg.1396 Permease of the drug/metabolite transporter (DMT) superfamily
MSRESGSATAIGAAAIGLWACLAALTGASRTVPTFEALAITFAIAAVAALVGFTAMRGWA
GVRHGLTLWPRKAWILTTVAIFAYHALYFAALRLAPPAQASLINYLWPLLIVLFSGLIPG
GTTKLGGPQILGAIMGFAATLLLVGGPGPVEASGTAMAGYLAALVCAFTWSLYSVLNNRI
NAPGSEPMIVVCALVAVLAALCHLAIGETFVMPDFGASLSLLALGIGPIGAAFVAWDHAT
KHGKLALLGAMSYAAPPLSTLILVLSGQAEPSLTLLAATLLVVAGAGLAAFGSRLKRPVV
SPLPEGEVDARSAAGQGLGKPPERS
>fig|1122132.3.peg.1451 Permeases of the drug/metabolite transporter (DMT) superfamily
MVLGIFLYSANDTLGKWLTATYSVGMIMLVRSIAAMCVLTPFIHKQGGLAKLRQAPRPGL
QLLRVFVTVGEIGFFYWSVSLLPLADVMTYYLAGPIYVTALSAVLLKEKVDGPRWLAILA
GFIGVVIVLQPSSESLSWGALIAIGGSLFFAALMIVTRQLRGTPDSTLLTFSTMATLVTG
AVIAPFTWVTPTPIDFGALALIGVVALLAQLCVTRSLRLAPASVVVPYQYTMLIWAVVFG
YFVFGDEPKISMLIGAAIIIAAGFYIFWREQRTGKPKPGDTIAEEVGDNVPG
>fig|1122132.3.peg.1466 Permease of the drug/metabolite transporter (DMT) superfamily
MKPSELFAYLFLAVTWGFSFLILLKVVHAFGWVGAVAFRAFIASGVLLVVAWATGRRLRF
AAGWRPFAVVGATTVAGQLIGLSFATPRIGTAMAAICVASIPLFSMVIGRVWGNERMSGR
SVAGLVLGFAGIVLLVGFPAVPVTPGFVLGCAAALASAFCAAFGSNYANRHLRYTGALEV
TIGSFFAGGLLALPLLPAVPVPGVPGPVDYAYLLLLGGVMSAVTYVTYFWLLGRIGATRT
ISVEFVVTVFAVLIGAGLLGETLTLVQLVGAAVIIAGCALVLGIVPSRPLREKAR
>fig|1122132.3.peg.1678 Multidrug resistance protein B
MAGPQLPPALPEMTPRRTLGFVAMAVGMFMAILDIQIVSSSLTEIQAGLSASAQEISWVQ
TAYLIAEIIMIPLSGFLGRALSTRYLFAIAAGGFTITSIGCATSSSIGEMIVWRAAQGFI
GGGMIPAVFAAAFTIFPPNRRAMVSAIVGLIATLAPTVGPTIGGYLTSIFSWHWLFLINV
IPGVFVTIGVLACVDWDKPNLKLLQHFDYIGLITLALFLGSLEYVLEEGSANDWFQDETI
AALAVVAVVAGILFFWRVLRAHEPIVDVRAFQNRNFATGALFSFMLGVGLYGLVYLYPVY
LARVRGYDSLQIGETMFVTGLFMMITAPIVGRLGQKMDPRYMMAFGLSLFALSCLELVPI
TKDWAFSELFIPQAMRGVALMTSMMPVSMLALGTLPPERMKNASGLFNLTRNLGGAVGLA
VITTVLNNRWDLHITRLHEQVQWGREAATERLDMMTKGFAATLGSDANVAALKTLTLAVK
REALVMAFSDVFLVLAVMFGLIVLLVPLASKPQAAPAGGGGGH
>fig|1122132.3.peg.2579 Multidrug resistance efflux pump
MQIKQIFKSGITLTAFAIGVLGVLMVLYAWQLPPFRSSVETTNNAYVKGQVTLLSPQIPG
YVVAVPVQDYMTVKKGDLLVQIDDRMYQQQLAQAQATLQQQQAELSNFAENRLAKQASLD
LAKAQLQSAEAGQEKAELDDKRTGTLVDRGFSTQSSGDQTRVALLQAKSTVAQAEAAVKI
AEQNLALTDAGKASLEAAVASAEATVKLAEINLGNTRIVAPVDGRLGEVAAHVGQYAAAG
TQLTSITPSTVWVIANFKETQLAHIDVGLPATFTVDGLGDIELSGRVMRIAPAAGSEFSV
LKADNATGNFTKVAQRIPLRIEIDPGQSTIADLRPGMSVVVRIDTADKPLPAVATLQ
>fig|1122132.3.peg.2671 Glyoxalase/bleomycin resistance protein/dioxygenase
MLDLRVHHVSIVVTDLERSVAFYQKAFGLERLARPPFKTDGAWLACHGIQIHLILYPEGT
FRTGPIDNSDYHFSFHTRDFYGILDHLLEQGFREDVGEDDPMRLFVIREGLAGFPQLYLL
DPDRNIVEINGAP
>fig|1122132.3.peg.2858 Methylenomycin A resistance protein
MTFAAPQKSTWIALLVAVAFFMENLDGTVIAASLPQMAASFGVEAVDLNIGMSVYMLTLA
IFIPASGWMADRFGARTVFAWAVFVFTIASVFCALSDSVLTFVLARILQGAGGAMMVPVG
RLVVLRNASKSELMRAIAVLTWPALSAPILGPPLGGFITTYASWHWIFILNVPIGIVTLA
LSFWLIPNERVAERQSFDWLGFILTSIACAGLMYGLDLVGQSHVDWVVGAGILAASALFF
WVALRNSSRHPHPLPDLYGLAIQTFAVTMKGGSLFRTAVSAVPFLLPLMFQLGFGLDPFQ
AGLYVLALFAGNLAMKPFTSLVLRTFGFRTTLIGNGLFFVATLFGCAMLTPATPWPILMI
VLFLSGAARSMQFTAIGTMAFVDVPQDRMSGANTLFSLVQQITFGLGIALGAIALRLADA
WLTPDIEGLTLADFHVAFLIVGVVGLFGLYDSFALPRDAGTAVSRHRLRERAVATPRP
>fig|1122132.3.peg.3099 Multiple resistance and pH regulation protein F precursor
MIAAALFAVLVAMALVVVRALRGPTTFDRLLAANSIGNGAILVLALFGFLTGRPEFLDLG
LTYALLNYVGIFAVLKFFRHGSLGAEAEVER
>fig|1122132.3.peg.3122 Permease of the drug/metabolite transporter (DMT) superfamily
MSRPDWALLLILSTLWGGSFFFIAIAGRELPPLTIVALRVGIAALILLGLVAIGGKSLPK
SWRVWRVLLGMGVINSVLPFSLIAWGQTQVPSGLAAVFNATTPFWTALAVQFLTADEKLS
AGKIAGIVLGVAGVGVLIGPGAFLDFGAHGWGALAILLGALSNGFAGALGRNIARLRVEP
IVAATGQMVMATILMIPLALLVDQPWQLAMPGWQAWASILAIAALSTVLAFLIFYRLLAR
AGATNTSLVTFLVPVSAILLGTLVLGERLELQHIAGMALIAAGLVAIDGRAWRWVRARRA
AEAG
>fig|1122132.3.peg.3206 Glyoxalase/bleomycin resistance protein/dioxygenase
MLAEDVAKLATFYRDALGLRVDVTEQNYVAFGGEGIRLAIFSRIGMSPNTHDHPDYRTPF
TGQAFELNFECASTDDVNERFSHIVANGGRSIAAPTKKHWGHYAGFFADPEGNIHSLFAV
LAE
>fig|1122132.3.peg.3566 Multiple antibiotic resistance protein MarC
MDFAFAIKIFSALFAIMNPIANLPIFLSLTTGMTEGEQRRTAILVTVTVAIGSLISAMAG
TAILGFFGLDVNHFRLAGGLIVLLIALNMLNGESSPSHAGSAEEQKSFKSASNVAFYPMS
IPILLGPGTISALVVYAHEAKAGGDVVAFSAGLIAFLALLGTVLISGPFIGRVVSPTIMT
VTKRLMGMILAAIAMEMLVGSLTALFPGWAS
>fig|1122132.3.peg.4149 Permease of the drug/metabolite transporter (DMT) superfamily
MAEVASRTGRATDVVGLAAIATTIIGWASAFAAIRVGLTALTPVELAAARYLTAAVPAGL
YLAIVRPPLPSRRDFVRLVVIGVLFISAYAVLLNTGEQTIAAGPASFIIQVNPILVALIA
MPMLGERFGLYGWLGTLVSFLGVGLIAYGSGDGLGLNVGALLILGAAFCTSISTILQKPL
LGRMPPLVVTAWVLLLGSLPLTPAIPETIAALRIAPATVLWSIVYLAILPTIIGYLTWAI
ALKRFPASMASNFLYCIAPTATLIGYLWLGEIPALLSLLGGALAIGGVLIVNLTRRR
>fig|1122132.3.peg.4259 Permease of the drug/metabolite transporter (DMT) superfamily
MMAAMTDRTMTTTTLRGSSAGDLVLIALFCLIWSSAFAAAKFALPYCPPLLLLSSRFIVA
GGLLLGLAVTAGRFRRPDGATLAKLILLGGLNSALYLGLSFSGMQTVSSAFTAVLISSNP
LLTALLAAPLLGEKMTPQKLGGLLLGMAGVAIVLRSRLAAGTEDWHGTLLVLAGLLSLVA
GTVLFKKLKPEGDLWTGTAIQSLGAGLMLAPVALATESLGDVSLTPSLVGGWLYLVIPVS
IGAYLLWFRLLQKKTATEATALHFLMPPLGLLFGWLVFREPVSLLDLLGIVPIAIGIAMV
TRG
>fig|1122132.3.peg.4307 Membrane fusion component of tripartite multidrug resistance system
MATPGKLGKALGAVVGLGIVAGAAVLGWTYLRHSELNPMSEDAVIQADLVNISSTVPGRI
IQIAVKDNDRVKRGDLLFAIDPVPYRLAVEQTKADLQIAEAALSTQQRTIRAETSNAAIA
SEQISRARVNLDLATQTLERLTALRPKGYVTAQQVDDAATAKRDATISLNQALAQREAAD
ALVSTLDGAEALVSARRAALALAERNLADTEVRSPHDGLVAGLTVATGQFVITGQSVFTL
IDTENWFVTAAFRETELSQIEVGACATGYVMANRSIPLRGRVTGIGWGVSSEEILMIPRN
LPYVPKTLNWVRIAQRFPVRILLDNPPPDLMRVGASALATIHSAERC
>fig|1122135.3.peg.42 Permease of the drug/metabolite transporter (DMT) superfamily
MPQQTNGSSGLLATLAPGSFVILWSSGFVFAKMALPYAETMTLLATRFLIAVALMLIISL
IWKARWPKSMTQALHIAIAGILLHATYLGGVFAAIERGLEAGVAALIVGIQPLLVAFVAG
LFLKEKVTLKQWAGLVLGVSGVVLVVWSKLEDGLGTELGVAIAVIALIGISIGTVYQKRF
CGEMDLRTGAVIQYTAAAVPTGVLAYFTETMVINWTGEMIFAMAWLVIVLSVGAISLLYL
LIRKGAASKVSSLFFLVPPTASLMAWILYDEVFQSTALIGMVMTVLGVALVNLKPIKRFG
LRSRPG
>fig|1122135.3.peg.181 Multidrug resistance protein B
MSDSSQSAGTNSQAQAEQKMTPQNILHLVIVCCGITLYALNNLITSTLLPSAVSDLQGIN
FINWSALVYSTAAIIFSLTGGSLKTSLGGRKTMIIAGLVFTFGALLVSQSSDMIFFLFAR
AIQGAGGGLILATCYTVIGDLFARHHWPKVFAWESAVWAVASLTGPLAGGFFAQTVGWRL
AFYLIAGSALLFVVAVRLCFPPKARLEQETITTSRKEKLAALPILRLIILVMAISSIAIA
GLEPDWSLPLLGVAFLLLLLLLQRDKLAKSPLLPREGINFTTPAGTGLLVIFLASVSTYS
FVVYGPYLLQTVHGLTPLNAGYLVAWESMSWSIAAMICARISQTVRWRPLLIPIGIGTSA
IGLYGISLFLFSGPLWLLTVAIFFAGAGFGIFWADLSSRIIESGPSEERDRRSGAIPTVL
MCGGAFGPALAGIPAQMAGFSDTATLAVLEATAYWVHIAFVPLVLLSLFLSFRVIRPRAT
SVSEQGSLRGTDSFVAAKPVLPTPPDS
>fig|1122135.3.peg.869 Polymyxin resistance protein PmrL, sucrose-6 phosphate hydrolase
MKSYSMKILILVLFTLVMSLGQLLFKKASMEINWSGGLLELFNPWLIVAITLYAGATLVW
VWILRTVPLNFAYPFTALAFVIVPVAASYIFKESLGWPNVVGTVLIMAGIAVISLKEI
>fig|1122135.3.peg.1403 Permease of the drug/metabolite transporter (DMT) superfamily
MERTARISSQDRFDPLLEFVLLGLLALLWGGSYLLIQISLETIPPLTLIALRVSIAAVLL
GVVMKGRGEALPKDKTTWGMLFVQALFNSIGAWTVLAWGQQYVESGLASVLNSTSPVFVF
FFMLFFVRGETPPLFKLLGACLGIIGVLLIVGPEVLQGLGRDALAQLAVLLGAVLYAGAA
VYGKRLSHLSPTVAATGTMIWAVFCLVPASLLFEKPWQVEMSERSILAALALAIFSTGLA
LLIYFRLLRTLGSLGVASQSYLRAGVGVALGTFVLGEQFDLFVATGVLIALSGVVLINIK
NKKKVFIK
>fig|1122135.3.peg.1417 Fosfomycin resistance protein FosX
MIEGISHMTFIVQDLDRMEAILCQILGAEKVYDSGDTSFSLSRERFFLVAGQWIAIMEGE
PLPARSYNHIAFKIPETAYDDCLLRIRDLGLELREGRSRVEGEGRSIYFYDHDNHMFELH
TGTLDQRLKRYAQG
>fig|1122135.3.peg.1483 Permease of the drug/metabolite transporter (DMT) superfamily
MNDAKKPLWLVLAPVIFTLLWAGGYGVAKVGLQYAEPMTLLSLRFSTVVILLVPFYLYLR
PALPKRRADWLHLVVVGVLVQAVYFGFCWWAFRTGVSAGVLAIFMSLQPILVAILAPTLA
RENVSWKRWFGLLLGLAGVLIVIIARSDIEPPTVIGVGFSIMGLLGITSGVLYEKRFGGT
AHPIVANIVQYAAGFSVVFPIAFFFETMQVQWNGEFIAALGYLAIGNSILAISLLLAMIR
AGEVSRVSSLMFLVPPLAALFGWLLLGEEMPPVAWIGMAVAAVGVAIAAHKRRKSDHAPM
VKQDRMKEV
>fig|1122135.3.peg.1581 Permease of the drug/metabolite transporter (DMT) superfamily
MTSLLYLGTVLIWGTTWLAIAFQIGDVAVEVSAFYRFTLAALAQIVLMSALGKLTWVPFR
QHRWFILQGLLLFCVNFLFFYNATVYTTSGLIAVVFSMATIFNMINGLLFHRQIPALRSL
IGAALGIAGVCALFWDDLGSGDWTGDNITGDNIKGLLLALCGTYCFSLGNMVSQHQQKQG
RNVLTANSYALVYGSVTLGIWCLLQGYSFELEITARYLGALLYLAVPGTVIGFALYLNLV
GRVGAEKAAYCTVLFPIVALSLSTIYEGYVWTPFALLGVALALVGNVIIFTKRKPVPVLS
ASTS
>fig|1122135.3.peg.1745 Permease of the drug/metabolite transporter (DMT) superfamily
MSPQKPGLRQYLLLLLLGAIWGSSFLFIKISLESITPVTLTAFRLLLAFLVMITFVFALG
KKFPTGFHIWRKYAVVAISGNILPFILISWGELHIESGLAAILMAIIPLSTLVVAHFWTD
DEKLSLPKLAGTSIGFAGVVLLVGPEALRGLGDSVLGQLAVAVASFSYGITSVYARKSGL
TKQDPMVNGASILLLASLMAIPLAFAIETPLQLEPSGRSLLALLALAVLSTAIAYTILYY
LLSTAGATYTALNNYIVPVAGMLWGYLFLSERYDAEAFTALLVIFIGIVVSQFGRRQKKQ
EARPCPEAV
>fig|1122135.3.peg.1819 Permease of the drug/metabolite transporter (DMT) superfamily
MRNPTFKDTFILILLAAIWGSAFLAIKITVHEVPPATIAASRLLIATVIIYGYMRSRGLS
LPRSKKFWIQIFFVSFFTMAAPFTLISWAEQYIESGLTAILMATGPLLALVLSHFFSTDD
RFTLFKLLGVIIGFSGVLLILGFDSFSEFGDDVPAQLATMVAAMCYAGSGLLVKRVREKS
NTITTASILLVATLQILPFSLLLDAPWQSLPASSLSTLAALVYLGAIPTALAFILRFYLI
REVSYTFVSYVGYLVPVFGVIWGTVFLGERLPAETLLALAMILSGIAVSRLSLGWFLALK
NNYKK
>fig|1122135.3.peg.1838 Permease of the drug/metabolite transporter (DMT) superfamily
MDNLTETKIPSGGILSGLLAGISFGLITPISPAVYDAGATPMTVTLFRFILGSLAMLVIL
GLTRGSFLVPAKGRLPLLSMSFFIFCVTIFYLSAVQYISVGLAAIVFYTFPVIVTIIDPL
LQKRTPSLLQLGLSLLAFTGITIALGPSLDSLDWRGLGFLCLTSFSMCGGLICGRKVVPL
VPNLTSLFYVNVIGIALSCLYLPLDNSLHIPDNLTEFSLTGLIAGLYLLAILAQITSVGI
IGPSRTAMFLNSEPVVTIAMAVLVLHEALGISQVIGALFVMLAIAGTCYRPVTRPKQQSA
S
>fig|1122135.3.peg.1864 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MARKPGKSRERDLTQGSLPGHFRALAVPASIGMLFNTLYNVVDTFYAGLLSTEAQAALSV
SFTVFFIPIAFGIGLGQGISALVGTAVGKGDRELARTFAAQGLSFAAAFSLCLAVAGYFS
IPFLLDLLGVPDSFHPLSTAYLQIIMLATPAFLIAFSANGILSSQGDTVSNQRALIGGFL
ANCLLNPLFIFGAFGIKGIGFDGLAVSTLVIEWCVAFFLLYQALGSRVLFGCRSADFLPC
WKTISELSGQGLPATFNFLTITLGVLVIQFFLQPFGATAVAAYGIALRIEQLILLPGLGL
TIALLPIIAQNNGAAAHDRIRKAFWWCLGTGGAMMLAGGVILLLSGNFLLGLFTSDPAVI
TVGFNYLLLAAPMLPAYLMLFAMMSFLQGVKRPIWTVWIGIYRQVIASAGFAALFIHLFG
WGSWGVWAAVFASVWSGLLLSSLIVRYVARKEIGGLGTPFSSAKQSLSGKQKQ
>fig|1122135.3.peg.1867 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MSARTSPPENMFLAGSLPRLFLKTAAPIILVMLVSGFFTVVDAYFLGAFVGPEALTAVTM
MFPVFMLIVALSTWVSGGFSSVVARLLGARKHDEANAALVSAILLSAAVCLLLITLFLFA
GTGLISWVTKGSVPLSEMGYSYISLLIFFSPLQFLLTINFDALRCEGKMGFIAFLSLLST
LLNIIFNYILIVKLDQGVAGSAYGTILAQFLSITAVGLYHLKARSAFTFSLAALPNPTRF
WKRFLALGXPASLGYLGVSISSAAILYSLQQWGHEHYAATVAAYGIITRIMTFTFLPLLG
LNIAFQTVAGNNQGAKLWPRVNDSLKLALLSAFLYCGSLQILFNVFAEQIAFVFVEDSMI
AGETQRILPQITLFYFAFGLSMVLSGFFQAIGDAKRSAILGLSRTYLFSLPLIFTLPFFF
GEPGIWFAAPMAEFLMILLSLLVLFLNAGTSGMKMGLFRQTI
>fig|1122135.3.peg.2324 Permease of the drug/metabolite transporter (DMT) superfamily
MTDLNFTRKQAGIKTMQQPQINSGILQMSLAMVLSGFIGLFVFESGQSPFNVVFFRCVFG
ATGLGLYCWYKGYLTKEVWVARNITLALLGGAALVCNWILLFSSFELASISVSTTIYHTQ
PFFLVIFGAIFLGEAFSLNKMIWLIIAFSGLVLIVNPDTESFAGNIEMLKGAGLALGAAV
LYTITTIVTKRLKQMKPHLIAFLQVSLGVVMLAPFVDLSAAPSDVAPWGFLIALGLIHTC
FMYIIMYSAFQKLQTPVIAVLSFIYPVVAIIVDYVFYEQNLSMMQILGIVLILLSAAAVN
LGWKLLPGRNVPAKKTA
>fig|1122135.3.peg.2399 Permease of the drug/metabolite transporter (DMT) superfamily
MLIAAAIWGSTFVVQQLAMETMGPMTFTAARFFLGTLVVLPLAWRELKKRKSVAQDTARY
HLTPFDWAMMVGIGVVLCIGTVVQQIGIIHTTVTNAGFLTALYVPLVPLLGLIFFRKRPH
WVTWFAIACSLTGTFLISGMDSSFSLGYGDALVVSSSVFWGLHVLLVGVLAAKTTMPLTL
AAVQFAVCAFLATLGGMLTETVSIAALLSTFWSIAYAGAVSVGLAFTLQVVGQSYTQPAD
AALILSMETVFAALAGALFLQERIGSTEAIGCALILSAILMVEIIPQLLRRKLRFS
>fig|1122135.3.peg.3345 Acriflavin resistance protein
MHSLTGWFIKNPVAANLMMAFFLFLGWLALTTIRIEGFPRIPPESISITTSYSGASTAQI
DELITRKIEKALEGLEGVRSISSQSNNDISVVTLRRSGGQDLQKLLDKVRLRIDGISDFP
SAAERPVIEDGGFDFPALYLNLHGQTDPVTLQKLSELLREELLSRPELSRMNIWGLYERE
MQIELDPQILQRHDLTVADVVTRIRLNSLNFQSGVLRTRGGTIYLKADNQARFSTEYAAI
PVVERTDGTRILLGEIATVQDNFKEGDYLFRFNGELTSGMEVLIGQKENLLRVSEVVHDV
VETFRTRLPPDIKLTIWGDSADYIAERLGLLKDNGIQGLLLVLLVLSLFLNVRLAFWVAM
GIPVSLMGALAVAGSKWVDYSLNDVTTFGLIIVLGILVDDAVVVGESVFEERQSAQDPFL
ATEKGVKRVAVATVFGVLTTIAAFFPMLLLDNPLGKVLAGFSGIVIFALVFSLIESKFIL
PVHLAHTNLHQQPRFFPGRLWARIQQTTQHLLLEFRDRIYAPLLVSAIRHRYATLVLFIA
AATLGIGLIGLGKIRTVFFPDVPGQVITVNLEMDARAPFGLTRDNLDRIRVIGEELSKSL
QQEKSLEAAPVRSMFLIISDTSTAQLFAELTPVSERPDLGIIEFMEQWRQRTGQIEGATQ
LQFTGSEELAGGFLLRLYAKDTDLLALASKDLREFLAGINGVNNVRDSLTPGQPELDIRV
KPEARHLGFTTETLASQIGNAFGGAEVQKIMRDGTELKVIAQNTDKTRDSIDDLLRSRLR
SNNGNWIPFQSVAEIRGGYVSGTIHRENGKLVNTVAASINRSLVAPEEVAQAVFEQLVPE
LVARYPGLEVKKAGELEEIGEIQGGMKQALLLAAVMIYVLMAVPLKSYWQPFIILAIVPL
GFVSAALGHLIMDLPLSVLSFFGMLALTGVVINDSLVLITSYNQLRERGIAASDALCQAG
LGRFRAIFLTTATTVIGLTPLLSETSEQAQYLIPAAVSLAYGELFSTALMLILVPVLLAI
TEDFRRAFLGVGQNDANDPAPPEPT
>fig|1122135.3.peg.3377 Permease of the drug/metabolite transporter (DMT) superfamily
MMPVSSENSVDGGSYGEGAMKGPRLFGSPVSLLLVTGTLIGFNFPLGKIAGEAGVSPMIW
ALIVSLGASAMLLPVQLLRRRLTLPKGQMLRYVIVSALISFVFPNVLLFSVIPHVGSGYA
GLMFALSPVFTLTLAVLFRLKTPGRLGLAGIGLGLVGAMLVSITRGAAPEAPELIWIIAA
LLVPATLACGNIYRTMDWPDQAQPDGLAFWSHGFALVVYLLLLLVSEGTIPLAQLSLVPW
TAVAQGVVAGLTFPVFFRLQQQGGPVLLSQIGYVAAAVGLLVATALLGEVYSAMTWFGAG
VIALGIAVTVIAQVQERKEMTR
>fig|1122135.3.peg.3617 Multidrug resistance transporter, Bcr/CflA family
MNKIFLKILPESIRVMPSVKETESRLFIALLIFLMALGPISTDLYLPSLPSIAAELKADQ
AEIQLTLSVFLLGFATSQLIYGPLSDRFGRRPVFIGALVLYLLASLTCSFSNTIEELIIL
RFVQALGACAGPVLSRTIVRDVYRRDEAARIMSWMGMAMALAPAVGPVIGGQVEILFGWR
ANFLVLSGFSTLALLWLLLRLPETNRDLNMEAMQLPRLIRNYFGLLRNTRYMGYVLISTG
SFSGIFCFISGSPFVLIDQLGLSPDVFGLYFAVIVVGYMAGTFLSAQFTLRLGLHRMIMI
GSSVSFAGGLIAVGLSLFGELNLLNVVGPFAVFTIGAGLTFPNNMAAALAPFPRIAGSAS
ALMGFIQMIFASGVGVLISSYNDGTALSMTASLAGVTGMAFASYVFLIHPHKLETLDSPT
TPAI
>fig|1122137.3.peg.143 Permease of the drug/metabolite transporter (DMT) superfamily
MTADTPAPVQMGLKEWSMLGFLAVLWGASFFAIEIAVTELPPVTIVNIRVGLAALVLYGY
LRVAGIAPPFKGRSDKALVLLAFVLMAIFNNIIPATLIVWGQTHITSSLASILNATMPLF
TVFMAHFFVSGERLSLNRLAGVLVGFSGVVFIVGPYALEGMLSGVAGQVAILGAAFSYSI
AVVIGRRFVRLGIKPVQMALGQAGTAAIILLPVTLIYDKAYLLPVPSWHVIAALVSLATL
STAFAYLLYFRLIAEAGATNASLVTLLIPVVATSLGVSFLGEVFEPAHGIGLLLIAFGLM
LIDGRLGKRRPRLRAEAVPPEGR
>fig|1122137.3.peg.277 Bicyclomycin resistance protein
MHEQHTNPPATDGSKTAGSQAMIAFFTIVAGTVLGLAGIDLVLPSVPAMPAIFGTDIANA
QLVLATYVAGMSVGLLMFGALAGHFGRRRLFIGSLLAFGVLSLLAVMTDNIHVLNIIRFF
QGAAASGGAVLAPGLIRALFSELGAIRAVSAMGSIESLVPGLAPIAGAWLYAEYGWKASF
EITGTAVLAICALVILIPSLLPHIGQKRSGSSASYWRVMKNKSFIRYGLSHALVLGGLLV
FVFSTPAVVIETMDGTIEDFIRMQFVGVCLFIVSANVNGSLVKRFGNEKVIMAGTIIATL
GSATLFAYALFGPNNPYHLVYMFWILNLGHGIRSGPGFVRALQTTHGEDDKGSALMILAT
MLTGAVGTAIVGPFIQFGLVGPTLALVLIVVPALLLMYIFPPFKEGDQPSERG
>fig|1122137.3.peg.396 Tetracycline resistance protein
MPVIIFAVFIDLLGFGIIIPILPFLTLKYGGDAFIGAALMSIYSLATFAAGPIWGRLSDR
IGRRPALAATFFGSTIAYIMLAMSDSLVMLFVARAMSGMMAGNVGIAMAAMADLTDEKNR
GRAMGLIGASFGLGFAFGPFIGGLLGGVGGEANVFVPGLAAAGFSFCAMVLTARFMPETS
KHRVEDASDGPPEPLPHWTKVIRTHGTLALYVMFFVTAIGQSICFAITPFWANATLGWNQ
TQVGFLLAGVGLCVAAIQSLGVGPLFRIFGEVRSLILGAVTHLVGIIILFAAPAHPVTAI
IAFPMIMSGLTISFPALNSLISQRSDKRIQGTALGLSSGVSALGRVFGPLSGGFFFEGFS
PDTPYLAVALTGSIVFVWAIYEVRRLGAMRV
>fig|1122137.3.peg.493 Permease of the drug/metabolite transporter (DMT) superfamily
MQQDMSTPTPGASLGIACGLGAALIWGAWPVITTMGVKANISPVQVVMLRFLVAGILLAP
FALRGPSTLRDWGKAAVFALFAGTPYALLVTSAFEYAPASHGGVIIPGTVLLVSLMAAHL
WLGDRLTKLRAFGAVLILIGLGGLAGGAAGGLRTMFGDMLLMAGGLSWATYTFLLRRWPM
DGLRVASRVAFLSLILVGGLALAGYGEGLTSLPLETLALQGLWQGILSATVALLLFNKAV
GILGSGRASIINALTPVIAVLLSFLMLDEVPTLIEFAGLITIMAGIAIALGIRIKPIRRK
RDTAHVPEVS
>fig|1122137.3.peg.607 Multidrug resistance transporter, Bcr/CflA family
MHLSKENTAGLALLLGSVVALMPLSIDMYLPAFSDIGAHFGTVQSQVELSLTVYFIGVAL
GQLVYGPLADKYGRRIPLIIGLSIAAVTSLACAVAPSVELFVISRFFQALGMCAGGVISR
AIVRDMFEPIDVAKFFSLLMLVMGVAPILAPIVGAQLAINFGWQSIFYLIAAVCVIDILS
VSFLLPETREPNPGVRLSATFSTYRDIIKDRHFLGYSMAGGAAFSSMFAYITGSAFVLID
YYGVAQEDFGFYFGANAAGFIVMSQLNRWLLKHFSYKVIFHTALKVLLGAGIALAICGVV
GVPLWVFLIPLFIYIASLGVVSPNGMAGALEGEARRAGAASALAGSLQFSLSFVFSGAVG
IIHAADPLPLCLIILSGAVIANLFARMTKGPARKAAA
>fig|1122137.3.peg.996 Glyoxalase/bleomycin resistance protein/dioxygenase
MLEKVAFTVYPVTDVPRARAFYEGLLGLDTHGTEKIGKEMAWIEYDLPGGGCFAIANFTE
NTPHATAGGTIAFEVNDLDALLAHLKSNGVEFMSDMTHSPACRMAVCLDPDGNSILLHQL
KNK
>fig|1122137.3.peg.1690 Multidrug resistance protein B
MSQATRHQTPVQEIAHHRGGLIFCLMLAVSLHTIDATIVNVALPHMQGSLQATFDQISWV
VTSYIMASVVLTPLVGWAAARFGVKRLIMLAMVTFTISSVLCGISLTLEAMLASRVLQGA
AGAPLIPLAIATMNRLSTSPGERARMMALFGLGTMVGPVLGPSLGGYITEVASWRWVFFI
NLPVGIIAVLGIAATMKPGAGLPGHRLNLAGFLSLAIAVGSFQLALDRGETEDWFESAEI
IAYALICVASLWVFALNSRFSNRPFLPGALFRDRNFVVGMVLILITAGNMTASVVLQPPM
MQNLMGYPVLDTGILLMWRGIGMVFGMMLAPRLTQVMNPRWLLVIGGISMAAGLSPFIFL
TTETPAVLLSIPPIFHGFGIGIMFVMASTIAYATIPHELQVEASSVFSLIRGLGQAACIS
IVVALVSRYSQINHAELVERLTPLRPYTPSGTISVLTSTPEQLAQANLLVSQQAAMIAYN
NAYLALLFAAATVIIAAFLIKPRQFDDEHAVEHPVEA
>fig|1122137.3.peg.1691 Multidrug resistance protein A
MKRLILYVSVPALILAAVFYVYLTGGRMVTTDNAYVRAGILTGASRVSGEVVEVLVGRNQ
HVDEGALIARLDDSDARVKLQEAEVGVISSRHIVAALKANYRKSVAALEKERQSLAYETR
ELKRAEALARDKNLSEAALDNQRFEVEDARREIAILEEAVQMALTQLGGDADIPADQHPM
VLKSLAAVEAAKVALEHLEVRARTGGTITHIDLHPGEYISAGYPIYGMTVDGDLRIEANP
KETELTYVRIGQSVDVIVDALPGLHFTGKVTSIDPATGAEFAVLPAQNATGNWVKVTQRV
PVQILLDNGQDLSALRSGLSAEVSIDTGHERKVSDLTSMVGL
>fig|1122137.3.peg.1966 Permease of the drug/metabolite transporter (DMT) superfamily
MGVFLAFFGCVLIWGSTWYAIELQLGVVPKEWSLVYRFGLASLVLFAICFIRKERLRIRL
QNHLWMAITGMTLFSTGYVFTYWGTEYLTSGLVAVTFSMLSFLNIVNARIFLGNPVTPST
IGAALIGIAGLVLIFMPEITVLTLEDDTTLGVALCLAATVMASIGNVSAGAASTRSVPVL
SFNAWSIGYGALTNLVFALASGKPIAFDPHAPYVLSLLYLSIVGTVIAFTMYIWLIGKIG
VGRAAYMAVMVPVVALVISTFMEGFVWTIEAAVGLALVVAGNVLMINRKAKAVTPAAPDC
VEPEKL
>fig|1122137.3.peg.2205 Probable antibiotic-resistance protein
MAAIDVWAQVTTERMAREPWMATLLRWTGREGEVIVPTIADTIAAMDAAGVDIAFLSAWH
GPRGSLISNDEVAAQIAEAPDRFRGLATVDISNPMEAVREIRRVVDGKTFVGVRLVPWLL
DLPPNDRRYYPVYAACVDAGVPFCTQIGHTGPLCRSEPGRLIPYLDDVLLDFPELKVVGG
HVGFPWIDEVVSLALKYPNFYVDTSAYAVHRLPDDLVKFMKGPGGKRVMFGTNWPMLSPA
QCLKALDSLGLTDEGKFNFLEGNARRVFGL
>fig|1122137.3.peg.2531 Acriflavin resistance protein
MSDGDDDQKIEGRGILSLVASFLENPVMTNLLMIFLIVGGLMTAVTMRSEVFPTVDVGTI
TVSVNYPGATPLEVEDSITRRVEEAVLGINGVERVRSYAFENRASVVLELEDFVDAYRIK
DEVQAEIDALIDFPPGNAEEPIVAVTQSLSNVLTLVLVGQAAEEDLRRTAELLERDLLTL
EVVSAVNLRGTRAREISIEVSEDTLRKYGFTFTEIADAVRRSSLELSGGTIKTESGQILL
RTDAKARVGEQFKDITLRATTSGELIRLSDIATVTDGLTDDELVNTYNGAPAIFLDILRN
ESKDILLVKDQVAGYVETVDLPEGQSLVIFRDQTEILADRISLLTSNALMGFALVFLLLV
ITLDFKLAFWVAMGIPISFLGGFLIFGSVGVSLNMVTLFALIVVIGIVVDDAIVVGENIY
AEQQAGFKGPRAAFEGVKNIFAPVLVGVLTTMAAFAPLLFQTGTFAEITRPIPIAVISIL
FVSLIEAMLILPSHLSHEKRWSRGALRSFQVKVSRALDSFAVGPLQRLIIKSSEFRYVTL
AAAVGFIFIAFSLVGAGFVRVVFFPNIEGTEISANLAMPEGAPFDATAAAMEQMETALNK
VAADIKAETGEDVIRAVAITTGAKFSQASGPGAVSSNSLASHLGQFTVELVPTDARSVSS
REISRRWQQEVGSVPGAETLTFAATIGPSSVDVGYELSHADQAELQKAASDLADKLSAID
GVSQIDAGLDLGKRQFEFHMKPAGLAAGLRPQDLARQLRQAYFGEEVQRIQRGRDEIKVF
VRYPRDARRDLSALANLRIRLPNGDGVPLDHVASVTEGRSPTSIERVNGRRILTVTADVD
ESVTTPNVVNDIIQSDILPAVMENHPGLRWQLEGGSREQREDFAALARGFMLALLVIYAL
VATQLKSYLQPVIIIVSIPIGIAGAILGHKVLGYDLSFISMFGIVALSGVVVNASVVLVD
RYNIELKDPDTSPLDAAVRATLRRFRPIALTTLTTALGLLPIISETSPQAQFLIPMAVSL
ATGLLVSSALMLFVLPAIVLIVEDIRKLVGAAPPEAAVETE
>fig|1122137.3.peg.3035 Acriflavin resistance protein
MNDKSELLSQLKIDRSQKEAPRSSSKFAYLLGGGALAALIFGGAYMVIGAGGDEQPTAND
AANTSAQQSAATAQSSNAGTATPSAASTTVAPSDSVLNASGYITARRMATVSAEVIGLIK
DVTVEEGMAVKAGQVLATLDATLPQVDLDLAQAQIKVLEARLASTNANLAEAKRVLARAS
ELKNAEFSSEASVTRAQADVDSLSASAASTRADIEVAKLSVLRQKERLDDYTIRAPFDGI
VTVKAAQPGEIVSPSSAGGGFTRTGICTIVDMTSLEIEVDVNESFIGRVFEGQEVKANLD
AYPNWDIPASVIAIIPTADRAKATVRVRVGINISDPRILPDMGVKVAFLKA
>fig|1122137.3.peg.3121 Acriflavin resistance protein
MNKLIEWWARNGVAANLLMVGIFLAGTMGFFSMEREMDPQVRFPGLEISVSWPGAGPQEV
EEQVVARIEESVRDLDNIEWVRSSSGEGFGEVYILAEQSVDFTQFMNDVKIRVDSISSLP
RDIEPPRVSQWVNRDEFIRVAVHGNLSERELKRLAEKLRREAAQLPSVSIVELFGVRREE
VSIEVSEESLRRYNLSFSDVALAIRANSLNTSGGSVRTEAGEYQITARNMADTEHDFNNI
IVRQTEGGATIRVGDVATVVDGFEDNEILATLNGEPAVLLQVMTTERMDIVKASESINEW
ITKRQDSLPPGAKLTLWTDNNEAFQSRMETIGGSAFQGLVLVVLVLMLTLRPKVAFWVAM
GIATAYAGAFVLLPALGISINMLSTFAFLLVLGIVVDDAIVVGESIHTESQRTGGGITAA
VFGTQLVAKPVIFAVLTTIIAFMPWIFLDGSTSEFTRHITWVVIMALVFSLIESLMILPA
HLAHLKPREKLGRFGRLQKKIADGITNFAQRRYRGIAQWAVRNRYITFSVFVSVLILGFG
LFSTGYVKKSFMPEIESDEITVNVTLPEGASYNRALDILAQLQEGERKLVEEVEARTGGK
LIENWYTRSRRDSVLAIVKLSPPEERDMSAKDASIRLRELIGDIPDAKEVSVRYTTSDND
AGFELSVRHPDLDVLREAVGDLEDKLRTYEALYDVRNNLEGASEEIRITLKPGTEKLGLT
LADVSQQVRQAYYGEEVQRIPREGQDVKVMVRYPRESRRSIESLKDFRVRTADGREVPLM
AVAELEYAPGIKRIQRWNGNRAARVSADMKENIRSQVMEDLNANFFPEWEKKYPGIVRGA
IGQAEGEARFIADVLKLYGMALFVMYMMLAIAFRSYWQPIAIMIAMPYAFVGAIFGHFTV
DMTMAIFSYFGVAAAAGVVVNDNLVLVDYCNKLRERGMAPMEAIVEAGVARFRPILLTSV
TTFVGLMPMMMERSIQAAFLQPIVVALASGVLIAFFVTLLMVPALYSIGDDFNRGFATTK
GRIKGMFGSRSNKAPAQAE
>fig|1122137.3.peg.3667 Acriflavin resistance protein
MDFLTRLGLNRSRFTLLLMIALVLSGLLLYKDFPKREAPEITIRTAIVSALYPGMPPERI
ENLVAERVERKIREIAEVKEIRTILTTGRMRTYVELKDSVNDLEPIWQSLRDKMSDISRE
LPEGAYGPFVNTDFGEVTVASIAMTAEGFTYREMEESAKDMQRRLYTVDGIAKVELFGVQ
EERIWLELDARRFKAVGGQLNTLINDLQNQNVVLPAGEINAEGASILLEATGDFKSVRDI
ENMLTRAVGGDELIRLKDLVKVRRGYVSPPENRVYYNGRPALVLAVQMQPGYDIEDVGER
LTEAMHTFEHTLPIGYELNFATYQPTEVSKTVAGALSNVGQTFIVVLLVVLAFLGVRSGL
VISSIVPFAVMFALLGMNALGIALEQVSIAAVIISLGLLVDNGVVIVEDILTRVDRGSKR
RTAALAAGSQYAVPLAVSSLTTIFAFTPFFLLEGSEGEYAFSLGAVLALTLIGSWITALY
FLPLICARVLRKRTEGEEGIEHKAEAEDLPAFARMYENMLRPSLRAAAFVVIGTYGVVIV
TGQLFTGLPKEMFPVSDRNEVLIYLDMPKSAHFEATERVALDVSNWISDGEVNPEVEDHI
IYVGEGGPRFYLSLNPVDPSPSKAFILVNTKSPEQAAEFGARAKRYFYEQVPDARFTIKR
LAMGASESGQVKIEISGPEHEPLLVAGREVERIFAGVPGIVQNESDWGEKLVKMVIEVDQ
DKARRLNMSSQTLAQNLNAYFDGFEVSNFRDDDSTIPIMLRALERDRDSLEDLLNIILPG
EDSIVPLEQLAVLKPALEYSQTWRKNQQPTITVTAKSSQLPAAELYAQVKDQIDAIPLGE
GYQVVVGGELKDSAEIYGKLGAGLPFALLLMILVVMYQFNSFRRIAIIFMSVPLVLVGVP
FGLMITGQPMSFFAILGLISLSGIIINNAIVLVDQIDIEREEMRLMDAIVSAAGQRLRPI
MLTSITTVIGLLPLYLFGGPLWEPLAVVMMFGLAMASVLTLFFVPATYMLFFRTQS
>fig|1122228.3.peg.1390 Drug/metabolite transporter (DMT) superfamily protein
MSKFSPKVIGSLLVIIASIFWGISGVSGQYLIQRGVEVPALTSLRLLISGVVLVSIVAIR
RPEGITPALKSKDFLIGIALFGIFGIVANQFAYLKAIEYTNAGTATVLQYLTPIIVLLYT
CIRLRIPPALLEIVSIILAIGGTFLLASHGQIGNIQLNPAGLTWGILSSFTYASSILISA
AVVKKWGSLLSIGFAMLFGGVIFSLATRIWTYHFTMDMPMFVAYVGIIGIGTILAYTLFI
KGTTMIGAVQGSLLASIEPVASVILTVAIFQTFFYPADFVGMVLILCSATIISTKDVIAR
FFTRSWHKRIS
>fig|1123236.3.peg.667 Fusaric acid resistance protein fusE
MGTVVRIIVTLIIVALAVLAGRWVWERYLHAPWTRDGRVQAHITTISPDVSGWVTQLAVQ
DNQKVEKGELLFTIDNARYQAAIEEQQAAVKARELAWQLAQHEYQRRTKLARNNTISQEE
LEVTRISAEQARAEYNLAMAKLNTLQLNLQRTRVKAPQAGTIVNLDLREGNYVSQGKPVL
SLVRRGSFYVTGYFEETKLSLIHEGQRATIKLMSSNQPLTGKVVSIGEAIADTNINRNEQ
LLPHVQQTFNWVRLAQRVPVDIELDPVPENVRLVAGTTASIHLNEQ
>fig|1123236.3.peg.1751 Methylenomycin A resistance protein
MPSLSHKTATALLVAAALFMEILDATIITTALPIIASEFGVPAAHLSVGVSAYLVAVTIF
IPVSGWAADRFGAKRVFSLAILIFVGASVLCGLSETLLQFTLARILQGIGGAMMVPVGRL
VVLRNLPKEQIVKAMAILTWPALGAPLIGPVLGGWIAQTWHWSWIFFINIPLGAVALLFT
HWLLSNEKGQWQKFDVVGFTLSGLGFGMLMAGLESFSARPDDMTIPALLVVAGVVILSLA
VRHMLTTSNPLFSLAALRFNTFRATMTGGSIIRIALSSAPFIIPLMLQVGLGYSPVEAGT
LLLWLFAGNLAIKPATTWIMNTFGFKNVLVYNTILVATGFFVLALCSESTAGWELGLILF
LSGMTRSMHLTVLNTLSFADVPQTYIRDANTLSAVLMQMTRGMGITAGALALALATFIID
ESRNTPVTADFQLTMVFMGVIALLSLFNSVRLKPGIGNAVLNERQAS
>fig|1123236.3.peg.3117 Bacteriocin resistance protein, putative
MKYILNKTTTAIALLLSTHLANAGMINIADDYSVRLESMVDKRFDRIYRQQFDFSCGSAT
LASLLSFHYNDTVDELSVFKDMFKHGDKEKIRAQGFSLLDMKRYLTRRGYISNGFRITLQ
QLAQAKRPAITIINTGGYMHFVIIKAQRDNRIVVGDPAVGLKIMTQEEFDAVWENDVFFL
IQNNEDVAAYHYQFDKHQQPYAPANLAMPVDIQRLDILSVVAPGNWDF
>fig|1123236.3.peg.3622 Acriflavin resistance protein
MKIATYSIKNPLTVWLLMVIFFVGGIFAVIEIGKLEDPAFAIKQAIITTDYPGATAEEVE
EEVTEQLESRIQQLSQLGDITSRSLPGQSQITIKLRDDFSGEQLPQAWDELRRKVEAATM
RLPQGARQPVVNDDFGDVYGMYYAVIAEGFSHKQKRELSSRLRREVLTVPGVTRAQLGGV
PEETIYVEVTQEKLASLGISLNQIAGVFQTESAIADTGSVRVEDRRIRLVIPPSDDSADT
IRNLKFGIPGTTEQLHIGDIADVYRAETENPTQLVRHNGEAAFTLAIAGRSDKNIVDIGN
RVTSHLNTLREKLPLGVEILPIYEQHKVVDQAIQDFLVNLAASVTIVVAVLLFVMGWRVG
VVVGGTLLLTVLGTVLFMWIFSIQMERISLGALIIAMGMLVDNAIVIGESMLLNRQKGKN
SVEAAEEAAQQTQFPLLAATVIGILAFAGIGLSQDTTGDFMFSLFAVILISLLLSWVLAV
TVTPLLGHYLFKAQSGDTDEDIYDTRGFRAYKKLLSGALRHRRLTIVFLVMTTAAAVVGF
GWVKQSFFPPSNTPIFYVDYYLPQGSDIRATEDDMKAIEATILQQPGVESVTSLIGMGAS
RFMLTYAPELPNPAYGQFIVRTEQREQIPAIMKALRERINRSHPQAEVYTRRIFFGPAEG
AKIEARFMGSDPEVLRALGQKAQNIMYASDSITDIRQNWRQREVIVRPVIDEQQARIAGL
SRTDIADSLEFATVGKRVGVYREEDRQVPVVIRPPAGERRSMSWLEDRLIYSDAEQTFIP
VRQVVKDFEVHSENGIIHRRNRVRTLTVQAEPVGDLTAATARATVVKQIESMALPPGYAL
EWGGEYESSREAQAGLATKLPISFLSMILITILLFNALRQAALIWIIVPMSVCGVTAGLL
LTGLPFSFTALLGLLSLSGMLIKNAIVLVDEADIRRTTADNLHDAITGASLSRLRPVMLA
VLTTVLGMLPLLWDAFFASMAVTIMAGLTFASLLTLVAVPVLYSLFFSEKDMHP
>fig|1123502.3.peg.165 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MALSERMLELRDAPIRKLLWKYALPAIIGSSVSALYNIITRYFIGNADYLNDDAMSAMGL
ALPIMTIIAAFGMLVGAGAGSRISIYLGNEDYEKAERVVGTSLLLTLVITLTISFIFFFT
LTPLVHFLGADEGSYQHTYDFLKYFLPGAIFSNLCFSFNNMMRASGYPKKAMYTMLLTLV
LNGIFAPIFIYWLKWGMEGAAISIILSMFIGTLFVMQHFVNGHSVLQFKAKYIRFDAQIT
KAVLSIGLSPFLMNIVSSSIIFIIIQQVRVYGGSVAVGAYTIVNVLLMLVVLVLLGLTQG
MQPIVGYSFGAKEIARLREALLQTIKIGVGIGIVAMVIGVFFPEWVIMPFNPSPALSDVA
ISAIRIVTMLFPLVGFQIVVTIFFQSIGKVKHSIFLSLSRQILFLIPGLFILPHYFGIAG
VWYAIVVADLISTCTAALFLWIQIREFNRYLKGNA
>fig|1123502.3.peg.292 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MISHVSIQMVAATAASNQFFETSVAILNFIGVGCSIVVAQYLGAGDRETTRKAIHLSITL
NLMLGFVTFLAIWFFGHDLLSVMNTPENILNMAYDYFHIIGICLIFEAVAIILASCLRVY
GYSKAPMYVSLIMNIVTVVGNIFVLYGVFGFPQLGLSGVAGSTLLGRIVGVALLFYLLFF
GIKVRLEWRMFFQFHKKILQQILKIGLPSAGENLSWTAQMLVMLAFVGKMGEDALAAHNI
YLQLSYMLMLFALAIGIGNEILVGHLVGASNFNAASARTWKSLRTGMLVTFAVVVVFYFA
RYLVVDSFTEDPIIKELLLPLFLLSILLEPGRTQNIVMVNALRATGDARFPFYAALVFMW
GIAIPVGYYFGFVLEMGLIGIWIGFLCDEWIRGLVNAWRWKSRKWETKRLNIEH
>fig|1123502.3.peg.377 Permease of the drug/metabolite transporter (DMT) superfamily
MSTEARGHLLALLTIVLWGTTFVSTKILLQHDLSPLEILGARFLLGACFLMLLYPKRLKG
TTWREELCFALAGLCGTTFYFWFENHALLYTLAANAALISSTSPFFTVLLARFFLKEECI
RPIFYVGMLLSFVGVGLMSFSGLQSFELSLKGDALALGAAFIWSIYAIVSKKMGSFGYNT
IQTTRRTFWYGLLFMLPMISWQSLDFSHDALLNYVHQYASPVVMFNLLFLGLGASALCFV
TWNLAVKILGAIKTSLYINAVPMVTVIFSTLILHEHITLLSALGILLVLMGLGISQYQRK
SSNS
>fig|1123502.3.peg.379 Multidrug resistance protein D
MFPQIVETLYSPILPALSSAFAVSEAAAGQTLSLYFMAFAIGIVLWGYLCDRLGRRITFI
LALSVYTVGAVTALWVTDFSALLICRMLMALGAAIGSIGTQTVMRDAYSGEALRKTFAIV
GILMAISPMLGIFMGTLLEMHLGYRAIFMALVLFALMLLLWTILSLPETRPHNMQRVALL
PIARVMLKDGVLLRHMVMIAGFNLMLFSYYQLAPFWLTDLGYPMTLFSYTGLLLGAGSLL
GALINRRCTQAHVPARTLIRIATMVLLISALMAFSLRHSLWLLLPMGIMTFCYGIAIPNI
LAHVLDDYHNARGTAGALLGLGYYLLLGLGLMLSAISGHLAGTLLVTALFMLCINLSE
>fig|1123502.3.peg.1001 Polymyxin resistance protein ArnC, glycosyl transferase (EC 2.4.-.-)
MTQPIKISLVVPVYNEEAALPIFYQAVREAPFLKDYDLEIVFINDGSRDQTEAIINALAI
SDPRVQALSFTRNFGKEPALFAGLEHATGDAVIPIDVDLQDPIEVIPELIEKWQAGFDVV
LAKRIDRSSDSFLKRQSAGLFYKLHNKISTPKIEENVGDFRLMSRNVVENIKKLQERNLF
MKGILSWVGGQTAVVEYVRAERSAGDTKFNAWKLWNLAVEGITSFSTAPLRIWAYLGFVV
ALLSFSYGAYMIFEKIVFGNPVSGYPSILVSILFLGGIQLIGIGVLGEYVGRIYMESKQR
PRYLLKKMGSDKK
>fig|1123502.3.peg.1053 Multidrug resistance transporter, Bcr/CflA family
MGIAHPHKMDCMNTQHTQTRIITASLIMLMALLTALDSMAIDMYLPAMPDIASDFQISSG
KVQQTLAIFLAGLAIGQGLYGPLLDRYGRRLPLLIGIVIFIIGSVLSALVPNVEWMLAAR
FIQAIGASAGLVTPRAIVSDTCDLKDSARVFSLLMNAMMLGPILAPMLGGFVLGFGEWRV
IFYIIAIIGGITLLWAWQQVPETLAIEKRTPLNLKAIAKTYGGQFTNRTFMCYAMASGFA
MSGLFLYVGGSSFIFREHFALSATHFSYLFALNSAGLVIFGAVANRLLVKGLSARGLLMI
GMMMHTGFALLLFILTQSMTLSIVPYALLLAGAISALGFVLGNVTALTMHYGGPQAGAVS
AVMGVLQYLLPALMGYVVSLFAQSISVLPLAIGICGLMGILFIFASQDKTA
>fig|1123502.3.peg.1120 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MLISGTYQLIDGFFIGHFIGPEGLAGVNIGWSYITVLLGFGLLVGVGTGSLYSIAKGAED
DETARAIIGQSIPLILIPGLIFGIILYVAAPSLVYMLGDPQYQVSKTFQTAALMAVDFIR
VFAVSSPLVIGSLALPFLVRNMGNPYRATLYMAIGVTINIICSYFMIVVWEWSIFGAALA
SIIGESCAMFLGLYYILYQSGENLQWRHFKPRPKLLKEIIINGASTFFMYIYVGFIMMLH
HMMLVKYGGTIAVSAYTITGYIVTIYYLGMEGIANGVQPIISRLYGRENFLSTRAIIRMM
VIVGMTYGIGLTILLQIFPGFFTRLFTSDQELSKVTIHAINIHLSLLFLEGVFVMVTVFF
QAIGEGSKALVISIGNLLIQVPFLLIVPKYFGLDGVWISMPLSSFLLAIPVVYWAYIRYR
HIV
>fig|1123502.3.peg.1141 Quaternary ammonium compound-resistance protein SugE
MNNKAWFYVGLTSVFELIWLYGFNRADAPWEWALVVLFIFMDLNFLAKACQYLAAGTVYA
VFAAVGTIGTILMDTFLLEQTISTAMMVCMGLILLGVLGLNLSDPSVDEEEENHG
>fig|1123502.3.peg.1142 Quaternary ammonium compound-resistance protein SugE
MANYGTWIGWGLVTLAVAAEMVGIFGLSLYTRKKNLINRLLYFGGLAASFVALYYSFHYL
PVSIAYTVLTGIGTAAAVVINIMFFNESKDIKRIISLAFIIAGVCGLKFLS
>fig|1123502.3.peg.1360 Permeases of the drug/metabolite transporter (DMT) superfamily
MTGLIFVLWIANVAFDTLGQIAFKYAATIETKNDTMASYWQGLLRQKWLWIGVIAYIVEF
FLWLAFLTLVPLSKGVLLAAMNIITIMIAGRLLFNEKLIPLRVIGIAFITAGVAIVGIF
>fig|1123502.3.peg.1401 Permease of the drug/metabolite transporter (DMT) superfamily
MNWAAMLYPLVAVMIWAMNAVVNKLSAGVIEPAAISFYRWVLAFLILTPFCIVGTWRNWQ
QLKPLLWKFAVLGFLGMAVYQCLAYYAAYTISATMIGIFLSLTPLLTIILSLLILRTPLT
VGLLVGSGLSFFGITWLISGGNPAILLDIGIGKGELMMLIAASAYALYGVLTMKWKIQAQ
VSTWQSLYWQVIFGVLILVPLFAMTDNVAITRENVNLILFAGIPASIIAPFLWLQGVARL
GASKTSLFMNLSPLFTAIISILFLHENLEPYHIIGGAICLIGVIIAQRVNKVVSLETLRK
RANKKAFE
>fig|1123502.3.peg.1560 Multidrug resistance protein A
MQKMTRTLLGLGALFIALVVVLYLVAHQQKEFVLQGEVEANRVDISVRVQGRAKEVFYDL
GDNVKEGDTLVILENPAMIAQQITAEAQYNVAKANRDVAYSTRPEQIEIQKALLASAEDG
VTLAKQSFDRVQKAIQKGGVSQQVFDEAKTSYEVALKDKLAAEASLQLAENGASIETKHL
ADAQVAQAKAALNQVNTDVDTLIVKATANGQVTAKVAEVGQLYNPGTPLYSLIDLTDMWV
TFNIREDFLRAAKIGDVFEVEIPALKETVEVKITALNALGQYANWRATKATGEFDLRTFE
VRAKPIKNIEALRPGMSVIAKWNTRKAQ
>fig|1123502.3.peg.1789 Permease of the drug/metabolite transporter (DMT) superfamily
MLFLGLFWIFSGKLRHEKWHLPEVLRILLCSVFLILNWVYFFKAIEVSGVTVAISIYHLA
PVIVMILGAFIYKERLTLIPVLAIVICFVGTLAIAEINRTASVAEFFSPGLIFGLLSALF
YALLTLTGKGFKYASSYAITTIQVAFGALLLVPFVDFSAFNGLTELNWFYIAITGFVHTG
IVFYLFFDAIRHLSTQMIAILVFLDPLVAILMDLFITGFIPSMEQWIGIVLIFGGMALTL
MPKKKAALI
>fig|1131462.4.peg.243 Permease, MDR related, probably tetracycline resistance protein
MNSKKILLILGLAGFVVMADNWVVSPILPSISKDIGVDIASSALIITAYMVPFGLFQLIF
GYLADKFGKRQVISFSMVFFTIATALCALGSGLTDLVIYRALTGIFAASVMPVSMALIGD
IFPINERQSAIGTFLGISFLGQGLSMLLGGSIAYFLNWRGVFAVYALLSVIATVLLLTVG
KKIPSSKSETSQVLTPYINLITNPLSLKIYLLVLFEGFLLMGIFSFLGGFIKTTYDFNNF
MIGLIMTVFGLMAVAGGRISGKIASRVGRKKTILIGLICTLVGNLIFILLGNVLAIFIIG
VGLLGLGLMLAHSTFLTIATGFAERWRGVAMSLVAFCMMGGGGLGTAIGSRIVGNSSYLT
LFSVYGIGLIVLILAVLLVKKSFMLNSVELK
>fig|1131462.4.peg.256 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MDKSFEFGNKSIGKLLWQFSWPAIVGMLVNALYNIVDRIFVGRGVGTLAIAATTVAFPIM
LLLMALGMLVGIGATALISIRLGEQKKDEAEKIVGNALTLLIMLPLLFMVFYFSFSEQLL
VFFGANQEVLPNALDFTNIIVAGSVFGAIGFGMNNFIRAEGNPRIAMLTQILGAVINGVL
NYIFIFHLGLGIAGSALATVSGQFITSLWVLGYFLLGHSTLKLRLKNLKPDFPIYLAILS
IGFAPFAMQLANSVQNMLLNKSVMLYGGDLALSAIGVIMSISTLFFMPIIGVSQGAQPII
GFNYGAGQFERVKATLKKAIIASTCIAVVGYLVIHFWPEQIIGLFSDNDKALTELATHVI
LIFFTMFPLIGFQIICSSYFQAVGKPLQSSVLSLSRQVLLYIPLLLVLPHFWGIEGVWRA
APIADILSVLITATLITLEMKRLSKNQPAVSVG
>fig|1131462.4.peg.768 Permease of the drug/metabolite transporter (DMT) superfamily
MQKQKFAVFQALLAAALFGISTPLSKLLLSHLSPIMIAALLYLGAGTGMFALRLIIKVNR
PLSKEAGIARKDLPFTIGMVILDISAPILLLVGLSTTAAANVALLSNFEIAATALLALWL
FKETIGQRLWTAIILITASSMLLSLKDIQGLSFSAGSIFVLLACLCWGLENNFTKMLSLK
DPMQIVVIKGLGSGTGSLLIAFVTKQMTADYSYILFTLILGFFAYGLSIFFYVRAQRDLG
AARTSAYYAVAPFIGVGLSFIVAKEPITNNFIIAAILMIFGAYYAAREKHDHQHSHEVLC
HEHRHHHGDGHHTHVHGDFTSGEHSHPHEHETIEHAHHHAPDMHHKH
>fig|1131462.4.peg.1849 Efflux pump antibiotic resistance protein
MNDHHDHTHDDSKTVKRTLLFIATAGSFLTPFMISSINIALPAIQKEFAADAVVLSWIAT
SFLLSSAVFLLPIGKLADILGRTRLYKWGIISFTAFTLITGFVPNIELLIVMRVLQGISA
SMIATAGMALITSAFPPQERGKALGFNVSAIYVGLAVGPFLGGFLTEYWGWRSIFLVLVP
LGVLITVLTITYVKSDWADAKNDKLDIPGSLIFAVTLIALIYGSSILPDILGIILILFSI
VCFVFFVKRQLKIPNPVLEIRLFQNNRVFAFSNVAALINYAGSYSVTFLLSLYLQYVQGM
SSEHAGIILIIQPIIQSLISPMAGRLSDKKEPAKIASLGMAGTAAGLFLLSFIGPHTSLF
LIIAALMVLGLGFALFSSPNTNAVMSSVDNHYYGIASASLSVMRVLGQMLSMATATLLIS
IFVGKNQITPEYYPQFIQSIRLAFLISACLCAVGIFFSFSRGKIHVNNNQA
>fig|1131462.4.peg.2462 Daunorubicin resistance ATP-binding protein
MAMIYVEELVKQYDKAKTPAVKGVSFAVNEGEFFAFLGPNGAGKTTTISILTTTLSKTSG
IVTIAGYDVEKEAKQVREKVGIIFQQPSLDLQLSAEENIRFHACLYGMFSYRPTFRLMPS
AYKDRVMELAEIVGIQDALFKPVKKMSGGMQRKLEIIRSLMHTPSVLFLDEPTQGLDAVS
RRSLWEYINTVRKEHGTTVFLTTHYIDEAENVDKVCIVNQGRVASCCSPEEMKKSLVRQE
LILDADDREGLTGELSELGLFHKKDAHIIVPYQDKTAQEIIARLNTKLTLLKINEPTLED
AYVEYLNRTGGAAA
>fig|1132443.3.peg.3976 Outer membrane component of tripartite multidrug resistance system
MRLFKPVIGCLFLISGCAWIPEGDKPAEFMTAPSMDHALSEFHEKQATASLERWPNERWW
QEFGSSELNSLMANGLKDNPGLKAASDRVREAEALARVEGSRLLPFIDADADVAYERVSA
HGLFAALNRKEAAGAHIVASKINLLNFRYEFDFWGKNRAALEASLGEAAADKAEMADTLL
RLTTAIARSYFRGVALRHQLDLATEMVKLRQDLLDISETRLRLGLDSVDPVKESSINLEQ
ARKREALTRDQLDLQRNLLAKLIGKGPDSTQHLFLDKVNIPRDLALPDKLPLELLRHRPD
LTSALFRAEAAAQRIKEAKARFLPTIDLTAFAGVNALRLTKGASTLANVLFSGSSVAYGV
APGLRLPLFEGGRLRAELSAQRAEYDKSVELYNDTLLHAIQEVADSLSGWKESLSILEAH
GRLMSSQRKNQELAEDRVRAGLDDRRELLDRRHAVLEQEYVLKTLETDHLAARVDLIESL
GGGYSKEIEIIQQLIRHKPEHPEGFDLYKWLIFSQKE
>fig|1132443.3.peg.3977 Membrane fusion component of tripartite multidrug resistance system
MNVSHRTIRARRKRYLQLVLLASLAGGLIYAGFWWLHARHWVVTSNAFVSGNLIPVEADA
TGIVTQVLTEESRYVKKGELLVQLDRHRALTALNQSEGKLGQTTREIGALFATRRQMCQK
LIARSASLSRVRHDVVRLRQAAPNGSVSEQALQNAEDEMAALDAQRLEAEAEFNAVEARV
GGTTPKRHPDVETAKHNFIAAYLEYARQHVYAPASGYVAKRKVQVGNRVQPGDPLMTIIP
LDHLWVEANLRETELMRVRPGQAAEIAVDLYGRHLTFHGTVEGLVPGTGSVFALLPPDNA
TGNFIHIVQRVPVRIALRADEILKNPVRPGLSTVTSIHVEESERPPGDSLVTVSSREYAT
DIFAGELTEAEKRAEKIIEDNLPFSSDFAEYRCHAGER
>fig|1132443.3.peg.4003 Multidrug resistance protein B
MKTLETSSPNLILETPALEKNNGSHLGLPQWIGFIGMVFGIFMAVLDIQIVASSLEQIQA
GLSATREEITWVQTAYLVAEVVIIPLSGWLARALSTRYLFALACGGFTLMSLFCALAWNL
PSMVIFRALQGLFGGAMIPTVFAVIYTLFPPRLQPAMVIVVGLVVTVAPTAGPVLGGYLT
DAVSWKALFLVNLAPGLLVSLSTWLFVRVDEPEWDLLDKIDFRGILYIVLFLGSMQFVLE
EGVKEQWFESREIGFFALIAVVSGTAMLYRELTIEHPIVDLWAFRNRNFAVGCIFSFILG
IGLYTIIYLMPVYLANVKGLSSLQIGQYVMVTGLFQFVSAFVAGPMAKILDSRWMLALGL
LLYGLGTWMNGNLTYEAGYWEFFWPQAVRGFALMFCFLPINSLALGTLPAEEVKNASGLY
NLMRNLGGAIGLAVANTLMIQLNKGNYAVLREKVTGGSAEAQAFLSGMKQHLIASSSPDP
ELAALKQLYGLAMREAEVLTLNTLFHILGLVFFAALLLMPWVRKVSAGEDPGGGH
>fig|1132443.3.peg.4004 Multidrug resistance protein A
MHSPFFKSPFFIIALVLAASAGGLLYWFKTIRPFETTDNAYLKAHISLISPKESGYVREV
LFEDNRKVMPGDLLVVIDDHDYQAKVAQAEAQVMLEKATMATLETDKQAQSAMIRQEQAN
MAASEANVEKSGKDLQRFRNLAAEGAISAQTRDTAESAYKQAKAERDKYLSTTQEAISRL
SSLDARITETQARLKAALAALELARIDLANTRIFAPFEGVIGNRSVQVGQLVQPGTVLAY
LIPSDGIFVEANFKETQIARMQPGQTVEIGVDALPDQQFTGMVDSFAPASGSEFSLLPPE
NATGNFTKIVRRVPVKIRFRAGTSLSRLRPGLSTTVRVKVR
>fig|1132443.3.peg.4743 Permease of the drug/metabolite transporter (DMT) superfamily
MPGFFIEKFFCFRMRVCLAYVIVILLWSTTPLAIKWSGEGPGFLFGATARMVIGAGGILL
ALAGSRKRLPWHKSALMTYLAVALQIYGSMMTVYWGAQFIPSGWISVLFGLTPLMTALLA
VYCLGERNLSLGRFLAYFFGIAGLGVMFGSALQSGRNAVMGITAVIIAALLQSLSAVWIK
YINAGLPALVQVAGGLLFALPAYLLTWAVADGHWPILLPPISVASILYLGIVATTFGFVL
YYYLLTRLEATQVALITLVSPVLALLLGRTVNQEPLTFRVLAGSLLILSALVLHEYFDRV
VGLKRVVSNGKSRH
>fig|1140.3.peg.464 Permease of the drug/metabolite transporter (DMT) superfamily
MGDDQSDRLRCAGLPLKFPVSLQLAIATALWGGTFTAGRIAVQQLSPLAVACGRYLLATT
VLLLILWQREGWPPLNRRQQLLLFGLGVSGIALYNWLFFIGLSLIPASRAALIIALNPTA
IALGAAIWTGDRLRSWQWAGVGLSLIGAILLLGSRQAGALTLPGWGDLALVGCVLCWTVY
SLLARQALRSLSPLTVTTGACCWGSVLLIGLWLGQGAQLPVNVSFSTGSAIAFLGLGGTA
LAFCLYANGIERLGAARAGLFINLVPVFGSAIGALLLQEPLSGLTLLGGLLVLAGVGLGT
LQRLQPVPISTTEPVGGDRSPGPPALGHDR
>fig|1140.3.peg.986 Permeases of the drug/metabolite transporter (DMT) superfamily
MPTEIRLAPWLLLASLTATCEATKDLFAKRSLQQLSATRLAALLSLLTTLLLLPIVLWQG
IPAIGPNFWWSCLLGSSLNLVAFWLYARALQMGELSLVAPIVNLTPLFLLLTSPLIVAEH
LAWQDSAGVILLVIGAYQLNRRDRDSSSRLQPLIDLWQQPAQRIMVVVAFLWSITSNLDK
IGVQSSDPYFWLLCLFGSTGIVLLILGRGLGPVRKYPWRSLSAMAIFNSVGVVAQMVALN
QATVVQIISVKRLSTLIGVVYGAVFFGEKQLRQRFLGAALMMAGAIVLL
>fig|1140.3.peg.1243 Multidrug resistance protein B
MNQIIQKIRDFWSGTQGENHCWWALAAVECGNFVVYMDGFIVTLALPAMARHFDVGLPIL
KWVVVAYLLAVTVTLLPAGRLADIWGRKRIVVIGMSVIFISAWLCMLAPTVKILIACRVI
QGIGGGLVLANVMAEITAVFPKQDQRKAMAVNASVLALSQVTGLVLGGLFIVQFGWRSLF
LIILLVSLLGLILSIGILKLRSRTQGRASLDWIGALLAIGATSAPFIFVEELSKNLLNPS
SLLLLAVGVVALLLFVFVEQRVRQPLLNLSLFRSRAFTCGSASAAFYFVSAVSCYFFLPL
YAQLVLGLSPVMAGVLLIPLSVAITVTSLTIGRLGNRFSARTLSTIGLLCVSVALLGLSS
LGANASSTAIIAPLILQGMGGGLFNPPNNTATLNQVPPENLSVANGFLSTSRNFGQAIGA
AIAATLLAQGLSAAGAGDALAGAAGVRLSGFQLEAFLSAQRSAFQLAATLGLVGAVISVL
RPRRAPTAASLKSSGTAQ
>fig|1140.3.peg.2421 Multidrug-efflux transporter quinolene resistance protein NorA
MARQRLAFFSVALNVFMDALGVTLLLPILPELLRPFGSNAFLLGAFASVYTLAQFISTPV
LGSLSDRFGRRPPLILTLVFTGLAYVLLAVGSLVENLPLLFAARILAGLAGGVFAIAQAY
IADRESDPLKRSTQFGWIGAAFGLGFLFGPALGGLLSGINLRLPIWFAAILAFINAALTV
FTVVESLPPERRRIVPWQDLNPLKQLWAVSRNPKLRRSLASAFIYNFAFAGFTSLFVLFV
QNRFGWTPLQVAGVLIAGGFTSALGQGLIFGRLLPYFQEKGLALIGLGGMAVGYLWLAQV
PTPGSQLYPAQILTALFGGFVIPALSGLFSRRVTAEEQGQVLGSVQGWQSLAQVIGPLIL
GVVYDRGGADPFFWSLAALNAIAVLLLLPRSRQPLE
>fig|1146883.3.peg.216 Vancomycin B-type resistance protein VanW
MIFRRAGAGRVPRGVTATAPRDRGTAPGRGVATSGARRVPRGVTATAPRDRGTAPGRGVA
TSGARRVPRGVTATAPRDRGTAPGRGVATSGARRVPRGVTATAPRDRGTAPGRGVATSGA
RRVPRGVTATAPRDRGTAPGRGVVRRTTV
>fig|1146883.3.peg.2312 Probable antibiotic-resistance protein
MSTLNLDELVAIDVHVHVEQDLHGHKSMDDELLAAASKYFKGDPYHPTVPQIAEDYRAQR
MAAVIFTVDSELATGHPTLSNEEIAEAAAQHADVLIPFGSIDPARGAAGVRAARRLVEEH
GVRGFKFHPTIQAFEPNDRRHYPLWAELESLGVPALFHTGQTGIGSGLPGGRGFKLRYSD
PMLLDDVAADFPGLTVIMAHPSVPWQDAAISVATHKANVYIDLSGWSPKYFPPQLVRAAN
TMLRTKVLFGSDYPLLRPDRWLRDFEQLEIKDEVRPLIMKENAVRALGLRGA
>fig|1146883.3.peg.2356 Permease of the drug/metabolite transporter (DMT) superfamily
MPCHGRRRGDRFGTVRLARVTATTSRVQTLGGPALFVLLWSTGFVGAKYGLPYAPPFTFL
AVRLGLAAVLLALVAAALRSARMPDRAQYGRASVAGLLLHAGYLGGVFYAISLGVPAGVA
AVVVSLQPVLTAVLASHVLGERPTSRQWVGLVLGLTGVALVVGPGVLATGSAEPLPTVGL
IACVVALVSGTLGTVWQKRHGDGIPLVWGTTVQYAASAALLLVVALVTEDPSIRWTGEFV
AAFVWLVLVLSIGAVLLLLLLLRRGTAAGVSSLYYLVPPATAIEAYLLFGETLAGLSLVG
IGVTALGVALVVVPQRKRVDQAGSSPE
>fig|1146883.3.peg.2688 ABC daunorubicin resistance transporter, transmembrane permease component
MSAAPTAATDAADTAAVRRAIASTARPPRPGALSAALTFGWRGMLKVKHVPEQLLDVTVT
PVMFVLMFTYLFGGAIAGSTSAYLDYLLPGILVMSVLFTTVYSGVALNTDVTKGVVDRFR
SLPIWRPAPLLGALLGDSVRYVLAGTVIIVLGVLLGFRPDGGFPGAVSALALVVVFSFGL
SWVFSVLGLLLRTPNAVMNAGFMGIFPLTFLSNVFVPPATLPGPLAAFVEVNPISILATA
SRSLMAGEPDLTAILVSLAVAAALALVFLPLTTRLYRSR
>fig|1146883.3.peg.2716 Glyoxalase/bleomycin resistance protein/dioxygenase
MRMIFVNLPVTDRDRADAFYGALGFRRNDQFSDERCVSYVVEENIHVMLLTRERFADFVT
GAVGDPAQATSVLICLSADSREEVDRLVSTAVTAGGKPWLPPQDHGVMYGASFADPDGNV
WEVMWMDPTVVQG
>fig|1146883.3.peg.3025 Glyoxalase/bleomycin resistance protein/dioxygenase
MPAPSHAVPGRSGAERIHHAGLSVGRMPSFPGIAHVSLTVTDVDTSTRWYTALLGSEPRR
TMTDGPFVRRVFAVPGGQAISIVQHDGAPPADTFDPRRPGLDHLSFEVGAEAQLHAWERR
LAELEVEHSTVQRADYGSVLSFKDPDGNALEFIASS
>fig|1146883.3.peg.3068 Vancomycin B-type resistance protein VanW
MLAAAYGVDLLAASGEIPRNTVVAGVDVGGLAPARAAQLLEEELAPRVVADHTVTAADVT
GTLSPATAGITLDVARTVDAAEDQPLNPWTRLVTVFSDREVEPVITGEETALAAQIEGIA
AQVDRAPQDATIAIEGTTPSVVEPADGRALDRDGAAEAITDALASGGDPSVPIELPVDVT
RVDVDVQEAERVLEETVTPALSAPVRVVSQDGGTSAEVPVEAIAAALTFTPQDDGELAVG
LDAPALQAALGDELGAFGTPAQDARFEVSGGAVTVVPSVDGTGIAPAQLVEQLLPVLDDE
APRSVTAELGPVPAEFTTAEAEALGIREEISSFTTRIGNPASGENIRVVAKEVDGAVIMP
GETFSLNGFTGPRGTAQGYVEAGVINNGEFTTAVGGGISQFATTMFNAVFFAGLEDVFHK
PHSYYISRYPAGREATVYYDSIDLTWRNDGDTGVYVDTAWTPESLTVTFYGTERYEIQSV
SSERYNIRQPVVQDKPDSPTCEPQSGSTGFDITVTRIFRDLTTGAELKRENFVTRYAAEP
IINCVPAEPPAPAPEGTAPSPAPAPGGRRPAHGRAA
>fig|1147128.3.peg.826 Drug resistance transporter, EmrB/QacA family
MVIVFITQLDGGAVPTMLPSITRTFGLTTMGSSWVVGLYTLGLVVGTPITSNLSDAHGAR
KVFLWELAFWFLGCLMTAVSPNYAVMLLGRFIQSLGDSGIMVLSMNVLLQRARRNNQGRK
VSTVGIIAGLSAMVSPVLSGMLLGITHGWRAYYFMMLPFLAILFILAWFMMGDSQTDRAW
KTDYLGLGSFSIALALLMVAITFLQYGTAYLALIIGCLLVTVVAGAVFLVHERGLGDSKE
TMPFLPIRLLKLPSYGLTLLLGTLGGMFFSLFVYIPTYVHSVFGLPVRSAGMVMVGVGLG
SVVGSWLGGLLVDKFGYRTTLVFSSSLIGLMALVITLTLHNLQLFMVLSFLMGVGMGSMM
SSPLQVIAGRLAGPENRMQAIGGLSACKKIGTTIAPLLFASAIELGKVGGQAGLASYRNM
FLVVIVIALVNIGLTYCIPFSQKEVADD
>fig|1148.1.peg.28 Multidrug resistance ABC transporter ATP-binding and permease protein
MLLSPQSNRQVLMAYLSPQWGQVLALAIALGGSIILQVLNPQILRYFIDTAMAGGPQTIL
VWLALGFMAIAVVRQGLEIVATYCSETVAWTATNNLRLNLARHTLNLDLTFHKNHCPGEL
VERIDGDVDALARFFSQFVLQVLGNGLLVVGVLVVLWFEQWQAGLGLTLFALVALGILSR
LQSLAVGPWQVYRGISADFYGFITEYLAGLEDIRGNGAVDYVMNRFYTLIRNWLRAFHQA
RLQSTLLWGSTVGLFTVGNAIALALGAYLWRVQGITIGTVYLLFYYASLLQDPIERIREE
LEQFQQAVASLYRIQDLIRQSPSPRLGRSQALPSGSLSVEGKNVWFSYPTTASLKPGDGN
HELPEHRQGHHHEDADYALQNLTWHLPAGKVLGLLGHTGSGKSTFARLLLNFYAIQQGQI
QLGGINLGEISQRELHQRVGFVTQDVQLFQTSIRNNLTFFNPHIPDRLILQALNDLGLEP
WLATLPQGLDTELGTDGGGLSAGQAQLLAFARVFLKDPGLVILDEASSRLDPLTEQLIER
AINRLLEHRTGIIIAHRLKTVERADQILILDRGKVLEYGDRPALAHNPASRFSQLLRTSS
AIKLT
>fig|1148.1.peg.49 Antibiotic resistance
MSPMELTPETKAAVVTQGLTKRFDRQGAVTNVDLSIAEGAVYGLMGPNGAGKTTLIRMLA
TAEEPTKGEIYLFGDRLVAGADNLRIKQYLGYLPDDYPLYEDLNVWDYLDYFARLYHLKN
PGRRHRIQEVLELVQLTSKRHSRINSLSRGMKQRLSLARTIIHEPILLLLDEPVSGLDPL
ARQQFRDIIRVLQAAGMTILISSHVLSDLAELCTAIGVMELGCLVESTTLADLYNRLGQR
TISIFLLEGVEQLQDCLKNQPGVEDWQINYDQGDQPNSAPGTHCSVIFSGSPEDSANLLR
NLIYAGCRVSQFHCQQEDLESIFLKLGHQQVS
>fig|1148.1.peg.168 Transporter, drug/metabolite exporter family
MRILSNVNLMGLLIVLLAAIFFCFHNVIVRILYSQQNILGIWQVGGFVTPTLSHSFLLLL
LRMLWVVPLMALISQRLYGNTWREINQLKQPVNRPVIWEAMGCGFLMFLYLVLLYISISF
IPTGIAITLFFTYPIFTALLAWRLFNDVPSLLRWLVIGLTLIGTFLTIPYAYGGEQQTLV
LGVSTGIASGIVYAGYTVFAQRSFQRLHPVPFTWISFATTLILSILCLIIWQPHEGNLPW
LAITIGSLLSALFTLAGHVLNNWGIHLIGASRAAIIGATNPALTVVLAGLAIQESLTNIQ
IFGVCLVTFSIALLNYEKVSPSTGKNSLK
>fig|1148.1.peg.687 Multidrug resistance ABC transporter ATP-binding and permease protein
MTKPIAPLLSLLNYSRVHRAKIYWAVTCSLLNKIFDLAPPALIGLAVDVVIKQQDSFLSR
WGIVSVQSQLLVLTVASAVIWALESIFEYAYERLWRNLAQDIQHDLRLDAYAHLQQLDLA
YFEERSTGRLMAILNDDINQLERFLDVGANEILQVLTTVVVIGGAFFVITPDIAWMAVVP
MPFVLLGSIYFQSLLTSRYALVREKVSNLNSRLSNNLSGIMTIKSFATEAEEVERLRQDS
DAYRDSNQRAIALSAAFVPLIRVIIFAGFSTILYFGGLDAVRGNLAVGSYSMLVFLTQRL
LWPLTGLGKTLDLYQRAMASTQRVMQLLATPIQAHPGELSLHPSQVQGELVFQNISFAYP
HRSAVLKNVSLRVPAGQTIGIVGATGSGKSTLVKLLLRLYEWDSGDILLDGVDLKKYFLG
DLRRSVGLVSQDVFLFHGTVRENIAYGSADATLAQIERAANLAEAEEFINQLPQGYDTII
GERGQKLSGGQRQRLAIARAILKNPPILILDEATSAVDNETEAAIVRSLEKITKNRTTIT
IAHRLSTVRYADQIYVLENGMVQEMGSHESLLAHQGLYAKLWRVQTGLRSGVS
>fig|1148.1.peg.861 Multidrug resistance ABC transporter ATP-binding and permease protein
MNRASPMTQAVPGLWAVITTFWPQIRAQWRLLLVAMVTLLADVGLRLLEPWPLKLLIDGV
LIPTQTQPSLSLWGFTNLNAAWLLMLIAVGVIIIAVSRAIATYWNTVSLAIVGSRVMAQV
RDQLYGHLQRLSLRYHYQARSGDLIIRVSSDANRLQEILLTAALPLVVSLLTLGGMVGVM
AWLDLKLTLLSLATFPLFWLAANRLSAKIRHASLTQRHQEGAVASTAAESLSAIKLVQAL
SLEQAFADLFSRQNQRSLQENIETKRLAANLERLVDVLIAFGTALVMGYGGHLVIEDALT
AGTVLVFLTYLRNAYKPVQNFAKYTGRLAKAAASGERILNILAETPDIQDKPGAIPAPFF
QGRIEFKYVSFGYHPDQAILDGLNLTVRPGEKIALVGASGSGKSTLLSLLLRLYDPTAGK
IFIDGHDLRDYQLTSLRNQMAVVLQESLLFAATIRENIAYGIEGATMAEIEAAARLANAH
KFILELPQGYDTVVGERGTTLSGGQRQRLAIARAAMRQTPILILDEPTSGLDKVNEQLVF
EALERLAENRTTFLVTHNLQLAIAADQILYLYQGQIREQGTHAELLARQGVYADLFQRQT
LATVTKSLGR
>fig|1148.1.peg.994 Multidrug resistance ABC transporter ATP-binding and permease protein
MGRMAKYIGAGDVRSILIMAGVAAGIFLVRGMAQYGQDTLMAKAALNMALTLREQTYAHL
QRLSLSYFEEAKTGDLSYRLTEDIDRIGEVVNKLFHDFVPSALQLVVVFGYMFYLNWALT
CAVLVIAPLMAVLIGFFGEQLLKFSRRSQTRISNLSSLLTETLGAIRLVKAFAAEDYQLD
LFREEAQQHRRSQFLAERMKALQFVVVGFLEAMGVVVLFCLAAWQISLGNLTGIEFISYV
TGVAMLIDPISHITSNYNLFKQGEASVDRIFEIFDLQPSVEDSPTAIAIDHLQGAVDYDH
VDFAYLEDKLVLKGINLQAQPGEMIALVGASGAGKSTLVNLLMRLHNVTGGCLRIDGHAI
DSITLKSLREQIAIVPQENILFSGTIAQNIAFGKTDLDLAAIEEAARIANAHQFITELSQ
GYYTYVGERGVTLSGGQRQRIAIARAVLRNPSILILDEATSALDSESEALVQEALERIVQ
ERTVFVIAHRLATVRKATRIVVLERGEIVEMGSHQELMAHQGRYARFHAQQFAS
>fig|1148.1.peg.1257 Quinolone resistance Nora protein
MSSFQTLRQLSPSTQKTFALLFASVLMFWLSLTALLPTLPMYAQDVGATKQQVGWIMGSF
ALGLLGSRIWIGQLVDRRGRKIAIVIGALVVALAPLGYLLTATVGALMAIRAFHGICLAA
YTTGYNSLVVDLSPPQQRGEIIGYMSLAVPIGMGFGPAVGAYISQSIGYEFLFIASSLLG
FISLVLALQVRENRPPDQSSAEDVFGDRPRPRSIGKLLTSRSMAVPTLVLLLIGLLFGNL
ATFLPLFVREIDLATYAGVFYSVAAIASFVPRLFLGSLADTYGRGLFIVGSLICYLLSMV
CLAQADNSWELLTAAALEGAGSGILLPTTIALISDRSSLEERGRVFSVCMSGFDGGIAIA
APIMGVLNEIFGYRHVFWLSGGLALAAIMVFGIFSNPTIGRSLRFCIGRSRDLYATPQ
>fig|1148.1.peg.1985 Acriflavin resistance plasma membrane protein
MSSPNSVFSLSGLAIRRHIATLMLTLAIIVLGVFAVFSLPVDLLPSITYPRIGVRLDAPG
VSPEVAVDEITRPLEAALSATEGVVQVYSQTREGQISLDLFFEPGGNIDQALNDATATFN
RARNQLPDDLETPRLFKFDPSQLPVYEFAVTSPELSGPSLRVFAEEELARELGVVPGVAS
VNVSGAAQEEVRINVDLQRLQRSGVSLTQVLDALQSRNVDISGGRIVGTESEPLTRTVGR
FASAQEIEDLVVGTVSGLEDQSAQKVYLRDVATVIDGTEEERIFVTLNGNPAVKVSVQKQ
PEANTIEVVDGVKKRLEELRTEGIIPQAAELTPTLDDSVFIRNSVNNVVVSGLIGTVLAA
IAVLLFLGSLRQTLIIVLAIPLATMAAIIVMKAFGLSLNVFSLGGLALGVGIVVDNSIVM
LETIAEGAGMTPGKVNPLPLTKGEMRNQAIASSQTVESALVASTSTNLVAVLPFLMIGGF
IALIFNELILTISFAVAASILVAVTLVPMAASRLLAIRRRSGLGNWLFFREFNRRFAGAT
AAYARFLSILIRHRLVAVASIFIVFGGSSLWMIGQIPQEILPRINTGQASMFAQFPPGTP
LEENQRLMAIVDDILINQPETEYAFTTVGGFLFGSNVNANALRSSSTITLKPNTDVEAFT
ERVTAELEALNLVDIRLRMAPGQLRGLILSNSPLRNVDVDVVLQGNDADVLDEAGRAVLA
ELGEKVTLARFRPDADPRQPEVQIRPDWQRATELGLTTQAIGQTVQTALDGAVPTQLQRE
NRLVDVRVKLDNDLLSGPGDLAQIPLFIDGDRPIRLGDVATIDQGRAPGEIQRINQRPVF
LIAGTLVEGASLSEALTEVDQVLSAMEFPPGVSRLPSTAAASNEQLQSSLVILGGLAAFL
VFVVMAVQYNSLLDPLVIMFTLPLALAGGILGLYVTQTAIGATVIVGTVLLVGIVVNNAI
IMVELANQIWAEEGISREAAILRAAPQRLRPILMTTITTVLGMFPLALGIGQGSELLQPL
GIVVFSGLSLATLLTLFLIPCLYVLLHQWEGVDIEKVKTDLESRLTEEDVPTKIQ
>fig|1148.1.peg.2120 Acriflavin resistance plasma membrane protein
MLLSISNVFIKNPVLTTVCTIVIILLGAIALPLLPLAKLPDMAPKQVQVTTNYVGSDAQT
AVDNVTTVLERQINGTEQVIYMNSTTDNTGTSTINVYFPVEMDRNIAQVLVQNNVAIAAS
SLPEVVNRQGVTTQTQSPSVTIAYGVYSENDDQGKPIYDDIFVSNFVDRVLLDEIKRIDG
VGSAILIGASEYAMRFWLDPDALAARDLTAADVTNAIRSQNIQVGVGGVNLPPVTDQQRF
QINARALSRFTTPEEAEQIVVKVGDDGTLIRIKDVGRATIGTQNYIQTALFNNAPAVAFV
IYQLPGTNALDTANMVKEKMAELRPLFPPGLNAEVALDNTLFVTASLEEAALTLIEAILL
VILVIFIFLQNWRTTLIPALAIPVSLIGAMAFALAFGFSLNQLTLFGVILATGLVVDDGI
LVVEAIEVKLDQGMKPFQAALDAMGELTGAVISTSLVLMAVFIPVTFFPGTTGIVYKQFA
VIMASAVAVSTFNAISFSPSMSAILMRPKKEVHGPLAWFFNLFNRTFDWLKERYGNIITA
ILKVRLLAIPIFIGSLILTVIVYNITPTGFIPEEDQGYFFMLGNSPAGVSIEYTKDVISQ
ATEIVSARPEVEHVLGMGGFSFLGNDSSKSLFFVKLKNWDERPGQKGSVFGLLAEINREL
AQKIPDAQVFAVNAPPVDGLSSTGGLDFYIQNRGGMPLENFLDYVQQYMEKLRQEPALNP
RTVFTQFTFNAPLLEIGVDREKANAQNVDISEVFNTIGIYMGSSYINQFVMESRLYQVYA
MADGQFRSNPRDIGRLYVRSRTGALVQLSNLIDVKQTTYPPILTNFNIYPAVDVQASPAA
GYSTGQAMATMERLSKEMFPDSIGYAWYGTGYEELQSAGAAPIIFGLAFIMVFLVLSAQY
ESYVDPAIIMMTVPLAILGAIGAILLRANFMVATNMVWPTVNNNVYAQVALVMLIGLASK
NAILIVEFGNQAMDLGMKIPQAAAFAAKERMRPILMTAISGLVGFWPLVIASGAGAMSRW
SLGTAIFGGYLISTILSLFLVPVLYTLVKEAEARFLKGEKGEGDSNPPPPSGEDNGEPVN
NPS
>fig|1148.1.peg.2160 Daunorubicin resistance transmembrane protein
MSQTLTPPKITSLLAPQAAPANPPSLTVEFFQETIALTKRLFIQLQRRPTTLVAGIIQPF
MWLVLFGALFLNAPQGLFGNDLNYAQFLAPGIIVFTAFSGALNAGLPVMFDREFGFLNRL
LVAPLASRYSIVAASTVYIISLSLIQAAVIVGASALLGAGLPNSFGLGMIALIVFLIVLG
VTALSLGLAFALPGHIELIAVIFVTNLPLLFASTALAPLDFMAHWLQVVASLNPLTYAIE
PIRYIYLNGNWGLDSTVLTAPWFSLNFAQVLGVLVLFDGLVLLLIQPLLKRRFL
>fig|1148.1.peg.2161 Daunorubicin resistance ATP-binding protein drrA
MGKSYLMGVAVQVKQLRKKYGAIPAVKDISFAVPRGEIFGLLGPNGAGKTTTIRCLCTLA
KPDGGELWIDGVNVLSDPRQARRRLGYVAQEVAIDKILTGRELLQLQASLYHLDAISSQK
RIDQLLDILGLTAYADQKTGTYSGGLKKRLDLAAGLLHQPTVLVLDEPSVGLDIESRFIL
WEFLRQLRDAGTTVVITSHYLEEIDALADRLAIIDQGTVIATGTPTELKDRVGGDRVTLR
IKEFTADQEAEKASQILRSLAFVQEVIVNQAQGNSLNLVVTPQSNPLSQIEKALLADGLP
IFSLAQSRPSLDDVYLAATGKTLMDADLAAAAQRDLKAEKKQAMKAS
>fig|1148.1.peg.2631 Quaternary ammonium compound-resistance protein
MAWPCLSVRLVHEGKYGLFTSKRRGSLTLLTGAKRLTLTEWKTIGLLLTMVTTQVLGDIW
LSRGMKVFGAVEDYSLAGLWTLFLYLLTSPWIVVGVITLLFALFLYFTATSRLDLSLVLP
LFSSSYILNALLAWLILGEEVSFYRWLATFMIASGVFIVCWSEHRHRSQLMGEKFSPTPA
PVVPVKSSRRSPLWLFPVGIALSRVWFGILILIFTDSAGDVLIARGMKQIGPVRLQSPLK
MVKLIGRILSHPSVLGGIGCQTISFVTFISLLSWTDISLIRPAGALGYVMSLLGAKFLLK
ETIPLARWLGIGVITAGVALIALDEVNLVDQILLFFL
>fig|1148.1.peg.2643 Multidrug resistance ABC transporter ATP-binding and permease protein
MAAPSVKQLLRYLTPHWRAIGAGTFALFLANALGVYIPILMRDSIDDLMPPFEASDVARI
VVLIVVLASLMWFIRMASRILIFGVGRQVEYELKQKIFDHLLKLEPLYFTENTIGDLINR
ATSDVDNIRRLVGFAVLSLINTVFAYALTIPAMFALHIPLTLLAVSVYPLMLMSVNLFSG
KLRDYQLEVQEELSALSELVQEDMSGISLIKIYSQEDNERQAFQTRNQKLLQANLKLARI
RNFLFPLIEGLAYLSLLILLAFGTGLIQDGSITIGDFIALIILVERLVFPTALLGFTITA
YQRGEVSIQRVEAIFHTTPKILTVPQPLPFSPAQATGKITARGLNYCYPGSDLPALEQVD
FTVYPGEMVAIVGPIGSGKSTLVNVLPRLLDIAPGQVFIDDYDITQIALSDLRSAIAFVP
QESFLFSTTIAENIAYSDPSQTDTAIEQAAHQAHLDQEIANFPQHYQTLVGERGITLSGG
QRQRAALARALILDAPLLVLDDALSSVDNQTATRILHYLARRNNTVLFVSHQLSAAAQAD
RIFVMDHGRIVQTGSHEELLQQSGLYQSLWQQNELEKVLS
>fig|1148.1.peg.2644 Chloramphenicol resistance protein
MSEPKPSQPNFSHLEEADYTGRMRQHDRLFGLLAIAAGLIFLQGYMIAPLIPRLAEIFDV
SAQEIGFIVPAYMLAYALAALFYGILSDRFGRWPVIQISIIVFITCTALTATAQTAAQMT
FWRLLTGLGASGVIPLTFALIGDMFPYNQRGAKLGLVFAAMEGGMAAGSAGGAILEPFLG
WQLLFIGTATAPVIVLWRLRRYGALFDAPKATKIPALATVFAGYWAVLSNFRGMRTYGYV
LCNGIYHSGVYTWLGLYLSQRYEMDTLSIGLNILGYGVPGLIFSPLIGKAVDRWGRRWLI
PPGLAMAAIAGLTMVPFIPPLAVTMAILVMSLGYDLTQPLFVGIVTDLAEEDTLGQTMGL
KVFTLFTGFGIGSWLFGEVLHWGFEVALVAFGVMQLLSAIAAIPLFWNEKPSPINVSA
>fig|1148.1.peg.3100 Acriflavin resistance plasma membrane protein
MRINSSSKNRTQKKLGIPSMQSPRAPRWNLSHWAIDHPRFTIGFWLAIAVAGLLTFSSLK
YALFPEVSFPVVIVQSSGAGLDLAQTEQKLTIPLEEKLVTIADADVQSSTYPGQTVASVI
FLMGQSLEQATTAVEQSLQGVTLPAGSEITVAPYNLNESVAVTYAVASETLSLEEMAAPL
QQELMPQLQNIAGVLRVDLLGDANFRSPGVKALAQQTINPPTLTRHNGQDVLAVQVVKTA
QANTLEVVDRVEQLIVEQAPKFPQLKFIEAETTAGYIREATQATIEALLGAIVLAVLIIY
PFLRSGWATLISAIAIPLSLLGTFIVMAALDFNLETLTLLALALIIGIVVDDAIVDVENI
ARHVEAGEPPKRAAKIGTEEIGLTVSATTFSIVVVFLPIALLGGTLGEFFFPFAVTVSAA
VIVSLLVARTLSPVLTVLWLRTQTPRPQSWFSRGLDALGNGYQRVLAWSLGHRWWIVALA
LVSLMAGLAIIPLIPQGFVPTLDRGEFNVIFQSAPPKIAGALSTPPRGNNNDTSAGGAFG
WIDQLATNPEAVLLRRGRRVAEELEPPILADPAVTETFTVVGIQGNPLQGKIYVKLDSDR
EVTTQTVQTEVREALPEIPRVTTRVENILFVQTGDDTPLKLALLGNDLDLLQTTGKALEE
KVMALPGLTQISLTGAEPDSTGILRLRGQRAVYLSASLLPNYALGDLTQQVTAIAEGLLP
PGVELSVQGESARVGSVFREFALAFLLSLLGMAAIFLGLFRRLLEPMVVLLSLPLSIVGA
MVGLLVTQSEFGMISLIGLIFLLGLLDKNAILLIDYANQLRHRGLSRQEALLQTGHIRLR
PILMTTSSTILGMLPLALGWGAGAELRQPMAIAIIGGLFTSSVLSLVVVPVLYSLLDDVW
GQKPRPEKT
>fig|1156986.4.peg.1163 Permease of the drug/metabolite transporter (DMT) superfamily
MQTQMTSLLKSQYRLPLFYLILGAVAIGFAPIFVRLSEVGPIATGFWRVALAFPLLTLFS
IDQGTTQPDTSQPISWRDYAWILFAGVLFGADLATWHFSIHYTTVANATLLANFSPVILA
LWGWLVLGQRPQAQLVWGLVLAILGVAILVHPNLQLGQSTWRGDALAFFTSFYYTAYLLA
MNRARRIFSAVVSMAIASFSSMLFLALLMWGTGEVWFPVSLTGWFVLLGLAFFSHILIAY
AFPYLPATFAATTLLVQPMIAAMAGWFFFAEKLSLLQITGLLVALGGIFLAKKTI
>fig|1156986.4.peg.1716 Permease of the drug/metabolite transporter (DMT) superfamily
MIGFFNAVAYLSQTIGLQTVSSARAAFITGASVIWVPLLSPLFCLTWPTRLDFICAGLGF
LGLYILTSPGQQSLTSGDLWIILTSLSFALQILFLQRLNQTITHYPLFTFYQILFTLPYV
MLGLQHPTFSAALQPAALTGILFCAIFATSLAYYLQNLCPRAGFCEYIRSCPE
>fig|1156986.4.peg.1913 Permease of the drug/metabolite transporter (DMT) superfamily
MDCSIQKSTYLLFLLLAIFWSGSFVAIKAMVLWIPPLLSAMFRIGIALLFLIGLLIFLRK
PVHAPFSLRWRLWVTGLFSQGIPFSLLFWGEKHIAPGLAGILNGTVPLWAFMLGLFSPKT
RDISPLKCVGLIMGLIGTAVIFGPMLDTQGLQPDVLGLIAILLMAISYAIGSLLAQHLLR
DTTFKLDVYTNIYHQHWASFIFVLLLTLFFESWPSSTIFTQHPIIAISALYLGIFSTALG
WLIYLYLIREWDAVRASAVMYLVPIMALFWDFLFFHRIPQWTEGVRVSSSF
>fig|115711.7.peg.812 Multiple antibiotic resistance protein MarC
MLILLNLSLLFYVLFDSPGSIPVFVALLKNFSRKKQQRVILRECLFALGALILFVTFGRS
FFQFLDISLYAFQIIGGFLLFTVSIKMMLAPMPEKAKDDTSKTEPIFFPLAFPVITGPAV
ITALLSYMEEGIYSREIIFTAMIIAWAFSLFTLLCSSFFDRLSGNFGLLALERLFGIALL
LMSVNLMLKGISIAFNIGFYIG
>fig|1157951.4.peg.1405 Albicidin resistance protein
MLFQVGEIAQKTGLTIRTLHHYEEIGLLVPTARTDAGYRLYNVECLERLTQIQMLRQVGV
KLKDIGKILDGHSGNMAQLLQERISALSEQMKQIAKLRYRLEQLQLQMQAGDILTQADWF
SILEMMSMYDKYFTPKELEKMPLYTANTLKSQEWQQRVETVKNLMQEGVTPDSEQARKVS
AEWMIALERDTGGNPDFFARLNKIHLSDNEFALSSGITEEMIEYVAKGFSEHQLAIFKSY
LTDSQFAFVREHYFESGKVWPELIAGLYRAQQSGVSPESPEVQSLAKTWLNMFNQFTGGD
PELQEKIRQIYRENPVISQGTWMTPEIGQYLFAALTAH
>fig|1157951.4.peg.1990 Multidrug resistance protein A
MTGYISRILVEDYQYVREGDVIAEINNQEELLNQQIAKANYKKAQQQLNNLADEIKEYDL
TIEKLWNRYKAAGIEVSQMQRSPLLRKELIKSGAITSQNYLDANSDLQRLIKLEQAAKAE
WEQAKQSKLLLAQQENIRLAERDIALANYQQANTQISYATITAPFDGQLNKIKLNVGSLV
TPGTEIVTVTPRSQPYVIAHLKETQLKNVQSGQSVAISVDAFPDMTFSGVVRDIGAQSSG
ESALIPADNSSGNFTKVVQRIPVYISLLSEQSAIDKLRPGMSVIVNIDTQSTQSQGD
>fig|1157951.4.peg.1991 Tetracycline resistance regulatory protein TetR
MKTPKITRLQILETALQLLETEGIDGLTMRKLADALNIKAASLYWHFSNKLSLVEGMADH
IVAEVALNECDSDDWKSNLLKITTQLRKALLQHRDGARVFAGTYAISDNVLRINNALIKT
FVQSGMSADKAASCTMTVFYFILGCCIEQQAALFSNGSDLQEKLNEFNKLSNDKYPYTWE
AKATLFSDNYDQRFIDGLNLIIGGLGTSK
>fig|1157951.4.peg.2082 Multidrug resistance protein B
MKLLKNHLIIGFLFGIQIISMGAMEMSGPFWPIHLQNNSSDSLLPFALTMVYVAPMIGIM
LTSTFWGKVGDRMGNKAMIIRALLGLSITQILLSFCNDPWLILLLRFIQGACAGYIAPAQ
AYGVAVTAPRKRTHLFALLQVSTNIGSLLGALAGGLILDYLNFFWINMMAGWLCMLSAVA
VFLFLPSDKHSPLLSPANTAHTTKKNGSPQTIVKQLMLLTGLLLMIRLITLPSFSLYIEK
TYSTDYWVIGLIYGLQAMGVILSAQLWAKWFEHQSIVASLTRLRWIIFGCAAIAISLANA
SIIWFALLYFIWGILLGATTPILTALISSASPAKHQGYVLGLSQSINQFASIGGISLGSI
LIIYPGINMLFYYISVGYLICLSTIILLTKHIINKEQYEKKV
>fig|1157951.4.peg.2457 Membrane fusion component of tripartite multidrug resistance system
MKKRTIALILLMLILIAAAALFHSHNQFLLLQGEVDAPEVMVTSKAKGRVIERHVERGDD
VKKGQLLLTLESPELTAQYAALKAARDQAKAQLAQSLHGTREETIRHLQASLAQANSQYQ
NASREYQRLSNLSAKGYVSANELDNARKAKEVAFQQVQGAKAQLEEAKNGDRIELRQKYE
AALNEAEQKLAELQVQLDDLQVKAPVDGEIGPIPAEVGEIFNAGSPLLTMVRIPQSYFIY
NLREDILVDVKKGDRVQLDVSALGDKKIEAEVRYIAPKGDYATKRATRATGDFDLKTFEV
RLYPVEPVDGLRPGMSVLWRWDK
>fig|1157951.4.peg.3043 Permease of the drug/metabolite transporter (DMT) superfamily
MRQYNYLIYALMCVLIWSFIPIVSRFGQNGLDSFQFLFWSNLISAMSVILVALIAGYKPT
KLFILPRDILLKVFVLGFLDCLFYLLLYYGYAIENGIAVLVIQYSWPLIIILLSVFLLKD
KLAGRQIVGVIIGFIAVIITFTKGHITQLQVEDPVALLFVFSGAFCFALMSVFSRQYSID
PYISTVWLFIFSTLTSLVLLLSFSELQLPSKAAFWPTVINGVLINGVSYILWFKAMNTGH
SAKIASIVFLSPVLSVLWLVVILSDPFEIAYIIGVLLVIVSGVLCVGQKRKQSY
>fig|1157951.4.peg.3161 Multidrug resistance protein D
MKRPLSLWLAVALMMFPQIVETIYSPALTGIAIAFHVNAEQASQTLSLYFFAFAFGVVFW
GRMCDTLGRRPTILAGLLLYGVASIGALFVTHFYLLLLMRMLSAFGAAVGSIGTQTAMRD
CYQGHELSKVFSIMGIALAISPAMGMLAGSLLVSSGGYQAVFIGLAVLAIGLLLWSCYRL
PETRPANVIHSPFLTTLFTMIRDKEIVRNVILIAFFNINLFSYYQLAPFHFEQLGLSQQQ
FGLTGILLALGVGIGSTLNRHLLGKNWSPEKLVKLSSFVSLISGCLVFILMHSVWFIAPV
IGVVIGYGIAIPNILAHALSRYSDNKGTAGAILGLFYYIGLAVGLMVAGWSQHLGGVLVI
GSIILSLSSLRYRTQ
>fig|1157951.4.peg.3896 Polymyxin resistance protein PmrL, sucrose-6 phosphate hydrolase
MIAQLLLLLLVSVLTCLGQIAQKQAVVCWQGDKHNKTASAIRWLVLALLMLGLGMLFWLK
LLESMPLSIAYPMLSINFVLVTLIGQFVYHEQTGLNHWLGVAAIMFGIFLMSISG
>fig|1157951.4.peg.3897 Polymyxin resistance protein PmrM
MNKGYFWVIGSALLVTIAQLSLKAGVVGLPSFTLGWHWLQSEWLLANLANLSIVFVGLVC
YALSMLCWLFALKSIPLNKAYPLISLSYVFVYLLAVILPWYHEPATWLKAGGVAFIILGV
WLISRPTKGQSQK
>fig|1162668.3.peg.397 Acriflavin resistance protein
MSQSSNQKPAMTLIKKYRGFSLLLTVVLSILGIVKAWNLPMTLYPSIDFPRVSVIVRSPD
IPFAEMESRITRPVGITLRGVQGVRELNSRTMQGSAEFFLRFSWHEQMSLALPRVAQAID
RIRGDLPAGTSIQAIRMYPSDTPVLTVALSSTSDNLPQITRIAKTRLIPYISNLPGVWKT
EIAGGKNPEIHVEVDPYKLSGAHRTFSDVISALSTQNRIGVIGPRTEEHRLKTVQIDNTM
TRTAEINKIFLPSPSGVPLPIDLLATVRRGVRPSDETIRISANGSPAVLLLVYRAHGGNA
LTIQRALLDHMNEFRRLLPKGCTPAIVYDQGALVSDAIRHVIWALAIGLSGAMALVILIL
RRGYPILLMGSLLPAILFISAGILGLLGETLNLMVLGGIAAGVGLVIDDFIVIIEGGRHA
HRMSGLLVPFVLSGLITILALVPLFGMNGLVGAFFAPLAISFVTLLGVSLLVNTFVTPAF
IHQEKETPVPISTGILTGLSPAVILGAGTLAFALLLLPLTHLKTNFMARMDEGSFTLDFH
APVGSSINDMDRAVLRVEDHIRALPGVIDTTRRLGTEMGFYITEPNKGDFVIRLSENHPK
STFELIRELRPWVQKNEPELDTDYSQVMEDSLGDLIGVSAPVVVEVHGQNRKDLLGTARM
IRDRLSGIPGLVDLHLSVRPMGDTLDGHVIAPLASLAGLTPEAIIAQTREDLMGITATTV
LSPGGPLPVRVLYPSEYRNGLIPLSHLPISESDGSLIPLSQVVTFTNTPPATEEEDKNLS
PILRIEGRLDHGNLGGVIKEIKAKVSSLTLPKSSWVTYSGAYKQEQKSFRTLGEALLGSV
LLIVTILYGTFRKWTPPLVLTAGMAFSVLSGIAALTFSGRTLNISSFVGLILVVGLSAEN
GFLVANRFESAEGNASEKLKEALSDRFLPIVMTHLANAAALLPLALGGGAGLDMERPLAV
AVLGGLVGSFFSSVFLIPSALSLFTRTVSPQEGLPDVQI
>fig|1162668.3.peg.496 Acriflavin resistance protein
MTGEKHGPGFAGWLSRTFIDSPLTPILILISLALGGLAVLKTPREEDPQIKVPMMDLFVS
DPGMSATEMSRHIVAPLERHLSRIKGVKAVYSQSESGTAVVTVRFHVGEPMGKSLVKIYS
EVMKSRGYLPRDAGPVLVKPMDINDVPVMAVTLYSKTESDAVLHRLSEEVATSFKRIPGT
GQVTVIGGRRRTVRVVLSPSDLTAHHLTAMDVSAAIWRSNRSIDLGSFDRNNISYQVALS
GTLTRVSQVRNLVVSVQHGKSIRLFQVAKVTDGPGPLESYVWIGHPATSPLSGDETAVTV
AVAKKKGINAVVVANQILQKMKDLSARKIPSDVQWTVTRNYGHTANEKADDLLLHLVVAT
VAVILLVALGLSLRESGVVAVAIPVTLALTLFGSMVIGYTVNRVTLFALIFSIGILVDDA
IVVVENINRHFHFLGGKRDRDTLLERAVVAVGEVGNPTILATFTVIGALFPMAFVSGLMG
PYMRPIPVNASLAMTGSLLVALTVVPFLALRMVPPAGHVNKIMGKVDAGIRHLYRSIMLP
LLNSRLRQNLFFASVLLLTVGVMAFFDTRTLLLKMLPFDNKSELDVVIDMPAGTTLESTA
RTAMALERVILKDPSVRSDQAYVGLAAPFDFNGLVRHYYLRRGKRVAEIHINLLPREKRS
LQSHRIAEEMERKLAPVAHSFGARIKMVEVPPGPPVMAPIVAEVTGPDQKSISDYAKKVR
DVFQHAEGVIDVDSTLPDPQVRYRIRVDQEKAALSGVSTEQIEKALTLGLHGETGELHTT
SGKGYVPIVLDVSRKDRSSIKDLDSIMVRSNNGRLLPLGTLIDVSEEGAPAVLYRKNLRP
VVYVTGNTIGSNRSPVYAAVDLSRKLPPSELSGHPEAVRQYFWGYPSSNDKISVRWGGEW
HVTYVTFRDMGIAFIAAIVVIYLLIVIQFKSYVTPLIIMSPIPLALIGVIPGHVLLGSNF
TATSMIGFIALGGIMVRNSILLVDFLHTKKAEGVELKQAVLEAGAVRTRPILLTALALVA
GSFVILSDPIFRGMAIALLAGSMVSTILTLVLVPLLVARVEGKRWPDGRQMVSGN
>fig|1162668.3.peg.1745 Inner membrane component of tripartite multidrug resistance system
MTETPVATAAHEGDLGYPMRERILVTVCAIGATLIETVDSTVVNVGLPKMMGGLDATVDE
VAWIITAYSIGNILMIPMTRFFADKIGRKVYFTGSVFFFTIFSFFCAQSTSMPELVIFRM
LQGVSGAAFFATSQALLIEAYPSRLVGLANALFAIGISLGPAVGPVIGGYIAYHLSWPWM
FYINVPIGIVLTALSYKVIRNSPFTNHEETADVWGILLLALGIPALQIFLENGQEFAWFD
SPLIRASFWIAVISLPLFIVRQFMAKHPLIDLRVLKNRSLAAGCFGLFFLGIVYFGTLFT
VPLMGQILLGWNPYKMGVVLLPGILSFTFTAMFVGGAMGKAPLLPIMFAGMGILLLSLHG
LSSLSIQIGPDAVFWPLIERGIGLACLFPPIMTLAMSTLSREKVSSGAALVSMMGQIGGT
VGIAFMTTMLERFEQQHRSDLSAHLSNSAPFFEQHSQMLNSLFIAHGVSPQAAGPLSFAL
MNQTLDAQAMMLSFGNLYLLTSISCLLLLFAIFGFERSAISHPQKATVAD
>fig|1162668.3.peg.1746 Membrane fusion component of tripartite multidrug resistance system
MNKHYLKFLAGGTFILALVLMGLWWVRDRERNVSTTDAFMTARPHMVTTRIPGVVTKIYV
HDNQIVHPGDLLLELDPKDVLARLDVERADLVSVTRKIPLDVSQMRIAEQNLLKAQSDRD
RGVVLSRGGYATEEDLEHLDVALRIAHHELSKAKKQISLDRAMVKKMQAALAADLLNKHY
LKIVSDVSGRFTNRTASLGMYVSPGLSLATIIPFHTWVIANMKETRITHMKVGDPVTIHV
DAYPDRVFKGKVESIQQATGAIMALLPPENATGNFTKVVQRVPVRIALLPDSDPDHLLIP
GLSVVPTVHVDPSYHPAFGH
>fig|1162668.3.peg.1773 Drug resistance transporter EmrB/QacA subfamily
MRLSPFFSSREISPWLVLATVILGVGMPLADTTITNVGRVFIVSTLGVTSYEAGWLTASY
SLALAVGVPLSHRLRGFLEEKDLYSGAILTFMLGSLCMAGSVNFTEAMLSRGIEGLSAGI
LLPLAPILIQESFPENLRSLAMSYFALFGAVWVTLGPTIGGFIIDNPGWQWAFAINIPIG
FLAIFFAQAFLSNHPRQDPRRFDGTGFVLMATSLGCLFTGFMRAEWVGWHSSGTGFLLFS
GLLLFFLFWIWSALSRDPILPTEVLRKPLFIGILAIVFMQSTQSFGRLYLLAPFLEKNYH
FMAHDAGALVAVGALTEILLSLSFLFSRFLAGKWAILLTTGCILVSISNIDFLFLPATGF
SLSFIVKSQLIFGAGLALTQISLPPLASKLFPQSKVRAATTYLLFAQFIGGAWGTMLGRH
LVLHVKPVFSQMLPQLSTHRMGHSDIFLADRLAQSYTSNIIFYDLGIIGLIGAFLAFVLI
FFLSEKRVGESDRKEKETLAGLPANGKR
>fig|1162668.3.peg.1774 Multidrug resistance efflux pump
MAEESQNHSPEKRSSLFSFAVVTPLLGFLLTVLWGISHWYGETRYVSSDDAYVQGKITYV
SSRQPGRLIGLAVNEGDPVQFGEILATIDRTGDAYLRPQDTTKNLQAFTRIKRDMAKLRS
LEKREKDERDHYQRAKALLSEGYMSPQKLEDLKTNWQQTHVEIVESRKLISAEQQSLDIS
EVHPRNRIVYAPIEGQVAQRLVNLGESVKADQPIVSIINLKDLNNIWLDAFVRETQVWKI
RAGQKVQIHIDGWPKDTFTGHVLEFIPAASQAFSLLPTQNASGTFVKVVQRVPVRIVFDS
LKNRILLPGMSAEVRIDRTSPLSRSGKDHR
>fig|1162668.3.peg.1832 Acriflavin resistance protein
MFLSTFAIKRPVTTLIIFIALISSGLYSYFSLGRNLFPRVSFPILSVTYLLPGVSSKVLE
KTVVPPVEEALSSLPGLKHLHVVSLSGVVSLTAIFSEHSDPRLIYPRLQEKVESVSPSLP
SGTAPPIISVVNPTSLPLLWVILPIPDSMDSRVITDWAMMNLVTPIRKLSGVADVKPIFP
AREVLHISLHRKELTKYLVPVTSVLESLKKVGLSIPAGTMTSGKEEIMVETLDSESTVAS
LSSLPVPDGKGRTIPLSRIATISIGPVRETEIFRIDGTRAIGLRIFKKKGADGLSLSGKI
RKIILERKAVAAVSGVNGQSIVLDPVIRMDRSEMIRKNNRELLETLLFGGALTVLVIWIF
LGSFKTTMIASISIPSSVIATFLMMKMAHFSLNNMTMLGLSLVVGILVDDAIVVLENIHR
HGQMGKPFDQAVSDGVGEIGMAVMATTFSIISVFAPVAFMHGIIGKFFFEFGLTVSFAVL
VSMLVSLTLIPVMMNFSSGSGMKSVSSRVLDGKMDALISKYRALLIKALDHPGSVAGVGF
LSIALAAGILYLLGADLVPRTDDGAFVVRMTAGEASSIDFSKTIFKDVASKIRQQKGIDS
VFYQIGNSYGGSSNRGYFYVLMKPLSMRKTSEEDAIVHLRKLLLTYPAIDFSIDHLSPLG
GNGTDVPIQIILQGPDRKRLASLVESLRMDLEKTKGFVDITTREGERQKLLAVVPKKNLP
AGSSASELGGTLHLYLAGMDTGWARVDGRTIPVHLSMISKDLSSPSDLESLPMMTSTGKV
ILLGDMARVESAVQFKRRVRDDRMPSVTLESNLSGNIPLKTALDDITQWKKDHLPGNYRL
RFGGSGDVMNNAIGSFMMAIGLAIIAVFMVLASQFESFVQPFIITLSIPVSLSGAALALY
LTGNSLNIMSAMGLIILFGLVAKNAILMVDYTNTLRKRGYSRRDALLAACPVRLRPILMT
TVAMVAGMSPMALGIGSGGPLRAPMALVVMGGLISSMLLTLFIVPVAYDFFARWNVFSQK
NEVKD
>fig|1162668.3.peg.2927 Permeases of the drug/metabolite transporter (DMT) superfamily
MPLPDSTIPPEPIMARRQVRWAIMASFLFALSTPPAKVLSSEQTPFLLCGLFYLGSIFGI
IPSILSTPRENGAGGWRKLLLPEKPKQKEIGIAILSVLIGGGAAPILLIWGLKHYPASLG
SLLMNAEGIVTVLLAWLIFREPLNMRLSIGAILGAAGCAIASDSEGSHGFSGAIPFFLAA
GLWALDSNLLRFLSGWSPVTITLWKGLGSSFLLLPLGLFLPHPPMTISIMGEALLTGGLG
YGLSLILFIRSIRAIGVSATGAWFSISPFLGAFLSILFLKEPVTRTFYEASVILFVAVLF
LNGPMSPKTSSDIPRHTG
>fig|1163389.3.peg.10 Permease of the drug/metabolite transporter (DMT) superfamily
MIIFKPSYASIHSSTFALSSLVYLGIFCAGIVYFLYASLIKVADPVFTSFTNYLVLFLEL
FLVY
>fig|1163389.3.peg.11 Permease of the drug/metabolite transporter (DMT) superfamily
MIAFARSFIGCLILCFVCYFLGLKSKSFKKDFAIYSLIAFLEATMPFMLIPWGQKFTSPS
ITAILTGTVLFFLLFYLDH
>fig|1163389.3.peg.27 Membrane fusion component of tripartite multidrug resistance system
MKISKLMAVVIILFIIIFLICIFLYFDASFERDAYLYANFTRVNSVENGQVQKIYIKKGS
YVNKGDTLFELDCRYITKELNILQSQDKKIALELKDIVIKIKLAEKQRDLARESLIVEKR
NFERYKLLIKDGAVSDQQKDLAEKNLISSESQFVKACQNVDNLKIRQNDLLSDEKITQSK
IGQKEYSLSRCSIKATTDGYISNFILQKGDFINKGEDLFSIVDTHKWYVVANVKESNIRY
LSVGQTISMTTSLTGFKKYTGRIVDIEKGITRPEYNNFSALYHIERNIDWVRLDYRFPVL
IEVLSKDTKEFRLGGDVHVWF
>fig|1163389.3.peg.102 Multidrug resistance transporter, Bcr/CflA family
MIYGPLAKRYGDVNTLRIGLLINIVGIIICLFGGYILSMPILLVGRFITAIGSSAGFYHI
K
>fig|1163389.3.peg.349 Multidrug resistance transporter, Bcr/CflA family
MSNDPFKKISSDKTVILIICLFGLMSQFATDSFTPSLPHIADYFHAAAKDIKLTVGIYFF
GMTCSMLGFGYLSDKYGRKQALLAGYLVFCIASIFCMLAQSEKLLLFFRFLQGIGMGSSF
VSFRAIMKDVFSDNQSLAKASLVITSIVSLTPPLSSSDYWRNYPRDYWLAW
>fig|1163389.3.peg.350 Multidrug resistance transporter, Bcr/CflA family
MFFNIQLLTFVLIRIYTEIGVASAIFGFIQIAITTISSSLVSSISLNNQFLFGLLMMVPP
LLIVILKIIDLKKLL
>fig|1163389.3.peg.572 Outer membrane component of tripartite multidrug resistance system
MQVNQAKLKSLISIVNLYQALGAGYNVDNYIDPHYDNPAFDK
>fig|1163389.3.peg.573 Outer membrane component of tripartite multidrug resistance system
MIKNKIISSVLITTTFLISSCSFFDPKYERPEVKAPALWNSQDKNVEITKNWNLTKIAWW
REFHDPILNNLITTALKDNNKLQVSIGNILQANAEINKANYGWLPTTSVGGGGFVAQAFD
INSNSSIPQLNNVGTQTADGSLVGIIPSYTINIARQFKLGEISRLSKKMQVNLKNTTRLS
IISQVSAAYFSLIAAQEQLKLQTQMVNQLELLFYYAKNQHKLGATSPMLEEVIRQQLEAQ
KGKVDMIKNNIVHFQNTLKILMGRNPGKIVTSRMLNDIDADVKVPVNMPSQVLENRPDVA
IAEYKLQTANANIGLARSQFFPSIDLTGTFGNATLALGELATMNAWAWAAEAVTAVPIFN
LSILADSDKAKAQFYQAYYDYISTLQKAFQDVDDTLSERSANRKKLYETNSFSEINRKTR
KYIL
>fig|1163389.3.peg.574 Membrane fusion component of tripartite multidrug resistance system
MTEEKILDTQIPEKKQEQNVKKESKFSPKKIAIGLGIITLTTLSIYGYYKYNKVFPNTDN
AYVNADVINISPKVGGYIEKVYVQNNQYVHEGDKLVQIDPKDYQLQVANANAKIIQAKGQ
LAVAQEQVSVAKSNLTKAQSSLDTATSMADRYIKLYKEDAGSLQDAQKYINQKIQAEKAK
DEAYSSLKQALVQVEIAKAQVGAAKVGYDNASLNLSYTTLIAPDDGYVSNLKIYKGQLVS
TGQPLFGFIDNKTWWIDANFKETDLDRIKPGQSVKIELDMYSHTYTGTVNSISYATGSVF
SLLPPENASGNWVKVTQRFPVKIVLKNDTKYPLRVGASTIVKVDTL
>fig|1163389.3.peg.575 Inner membrane component of tripartite multidrug resistance system
MQTDNTTKIGFWSQKRTIVALAISLLALAEIVDLTIVVVAIPQIMGAIGANVETIADVTT
VYIVTAAIFILLSGLIIEKYGIKRVALVSSVIFGISSIMCGLSTSLAEMIVFRAFQGMGG
AFLPSIAQTYISTNFRNEEYNKMMTVYSMVIVMGPIIGPVLGGAICENMSWEWIFYVNVP
LCIVAFVIIFFMMDATKIKKIKIDYISFGFMAIGVGCLELFIDNGNTNDWFSSIEMIILL
SISIVSLGFFIWRGLIYSSVVKFRIFKNFNFILACFLCFMFVLLFSAAMAYLPTMLQQVY
GYPVDLAGYITAPRGVAAIFGAVITQNFLVKKLGIRTTISLGMLTFGASCLMQASFSPTA
SEFGIVLTTAIQGPGIMMFFVPFMSVLVVGVADEDMGDMSGSFNFFRNFGSSVGTAFVAT
FISRNQQTTYQELSQNISYMNNSFQAWTNTLPIANNTEAIAIAKQQVLHQSSLLSYVNSF
YVVGILSLLLAIVPFLLKEPPKDAAVQAMH
>fig|1163389.3.peg.799 Multidrug resistance transporter, Bcr/CflA family
MYKGIRPSIFILILMVSLGPFGDTIYAPALPEIKTILGTDYPHVQLTITSYLLGYSVSQL
LYGPFSDRFGRKPVMLVGSGFFIISSIICLLSTNVDTLIYARLLQGFGAAAGGVIATVAV
KDAFKVSEQGAIFAIMNIAFALAPAFGAILGVFLSPNLIFWILLVAATFLFVQVTVFFPE
TVKEKNIDALTLRSFFKNYFALFKDHQFFFATFVLGINISVIYACLVTAPDIFINILKLE
KANFLYLLTIMVTAVVLGSIICSKLSRIIAYKHLVNFGMLCTLISGLLFIYAFHKLTGLT
LSIALTGVLSLTFIGVSFSVPLLTPIALENFTATAGAASSVMGFMQIGIASVTTAVISQI
DFGSEFTLAFAFVLLPLIGLIIFFPYSCYFLKK
>fig|1163389.3.peg.864 Permease of the drug/metabolite transporter (DMT) superfamily
MIPFIGSLFKVDRLTIYGIVASGVSLVEIYALSGASFDNFTIGYLWSVLCALMYAVSVVY
LSYETRKDHRSEAFEDLRLLIILQVAFGIPMPLITDVSSFMYLHFNYILIIAIVFCSIST
ITCYYLQNTYQKHLSMSQVLLSSLLSLFLQQFLGNLSIMKKYIYQLLLEAH
>fig|1163389.3.peg.865 Permease of the drug/metabolite transporter (DMT) superfamily
MSIQRKAVFVLFIVTILWGTTFPLIKISLEYVSPGLFVAFRLGLSCLLFLPLVLRAEFNN
KLYLLKVGAIFGSLEGMSFYF
>fig|1163389.3.peg.996 Zwittermicin A resistance protein ZmaR
MKLLEKFEYIKIYSEFDDFIIYFPIILSVVDNKQEGYVFQEGSTFIIVHKFGFCYILGEY
YDYAKLIDRISEKLKVLVPKLRLYDPNGKLKDSRYLLHDRCTRIKYIHSLNMHNDFESQI
EFFDIQDKDDSVYDFFDLELDSRYWSTCLEFRENSFAIVDEYNIGICYAAAISHGYAETD
VFVNKKVRGKGLATGLVKSFVNKCISNNVIPVWDCYSNNQASINLANKTGFKRVFEYYFY
NINI
>fig|1163389.3.peg.1081 Permease of the drug/metabolite transporter (DMT) superfamily
MFIASLSGSVVLFILAFIFNEQIVPTTSRGIAILLAIALFGYLLGNILYISRIKHISLAM
SSLVLLIGPVFALLYGYVLFRETFSIQQLVGMFIIILSVYLGKRY
>fig|1163389.3.peg.1082 Permease of the drug/metabolite transporter (DMT) superfamily
MYILYSFLAITKDEEKLSKKSLYIAALTGFFLALDLAFYSISLIYTSIAEASLLTNPCPF
ITTFIAIIFLKEKVSLKYYLVLLVAFIDLLLLMSQAGLSSQHLLGNWLAIISAICLCSFY
YLF
>fig|1163389.3.peg.1208 Multidrug resistance transporter, Bcr/CflA family
MYKIRKGSKYLVFFVVIFVALPPFAIDAYIPAFGNILVSLMLM
>fig|1163389.3.peg.1288 Multidrug resistance protein D
MRVISGIKRENLLAYFLTYVGYMTLTISMTLTPSLASNLSLSDYVTQIAMSLSFFYV
>fig|1163389.3.peg.1289 Multidrug resistance protein D
MFSISAILFATLTDVFTEKRVLFFSQSLSIFGLICLGLSDNIYAVYVGFVSLGLGMGCYS
SIARALISRNADNNS
>fig|1163389.3.peg.1290 Multidrug resistance protein D
MKKAYSVLSVMIIVAPIVSTYLALLLIPISWRAAYFCMATIEMVLFIFSIKILTADDQRK
IVISASKILSGFAHALSQPRYLLNVMIVAILFSFYLGVLMSSFKGLLVDELNMSIDVFTI
VFLVTSLLYILGIFSYRF
>fig|1163389.3.peg.1291 Multidrug resistance protein D
MATGAAMSNITKGHGTAAAMITFSVALCMSIWGFLKAHFKYVKLSFYTFGFED
>fig|1163389.3.peg.1375 Polymyxin resistance protein ArnC, glycosyl transferase (EC 2.4.-.-)
MESFLRDLANKLLQITPNYTIIVISDGSSDNSVEIIQSLVGQLNIKFISFSRNFGQGAAI
TVGLEASEDADAAIIMDCDFQHPIEVIDEFYEKWCEGFSNIYGVRNRTDQSATRSFLSEI
FFKVSNELMEVKIPANAGYFRLLDKQCIKAFNSLPENGRFIRGLFAWIGFKGYPVPFDVA
DRQDGTASRWGYRKLFKLAFTGIFSFPSVPLRLISIFGLLVSLVAMSYGLYIFIESLFFG
GNVSGWPTIVVSIMFFSGVQLISLGVLGEYISRIFEEAKKRPRYIIDEDESRNL
>fig|1163389.3.peg.1589 Permease of the drug/metabolite transporter (DMT) superfamily
MGIYLILGVREGNVNTCSLCAIFAGVLNAASQVVLYNASKKEDVFIINLWIYTYIGIFLL
LLLPFNISAISSLNEVSMKPVSIWVSVAIIIFGISSQIFRVKAFKYTKDPSLIAPAMYFS
VIVAALLEVVFYDSSIGYMEMIGILMVCVSSILSLIRK
>fig|1163389.3.peg.1715 Permease of the drug/metabolite transporter (DMT) superfamily
MNSSLLQGYVKIFLALVFWASLYHIAPLPLEYVDIYLVGLIRYAMASLIFLVVHYFFTKT
LFPRLNLRQWLYVIAVGFFGVFLYNIAFLWAEKLISGNIVVIIFSFSPCLITILSSYMFQ
MKVNQQAKIGILVALLGTIGVVMFSSNSFMECSTGINMNLGEILSILAVLCFSAYAIFGK
CCVRAGVNMITINTYGAIVGMIMFAVVSLFKSDFSELAHTDIKFWISMLYIAAFATVLAY
LWYLRALEEIGVYKTAVFQNTMPFLVILIGFVLYGETISILSLLLGGVVFLGVYMTNVAV
SKRA
>fig|1163389.3.peg.1725 Teicoplanin resistance associated membrane protein TcaB
MKNITRDSKLFPIVLALFAALTPLAVNTYAPAIPLIASDFGVSDSTVLTTFATYFIGFSF
GMLFWGAISDKYGRKKVIIIGSVIYIISTVLCSYSYNFKMLEIMRLIQGLSDSVGAVIAF
SIARDCYKGAKLTNLVTSIIIILLIAPIVAPIIGTILTNLTHTWQSTFHFLTIYGVVMLL
CAFLIEETLEHKDRKSSLIKLIPSYFQHLSNSRFMLATIASSTIFAALFIYISSSALIYL
GNYATGSLWYCIYYGLCCIAAIFANYLIKRHSSKVQQLKFLYYSVALITISCIVSIIFNS
LNLDNAFFYTLIMFVLCGNVAFSSTLIYSFAIDQIDHSFGTANSIVNFIKNMIAASGSYF
ISFYHGRDLVIASPIAQFIFTLATVILLFGIYKLNKKVINS
>fig|1163389.3.peg.1902 Permease of the drug/metabolite transporter (DMT) superfamily
MLMVYSNEAYAELSTANFTSIFVVIYIGVFPGALGYLFLGYAFRNIPTTVAISSLYFMPI
ISLFLGWIFLEETEAYISIVGGIISVVGAFIISKYGLNKKTN
>fig|1163389.3.peg.1903 Permease of the drug/metabolite transporter (DMT) superfamily
MLNGFSAGGLSLARYGIASIVMLIIFVRQKNKTKPNLKDLLRFAILGFFGFLHIMYC
>fig|1163389.3.peg.2170 MFS family major facilitator transporter, probable multidrug resistance protein
MWKYSPIKTILILGPMVFAFALAMDVYMPVLPDMREAFNTTQQMVQATLSLFLVVTGVGQ
LILGPLSDQFGRFKIILTSSIIFLIGSVLCAISQDIEFLIFSRVVQAVGCCGLSVCAFAI
IRDAFFGKTSSMIYSFINAIISVSPVVGPLIGVQLAIHFPWYSAFIFLTILAFVSFLIIV
FFVKESLPVERRKKITWSVFARYLHVLKSLQFWAYSLAAVSGVVSFFILFSMTPYIINYL
GYPISEIYIVFGSAGVAFLIGSIFAGVIVNALGVYNTAFLGVVCVFIAGVLSFSIYEVWG
LSLWGFFAPCFLATFGCALTAGTGASGSMEPFYEMAGVAAGLFGTMEFAISGIIGSIAML
FPATSSLPIAITMIIISIIAASLLIIVKITQTKE
>fig|1166018.3.peg.251 Outer membrane component of tripartite multidrug resistance system
MNRLILLFLLTGTAVLAQVSPPGGAVTLQPGAGTVQPSAPATAANVPVGNGASNASAAID
LPTSGVLRFSDPILADLVQLGLTNSPNLRAAVSRIEESRGRIRIAQSFLQPSIRSSALIT
TQSLSEHRPVAIPTATDRLPRFQLNTFQLLPVDASWELDVFRRIRGGVTVAQLQAQSFEA
DLNALRLTLAADIARTYYLIRGNEAEQAVFQRNIAARDSTVRIVRERFRVGLVNQIDVQR
AETDLAQLRVQIAGLQRARVELVNALAQLTAQDPATFNLATGTLPASVPTFPYANIPPDL
LRRRPDLLQAERAIQVADAQLLVQQASTQPRVTLVGSGGVLSGQIASWFVPTSATYLLGV
NASVPLYEGRRNRETVALSKQQTRTSQQVYEQTLQVAQREAETALDNLTYLREQLGLQNQ
TVALARTTEQYNRELYVKGFTTYLEVLDAQRTVLSAEQQAVQLRSQEVQYVVALLRALGG
DF
>fig|1166018.3.peg.2141 Outer membrane component of tripartite multidrug resistance system
MKKYLVGLSLWGLSVGGALAQPAPQVLPLDQAIQLALKNNKGLKLADSRTAAAQARAQEV
KDRNLPQATASLAYSRYSLTGPFAFGEGSDGKPLFGIPAGSFPATIGGVTVSKEVFGGFA
EKSAKLSADLLAQASKLDAQRNREELVYTVTEAYYNIVKLIRSTAVIEQNIRQFDERERE
AKNLQKEGVVTANEVLKIQLQRNNLQLSRQQVEKSRQTALYNFGLLIGQPEDQPISVDTT
LRNPATTLAPMSDFLTKAVQVRPEVQANNLRVQAADAQLRTVKSAMYPHLGVSAGYNYIN
PSARVIPEGNSFISAWNVGAGISYNIGSLYNMKGRLNTAKTAIDQATIAGQQQTDQIRSE
VVTAYNNYQLALEQQTVIRTAVDQAQENYRLAESRFRNGLVGSTDLLEADSFLIQAQLNV
INATVDAQLAYQRLLKASGINLN
>fig|1166018.3.peg.2142 Membrane fusion component of tripartite multidrug resistance system
MNTKLLLRVGGVIILVAALFFGYSEFRYLQRYETTDDAQIDGDVDPVTPKVGGYVKAIRF
KDNQFVHEGDTLFVIDDADYRIRVAQAEAALQSAQAGVGVSRSQVNVAAATIQSSQATVQ
TARNQVATAQANLAAAQARARKASQDFDRYSRLLAEKTVPQQQFDAVQAERDAAQAQVQA
AQAQLQTAQAQVAAAGTQTGVTSSQRRATESQISVVQATIKQRQTELDLANLQLSYTIVR
APASGVISKRSVQVGQLIQAGQALCSVVGNDNLWVTANFKETQVGQMQPGQQVNIEVDAF
DGEKFTGRIGSFAGATGAKFSLLPPDNATGNYVKVVQRIPVRIELDKNSPLFARLRPGMS
ATVAVDIQK
>fig|1166018.3.peg.2143 Inner membrane component of tripartite multidrug resistance system
MKLGFDKWVVVLTVTTAALLQTIDSSIVNVTLNQMMGNLGASLGDISWVVTGYAAASAVM
ITMSGWLSAKLGRRNYFAASIVVFTIASVFCGLSTNVWELVFFRVLQGIGGGGLLTTAQS
ILIQTFPKEDIGIANAIFGMGVIIGPSIGPTLGGYITDNLSWNWVFYINIPFGILATVMT
YAYIKEPAEKVAAGSMDWLALIMLTVGIGGLQIILEKGQENDWFDSRFITLMTTAAVLCI
VGFIWRQLTVDIPILDLRLLRRRRYAVGTLFNFILGFGLFASVFIIPVFCQTILGFTASQ
TGLLLMPGSIATGLMMPVVGGLLRKNFTSPIVYAGIGFLMFFGFCFDLSFISLEAGPDYF
FWPLIVRGIGMGLIFIPLTTVTLADLKPVEIPQGSALSNTIRQLGGTFGTAIMTTYISTR
TVFHSSRLGDNISVYNPLSADRLRQYTQLFLSKGDALVTATSKAYRLLQGSVVKQALVMT
YADAFLIIGGFFLVCVPLLLLFIGKKIEAPAHVEMAME
>fig|1166018.3.peg.2209 Permease of the drug/metabolite transporter (DMT) superfamily
MGHYTLFIVHYSLTPMQTPITASAPPRTRYWVGALCVFLAAFCFALKGVLIKVGYGYGVD
SIDLLTLRMLFSMPFYGGTLLWLSQRLPPLQLPAKQWGIVALLGITGYYLASYTNFLGLL
YIDASLERILLFCYPTFVLLMNATVLKRRVAGLQWLALALTYTGILIAFLPHLTSGENTH
MIWLGAFWVVLSGLIYAIYLVGSDTMIARLGAQRYTCYALLAAVVPTVVHNAIENGLHLA
QFPLRVYGLGLLMALVNTVIPTFLMAEGIKRVGSSNASIIGSIGPIFTIVLATSILGEHI
SGWQFVGTALVLAGVFLIGWKGKK
>fig|1166018.3.peg.2272 Acriflavin resistance protein D
MFAEIFINRPVTAIVASIIIVALGVLALLSLPVGQYPDITPPVVQVTSNYTGADAQTVEQ
TVATPIETQVNGTPGMSYVQTNATNDGRMTMNVTFDVGTDVNIAALDVQNRVGIATPQLP
EEVTRLGVTVRKRNPSLFMLVAIFSPKGTHNVSFLDNYTNVYIRDALLRVKGVGDIFSRA
DDFSMRIWLKPDRLAQLGMTADDVTAALQEQNLQVAGGSVGGPPQPSSQAFEYTVFTNSR
ISKETEFENIVVRSDPARGSLVYLKDVARVQLGKFSYASNSFVDGKRAAYLLVYQLPGSN
ALSTAQGVYAAMDQLKKTFPKDIDYVVPFESVSVIQVSISEVVQTLLEALVLVILVVFLF
LQSWRATLITLLAIPVSIIGTFALFVPLGFTINTLTLFAFVLAIGIVVDDAIVVVEAVQA
NIDEKGLSPRDATREAMREISAPVIAIALILAAVFVPVGFIPGIVGRLYQQFAITIAVSV
LISAFVALSLTPALCTLLLREQHIDENAKGLNKFFYKFNQWFGRVTNSYSNGVQRLIKAT
PLVLVGLAVVYVGTVLMFRAKPTGFIPTEDEGRLIVTYEIPEAASTARSLAVLNRVMDTL
RRQSYVNHFAALGGLNAITFASKSNSGTVFMSLKPWEERKERGLQADSLVVKLQRALSSI
NDARVQVVQPPAIPGLGQSSGFTFEIQQRETNDDVRAFDGVVQNFLAEANKRPEIGRAFT
YFTAKSPAYRVDVDRDKCKKLGLSVSNVYRTIQTYLGSQYINDFIIYGRKFRVVAQADTM
YRSDLKALNQFYVRNSNNQLIPISNVITTSVIENAPLISHFNLFRSVELNGAAKPGFSSS
QANDALREVADKVLPAGYSYDFSGLSREEINAGSSSVYIFLLSVGFVFLFLAALYESWSV
PFSVLLSVPLGALGAIIALLLFPYLSNNVYAQIGLITLIGLAAKNAILIVEFAKERVDKG
EDLLESTIEAVRLRLRPILMTSLAFILGVIPLALATGAGGVARATIGRTVLGGMLAATSL
AIFVVPVLYVGITRLAYGKKGLEALKKNAQKDKPDDASQAPEAGQPQQA
>fig|1166018.3.peg.2326 Permease of the drug/metabolite transporter (DMT) superfamily
MQLEATSRVRLLLAFGAIYFVWGTTYLANLYALQGIPPFIISALRYLLAGLLLGALALGK
GQVMPSGTTIRDLAISGILMLVGGSGLVVVAEQYIASGATAVIVATEPLWFVLLDRPRWR
HYFSNKKIVAGLLIGFAGVLLFAQFGPESQATQQNATYQLIGTAIVLAGALLWVVGTLFA
ARRIQPDSYNLWHTTIQLLAASLFAALIALANGEWSTFSMQSVPLPAWGGLAFLIVFGSL
IAYLAFAWLITVQPPALVSTHTFVNPLVAVLVGWLVAGEGVTAGQGIALAVVLVGVVLAQ
LGKVRSEA
>fig|1166018.3.peg.2618 Tetracycline resistance protein
MFNDRRLLHIYAIIFLDVVVGSIIGPVLPEFVRGHTQPQLWLALGTSLFLGVQLVSAPLL
GKLSDAYGRKPIFRLSALGTFLADCLLLPVRMGTYLANRLSDGLTNGLYATVRSAITDIS
PKEALFRNLGIEGAIISLGFVIGPAIAGLLITTLNLTEPVEQARYVVMMAVGLSGLNVLL
SFLLRETHPNDGAANTRGVLWTDLKVALAQSLNVGSLLARLRQKEREHPGLLNLVLMQVA
LTMAVGYYNYFVAYVSLGTLQMNATDISYFFMYFGGLSVAISYGFYGFIADRINQQRWIF
WLAAVGAPVLASYGLVGTSRVWLYVIVTIDCFTYSLIQGLIEGLMAQKTTDTDRGEIFGL
NQAMQGLASFGTTLVFGALSIIDLRLPFAWFAACLVVVAWLARK
>fig|1166018.3.peg.2733 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MQTESPLLRPPSLRTDLIDTLRLSIPIIIAQLSNMLMSVTDNLFIGRLLGPVPLGAAGLS
ASLSLLLSSIGIGALSVVSALVSQAHGRADAADINRQYRAGLRVALLLGIVFGGVVAIAA
LGIEWFGQTTAVNALARPFMLIMSASNLPLFVFIAARQLSDGLSYPRIAMVITVAALVVN
ALFNYLLILGIGPFPTMGVQGSAMATLLSRVFMAVAMLLYIHRSRQFRPYFELAFNQQPI
LASMRQIIRLGLPSGLTFFFKIALFSVAIILVGWLGTNQLAAHQIAINLVSSTYMMSMGI
SSAVAIRVGNAYGRGDRDGIRQAGLAAFILTGLLMGTTALIFMLFNETLVSIYLTDAPDV
TRMAAMLVFMAGFFQLADGFQVVGVGMLRGLSDVNVPTVITLFSYWLVALPTSYVLGFTL
GYDVLGVWVGLLVGLSVAAMLLTSRFFRLAD
>fig|1166018.3.peg.2768 Membrane fusion component of tripartite multidrug resistance system
METESSTLKTYLPRLLGVIVLLAGAYWGFTAYRHGQQYESTDNAQIEGSTAPVLARVAGY
VQDVNVDDYATVKRGQPLLTIDPQEYEVALQQAEADYESTLADIRTAQADIRNAQADLAT
AQANSRNTQQSLRVTQSNAEVQAARRSKAQTDLQRDQNLFNDQSLTRKQLDDSKNNLDVQ
ERTYRASEEQIALARSQQGVAQAGILKAQAGIQRTQANIQKMQAMLKVKAAAVQNAKLRL
GYAKLTAPIDGKIGKKTAVVGQYVQPGQTLMTIVNNSTFWVVANFKETQLENMRVGQDVE
IKLDAYPDLDVKGRVASLSESTGAKTALLPPDNASGNFVKITQRVPVKIEILNPDQLKDK
LRAGLSVDAAVRVAN
>fig|1166018.3.peg.2769 Inner membrane component of tripartite multidrug resistance system
MAETALASPPVEAQPALPTGFKKWIIVITAITAAIVELIDISIVNVGLNDIAGNLGVTIE
DVSWVVTAYAIANVIVIPMTGFLQRYFGRKNYYIGSIVLFALASYGCGLATNLPMLVLFR
FLQGVGGGALLSTSQGLIYDAFPLSQRPTAAAIFGAGIVLGPTLGPTLGGYIIDNYHWSW
MFYINVPIGLLATYLSYTFIDKKADELNIDRGSIRIDTLGIALLAIGVGSLQYVLERGEA
DDWFDSLAIRYLTAATIITVPLFIWWELRGTNEPVVDLRVLKNRNLTLGAILITIVGYGL
FTSVLLFPLFAQRIVGLTATQTGLLLIPGGFVTLPMFAISGRLLAKGVSPRNIAIAGYIA
FGTFCFIMSTYNMDATNSYFIWALIIRGIGLALVNVPLINQSVSTLEPRQLPTGIAIVNM
MRQLGGAFGVAITNTYVTQRSAVHRGDLVSHLQPGDPLLTDRLNAISQGLMSRGINAFEA
MSGAYRNLDLIIQKQALMLSYLDTFRLAGLFFVVSFPLLFLLKSKKMSAEAAKAAADAAH
>fig|1166018.3.peg.2770 Outer membrane component of tripartite multidrug resistance system
MRFPLLSILVLLPGLALAQQSTALPDDLRALVQQASANFPLLKQQEQQIQATALQADLAR
TALRPQIGLNGSYQYIDPVPKATLPVNGRDVTLQFQPNHNVNANVAISQSLYDFGRTNAA
VQRAGDNLRIQQRQQELTRHNLTYQVAAAYYGIGFLQRSIVVQDSVIRTAGDNVNVLSAR
LRNGDALQYDVITQQVRLKTAQNRKIDLQNQLDRQRALLTYLTGNADPAVSAASQQFGEP
IQPFALDGQLQTALASNKDVLAAQDRVKLAETEIRIDELSGRPNLVLQGATGFRNGYVPD
VNTPKFNVAAGVAFSMPIYAGRRYRLQNQVAKLNLNANRYAVENANAQLRQQLTQLNADI
AANQTRLQNLNTQVLQARKALELAQTRLRNGVITTVELESAETGIEEAQLAQLAFQYQLL
LNQLELKRLLGESL
>fig|1166018.3.peg.3528 Permease of the drug/metabolite transporter (DMT) superfamily
MSATTTTHEPVINTEKRPLLAWVLLTAIALIWGSSFILMKKALAVFSAQQIASGRIFFAF
LFFLPLILNQSRRPDVREALRQRWVALLVSGVVGYLLPAFLFAEAGAHIPSALSGTLNSL
SPLFVLLLGTLVFGQTFRANQVWGIMLGFTGSMILVFFGESGSFSINGYALLVMLATVMY
GVNTNLIAKYLAHLPALVAIPWTFAFIGPVAGISLFSTDFLSRAQQANTFIPLGAILFLG
GMASGVSSVLFNRVIQLASGVFAASVTYLIPVVAIVWGLFDGEAVSLQQYVGLTISLLGI
YLVNKRS
>fig|1166018.3.peg.4227 Permease of the drug/metabolite transporter (DMT) superfamily
MSQPSRTAQFIPGFLFAMLWASASVATKFGVQSVAPLVLATVRFLIAGSGMLLFAYGIQR
GNPLPKGIEWRRLTIFSFLNTALYLGLFVLALKQVSAGIGSLSTATNPLFITLLSAIWLR
RPLRWQEGAGLLLGLLGVVVATIPLLEQAYATVDGLLILLGSMISVSAATVYYARYEWAL
PTLVINGWQVLLAGFMLLPITLLTTDLSTSQFDVRFWASVGWLIGPVSVVALQLWFGLVR
VDAVRASLWLFLCPVFGFIYSALFTGEPITLYTLAGTLLVIAGLWMGRK
>fig|1166018.3.peg.5090 Permease of the drug/metabolite transporter (DMT) superfamily
MTIDSPRSDVRQPDRVQLWSALGAVYLLWGSTYLFIHFMTEQMPPLYMASVRYLVSGSLL
YGYARLTGSKRPTRQHWQSTALIGFFLLTIANGALTIAVQYIPTGMAALLGGLLPIFLLI
LNWLWFGRVRPTTLSLLGVGVGVVGIYLLIKPDRLVSTGGVHANLIGTSLVAAGNLSWAV
GTLLTPRLPQPGQTLASGMQMLLGGFFLLIISLLTEPVGVFSILIAPTKALWSVLYLVIF
GSIIGFSSYAWLARNATPSLLSTYAFVNPVVAVLLGVLFAGEVFSGRSLLGAGVALIGVV
LLTLGRK
>fig|1166018.3.peg.5192 Permeases of the drug/metabolite transporter (DMT) superfamily
MLLFVGTITSLALLVRILANPLANVFQKKLTHQSADPLFVTAVTYTGLFIACLFVYRWET
ARHLRLDFWANALLMGVLAVLGNTLLVKALQTGDLSVLGPINAYKAVVSLVVGVVLLGEV
PSVAGLLGVGLIVAGSYVVLQPKRGAGGGGWRLMGQPEIRWRVLALICSAVEAVYIKRAV
LLADATTVFVVWCALGCVLSWGWYGSLHRSTLVGQWQLVAKHRLSYLALIALVGLMQLST
TVVFSGMQVGYALALFQTSAVVSVLFGYQFFGERQLLPKLLGATIMAIGAALIVLVR
>fig|1166018.3.peg.5470 Multiple antibiotic resistance protein MarC
MPLNFKEIISVTLILFSVIDVLGSLPVIIDLRQKVGTIESEKATLASGVLMLTFLFVGER
ILKLFGVDVQSFAVAGAIIIFLIGLEMILGRTIFKSEIEADSAAHIVPIAFPLIAGAGTL
TTLISLRAEYQIGNIVVGVILNLILIYIVLKSAAWLEDRIGPGGLNVLRKVFGIILLAIS
IKLLKSNLLPANF
>fig|1169145.3.peg.480 Permease of the drug/metabolite transporter (DMT) superfamily
MEDNRFAATWRWMLVTAIAPVAWGSTYVVTRAVLPDEALWGAVIRALPAGVILLAISRRR
PHGAWWWRSAVLGVLNTGGFFALVYAVAQRLPSGVASTVMAASPLVMMAAGRVILGQRPR
ALALAGGAAGIVGVALMLFGGADAVDGLGVVLAVTALVGSAIGYALATRWGSTDLVASTA
WQLLAGGLLVLPVAVIVEGAPPALDDAAIAGFAYVTVVATALAFVAWFAGLRHLPAGTVG
LIGLLNPVTGVVLGAVVAGEALSGRQLLGLAIVLSGIALGRLPKAGQLPRDSRKLRVGAK
NVEPVAAVEKSRMRS
>fig|1169145.3.peg.1366 Drug resistance transporter, EmrB/QacA subfamily
MRRTTRDWLALSSLCLGFFMLLLDSTITSVALPALIAGLGTTSTLAIWINSGYLVAYAVP
LLIAGRLGDRFGRRRVYLIGLAAFTIGSVLCAVSQDIGSLIGWRVAQGVGAALMTPQCLT
IIRTLFAPPRLAIALGIWGAVGGAATVAGPILGGLLVGAAGWPSIFAVNLPIGVITAVAV
LLWVPASERLPARIPLWAMAGNALGVAALVMGIQGTDAASSSVANIPRWLLVVMGAALVT
SVVWLQRRSLDRALLPVSLFRSHGFVTASWGAAAAAFCVGSAPIPLMLALQEDRGLDVVT
ASIVLVPMGVVCLLAAPVSARLNNTVGLRVVAVIGGVALVLSIGGTAALVWAEAPIWAIA
GVFALFGIANSFLWSPFSIATVTSVERSSIGAASGAFNSVKQLGAVLGSAATAVVLAWTG
NAVALAVLALVGVLSIVAASLLRVTPTDAGDASDQDRGGILIGTVVGGAGAGLGLGFPTA
NLDLEERAGLPADGVYIGGFRAETWSEPLPALISIGTNDTFPGRAHTIEVHVLDFAGDLY
GRRAEVTTDRLIRTQRAFASPEELVEAMRQDEREARSLLIARQSHERKVS
>fig|1169145.3.peg.1400 Permease of the drug/metabolite transporter (DMT) superfamily
MKANRGVLAGLAVVVLWASAFPAIQVAAPAFGVIGLSFVRLAVAMIALLAFAAVKRVSLP
RPRDFGWIVAAGFFGMTAYQLLLNESELHVPAGTASIIVAAAPLVSVAVAFLLFREPVTR
FTVVGSLIALAGVAVVCLARAGVSLSASVWIVVAAMVVQGIYHPLQRPLLKTYTGLEVAT
YTMVAGTAMTLPLVPFGWGRLVEASPTGWIAAVYLGLLPSALGFVLWGYAVGHLPVAIAT
SLLYLVPPIAVFIAWVWLGEIPLPTELIGGLIVIAGVVVISQGARLVRRAHRRQPATVSI
ER
>fig|1169145.3.peg.1662 ABC-type drug export system, membrane protein
MTTTALPASRPQRRNGPTFLTHTLLLTGRQLRAAWRMPAFLVMNLVQPVIWLLLFGQLFK
SVIDIPGFGVGQSYLEYLTPGVVMMLALFGSAWSGTVYIQDMDRGVMDRFLTSPTNRGAM
IVSTLVYQSLLAVVQSLVVVGIAFWAGARFEGGVVGILLLLLGVVLLTAVFCSLSNAVAL
LAREQTALIGISQLITLPLMFLSSAIMNTKLSPEWVQNVSAYNPFEWAVIVGRQALSAHP
DWATLWAHAGLLAALAVVMAAWATSAFRVYQRSA
>fig|1169145.3.peg.1767 Glyoxalase/bleomycin resistance protein/dioxygenase
MAIESVLLNVTDIPRSVEFYRRHLGAEVIGAGDDSAVLDLVTAQLVLYRIDTPAESTWVG
DDLQRGFRHVGFKVSDLDARVDALHDAGVPFHLEPIHAEGDVRITFFYDPDGTLLELVEG
PLQYHEVYDRSAVERDWGLGDPDRPRFDHVAETVADLEATKEHYGELGYSLMSGIHQPSD
DRGFEINFLRHGDSSLEIFTYDKAEKAERSPQLDAPGFVAVAFEGRTAPGTVVGTTGDRE
VYSGPDGLLYTVANA
>fig|1169145.3.peg.2606 Multidrug resistance protein B
MERQLKPWPALWALVIGFFMILIDTTIVSVANPSIMEGLNLGTDYNAVIWVTSAYLLAYA
VPLLITGRLGDRFGPKNLYLIGLVVFTLASAWCGFAGSIGFLIAARVVQGLGAALMTPQT
MAVITRIFPPERRGAAMGLWGAVAGVATLIGPLLGGVLVDSLGWEWIFFINVPVGIVAFI
LAMRLVPKLPTHSHSFDVLGVILSGVGMFLLVFGIQEGSTYDWGVIWGPISVWGLIIAGI
VVLAAFVVWQAFNKKEPLLPLPLFRDRNFSLSNGAITTVGFAVTCMALPLVFYFQTVRGL
TPTESALMLAPTAIFSGVLAPFVGRLIDKVNPRNIATPALVLFAFALFLYSRMLSPDVNI
FLLLIPSALMGIAMSGVWGPISTTATRNLPMNQAGAGSGVFNTTRQIGAVLGSASIAALI
EGRLAVDLPKIPGGANASEAAAGTELPQALHAGFTQAMSEALLLPAAVAFLGALVVVWWE
RPKPPAWARQAGGAGAGAGAGAAAAGAPAAEGAPVAAGATAESADAATHGAHAAPVPVDA
TPHGAHAAPVPPATDLAPGDEPPHGLHAAPVTD
>fig|1169145.3.peg.2727 Glyoxalase/bleomycin resistance protein/dioxygenase
MISSAVTLSYRDAPAAIAWLEALGFDVLQLQSGQDGSVLHSELRWADTVVMLASNDAAYD
VPPLVGASTGVGLYLVTQDVDGMFARAVDAGATVVFPPEETEWGSRRARVLDPGGREWSF
GSYRPGEQWSASA
>fig|1171373.8.peg.200 Multidrug resistance transporter, MFS superfamily
MTSPQQPQEQPAGAPALSTTLLAALALLSAAGPLGTDMYLPTLVRMAGELGTTSSMTQFT
LSAFMIGMAVGQLLIGPLSDSYGRRRLLIGGSVVFFLTSAAAAFANSIGLVIGLRFLMGA
AGGTGSVLSRAIIPDLAHGRAAARGFSVMMAIQGFAPVLAPILGGLLAEPIGWRGIFAVL
AGFNLLMVAAAVFMVPESLPAARRAPGGLRRLFPSIAMISRRRVFVGHALSMAVMFGVMF
SYISASPFVLQRQLGLRSTMYSLAFAANAVMVTLASILNTRFIKHFSLRGIVRTGLTLGF
VGSVGLVLNGLFGPWLWVTLPLLSVTVFGMGLVMGNATALGAAQVRDAAGAGSAMMGALQ
FLVAGIVSPLVGLGSNPALTMAVVMLVCAVLANAAHYLVARPTSE
>fig|1171373.8.peg.459 Permease of the drug/metabolite transporter (DMT) superfamily
MTPAAAHRLGVILIAVTAVLWGTSGTAATFAPQVGPLAIGAAALGIGGLLQGLISIGAQR
RAAPRLRAHAGVVAIGALTVAIYPLAFYSSMRYAGVAVGTVISLASAPLASGLLDRFIDH
RRLGPWWTAAAGMGVVGSVLLCLSRGGDDAAGPGRAVLGVLLGLVAGATYAAYSWAAHRL
IDAGIDRAASMGSVFGIGGLLLMPMLALTGAPILAGPGNLAVAAYMALVPMFLGYVLFGM
GLVRVPASTATTVTLLEPAVSALLAVTVVGERLGARGWTGMAIIAAVLIVLAAEPGSDKA
GPVPGGAAQEVAVP
>fig|1171373.8.peg.672 Multidrug resistance protein B
MSDSWTSPAPRDPRLASVDPRLNRPWPALWSILVGFFMMMIDASIVTVALPRMQRELHAD
LTLLAWVTSAYLLPYAALMLITGRLGDRLGLKRVYMTGLAVFTLASLLCGLSTTAGMLIA
ARALQGVGAAIVSPQTMSMVTRIFPPDGRGRAMAIWGATGGVANIIGPLLGGVLVDGPGW
QWIFYVNLPVGLLGMVAAARFVPALPGTSGRLDWPGVLLSAAGLGLVVFGVQEGQRYSWG
AIAGLITVPRLIVVGLALLVVFVAWQHHMGHEALVPLRLFADRNFSAAVVGIAAMGAIVF
AQNYPLTMFLQNVRDLSPTEAALATLPSAVMSILLANPVGRWLDGHDPKPLAVTGFGCMA
VGLSWLALAMSPSTPILTVLAAMTVIGVGNAFIWSPLSVTATANLSPKLAGAGAGLYSEM
QQVAAVLGSAGIATLMTWRTQTRPDLARAMGDSMWLSVVLAGAGLVACLCFARPRRAADW
QRG
>fig|1171373.8.peg.1245 Permease of the drug/metabolite transporter (DMT) superfamily
MVGFRSSRLAPAALMVMALLWGSTLVVMKGAYAHLSPTDLLANRFLVGALALGLLVPRAW
RANARTIGKGLLLGLLFGAGQVLQAVGLSSTPASVNGFIGGLYVVVTPLLGAIFFGKRVP
RQIWIAVALATVGLGSLALDPADLGAGIGVGELLTFAASVCFAAQIVALGRFATARNVAS
LALYQTIGAALVCAICAAPGGIRIASSGSEWFAVLYLGVVCSAAIAVLQSWAQARVEATR
ASVIMCTEPLWGAVFAIGLAGDPVTLRIILGGVSILAAMVMVVRPPRRRRGLTQDEAGPR
QIEQAGIGDLVGDSK
>fig|1171373.8.peg.2328 ABC-type drug export system, membrane protein
MSEQVVAPPAVLAEGRNIVVVTASRIGAFCLVELQKLKHDRTELFTRAIQPVLWLTIFGT
TFSRIRAIPTGRISYLAYMAPGVIAQSALFVAIIMRVPMTWNPLRWLAVFGVVMLGSAFF
CCLSLTIAGIVLHRDRLMGIGQAITMPLFFASNALYPTAIMPGWVKVLANVNPLSYEVQM
MRGLLLGEPADYLQDLGVLVLAAIAMIVVASSLLGRLSR
>fig|1171373.8.peg.3007 Permease of the drug/metabolite transporter (DMT) superfamily
MRAGSIVVWKRGLMASTPQAVQSRRATAIGVAAILLWSGIVGLIRVTTQHFGATLGPSLI
YTLAAALLWLTRRPKSLRGFSARYLLLGGGMFVIYEVALAMAVGLSDDAHQTIEVSIVNY
LWPTLTVALAAVVNRRERRPGLLIIPGVLLATVGVVGAVGGEAGLSPTRIAANVMSNPLP
YLLSLMAAAVWAAYSVFSPRLAGGRDGITVFISGVAAALWIVNLVSPAPVGDITASGVAG
LIGAAAVIASGYASWNVGILHGNITLLASASYATPVLSTAVSSLLLGAVLPLTFWGNVLL
VVAGSLAGWWATRRTGRR
>fig|1171377.3.peg.25 Permease of the drug/metabolite transporter (DMT) superfamily
MMQKYRGEWLLLLATLTAAFGWLFSKNAIVELPAVAFIALRFSFATLLFLPFALPQLKSL
NRQQWRYAVFVGLSFCLYLFFWVMGVKYTTELGKGAFLLSLAMLAAPLIAWGLYRQRPIR
RFWFALPSAIIGMYLLANNGTEQSGFQLDTLFFLFTAFWAAVQFVLNSRYAQHLPVLALT
TIQLSMVAISASIYSALFETFPTQISSPTWLWLTLSVLIGTNARFLLQTWGQKLSDLGNG
ALIMILEPVWTLLLSTLFMAENLSTTKIMGSTFVLSALLIYRLNVMRQK
>fig|1171377.3.peg.101 Bicyclomycin resistance protein
MTTTRPAWAYTLPAALLLMAPFDILASLAMDIYLPVVPAMPGILNTTPAMIQLTLSLYMV
MLGVGQVIFGPLSDRIGRRPILLAGATAFVIASLGAAWSSTAPAFVAFRLLQAVGASAML
VATFATVRDVYANRPEGVVIYGLFSSVLAFVPALGPIAGALIGEFLGWQAIFITLAILAM
LALLNAGFRWHETRPLDQVKTRRSVLPIFASPAFWVYTVGFSAGMGTYFVFFSTAPRVLI
GQAEYSEIGFSFAFATVALVMIVTTRFAKSFVARWGIAGCVARGMALLVCGAVLLGIGEL
YGSPSFLTFILPMWVVAVGIVFTVSVTANGALAEFDDIAGSAVAFYFCVQSLIVSIVGTL
AVALLNSDTAWPVICYATAMAVLVSLGLVLLRLRGAATEKSPVV
>fig|1171377.3.peg.126 Bicyclomycin resistance protein
MTKANSKFFLVLLLGVLSAFGPFVVDLYLPALPQLAEFFHTSTSMTQLTLTTAMIGLAVG
QLLLGPISDKFGRKKPLILSLLIYIISTIAIMFSPNIETMIILRVIQGLSSAGSVVISRA
VATDLYRGREMTRFFGLLMTINGLAPIISPILGSLLLEYINWQGIFAFLAFIGVAVTLFS
LRLKESLALENRLQGSVISVFGSFRKIIKNRVFMQFVGIETFLFGAMFAYIAASPFILQS
VYSLSAFAFSLCFGANGTALVLGSNFGSRLANRSALKWGVLGFCFAVVYTAAMLLIQPHW
LLVELGFFFTMLMMGLPLPAISSLAMESEREYAGAASALLGFAPFFLGGIVSPLVGIGDI
FYACAIVMLLCAIIGFRLYWSVKDQIKNET
>fig|1171377.3.peg.403 Permease of the drug/metabolite transporter (DMT) superfamily
MNKYSLALLKVHGTAIFFGLSGVFGVLIESSSEALTLGRAIIAFAFIALYFLFKKRPLTK
LTYQEKLMQFVMGGLLALHWISFYLGVKIGGVAVGTLGFASFPAFTALFEMLFFREKPRV
RDFVLLIAISFGLILITPAFEFGNQVTQGLLWGIFSAFSYGVLAVMNRHSATKLSGVESS
LWQYLAIMLILLPFYSGELFFASLSDWFWIGCIGVFCTTFAYTLYVSSLDTINARTAAMI
ISLEPVYAILVAWLWFDDVPSLKMVLGGALIIGAVAWANLKK
>fig|1171377.3.peg.726 Permeases of the drug/metabolite transporter (DMT) superfamily
MSHDHDTPSKWEISSHAALPVVLMLFIQMLAHYIGSPANSIFLSPYLIAFFVAALLALVV
LWKGQICPGQKGRLAFVLPFLAAFALGNFLYTAFFTPKHILLSLANLAALFIPLLYWRFP
DDEPMQKIFSYLGFALGAIGILAYSICYWVELPSLLNWVRGNYFAQIQLGLLLLGWYMML
AKSRLDGFFKLLVQLSLIVLIFNYIWVIFVLYQELNIMPELATLPYFAFFALQFVVLAML
AWLLIGKQGKNIKNPVAWTAATFLSMLYPLTNIF
>fig|1171377.3.peg.827 Permease of the drug/metabolite transporter (DMT) superfamily
MLSRRYLILINLFYVLGIGLNIVLLRFLSQHIEPLNNNGIRFLAGGIVLSLFAIWQYPTQ
LRLLLTQPKNILMSILVGLMLAANMYFWLKGTQLTNAVTASLFGVLAMPFGVLIAALFYP
DERQKTRYKGFWLGSALTILGALGFIWYGNSLTIGEGFMLGALFLFLSICIRNTQNLIVK
SARSVSMFAFSCFTSLSASFSSLFLSMQNSTLSELHSLPVWLIVLLIAAGIYAVFAAMAL
AFNIIQQQGLITYQVLELLIPITTAIAAYFILGEAIHFIQLVFAIIVIIGASCALGIIKV
SRHKVAASAKSA
>fig|1171377.3.peg.894 Bicyclomycin resistance protein
MNVAKREHLCFVIIMGMLAMLPPLAIDMYLPSFIDIAQDLKVSQESVQATLAVFTIGFAG
GQLFWGPVADSFGRKPIILLGLVGSAIAALFLTHVENIQNFYLWRLIQGLCGAAPAVVLG
ALVRDLFERNRFAQMMSVIMIISMIAPLLAPILGGYLAKWFHWHSIFYALMLMGGLCALL
IGFKIPETLVKEKRQPLNFSNIIKNFVALISHKPTLGYVLVGGLSFAGMFCFLTSGSLVY
IGIYGVSPEHFGYFFIMNIAVMMVMTVINGKLVVKVGSEKMLRVGLVIQFTAGLWLAISA
TFQFGFWSMAFGVPFFVGVLSTIGSNATAAILDRYPQMAGTANAVAGTARFGLGSIIGGL
LSMVTLTSERPMLYAMALCTFSCFAAYYFLCCRNKAQ
>fig|1171377.3.peg.896 Multiple antibiotic transporter
MDILNFAIYLQFFIGLFAIVNPFGTLPIFFSMTAHQYETERNRTNLITSISIAVILLVSL
YFGKIILDAFSISLDSFRVAGGILIVSIAMTMISGKLGEHKQNKEEQKADLTEYENIAVV
PLAMPIMAGPGAIGSTIVWGTLYHNWVDFVGFSVAIVLFALICYVLFRFSAPLVKKLGRT
GSNVVTRIMGLILMSLGIEIIVAGLSNLFPGLTAVS
>fig|1171377.3.peg.1322 Permeases of the drug/metabolite transporter (DMT) superfamily
MLELILAILCSVTVGVLIKVARQKGVAIDQSIAVNYLVAISLTFALLKPDFNGQSIMEIV
QTNPSSYIFFALGFLLPSVFLIQAKALEYAGIIRTDAAQRLSLFLPILAAFTLFGEAVTS
NKLVALVLAFIALGCLLWRSQQGMEKGGMIAVISLALVWVGYGVNDILFKQMAKTGSAFP
LTLVISFIFAACLMFIYLLLKRTQWHIPSVAVGLLLGTLNFGNILFYIKAHQAMKDDPTL
VFTGMNLGVICLGTLIGALIFKEKINKINYTGVVVAIVAIVCLFYWR
>fig|1171377.3.peg.1645 Outer membrane component of tripartite multidrug resistance system
MTSFAIFSVILTACSQMQINTESGISLPERFDQAEAAKGSAQIRQWWRNWHDPQLTTLIE
KGLNENLDIRLARARLSEAQANSDYAEAERGINIGASGSAVGGVSDVNTGVSNPGRSRSG
GAYGGISASWEPDFFGQKRSDADAAQAVALSAQEQVYAAQLLVSSEIADNYFRIHALEQQ
NAVLEKNIKTMRELQRYVQGRFNAGQATAYEVNEIAAQITALQARQATLKAQADVFQRNI
AILTGTVPQGFSIVKSGNPLAKIPAAPSGQLPAAVIERRPDIRANALQIQAAAAKSASAR
ADLYPRFNLNFMGRGGRIELNNDLSHISGLSGLAGLDVQLPLFTNGRIQANIDAADARLK
AALIQYDKTLLTALGEVDSAYQNHRSLTAQTRLLQKSHTQAQKQASDAQLLFKHDDKTLD
VAIRARVTALNYQEQLIQSQLAQAQNLLGLYKALGGGWL
>fig|1171377.3.peg.1869 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MNLQWHRYPQNTKNLFKLALPIFISQLASSGMGFADIVMAGMISDNDVSAIAVSNSIYFP
LLLFVIGVLNAITPTVSYLNGSNQRHLISHQVKQGSWIALLFSLPLFTVYLGSDWILQSM
DTPAAFAHKAADYMAMLCIGLLPALMAVNLRCFNDGLSNPRPAMLITFFGLLLNIPLNYI
FMFGKFGLPAMGAVGCGLATSIVNWVMFLLILHYCYRSSSQKDIGLFNRFWEKPNRVTQV
KLLKLGLPIGFALFTEVMLFATSSLILSPLGAQVVASHQVALQTSSLFFMIPLSVSMATT
IMVGQTLGAKDVQGAKYLTFHAIFTCILIAFAMAVVILSLKDWIPHIFTSDPTSITIASS
LLIFSAIYQIPDSVQSVCNGILRGYKYTRPILGVTLICYWLIGMPLGIVLARTDWLVMPM
AASGFWLVFCICLSIAAMFFFYYMRKIQCLSDEDLLARLERIK
>fig|1171377.3.peg.1886 Permeases of the drug/metabolite transporter (DMT) superfamily
MQQKPLRGFLYALLASMTWGTLPIAVQPLLATIDAQTLVWYRFWVAGLGLALFFVLTKRL
PSARAFSPRVFKLIFLGVCGLAANFFLFSEALNYISPTTNQVLWQLAPFTMILCGVVIFK
EKFGQHQKMGLILLLIGLAAFFNERMGEILQFGDYAVGILISASAAIIWVCYGIAQKLLS
ATFSSQQILMIIYLGCGVAISPFVSPSQLFEINGFLIGCFLYCCLNTFIGYGAYAEALNY
WDATKVSVVTILLPIFTMIFSHLGHWLMPDFVPELTMNWLSYLGAFIVVAGTILSAIGHK
IFK
>fig|1171377.3.peg.1887 Vancomycin B-type resistance protein VanW
MIPLFIEDNKAFIYTAVDFSATTNGIMNAETVDVINLNANISGNSFTGSANSASLSGTAK
VEGKFYGENAKELGGMFKAADWVGAFGASK
>fig|1171377.3.peg.2189 Permease, MDR related, probably tetracycline resistance protein
MIFLQAKGLSMYEISILQMALNITMFLFEVPSGILSDKFGRKPPAFLGISFSIIYLIGML
YLNEFFYLVIVFIVYGIGISLLSGVDQSLIYEQLDYYGKQEIYHKTIGFYNAISIAALAV
SALVGGWLAENKYWELIFYFGVLFQLMSLLFLYFIKDFYKLLPHNNKAKKSFFGIGILRV
DGKVLFIICILGIFQGVFSSVVLYYQKVLDYAGVSIFYISILYSLSFVFSSFSSVMSGFV
SEKIGEVKAVLLFSLLLLFSFFYLYL
>fig|1172188.3.peg.65 Glyoxalase/bleomycin resistance protein/dioxygenase
MTEQRTYPEGVTSWVDSEQGDVDAAADFYSGLFGWTFDEATPPGVPFRYLIARLDGQDVG
GLGGPATPAAEGAGGGGGDAARWHTYVAVDDAEAATGRVKAAGGAVVQPPTVAGEGGRSV
IVRDPQGLEVRLWEARGRLGSQVTNVPGAWNFSDLHTDEPAAAQQFYARAFGWEFADVGF
ATMIRVPGYGDHLAATTDPGIHERQSGAKVPPGFADAIGWVVPVAPDAEPGWHVTFTVAE
RDAAADQVVRLGGSVVRTGDSDWTRTAVVRDPQGALFTVSQFLG
>fig|1172188.3.peg.659 Phosphotransferase (aminonucleoside antibiotic resistance)
MTARAPGRSPLDGGAACLLVVGAPGAGKSTVTRLVAGRLSRAALLEGDTVSRLVVSGRVW
ALGEPADEADRQTRLTNDNLVALAASFADAGFTPVIDWVVPDRAQLDLYVAGLGDRGLAL
VVLDPGGDVCRHRNELRDPEEQFDFDGQEALVATMRRGFGEVGWWFDTSALTPEETAEQV
LAHAYALGRRGL
>fig|1172188.3.peg.1479 Glyoxalase/bleomycin resistance protein/dioxygenase
MSSPIQRRVGQVFVPVRDMAAAIRWYAAVLGFEPGAASHEDTIYDVPTDGETRLALDANR
PDFIASGPPRFFLWTDDMAATVEHLRRLEVTITSDVEDIGSVFFVQFEDPDGNALMVCQR
T
>fig|1172188.3.peg.1825 Phosphotransferase (aminonucleoside antibiotic resistance)
MSELDESGPRGRLVLVTAARPQARAALASAVAARLHGAVVVDGAALEAAVTSGAVPGWDE
PPTSEQLRRRLLRWSAALAVAETYQLEGLDAVVAEDALGDRLEDFLDLVEPEPVHVVVVR
DGADPATPHWGLWVDGTDPVGATAADVVSRLADALVATSAT
>fig|1172188.3.peg.2061 Vancomycin B-type resistance protein VanW
MAHDWSDDTRRERRSTVLRLLVATIVLGGGYAGLCVWSSQHVPASVSVGGIRVGGMTPES
ARAAIARGSRSLLDTPIVLSVPGRPAPIEVVPRDAGLTVDADRSLEGLTGFTLDPRVVWD
KLTGSVRTPLLTTADDEALTAYLDRLAPGLAVAPVEGRVSFPDGAVSVDMPAPGSTLDVA
ATKLALRRAFPDSTQATAVVREVPPAVSADVVQQVGSQFGSTAMSRPLTLVSGATRVLLS
PAEYAPMVSVVPDGSGGLTPRFDEPGLARLVAGKVTVPSRTASSARWVFEPNNGKPRLVP
SVDGLTFDEDAVARQVVAAISGTERTVDVRAAVAQPPFTTEDAQKAGVTTLVVDFRSPFP
TNDATRTNNLVVATKRINGTYVPPGGTFSLNGILGERTEDKGYADGTVIIDGRLTRGTGG
GISQVSTVVYNLAYFAGVDFLQFSPHAFFIPRYPEGREATVYWPTIDNKWKNDTPYGMLL
QTWVEGGFVHGRVWSTKTWDITSVKGPRRNVVPPKTIRTDSLKCYPQQPNPGFDVTVTRE
WRRPGSAALVRSEPVSTHYVPEDHIICTNPAATPP
>fig|1172188.3.peg.2492 Permease of the drug/metabolite transporter (DMT) superfamily
MAVTLLLWASAFVAIRHLGRDVPPGALSLGRLLVASVALGVLVFRRPRTWPARRDWPLLL
LCGVGWFGIYNLALNEAERRIDAGTSALIVQIGPIIVALLATVFLGEKMTRWLLIGMAVG
FAGVVVIARGFSSGDSGDMVGVWLAVLAAVTYAVGVLAQKPLLGRLPGPEVTWLACVIGA
VVCLPWSGELVSVVRDRDPSTLWWIAYLGIFPTAIAFSTWAYVLARSDAGTLTLTTFLVP
FIATLIAWALLSEVPPPLTFVGGALCIAGVLLTRRKPRVAATAED
>fig|1172188.3.peg.2634 Permease of the drug/metabolite transporter (DMT) superfamily
MEGNRASWTNVALTALPAAIWGSTYAVTQQWLPPGRPLFAATVRALPVGLLMLLWLRRLP
RGDWWWRSLVLGSLNIGLFYALLFFAAYRLPSGLGATLVATAPMVTMAVSWMLLGQRPAR
VSGAAGLVGLVGVALLVLQNGLDKPLDPVGLGAGLLAVVLSSCGFVLTRKWAPTDDVVTM
TSWQLVAGGLVLLPIGLVVEGAPPALDLPAVGALVYLGLLGSGVAYVLWFRGLAILGPTS
ASIIGLVNPVIGVLLGVALLGERFGPVHLVAMVLVIGSVLAAQEPVRARFSRRAPSTGER
TSTRRHTPALPSGAPAGKAVAWPPTPTTLSTSSSSGSDRAVSTSPGASPSAACACSASTA
DSWAVSAPTGAASRRR
>fig|1172188.3.peg.2684 Glyoxalase/bleomycin resistance protein/dioxygenase
MPVHEESFAPGTPCWADVMVDDLDRARDFYGSLFGWTFEDLPPEAGGYVMARKDGHVVAG
AMAKNPDDPGQVSAWTVYLATDDVDATAERAQAAGGVFFLGPMDVLQVGRLAVGADPAGA
AYGLWQAKEHTGTDLVDEPGSLCWAESMSRSYEASRTFYTDVFGYRLQEIGEGGFQYSVA
TLDGDKPVGGIGAIPAAAPADVPSHWMAYFAVADADAAADRVTALGGTVRQPPFDTPYGR
MALVAGPQGETFSVMQLPEQPAAD
>fig|1172188.3.peg.3025 Glyoxalase, Glyoxalase/Bleomycin resistance protein/Dioxygenase superfamily
MPIKLENVGIAVDDLEATIAFFTDLGLTVLGRDTVSGEWTDTAVGLDGNHARIAMLQTPD
GHGRLELFEYIHPSAIETTPTLPNEIGMHRVAFSVDDIDEALAIAARHGCHPLRGVATYE
DVYRLTYLRGPSGIIVMLAQELTGR
>fig|1172188.3.peg.3297 Drug resistance transporter EmrB/QacA subfamily
MAEASTSAGSGRSGRAAAQTAASAGGVLAATCLSTFVVNANTSAVSILLPAISADTGMDV
TTLQWAVTGYSLVGAAVIVTSGSLGDVFGRKRVFQLGLMLFVVSCIFIALSSSGGAVIAG
RVIQGAAGATILACGLSLLSVANDGEAQLRAVSLWGAAAAVGAAAGPLMGGVLVSVMGWQ
GLFWVDAVIAVVCILITYRRVSESRDTTRSRSIDYAGSLLIALTLAPLILALSKGGDWGW
ASVATIACLAIGVAAGFAFVAVERRVAVPMLDLALLRNRVLVGSTVAILIGAGTINALMY
LLSLYFQDPNALGFTTLQAGLATLPATIGLVAIAAAVPKLTARLGGRQVVAVGFLLTAIG
FAVIGFVDADWAYRAFLLPLLAVAVGMGMSNGPASSASTACVPEKQVGSASGVSNMARYV
GAAVATALAATIYGAVIADGTAKGRPPADALASGLATTSWVMAGFSLAGVLMAVLMGRHQ
AATGTIHDSAAAAASTAMTLRTTATGAVATGAAKGA
>fig|1172188.3.peg.4078 Oxytetracycline resistance protein OtrA
MDTPPTPPVRPGRTLGLGILAHVDAGKTSLTERLLLHAGVIAELGSVDDGSTQTDTLALE
RDRGITIKAAVVSFELGRPGDPDPLTVNLVDTPGHSDFIAEVERSLAVLDGAVLVVSAVE
GVQAQTRVLMRALRRLRIPTVLFVNKVDRSGARTEVVLREVVDRLGVTPVPLGRVVDEGT
RAAAVVPDGLADLGLPARGPAEREDAEPEGGDRDAAAARERVVEALSRADDRLLADWLDA
PHRVDASRLRAALGEQTRRGLVCPVLLGSAMTGAGVEDLAQALPDLLPARTPDPDAPLAA
TVFAVQRGASGEKVALVSVTSGSLAVRDRVLVHDGRTEWSPAPDPDPRHTTSASGDDGAR
CREERVTGLSVHARGEVRRVARVPAGRIARVVGLERARIGDLVGDAALARPLVHEFSPPT
LETVVEACDPAERALLHTALTRLAEQDPLIDLRHDEVRGETHVSLYGEVQKEVIGATLEA
EYAVAARFSTTSVICRERVTGSGAAFELIDVAPNPFLATVGLRVDPGPPGSGVRFSLEVE
LGSMPASFFTAVEDTVRATLGQGLHGWPVTDCVVTMTHSGYWPRQSHMHQKFDPSMSSTA
GDFRALTPLVLMEAVRLAGTAVEEPVHRFDLEVPSDVLGAALSMLGHVRASPRETAVLGP
VTRLRGEVPAERLHELQQRVPGLTSGLGDLVTAFDGYRPVVGPAPTRSRTDLDPLHRREY
LLRLAGKLSAQPHSSERPTTLE
>fig|1172188.3.peg.4145 Phosphotransferase (aminonucleoside antibiotic resistance)
MSDRPLHTAVDIPQVIVVTGVMAAGKSTVSQLLAERFTRAVHLRGDEFRRVVVRGRVDMS
PHGDPEAERQLALRHAIAAHSANEYAAAGFTVVVQDLFVGTTLQPFLDRLTARPLSLVML
APDVGTVMQRESERVKVGYGDLWSIRDFDHKVRTETPHIGLWLDSSQQTPDETVEEILAR
LAEARIS
>fig|1172188.3.peg.4451 Permease of the drug/metabolite transporter (DMT) superfamily
MTPAARTRLATLLLVALTAVWGSTFFLIRDLVETVPPVDFLAVRFSLSAVIMLLVFWRPV
RALSRRQVLVGVGLGALYGLAQIFQTQGLATTPASVSGFITGTYVVLTPVFTAVLLRERV
AGSTWAAVGLATVGLALLSLNGFSVGVGEAITLLAAALYALHIVGLGRYSASEIATGLSV
VQMVVIAVLCVVGALPGGVVLPSGPRQWASVLYMVVFASILALWVQTWAQAHMPATRAAI
VMTLEPVFAAFFAVTLGDESATLRMVVGGALVLTAMYAVELLARRRPGELPVEALHHEV
>fig|1173022.3.peg.2517 Permeases of the drug/metabolite transporter (DMT) superfamily
MSSSVEKSSSPNSLLSGQNVVYAGIAWSVLALLFYLLFSISVPGEERPFWYSMGTYFFEE
VPFLAAALLCFRNWRSPQIASGRNVWLGIGLGLLSFFIGNLFFGWWELYWGLDPAVSPGD
LFYVLFYVCLGCGLVLAILPRRLNLEPWQWATVIASAVSAIALAIWLLSSPPANAQEASA
IAQPARSAIASTPITQQRDSNTPSQTLIAQKAPNVKVTPKAPATKAPPVPANTSKNQPPG
WVLSLEKVLEPLAAPLSLFYIAGDVFLLIIAALLLLAFWGGRFAQSWRMIAAAAFSFYIA
DMWFTYATDHITDYQSGFLLEVFWVFSGVLFAIGAALEYDNSIRSRRAGRKRA
>fig|1173022.3.peg.2687 Glyoxalase/bleomycin resistance protein/dioxygenase
MFLNSIFVTLATSQLDILVQFYTNLIGIEPESYIPQIYAEFRLNNLRLGIFQPKEANRQE
FDNSGRNPISLCFEVSVLESAIAHITALGYPPPGKIINASHGREIYAYDPDGNRIIFYQS
NKLD
>fig|1173022.3.peg.4533 Vancomycin B-type resistance protein VanW
MNTNNKEKFLPSIKKIIPGELKRSLKIKSRYIGDILTGNAQSMVNFIPINEINKYQFQPQ
SSISQVIKTTSYSENKKHNLALAINRLENIVIQPGKLFSFWHLVGNPNSKNGYKEGRTII
NNQLQSDIGGGLCQLSGLIYWLILKAGLVPTERHPHTHDIYTESTRFAPLGSDATVVYGY
KDLRFINTLPVPICWQFKLLPAEIIASLCSTQKIHQFEIEFRREESNEQRIVQTVRLAQG
KEEIIDTSYYLVLKN
>fig|1173022.3.peg.4649 Methicillin resistance protein
MQSWAWGDFKELEGYQTFRYGLFADNTLVGGAIFYFYTHASQANLLIAPGAPILTPPYLE
SGMQLLLRKAEELAKKLGAIALRIEPLWTKKPDYLSNFVRAPVDLLPSETLLIDLEVSEA
EMLAAMKQKGRYNLRLSWRYGVETEFTTNPQAIPVFYDIFWETVKRQQFFGEPYCFFINL
CQTLFQANMAEIGLAKWQGEILAAILVVYCGNRATYLYGGRSFEHPQVRATYALHWAAMQ
QAKQRGCTIYDLYGFTREPKHSYAKFSQFKSQFGGIPVTTIGAQDYFFYDQLADTLINLF
KNIGGNET
>fig|1173026.3.peg.24 Permease of the drug/metabolite transporter (DMT) superfamily
MCAKHRIDRETIGLGYGFLGVLGFSLTLPATRVAVVKLDPTIVGLGRAIIAAFLAVIVLW
ANHQRRPARKHWRGLIIVAAGVVLAFPLLSAWAMQQLPAAHGAVVLALMPLATALAGSII
VRERPSRRFWLASITGSITVIVFAIFSGAGQMQWADVVLLGAGMAAAISYAEGGRLARIL
GGWQVICWALVIAAPVLSVPFAKAVLQHGLVASPTAWLGFGYVSIISQLLAFFPWYQGLA
IGGVARVGQMQLLKPFLTILASAILLGEAIAPFTLIAAMIVVTSVAIGRTSAIQRN
>fig|1173026.3.peg.703 Permease of the drug/metabolite transporter (DMT) superfamily
MQIWQAPKPWQVGLVLVIGVFGISTASIFVRLAFAAVPGVSSVGFSLVLSAARLIISAIL
LLPAWRYLRSSPPSRTSVYYASVAGVCLALHFATWITSLAYTSIAAASTLVSSPPIWVAL
LSWLWLREKLSPLTLIGIGVALAGGIIVALRGSGVDSVASRPLLGNFLALFGAWMYSLYL
LLGRKAQQEGLGLGSYIAIAYTTGALILLPLPGIFSVSYTGYPSIVYVYILLIAIFSQMI
GHTSLNWGMRWLSPTLVTLAALFEPVGASLLAYFLLGELPGRLTLLGAAILLVGVACAIV
GARQNKLGQTKLSE
>fig|1173026.3.peg.1148 Permease of the drug/metabolite transporter (DMT) superfamily
MVVYLKLILTAVVWGGTFIAGRVIVQDLDPFSAAFCRFAVSSICLLFLTLKQEGQLPRLH
QKQLIQVILLGMTGVFAYNAFFFLGLQTIAASRAALIVALNPTFIALGSALFFKDKLTAF
KIIGIIVSLLGAALAISRGNVVNILDDNLSIGDLFLFGCVFSWVAYTLIGKLAMQQLSPL
VATTYACLIGTIALFFPALSEGILQHFFQINFVTWLVIWYLGFLSSALGFIWYSEGVRVI
GPAKAAIFINLVPVSAILLAAVLLREEITLSLLAGGILVVMGVFLTNKA
>fig|1173026.3.peg.1345 COG0697: Permeases of the drug/metabolite transporter (DMT) superfamily
MASDRTMEQFKLGSVSNTPQDLISNGFAAIALGMALLGIAFASILTVVAQYEIGPNATTF
NRLGIAAIAFAGWNGFRFVSQIHAHSVSALVYTWRDRSLLAIAGTSFAASLTLWAWSLTQ
TSIANSTLLNNMMPLFTTLGAWLVLGQKFSARFVLGMAIAVCGAIAIGIEDFQGANSNLF
GDSAALGAAMLAAVCLLSLEQLRLKFATPTIMQWTCLIGSLGVFPVILLTQEPLFPTSGV
GWCTVISLAIVCQVVGQGLLTYSLAKFSSGLVAVSMLAIPAIAAVLALIIFAEKLSILNL
CAFAVVLAGVYLAISARSD
>fig|1173026.3.peg.1808 Glyoxalase/bleomycin resistance protein/dioxygenase
MKLGAIHHIALTVSDMERSEAFYNKLLGFMGYEQGEKTEQLILWASSHSAMTISPAKQQF
HQKCDRYSPGLHHLAFSADRREDIDKLYQELLEQQVTILDPPAEYDYLPGYYAVYFLDPD
GIKLELAHTPT
>fig|1173026.3.peg.1811 Permease of the drug/metabolite transporter (DMT) superfamily
MKPIDLARLFLLAALWGSSYLFIRITAPVLGVFFTISLRVIIAACALGLYGVLAQQLSTL
KTRWLSYLLLGLLNNVIPFILIAIAIVNLNASIAAILNATTPLFTAIVAAIWLKEPLNKR
KIVGLLLGIVGVAILVGWSPLLLSLSVILGGLSALIAALFYGIAAVYARRRFRHNRATET
AIGQLVGSSVLLIPVTFTSIPNTVPSTEVILAVITLAIACTAFAYLLYFQLIAKAGATQA
ATVTFLIPVFSLLFGKTLLGEPVNFGLIIGLITILLSIWLVFNTKH
>fig|1173026.3.peg.3594 Permease of the drug/metabolite transporter (DMT) superfamily
MNYNNAPEGANFGLLMIMVSAILWGTVGVFVQTIYTLSESNSFSIGFLRLAISLPVLFLA
CARTLGWQMLQIAKRDLALMLLTGAMTAFYQVCYFTSISYIGVAAATLITLCTAPVWVAL
LASLILHERFTLGILLAGLCALGGTSLLVNIQPEQIAVRSQILGVGLALGSALAYASVTL
CSRLLSRRYHPLQSLTVSFFAGAVFLLPIALITGLVLQYPFVGWIALLYLGIVTTAFAYV
LYFSGIRHTPATVASIATLLEPLTSTILAWWLLGENLGTSGIIGGVLLLIAIGILYWDLR
WNQRHSRRN
>fig|1173026.3.peg.3917 COG0697: Permeases of the drug/metabolite transporter (DMT) superfamily
MSIAATELFTLSFVVQLTLALATYTIGVANWVLALRVVKLSVAYPLSSLNYVGILFGSYY
FFNETITFTRILGVLLIFTGVLFVALSQSGRQLISK
>fig|1173026.3.peg.4327 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MTVMQMPKHIHTEVREFLKLAIPLASAQVAQSATGFADTVMMGRMGAEVLAAGGLAALIF
LSIMTTASGVVMGVSPLIAEAFGAGKKTRIEQVARQGLWLALLVALPLMIFTAHLDTWLS
YSGQTAKNVQLVNTYLDIMLWGLFPAVGFAALRATVSALSQARPVMMIVVTGTTFNIIGN
YVLGFGKFGFPRMGLAGLGVASVIALWGMFFALALYVFKNQNLRKYRIFQELHRVRLRIL
WELTWVGVPIGLFSGLEIGFFLVVTFWMGTLGTEVLAAHQVVFQTIVVVFMVPLGISYAT
TVRVGQWLGRRSRIGIQQAAWVSMGMTTVFMVGVSIAFLLFPKQIVGIYLDVQNPENAAI
VAIALPLLIIAAIAQVLDGFQKAVYGSLQGLQDTQIPMLLNVLGYWGIGLSVGYGLGFWF
NLGSIGLWIGQSVAIATVAGLFTWRFHKLIARQTLN
>fig|1173026.3.peg.4463 Permease of the drug/metabolite transporter (DMT) superfamily
MTAKLFAPREWQLALPLAIFLHLFYVAPLAVLLASSFQTAPDVPSFTLAQYWQFFQDAVN
RKVLLDTFWLGVQVTLSCLLFGYPVAYIYANAPAKWKGLLTFLILLPLLTSSVVRTFGWV
VILGRQGLVNSLLQGVGFIEEPIRLLFTHQGVAIAMTQIQLPLMILPIVASLAQIDPRLA
AASASLGGGAWRTFWKIIFPLTLPGIISGCLLVFAITVSSFVTPSIIGGGQIMYMPTLIY
QQGVVLLNRSFAATISAILLVMVLIVVFGLSSLGQKSRDYVR
>fig|1179773.3.peg.563 Probable multidrug resistance transporter, MFS superfamily
MKRLLGKVAIDTRPLRIPAFRRLWLSTLVTAIGSQLTAVAVPKQVYDITGSSGWVGVAAG
VALVPLLVFGLWGGAIADVVDRRKLMVVTNIGIAITSVLLWLQAAFDVQNVWLVIALLGL
QQVFFAANAPARSASIARLVPEDQLPGAVALGSTVMVFGGVFGPMLAGALMPVVGLSTLY
LVDSIALTATIWAVWKLPPMPPLDGVVRRAGLADVIDGFRYLSVQKIVMASFLLDIIAMV
FGMPRALFPEMAEVTFGDPPGGGLALGWLFAAIPLGAMVCGLVSGWTSRVSRHGVGVVVS
IIVWGVAMIGFGLSNALWWAVVFLAVGGAADMISMVFRTSILQTAAPDEMRGRMQGVFVV
VVAGGPRVADLLHGTTGALIGPGAATAWGGVAVVIGTVVAAIAIPAVWRYRVTLGTAGET
SPKP
>fig|1179773.3.peg.804 Daunorubicin resistance ABC transporter ATPase subunit
MADVVKVYEGGRKPAVDGLGFAVRRGEVFSLLGPSGAGKTTTVGVLTTRVRPTSGRALVE
GVDVVADPRKARQVLAVVPQRNTLDRALNVRQNLLFHAAHHGLGRAERTRLADGVLNRMG
CRAGPAVPALHRHRPGGRPAGRPADRRAARRRGGRPGRRQAEPGGRLHRPGTARVPHAGG
RPAVPAGGGGEDGVRGVARAARGGADDPDRVRCARRLVGAVGGPGGAAGDRPARRRARRS
AW
>fig|1179773.3.peg.992 Drug resistance transporter, EmrB/QacA family
MSSRRLAIGAGALAVLLGALDAYVVVGVLVDMVRDLGIPVNHLERATPVVTGYLLGYVAG
MPLLGQLSDRFGRRTVLHLCLAGFAVGSAVTALAGDLPLLVAGRVVQGLAGGALLPVTMA
LVGDLWDERRRAGALGVVGAAQELGSVLGTLYGVGVASLFNAWSVFESLEPQSWRWVFWV
NLPLAAVAMLVVQRTVPGGSGRPVRIDVVGGALLALSLGLLVVGLYNPDPEHAVLPPWGW
PALGGAVAVFGGFVWWEKRSPVRLLDPTGVVMRPFLASLGVSLAAGAALMVTLVDVELFA
QTVLRLDSAAAVALLARFLIALPVGALLGGWLASRVGDRWVAVVGMALAGVAYVLISRWP
ADVPSSTLDRDLVVAGFGLGLVIAPVSAAVLRVVPATQHGVASAAVVVARMTGMLVGVAA
LSAWGLHRFRELTANLNTPLPFGVEPAEFTRQAEQYQRALTEALLTEYHEIFLITAVICA
AGAALALLLPAKTSSPDLTATRPRTG
>fig|1179773.3.peg.1037 Multidrug resistance protein B
MLGNDVRSGPRLPGEVWVLVVASFIIAIGFGIVAPVLPAYAKSFDVGTFAVSAIVSAFAL
VRLLFAPVSGRLVSRFGETRTYVVGILIVALGTAACGFATAYWQLLVFRSFAGVGSTMFT
VAAVGLLIRITPAPMRGRASGLWATGFLLGNIAGPIIGAALAEISIRVPFVTYAAALVLA
AAVVWWFLRRSTLAALDPNVEQTTLSVGQALGSPAYRAALASGFANGWAVFGVRISLVPL
FVVEALNGSPALAGISLSVFALGNAAVLMISGKLSDTIGRKPMAMSGLAVSAVGTIWLGF
TTGVPWFMAASLVAGIGAGLLNPPQNAVVADVIGTKAKGGPVLAAFQMVADCGAIIGPLL
AGVLVDHVSYGAAFTLTGVIMIIALVVWAFAPETLPREPSAHVAEVVANESGRLDEGPEV
PTGERLAGRPRQPDA
>fig|1179773.3.peg.1188 Small multidrug resistance protein
MLKWTLLGLAIVFEVFATLCLKASDGFTRLLPTLGLLVGYAAAFYLESQVIRLGLPVAIT
YAVWAGGGIALVAVAGRVLFADPIGPATLAGMALIAAGVGVVSAAATT
>fig|1179773.3.peg.1469 Permease of the drug/metabolite transporter (DMT) superfamily
MGKFVLLSAIWGSSFALIKVAVDAGVPPVWVAFFRCLFGALALWAVCAVQRQGVPRDRRL
WGHALVVAALLNSVPFTLLAYGETKVSSVLAGVFNATTPLMTLVFVLLIVPQEKISGAKL
TGLVVGFAGVLVVLRAWEGLGDDVLVGSLACLGATFCYGAGFAYTRRFFSGGPQSASALS
AVQITCGTAQLAVAAPLVGGLPSWPGWQAAAALLVLGAAGTGLAYVLNLDVIREAGPTVA
STVTYVTPLWSTALGVLLLSEPAGWNTVVGGVVVVAGVLLARKPTNHPMGQKSTRTVVQV
DKPGPA
>fig|1179773.3.peg.1679 Tetracycline resistance protein
MMIMTAVEVVQRRVLRVLGVTQVLGAAGVTIGLAVSTLIAAVLSGSDAVGGLAQTAAALG
AALFALPAARLAARRGRRPALILGYGAGAIGAVVAACAVVLGSWQVLVAALVLFGAASSA
NLAARYAGTDLAHPQRRARSLAIVVWAATLGAVAGPNLADPAGQFAARLSLPVGAGPYLA
AAVLFGAAALVVLRFLRPDPLTLAQSAAPVTPAHCAGGVGDTRGSAAVWRALPATGKLAL
GGITLCHTAMVGLMSMTPVHMDHAGASLRVVGVVISLHVAAMYAASPLFGWMADRLGRVP
VLAIGSALVVAASGVAGMAPAHDAPQLAAGLTLLGFGWSAGLVAGSALLTESVSPTDRPA
AQGLSDLSMNIGGAVGGVAAGIVVTAWSYAALGLLVGFTALPLLVACLFTSLQRSR
>fig|1179773.3.peg.2719 Multidrug resistance protein B
MANAVGKVAERGREPVEVGRGARNAIVAVIMLGMLLAALDQTIVATALPTIVSDLGGAGH
LSWVVTSYLLAETIMTALIGKFGDLFGRKPAFLVSVALFMVGSFLCGWADSMTWLIVARA
IQGLGAGGLMVTSMAVIADVVPLSERGKYQGLIGALFGVSTVVGPLLGGLFVDHLSWRWA
FYVNLPLGVLVLVVGFLRLPGVRTTAKPRIDYLGILLIALAATGLTLVTSWGGVEYEWAS
PTILWMAAGSLVALALFVRVELRAAEPMLPMRLFRNPVFTVCCVLSFVVGFAMLGGVTFL
PTYLQYVHGASATQSGLEMLPLVVGLLVASIVTGNVISKTGRYRVFPILGSLLMVAGLLL
LSLLDVDTAFWEASAYMLVLGLGVGMCMPVPVVVVQSTSSYEDLGVATSGVSFIRTLGSS
FGVAIFGSIYASNLPEKLAAALPPGVDPRAASNVQALHALPDQLKAPIVAAYAETLQGVF
LWAAPVAAVAFVVALFLREVPLRDTARAAATGNNGVGESFAVPQSTVSSQELEKLVALIV
SKERRDPTPEVLAGSGLPLTHAQAWLLVKVFRQSAHRGAATLDRLAAETKVPPGIFEPVA
RQLMTKGLLTESDDDYRFTPEGSATFARLVSSWRDWLHVKLVDWQCDDPEFTEAVDRVAA
DLVITSQSLTTRHPTPV
>fig|1179773.3.peg.3149 Multidrug resistance transporter, MFS superfamily
MAQVRTGPRRLAVVGLYAGGFLGPFGGAMTSSVLPEIGADFQVSAGAAATTLTGYLLPFA
GFMLFSGTVGERWGARRTVRIAYLVYAVASVLCAVSWSFPVLLGGRALQGVANAFTTPLL
LAAIAAVTPKERLGRALGVFASMQAAGQTSAPLVGGLAAEASWRWAFVGAALVAVLLAAA
GVPADPPRTEQPPRLRTAWRPEVLRLAAAGFVGWGCLGGVSFLVALRLGDDFGLGAGERG
LVLTGFGVVGIVCARLTGWMIDHVGPRRCVLLGTTVGSVLLVLIGVLPSLVAVGVLWAVA
GAFSQAVIVGLSALVLGRGGNRGGAISVLQSFRFLGGSASPMAFVPLYHLSPAASFLAPA
ALVLLIPPALLLWRGRDRS
>fig|1179773.3.peg.3266 Permease of the drug/metabolite transporter (DMT) superfamily
MSSAVVRTRLAQGPLPILAACFLWGTTGTVSSLAPSSAPASAVGAAGLVIGGLLLFLTAR
GTRDVLRTADRRLLLLGAVTVAGYALAFYPAVARTGVAVATTVALATAPIVLGIKTRPLV
TLTAVTGCAVLVLGGGDAHVDLVGVALALVAGLSYAAYSVICAHLIALGHPSRAVVGTVF
GGASVITLPVLLLLGVSWLGTYGGWAVVLHLSVFTTFVAYLLFGHGLRHTTAASATTLTL
AEPAVAAVLGVLVLHERLPLVSWCGMALLGVALLTLARR
>fig|1179773.3.peg.4170 Permease of the drug/metabolite transporter (DMT) superfamily
MLNRSVVRMGLLALLWGSVFLWIELALTGLTPVQITVIRCALGTAVLLVLAGFGRQKLPR
DQATWGHLVVAALFCNALPFVLFGIGQQTVDSGVAGVLNATTPLWSVLIGLALRTEPRLT
PARVGGLVLGFAGVVLIFAPWQRDGLASWGALALLGAAASYAVAFTYMGRTLVGRAGPMA
ISAGQMAAATGLSALGLPLSGPAHPNATALVAVVILGVFGTGFTFVLNYRIIEEEGATSA
ATVGYLLPVVSVGLGALVLGEPLTPRIVAGMAVVLLGVALTRSAAAKPPQEGSAPRPSPV
LPTERDQPGGHSTEPR
>fig|1179773.3.peg.4465 Permease of the drug/metabolite transporter (DMT) superfamily
MLSPSRAGLGWGLVGVAAFSFTVPFTRVVVGGGMSPLFVGSGRAVVAAVLAAGALAATRQ
RLPRGGQWARLAVVAGGVVVGFPLLTSFALTSASAGHSAVVIALLPAVTAVIAVLRGRER
PPRSFWVMAAVGAAAAVVFASLRGDGIGGPHWSDLLLLGAVLAAGIGYAEGGLLARELGA
WQTVSWALVLSAPLMAALAGFAVVRQPPTGTPGEWAAFGYLAVVSMFLGFFAWYRGLAIG
PMAQVSQVQLVQPVMTICWAALLLGEQLTWSTALGGVAVIACAAVAVRARLGATQVGTGQ
GLPVDREG
>fig|1179773.3.peg.7039 Permease of the drug/metabolite transporter (DMT) superfamily
MRWAALGVVYVVWGSTYVGIKFAIETMPPLLSAGTRFLAAGLVLALIVGRRLRMTWPQFR
TAALLGLLLPAWGNGLVVVAEQSVASGLAALLVASVPIYVVLLRRLGGERPPRVTYVGVA
VGLVGLAVLLLHDVGGSSWWGPWAVLLAAFGWALGSYLNGRLPTADPFAMSAVEMIVGGA
LLSLVGVVAGESVTLSEVSTTSWLAWGYLVVFGSLLAFSSYVYVLGQLPVSTVATYAYVN
PVIAVLLGVWLADEQFGPWQLAGGLLVVVAVVLVVRAERKCRTEVGVSEPCRR
>fig|1179773.3.peg.7074 Glyoxalase/bleomycin resistance protein/dioxygenase
MGGATFPDMTLTIGMITIDTADPHKLAEFWTKALDTEVRHDWGEFLIIGPAVEGGLQLGL
QRADDIAPGKNRVHFDAHVPDRAAEVARLVELGATEVAEHTVPGLTWTVLADPDGNQFCV
GQPG
>fig|1179773.3.peg.7126 Permease of the drug/metabolite transporter (DMT) superfamily
MKPGHAALAVLTTTIWGVNFVVIKVGLDEFPPLLFSSLRFLAAAVPALWLVGKPRVAWKW
IAAVAATLGVAKFGLLFLGMSEGMPAGLSSLVLQSQVIFTIAFATVLLKERPRPVQLVGI
AIAATGIVLIALDYGLTSPISALLLVVLGAIAWGLSNVATRYAKPPDALSFIVWVSAFAT
LPLLLLSVIFEGPSAIITALGNASWAGVTSLLFVAWVSTLFGFGVWGFLLREHNASTVVP
FALLVPVAGMFSGWLFLDENLSPVRLGAAALVIAGMAATTIPRPARVLTPVP
>fig|1179773.3.peg.7154 Glyoxalase/bleomycin resistance protein/dioxygenase
MDLQAAIDFYTGLFGWTYADIAGHTVAVVDGLPVAELLPADGGFGWTLYLNTPHARATAE
KAHSIGGHVLREPDEVSTLIADPTGGVIGFRHVPPDWLFGTDGHGAYAWAELNTRDGAAA
DEFFQELCGFEMTQIGDGHAVDYTIWAVQGDTVLGRQRMGSAFTPDTPTHWMVYFTADPE
IGTDSVASRVLELGGRVTVEPYDSPFGRVTVVTDHTGAAFSVIDPSRVVPLSEEDTGAPV
DDPYDD
>fig|1179773.3.peg.7198 Quaternary ammonium compound-resistance protein SugE
MHWLYLAIATVFEVAFALGTNATKGFTRLVPSIVTLVAAAGGIYFLSLALRTLDVGVGYT
IWTGIGSVGTVVLGVLLFKERLTGARVLCFGAIVLGVIGLRVAAGV
>fig|1184607.3.peg.886 Permease of the drug/metabolite transporter (DMT) superfamily
MRLRDVLTTAVAPTAWGSTYFVIRHWLPAGIPLTGAALRALPAGLLLMLLARQLPRGSWW
WRTALISGLTVGGFFALIYVAGQRLPSGVAATLMASSAIVLLVMGQVLLGEKAPLRKYVG
GFGGIIGVGLLVGGASLTLDPIGVAASLLAMTSSSLGFVLTKRWQPPVPPLTFAAWQLTA
GGLMIAPVALMIEGNPPPLEMSAVVAFTYLVIIATALAYAVWFHGLQRLPAGTVGLIGLL
NPLSGTLIGLLAAHEKLSTLQVAGTVIILAGVTAGIDRKPEERGEISMESTGEKPAVPHA
EKTPSDSELLCTKQ
>fig|1184607.3.peg.1886 Multiple antibiotic resistance (MarC)-related proteins
MNVIDGAVFGSVFISLLVILDPPGALPVFISLTKSYTRQERLLVAARAAGVAFGLLLTFA
LIGKEILDYLKISVPALQISGGLLLLIIGLELLMGKEADPTEIGRTHVALVPLAVPLFAG
PGVIVTIMVSMQRATTAGQRGAIILALAAAMAVVYLSMRYAGAIHRVLREGGTILVSRIA
GLLCSAIAVQMMADGVIGFVRLV
>fig|1184607.3.peg.2153 Multidrug resistance efflux pump
MTSSCFFINLPLIPLFFQSFEGAPQILLGPTLAISFALSALLGPFWGRLADQYGYRLMMQ
RASGLLVLTYVVTALVPNAEALFVARVLNGLASGFIPAATAYAIRATGEHKRNRTLTTLS
AARNSGAVFGPALGALFAAWWGFRAAAGRKASKSSGARCPMRADPPPVVGSGGFAEGHSR
KMGGGGYLIE
>fig|1184607.3.peg.2631 Permease of the drug/metabolite transporter (DMT) superfamily
MHLTVLAYVFCLVVWGLNFIAVKIQGTPVALEVSLTYRLAGAAVMFLCLAFVVRPSGRPS
RQDLRGIITFGLCNFALSYLFLYYATIWSSAALVTLLFSLKTVMTPIALRISLGDRLSPR
IMIGGVLGIVGVGILVYPMLAGGAQVASLKGVGFALIGTLLTAVGDASSARNARQGVDPV
YSNSIGFIAASLLLLVVCLVQGQKFDIPMSISYLGALAYLTVAASFLAWFFYLKLVERIG
AAVSSYMVALFPAIGGLASVAIGESEPSFHLLFGCLFSCVGAAVALGLGRVFSAARSRLP
>fig|1185876.3.peg.865 Small multidrug resistance protein
MQAWFFLLIAATFETAWTYSVKYMKFTDLKLLRWHNFYSPQIGLPILAPIVGYVVFGIAN
IYFFSMAIKQIPTPTAFAVWTAMALILIKLVDVFIFHANWSVTELFFLMLIGIGIVGLRL
YAAA
>fig|1185876.3.peg.1011 Glyoxalase/bleomycin resistance protein/dioxygenase
MATQQFYAHQLLLPMVSYTYWSATFRVGWSELVFRQTNKPVKPYHFAFNIPLYSLEQYQN
SFQLPYIDTSPSHCKVAYFPKWKARAAYFFDTNGNLVEFIERQDAGFIEPAEDIFQGISE
IGLVTNDVPATTRQLSRQFGIGQFLKSQPMNDFNAIGDDYGLFILAKTGRNWLFTDVPAA
QQQCKVVFQTDGEQTHSLRI
>fig|1185876.3.peg.1913 Glyoxalase/bleomycin resistance protein/dioxygenase
MDAQLIQTLQATHIAAWNEKDRTKRATLLQSIYADTITMYDKELVLHGIEAVSDFIEKLQ
REDPAFQFSAAKPIESVQNGVRLYGHIDTAQGRLNSMDFFVMDEGKVLHLYAFIDIP
>fig|1185876.3.peg.2141 Multidrug resistance transporter, Bcr/CflA family
MTDVIKVGLTMTRRQQFSIILILGTLSTISPFSIDMYLPGFPAIASDLNTSIAQVQLSLT
AYLVGISVGQLLYGPLLDRFGRKLPLYAGLGVYVLASLGCAVSTSIETLILMRLLQALGG
CVGMVAAQALVRDLFPVDQTAQVFSLLTLVIAVSPMIAPTVGGYATVLFGWHSIFVILAV
ITALILLAIVYVLPNGRQADASISLRPQAVLGNFYTVIRQPQFLTYALVGGIASAAPFAY
ISGSPDVFMNIYKVSEQEYGWIFAVLAIAILAPNQLNHVLLKRYSNQQLVSTTLVYQSVV
GFFLVLGTWAGWYNLYGLLGVLFLFLLGQGLVAPNSAALTLAPFVRHTGSAVALMGSFRM
GVGALVSALVSVLHNNTALPMVGVMAGCIFSGFLILLLGQRAIRYRSQHTDVGESIAEAT
L
>fig|1191523.3.peg.150 Permease of the drug/metabolite transporter (DMT) superfamily
MEKLKVAGGYILICIIWGSTWLAIRLGLDSIDPIISVGIRFLLASGFIYFLMKFNDVELQ
VDKKSVKIYLMLAFFSFIIPFGLVYWAEQFIPSGLASILFAIMPFGVIIFSRLMMPQNRV
GLSQLAGVALGFAGIVIIFSENIHIEITNYLWGMIAVLVSSMMQAFIAVAMKKHGGHLHP
LSMNFLPLLIAGIVLIPIAFIFETPSRWIFDAKSVGSILYLAFFGTVVTFTTYYWLLKRM
NVVILSLSAFITPIIAVVLGWLILDEYFSQRVIMGSSLVLIGILFANFKGLIKYFHMRRS
RVNI
>fig|1191523.3.peg.711 Permease of the drug/metabolite transporter (DMT) superfamily
MKKSGLRYALSAVFLWSTVATAFKLTLEGMNYAQLLFYSSLTSTLIFASLIFIRRKSIGE
TLFSKKYIKNNIALGFLNPFLYYLVLFKAYSLLPAQEAQPLNYTWPIIISIFAVIFLKNK
INFRIILGLIMAFTGVIVIATRGNILSLHFHNLFGVSLALGSSLLWGLFWTFNLLDSRKE
DEKLLGSFFFGTIYTFIYLAAFGSFAISSYKYLLGAVYIGFFEMGITFILWLNALRLSDN
KARTATLAYLSPFISLLFIWLILGEKLLLSSIAGLILIVSGIIIQRLNDSIRS
>fig|1191523.3.peg.1700 Permease of the drug/metabolite transporter (DMT) superfamily
MISDTKTRAYLAWAAICLIWGTTYLAIRIGVEDLPPLLFAGFRWFLAGPILFLFLIKKGC
RLPGWQDIKRSAVVGILLLGFGNGFVVFSEQWIPSGLAALLITTVPFWIVGIESFYVRGS
NLNMKIIIGLLAGMSGVTLIFGSNIISIFDPHYIKGVAGLFVAVTSWSVGTVYSKYNATE
VHPLMSAAVQMTIAGTLMTSVSLIIGEHKNLTFTPESVAAFFYLLIVGSLIGYGSYIYAI
EHLPVSFVSTYAYINPVIAIFLGWLVLDEVINLELFLSSAIILSGVYLVKRGSVEARTKL
SRTDR
>fig|1191523.3.peg.1868 Permease of the drug/metabolite transporter (DMT) superfamily
MKNKFSPAHFIGEGALLLMTIIWGGTFVIVKEALNDITPMLFIAARFSIASLLVFTFLLF
KRYQLNSSALRSGFLLGFFLFLGFAFQTAGLKYTTATKSGFITGSLVVMIPALQLLIEKK
KPTKGALMGTALVFVGIIFLSSGSAAPSSFLAEFGKDFNTGDYLTLICALFFALHVVYMD
ILSPGHDFWLLFFAQLITVAALAWITAIFFHSVSFESLYLNINGNLINGILYTSVLATFV
NFGLQTRFQKEVSPTKAGIIYSFEPIFAALFAYFLLNEKISNFGMIGGVFIFGGLIISEI
YDYYFNGGKKT
>fig|1195246.3.peg.249 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MLPFSRFEARTILKLSGPIVLAQLTQTLMYFVDTVMAGRVSATDMAAIAVASGLWLPVVL
TMQGLLLALTPIVAQYYGSKQTKPISHYTLQALYLAFIMAALLFVLMLFADIPLSRLNMD
PLLREKTLDYLFYVSFGLFPAAGYMVMRNLFEGLGNTKASMWIAFVGILVNVPANYIFIY
GKLGMPAMGGAGCGVATSLVFVAMFIAMLVYGYTSRSTRPYRHWPEKLWLSLKDQWQIIR
IGTPIAFSIFFEVTLFACIPLVIVHLGPIAVAGHQVAHNYSAIVFMLPLSLGLATTIRVG
HLVGEQNLMELKKAISTAIVLSVAMSLLTVIFTLLFRKYVAALYSPDPAVIALASSLLIL
AAIYQFSDAVQVVAACALRGMKITTPVFFITLISYWPIGFGLGAVLGLTNWLVEPMGPHG
FWTGIIVGLTCAAIALAMVLRKQINRMEHEFKTGATA
>fig|1195246.3.peg.1888 Permease of the drug/metabolite transporter (DMT) superfamily
MALLAAACWAFGSLLSAQAATHLGAFAFTRYRMLIAMSLLWLLSFATGSWQSLQLPQVLL
LILSGAIGIFIGDTALFAAMNRLGPRRAGVLFATHALFSVLLAYLFLGETLWGMTLVGSG
LLVGGVMIAIAFGKRREEQHQWEASPAAMKSGVALALLSALCQAVSTLMLKPLMSEGLDA
IAGSAVRMSTGFVLHLLVLLLGLKVARSYLPLTWRVFWLVAVNASLSMVLGMTLILQALK
TGDAGLVALFSSVSPVLILPMLWLVYRRRPAWGAWLGALLTVAGTALLL
>fig|1195246.3.peg.1958 Multidrug resistance transporter, Bcr/CflA family
MKFVSPSLWQVMLLAAVIAITPLAIDMYLPALPLMASALATTNALVQQSLSIYLAAYALG
MLLFGPLADMLGRRPLALFGLAGFLVASVALSLVSSIEGFLLWRALQAFCGAAATVVIPG
IVRHLYQQHTAKGMSYVSMIMMLAPLIAPAIGSGVMYVTHWQHIFSLLALYAAIMLLLCW
HFLPEIKQQSGNSARPAFFSGYQQVFANRSAWPFIAISMFASFSFFTFLTAVSFVYISYF
GVSEQLFALLFGLNVSALMLANFTNSRLVTRLGPMRMLSIGLVLALLAATSLTAVNAAGL
GLWFTVLSIAPLMASLGLMATNADALILMQFPQHSGTATAVIGTLRFGSGALAGPLLGLL
YTGTALPFSLLMLAGTLCILGSVIWAKALGH
>fig|1195246.3.peg.2591 Ampicillin resistance protein
MTLISMLLALIIERLAVRSDAWQARPYCQAYLKLTAGSGLTKLAEHQLGRYLWILLPGLL
VALLLHLLDNRLLTLVVNTLVLLVGIGCWHYRQLYKQYLNAQERGDEEAAYLAMQQIRHD
SRSDIDSSNGLTLVWLNFRYYAAVVFWFLVLGAFGVITYALLRHLNEQTQTEGAEPVAAS
SDTFAATDDALAETETGAASTADAVTVDEPVVFAETAADTPDSSAAVAKKDALSCMLHWA
DWFPARLFGLGFALVGHFSRASNALLGYFLDFTASNEQVVKDVARAAEPLPEEALNGIED
TSSMVQLSKRNMLFFLAFTAILTLTGWLG
>fig|1195246.3.peg.2675 Permease of the drug/metabolite transporter (DMT) superfamily
MQNILLYLITVLIWGSTWFAIEFQLGEVAIEVSLLYRFALAAALMWLYCWYRKLDMRFSL
RQHGFILLLASLNFALNFLFIYQAQQYLTSAMTAIAFTTMLLMNIINTRLFFGKPVAKRI
YFGALLGIAGIVVLFWPDLDGIDFTNTSLLGLILILSGALSASFGNMVSVRNSREQMPIM
QVNAWGMLYGTLVLLAAALIKGHSFTFSTEPAYLLSLVYLAVFGSVIAFASYFALLKQIG
PEKASYTIVLFPLVAVVLSTLFEDFHWTSYTFSGFALVLLGNAIVLTPFDRIRALLNREQ
PKLAN
>fig|1195246.3.peg.2732 Multiple antibiotic resistance (MarC)-related proteins
MSVTLLIDYWLIAITALFVVVNPLTTAFIFVSLLPNANAAQRARAAKRSTLVSAGIFLLF
GLLGSFIFKVFGITLEAFRIAGGLILFGIAMSMMQKGLDDGEEATGKEPQTDGKLAKDVS
IIPLAIPFIAGPGAIATVMILTSEAQNVWHFITVFLAIGITTFSCYLAMIYAHVLVRYIG
ETGKEIITRLFGLILSVIAVQFVINGVLDIYRSL
>fig|1199245.3.peg.872 Polymyxin resistance protein PmrL, sucrose-6 phosphate hydrolase
MIYLLIFVVVLLSCAGQLCQKYAANMMPGAGTLGARLRWIATSFLLLAGAFVAWLWVLQR
APIGIVYPILSINFLLVTLATRLLWLECISLRHGIGLLLMVSGIVIMGASL
>fig|1199245.3.peg.873 Polymyxin resistance protein PmrM
MGYRWAYCSVLLVSVAQLLIKWAMMHLPPICSPLLWVDSGHTTPLRVLAGGIIAYFLSTG
CWFMALRRLPLNLAYPLLSLSYVLVAIFSLMIPAFHETYTLSRLMGVALICSGVWLIYHP
SGRNNK
>fig|1203568.3.peg.324 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MSQSQGLLRGTPWKAIVLFSVPLLIGNVVQQLYQFVDAMVVGRHLGVLALASVGASMSLL
FLITGFAWGMTSGFAIPVAQAFGANDIKGLRRSVAAGAILSGATSLLMTLVGTIFIRPLL
QLMKTPPELIDDAATFGFWSFLFMFTLVFFNFLAAIIRAVGDSRTPLVFLAIACLLNVAL
VIVFVAVLDWGIAGAAFATAVSQLTSVLLCVTWVRWRIPVLHMGLDDWKVTMPELREHLN
LGLPLGFQTSVIAIGTIAVQVRLNDLGPNAVAAFTAAGRVDGIAVTFLASLGLATSTFVA
QNYGARQIDRVKHGVRQSLVVSIIVSIAIGLALFLLGAVFVELFIGNEQPVVLNLAHDAL
KIYSVAYWTLGVLFVVRGALQGLGHMKPPFYSGIAELVMRVFTAVVLGALFGFIGVAWGA
PLAWIGSIALLIPSYIVISRKLDERTYRSGPRTEEIEVLSAPLLAEKGVVADPTILQGES
FEDVRTGPIPIVRDRGETGQFPALDETYVLMDDQSTSENPEDEQR
>fig|1203568.3.peg.848 Glyoxalase/bleomycin resistance protein/dioxygenase superfamily
MPAPNLFLTYVSDVERSTDFYSRLFEIEPTFTSPRYVAFEVAPGVLFAIWTGHDENLASA
TPRTNEIGLMIPGPASAIDDVYEEWVAKGVHVIEEPHDDVFGRTFVIADPDHNLVRVSPV
D
>fig|1203568.3.peg.1216 Glyoxalase/bleomycin resistance protein/dioxygenase
MRDATFAIRQVTFDCDDPSALAEFWSSATGCAIAADYGDFVLLDSTPALGFQRVEDPTPG
KNRVHLDGGGVEREALVERLKKLGATELGSHEAPGLVWTVMEDPEGNEFCVGAPTPG
>fig|1203605.3.peg.375 Nisin-resistance protein
MNPIKKTRKVKIIIASVGIVLLAVILAAVHFIGPLFGFWLIPPSPKAHGKYAISLMDRGL
HANTPQWQTKRAEALDAIGKARSREEVTPIIEDALKVAGGKHSFLTTDEQRKEDETLFEL
PTSQADGGVVTVHLPGYSGTSEQGQQYADTVANALTASGACGAIIDLTMNDGGDMGPMLA
GLSPLLPNGEVVTFNTSLGDMVVTLEGGSVKGGGTPTKTDAGATKLNIPVAIITSADTAS
SGEQALLAFRGLDNVRVFGQPSAGYASVNQGFPLYGGLLMQLTVGETIARTSEHFGEIPI
DPDEVVSLDEAPTTAREWLASKGCN
>fig|1203605.3.peg.901 Probable antibiotic-transport integral membrane leucine and valine rich protein ABC transporter
MMRRLGATVWVDLRRQVTEGFWLVALVVALLLAAVLRAVDVEWAVWWPVVLLADLTITAF
YFAAAHVLMQRVEGTLNAQAVSPLRPHEYLASLVVSLAVLSLVEMSVLVLVGCGRRLNWF
AYLAAAAVAAALYVLYGFIAVSKYPSISRFLLPSGLWTAVFAVPMLPLFGAPSGWWLWLH
PLHPVVVLIQVAFGWLAAWWAVPALIVAVIWVLIGFKVASARFQRFLVGDQV
>fig|1203605.3.peg.1730 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MMQIKISDHFTFAKLLRFTAPTAAMMLFTSIYAIVDGLFVANFVGNTEFAGLNFIYPMLQ
MISSLGMMLGSGGSALVAKTLGEAQPERANQLFSLIIRATIVLGVVASAIGAWLVPDVAR
GLGATGQLLEASTLYGRIFLVGLTTMMLQAVFQSFFTAGGRPHTGLWFVIGTGITNMALD
WLLIVPLDMGLAGAAWATVIASLAGGLLPLIWFLRPNPSMLQLGKAVRDWRALGKACTNG
SSEMMANIAMAVVGMLYNYQLLKYTGADGVAAYGIIMYAGFGFAAILLGFAFGVSPLIAY
NHGARRTDELRSLFTKSVTLVTIFDLVMTITIFLVVRPVAGLFAAGNQNLLDLTVQGGRI
YALAFLLIGFNILGGILFTALNNGLLSAVIAFCRTLVFECLCVLVLPGFFGVPGIWASAV
VAEVLAFLVTLSIVLGARRHYGYL
>fig|1203605.3.peg.2442 Multiple antibiotic resistance protein MarC
MELVISSAVIFTMVMDPLGNVPLFLTALRNTAEDRKKRVLVRELLIALVLMLLFLVGGRG
FMRLFHVEAPSLTVAGGVVLLLIALRMIFPTPERSLRERIDDEPFIVPLAVPYVAGPSLL
AMEVVLVSGNPGAIGQYLIALLLSWAVSAVVLFFSASLHKVIGEKALTAVERLMGLVLVI
ISIQMMLSGVAEYFSLR
>fig|1206109.5.peg.275 Multiple antibiotic resistance protein MarC
MFIEYIHSVLFFFITLLPVANPIASTTLLLTLGKKIKAKERKKQIYFATLYVGIIILVCF
YAGKNILNAFGVSINALRLAGGIILLYFGFDLLFNVTEKKQITEKNHLQQSHLNISFVPL
ALPGTAGPGTIALIISSSSSLPSSCLIHFVIWSVTALFTLMFLICLLSANKIFKRIGPSG
IDAISRIMGFILISMGVQFIITGFQNMLIVLFHL
>fig|1208365.4.peg.242 Permease of the drug/metabolite transporter (DMT) superfamily
MESKDWFLLTLLAAIWGSAFMFIKISAVDFGPILLVTLRLLIAGVVFMPLLLQRKYRLLF
RSHLPGILIIGIFSNALPFTLFAFASLGATSNMLGILNGTTAFLTTVIAYFWLSESISTK
QVIGLCLGFFGVIILVNPANGSATLTASLCALFGSLCYAFNGNYLQKYHANSDKKVLIGW
SMLFGGILMVPIAAFNLPEAMPNLNSIFALLWLAVVSTGIGYLGYIRLIERIGAVKTSTL
TYLLPVFSILWGAIFLQEKITIFIFGGFIFVMMGMYFSNTTTRVKK
>fig|1208365.4.peg.1080 Glyoxalase/bleomycin resistance protein/dioxygenase
MKIQSLSYLLIETTDLQEWADYAKDVVGLMKNDSLSDEQNLFLRMDEKSFRFHIKTGSSK
KYLAAGFSLSDKAAFDNAKSELDKAKVDYEDLGHEIAKLRCVEECIGLHDPAGNRLELSY
GSKDASEPFASTQDIKGFITKGLGFGHVVFAAPNLELAHRFYIDILGFGDSDYMNFPMGP
APDAPEVKLNFMHCDNPRHHTVALYESPIPPSGLIHTMVEVNNIDEVGHGLDRAMQNNVH
ISSSLGRHSNDMMVSFYMQTPSGFDLEFGYDGWQVDWDNFEMQKSKIPSFWGHAFSPPES
>fig|1208365.4.peg.1253 Acriflavin resistance protein
MIKIVDFALSKARTTLALALLVIIAGSIARSSLGVAADPNIQLPLVSVSVFLDGASPEDA
SRLIARPLETRLRSVPGVKELSSSARLSYARIVAEFEVGYSIDTALRDIKQAVEEVKFEL
PREAEDPQIREYSFAMFPVMNLSLVGSASVRQKVFIARELQDRLESISEVLAADLVGVPE
EVLVGIIDKSKMETYGITLNQLYNAISSNNLIIPGGAQDTGSGKFNIEVPGIFETAEDVY
NIPIKVTQDAVVTLSDIGEIKRTFKDYSSFAKVNGEDAITLEIRIRVGANAIDAKNKILQ
TVSNFQDTLPSNLTIVKTNDETVWAEMMISELEGNIITAIFLVMVLVIASMGVRVGMLVG
LSIPFCFLLTFIVLKVIGIEFNFLVMMGLLLGLGMLIDGSIVVTEYADRKISEGLNRLEA
YRLASKRMFYPILSSTATTIAAFIPLIFWPGFTGQFMRFLPVTVFIVLSASLVYAMIVTP
VIGSIFGQRRSTLVSGDNEETGEIVFDKISAFYGKWLRVFVKNPGETLIAVLMLLWFLGY
AMYGTFGKGTIYFAEVDPFAAEINIRARGNFSAVESKEIMERVETRISSVNGIENLYLTT
GSQWFNSGGDTMARGFLEVKDTGDGQFTGNQVIQDVQSAVAAIPGIIVEIKPEEGGPSFS
SPIELGIFGNSEQRVASVTEKIEQYMQEEVVGLKNIRSTLPHPLIEWKVEVDKQKAAQLG
VSMIDIGALVQMLTNGFKVGEYRPDDSKDEIEIRARFDSELRSLSGIKDLKVNSINGLIP
ISTFIELIPSQNRQSVVRRNGKFFHEIGLATESGYLPSDKVKEMGAWLEMQDFGPGINTK
FRGQQEETEEVTAFLSGAALTALALMLILLVTQFNNFYQSILVLSAVFMSVVGVLTGLLI
MGKPFSTTMNGIAIVALSGIVVNNNIVLIDTFNRLTREFPDLIKEDVIMKTCKQRLRPIL
LTTTTTIFGLLPLAVGVSIDVLSREIIIGSRVVEWWTLLASSIVFGLSFSTILTLIFTPA
ALILPSRIKAWLQARYGLFKTST
>fig|1209989.3.peg.264 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MLVGNIAQQLYNTVDSIVIGRYVGDNALAAVGSALPIFNFLLVFFVAVSTGAGIMVSQYF
GAKDREKLSRSIGACITLTAIVATIIMIIGPIVVRPMLVLINTPESIIDWCASYLLILLV
GNWGFSYFNILSGILRGLGDSLSALMFLLISTVLNIFLDIWFVAGLNMGVPGVALATVIA
QVISAVLCAMKLKTMDYVFDLNLNMLKPKKEYVVQLLKLGLPSGLTQVIFSLAMITVQSL
TNTFGEMIIACNVIVMRVDGFAMMPNFTFGVAMTTFAGQNVGAKKMDRVEEGTRQGLAIA
VGVSIVITIIILIFGRYLMDIFTDTAELVDLSMKMMRILAVGYVAMAVTQVLSGVMRGAG
DTMTPMWISLITTIFLRVPIAYGIAYLTRSAQYPNGRPESVFVSLLIAWVSGAVITSIFY
KKGNWREKVLLS
>fig|1209989.3.peg.1147 Antibiotic ABC transporter, ATP-binding protein
MDEPTASLDPLIESEVYEDFTRIGKDKTVILISHRLSAAKLCDKIIVLNNGEIIEQGSHA
DLMGTKGKYYEVFTLQKHLYT
>fig|1209989.3.peg.1605 Vancomycin B-type resistance protein VanW
MRIEPIIKYKQDKLAQLFDEINKVIMVKPINAVFKTDNDIVHIITDVKGQILDEDMLKEK
IKEAIWTKNQTLVIPVKVWNAEMTKEDLEKMGIRVKIAEYSTEFDKTLKNRTENIKVASE
MLNGCIISPGETFSFNKVVGERTSDKGYKKAPAFINNEVIYDIGGGICQVSSTLYNLALL
TDLEIVERMNHSLPVGYVPLGRDATVSYGTIDLKFKNNTGGYLLLTSEITNDKLIVKFFG
NKKIDKYVELFSETIKTIPSPIIIKKDFNLEKGEIRIEQGNAGYVVNLWKRYANEKNEHK
VLISSDTYNPTPTLLYVGEKVKEITDDKNINATIIP
>fig|1209989.3.peg.3085 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MYSNGINSKAFAEGKVEKVLLRFAFPAIISLLVSELYGMVDTFYVGRYVGPNAIGALTIA
FPIQRLLSSTGLLIAAGACTKVAKYFGEKDYENLKITITNAIMLTVAVMTLMPLIIYIFM
EPILLRSGASSVTLPMAKTYTAIILIGGIFQGLTFVTCYIINSLGNPKVTLYATSFGAVF
NIIIDAILVINYNMGVKGAAIATVVSQIAACTFAMYNFYKVARSINLKNNFSIDIEILKS
IIAIGFTTFIIEISDAIVAVVLNNVLFAHGGDRAVIVSGTIMKVSMLMYVNIIGIASAMQ
PMVAFNYGAKNFKRLKETIRKTLKVVILTSVFLWAIMMLFAEPIIGSFVKDEALMKECAR
AYRIMISIFPTIGLYYISTYVYQAMGEAKMSFLLSIYRQLVLFIPIVLIFVKHWSVIGAW
LAYPATDIIAAITGFIYIRRVKEDINEYVDRAEAARLIIDS
>fig|1215343.11.peg.599 Modulator of drug activity B
MNKVFILNAHQYYGFSSGKLNAAIIHHIDEHFKRKGFEILHTHVMDKYDVKEELDKHLWA
DVIILQTPVYWMGVPWLAKKYMDEVYTAGVDGILCKHDGRSSKAPKDNYGGGGCAIGKKY
MLSLTFNAPKEAFDDPSQYLFQGKSVDDLFYPYHMNFRFFAMEPLPTFSCYDVVKNPEIE
NDFKRLEEHLNTVFKK
>fig|1218108.3.peg.29 Tetracycline resistance element mobilization regulatory protein rteC
MKYFLQNILLEIHNKENKISAQSKRLIDEAYEMTLYLQDLLFSVKKYIIEEGFKNDAEEI
HFFHTIKPQILGKLIFYNKVYRIETTCPVSNGKMYYSYFSTQFANLKREYIEHICNSDFY
RYYRSGRTDRDDTYFKRGNINYQDGLNSIVFEIDPAFSTFFDYKIARIIANELLYSYLLT
KINPDEGPDMILQKQESSKDIFWTDSKNALIELVYALHASGVISHGKIGIRKISLMFQIL
FHIPLGDLHHSFHRMKTRAGSRTAFLDQLKISLEEYMDKDL
>fig|1218108.3.peg.46 Tetracycline resistance element mobilization regulatory protein rteC
MNDFCKNIIRDLDDEINELSIEFNDSLALCEKAIGLTIDKIAKLKQVVLKRGFKDIEEEI
HFFKHLKPNVLSKLIYYNSIYKIETKKPYGGEKVIETHLNNELFNLKRFFDNNLEFYKYY
RTNSTYLDHKYFVRGKYDIKLSLDTYYFESDHSFSTSHDYKVAKIIANDLIQVYLEDNLS
NNIRYSTLKSAEKIKSTLVWTASKTALIELIYALHTQGVFGNGTIDIKVIATYFEQTFNV
NLGDFYHTFLELRNRKTNRTKFIDTLKEGLLRRMDEQEEK
>fig|1218108.3.peg.434 Membrane fusion component of tripartite multidrug resistance system
MEENNQEKKKINSKFIIVLGTLIILGGGYGIYKYLHGQAHEITDDAQVEAKITPVIPKVS
GYIQKILVEDNQMVHKGDTLVVLDGSEFALKLQQSQDALSQAEGQLGVAHAGVSQAGAAI
GVTEAGAVAANTTIETAQANVNTAQANVEAAKVQVWRTKNDFDRYNKLYQNQSITKQQYE
QALAAKETAEKQLRVVQEQLGVSKAQLASTAKQAQATAKQVNTSKAQADASRAQIKVAEA
TIGQSKTNIENAKLYLSYTYVIAAEDGQVSKINLQPGQLVQAGQSLFNIVTVNNLWIVAN
YKETQLEKIREGQEAIIKVDAYPNHEFKAKVTSLSPATGAKFALLPPDNASGNFVKTVQR
VPIKIEFTDKKDEMLKLIRPGMNVEADILLKSNTSVK
>fig|1218108.3.peg.435 Inner membrane component of tripartite multidrug resistance system
MEENNLIEYGSRRVIITITAIMCALLEIVDTTIVNVAMNDMKGSLGVSLTDIAWVVTAYA
IANVIVVPMTSWLSQQFGRRNYFAVSIIIFTAASFLCGNATTLWEIILFRFIQGLGGGAL
LVTSQTIITESYPPEKRGLAQAIYGMGVIVGPTLGPPLGGYIVDNWSWPYIFYINIPIGI
IAVLLTLSFVKSPKYAEKSKLSQVDFLGIILLAIAVGSLQYVLEHGQQDDWFSNSTIVIL
SISSFFGFILFIWRELVFDHPIVNLRVLKDNNLAVGTILSFVLGFGLYGSTFIIPIYTQS
ILGWTATDAGLLLIPSSLMTAFMMPIIATLLQKGVEPKYLVAGGFFIFFCYSFWSFKILT
PDTGSEHFFWPLIVRGVGLGLLFVPITTLSLSNLKGQQIGEGAAFTGMMRQLGGSFGIAI
ITTFISRWTVGHRTDLVSNLDTSDFDVQKHVQSLQMSFIGKGFAPNEALNKAYNLLDLQV
TKQATVLTYMDVFLYLGVIFLICIPFILFFIKKGAGKVISAGH
>fig|1218108.3.peg.687 MCBG protein-like (microcin resistance protein)
MGTNYHCEEEFLKLNFTETQNLSGDYENCKFINCELNGLDLSDLKFIACEFIECNLSNTI
LNNACFQQVDFKNCKMIGFNLETCNPFGLNVNFVHCVLNDSSFYHLLLKKSRFIECSLQN
VDFSYTDLSNCFFDHCNFSDATFDQTILKQANLKTSYNFRINPNENQLKGAIFSKENLIG
LVQHLGLKIE
>fig|1218108.3.peg.735 Acriflavin resistance protein
MIIVLFTILTLGGLFSYTQMGYELIPKFETNVVTISTVYPGASPNEVENSVTKKIEDAVA
ALENVKKVESKSYESLSVVMVTLNSDANADLALNDAQRKINAIEKDLPDDVDPPSLTKFS
LSDLPIITAGVTSSKLTEKDLYDLLDKKIEPVLSRVTGVAQVNLIGGQEREIQVSLDPVK
LKGYGLSVPQVQQAILTSNLDFPTGSVKTRENSTIIRLSGKYKSVDELNSLVISSMNGIQ
VRLSEVAFVQDSQKEVEKIARVNQSSAIIVQVVKQSDANAVAVSELMKETIQKVEADYKK
EGLKIQIVNDTSDFTLAAADHVIFDLVLAVVLVAIVMLLFLHSIRNAFIVMVSIPASLIA
TFIGMYLMGYTLNLMSLLGLSLVVGILVDDAIVVLENIYRHMEMGKSKIRASYDGAKEIG
FTVTAITLVIVVVFLPIAMSSGLVSNIISQFCVTVVIATLLSLLSSFTIVPWLSSRFGKL
EHITGKNIFEKFILWFEKQLTKFTHFISDMLEWCLKSTSRRIGVFIGVFIVLFGTIGILM
GGKYIGGEFFPKTDKGEFLVQMELPKDATIEESNFVTQKAEKFLRGKKEVVDMITTVGQS
SEGFGAAQATAYKSEIDVILNDKSEREDNSFIYAAKVKRELQEELVGVKVKTVPVGLIGA
EQAPIALVVTGPNLESAMKFAELAKHELEQIKGSSEVKLTTEAGNPEINVQVDRDKMSAL
GLNLQTVGLTMQTAFSGNTDGKFRAGEYEYDINIQYNDFNRSNINDVRSLIFVNDKGQQI
RLDQFATVTQSSGPSFLERRDKTPSVTVEAQSVGRTTGDIVTDFKESLKKIDNKKPTGVS
YVWGGDEENQSEGFGTLGYALLAAVILVYLVMVALYDSFIYPFVVLFSIPLSLIGVFVVL
ALTNNSLNIFTILGMIMLIGLVCKNAILLVDFTNHRKEAGETTHNALVQANHARLRPILM
TTIAMVFGMIPIALAKGAGAEMNNGLAWVIIGGLVSSLFLTLIIVPVVYSLFDSAIRRFS
KGEKVDYEAEMVADYEARQIKEEWEE
>fig|1218108.3.peg.760 Permease of the drug/metabolite transporter (DMT) superfamily
MENKNLLKGVLFVAMGSSFYGMLATFVKVAYDQGYTTAEVTASQFVLGIIILGIINLIMS
KKNKNTPAVKPKDKRRLMLAGTSLGFTSLFYYLAVQYINVSIAIVLLMQTVWLSILVESV
LSKKIPSAKKLVAMLLVLAGTVLATNLINQEIELNPKGLFWGFLAACSFTTTMFTSNRVA
TYLPPYKKSIYMLFGGGIIVALFVFFSQLGPYYFSGLMDLYRNFSDDVTSIHPLNLEIFF
TWGLFLSLFGTVLPPILLNKGFPNTGLGLGSIVSSIELPVSVTMAFIVLQEQVLAIQWTG
IAIIIFAIVISNLNFKKN
>fig|1218108.3.peg.777 Drug resistance transporter, Bcr/CflA family
MNNQNKSFLWLIIFLIGFPQISETIYTPSLADLAKTFHVSGNQIQQTLGIYFIGFAIGVF
CWGIISDFIGRKSSMLCGILLYILGSYLCLISKSLEFLLFSRFIQAFGAAAGSNVSQTIL
RDVCTDKERMVIFSKISAVLAFSPAIGPLLGSVVAEIWNVSMVFKLLLLIGVLAFLWSSI
SLKETLNRDIKITDSYKSIVISICKDRYFWLYGTLIGTINGVIFSYYGEAPFIFIEDYHF
SIIEYGCIGFIVAAACFSGANYCRKKIGLIDAKQILNKGNLFFFTGIAGLFILNFLPLKE
KVNVSFLLAGIFLMMFGLSVILPICLSNALNNHKAYLGIAGALLGLFYYCIVGGLTIIMS
MLHGTSAIAFPLFLFFCFLMNAFVISRLK
>fig|1218108.3.peg.1103 Multidrug resistance protein B
MKKILKIYIDAYSGLSQESWMLAIVMLLNRMGSMVLPFLGIYMISELGFSLESSGIVLSC
FGVGSVIGSWLGGWITDKIGNFKVQAISLFLSAPLFLILPYFKTVESFAVIMLVLSTISE
MFRPANSVAITRYAKKENITRAFSLNRMAVNLGFSIGPSMGGFLSNYSYDLLFYCNAGAA
LIAGVVFYVFFKGRKERNAATETTSEKVIIEKERNAYTDTPFLMFNLFCVLFSVAFFQIL
NTLPLFYKDVVHLTQTEIGLLMGFSGFLIVVFEMLLIHYTEKRFSVTQLLVFGSFITAIS
YFIFTFSHTLGMLYLAIGLMSIGEMLVLPLMSTVTAFRSQKNNRGAYMGLNGMSVAIAFI
ISPFLGTHVATDYGFSTLWIITTIVLIIVAIGYHFFTKPLLPKNI
>fig|1218108.3.peg.1323 Permease of the drug/metabolite transporter (DMT) superfamily
MILGVLALTWGSSFILIKQGLVAYTPYQVGALRLSIAGGILAIWGIPSLFKIPKNKLRYV
ALAGFCGNFIPMFLFPMAQTHVSSSMAGILDSLVPLFILLFGALLFNIKGTKNQVSGAVI
GFLGAVLLIGGDGFSGENSLVHCLLIVLATALYGLNSLILTRYLNDVPSFQLSSALFTIW
LLPSIVILFFSGFFDTFEGTEQQLKSLGFVTILGLMGTALAMILFYRLIQATGSLFASMV
TYLMPIISVFWGFLVGEKITWFHLVGFAMILSGVYLTQKKEKKVEIV
>fig|1218108.3.peg.2106 Permease of the drug/metabolite transporter (DMT) superfamily
MKGNQPSKWLIIAAYFVVYVVWGSTYFFIDKALHGFSPFILGSFRFIAASTILMGYCKLK
GYKLWDKQIVKQCMFTGFMLLFIDMAGIIWSEQFLPSGIVAIMAASAAIWFIVLDKPKWK
QNFSSIPTILGVLLGFIGVLMLFYEQTTTAHADADQQFLNMIGLIVLIFCSIAWTLGSLY
SKYVTEKQKKEVTKPKEELNIMVKTAWQMITAGVLFNTVAMFNGEYANFNLENVATEDWL
AMAYLVTFGSILAFGSYVWLLQHRPAVEVSTYAYINPIVAVALSYFFTDDIVTHLQIYGL
AVILFSVLLMNWNLYKNTKLVQKILHFVSRKHYAH
>fig|1218108.3.peg.2182 Permease of the drug/metabolite transporter (DMT) superfamily
MKFKGYAYGLISSISYGLIPLFILPIKQANFSIDTTLFYRFFFSALIVGVYLFVKKQSFR
VHSKQIPVLIVLGLLYGISADALFLGYDYLSAGIASTLLFVYPLIVAIIMVVFFKERITI
STIAAIAFVLAGIFLLSFKDGQFKLNPIGLGIVFISALGYGLYIITVNKSSAREIKGFTL
SFYSFLFTTIYYAIKMLIQKESFILPSLELTFNFFTFAFVTTVISSIALIFAIKNIGSTA
TSILGASEPVVAVAVSVIIFGENFSMSLALGIFMIIFGVTLNVVGDAYQQKRIKSS
>fig|1218108.3.peg.2434 Bleomycin resistance protein
MFLEIHPKLPMRSKEITFKYYVDHLGFVPFLNDLEDYFMVRKDGIEIHFFKFEELVPEEN
YGQVYIRVADIELLYETFVKNKIQIHPNGKLQVKPWGQIEFSILDPDHNLLTFGQAV
>fig|1218108.3.peg.2748 Permease of the drug/metabolite transporter (DMT) superfamily
MKDIKLLIAISIVAIVWGTTFLGIRVAVETIPGWFVAGIRQFIAGIIMFILLLYKKELKW
IGWKNLSYQLIFSSLMLIAANGLTTVAEENLSSSLAALISATSPILVFLGSIFIGLQKFS
FKGLIGVLMCFCGVLFIFWDGLQELANPEFRTGILLLFCAITGWATGTIFTKKMNIQSKN
ISLNLFYQFIFAGIIQIIFAFIFSDNYNFGNWSTKSISAMLYLAVFGSVITFFSFHYALT
KISPIQVSILSYFNTIIAIVLGWLILDEEISKKFIVATILIICGVFITNYKPEIFKKK
>fig|1218108.3.peg.2967 Membrane fusion component of tripartite multidrug resistance system
MGKQQTKGEKRMNRMLSVVAWIFITIGILAIAWFYFFSRSHVNTNDAQVRQYITPVSSKV
SGFIKKVNFDENQFVHKGDTLIVIDGREFQNQIDMAEANLASTAQSVLTYEKAVETKASD
ISIVTANIEAAKIEVWRTEKDYNRFKNLVEEDAATVQQFEEIEAKYKQAKANLSALEQQR
NAVSVSTSAEQTKVAPVRTQILQRKAQLNNAKLTMSYTYIIAPYDGWVGTRNIQQGQLIK
EGQALVQVVSKEKWIIANFKETQIGEIDMDKPVIIKADAYKNLEFEGKIKSLSPASGSEF
SLIKPDNATGNFVKIEQRFPIKIMLKDSKNNEKLRSGMNVIVSTEKLEN
>fig|1218108.3.peg.3026 Glyoxalase/bleomycin resistance protein/dioxygenase
MKYAYTIVYVKNVTETIAFYTKAFAFETKFITPENDYGELISGETTIAFASVELGNSNLK
KGFTAIEKSAKPFGVELAFTSENIETDFKTAIDAGAIEFEPLTEKPWGQKVGYLLDNNGF
LIEICTPIAH
>fig|1218108.3.peg.3031 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MNRQKQIILNDNLPKVMWELSWPAVVAMVLYGLNNFLDGIFVGHLISNTALAAVGVAYPL
AQFAQGFGTLIGTGIGSAISIWIGAKDSSKLEKAFGTVNYLTLLFSVLITIPCYIFADKL
VYMMGGREEILTLGVEYFRVTILGSFFWIHGLALNMIIRAEGRMKTAAWMIAVGLVVDLA
LKPLFIDTFGWGVAGAAWATNISMIIYTLLGIWYYAGGKSSFKTKFWSLKKEKEIMKETL
SLGTPGFIMMIMIVIQNIVVFNALAEYGTAADITFFTAVNRFYILLNTPLWGLMRALQPV
TGMNYGAKKYDRSIKAYRLFSFVGLVILLPFWLFVMLFPSEVLTIMIPDMKFLPGQLMDF
RIYMSVLLALPFVFMAMVWFPAIEEAKPATLISILRQMVFYIPIMLIVPGFYGVSSIYLA
SAVIDWVIFFIVIFTVWKSVKKLQAKSIVTP
>fig|1218108.3.peg.3160 AcrA/AcrE family multidrug resistance protein
MVGALAMALSSCGKKDNAAQQAQGPTPYPVVDVPTKVVTSYDEYPTNIEGIVNNEVRAKI
QGYITEVYVDEGQYVQAGQPLFKLETNVLTQNADALRSGVGAAQASVKAAQANVSAAQAA
VNAAQVEVNKLTPLVQKNIISNVQLETAKANLAQAQAGHNQAVAALAQAKSGVTQAQANY
KGAQANVDYSVVRAPVSGVVGSINSRQGTLVGPTDQTAITVVSNTAKVYAYFSMNEKEYL
NFISKSEGATLKDKLNKIPPVELVLANGDIYPEKGKIQTVTGQINPTTGTIDFRVTFNNA
AKLLANGNSGRIRVPKTYVDALVVPAAATFEQQGMTYVYKVKNDSAIATPITVVDNTGNI
VVVKEGVKKGDKVVAQGVGKLRDKTPIKPTPSNFDQIVESTKPVF
>fig|1218108.3.peg.3265 Modulator of drug activity B
MKIFIINGGQKFAHSGGAFNNMLNNWTTDFLKEKGVEFRVTNINDEFDAFDEVENFKWAD
TIIYHFPVWWFQVPNRLKYYIDEVFTAGHNNGVYKNDGRSHTNPDINYGTGGLMHGKKYM
VNTTWNAPETAFTMEGEFFDQHSVDEGILFGFHKMNQFAALERIDGFHFHDLEKNATHER
IDAYEKIYKAHLERVIG
>fig|1218108.3.peg.3374 Glyoxalase/bleomycin resistance protein/dioxygenase
MKNYKPEQYNSLSPYLIVDNALKLVDLLVAVFDGKILRRFDREDGKIGHIEVKLDDSVIM
ISDSTEEYAANKTMLHLYVPDVFKTFEKAVENGCEPIEKPGDPDTRGAFYDFAGNYWAVS
TQTD
>fig|122587.1.peg.167 Bacteriocin resistance protein, putative
MDFSCGAASIATLLNNFYGRHYSEAEILDKMDKTQMRASFDDMQRIMPELGFEAQGYALP
FEQLVQLKIPVIVYLKYRKNNHFSVLNGINGETVLLADPSLGHVSMSKSQFLSAWKTRDG
EMEGKILAIVPKNTDFVRNQMFFNKNPVRQTRFTVEQIQMRQKR
>fig|122587.1.peg.1425 Multiple antibiotic resistance protein MarC
MRRQFAASDACRTGLKEGEIMGLGMEIGKLIVAFLVLINPFSALSLYLDLTNGHSTKERR
KVARTAAVAVFAVIAVFALIGGTLLKVLGISVGSFQVGGGILVLLIAISMMNGNDNPAKQ
NLGAQPETGQVRPARNAGAIAVVPIAIPITIGPGGISTVIIYASAAKTYGDIALIIAAGL
VVSAICYAILIVAGKVSRLLGATGLTILNRIMGMMLAAVSVEIIVSGLKMIFPQLAG
>fig|122587.1.peg.1887 Permease of the drug/metabolite transporter (DMT) superfamily
MFYQILALIIWSSSFIAAKYVYGGIDPALMVGVRLLIAALPALPACRRHVGKIPREEWKP
LLIVSFVNYVLTLLLQFVGLKYTSAASASVIVGLEPLLMVFVGHFFFNDKARAYHWICGA
AAFAGVALLMAGGAEEGGEVGWFGCLLVLLAGAGFCAAMRPTQRLIARIGAPAFTSVSIA
AASLMCLPFSLALAQSYTVDWSVGMVLSLLYLGVGCSWYAYWLWNKGMSRVPANVSGLLI
SLEPVVGVLLAVLILGEHLSPVSVLGVFVVIAATLVAGRLSHQK
>fig|122587.1.peg.2006 Membrane fusion component of tripartite multidrug resistance system
MKSGNSEPNLMDTHTDETKLQNTQAKRKRRLTALTLLFALAAAAAGSAFFLWWQHEEETE
DAYVAGRVVQVTPQKGGTVRKVLHDDTDAVKKGDVLAVLDDDNDVLAYERAKNELVQAVR
QNRRQNAATSQAGAQVALRRADLARAQDDLRRRSALAESGAVSAEELAHARAAVSQAQAA
VKAALAEESSARAALGGQVSLREQPAVQTAIGRLKDAWLNLQRTQIRAPADGQVAKRSVQ
VGQQVAAGAPLMAVVPLSDVWVDANFKETQLRHMKIGQPAELVSDLYGKQIVYRGRVAGF
SAGTGSAFSLIPAQNATGNWIKVVQRVPVRIVLNREDVDRHPLRIGLSMTVKVDTSAAGA
PVSKTPGAALPEMESTDWSEVDRTVDEILGQSAP
>fig|1230341.3.peg.1100 Broad-specificity multidrug efflux pump YkkD
MAWVYLIIAGLGEMFGVLMINKFHSERSVTSILLLAAGFSASFLFLALSMETLPMGLAYA
VWTGIGAAGGALFGMILYGEPKDGKRIFFLSLIIAAVIGLKLVSP
>fig|1230341.3.peg.1283 Permease of the drug/metabolite transporter (DMT) superfamily
MKMRGIVLVVLAAVFWGISGGIGDILMGKGWSPLVISFYRGGVGLILFAGWWLAGKKEKP
VFTPPIILFSVLAGAGVAGNFTFYFFAIEASSIAVAATLMYTAPVFVLLASFLLRIEDST
WFKWGCIIGVLLGIVLLTGAYNTDNLSGGVFGITAGLAAGVSYALFIFGFKKATAIGDPK
TILSVAFLTFCLILLPFNDMTEVTYAVTSGDAGWFILLGLVGAGISFIIYVIGMRGTAPS
TASMVAMAEPVTASLFGVLLLGDTLTIIQLAGMAVILFTITILSVKQSGS
>fig|1230341.3.peg.1507 Permease of the drug/metabolite transporter (DMT) superfamily
MPYFLLIFVVIMFSGNIIIGKAINDLPPYTIAFLRLVVAFIVLLPIGLRSARQYKETFFK
YKKPFLIMTLTGITFFNTFIYASLQFTTSTNVSVLETIIPVVTVILSAYILKEKIYKIQW
LGVFVSLLGAMWVVMDGNIFQLAAIEWNIGDAIMIGAIATWAIYSIFVKQYMPLFPNYGA
LLVMSGLSVLVLLPVVILEWIIHGVPAFDAGNMAGILYLGVFPSFLAISMYNLAVDKVGA
SKSSIFLNLLPVFTMAGAAVWLGEDVTFTQVGGALTVIAGVIVTTQGDRISRRRI
>fig|1230341.3.peg.1857 Multidrug resistance protein (efflux transporter)
MAKIPEKWLVVVSVLFGTFTVILNNSMLNPVLPRFIEIFDTTAVGAGWILTIFMVSMGMT
MPLTGYFGDRFGKKKVYLVGLTLFLVGSTSGFFSSSLGMVIASRAIQGSAGGLMMPIAMA
LIFNSFPRNERGLAVGIYGVAAMVAPAIGPTVGGLLIQVLEWPWLFAVNIPFGLIGLLLS
VKFLEQTESDPEKRFDLIGFLLVTSAIGGILFALGRGRTPEILFEPLNLGIIITGLVLIF
VFVRYEIRQEQPLLNLSVFKVPTYAISILITSSASIGLFSGIFLLPLLIQNVYGLNEVWT
GLLFLPAAAMSGVFMSFGGRLLDKKGPKYVLPPGLAIMGISTVGLGMLETSSPFWWILLL
NAIRGAGMGMSNMPATTTGMNAIPDEYVAQGSAMNNIIRQIASSLGIVFFSIYYEVRRAQ
IAVGTNMQEATLQTLNEAFLVSSAVLFIALPFAFFMKGVQDD
>fig|1230341.3.peg.2100 Bicyclomycin resistance protein
MLHNPTGKERFGLALLLGMLGIMGPLNIDMYLPSFPGIARDLATTASMVQLSLTACLIGL
AIGQIVVGPISDASGRKRPLTVFLFLFAIASLLCALAPNIYILIIARFLQGFTASAGVVL
SRAVVRDVFDGRELTKFFALLMVINATAPMIAPMAGGAILWFPFSSWHTIFYFLSLLGLI
IVFTVTWKLPETLPKERRTPSSVGASVKTIGRLLVDRSFIGYALTIGFVHGGSFAYVSGT
PFVYQGIYGVSPQVFSILFGINGLAIITGSFLIGRLGGIIHERKLLQTAVITAVAATFFL
LIMTITKGPLPTLVISIFIYMTCMGMVLTSTFTLAMEKQGHRAGSASAVLGMLPLLFGAA
ASPLAGLDESTAVPMGLILFSTSSLGLVTFFTLARPYAVKKV
>fig|1230341.3.peg.2515 Permease of the drug/metabolite transporter (DMT) superfamily
MSDRNKGILLLLISALGFSMMGAFVKLSGDLPTVQKAFFRNIVAAAITLGFVLKHKDRIF
GKRENQKLLLSRSSLGSVGIVMNFYAIDNLVLSDAEMLNKLSPFILIIFSGIFLKEHARR
YQIVSIIIAFLGTLFIIQPEFSVQVLPYIIGVLGAVFAAGAYTMLRVLGNKEKHYTVVFY
FSFFTTVLLLPFTIFFYEPMSVQQWIFLLLAGAFATVGQFGVTLAYKFAPASEISIFFYS
TVVYSALLSIVLFGQIPTLWSVIGYVIIFSASFYMFLKNNHIDKKQLARQEEKKAFRSS
>fig|123214.3.peg.958 Glyoxalase/bleomycin resistance protein/dioxygenase
MDKLPEDENSIEKGVIFRPHHVSITVKDPEKSRNFYKLFGFKEVFRWSDSSTTVIHMKLN
DLILEIFSFKETESSSDQRESLEEELKIIGVKHFALRVKDIQKAKKFLSEIGIVPENTRI
NKGRTGILYFFIRDPDGIFVEIVQDDRNI
>fig|123214.3.peg.1176 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MNKKILHLAIPAALTNLLDTLQLLIDILMVGRISPEAVGAVGLSGQLIILIYSFISIFYI
GTNVLVSRFYGEKKPEEAGKAVSGLLIISVLFSLPFFIYTYEFSGSYFSLMGAERSVINL
GTDYTSILSLSIPFLFIGAVLYSSIVASGDTKTPLIISLFTNLLNTFLNYCLIFGNFGFP
RLEVEGAAIATTISYILEVLIYFFIFLSGKTGIKPELSLSFHYVLKALKVGIPAGIEKFV
SFGSFLIFVKIVTGFGTYVLAGYQIGLRIEGLAFMPGFGFATAAMVLVGQYMGAKEPEKA
EKSVIQTVKLAGLFMGIVGVFFIVFPEFFVSLFTDNIKTIREGSLYLRIVGVSQIPLAVD
FVLNGALKGAGATKVTLIINSLSFWIFRIIPAYISAKIFNDILIVYIVMTIETFIKGFIL
WTVFKSGFWKKIKI
>fig|123214.3.peg.1496 Acriflavin resistance protein
MEDKNRSYGLAGRIARAFIKSPLTPLMVLASLLLGLFAVLTTPRDEEPQIVVPMIDIIVP
FPGSEADEVDKLITKPLEKIMWEIPGVDYVYSYAGDGFGVTTVRFYVGEDPEDALVRLYS
KLMSNYYRMPQGAMEPIVKPKSIDDVPILALTFYSDKYSSYEIRRVVEQVEDELKQLYNI
SETTILGSKPKSIYIYFDPSKLNAYHILLPQVVQALQYANSSLPSGEFDKGNYRFKLRTG
QFLNSVKDVENVVIGVYNNKPIYIKDVAKVEIGEGEVTNIVQFGYGIRGEGDKNKLYNAV
TLAIAKKTGSNAVVVAEKILEKLETLKGKVIPADIHVKVTRNYGETATEKANELIEHLLI
ATFSIVLLIAVTLGWRESLIVAVTIPVTLAIALFLSEMYGYSLNRVTLFALIFSIGILVD
NSIVVLENIHRWFSMRKLPNEKAAIVATDEVGNPTILATFAVIVALLPMAFVSGLMGPYM
RPIPINASVAMFFSMLIAFILTPYLALRWLKHDHEHESPEALEKEDEARAGILAKLFERI
YMPLFLSRIKRYIFLGFMGLLLVGSVWLFVERVVLVKMLPYDNKSELFVVLDMPEGTPLE
KTYKVAKEIAEYAKNVNEVENYVIYAGIPAPFDFNGLVRHYYMREGTHYAMIKINLIGKH
ERKAQSHQIAERIRGDIERIAKKHGAKYVAVVEPPPGPPVLSPIVAEVYGPDYKTQLKIA
DEIKNIFEKAEGVIDVGIYANLPQRQYILKPDREKIKRYGFNEDMIVKTVRIALAGYSVG
FIHSAEDLNPVNIVVRLDEKYRTSINDILSMKIPTPKGAIPLGSLVTVKEGSAKNDIYRK
NLQKVVYVIANVDDTVGSPVYPIVDLSEKIRNIKTPDGKGVEILLTHQPHLEDRYYVKWD
GEWQVTYETFRDMGIAFAVALIVLYILLVGWFGSFKMPMVIMSPIPFTLVGIVPGHFIMG
AFFTATSMIGFIALAGIILRNSILLVEFTQQKLQEGYALEEALLEAGIVRTRPILLTAAA
VVVGAFVIIFDPIFNGLAIALIFGTIASTLITLVVVPVLYYMIVGKTAVKLDMPPAVPVD
EKPEK
>fig|1234409.3.peg.194 Permease of the drug/metabolite transporter (DMT) superfamily
MKEKQKGVLLAIIGALCWGIQGPISQFLFQEITLPTEWLMGVKMTLAGILILLFTAWKEK
KAIFGPFKNKKDTIQLLLYAYVGLALVQYMYFLTIKASDAGTATILQSLGTIMIIIFTIF
VYHKWPNRNEWIAVVVAIIGTYLLVTQHGTLAITKKALIFGLLLAFGGAMQTMLPVQLLK
KYSSFTLLGWGMLFGGLLFSIIHPFWENTPEMNGMTISALIFIVLFGTVLSYICFTTSLK
YISATSAGLLASFEPASATLGAVLFLGTSFTGTQVIGALLVLSTVFILALPIPKKKGEQ
>fig|1234409.3.peg.437 Drug resistance transporter, EmrB/QacA family
MTKQRKLIVTIALFIATFMSAIEGTIVTTAMPTIISSLDGLSVMNWVFSIYLLMSAIMTP
IYGKLADLKGRKIIFIIGILFFIIGSSLCGLSQSMEFLIFSRAIQGIGAGSILPLSLTII
ADLYTAEERANIMGLNNAAWGIASIIAPLLGGMIVQYLNWHWIFLINVPIGIIVIGMVFF
GLKENRNNFNSVGKLDIKGAALLMIFLLLFLYAFQLFGDQGFKAPVFLLLIISVIILLLF
IRIEKVTENPIISPKLFNSKSVLIINCVTLCVSGFLTGIDVYTPMWLQTLNGSSATLSGL
ALAPMSIFWMVGSFLAGKLLSRLEVKKILLIGSSLLFVSTIIYSIYPISTPYFVFCIIGV
LLGIGFGMSITTSAVAIQESVETKLVGSATSLNTLFRTLGQSIMVAIYGTVLNMSMNSEM
TKYPQIHQEDLNRFMNVQEVHNVPTGILQSLRSIMYNGLHHIFITSVVIMLLSLVFLLLW
KAKNTNKNEKNEK
>fig|1234409.3.peg.481 Quaternary ammonium compound-resistance protein SugE
MYLLLLALAGLCETVMVYTMRKSAGFKVKSWSILTILVAICSLTLLSIAMTMTEVGIAYG
IWVALGSVGSLLVGTILFKEHLNLGQWIGIICIIIAVIGLKMTV
>fig|1234679.3.peg.310 Drug resistance transporter, Bcr/CflA family
MKKSIETKVKAPALLLLIVLVGFPQISETIFTPSLPDIALAFQTTMGSVQLTLSIYFFAF
ALGVFFWGLISDYIGRRPAILYGVVLYGVGSCLCLWADSIEFLLFARFVQAFGASTGSVV
TQTILRESTTGNQRHALFAQISAALAFTPAIGPLIGGFVDQYWGFSAVFLVLVVMSIGVF
GYAYFGLAETLDASSRSSVALRPIFKRFLKNKKVLTYGFLIGAINGVLFSYYAEAPFIFM
EYFHLSAAIYGLLGIVIALALIIGSMLSKRWLAIWQPEKIIFKGIQIMLVGAVILLTLSF
FNFIPGVIQFSCYLIGIFITLIGTGTALPNCLSLALVDFQDVIGSAGGIFSLYYYLLVSL
ITLGMSVLHNGTLWAMPLYFIGIGIFMLILTKRFIYLLKE
>fig|1234679.3.peg.479 Multidrug resistance ABC transporter ATP-binding and permease protein
MARNKFDVDEELEQEFNKEHYQRLFQYVKPYKKPMLTTLFVILIANIATMLGPYFTKLVI
DDVIPNKNMTLLGWLAVAFIVSVFVTGWCMRYRIQSITLIGQDMLKDMRSDIFEHLQKLP
FSYFDSRPHGKILIRVVNYINTLSDLLSNGLINLISDVISVVITLIFMFAIDFKLTLYSL
ALLPVLFIFVMIIKNKQRKAYQVLSNKQSNLNAYIHESIAGIKVTQSFSREDENYKIFSE
VSNEYRSSWMHAVKVQFLLWPGVQNIAVITTCLIYFVGIRGLGVEVSTGTLIAFIGYVNN
FWNPVINIGNFYNSLITATAYLERIFETLDVEPDIKDAPDAFELPPIKGDVRFRHVTFRY
EEGKDILKDISFHVLPGESIALVGPTGAGKTTVINLLSRFYDINEGEILIDGVDIRRVTL
HSLRKQMGVMLQDTFIFSGTILDNIRYGKLDATEEEVIAAAKVVRAHDFIVDLKEGYHTA
VKERGSTLSAGQRQLISFARALLADPKILILDEATSSIDTKTETLLQDGLDKLLEGRTSF
IIAHRLSTIKNSSRIFYIDQGTVQEAGSHDELMAEKGYYYQLYQSQFDLLKEI
>fig|1234679.3.peg.567 Quaternary ammonium compound-resistance protein SugE
MGFISLVVAGFCELGFVVLLKKSEGFRLKSYGILSMIVMGMSLYLLSIASKTIPIGTAYA
IWAGIGASASVLWGMIFFGESRSFKKIIFVTLIIIGVVGLKLTSH
>fig|1234679.3.peg.729 Quaternary ammonium compound-resistance protein SugE
MNRSWVYVIIGAILEVAWVTGLAHSTTIWQWIATIISVTISYGLFTLAAKNLPVGTLYAV
YTGLGTVGTILVGIWLFNESIYPLKAFLMMTLLIGIIGLKLVEAKGK
>fig|1234679.3.peg.787 Glycopeptide antibiotics resistance protein
MFFLQNLYEFTESNFGDTINHFPLIKLIFYSVDRTLRYFLVWLLIRGIYLLYKHLKGTKI
RVAREFVVQFFVFYVILLFQLTVFRGEYSITNVYIELRPLSEVNWQPFTETFKLTQGTSL
FDFYYNLYGNIFWFIPLGFCVAYLSQNNHPFLRTFFIGLFCSIAIETMQFLFRTGIADVD
DVMFNTTGALIGFVLYEVYFLLKKLFSKQKRRKEAV
>fig|1234679.3.peg.1013 Multidrug resistance protein B
MQMNKKERLPRDLWIVAIGMVLLYTGLSFIWPFNMLYMTENLGMSDTAAGTALLVNSGIG
IIGSVIGGIIFDRVSGYVSLAIGTGILVLTTGSLFLFHGHPAFIYNIWAVSVAMGMVFAG
LYTAAGLTHPSGGRTGFNTIYVAQNIGVAVGPFLAGFLAKDGLGNVYTGSFAFALIYALF
FFVYFRKIDWHSNKVTSETKHKQKGTVRGKATKIGLISFGLLLLTYLFCQLPHVQWQSNL
STYMTSQKGVTTAQYGNLWSINGTLILIGQVLIIPLVARFKEKLSLQIYIGIGLFFCSFL
FAMQAESYGGFLLGMILLTLGEMFAWPAIPAIAYKLAPVGQAGLYQGLVNGTATAARMIA
PIFGAVVVANLGGITSLFIAIFILLGLAIVSLFLQQKTQKMMDI
>fig|1234679.3.peg.1082 Membrane component of multidrug resistance system
METKYQNSHIVTILGVIIMGTFVTILNQTLLSTALPSIMNDFSITATSGQWLTTSYMLIN
GIMIPITAYLVERFTTRQLYLFAMITFFIGTAIAATADVYWVLIIGRMVQAVGAGVVLPL
QTIVILYMFPIEKRGAAMGLIGLGMNFAPAIGPTFSGWVVQNYHWSMLFYFILPFALIDI
IIAFFVLKNVSEVGKPKLDWLSVIYSTLGFGGLLFGFSNASSHDFLSINVLGAILVGIVS
MILLVLRCNRSEHPLLNFKVFKIRGFRLNMIISFIILAGMYGGIILFPIYFQSIRGWSPM
KSGMILLPGSIVIAVMSPITGRLFDKYGGKKLAITGLFLITIMTFCIGFLDLNSSVTLIV
SIQLIRSLGISLTLMPLQTGAFNAVPLDMAAHASAMFNTQRQLSGSMGTALFVVIMTMVS
NSQSAVALGSPILASLKGFQFVFMVVGLFSLAGFLLTFLIREKRKNIEVDVLRN
>fig|1234679.3.peg.1742 Multidrug resistance ABC transporter ATP-binding and permease protein
MLKRFFSYYRPYRKLFILDFSCAIVAAILELAFPIVVNQVIDKLLPTGNWSLIVTAALSL
LFFTL
>fig|1235755.3.peg.47 Glyoxalase/bleomycin resistance protein/dioxygenase superfamily protein
MIKKLAGVMLYVDNQEEAVKFWRDGLGFTVVSEEELPEGYKAVEVAPDGKSETSITIFEK
AFIRKYSPELGMGTPSLMFETEDAGALYEDMKSKGITVGEMTEMAGSKVFNFKDGEDNYF
AVSESD
>fig|1235755.3.peg.220 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MYHTDSKREMYAILMRILWPILITQILLYSMNMIDTMMSGRASVEDLAGVAIGSSFWAPV
STGINGILLAVTAIVANLMGADEKEKVHNTVTQAMYIAVAIAVIVLLSGLFFLDDLLRMM
DLAADVHDISYHYLIGLSTGIIPLFLFSVLRNFIDAQGLTRVSLYVISMSLPLNVFFNYS
LIFGNFGFPELGGIGAGYATAITYWLIFFIAVFMTFKVEMLAAFKLFRRMAVPSPEVMIH
HLKIGIPIGVLLFVETSIFSLMTLLIGIMFTTDIIAANQIVLNFTTMLFMLPLSISMAMT
IVIGFSAGGGRFHDARRYKMMGLATSLALISASSLLLYIFREQISYFYTDDPAVVAIASP
LFLFAIIYQVSDALQALFHGVLRGYKDVIIPSVIAVVSYWPVGLTAGYLLAAYTALGVYG
FWIGISLGLTCAAAGFFMRLFTIEKRNMFGQGESAQ
>fig|1235755.3.peg.402 Drug resistance transporter, EmrB/QacA family
MDNTTKYEYLSENSNVKTLPIMLSLIIGTFFAILNETLLNIALTTLMHEFDITLPTVQWM
ATGFMLVMGIVIPVSALLLQWFTTRQLFLGTMIIFTVGTAICAMAPTFPVLLSGRLIQAI
GTGMLMPIMFNVFLLLYPPEKRGKIMGLVGLVIMFAPAIGPTLSGVIVEYLGWRFLFITV
IPFSLFSIIFAFIFLVNVSEVTKPKIDIPSIIFSTIGFGGTIYGFSSVGKSDAGFMNPEV
MVAITAGGIGIALFAFRQLRLDEPIMDLRVFKYPMYAHAVILFLIIIMTMFASEIILPIY
MQGPLALSAAAAGILLLPGSLLNGALSPFMGALFDKLGPRPLMIPATLILSGTMFLMSRL
DTDSQPWVILVGFMLLMISVSATMMPAQTNGLNQLPKRLYPHGTAVVSTLQPVAGAIGVS
VFISIMNARQMNFLGNASNPDDPATIDQAMVAGVELVYFIAFTISIVAVIMSLFVYRAKP
TDSMKMQQPDIQP
>fig|1235755.3.peg.466 Antibiotic resistance protein
MSETKQKIWTKDFTLIVIANFFIFAAFQMTLPTLPLFVQEIGASDRWIGIVVGIFTFSAL
LIRPTAGKMLDTKGRAPVFLTGLVIFVISMFSLAASYTIAILLLVRIMQGAGWGLSSTSS
GTIATDLVPKERRGEGLGYYGLSGNIALAFGPALGLFLTDHISFTMLFSICGILGFTALM
LALNIRYKKGEKPEQDPKTKDTYVPHFDIVEKRALPAASLLFFITVTFGGIATFLPVYTF
QKGFDSQYIQFYFVIYAAFLMLSRLFAGRLYDRRGIAVVFVPGSLSIIAAMIMLGFLPNP
AYLFIAAALYGFGFGCVQPALQAWAVNRSENNRRGMANATYFSAFDLGVGFGAMMYGFIA
EAFGYSTIYFTSAFSVTLSLILFIIMMNRLNKEQSNAPGI
>fig|1235755.3.peg.904 Fosfomycin resistance protein FosB
MKVGNINHLLFSVSDLDISIEFYENVFNAKLKVRGRKTAYFDLDGHWLALNEEKGIPRNE
IKYSYTHIAFSIEESEFENMYEKLENLGVNILNGRERHARDGRSIYFTDPDGHKFEFHTG
TMQDRLDYYKEEKDHMSFHD
>fig|1235755.3.peg.1356 Permease of the drug/metabolite transporter (DMT) superfamily
MSNMKKSAVTLLGVAVICIAFAAIFVKLSAASASIISMYRMLFASLLLIPIVYRHRSEFN
RLSAREWLSLIIAGGFLALHFGFWFESLQLTSVASSTVILALQPIVAMIAAYLIYRERVA
RAVAISVFISFSGVLIISWGDFSFSDMSALSGNMLSFLSVVAVVCYFMIGQRSVKNLKHW
VYSFVVFTFAGFFLLAFNLIAREEMMSYPPREWILFLMLAIFPTIAHVIFNSLLDAVSPT
TISMSMLLEPVGASLLAYMLLSETLDVLQLIGGVIILIGVYFFLMAQRKNNYIK
>fig|1235755.3.peg.1755 Chloramphenicol resistance protein
MNKKLLITFTVGVFLLGMMELIISGILELMSDDIGISHAMTGQLITVYAVSFAVFGPLLV
KMTEKFRPKPVIIASLVVFIIGNLIFGISNTFLMLSLGRVVTAVAAAVFIVKIMDMTVLL
SRPEIRGKMIALVYMGFSAANVFGIPIGTLIGQQFGWRIIFWLVIIIALLVGIGILSLVP
DRKGEELGEPVQDKVLDKRNVFLYIGVTMAVLIGNYIVIGYISPLMTSNGFTLESVSVAL
LIAGAGGMTGTYIGGLLVDRIGSKRTIIYMLILFMISMAILPLLYGTPVLFYINLFLWSV
FQWSTSPSVQSGLVENVQGSAAMVFSWNMSGLNLGIGIGAVIGGIYISNFDISFAPWLSV
AIVGLGLLSVSFVREHEEIV
>fig|1235755.3.peg.2123 Membrane component of multidrug resistance system
METNNNHKPDYRLIVILLSGAFVALLSNTFLNVALPSIKNDFDISTSTVQWVSTAYMLVS
GIVIPTTAFLMQRFSARKLFIAAMVLFLTGTLVAGFSPVFPVLLLGRMIQASGSAILMPL
LMNVMITSFPPAQRGTAMGLFSLVMFFAPAIGPTLSGFVVQHYSWHMLFFMMAPILLIVL
SIGWFKLPGTDTHYTTKLDIPSVILSTLGFGGILYGFSAAGNSGWMRADVLIALFTGFVA
TFFYIKKQTRMDKPMLDFKVYKFPMFMLASLLIGTMNMALFSGMILMPIYLQDIQGISPL
ETGILLLPGALIMGFMSPVSGRLFDMFGPKVLAITGLVLTVSTTSFFSQLEVDTSYTFLI
ILYSIRAFGMTLVMTPVMTNGMNQLTPELTPHGSSINSMLNQVSGAIGTALLITVMQNRM
NQKLSSVAPSDTAAVNQAMLDGINFAFLIATLLLAVALILAFFLKRVASDEVIGNDMTKA
RPIESDE
>fig|1235755.3.peg.2448 Multidrug resistance protein, efflux transporter
MAEEKVQSKGVVVVIIAAAFLLTFNQFLLITAFPTIMAEFDINATQVQWLTTAFILTTIV
FIPMSGYLSTTYSSKTLVIIAITCLLAGTIIGAWSPNFGVLILSRVIQAIGAGIILPLIQ
TILLIVFPYDRRGFAMGLLGAVTNVAPASAPSISGIIIDYLDWRSLHWVLLPFILITFIL
AIFFMKNVLEQQRTKLDIRSVMLSAAGFSLFIFGLSNISVYGFLDPMSYVPLTAGILGVL
LFTRRQFNIGTPVLNLTLFRNRTFTLAIILIFINMMLLLSTETILPMFAQSALGTSAFLS
GFLLVPGTVILSIITFISGSLYDCYGGRTIAIIGFLCTTVSLVLLNTVGMGDSPYWIMVH
FCLFMTGFGLTLMPLVTVSMSELDDRDIPHGSAIVNTVRQFAMAFGIIILTSIISITVAV
MDAPQAQSTYTGTSYALAVMAVLAFAGFLMTMLIREDRYG
>fig|1235755.3.peg.2548 Permease of the drug/metabolite transporter (DMT) superfamily
MILSAAVLWGTVGTAKTFAPAGADSISIGAMRLLVGGLVLMAVAILMGKMTLKGWPLKSV
LLAALSMALFQPFFFIAVSLTGVAVGTVTAIGSAPVFSGMIEWMVFKTRPAGVWWLSTFL
AVTGCIILMFNSSAVTVDPLGILSALGAGISFASFTILNSGLVKNHHPIASAAIIFMTSA
IMLSPFILIYDSSWLLETEGFLAAMHIGVLATGLAYYLFAIGLRNVKSSTAVTLSLAEPL
TASLLGVFLVGEILDSWSWTGLLMLLMGIVLLVVRPRRKRAGAEA
>fig|1235794.3.peg.1041 Multidrug resistance protein, efflux transporter
MHLSEKGHTYALFAVVVITCALGSLTQTVMNSMLTEVCADFSIDAAVGQWVTTIYMLVMG
ITVPVVVFLAKRFSLKRLVFMALGFYLAGSAVGFCAPAFGVLLLARVLQAVATGITLPLV
QTVAMTRFPRERTGTAMGIGGIAMGFAPNIGPLIGGALANTTGWRSFYIILVGLLAVLWA
ANALLVKSHGDRESQAVFDGPSFVQSTLGFGGFLLGASNAATMPLASPEVWMPALLGLAC
IVVFVRRQLVIPNPLICLDIFRSRHYRAGFVAQNCLFASFMGITLILPLFIQGPCGMTAL
DAGIAFIPATVVALFVNPLAGVLVDKVGARIVCITSAAFLTVGAASFVFVGADTPLWVLT
LLQGVRAVGVSGLVGPLNSYGLAGLNRGIVMDGSAFFATVRQACASFGTALMMLIISVVG
LVFAATDPADAGVTAAALPYNLAFALSTLFAAVVLVTAVWKIR
>fig|1235794.3.peg.1128 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MTEQHTSREPDDARHFSPQGKEGGAAGGSAPRGEKLEARSAADDKVLRMGSASIPKLILE
FAIPSVVGMLINGSYAIIDSVFLGHAVGEIGLSAMTVANPIMVVFMAIAMLVGNGGNALA
ALRLGEGKREEAERVLGNVVSLSLVMAVIVAFLGWFPASTDWLLSLSSATDEVRPHATVF
IQIICTGFILQCIGLGVNNFIRTCGAPNRALGTMVIGLVSSVAFNFLFVIMLGWGVAGSG
LATVLGWGCSCVAVLWYFCGRADVPMRLRLSTMGLRPRMDGTIVAYGFPSFCVQAGMAAV
NFVLNFQLVKYGALSPIGADDALATIGVVQRIAQFSIMPLVGISIALQPLLGFNYGAHKV
DRVRKTLWYGIGAATAISLLMFALVQLFAAPIAHAFGIKHDGLVDFTAFAIHLQFLMLPF
VGFQIVSANYFQATGQPARSIFLTLTRQILFLLPLLYVIPLWLPAVAPQYNGLDALLFAM
PIADFLSIFTTALFIGWEMVRLRRLARKYAR
>fig|1235794.3.peg.1378 Permease of the drug/metabolite transporter (DMT) superfamily
MKAHLLALFTILVWSTTFVATKVLIAAGLTPLWILVIRFTLGFLALCCLRPRRLPLADRC
HERLFAAAGLAGVTCYFLLENIALTFTSATAVGAIAATAPLFCALIMLARGSRPAAPAPF
ALGFALAMAGIVLVGSASGKAILAGSAEANFIGCGLSFAAAVVWAIYSTIVGRIAEAGYE
TLAATKRIFGWGLLFMAPALLVAGPAPLAALAEPVVTGNLLFLGLGASAACFVTWNFAVK
HLGAVVTSTYIYLVPALTGTASVIVLGEPLTAPIVGGLGLTIAGLALSNRSHEKKRVPKD
PPSEQTCITET
>fig|1235794.3.peg.1380 Permease of the drug/metabolite transporter (DMT) superfamily
MSQWKQARWPFVAFVLIEVVIFGSGSAVTKFAYESITPLWCLAVRFGLATAVFALFFGRR
MARRLHGVRVRTWLPQALCMAVSYLCCNVALDLTTATNVGFLVALPVVFAPILSTLAERG
RYPKAIIPFQVGVAAGLYLLCSQGGSLAVGAGELFALASSVALAGALVFGKQALVELDAV
TVAGTQIAVAFALCLGCALLWEPALNVAAVRPVAWGIIAFLALFSTCLAFFLQSLALDRL
SSTTVSLLLTGEPVFTALFAYLFLGEILSPMGLAGAMLIVGTVVAATYVDGRADAPAHEA
APVPTRLPRRVVRPRLFVRRVREDRMAA
>fig|1235794.3.peg.1387 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MSVDMSKHFSTSALIKFTLPTIAMMIFTSCYTIVDGFFVSNYAGKTALAAVNLILPPVMM
LASFGMMIGTGGSALVAKTLGEGDNARARRHFSLLIIFAFVLGSVLAVGGWFFMEPTAAV
LGATGQMAKDATLYGRMMMISMPFFILQYAFQSFFVTAGKPKYGFYVIVVAGVTNIVLDF
LFVGLFGWGLVGAALATNIGELIGGGIPLVYFARKRSTPLYFVRPHLRWPVIGKACANGS
SEMVTNIAMSMVGILYNWQLLRFIGEDGVAAYGVIMYTAMVFAAVFMGYSIGSSPLMSFQ
YGAQNHTEMRSLLWKSLGLIAVASVVMFLLGQTLAAPLSAIFVSYDAALLELTAKAYRLY
ALCFLFMGFAIYASAFFTALNNGLVSALISFLRTLVFQVAAVIVLPMLFGIDGIWLSVTI
GDALTCLVAATLMIALSGRYGYRKRGEKPAAA
>fig|1235794.3.peg.1408 Vancomycin B-type resistance protein VanW
MAPRSHVKQPMPDDRMAGARPLPEHPALGRRPRFPAASPYAAPLIAVCAVALSACMAFGN
PVIWESAAQKEPAPVDEPAASNPAPAPEPEKAEEEPAPEQETIGEYQAISQSEDPGRSEN
IRLATEAIDGTVIEPGGTFSFNDVVGNTSAERGYQEAAVIRNGEVAQGDGGGVCQVSTAL
YIAAVKADMEIVERHPHSVPSDYAPIGLDATIVYGSFDLRLKNNTDHAITIHAKAVGQTV
DVSIEGDPLPEGRTVDATSQIVSRYERDDAAGTLRQYYVSEAFRVYYQDGVRTTRDLLSS
DIYQVDENTPVTTSEGSVDPNK
>fig|1235794.3.peg.1783 Permease of the drug/metabolite transporter (DMT) superfamily
MSQNLETARPCYDATAMVSLMRHTNVPPWVYKAALLLSAAIWGMGTVVIKSTVDAFPPSW
LVGVRFLGAGLILGAVTLPRIRQAYARNKRGHLRDGAVLGALLFASYWCNSTGLTDTTAS
NSSFLTTLYVVIIPFLGWIIIAKRPTRFNIAAALLCVAGVACVAYGGDGAFSLRFGDLIT
LASAFFLSLHVLYTAKYAPGRSMTLLTVIQFVTAGILGLIVGAVTEPTPRFAALGADTWI
SLVYITVFASCVALGLQNMAVARVDPAQASLFLATESIFGVTFSILLLGEVLTLSSFAGF
ALIFAGIVISEYLPLRAEKKAAERDEGLTAPASQDYTLQAKAAAEAAALELDEADTALR
>fig|1235794.3.peg.1881 Drug resistance transporter, EmrB/QacA subfamily
MLAVLVFGAFVTVLNQTLVTPALPSIMVEMAVDQSTAQWLTTGFTLVNAIMIPITAFLQD
RFSTRKLFVFSMATFAVGTLMAGVGPNFPVLLGGRLVQAMGAGILMPVTMTVLMLVFPVD
RRGSAMGIFGLVIAFAPAIGPTVAGFVIDQADWHILFYIIFALSLVIIAASLFLVDNKAP
ANKGDSVLDPLSLVLSTLGFGLMLYGFSALGSAGLTLVPVATTAVGIVGVVWFFIRQTRL
PHPMLRVDVLKNRRFLIGTIIGMLVQGALLAAGILMPIYVQSLHGLSATVSGLVLMPGAI
LMGVMNPIAGKWFDRHGPRRMAIVGMSLLTLTTFAFAILNLTSSIIYLTIVYTVRMFSMA
LVNMPITTWGMNALDNKVMNHGTSVNNTLRQVAGSLGTAIIIAVSTQVQNFATPGLGAAQ
GTMLGINAAFLVCTLLCLVGLVMTIMFVKDKPGEEAAVDEGGTRKSLLTSIMKTDVYSLS
QEATVEEAMRLFVEKNISAAPIVDASGEPVGFISDGDILKRLSPRRSSFTDPIVLINRTV
PDEEGYDEKLAKVMQMRASGIGAASPICVSVHANLTDVCRVLAENHLKKVPVLEEGHIVG
IINRSDITQYSMAAYLAGNPDRAVYCGDGPSGQHECVEEKQCDCGCEEGK
>fig|1235794.3.peg.2036 Permease of the drug/metabolite transporter (DMT) superfamily
MDIASRTNGEGNRRALLIGGVGYGIICGLTFPLMISNTFLREMSLSHGAGDSFGALFFLA
YAAAMLALALWHLVGRKPLPRASLVVALGAVLLGNGLMLLRYLSIIEGGWSYAIVTGLSI
GFGLAVAELGWMEKIVTMGKADGTLLPRMVSLAYLVGGTAAAFIFLATGPVELTFALLTV
LISGALLTRTPNVADEPPSHAPSRSDNVNLVKAISYLAVFSFVFGAVSQMVETSSHSITV
IEIQATASIIGAALIFLAASLGRKRIVPISDLYGLLFPVVAGALIALPFITTPWVHGIAS
VLIFAAFYLSGMNVRIIVSQLCRGDRISLWVYLGCALGVGSLLVIAGVAFGAAVLSQGSP
ETALALIALISLFILALNPILAHRIEQRASVGADTGDSATAAVPTTQAAENAVEGFAREH
SLTARESEVLLLLCQGRTRTYIADELGLSPNTVKGYIRNVYQKSGSVDKQDLLDRVELFR
ERR
>fig|1235794.3.peg.2352 Nitroimidazole resistance protein
MFVPMRRSKQQLPADECAAILRGATAGVLGTAGTDGYPYAVPVSFAYVPSSEDDAAPDAV
RGRIFLHCATTGHKLDALDADPHVCFTVIAQSEPVPEKLTDRFCSVIAFGTARRAEGDEK
AEGLWALGTKYAPGLDAVVSDEIATTAHRTEVIAIDLESVTGKEGLELLRERGA
>fig|1238674.3.peg.447 Multidrug resistance transporter, Bcr/CflA family
MARQKLGALQLFLLGILSAFGPLSLDLYLPGLPEMQQNLNTTPTMIQLTITASLIGLAIG
QIIIGPWSDRVGRRRALLVGVGIFTLATVGIILTPNIYGVILFRFIQGLGGSAGIVLSLA
VIADSFEGLQLTRNVALNQMINGVFPIVAPVIGGVIIALSHWQMTFIVLAVLGAVLWVAI
YTSLPETAPEFDNSHAQMTPKQTFKTLWSNKGFMFMAWTQAFMMAGLFAYIAGSTFVLET
IYDLSILQFSIVYAINGLGILIAAHISAKLAAKMGEYHALGVFVIISLMGGSLVWLNVVL
SNHVLLMCLAFFLIVAPVGGVSSLTTSIAMQHVQTGTGAASGILGLMRYAMGGLVSPLVG
LMGADSLIPLAIVIAVVQVLGTMMYLKSRP
>fig|1238674.3.peg.1194 Quinolone resistance protein
MEIKDARLALDELEFGNTYIDCHLTYSNDALRLENITLKHCTFDQSDFSQSEWQDCVISQ
CDFSQADFSSAIIYRTTFDHTKLMGANFTKSRLNNVQIKNCMADYAIFAEGQWQAVTFDD
VRLRDTSFQATKIRQGLIFKGCLLDDADFYETSLKGVDFSQSEFSSLRFSMEQAQGAIMS
AEQAVQIALNHGISVL
>fig|1248916.3.peg.619 Glyoxalase/bleomycin resistance protein/dioxygenase
MKRLHVHVGVTDLAQSIAFYTNLFGTGPTLVKEDYAKWMLDDPRVNFAISHGHAATGIEH
LGIQAETADELAEVTARLNQADAPVLAEGETICCYARSEKSWTTDPQGVVWEAFHTMEQA
RTYGSSPMLDTLAAMAPAPAKGGCC
>fig|1248916.3.peg.872 Permease of the drug/metabolite transporter (DMT) superfamily
MASAAPEPRFTPVAWFAFIACTLIWGGTWFVIRTQLGEVPPSWSVTWRFALGAAVMFALC
LVRRKSLRLSLRQHGFALLVAVTQFVLNFNLVYRSEQYLTSGLVSLTFAFLLVTNAALAA
LFLGQRVTGRFMLGSAIGLAGVALLFAPDIGKPGGEQIGINNTTWGLALAFAGVLSASVA
NVLQATPQGRAMPLEAGLAWAMGWGALIDGAVAWGLSGPPVFSTAPVYLAGLAYLGIVAS
AVAFSLYYILIRAVGAGPAAWSGVVVPVVAMGISTLLEGYEWTATAVAGIVLALIGLGVA
LKAKAQQ
>fig|1248916.3.peg.1295 Candidate antibiotic resistance protein (acetyltransferase)
MSIRPARMEDAPALAAIYAPAVLTGTASYEVEPPSAAEMAQRLMKVKSHGWPWLVHVTMG
TVDGYAYVTQFRDRPAYRFSGETSVYVAPNAQRTGIGQALLMAVSSAARTAGFRQLIAVI
GDSGNNASINLHAACGFERAGLLKQIGEKFGKPLDIVMMQRSLIG
>fig|1248916.3.peg.1365 Outer membrane component of tripartite multidrug resistance system
MHRKTFLLIPALAPILALCACAVPPKLGAAPMVRAPATAASTVTLAAKGAVDWPATDWWQ
AWGDPQLNALVAEALAGNPDMAAAEARVVAADAAARQSRATLLPSLTGNASLGGQQLSRN
LGIPPQFVPPGVLESGLINLQAGWNLDLWGQGRAQLRAARREAEAVAVERTQARLFLAAS
VAAAYADFGAALDRLAVTREALAIRQQTLDLTANRVTAGLDNDGARAQAATRLALAQSDL
AAAASQVTAARRRLALLVGAGPDRGFSITPPKIKPLPPGLPEAVSINLVARRPDIVAARL
RAEAAGAREMAAGRAFLPNLTLNATIGQQSLGFGKLLEGNSLYAQFGPALSLPILDGGRR
AAEARSARAARVAAVAAHDAALLRALNEVADAAGAVTVLGLQREALTQGLAEATRARNVA
ALRYDAGLSNQLLVLTADDAVVTARRTLADVDAFRLAADVALVRALGGGFREQEGQ
>fig|1248916.3.peg.2449 Drug resistance transporter, Bcr/CflA subfamily
MHAPSASRQPSLGEILLLGSLTGFGAVTIDLYLPTLPAIARDYGTSAAAVQLTLSTFFVG
MAIGQLFFGPLSDRIGRRPTVLIGCAVYVVASLFCALAPNIEALVAGRFFQALGCCAAMV
TCRAIVRDRYDHRDSARIFSLLMLVLAIAPLLAPTIGGWIAMAAGWHAVFYAFVAVGVAV
AGAVAWRLEESRSAATAQAARGNDVLSTYARLLGHRRLIGYLLVGAANGATLFSYIAASP
DLVVNVWGFSEGQFGLVFAAIAVGIVGSSQINRALLRHRSPDAILAWATLGAAMAGLALW
LATQADAPLLIFMPILFVALSSNGLIAANASAGALNVDPLRAGAISGLMGGVNFGVGALA
SALAAALHDGTARPLALNVAVALLVAATAFHLLAKPR
>fig|1255043.3.peg.1146 Glyoxalase/bleomycin resistance protein/dioxygenase
MTTDLLGSVPVLHISNAERSCEFYCNKLGFQKNWQHQFEPGFPLFVSISRGSVTFFLTEH
PESSAGAFVYIHAEDVDALAQELQARGVTLGQGPVSQPWGMREIQLEDPDGNRLRFGQDI
EEKIS
>fig|1255043.3.peg.1742 Permease of the drug/metabolite transporter (DMT) superfamily
MSVPAAYLGVILIWATTSLAIQWSGDGPGFLFGVAARAAIGAVLALAIARLSRLRVWRRD
AFGVYMVVALGIYGATLSTYWAAQQIPWGWISVIFGFTPIATSAMAALWLPGQGLTRVRL
AGALLGVGGLAAIFSGGAAAGITTVDRRAGRL
>fig|1255043.3.peg.2529 Bacteriocin resistance protein, putative
MPRSVLNRLLRPPADFRRVQRQSWPESCGAAALATLLAEVHALPVTEADVLERLGTRKVV
GLDQLQQVCAQYGLRAFGYALDWDGLGRAGRPALLHLPGASAVGHFAVLRGIGPARVWLA
DPARGNLRLARSQFLRRWAPRGAEGRALYVAAPEADWLPLGEEALRAPPVADEDWFPARQ
SPQRDGVPDMDD
>fig|1255043.3.peg.2790 Multiple antibiotic resistance (MarC)-related proteins
MIEVAIVAFATFFVTVGPVDVAVVYAALTPHHPESARRTMAIRATLVATGILLAFALVGE
TLLGWLGISLPALRTAGGILLLLIGIDMVFARQSGGVSATPSETREASRRTDISVFPLAT
PLIAGPGAMGAAILLMAGAADWRHQATVLAMLLLVLLLTLVCLLAAVRIQRFLGIIGAQV
LTRILGVLLAALAVQFIFDGIIASGVLS
>fig|1255043.3.peg.2949 Acriflavin resistance protein
MINPARLTVHRPVMTGMATLIVILLGLAALTRLPVDLLPDITYPVLTVTTAYPNAGPEEV
EQLVTRPIEQAAAAITGAREIRSTSSEGSSNVRVQFGWGTDLREAVDDLRDRLARIASQL
PEGADQPLVRQFDTQASPIMQLGVGSALDPIQLRALIDNRIAPRFERLPGVAAVDVRGGL
EREIRIEVHPERLQALGIGLDTVRSALQEASVVSPGGPVVEGRREFRLRTEAQFRDLEEI
ANTVVRRDETGPVRLFQIADIRDTHQRPTRTFRVDGADGMVLAIRKLADANTVDVAAAVR
AEVRRIERDFPQVAIQIPSDGSRFISRSIANLGQAILYGSALAVLVLLAFLRNLRFTLVA
ATAIPISVIATFGLVYFGGLTLNLMTLGGIALGVGLMVDNAIVVIESIARNREENPGLGI
PEAAIKGTGQVSAAIVASTLTTLAIFLPLFFAEELAGQLFKPLAAVVAFALAVSLIASLT
LVPMLMARRMLHSASAATATPHGLERTYLRLLEPALRHPWWVVLASLALLLFALQGYRGV
GTEFLPATDEGDIRINLSMEPGTRLEVLDAVTREVEATVRERVPEAQHMVTSIGASAFGF
GSPSSSNLRLNVGPRDARDRSSEEIAAALRQAIGQPPGVTVRVRASGGIFMRGFGRGDDT
ERLSIEVRGFDRVAMNAVALAFGEAVEDIPGVTDVRVGDDGGQPEFLTRIDRARAADLGV
DVRSIAQAIETAIGGSRAGQLRTGGTETRIWVQVQDAEHRRLDELLNLTVAGAGAGGERI
PLRSLVRFEPVIGPSSIQRREQARIATLFVNVAERPLGDIAADVRAALAQIPLPDEVDYQ
VSGDIEEQEAAFSELFLGTVLAILLVYMVMASLYESLRDPLIVMFSVPLAAIGVVLALRL
TGTTLNVQSLIGVMLLVGIVVNNAILLVDRMARLQRGEGRAVRDAVLLAARQRLRPILMT
TLTTILALVPLSLGLGEGGEAQAPMARVVIGGLISSTLITLFLIPALYLIVHRTATATAA
PVVPPSRETA
>fig|1255043.3.peg.2973 Acriflavin resistance protein
MSEHNTQQAGEGQEPEKDLGLAGRMAQSFIHSPLSPLLLLATLAIGVLGLIITPRQEDPQ
ISVPMVDIFVSYPGVPSEQVASLVARPLERLMSEISGVDNVYSVSHRGQSMVTVQFDVGE
EMESSIVKVHDKLMSNRDLMPPGVSEPMVKPKGVDDVPTVTLTLWSHDLDDALLRQIALD
TLQYLNEVPNTSQSFVVSGREEKVRVEVQPERLAGHNVTMDQIAQALQAANSERTAGSVE
IGATSTPIYTGAFLRDAEDIGRILVTVEEGRPVYVRDVAEVIYGPGEVDRFVRYYTGVAG
HHADEAPEGAAAVTIAIAKKEGSNGVAVANGILERLEMLKGQVIPDNVEVSVTRNYGETA
NAKVNELMFKLFIATAAVTVLVFIFLGLRAALVVLIVIPVVLLFTVFSAWLMGYTIDRVS
LFALIFAIGILVDDAIVVVENIYRRWLMKRGVDTETTVDAVAEVGNPTILATFTVIAALL
PMGFVTGMMGPYMQPIPALGSVAMLFSLVAAFLFTPWLAWRLRPTMDYLQRAEEKEHKQN
EMMGQFFSKAIPGLVHNRVYGWGFLIGIVVVFFLTVMLFFTKDVSVKMLPLDNKPEFNVV
INFPEGTALPQTATLTHELAMVLRDLPEVTAVQAYVGTASPFNFNGLVRHYYLRQEPWQA
DVQVQLVDKGDRKRTSHQIAVEARELLAPMADAAGARIQVVEMPPGPPVLQSVVAEVYGP
EPEIRRRVARDLERMFDNAPHLDDVDSFLQAQYDVWHFIVERDKALRRGVTVDAVNRTLE
SAIGGQIVGDVKARSLVEPHLIQIRLPMAVRSDLQRLLLLPVPTMAGGSVPLSELGEFVR
QPQDEPIFHKNLRPVEYVTAETVGRLAAPIYGMLEVQEQLKEYRLPRGGELDPHWVGPPP
NDGTVGFEWAGEWTVTYETFRDMGIAFAIALVLIYMLVVWEFGNFLLPAIVMAPIPLTLI
GIIPGHWLLGAEFTATSMIGFIALAGIIVRNSILLVDFARHAVAEGQSVMDAMIHACQAR
TRPILITAFALLAGSSVILFDPIFQGMAISLMFGTIVATLLTLLVIPLGCISASRTLEEN
ATGGGSGGGAACAVQPEPGGDPGHEGPRFPSSTKMTDPSGGPVMKFIGLAGLYLRSLAAS
FVEGVVQLMRALARWILRLVGGDDRPPSGGGGPTGPAAPPDGSGGPAGGAPSGVETGQAE
SGERDGSGDRAEAADDRSRTQPGSDRVRSASGGRAGGESAAEKTPSGTAAPGAGEKQQRG
SASAEPKPASARTSKPASAAAKTKADPGEASAPADRGAPPRKAGSATGAPEAESDDDEGA
KAASSGSAASSARRRRGIRLK
>fig|1260251.3.peg.361 Permease of the drug/metabolite transporter (DMT) superfamily
MIARDWLLLIILSTVWGGSFFFFEVALQTLPPFTVVLGRVSMAAAALLVIARIRGEPLPF
SATIARRYLLLGAISNAIPFSLIVWGQTQIPSGLASIINAMTPIWAVLVGLLIRSDERMT
AGKAIGVGLGFLGVAVLMGPDLLRELDPYSLGQLSVLGATISYGFAVHYGRRFGATSALV
NAAYMLTAATVWLLPVAILVDHPWTLSPGLSGWTALLGLSLICTAFAFLLYFRLLASAGA
TNMSLVTFIVPVSAISLGALFLGERLGPTAFAGMGILFVGLAIIDGRAARMLRTGTHALW
SGLLGRRVVSKRPE
>fig|1260251.3.peg.370 Multidrug resistance transporter, Bcr/CflA family
MFNQRYRAHPDGTLMIIMLGVFTAFAPLSIDLYLPGMPAMEADFGVSAGLVQQSLSLFFV
GLAGGQLLYGPLADRFGRRYPLLAGSLIYLAAGLLCALAPSIEWLLAGRLLQGFGAAAGP
VIARAIVRDVYAGRRAAQVMSFVILVMTLAPLIAPVVGGWLTTALGWRANFWALVAFAVI
CLVMLLMALPETHPAERRPRTALRHLFAGYLPILRDRAALAYLGAGGMAFAALFAYVAGS
PFVYTRVFGVAESNFGYFFALNVIGLLIGNLVNSRLVMHFGQQIMLTAGVLVMATASVSM
LVMALAGITEQWLITPALFVALGTVGIIAANTVSGLLDRHPRHAGAASALFGVAQFGLGA
LSAVGVGLVSVGPLLTMTLVMAAAALVATASVIALWWQLRRPALAV
>fig|1278308.3.peg.392 Tetracycline resistance protein
MTTTVGAIEHLQRRTMLVLVVMQVIGMIGVGAAPSVGILLATEVTQNEAIAGLARSSSTL
GAALMGLPLGSLAARRGRRVALTLGWYVAAAGAALLVFAAQFSLVVPLFIGLFAIGAGTA
AGLQSRFAATDLAPVAGRGRALALVVWVGTLGSVLGPNLGVPGEWLHDRIGINVFGGAFG
IAAVCLALAATVVWIWLRPDPLVTLQARAGVSTVPGAQRPRLGQALAEVRRSGPGRLALV
GILVGQSVMVAVMTMTPVHLAHHGDTITVIGLTISLHVAAMYVFAPLVGWCVDRLGHRVT
IAIGVALLAAACLVGAAWQHETAAIVTALGLLGVGWSFTSVASSALFSVAVSDAHRAQAQ
GGADALSNLCAAVAAFASGPLMAASDFSVLSLAALVLLVPLAVLLVPRRATG
>fig|1278308.3.peg.1222 Drug resistance transporter, Bcr-CflA family protein
MPHERRLTPLLLTVLGFIAAVGPFATDMYLASFTEIATALGTGPAPVQLTLTAFLFGMSA
GQLVNGPLSDRLGRRPVLLVGLAVFAASSVAMVFTPNIELFIALRVVQGFAGSASVVIAR
AIATDLSLGNTAVRALSMIAMVTALGPLIAPPIGGALATWFGWRGVLAALAVISVTMLAL
ALTFVAESHPPTARPTGHLLAPFRSFATLLRDPVFGGFALAFGFGFAGMMAYISASPFVG
QHLLGMSQLEYSLSFAAGASALILANLANARIAPRVGAGRMLVVGLALLVAGGVGFAVLA
ATGALSIPTFILCAFATTAGTGFTSANSSALAFTRTGPAARGAGSALLGTGQFALGAVAS
PLVGLWGEGTALPMALCVLVAALVAATCGLAALRRSRR
>fig|1279017.3.peg.786 Acriflavin resistance protein
MNIIEKYSPVIISCGLLLICLGVFYGVKIPNTLLPNIDRPQIALATSWPGKTAMEIEQAL
VAPLEQELSSLGFLEEIQTTISNGFAWTLITFHSNADMEQMYIDVLSRLNQVPNWPSQVS
APRLYNFSNGAGATLASFFLYSTNQATEQELSQAFRDHVQPAFSKIPGVASVTVAGTPIE
QRIDIEFDPRGLTQASLTINEVQSRLSDLVDRSGGNLTIGSREYALHFKGQIPIADIEKL
PIATRGPHIIRLGDVAKVKNRMASDWNYFALEGNRSFYFYLMPTEDINVLNTIDMIKTLI
SDLNEGELGRLGMEVAISRDDSKSIRNSLQLVYSSLILGAFLACIILYWFLRDFRTLVLI
FTSIPACIALVILGLYLGGRSINVISLAGIALSIGLMVDAAIIVIENIQRLRGQGASLLT
SIRQGTKEVTGALTASTISSVIVFLPILAMQSATGQLFTDLAYTISSALIASLLFALLLL
PALARHLLKDSPQVNPKGRTQSLNRILQRWTAISVIPIGRVTFRNCVLVLGLPVALLVTY
LSSPSVDVLPDPKQAMISTFINFEGPMAVEVVEREVGQVIMDRIEQGKGRFEEQIVTYGT
LCYPTMCHLYIYTQGDWDFEAFKKWIDKDIVSGLIGTRIHTQQGGLLRFAMPNSRVSQLD
IKGAELPVLQAAGRDLLEHLRSEFPGAQILEGSALSNRGLRIEFEPNQDQLIRMGMTLPE
FNRHLMALTDGIYIGNFYTGTNTLPFYFKAKEPANLEQLLNTEIMIAGQGLIPLRQLTSA
QITQAPDSILRVGQEVSTSLNLTPPTGVAMKDFTEQVDRSVLAFLNKSQYGDLHTQFRGS
ANELKLFLQEFFQIFCVALLILALLMYFALRSLKLALAVLFAIPLSFAGGMLSLRLLNLF
VMQNLDVITMIGFVILMGLVVNNAILLVNQFQSSINKGMHQFDAIKSAVSLRIRPIMLTT
TTCIFGNLPLVLSPGDSAAIYRGLATVITGGMLFSALFVLGFMSAMLSLKVFAAHRINPT
SVVRELTPEGGI
>fig|1279017.3.peg.875 Permease of the drug/metabolite transporter (DMT) superfamily
MSQAQGLPRAFWLLLIGSGFFQMIYMGGLALAYQRANMGLVYPIARALPVLLVALATVLL
GQTLPWLAWLGMLLVTIGCLLVPLVYFRQWHWRAYWRADCAWALVAALGTVGYSLADKGA
LLHLETALDGAVRPMAMAYSYLGMQFFASGLWLLFGCLGSNGRAQLVRSLGDLKLGLVTG
LMMGATYGLVLLAMAMTENVSYVVALRQLSIPLGVGFGIWLLKEPAYRPQLLGVGLVCAG
LIAVSLR
>fig|1279017.3.peg.1610 Drug resistance transporter, EmrB/QacA subfamily
MKYKHISFVGLCLGFFIVMMDMTTVPLMYTTLMDEFTVSPARVAWINNIYLITYAASLLL
GGRLGDSTDRKIVLIGALLVLGLGAAISGAGQTFVEVIVGRALMGIGAGFLTSQSMAYIS
ILFAKGGRGTALGIWGAVAGIATATGPVITQLLLTTADWRWVMWINIPFVLAALVIALRC
LPGDPGSGIRLSETFASAVYGLCLAGVIIGIHYISVAGILRGVGIALILIGAAVIAILIR
KEVKNKSAYILSPELWFDGTFFRICFISGLLGLGVASFYLPLAFLLDVCMNFGPVAISVL
MMTIALSNALVGPYAGHLSDRIKPEGIVRSGLMLFALANGLLGFIGVLMPGGTVTFIALF
LVMMIGGAGTGLAFAPLANLALSRVSFEALGRAAAFFNSIRQALSAMGAVIVAILFDWIV
RLKLGIDLEITATNLRESPGITGLATLVCFLLIALGLSVAAYLSRSSRQDSVQREVLNT
>fig|1279017.3.peg.1757 Acriflavin resistance protein
MKTLSRWFLDNPVAANLLMAFILVAGLLTFQNLRVESFPQIPPTEVEISVVYPGGTARQV
DESITQRIEEAISGVAGIKRITSQSSKGYASLVVKKNTNVKLDRLIEDIRNQVESIEGFP
ALAERPRIYRSEYTNLAAFVMVYGGDNNDSLQQVSSRVERVLKKHPAISKVTNLGKRKQL
LAIEPDLRKLQRYGLSLENLTERIRQWSVEYRSGELRTANGNIVLQGSSLADNLAELRNI
PIITTSTARVRLSDIATVKRDYEQTDSIVRYQGQPAVALMVSTSQKDNLFHIHEATKSVL
ESLESTLPRNMQLDVMADMSPYISEQLDLLSSNALQGLLIVLLLLVLFLDTRLAFWVALG
IPISLAGAITLMGFPSLDYSINDITLFGMILVLGILVDDAVVVGESIHQARQNTTDTKEA
AWKGVEAVAVPTVFGVLTTIAAFSPMLWIENELAKVLSGFSAVVIFALIFSLIESKFILP
AHLSYPNTHTQTSGAIKRWIEIAREKCNRLLNRFSDKIYIPLLSLSLANRKISISLFATF
LLLAYGAMFKGHIASVFFPEIPGRYATVKVTMQHGAANTLTERNTDQLEQAIKRTANRLQ
QEYGLPESPVSKYIVSKEGTKTIELTAELTHDALARVESNRFLEELRLQTGILEGSYAVK
FSLTEEPAGDTAIAVSASNRDQAKQVAGRLKALLAELPGVNDVYDDSQLAKRQLKITVNE
RGASLGIDQSHLAVLIGGAFGQIEIHRLLDKGEETLVLARFPQTETKTLEQLKATPINLD
NNSYVSLGEIAQLKYEREPEVIYRRNRDEVVSIYWRQNRSVSSPENNWERLKEELVPELE
RLYPGVQIKAVGEFAEIVEVQAGFKKSMLLTLLLIYVLLAIPLKSYWQPLIIMSVIPMGF
AGAIIGHGLLGFPVSLLSLFGMMAMTGVVINDSLVLMSRFNQLYAQGVPVKTALLQAGKS
RVRAIFLTTVTTICGLLPLLAETSEQAQYLKPAAISLVFGELFATPITLILIPLLLSFGQ
YKNTSRSDSASLTEQSLLQEVRQL
>fig|1279017.3.peg.1957 Acriflavin resistance protein
MNELRVEDGDIDTKTGAIAWMARNHVTANLLMLVFLVGGLIFSVIVKKEVFPEFSLDLVS
VSISYPGASPEEVERGVLVAAEQAVQGLVGIKEMRGSAREGSAVLNLELEGDADANLVYQ
NIQQAIDSVTTFPADIERPQVNLAERKRDVLDLVLHGNLDERSLRALAMQVYDKLEAHSG
ITQLEAQGVRDLEVAVEIRRDDLRRYDLTLAQVATIVQNAAVDIPTGSVKTDAGEILVRV
TERRDWAREFGDIVVTQGGGGGAVYLRDIATVSDALEDEARNMVFNGEPAVGIKIYRVGD
QTPLSVSDAAREVIDEVRASLPQGVSLTIRDDDSEIFKERLSLLLKNGFIGLLLVFVVLG
AFLELRLAFWVTLGIPISFLGALLFLPGLDISISMVSMFAFIIALGIVVDDAIIAGENIH
EWRQKGYSNLQAAIAGARQVAVPLTFAILTNIVAFIPLMALPGFMGKIFGVIPFVVGSVF
IISWVEALFILPAHLAHSRRGYKSPRAQRFAARQERLARGLDRFVQERFRPLLEACVRHR
YTTIAIAISTLLVVGGYAASGRMGFTLMPRVERDSGRFAVTFPTGTAQHQLEKARSQIIA
GGNKVLEQYDRDAVFLGNRGLMGDDSVQVDFFFVPSDQREFSTGEFVRAWRKEVGVIAGA
LSATTASDRGGPGAGSSLTVELRHIDTAVLDQAAARLGAELAKFPNVSDIDAGVTLGKTQ
LDLTLTETAKSLGLSAEEIGRQIRAALYGDEALRQQRGRDQVKVMVRLPESERVSMDDVN
NIMIRAGSGLWMPLTDLVVIDKGRAYATINRRAGRRVLTASANVEPSDQAALVINELDRS
VIPQLQAEFPGLTISYEGRQADEREGLASLGLTFLLAMAVLYLLLAIPLKSYMQPLIVMV
AIPFGVIGAILGHLVMGYGMSMVSLLGMVALAGVVINDTLVMIEYSNRLREEGVDVETAI
KRAAARRFRPIVLTTVTTFCGLMPMIFETSVQAKFMIPMAISLGYGILAATAISLLLVPC
LYLMFGKDIPRLFSALKNALESFTGTARAGN
>fig|1279017.3.peg.2431 Permease of the drug/metabolite transporter (DMT) superfamily
MKRKQVQAEVLLLLAALFWGVAFVPQKVAMADIEPLAFNAWRFILGGLILVPIVYWLSSR
RDSQPGEVGGKHVNHRWKACLPGGAVLGFWLFLGAALQQVSLLYTTAGRAGFITGFYLLL
VPVIGLSLGHKTNRWTWVGIALALFGLYWLADFAEESQLIGDLMVFASAFVFAIQVLSAD
HLVKRYDALRLACIQFLVCGFLSALASLFTEEATMQSAVDAAWPIAYMMIFSTALAFTFQ
LLAQRYAAPSHATVIMSLEAVFALAAGWLFLNEVLNARELIGCGLMLAGMLVSHYGNHNG
THH
>fig|1279017.3.peg.2842 Glyoxalase/bleomycin resistance protein/dioxygenase
MLKHPDHVTIVVNELQSSVKFFQLLNFELEVTDLISGEKVSKYLQVENVEADHLTMVLKN
SSPRFEIQLLHYRNPKVKSDPSIFSLARPGYNHLCFAVDDIEKTLKFLNENGIRTRSEIL
EYQKRKLVYIEGPEFITIELAEWL
>fig|1279017.3.peg.2983 Acriflavin resistance protein
MNGIIPWFVRNSKAANLLMIMIIIGGIFGISGIDREVFPAIQPGIVEVNISYPGAGPAEV
EQQVTVRVEEAIAEVKGIKEVNSASRRGHSSVEVQAVDGYDELRLLNDIKVQVDSINTFP
EGIERPIIRLQEWDTQLMMIAIGGPVSERQLKETALDLRDKLTLIPGVRSVDIWGERPDE
LSIEVSELDLRRYNLSFNDVADAVRRSSLDLPAGMVRSDRGDIQVQTRGQAYSAEDFERI
PVVSRADGSVLLLRDVATVRDGFEEYNNVILFNGNPAMNLRVVQGEPLDVVGTAERIKTF
MAEARTQLPPGMEFDIWFDFSKAFEGRMNLLTTNALSGFVLVFVMLMLFLRPALAIWVTV
GIMVAFLGALWLLPITGVSLNMLSLFAFLLILGIVVDDAIIVGEAVHAAHDRGVTGLAAA
EEGVKQVSAPVIFAVTSTMVFFIPMLFLPGYTAQMMLALPVVVLLCLAFSLVESLLILPA
HLVGMKPEQPAKTRVGIKLQKLRGHFAGAMKTAGDKYYLPLLKKSLGNSRSTVMIFISAL
GLSISVFMSGYVGSSFSPQVPSDLLELRASMASGEPFHEAERVMNQVLAAADKLAADEEM
LKQNNGEPFVQNSMVFNWRGNIFVILQLTDGELRDVTSKTLALRWRQLIGEMPASVEDLN
IDATINDGGNGMSLNLSTASGDMDELRAAADAVKEKLNTYAGVYDVRDNLTSARRDIEIQ
LKPYATTMGINLADVARQVRQGFYGEEVQRIPRGREDVRVMVRYPQEERASEEQMDRVRI
RTAEGEVPFSAVADAVYVPGYTTIRRNNRERTVRVFAEITPNTSSAQEILKDMRETLAPE
LKRQFPGFSLRTAGEMQEEEEFNGAILAFFVLSLFAIYALLAIAFRSYSQPLLILTAVPF
GFFGAVVGHLLMGHNISIMSMLGFLAAAGVVVNDNLVLMDRINQLRAQGWAVMDAVVQSG
RDRFRPIILTSITTFIGLVPIMFERSIQAQFLIPMVISLAFGVLFATAVTLILVPNLYKV
IEVIRPKSKRLGEGEAPVSLETV
>fig|1279017.3.peg.3396 Multidrug resistance protein A
MTDKLNLNLDRTTQRKLGLILVLVLAALAVGWSLFGSGDIVETENAYVKAEKVSLAPEVS
GVVTKVLVSANQVVSKGQLLIQIDRTAFELAVTEAEARLSQVRNDLLARRAEYAEADAAL
QQARKDADFYRRQLERNEKLGKVAFSEAELDSARQQLERARAQITINAEKLSSLRAELGG
DPGSALEDQADLKVAQAQLDKANYQLSRTRIIAPVDGTIANTVPQVGEMATAGLNLLNMI
GSSGLWVEANLKETELAKVRTGQQAEVTLDAYPDFEWQAQVDSMSPASGSEFALTPPQNA
SGNWKKVVQRVPVRLRLYPLKDAPQLRAGMSAKVRIDTSEDAKVVSARASTDESGRVVL
>fig|1279017.3.peg.3628 MFS permease (drug)
MSGATVAPSLPALENYFSQHPDSALLSRLVLSLPALMIAIFAPLAGIISDRYGRRRLLLL
AVGLYGFAGTSALLQNSLEGILASRILLGVAVAGTMTSVTALVGDYFTPRERQVYMGQQG
AFISLGGVVCLLAGGLLADLHWRGPFAIYGVALLLIPAVLIYLPEPKRSYTLKKSKSIAE
KKIYWLGFSALLGAAMLNSLAFFLIPTQLPFLLQEIGASSPSQAGVAIAAGNLMGALASL
TLFPRAHKIFGKFGIFAFSFTVMATGMGLISIAESFSGIIIAMAIYGSGMGTLIPHIFST
GLESATENMRGRISGALTASVFIGQFLSPFLSQPWVNHFGLASAFSTVALGLLLLAVIAL
ITHWLKTKTSTEIKLR
>fig|1279017.3.peg.4159 Acriflavin resistance protein
MYQDKKTREEVLEAESEHRFNTARFFVDNPSISWALLVGVMLWGVFAYFFMPKSKDPDIP
VRIAMATTTWPGQSAVKVEELVTKQIEDAIAQSEYLYQPDARSFGVKSLTLNGISMVQAQ
LAPHTDVTKAFNDLNLKLIDAQNTLPAGVESTQLNTEFGDTAAVLLAVASPPAGADEIAL
RAKTIREALSKIRAKNASNNREKEKQKVGQRVSMVVALPLSVAGINAEAALQVFSNWMEL
EGYGADFKILHGPGFVGVDFFSDKSDKQLAEARKLFLTQRLSAQTFFPDAWQPIIVRDLA
STRARLSMVAGAKYSYRQLDDFSELVAANIRTLPQVKRVLRSGVLHQQVNLIYSQERLAS
YDLRPDMIAPILNARNNIIPGGTLTVENMDIPIFPSGDFNNYKEIGDVPVALSEDGTPVY
LRGILDVTLGYESPPTLLNYYIYKNKQGNWHRHRSINLSVQMLDGEQIGELGKALDKVLA
RVKVDLPPDLIIERVSDQPRQVKESVGLFIEALIEAIILVVIVAFIGFSDWRSAVLLMIS
IPITLAMTFGFIQFMGVDIQQVSIAALIIALGLLVDDPVVAGDAIKRQMAAGKPSFLAAW
LGPTLLAKAIFFATLTNVVAYLPFLLLTGNQGDFLHSLPVVMACALIASRIVSMTFLPFI
ANIILRPPKVKELSLDLKRKQGLTGHYYRLAGWAIDHRKLVLLTTTVILVCGFALKSQLK
NAFFPDDVQYLSYVDIWLQNDASIDATDSVANKAEQIIRETIAQYQKEIGRDDSILEALS
TTVGGGAPRFWYTINPQQQQPNYGQIIIRLSNKDLTPVLAPKIQQALTENIPGAYLDVRQ
LQTTPVTYPFAIRVSGRVTTGSVQEEQDILLLRQTAEKVKEIVQQSPYARTVRQDWSGES
LTLLLNVMEDRAAMSGVTNADIALASSTGINGTEVATLRQGDKEIPIVARLRLDQRGQLE
DINNLYVFSADSDVRVPLEQVAQTSIRFRTERIHRLEKFRTITVFAFPYAGFISSDIMAD
VKDELDELENTLPSGYQLQVSGDAANAKHGFLQLLMILCVSSSAIFLALVFQFSNLLKPL
VVFATVPLGMVGALLALYVTGQPFGFMAFLGIVSLVGVIVSHIIVLFDFIEIRHAVGDPF
REALLDAGIMRLRPILITISATTFALVPLAVHGGPLWQPLCFAQIGGLILATCGTLLLVP
VLYTIMVVDLKWIRWEERGVKEGDGDIPVTA
>fig|1279017.3.peg.4226 Fusaric acid resistance protein fusE
MKKHRKYILTGGMVFLALFSLVLQFWKYLNNPWTRDGKVQADIIQVTPRVSGQVVELPIR
DNQFVNAGELLFQIDPRIYEAALAEARAQYEEAIDTYNAQRENILAYEARLRESSAAIDL
AQSNINALDAEIMKSRAEFERQQELLPQRATSVRSLQAAQADYESSVEYRAGAEASLAES
LAVLEQSQADLARVRAQLGALGADNPGVRAALAMVRQAELNLEYTTVTAPVSGYVTNLDF
RYGDQAVANQPALSIVDVSTYRIEGYFRETFIRRISPGDKAIVTLMAYPHRPLKGYVESI
GWGIAQDDGTAGNDLLPRVNPTFEWIRLAQRIPVRVHLTERPESVDLRVGFTSSVLILSD
TASAEQDEAAHSP
>fig|1279038.3.peg.162 Drug resistance transporter, Bcr/CflA subfamily
MSSVTAPSLPPTTPQPGLGFLAPLVLFTTVGPVAMQMFLPALPAIQQDFGVTAAEAQMTI
SLALLSFGLSMLVYGPVSDRFGRRRPLQIGMFLYCAGCLLCTIASSLDMLIAGRVLAAIG
GAGGMTLTRAMVRDTYPPSQVAPALSQLMIGQIVPPMLAPVLGGLIAVSFGWRAIFITQT
AVACLALLLVLRLPETLRERHIGASPLTLLTNYGALLRHPRFNAFTLFNAVGIGGYFLCL
AGAPLVLINALHLSPADYGLIFILVPASFMLGNILTSRLARRFAPRVMIPLGAVFSLAGP
VVGLVLVMFLPLTPWSVMIPAGIMTFGHGLSMSSAQAASMAVRPALAGAAAGLGGFLQMA
VGALVTQGFGLIHDGTATPLLAGMAISSLSAVAVYGGCLMLDRRRSPGRAD
>fig|1279038.3.peg.356 Permease of the drug/metabolite transporter (DMT) superfamily
MPALARPSSFLWLALPFCVLWTSAFPAAKLALPDCPPLLLLTMRFLLAGALLMGWAALRG
ERLPGSRRVWGQLAVFALINPTLYLGLSWIGMVKASSALSTILISLNPVVVTLLAALFLR
EQLTGRKMLGLLLGLGGVVLVVQARLSGSGAEDPFSVLLIGLALIALAASTLLWKLWPLT
TPRLMGTALQLLLAGVFFLPVALLTESPAGIHWTPRFLWAMAWIIGPVSIGAYLLWFRML
DTVSASEASAWHFLNPPLGLAMGVVALGETLQTGDLIGIVPIAAGIALVTRSTAAAPAPA
SAR
>fig|1279038.3.peg.372 Permease of the drug/metabolite transporter (DMT) superfamily
MPKPALLSSPPVLLLITGSILGTLAPLSRVAAGAGIPSAVFVFWTCLTAGLLLGAIALLR
GQPLQRQHLRYSLIAGLISLGLPNLLIMVVVVPLGAGMTALTYTLPPLFTLGLAALIGYE
RLTRWRSLGILFGLAGAVTLVFSRFSLNGDSAQMLWMGLALLIPVCLAIGNVYRSRSWPA
GAAPLTLAAGMLLSAALWVLPLGLYQGLLTGLPHWSVIAQGLASTLMYVAFFALQRAAGP
VYLSQIGYVGATMGVLAGVVAFGERPGLPVACGVALIVCGMLCTNRRPAHP
>fig|1279038.3.peg.537 Permease of the drug/metabolite transporter (DMT) superfamily
MRPTQLDTFAMTTMVLLCATWGLTQPTVKMAAAEIGPVLQGGLRCLIAAVLVLLWCRLRG
IRLFDHDGSLKGGLLVGALFAAEFAALFKGLEYTQAARAVLFLYCAPFVVALGGHFKLGE
KLAPVQWLGLTCAFIGLLVGMGDSLSLPGGQELIGDLLALIAGLLWAATTLAIRMTRAGA
VTPAKTLLYQLGTSVVVMIPLGLMMGETWPHFGTLSETAWGVLLFQGIIITFASYLMWFS
LVSRYPVGLLSAFSFLTPLFGMAFGALLLGERLTLPFLSAAVLVGLGIWLVNRRRVKIAG
>fig|1279038.3.peg.673 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MARLARFAEPADLADPRLKRLILTLALPSVAGLLINALYHVVNAAFVGGLGTPAVAAISL
TLPVFSLVAALGEGIGVGVAANVGRLLGEGRSGQAGAIASTGLILATVIGLLVTGALLLA
QGPVITLLGGGGETEPLARIYISILAFTCVLTLIQIVCDFIAIAEGNSRFSMYTLLGSFA
VNIALDPLLIYTLEMGIAGAAWATILAKGVALGAYAVYFARRWGVVQVHTRLIRWRRRVT
GPILAIGMPTTAASILTAVSFAILYHMAGRYGGESAVAAIGIAARVVLLGYFPIIGFCLG
AQAVISYSHGAGDYRRLRDGVRFMLLVTTAFAAVFSAVMLLWPQAVVSLFSDDAGVQAQG
ASALVAFHLFFLLAGLECVLLVLLQSLGKGRLSAVVALAQRGYLLLPLLLALPLVWGMQG
VIAGPAVAAGLAGLIVVPMFLWQMRTLKAQG
>fig|1279038.3.peg.887 Permease of the drug/metabolite transporter (DMT) superfamily
MSRLQAHALLLIAAMIWGSTFVVQKLAVAPDTSGGESIGALAFTGVRFLMGALVVLPLAL
REARAASQSLTRADWLGFLGCGVSLFAGAWLQQVGLGMTTVTNAGFITGLYVPMVPVIAL
LLFRRTPHWAVWPGAAGCAAGIFLLGGGHIDAFNTGDAWVLAGAVFWAIQVTFVGIFASR
SGRPLALAVSQFVIAGVLGSIAAGLLETPRLELFEKAAFELAWAGFLSVGVAFTLQVIGQ
RYTHPATAAILLSSEMAFAALAGAVALGETMGLIQAVGGALILGSIILVEVMPTLQRRPL
KAAE
>fig|1279038.3.peg.899 Permease of the drug/metabolite transporter (DMT) superfamily
MSQVSSPASSSAPTASVSDSRNLGLYAGVVAIWGTSWIALKLQVGSGVEVLPSVAYRFGL
AAAVLFGWCLLRGLPLRFSRAQHLRMAAQGALMFTFNYIFFYYAALYLTSGLLAVASSTV
ILLNLILGLLFLGQRLEPRLVLGICLGLIGVGAVFWPEISHFSLSDAGTRGLLLSLGGTV
CVALSMTLSARNQKAGLPVLQTNAFAMTYGAILTVALAIISGTPFSFAPTVAYVGGLLYL
ALVASILAFGAYLTLAGRIGPTRASYASVLYPIIALALSTVFEGYHWAPSAILGLGLVLI
GNILVLYRKTPAR
>fig|1279038.3.peg.1025 Permease of the drug/metabolite transporter (DMT) superfamily
MPLPHIALAVLVTALWGINFVVIKIGLHDFPPLMLCALRFLFAALPAVFFLRRPDVPWKW
IVALGATLGVVKFGLLFVSMKVGVSAGLASLVLQTQAFFTILLAVLLLGERLTLMRVLAA
AIAFSGIGVLVSGADTAELPLTGLALAICAAVAWGFANLIQKRCAGSKPLNLMVWASLIP
PVPLMLLSFGLEAGPAQAWQTVQAASLAGWGAVVFLAAIATLLGFAIWGWLMGHHPAAQV
APFTLMVPVWGMGSAALLLGESLTPAKLLAAALILSGLILNTFGDRLLQRLRPQTP
>fig|1279038.3.peg.2077 Membrane fusion component of tripartite multidrug resistance system
MAKRVLRVLVLTGVLTGLVGGAAWFWKSRQGHEHTDNAYVHGDLTVISPKISGHVVDLAV
EDNQPVRAGQVLLRIDARDFQVKVDEAAAALQGAEAAILGIDRRIDAQKTVIEEAEAGIR
TWQAELDLAQRELGRTASLVKEEAASRQRLDSNQAALSKARAGLDQARAKVESSRAQSAV
LEADRVRQQAAVAEARAKLDAATINLANTEVTSPVDGVVGNRAVQLGQFITAGSHLLSVV
PLDTVWIEANFKETQIGAMRPGQPVTVTVDAYPDLRLTGAVASFSPASGAQFSLLPPENA
TGNFTKVVQRIPVRISLSADNPLRGQLRPGLSVVVDVQTGAGGTGSANAAER
>fig|1279038.3.peg.2527 Acriflavin resistance protein
MNVSELCIRRPVMTLLLSIAVVVLGLFAYKKLPVAALPSVDFPVINVSASLPGASPETMA
ASVATVLEREFSTIAGVESITSSSNLGSTSISIQFVLDRNIDSAAADVQAAINRTLRRLP
SEMTTPPSYRKVNPADAAIVLLALSSPTMPLSQLNDFAETVVQPRIATLSGVAQVLVYGS
QKYAVRVQVEPNALALRGIGLDDVQKALASANSNTPVGSLSGARQQMILTSNPQLPDADA
FRNLIIAWRGNAPVRLGDVATVLDSVENARTASWYNGTRAIVLAVQRQPEANTVEVVDLV
RQQLPAFRAQLPPSVSIDLMNDRSTSIREAVEDVEFTLILTIVLVVMVIFLFLRRAAATL
IPTLAVPISLVATAGAMYLLGFSVDNISLLALTLSVGLVVDDAIVMLENIVRYIEEGLKP
FDAAIKGAREIGFTILSITLSLVAVFIPILLMGGVVGKVFHEFAVVVTIAIMVSAVVSLT
LTPMLCSRFLTREKHGEEEGPVGRALEAGFDALLRGYKRGLLWSLDHMAVMGLLMIATVI
GTVVLFREVPKGFFPTEDIGQLSVSVEAAPDISFDAMVEKQKLVAATVQAHPAVAGATSA
IGGGASSVISSGRMFVTLKPRSERPGIEKVIQDLRKEVGKIPGIAVYLNPVQNLRIGARS
SKNTYQYTLQGLDLHDLYDWSDKLQDAMRRIPQLQDVASDLERNNPQVYIDINREKAASL
GVNVDQVRSTLYSAFGQREAATIYTPSNDYAVLIELDPRYQQDESALSLVYVRSSTGSLV
SLDSFAAVRRTVGPLSVNHQGQMPAVTLSFNLAPGVSLGDAVDLIHEAERALAMPVTITT
SFAGTAQVFQQTLSNQGVLLAAAVLVIYVVLGILYESFIHPITILSGLPSASLGALATLI
LFKEDLSVIAIIGLLMLIGIVKKNAIMMIDFAVAARREQNLSPREAIEQACLLRFRPIMM
TTMTALMGTLPIAIAFGAAAELRRPLGLAVVGGLVVSQTLTLFITPVLYLYFERLSQWLQ
GLGRRPDSSDAPQAAE
>fig|1279038.3.peg.2889 Permease of the drug/metabolite transporter (DMT) superfamily
MRDAFYYAFCVLAWGSTYFAVTFLKGPVPPSLSVIYRLVIVAVVFALLHPLLRRRLTGLS
ARTHLWLVLFGLGNFGLSYAMMYAAVTMIPSAHAITLFAIKVVMTPVLLGLFLRERIPRA
IWVGGVIGIAGVVLMFWPQLAGGDLRGDAWMGFLLTLGGAAITSFGDVASTRLIRAGGDP
MTLTFWGTTYGVLFLIVVALVQGQALVWDPSLHFALAMGWLVVACSIVAWLMYMHLVKTI
GPARCSNMVTLFPVVGVALSLAFEGVAPTVNVLGGAALVTAGAFLANRGKLAA
>fig|1279038.3.peg.2916 Multidrug resistance protein A
MTDSSAAAAVLPARSGGVDRLRLALFAALPVALAAGAYAYASGGAVMSTDNAYVQADMVA
VSTDVSGLVKSVDVQENQPVTAGQVLFRLDDLPFRLTLQRAETKVQTVRNDLLADQAGYR
DLQAQIQRAQADIAYYANELERKRQLVNSNTTPRSAFDDARHDAQTAQLKLASLTQQAAA
MAARLDGRPADDVETYPAYRDAVAARDEAQRQLDHTVVRAPMDGVVTRVPSLQAGQALPA
ATPAFSLVATDHVWIDAQPKETELTWVHAGQPVTVTVDTYPGAVWHGTVDSISPASGASL
SLLPAQNSSGNWVKVVQRIPVRVRIDTPEGLPPLRVGMSATVDVQTGHVRGLPLVGDHG
>fig|1279038.3.peg.2917 Multidrug resistance protein B
MADGPVPAAGFQPVPHRGMITACVTLAVIMQALDTTIANVALPYIQGAVAASADQINWVL
TSYIVAAAIMTPPSAFLARRFGRKRVLMGSVSGFIIASVLCGIAQSLPEIVGFRLLQGLC
GAALVPLSQSILLDLYSAEERGKAMALFGVSVMVGPVLGPVIGGWLTENTSWRWVFYINV
PIGVLAVLGLSAFVKETARDTAARLDWVGFGLLSLTIGALQMFLDRGQQLDWFSSVEIQA
EALLAAVAAYLFIVHTATARRSFVDPSLFRDRNFVVGLIFIFTIGITYLASLALMTPYLE
SLMGYPVVTAGLVMGPRGLGTMVFMFLVGRLIGRVDTRLLLATGMAMTAWAMYDMSGWTP
DVAASTIVWVGFVQGAGLGFLFVPMSAVTFATLPLQKRAEGTGLYNLSRNIGSAVGISVM
AALLTGNTQINHAEIAAHLTPFNRILEQPVFAHVYNPATAAGQAALDGLVTHQAVIIAYA
DDFLLLMVLSLITIPLVLLLRSPKQAAGTKPEPVVAD
>fig|1279038.3.peg.2963 Permease of the drug/metabolite transporter (DMT) superfamily
MPETAAMPALPLTSSPLRTGLLLGTLGVILFSLTLPVTRLSILLSGLSPLAVTLIRLDVA
SVLAALFLLLARARLPARALLPDLMAVAGGAVIGFPLFMAYAVTLIPPEQSPASHAIVVN
GLLPFATAVAATLLCGDRPSPGFWLVALAGSGCVVGYALTLGGGAFSVGDVAMAAAVLSA
ATGYACGSRLSRHLPSWQVICWAVLLCAPLALPLTIALPWIDGPIPAAAWSLPSLASLLY
LGAISQLIGFFAWYRGLSLGGTARVSQVQLLQPFLSLLGAAVLLNEVLTPLTLIMTVVVA
TLVMIGKRMPVKVG
>fig|1279038.3.peg.3172 Quaternary ammonium compound-resistance protein SugE
MSIHWIILLIAVFTEIAWALSLKAAQTNPGVLTIGASIALTATNMLLLSFAMRGIPVGTA
YAVWTGLGAVGVVAAGIILHADPLTLKRVAFMAVIIFGVIGLKLVGDEG
>fig|1279038.3.peg.3443 Permease of the drug/metabolite transporter (DMT) superfamily
MSVRDTLLALFVMILWGANYVAVKLGVSEFPPLLLITLRFALVAVLLVPFYRITRRQVPG
VLLLSFSFGSAHFALLFVALQMTEAGTSALLLQLGVPFSTLLGVVFLGDRLGIWRISGLL
VAFSGAAVLAWGPHVPAFAPAALLIVSAFFWAVSNLLVKKVTDVSPIALTGWMSLFAVPQ
CLLWTLLFEHGQIEAIQQASLVGWGAMVYTAVGSSIIAYGLWYWLLGRYTVSQVVPISLL
NPVFGVIVGAWVLGEAVGPEKIAGGLLTLGGVGIILWRQAKRGGA
>fig|1279038.3.peg.3556 Permease of the drug/metabolite transporter (DMT) superfamily
MSGGAATPPGRSLTKYLMLLAISLFWGLNWPAVKTILSQVPPLTLRAVGFSLGAVIILSL
TRLTGRSLSIPRRDWPSLAAAGVCNVLVFNLCTAFAQLGMATSRAAVIAFTMPVWATLLA
IPVLKEWPRRQQIAGLVCGMAGLAVLLGPNGLQQGFGPGLMLIAAVSWAIGTIVMKRHVW
GGAVMAVTGWQYVISAVPMVILAALLETPPDPSGFPPQVWLAISWHLLLSLCAAQVLWFV
VVSRVSVGQAAVSTLLIPVVGVTGSVVLLGDTLTPALVIALGLILTGVACVLLPAKKR
>fig|1279038.3.peg.3702 Polymyxin resistance protein ArnC, glycosyl transferase (EC 2.4.-.-)
MAIALDGAVTVASESSGQGPFLSVVVPVYNEGEALHALHSRLTAVLRQMPVSRWEIVLVD
DGSRDTSFEVIRDLAAADPAVRGLRFARNFGKEAGMAAGLRAAAGDVVVLMDGDLQHPPE
LLPEMLQRWTDGAQMVTAVRRSRQTDPTTRRLASRMFYWLFHYVSEVEIPEGAGDFRLFD
RAVVDAINSLPERNRFMKGITSWVGFRQVLIDFEPAERVGGQSAWPFLRLFRYALDGISA
FSMVPLRVWSIAGVTIALLSVIYGGWLVVRTLIWGIDVPGYASLMVAGLFTSGIQLISLG
ALGEYIGRIFNEVKGRPLYIVADRVGQDPRSDAKTETRS
>fig|1279038.3.peg.3744 Permeases of the drug/metabolite transporter (DMT) superfamily
MSAAQTPPSSQAAGLLTSPWVMMVIPPLLWAGNAVVGRLAMAQMSPYALSFWRWSFALLL
LLPFTLRSTLAHWGVIRANALHLISLGVLSVGAYNTLLYMALQTSTAVNVTLVGAVMPLV
ILLLSRILLGEALTVWRVAGLAASFFGVAVVLARGDLSRLTALDLHRGDGLMLLAVLAWS
VFSVRMKARPLGLPPMVFLTVQMLTGLWVAVGAYLWDLGTGGGQVPMTLEALSMIAYTAI
FASLVAFLAWNRGIVRLGANLSGFYVNLIPVFTAVLAVPVLGEPLQAYHFIGMGLIFAGI
GLAAVRGKQQKAEGR
>fig|1298593.3.peg.419 Acriflavin resistance protein
MNLFGYIHRYKRLILALTAMFMLLGIASWLTMARQEDPSFPYRTGTIRVVFPGVSAEQIE
KLITEPLDEQLAEVEELRRVKSTSRDNVAIFVVELLDRIYDTDAAWDRVRRAMEKAEQDF
PKGVVEYVLEDRRMDIPAAVISIVGTADILELAHQAEILKRQLLAVNGVSRIEIEGDPEK
ELRIDLDSAILSQLSINRDQVVAAIQVHNQIIPGGVVRIGDHALRVDTGSDLQQKSDVES
IPIRLATGQYIPLSAIAHIAFVAREPSAAQTYHNGMRSVSLGIYAKRGQVDAIVFGEQIR
QRIDAVRADYQPLDIVETFFQPDYVADRLEGLQFNLLGSILIIAITVIAALGWRNGLLVA
GVLPVVAIIVLALYNLGGGVLHQIAVIGIVISLGILVDNAIVVVESIVQELQAGRSRLEA
VESAFEQMAFPLFTSTGTTVAAFIPLLLSKGGTGDFTRGIPVMIILSLLVSYVISVLVLP
LVAERLVGIPKHDNQRWIKKISDKLIYISRYKAKLALLLVVGVMALTIMAFPLLKLQFFP
QADRNQVVIDMTLPGDSSLERMAEVSADVEQKLLARDDVVGVMRSVGMSGFRFYYNLLAT
IDSTNSARLMVNTRDMAANQAVIDWITHDIQTALPEATIIAKRLGQGPPTPAPVELRLQS
DDPSSLYQAADQVLAILNALPETTMIRSDKDSGLAELSVNIDKTIAQELGVRRDQVAASL
FGQTRGLDAGEFLYSDDPITMRVRSAAGDLTTTAELSGQYIYNAAGQSVPLDAVATLKSQ
WTSAVIRHYKGIPTVTIHSELMPGAAYNTVLKKVFAALDENPLPGAVTLQLGGDAEGSAD
ANRAILKSVPIGVMLLLLFMLVQFNSFRRLTIILATIPLAAVGIIPGLVLSDQPFGFQSL
LGVIALIGIVVNNAIVLLDVVDARLREGADIDSAVAQSIDARTAPILLTTATTVLGLLPL
AFSASTLWPPMAWAIISGLLMSTLLTLIVIPVLCRMMLKTNPVAM
>fig|1298593.3.peg.796 Drug resistance transporter Bcr/CflA subfamily
MYLPAMAQMAGSLDSDIHHVELSVSTFLLGFAIGQITGGPLSDRYGRKPIIIAGLTIFAI
ASLTLSMTTSLSGLLILRAIEAIGGGLATVNSTAIVRDRFEGKDIAKVLSMVAMIMMTAP
LVAPMLGSLIVSFSNWRSIFMLLSVYSAFVMILLVWLLPESHPPHRRSRAKPWVGYGVVL
RHKVARRFILTLACAYSGMFIFITASPYLYLDYFEQSAAQFPWLFGANVVVIMMVNRINM
LLLNRFKPIDLITTGISIQVVMGCILLTLSRYFPDAFTLWTVLPLMMAYVGALGLISANS
MATVLQYFRDVAGSATALIGVVQFCGGAAFGLLWGQLHDNTPVPMMAMMFLSAFCAFVAL
MAARYSREIYEAPAT
>fig|1298593.3.peg.993 Acriflavine resistance protein A (AcrA)
MSGIILKRFFEEGASVNAGEKLYQIEPTLYEAELASAEAQLAVAEANAYSAHLRAERYKK
LSKNSAVSEQELDDSEATAKQTEAQVKAAQAAVRSARINLSYTEITAPISGVIGRSTITE
GALVSAQQSTALTIIRQLSPIYVDIQRPASSVLLMRNPALPREVTLSLEDGTSVEKTGEL
QFSDANVDPGTGTVNVRALFENADHLLLPGMFVRANVPSSLIENALLVPQQAVMRQAGGA
TTTYVVNSDNVVEVRGVEVTRAIGDKWLVKSGLKTDDRVVISGLQKIKPGVTVTPEETK
>fig|1298593.3.peg.1495 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MTFKAQEVKAIIRLTLPILATQLAQIGMGTIDTIMSGYVSTRDLAGVAIGTAIWMPIWML
LAGILVALSPMTAQMNAARQRDAMPRLLAAAIYLGLVAGALAGIVVAAIAYSLPSIIEDT
ATAIIARDYLYFIALGMPPSGIYLAYRFYAEAVNHAVFPMRIMLVALLMNIPLNYIFVYG
ALGMPEMGGPGCGVGSLLVILFLMVANAWDTRQRRITKEFPLWEHVRHPNMEYVKDLFRI
GMPIGIAIFFEVSLFTVIALLITDLGPTVVAGHQVALNISSLTFMIPLSAGMALTVRVGH
HLGSKDIIAARTTAWLGVKLNFGLALFNATIIVLGASYIAGLYSPDPLVVAVASSLMIYA
AIFQISDAAQIAAAGALRGYRDTVAVMIITFVAYWLIGLTSGYWLAYGESTQLGAKGFWM
GLVIGLSCAAIALCWRLYLISQRPEVISTEEKALNN
>fig|1298593.3.peg.2274 Permease of the drug/metabolite transporter (DMT) superfamily
MLNIAIFTSLLFIAIGRLPGGIAATLVATLPLQVIMIRAIFGIRPEMHHVFAAIGGVVGV
ACLVWQSTESLDSWGVVAALSASFIMACGILLTARWIKDIPPLQFTSAQLFISGVVLLLY
VILSGREVPDITPSGMLALAWLGPIGMGMGYWLWFRAMKAIPIQRLSFLGLVNPVVAVLV
GVFFMSEEISTGQLFGMCLVLLCVVVGQRK
>fig|1298593.3.peg.2315 Permease of the drug/metabolite transporter (DMT) superfamily
MFSKEALAEFPPLLFIGTRFLLAGLLLTIPGFKPLTRLTKKQWKASAGVGVLFGAAMSFW
IIGLFSAKHLGEGSFITSLSVVLVPLVSWLLFRDSISRSNWIALPLAFTGLGLLSLQHGF
QPEPSQLFFFISALLLSLTFILNGRAASHVPALALSAIQLSIVGIVALSLSAATETWPDH
WTGNMWWWLGLSITVGTAARFFIQTYAQGMSSPSHAAVIMIIEPVWTSLFAAAWFGERME
PSQLFGCSLIFTALVVNRWNAVRKWLKRS
>fig|1298593.3.peg.3261 Acriflavin resistance protein
MKSSISWFANNPVAANLCMICILVLGFLSIPETRKELLPNVSLERISIQSKLPGASVETV
ESSICRPIENRIYDIQGTIDLTSYAYEGICSITLDVDEGFVTKEIVDEVKSRLEAKDLLP
KEATTPDVVELTVRNRVAKLILSGPVSYSVLTASARQLRTDLLEFSAVSIVELEDMKKSE
IRISIPAFNLQKYQISFDEISAMIQKQSGFLPGGMLQTSEGDVLITSDAYRDSSESYANI
VIAADPDGGEVRLGDIADIIDNRFSNQPQASFDRQPAVSIDVFRVGNQNITDISDVIHNH
LADSNLPQNVKVYVWQDESKNFQSRVDLLVSNAFSGLVLLFIVLLLFLSARLSFWVSLGI
PIAFLGTIFILPVFDVSINIVSLFAFILVLGIVVDDAVVVGESIHLQNQKGLYGTEGALQ
GVFEVYKPIFFAVATTVVAFLPLVSLPGPEGKLMRAIPIVVIGTLIFSLIESLYILPAHL
SGTHKNEKPGNKVLTAIQNVFSVFLDTLIKWVYTPVLTVCLRNKGLVVLTFTVVFALFMV
LLSQGWIKTALFAAIEGDVVVANVAFPEGSPREKTEKALRHLIAAADQVQAEYEAKDASA
IEHIYSVVAPKNTFTSYSVDKSMDHKGQVIIELPSSETRTYSGQDVLARWRELAGDIQDT
TSLQYSASLNPTNPDIQIEFSGYDIDDLMSAANQLAEKLREYDGTFDIHTSQEEEKQEAE
IKLKDNAVALGLTLESVIRQINRAFQGNVVQRIQTQDDEVEVWVGLPKNERSSPWYLENM
HIEYAPGQYVSLSTIAAIEYRPSKTHIKRYDRKRVISVSAFVNPAQNSVKNIQTDLATNY
LDGLVKNMPGIKWDVGGYQRAVTLFLDILMKYYLFAILAMYLMMAVLFSSYSQPLLVLYA
IPFGLLGSVTGHILLDLDLTLWSFVGMVAVSGVVVNDNLVLIDYINTQRAKGENVFVSVC
EAGRVRFRPIMLTSLTTFVGLAPLISETSVQAQFLIPMAVSLAFGVVFATLISLLLVPAT
YLMMVEWQTTLLRLFKQTPKGSSEDPVEAAYQRGFEQGTRNARKAVCPYKDDVLSSSWEA
GLNDARNL
>fig|1298593.3.peg.3287 Permease of the drug/metabolite transporter (DMT) superfamily
MFDRPRSSVQYMLLSALGFALMAACVKGAANSGIPVLEIVAARAIVSILLSYLDIKRKRL
SVWGNNKPLLVARGSIGALALICVFYAVSTLPLAQATVLQYTYPAFTALIALWFLRESVQ
FSTMICIGMSIAGVIVMMQPNFHEGVLASTSMLSITAALVGALGSAVAYVMVRHLSQTED
SSVIIFYFPLVAFPIASAALLSADIFVSPNIEQLGLLLLVGIFTQVGQIGLTKAMAMAKA
GKVAAYAYVQVIFSVILGWLFFTEIPSFWAAVGGLIIMSGALINTFYKR
>fig|13035.3.peg.1380 Acriflavin resistance protein
MVSSSTPEQDRPLNIVGRITAYFVNSQVTLLIIVALVIFGLAAALFTPKEENPQITVPGA
DIYFHYPGAPAEVVEETVTVPIEAKIRELPGIDDIYSTSQTGQARITAQFFVGEDWENSL
FRLQNHLFNSQDELPQGVNYQVNPLIVDDVPIVTLTITGENYSDNQLRRVGERLLRELRQ
IPDTGNLTISGGQPRVMRVDLNPEQLAAFQLSPAAIAQQIQAANIQVQAGDVSVGNRRIF
IEGGNLLETADELKAVVVGQGENGSPIYLEDVATVSDGYDDRVTYSRLLNRKDWDVTAPY
PDPSLQPEEDFEERPAITIGIAKKKGTNAVVVAQQIFDRVDELRDEIPNDITIAVSRNAG
RTAARAVGDLYSSLFQAIAIVVILLIAFLGWRDALIVALAIPLTLAGTLLVGWIAGQTIN
RITLFALILSLGILVDDAIAVTENIHRRFEEMPDQSFSQKVRTATLAVAELGVPILLSTI
TVILAFIPMAFVTGMMGPYMGPIPFNVPVAMIISTSLAVIVTPYLAVRVIKVKGRSTDNN
ESNDGQASEEVPNRIYTFYRRIMEPLLDSATRRRFLIFFVVGLLLASFALPLTQAVKFRM
LPKADEERFLVQVDAPLGTELVETDRIVREMETVLKEDSEVIQFESYVGTAAPIDFNGLL
RGNTHRSGEHLADIRVHLTNDDARSVSSEDIVFRLRPQLTEIAQENNAIVKLIEDPPGPP
VRSTMLAEIYGPDYERQRELSKQVADVFRNTAEVVDVDDSVKNQIPQMKLEVDRAKANQA
GLSTQEIAETINMAIRGVDASTLQVPGELTPVQIQVRFAEANRQSIDDLRRIQMPTPEGN
LVPLTELVTFTSTTVDQPIFHRNQVPVTYVFGEMNARSSVYAVMEQMIHFFRNPLPEGYS
IKWEGEWQLTLEVFRDLGLAMLVAVILIYIILVGQFRSFKIPLIMLGAIPLALIGILVGF
SLNGVYFSATGMIGVIALAGIVVRNAIVLLEFVGDRRKEGIELKEAVIEAGAVRFRPILL
TSVTTMLGTLTILSDPVWSGLAWTLLTGMLTSSALTLFIIPLMYYGDQRSSRKQEQTPVN
EKQLVADN
>fig|13035.3.peg.3896 Permease of the drug/metabolite transporter (DMT) superfamily
MQNLIYSNFSLAALFVLLWNSGFIGAEYGLPYTGTFTLLFWRYGALTLVLFAYLLLTKQL
ARQPLKTILHTSLVGVLAHGVWLSCALLALEQNVPAGIVALVVALQPLATGAFSGLVVGE
QASRWQWLGLITGFLGVAIAVGTRIQVNDEASFFGYFIPFGSVIAITIASLLQRRRETSS
QNYPRLSVAETLFYQSFATVLILTLPAVSIEKLEIQWNLALIATLSWLILGVSLASYGLM
WKLLSRLDATRVASLFYLGPPVTMAMAWVAFGDTPQLADIIGLLVVTAGVMFVQFPQLRP
R
>fig|1303518.3.peg.248 Permease of the drug/metabolite transporter (DMT) superfamily
MAFGPFTLTFVRFAPAGLILLLLARLRRRLPPIAREDLWLFLALGGIGIAATYGIFYFGL
QRTTATDASLLFACEPILIALFGYLFLKERLSWLQWTGFLVGITGIWLIAGRALGDWLAL
AGLACECCVSVPAKRLAMRYPGLLVVAYEMLIGAALMLPLALWEWHHHPHEVSLRPLAAL
AFLSLVCSVFCYGIWYRLLSRHAISQMGVFILLQPLLGPLYGHFLRGETLRTNTLIGALL
VFCGIALTIYRKRSSTDSLRG
>fig|1303518.3.peg.320 Membrane fusion component of tripartite multidrug resistance system
MSDENRDSRVLLEPEQKVETPSTVSDGLGAEEGEAPKRKATIKVVGLVLLFFALIIGGIV
GYSYWRYASTHVSTDDAYLTTDVVQITPQVSGSVAKVYVTDNQHVQAGQLLVMLDDSTYR
AAVEQAKANLKAAIAAAQGASTGVGLTQQTTLAQITQAEAGVTQAQTGVETASADVSRAE
AAYAAAQTGVQTALQTAKTAQAGVVAAEAAYRKALQGVQAAKQRLADAEATLQSAKANVV
AAQAKAKQAATDAKRYDQLYQEDAVSAQTRDAADTAAIAAQAALESAQQAVSQAQALVGE
QQAALNSAQQEVTTAQANLQQARAQYAAALYGIKVAKDSAKQAQAQYLAAQKGVNAARAR
VQQAEAQLQQAETAPAQVAVQKSNAHTAAARIAQAAAALHEAEIHLQDTRIYAPVTGRVN
AKTVEIGEQVAPGQALMAVVPDDDIWVVANFKETQITNMRPGQPAEIHVDAFPGITYHGH
VDSLASGTGAVFTLLPPDNATGNFTKVVQRVPVKIVFDPKQPGLDKLRAGLSVEVSVKVK
>fig|1303518.3.peg.331 Inner membrane component of tripartite multidrug resistance system
MTASNLAAKNGRRVVLTDTGEELSPYRWIILVGLITTAILEVLDTTIVNVSLPQMAGNVG
ATTEEISWVATGYILSNVIVLPLTAWLASRFGRKRYLVSSIILFISASFMCGTSRTLGEI
VLWRIVQGAGGAAFISTVQATIREIFPREQQGTVQAIYVMGVIIAPTLGPTIGGWITDNY
TWPWIFFVNVPIGIVAALIIGLFLTEAKHKMQIEKVDWLGISLLAVGLGSLQYVLEEGNR
NNWFDDPVITRLTILSAIALIAMVIWELSPRNTSPVVNFRVTRNRDLSAALILFLILGFG
LYGGVFLYPLFAQNVLGFTATLTGLVLMPGGIATGIAAMFCGRMLNGKVMRADPRIFIWT
GLTLFIYSMWSLAHLTPQSGEPAVRLALIIRGLGLGLLFTPINLVAFNSLKGVEIAQGAS
LLNLCRQLGGSFGIAILSTYLDNMERFHATMLSTHLYPENPYFQSRLTMLQHYLMTRGHD
AVQAHKMALALISYTVQSQAATMAFNNAFLLIGISTLCVSPLVLIMRVRRKPSTNAAAEA
MH
>fig|1303518.3.peg.776 Vancomycin B-type resistance protein VanW
MSRSDRHLLQRISAWRQEKGLLRLFVLLPLPLLAIGSSLLLLYSHHLHSEDVIASGVHLF
TLDLSGKTPEAARGEILQWAQDRAATLLTLHAQGIANHSSVSIRARTLGLGIDVDSTLQT
AEDAGRTGWLSKIVSLIRSSKPDYPIAPTVTVDQKQLHEALTHVAHLTQVPPINARIVLL
PKGGFGLKHEVSGRAIDVDAAASIVTRAWQQFNTPPAPSTDTTDRDGAATTGNLEDRLEL
NLPTQVIQPRITYNILHTIDSKLSSYSTWYAEGKRGHNIEVATEKIDGTLLLPGQIFSFN
NTVGPRVLASGFEVAPVIIHGQLQPGVGGGICQVSGTLYNAALKAGLKTVLRNHHSFPVS
DGGIPTGRDATVAYGELDMRFQNSLPYPVYIVGRAHGGLLTFDIFGHADPDRTVQLVRGR
LHEGDVPVEIIHDPNLPPGRRVVEQKGRPDVRTVWYQIVRVNGKVVSRDVIPSHYEGQPE
IVRIGVKASPAARQPKAHPPTVQPAQPPAPG
>fig|1303518.3.peg.1132 Permeases of the drug/metabolite transporter (DMT) superfamily
MSPLKWKAAFITFIAVFAISFGEAMLSRGMKQIGDGTLWHQVGAVLHNHWVIIGTTFMAA
YFFLYMWALKIAPFSFVLPITALSYPLGGLLATTFLKEHVGPLKWLGYVAIVIGVILVGL
GEASGK
>fig|1303518.3.peg.2341 Vancomycin B-type resistance protein VanW
MRWTEALGLGLFALASGYGFLQIAATSPPREVRIAGYVSSLRGRSPSQRRNARLAAWAVN
GAVVPPGGLFSFDKRVGSWSADHGYVQAPVSYDGELVNAVGGGVCQTSSTLYNAALLAGM
QIVERHPHHFCPEYVPPGRDAAVAQTIIDLRFKNPYPWPVRIECRATQDTLEASFWAPKQ
PTLQAHVETQILSTTQPQRKTMILSNNSRGHGLHARLLSIGVPGYRVITYRTFTRPDGTI
VRRERISDSTYAAADRIIGIYQTSLR
>fig|1316932.3.peg.466 Permease of the drug/metabolite transporter (DMT) superfamily
MFKKYFGEIILFLVTFIAAAGWFFSKHALVGLPPIGFMGGRFILASLILLPFSYRELYRL
DKVQVKYSVITGLTYGIYTIFWVLGLAFSTVFGEGAFLVSLAMLIAPLLSWLIFKHTPPK
IFWLALPIALSGLYFLSAEKGIFHFSLGSTIFLVSSVFGALYFVLNNQYAKQVSLFPLIT
IQLAIVGAVCSLYSYFMESWHFPILTEVWLWFAASVLIATNLRFLMQTLGQKYCHIGTSA
LIMLLEPVWTLLLSVMLLGEQLSATKWLGCSLILIALIIYRLPILRLKK
>fig|1316932.3.peg.670 Permease of the drug/metabolite transporter (DMT) superfamily
MLYLLIATLIWASSFIVGKVAISAFDPVQIMQIRLTLAAFIALPFFIPAYKKIQKNQHIK
VWLISFLTFPLYVILQFSGLKLTSAASAVALLGLNPLLTVLVGYFCFKKQATRLDFILSL
FACLGILIMASGSDDSGSINVLGLLLVTLGSLSFIVGMYLSKEILQSVKVIDLTKIMLVQ
GAITALPITLLFAENWQLPTSLSAWASVAYLGIICTSLAILLWNKGISQSSPILAGILLA
LEPVFGLLMALVFLSEQLSLVTWVGIIIVICTALLSVLLPMMKRYKRLI
>fig|1316932.3.peg.2559 Permease of the drug/metabolite transporter (DMT) superfamily
MISSSLKLGYFSLIVATLFWGGNFVLGKVLSGAVQPITLTYLRWLPAFLILVLLFFRPTW
RVMHLLKPRLGVMWVLGLLGVILFPATLYEGLKTTTALNASLYLAISPVLVLFLNRLVFK
EKISPIILSGAIISLLGVLWLLMQGKLTRLFSLAINQGDLWAIASTISWAVYCCVIRLRP
QGISNTVFLTVLVGLAVLTLTPFFIYEYVAESAKNLANLTALQWSGIGYLVIGPSILSYA
FWNFGIAIVGSAKGAVMTNFTPLFAAMFSIILLNESVHTYHIISAILITAGILICSYKKH
>fig|134676.3.peg.429 Multiple antibiotic resistance protein marR
MTERVMTTERTAASLAKTLREAIIRFSRRVRQARPVGDLTFSQLSALTSLQLHGALTPRE
LADVERVQPPTMTKIVGKLEDRGLVARTPHPTDGRQVILAATDEGRAVYTQNEDIRNEWL
AGQLDRLTPEERDTLARAAEIMLRVARG
>fig|134676.3.peg.479 Multidrug resistance protein mdtL
MTTATARQPAPTVVPARLSRPAAFTAIAAILVTFAAASAVPSPLYVVYQHLWGFSPAMLT
VVFAVYVVALIATLLTLGALSDYIGRRPVLAGAILLEAVALTLFLTAGDVGTLLAARVVQ
GVATGAALSTLGATLIDLNPAHAPGRAGLISGIAPVAGLGIGAFGCGVLVKFAPFPTHLV
YALLLAGMVVAALAVAWMPETSGRRPGAAASLIPRLGVPARLRGDLFALIPIIVASWALG
GLYLSLGPSVASDSFGIHDHLAGGLVVALVCGTGAVTSFLLRQVATPRVLTIAGSGLLLG
GALGFAGLETGSLPLAVIGSIISGAGFGAAALASFSTLARIAEPHERGELLAVALTISYA
ALSIPAVIAGQTATHIGLHITALWYAAIVAALALLALVAQRLRSRSRA
>fig|134676.3.peg.506 Antibiotic transport system permease protein
MTGLGGLLRLILRRDRVILPLWVLLLGLLPRVYLTGFEKLFATDADRLNYAHLSAANAGF
VALYGPLSGDSMGELVVWRAGFLPVMIGLAALLTVIRHTRAEEEAGRSELIRATVVGRWA
PFAAALLVTLTGCLIVGVLVTVTMIGGGLPVAGSAAFGAVFTLSGWLFAGVAAIAAQLTS
GARGARTIAVLALGVSYVLRLGGDISAQGDGRLGRLSWLSPIGWVQRIFPYGADDPWPGL
LALLGTGATVAVGARLLARRDLGSGLIADRLGPAHADRALGSPFGLAWRLHRGRCSAGPP
ASARSGWSSAGWAPAWCSCPGRAAGSATCSAGSAAAGRSPTRTSPPPPGSAGWSSRCTRC
RPPCGCATRSRPATRS
>fig|134676.3.peg.507 Antibiotic transport system permease protein
MRDEEQTGHAELILGTRASRVGWAAGHLLFVLLGPVVALAVEGLLAGLAFGEPGRVPAAS
LAQAPAVWVLGAIAVLLVGALPRHSAAAWGSVAICLLVLLVGGLLGMPQWVLDISPFTHV
PQLPAAGFTVVPEIVLILIAALLSGAGLTALRRRDIPA
>fig|134676.3.peg.1586 EmrB/QacA subfamily drug resistance transporter
MVLSLAQLMVVLDATIVNIALPTAQASLHFSNADRQWVVTGYALAFGSLLLLGGRLSDFF
GRKRMFLIGLIGFASASALGGAANGLEMLIVARALQGAFGAALAPAALSLLSTTFTEPAE
RGKAFGIFGAISGAGGGIGLLLGGVLTEYVSWRWCLYVNLVIAALAVAGAMLKLKDEPSG
AHGRIDVPGTIAAVVGLVGLVYGLGKAETDGWTARGTLGPIIVGVVALILFVLIERRVEH
PLLPLRVVLDRNRGGSYASIAIAGAGMFGIFLFLTYYLAVVLHFTPVKTGLAFLPMLGSV
MLTATTAGSILAPKVGPRPLVPLGALVAAGGLLLLTRLDLDSTYASGVLPGLIVIGLGLG
LVFAPTQNAATSGVEHRDAGVASAMINTVQQIGGSIGTALLSSFAATAATDYAKGKQPSQ
LLQLQAQIESYHTVFWWSAGFFVLAAVVALVLFRTGPLDVDPDAPPAMAH
>fig|134676.3.peg.1690 Glyoxalase/bleomycin resistance protein/dioxygenase
MPIRTITVPVKDLDAARALYTRLLGVEPYADAPYYVGFRPDGGPELGLDPHGDVAAGPIV
YWHVDDINAELTALIAGGGTEERPVHDVGGGTLIATFRDADGNLFGLHQGAAS
>fig|134676.3.peg.1962 Multiple antibiotic resistance protein marR
MRLPRLIFLLFNADRAVRRWIDARSADTGIGASGAGVLFYLAGHENALIGDVTAALGASP
SGMSGLVNRLERSGCVSRSPDPADARAVRLTLTPRGRESVTRARDLVDDLNQQLTAGFDE
AEVAVIERWLEHVSRRDFR
>fig|134676.3.peg.2114 Multidrug resistance transporter, Bcr/CflA family
MSITQAPPTARHRARLALILGALSAFGALTIDMYLPAMPGMADELDAGATLVQLTLTVFV
VGLAVGQVIVGPLSDAWGRRRPLLAGMALYVTGSLWCALSPTAGYLIGGRVLQSLGAAAG
TVLARAIVRDLYQGTAMTRFFATLMVVNGVAPIVAPVIGGQLLTFTTWRAVFLVLAAVGA
ILLVTVALALPESLPRERRAPAHPRATLRAFRTLGTDRHYLRYVVAAALMFAAVFAYISG
SSFVLQDAYGLSAQQFSLVFGLNGLGIVVFGQIGGMLVGRVTGEHTLLRVSLSIAVLGSA
GVLVCAVAGLPLPLLLAFLFLPVAMLGIVLANATSLALAGHGSAAGAASSLQGLLQFLVG
SLAASAMTLAGPATAITMGATMVICSIAALATLR
>fig|134676.3.peg.2243 Multidrug resistance protein mdtA
MAGIVGGALLAVVHSHQQGGATSTIVAVRVGKGDVTLDVATSGTVRPATTRELSFAVNGT
VASIAVRAGSKVKAGQTLAAVDATAATAAVTDARNTLTDAKSRLTDARDQAARVTAAATA
CATAASDRGLLATAASDRGFLATAASDRGFLAGADVSPTATVAVNSCTTRGYPDTGNDPV
LTAQQAVNRAGEAVTRAEAALAGAVITAPIAGTVVSVAGSVGDTVSSGKTFVTLADTYTM
QVEAAFPEADAGSLAVGQSATITLADHDDALTGTVVQVDPVGTSDGTLVRYGAVLSFSAP
PSDLLVGQSAQVAVRVGETRNVLRVPSTAVHDISGGSGTVLLRVGGRSSERTVTVGLRGD
QYTQVTDGLTADDQVVRSW
>fig|134676.3.peg.2517 Permease of the drug/metabolite transporter (DMT) superfamily
MGDLLLLAVAVVWGSSYLTAKTLVAAGGVLVLLALRFLISAVALLPALAVRRSRGRFDRR
ELLVGVGLGVTQTSVLILETFGLSMTSATNAGVLISLTILMTPILEGFTRRRWLPPAFFG
GAAAATLGVVFLVAGPGLRTPSAGDALMLAAAVVRAAHVTLSAHLTRGRSHDTATLAALQ
TLTGAVVCSTVAARALPAAVAAYGPAQWAAVTYLALGCSVFAFVVQLWAIRRTSASRASL
LLGTEPVWAVLFGVALAGDRLTPAALLGIALVLAGTYYGQRLEGRSRAERSPTYARGNDI
VRRTPRPRVGARSVRRSRGI
>fig|134676.3.peg.2884 Small multidrug resistance protein
MRYVLLAVAIGSELFATSMMKATDGFSRLWPTLVVLAGYGVSFVALSQAIKGGIQVGIAY
AIWSAVGTAAIVVIGALFLDEPVTLAKVGGITLIIAGVVMLNLTGAEAH
>fig|134676.3.peg.3133 Antibiotic transport system permease protein
MRAYRALARATARSALAYKNNLFLGLGAVFVQFIAMLAVWRVVLADGSAVQGFGWPQMRA
YLLVAFAAGTLVSVFGDFRTAARIQSGLVALDIIKPVDFQRARLAETLGGTWLEALVVVV
VGGVTLALTGGVPTPPGAALALFAASMLMLVPLKFLIVYVSTLACFWTQNFIGVQWARIA
LVNLLSGALIPLAFLPGWLAAVAQWSPFAGLVSTPALIFVGQVGVGRGLALVAAQLGWVV
ALWFGARLIWRAALRQLTVHGG
>fig|134676.3.peg.3316 Glyoxalase/bleomycin resistance protein/dioxygenase
MLGSAAPIAFLPSTDLERSRRFFADTLGLVVAEVTPFACVVRVGTTMLRVTKTDQLQPQP
FTVFGWEVADIDAVVAGLSGAGITFVRYDGLEQDGAGVWTTPGGDRIAWFRDPDGNTLSL
TQFLPH
>fig|134676.3.peg.3483 Lysostaphin resistance protein A
MATVFFAVATVAAGVFGAVQPFTGIPEEVIQLTQFGPAVAVAVLAGVWPARTRALLHGAG
SGEARTGPVLLSTAVLIVAGAVGAHGVITGGVGFTRPEHPFLLIAVAQLIGACGEEIGWR
CLLQPLLRTRFGPLTASVLVGLLWGLWHVPVFAEGPWYGGLFLLATIALSVVMGLALERA
RSYRLLLAAGFHTLINLGMLLFMNEESGAVLPIALFGASAAVAALVGTASRR
>fig|134676.3.peg.3573 Multiple antibiotic resistance protein marR
MQALMLASRAFVGITVRALAAVPGEVTLPQFRTLVVLAARGPQRSIDIAEELGVNPSTGT
RMLDRLIGKGLVRRTRSATDRRVVRLRLTPDGQRLVEQILDRRRRELERLVDGNPGLWSP
PVIEALTAFATAAGEQAAATERSAAGKPPAVGAQAAGPSGPDWWLGWTPGDAVGENIA
>fig|134676.3.peg.4430 Multiple antibiotic resistance protein marR
MGMTSGEGRGAQLLPVLGQLVRFLRQLEGPDNPSSIALAVLRRLADHGPGRVTDLARLTR
ASQPGMTQLIGRMEKAGQVRRVPDPHDGRGVLVEVTDAGRELLSRTYAYYATTLDRLFEQ
LTPEESDTVVAALPALERLARAGERESAGTR
>fig|134676.3.peg.4494 Glyoxalase/bleomycin resistance protein/dioxygenase
MTSRIGDIIVDCRDPELLAGFWCGVLGYRIFARDATGVAIRGATSSPDILFLHVGDRKAT
KNRLHFDVCPTDRGQDEELTRLLALGARRSSIIGSGSWVVLEDPEGNEFCLMAKRIAAEP
APFHDA
>fig|134676.3.peg.5630 Multidrug resistance protein mdtH
MTVLLLATLVNAIGNGAYVTISVLYLTTVAGLSPAMIAIGLSAGAAAGVLAMTPLGYLAD
RHGPKRLSILALIVLAGAYTALLAVRSPLAFGLLSCVIAVATALVKGANGALAAGSVAAS
GRLRMRARMRTMTNAGIGLGTLGGSIPLLLQTDRAYVVILLVNAATFVVAAALLTRAPAV
PPQVTPPGGPRLVALRDRPFLVFAAVDGLLSAVYNDLLGIGLPLWLAAGAHAPLWLISVT
LVINTAGCVLLQVRTARDVHDLPGARRAAVRGCLILALSCAVLAATAGHPPWLAGTLITL
AAIIHVVGELWLSTGSWGIVFAITPPWAQGQYQGTYFAGRGVGDMLAPPLVTACVLGLHS
AGWLVLAALFAAGGAIYPPVTRWAAARITSIERTPAPA
>fig|134676.3.peg.6051 Multidrug resistance protein B
MRMAQLEPKRGGALAAVALAQFMVTLDMTIVNVALPSLGGDLGFEPTQLPWVVNVYALLF
GGLLMLGGRAADLFGQRRILLSGTALFALASLAGGLAQAPWQLIAARAVQGMGAALMAPA
ALALLTLTQREGRERTRALGVYAAVSAVGGAAGVLSGGLLTQFAGWRWVMLVNVPMAACV
VVLALIGVPGGQLSSGPRRTLDVPGAVLVTGGVGALVLGLLRTDHYGWASATTLVTLGIA
VLLIVLFLLWEARGIKSDPLIRLGLLAKRNVAGANLFILLLCAGQFAAFYFISLYLQDVL
HLDAARAGAAFLPLTLTVVVAINISTRLVPRLGPKPLLVTGGLLAAAGFAWFGALDADGG
FLTDLLGPSLLTGLGMGLSFVPLTGAAVGGLPRHEAGMASAVLNSSRQIGGALGLAALVT
AQASRTDARLAAGDPPLEALTSGFGIGLSLSGALLLAAALVALIVLPGKRAAGVPAGEPA
AQRGASSSSPWPTNAPAGSPPLDAASSVTEPR
>fig|134676.3.peg.6396 Aminoglycoside/hydroxyurea antibiotic resistance kinase
MVEIALPDSFTRRVAQCWGAPGTRWLADLPEIATRVLHDWDLHLDRPCPLSLNWVTRVRR
ADGSAAVLKMGIPGADHLSDEAAALEFFAGRGAVSMLAHDAARGAILLEEVRPGRPARSL
VPDRDEDATAALIGVIRGLHRPAPPGIALPELAARRATFDEHLRRFPDDGPLPRHLVERA
GRLLTELCETAIERVVLHGDLHHDNVLAAGREPWLVIDPHGLTGDPGYEIGAMLYNPYPM
DDDTVLRLVPGRIEQLADGLDIPIERVVAWGFVQAVLSEVWNATGDGIATGRPLRLASLL
LPRLP
>fig|134676.3.peg.6578 Multiple antibiotic resistance protein marR
MRRDLLDLPVLLLGAATTLVDSINEGVRARGFTDLRPAHGFAFVRLAPDGATVIELAEHL
GVTKQAASQMADELVRKGYVERHPHPRDARARLLTLTPRGWACTRAADEAATEALQPWAD
TLGPAHLATVRSALAQLTTPGRIRPTW
>fig|134676.3.peg.6774 Pleiotropic drug resistance protein 3
MSSMSLGRGHVEVLQFLRDRTAVVFTFLFPAMLLLLFGTIFGNDYDRAGASAAQVYTASM
LAYGVLTTGFVTMGSGLALDREDGTLKRLRGTPLPVTSYLMGKLILVLTLSVAEAALILL
VGVVVFDMPLPPASHWVTFAWLMILSVTCCSLLGVAVSAVVRHARSAGAILNVPVVALQF
ISGVFINPITQLPSWLITVASFFPIKWMAQGFRYVFLPDSMKSLEAAGAWELGRVAVVLG
VWCVIGLALCLVTFRWSDKDR
>fig|134676.3.peg.6971 Lincosamide resistance protein
MAGRHVSTAADVVALFDALDVHRVQACLGGGWAVDALLGEQTREHSDIDLWLPATHLEWA
FRAFAALGVDRLFPTPGDRPWNFVLHDGDRRKIDLHLYETRPDGRLHYGSALTGEPFPAA
ALSGRGEIIGRPVRCEAPVWAVTWHTGYPPRAADRHDVPLLCARFGIPLPETFA
>fig|134676.3.peg.7298 EmrB/QacA subfamily drug resistance transporter
MSATGGAPPLSHRQILQVLSGLMLGMFLAALDQTIVASAIRTIGDDLHGLSLQAWVTTAY
LITATISTPLYGKLSDIYGRKRFFVTAITIFVVGSAACSFATSMYQLAVFRAVQGLGAGG
LFSLALAIIGDLVPPRERARYQGYFLAVFGASSVLGPVIGGFFAGADEILGLSGWRWVFL
VNVPIGAVALVVVAKVLHLRHTRRDHRIDWWGAVALCVCLVPLLTAAEQGRTWGWTGSRT
VLCYAVGAAGLVAFLVAEARMGAEALIPLRFFRNRTFALTSFAGFVTGMGMFGGLALLPL
YLQIVHGASPTRSGLQLLPLTAGIMAGSLISGRAISATGRYRVWPMLGAPLMIGGMGLMH
SLAVDTPYWRTGVFMGLFGLGLGFVLQPVTLAVQNAMPPQDMGVATASATFFRQMGATAG
TAVFLSLLFSRVGDRIRDALRVAGADPAFQKLMADPANRRVLGGSLDDTSFLRHVDPVLA
RPFESGFAATIADICLVAGGVLTVALILFAFLPQVPLRGSAPAGPAELSPSSGSATDLSP
SPGSATASPASSRSPHSPSPPARSVDALSLSGVVTGLDQRPLTGARLTLADLAGGQAARA
VTGPDGRYLLTPEVAGAYLLICAADRHQPAAIRLTVTGADARDVRLAAGGRIEGDVVDQH
DRPVAAATVTLTDAAGAVVASAITGPDGGYVLAGLYPAEYTLTGIAPGARPAARTVVLDT
GGVSRADLLLAGNGTLTGQVRAAASGHPVPEASVMAVDEAGAVVATTWTDADGRYAFADL
VPGAYTVTASGYPPVADRVELIGELTAHDIMLGGPREGSRLISP
>fig|134676.3.peg.7397 Glyoxalase/bleomycin resistance protein/dioxygenase
MLDHVGFQCADLAASAAFYDAVLAPLGASRQMDFQVAIGYGNGHPDFWISTLTEGDGFRE
SHIAFGAADRAAVDAFFAAAVASGAEVLHEPRLHPEYHEHYYGAFVRDPDGNNVEAVCHR
PE
>fig|134676.3.peg.7933 Multiple antibiotic resistance protein marR
MPTEPNLADIAEQLRQSIGRLVRTTRAHADSLPRTHAETMGYLSREGPHTIGELAARRRV
THQSMSRTVAELDRLGYVSRAPNPADARGFVITLTETGAAVLDTDRAARRDWVAAAIASR
LTPEEQRLLARIPALLDRLADGAGT
>fig|137722.3.peg.381 Permease of the drug/metabolite transporter (DMT) superfamily
MPADRSVPAKGLRLADQAWLLMMMPPLFWAGNAVMGRAVAGAVPPVGLAFWRWFLGMLIV
LPFAWRHLRHDLTPMLARWKSVLLLATLGIGVFNTLQYIALNSTTALNCVMLQSSMPVMI
VLMSVVLFRDRVGAMQGLGIVVSLAGATTLISHGDPATLLGLELNSGDLWMLAAVVIYAA
YTTLLRRRPAVHGLSFVVVTFAIGALELLPFYIWESLGGHPMRVSGITLLAVGYTVLFPS
IAAYLCFNRAVELLGPNTAGLAIHLVPVFGSLLAILFLGEQLHPYHGIGIALIAAGILLA
TRRRA
>fig|137722.3.peg.662 Permeases of the drug/metabolite transporter (DMT) superfamily
MSDASSFSVDHAQRTQRLALIALLLGALGIAFAPIFVRLSDVGPAAIGFWRTALATPLLA
LWMASESRSGSGRASRRPSGLADYGRLSLAGLFFAGDLAIWHTSIRYTSVANSTLLANFA
PLFVAPAAWFLFKERITGRFVLGMLLALAGAVVLMGQSLRLSADHLFGDALGLLTAIFYA
GYILSVGHLRGEFSTATIMTWSGAITAAVLLPLSLHDGEAMLPAGPSGWAALVGLALFSH
AGGQSLIAYALAHLPASFSSVSLLMQPAAAAILAWILLNEPLGRWQAVGAAVILGGILIA
RRASR
>fig|137722.3.peg.1529 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MSSATLPTPEPLRARLAAHIGELLRLAAPVIVSRAGLMVMMAVDTAIVGRFSAQELAYYG
LAHLPGNIMVGTGVGLLMGTVMITAHAFGAGTDAECGRAWRRSIPYALLLGVLFALVSLL
GDPLFQAGGQTPEMAAGGAHVLAVLGLGAPGMMLYITTGFFLEGIKRPLPGMVAMVIGNL
VNAALAWTLVWGHAGLEPLGAVGSAWATTIVRWGMGLGLVAYVWWMRDHDRWQLRRPVAD
WWSGAARQRHLGYAAGLSIGVESGAFGGLGLFAGMISPLALGAYTVGLNLTALPFMAAVG
LASATAVRVGVAYGRGDRSDMALAGWTGLGVTSAILAGVGILYRSVPEALGAIYTGDPEL
LEAVVPLIAFAAWILIADGGQTVMANALRGRHDAWVPTALHFFSYAVVMIPVSAFLVFGL
GHGAHGLFEGILIASLVSVTILSLRFAALSRR
>fig|137722.3.peg.2265 COG0697: Permeases of the drug/metabolite transporter (DMT) superfamily
MSVAHTLQALVVMALWGLNFVVAKWALAEFPPLFVMFLRFALVAVLIIPFFRVPRDKLWK
IALLSVTLGSIHFPIMFTGLKGIDAATASLAAQAQVPFSSLLAAVVFKDKLGWRRAVGMA
AAFAGVAVIAGEPRLGDQMASLLMILGASLAFAVASVQMKLLGSVNGFAVNGWMALFAMP
QLLGLSLLLEHGQMEALANSSWVGWASILYMAVGVTIVAYGLWYPLIGRYDVNQTMPYLL
TVPVFGVASGALLMGDPLTINLAVGGLLTIGGVAVIVKRRPRTVSETVTNPT
>fig|137722.3.peg.2368 Permease of the drug/metabolite transporter (DMT) superfamily
MEAGTAVILNVTTPIFAFLITLLLTRHEELTVGKAVGVGAVDEIGRDLPAQGAIILATVC
YAGAAIYGRAFKGLDPIMPAAGSLLCGAALLLPISVVVDRPWTLAPSGPSLLALAGLSVF
STALAFVLYFRLVDSL
>fig|137722.3.peg.2956 Permeases of the drug/metabolite transporter (DMT) superfamily
MAILAAVLFGVSTPLAKLLVHDLSPWMLAGLLYLGSGIGLGLVRLARGLSASPERNERSI
HGIEWFWLLAAVFAGGVAGPVLLMFGLTATPSSTASLLLNLEGVLTALLAWFVFQEGFDR
RLVAGMAAIVVGAVVLSWGGAVDIAAGWGPAAVAAACLMWAVDNNLTRKVSLADPVDIAT
IKGLVAGSVNVGIASVLGDGLPAVPTAAAAMLVGLLGYGVSLVLFVIALRHIGTARTGAY
FSTAPFVGGIVSLVIFGEPLTAGLVTAAVLMGIGVWLHLTEDHDHEHDHNEIEHDHPHVH
DEHHQHGHDGPVTEPHTHRHRHGRLRHRHAHFPDAHHVHPH
>fig|137722.3.peg.3607 Permeases of the drug/metabolite transporter (DMT) superfamily
MTANAETADLLPAKADSVPYAVGCFLVAIVLFAAMDTLIKVLTAGYPVPQLMFVRSLVAF
LLVGGYTLAWGGGFAAMRTRRPLGHVWRAFAGLISMGCFFYAFRELPLADVYVLSFAGPL
FITALSAPLLGEPVGWRRWAAVVVGFGGVVVMAQPSAGAPLVPVLVGLTAALFYALAALA
VRGLSRTETSASIVLYLLLTTTVVSGALAVPVWTTPTAAGLGLMALVGALGALAQVLLTQ
AFRRAPPAVVAPFEYTGMVWASLFGWMVFGDLPTAPVLAGAMVIIGSGLYILHRETMVAR
RRLGS
>fig|137722.3.peg.4606 Multidrug resistance protein A
MTGMRAFRWVIGGAAIAALGTTLWFATRLPPLTVQGEVSADRVDISPRVAGRVARLGADT
GDRVARGTVLVELESPQLVAALSAAQAALGVARADLDRVNSTRAETITARRADLASANAD
VTLYQDNYGRQAQLIRSGNTPQARLDEAARNLEAAVRKRESAEAALHLAVTGASPEERAL
AAAQVKQAEAALRQRSVDVEELVVRAPMDGQITTKVSELGENFSAGAPLFSMVDIAHPWF
TFNLREDLLSGLAVGDGFRITVPALGSKEIPVRVTMINVQGQYATWRATRATGDFDLRTF
EVRAVPAEPVEGLRPGMSAIWVRQGR
>fig|137722.3.peg.5609 Multidrug resistance protein A
MTTVTDRDTETTPAAPQPVAKPVRRSRWRRWLLMAALPLAVAVGGGYEYVVGGRYVSTDN
AYVQQDKVTISPDVSGRIVEVAVRENQAVHRGDLLFRIDDEPYRLALRQADAALASARLK
VEQLRADLGEALAKQAAAEEKVSFQQREFQRQQDLLKTGVAARATYDSVRHDLMAAQQDL
NTEKQSVVSARAALGGDPDIPTDRHPTVLEALAKKASAQRDLDHTVVAAPADGVVSQTGR
LLVGQYAATGLSMVSLVMSGSSWVEANFKETDLTHMAVGQTATVVLDAYSGRTLTARVES
IGAGTGSEFSVLPAQNATGNWVKVVQRVPVRLRIEAADGNAVPLRTGLSADVEVDTGYSR
PLPGVIGDAVAAIR
>fig|137722.3.peg.5778 Permease of the drug/metabolite transporter (DMT) superfamily
MRASHILLAVAVAAVWGLNFVAIKVGLRDFPPLLFSCLRFALAALPLALLGWGKGPPVPW
RYVIGIGVTLGVVKFPLLFLGMDAGMPAGLASLVLQAQAFFTAIFAAFALGDRPGPRQLG
GMAVAFAGVGLIALEMPAGDSLLGLGLTMAAAAAWGVSNIVMKQARAPDLFSLMVWVSLI
PPLPLLAMSLALEGPERIVHAVTTLTAVGVGSLLYIAVAATLFGFGAWGFLMRHYPASLV
APFSLLVPIFGMSSSALLLGETFTTAKLAGGLLVFAGLALSVLRLPAPRRAGA
>fig|137722.3.peg.6410 Bicyclomycin resistance protein
MLARLAAVRSRSPAESPFFIAALGVLMSFGPMGTDMYLPGMPAIGRDLHAAQDQVQWTLS
AFFLGFGVGQLLWGALSDRFGRRIPVATGILLYAVGCVGCSLTVDVGHLAAWRFIQAVGA
CAGPVLVRAMIRDVFERDRAASVLSMMMLVMGAAPIIAPLIGGQILIWANWRWIFGAQAA
FGAIAMLALATLPETHPPSRRTSLRPMGLFQSYRSLLTNRRYLGYAVGSSFIYAGMFAFI
SGSPFVYIELFGVRPENYGFLFGINIVGMMIVSTINSRAVMRFGSDRMLRIGGWLSAASG
ILLVACVLGGWGGLWGLVGCLFLFMSLTGFCFANSMAGALQSFPQMAGSASALAGMLQFS
SGAVSGWAVGLMADDTALPMAAVIGGAALVSLALNLWLVRPIRRRLPAA
>fig|138119.3.peg.89 Drug resistance transporter, EmrB/QacA family
MNIRKTPLILSLMLAMFLAAVEGTIVTMATPTIARDLQGFEFISLVFSVYLLTSALSTPA
YGKLADLYGRKNILSIGIIIFLAGSFLCGLAQSMVMLIVFRAIQGLGAGAIFTVSFTIIG
DVFSLAERAKIQGALSTVWGIASLVGPFFGGFLIDVLSWHWIFFINIPFGLLSVILLQSS
LKETFAKKKPSIDYAGTLTLSLAIVVFLSIFLFDRSTSPYPSLWVAGLLLLTFFLLYAFY
KIEKKAAEPIIPFAIFTRTTILVNLISFLIYAVLMGVNVYLPIYLQNILGYRPTAAGLAM
LPMSVSWLIVSFILGRLLVRYGGKNVILASNAVLLLSTLLLFTLGIDTPLPIILVYGFIM
GIGFGGASAALTIIVQDSAEYSQRGAAVGTNSLLRTLGQTIGISVFGTIFNLYITKYFTR
QGIEGINPGNLYQPDLSHTALAAEQITLSLNSSMHVLFTAFIIITLLSMILAMTMPGMKK
EKQA
>fig|138119.3.peg.357 Transcriptional activator BmrR for multidrug resistance transporter
MKEQYYSIGQVAKLSNISIPTLRYYDQIDLYKPAHVDTLTSYRYYKESQLYILDMIKSLK
YIGTPLTDIKTVLNYTPAELFCFLEHQEDVIEGKIQGLQEIHKNLQQTKKQLQQQMKTAL
ATDVFEKTEDLQIFTLPVENYAPQSIPNDCYGELIKLVEAEGSRISSHYGCIYPLLDYNS
MDEVRCTHIFTPLMTDRLNSHPAYRRNIRLISESRFIGIAFQYHPDRYIEHYQRLYHYIR
SKELPVADHVYDLFTPTRYSQHKEEEFMVELKVQLL
>fig|138119.3.peg.494 Probable antibiotic-resistance protein
MNIIDFRFRPNTEAILKGISSNPAFKGMCQSIDFNKMLPQTLEEVVEELDRHHVVKAVIS
GRDCETTYGAQSNNPSVIEFCHKFPDKFIGFAGLDPHKGMAALAEITHAVHEEGIKGAAI
DPYLARIYVNDAKYYPIYAKCCELGIPLIIATGPGTLVPNAVIDHVAPRYIDFVARDFPE
LKIIASHGGYPWVNEMITVAQRNANVYLELSEYEFFPQSSAYIEAANSILSDKIMYASAH
PFVDFKLALKNYEQLPLKPEVREKVMYKNAAKVLGLSDGTFSASKAMDAQEVQMIIENVI
AQLSQRGLLADR
>fig|138119.3.peg.510 Multidrug resistance protein B
MNTQYLNKFNIPRPILVLIIGGFIHSVGSSFMWPLNSIFMHNILGRSLTEAGALISLQAL
ATLVGQFISGVLADRFGSRRVMIYGLIGTILPLILISCFPVWEVYAPGLLFYGFAIAFIF
VPINALVFTLWPEGGRRGFNLLYVFNNAGVAVGTALGGFIAALSFKLVFLLNGLFFFIYL
LMVLIFLSAKDIQSKPLSKSRVKVPIFKDRGFPVLIALCAAIFLMWGAYIQINTVLPVTM
TNLGYSLPQYSILWTLNGVIIVAFQPVIHWIIRHWAPTLSRQFYVSCLFYAIGFLILLGN
FPYPSYFIMMIIITLGEMLVLPGVPAAAALIAPEGKTATYQGVVGGAASGGRALGPILGG
LAFDHYGGNMAWALALVFVSIALLPFYLYQRRERTFTQGTGAKEQAI
>fig|138119.3.peg.777 Drug/metabolite transporter (DMT) superfamily protein
MNELIVVKGEEKAQNIRTKAVRGTILTLIGGISWGFSGACGQYLFSVKGIDPHWVTVVRM
LTAGLLLFCLVLFKYREQMVGLLSNKRDRRTLIVFSIFGLIACQYTYLLAISHSNAGTAT
VLQYLGPLLIMIFVCGMDRRLPTKTEGVAIALAVTGTFLLATHGNVSNLVISAQGLFWGL
MAALGLMLYTIIPGKIINKWGSIVVTGCGMLMGGSILLVVIRPWQIPVSLDWQVFWGMLA
IIVIGTVVSFTLYLQGVSDIGPVKASMIASVEPVSAALFSAFWLNTAFVWIDMVGFALII
TTVILLTRQGSSRD
>fig|138119.3.peg.911 Drug/metabolite transporter (DMT) superfamily protein
MSDRNQGYLLIILSAVFYSTLGILGKYIYNTGIEMSLVIVLRLFATVILLGLFLLITRKE
PLLTFSRVVLFQGIFFIATAITFFLAVKYLSAGLATVILFAHPALVAVLAVIFYHEEIGA
AQIVGLILALLGLFFISGLYIESSTALSPLGLILSVLSAVAYGIYALLGQRVVKTDGIWT
ITFTISLMGLVISALIFPHNLPALLSITPYQLFLGFAMAFLGTILPVVLFLKGVQKIGSS
VGTLISIIEIPFALILAYLLLGEVLTPMQVVGTLLILIATTMAVAVKNQKENNERN
>fig|138119.3.peg.1108 Probable antibiotic-transport ATP-binding protein ABC transporter
MMIKVEGAFYRYPGAPRDVIQDISFTVRKGEIFGFLGPSGAGKSTLQKILTGVLRDYQGW
VQVLGTEMKHRKSSFYERIGVDFEFPNFYGKFTALENLQYFASLYHQKTLDPLTLLEQVG
LQHDAHKRVASYSKGMKMRLGFVRCLLHNPQLLFLDEPTSGLDPANARILKDMMLEQKAG
GKTIILTTHNMHDAGELCDRVAFIVDGKIRALNTPQAFQVERSGSAEVNYSYRRDGRTVD
RRSTLTQLGQDDEFVKALQNGSLLRIHSKERTLEEVFIALTGRQLQ
>fig|138119.3.peg.1170 Permease of the drug/metabolite transporter (DMT) superfamily
MKYKPELGILFVTILWGASFAVSKLIMADITPNYYTFLRFAGAFLVLAICFHKRLRHIPK
QTLQAGVLIGLAIACGYVLQTMGLNYTTASKAGFLAGLYVVLVPVMESFLCKCLPRYNMI
LGVCLATAGLALLSLERDFTIGFGDLLVFVGAVFFAVSMVLISRFASKHDPMVLAIIQIG
VTALFSLVLAVFTEPGLSAVQFTPVLLGLVLFAILFGTAVNTAVQNWAQGYLTATTAALI
FVLEPVFGGVFGWLLVGDVIGMKQISGSALIISGMLVTLLLKPGQRAQSKADQGVQLSGR
S
>fig|138119.3.peg.1437 Permease of the drug/metabolite transporter (DMT) superfamily
MAQGCRTAQWKGRVITMAEKRMAYLAAIVYAFIIGLSFMFVKLTLTVATPLDTLAHRFTV
AFLAATLFILFTKHKVNIGWHDVAQIAPLATLYPILFFGFQIFGLARTTSSEAGIIQSTV
PIFTLLLAVFILKEKAGRGQLISVFLSVFGVIYLLAMSGAESQTANIVGSVLIILSAFTN
ALYNVLARRLTQRYSLLTLTYIMTLFGFIAFNSLAIGSRMLAGTVGEFFQPLLHWQFVVA
VLYLGILSSLVTSFLANFVLSKIEAAKMSVFSNVATLITILAGILFLQEAFHFYHVIGGM
MIITGVVGTNLLGARSKAKEKAKDVEE
>fig|138119.3.peg.1443 Multidrug resistance ABC transporter ATP-binding and permease protein
MAGGFRTQQPKAPALVNRPGAGNRFVPAAKPKNTKGTLGRIVKIYLRWAKSIFAVILLTA
ASSLVAVAIPYYVGQAFNTFHIADRSVDTARLVSLLLIILSLYLGNLLLNLLNGTMMLRL
SQKLVYTLRQEFFAKMQRLPLGFYDTRSHGDTMSRITNDMDNISSTIAQTTTQLIASILT
LAGSLAVMLSLNVPLTLVVLLCVPLVFVLTKTIATRSRAYFLAQQRSLGALNGVIEENIL
GLKMVKAFNRQEEVLRKFQEINQGLRASSYKAQVWSGCMMPLMNVINNLVFAAVAICGGI
LTLSQGLAVGTVVSFLTYSKQFAHPLNSVAGMFNTIQSALAGAERVFEILDYEEERADEE
NALEMEHPAGAVAFDEVSFSYDKTQPILKEVSFQVNPGEVVALVGETGAGKTTIVNLLTR
FYDADSGEIRIDGVPVTRIKRASLRRCFSVVLQDTSLFSGTLMDNIRYGREDATEEEVIR
AAQIAHAHGFIAKLPQGYGTRVSAANDTLSQGQKQLISIARALLCDSPILILDEATSSVD
TKTEKDIQKALVSLMQNRTSFLIAHRLSTIRDADRIMVIGEGQILESGNHQSLMTKQGRY
YEMVMSQLGSQMAKSFSLKA
>fig|138119.3.peg.1472 Drug resistance transporter, EmrB/QacA subfamily
MGKSGKAPELEPIPKNIMNIAWILVLGAIMPLLDSTMVNIAINHLSHDFSIGLDLIQWVI
TGYVLAMAISVPLAGWMVQRFNGKWLMIGANILFLAASIASGFSWSIHSLIIFRVVQGFS
AGFIMTLVTTLCVETAGRERMGRLMSTIGIPTVLGPILGPVIGAVIVQFLSWRYIFFVNI
PLGILAITLMIWKLPDFTPANIKAKFDFIGIILLGTASAALIYGITKAAKSATFNNSTTI
AYGVAGIAILAIYMIYAALKKDQAILPLHLFRLKNFSAVMVGLFLAGIATNGPMLLLPLF
FQNIKGFSVLNTGLILIPQGIGMLIARPLIGKLTDKWGARNVVLVSLALTIVGTIPFIFI
NEASSLFVVSLVLFVRGVGIGGVTIPMMTDAYTGMVKQEIAQASVGTRLMQNIGGAFGSA
VMATAVSLSIQGKTPTIPLMTTAYHDGFMLALVLSLVLVIPSLFLTNKTAKQ
>fig|138119.3.peg.1558 Tetracycline resistance protein
MFKNGSDHEQNTEQTIDKKALLFGLMSVFLCGIGFSIITPVVPFLVQPYISNPEEQAIAV
TLLTSVYAACVFLAAPVLGALSDRYGRRPLLLICLLGSAIGYLVFGIGGALWVLFAGRII
EGITGGSIGTIFAYFADIIPPQQRTKYFGWVSAVVGVGTVIGPTLGGLLAKFGYSVPMYF
GTVITLLNVVYGLFYMPESLDKNKRLQEISLIRLNPFIQLANILSMKSLTRLLVSAFLLW
LPNGSLQAVFSQFTLDTFHWQPALIGLMFSIMGLQDIIAQGFIMPKLLLKFSDQQIAMLG
MAAEIIGYSFIAASALFVFYPLLIAGMFIFGFGDSIFGPSFNGMLSKSVPSGEQGRIQGG
SQSIQSLARMMGPLIGGQIYVSLGHAAPAFMGMLLIAAAIPVLHKRPQANM
>fig|138119.3.peg.1757 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MEQITTIKLKVHQFIHILLPILISQVALFSMSFFDTAMSGQASSVDLAGVAIGASLWAPA
STGLGGILIAITPIVGHLLGAKRRNEVPYNVLQGIYLALAIAFLLIVAGAMSLDGLLSLM
NLEPQVRFIARGYLLAIAFGIPPYFVHQVLRSFIDALGYTRITMLITLLSLPINICLNYI
FIFGKFGLPAFGGIGAGIATSMTYYCLMLIALFIIHRHPYFKEFALFKRLPPLSWKTWLK
QLKIGIPIGFSIFFETGMFCAVTLLMSRFNTVTIAAHQGAMNFASMIYMIPLSFSMALTI
LVGFEVGARRYHDARQYSLIGLAFSFSIALLTALLLFLFKEQVAWLYSKEWDVILLAKQF
LIYAIFFQFSDALATPIQGILRGYKDVNLPFITSLISYWFIALPIGYFLAAYTSFGAFGF
WIGLISGITTNACCLLLRLRYILRRQVAV
>fig|138119.3.peg.1921 Vancomycin B-type resistance protein VanW
MLRRKPWVFLLVILFSQLSLSILLGATVTYGAGYAKAPEGLTVWEKDLGGMTKDEAYAVL
AEVIPKAVVYDRTVYFLELNQTDQDLKDYLASQYIISTGNVITDAFEYLHRMSRTIPSPE
LLNQEEVLAQLRKFALDIDQPGKAAEAYYENGEIVIEEGSLGVRLDVDKSWEQLQQSIGM
ETVPLVTEVIVVHPTTAELEKVKDPLGDYTTYFNPSFHERVTNVRLAAEAINGLILPPGG
EFSFNDTVGKREPERGYLPALMYMGNRVVTDDGGGICQDSTTLYQATKQARLEVLERYSH
SLPVSYVPLGQDATVAYGALDFRFRNTTQGYLLLNAATGGNWIRVRIFGVADSEHPALDE
PDGYPVKPREWSK
>fig|138119.3.peg.2130 Daunorubicin resistance ATP-binding protein drrA
MRKVFVTKEKKGPWRSRKKEVVAVNTLDLAIRPGEIVGLLGINGAGKTTTIKMLSTLLVP
TAGSIMVDGTDAVKEPMKVKKRINMIAGGERMLYWRLTARENLAYFGSLYGLSGKALTER
IHRLLQAVELEAAADTPVEQYSKGMKQRLQIARGLINNPSYLFLDEPTLGLDAPIAKHLR
EHIRNLAVKEGKGILLTSHYLTEVEALCERVYIIDQGELVLHDTPKRVIQKVAAGEILSL
WVSGLLPATHEHLRQMLVPLEASLTILEQSDGVELRIQSKGEITAQVLKFLFEHGVIPHR
LEVEKPKLEDAILKLAGREEKGREKA
>fig|138119.3.peg.2416 Vancomycin B-type resistance protein VanW
MNLTPEAVSSDPDQLPPGTFLDDLALGGMMQEEAKEKIRSWSKDKLEENLFLVYNETEIQ
LTPEELGITLDFERTWQNLSENTGQESPSVLAIDYVMANQVLHEKLAEFNRSAVDASFKI
ENDQFKITPAISGEAVNVDAFFDEIKEVSLGDLPKRISLTGVEIPAAVTTESLEALAFDG
VIGEYTTKYNAGDKNRTANLITAAKKMDKAVLKPGETFSFNGTIGPRTAETGFKDAYIVI
NNEYVKGIGGGICQVSSTLYNAALLANLSIVERHPHAVVVAYIPLGQDATINYPNLDLKL
RNDSSSYLYFRTKVEAGNLTIKIYGKKTGVKVRFEKEIEKELNYHTVRKIDPDLLPGAVI
QQQSGSKGYIVKTWKIVTDAQGKETKQLLSRDSYAPTNRILKIGAD
>fig|138119.3.peg.2666 Drug resistance transporter, EmrB/QacA family protein
MLILGFIGLLFGMFSIGVMQLILATAMPFIVEEIGGGALYDWVFSSYMLASIATIPLFAK
FADIYGKRKFFILGMCFFALGSLCGGFAATMPYFIGARVIQGVGAGIISPVAMAMVSDMF
PAEQRGKMIGLFGLVQLLSNLLSPPLGSFITKELGWSWIFFLNLGMIAFSMLLVLLGKTV
QESKSDMKLKEIDILGGLLFGGFCLLAVTLANALSHQGRFGVLGAALLPALIFTGTMLVL
NERKQKNPIIKMEFLKTQIIRRSLISAVLSGAIMYGLAALLPLCGVMLSRQGFPLDESKT
LLFFMVSLTSGLLGGSRLNKLQLGQVPRYLWLILSVSSVFLLYSLYTVKIVPFCLFLILM
GLSAGGIMATFLINSQNAVESEDRTVLSGLVQLGRYFGASIGVTLLIGMLPEVSLISGVG
EFIGAFGLLVLLCLAGVLNEIL
>fig|138119.3.peg.2841 Permease of the drug/metabolite transporter (DMT) superfamily
MRWGNKMLGQIIISVILGAFGQILVKIGAKNLELDFAPENLLRSLGAIMQNFPVMSGLFL
YGVSFILWIKVLTKTELSYAYPFVSLGYIFIMAFSVMVFKENISFYRVLGTVLVIVGVIF
ISRS
>fig|138119.3.peg.3113 Glycopeptide antibiotics resistance protein
MLWSKNYKHISIIRELLVMAFVIYCLAVIRVTIFSLHPSAGFGQSGTPSVNIIPFAEMFR
GFHPNHFSLGYMIRHLESNLIGNILLLLPLGFFLPMLWSKFRSFKRTVVIGILSSLSIET
VQYILAYLGLSSGRASDIDDVILNSIGVIIGYMVFQAISCGIKCFRKYSTFTKVD
>fig|138119.3.peg.3180 Vancomycin B-type resistance protein VanW
MKRKRLTQLFPFLLPVRRTQRKLFFYTEMYFDRNHYAKAKAPEFLPFCVYETKSKLLNEN
TGMDMRYQENKVFNLRLAAETVNGLLIRPGETFSFWQRVRYAEKNERYKDGLCVVNDELI
TVPGGGLCHLSNLLFWLFLHMPLTIVERHAHEIKDFPSPDEDEPDGVDATIHEGWLDLKV
KNNTNLTFQIEIAIDEPYIYGRIFMDQAKRYSYEVVNRDKSFFKKEGKTFERVSVCRQVI
DNESKQVVSEKLLYTDVFEIGYVLPEGTAIADEKA
>fig|138119.3.peg.3184 Permease of the drug/metabolite transporter (DMT) superfamily
MFMPRGTPFPRGIFVLSDQRFLFSTHSLLGDLSMQQSKQASNRSIWLIALGAAMWGLDGV
FIVSLLQHVSSSQIVWLEHLLLFLFAAPVLIWKRQELKQLNGGDWLAVLFIGWGGSALAS
ILFTAGFTYGNPNVVLLLQKVQPIFVILLASWMLKERMRKDFYALFVVALIGAYLLTIGL
HLPTSEVSLAQLLGSLCAIGAAALWGGSTVMGKRLIGKLSFTTLTALRFAVALPLLTVIV
LVQQPNWADLGQSLHLAPVWANLLYQTLVPSLLSLLLYYRGLNGVRASHATIAELAFPAT
GLLVNWLILHQTIDLGQWLGFAIVWLVVLQLSRMPNAPKSAVKTSETANLAGL
>fig|138119.3.peg.3464 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MPSVKMNQGNNVLGTQPIPGMIWKFAIPAIISAMTNQVYNLIAQVYIGWSVGDLGIAATN
VAFPLAILITALSALFGMGGAAKFGLYMGQGKPEEASQTIGNALVLMVVSGLAVSIAATV
FLRPLLYAFGATEAIMTYAIPYTLITNIGIPFGILAVGASYLIRADGSPSFSMLVVLSGV
IFNLIAAPVFLFGLEMGIGGVALATTLGQMLSSAVAIYYLRVKFKSVSLKREGFQLRGAV
IKGVCALGSAAFFTHLAAAAVQIVQSNALRYYGAQSIYGSEATLAAAGAVIKVMAFLMSV
VIGISLGCQPIFSYNYGSKRYDRVKEAYKLAVSYATMVSVIAFLCIQIFPRPILSIFGSG
NPLFYDFAVQYMHIYLFMTFANGIQPVTSTFFSSIGKARMGFWMSLVRQVILLMPLLLIL
PIFWGINGVLWAGPLADGIAVVLVILFAAREMRIMTGLQLKQVPDAGIARNS
>fig|138119.3.peg.3466 Daunorubicin resistance ATP-binding protein drrA
MSNAIEITDLRKSFSVKAKGRIIKVEAVRGVTLAVKRGEIFGFLGPNGAGKTTTLRMLTT
LLPIDEGKGTICGYDLVGQPQEVRRHIGYVSQLGGADWEATGRENLILAGQLYGMKRHDA
EQRTGELLAVFELAELADRVVRTYSGGQRRRLEIALGMINRPEVLFLDEPTTGLDPQNRA
NLWEQIRKLKEGGTTIFLTTHYLDEADALSDRLAIMDCGIIVAEGTPQELKEQISGDVIQ
IRLADDRTQQAKRLFDKVSFINEIRLEGEDIYLYAKNGAQVLPRIFEMLEAEGVQTQSVS
IATPSLDDVFLKQTGRLLRDGKEDIA
>fig|138119.3.peg.3492 Permease of the drug/metabolite transporter (DMT) superfamily
MSASRFTLLIVVTTFLMGSSFAVVKIGLIYSSPLLLAALRFILAGGIMGIIVGVLKRTHP
TTKGQWVKLLIIGAFQTAGVMGCIFLSLRTITASESAILTFTNPLLVVLFSTVFLKMRYR
LYQWIGVILGLVGVSITMGAQIEFRIGVFFGILSAVFWAIATLLTKRWGGLTDIWVLSAY
QMLFGGLILWVGSFILETPFFIVNGTALLILLWLSLISSIVQFALWYYLLQKGEPGKTSA
FLFLAPFFGVLTGWLLLGDPLYPSLLAGGLLIIIGIFLVNKDFNRKRVSAN
>fig|138119.3.peg.3793 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MATTLVEEKEKQKHFILSGNLWKVMADLSWPAIVAMVLYGMNSVMDAFFVGRYVGEAALA
GVSVAYPLSQISVAFGSLIGVGAGSVLSIALGAKDRKTQEHLLGNVNLLSLIVTAVYMLL
GLAFSTQLIAMMGGRGEALILGDQYFRITIYGAFFWVYGLAGNMIIRAEGKMKTAAVMMG
FGLAVDVIFKYLFIVVFQWGVEGAAWATNIGMLVYTLVSWLYFSKGWATFHSKLASLRWD
QKIGTSVLRLGASSLIMSVMSLVQAIFVFNALSKYGTTWDVAFYGVVYRIFTFLLTPIFG
LMRALQPVIGINYGARQYDRVISSYKIFAVTALVLTLPFWLLSIAIPGPILGLMMKDAAF
SGADLLYFRVYMAILPVLSFIFMAMTLFPSVDKGKPAAMIGIARQLVFYVPVMIFLPKAI
GVAGVYYGSLAIDAVIILWTLFMVRKEFSQLRQKARSDKPESIAYSL
>fig|138119.3.peg.3803 Permeases of the drug/metabolite transporter (DMT) superfamily
MMGSNLAGAQTWQIVAVYAAYAFLVLGAVCLVFMLAAVFRQGDERRNYILTKACTHTFLI
YTGIVFVMGMYALFFQKHHNFSMESTPVASLGLIAILFTGSLFLNKRKYGN
>fig|138119.3.peg.3840 Drug resistance transporter, EmrB/QacA family protein
MLGGSNMTNEQLSRKSPWFSYLGLLLGTFTMIEAMAFQIPALPVLTKEFGVPVATAALIS
LCYYLTATVCGPVFGNIADQIGRKRIAMIGMIIFAISEFMAAFATNYPFFLLARLCQGIG
VAAVLPAGLSYASYLFPPNKRGIAVGVYTAVGTFASAMGGFLGGILIAKFGWQSLYIISG
VLAVLGIALVQITVPETPTAERKPFDYIGSILLLLTIGTWLSLSVLVANFGWVSPYTLGM
LGLALVFAISFWNVEKRTSHPFMDLSIFKNRYFAVPILLYFFIALCSQGSVFTNSYFVTA
KPGLGTAYVGIMTGVIYLAGAVTSLLSGKLIDSFKIKTVLLIGMGTFIVGTLLYSQYTVD
TPFWYIVLTLVFMSGSLLFMAPACMKMSMSAVPPEKLGSGSGTYIMIRDLGSPSGQTTML
AAFGAISASSLAAEITAEAQNSGVSQDMIPAVVEAGKTAGKVIDPALTDHLAKIGVSFQD
LYAKANFDGMVIAINQMSTIIIAIAVAAFIAAVFVLPNTNGGPGGLDPKNK
>fig|138119.3.peg.3928 Vancomycin B-type resistance protein VanW
MKTKKYVGLALLFISLTLAITLGINFMLYAKDDHLFSEGITISGIDVGSLTKEQAQEKIN
QTLENWLAQPLEFQAGGEVITLPLAALNPQVDLETPLNEAYKIGRKASLFARTQKATTAQ
DARFELGLTWDEQRLAETLAESLGLLNKEPVDATFKIGANNLMEIQPEQPGQAVQADALV
NQIKELEPFQDPAPLKVELQEVAPALRAADLEAKKIDGLIASHTTWFDAANLERTANVRL
AAEALDGTLIEPGEIISFNGIVGERTGDKGYQDALIVVNGEFVPGLGGGICQVSSTLYNT
GLLANLKIEERTNHGLAVAYVPLGQDATVVYGAIDLKMRNTTGGYLLLRSKISNGSVTIE
FYGKKTSGQEIVITNQVEKVIPFETEIIHDPTLAPGTQIVKQNGQNGYIATATRTIKVNG
QVVETQSLGRSSYIPSNKIIVKGPEPPAKPKPDPKPEQPAPETPQEPETPAEPDPTEPES
TNSGAGASETEGEPGTEAPGDEG
>fig|1538.8.peg.371 Permease of the drug/metabolite transporter (DMT) superfamily
MGYVFIILAAVIFSTMEIVGKLAVGLNPLQLNFLRFLIGGLILFPPTIKAMRNKKMKFKK
DDLYYFLGTGFLCVVLSMSLFQLAITFTKASTVAIIFSTNPVFTVMFAYLFLKEDLNRGT
IISIILSLVGIVCILNPFGTVSDVKGIVLSILAAVTFSLYSVVGKLRSEKYGSITLNCVS
FLVGDIIMLVIILLSNLPVVSSIINPKGGLSFMSHIPIIYGISAANIIPVIFLGIVVTGL
GYMFYFMAMDETSATTASIVFFIKPALAPIFALIALSEKIPMNTVIGICFILIGSYFSFT
AKGGTRVEEVES
>fig|1538.8.peg.414 Membrane component of multidrug resistance system
MEENNNESIYSWLALIVVVIGTFMSILDSSIVNIAIPKMMAVFGVSMDDSKWILTSYTLA
LGAIIPLTGYLQEVFGSKKIYMFALAMFTLGSMLCGFAWNNTSMIVFRIIQALGGGMIMP
VGMSIIYEIFPRDKIGLALGIWGIASMAAPSIGPTLGGYIIQNMNWRLIFNINVPIGILG
VILAGILLKDSQKITFKSFDVIGFLSSTIGVVSILYVLGEWTSIDWSKVQYPLLLTLGCL
SLILFVVNELTHPQPLLDLTVFKLFDFSVCQIIICVLTMALMGGVYVLPLFLQNIRGYTA
METGLIMLPAALVVGILMPVSGNLFDKIGAKPLVIPGLIILALSSYHLSVLINMNSSREM
ITLILCIRSIGLGFTMMPINTAGMNVVPQNLIGKASALSSTIRQIASSLSVTIMSAIIQS
KTNYNYLKLSEQINVYNKPANDTINILTKSYMQEGLPQGTAKASALSTLSKLFQGQATID
AMAYAVAITSVIVIVTIVLTLMMKSKKTVKGDDHNTNTKELAATK
>fig|1538.8.peg.446 Drug resistance transporter, EmrB/QacA family
MEERLEESNYQQRNYNVVPITIALIMAGFLCMLNETLLNMALKNLMVQFSISANTVQWLS
TGYMLIMGIAIPVSALLIQSFTTRQLFLTSVTIFLVGTVISGFSTAFSILLVGRLIQAIG
TGILIPNIVNTLLIINPIEKRGKALGIFNLVMFCAPAIGPTLSGLIIQSLNWRWLFFIIL
PFSVISLALGYKFIENVTELTKPPIDFLSIVLSTIGFGGFIYGVSNIGSSYTYLIAAPII
ISCIALAIFVLRQLHMSQPMLDMHPFKESMFSLGCILMIIMHMINFATMLILPMFLEGAL
GLSAFTAGLLMLPGGFINGIISPISGHLYDKFGPKALIIPGYAISTITFFLLSRFVSMSI
TIPVIIVLHCLSLVAVGLINTPVQTNSLNQLSPKYYPHGTAIMNTLQQIAGAFGTSLFVA
IMSASQKKYLFAAGNPSNAKSQALSLVFGVKHAFTIETFVLVIALILSLFIANNAINKKS
KSIKA
>fig|1538.8.peg.812 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MERSVKLRDEKVGKLLLEFSIPAIIGMLVNSLYIVIDRIFIGRVVGAMAISGVSLTFPIS
ILIMAFGMLVGIGAAARISIRLGENNKDEAEHILGNAFVLLIIVSIVITILGLIFVDPML
RGFGASDNTIGYARQFITILISVSTFQTVGFGLNNVIRSEGDPKTAMNTMLIGGICNIIL
DFLFIYILHFGIKGAAIATSISQGINMIWVLYYFLKGNSMLRIKKKYLRLNKDIVASIFS
IGMSPFAMQVAASLVNVILNKSLAIYGGDLAIGAMGIINGISTMILMPIFGINQGSQPVI
GFNYGAKLHRRVKKALLLAIAAATFISAAGGIAVQVFPTVLVNMFNKSDMNLTNITVNGI
KIFMIMFPIIGFQIVSSNFFQAIGKAKISMFLALLRQVIVLIPMLLILPRIFKLNGVWMA
APVSDAVASILTALFLYFEIKKLNSNEKENLSSPEISAELTK
>fig|1538.8.peg.1398 Antibiotic resistance protein
MGEGIGYLGISQIIATAFGPEIGIEASNRFGMSKTFIVSAVLIIIAAVCMNFLPNKNQIS
IKNTVDKKHAIHLKDIIAFKILPLSLIGGLFFMGNGLATSFLVLLGEERKINGIGMYFTV
NALFLIFTRPMSGKLYDKKGLSTVMYPALLFSITEALLIAHASALWMILLAAIFKAFGQG
TAQPALQAECFHKLGSQKKGLASSTFFIGANLGQGLGPLLGGTIASSLGYVWLFNFSALA
LLCGIFAYAIYNKKTCSSYF
>fig|1538.8.peg.1442 Vancomycin B-type resistance protein VanW
MIQPIDRNQIIPKKRKLKRKLKINKKKMTRSLIILSILTYIIHSLWIHFLVTRYDNLIYP
GVKVEGINLGGKTKDEAIDTLKRKYVNQIFKKNIIIKVQDKVYTINYSKLNIKYNLDDVV
QDAFKYGKCGNTHNKYKNIKSKNGKQFNLKYSYNKKEINNTISKIENELNRAPVNASITK
DEDDKFKIDLEKDGQEVDRDKLFNDIDKKINNKNMNDVYISGTIRKVAPKIKKSSLVNIN
TKISSFSTNFSSSDDNRSNNIEVAAKTLNGTTIMPGEIFSFNKIVGKRTKENGYKSSKII
VGNKLQPGLGGGVCQVSTTLHNAVVRCGIVPTEREHHNIPVTYVGLGMDATVDYGHIDYK
FKNTLDFPIYIECLTKNKNLVINIYSNSKLNNKIYNLINKVDKASNGKATIAKVYLVTYE
DGKETSTKWINTDNYIK
>fig|1538.8.peg.1498 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MEIENNTLKQGKIRKLLLKFAIPSVFALLVSELYNIVDTVYVGHYIGVTTLAAITIAFPI
QKLLVALGLLIAVGASTYAARSLGEKNYSEFKKIVFTSFSLVLISLTIVSLIIFIFRRPI
FYVLGADNLTYPLVNKYVSILLLGGIFQSLSVVACYIMISLKKTKALLYTNLIGVTLNIL
INYILIVKLHFKIEGAAIATVLSQITAFTFAFYKFKNIIREFHMEFSMHSIHNSVTKEII
WGIITVGFSTFIIEIEDALVTVVLNNLLYTEGGESAIVMVGVITKISMFLFVTIIGISSA
MQPIVAYNFGAENYDKVKKVLNTSIKVVLITSFALWSIFMLFPNYIIGFFLNDTTLLNKT
VKAFRLCICLIPLTGIYYVVINYYQAIGEAKKSFLLSIYREIIVFIPLAILLVQLFGIKG
AWAAYPITDASAVLTSFYFLNKALKEDFNQVGVSEKF
>fig|1538.8.peg.1538 Quinolone resistance protein
MVQNSNVTKVLKPKIKDNLPEVDLLQEGISDYDSISSVLVNECLVENFKARRVSFNEVIF
RNVKFINISFEQVEFLDVRFENCDLSNVNLSEASIHRVEFINCKLTGSNFTEAVFRNVMF
DQCSGQYTCFRFTDFKQAIFSNCQLPYVDFYESKFSKLELKDTDITQGQFCNTKLKGMDF
TSCRIDGIAAGVEDIRGAIISYTQAVSLISILGVVLKE
>fig|1538.8.peg.2731 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MKQKLSNEYYLENAPITKAIAHLSIPMMIGMSVGTIYNVINAFFIGLLNNTDMLTAVTLG
LPIFTILMAFGNMLGAGGGTFITRLVAKQNIEKAKKIAGYTFYSSIIIGILLGIILTIAL
TPIVKIMGADTSAIINYTKSYSLTMFIGGFAIVMNFALEQVVRAEGASKESMLGMVVSTI
FSLIFDPLFILLFKFNVVGVALSMILANIASSIYYVYYLETKSENLKGFIKNFNISLKDK
IEIYKIGVSELLLAGFLIITTLLLNNYSIRYGESVVASFGIALRIVQVPEFIAMGLALGI
IPLIAYNFSNENFKRLKDSIKQSALWILGLSGGVVTLVYIFRNVIIHLFSNDAAVLSVGV
YIMAAMLISAFFNGFTTLFIGIFQASGQGTPSTIMSITQGILFIPVIIVLNNFFGLHGVI
WSMTITEIITFLTGVILYIIFNNKLKKNQVVAN
>fig|1538.8.peg.2979 Drug resistance transporter EmrB/QacA subfamily
MNSVKSKTGVSTVIIIMLGTFISSFDINVVNTALPIMQSYFHAGMSSIEWIIVGYLMVLG
ATQLTFGRLSDMFGHKKIYVAGLMLFTISSLFCALSTSIVMLIIFRITQATGASMISSSG
SPIIIDAVEPKNRGKSLGMIAISVAVAVCTGPALGGLLASRAGWSSIFFINVPIGIVVSI
LAIKVIKKDDKRRNEVQFDFAGSTLIIAAIFLILLPLNLLSKSYFNIGSIVSFLGGIFVL
LLFIAFEKKSKHPILNMELFKNRVFTGSTFAAMFFYMGEFILVFLAPYYLQKMRMLTPFM
SGVMMLPMSIAMIIAAPLSGTISDNFDSRYIGCIGLAVMALATLFVGGFNASTPIWMLAV
VFFIYGLGGGFFQTPNTSAVMGSVTADRRGVASAALGTMRTFGMMSGEAISAALIAFSMN
KSAAAFISKGLKSTLLWQAEFRFSTKVTCIVAAICVISAIVLSFMRGKSAAPCGNAVVKT
N
>fig|1538.8.peg.3124 Drug resistance transporter EmrB/QacA subfamily
MNEIDEGKYKKWMIFAVTSMANLVVSFSINSLNLALPTLTKEFDVSQNSISWLALVYSLI
PCCTLLIFGRTAELYGYKRQFKIGFLFFGAVCISAPLLSVNLEVLIFFRCLQGIGYSIMI
SITQAIVSRTFDSKERGKALGINSVFISIGMAAGPTIGGFLLTHSSWHAIFYFNVPFCIL
GFVATCLVMPDDRTEVSECKSMDWLGAILFSMSIGAFSVGLNFSIKWGWKSVSFLGCMLF
SVLALYIFIMREKHTESPLMSLHLFKSRTFCMANVVCMLSYLVQQLITYLVPFYLVDILL
LSSDQSGLIMLASPIMMMVMSPVGGSMSDKHGTRLPSGIGLIFICVSCLFMSLLKKSSNY
TVVIFTLIAMGIGNGLSVSSINAAILNSVPRKHAGVASGMLATMRNLGQTLGVASSSVIL
TSRQIVYNKNTNLSVKDIYLFAQRDTYYFGILILIVALVFVFLLPRSITDKSDMV
>fig|1538.8.peg.3353 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MNLNNEKLKMMRDEKISKVLLKMGIPTMIGMMVSALYNVVDAYFVGGLGTSQMGAVSITF
PIAQVIVGLGMTFGNGAASYISRLLGEENEIKANETASTALVSSLIVGIISIAVSLCFLD
NILIGLGATKTILPYAREFAVIYITGSILNIFSVTMNNIVTSEGMAKLTMTSMLLSGIFN
IILNPILIYSLGFGIKGSAISTVISQALASILYIWYMLNKKGSLRFSIYNFRFDSTIFIQ
IFKVGIPILVYQLLSSASMGLSNTAARSYGDSAVAAIGVVTRIMALGSYVVFGFMKGYQP
VAGYNYGAKNYDRLNEATKVSLKWATIFCTVIALILIMVPDQIVSLFSKNDAVLINIGGR
ALRANGIIFILFGFEQVYMCLFLALGMGKEGGILSISRQGMFFIPAILVMPQFLGIEGVI
WAQPAADLLTVILTALFMLGVNKKLNNFMNQKEYLN
>fig|1538.8.peg.3975 Permease of the drug/metabolite transporter (DMT) superfamily
MKKRLIGSMCLFLAACIWGGMYVVSKYILEFISPITLVWIRYAIAFVVLFLILMFFNYKK
GRKVVIKKKDWLLIAWIGFIGYFISICLQFMGTKLSDAHMGSLITASTPVFVIIFARFIL
KELFTKKKMISLILATFGVIIVIGLDSMFMKHLLGNIILVGAAVTWALASVYLKIVSKRF
NSLIITTYAMLFALIFTTPLMLTQHNNFTLILNNRNLILGIIYLGVVSTAGAFFLWNKGI
GLMDVGIGSLFLFFQPVTGSIFGWLYLHEQLTFGFFIGGTLIVIAVIIAITKEDN
>fig|1538.8.peg.3977 Vancomycin B-type resistance protein VanW
MMSGKRKTRKSKRKSGGTLKILGLAALTIFLSISCGFIVYHYNDVKYWDNLIYPRVSINN
TDLSEKTKDQAKSIMSSEYLNKFQQKQITITAGNKSYELPYSSLSFTYNLDDTIKLAYSY
GKSSNIFKKYELLKNPKNVNYNLKFSYNTKVIDNMVDKIASEVDTEPVNASLEMGGVKFS
VIPQKDGIKVDKEALKKDIESKIDNNSDQDLTVKAVLKTTKAKIKEDDLKPVDTLISSFS
TAYGGISSGERANNISLATSSINGHVVMPGDTFSFNDVVGQRTAAKGYEAAPVIIGDKVE
SGLGGGICQVSTTLYNAVAKAGLTSTERTHHTMPVHYVPEGMDATVDYGNIDYKFRNDFK
YPIYIQGYTSGGNIVFNLYSNSSVSK
>fig|1538.8.peg.4067 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MKFERGVCKLSEKSTKINESYIENEKLGKLIMKFSIPCVLAMVVNALYSIVDQIFIGQGV
GYIGNAATNITFPLVVLALGFSLLLGDGAAAFYSIKLGEKNKEEGAKAIGNAIVLMVILG
LIFLAVGYIFMKKLLWSFGATSTNISVALDYMRIILIGLPFMILAAGLNSIIRADGSPEY
SMLAMIVGAVINIVLNPILIFHFSMGVKGSAIATIIGQILSCTISLSYLKKFKNIKFKRE
YLKLDVKVSKTVMLLGISSLITQAAVTIIIIVSNNMLKIYGAQSIYGSDIPISAIGIVMK
VNDLLLGVVIGIAIGGQPILGYNYGAKNFKRVKDTYFMLIKIATVVSIIGFIIFQFFTQS
IVNLFGQNSALYNEFALKSFKIFLMLCMFIGFELTSCIFFQAVGKPGKAMLLTLCKQTFF
IVPLMIILPKFLGVLGVLYAGPCAEILSVIVTIILITSELKKYSKLTVS
>fig|155920.1.peg.160 Permeases of the drug/metabolite transporter (DMT) superfamily
MLISSKVRTAQLQIHVCVLLWGFTAIFGRLITLEALPLVWWRMTMVVFSLVLLPRVWRGL
RALHPRVMLAYAGIGALVALHWLAFYSAVKLANASVAATCIALAPVFTAVVEPCVVGRPF
RARELLLGLMVLPGVALVVGGVPDGMRIGIFIGVVSALLAALFGSLNKRMVVHADPLTVT
ALELGSGILTLTGLMLLLSLVFPTLHEMPWQIPSAHDIFLLLILSFACTLLPFALSLVAL
RYLSAYSLQLVTNLEPVYSIALAIVLLGEQRELTGLFYLGVAVVLGVVLLHPMLERRGRA
SSPQ
>fig|155920.1.peg.1197 Permeases of the drug/metabolite transporter (DMT) superfamily
MVTQGQLPLRAAMLMLFSTLSFGMMAITIRYASTQIPTTEIAFFRNAFGLLVLLPLILGP
GKPLPRTQHGPRYIARSMLGLISMLCNFWAISHLPLTQAITLSYSTPLFATILASLWLHE
VVRLRRLLAILAGFAGILVLLQPWSGTFSPALLVALAAALLNAVITIQMKQLSHLDPPDT
VVFYTYAFWVPLSLLLALWQWHWPEGVEWVWLIATGIFGTIGQLLWIRALRLGEVSTLQP
IGFMQLPLVTLLGWWLFGEHLDRYTALGASIIIGANVYITHREAVLARRTAAETIQKGVQ
SNGINRAQGPS
>fig|155920.1.peg.1713 Drug:proton antiporter
MSTSPASSATLRTLLCHPGFTAVLAYRIAATLSYQIVSVTIGWHIYEITRNPLLLGLVAL
AEILPFFCIAPFAGYLVDHLPRRRLGMFASLGLAMTPTILLIAAFNTAPVQTTWPIYVAA
SLSGMVRSFIVPVYNALFARVLPREDYARGAGLGTVAFQASLVLSPMLGGILIALGGKEL
AYAAGVVAAIIALLALALLRVEEPAVDKPRAPVLGSIAEGLRFVFSNQIMLGAMALDMFS
VLLGGAVSMLPAFIQDIFHYGPEGLGILRGTPALGSVLAGLWLARYPLQRHAGRTLLLAV
AGFGICTIAFGLSQHFWVSAGILLVYGACDGISVVLRASILQLVTPDEMRGRVSSINSIF
IGSSNELGAFYDGVMARFIGLVHAVVLGGFMTLVVVGITALKAPRLRRLDLRDL
>fig|156586.3.peg.266 Permease of the drug/metabolite transporter (DMT) superfamily
MEKKPVLIILSFFAVYVFWGSTYLWNKMAVTELPPFMLASIRFTTASAIIFVIAVLSGKK
LTITKKQLLNTVLAGFLFLAYGNGVFVWALKYVDSGFASLLASLQPLVLLLMMRFVQRKS
LKIKSIIGVFLGLLGMYLLVSQKGLQMQEDSWIGIIMIMSCIISWSAGSLFVAKADTPSN
FFITTGYQMLSAGVILAIGSWAFDESWSEPLSWQLNTQIAIICLILFGSIAAFTAFNYLL
KVVSTEKVATSSYVNPIIALLLGWYFLNESITMQSMIAAAIMLTGVYFINSRKVR
>fig|156586.3.peg.714 Multiple antibiotic resistance (MarC)-related protein
MDDLLTFAFTVFTGFFAIMNPISNMPIFLTITEGADKETKQRINLKAIIVAFIIVSTFVL
LGNYIFELFGITIPAFKITGGILIFFVGFEMLQSKKSNIKRLKTVNYDENIAISPLAIPI
LAGPGTIVTATNFVANTSSYADIAVVLLVFALMCLLNYIAFSLSDVIAKKIGDNVISVIG
KLMGLIIAIIGTSMIISGLKLSFDVLN
>fig|156586.3.peg.1454 Multidrug resistance protein, AcrB/AcrD family
MLKTFIERPVLSTVISIIIVMLGVISITTLPIEEYPDIAPPTIKVTANYTGANAETVLES
VIVPIEEQINGVEGMTYITSTASNTGTAEITVYFDQETDADIAAVNVQNRVARATPLLPS
EVTQTGVVTQKQETSALMFISMYSESENYDATFIQNYLKINVIPAMQRISGVGDVSVFSQ
QDYAMRIWLNPEKLASYNLIPSDITAALAEQNLEAAAGSLGENNGESFSYALTYSGRFKD
EAQYSDIVIKALGNGEFLRLKDVATIELDAQSYASNAMSMGNPAVFMGIFQTKGSNAQEI
IENIKSTLEDVKADLPEGLDIFVPYDTSLFLNASIDKVITTLLEAFLLVFLVVFIFLQDF
RSTLIPAIAVPVSIIGTFFFLNVFGYSINLLTLFALVLAIGIVVDDAIVVVEAVHAKMDE
GEHNPKKATITAMNEISGAIISITLVMAAVFIPVTFVTGPTGVFYEQFGVTLIIAILISA
VNALTLSPALCALLLKEHKDDEELKGKGPLKRFYTLFNRGFNATIEKYGKSLQFLYKRKF
VSVLLLIIAVVGIYWASTTTPTGFVPNEDRGIVFANIELPPGASLDRTDAVSRKLYAQIE
NIEGIEAVNFIKGRSLISGAGSNYSFGIIKLKNWDEREEASLSAEAITGKLFGVAAGIPD
ANIIFFSPPSIRGFGNSAGFEINLLDKFGGEFTDLDQANKDFSMALMSHPEIKYATSSFS
TSYPQYEMEVNVPLAKEKGVSVSSIFSTLQGYIGGIYASDFSRFGKQFRVYIQALPEDRA
DENALNSMYVRTDSGEMTPITQFVTLERVYGPQSVTRFNLFNSTMISGATNEGFSTGDAI
RVIEEEVAKLPSNYTVAYSGLTREEVNAGNQTTFIFILSILFVYFLLSAQYESYLLPFAV
IFSLPFGVFGAYISTKFLGLENNIYFQIALIMLIGLLAKNAILIVEFALARRKNGESIVD
AAIHGAKSRLRPILMTSFAFILGLMPLALAKGVGSEGNNSIGSGAAGGMLIGTILGVFVI
PILFILFQWLQEKVSGKPAVQTIED
>fig|156586.3.peg.1455 AcrA/AcrE family multidrug resistance protein
MMKRIRNTVIILSISIGVLSCGDKAQPKTLSEAAPSPYPVVQLQSKTVTGFTEYPTTIEG
KVNSDVRAKTSGYVEKVYVDEGQKVRKGQTLFKLETQSLSQDAGAAKAQVNVAQVEVDKL
IPLVEKNIISPVQLETAKANLAQAKANYSGVTANIGYATIKSPIDGFVGAINFREGALIS
PSDATPLTTVSQIDEVYAFFSFNEAQYIDHLQRSKGQNKAERIKNSPDLTLVLANGKEYS
EKGRIQTSTGQINQSTGTIQIRAAFDNPNEILTNGNSGKIKFPIEYKDAIVVPQTATFEQ
QGNIMIFKLGADNKVETSILKVQGTVDNLYVVESGLEPSDKIVISGIGKLKNGMAIAPQD
TSFEEAIKPVATLFRN
>fig|156586.3.peg.1462 Permease of the drug/metabolite transporter (DMT) superfamily
MKADLKKAIIFMLLSTLAFAVMNGVVKYLDGFSAYVKVFFRSLGTLIFTMPYLIFKKIPL
LGNKRTLLIARGVIGAVSLILFFMSLKYLPVGTAVTLRYMSPVFAAIFAVIWLKETIKPW
QWMFFLMALAGVFVLQGFDGTSSVIGLLLVLTSALCMGLVFVVISKIGKQDHPMVIINYF
MIIGTILGGILALNDWKTPVGNEWLLLLGLGVVGFIGQLFMTKSFQIASTNQVAPLKYLE
VIFTVIIGVLWFLEVYTLWSVLGIALVITGLVLNILYKSKQSS
>fig|156586.3.peg.1772 Acriflavin resistance protein
MKEGLAGKVAKVFMNSKLTVLLMIVFMVVGVYSSFLIPREEEPQIDVPMADIFVGYPGAS
PTEVESRVIKPLEQLISNIKGVEYVYSTSMKEQGMVIVQFYVGEDIERSFVKLYNEINKH
MDQMPEGVTMPLVKTRAIDDVPMLGLTLWSENYSDYQLGQMAHELEAEIKKINDVAITHK
IGGRERQLRVVLDKDKLASSGLDFMQVSKMIKANNAQLNAGKFDKNDTEFIVNTGDFLAS
TTDVENLVVGVQQNQPIYLKQVAQIIDGPEVPQSYVSLGFGQGSDKKTDFLSEYPAVTIS
VAKRKGADAMKIADVIIAKVEHLRKTLIPDDVQVEITRNYGETASHKVSELLLHLIGSII
AVTFVVMLAMGWRGGLVVFLSVPITFALTLLSYYMLDYTLNRITLFALVFVTGIVVDDSI
IIAENMHRHFKMKRLPFKDAALYAINEVGNPTILATFTVIASVLPMAFVSGLMGPYMAPM
PIGASIAMILSLFVALTITPYLGYIFLREKDKKGAVEKIEKPLEETLIYRLYNKFERPLM
ENRYKRWLFLIGTFVVLLGTMGLFITNSVAVKMLPFDNKNEFQVVIDMPEGTTLERTGAV
AQEISQYLSTRPEVVNYQNYIGTSAPITFNGLVRHYDLRGGSNMADIQVNLIDKEKRSAQ
SHDIASLLRPDIQEIAAKYNANVKLVEVPPGPPVLSTIVAEIYGPDYEQQIIVANEVQNI
LKNTDDVVDIDRMVENDQTEYQFTINKEKAMLYGVAPQQIAYTMHLALSDRPVTNLYDED
AVQQIGIVLALDEKEKSTIQDISQFKVVSNQGTMVPIADLVEISESISAKSIYRKNQKRV
VYVMADMAGELESPAYAILGMEEKLKSIPMPAGYSISEMYLGQPDFEDDYTVKWDGEWQI
TLEVFRDLGIAFLGAIILIYILIVGWFQNFKAPIVMMVAIPLSLIGIILGHWIMGAFFTA
TSFIGMIALAGIMVRNSVLLIDFINLRTAEGVPLKQAAIEAGAVRTTPILLTAGTVVIGA
FVILFDPIFQGLAISLMGGTIVSTVLTLLVVPLVYYMIEKKNYK
>fig|156586.3.peg.1832 Acriflavin resistance protein
MRKVIAYFIKHSVAVNVVVVGFVIFGIFGMLSLKSSFFPLTDSKIINITATYPGASPQEI
EEGVVLKIEDNLKGIEGIDRVTSASKENAGSITVEILKGYNIDFMLLEVKNAVDRVSSFP
VGMEPLVVSKQEQSRPTISFALSGDNVPLITLKQLARDIENDLRGIDGISQIAISGYPDE
EIEIAVNENTLLGYDISFEEISNAVASSNILTTGGNIKTDREEYLIRANSRSYYGNELSY
IPVKTLADGTSVLLKDVAVIRDRFSETPNATYYDNKLAVNITVTSTNSEDLIDAADKVKL
YIEDYNQRFTNVQLDIVRDLSVTLNQRTALLTENAIVGMLLVLIFLSVFLNTRLAFWVAF
GLPIAFLGMFIFAGQFDVTINVLSLFGMIIVIGILVDDGIVIAENIYQHYEDGKSPVQAA
IDGTMEVIPPILSAIITTLLAFSTFLFLEGRIGDIFGEVSVIVILTLLVSLVEALIILPA
HLAHSKALQPRNDQPKKGLARVFQKMRVVNDYGDKAMNWMRDKLYAPVLRFSLANKFFTF
ALFIAALVLTFGSMNGGIIKTAFFPRISSDQVSINLSMPNGTSEFITDSIINSIEKKALI
VNEQLTEEYLKGDEYGDSIMLFENIIKSQTSSSAASLSINLLPGESRPETVNSEIVSNRL
RELVGEIPGAETLTFGSGGNFGGSPVAVSLLSNDINELKAATAEFKEILSNNPLLKDIED
NDPAGIKEINLELKETAYSLGLTTRTVMAQVRSAFFGTEAQRFQRGQDEIRVWVRYDRDN
RNSIKDLDEFRVLTPSGDRVPLRDIASYTIERGDVVINHLEGRREVLISADLKDPSGSAT
DILANIKSEIIPDLQKKYPTISPNYLSGQAREADKFSQSAAVAGPIILLLIYFVIAFTFR
SWLQPIMLILLIPFSFVAVGWGHWIHGFPVNILSLLGIIALIGIMVNDGLVLIGKFNSLL
KEGLGFDEALFEAGKSRFRAIFLTSITTIAGLAPLLLEKSRQAQFLKPMAISISYGIGMA
TVLTLLMLPLFLSFGNNGKAAIYWLRTGKKATKRDLTSVAKELEEQKHNDEA
>fig|156586.3.peg.1877 Multidrug resistance transporter, Bcr/CflA family
MKVKQVDKENVSKGRKTSVILVLGTLIAIGPFSIDAYLPAFKQIAGDFKVETSAIGFTLT
TYFIGIGLGQLAYGPLMDRYGRRRPLIAGLILYITTSVLSAYAWDVSSLATLRFFTALGA
CAGMVASKAIVRDLFDDDKVAEVLSTLMLIMGIAPIIAPTIGGFIIEHYHWDMIFYGLAG
FAALMLFNVIFILPESSKPNPATSLHPVPVLKEYWTIYKDKAFFLFSTARGFVIGALLGY
VAAAPFIFLDFFNMAQSDFAIIFGSNAAGLIAGSQINRFLLRRFTTFQITYTISILLVVT
TLLLVGHISFFEPEFWVVYPLLFLMMTFIGFQNPNVTALALQPFTVRAGSASAFVGAVSM
IFGSFASWYVSRYVTVSVLPLALMLAGCALLGYAAIETFRIKYARGYAFAKAYLKHPYVS
LKRENAS
>fig|156586.3.peg.2072 Drug:proton antiporter
MTKNDPYAALRFQEFNIFLLMRFLLVFGWSMQFIVIEWQVYSLTKDPWSLALIGLMEFVP
AFSMALFAGHIVDQSEKRNLLAICIGAFSLISLGLFLLTWPEVVGEWSTDSILYCIYGLV
FFGGFLRSFFGPILFSLIALLVPKNAYPNAATWSSSAWQIASVVGLAFSGFSISWYGVHW
SLGIVFTLVFLAFITVFLISKKPILNTKINEPIMQSLKEGLSFVLKTKAILGALTLDMIS
VLFGGAVILLPVFAQDILTVGSEGFGILRAAPSIGAILTMIATAYIPISKNAGMKLLLAI
FGFGISIIIFGLSTSFWISVVALFFSGVTDGVSMVIRQTILQLKTPDHMRGRVASVNSMF
VGSSNELGAFESGVTAKLMGTVTAVVFGGSMTLITVITTAIISPTFRKLDLREDFKSK
>fig|156586.3.peg.2208 Permease of the drug/metabolite transporter (DMT) superfamily
MDNSKLKYIYLIILSLIWGTSFILIKKALGDDGSGHLVLQPLQLGAGRTIISGCILIAIG
WKSFAATDRKDWKWLFVSGLLGTFFPAFLFAYAQTEIDSAISAILNSTVPLITLIMGAVI
FGIAFSRTQLLGVIIGLAGAIALVFSGMKNNPEQNYLFAGLVFIACLCYASNVNIIKRYL
QNIKPLAIATGNFIFILPLAIIVFFGADGASIEFTSEPVLKSLGYIIVLCVFGTVAAKIM
FNKLVQITSPVFASSVTYLMPVVGLTWGMLDGEIFSIWQVLATMVIIFAVVLVTRNKKTS
N
>fig|156586.3.peg.2592 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MSTKPSSKSQILGTDSIPALLIRQALPASIGILVMSLNILIDSIFVGNWIGSIAIAAINV
VLPVSFFIAALGMAIGIGGSSIISRALGANNYEKARKVFGNQISITLLITIPCVVFGLWF
MDSLVFSFGGKGAIFEPAKIYYRIVLYGVPILALCMMGNNVIRAEGAPAHAMIAMLIPSV
GNLLLDFILINQFNLGMAGAAWATTVSYILCFAYIAWFFISGKSELIGNIKDLIPEFNIL
KEIGGLGFVTLSRQAMSSVLYLILNNVLFELGGEESVSVFGIVGRMMMFALFPVMGITQG
FLPIAGYNYGALKWSRVREVIFTSIKYACIMGIFIFMGLFFFTREIAGVFTKNETVIEQA
SFALKLVFIAVPIISIQLIGAAYYQAIGKVIPALLLTLLRMGFILIPLVLILPQIYGELG
VWISFPIADILSTIITAWYLWIAMKKLHRS
>fig|156586.3.peg.2596 Permease of the drug/metabolite transporter (DMT) superfamily
MSKRAVAIICGFLVALFYAYNFTAAKEVTPEFVGPYGLTWYRVVITCVIFWVIATIVGPK
EKVPLKELPLLALAAFCGVGFNMVTFMKGLSLTAPISASVLMVTTPIIVLLLSAIFLKER
LYASRILGILIGFSGAALLIFLSNSGSNENATNPALGNFLVFINAVSYSFYIILAKKLTT
RYHVFTLMKWLYLFGVIFITPFGITEGLSFDFSTANTDTLWYIGYVVLFATFGTYMLNII
AIRTLKPSVVAVFVYLQPLLATLIAVGLNKDEITLYKLIAGGLIFTGVFITSIPKKAG
>fig|156586.3.peg.2654 Glyoxalase/Bleomycin resistance protein/Dioxygenase family protein
MKAKVTGIGGVFFKCADVAATKAWYHKHLGLPVDDYGCTFWTGPTTDKASQQWSPFKEDT
TYFNPGDQEFMINYRVDDLVKLIEQLKSAGVQIAGEIEEFDYGKFGWIIDIDGRKIELWE
PANEELFEK
>fig|156889.7.peg.1535 Multidrug resistance ABC transporter ATP-binding and permease protein
MNLILTPIGRFLHRIRHLLPHYQRYRRAFVWGFLLLIATNASAALIPYLMKLAIDTLQRG
EGMTDVKTYALLLALLAVLTALLRIRARTHVFRIGREVERDMRNLYHAQLQDLEAPLFDH
ARTGDLVSRGIGDITALRMFMGPGFLQLTNASLVYILVLPAMLWLNPWLTLMALLPLPFV
VIAARQLTKRLYRYSRMVADRFGGLTAFVQESVAGMGVIRTYAREDAWNQRFYEETDKLY
ATQQDHARLQGMFQPLMLFSGGLGAWIILAVGGPGVVQGNLTVGDFVAFTGYLTLMIQPT
VALGWILTVMQRGLAAIDRLSEVLDITPSNADHPQQALHPEPTTPYAIEIRHLNFFYQQD
RRIAPRSKEAAPSHAVTTAAGDGTEPAAVQTLHDITLTVPHGHFVGLAGRIGSGKSTLLR
CLSRTYPIPQGSLFLDGVDLAHVPEAQLRQHLTMTPQESLLFSRPLLENLLYGQPDEDEA
CAWEAARNAAFDEEVEGMPQGMETLIGERGITLSGGQRQRAALARALVVNPRILLLDDIF
SSVDARTEAHILNALLDRPDRPTMVMVCQRVAALHRADTIYLMDQGRICETGNHQSLMQS
SSLYQALHTEMQRKEQLEEMEQPEVQP
>fig|156889.7.peg.2474 Permeases of the drug/metabolite transporter (DMT) superfamily
MVATIDLFRVTTMFPSTALQAYLARTLSPNVRGALWLLQAGLFFSTVGALVKWIGSDLDA
MQIVFLRCLFGMLLLLPLLLRKGGAILRTQRPRIHAVRAVVGILAMLTTFYAYANLPLAD
VTALSFTNPLFMIPLAVLFLGESIHWRRWSATLVGFAGVVVMLRPGDAPFTLALWAAILS
PLLIAMVQVLFKRMSSTESTLTIIGRYAVASTLLSLPLALGVWRWPTLEALLLIALASAF
GNLASAMLVWAYKVGEATAIAPFDYTRLFFATGFGIWIFDETTSLHTWLGAAIILAATLY
IVHRDRLDRLPKAIAVE
>fig|156889.7.peg.2629 Acriflavin resistance protein
MNLARISVARPVFTSMVTLMVVILGLVSLSRLQIDLLPSIELPTLSVRTQYEGASPEVME
RLVTQIVEEIVATVPGVVEMTSQSSEGNSTVKVSFAWGTDIDTAALDVLATLEDEINELP
EDITRPRVSKFDVDSFPVVILGISSDLDPVPFTQLIEEQIRYRFARIAGVAQVDVWGGYN
RQVRIELDPDRLNALGIPLADVLTAVRNANLDRPAGTLEEGQFEITLRAPAEFVDLDEIR
QTVVVLRDGVPVTLGQLAAVHDRYEKLTRMVRVDDRPGIRVAIRKQAEANTVEVAKRVLA
EIEAVNQAYPRIHVVPVINQGNFIERSIANVARSVLYGGGLAVLVLLFFLGSVRSTVVIS
LAIPISIIATFMLLYFGGFTLNLMTLGGLALGVGMMVDSSVVVLENIVRRRHEARESLHT
ASLMGAQEVTSAIIASTITTLVIFLPLVFVRGVSGILFQELAYVIIFSLICSLLVSLSLV
PMLISKLGRGGEGSVDLPRWADRWQSAMQQSYANLLQRVLEHRWKTVLAAVTLLAGSMLL
LPYIGTEYLPPSDEGEVRITGEMAVGTRLELLDQQAQRMEAIVRQAVPEIQSSVVNVGRW
RGKTNAEIRLALAPVAERSRSNVEIAADLRRRLAGQIPGMKVRTRAPQGQFLLERLLAAE
EGITIEVRGYDLQVLDGLAQAAMAAIADLPGVTDSEASKIAGVPQRGIHIDRAKIADLGL
SVQDVTSAIETAVAGSKAGEFRAAGNAYPILVQLADAEKRGLDEILDLTLRTPAGELVAI
RNLVSTVAGQGPLVIDRKDQQRLVTVSANVAGRDLGSVAAEVQERLMLIPRPAGYDLLLS
GHYEEQGKAFRELIISMLLALVLVYMVLASQYESLRDPIIVMLSVPMAAVGVLLMMFLTH
TTFNLQTFIGCIMLVGIVVNNAILLVDQAGRLRQAGMSGKQAVTEAGRRRLRPILMTTLT
TVLALLPLALGIGEGADMQAPLARAVISGLAGSMLITLVIIPVVYTLFHPDPAPGSTQPA
VEASVP
>fig|156889.7.peg.2791 Permease of the drug/metabolite transporter (DMT) superfamily
MLQNNSYQRGVVLMLLSAVILSSMGLLVRGMTQAQDWQVVLWRGIWATTGMGLVLLVQNR
GGSWQRIREAGWLALLGGVFQGGGSIGFILSMLHTTVANAMFTMSSMPLFTALLAWLVLR
EPLHKITLLAIAVAMAGVGLMVWDGMSYGGALGNLLALGAALCAACLVVVLRYGRGRNML
PTLIFGALISVMVGGVMVPGSWMIPWRDWLLCLLLGGGVTVAGHLLFLLASRDLSGAQLT
LVGLVEFALGPLWVWWFMGEEPSGWSLLGGAVVSLAVVWHTVWGAAWVKPLPGPA
>fig|156889.7.peg.3354 Permeases of the drug/metabolite transporter (DMT) superfamily
MEMIGWLPLALAVALFTALKDLLNKRSVAQLNPWTVARMQHLAAFVVLLPLLPFISVPEI
GPNFWWALLGSGTINVVALLLYVQALHHSDLSLTTPMLTTTPVFLLITSPIIVGEFPSLT
GVMGIVFIVLGAWLLNVQQRHIGFWAPFKALYRERGPRLMLIIAFVWSVSSNLDKVGIQN
SSPLVWLLSLFAFIALGTTLAAHHFGPRESGADWRPHTATLWIQGGLFSAAALCQFLALE
LTMVPYVIAVKRTSALMAVVLGVWLLKEQGGRERMLGAAVMFAGFLLITLAQA
>fig|156889.7.peg.3490 Tetracycline resistance protein
MKRKSTISIIFFTVFLDLLGFGLVLPLLPNYASDPMFHASTMEIGVLMGIYSLMQFLFAP
LWGRLSDHIGRRPVLIIGLFGSALSYLIYGLAESLMVLILSRALAGFMGANIAAAQAAMA
DLTPPEKRAQAMGIIGAAFSLGFVLGPAMGGYLASTYGISAAPLAAALITGLNAVAALFL
LSETRDLSTEQQQPLSKRAHPLSLHPWKQARNYPGALMVCLFMGLFITLFAAFEMALPLW
TQIIMGWDSGSQTMAENGHLFAFVGVVMAIVQGGIVRRLVPKIGEVRTAYSGLICIALGL
MLLGQASNYTTLLIALGLAATGAGLVHPAFSSLVSLNTDKDKQGLMMGLFQSMGALGRVL
GPLWAGIAFVSLKGNLFFVSAMGMTVLLGALIPLSRDRIKDARQIAAQDAKS
>fig|158878.1.peg.34 Bleomycin resistance protein
MRMLQSIPALPVGDIKKSIGFYCDKLGFTLVHHEDGFAVLMCNEVRIHLWEASDEGWRSR
SNDSPVCTGAESFIAGTASCRIEVEGIDELYQHIKPLGILHPNTSLKDQWWDERDFAVID
PDNNLISFFQQIKS
>fig|158878.1.peg.41 Penicillin-binding protein PBP2a, methicillin resistance determinant MecA, transpeptidase
MKKIKIVPLILIVVVVGFGIYFYASKDKEINNTIDAIEDKNFKQVYKDSSYISKSDNGEV
EMTERPIKIYNSLGVKDINIQDRKIKKVSKNKKRVDAQYKIKTNYGNIDRNVQFNFVKED
GMWKLDWDHSVIIPGMQKDQSIHIENLKSERGKILDRNNVELANTGTAYEIGIVPKNVSK
KDYKAIAKELSISEDYIKQQMDQNWVQDDTFVPLKTVKKMDEYLSDFAKKFHLTTNETES
RNYPLGKATSHLLGYVGPINSEELKQKEYKGYKDDAVIGKKGLEKLYDKKLQHEDGYRVT
IVDDNSNTIAHTLIEKKKKDGKDIQLTIDAKVQKSIYNNMKNDYGSGTAIHPQTGELLAL
VSTPSYDVYPFMYGMSNEEYNKLTEDKKEPLLNKFQITTSPGSTQKILTAMIGLNNKTLD
DKTSYKIDGKGWQKDKSWGGYNVTRYEVVNGNIDLKQAIESSDNIFFARVALELGSKKFE
KGMKKLGVGEDIPSDYPFYNAQISNKNLDNEILLADSGYGQGEILINPVQILSIYSALEN
NGNINAPHLLKDTKNKVWKKNIISKENINLLTDGMQQVVNKTHKEDIYRSYANLIGKSGT
AELKMKQGETGRQIGWFISYDKDNPNMMMAINVKDVQDKGMASYNAKISGKVYDELYENG
NKKYDIDE
>fig|158878.1.peg.42 Methicillin resistance regulatory sensor-transducer MecR1
MLSSFLMLSIISSLLTICVIFLVRMLYIKYTQNIMSHKIWLLVLVSTLIPLIPFYKISNF
TFSKDMMNRNVSDTTSSVSHMLDGQQSSVTKDLAINVNQFETSNITYMILLIWVFGSLLC
LFYMIKAFRQIDVIKSSSLESSYLNERLKVCQSKMQFYKKHITISYSSNIDNPMVFGLVK
SQIVLPTVVVETMNDKEIEYIILHELSHVKSHDLIFNQLYVVFKMIFWFNPALYISKTMM
DNDCEKVCDRNVLKILNRHEHIRYGESILKCSILKSQHINNVAAQYLLGFNSNIKERVKY
IALYDSMPKPNRNKRIVAYIVCSISLLIQAPLLSAHVQQDKYETNVSYKKLNQLAPYFKG
FDGSFVLYNEREQAYSIYNEPESKQRYSPNSTYKIYLALMAFDQNLLSLNHTEQQWDKHQ
YPFKEWNQDQNLNSSMKYSVNWYYENLNKHLRQDEVKSYLDLIEYGNEEISGNENYWNES
SLKISAIEQVNLLKNMKQHNMHFDNKAIEKVENSMTLKQKDTYKYVGKTGTGIVNHKEAN
GWFVGYVETKDNTYYFATHLKGEDNANGEKAQQISERILKEMELI
>fig|158878.1.peg.43 Methicillin resistance repressor MecI
MDNKTYEISSAEWEFMNIIWMKKYASANNIIEEIQMQKDWSPKTIRTLITRLYKKGFIDR
KKDNKIFQYYSLVEESDIKYKTSKNFINKVYKGGFNSLVLNFVEKEDLSQDEIEELRNIL
NKK
>fig|158878.1.peg.103 Probable antibiotic resistance-related transmembrane efflux protein
MNETYRGGNKLILGIVLGVITFWLFAQSLVNVVPNLQQSFGADMGTISIAVSLTALFSGM
FVVGAGGLADKIGRVKMTNIGLLLSIIGSALIIITNLPALLILGRVIQGVSAACIMPSTL
AIMKTYYQGAERQRALSYWSIGSWGGSGICSLFGGAVATTMGWRWIFIFSIIVAVLSMLL
IKGTPETKSEITNTHKFDVAGLIVLVVMLLSLNVVITKGAALGYTSLWFFGLIAIVIVAF
FIFLNVEKKVDNPLIDFKLFENKPYTGATISNFLLNGVAGTLIVANTFVQQGLGYTALQA
GYLSITYLIMVLLMIRVGEKLLQKMGSKRPMLLGTFIVVIGIALISLVFLPGIFYVISCV
VGYLCFGLGLGIYATPSTDTAISNAPLDKVGVASGIYKMASSLGGAFGVAISGAVYVGAV
AATSIHTGAMIALWVNVLMGIMAFIAILFAIPNDDKRVKDAK
>fig|158878.1.peg.107 Permease of the drug/metabolite transporter (DMT) superfamily
MNKLRDTTFLSYLFTIILWGSAFPMIKIALNDFSAESLSAFRLILATIILLPFVIIKKLP
TPELRDIPVIFILGFCGFVIYHTALNFGETLISAGISGILVSTTPIFSSALAYIFLKEHF
SKWNWLSSLVAFIGISIISISKDDYTTINVLGVFIILLASFSESLYFTFQKKYIEKYGFI
AFTLYTIMASSPFMLIFIPEIINDIHGATFTSIVSVLYLAIFPTIIPYVLLAYIVKSVGV
SDATMSLYLTPIVSLLLSYLLLDELPTTLAIIGGIITLLGVSLSNFFQNT
>fig|158878.1.peg.334 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MKDEQLYYFEKSPVFKAMMHFSLPMMIGTLLSVIYGILNIYFIGFLEDSHMISAISLTLP
VFAILMGLGNLFGVGAGTYISRLLGAKDYSKSKFVSSFSIYGGIALGLIVILVTLPFSDQ
IAAILGARGETLALTSNYLKVMFLSAPFVILFFILEQFARAIGAPMISMIGMLASVGLNI
ILDPILIFGFDLNVVGAALGTAISNVAAALFFIIYFMKNSDVVSVNIKLAKPNKEMLSEI
FKIGIPAFLMSILMGFTGLVLNLFLAHYGNFAIASYGISFRLVQFPELIIMGLCEGVVPL
IAYNFMANKGRMKDVIKAVIMSIGVIFVVCMIAVFTIGHHMVGLFTTDQAIVEMATFILK
VTMASLLLNGIGFLFTGMLQATGQGRGATIMAILQGAIIIPVLFIMNALFGLTGVIWSLL
IAESLCALAAMLIVYLLRDRLTVDTSELIEG
>fig|158878.1.peg.338 Glyoxalase/bleomycin resistance protein/dioxygenase superfamily
MNIVGHHHISMYTKDAKRNKDFYTNVLGLRLVEKSVNQDNPSMYHLFYGDEVGTAGTILS
FFEIPHAGHKQPGTETIYRFSLLVPNQAALHYFEKRLDNNGITSERLYYLGQEGVVFKDE
DDLEIILLVNDSFEVPHQWQHNAYSEIPQVYQILGIGPVELRVRNAARTVEFLENVLGYR
KRDNKSFDVLTLAPQGLYSDFVVIEQQGQRERPGRGYIHHIAINTPQMSDLDAIYKKLQQ
QTQSNSGIIDRYFFKSLYYRHNSIMYEFATEAPGFTIDTPLEQLGSQLNLPDFLEAEREQ
IESKLHEI
>fig|158878.1.peg.398 Tetracycline resistance protein TetM
MKIINIGVLAHVDAGKTTLTESLLYNSGAITELGSVDKGTTRTDNTLLERQRGITIQTGI
TSFQWENTKVNIIDTPGHMDFLAEVYRSLSVLDGAILLISAKDGVQAQTRILFHALRKMG
IPTIFFINKIDQNGIDLSTVYQDIKEKLSAEIVIKQKVELYPNMCVTNFTESEQWDTVIE
GNDDLLEKYMSGKSLEALELEQEESIRFQNCSLFPLYHGSAKSNIGIDNLIEVITNKFYS
STHRGPSELCGNVFKIEYTKKRQRLAYIRLYSGVLHLRDSVRVSEKEKIKVTEMYTSING
ELCKIDRAYSGEIVILQNEFLKLNSVLGDTKLLPQRKKIENPHPLLQTTVEPSKPEQREM
LLDALLEISDSDPLLRYYVDSTTHEIILSFLGKVQMEVISALLQEKYHVEIELKEPTVIY
MERPLKNAEYTIHIEVPPNPFWASIGLSVSPLPLGSGMQYESSVSLGYLNQSFQNAVMEG
IRYGCEQGLYGWNVTDCKICFKYGLYYSPVSTPADFRMLTPIVLEQAFRKAGTELLEPYL
SFKVYAPQEYLSRAYNDAPKYCANIVNTQLKNNEVIIIGEIPARCIQDYRNDLTFFTNGL
SVCLAELKGYQVTTGEPVCQTRRLNSRIDKVRYMFNKIT
>fig|158878.1.peg.695 Quinolone resistance protein NorA
MNKQIFVLYFNIFLIFLGIGLVIPVLPVYLKDLGLTGSDLGLLVAAFALSQMIISPFGGT
LADKLGKKLIICIGLILFSVSEFMFAVGHNFSVLMLSRVIGGMSAGMVMPGVTGLIADIS
PSHQKAKNFGYMSAIINSGFILGPGIGGFMAEVSHRMPFYFAGALGILAFIMSIVLIHDP
KKSTTSGFQKLEPQLLTKINWKVFITPVILTLVLSFGLSAFETLYSLYTADKVNYSPKDI
SIAITGGGIFGALFQIYFFDKFMKYFSELTFIAWSLLYSVVVLILLVFANGYWSIMLISF
VVFIGFDMIRPAITNYFSNIAGERQGFAGGLNSTFTSMGNFIGPLIAGALFDVHIEAPIY
MAIGVSLAGVVIVLIEKQHRAKLKEQNM
>fig|158878.1.peg.1057 FmtA protein involved in methicillin resistance
MKFNKVKLVIHACVLLFIIISIALIFHRLQTKTHSIDPIHKETKLSDNEKYLVDRNKEKV
APSKLKEVYNSKDPKYKKIDKYLQSSLFNGSVAIYENGKLKMSKGYGYQDFEKGIKNTPN
TMFLIGSAQKFSTGLLLKQLEEEHKININDPVSKYLPWFKTSKPIPLKDLMLHQSGLYKY
KSSKDYKNLDQAVKAIQKRGIDPKKYKKHMYNDGNYLVLAKVIEEVTGKSYAENYYTKIG
DPLKLQHTAFYDEQPFKKYLAKGYAYNSTGLSFLRPNILDQYYGAGNLYMTPTDMGKLIT
QIQQYKLFSPKITNPLLHEFGTKQYPDEYRYGFYAKPTLNRLNGGFFGQVFTVYYNDKYV
VVLALNVKGNNEVRIKHIYNDILKQNKPYNTKGVIVQ
>fig|158878.1.peg.1761 Multidrug resistance protein B
MNIPKSVWWLVIGMALNITGSSFLWPLNTIYMKQELGKSLTVAGLVLMINSFGMVIGNLL
GGSLFDKLGGYKTILIGTFTCLCSTTLLNFFHGWPWYAVWLVMLGFGGGMIIPAIYAMAG
AVWPNGGRQTFNAIYLAQNIGVAVGAAMGGFVAEFSFNYIFLANLIMYVVFALVAVTQFN
IEINAKVKYPTHLDITGKKNKARFISLVLICAMFAICWVAYIQWESTIASFTQSINISMA
QYSVLWTINGIMILVAQPLIKPVLYLLKGNLKKQMFVGIIIFMLSFFVTSFAENFTIFVV
GMIILTFGEMFVWPAVPTIANQLAPDGKQGQYQGFVNSAATVGKAFGPFLGGVLVDAFNM
RMMFIGMMLLLVFALILLMVFKENNTQPKKIDA
>fig|158878.1.peg.2166 Drug resistance transporter, EmrB/QacA subfamily
MAKVELTTRRRNFIVAVMLISAFVAILNQTLLNTALPSIMRELNINESTSQWLVTGFMLV
NGVMIPLTAYLMDRIKTRPLYLAAMGTFLLGSIVAALAPNFGVLMLARVIQAMGAGVLMP
LMQFTLFTLFSKEHRGFAMGLAGLVIQFAPAIGPTVTGLIIDQASWRVPFIIIVGIALVA
FVFGLVSISSYNEVKYTKLDKRSVMYSTIGFGLMLYAFSSAGDLGFTSPIVIGALIISMV
IIYLFIRRQFNITNVLLNLRVFKNRTFALCTISSMIIMMSMVGPALLIPLYVQNSLSLSA
LLSGLVIMPGAIINGIMSVFTGKFYDKYGPRPLIYTGFTILTITTIMLCFLHTDTSYTYL
IVVYAIRMFSVSLLMMPINTTGINSLRNEEISHGTAIMNFGRVMAGSLGTALMVTLMSFG
AKIFLSTSPSHLTATEIKQQSIAIGVDISFAFVAVLVMAAYVIALFIREPKEIESNRRKF
>fig|158878.1.peg.2169 Multidrug resistance protein B
MYRRRYFMRLKSIITVIALILIMFMSAIESSIISLALPTIKQDLNAGNLISLIFTAYFIA
LVIANPIVGELLSRFKIIYVAIAGLLLFSIGSFMCGLSTNFTMLIISRVIQGFGSGVLMS
LSQIVPKLAFEIPLRYKIMGIVGSVWGISSIIGPLLGGGILEFATWHWLFYINIPIAIIA
IILVIWTFHFPEEETVAKSKFDTKGLTLFYIFQSTFKNN
>fig|158878.1.peg.2352 Membrane component of multidrug resistance system
MTTTFIISYIILALIIVGVINLFLIRSRKKGKRQQKEQQFTTRQSNQSKFKASDLDKTTD
QSTQRMTHEELRVDNQDDHSQVSLNGYTKGSEKDQEAFTNNNGEEAVAAKNPESEEYKVN
EKIKKEHKNFIFGEGVSRGKILAALLFGMFIAILNQTLLNVALPKINTEFNISASTGQWL
MTGFMLVNGILIPITAYLFNKYSYRKLFLVALVLFTIGSLICAISMNFPIMMVGRVLQAI
GAGVLMPLGSIVIITIYPPEKRGAAMGTMGIAMILAPAIGPTLSGYIVQNYHWNVMFYGM
FIIGIIAILVGFVWFKLYQYTTNPKADIPGIIFSTIGFGALLYGFSEAGNKGWGSVEIET
MFAIGIIFIILFVIRELRMKSPMLNLEVLKFPTFTLTTIINMVVMLSLYGGMILLPIYLQ
NLRGFSALDSGLLLLPGSLIMGLLGPFAGKLLDTIGLKPLAIFGIAVMTYATWELTKLNM
DTPYMTIMGIYVLRSFGMAFIMMPMVTAAINALPGRLASHGNAFLNTMRQLAGSIGTAIL
VTVMTTQTTQHLSAFGEELDKTNPVVQDHMRELASQYGGQEGAMKVLLQFVNKLATVEGI
NDAFIVATIFSIIALILCLFLQSNKKAKATAQKLEASSNNNHE
>fig|158878.1.peg.2355 Teicoplanin resistance associated membrane protein TcaB
MNDLTHFNKRSPIFIIILGSLTAIGALSIDMFLPGLPDIRHDFQTTTSNAQLTLSMFMIG
LAFGNLFAGPISDSTGRRKPLIIAMIIFTLASLGIVFVHNIWLMVALRFLQGVTGGAAAV
ISRAIASDMYSGNELTKFMALLMLVNGIAPVVAPTIGGIILNYSVWRMVFVILTIFGFVM
VIGSLLKVPESLTVTNRESSSGLKTMFKNFKILLKTPRFVLPMLIQGMTFVILFTYISAS
PFIIQKIYGMTAIQFSWMFAGIGITLIISSQLTGYLVDFIDSQKLMRGMTMIQIIGVILV
TIVLLNHWNFWILAIGFIILIAPVTGVATLGFTIAMDESSSGRGSSSSLLGLVQFLFGGV
ASPLVGVKGEDNPIPYIIIIIATAVILIILQIYNMKVFKTNR
>fig|158878.1.peg.2356 Teicoplanin resistance associated membrane protein TcaA
MKSCPKCGQQAQDDVQICTQCGHKFDSRQALYRKSTDEDIQTNNIKMRKMVPWAIGFFIL
ILIIILFFLLRNFNSPEAQTKILVNAIENNDKQKVATLLSTKDNKVDSEEAKVYINYIKD
EVGLKQFVSDLKNTVHKLNKSKTSVASYIQTRSGQNILRVSKNGTRYIFFDNMSFTAPTK
QPIVKPKEKTKYEFKSGGKKKMVIAEANKVTPIGNFILGTYRIPAMKSTENGDFAGYLKF
DFRQSNSETVDVTEDFEEANITVTLKGDTKLNDSSKKVTINDREMAFSSSKTYGPYPQNK
DITISASGKAKGKTFTTQTKTIKASDLKYNTEITLNFDSEDIEDYVEKKEKEENSLKNKL
IEFFAGYSLANNAAFNQSDFDFVSSYIKKGSSFYDDVKKRVSKGSLMMISSPQIIDAEKH
GDKITATVRLINENGKQVDKEYELEQGSQDRLQLIKTSEK
>fig|158878.1.peg.2357 Teicoplanin-resistance associated HTH-type transcriptional regulator TcaR
MVKHLQDHIQFLEQFINNVNALTAKMLKDLQNEYEISLEQSNVLGMLNKEPLTISEITQR
QGVNKAAVSRRIKKLIDAKLVKLDKPNLNIDQRLKFITLTDKGRAYLKERNAIMTDIAQD
ITNDLNSEDIENVRQVLEVINHRIKTYSNHK
>fig|158878.1.peg.2434 Bicyclomycin resistance protein TcaB
MQSTKTKTKHFSFLLLITLGVMTAFGPLTIDMYVPSLPKVQGDFGSTTSEIQLTLSFTMI
GLALGQFIFGPLSDAFGRKRIAVSILIIFILVSGLSMFVDQLPLFLTLRFIQGLTGGGVI
VIAKASAGDKFSGNALAKFLASLMVVNGIITILAPLAGGLALSVATWRSIFTILTIVALI
ILIGVASQLPKTSKDELKQVNFSSVIKDFGSLLKKPAFIIPMLLQGLTYVMLFSYSSASP
FITQKLYNMTPQQFSIMFAVNGVGLIIVSQVVALLVEKLHRHILLIILTIIQVVGVALII
LTLTFHLPLWVLLIAFFLNVCPVTSIGPLGFTMAMEERTGGSGNASSLLGLFQFILGGAV
APLVGLKGEFNTSPYMIIIFITAILLVSLQIIYFKMIKKQHVA
>fig|158878.1.peg.2452 Chloramphenicol resistance protein
MSIMRLFTFILSIFIVGMVEMMVAGIMNLMSQDLHVSEAVVGQLVTMYALTFAICGPILV
KLTNRFSSRPVLLWTLLIFIIGNGIIAVAPNFSILVVGRIISSAAAALIIVKVLAITAML
SAPKNRGKMIGLVYTGFSGANVFGVPIGTVIGDLVGWRYTFLFLIIVSIIVGFLMMIYLP
KDQEIQRGPVNHEAPSHENHVTSKILRPAEVAKYLIITFLVLIANSVTFVFINPLILSNG
HDMSFVSLALLVNGIAGVIGTSLGGIFSDKITSKRWLMISVSIFIVMMLLMNLILPGSGL
LLAGLFIWNIMQWSTNPAVQSGVIQHVEGDTSQVMSWNMSSLNAGIGVGGIIGGLVMTHV
SVQAITYTSAIIGALGLIVVFTLKNNHYAKTFKSS
>fig|158878.1.peg.2462 Antibiotic resistance protein
MKGAMAWPFLRLYILTLMFFSANAILNVFIPLRGHDLGATNTVIGIVMGAYMLTAMVFRP
WAGQIIARVGPIKVLRIILIINAIALIIYGFTGLEGYFVARVMQGVCTAFFSMSLQLGII
DALPEEHRSEGVSLYSLFSTIPNLIGPLVAVGIWNANNISLFAIVIIFIALTTTFFGYRV
TFAEQEPDTSDKIEKMPFNAVTVFAQFFKNKELLNSGIIMIVASIVFGAVSTFVPLYTVS
LGFANAGIFLTIQAIAVVAARFYLRKYIPSDGMWHPKYMVSVLSLLVIASFVVAFGPQVG
AIIFYGSAILIGMTQAMVYPTLTSYLSFVLPKVGRNMLLGLFIACADLGISLGGALMGPI
SDLVGFKWMYLICGMLVIVIMIMSFLKKPTPRPASSL
>fig|158878.1.peg.2746 Antiseptic resistance protein QacA
MISFFTKTTDMMTSKKRWTALVVLAVSLFVVTMDMTILIMALPELVRELEPSGTQQLWIV
DIYSLVLAGFIIPLSAFADKWGRKKALLTGFALFGLVSLAIFFAESAEFVIAIRFLLGIA
GALIMPTTLSMIRVIFENPKERATALAVWSIASSIGAVFGPIIGGALLEQFSWHSAFLIN
VPFAIIAVVAGLFLLPESKLSKEKSHSWDIPSTILSIAGMIGLVWSIKEFSKEGLADIIP
WVVIVLAITMIVIFVKRNLSSSDPMLDVRLFKKRSFSAGTIAAFMTMFAMASVLLLASQW
LQVVEELSPFKAGLYLLPMAIGDMVFAPIAPGLAARFGPKIVLPSGIGIAAIGMFIMYFF
GHPLSYSTMALALILVGAGMASLAVASALIMLETPTSKAGNAAAVEESMYDLGNVFGVAV
LGSLSSMLYRVFLDISSFSSKGIVGDLAHVAEESVVGAVEVAKATGIKQLANEAVTSFND
AFVATALVGGIIMIIISIVVYLLIPKSLDITKQK
>fig|159087.4.peg.201 Permease of the drug/metabolite transporter (DMT) superfamily
MPQKALSLTYAKLVAAMFMWGGTWIAGRIIAQELSAPLAVASIRFVVTALALAGFALLTG
KGAPAPKTTREWGVVSGLGFFGIFLYGLCFFFGLQHITAGRGALVVALNPVVIVLAAWLF
GHERMNRRKALGSAIALAGCLTVIGNGNPLALVEGTVGIGEWLIVGCVMSWTAYTFIGRM
ATRTLSPLATTLYASLIGALLLGLAALVQGDIAPASWSWRVWTGLFFLAIFGTAIAYTWF
TEAVHTLGAGHASVFINLVPVFAVLQAALLLDERLGLPVLFGGLLVIAGVWLTTKQKISL
EISK
>fig|159087.4.peg.1483 Multidrug resistance protein B
MKAIISGKDEAASSLRWRLASLSLPVLLASLGTSIANVALPNLAEAFNATFQEAQWIVLA
YLLAITTLIVSVGRLGDITGRRRLLLAGIFLFTLASGLCGIAPTLWLLIVARALQGLGAA
VMMALTMAFVGETVPKAKTGSAIGLLGTMSAIGTALGPSLGGVLIAGLGWRAIFFVNVPL
GILALLLVWRYLPGDRKGPNVDRVGFDAIGTLLLALTLAAYALAMTLGRGRFGQLNMSLL
MLAAAGIGSFVFAEARVNSPLLRLAMFRNLDLSASLVMSLLVSTVMMATLVVGPFYLARG
LGLDAALVGFVMSVGPLVAALTAVPAGRLADRFGAQRITRIGLLGMAAGAGTLSLLPTMV
GIPGYLAPLVILTSSYALFQTANNTTVMSDVSPEQRGTISGMLNLSRNLGLITGASLMGA
VFSIASAATDITTAPPEAVATGMRITFAVAAALVIVALAISAGACRWTLRKRELAA
>fig|159087.4.peg.1503 Multidrug resistance protein B
MAHLQGRFSRHRSLMPQRSGKITKKALASSEAPYTFLPANEQPTIPMRRLRPATSFDTLS
QRYGERYKWMVLFILALGTVAGVLCTSSFNVAVPALSRHFRLGQDQVQWAMTGFLAAMTV
GMLPTSWLLDRLGFRIIFLLSLAVLTLASVGGYFAPSFTLVVAARILQGLAAGVLQPMGA
LALMRLFPPEIQGRASGILIFSIALTPAIAPSLGGALLDRFGWESIFLLGTPFAVIAALC
AIYLLPAPREIKRKPFDWLGLGWLTLGAIALIESVSSLQHSGLASPWTMGQFALAFVASA
LYYRHARLRSDPLINLDLFRQRTFAMGTLVSFAYGFGLYASTYLIPVFLQNALSFKAGAA
GMALLPSGIALVVMLPLAGRMADHYSPKWITLIGLVAFGASFLIFSIRGGAIQYAEIIAA
TIIGRIGLGMILPALNLATLRHMEPHQLGQSSVVTSYARQLGGVMGVAVLAVFVEWRETV
YGTVPPGIYSAYSQGFLLLTAVFSLAVLAACFMRTEGSRPSPK
>fig|159087.4.peg.1896 Fosmidomycin resistance protein
MTTATLPAPQRSDIEVISVIGFVHGVSHFFHLLLPPLFPWLMAEFGLSFTAIGTTMTVFF
IVSGIGQASAGFLVDRFGAARVLGAGISCFALAGVLLYFATGYPMLIAVAALAGLGNCVF
HPADFTVLNRHVSQQRLGHAFSAHGLSGNLGWAAAPVYITGLATAYGWRTAALGASAVAI
AALALLFWRREALTDPVEHHTEKASEPAGTTFAFLSSRAVWLCFLFFLLITAAFGTIQNF
ASPILQALYGLSITTAALALSTYLVGGAAGIVLGGFLAQKGEHDHLIAGALGVAALLAIL
LAAGIMPAWSILPLMAGIGFCTGTAGPSRDLLVRRAATARFGKAAYGRVYGFVYSGLDLG
LAMAPVIFGGLMDARHFSEVLVGIAILQFLAIFSALRVGKAV
>fig|159087.4.peg.2791 Melittin resistance protein PqaB
MQARPILRSIERFLLSPFSLVLAIVIAFVLNAYSLPLTDVDEGAFSEATREMMARGNLIS
PTLNDAPRHDKPILIYWAQAVSVSVLGVSEIGFRLPSIIASILWLLFLYRFCLHHADRRT
AQVAALVMALSLAVGFIAKAAISDALLNLFIALSMFGIYDFFCSSRDGKSPQQIRRLLFF
VYAMLGLGFLTKGPVAVMFPLLISGIFFVSAGAWRDWLKAAFFWPGWLLFLAIVVPWHVL
VYLDQGDAFFRGFYLKHNLNRYSNTFEGHGGKWYYYLVVLPFVLMPFTGWLLAIVGQLLR
KLCSVPLGLAYGEGLFERYLILWFVVVFGFFSFSGTQLPHYLLYGCTPLFILLARYRPEF
ERRWLAYLPLIAFTLLLAALPEILVFAAAKAGKPFEKTLLDGLVAAFSDEARWLLPLLAV
AVIALTLWRNLPVWQGLIIAGLLQALVVGAVIAPRVIGVTQGPIREAAMVAKQSGGTVVA
WRIIMPSFSVYRQSATPTRVPVEGELVITRTDRRHEVQALLASGLTMRDIYVKSFVTLAR
VEREAAR
>fig|159087.4.peg.3510 Probable multidrug resistance protein norM
MRQSRPMFATAVRGLIAHAFPILIAQLSSIGMMVVDTAVLGHVSSLDLAAVAIGGGIHVS
VVFALVGILQAVAPVVAHLHGAKRDDEVAGILQQGFWLALLLSVPGILFLTHPGVALGMA
DMDAAVEAKVRQYLGLLAWSLPASLCYRTFWAFCNALGKPRVLMGIGFFSLCLHAVLAWG
LALQGWLGEPLGVVGCALSNVLIGWLACLSGGAYLAFGPLGKRYQPFADWQSPRWPIWRE
LLRIGVPMGLSNLVEITSFTLIALFVASLGAPVVAGHRIVANISALIYMLPLSLAIATMA
ALGQAVGARDPLRARATIRAGLVLAACSSSMLGLLLWLGAQPLINAYTDDPAVRSVALGL
VAYIAIYQFFDALQTIAGHCLRAYRVTFFPMLVQTFCFWGIGLLGGAWLCYRWQPPLGVA
GFWLASVISLVFAAVMLLPLLGKAIQAAESTP
>fig|159087.4.peg.3683 Permease of the drug/metabolite transporter (DMT) superfamily
MLAALGFSLKAIFVKLAYPYGVDAITLLALRMGFALPVFLWVGLAGQKAGASLSRRDWGQ
LVLLGCLGYYGASILDFWGLEYISAGLERLILFTYPTLTILIGVLFQGKPFTRREGIAVA
LCYTGIGFAFIHDLGLGEPRNVLIGGALVFGSSISYALYLSGSAPMIARLGAMRFSALAM
LVSSAVTLLHFMATQPFSAFIQPMPVYGWGLAMAIFATIVPVFAQSAAIRRIGAGRASLF
GMVGPMLTIGFGRWLLGEHISPEQTIGATFVVIGILIVSRR
>fig|159087.4.peg.3898 Permease of the drug/metabolite transporter (DMT) superfamily
MKNLFANPYLLLTLTVLSWSGNMVIGRGVRGDIPPLTFAFWRWVIAFALILPLALPHLKT
QWPLLKKGWKPLLVLGLLGVGGYNTFAYLALQDTTATNAALLNSFIPIATIAISWAFLGK
HLRRIEGIGVVVSLCGAMTIISRGDIAVLAHLNLNVGDVWMLVAVLDWAIYTVALAWRPA
GVHPMLMLGATTIIGLSALAPAYAWEMAQGRVMNIHFGSLSALAYVGIFPSFLGYIFYNK
GVAEVGPNKASLFIHLMPVFGTLLSFLFLGEIPFWYHYLGIGLIFTGIWLTTKR
>fig|160488.1.peg.34 Polymyxin resistance protein ArnC, glycosyl transferase (EC 2.4.-.-)
MQTLHRFPERPDPLLTIVVPCFQEEETIPEFHQRITRVVKRLPVSCEILYVDDGSNDRTA
DILRHYQDGSSVRCLSLSRNFGKEAALSAGIDHARGSALIFIDVDLQDPPELIAAMVDYW
QRGYDVVNMQRNLRIGDSWFKRMSARAYYWVMQRLVEKVDMPADVSDFRLIGPAPLAALR
ALDERSRILKGMIGWVGFRTIELPYNRTVRHAGSTKWNAAGLFNLAIESIVSFSRKPLRI
FSLISFGLFVSSICYMLASLVAGSFDIHHLIVGMASFMCVGVAMVGEYLGVTLAEVKRRP
LYFLKHSNKADPVSLHPSMASIEGKKC
>fig|160488.1.peg.175 Inner membrane component of tripartite multidrug resistance system
MNGFFSSVPPARDWFYGVRTFGASMIALYIALLMQLPRPYWAMATVYIVSSPFVGPTSSK
ALYRAVGTLLGAGGAIFLVPPLVQSPLLLSIAVALWTGTLLFLSLNLRTANNYVLMLAGY
TLPMIALAVVDNPLAVFDVASSRAQEICLGIVCAAVVGAIFWPRRLAPVVVGATGNWFNE
AIRYSDTYLARDASADKVGGMRGAMVTTFNSLELMIGQLAHEGAGPHTLKNARELRGRMI
HLLPVIDALDDALVALEGRAPAQFAQLQPVLEAAREWLKGTADSASVAHWATLHEQIGRL
QPATAALDQRAELLLSNALYRLTEWADLWQDCCTLQHALRTDDAKPWRAVYRHWRLGRLT
AFFDRGLMLYSVASTVLAIVVACGLWIGLGWNDGASAVILAAVACSFFAAMDDPAPQIYR
FFFWTLMSVIFSSLYLFLVLPNLHDFPMLVLAFAVPFICIGTLTVQPRFYLGTLLTIVNT
STFISIQGAYDADFFTFLNSNLAGPAGLLFAFIWTLVMRPFGVELAAKRMTRFAWRDIVE
MTEPATLAEHRQVGVQMLDRLMQHLPRLSQTGQDSGVALRDLRVGLNLLDLLAYMPRAGQ
QARERLNTVVEEVGAHYAACLRAGERLHAPAALLRNMERARLALNLDELYERGDARTHLL
HALSGLRLALLPGVEVMLEPAEQPQLPPGLDGAPL
>fig|160488.1.peg.177 Membrane fusion component of tripartite multidrug resistance system
MKKPLLTLGRVVLTLLVVTFAAVLVWQMVVYYMFAPWTRDGHIRADVIQIAPDVSGLIQK
VEVRDNQTVKRGDVLFTIDQDRFTLALRQAKATLGERQETLAQASREAQRNRKLGNLVAA
EQLEESQSREARARSAVSEAQVAVDTAQLNLDRSVVRSPVDGYLNDRAPRNHEFVTAGRP
VLSVVDSASYHVDGYFEETKLGGIHIGDAVDIRVMGDNTRLRGHVQSFAAGIEDRDRSSG
ANLLPNVNPAFSWVRLAQRIPVRIAFDEVPQDFRMIAGRTATVSIIEGQRP
>fig|160488.1.peg.178 Outer membrane component of tripartite multidrug resistance system
MKQLILAGLCLSLGACMMVGPDYEVPGDAAVQRNDLNGPLRQDADSVVSAPVPEDWWQLY
QDQRLNELVRQALSANTELRVAAANIAKARAQVEVAESQGGFNGGVKLGAQRLQESGEAF
LQPEKVPVANIGEAIISASYQFDLWGTFKRGTEAAKANADAVQAAADTARITLVADVVKA
YTQVCSANEEYHIARESLDLQEQSVKLNQRLRDAGRGDETQVTRSQTQFKSLRAELPRFK
AERETGMYTLAALLAKPVDQLPAGTADCAELPHLNQLVPVGDGAALLKRRPDVRQAERQL
AAATAYIGVATGALYPDISIGAQVGTIGILENLGEPSTNRWGFGPQISWSIPTNGTRARI
RMAEASTQAALAHFDGVVLNAIRETQTRLAQYSALLDRRDALAEAEKSAKEAADQTHRYY
QAGRESFLADLQATRTYTDMRAQLAAANSQVAQGQIAVFLALGGGWKGTAKP
>fig|160488.1.peg.582 Multidrug resistance transporter, Bcr/CflA family
MNLRMVLILGALSAFGPLAIDFYLPAFPAMAQAFATDEKHVQATLAAYFLGLSIGQLAYG
PVADRFGRRKPLMFGVTLFTLASLACAYAPNLDTLVVARFIQALGGCAGMVLSRAIVSDK
CDPVASAKVFSQLMLVMGLAPILAPMLGGVLVNLAGWQSIFLALSLFSAGCLLAVSLGLP
ESLPEHIPRQPLSGALRQYLRLLADRVFLGHALTGGIAIAGMFAYIAGSPFVFIKLYGVP
AEHYGWLFGTNAAGFILVAQVNARLLAKRGPAFLLGRAVWLYLVAGLVLLGVAALRPAQL
WPLLVPLFICIASLGCIIPNASACAMSGQGARAGSASALMGCVQFSVAAGAAALVGLLHD
GSAVPMAIVISLCGALVVSVALLTRRLQAKAPA
>fig|160488.1.peg.1261 Inner membrane component of tripartite multidrug resistance system
MTSLTAPSAALAAAPAPAAPAQTAFGLQVVVGLFGVLLAVLCAGLNESVTKISLADIRGA
MGIGADEGAWLLAVYSAASVSAMAFAPWLATTFSLRRFTMSAVGLFAVLGLLQPFAPNLH
SLMLLRVLQGFAAGALPPMLMSVALRFLPPGIKVYGLACYALTATFGPNLGTPLAGLWTE
YVGWQWAFWQIILPSLLAMVCVGWGLPQDPLRLERFKQFDWRGVLLGLPAISCTVLGLSL
GDRWGWFDSPLICWLLGGGLLLLVLFMYNEWSEPLPFFQLRLLQRRNLSFALVTLAGVLV
VLSGVGSIPSAYLAQIQGYRPAQTSPLMMLVAMPQLIALPLTAALCNIRAVDCRWVLGIG
LAMLAVSCVGSSLLTSEWIRGDFYPFYLLQVFGQPMAVLPLLMLSTNGMTPQEGPFASSW
FNTVKGLAAVIAGGLLDVLGTLRRHFHSNHLVDSLGNAPLVDGNAAGLAKRIHDQAQVLT
SADLYLVLACIAVALICLIPFVPTRVYPPRAVA
>fig|160488.1.peg.1262 Membrane fusion component of tripartite multidrug resistance system
MRWLEPWMISRTIEMTNNRKTLFIGSVLAVAVLAGIVGPWMFGSDHRQSTNDAYVTADYT
VVAPKVAGFIKQVLVEDNQQVTAGQLLATIDARDYQAALDAAQAQLLVAQAQSADARATL
ERQDALIAQAEAAVKAAQAEVAFADHEVNRYSRLAEQGAGTVQNAQQARSAVDQARARLA
NAQAARVAARKQVDILTAQVASADGQLKRAEAGLEKAQLDLSYTRITAPVDGMVGERALR
VGAYVNPGARLLSVVPLQQAYVVGNFQETQLTHVQPGQPVRISVDTFSGETLQGHVQSIA
PATGVTFAAVKPDNATGNFTKVVQRIPVKIVLDDGQPLLTRLRVGMSVEATIDTRGDKLD
GKEVSAR
>fig|160488.1.peg.1263 Outer membrane component of tripartite multidrug resistance system
MKPGLRLSPLLLAVLLTGCTLGPDFQRPDSQAPQQWAPLQGEAAASQPQAEPLELRWWET
FHDARLSALIQRVAERNLDLQMASARLLQSRALRSTLAADEVPSVDVNAGYSRARNSADG
LSDPSGKAGKEAFNLWQGDLVAGWELDLWGRVRRQVEAADATVEVAENDRRGVLLALLSE
TAGNYIQLRAVQHTLDVTQDNLRVARHSLKLSQDRQAEGVATRLDVAQASAQVASIESRL
PSLEAQRDDLINALSLLAAEPPRSLQAELLQGGELPAPQQKFAIGLPSELAERRPDIRQA
EARLHAATASIGVAKADFYPSIRLSGSVGFQALQLSDFGGWDSRRFAFGPQMSLPIFEGG
RLKGTLELREAQQQEAALNYRKVVLGAWHEIDDVLRLYNASQLRRDHLAEAVRQNRIALE
TAQRQYVEGAVDFLNVLTVQGALLASEEQWIDSSAAVSQALVGLYKALGGGWQAFDEPPP
NAHG
>fig|160488.1.peg.1265 Permeases of the drug/metabolite transporter (DMT) superfamily
MLIGALLILTWLVLLLRYPAKALPISLAAVCGLGLVALFVVWQDSRESSRLARLDLRLTY
APEHCPADRALQVRMKNGNDVPLTELRWRVAAYAPGDTVNLAENTYNAPRYRGPGELQPG
AEWQDCLPLPPLRSGYRPQTLEFRAEHLQGTFAN
>fig|160488.1.peg.1377 Drug resistance transporter, EmrB/QacA family
MTAALPPTALRNVLTALMLAIFLGALDQTIVAVSLPAISAQFSDVGLLAWVISGYMVAMT
VAVPIYGKLGDLYGRRRMILTGISLFTLASIACAMAQDMPQLVLARVLQGIGAGGMVSVS
QAIIGDFVPPRERGRYQGYFSSMYAAASVAGPVLGGWLTEYLSWRWVFWINLPLGLVALW
AIRRALADMPVQRREAQVDYLGAMLLILGLGSLLLGITLVGQGHAWADPAVLALFGCALL
GLALFIAHERRCPEPLLPLSLFGNRVAVLCWAVIFFASFQSISLTMLMPLRYQGITGAGA
DSAALHLLPLAMGLPMGAFTGGRMTSRTGRYKPQILAGALLMPVAIFAMALTPPQSALLS
ALFMLLTGIACGLQFPTSLVGTQSAVASKDIGVATSTTNLFRSLGGAMGVACMSSLLLAL
LHQGGFELSGNPLLGSLKAAEVDPGTQGRLLETFRQLLMGSAVVAVLGLLAALALPDRQL
RGR
>fig|160488.1.peg.1957 Multidrug resistance protein A
MLAGGGHRAPAMARTSLVDGPCAAVKFVYISGTIVPMPAQLKRRLTLFFALVAIIALAFL
GHWYFKGRFYESTDNAYVQGEITRISSQLGARIETVPVEDNQHVSKGDLLVRLEAADFEL
AVERARAALATREAEYAQAQSRLTQQGSLIAAGQAQLAATQATFDRSRLDLSRAEKLRKP
GFVSEERVTTLSADSHVAGSQVDKARADLQSQRQQVTALNAELKRLDAQIANARTDLAQA
ELNLTRCEIHAPISGTIGQRNARNGQVVQAGAYLLSIVPDEDIWVQANFKETQIGRMHPG
QRAELLFDSYPDTPIEGRVDSLFAASGAQFSLLPPDNATGNFTKVVQRIPIKLTFHADNP
LHGRIRPGMSVTATVDLRSEDEGHNGR
>fig|160488.1.peg.2014 Fosmidomycin resistance protein
MPCARGARCSTGIDMPHAGPKLLTQIAAVHFVSHVHIMLIPALLPVLPGLLGVGFVELGV
ALAVFNIVSALVQAPLGYAVDHYGARKVLKAGLLLGSLSFVLLAASPGYAVLLVAMAMAG
LANGVYHPADYALLANGIEPARLGRSFSIHTFAGFLGSAVTPAVFLGIAAALGTRAALAA
GAVFGVAALLLISIPGSGVYRVARPANKQDTGPTAATGRVRLFTPMIGVLTVLFILLNLS
TSAIEKFSVAALVQGQGLTLAWANAALTAFLLSSAAGVLCGGALADRTRRHGLVAALAFA
LAAALTALVALGLLQGWALVVVLGAIGLLTGVIAPSRDMLVKAAAPPGAEGKTFGLVSTG
FNVGGAIGPVAFGWMLDQRLPNGIFVASVVFMLLTVLLTLAQEMYSARRRATEQLARAL
>fig|160488.1.peg.2048 Membrane fusion component of tripartite multidrug resistance system
MDGTGFARVRGQARSHTRQLLEIEQDSGSHNRQPAGPIRDWKPTMNVAVDKPSPAETEQR
PSAKTRRRLAVIASGSLAAITLLAFTSYWFSTGRYLETTDDAYVRADWVALSPRVAGYVA
KVEVADDQPVKAGDVLVRLQNRDYRARLDQARAGVTEAQAALAAAQASQQVATERIDQQQ
QAILQAEAVVRSATAEQRRSELDVQRYRGLVRDDAATVQRLETASAHASQAQAALQGAQA
ALRQQRSQLAMAKARAAQAEAELQQRAAALARAQAHQQLAEQDEQDTVIRAPITGVVGQR
RVRTGQYVVPGQPLLAVVPLQQAYVVANYKETQLARMRPGQPVEIRVDSFASQPLHGHVA
SFSPASGNVFALLPSDNATGNFTKIVQRFPVRILLDKPLDGPQVLPGMSVVSTVDTRPAE
VADAH
>fig|160488.1.peg.2049 Outer membrane component of tripartite multidrug resistance system
MMPLLHSFPGPARLATALGMLAALAACGHQPTPAEPAVALQADPLANMPAGVSKQPLPER
WWALYQDPQLNRWVQQALAHNQGLAQAEANVQAMLAGIGEFDARRWPSTDMGVAATYGRS
ADDQTLAEATDSNAPSQWQFNPGLELAYQVDIWGQVRAAIQRARVQAEASAAALDLVRLQ
VVAQTTRAYIDQCTYAARLEAAKQALQTLDQSVQLSQRQRQAGVATALDSERLLGLREQV
RAQLPMLSARRQMALYELSMLSGQASVAEATTCVAIPTLSVPLPAGDGWHLLERRPDVRQ
AERELQAATLETDIVRADLYPKVSFGASLTSSDHHLANLGDSRAVMFGIGPLIRWEFPNL
KANRARVSKAEALQRAQVARYRGVALSALKDVRQALARYDGERQRLQALDAALAHSQHSF
ALAQGNYRAGTVDGLALLDSEREMISLRANHTEARGRLAQAQVNLFRALGGRW
>fig|160488.1.peg.3277 Bicyclomycin resistance protein
MNSRLETHANEAEGDAQRANVLTAKVILLLAALAAISNLSTNIILPAFPEMARQLNVSSQ
ELGLTLSSFFITFAFAQLLVGPLADRYGRKRLVVGGLMIFVVGTFWAANAATLDMLILGR
VIQAIGVCAAAVLARAIARDLYEGENLARALSLTMIAAATAPGFSPLIGSMLNTTLGWRA
LFIAVGMSAILIALFYLRGIGETLPAHRRVTQSVPAILIAYGKLASNRLFILPALATSLL
MSGLFASFAAAPSILMEGMGLSSLQVGLYFAATVFVVFAAGLAAPRLAHRWGSRAITLSG
LATACTAGALLLVGPSNPSLGWYSLSMVLFLWGMGIANPLGTALTMTPFGKEAGLASALL
GFLTMAIGAVSTWMVSTPKFPTIAVLGATQTSVCFLAMVLFAWYVKRKAIVR
>fig|160488.1.peg.3515 Inner membrane component of tripartite multidrug resistance system
MSNNAAAQFTPPSLLLTTIGLSLATFMQVLDTTIANVALPTISGNLGVSYEQGTWVITSF
AVSNAIALPLTGWLSRRFGEVKLFIWATLLFVLASFLCGIAQSMPELVGFRVLQGVVAGP
LYPMTQTLLIAVYPPAKRGMALALLAMVTVVAPIAGPILGGWITDSYSWPWIFFINVPIG
LFAAAVVRQQMRTRPVVTSRQPMDYIGLLTLIIGVGALQVVLDKGNDLDWFESSFIIVGS
LISVVFLAVFVIWELTDRHPVVNLRLFVHRNFRIGTIVLVGGYAGFFGINLILPQWLQTQ
MGYTATWAGLAVAPIGLLPVIMSPFVGKYAHRFDLRVLAGLAFLAIGTSCYMRAGFTSEV
DFQHVALVQLFMGIGVALFFMPTLSILLSDLPPHQIADGSGLATFLRTLGGSFAASLTTW
IWIRRADQHHAYLSEHISQFDPTTRHTLEQLGGASPQSYAQLEQILNGQAYMMSTVDYFT
LMSWVFAGLILLVWFAKPPFTAKAGPASAGH
>fig|160488.1.peg.3516 Membrane fusion component of tripartite multidrug resistance system
MATPTDTPTPSVAPEPSRKRKAWLLGLLLLLILAGVGTWAWYSIVGRWHESTDDAYVNGN
VVEITPLVAGTVTSIGADDGDLVHAGQVLLQFDPADSEVALQSAEAKLARSVRQVRGLYS
NVDSLKAQLETRQAELRKAQQDFNRRKVLADSGAIAAEELSHARDDLSVAQAAVNSARQQ
LSTSSALVDDTVVSSHPDVMAAAADLRQAYLDHARTTLVAPVTGYVAKRTVQLGQRLQPG
TATMAVIPLDQVWIDANFKETQLREMRIGQPVEITADVYGSEVKYSGTVDSLGAGTGSAF
ALLPAQNATGNWIKIVQRVPVRIHLSPDQLKDHPLRIGLSTVVEVDLHDQSGPTLAQQPP
QKASYTTQVYDHQLMEADNLIARLIHENSATGKTAQR
>fig|160488.1.peg.3554 Bicyclomycin resistance protein
MNRPAGSLRRHLCSTLLILLCLLGVFPLDVILPSFPALSDEFRVDTKQIAYSVSFFAVGV
AMAQIVIGPLSDGIGRKRLLLAGLSVSIVGALGCVFSTHYETFMAFRLVQALGCGSLVLG
QALVQDLYSGTQRNAMRILLTSASGLFISLSPLAGAFLQQSFGWEASFTVFVIIAAIVSL
LSCVLLHDTPASHDRAPSMSSYRVMLRDTDYLAHSMLSSLAFACHFSFIVIAPLLLMGRL
ELTAYQFSLVFIGYGLAYIVGGMAAAYLNSRVSPQTQIKAGLLLISTAGITLLMWEWVAG
LSVLGALLPMIVCTTGTTLVRPAATTQALARYPRQAGAAASLNTTLLFAGAGLTSSVVAG
LESELPAGLGVLFMVASLCGGWLLACTKDDGMQRC
>fig|160488.1.peg.4505 Permease of the drug/metabolite transporter (DMT) superfamily
MSPIALARLLTLAAVWGASFLFMRIIAPELGTVPTAFFRVSIACLGLIVILAAARVRWNF
QGKLGACLVLGMINSGIPATFYSVAAQVLPAGYSAIFNATTPLMGVLVGVLFFREPMTLA
KLCGIFLGLFGVGILSGAGPVALDMALLQGALACLAATTCYGFAGFLARRWISGLDSRLS
ALGSMLGATLMLTPLFGWSALTQPPASWGGWEVWLSLLGLGLLCTAFAYILYFRLLEEIG
PVKASTVTFLIPVFGVLWGAWLLNEPLSMAHLYGGLLIGLALWLVLRPARS
>fig|160488.1.peg.4543 Permease of the drug/metabolite transporter (DMT) superfamily
MNLSLYLLTVLIWGTTWIALKLQLGVVAIPVSIVYRFALAGLILFAFLLITRRLQPMNRR
GHQICLAQGLCLFCVNFICFLSASQWIASGLIAVVFSTATLWNALNARIFFGQRIAGNVL
GGGALGLLGLGLLFWPELSHHAASRETLYGLGLALLGTLCFSAGNMLSSMQQKAGLKPMT
TNAWGMVYGAVMLAVFCVVSGVPFSMEWNARYIGSLLYLVVPGSVIAFTAYLTLVGRMGP
ERAAYCTVLFPLVALNVSAVAEGYQWTAPALLGLVAVMAGNVLVFRKPRARVAEGVVVAK
>fig|160488.1.peg.4884 Drug resistance transporter EmrB/QacA subfamily
MPERTPLDPVTARWIPWVVAIAFFMQSLDGTILNTALPAMARSLAEDPLRMQGVIIAYML
TVALLIPASGWIADRFGTKRIFFSAILLFSFGSLLCAAANSLGFLIFARVVQGLGGALML
PVGRLVVLRAYPRSELVRIMSFITIPGLLGPLLGPTVGGWLVEILSWHWIFLLNLPVGLL
GCIAVWKFIPDLRGAERTTFDGPGFLLFGAAMVLITIAMEGLGELHLPHLRVMLLLFAGM
ACLAAYWLRAGRDPEPLFSPSLFRVRTFAIGILGNLFARLGSGALPFLVPLLLQVALGYS
PAQAGMSMIPLAAAAMLAKSIARPLIERFGYRIILTGNTLLLGILLASLGLVDEQTPYWL
LLVQLGLLGAVNSMQFTAMNTVTLIDLDDASASSGNSLLSVVAQLSLSLGVACAGALLGG
FTAAGSAEGVETTLGAFQLTFVTIGVMAMLAAAIFLQLAPTDGRRARRPEQHMES
>fig|160490.1.peg.168 Multidrug resistance ABC transporter ATP-binding and permease protein
MLKDAILRYKWYALGSFFMVIGVVASSLLQPHYLKSVLSAVIQNNQEKIYEVGKPLLIIA
LLGLMSGAINTVLAAKIAQGVSADMREKTFRKIQDFSYANIEAFNAGNLVVRLTNDINQI
QSLVMMMFQILFRLPILFIGAFIMAVQTFPQLWWVIVVMVILIALIMGLVMRQMGPRFGK
FQRLMDKINRIAKENLRGVRVVKSFVQEQQQYTKFKETSNDLLALNLSIGYGFSLMQPAL
MLVSYLAVYVSINVVSTMVETDPTVIGNIASFMTYMMQIMFSIIVVGSMGMQVSRAFVSM
ARIRQILSTEPAMTFENEKEETISGSIVFDDVSFTYPNDDEPTLKHISFAIEPGQMVGIV
GATGSGKSTLAQLIPRLFDPQDGQILLGGKPIKTLSQTTLRQSVSIVLQKAILFSGTIAD
NLRQGSAKADIDAMQKAAQIAQAKEFIDRMDSRYESQVEERGSNLSGGQKQRLSIARGVI
NHPKILILDDSTSALDAKSEKRVQEALSHKLEGTTTVIVAQKISSVVKADKILVLDQGQL
IGEGTHAELVANNAIYREIYETQKGREE
>fig|160490.1.peg.169 Multidrug resistance ABC transporter ATP-binding and permease protein
MKTARFFWFYFKRYRFSFTVIAVAVILATYLQVKAPVFLGESLTELGKIGQAYYVAKMSG
QTHFSPDLSAFNAVMFKLLMTYFFTVLANLIYSFLLTRVVSHSTNRMRKGLFGKLERLTV
AFFDRHKDGEILSRFTSDLDNIQNSLNQSLIQVVTNIALYIGLVWMMFRQDSRLALLTIA
STPVALIFLVINIRLARKYTNIQQQEVSALNAFMDETISGQKAIIVQGVQEDTMTAFLKH
NERVRQATFKRRLFSGQLFPVMNGMSLINTAIVIFVGSTIVLSDKSMPAAAALGLVVTFV
QYSQQYYQPMMQIASSWGELQLAFTGAHRIQEMFDETEEVRPQNAPAFTSLKEAVAINHV
DFGYLPGQKVLSDVSIVAPKGKMIAVVGPTGSGKTTIMNLINRFYDVDAGSITFDGRDIR
DYDLDSLRQKVGIVLQESVLFSGTITDNIRFGDQTISQDMVETAARATHIHDFIMSLPKG
YNTYVSDDDNVFSTGQKQLISIARTLLTDPEVLILDEATSNVDTVTESKIQRAMEAIVAG
RTSFVIAHRLKTILNADHIIVLKDGKVIEQGNHHELLHQKGFYAELYHNQFVFE
>fig|160490.1.peg.357 Multidrug resistance efflux pump PmrA
MNWRQNLKVAWLGNFFTGASFSLVMPFMALYVENLGTPTELVEYYAGLAVAVTALASALF
APVWGKLADRYGRKPMMLRASFVMTFTMGGLAIIPNVFWLLILRLLTGVSAGYVPNATAL
IASQAPKEESGYALGTLATGVTAGALIGPLLGGILAELLGIRQVFLLVGVILFLCSLMTA
VYVKEEFKPVRRFEMIPTKVILKQVKSPQIMLGLFVTSMIIQISAQSVAPILSLYIRHLG
QTHNLMFTSGLVVSAMGFSSLFSSSYLGKLGDRFGNHRLLLAALCYSFIMYFSSALAQTS
FQLGVLRFAYGFGVGALMPSINSLLTKLTPKEGISRVFAYNQMFSNLGQVIGPFIGSNVA
VVLGYRSVFYVTSLIVFVNLIWSLIIFRKYIKVKDIV
>fig|160490.1.peg.373 Daunorubicin resistance ATP-binding protein drrA
MVMIEVSHLQKNFSKTIKEPGLKGALKSFVHPPREIFEAVKDLSFEVPKGQILGFIGANG
AGKSTTIKMLTGILKPTSGYCRINGKIPQDNRQYYVRDIGAVFGQRTQLWWDLALQETYV
VLKEIYDVPEKAFRKRMDFLNEVLDLNEFIKDPVRTLSLGQRMRADIAASLLHNPKVLFL
DEPTIGLDVSVKDNIRRAITQINQEEETTILLTTHDLSDIEQLCDRIIMIDKGQEIFDGT
VTQLKQSFGKMKSLSFELKPGQEQVVSQFMGLPDITVERHELSLDIQYDSSRYQTADIIQ
KTMADFAVRDVKMTDVDIEDIVRRFYRKEL
>fig|160490.1.peg.374 Daunorubicin resistance transmembrane protein
MWSFWKRYRPFLSAGIQELITYRVNFFLYRIGDVMGAFVAYYLWKAVFDSSKQSLINGFT
LSDMTFYIIMSFVTTLLTKSDSSFMIGEEVKDGSIIMRLLRPVHFAASYLFMEIGFRWIV
LMSVGFPFLMVLSGIKVMAGLSILQVLASSCLYLVSLLLAFLINFYFNICFGSSAFVFKN
LWGSNLLKNALVAFMSGSLIPLAFFPKMVSIVLSFLPFSSLVYTPVMIVIGKYSLSQIMV
ALSLQIFWLLVMVVLSQVIWKKVQYHLTIQGG
>fig|160490.1.peg.411 Multidrug resistance protein B
MSHHQQTVSKQTIMAIIAIALIGFSGILSETSMNVTFPTLMSVYQLPLNSLQWMTTIYLL
AVAIMMTTSATLKKNVRERPLFFMATGLFTFGTILAVLTQSFAIMLLARIFQGIGTGLVM
PQMFNIILERVPMHKVGLFMGFAGLIISLAPAFGPTYGGFMISHFSWQWIFICILPVPLI
AGILAYYYLEDSPVSEKVPFDWLAFIALSISLTSALLAITSLENGSVNLYYLGLFILSFI
LFLYKNLTAKQPFLDIRILKIPSLTFGLIPFFVFQLINLGINFLTPNFIVMEKIANSSQA
GMVLLPGTLLGALLAPAFGKLYDQKGARLSLYLGNALFSLSLIIMTLQTRHFMLLPFTLL
YILFTFGRNMGFNNSLATAIRELPAEKNADATAIFQMMQQFAGALGTAMASLIANSQAEF
TSGVQSVYLLFTIFALLDFIFFFAMFYHLGKKGLA
>fig|160490.1.peg.1428 Quinolone resistance protein NorA
MPFDSNTYIIPLKYIIFCFFCKMFMKIERSSFSMEEKLFNKHFVAITVINFIVYMVYYLF
TVIIAFVATRELGAQTSQAGLATGIYILGTLLARLIFGKQLEVFGRRLVLRGGAIFYLLT
TLAYFYMPTISMMYLVRFLNGFGYGVVSTATNTIVTAYIPARKRGEGINFYGLSTSLAAA
IGPFVGTFMLDNLHIDFRMIIVLCSVLIGCVVVGAFAFPVKNMSLNAEQLAKTKSWTVDS
FIEKKALFITAIAFLMGIAYASVLGFQKLYTSEIHLTTVGAYFFVVYALIITITRPAMGR
LMDAKGDKWVLYPSYLFLAMGLFLLGSVSSGGSYLLSGALIGFGYGTFMSCGQAASIQGV
DEHRFNTAMSTYMIGLDLGLGAGPYLLGLIKDLALGSGVASFRHLFWLAAVIPLICTLLY
LLKTKTRQVVS
>fig|160492.1.peg.243 Acriflavin resistance protein
MKITHVAMSANRLTLFTAVLLLIAGIATFLNFPSQEEPSVTVRDTLISVAYPGMPSEQVE
TLLAKPIEERLREIVGIKKIVSTVRPGSVLIQLTAYDNVKNLETLWLRVRAKVAEAGTGL
PTGTLGPFLNDDFGRVAVASIAITAPGFSMSEMREPLRRMREQLYTVPGVERITLHGLQE
DQVYVAFDRAKLVEAGLTPGAVIQQLQAQNVVTPGGLVSASGMALTVATSGEVGSVDELR
RFLVSVPGSASAREVPLSQIAQVQVMPADPPQTATVYQGQPAVVLAVSMTSGRNISEFGN
TLRAALEETSQLLPVGFQQHVVTFQADVVNREMSKMHHVMGETVLIVMAVVMLFLGWRTG
LIVGTIVPLTVLSALIIMRAINIELHTVSIVAIIMALGLLVDNAIVIAEDIERRLAIGEN
RRHACIEAGRTLSIPLLTSSLVIVLAFSPFFFGETATNEYLRPLVIVLAVTLLSSWLLSI
TIIPLLCLYFAKAHRAPTEDQGHNLYDSAFYRSYRAIISRVLEHKVLFIGSMLALLAVAV
IVITLIPYSFLPKSDRLQFQMSITLQPGSDSRQTLDTVQQISHWFADKQINPEVVDSIGY
VADGGPRIVLGLNPPLPAPNVAYFTISVHPGTDIDAVIARTRQHMHNAFPYVHAEPKRFS
LGANDAGVVIYRIVGPDEAVLRQSAKQISEALSALPGTYDIYNDWQARIPRYIVHVDQLK
ARRAGISSEEIAQALQMRYSGVNASLIRDDGVAAPIVLRGNATERATQGNPGDTLVYSQA
GGTPLPLSAIAKIENDTEPSTLMRRNLNRTITIIGHNAGMTTGEIVQALAPKVASLKLPP
GYRIELGGEIEDAAQANQALLQFMPHALVAILLLFIMQFNSFRKLFIVVASIPFVLIGAA
TALLITAHPFGFIATFGLLALAGIIVNNAVLLLERIEVELADGLPRREAVVSAAVKRLRP
IVMTKLTCIVGLVPLMLFGGPLWTGMAITMIGGLALGTLVTLGLIPSLYDMLFGLRFGKR
NVVETAG
>fig|160492.1.peg.1761 Drug:proton antiporter
MKPSEPDAASARAPDAPTPAAQRRAQATLIAVLLGFFVITLDAVVVNVALPTLAHDLGAS
VDGLQWVVDGYTLMFGALLLSAGALVDRIGARRAFGLGLVVFILASMACGGAPTLATLVV
ARLVQGAGAAVMMPASMSLIRQAYPDPVRRGHAVALWAMGGSVASTSGPVIGGWLVSLDW
RWIFFVNLPVGLLTLAFLARTPASPRRASPFDAVGQVTAILAMGALIYGAIEAGAQGLGA
TPVLAAFVLALAALAAFVWSQRCGAHPMVPPGLLAPRNARISMAVGFTFMVGYFGLPFVM
SLYLQQHRGLSAPATGIAFLPMMLIGLVLTPFSARLAHRFGARTMIVSGLLSMAVGLAAV
ASLPASAPVGWIAALMVLVGLSGPFVAPPVAAVLLSSVPGALAGTASGVFNTSRQVGGAL
AVAVFGALLVQAPSFMTGLRASLWLAAAIALVTAAMALRLQSTAAPEPSSTG
>fig|160492.1.peg.2371 Acriflavin resistance protein
MSRTHHVGFSTIFIRRPIATSLLMFGVLLLGILGYKKLPMSALPEVDAPSLVVTTQYPGA
NAKTMAALVTTPLEHQLGQISGLDIMSSDSSAGLSTITLQFSTHKNLDIAAQDVQAAIHQ
AILPSALPHQPIYNRVNPADAAIITLKLTSDTLPLRELNTYADAILAQRLSQISGVGLVS
IAGNVRPAVRIQVNPAQLSNMGLTMESLRNTLTQANVNAPKGSLNGKSQSYSIGTNDQLK
DASQYRDTIIHYQNGHPVRLSEVADVVDGVENDQISAWANAKPAVLLEIRRQPGANIIQT
VEQIRAILPQLRAVLPTDVHLDVFSDRTETIRASVHEVKFTLLLTIGLVVAVIFVFLRRL
WATLIPSVAVPLSLAGTFSVMAFNGMSLDNLSLMALVVATGFVVDDAIVMIENIVRYIEQ
GKSGREAAEIGARQIGFTILSLTISLVAVFLPLLLMPGVTGRLFHEFAWVLSTAVVISML
VSLTLTPMMCAYLLKPDTLPESDSPTPSTKITLWTRTVALYERTLDWVLMHQQLTLVVAL
VTVALTIVLYVTIPKGLLPEQDTGLIIGVVQADQDIAFSQMEQRTRAVADALRKDPAVTG
VSAFIGAGTINPTLNHGQLSIVLKPRNQREGLNTIRPRLQRAAAGIPGIVLYLKPVQDVT
LDTHVAATEYQYSLSNVDATELATWATRMTEAMRQIPALTDVDNNLADQGRALQITVDRD
KASLLGVPMQTINDTLYDAFGQRQISTIFTELNQYRVVLEVAPHFRTSTALTQQLGVASN
GSGALTGSNATSFGQAVSSNSSTATGIGNRNTGMTVGTGRIIPLSALADAKVTNAPRVIS
HQQQLPAVTISFNLAQGYSLSHAVKAIEQARTQLQIPPQVRVQFIGKAVEFTSSQSDIVW
LLLASIVVIYIVLGVLYESYIHPLTIISTLPSAGVGALLALMLCGLSLSVDSIVGIVLLI
GIVKKNAIMMIDFAIEARSTGSSAHDAIRRACLLRFRPIIMTTAAALLGALPLALGDGIG
AELRRPLGITIVGGLLLSQLITLYTTPVIYLFFERLSERLRLWRAHRTSVQATPQRV
>fig|160492.1.peg.2372 Acriflavin resistance protein
MNLSAGFIKRPIGTSLLAIGVFVLGLICYLQLSVAPLPKFQIPVIAVKANQPGANASTMA
TTVTAPLERYLGQIPGIKGMRSSSSENNSNIFLLFQSNRNIDSAAQDVQAAINAAQADLP
SGLLTPSYEKANPNDDPVIALALTSDTQSMDALYNVADSLLAQYLRQIQGISSVDIVGAS
TPAIRVDVDMQALNALGLTMDQLQNAVRAANVTSPTGFLSNDTRTTEILLNSTISKAADF
AHLVIATQPNGRIVRLSDIAQVYDGQQDAYQAAWFNHKRAVVMYVFLRTGANVVETVDRV
KAELPALRTYLPSGTVITPYFDHTPTIRASLYEIQTTLLISLAMVMLTMALFLRRLAPTV
IAAATVPLSLAGGAIVMYALDFTLNNVTLLALVIAIGFVVDDAIVMIENISRHLNTGMSP
LEAALTGAREIGSTIVSITVSLVVVFAPFLFDHGMIGTLFREFGITLVAAIIISMLVSLT
LTPALCSCFLSAHVVPEKSNGIGAWLERMYLRILRLYTVALDFSLRHALLLALTPLLLIV
STVMLAGTIKKGTFPIQDTGLIQGRADSSTTVAFQDMINRQHRITEMLLSDPAVKSVAVR
LGSGRKGSRTSFNIELKTRAEGRRESTDTVMIRLSTKAAHYPDLALRLRAVQDLPSNSGD
GANQGAQYRISLQGNDLKQLEGWLPKLQEALSKNPKLRDIGSDMDTAELYQNIVIDRGKA
AQMGVSIGAIDGALYGAFGQRQISTIYSDTNQYTVVINALASQSATPAALDQIHVPNRSG
KMVPITAIAHQVPALNPPQIKHDNQYTTMDLSYNLSPGVSSGEAEAIIEAVIKGLRMPGD
IHIAEDNSFKQDLNPNSMKILLIATLLAVYIVLGMLYENLIHPITILSTLPAAGMGALLA
LYVSDTELSAISMIALVLLIGIVKKNAIMMIDFALVAQRERGLEPHAAVREASIVRFRPI
MMTSMVAILAAMPLAIGVGEGAELRRPLGIAMIGGLLISQSLTLLSTPALYVIFSCLSQR
WHAWRGKYMAARSH
>fig|163164.1.peg.87 Multidrug resistance protein
MCWLYLLLSSILEILWAVTLKFSNSFTKVVPSIATLVIMIISIYFLSLAACFLPIRLCYA
VSSGICTIGITIIGATTFTENINLSQVLCIVLIVIGSIGLKLSI
>fig|163164.1.peg.88 Quaternary ammonium compound-resistance protein SugE
MNWIYLLLSSLIEVFWVITLKHSYGFTHLVPSIISILSMALSTYLLSLATRSIPIGVCYA
IWTGVGAIGASILGVYLFDEPVNLFEVICFILVTFGIIGLKLFDTAKQTVDKME
>fig|163164.1.peg.222 Bicyclomycin resistance protein
MLLPFLLILSLIAKFIEIDISVPSFPDMVHYFNVPEGIIQLTIAYNFLGFCIGGLFFGPL
SECYGRRRIMIIGNTLLLIGAVGCVFAPSIFWLLISRFVQGIGVSTSVVVFAIVADSYKG
DEAVKFIGIMNSVLTVVMAIAPVLGSFINEIVGWRGNYATVAILCLISWVLLLLALPETK
KNRDIFSLKKTMKDYRKLLSNPRFVTLSLMSSLFSAAYMSFITCGPFLYMKTFGLSSTIY
ALHQGAIVGCFSLISLFAGKILQKLGAIKCVISGTSVGAIGSLLLVIFSIIVPHSFYLVT
LSMIIFSIGCAIFQPVIFNASINVFPEIKGTASSAVSFIRAFIMAIFIGLTSYIYNGQTI
SVAVLVLSAIVLELVFTVYLLRLKDPM
>fig|163164.1.peg.341 Bicyclomycin resistance protein
MKTALSQNIISLIMILSVAIVDMATDLYSVALPSIANYFKVEGSVVQLTISLNLVGFAVS
GLIYGPLSDHYGRRPMMLIGMTIFTLASVMCYIADSIMLLILIRFIQGAGAGVAGVVGYA
AIRDMYSGSEYSRVISKLNMVVALSPGIAPVVGSYIISHGYHWKFLFFIMSLAAIAILIF
IYFKLQETLTVNKNETSITNITTNIFKQYISIFRNYRFLGFSAIHGLTFMWLWAYIANYP
FIFESMGIEVQYFGYLISIIVIFYIIGTLINRRYVPKVGVSKMLIIGLVLPIISNSLLVY
FYFADKLNIFILQTAWIPANIGLALIISNNVTSALETIKGIGLGSAVLSFCNMMFGAIGI
YIVGKFFRYGILPNLLLTIACSTIAILMYSQLKCTEKHRE
>fig|163164.1.peg.1193 Multidrug resistance protein D
MQSLLIERNRAVVLLLIVIFIFGSYVYVKMPRESNPGIQIPIISVFVGLPGISAQDSEKL
LVLPIENELRSIEGVRELRAFATNDGAHMILEFGTEYDNKEVLDNVRSKLSNIKSKLPVE
AESPIINEINLSLFPILNVGLIGNLPERALTEIARKLKKEIESLPNVLKVEVAGMRKETV
EVIVEPTVLTKYNIQSNEIFQAISSNNRLVGAGSLENDTGKYSIKISGLLKDIEDIMNIP
IRSQGDAVLRIKDIAKVYPRFEDHQGFARINGLPSVVLGISKRNGKNIIDTVNQVKYLMD
KAKDQLPENLKVVYLNDQSKNVLDVLDDLENGIIFAVLLILIIMMLSMGTRIAILVALSI
PGSFLIGIIALYFMGITLNIVVLFSLIMAVGMLVDDAIVISEYADRKMICGMDKVEAFYT
SVRDMFYPVLSSTLTKLAVFFPLLFWPDTVGKFMQYIPITIILTLTGSLIMALVFIPTLG
AIFGKPSITSKKEIKKMSAIESGEIKNAGPIIRAYIRMLEKVLDHPKKFVCATVFVLFSF
SVLYFTFGPGVKFFPKVDSDNILISVKAKESLSAKERDLILKEVEERILSIEKEIHVSYA
RSGAFSDNVIARIQLELMDWRFRRKAKHILNDIRSSVQDMKGIIINVQEEKPGPSADKPI
QINLSGSVSSLNLAAEKILEIMNQPSSGFINIQDSRSAPEIEWNMSVDKSKATSSEVSVA
TIGDFIKMVTNGVLIGKYRPNNTDEEIDIVLRFPRKDRNMKTIDNLFINTVNGPYPMSNI
VKYAPEKKVNKLNRIDGLRTVTISADVDTGYLVDERVKFIQNSIAQDWDKGVKIDFKGDK
EDQQKSGAFLLKAFILAITLMILVLVTQFNNVYHTFIVMTAVFLSTTCVFFVFFLIQQVF
VVVMCGVGIIALAGIIVNNNILLLDAFHHQIKVHKNDIKRCVINAAISRVRPILLTVATT
VLGLIPMITRLNINFFTLQITYDAPSSQWWVDISTTIASGILAATVLTLFFTPALLVIQK
HEKT
>fig|164546.7.peg.26 Multidrug resistance protein B
MMRVIGGIVLCILLAALDQTVVIPAVPAIANDLNGFGHLSWIVTAYLIVSTVTTPLYGKL
SDSFGRRRLLMVAITLFIGASVACALAQTLGQLILFRALQGVGGGGLMSLAQAAIADVVA
PRQRGRYQGYLATVWAVASIAGPLVGGWVSDHMSWRWLFWVNVPLGLLAMFMCYRGLAML
PARGGRARVDWLGALLLAVAIVAFLLAMSWGGDVYDWLSPELGALLLAAVAAVLLLTWQE
RRAADPMLPPRLFANRAYVLGVAASALAALDIFLCIFALPLHFQLVRGADASTSGLLVMP
FLLATVAGNFIVAWLAPRVGRLRGILTAGYIAGALGLIVLALVTPAVPLAVVLAAMTLAG
VGLGITMVATLMSVQNALERRDTGAGTGALLVLRSLGSALGGAVAGTLLTLEFRHALAAS
GVTQALDLGALRHGSEAFAQLSPSVRAVLAGGVESGFHLIFAVGAAAAVLALLIVRRMPD
VELRSSVTEHAATLAMD
>fig|164546.7.peg.160 Permease of the drug/metabolite transporter (DMT) superfamily
MPSQQPQRGGAWRMVAAMVLSGTIGWFVVTSGQPPLDVVFFRCLFGGAALLGVLTLQRGW
VRMTRAQAGWLVLGGVTLVLNWLALFSAYAYSGIAIATVVYHTQPFFLLMLTSVLQREPF
PFARLPWLVLAFAGVMLITGLEHGAGGASMLAGIGLGLLAALLYAVTTLATRRLQAIPPG
QIAGLQMVLGVLMLAPLAHPAAGSYGGGTWGALLALGLVHTGVMYTLLYGAFQRLSVVSI
ATLSFIYPLVAIVIDVMVFGVVLGPLQVAGMALVLLGVVANQLGWALPLRRRARG
>fig|164546.7.peg.1091 Permease of the drug/metabolite transporter (DMT) superfamily
MRDRRLPAACPMTASAPTAPTDARDKLAGVLLIAVSASAFGAMAIFARFAYAAGADVYGL
LLVRFLLAAAALAWVMRTRGIALPPWRRVLALAAMGGIGYVGQSFCFFSALNHAQASLVA
LLLYLYPLFVTILAAVFLKERLTTAAVVALVLCSVGAGLTVGGGAGSPLGIALGLAAAVI
YSVYIIVGARLTAGVNPIATTTVICTAAALVYGAVGLLRAGAGTPPQFPADAGGWLALAG
IALLSTVLAILTFFAGLQRLGAAQASMLSTLEPVVTVALAALLLGEQIGPAQAVGGGLIL
AGVLWLTRRGSAPAPARADMQGN
>fig|164546.7.peg.1706 Multidrug resistance protein B
MSEGPATPEGSGQRTGLPTRQALRARYGERLRWLVLATLMLGTISSIVSSTIVNVAIPDL
SRHFVLGQERAQWVAASFMIAMTLSMLLTPWLLNRYGLRRTFLGASLLLGAGGLLGGFSP
TYGVMIAMRVAEGIAAGIMQPLPNILILRVFEEREQGKAISMFGFGVVLAPALGPSLGGF
LVEAFGWRSIFFVVVPLTLLAVLMARRFMAVDSIMMGERQPLDWRGLGLAGIATVSLLNG
VVEMRESVPAGLALSGFGVLMLAAFVMWQLRAAYPLMNMRLYSYRQFAAGAVVAFIYGAG
LFGSTYLLPVYMQMALEYTPSRAGLVLFPAGVVLALTIAVAGRFTHRIPPHVQVSFGLAL
LSLSFLLMALGSRATPYLVLVGLAVLGRIGLGCILPSLTLGAMRGVDFTLIAQGSSCINF
LRQLGGAIGVSLAGVGLQWRLAGHGALLGQAGDTAVQAARIRAFDETFLAVGVVIASAML
AAWRIRPRPVPAA
>fig|164546.7.peg.1798 Outer membrane component of tripartite multidrug resistance system
MKPVLSFRFTQPASSRKLARRAGTLALTAIAAAALAGCAALGDSHSTQTMADPAAMATSQ
TLPGEHGQWPSQDWVDQFKDPQLSALVDEAVKDNPSLQAAFARVEASRAMAEATRSALYP
HVEFEGSLIRQRLSETDLFEGTPLAGSWQNQSRLQVGLSYDFDFWGKNRDALEAALSDDR
AAEAESQASRLILATSIARNYARLAALYAQRDVAERAIAQRRDLTELSRQRLAAGLDTQV
ETTQARGTVAASQTDLQRVDEEIALARNQLAALLGKGPDRGLQIERPVLLAQATPTLPDN
LTIGLLGRRPDLVAARWRVEAASKDINVARKEFLPDVSLSAFAGLAALDPSRLLMGISRT
FGIGPTLRLPIFEGGRLRANLKGKYAGYDIAVANYNQALVDALRETADTMTSIRSVDKQI
QTQREALDLAEHAYALATTRYKAGLGTQLTVLNAESNVLQQRRLATDLQARRLDLQMGLM
KALGGGYQEPAEGHESVAHGQAQQPDNTKAGARG
>fig|164546.7.peg.1919 Multidrug resistance efflux pump
MNDTPQPSAAPTVTPPPAPPPPTADTSKKGVRWVLLLIVVSLAWYLLADRLTPYTQQARI
QAFVVPVAAEVSGRVIKVHVRNNQDVAAGTVLFEVDPQQYRIAVDRARAELESTRRQIGA
STAGIESAQASLRAARANEVKARQDSERLERLYSEDPGTISLRRLEVARASLEQAVSQVA
AARAEVQRAREQEGGSDEDNAKLRSAASALEKAELDLANTQVRARAAGLVTDLRTDVGQF
AAAGNPVMTLIPIHDVWINAEMTENNLGRVEPGTPVAIVLDALPGRVFEGRVRSVGYGVN
VGPGTPPGSLPTVQNSRDWLRPAQRFPVIVEFDRGELAPLRGIRVGGQAEVMAFPTEGNP
LNPLGRLFLYLMSWLSYVY
>fig|164546.7.peg.2319 Acriflavin resistance protein
MWFTRLSIRNPVLATMMMMAFIVVGLFSYQRLPVDQFPDITFPVVVVQTEYPGAAPESVE
SDVTRKVEEIVNTISGIDEIFSHSYQGTSVVVIKFDLSVDVGQAAQDVRDKIALIRPQFR
DEVKDPRVLRYDPSDAPIFYLSVSNAPGASRSQRELTTIADQIVRKRLETVRGVGAINLV
GGTRREVEIRIRPAQLEALGIGVDQVMNAIRNENQELPAGELRSSAAETVVQIKGRVPTP
DAFRQIIVARRAGQPVTLGEIADVRDGQEEQESLALLDGKRALFLSVVKAQGQNTVDTVD
GLVRMTDEVRKLVPAGVQLNVVNDTARGIRSSVKEVRSTLLEGAFLTVAIVFLFLGSWRS
TVITGLTLPIALIGTFGVMYLCGFTLNVITLMALSLCVGLLIDDAIVVRENIVRHNLMGK
DHRTAALDGTNEIGLAVLATTFSIVAVFLPVGFMGGIIGRFFHQFGITVVAAVLISMFVS
FTLDPMLSSVWHDPDLHGTGNKRSWYGRTVGRLLDWFSASMDRLGDGYAGMLGWALKHRL
ATAIIAAATFFGSFALVPLIGTEFVPNADLGETQVGFTTPVGTSIEVTEAKVRQVEAALK
SFPEVAYTYATINSGNASGRNNALVSVRLTERRARSLTTAQLNPLIRERLASIAGITLTM
VGMPDGAGGQKAIQVSIQGDDLDELRRLSREAGARMAAIPGLTDLDSSMKDDRPTIEVRI
RRELASDLGVGVAQIGNALRPLLAGDAISSWRAPDDENYDVRVRLPKDARTGMADLSALM
IASSHANADGSPKMVPLRQIAELVPTTGANQISRRDLNREVELTANVAGRSAGEVARDIK
AALDGVNWPAGYKYRFGGSTKSMNESFGYAVSALALAVIFIYMILASQFASFFQPIAIMT
SLPLTLAGVFAALLLFGSTLNMFSIIGFIMLMGLVTKNAILLVDFANQARQGGVDSAYGR
EPLSREAALVEAARVRLRPILMTTLAMIFGMVPLAFSLGEGAEQRAPMGQTVIGGIITSS
VLTLVVVPVIYTYLDDFGAWLRRLWQGEPRATAAAPAQAGSGQPAAGGRPAPAEASAE
>fig|164546.7.peg.2600 Permease of the drug/metabolite transporter (DMT) superfamily
MAHFPALGFRLLCMAGGLVALGVALRLRGDSLAVPRREWGTVVRLALPNMVVWHLFAICA
VKLLSSGRAAILGYTMPIWAVVWGLVFFRERIGAWAWLGIGCALAGTVLLLSGEFAALTG
SPAGTLLMLLAAAGWGFGTQLMKRTQTDVPIGAMTFWMLAVTLPFLALGTLLLEDGWRMP
TAIEWAAIAYNAVVVFAFCHLVWFGLARSLPPVVSSLSIMFIPVVGVFSGMWLLGEQPHW
QDYAAIVLMFLALSSVMLAPLLWRRLRGVPG
>fig|164546.7.peg.3574 Bacteriocin resistance protein, putative
MMKPLGILLACVPWLLATAHVPQAQAADVALYGPVGEPYSVRVTSIREARFKSTIRQQYD
FSCGSAAVATLLTYQYGHPINEATVFQNMYLNGDQQKIRAEGFSLLDMKRFLAALGYEAD
GFELPLSKLEETQVPAIVLIVENGYHHFVVVKGVKGNRVLVGDPARGTRAMSREQFERIW
DSQLLFVIHNRTERARFNVAADWRVAPSGPYWMGVNRDNLFFTVMPRHGAGDF
>fig|164546.7.peg.3690 Multidrug resistance protein B
MFGLTLGLVTGIDFSSTLMMGVASQHIQGGVGAAPEDYLYAISAYAATAVLMNMVLDQLA
RRITYKRFTMASLLVFIAGSLICAEFASPAGLITGKAVQGLGAGGLFAASRILVQLVSTP
AERGPLMLRFGGGAFSMLAITPWLTSIFLDDIGWRAVFLFQAGIALPVLLSVALTYPAPA
PRDSHPPVSTLDWPAAIAAALGALVFLHTLQEMRYTRFFSSLEMPLAALCGVALFAFSGW
RLYRHPDPWIDFSRLAGRQYLYGLGFYTLYYLLSSAWSFLLPTLTQTGLGLTFRTTCMLL
STSGTVSAIGAIVITLGMALVFRKRRVIAIGFIVYACAALLLSTQLMPGAPDYALVPVVL
LEGLTPVLLMVQVASMTYLDVPVEDFSHAYQFKNVCKQIASAMGTGLASVFMQDGLAQHR
THLVEHITRFNPVLQMPDALSAAGLAKLSQEVDRQATLLAGMDLLHGFAALCVAGAVFVL
VQRSFR
>fig|164546.7.peg.4367 Permeases of the drug/metabolite transporter (DMT) superfamily
MPASNPSTRRIDWTTLFLLTFPPLSWAGNAIVGRLAAGTVPPVALNWARWVLAGMLLAPF
AWRGVVEHRAVLRRHAGVITAMGILSIASYNALQYLALTSSTPINVTLIGASTPLFLIVI
GALCFGERVRPWHVAGALLCMVGVTFVLVRGELARLAQLDLVPGDLYMLAATIAWSAYTW
LLRKQRPALPLPVLLFAQIVTGVLASAPVTAWELLTLDQPLQWNGKVAGILLYVATIPSL
LAYFAWDRAIARAGAQLPVFFITLTPVFAALLSTVLLGDWPRWYHGVGLAAIAAGIWLAQ
RR
>fig|164546.7.peg.4630 Outer membrane component of tripartite multidrug resistance system
MGPDYRVPDRAAVRDAVANGPLQGAQAPHVAIAPVPDDWWRLYDDERLDRLITKALAANT
DIRAASANLRRALALLHEVESENLPQGSAGASVARAQLSGESFLQQAQPPVFNLGDLGLG
ASYLIDFFGKLARADEAALAGAQASEATLDMVRVAVAAQTVRAYVQGCAATHALHAAGQQ
LAVQQRTLDATRRLLAAGRAEPAEVARERARTEALRATLPPLQAARSAARYRLALLLGQA
PATLPDADVACDAEPALRAPLPVGDGAALLRRRPDVRQAERELAAATARIGVATADLYPS
IRIGASAGLTGVLSHLGSGPTARWSLGPLVSWSWPTNGVRHRIHGLEAAADAALARFDGV
VLRALQETETALSAYSRERERHAALHAASEHATQVAQQQRRLWQAGRVPWLAHLDAERDL
AAAQAALAASAGEVAGRQVDVFLALGGGWQTARRLAVVPGTMDEKND
>fig|164546.7.peg.4633 Inner membrane component of tripartite multidrug resistance system
MLALYLALALGLARPYWAMATVYFVSHPLTGATRSKAAYRVAGTVLGATAAVATVPQLVN
MPLVLMGAIALWISVLVYLSLLQRTPRSYVCLLAAYTLPIVALPAVSQPAQIFDIAVARI
EEIVIGIVCAGLVGSVVFPARVAPALRARAATWLADAAAWAADILGGSPRADHSRHRLAA
DILQLDQLISQLAYDTEGSYTLRHARALRRRMTMLMPLLSSLESVLQALRGHADGIPPEL
REALAATAAWLGSDAATAPPAALEGCGVPSRPGARGWHDGLAATAADQLQRLCALYAECR
ALQQGIGDRSAGTPPALGESGPEAAGHHHDHGMLLFGAVSSGLAVFCAGLLWIFSGWEDG
AGAVVVASIACCFFAAVDEPRRMAGAFARWSAVCLAISSGYLFLVVPHAHTFEALAAMLA
LPYLGIGLLVARPGFQLIAMLLSVNTAAFANVQAVFDADFLAIFNTCLASAAAMLFAPLW
SVATRPFGARAAARRLVRASWRDLAQAATLRAADGDARLGARMLDRLGQLVPRLGAAGDA
LSADGFHALQVGYCALALRRALPDLPQPARKPVRRVLAALARHFRAQLRAGHRVPVSARL
AAAVDDAMASMAASGPTGQRGTLGALVVLRVTLLPALAMTPSR
>fig|164546.7.peg.4971 Permease of the drug/metabolite transporter (DMT) superfamily
MLLCLLITYVVWGTTYLAIRFTLESFPPLFMMGTRFLCAGLLLGAWLAWRGTPMPSARQL
RHCAVPALFLLVGGMGLTAIAEQTISSGATTVMIGSMPIFALIWGACFGNRPKWFEYVAI
AIGSAGILVLTAGEEFQVSAGGVVALLLAVASWSFGSQLARRLDLPPGAAAFAAEMVIGG
AVLMALSLLRQEPWPSAVSAQAGWAWVYLVVAGSLVAFSAYMYLVSTVSQTLAASYVYVN
PPVALAMGAWLGGEQIAPQTLGAVVLILAALTVLSLGTLRAARAQAA
>fig|164546.7.peg.5085 Bacteriocin resistance protein, putative
MRDEGVVRQQYDYSCGAAALATLLRHYYGEAVSETDVLKQIAAKGPATLSTLSAAATHFG
YEARGYALSLEALRQINVPAIVFLHVGNDNHFSVLRSIDAHSVELADPSLGNRIYSTTDF
LRLWTTRLNRNYPGRALIVMPRDARRAANPAFMRPIPARFAGLTLRPFRP
>fig|164546.7.peg.5170 Inner membrane component of tripartite multidrug resistance system
MAGALGAAWAGAPDLAPWLHSLKVFGAAMLALGTALALGLPRPYWAMATVYLVSSPLAGA
THAKGAYRVIGTLLGAIGAVALVPWLVDQPMLLMAAIACWTGTLLYLSLLEPAPRNYICL
LAAYTLPIVALPTVTHPGTVFDIALTRIEEIVIGIVCASVVSAVVFPSRTAPALAARAAA
WMDHASRWTTDMLAGGASAGQRHDSFSTLAADILALETQMAQLAYESGNAHTLRRARALH
QRMTALLPLVLALADTADALRRHRAGMPEHVAQRLRATLAWIAGAAGSSRPPPSWYPAGR
APAAPADWHARLVAAACVYLDELGDLWQDCRLLQASLRQGGSDPAALRYRVEPAGQARHH
DHAQLLFRAATAGSATLVAGLLWMASGWVDGAVPVGLAALASCFIACTPEPRLVAGRVIA
WSVACALLSWYYQFVVLQLAHDFGSLAALLFGPYLVIGAMTTQPRFALFGVLLAVTAASF
PGPQNLGTASFAGIFNGSLASLAALVFAALWAVLMQPFGQQLVAYRLARANWNEIALAAH
PRAPVNSARLRGRLLDRLLRQWPPLTRRNHASHEQAANALADFLVEVAVLALRRATDRAV
ARVLAGVARHYRRCARAGHAIPPAPALAAQIDAAFAALATPAHGSPRAALAALATLRLAL
YPHDQDGRHARH
>fig|164546.7.peg.5282 Acriflavin resistance protein
MADHDLSRLKIDRQAAAAGVRLRPRRRWLRYAAIAVVLLALAGIAIRLASPRPVQTATVT
SAFPTQNFTLLNATGYVVPQRKAAVASKAQGRLEWLGVLEGSRVKKDEVIARLESKDVAA
SFAQAQAQVQVAQANLALQQAELKDAEVNLRRSRILIVPNAISRTQYDADVARFDKARAS
VNSSRASVVSAQANARAAEVAVEQTVVRAPFDGVVLVKHANVGDNITPFSAAADTKGAIV
TIADMETLEVEADVAESNIARIRVDQPCELLLDALPGLRLAGQVSRIVPTVDRSKATVLV
KVRFVDRDARVLPDMSAKIAFLSRAATAQDRQPVVAVQPAAIATRDGRQVVYVVRDGKAH
EMTVKTGNKLGELVAVQGVKPGDVVVLSPGDQIGDGSRVATSKP
>fig|164546.7.peg.5296 Permeases of the drug/metabolite transporter (DMT) superfamily
MPRPLSTAAWLPAAAFVLIWSTGFIVGKAIVPLADTSLFLLGRFAVAGLMFVGWSLAARA
AWPPLREAPRHLLAGALMQGLYLCAGYGAIAQGLPPAIMALLGALQPLLTALLAIPLLKE
LPSRRTWQGLALGALGVALVVAPAMQAGLDGAARPLSPWIVLLGVLAIVSITMGTLLQKT
AIATCDLRASSAWQSLGALLVAAAMVAVQAAGAPLHWHGAPALWAGLAWAAVGLSGAGTW
LLVSLVRRGQAANAAALMFLAPPLAALQAWLLFGERLSGVQALGMAVAGAGVWLCQTRGR
MRHAEAR
>fig|164546.7.peg.5710 Permease of the drug/metabolite transporter (DMT) superfamily
MTNNEDCAARFDAPRNTLATRTTSTALWATPLFVLLWSSGAIAARLALDHATPFALLTLR
FALVCAVLGALGLARKRLLPPRGERLHTACAGLLLIGGYAVFYFLALDHGMTPGVLATVL
GAQPMLTLLLTERRASAARLGGLALAFAGLAMVVADSLLLARLSPAGVLCALASLASMTL
GAILQKRSTRAPAEVLPLQYGASLAACLLCLPFQPFAFEASLAFAAPLLWLALGISIGAT
LLFYRLIHAGNLVNVTSLFYLVPAGTAALDYLLLGNRMTALALAGMGAVLGGLGLVFRGG
RNPMPG
>fig|167555.5.peg.1690 Permease of the drug/metabolite transporter (DMT) superfamily
MILPFALWGTSMAAMAPLVNAAGPEIVASLRLLPAGLVVLASVPFLKRSWNISKDDLVWF
LVFTLIDATLFQVFLAKGLMETGAGLGSVLIDSQPLMVALLARILFGDAINPIGWIGLVL
GLVGIICLGVPTELLENWFLLGNFESGSNFLSHGEVWMICAATSMALGTVLIRFACRNSD
PVAVTGWHMVLGSVPLIVWHVFDKNWPLFPDWSAFEWTLMSYSSLFGSALAYGLFFWFAS
RKELTSFSTLAFLTPVFALITGGIWLGERLFLLQWIGVVLVLISVLFVSQRRRFWGNKSD
NELIKEA
>fig|167879.3.peg.97 Permease of the drug/metabolite transporter (DMT) superfamily
MTVTSPRIATILLLIVCFIWGVEFVPIDLAIEVMPTNTFNAIRFAVATLSMLPLLWFVQK
KNKGNSKPIDYVLLIRSGMLLGFFLFIGFYTQTEGMRFTTVTNAGFITGLCVPLVPVLGF
LIFRNVVPKSVWIGVVTATAGLYMLTIGDKLVFNKGDILVLICAFGFAGHIIMTDRFVDN
LPIIPLSIVQIFAVSIYSTIAIFIGPDPVFYYQDAEPVSWYQQLFTPLMIFAILVSGILG
TAYAFWAQSVSQTLLKPHKVALIFAAEPVFACIAAWVFLDEVLGEKGMIGAGLILAGMLV
SELGDRKKQPELRALDQTAALK
>fig|167879.3.peg.540 Acriflavin resistance protein
MNITQVAFTYRKSVFLIIAVLLINGLFAYFTLPAQEDPTITIREAIVSTSFPGMAPDRIE
QLITKKLEEEIRKIPQVKEIKSSSATGISIIHVKIYDRYFNLDDIWQNLRNKVTAAHNKM
PSGTHTPFVNDEFGDVSVVTLALTADGFDLGEMYDIAQHIRDTLYGVEGTKKIEILGRQE
ERIFLEASNAKLAQLGISPQSLINELQKQNIVRSGGEVNTGAISFIVEPSGNFNSLVEIG
DTYISIPNTEDFIALKDVVTLRRDFIDPPDKTAYLNGQSAIFFAISMLPENNLLEYAPRV
LNKINEIESSLPIGYNLEIATYQADQVAKTINGVSVNVLQTLAIVLVVVILFLGLRTGLI
VGAIVPFVMLTTLSIMQFSDMKLERMSLATLIISLGLLVDNGIVIAEDFKRRLEDGVDRY
NAMLQGSKELAIPLLSSSVTTVLFFLPLMLAEHVAGEYTRSISLVILITLLTSWILALCV
TPLLCYFFITLPENKKAKVENNESTREEPGKFYRYYETFLHWLLKHKALFMTAMLALFIG
SILSMKYVAKQFFPDSDRTQILVNIDLPNGTSSTETNRQMKDIFTWLEDETRFDFIESYS
AYVGFSGPRFVMSLNPEDPAQNKGFMVLNVKDETDISATVLSLDEQIEHDFPNVSARVKK
MFLGPSDSSTIKIQVKGPDKEVIYKKAQQIMAVLHDVPNTIDIRTDWENLITKIDVQIDQ
HRAKRSGLTSEEIAQALDAYFSGSKITEFREGDNIIPVVLRAEQAERQSLDRLRTLNIYS
NKTGKTVPLFQVANLAPYNQFSIIHHEDLFRTISIQARNTDVAAEDLKLIIDAKIQALAA
DLPINHNIEYDGVIKESRAAQKALGASMPIVLGLILILLVAQFNSFRQAAVITLTIPLSF
IGAVLGLFLMQAPFGFMVTLGLYSLAGIIINNAIVLIDRIKIETASGKSDYQAVVDACLT
RLRPIAMTTITTVMGLLPLIIGKDPLFYGMANVIAFGLGIGTILTLAVVPALYCGFYKIT
DVQVEPV
>fig|167879.3.peg.1801 Multiple antibiotic resistance protein MarC
MNLLMEHALTVFMAFFAIMNPIANTAVFAGLTGDKNKLEQRKIAAKALIITFIVIASFAI
LGKSIFHLFGITLPALRITGGILVFIVGYHMLQGSGSKLHHTQGDDSSDSDVAVSPLAVP
LLAGPGTIATAMNYSSSNGWMEIIITLSVFAALCLITFICFIFSSRILAAIGKSGLSIVT
RLMGLILAVIGVQMLLVGIKAVISTLG
>fig|167879.3.peg.1823 Acriflavin resistance plasma membrane protein
MTAKSLMKSKSITSNKSILSAPSLWMIDNPIASSLLTFSIIILGLLSFNSINQESSPSFQ
INEILIETSYPGATPKDIEQGIILSIEHQLRDNPNIDRISANAYEGSAEIIVELIEGVNP
DTILSQVKNSIEGINSFPVEMENPTITFVEELDSIVEIGLHGNVSELLLYREASQLKQAM
LDALDLAKIDIQGARSPEIVIELNQVKLRQYQLTLAQVLSKVKTSVTDVPAGSINTQGGE
ILIRTLGRKELSEQFSDITIITDDSGNSVTLADIATISDSFQGQIRPFKVNSDAGLELKV
YQNKNSKPIEISKEINAFITDYQSEIPAGLTLTILQDQSDPFSQRINLLISNGLIGMLLV
ILVLSIFLDLRLAFWVSMGIPISIIGTLGLMPLLDIPINMITLFAFIITLGILVDDAVIV
AENIYLKIQQGITMNIALKDGVKEMTLPVVFSVTTNIIAFIPLLYVPGELGVMYKPMTLL
IFAIFTVSLIEALLILPLHLRHIDKPMRFRVISNVQAHCFKRFDHLKTAIYAKWLRTSCN
NPVTIIIIFLSLATLVFSWVYSGRVDSSFVPKIESTRIDAEVEFPTGAPLKNKIDIINYI
EAAGIKAIESLNGQDDYKFRMQDIGSSSGSSTFMIVTDDQRNFTAKEFVDAWRINIGEVP
GVKSIFFDYQVGPGGGKELVIELGHKDADILTLAAKELMNGLNRISGVTDIDSALMDGKL
QYNLTPTPLGKSLGFNSDNLGELIRLRFFGGEAIRQIVAGDEVKVRVMMQRSQQYYANQL
NRLIITAPNGDSVELSQVASITTTKAATSINRVDGIQLVEVTASILRQVASASLILKTIE
EDLLSNLSAKYPELEVELGGEARIESKVNAEIIKGIGLAFALIFAMLAIIFRSYLDAILV
LLIIPFCLAAAMLGHIVMGYSFSVMSLFGMIALSGLVINGSFVMLLKVKALRKEGMGHKE
AVIEAALNRFRPVVLTAVTTAAGLFPMLFETSTQALYLVPMVISLSFGSVFSIATILLLS
PAMFTLSEQFKVNNEKTESLTKSTINTSKVRAFG
>fig|167879.3.peg.2319 Acriflavin resistance plasma membrane protein
MFKSITKESATDKKAAQKYNSIAWMINHGIAPNLLMLLLIVGGLVMSFIIRKEYMPDVTL
DRVGIVINYPGASPDEIESAIALPIEAIITPLEGIKEVKTIIRTGRLFIRAELEGSDNAQ
KIFQDVQQAITRINTFPTEMDKPRIFLASKVRDVMEIVVHGDLDAIGIKRLSEEIRDRIL
QSVDISKVTLHGTAKEEIHIDISQHMLNSLQTDLSTIAKKISLLTKEQSTGTIKSNSGNI
LVKVDERLLWADEFAQLSIMPDKNGGALQLKDVAKITEGFADSKSMITFDGQLAASLRIY
RVGEQSPDKIGKAIEAMWPELEALLPPTAGLTIIDDDAKNYQKRLSLLLKNAFFGLLLVL
FFMSLFLDFRLAFWVVAGIPSAFLGAILFLPSFGISINMVSMFGFIIALGIVVDDAIIAG
ENIYTHMQEGMPFSSAAQLGAQEVAKPLTFAILTNIIAFIPLLFLPGFMKLMFGAIPVVV
ILCFVISWLEALFILPAHLARINQKTTKTPGNNILSKSAYYFSFAMQKAQQNFDKALESF
IQHPYLSVLKKCLSWPALTLSIASLILLWVLGYAFSGKMGFSLMPKMEGRWVKASIVLPE
DFTLMQMNKVKDKLESNAKEMLSKNEIEQAVISIRSEIFENTLEVGLLLVDSEEREISSV
DIKSLWREQSKLLGKQSLNNLGKLRFGSARKNSNSQIEASITLELRHNDTNVLSNAAIAA
QNYLQSDQQSGQYITSITNSMEQGNPQWSLTLNENGQSLGFNGSDVAKQLRSSLYGARVT
RQHRGQNEVTVLVRLPLRERQSSGDIENLLISTGDGGFVPLNEIANISKTYSPATIKRYK
NQRIEQLYIEVEDETKTPQVNDFIHQQLTLRLTRQFAGLKVSMSGDQKEIAQSVSKLELG
TLFALTGIYILLAIAFKSYLQPLLIMAIIPFGAVGAILGHLLLGFGLSIVSLMGMLALAG
VVINDSLIMVEYANKQVTQGHKPKQAIINAGMRRFRPILLTTLTTFGGLAPMVFETSRQA
QFIVPMAVSLGFGILFTTFICLLVLPCLYLITSEYNDIKA
>fig|167879.3.peg.2693 Permeases of the drug/metabolite transporter (DMT) superfamily
MEIWIYFTLLAATMQAVRTAGQKQLSGKLNSMATTGVRYVFALPFAWAYLWWMLDFRQVA
VPALNNDFLQYALIACVMQIVGTVCLVAAFRYRNFAVATSLAKTEAIQVAIVGALVFGAT
LSGLGWFSVIVGVVGVFLVSKVRFNLRDILADSQGLIGMGYGLAAGLGLAITTLLIRESS
LALNTDLMVSAAVTLVFMITVQSVISLIYVYIQDKSQLPLMMKHWRLCLFVGVTSVLGSI
GWFTGASYQNAAYVKALGQVEFFITLALTYRVFKETVTLKEYLGMFLIVLSVVILLLWS
>fig|167879.3.peg.2798 Permease of the drug/metabolite transporter (DMT) superfamily
MSVSIAYLAVLLIWSTTPLGIVWSSESINPSLAVLLRMLIALVLGALVIKIRNIHIPWHK
QAVKLYSFSALGIFGGMLCSYLSAAYLSSGIISLVFGLSPVISALLAKKILSEPNISGMR
KFSMAISLIGLAVVCSDNFTLADDGIYGIIFILMAVFFFSLSGVLVKSVSLAIHPLATTV
GALSVATPLFLVSWLLLDGTLPIETWQAKSLWATLYLGVFGSLIGFYAYFTVLQKLSASN
VTLITLITPVIALTLGAVLNGEVINDKLILGAFMVLLGLSIYHFGHLLPRLKKKRARS
>fig|167879.3.peg.3142 Permeases of the drug/metabolite transporter (DMT) superfamily
MTKSTPHPSSIIKAEQQSLLYLHIAVFLFGGTALFSKLIGLPALDITVYRTGIAALALFI
LLTLQKKQISLSSMKDYGIAILLGCVVGLHWVTYFTGMQMAGVTVGMIAFFTYPVITVFI
EPFFNRTVPKMKDMITAFVVIIGIVLLIPEISFGNQITLGIVTGIISAVFFALRNILHKN
YFSHYSGPHTMLYQTLVACLMLCLFVEVPPMQVTESDWLLLLLVGVVFTATPHALFASSL
RSLSATTAGLISCLQPLYGSILAIILLHERPDILTIIGGLLVVSAAIFETWSVSRGRR
>fig|167879.3.peg.3176 Acriflavin resistance protein
MNYTRAALKNPAAIIVIVVLVMVFGLLSVAKLPIQLTPDIEQPQITIFTGWRSAAPSELE
SVIIEPIENVVKNTQGVIRVDTSINQGFGRINLTFDVGADMQKAMLDVINNLNQVPPLPI
DAIEPIVSANGGGNTATMMIKTLPDNPVEDFGQYQKLIEDVVEPRFARIPGIGEVNLASH
RQREIRVTFDPVKTASLGLSIAEISSVITNSNDTSAGTVNVGRRQYVVRFSGQYSLDNLT
QMIIGYSDERPIYLQDIATVDNTLADRQGFNLRNGQPSYYLTLRRQNGENIVALLDKINI
AIKELNEGPLKAEGLTVDLSFDSSVHIRNALSLVQNNLGLGVLLSLVILWLFLRGMRNIL
IIAITIPVSLLVAFVALSLFDRTLNVISLAGLAFSVGLVLDAAIIVQENIVRLKSKGMDN
HKAVLKGTTEVTGALFASTATSVAIFLPILFMKGIEGQLFSDLALTLSIAVIASLLSAIT
VLPIASKYLLKDVSDIDPFAHYWERLTVLVMKLTNSKFKRVTWISLLLAGSLIISFTLLP
KTDFMPRAPTDGFFFSLDMPPGGNVDFIEHEMASLVKKRLAPYLTGEKSPKIKSYNFYSF
GSNATGGFIYSDDPSRVEELMKVVKADVFSGLPDTEVFMFRGSMINISGNGNGRTIDIDI
HGTDIEGLMEVAKTGIAAINENMPDTTAFPIPSLNLAEPELNLLPNDQRITQAGLNRSDV
ARAISAYTSGLFIGEYFDGNHRSNIILRGEQWETPDELAMMPMHTPLAGIQTLGELTHIT
RSAGPTELKRINGKRTVSIQVSPPATMSLEEATALINEKVIPKMQLDLPENSAISLSGNA
NQMASAISDMISNFILALLILFLLMTALFKSAKDSLMVLLVMPLATAGGVIGLSILNIFT
YQSLDLLTMIGFIILLGLVVNNAILLVDQTNQGGLEGLSRCDAVAQAIRIRARPVYMSTL
TSLFGMLPLMLMPGVGSEIYRGLAAVIVGGMTVSAIFTLVLFPSLLRMTQGKHASPTTNI
VSISATEQELRISNR
>fig|167879.3.peg.3260 Glyoxalase/bleomycin resistance protein/dioxygenase precursor
MKLGAFSVSLAVSNIEASKVFYQKVGFEVIGGDQTQHWLILKNGEHTIGLFQGMFEGNIM
TFNPGWDKDGKTLESFTDIRELLKEFEAQDVEIIQQSISGESGPSSFSIKDPDGNAILID
QHV
>fig|167879.3.peg.3458 Multidrug resistance efflux pump
MDMLIILTYTALCVAIFKTFKIPLNKWSVPTAVLGGVVLLSSIMIIMNYLHPYAKYGKEV
FATIPITPLVAGNIKSVDVIPNIEVKKGDVLFTLYNEEQTIALEKADAAVEQAKNQVLQN
DQALLAATGQVAKADANKDRTKASYYRYMEGHLKGGESSPFTQQELDNRREFYEAALASL
DSAQATERKVRLLTESNILGENTQVAQLKAARNRAQLDLERTFVRAPVDGMPTQVALRPG
MRAGILALRPVMSFIPTEKRRFAARIWQNSLLRLEKGLDAEVILDAVPGHVFKGKVVEIL
PAMAEGEYQGNGVLRGAGSLATHGFTIAIIELEENLDDYNLPRGVQGQAVAFNPKGDFLH
TSMVRKILFRMMSWIKYVYPIK
>fig|167879.3.peg.4022 Permease of the drug/metabolite transporter (DMT) superfamily
MSKSLGFKVSVSFVNIFALPFFFVLLYGSGFVGAKLGLPHSTPLSFLSLRFMAAGLILLI
IAKLIGNQLPNWREAIHISVAGSLTVCLFSVGVFVSIDMGLSPAVSALIVALQPILVALF
ARKLVNEQLNLAQWFGLLFGFLGVIVVVIDSIETTSFSWVAIAMSVLALFGVTFGSLYQK
RYCADMEIFYGGAIQSLVSGLICLALLPFFESFKVVWTGEFIISLVYMVVGVSLGALSLL
YIMIQRGEVSRVASVFYLVPVSAAVSAYLLFGETIESTTLFGASIIALGIFLTNRKSQNN
MVVSMNK
>fig|167879.3.peg.4315 Multidrug resistance efflux pump
MSEQEQQKDATVQEAKTVIETQDPVRKITKYVLIITALIFVWYIIADRHAPWSDQARVQT
YVIPIVPQVSGRVIEVLVKQDQIVAPGDILFKIDPSDYELAVENAEASLEMAGQEIGAGM
ASVVTAQAQLVVAETNVEHVNAQSSRVFEMEDKNVLSHSEGDKARAAIKASKAQVVSAEA
NLDKAKQSLGKEGNANPRIRAAMAQLKKTQLDLSRTVVLAPSYGGITNLQIDTGFYAKAG
AASMTFIEGNNAWVQVNLRENNLANLAIGNSVEIALDVNPGTIYQGKISSIGFAVDTSST
SAVGGLATVESKTGWLRDAQRFPVMITFDDDSTKGKRRLGGQADVQIYTGDNWFVNSLGW
LWIRVLSILSYVY
>fig|167879.3.peg.4769 Permease of the drug/metabolite transporter (DMT) superfamily
MKSKQNQSKQMTGMLYSLLGVLLLTPDALILRWVTIEHSEVLLWRGIFFSLGFSFIVLVR
HRSNAVRALINAGWPGIITGFFFAMNTYCYTQALQQTGAATAMMIISTAPVFAALIAWLW
LGERISLPVGLTITMTLLGMAIIVSDGDDGNSLFGNMMAMGCAIFMAINFNWARRYASLD
ITPGLIFGGLFIIALGWFNTSVVAARPDEIGAMFLSAAIAMPIGFVLLQIAPRYISATEV
SLFLLLESIIAPIWVWLGLGETPSNITLLGSVIVLVALLLYCYVVRLKAQTILTTKEA
>fig|169963.1.peg.108 Multidrug resistance ABC transporter ATP-binding and permease protein
MESMKWIWQYVRKYRLLMIGVFILIFIASGISIIYPLLGGKVIDDVVYQNKTNLLIPLLL
IMIISTIIRTICRYTYQIMCERIGQNSLFRIREDLYKKLQSLDFDFFNNTRVGDIMARMT
GDTDAIRHFVSWVSYNILENVFLFSFAIIIMATIDWKLTLALVIVTPLIAVLTMKMSSKA
QPVFYEIRESFSRLNSMVEENISGNRVVKAFAREDFEMKKFHEHNEDFKKRNLDSADVSR
TYLPVLDSLAGMLVVITLIFGGYLVIKGQMTLGDLVAFNGFLWMLNGPMRMSGWLINDVQ
RFIASSFKIQDMMVTDAKIPIHAEKPAPSLQGHVEFKNVSFHFEDDPNTDVLKNISLKAS
PGQTIAILGETGAGKSTLVNLICRFYDPTSGEILIDGVDARKWHVRELRNHIATVMQDIF
LFSDTIEGNIAFGAPDATMEDVRRMARIADADHFIETMPESYDTIVGERGVGLSGGQKQR
ISLARALLKNPSILILDDTTSAVDMETEVKIQGELKKITENTTTFIIAHRISSVKEADEI
LILNHGEIIERGTHTSLLAEKGYYFDIYNKQLGTEANVNG
>fig|169963.1.peg.490 Permease of the drug/metabolite transporter (DMT) superfamily
MQKEKAPIGLYFLLIAVMASWGFNVTMTKVLVSYFPTVTMTSFRIFTAAITVIIILFITK
KLRLPTKQEFGLILLASIFNIVIHHFFLSNGLKLTTGTNAGLILGSAPIVVAIFSVIFLR
ERIGAWRALGFLAGIFGVSLVVLSNGTGISGISLGDIDIFIAMASQAFSFIIIKKLAGSM
DTGLMTGYMLFLGSVMLFGLSRFMEPDGMSELVTVHSWKLWLLFVVSAVVATAFGNFVYN
YAVGKIGPSRSAIFMNFNPLFSLIGALLFLGEAIKIPQLVGFGFIIIGVLLGSGALMDLI
YERKKTKVRDPEKLLEKEV
>fig|169963.1.peg.514 Drug resistance transporter, EmrB/QacA family
MQQEATGGQKIRPIPIIASFLMAGFIGLFSETALNMALSDLIQVFDISSATVQWLTTGYL
LTLGILVPISGLLLQWFTTRGLFFTAVSFSIAGTLIAALSPTFAMLMIGRVVQAVGTALL
LPLMFNTILLIFPEHKRGSAMGMIGLVIMFAPAVGPTISGLILENLTWNWIFWISLPFLI
IALLFGMKFMQNVSVVTKPKIDILSIILSTLGFGGVVFAFSSAGESGWGSATVLVSIIVG
GIALGLFVWRQLTMEKPLMDLKVFKYPMFTLGLILVFISFMMILSTMILLPLYLQNSLAL
AAFSAGLVLLPGGVLNGLMSPFTGRLFDAYGPRALVIPGFIVAVVALFFLTRIEVGTSAL
TIIVLHSVLMIGISMVMMPAQTNGLNQLPPKLYPDGTAIMNTLQQVSGAIGTAVAITIMS
AGQKAYMETAQGVGPEQMVASLTAGIQNAFVFGLIMACIGLLCSLFIRKAK
>fig|169963.1.peg.738 Multidrug resistance ABC transporter ATP-binding and permease protein
MLEVKHLKKSYKLGKKNETPVLKDINVTIQDGEFAAIIGKSGSGKSTLLNIISGLDTDYE
GKVLYNGEDLQDIDLDAYHFNHIGFIFQSFHLVNHMSVVENVKVPLYLNPELSESDRNAR
ALDLLKQVGLEDFASKKPTQLSGGQKQRVAIARSLANNPDMIIADEPTGALDSVTSDEII
KLLKALAAKGTTVIVVTHDLNIADQTDAVLRLADGEVISFERKKEVVQKVTHKNEKKLRL
NWWATAKISFKSFFNRKFRNLLVALGTSIGIIAILLAFGLGNGVNQSLSKIFGTTFSPNQ
ITTYYKEDGGSKSPEPTTPLTSSEIKKIKQLYEDENITEIYERTTVQGIKFEYDGEYLKG
ISGEMQEANFKPSRYEDLTVKDEYLLSGKMVTSDETGAVIPSSVAKAILGKKDSDELTKS
DGDKLIGKKITLVYAGRNSDTKNTVKTETTISGITNPSKEGFARGFDVSTKTMNDFIKTT
GIEKPILSVDAFTKTTAEAEEIVEKYEDNKDWANYSITNANAFVDTFSQFTDIIVYLIAF
IAGLSLAVAGVMIAIVLYIGVVERTREIGVFRAIGYRKRHIRGLFMMEASYIIILANVLS
SLVAVTIAKIASPILETKIGFEDMIHISFWNFLVTLAITITIGFIFSIYPSNKAAKLDAA
EALRSE
>fig|169963.1.peg.973 Drug resistance transporter, EmrB/QacA family
MEQTKVKAVTIAVFVATFMAAIEGTIVSTAMPTIVSQLDGIELMNWIFSVYLLTSAVTVP
IYGKLSDLYGRKNIFVIATIIFIIGSSLCGFAQNMEQLIIFRAIQGIGAGGILPSTMTII
ADVYPFEKRAKVLGFMGSAWGIAGVFGPLVGGFLVDQLSWHWIFFINVPIGILTILLILL
YLREKVEHVKLPIDYLGASLFTVALLGLLFALQRAGESLNWTEPLVVILFAVSIVLFIAF
YFVEKRAKDPIMPFVLFKNPVVLIGNLIGFLISAFLIGINVYIPMWAQGMLGHGATIAGF
MLAPLSVTWIIGSFIGGKLLMTLGNRHTVGIGVLITAASGLILALFPASTNDIFFYLNSA
FMGFGFGIIFTTTTVTVQDAVPRFQTGIATASNTLFRTVGQTIGVAVFGTIFNSVLTSEF
RAAAGSEVNRSNLNQLISPQTSGNVSTDLVDPLRDILYSGLHTVFWVMFACCIVSYFIHF
ILPKKHISGEK
>fig|169963.1.peg.1838 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MQQTVTYGAKWKQFLTIFTPIVITQLTLFSMTFFDTTMSGNYSNQALAGVAIGSSFWAPV
NAAFSGLLMAITPIIAQLIGAKKEKQVKNTVHNGLYIALFLAFILILINFLVVPMILTHM
PVTAEVADIARHFLNGICIGIPAFFISAILRSFIDSLGLTRVTMLITLCTVPFNIFLNYC
FIFGNFGFPEMGGAGSGYATGITYWLVVLVSVILIQTQTRLRKFGVFKGLTALRFSKIKE
IIGIGVPNGLTILFETSIFSAVTILMGAFGTETIAAHQSANSVCTLLYAFPLSVASTLTI
LGGYETGAKRLKDAKQYRHIGMAAAILIGCVNGAILFFFRDIIAGFYTNDPALSNLIMHF
LVYAILFQFADAVLSPVLGALRGYKDVTVTSIVAFISYWLIGLPVGYGLSFTNLGPFGYW
IGLSTGLFVAAFILSIRVRKTEQKLSFNTKDAEISN
>fig|169963.1.peg.2078 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MAKNMEILETDSVKKIYFRYLIPSLVGMLLMSLNIVIDGIFVGHKLGGVALAGINIAVPV
FTIFTAISIWIGIGAATQFSFAIGEKNVAKAQTIFTNAILAVVSITVIIGIIAFIFKVPL
AYFLGANDDTIGYVLEYMNILLVFGFALTLENILSIFVRNDGDPNLSMIALIVTAISNVI
LNYLFLFVFEWGVTGSALATMIAIIIGVLILTTHFFKKSSRLKFVKVDWNKAFFKKTLAI
GLPSFLAEVGVSVFTLGYNISIAAIAGTAGVAAFSVLNYTHSVILMLFLGMGSAIQPLIS
YYRGAKARQKELETLKIAIVVAFSTGVGFLLVGFFGSNLLVSMFGNFSVEIRELASNGIK
LFYTAYLFMGFNFVMMTYFQTSDKVKMATWITISREIIFMVIFLLVLPPIIGIPGVWLAI
PISEMIVAASIVFYMKKKHILFK
>fig|169963.1.peg.2578 Multidrug resistance protein
MNSTAVERPVDVNGKSYSRSLLVVTMIIGAFVAILNQTLLATALPMIMDDLHITAATGQW
LTTAFLLTNGIMIPITALLIEKISSKTLFITAMTVFTIGTIIASVAGSFPILLTGRIVQA
AGAGIMMPLLQTIFLLIFPREKRGAAMGLMGLVIAFAPAIGPTLSGWIVDSYDWRVLFLI
LIPIAVIDIILAFFGMKKVVKLTDTKIDFLSIVMSSIGFGALLYGFSSAGNDGWGDTTVI
TMLIVGVVVIALFVWRQLVIDNPMLELHVFKYPVFSLSVILGSIVTMAMIGAEIVLPLYI
QTIRGESALQSGLLLLPGAIIMGIMSPITGIIFDKIGAKWLTITGVTILTIGTIPFMFLT
MDTPLWYIVVFYAVRFFGISMAMMPVSTAGMNALPNHLINHGSAVNNTIRQIAGSIGTAV
LITVLTNVTKDNMPGKALMATDPASFAQKAQDASLDGMRAAFMVAAIFAAIGMILSLFLK
TKKQEPIVKEYTK
>fig|169963.1.peg.2714 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MKEQSKRLGEDSIPSLMARLSIPAFIGMFVMGMYNIVDTIFVSYGVGPSGVAALSIAFPV
QMILMAMAAMFGIGGASIISRSLGAGEQKHADKVFHQVIWLVLISSIFIAIVTFIFLDPL
ITLFGAPADIHDIASDFLSLILLGAVFQTFAMAMNNIVRSEGNAKTAMLTMIISAILNMI
LNPIFIMGFGMGVRGSALATVIAQAVGAIWLLIYFLSGKSTLSLKGFSFRMDFPLIRRIM
AIGFPSFIMMSAGSIVTVAVNWMLNIYGGTMAIAVYGIANRIASFVIMPINGVTQGMQPI
VGFNYGSRQFERVMKAVKVSMIAATVMSLIAWGLVEIFPGLLVRIFSNDPELIAQGTTAV
RFMLLAAPTIGFQIVCGGLYQALGRARISFIISLMRQIICLVPLLLILPHFFGLDGIWYA
FPLADLGAFAVCLVIMSKTWRRIFKNPEIV
>fig|169963.1.peg.2902 Multidrug resistance transporter
MNTGKWITAAASLLAFMGIGVVDPLLPSIAESIGASHSQVEMLFTAYIFTMAIMMIPIGI
VAGKMGDKKLIVIGLFIVTIFALLCGLSDTIGALSIFRAGWGFGNSMFMATAMTMLIALS
ETPGHAIGIYEASMGLGMAFGPLLGGILGNISWRYPFFATACLIFIAFLLILFKVKEPKK
VAPAPTEKNEVAIKQMLHLFKYRPFLQIAFSGMFYYYCFFTILAYSPLVLGLSAIQIGFV
FFAWGLCLALGSAKVSHALEIRFNSKQILKGSLLACAVILALLGFIDNTAVDIGLIVISG
LILGINNALFTTTVMEHSPYARSVTSGAYNFVRWLGAAFAPLCSGLLSEALGMKMPFIVA
SIICLAGMGLLFIKLKPAHFTLQQSTSIKSE
>fig|171101.1.peg.50 Teicoplanin resistance protein
MLESKKTTRYVFYVYLMLLTWGILFKFETNPEFIAFFLAPRYINWIPFSEPLIVDGKIVF
AEMLFNLISFIPLGVCFPLIKTNLSSLRIVGTGFLISLLFECLQYILAIGITDITDLTLN
TLGVCVGLLIYQIFIRVFKSQTRKWINILGMLSLGFAYLVLLLLHLIGV
>fig|171101.1.peg.137 ABC transporter ATP-binding/membrane spanning protein - multidrug resistance
MYTIIKSNIKKFSLLTIFIVAGQLLLIYAATINALVLNELIAMNLERFLKLSIYQMIVWC
GIIFLDWVVKNYQVEVIQEFNLEIRNRVATDISNSTYQEFHSKSSGTYLSWLNNDVQTLN
DQAFKQLFLVIKGISGTIFAVVTLNHYHWSLTVATLFSLMIMLLVPKIFASKMREVSLNL
TNQNEAFLKSSETILNGFDVLASLNLLYVLPKKIKEAGILLKMVIQRKTTVETLAGAISF
FLNIFFQISLVFLTGYLAIKGIVKIGTIEAIGALTGVIFTALGELGGQLSSIIGTKPIFL
KLYSINPIESNKMNDIEPKEVNRDFPLYEAKNICYKYGDKEILKNLNFCFQRNEKYLILG
ESGSGKSTLLKLLNGFLRDYSGELRFCGDDIKKTSYLNMVSNVLYVDQKAYLFEGTIRDN
ILLEENYTDEEILQSLEQVGLSVKDFPNNILDYYVGDDGRLLSGGQKQKITLARGLIRNK
KIVLIDEGTSAIDRRTSLAIERKILDREDLTVIIVTHAPHPELKQYFTKIYQFPKDFI
>fig|171101.1.peg.1734 Multidrug resistance ABC transporter ATP-binding and permease protein
MILLAILFTCFSVYLELEVPTYISKITDLLGSQGTNLDELWQPASMMMGMPFLAFLSVVA
VGFFASRVAASYTSRLRSDIFNRVLDYSQTEIKKFSIPSLLMRTTNDITQVQMLITMDLQ
VVTCGPIMAIWAIGKILGHSEYWLWAVLVAVIVNVLMTTVLMTLAFPKQSLIQGLTDKLN
SITRESLTGIRVVRAYNAEDYQNEKFAAVNDELTR
>fig|171101.1.peg.2134 Drug/metabolite transporter (DMT) superfamily protein
MSNSLKGTLLTVVAGIAWGLSGTSGQYLMAHGISALVLTNLRLLIAGGILMLLAYATAKD
KILVFLKDRKSLLSLLIFALIGLFLNQFAYLSAIQETNAGTATVLQYVCPVGILIYSCIK
DRVAPTLGEIVSIIFAIGGTFLIATHGQLDQLSMTPAGLFWGLFSALTYALYIILPIALI
KKWGSSLVIGVGMVIAGLVALPFTGVLQADIPTSLDFLLAFAGIILIGTVFAYTAFLKGA
SLIGPVKSSLLASIEPISAIFFAFLIMNEQFYPIDFLGMAMILFAVTLISLKDLFLEK
>fig|176279.3.peg.1878 Chloramphenicol resistance protein
MKDNKMLFIIFMIGTFTVGMAEYVVTGLLTQIADDMKVSISSAGLLISVYAISVALIGPL
MRIITLKVHAHRLLPILVAIFIISNLVGMLAPNFNVLLLSRLMSAAMHAPFFGVCMSVAA
TVAPPAKKTQAIALVQAGLTIAVMLGVPFGSFLGGFANWRVVFGFMIVLAIITMLGMIKF
VPNVSLSAEANISKELTVFKNPHILIVIAIIVFGYSGVFTTYTFMEPMIRDFSPFKIVGL
TVCLFMFGLGGVIGNLITGNVPEDKLTKNLYLTFLLLFVTIILFVTVIQNSILALIICFL
FGFGTFGTTPLLNSKIILSGKEAPLLASTLAASIFNVANFLGAIIGSILLSIGLPYIQIT
LISGGIIVLGMLLNLVNQLYEKKHITFNEYS
>fig|176279.3.peg.1946 Multidrug resistance protein
MLEITVLVFITIFGVGSQFFSNLAYSLNQGILQTSFGIGSQYLIIPSVLANFTFALGIPL
GHTLTHKYGFKRNYLCFVFIFLIGSILGLLSFNLIILSIAKMIQSFSSGVLFFTLLPKLF
LNFPKQYRNVFLLMVIVGLFGSNALGGLSGSLSLELDRWHWIFVVNIISAILCLILGNVI
LRKNEYHQTSDIHISRSMMITLVLSTISLMIPMSLLTQKGYHSLWVWPILLIAIFFIVNF
IITNRQATHPIVHFHTLFSKKPFVGATMAISSHLTLLTGIAGINVYIVRILKLPFDISLH
FYFFFFVGVIITGILKMFFYSSVGAGFLGTLGSSALLYVSIHWIILGNTINIPLLYIQGL
LLGFGASMTLVSGSMATLLDGDLKEAAQRSQTMHTIRNFSAAMLIPIIAYTIKNHIQKGT
QSIYAENITDKMIYLKKLQDVAIDADHQIFLLMIIFNMVMFVSSIIQMILGKGRRITPPR
ES
>fig|176299.3.peg.55 Permease of the drug/metabolite transporter (DMT) superfamily
MTRVQANMLLLLAAAIWGGGFVAQSSAMSSIGPFWFVGLRFAIAAIAVLPFALMETRSLK
SPPRRREIGSFILVGLALFGGATTQQVGLLTTTVTNSSFLTGLYVIFVPVIAVVLYRRHP
HWVVWPCALMMLGGIFLLSGGAFETLTTGDILSIICAFFWAIQITLAGRFVSESGRPLAL
SFTQFAVCSLLSCMIGVVFEPISMAAIEASMMEILYVGLVSSGLAFVLQVIGQRYTTAPQ
AAIFLSSEALFGALMASIFLKETISSAGYVGCLIIFVAILIVELVPELTRKRQKTVAEAS
>fig|176299.3.peg.222 Permease of the drug/metabolite transporter (DMT) superfamily
MALPHIFLALITVFLWGFNFVAIKVGVADMPPLFLTGVRYLFAAVPLVFFLPKPNVPWRH
MIVYGMAMGFFQFGLLYPAIKLGLPAGLASLVMQSQAFFTLALAVVFLGERPLPSQIAGA
IVAFGGLAVIGMERMTAAALIPLLMGVGSAIAWACGNIVNRRIGQVNVVSFIAWTSLVPV
LPLVLLSLVVEGPDAIVEGLQNATPTMALVVIYMAYGATIVGAGIWSYLLLRYPAGTVAP
FSLLVPIVGFISAYLAFAEHITIFEIIGAALVILGLALNVFGRRIGVSRFWVRSPQG
>fig|176299.3.peg.1128 Glyoxalase/bleomycin resistance protein/dioxygenase
MAAMMRFPLVCRPEDDKIIVYGRPSSHRPACATKETLTIIRNALVPELAVSDWQKSRAFY
CDLIGFHVVYERPEEGFAYLALGDAQLMIDQIGATRTFVSGNASLEPPFGRGMNLQLAVP
SLQPILFRLERALIGLVLEPEEKWYRRGTVEVGNRQFIVADPDGYLIRPFESLGERAFRF
G
>fig|176299.3.peg.1364 Multidrug resistance protein B
MTSMALEVLVCPPCRKNGKDTALSSMEMVEKNGWGELLSGANLSLLTVISSGIGLHAFNQ
FAVVTALPVAVNDIGGAGFYSWAYSLYFVGSVAGGVTAVLFRERFGARAILLLCCLIFSF
GSVLSAIAGDFLWVVVGRALQGVADGLIVAVCYSLIPAGFRSGLLPKVFAIEAAIWAVAS
FIGPLTGGFATQHISWRATFLLSAPLIIVLVVYTVVAVSAERPVVATRRPLVPLLLCLVG
ALAFSAPSAFEDASLRAISLLAGAALLWASLRAGIQPSSGLFPRDSFRLKTVLGSGFWVL
FLMSYAHALGSVYLAYVAINLWQHEPTFAGFIVVTMPLAWSFVAMLIGSLRSNRLREICL
HYGPYQMVPGCVLLGLGLATGNWGEMLLGQTLIGSAFGMSWAGISQAAMEAAPEEERKMT
GALLPTVATLGSAAGAGASGTVAAATDLVVQIDRADVTTPMLYLYGLGVVVSLLAIMTAR
GLRGERR
>fig|176299.3.peg.1688 Ribosome protection-type tetracycline resistance related proteins
MRTLNLGILAHVDAGKTSLTERLLFDVGVIDKLGSVDTGNTQTDSLELERQRGITIRAAV
VSFTIGDTVVNLIDTPGHPDFIAEVERVLGLLDAAVVVVSAVEGVQAQTRVLVRALQRLA
VPFLFFINKVDRVGARYDEVVRDLADQLRVRPVVMSKITGAGSKHVQVAATDTECEPLFT
ILCETLAENDDELLRDYLLTPDRVDAGRLSLLLGQQTACGVVHPAFAGVAMTGAGLPALI
AAITEMLPARDPDPEGEISGKIFKIERGWGGEKLSYLHLASGTVRLRHILPLPQGPARLT
GIQLFKDGRVQNANSLGAGQIARVTGLAGARVGDSVGVDAVADGAFHFAPPTLETRVVSR
RPSEHAALWLALNQMVEQDPLIGLRRNDETNEVFVSLYGEVQKQIIQSELSTGFGIEAEF
EDSTVICVERLSGSGQGLQTIFREPNPFFATIGLRVEPRPDGAGNSFALEVEFGQMPASF
YRAVEETVFDTLKQGVFGWQVQDCHVAMTAARHTSPSSTAADFRKLTPWVLGTALKQAQP
FVCEPFDHFHIEAPAAAITRLISLLAKAGAATKNSVISGGVATLEGTIASAAVQGVQQQV
PGLTSGLGGMETSFSHYAQAESPPSPRRRSGPDPFNECDYLLRMRRNAE
>fig|176299.3.peg.1896 Drug resistance transporter, Bcr/CflA family
MPPEPIMSTKRTAILGALLTALAPISMAIYTPAMPELTRVFATNESAIKLSLSLYFAGFA
LAQLLAGPASDAFGRRRASLVFLSVFLGGGLLAIFAPTIEVLLLARLIQGIGASVGMTVA
RAIVRDQFTGAEASSIMNLIGIMLAVGPALGPTIGGLSLAAFGWKSVFFLMAGLGAAAIF
SVVIFLRETTVPDKSLIRPRRLLSAYGNLLTEPRFLLAALVLGGSIGALYAQATMLTFIL
INTVGMTPTAFGIGMLMQTGAYFFGSIALRYIAPRLGDRRSVMLGLCFSGTGGLLILLSV
FLIPPSFFSIMGPVAVATVGIALLTPSMVTAALAPFPHIAGSASAMMGFIQMGSGFAGGT
AASLIGSPLTGFGIVIPVMEFTAVASYIGFRIVSRSKT
>fig|176299.3.peg.2585 Glyoxalase/bleomycin resistance protein/dioxygenase
MTTPPFSLVGIDHVVFIVDDMTRALDFYRNVLGCTDGYSYPALGMEQVWCGNALIVLWDV
THPGGTKAAPPVAGGRNVDHICIATGPLNHDALRAHLAKFNVTIEQEAFHGGARGMGYSF
YFRDPFGNKIELKGPAEYPDGRAENA
>fig|176299.3.peg.3739 Tetracycline resistance repressor
MAIGRDRIVDEALRLLNEVGIDKLSTRKLAERLGVQQPALYWHFRNKAELLDAINSEMLL
RYHCDRLPKPGQDWITFTLANARSIRKTLLTVRDGARLTAGTRPSVAEFADVESVLQLYV
ETGFSAEEAFGIAICITRYVVGYVLEEQGERERDRMDQHSPNTDIMAELAQFPLLAKALE
SFPTVGTVNTEAVFESGLSYLLAGMKEKLREKQSR
>fig|176299.3.peg.4861 Permease of the drug/metabolite transporter (DMT) superfamily
MPVKYLLFSLLAVLIWVGNTIVSKLAAGAIAPGTIAFERWFIAFVILTPLVYRDAWRHRR
TIAAHLPKLILLGLLGMAACQGLGYYAAGLTTATNMAIMLSLVPLLTLILSAVFLAERPS
SLAVIGGIISLSGIFIVLGQGDPSRLLSQGVGRGDAMMLAAVLAYAGYGILLRRWAIPLA
TWTSIYVQIGAAVVLLVPSYLLSAPSALTLPNTAMVLYAAIPGSILAPFVWMTAVKHLGA
ARTAIFMNLIPIFTAIVAAIFLGEALYIYHLLGGGMTVAGIILVQRKPFREKSGQKAVVA
RAQ
>fig|177437.4.peg.225 Glyoxalase/bleomycin resistance protein/dioxygenase
MSIKSVNTILYCTRWAETVEFYDKSLNFQRLTTREWFVEFFLTESARLSIADESRCSIKG
ARGMGITISLAVDNLGAAHRKFQIKKLSPTPIKDLWGARVFYLYDPEGNRIEFWE
>fig|177437.4.peg.547 Permease of the drug/metabolite transporter (DMT) superfamily
MTYLKLLLTAIFWGGTFIAGKFLAGDVNPLDAAFVRFAIASIFLLVITRKLEGRLPRIQA
KLILPLILLGATGVFAYNILFFSAFHHINAGKAALIIATNPILISLLSALLFKERLDLIK
GAGIIMSVTGAMVVISNGHLTDLVSYEIGRGELLIYGCVASWVAYSLIGKSVMGSLSPLA
SVCYSSVIGTVFLGIVSIFKGDLTTMGAWSIIDWFSLFYLGFFGTVLGFLWYYEGIREIG
PMKASVFINFVPISAILFAWLILGEPVTASLLVGAALVVSGVYSTNASGIIKRYLTAKG
>fig|177437.4.peg.1027 Permeases of the drug/metabolite transporter (DMT) superfamily
MVSALLFGGATPAGKALLGGVEPQALAGLLYLGAALGVLPVVMGERAFQWPWHAGRNTFL
LLAGAILLGGILGPFLLLLGLKIASSGSVSLWLNLELVATVLLGHFVFQENLSRRAWVAA
GGTLIAAMLLAGNDAGGFFPGLLVFLGCICWGFDNHFTALIDGISPAQTTLWKGSVAGVF
NLVLGGAVAGGIGSPGVVIMALLVGVVSYGCSITLYVMAAQGLGAVRSQMVFSVAPFFGL
LLSVTVLGETFTHVQAVAALLIVVSLFVLFSEQHVHNHRHIAMSHQHSHSHDGLHHNHGH
EGFDPKESHVHWHDHAPEEHTHKHWPDLHHRHDHKKEP
>fig|177437.4.peg.1294 Permease of the drug/metabolite transporter (DMT) superfamily
MPLFAILRCFIKRLKGKFLKNWKPYLAGVLVVLIWSGWITISRYGVHTRLTPADITLLRY
CTAFSVVLPFAVRYPWRKFTLYQYLVVGLGVGFPYTMVSFYGLIEIRAAHAGVLVNGMLP
VFGAIAALLYFKQRVSAVCYGAIALIFAANIVMIGGNFFSSEHLLGIVLLLCAAVIYTFH
MVGVRLWGFTWKDVFVVVPVVNVALFLPLWFFFPSTGFKVPVPEMVLQATYQGLVVNIVA
LSCVAYAIRHLGTITVSLFMSFVPVITAIFAWLLLGENLTGQEITGIVGCTGGLLIYSRG
>fig|177437.4.peg.1736 Multidrug resistance ABC transporter ATP-binding and permease protein
MHGHRNNIFSVQVGEGVARDLREALFVKIQSFSLGNLDNLKTGELMVRLSSDTSAVQRLV
LISLRIGTRAPLIMVGSLILMVNTSLGLALTMVPLLMMSRLSNVWANGMASSKWIYGLIS
TWFPGFTRSTTAGSPLTKQIS
>fig|177437.4.peg.1739 Outer membrane component of tripartite multidrug resistance system
MALSGGCVPVGPDYVAPGFNRMPGRWTPEMTGGMSAVPLDSKALASWWIVLDDPVLTGLI
TRAIDVNLDLRKTRAVLREARARLLISGTDAFPTIKTDASAVRRYQDDESGSSYNAGFDA
FWEMDVFGRVQRAREAATADLEADQESMGDVRVSLVAEVALNYIGVRSFQARLAIAQKSL
AVQEETLQLTQWQRQAGLTSQLDVEQARSSLEETRASVPDLQTGLGQVMNQLALLLGQYP
GTLYKALSVPAPVPVAPMEIAVGVPAEVLRRIPTVRQAERQLAAQTARVGVATAEQYPQF
TLNGSIGFDALSIHDLLFESASRIFSIGPAFSWTLFDAGRLRQNIEVQNALTQQAAIEYE
KAVLTALKDVEDALVAYGGEQVRRQSLLGASTAQQDALDLARDQYASGMVNFQVVLDAQR
SLLSLQNQLAVSNGAVTSDLIRLYKALGGGWTPLSASGATKAH
>fig|177437.4.peg.2213 Fusaric acid resistance protein
MRRQNKGNGGLYAVWFIILVATVAITRFYGLESSNFYGIAETREIVVNFEGAVEIKKINV
TEGQSVEQGMLLVELSSPDLMLKINQISHQLDQLKAQKGVDKSEIQSRLRQLKAEKAAKE
SELRNQIAQLENQYKINKSLLSGLKSISGNGGYGNAEGSSPMELKIKSLKEELSLCVNPL
AIQIELFEKILANSKNPVKIQVERLEQELTLLANENNKLNIYAQISGIIGSVNFKPGAKV
SPFAPILTLHTRTPSFIKGYIYENAYADIAMDEHVNVASLAIADRNITGVVIGIGARIVA
YPERLRKHPDLQMWGREVVIQIPENNHFILGEKVLITSSVKKPGGVEQLKRLFTPSESVA
DVLLACKNFLFEEDILPIIPLETQGIEASALLYLKDIDRYMVLSDDTPGNAPLVMLMDSH
GRITRETAIAGLEKIDDMESVAEADQGILYISSSLSTAKNGKVKETRKNLVSVQRQGNHF
TLVKTIDLYSQLMTHAQREAGQPWADFILGAISKKNLDMEGMMYREGSLFLGFKAPLMNK
ESVILKIDEIDCAMETQTFKPHQISIWRSFSLIPGKGQLQEGISDLLYFKGILYLTGTPL
MKDKGSRSGTLWKLDEATGTPVCLAHFNDLQPEGVASGKEKNSLIICFDQGHKTKSKTCK
IKVN
>fig|177437.4.peg.2275 Fosmidomycin resistance protein
MTENTKLNVKVVAALTLVHFTGDFYSSFTSPLLPVYVDKLALSMAQVGLLTGMIRLLAFV
VQPCVGYLADRYQTRAFILWGVFLTVTCIPFSGIAPNFYVLMAVLAAGSAGSSMFHPSVT
GMLPLYSGPRRGLCMSIFNTGGTLSFAIGPVFISWYVGRFSLEAMPWTMVLGLMSILFCL
RAIPMPVSEGMQNSGFWGSLNESLGHVWKPISLIWIVMVLRAVAGQSFITFMPIFLVQKG
YDLISVGFIVSLFILAGTVSGLLSGSLSDSMGFKRIFFVTHLLMTPALLAYLFMPGAFVY
AGAFIGGFFALATMPLGVLMAQRLAPKGRSMVSSLMMGLAYGLGGLFSPLVGKLADIYSI
ETVLFWTAFVPLITLIPIVKFPQLEKEA
>fig|177437.4.peg.2458 Permease of the drug/metabolite transporter (DMT) superfamily
MKIKNRLENSQILTGYLFAIAATAIWSGNFIVARGLNETIPPITLAFCRWLVAVIVFLPF
ALKPLIAQWGILKKNMGYLSVTSLLGITIFNTLIYFAGHTTTAVNLSLISITFPIFIVIF
SRIFFRERLTLNKGIGIVLVVTGVVLLITRGALSSLLNISFAIGDLWMLLAAIIFAVYSL
LLRSKPQQLSIWAFQAATFILGLIFLFPFFVWEYTITPSIPFDTKAVVSILYVGIFASFF
AFVLWNKAVVAVGPSKAGMVYYTLPLFSGFLAHFFLKENVTIIHFYSVLLIASGIFTANY
EFKGLKRISTAQARP
>fig|177437.4.peg.3442 Multidrug resistance ABC transporter ATP-binding and permease protein
MGPFELIRPYFIERRAYLAAGLFSLLVVDLLQLFIPRIVKRAIDGIASSSLDAGALLRYG
GYILLAAIFIGVFRFSWRYCIMGTARRVEEGIRERLFNHVITMPAPFFDRVSAGDIMAHA
TNDITNIRMALGMGLVGMTDTVVLGLTAVVFMGYINLELTVLALFPMPFIAIFTKILSKR
LFLAYMAVQESFSRLMEASRERFAGIRVIKAFNREDAETLSLTQESQAHVDANMHLVRLR
GLIFPMVTLLTSISLAVVVGLGGRKVIQGTISPGDFVAFIAYLGLLTWPVMALGWVTNMI
QRGKVSIDRINTILNTSVAMGNMDNALTPQKITGNIQIQNLVFHHGSGKDRTRILDNVSV
TAGPGGILGIAGPPGAGKTTLVGLIPRIYDPDSGRILIDGMDVRNIDIHCLRRFISFMPQ
EPFLFSGTILENLKLADALAGQDQINGVIEMAGLTKTIESFPKGINTMIGEKGVMLSGGQ
KQRIALARALLKRAPILILDDPVSQVDIRTAAGIIDTIEALSTSITVIIVSHRFQAFRRA
DNIIVLDKGRIVESGNHEQLVAQGGYYARAQVMQSGGES
>fig|177437.4.peg.3509 Acriflavin resistance protein
MNPARFALNRRTFLAILTLLLIGGGLLAFEHLGRLEDPTFTIKTALVITPYPGATPLEVE
EEITEKVEEAIKSMGQVKEIYSTSQEGISFVYVEMKDAFNKRELPQIWDELRRKVADIQA
TLPPGAGPSQVNDDFGDVYGVFFALTGDNYTLAQLKDQAEYLKKELLLCKDVAKIDFWGI
QQQVLYIEFEPSKLAGLGISPDLIYQTLHLQNVVESSGKVDVNTEYMRISPTGEFKSETM
IADLLIGGAGSMVRLGDIATITRGYWEPPRNMMRYNGRPCIGIGVSTVDGGNVITMGDSV
REKLHELEARQPPGMALNTIYYQSRVVTESVNAFLINLAEAVVIVVVLLMIFMGWQSGML
IGIILLLTILGTFMGMLLMGIDLQKISLGALILALGMLVDNAIVVTDGILVRVTRGESRE
SAAVQVVRENQWPLLGATFVAILAFAAIGYAPGNVGEFCRSLFQVMALSLLLSWLFAVTI
TPLFCVWFLKTPESQAMKDPYGSRIFRIYRRMLHLALRWRYLTLVVVSLLMLLSIIGFGS
IPSAFFPDSTQRYFYVNFWKSQGTHINHTADDLAKIEQFVRQMDGVKNITTFAGEGALRF
LLSYDYQIPNPSYGQLLVEVDDYLQINGLVKQVNAYLAANFPDAEPYARKIVSGPPVTFQ
VEARFRGPDIKVLQDLADQAGKIMEQTPNTRDVRTDWRQQVRVIRPEFSQSQARRSGVTR
SEFSSALKWQFTGVVAGLYREGDELIPIITRPPEKQRNSVGDLDNVQIYSHANRLFIPIN
QVITGVKTVWEWPLIGHRDQQRAVTVQCNPARGLAAPLRLAMAQKIEALDLPPGYSLEWA
GEFEASNDAREPLGKIFPLCVLGMFVIVVGLFNSVRTPLVIFLTVPLSIMGIAAGLLIMD
LPFGFMAILGFLGLSGMLIKNAIVLIEQVEIFLKEDYPPYKAILDSSVSRMRPVIMASGT
TILGMLPLVFDPMFATMAVTIMGGLFVATFLTLIVVPLLYCLFYRIKSEKRYL
>fig|177437.4.peg.3643 Multiple resistance and ph regulation protein f
MDTYILYSAIVLSVFMAIPLYRSVVGPTVQDRIMGVSAIGSKTTVLLIMIGFIFERVDMF
IDIALAYALLNFIAVLAASRYFHKRKGLYQEMDR
>fig|177437.4.peg.3651 Permeases of the drug/metabolite transporter (DMT) superfamily
MGSLTAIHLAVVLFGFAGLFGKFLTCTPLVIVFGRTAFAALALLPLVLASKANPLGEKTP
RLKVYILQGVLLAVHWCTFFLSIQISTVALGLLTFSTFPLFTTLLEPFFFKQQIKQKDLV
MALIVFAGLILVLPSFDFSQKPAQGAVWGTVSGFTFALLAIFNKKNLTFEPPVRLAFFQN
LFAAATILPIFIFVPQTVPAPGEIILIATLGIVFTALAHTLFISSLEGLRATTVSIITCL
EPLYGIILAALLLHEIPGLRMVAGGTIIVLSTLFASLNRKHSQ
>fig|177437.4.peg.3972 Ribosome protection-type tetracycline resistance related proteins, group 2
MTITPSGVIYRETVIKNAQATVRYTMPKPCWAVMTFNVEPGALNSGDFLLATPMGIMAAL
KNAGTRLLEPFYALDIKAPQKLLGTITNDLNNMRADLGIPRFEGNLFALGGTVAVAPAMD
YSIRFNACCSGKVRLKLTLGGYQFSTSSQWTLENLTFSGLEGHGGVTIGWGSDNLIRRAD
FPARITEIQKIHGHPPVQ
>fig|177439.1.peg.119 Permease of the drug/metabolite transporter (DMT) superfamily
MPEKTARPLLIYLYLTLTMFFWAGTFVAGRILGQNLPPSVAGFLRFFVASSSLFLVLRIK
FGAIPRPEKEQLLPLLLLGFTGIFAYNIFFFKGLQHIEAGRAALFIAATPLMITITATLF
LKERLSLKGFLGVLLSFTGAVIVISNGHPEKVLQGGFGIGEQSLLGCAASWAAYTLASRK
VLISMSPLSAVCFSCMLGTAMLFPFAIGDGLFTLMPQITDLGWICVLYMGVGGTALGFCW
YYKALKAIGTTKTSIFLNLVPIFTLILGHFILGEYVNISVLAGGLLVLTGVTITNFQKDN
>fig|177439.1.peg.153 Outer membrane component of tripartite multidrug resistance system
MFASQLRRSLLLLLTPLLLLSCSMIPPKEAHHQQLLTPEEIGIRAEMQIRTCRWWEDFRD
PQLNTLIEMGLRQNLNLQQVSYRLSLAKQQVLLNQAGQKVQANLKLNGGGLAAKGDFPSQ
NSAFALALPMVGYNLDFWGKIENRVLAASNREKAAQVNVTQARLALAVSIAQSYLNLQNN
RQQKQVLHRMITNQKAAEEIIVGSVKRGFLPYEELLQSQSYSHLLRAELTGAKAQEILAK
NQIALYLARTTEQLAPLVDGKLTLIAPLQEVLSIPMNLLARRPDIQGKKWIVQAYAAEIK
VARTAFYPDFNLMLGGAFLAMTNIHPDKLSLLSGSIATSLPLYDGGLRDAGLSIANIMYD
RAVLDYNQSLLGAVREASDAIILLKTSQEQEMLTGISTEKQRQAYDIARKKYQRGISPYL
LMNQAESRWQQTFLNLIKTETATLQSQLRLIMALGGGYSPKAATEK
>fig|177439.1.peg.154 Membrane fusion component of tripartite multidrug resistance system
MPTTSQENKPKRNLLIAIFLIAIAIGIVIWIFLSQRQQESTDDAYVIGNTIIISSKIAGT
VQKISVSNTEFVDQQQILIELEQNDLLIQEKIAEANLTRIVRTVKSQYLTTGQLKDNIRA
TDFKIAELEADLARRAGGDLDGTVTLENLQHMGQAIKIARAQRDSARQGLEAKQTIFPGE
ELQNNPEIKLATAHLQEIYLARINSTIIAPMHGLIANRSIQAGERISPGQPLMAVIPLDN
VWVVANFKETQLGDIRIGQAVELISDIYGKKLPFEGIIAGIGAGTGSAFSAIPAENATGN
WIKIVQRVPVKIFISPDQIKKHPLRIGMSMTVRVDTKDQEEKSFQHIQQHDDISAIYQSH
RQLAEQQARDFLNTLLIHNNK
>fig|177439.1.peg.155 Inner membrane component of tripartite multidrug resistance system
MANSPQSTQWLQGIKLTAATFSLAMAAFMMVLDTTIANVAVPTIAGNVGVSVDQGTWVIT
AFGAANAISMPLTGFLSHRFGEVRLFLFAVIGFTLTSFLCGTATSMESLVIYRILQGAVS
GSIAPLSQSLLLRCYSKEKRGTALALWTLTIIVAPIVGPILGGYLTDNYHWSWIFFINVP
IGIFVLISCSMLLKGKETTRSRPSIDYIGIGLLVFAAGSLQMLLDLGKQHDWFQSTFIIG
LGLVALVSWGVMIIWEYYHDNPVVNVRLFKNRNFSLAVLIMGLGYGIYFGSSVLLPLWLQ
GVMGYTATWAGLATSPSGILAVVSAPMMAYLTRKVDLRLILTYAFVNFAIVGFWRANFSL
DNSFFIIFLPQLVVGAATMPFLVPLQRMIIDGLPSSQIATAVALSSFFRTLSGSFSSSVV
TTAWDDRMTFHYARIAENFTVYNQYSMGYLRDVHGNISLMSKIIMRQAYMLSTVDLFWAT
GVICLCLVPIIWLTKPINIEIE
>fig|177439.1.peg.196 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MNSFFSRPWSKFDFIKFVTPSILSLVSISLYMAVDAIFISRFIGTLAMAAVNIIMPLFSI
SIGIGVMVATGASATIGIELGQGKRDRANAHFSFVFCFLFLVFIGLIISQWAIGPERLAL
WLGASKLLLPYCVQYLNIFLFGISALVLQMFFEFFMRLDGKPSWALYSSLLGGATNILLD
YILIVRYGMGVDGAAIASCAGIFISCLNGAIYFLFKAKTLRFIRPLIDWPFLFRSMFNGF
SEMVTEIAAAVQTLVFNYLMLGYAGEAGVAAMSILMHLYFLMSSLYIGLGMGVSPLISFN
YGCRNPGKISELLTRAIQLTLFFALFSFAMAFCFGDNLIQIFAKGQVSVVHIAEGGIKII
AFSFLLNGMNILASAFFTSVNNGKISTLISSLRTFVFILGFALLLPPLIGVTGIWLSLPM
AELSTLLISLFFMKKYRQHYLLPATTGEVKEKNSMQLIKKKEKEEA
>fig|177439.1.peg.290 Permease of the drug/metabolite transporter (DMT) superfamily
MKLIFNSKYTPVIAIFVAMIIWASSFIALKIAFRSYHPMVVIFGRMLIATLCFMVFYKYV
FKGFKYHKGDYKPLLFMAFCEPCLYFIFEAIALKNTSASQAGVITATAPIFILAAASLFL
KEKYNLQSWLGALAALAGVCWITLASATSESAPNPIFGNFCEVLAMACATGYTVCLKSLT
KRYSPLFLTSTQALMGTFFYLPMLFLPFVEMPTEYVALPSFAIIYLGAVVSLIAYGLYNY
ALAHMPAAQGASYINLIPIFSVAMAWLFLGETLNLSQGFAAALIIASVWVSQKGMAKAHD
EKHSLKNK
>fig|177439.1.peg.671 Permease of the drug/metabolite transporter (DMT) superfamily
MSRLQANLLLSLAALIWGSSFVVQQIGTGNLDAASFTGARFLLGSLVVLPFALRQFLHVQ
REVRAFTLRDGLGIALTGSVLCVAAALQQYGILRTTVTNSGFLTALYVPMVPILALLVFR
KKPHWSAWPASICCFVGTYIMSGAQNVVLASGDLWVISSTIFWASHVLLIGIMVQKTEAP
LVVACGQFFICGILGLFLGQYLESPDLNVFAGALTGILCMGFFSVALAFTFQVIGQRYTP
APDAAIILSSETVFAALCGAIFLGERVSDFQLAGGLLIFGGIIAVEILPMLKTARILS
>fig|178306.1.peg.1656 Drug resistance protein, conjectural
MESTSLGTSTSRADLRAYAIFSAPYSLVVFLLPFYIFKLGGGGVEVGFAFSIYATAVVAV
RPVAGYLTDRLGRRSANLLGGLILASAMILLGASYGVFHIYISLFLAGAASSLINVATVA
YITDVGGLENPALYSKMRIAAAIGAVGGGAFIPIAYFLDKLWGYEVAFRASALALAFITL
TALPLLPHETMQLAARYKQGNLGLATCVTILAFLLGLASGLYGPQVLPYIYTKYNLSPFS
AVLAYLPAVFSWLYGPRLARPAPTRVILGVIAMATGLLAMYNAPNPLLFSMSWVLESLGY
AIVSTSLDQSLSRYVSGAYWGRGYGVYQAVNNLGYAIGAAFSGYVPNPFYNAIAPLIFML
PLAVICVKSRRISPRVSTSPLPS
>fig|178306.1.peg.1786 Tetracycline resistance protein
MRPIFTLLGVVAIHMLGFGIVIPVMPYVVKELGGGSEAYGVLVSIFSAVQMVSAPLWGAL
SDRIGRGPVITLGLALAAIGSAMAYGARSLAELALARAVSGMGGGTLGAVQALIADLSPP
ERRASNMALFGVAFGIGFILGPVVGGLLSVWGVRTPFIAAVIFSAAAAALSTSLPRVRGR
VGFSISLQFGAVAGLVLALNLAFSMFESMLVYYAADVFKMAPSDLGVLMLIIGLAVASAQ
PAVRRLEGRVAYTTSALAGFVATGAGIGVLPALGELGLYLGSAVAAVGQMVASSSLFALF
SQGERGRGIGFGALQSTASLGRIIGPSLAGWIYLKLGPSYVFYAAALLLLAASPAFWFWR
R
>fig|178306.1.peg.2372 Multidrug resistance transporter related protein
MDSYDIKYAWRATPLLGSVALLVMYTEAMLMPSLPKIQAEFNVTPADASWILTIYLISGT
ISAAIFGNLGDIYGKKRVLSLVMLAYAIAVTLTGYAPNFETLLLSRAIQGLGMAMFPLAF
SLIREEFPPHMVPTAQGVVSAMFGVGIIIALPVGAYIAQNYGWRATYHTATPIAVLLTFL
IMIYIRESRYRTPRSIDFVGIGLFATMAASFLLAISKGPDWGWLSPRITSLLALSAVSAA
VFLIHELTTDNPFIPRDIFNRNVIAATIAILIVAYAFQMNSQNLSYLFQMPPPYGYGLTV
LQTGLYMLPPAVVQIIVAPISGRLMWRLGAKKIATIGVVFAVIGYQLAAAHLYSGVWTLI
SYVTLGFIGLTLLNVSLINLLTFSVPRQRLGAATGLNTVFRNFGSAIAPTVAGTVLTNFN
TYVYYNTPAGPIYFSVPAKEAYVINIDIATSMFIITLLPILFSKEVLGGNATPK
>fig|180281.4.peg.359 Multiple antibiotic resistance (MarC)-related proteins
MEDLNRSVITLLALINPVICAVMLLERTPGVPHRRRLLLIGNVVLRTGLILLVSAAIGPQ
LLKRLGISLDVFQIVGGVVITSIGYGMFAPSPAPAAATGQESGSPENASLDPIVLFAASP
GTISTVLALSVMHGPDQGLLPTSLAVLIALAITAVVMAVMVLRPGASTRSNSSLVSRFLG
LILIAMGLQFVLTNLRTFFQAAG
>fig|180281.4.peg.814 Glyoxalase/bleomycin resistance protein/dioxygenase
MVSHFDHVTVVVQDVEAARRFFALLGFEEDKALVISGPTFSSYMGVDGIEAEHVTLVLPH
ATPRLEVQLLKYHHPQVHPDPEIANLCRLGFNHICFAVDDLEAEVARLTAKGVQLRNQMM
TFNTRKLVFLSGPEGITVELAEWR
>fig|180281.4.peg.2227 Mitomycin resistance protein
MGPAIAKALLSLGYRVPADLNGADPLDLYNRLGDLRGCRQDPCVLDVFIAITRFLNGEPA
RPWWAYSEDRRRRHPDL
>fig|182217.3.peg.677 COG0697: Permeases of the drug/metabolite transporter (DMT) superfamily
MGNTEVRPGAMTYVIFLLGILFLSFTAPWQKMSNFDPATGAFLRCLGGALCLVPFAFIEA
KKKGWLNKKGIWLSILAGLVLGIDFTAWNYSIFFVGSGIASILLNIQVIILPALALMIDK
EKIPLSYYILAPIMLTGVILAGGALEHGIVDPNGPQEVFGMSIMAVGTICGLTSGCCYGV
YLFASRRAGRINQGQIVQPIMIASFAQLVAPLIWAYVITGNGFDMATGVMVETAQSLDIG
EMIRGLREMHLPKDEIEQLTSVAHAVTAGDPINGVSWFWMFIECVLGQACAWTFAQYGSV
KLNPTLGAGLLILSPVATVAIIAPFLFGETLSTLQIVGVVVALLAVAYQNGLLKAIFTKK
IS
>fig|182217.3.peg.1605 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MEKVFKRIGAYSMLKAKIDLHKDSIRKLFFYYFIPLAFSMISLSTYSMIDGMFVGKKLGK
EAIAAVNIAWPIFPSLVAYELLFGFGAASIVGYFLGRGKTHRAKLVFSSVFYFVALSTFI
LSMALLPFSETIARLFGSNDALLAMSSRYIEIILMGAVFMVLHPLADVFVVNDKRPILAM
VAMLIGSLTNVFFNYLFIFVLEVGVQGSAYATIIGHGVGFLVLMQHFLFKKGQLSFIKRF
SFPAVISSAKSGVPQSTAELSFALMILIFNATIMHTAGERFLSMYGIIMYNAIIFWTTLF
SISQGIQPIASFSYGARNLERVKGVFLFGLKVAFLVGVVLYGIYYFLDEFLIKMYLQANE
QDLDFIQETKQAMNVYYLGYIFLGMSILCAVFFQSIQCTRSSFIITLSHTLIFIVVLLPL
MSHFYGIKGIWATYPIAQFLAFLSAMGVTYYEIKKGVFTTYREQSLINGAKK
>fig|182217.3.peg.1697 Tetracycline resistance protein tetA(P), putative
MKTLRKNILAYYGANFLLTLAQSLPHAILTPLLLSKGLSLSEILLMQSFFSFCVLVAEYP
SGVLADLMSKKFLFLFSNLFLIASFCCVLFFDSFMLMLLAWGFYGIANACNSGTIEATLI
TDIKENKQDLSKFLARNNQITYLSMIIGSSFGSFLYSKMHASMYMVAILLVLLCMLVVIF
YFKENKVTPKNQKSLSLLKEQVKSSLKELRDNPKLKILLVGHLIVPLFFMSHFQMWQAYF
LAQGIKEQHLFIFYIAFQVISILVHFLKASSYSQKITLSFLVVLLSVSPLLLTNMPYLFI
GVYALMVAFFTYMSYCLGYQFSSFVSKNNISSLSSLMSSCVRVVSVLVLSLSSLELHYFS
PLSIITTHFAITLLILFFFLYKAKVFSV
>fig|186497.1.peg.35 Daunorubicin resistance ATP-binding protein
MTMVDVISVTKTFSTPKGKVVAVDNLSFKVKRGQVFGILGPNGAGKTTTLRMMATIYRPD
SGRILIDGIDVVENPNEARKRMAYMTQEPDLSPTLSVRDYITYYFRFRGLSKREARERCS
YALKTFNLEEHANKKPFQLSTGLKRRVQLACVLSSDAPLVFLDEPTAGVDPKSKRDAWEL
IGEMVREKDMTIILSSHDLYEVEYLADEVLIINYGKAVAQGRPSELKRRFGKTLRIVTKN
PILDFEKLRDTLTSIEMVENVRAITKNSFEVKLNSLDAPINDVLQATMSLGLEIVDAFTA
TLTFEDVYLSIVDVGGEINGKR
>fig|186497.1.peg.36 Daunorubicin resistance membrane protein
MGRGKEFLSSFYVAMSRETKVGIDLEFWLGTMFEPLIYVLLFGPLMEKLVGGVNVGGEEI
SYLAFMFPGVLTLVGINQGFRGATTFIRDRFYGGLETLFTLPVSRSVLFMAKILGACIRA
FVAMATLSVLVIIVEDVSLTPLSFIQSFLVNSTLVVMLSSLMIWLLSKGENPNLPVAISG
IIMLPMMFLSTIFYPKEVFEGSRVMSLVVSLNPMTHASTLTRSFLYGISLPLSEVGISLA
YLAALRFLGFVLGLRGFTRALER
>fig|186497.1.peg.146 Quinolone resistance protein NorA - like protein
MLKSLWYLNFSTLFFFLGVSILNPLVSPYAITLGATPVIVGIVAGTVSIVSLSSKPLGGY
LGDRGFKFHAMFIGNIIGIIAVLLYVLSNILGNIWVFALGRAVHGFAMGIFFPSSLALAV
DLAPKGRVGESLGWRGMMFSLGNIVGPGIGGFISDNFGFVSAFIFSGIFSFIGSLFVLIV
WREIGSVKSEKASERGNYRELLRRSFVSASVSLFLISMAYSGVVTYLPALYKVSGFGQSV
FGMYMMFVGIASFIMRVFGGKIADIKGPIPVARVGILILGSSYLALAFNQYPPFSFIVGV
VSGLGFGLLIPALQYMALANLPGNIRTMGSSIYTMFFDLGMLSGQLAFGVVAEVRGYEGI
FPFIALLPFVSLITVHFPLLRREGNEG
>fig|186497.1.peg.316 Daunorubicin resistance ATP-binding protein drrA
MQGERVDFSCGWIRNRVHWRILKDFRSSTFWSYARNSWCHGGEKMKAIVVEDLEKDYGKV
KALKGISFEVKEGEIFGLIGPNGAGKSTTLKILATLLVPTGGRAEIFGYDVVEEAEEVRK
LISYLPEEAGAYKNLTGYEYLEFMAKLYAKTGKDYKKMLETGVELSGLGERLKDRISTYS
KGMTRKLLLARALMVEPKLAILDEPASGLDIINAYSIRQTIKQFAREKGITFLLSSHNML
EVEFLCDRVALINKGRIVEIGTPKELKEKYNAENLEEVFMSIVGGKKVE
>fig|186497.1.peg.323 Permease of the drug/metabolite transporter (DMT) superfamily
MNERRKAELVLLGATFIWGSTFPVMKIGVEDFPPITFIALRFGIASFVLFLALRKHIRKD
ALFPGLILGFTLFLGHGFQIVGLKYTTPSNSAFITSLYVVFTPFIAFLFFRKGLKMFDAF
SLSLAVIGLYLISNAELRLNYGDALTVVAALSFAFQIVLVEYFGNLGVGLAFWQIFWNFI
LSTVYAGIFEGISLPSDPKVLGGIIYTGIFATALSFTLQVKYQPKVESYKAAIIYSSEPI
FAHLLALAFLNDRLPPKGYLGAFLILLAVWLELYQERKNY
>fig|186497.1.peg.595 Daunorubicin resistance membrane protein
MNVFSTMIYRELKRFVRSPSRIMGSILNPLIWLIFFGKGWSGVFNFPMATRIFGGVDYMT
YLVPGVVVMTVFNMSFMQGLTIIWDKQFGFMKEILVAPASRVESILGRITGGAIVAMIQG
FIMVALSFTIADLKVSGIIPALVLAFFVGIAIAGLGVALALRMSSMEGFQVIVMMLMLPM
MFLSGAFYPVKTMPNWMQWLAKINPLTYAVDGVRYYLAGVTPTFGIINDWIVLIILALAF
AGIAGLEFRKAYLS
>fig|186497.1.peg.716 Drug resistance protein
MMPIIALYAISLGASLPQAGIIAALYSIAAIPASIIAGLLVDRIGRKRMLTLGLMWDAFV
VFLYGYVSSYHQLAILRVLHAFGGSLVFPALFTMARESDCEGKTIS
>fig|186497.1.peg.728 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MSEKTTKGVQLLRGDPKKAIVRLSIPMMIGMSVQTLYNLADGIWVSGLGPESLAAVGLFF
PVFMGIIALAAGLGVGTSSAIARRIGARDKEGADNVAVHSLILSLILGVTITITMLPAID
SLFRSMGAKGEAVELAIEYARVLLAGAFIIVFNNVGNGILRGEGDANRAMLAMVLGSGLN
IVLDPIFIYTLGFGVVGAAYATLLSMVVTSLFIAYWLFVKRDTYVDITLRDFSPSREILK
DILRVGLPSSLSQLSMSIAMFFLNSVAITAGGENGVAVFTSAWRITMLGIVPILGMAAAT
TSVTGAAYGERNVEKLETAYLYAIKIAFMIELAVVAFIMLFAPQVAYLFTYSESAQVIKG
DLISALRTLPVFLVLTPFGMMTSAMFQGIGEGEKSLILTIFRTLVMQVGFAYIFVHYTTL
GLRGVWIGIVIGNMVAAIVGFLWGRMRISALKKTSATGGKR
>fig|186497.1.peg.753 Daunorubicin resistance ATP-binding protein
MVELENVRKSINRKEVLRGISLTVKPGEVHAYLGHNGAGKTTAFRPILGLRYLPEYDLLY
PSLSVWDNLKRYASLKGVYDEKELRELLEFFELLECARKKVSALSSGTQRRVAMARAFLG
SPEVLILDEPTRELDPEWRLKFKRFLERYVKERNTAVLFSTHILSDVDELCEKITVIKEG
RVLFSGSLKEFKRGFPTGASISLKVENIKMVAEVLEDNGYYPNHERVHPAGKCRAVGNQH
APREREYNR
>fig|186497.1.peg.850 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MSREKIEANREKILNGPIVPTLLVLAYPIIINQLVHVLYNLTDTFWLGKLGRIELSAPGT
AWPLVWFLMSIGSGFVVAGFAFVSQYIGAGDYEKANRYAGALYSLLLIFATGMSIFGIVL
APYFLRFMKVSETIFPYALTYTRIIFAGIPFSFTLFAFNFLLRAIGDTKTPVKINIGTII
LNIILDPFFIFGWGPFPRLGVAGAAIATMLSNSVGSLIGGYLLFTGKVGIHLTLENLKPD
LKFYSRIFRVGLPSSIGDSTSALGFVVLTRVIFTVGRIYGEAHGIKGYEDVAFPTYSITN
RLTNFMFAFSDGISMAMGTMVGQNIGARKYERAKEIAEKAMLINFTILSIGTLLFAIFRV
PIFKFFVNDPMVIAESKKVVMYFSASLPFFGIFSAVNQVFNSAGHTKKSMVLGIIRLWIL
RIPLSYWLGVAMKDTAGMWLGMGLSNVIGALIGLAWFLKGSWLRGVIEEHH
>fig|186497.1.peg.862 Daunorubicin resistance ATP-binding protein drrA
MEAIAVEDLTKSYGEIKALDSLTFSVQEGNILGIIGPNGAGKTTLIRILSLLLKPDKGRI
LLYGHEVNSRKSEIKNFFALLPQEAKAHFYTLTPFEYIYHYLRMRGFSRKDAKIRAGKAV
EEFGIDYADKIMSTLSGGMVRKTLLAMILSADAKIYYLDEPTVGLDVENRLKLWEILREK
SKNSTVVITSHYLNEISSVCDNVLLLKKGRVVAFGKPEKIARQYLSQFHSKIVVFGEFTK
EDYTTRRAGKNTFVYAKSKSEEREVIEELKDTGIPFKREELTIEDIFLVGNLR
>fig|186497.1.peg.1047 Daunorubicin resistance ATP-binding protein drrA
MIIALEIKGLKKRYGNVEALKGITLEVYEGEIFALLGPNGAGKTTLIRILAEGLKYDEGE
IKVFGRTLSRETRRLIGYVPQESIAYDLLTVKENLEFYADIYNAPRERIKELIELFSLPE
KKKAKELSGGFKRRLNLAIALLYDPKILILDEPTTGLDVPSRRDFWEIIRGFKKDGKTVL
LATHYMEEAEELADRVAIMNEGKVISIGTPEELKRLIGEESIITIKGLLKGLEEISYPFI
EKDNEIRVRVRNPREALPKIVENLIKAGSIIKEIRVEEPTLEDVFIKLTGRRLE
>fig|186497.1.peg.1938 Daunorubicin resistance ATP-binding protein drrA
MKVVEVKDLRKLYPKKIPLPFRKVEYFEALKGITFSVKKGELFGLLGPNGAGKTTTIKIL
TTLLEPTSGVAKVLGYDVVKEPREIRRRINLVAEGERTLYWRLSGYENLRYFASIYYVPR
REAEKRIKELLEMVGLWERRNDLVMNYSRGMKQRLAIAKALINDPEVLFLDEPTLGLDVQ
SAVFVRELVRKLVDEEGKTVLLTTHYMQEAEELCDRIAIIDHGRIIALDTPEGLKKMVRD
NTIVEVKVRNYPGSNPFGLAKVEEQEGVAILRGSIDEEEIPRLVEFLVKNNAKVLSVEVE
EPTLEDVFIKLTGRGLRD
>fig|187272.6.peg.686 Permease of the drug/metabolite transporter (DMT) superfamily
MPVSLSLRNPVVLAVLGLVATTLFWGGNAVVARATSEWFPPFTLSFLRWVLALLIILPFA
WGQIRAYRETIRRHWRILWVLAALSVGLFNTLLYLAAQFTTATNITLVNSTMPVVIGLMA
LLFFGQRPRSHELLGIVLAFLGVLAIVSQGDREVLLNLELNPGDLVMLLAVCCWGLYSLL
LKRYGPDIPAVPMLAVMVAMGIPVIVPFLVWELIMVGPVQGTVMEMLPPLIYVGIFPSLL
AYLFWNNGVHVLGPARTALFIYLVPVFGSALAILFLGERLEPYHGVGAAAILAGLYVATR
GLPGRRPVEEEHP
>fig|187272.6.peg.1018 Acriflavin resistance plasma membrane protein
MIRWFAAHPTAANLVLVILVAVGLFAAPTLQRETFPDYRPGEVSIEVAYRGASAADVEDN
ICRRLHDAVKGVEHLDEFVCTAQDNRASATASMAPRGTMARFLGDIDTEVKAITDFPERA
DPAVVRELHRTDLVAAVAITGDLSLVDHEAYAQRLEDRLIALPGVADVITHGLSQRQWQV
EVGHDALAQHGLSAIELAARVAAQNIDSPLGTLETPDREILLRFTDERHDLVGLGELVVL
SDEGGGELRLSEIARLSEHREHTEEKVLMNGRRAVLLEVHKATHADALDVMEAMQGLLET
ERARWGEALTLTVTQDATSIVRDRLQMLVSNGLLGLILVLLVLSLFFRPRLALWAGIGLP
VGFLGAFTVMALTGLSLNMITLVALLMAIGLVMDHAIVITDNISARARAGSRALEAVVEG
ARQVLPGVISSFLTTVVVFTPLSFLAGELGAVLQVLPVVLIAALTASLIEAFLVLPHHLR
GGLDRIQSKGNSRLRQGFDRAFDRFREGVGSLADRAIRFRHGVLAGTLVILLASAGYLVG
GHLGTEAMPDIDGDVLEARILMPQGTPLSRTEAVAKQVSEAMAELNERLTPEQPDGASLV
RNLQVRFNHNPSAGEPGPHVATLSVDLLTAERRTVDLETLTAAWREAIGPIAGVHSLVIQ
EPGFGPAGTPIEVRLSGDDLDELQQASEHLKETLGTYQGVYNVLHDLRPGKPQYQFRMAE
GAHGLGLTAEATARQLRAAILGELGGTLRIGAHDVEILVRHTERDRNRLDALEELTVLGP
DGQRIPLAVATERKAAREWARITRVDGQRTVTVEANVNPRVANAQAIVNDLQNHWLPDFK
AAHPTLAVGFEGQVARSAETGGSVRRALLIGLIGIYVILSFQFRSYVEPLLVMVAIPLAF
MGALWGHVLMGYYLSMPSLVGAASLAGIVVNNAILLILFIKAHRDAGLSAVRAAGQASRD
RLRAILISSGTTTAGVLPLLAESSTQADAIKPLVISVVFGLATSTVLVLFVIPALYVIFD
EHRARRLRSSAEEHP
>fig|187272.6.peg.1119 Permeases of the drug/metabolite transporter (DMT) superfamily
MSDAVRRGATLIIIAELLLATMAATIKAASAELPSEMLVFFRNLFGLLLLLPLLVRGGRR
GLATRVPHLHLLRGLAGVGAMYCFFWTIAHMPLAEALLVKLSAPFFLPLIAWLWLRETLS
GRTVLAIAVGFLGVYFILQPNGAMQGAALQVGAVGLAGAALAALAKVTIRRMGPEESSRR
VVFWFGVTATTVSALPLPWVWQTPTGQTLVLLVVLGACATSAQLLLTRAFAIAPSGRLGP
FTYISVVFGSLYGWWIWGELLGPMTLLGMALVIGAGLLNLTLRRPAAPPARRPAEEHP
>fig|187272.6.peg.1125 Multidrug resistance transporter, Bcr/CflA family
MPHYQLAILLGMTVALGPLALDAYLPAFPAIAGDLGVSKADVGLTLSAYVFALGLAQLIG
GPLSDRYGRQRVLLLGLAVFAAAAFMVAQADSLNEMLAWRVVQGVGGAFCAVSVPAIVRD
QCRGNEAARLFGLIGLVMFIAPASAPALGSALLAVSNWPAIYYALGGYALLLGVLLHYRL
FRRIPVRVPARTPVQSLVTNYLLVLRHRVAMRFIALQTLAFSAMLVFITHASFIYQGWFG
FSSSAFAALFAANVAAMAVLNLVNRRLLLRFPSVHILRTAVATQHLAIALLILLVLLDAP
SWAVVACLMAVTGCMGAIVPNSLAGALDYFPNLGGTAAALLGATQFTVAGAVSALSTRLA
GEALLPIVLIMAVCSLGAVLLANGAPRAVQRQAAMQATPQGLDAPTPPSTPR
>fig|187272.6.peg.1158 Acriflavin resistance protein
MIRGDRAGGLAWFSRHPVAANLVLILMVVGGLYSVTQLNTQFFPNFELDIVNVEVEWQGA
TAEDVADGITRPLEDELRDLDGLREMVSTSAEGIAVITLEFAEGTDMAQAVEDAKERVGR
VRNLPPDSETPTINRITRYDPIARVLLTGEVQPDELRGLARSLEESLLQSGVARVQVTGL
PAEEIRITTRNERLLDLGLSFDRFAGLIASQSRDLPAGEVGEADVARQLRSLEQRRSVAE
FENLQLAIDGRNILLGDIARVERLPRDREVEVYFQGRPAVELLLERAEQEDALDSARILE
EWVAETRPTLPPGVELQVFDESWELISERIGLLVKNGLGGLILVVGILFIFLSGRVAFWV
TVGIPASFLAALTVLWLVGGSINMISLFALIMTLGIIVDDAIVVGEDGLSHYQRGESPFQ
ASEGGARRMFPPVIASSLTTVAAFLPLMAVGGVIGNILFDIPLVVVCVILASLVEAFLVL
PGHLRRSFEAMQRADGGWSGRIWRLLRRQRRQPAAEAGGRTGPPGPGPVRRRIDGAFDTF
RDRYFIPAVRRAIAFRWTTIAVGIALLIGSVGLVAGGRIAFTFFPTVEGTILYGNVSFVA
GTPRERTEAYLGELEQALLGAEEALGGDLLRGHLVYVGKKQSDGAGTQDRGDHYGAIMAE
LVSPDARTVSNREFMAAWRERVPEAAGLERLVVQERMAGPPGDDLDIRLIGPDVQRLKAA
SEALQDALASYTGVSAISDDLPWGQEQWVYSLTDEGRALGLDVAEIGSQLRATYLGELVQ
IFHERRDEVEVRVRLDEEERRGLAALSDFRVQLPEGGAVPLDSVAVLDSRRGFEALRHVD
ARQAVTVTADVDASVANANRILADLEARVLPELAARHGLEYRFGGRAQDQEETLADMRAG
LVLALTLIYIILAWIFGSYGWPLVVMAVIPFSLVGAFLGHWLMGLDLTILSLFGLFGLTG
IVVNNSIILVVFYRQLREQARMAADEALLEASRQRLRPVLLTSLTTIGGLVPLLFETSVQ
AQFLIPMAVSIAGGLAGATLLVLFLVPAMLSVYERAAERLQGDANRFREATDHG
>fig|187272.6.peg.2048 Bacteriocin resistance protein, putative
MPKGFCKGGDIVTLLKHRSFNRAQAGRDFSRVIPQSRPDSCGLAALATLMNEVLHLPTSE
AALQARLKHRRPASLTDLSKLSRQAGLKAHAYAVDLDLLLRVQRPAILHMGASRRIGHYV
VVRGVADDKAWLADPMRGNVHLDLTALKKHWYVPRKPFGHVLYVAGADEEWLPLNEEHLP
GSPPETVSDWFPPPAGR
>fig|187303.17.peg.49 Glyoxalase/bleomycin resistance
MKQPRPRVAPYLTVSPAAAAIAFYTGAFGAQQRALMPSVDGLRIAHCELLINGGSVMLAD
IFPEFGQTRVPMPGEHVTVSISLEYDKAQDVDDVCARAAKLGGKVETAPTNSFWGTRYAS
LRDPFGHRWILNAPLET
>fig|187303.17.peg.1071 Membrane fusion component of tripartite multidrug resistance system
MAPLERGRAESDGPPSSAARRVGFVRRHPALILLGALALIMLGVGGFIYWDYASHFETTD
DAFVDARQYSISPKVSGYLTAVEVTDNQHVSPGDVIARIDQRDYRIALADAEAQLAAAQA
SAKNLDAQIAAQRAQIGASEAQVEQSQAALRFAQQEATRSRTLVQRGTGTVQRQQQTSSQ
LGQEQARRERAGDTLQAARAQVQSLEAQRATAEARIGQASAQVDKARLDLSYTTVKAAES
GRVVRLTAAVGQLVQAGTSLAMFVPDNIWVTANFKETQLDDMRPGQPVQMRIDAYPEREF
RGRVVSVQPGSGTAFSLLPAENATGNYVKIVQRVPVKISFSDLPSDVVLGPGMSVVPSIR
VRPQLSIYERLRTRL
>fig|187303.17.peg.1072 Inner membrane component of tripartite multidrug resistance system
MSVADDVGAAGEASDSPNPWLIAMVVSVATFMEVLDTTIANVALPYIAGGMGVSPDEATW
VVTTYLVSNAVILTASSHLAKALGRKPFFLVCLALFTASSILCGFAWDIRSLLFFRVLQG
LGGGGMVPVSQSILADAFPPEKRGQGFALFGIAVVVAPVIGPTLGGWLSDNYSWHWCFLI
NGPIGLLSIAMVAVVLREPEDRPSAAPFDLVGFLLVSTFLGSLEVVLDRGQREDWFGSNF
IVGFAILSAAAFAFMIPWEATRENPVVDIRMIATRQFGACFAVMMALGAVLIATTQILPQ
LLQLSFGYTATLAGLVLSPGGVVTMAMMIVVGRLSSLVQPKYLIMAGAAIVALSIYNLTS
FYGDVDFWYFARTRIYIGIGLPLIFIPITTASYQGLPPEKTDQASALINVARNVGGSIGV
SLAQNVLAHREQFHLNRLAENTIPSNIQFQETLRRATEHFLALGGTASEARRQAVIWIGR
QMQTQASHLAYIDVFYALTLVAATIIPFALCLRRVRLGASNSAPAH
>fig|187303.17.peg.1838 Acriflavin resistance protein
MAGVNLSRWAVQRPTLMLFLMIAISLTGVYSYMRLGRAEDPSFTIKVAVVTASWPGATAT
EIRDQVADLMEKKLQELPFLDKIDSYTKPGFLAMQVTFKDTTPPKDVPQLFYQLRKKLDD
IAPTLPAGVRGPQVNDEYGDVDTVMYAVTGDGADYDVLDKVVQTLRQRLLAVQDVIKVDV
YGDQGRRIFVEFSEAKLASLAIQPQAVFDSLAKQNAINDAGVFETSSNRVRVQVTSDLKG
ADAIAAIPIEANGKVVRLGDIANVYAGFEDPPSFLARFKGRPAIVVGVVMGKGANVLRFG
ENVGAAVEEIRGKTPVGVDIDQIADQPKVVDEAIGEFTRSFLEALVIVLGVSFVSLGFRT
GIVVALSVPLVLAIVFIFMGPLGIDLQRISLGALIIALGLLVDDAIIAVEMMMVKMEQGF
NRIKAATFAWDSTAFPMLTGTLVTAAGFLPVGFANSAVGEYTGSMFWVLLVALIASWFVA
VMFTPYLGVKLLPDFAKLHPHHDPDEIYRTPFYRWLRAVVTWAVDYRGVVIAGVIGVFAL
AVFGFFVVPKQFFPYAERMELFLQLRLPEGSSIGASLEAAKQAEALLKDDPDAALYTSYV
GQGPPRFWLGLNPQLPNEAYSEIVIVAKDIAARERLKKKLETAIANGALPQARARVDRFY
YGPPVGFPVQFRVVGSDPATVRAIAYQVRDVMRGDEGVDDPHLNWNEQTPRVRLVIDQDR
ARLLGLTPQDVSNRLRLAISGVTIATLRDGIDQVEVVARAIPQERGDLSRIGDMVIYARD
GKAVTVSQVAKIVYDHEEPIFWRRNRDMSITVRSGVKDGVQAPDATMRIWPQLAQIRERL
PPGYRIEMGGAIEESKKGNASIFAVFPLVGLVMLTIVMFQLQNFTRVALVMMSAPLGVIG
ASLALNVAHAPFGFVALLGLIALSGMDMRNSIILVDQVRQDLERGEKYREAIIGATIRRV
RPVALTALAAILAMIPLSGSAFWGPMALTIMGGLFVATFLTVLFLPALYATWFRRHLGEG
LAEAKGARARTLADGLARGAAE
>fig|187303.17.peg.3387 Permeases of the drug/metabolite transporter (DMT) superfamily
MSRIRADLLLVLAAFIWGTAFIAQKNAGELMGPITFVGVRFLLSCVALAPLALYEGRHSE
AALKKGDLPLAGLIGFCVFAAAALQQVGLATTTATNGGFLTALYVVLVPAFVFAQTGVRP
RQVVLVAGLASILGAWLLTDSGRLQSWTSGDALVLIADIAWAAGISLVPTFLARTDRPYF
LAFAQFGVIGVLGAVVGLAGEPFSLDGLIAALPSILYAGLCSGGIAFTIQIVALKYTPAA
EAALIMSLESVFAAVSGAILLSERLTGPAMLGGALILLSAVLVEAGPAAQTIWLTQYWTW
LAQVWSRAR
>fig|187420.1.peg.193 Efflux pump antibiotic resistance protein
MNEYNDRSLRLYVLIAATLSSFLTPFMGSSINVALPVIALQFKIDAILQTWIPTAFLLAA
AIFAVPFGRLSEIYGMKRVFVYGNIIFTVSAILSAFSPSAMALIVFRAIQGVGSAMIFVT
GLAILTRVFPPYERGKAIGINTAAVYIGLSMGPVLGGFLTRFLGWQSIFLSTVPLTVIVL
AVSLLRIDGEWADAAGETFDIPGSISYCIFLFLLMYGFSALPDTMGALMILLSIGAFAVF
LRMELSSTSPVFNVRLFRNLTFSFSSLAALINYSATFAVSLLLSYHLQYIKGLDPGSSGL
ILVTQPIVMALVAPVAGRASDRFNPQTLAGIGMAVTSLALLSLSILDRTTPVPMIIVSLF
VLGLGFGFFSSPNTNAIMGSVERKDYGIASATVSSMRLIGQAFSIGIVTLIFAFLIGRVP
ISPANYDLLIESTRICFLIFGVLCFVGVFAATARRNDG
>fig|188937.1.peg.168 Class H tetracycline resistance efflux protein
MNMETDPESVRQENRPDPSARERISLLPLLTVNFIGTLGFSIVLPFLVFLVNRLGGNAFI
YGLASSMYPAFQLIGAPILGRWSDIYGRKKILLFSQVGTLLSWIIFLGALFLPVVTLFQV
DSEVLGTFAFTLPLAALFFARAFDGLTGGNVSVANAYLADITEEKDRNRNFGKMSISSNL
GFIVGPALAGLLSITAYGEAAPVIGAVVISLIGTLLIIFYIPENKECSLEGPVEAKNIRK
VFGYEIKECRTVRETGKPSFREVFKLPNIPYMLGLYFLIFLGFNIFYTAFPLHAIAALDW
GIAEMGVYFTILSGLLIIVQGSILPRLSKRYSDASLIIFGSLMLGTNFLLLIPGNLFLTY
LATGFFAMGDGLMWPSFLSLLSKIAGKNYQGTVQGFAGSFGGLASITGLILGGLLYELLA
GRAFLLAGMIIYVVFLLNFRLRRFEKELKY
>fig|188937.1.peg.333 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MDERSQMLANEKISKLLLKLSVPAMVGMLVQAFYNLVDTIFVGHAYGADSIQAIGGIAVA
FPIQMVGMAVSLAIGIGGSSIISRRMGEREMKKANKTFSNLIFLSILSSLLITGAGISFI
VPLLKLFGATETILPYSLEYLEVILYGTVLFSLAMVTNSIARSEGNAKVAMNSMMMAGGL
NIILDPIFIFGFGMGIRGAAIATVLAQGIGVLYIARYFLSGKSTLRFHPADLKPDSKIIK
EVLAIGASPFARNVSSSFMIIILNNLLAFYGGDIAIAIFGIISKLLMFTLMPMFGIIQGL
QPIVGFNYGAKNFGRVRESVKLAIIITTGMSIAGFLVLYLFPEQLFGIFSGDHQLIVEGK
NAVRIVVLATPLIGFQVVGGALYQALGKARPSLFLSMCRQVLFLIPLVLILPKYLELFGV
WAAFPLADTLAFAVTLIMVIREFKVLAEEGENMRNDPMRNDPLAGN
>fig|188937.1.peg.497 Antibiotic resistance protein McbG
MEYQNEEFEAETFKDTDLTDVSFKDSRFIDCDFENCNLSNVDLDNTKFQNIRFKSCKILG
LDFSKCNDFILAFGFEDSFLSLSVFSNMNLENTDFTNCQIYDCDFVNTNLTNANFENSDL
KNSLFKKSNLSFTSFKNAKNYDINPNENFLKKTVFSIPEVISLLDIYDIVLG
>fig|188937.1.peg.2619 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MVSDEELRSGNIFNLFWKFTFPAVVGVIIVGIQEIIDGFFIGNAVGNQGLAGITLAYPPY
LIIIGAGIIIGIGSSSLTALKLGKGNKKEAFEIVHNAFPLSLLTGAIFTVGGLIFCETSL
GLLGTDGPALFFAREYLRIIFAGSVFMVLAISLDPLVRNDGKPRLCMHIMAAGVVINIVL
DYFFVMRMGMGMPGAAAATILSFVLPAVLLMRYLFGSEAKLKLRLRSMSFKPVTVLQIFK
AGTPSFAMQISFALLLFAHNYMLLRYGSELAVSAYGIIGYVFSIFYMLFEGIALGVQPIM
GFNYGAGSYERVSKTLKLTMLSCILVGVFGFMLICLFPETLVQLFSQNDPELLEITLRGM
NIGMFSLLVEGIVLLTSIYYQSINRVRAALFINLGKIFIFLFPLLFILPLFFGLDGVWSA
SPVAEYFMVILVMVMLSKEFRFLRESAKAVTGKPADLKTNAKANIRASTKAEAKYAPSVS
RSSVKAGSKESTGFVAFKHAENAESS
>fig|188937.1.peg.3100 MATE family drug/sodium antiporter
MNKKHASPKTAGKMSMETAEEKGNTEEKKAKKEKLEESRDGKEKTGSIPSQKVTEGVDVL
LGDPKKAVVKLSIPIIVAMSVQTIYSLTDTFWVAGLGADALAAIGFSFPFFVIQMALTSG
LGVGGGAAISRRIGARDKAGVDNVAVHTFVLMVILTVALTIFGLAFVRDLFMYSGAGGTT
DLGVAYARVIFAGSFVFFFANVSNSILRSEGDAKRAMQSMILGSVLNIGLDPIFIYVLGL
GVAGAALATVVSFACSGLLMFYWFFVKKDTYVSFDFHSFKFNLAIANDIFRVGIPSSVEQ
VALAMTALLMNLIIVNVSNTDGVAVYATGWRVASIAVAPLIGVSISVVSISGAAFGEKNF
KKARHALIYATEIGFLAEALIGIAVYVFAPQISAVFTQAETAARIAPELTRLLKIMTVFY
PAVTFGMLSASLFQGAGKGTSALIATLLRSLVLTPLFAVLFAYELGWGLLGVWWGLVAGT
VIGSLITFAWAQVYLGCMIKEEGIGEKC
>fig|188937.1.peg.3324 Multiple antibiotic resistance protein
MVSENLGFFIYVFSSIFVVVSPVGGVVTFISLTSKMTRKEKNEIAKKAVILACSIALFFA
ITGSMILNLFSISVDSLRVAGGILLFTIAFDMMQAKVSRESITEEEITQSQEREDIWVFP
IGLPLLTGPGTISTVIVLMGMADGVQQKGVVLVSIIATFLICLIVFHFSRRLHKFIGYNG
MLVFTRLMGLLLAALAVDLTSTGIINIFGLGT
>fig|188937.1.peg.3492 Multidrug resistance efflux pump
MNTCNLQKNVFPEFFGNINHELYVLSFSRFCEDLGSGMLVALIPLYISDLGASFFSGLPL
VTRAGLVITVFGLFSALTQPLMGRLSDRLDRRRPFILFGLIGYTFFSFLYSQVTSYEQLL
FIRLLQGITVGATIPAVIAMVTHISTSETRGKAVGVYTTIRGVGFGLGPVVGGAIARYWG
FDAGFYFCALLGVVSLGLVTFFVKETRGSPEPVSRKISGKKSYASVYSLAGAMLMMMVGI
MMVVALLPEYEVRLEASELSLGVAVSAYIFARLLFQAPLGSLSDRIGRKKLIVGGLFLSA
PLVVGMGYIASVGQLIIFRAFQGLLVAAIDTPAMALAADLSDGSSLSSRLSIITTAQAAG
MAFGPIFGGFLAGYMTFVTPFYACALLMLLAGFVVIKKVEEPEKVI
>fig|188937.1.peg.4097 Antibiotic resistance ABC transporter permease protein
MSFQFRAIYWRDMLKFFRFKSMLISSLVQPVMWLAFFGLAMSESFDQLTSLVPPMEGVQN
VDYLTFMGAGIIAMDVLFSSLFGGTSLMFDKKFSLLRETLASPVPRFHIILGVGLSGVTK
AFIQTSMIIGFGKLIGMDFFKGYTLTETLISIIGIFLLVGIFTLGFLFLSGSIAITIENP
EGMQSILTLLSMPLFFVSNALYPIESFPAILKFLSMFNPLTLLADGIRYFALGDNFTVIG
IHYVYTLFDISMSFLGLMIFALAMLATSLWRFNKVDV
>fig|188937.1.peg.4098 Antibiotic resistance ABC transporter ATP-binding protein
MTANVIEVNGLEHSYGSVKAVDNISFAVKEGEIFSFLGPNGAGKSTVINILTTLRKIQKG
EAKVNGYDVERESKHVRQSIGIVFQMLCIDHEMTVCENLEYHGKIYSMSKKERKERIDEL
LKLIELEHKRDTLVKDLSGGMKRRLELARGLMTKPAVLFLDEPTIGFDIQTRMRMWEYLR
EIKREGTTIFLTTHYMEEADQLSDRISIIDHGKIIVTGTSEELKNKLGKDLIYLETDDNN
TVAEILRTIGSVKTVTEDTKSLRVMIGEDVTHVLPQIIDKIRKAGIDITTINIKKPSMDD
VFVHYTGHGLREGEPQEKVEGLEPMGEPMGVSA
>fig|188937.1.peg.4503 Multidrug resistance protein
MKTDGIASDSNILNGKEYLVAVGVVLLGLFMSVMDTVIVNIALPSITAYFGNTISESQWV
VTAYLITITAFMIVFGKLSTYTGLKKMFLGGIALFTVSSLGCGMASSLLMLITFRITQAI
GGAMASSISMALIYRISPPDKQGKAIGIMGATVAIASLAGPGIGGILIEMFDWRAIFHIN
IPIGIIGLFIGIPYLKVTDTKKKGENIDWIGAVSFAVGITSLMVLFNAITTKGLYSMEVL
VTFTVMFFAFMLLGWNERRQIDPMLDTGVFREPMFFLPLLSTILFFAAVFMLNITMPFYL
EEVLEFTPLHVGMLMMAIPVVLIVGSPIVGWLYDHYLWQHFSTMGLLVAFSALLICAWAI
LDERLGIILFSMGLFAAGYSLFQSPNNIEIMRGLHKDRAAIASSIANTGRYFGMAIGASF
ASVILSIQFLSTELTKALPEIDINSLTLSSGVTLAIAALLCIIAAWPSYIRNRNN
>fig|190304.1.peg.3 Multidrug resistance protein 2
MAILYDSVITAFLLQLGLKNTQIGLLWSVVLLTQMLFDYPTGSFADRYGRLKIFTIGMVL
TGSAIVMIAYSVSISMLYISAILMGIGESQISGTLFPWFVNSLDKVDNLQEKEEYILKSN
GQVQYSTNIIGILTGFVISFLNLDYKFILILAGTFQAINGIFIYFSFQDNKSTETNLIKI
GKKSFQIFLKDYKLWIYTLTMTIHYSFYSVHLFIWQPRANLLGVIGSKLTGINSVYLSCL
VISGLIIKYKKEIKNYLYVLYVILIPISLIIIYQSQNLILYILGTILLGISNGMVAPQIM
STVHYFIPDEVRSSVISLLSSLSSIFLIFLQVIIGKILDIKGNYYLEILCVLFGIIYIVC
IILILKWLKENRNR
>fig|190304.1.peg.221 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MENKHNFMETESITKLLIKFSIPAIVGMFVNALYNVVDRIYIGNIKDIGHLGITGIGVVF
PVVILIFAFSLLIGIGSAAAVSLKLGMKDREEAERFLGVAVFLSFIVSVVLMIIIYFNMD
KIIYFIGGSNETFIYAKDYLFYINLGVPAAILGLVLNSVIRSDGSPKIAMGTLLVGAITN
IVLDPIFIFGFGMGVKGAAIATIISQYVSMLWTIYYFTSNKSKIKLVKKDIKFNFYKAKE
ICLLGSSAFAIQLGFSLVTYILNTVLKKYGGDTSIGAMAIVQSFMTFMAMPIFGINQGIQ
PILGYNYGAEKYKRVKEALYKGIFAATIICIIGYTSVRLFSDTLIKIFTTKPELQEITKY
GLKAYTMVFPIVGFQIVSSIYFQAVGKPRMSFFISLSRQIIVMIPCLIILPIFFGLNGIW
YAAPTADSIATLITYILVRKEIKKLDKLEEMLELRNI
>fig|190304.1.peg.937 Permease of the drug/metabolite transporter (DMT) superfamily
MKNIPAFIFAGFSGYAGYIALFNIATLFSSPSTLSVINALAPAITAIVAYFIFNERIKLI
GCLSMGISFCGILILTLWDGVLTVNKGILYMLAGCLLLSLYNISQRYLTKKYSSFDVSMY
SMLIGGILLVIYSPSSITNMFSISFTSLILIIYMSIFPSIISYFFWTKAFELAKHTTEVT
SFMFVTPVLATLMGIIILGDIPKLSTLIGGVVIILGMILFNKTK
>fig|190304.1.peg.1050 Acriflavin resistance protein B
MLIERGNKMKLIKIAIKRTIVTTMISISLLILGIFAMKSMRTELLPDIEYPVVKIITHWS
GASAEDVEKQITNKIERILPNVEGIENISSESSYENSSISVEFNYGVNIQDKVTEIQREV
FQIKNDLPNSAKNPIIKKTEVGAGAITLFLTFVSPDKKALFSYLENYVKPNLETISGVAE
VSILGGTKKQLQIQIEPAKLASYNLTPMDIYQLIRKSSMVIPLGSLMNGREEYVIQALGE
LESVEEYENILLHSNGDTLRLKDIANVVLTEEDPLNLGFNRGKPATTIAISKSSDGSTIE
INEKIMKAIKNMEETMPSNITYFKIFDSSESIKKSINTVGKSALQGLILASLFLWIFFKN
KKMTLIVSFAFPLAISTTFILMKGIHSTFNLISLMGLAIGVGMLTDNSVVVIDNIYNHIQ
EEKNSIEAAFIGTNQVFSSVLASTLTSIIVFLPIIFTKGIFKEMFQDMVWAIIFSNVAAL
LVSVTFIPMLASKFMKKNIIQTEGKYFSKIQRKYQKFLSISLKHKKKTVLISLLFAFLIF
GIGGKFVKFGFLTKQDYGYYSVIAEFQNGSDFEKIQELRNEIETIIKKESHTKSYFSIIQ
KRNGTISVNVDVGFKEKRKESIFEIVKKVRKEVEKIPDIRTTFFYEYAKGKPKKDIEFQI
VGTDLETIQILARQIYKDVLKIKGVTDVSSTLDSGGKKLEIIFKRDKIQSLNISIKQIEE
TISYYLLGGDRANTITIKSGNEEIEVLVRLSKDNRKSIKQLENLKIKVTDNSFINLSEIA
DIRKVENQLSIDKINRFYSVSIYVNDGGIGTQKIQEELVKIFSEKNKDSSIQYRWGGDAE
KMQRAMKELMLTFLIAIFLIYALLASQFESFLFPFLVMGSIPFSLVGVIIGFLITQHTLD
AVAMVGIILLIGIVVNNAIVLLDFIQQEEKESKNKKEAIEKACNLRLRPILLTSLTTIVG
MIPLSLGIGDGSEVYQGLGISIIFGMSFSTLLTLIFVPTTYYMLTSIFSKKL
>fig|190304.1.peg.1092 Acriflavin resistance protein E
MKIKYILLFLIIFIFTACKKDAEEEIIRPVKIQEINSIQDENFNIDFPAQISPTQKTVLA
FKYAGKIKSINFESGDFVKKGQVIATMDNKDYMVNLEAFSKKYEAAKAVAQNAEVQFSRA
EKLYKGGALAKKDYDNALMQKNVAISTFKEASAGLENARNTLNDTKIIAPYDGYIDKKIV
EVGTVVPEGGPVISFISNEITDISINASLKDVENIRNAKNIVFKDNSSEKVYPLEIKNIA
QNPDSINLTYPVIFTFSNLGKDEKFLSGQTGTVTISVKNNGNQEILIPLDALFEDNGSNV
YLFKNGVAVKTAVEIGELRETDKISIIKGLKSGDKVIVAGVHKLVDGEKVKLLGGTK
>fig|190304.1.peg.1250 Permease of the drug/metabolite transporter (DMT) superfamily
MQENHKYNIYMFIATIFFGMTYVLTKICLKYSTEFHIISFRFLIAFVVSLIFLQKKIFPV
KRTEFLYSLLLGALLFLVFIAMTIGVKYTTATNASFLISLSVIFIPFFSWFFNKEKPKKR
IFVVLIIALIGIILLTLDKNLEFHIGDILCLICATLFTFYVIMTEKIVKNNNPTALGVLQ
FGWVFLFSFLVQYPIESFVIPKNKFFWLSMVLLGIFCTAFGYIAQTIAQKNLSSTVVGFI
LSLEPVFSGIFGYFFLNEYLSFQQYIGAFLLLISVIYVSVKN
>fig|190304.1.peg.1520 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MGEERKELNPLGYKLIGKLLKSLAIPAIIANLVNALYNVVDQIFIGQRIGYLGNAATNIA
FPITTMCLAIGLTLGIGGASNFSLELGKGYPEKSKHTAGTAASTLIIIGIILCIVVRIFL
EPLMLDFGATDKILEYSMEYTGITSFGIPFLLFSIGVNPLVRADGNAKYSMIAIVTGAIL
NTILDPLFMFVYNWGIAGAAWATVISQIVSALLLLIYFPRFKSVKFSLNDFIPQLHYLKR
IISLGFASFIYQFSNMIVLVTTNNLLKIYGKNSIYGSDIPIAVFGIVMKINVIFIAIVLG
LVQGAQPIFGFNYGAKSYHRVRETMRLLLKVTFSIATILFIIFQVFPKQIISLFGEGDKL
YFEFATKYMRIFLAFISLNSIQISIATFFPSIGKAIKGAIVSLTKQLIVLFPLLLTLPIF
FGVEGVIYATPLTDLIAFTVAIIFLTNELKHMPKK
>fig|190304.1.peg.1614 Permease of the drug/metabolite transporter (DMT) superfamily
MMNKKRYFGDLMLFLAAFIWGTAFVAQVTGMDRIGPFTFNMARSIIAIICLGAYLIITKS
KLPKDIGVLLQGGLVCGFFIFMGTSLQQIGLQYTTAGKTGFITSFYILIIPFLTMIFLKH
KIDLLTWISIIIGFIGLYLLAIPNLSDFTINRGDFIVFLGSFCWGGHILIIDYYSKKVSP
VQLSFLQFVMLTILSGICALLFENETATMNNIFLSWKSIAYAGFLSSGIAYTLQMVGQKY
TNPIIASLILSLEAVFAALAGYIMLDEVMTSREFLGCSIVFLAIIFSQIPKDIFKKKYVS
LKK
>fig|190304.1.peg.1851 Acriflavin resistance protein B
MSLAGISIRRPVATTMVMVSFIFIGLLAMFSMKKELIPNIKIPVVTITTTWTGAVSENVE
TQVTKKIKDSLSNVDAIDKIQTVSAYGVSNVVVNFDYGVDTDEKVTQIQREVSKIANNLP
NDANTPLVRKIEAAGGNMTAIIAFNADSKTALTTFIKEQLKPRLESLPGIGQVDIFGNPD
KQLQIQVDSDKLASYNLSPMELYNIVRTSVATYPIGKLSTGNKDMIIRFMGELDYIDQYK
NILISSDGNTLRLKDVADIVLTTEDADNVGYLNGKESVVVLLQKSSDGDTITLNNAAFKV
IEEMKPYMPAGTEYSIEMDASENINSSISNVSSSAIQGLVLATIILFIFLKSFRTTILIS
LALPVAIIFTFAFLSMRGTTLNLISLMGLSIGVGMLTDNSVVVVDNIYRHITELNSPVME
ASENATEEVTFSVIASALTTIVVFLPILFIPGLAREFFRDMSYAIIFSNLAAIIVAITMI
PMLASRFLDRKSMKSEDGRLFKKIKAFYLKVINKAISHKGLTVLIMVVLFFFSIFVGPKL
LKFEFMPKQDEGKYSLTAELQNGTDLNKAERIAKELEEIIKSDPHTQSYLMLVSTSSISV
NANVGKKNTRDDSVFTIMNDIRNKTSKVLDARVSMTNQFSGGQTNKDVQFLLQGSNQNEI
KQLGKQLLEKLQSYNGMVDISSTLDPGIIELRVNIDRDKIASYGISPTVVAQTISYYMLG
GDKANTATLKTDTEEIDVLVRLPKDKRNDINTLASLNIKVGDNKFVKLSDVATLQYAEGT
SEIRKKNGIYTVTISGNDGGVGLGAIQSKIIEEFNNLNPPSTVSYSWGGQTENMQKTMSQ
LSFALSISIFLIYALLASQFESFIMPIIIIGSIPLALIGVIWGLVILRQPIDIMVMIGVI
LLAGVVVNNAIVLIDFIKTMRTRGYDKDYSIIYSCETRLRPILMTTMTTVFGMIPMALGL
GEGSEFYRGMAITVIFGLSFSTILTLVLIPILYSIVDSFTSKLMTRIKVISRKSKKKEAK
>fig|190304.1.peg.2038 Permease of the drug/metabolite transporter (DMT) superfamily
MLRKERIFLFLVLLLAIIRGSSYIFIKNIIDNQSPFEIIFFRFFLTEIILLIFYIKEFKT
LNHYDLIFGLLAGIFLFSAFAFQTYGLKYTTVSKQSFLTSLYIVIIPLLDFIFFKNKIKK
NVIALFFLILVGLLFISFKDFKNFEFYLNFGDILTILCALGFALNILLFSKIKKFNINVI
NITIIQMLTIGILAFIFQIIFEKKVINFSMNFSLIYLILICTMLNFTIQNISQKYVPAHI
IGLILSLEAIFGTVFAIIFLNETISQNFIIGTFLIAIAVILIQYFENKRGD
>fig|190304.1.peg.2042 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MFKKKIFKTIFKYAIPNVISMWIFTLYTMIDGVFISRFVGSTALAGVNLVLPLINFIFSI
SIMIGVGSSTLMAIKFGENKYDEGNKIFTLSTFLNLFLGIFISAIILLNIDRVINILGAN
KSQEVYRYVKEYLTIIVFFSVFYMSGYAFEIYIKIDGKPSYPAICVLVGGLTNLVLDYVF
VVIFHYGVTGAAIATGISQVASCTMLLLYITLNAKYVKFIKLNKINFEKISKIFRTGFSE
FLTEISSGVLILIYNLVILRKIGVLGVSIFGTVSYITSFITMTMIGFSQGIQPVISYYLG
KKNYKNLKEILKISIIFLGVLGIFCFMFVSLFSEYIGKIFFREQDMILYVKRVLRIYSLS
YLIIGINIFVSAYFTAIKKVIYSALITFPRGILFNSILLLILPNIFGNKVIWIVSFLSEV
LTIFICIYLLKKIKRKGILN
>fig|190304.1.peg.2050 Permease of the drug/metabolite transporter (DMT) superfamily
MRKDYFTRFFYIILMGFGFPIMRFMSIHFETVNNNAVRFLSGGFLFILICIFKFREELKK
ILLESKIILKLLLLGIFMSGNMYFFINGNKVGESLNFLKGTLFLGTAIFIQSIQNLLVKN
VAKKLHTIVISASTATLSGIIYLILSIHTGKIIQLKEVGEGMLIGLSLAGIYGMLTGMLM
AFYIVQKQGVVIFNIIQLLIPVSTAIVGYFTLGETINFYQGIGAIIAIFGCIIALKI
>fig|190485.1.peg.1377 Outer membrane component of tripartite multidrug resistance system
MNAASSFLQRRHPRAVRRLRPILVTTLALALAACASSRGLAPQGTVLEPGAVHAERTFGQ
AQLSPAAWPASDWWRALGDPQLDALIAEGLQHSPSLAAADARLRQAQARTGTAQADRGPS
LSVSGGYAGWQLPESMVGEERGGSYAGSAQVVLDFRYGVDLWGGKRAAWEAAVDQAHAAE
VDAQAARLNLSAAIAEGYAQLAYAWDLQDVANDELARAQKTLELTQRRRGAGIDSELQVR
QAQARVPAAQQQVQSAQQQIDEARNALAALVGQGPDRGLDIARPVLSQSLPPQLPSALPA
DLLGRRPDVVAARWRVEAADKDIAVAKARFYPSLNLTALGGVINSDVGKLLESGSVLGVV
APALSLPIFDGGRLKAGLAGSDAQYDLAVADYNQKVLDALREVADQVNAVRSLEQRARAQ
NDAVQTASAAFGLAQQRYRAGIGSYLEVLSVQEQLLTARQRMAGLHSQQLMASVKLRRAL
GGGFTPEPARDTAHTATSSAQPHS
>fig|190485.1.peg.2300 Outer membrane component of tripartite multidrug resistance system
MQCTDSLRLARMPLAAALASLLLGGCMLGPNYTKPPAVAETAVQAPTLHRASAADVVAAA
PLNHWWEDLRDAQLTQLVTQALADSPNLRAAQARLRANRALANQRRAERLPKLNASALYA
YAEPPQTIVDTLGGLQNGQQGQPPAQGSQALNLEKTELYTAGFDASWELDLFGRRRRAAE
GALAQAQASEAELADAQVQLAAEVGQVYLNYRGLQARLAIADSNLDKIRQSLALVQQRRG
QGAASDLQVEQIATQVQQQQAQRLPLQMQQQEALDQLALMVGREPGALDAQLAAPQPLPM
LPTQVRVDDAGALIRRRPDVRKAERELAASSAQIGEALNGYFPQVSLLGGLSWVAGSPSD
FNSDALTKLAVPMLRWSIFDFGRTRAQVEQARAGNAGREAAYEGAVLAALQDANTALSRF
GSARQQLVVARQAEASATRSAGLMQQRRDAGATSSIDLLDVQRQQLSAQDAAAQAQVQLL
VYYVALQKSLGLGWSEPPQAAAR
>fig|190485.1.peg.2301 Inner membrane component of tripartite multidrug resistance system
MNAAAATGERAGGSAGREKAEPGAWLAVLAGTIGSFMATLDISIVNAALPTIQGEVGASG
TEGTWISTAYLVAEIIMIPLTGWFVRTLGLRNFLLICAVMFTAFSVVCGLSTSLTMMIIG
RVGQGLAGGALIPTALTIVATRLPPSQQTMGTALFGMTVIMGPVIGPLLGGWLTENVSWH
YAFFINVPICVGLVALLLLGLKHEKGNWAGLLDADWLGIYGLTAGLGGLTVVLEEGQRER
WFESSEINTLSVFALSGFLALVISQFGQRAPVIRLSLLLHRSFGAVFIMIMAVGMILFGV
MYMIPQFLSVISGYNTEQAGYVLLLSGLPTVLLMPMMPKLLEVVDVRILVIAGLLCFAAA
CFVNLSLTADTVGMHFVAGQLLQGCGLALAMMSLNQAAISSVPPELAGDASGLFNAGRNL
GGSVGLALISTFQERRMTFHTETIGSAVTANASRAQDFLAGLNAQMQGSAGGEAAIRAVA
QLARLVQQQALVMTYSDLFWIFGVIVVCTIPLAFLLKPLPKGTHLAMH
>fig|190485.1.peg.2302 Membrane fusion component of tripartite multidrug resistance system
MSNHDQQSTDGQSTAADGQGNASRDDDAKKPSPLKNPKVKWTLIIVGVLVVVLLVIWLAY
YLIKGRYMQDTNNAYLQADSVAVAPRVSGYVTQVMVGDNQIVDAGQPLLQIDDRTYQATL
QQAEAAIAAREADIAAATANVAAQESSLVQARTQVASAAASLRFAQAEVKRFAPLAASGA
DTHEHQESLQHDLERARAQYEAAQAQAKGAQSQIQASSAQLEQAKAGVKQATADADQARV
AVEDTRLTSRIHGRVGDKTVQVGQFLAAGTRTMTIVPQQSLYLVANFKETQVGLMRPGQP
AEIEVDALSGVKLHGKVESLSPGTGSQFALLPPENATGNFTKVVQRVPVRIRVLAGEEAR
KVLVPGMSVEVTVDTRSAKDAKQRAEEESDRVQAQERAR
>fig|190485.1.peg.2321 Drug resistance translocase
MSSSVSEAGAAPAPRYPDYRIISLILACAIFMEQMDATVLATALPTLARDFGVAAPAMSI
AMTSYLLALAVLIPASGAIADRFGLRRVFSASIWVFIGGSILCSLADSLPTMVAARVLQG
AGGAMMAPLGRLILLRTVERRHLVSAMAWTLVPAFIGPMLGPPLGGFFVSYLDWRWIFYI
NVPIGITGFLLVRRFIPDIPSESAPARFDLRGFVLCGTALGCLLFGLEMVSQEDGIPRAS
WLLAIGGATALGYLWHARQHPAPLLDLSLLRIDSFRLSVIGGALMRITQGAHPFLLPLLF
QISFGFSAARSGRLILATALGALLMRSITPQLLRRFGYRNSLIGNGVLASLGYMVCALFR
PDWPPALMFGLLLCCGAFMSFQFAAYNTIAYENVPAARMGRASSLYTTLQQLMLSVGVCA
GAMILKLAMLAGDHPQPQQRDFSLAFCVVSLISLSATWWHVRFDKHAGQEMSGHRA
>fig|190485.1.peg.2579 Permease of the drug/metabolite transporter (DMT) superfamily
MSAQPSLQPALGVRDWRTPLELVFLGIVWGCSFLFMRVAAPHFGAAALVEIRLALGATVL
LPFLWVARSRFPLHRWPMLAAIGVLNSALPFLLFAWGAQHAPAAVGAICNAMTVLFTALI
AFVFFGERIGTRRAVALLIGFIGVLVLATGKSAGLSVGPAALAGATASLLYGIGYNLVKR
HMGDLPPAASAASTLGCSALLLAPVAWWQWPSAPVPASAWACAGALGVVCTGLAFLMYYR
LIQRIGPARASTVTYLVPVFGALLAWALLGEALTWTMLLAAVLILGSVAFSQRAR
>fig|190485.1.peg.3335 Permeases of the drug/metabolite transporter (DMT) superfamily
MSVAAAPPEAASRRAIWQLLLAEVLIGSVGVFVHESGQDPVTAVFYRCLFGALFLTVCGV
LGGHLRGLWRERRLLRDAAISGVLLVLNWVALFAGMARSSIGVATMVYHVFPFVMLILAA
VVQGERTRRADLGWTLLAFIGVACSADPLRLWQSADRSYLLGIGLTLLAALLCGASLLMS
RRIGRERPLAVVTVQCWVGTLLLMGFSSSAALHPGLHWAWLVGLGVIHSGIVYVLFYSSY
RHLHVATIAVLAFVYPLVTLLLDYLLYGHALAPVQWLGLGLIVCGTLAVNLKWRWPRWAT
GKAVLQR
>fig|190485.1.peg.3360 Nisin-resistance protein
MQIPEQANRLAIGVVLAGDGAVEVTALRLMAQPVVDAASAAAILDVAIPAIREHALQRSR
IDWATREPQLRAQAASMRKADAYAAIEALIAELDDGHSALLRPSTLRDVEAHATHATVQA
RLLQPDVGYVAVPGLMTSSSDVRGDYQRALSAALDGMASQARCGWIIDLRQNSGGTMWPM
VNGLQPLLGDHVLGYFLNADGEQTPWRARAVPPMSGVRVAQTDRPVAVLIGPNTASAGEM
VAIAFRGRPATRSFGQPSAGQTTSNRTVDLPGGGVLAVASSAMQDRNAQRLDGALQPDMA
LDPQADAIDAAAQWLRMQRCAPAQ
>fig|190485.1.peg.3610 Daunorubicin resistance ABC transporter, permease protein yadH
MNLHAIGAIYRFEMARAFRTLTQSIASPVLSTSLYFVVFGAAIGSRMGAIDGISYGAFII
PGLVMLSLLNESISNASFGIYMPRWAGTIYEVLSAPVAWWEIVIGYVGAAATKSVMLGLL
ILLTARLFVPYEIAHPVWMLGFLVLTALTFSLFGFIIGIWADGFEKLQVIPLMVVTPLTF
LGGSFYSINMLPPIWQKVTLFNPVVYLISGFRWSFYGKADVHIAVSTGMTFLFLLVCLGV
VAAIFRSGYRLKA
>fig|190485.1.peg.3796 Mitomycin resistance protein
MHPAKVDRAHLLRLTDLPNVGPACEKDLQQIGCRMPAQLHGRDAYDMYAQLCLRTGVTHD
PCVIDVFLSLVRFMQGEPARNWWDFSAERKATLAAERTGTRATAPPPGRRVANTSTSTGA
SSDGKHRP
>fig|190485.1.peg.3862 Permease of the drug/metabolite transporter (DMT) superfamily
MSSSHNAAAPAPARNGLVVLALLLVYVVWGSTYLVIRFALAGGAQPLTMVSGARFIVAGT
LLYAVLRWRGVAAPTPAQWKNVAFMGAALLLLGNGMVVLAERSVSSGLAATAVASVPLWM
ALFGALRGQHASRGEWLGIVIGFLGVVWLNAGSSLTATPGGLVLLLIAPIGWAFGSVWSR
GRDLPTPFMTAAGQMLCGGVLLVSTGLLLGERPHAWPTTQGLLAVAYLCVFGSIVAFTAY
VWLLHHVRPALAGSYAYVNPVIAVSLGAWLGHERFSAHDIGAMAVILCGVLVVTLAKARR
>fig|190485.1.peg.4053 Bleomycin resistance protein
MHTAWAVTPPMIAVMCSALIPSTEETRMNASANVGDQTIPILPRRSIAQTLTFYRALGFA
GDAHPHDAGYAILQRGDVELHFFAHPDLDPAACYAGCYLRVTDVDGVYAAMRAAALPAQG
IPRIDPVGDKPWGMREFAIVDESGNLLRIGQQLEP
>fig|190650.1.peg.105 Multiple antibiotic resistance (MarC)-related proteins
MTEANLAVNFFVALFALIDPIGNVPLFAAATLGAAAAGRRMVAVYIGLFMAAFLIFFYFT
GVGLLEFFGISMPAFRIAGGIILFILGLDMVRDDFTTMFADAAEGIEDQSPRAYAKQRFE
RLIVPFAMPLLIGPGSISTVIIYAAEAKDFGAAGMGIGVAVIAAVSLVTVLTFWASPLVS
KVLGRIGMSIVVRVLGLILCALAVQFVLVGVADATRGLIKNDAKAPYAESHK
>fig|190650.1.peg.380 Multidrug resistance protein
METRFVTPFHHLLVNNLVANITNFTIWFALTFYVYLETKSVFATGMIAGVYLVLTAACGI
WFGSLVDHHRKKLAMAGSSLASLLLYALALAVLLLAPKGAIADVGRPWLWALIGLSMLGV
IAGNIRTIALPTLVTLLIPEDRRDKANGLVGMVSGVGFLTTSVISGFLVAWGGMLAALTF
ALGFTVAALVHLLTVPVDEPRVEAEHGAPVAPRRIDLAGTIKVVAAVPGLFALILFATFN
NFLGGIFMALLDAYGLSMVSVQAWGLLFGFLSVAFIISGLAISKTGLGKNPLRTLLLVNL
ISWAVCCVFPLKSSIVMLAMGCFVWMLLGPYAEAAEQTTLQKVVPFERQGRVFGFAQSVE
QAASPLTAFLIGPLTQFIVIPFMTHGAGAAAIGDWFGRGPDRGMALVFTLAGVVGLIVTL
LAFGSKAYRQLSAAYAQGEPAPAA
>fig|190650.1.peg.1274 Tetracycline resistance protein
MWRARRGELSNCCVSSHRRLARGRVRRLRRRHRRLVAAQWAVRLHAALAGRDGLRGWPAG
GAFAQWQGVRGRRRQRLGARRATGVRLASGRLHPGHEHRGRGPFRSGGRGDPRHGRASRL
GQRACAARGASWLSQCGFPGPTWGMVAQPSGRACGAGQQRPPRGGRRGAVMNTTITGGRR
QAALGFIFVTAILDVLSLGVMIPVLPNLVKAFGGGDTAAAADWNVLFATTWGVMQFICSP
ILGLLSDRFGRRPVILTSIFGLGIDFLFMAFAPNLWWLFIGRIFNGMTAASFSTASAYVA
DVTTPENRAKGFGLMGAAFGIGFTFGPALGGWLWEFDHRAPFLVCAALALTNWLYGFFVL
PESLPPERRQPRFDWKKANPIGSLQLLRHHPGLMGLAGVGFLFQLAHNVLPSVFVLYMGF
RYGWSPQTIGLTLMASGIASILIQAFVVGPAVKRLGERGVLLIGLFAGFLGFSIYALAPT
SLLYLAGLPIFAFSGLIQPGLQGLMTRRVGPNEQGQLQGANAAMMGIASIIGPPLFLIPF
AFAVRHDATLHLPGLPILIAAVLMLAATLLAYAKAKPAPAPEPQPA
>fig|190650.1.peg.1512 Antibiotic acyltransferase
MFNAGTGFAQASATPVLSRDGPLDALRFLAALFIVLYHVAERAPVSLFSLSPAFGRGYLA
TDFFLMLSGYVLARTYGARVANSEVDTWTFLKRRVQRIWPPHLVMLALFVAFFLATTAVG
LAPQNPQWFQWDPLLPQIFLVQAWFVPGTSGWNMPTWTLSALIVAYALFPMVWRKVAASS
RPLRLLAMGVCAWVIIDQAALMAFGVHGYQLPLRFGLIRGVPLFLIGVLVARLPVTRLAE
QQALPLAVTSLAIVIGVQALGNFDYFSLALLAFLIYAAGASKPRAWRWAGAAGRLSFPLF
LTNTLTAVVWFGLVRMLDAKLGLPIAAQWTLWALAIPATIIAAWLFERLVDAPLQTWIKS
RSRSGGALAVGKMREASA
>fig|190650.1.peg.1613 Antibiotic hydrolase
MHVTRDVMVTMRDGVRLAIDIYRPAIAGEPTHAPLPVLLERTPYDKRGTNHGDRTRDDPI
PKSKPDLAVQFVRGGYVVAIQDCRGRYASEGVFEKYLGEGADGYDTIAWLAAQPWCDGRV
ATYGLSYGAHVQSAAACLAPPALAAMFLDSGGFSSAYHSGIRQGGAFELKQATWAYKHAL
LSPETQRDPARLAALEAQDLKAWFTRMPWMEGHSPLSAAPEYEKYLLDQWRTGLFGPYWT
QTGVYARGAYDTYADVPMVHMSSWYDPYAVTATENFLGLSGRKRSPVKLILGPWTHGQRS
VTHAGDVDFGPEATLDGALAKDYVALRLAWFDAWLKPDQHAKDPLPPVKLFVMGGGSGRK
TPEGRLDHGGHWRDETAWPPQGARVTDFFLSATGGLSTAREVVDEAFLEYVHDPLNPVPT
IGGAIASGAPVMEPGAFDQREGPHIFGCLPPYRALRDREDVLAFETPPLETDLEVIGPIR
ARLFVSSDGVDTDFTVKLIDVHPPSEDYPDGFAMNLTHGILRARYRERFDWETWMTPGEV
CFIEIEAFPTANRFLKGHRIRLDISSSNFPHFDVNPNTDEPEGYGFTPRRAKNRVYMDAQ
RPSRLLLPIVTR
>fig|190650.1.peg.1652 Multiple antibiotic resistance protein MarC
MDFSPLPTSSLIGAFLLAFPALFSIVNPVGAALIFDQAMGGRSRPERLKLARAIGFYAFL
VLLGSLLLGGYILNFFGVSIGALRVAGGLVVAIRAWGLLMDPEQNEDRKVNQTESAQSHH
DVAFFPLTMPFTTGPGSISVAIALSSQRPTEGDAVAPFFIGASLAAALVAVLVWLCYSAS
GQVMRLLGPSGARVLSRLVAFLLLCIGVQIIASGVENLVAKFLLAHPG
>fig|190650.1.peg.2761 Bleomycin resistance protein
MTDHATPNLPSRDFETTARFYAALGFEQGWRDDGWMILERGSLTLEFFPYPDLDPASSAF
SCCLRLDDLDGFYAVCKATGLPETTLGWPRLHPPRDLGPIIMAALIDPDGTLLRLIGNDA
>fig|190650.1.peg.2870 Bleomycin resistance family protein
MTNFIQVTPFLHVPDLEAALVFFVDLLGFEVPYRQPGYAYVHRETVGFRLLQADEATVTP
RGAGGFAYYIDVRDVDAVVAELTPRLAALPPEDVHGPVDQSYGQREFMIRAPDGGLLVFG
QAIDD
>fig|190650.1.peg.3644 Permease of the drug/metabolite transporter (DMT) superfamily
MRSRGEPLPAGGRMKTLAFVALALAGISWGLGFPTGKLILRETDAAHMVLLRFLVAAVAA
APFALRRPEVRALFRSPIVLLAGALYGVAFLVQFEGLAHVSVTVAALLVGAMPALIAVSA
RVLGEKVSRLSWAGVAAATLGAALIAGKPDGASSPLGVALSIAALFLFLTWLLVLRRAPP
APNPMAIPAVSIIVAALVVLPIALIMHGPPKLALSAPAWTAIVAQGVLATLLATAAWQYG
AAQVGAASAGVFINIEPLMGAACGVLLFGDHLTAALFAGGLLIIGGSFAVVMGERQAKPG
EIQATVAPTP
>fig|190650.1.peg.3688 Membrane fusion component of tripartite multidrug resistance system
MDDCVHLSLVCCAGPDYPARLLSFDKGLAMAASEKKKLVPLIVGGVAIAAVLVGGTLWFL
DKQHFESTDNAFVQADTVQVSPQVSGYVAEVLVADNQRVEPGQVLAKIDPSTFQARVDQA
IANAAAADAAVRAIDDKNSLEQAVIAQRAAGVTSAQADASRAKADLDRYNALADQGWVSQ
QKVQTTRAAATQSAAGVASAQAALEAEKRAAQSLGSAKAQAIAQAAAAHAAVEQAKLDLE
RTVIRAPVSGVVGARAVRPGQLVQPGVALMSVVPLGQAYVVANFKETQVARLRIGQPVEI
KADAFGKEKIVGKVDSFAPATGQEFALIPIENAVGNFTKITQRLPVKIAVDRSQLGAALR
PGLSVEIKVDVRDRSGPSFAEAAQVTPQVARQGAAR
>fig|190650.1.peg.3689 Multidrug resistance protein B
MADAALPADSPSAPATPGATAPVDWTKLFLGFGAMVIGQFMAILDIQIVAASLPQIQAGV
GASTDQVSWIQTAYLIPEVVMIPLSGYLSRLWGTQKLYLASCAGFIVMSILTGLSTSIDM
MIITRALQGFIGGAMIPTVFAVAFTAFPPERRVTASVIMGLIVTLAPTVGPTLGGHLTEW
LSWRWLFFINVPTGLIVLFGVARWGDFDKGDPSLAKGFDWFGLAVMAVFLMSMQYVLEEG
AKEDWLSDSLILWLTVVAVFGGVVFVWRQLTYRNPIVELRAFANRNFTVGVLMTAVSGAS
LFGGTFLLPQFLGRVRHYSASEVGTTMVISGLSMFLTGPIAGRLVRKTDPRLPMCVGFLL
AGFGMYMAHGVTKDWGFWEFAGVQACRGVGVMIAMIATQQITMSTLPPHMVKNASGLVNL
SRNTGGAIGLALLATSITQQTALYYDDLTSKVTQGSAAAGMIAGLTERMMQLGVADPAGA
ARKAVGGMMQQQATVMAFGDSFTLLAIGCFIAAAVSLLAAPVKNAPPPPSDAH
>fig|192952.1.peg.702 Multidrug resistance protein B
MHPDRRLIYVAVFAIMGLSNAVIPILPELAARYHSMYGEFASSLLFSGYFLGALATMLPF
GILSDRFGNLKFIGLGIALTVVSGVFIFLSENLWILIFSRFVEGAACGAFFPAAFSSLSK
CKDPGRCMGEFTFLFNAGLAAGALFSGLLADIFLKSAVLIFTLFALLSGIPLLYRLEELF
NPKKTGTNPKSLSGQDSLKSHFKHSFIKITGLISRRNSGIWLGSFLLNGAVGVLIAYYPD
YSLEILSKARLGGAIASLYICAMVTSLLAGRFKVKEKTIIRIGLAFSALGAFFAIKYPFF
GFSSLGGGSGVAMVGFALAVARMNADRGLAMGLFNTTIYAGLSLLPIVAGFLTETLSLKE
LFLVNGCILTVALLLKN
>fig|192952.1.peg.2552 Quinolone resistance protein
MKTSIPGDGSMLESRIIAAQSDDSYIERMRFEGDILSDVDIARIEFESVQFIQCQFSKCD
FSKASFYNSVFDNCNFANCIFMESYWKGSRILTCKGDGSNFSKSHMKETFLADGSFRYAD
FSSSLMENCSIRDCNFTEAFLSEIRLKKPTLKAVNFAGADFFKTLLKGIDLSDCIIDGIT
VSDTRNELRGAIVNAGQAIELAARVLGIKIV
>fig|194439.1.peg.104 Inner membrane component of tripartite multidrug resistance system
MSSTATTIPGAQALEHHYETGARKWIITATVIIAAMLELIDTTIVNVALNHISGNLGASI
EDVSYVVTSYAIANVIVIPLSGFLGNLFGRRNYFVASIVLFTGASFLCGISTNIWMLVFF
RFIQGIGGGGLLPTSQAILYETFRPEERGAATGIFSMGLVLGPTIGPLLGGYLVDYFAWE
WCFFVNIPIGIAAAWASLTFVKEPKVKPVVEKIDWAGIGLLSVGIGSLQFVLERGEQKDW
FETDYIVWFTIIAVVSLIAFVWLELHTDHPAVDLSVLARSKNLAIGAVLTFIVGFGLYGS
LFIFPVFVQRLLGFTALLTGLVLFPSAMLTGIISMPLGIALQKGASPKLLMTVGMVAFFW
FCWELGNQTLMSGAENFFLVLLIRGFALGFIFIPVTLLAVTGLHGKDIGQATGLNNMVRQ
LGGSFGIAITNTYVTQRVAAHRIDILSHLSPYDPAAVQRLQDMKQALGQYMSSPVEAGQA
AMAALEGIVVRQSYHLAYMDAFKMIAILFAVCLPLLLFIRVDKKETVDMSSVH
>fig|194439.1.peg.105 Membrane fusion component of tripartite multidrug resistance system
MAETQQSNIEAPDNEKGKPKPERSMGRLVIFGILLAIGLVWGGMKLIRSLSYEETDDAQI
AGNIYPVIPRVPGKVVEVLANDNQMVKKGDVLIRLDPSDYQIKRDMAEAQLLKARAAVSG
AKADIIAAAAAQIKLAADLRRSQNLQKQDVISRAELDAATAGATAASAQHAAAGDNYKAA
LAQAKLAEAELKNAELQLSWTTITAPADGKVSKKNVQPGQYVTPGQQLIAIVGSGDLWVV
ANFKETQLEHMRPGQKVIIKVDAFPGKELKGHIDSISAGTGAEFALLPPDNASGNFVKVT
QRVPVKIVFDEKTDLPLAAGMNVIAEVKVK
>fig|194439.1.peg.107 Outer membrane component of tripartite multidrug resistance system
MIAVSFSAGEPLLAAETSGAPLTLDEALRMTREHNPKARQALEELNAADAKVTESRSAWF
PQISGKAGYTYLDPVSEMTFGGLAMKFMPNNNYNARFTAEMMLYDFGRTASTVDLAKAAR
NSARLRQDMTLRDLSLATVQAFYSVLFLQEAVRVQQKEVAALQTNLDHMQKRYDQGAATR
FDLLTTQVRLAGAANREIDYQNQLRNQEITLRRLCGLDEKAPLSLKGSFDITAADMDADK
LAASALDHRPEVMLARENFKAASYKKNLATREFLPKIVGSASWGSTNGYVPDLDKMRTNV
AVGVELQVPIFDGFRKSAALREATAMKRSAEQQQLDAEQVSQAEVRQSVNDLKSSAEKIQ
TTRLQVSQADLAAKHARIRYDNGLATTLDLLDAEAALAEAELANLQARYEYVMNAYSVRR
AAGDLIER
>fig|194439.1.peg.360 Polymyxin resistance protein ArnC, glycosyl transferase (EC 2.4.-.-)
MKLSVVIPLMNEAESIGPLFDALASALQGIDHEIILVDDGSTDSTVAEIKRLAPANARLV
VLNKNYGQTAAMSAGIDEAQGELIATMDGDLQNDPADIPMMIAHLESKGLDVVAGRRAGR
KDGMVLRKIPSKIANAMIRNLTNVHIRDYGCTLKVFKRDVAKNLGLYGELHRFIPVLVQL
YGARMEEVDVRHHARKYGKSKYGIGRTLRVLSDLFFMVFYQKYAHRPMHLFGSLGFVTLF
LGLGINLYLLVLKILGNDIGGRPLLSLGVIMTFIGIQLITTGFIAEFIMRTYYESQNKKP
YIIREIIDKSK
>fig|194439.1.peg.1268 Multidrug resistance protein, FusA/NodT family
MKKRNQVMKRAVPLLLMTLLATIGLTACSPVGEYRRPEVRLPESYPGQTAAGKEMAAVPY
RKFFADPDLLELIDSAVENNHDLLIAMKNIDYAGKTLDVAKLWFLPEVDLSATYDYSRGS
RNSASALKGQARTSRNYTAQLNVSWEADIWAKLRNAKKAAVAEYLRSADVARAVRTTLVS
NVAQGYWNLKMLDEQIDITKRNIALADTTLTMMRLQFDAGNVTSLAVDQQESQLLSAKAT
LPKLEASRTAQENALSILAGRMPGTPIRRSTGYAPFVMPDSLGAGVPLALLSNRPDVRAA
EESLMEAHALTGVNKAMMYPSITITAQGGLNAIESSKWFSTPGSLFNALQGSLLQPIFQH
GQLKAQYEQSKIKRDQAELTFRKTLLVAVGEVSNALAQVEKTGEQETFAKARVAALRKAA
GNSRLLFNSGMATYLEVIAAESSLLQSELELADVQRSRLSAIADLYRAVGGGWRE
>fig|195099.3.peg.345 Multiple antibiotic resistance protein MarC
MGSELYLMFFAAITLLAILNPFGNLTQFLAMSDGLPLMLRKKLFRTILYTAFTIVLVFLL
SGPLFMNYIFRVSLDDLRVSGGLVLIIMAIKNLLFSTKIATKDFSSYQDMDDKEILRQSL
IPMAFPMLVGPGTLASVIVIAEDGGLDVALGGVMIAFIFMFILFHFAATIEKIVGKLILH
VFSRIAQVFIVAMGFKMIIVGLKDIFNL
>fig|195099.3.peg.699 Broad-specificity multidrug efflux pump YkkD
MEWFYLFLATACEIFGVVIMKELVNTKNKLYFLALIVCFGFSFTFLSLSMQNIAMSVAYA
IWTGAGTAGGVMIGVLFYKESKSFLKLFLITVIIACTVGLKFLS
>fig|195099.3.peg.700 Quaternary ammonium compound-resistance protein SugE
MNEKFNINIAWFLIILGGIIECFWVSGLKYSTEIWHYILTAIGVCISFTCFLKACERLEV
SITYSVFVGIGTIGVVLNEMFIFNEAVSIIKLVLIAILLLSIIALKWVSKEA
>fig|195103.9.peg.85 Drug resistance transporter, EmrB/QacA family
MEHVIKKGENAQEVKYNKWAILFCVVTMTFMSCIDGSIVNVALPKISYDLNKPILDTQWI
VTTYLMVISALVLLCGRIGDIKGKCKVFKVGVLIFTIGSFFSGLSKTLPLLIVSRAIQGV
GGSCAMATGMGIITAFFNEKERGKAMGLSASAVAMGVMVGPALGGILVSIRWDLIFWINV
PIGIIAFLLSMVYLPKMETNSKEKIDIRGTIVFAIFIVSSMLSITKGEVLGYTDKYIMLG
FIVSIVSFTVFIYLQKTVESPVLDLNLFKTKLFSLSIVCSALSFLAISSMNIIIPLYLEQ
ALQMSSLHAGLFLMIYPLCLSIVAPLSSSLSDRFNGRLISLIGISLLTVALFFMGRININ
STLIYLGTCCAIMGVGNGIFKSTNNALVMEKVPKHRLGIAGSVNSLVSNLAMAYGFTFAT
TILYGRMSYRLGYKVTNYIPGHEEAFLYGLDCVFFSATIMCLIASVVAFIRYRRKDI
>fig|195103.9.peg.161 Daunorubicin resistance transmembrane protein
MDFFKTIRVYSSFAKGTFKALSSYKANLLMGLIGQLIMISVTYFLWIAIYSSSQEGIMNG
FTLKEMLTYVMITLLIGIVTSNDISQEISFEVRDGSISTNLIKPINYRLRIIFIGIGNFI
FFFLTLFLPGAILISTYAILNGININLASILIFSISIILGCLINIYYSYIFGLLSFKFYN
IWGISQIARAIIMLVSGAMIPLTFFPEIVQKLFNFLPFSSIIYTPAMIYLNKLSYAQIAK
SLGLQLIWVVILMVLSKIMWNKVIDKLTIQGG
>fig|195103.9.peg.723 Permease of the drug/metabolite transporter (DMT) superfamily
MKLKGIILTMLSSITFGFAFTLGPMTYGLEGSNPVTLTFLRNFLSLPFLLVIILLLKIDL
RVTKKQLRDLIILGFVGNAITTLMLNMAFACIDVGIVTPIHFTYPIFVTLGCVIFFHEKL
SKQKVFALIIAMSGIGCFFITALNSASFGKSTLLGLILAVASGMFYAFYIIFMDKSGLKS
EPPFKITFYVAIASTVGMFIYGMLTKELVLSSLTHKAWGLSAIFAFLCTVVALSLLQVGI
KYIGASEAAVISTFEPITSVIFGAILLGEEITLMKIIACSLIFAGVLILSFAKEKSKSNI
KIKESVTN
>fig|195103.9.peg.1399 Drug resistance transporter, EmrB/QacA subfamily
MNNANENSKNTEDLVYKNRWFILAVLVMQPFMACLDSSIVNVALPILQKELGATMAGTEW
IVSSYLIIISASILIFGRLGDMHSKSSVFIKGILIFVLGSFLCGISPSLPILVLSRVVQA
IGAAMLMSTNQGIITDVFPPKERGKALGISGSFVALGSILGPALGGFIVTYFTWHYIFLI
NVPIGIICYIFAKKYLPIRIPKESESMDKPGATMFFIATILIFTSILISQHLGFTSIYVI
LGLIIGLIILALFLIYENKIKNPMLHLSLFKKPIFSVSLICAFISFTAINTINVIQPFYL
NDILGYSPGKISVIMTAYPIVLFVIAPLSGTLSDKIGSKILTLIGLFLTGVSMILLSSLN
SNSSETSIFLMLSLLGFSNGLFQSPNTNLIMSSVPKDKLGIAGGTNALIRNLGLAFGVSA
STSILYAKMSKLAGFRVLGSVPNRPDIFISGMRFVYILVAISCFICLIISIAEYIQSKKN
NK
>fig|195103.9.peg.1433 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MKNQYELKNEKIGRLLLKYSLPAILSMMVTSLYNTVDRAFIGSIKDIGAFAISGLGVTMP
LFTILGAFCVAISVGGSTNISIKLGEEKKEEAERILGNTFILSIVVALIIMIFGFSFLEK
ILYFFGASKETIIYAKDYMRVILIGAWFNFPGFALNNAIRAEGNPKLAGKIMIISCVLNI
ILDPIFIFLFHMGIKGAALGTIICQFIVFLWTMYYFTLGKSNLKLRIKGKILNKNILRAI
ILIALTPFFMELAAGFIHLITNRVLKDYGGDLAIGAMTSITSIYLLFLMPVFGLSQGMQT
IVAYNYGAKEYKRAKKTLLMTIIIATLILTLGLVLIRIYPREFINIFTKDKELINIALNG
LKIYTLALPTLGVSILGAVYFQSIGNVKKSIFLSLLRQVILFIPIIFIIPRVYGLNGVWI
SQPLADILATVLILIFLIKEFYIRDTHDLICRAERT
>fig|195103.9.peg.1469 Vancomycin B-type resistance protein VanW
MKEEKKKSSTGLLKSKKKIIISIVIVLAIIIGSIVAYIVSIQKKVEEWNDKIYPNVYVEN
VNLSGMTKEKAIEVLEKDVKEPVEHKTIKVQAADKSIEIKYSDLSPEYNIDETVNEAMNY
GKDLNLFEKNNLINGKDKKELNLDFKYDESKLTDYEKKLTEMVNQNAKNATISINGSNIS
VIEGEDGRAIEEDKMVSLVKEAINANPEDNSVVEVPVEVTKPKITKEMLSKIDGVIGSFT
TSYTSSDANRSANVEIAAKTVNGTILMPGDTFSYNNTLGERTTAKGYRDGAAYVGNKVVM
VTGGGICQVSTTLYRAVLRAGIMPTERHNHSMTTTYSGPSEDATVSWGSLDYQFKNPYDF
PIYIQGYTSNKHVTFNIYGNVQGMDGKTYELQTVVNETLKPSVKTVDDPNLPEGQKVVEQ
RPVTGYKSSGYLVTYQNGKEIDKKLIGHDVYKQKDEIIKVGTKKAEQPKQEAPKQEQPAT
AKPEEPKQEATQPSTSQPATNQAPDATPQTPNAGQTPPAQ
>fig|195103.9.peg.1678 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MSKKLDLLQDKESTLLRKYMIPSVAGMLGLSVCILFDTMFIGHKIGELGLAALNIALPIY
NLYSAIGLTIGVGGATALSVAMGQKKFHRVNRIFTSAVFATIIFCIIISLLEVFFLDKIV
YMLGASEATFPLAKEYLKIILAFNPAFIFASAFIVFVRNDREPKLAMYAVIGSNTTNIVL
DYVFIYIFNLGMFGAALATSIGQLVALGVLSIHFIKKNNTMHIELGGINLDNIGKVLKNG
VPSFLNEISAGFVIFIFNIVIYKFEGDLGVSAYGIITNIVLIFMAVFNGVSQGVQPLISV
NFGAKKEERVKEFLRLTRIIVLILGVGFLGMGLLLPNQMIGLFTSDRGRLLSITRQGIYL
YFIAFLFNGSNILNIAYLQAVEKSKESSLLSTLRGLVFVIIFIIVLPRIIGVYGVWLTIP
ITELSTLLLFLIFEIKSKRKNI
>fig|196162.6.peg.203 Drug exporter-1 ABC transporter (DrugE1) family, ATP-binding protein
MMEPTTTSHEASGSAIELTGLAKTYGRGATARPAVRPTSLSLPWGQVLGLLGPNGAGKTT
LIKMICGLVTPTAGTVRVGGWDLAADRSRAVLQIGAVLEGSRNVYWPLSAWENLLYFGRL
KGLRVAEVRPRAERLLRDLDLWERRQEQVGSYSRGMQQKVAVAAALITDPPILLLDEPTL
GLDVESARIFKDWIAHLARDDNKTILLTTHQLHVAQELAGRSAVIRTGEIIADLPTGELL
SRHAENRWEIRLAGSIDRIADALPGGAVTSTEHDQTRVLLPDDTTTLYAALDRLRAADAR
LVSVQKAQPTLEEVFLRVLRDDAAPSRIAEEVASS
>fig|196162.6.peg.390 Glyoxalase/bleomycin resistance protein/dioxygenase
MDLVQIAQRADDLERATAFYTLLLGSPPVATYEPPGLVFFDLGGVRLLIEHGAPSATVYL
RVEDIDAAVAQAREAGTEVASEPHVIFAHADDTLGPRGTDEWQAFIRDSEGNLVGLVEHR
PR
>fig|196162.6.peg.1052 Glyoxalase/bleomycin resistance protein/dioxygenase
MLNRLFHIAINSTDLDRSVAFYQRLGFQALQDRSVRNDMVKEAFAVPSGDLRFVHLRLGE
DDNATILDIVQWFHPDTEDTGTEPVAQHQRGLTRFSVLTDDTQAVYDELAAEGVEFITKP
TVVMTPEGGWKVALVKDPDGVVVQVTELLAAPAAG
>fig|196162.6.peg.1088 Tetracycline-resistance determinant tetV
MGPRSLLGGEKGLWAGSGVGRVRVRVQLESDGLGVAAVLVGDGDLVAGPVGPDGGDQGVG
AADQLVVDLGDDVALRQAGVVRGRAGVDVLDLGALGHLGSGPARDVGDGDAEAGVGRGLA
VDHLVDDRHHLVHRDGEAEPDRAGLPLHGAGGADRGVDADDVAVEVDERAAAVARVDRSV
GLDRGVRRAVALAVGADVHRPVQRTHDAAGHRRVEPERGPDRHDALADLEVARLPDRRGR
QPGDVLGLDHRGVRQGVGAEDLGLRGGAVVEGDPDRPVVAGELHHVVVGEDLAVGAEDDP
RARTGALGAGHVDLDHRRQHLGSDLLDGAGRCLGVGGVDDLRRRAAAGAARARRASIVER
APGGGAADPCRAAGHQRGRDDRGGEAGPARTTLPRLRVRRHPGRRALGRRTQRRRGGEVR
VRRSRRRTGGLVVHVSTMGGQPVTFLRPFWGGTKNSTPVRREFRATAGGGTGLNAPVTSL
DSLGTREDRLGPLRFRNFRLLVTGSATSSLGNAIAPVALAFAVLDLGGSATDLGLVVAAY
ALAEVATVLFGGVLGDRVARQLMMEGSNAACALSQATVAVLVVGGWATMPVLAGFGVVNG
CLGALSGPSSSAMTRMTVPAERLASAVALRGLLQTSAAVVGFAVGGVLVAAVGPGWAIGV
DAVTFAVAALCFGRLDVPHTRPEGARPSFVSDLGEGLREVLRHTWLWLLIGQALLYHLFY
GGAQSVVGPIVMEDGFGRSSWGLALGTLMAGFVVGGLVCLRWRPRRLLHVGTALLSLTAA
FPLAMALSDRLGPILVGAFVHGVGLQVFDVFWQLAIQENIAEDKLARVYSFDLVGSFIAR
PVGLVLTGPVAQAVGFHRWLVVVGCVMGGSALLSLLSPDVRRLERRS
>fig|196162.6.peg.1169 Glyoxalase/bleomycin resistance protein/dioxygenase
MALTESAVAVMLPTKDAARAQEFYEDRLGLPFAGSNETTGETTFRLSGGSQLVLRLLPDA
APSPNTAMSFEVDDIGAEIATLEGRGVAFEDYDLPGFATVDHILDQHGMKAAWFLDPDGN
VLCLHQPG
>fig|196162.6.peg.1358 Vancomycin B-type resistance protein VanW
MARVNQQPTVPAREKEGGKVVLLMLAGLVLLAGAAYGALYLAAGDKVPRGTTVAGVDIGG
RTPADAEEVLRTGLADRVDRPITVAAEGARSTLDPGEAGLTVDYAASVAEAGGGRSWSPG
RLWDYWTGGDDLDPVLDVDDAAFDAALDKLGEDLGTPPVEGDVKFRDGKVVVTDPATGEE
IHPEAARLAITTAYIAEDATDVELELRPADPEVDAADLQEALEAFANPAMSGPVTLVFGD
SPVRLDPADFGKVLGMGAEDGELVPDLREKKLVKLVDRGISQDGAPVDATVALVDGKPKV
IPAKPGVTYKPSDVSDAFLELVAREGDREMKVPSTVAEPDFTTKDARALKIREQVSTFTT
YYPYAEYRNINIGRAAELIDGTVLKPGDEFSLNGIVGERTRENGFTEGFIISDGIFKEDL
GGGVSQMATTTFNAMFFAGLKDIEHKPHSFYIDRYPVGREATVAWGAVDLRFENDTPYGV
LVHAHVTPATSSSQGVVTVSMYSTKYWDISTTTSDRYNYRQPATRTLTTPDCYPNTGYAG
FDVDVTRTFRRHGEDAVDHTEKFHTAYTPSDTVICKKPKQRGD
>fig|196162.6.peg.1427 Glyoxalase/bleomycin resistance protein/dioxygenase
MSNVPGAPTWIELFAADTDTARTFYGELFGWTVQGSGPEYGGYAQFLRDGAPVAGLMRNE
VGLPDTWSVYLRSTDVAATVASARQHGGQVVVEPMQVGDLGHMAVVADPSGAAVGVWQPL
AFEGTAVRAEVGAPSWFELHTTDYPAAVAFYRDVFGWSTHQMSDTPEFRYTTLGRDDDAL
AGIMDATGHFDGAPSTWVFYVQVADADATVARAVELGGSLLPDSGPHDTPYGRLAVLADP
AGVQLSVVGPNRG
>fig|196162.6.peg.2031 Permease of the drug/metabolite transporter (DMT) superfamily
MSKRTSRWALAAFAVVGFIWGSNFLFMKWAAEEISPRQIALLRVAFGLLPVLALGLARRE
FRRWHLRHTVHFAVMGVLATSLYYVLYAAGTERLPSGLAGALSGAIPLFAFMVGAVALPT
EPMTPRRVLGAFLGLAGVVMMARPWNVHGSVDPVGVLLMVTGSACVGASFVYTRRFITGL
DIPPTALTTYQMALGLVALLPLTDLHGIGAIRGDHRALVGLVLGLGLVGTGLSYVIFYYL
IAELGAATASAASYLPPVVALAIGWIGLGEPLRHADLAAVALILLGVAIIRAGARTYRAE
RGTQ
>fig|196162.6.peg.2738 Permease of the drug/metabolite transporter (DMT) superfamily
MTATLRRELPSVRIGLLQVFAAGVLWGTGGLVVTVLHERDGLGAMTVSAWRMALAAAALI
AFSALTGRWARTRAALRAHPVLAVLVGGGTAAYQGLYFLSVLMVGVSVATVVSLGLAPVL
AAGWEHLVERSTPSAREVLVLAAALGGLLLISGTAGDRADAPGDDPTLGLLLAVLAGVTY
AATTVLGHTLAKRVDPVALTTCATGAGAILLLPFFAVAAARGEPVLSSDPVSTTLLIYLG
VATMALSYGLLYAGLRTTSGSAATIATLVEPLSAALLAAVLLGERLPWPALAGGVLILAA
VVALRPTEDLSPVGAP
>fig|196162.6.peg.2940 Glyoxalase/bleomycin resistance protein/dioxygenase
MEVGPMSDEGSYGSVRYVVRDVQAAVDFYTTHLGFTVRSHPAPPFADITRGALRVLLSGP
ASSGARATPADVDGPGRNRIHLLVDDLAAEVERLSAAGVPLLTDVVSGPGGQQVLLADPA
GNLVELFEPAVAPARIGP
>fig|196162.6.peg.3399 Antibiotic efflux protein
MTSLAEIVAPRRLGTGFRWLLASSWVSNLGDGLALAAGPLLVASQTHDPFLVALAALLQW
LPPLLFGLYAGALADRLDRRLIVVTVDLLRAVVLVLLTLAIATDLVTITLVLVTMFLLGT
AEVFADNTASTLLPMLVHRDDLGVANARLTTGFITVNQLAGPPIGAALFAAGHAVPFVAQ
AVVVALGALLAAQIALPPHGRSRDERPQLRQDVVEAFRWVLHNAAVRTLVLTIFVFNITF
GAAWSILVLYATQRLGMGEVGFGLLTTVSAIGGLIGTLAYGWITRRVSLANIMRAGLVFE
TFTHLALALTTRPAVAMAIFFVFGAHAFIWGTTSTTVRQRAVPGELQGRVGSVNLVGVFG
GLVIGSGIGGGLAQHWGVTAPFWFAFAGSAVFVVLIWGQLVHIAHADEQGQPAGA
>fig|196162.6.peg.3936 Acriflavin resistance protein
MRNAAGPARPARPHHRHGALQDLPVRRLRRPSHTPLGAQPDAADHRPRPRRAHHRRRDHD
ARGVRPEPDVRQPRRHRPVRARRPHRHHAARRPPARTGRHRPAGPAVPRRAEGPGALGPV
DRDRAGGPLDGLVDPGPVDRPDRAAHRRPAARRAGPDRRQRRRRPPVLDRPRYPARRGDR
TDADHRAGPGGGARGVRTHRPLAAPGTGGR
>fig|196164.1.peg.2608 Multidrug resistance protein
MQHFHKVLVNTLIFNVVTGFLAYSLLFWVYLETRNVALAGILNAGYMGALAVTSIFFGSI
VDHNRKKTVMMASSCMTLVLFALAGVVWVLWMDSATISLDSPALWVFSILILIGSIVEHL
RNIALSTVVTLLVPEDRRDKANGLVGVVHGMSFLVTSMMAGMAIGFFGMETTLWVCLVLT
LLAVLHLITVEIPEPEIVTQHADATVPIAPAPSADGEVFTPNPVPSDLHTVSRGLDIRGS
LAIIRGVPGLLALILFTCFNNLVGGVYTALMDPYGLELFSPQVWGVMLGLTGLGFIVGGM
IIARVGLGSNPVRTLLLVNVGIAIIGIVFTIREWGWLFVAGIFVFMLITPAAEATEQTIL
QRVVPFRQQGRVFGLAMAVEMGANPLSAVIVAVVAQAYLIPWMDGPGADTALGVLLGDGT
ARGMALMFMLSGVITLIVVLLAFASRPYRQLSRYYASSSQDIAGQTAQ
>fig|196627.4.peg.1955 Permease of the drug/metabolite transporter (DMT) superfamily
MNDAGLKTRNPVLAPILMVVNGVSLYAGAALAVGLFESFPPALVAWMRVAAAAVILLVLY
RPAVRNFIGQTGFYAAVYGVSTLAMNITFYEAIARIPMGTAVAIEFLGPIAVAALGSKTL
RDWAALVLAGIGVIIISGAQWSANSVGVMFALAAALLWAAYIIAGNRIAGDASSSRTGMA
VGFTWASVLSLPLAIWWWPGLGATELTLIEVIGLALGLGVLSAVIPYGLDQIVLRMAGRS
YFALLLAILPISAALMGALALGQMLSVAELVGIVLVVIAVALRRPS
>fig|196627.4.peg.1956 Albicidin resistance protein
MLIGEVSKLSGVSARMLRHYEKLGLVEPKQSTAGYREYSEGDVRRIFHIEGLRSLGLSLK
QVGDALEDPDFDPQAVISEMIAETSARISMERELLARLKAVRHAQASDWESALDAVQILR
RLRSGDPAQRQAVAYDSVSGKEAVALETLVESALGESHLNAEGALSWAVVQRGEEAVALA
ARGLRSRDAAVRLRAVRIVASAPSAVADRVEWLRPMIRDPDALVRAETALALGKSGDESA
VEQLVSMVLTGLRDVEAAELLAGFGEPVQLDVFKKFARTLDDEETMSPTRGRIAQALAEF
NLAPVAFLVEQLVDDDNPTVAFTAAAIIKAKGLK
>fig|196627.4.peg.2691 Drug resistance transporter, EmrB/QacA family
MTSETLQAQAPTKTQRWAFLAVISGGLFLIGVDNSILYTALPLLREQLAATETQALWIIN
AYPLLMAGLLLGTGTLGDKIGHRRMFLMGLSIFGIASLGAAFAPTAWALVAARAFLGIGA
ATMMPATLALIRITFEDERERNTAIGIWGSVAILGAAAGPIIGGALLEFFWWGSVFLINV
PVAVIALIATLFVAPANIANPSKHWDFLSSFYALLTLAGLIITIKESVNTARHMPLLLGA
VIMLIIGAVLFSSRQKKIEEPLLDLSLFRNRLFLGGVVAAGMAMFTVSGLEMTTSQRFQL
SVGFTPLEAGLLMIPAALGSFPMSIIGGANLHRWGFKPLISGGFAATAVGIALCIWGATH
TDGLPFFIAGLFFMGAGAGSVMSVSSTAIIGSAPVRKAGMASSIEEVSYEFGTLLSVAIL
GSLFPFFYSLHAPAEVADNFSAGVHHAIDGDAARASLDTAYINVLIIALVCAVAAALISS
YLFRGNPKGANNAH
>fig|196627.4.peg.2753 Vancomycin B-type resistance protein VanW
MKNSGKNSAKNRTKGILIGVLVGLIAIFAGIYAVDVFLNKDNIPRGTTVGGVSISNLSAQ
EARTKLETELANDVVQPVTVTAGEQSTTFDPVASGVGIDWDATIEGTGEQSWNPITRFVA
LFKESESPIVSTVDPAAFGPTLDRMVGELYRDPISGNLHIDAGTLVVNDTIDGQAVDRTI
LEQAVTENWLNPEGVKAEPYVVPAAISQDTIDKLAEGAGAKAVSSPFVVRGDDGIEGTIP
VERMGEVVSFPEENGTIRVDINAEAATAMLAEGLKETEIEPTNAQISFSSGSRVVTPEVT
GHGINWEETLADLPNNLTGDGPRTIDAIYEDTPATFTATDAQNATFNEVMGEFTTGGFSA
ASGTNIRLTAQMVDGAVVSPGDTFSLNNYTGPRGAAQGFVDSGIILNGRSDTAVGGGISQ
FATTLYNAYYFAGLEDITHTPHSYYISRYPAGREATIFDGAIDLQFRNNSPYPVMISTSA
DASNVTVRIMGVDTTSVESINNGRWSTTQPNTVRVSGSDCVPSTGAPGFTTSDTRIISDL
SGNEITRETVTTVYDPSPNVVCS
>fig|198094.1.peg.173 Multidrug resistance transporter, Bcr/CflA family
MNEVNQEIYKPVKTNRLWMILVLGTLTAIGPLSIDMYLPSLPKLTDDLQTGASLAQLTLT
ACLLGLSVGQLFVGSISDIYGRRKPLIIALIIYVASSLLCAVAPSIWTLVLLRFLQGASG
SAGIVISRAMVRDMYSGSEMTKFFSLLMLVNGAAPILAPIIGGQLLQFTTWRGVFIVLGA
ISVFMLISATFVLRETLPPEERETGGLSGTLATYGKLLKDRLFMGYALSQGLVTAAMFAY
ISGSPFVLQNIYGASPQQFSLFFAINGIGIIIASQVTGRLAGKVNEKTLFVSGIVIAAVG
GLSLLLTILLGIGLIGVLCSLFLVVSSVGVVSTTGFSLAMRNQKQAAGTASALLGLLQFI
SGALVAPLVGIGGSNTALPMGIVIALCEIGAVLCYLFMARRSEKQFELQARQNLEV
>fig|198094.1.peg.564 Vancomycin B-type resistance protein VanW
MKLSKILIGSAIAGGILLCVGGVSGYQYVSKLNNQLDTTALPNTTFEGISLDGKNKKDIQ
AIINQKITELDQKSLTYIFQNDKQTYTWKDLGINYKEKDIIDKIFKEQEGNAINRYKMRK
QAENGELKRDYKLTPQLNTTAYESFMKDKYNKTLKNPVNAELSIEGTTVNISQSQNGEKI
DKGKLTDLTKQAITSGTSDITLPVTLLKPERSTEDIQKMGIKEVIAEYSTPMAGRNGNQS
FNVNKSANTLSGVIVAPDETFSFNGRVGVTDAAHGYKSAAVYSQGKVIQSAGGGVCQVSS
TLYSAALRADLGIVSRSNHSMPVNYLPLGQDAAVADYGPDLKFKNNTGNHIYIQAFSNGG
SITTRIFGTNTGKNVEVSSQVISRTNDKITAVTYKKVTQNGEVISNGQISKSVYKSAPKQ
>fig|198094.1.peg.696 Drug resistance transporter, Bcr/CflA family
MKKSKLTFILYVVCMSALLGSFAQNIYTPILPMIQNSFHTSLYLVNVTVSLFTFVLAIMQ
LIYGPLIDTKGRKSVLIPSLIISTIGSIGCAFSANIYLFLFFRAVQAIGIAAIPVVAATI
IGDLFEGKERGEAMSLYQMLLALAPAIGPLIGGYLGSINGHVSVFLFLSILGILLLTINI
SLLPETKPTVSQQPQSKKNHWFILKNKTGFSITLIGFIQFCIYFCFLVFLPSISTNLFHL
TASEIGLMFVPMSLSIMLGSYCFKLLQKRFTTKQALFITSFFNIICVTLFSFTYSINIPF
IIIVTSLYGFSMGLSMPTHTTLLTEEFVQERATAIGMYNFIRYLGMGTVPLVGGFLVFNQ
NYFWIFFLGAIMFLLIILYAMKMLRFPTTQKVK
>fig|198094.1.peg.774 Permease of the drug/metabolite transporter (DMT) superfamily
MPYFYVFLLLLTSLLWGGNFVVGKSLVDHASPMTLTSLRWIIAIVCLLPMVWFKEKKIIP
PRAAILPLILMGISGVALFNIFQFLALEKTSATNVGLISTLNAISIALFSVLFLKEKVNT
LQILSMILSFFGVILVLLKGNFALLFSLHFNSGDLWMIAAVCIWGIYSVCSKWATKTTTP
LMATLYSGIFGVILLLPFNIGSFTVTNINTSFITSLLYTGLISTVLCMVFWNIGVQKLGA
TTSGIFLNFNPIFTAILAFLFLGEELTWIQIVGTMIVMTGCYLFSHFKTVTVQPTGTLLR
KHS
>fig|198094.1.peg.877 Drug resistance transporter, EmrB/QacA family
MNMTTKSPASGKVDTSNMKHTPILIALLLGTMVALLNETLLGNALTVLMKEFDVTASTIQ
WLSTAYMLVVGVLVPITALLQQWLTTRQMFLIAMVTFLVGTLIAGFAPTFSVLLVGRIVQ
AVATGLISPLLMNTILIICPPEKRGATMGLIALVMMSAPAIGPTLSGVIVDSLNWRWLFY
IVIPIVIISIMIGMKYIQNVSEITRPKVDYPSILLSTLGFGGLVYSFSASGDLGWSDTKV
YGALIVGLISLCIFIVRQLKIDNPILELRAFKVPMFTLSVGLIVIVMMSLFSTMTLLPMF
LQTVLLVTAFKSGIIMLPGSVISAIMGPIAGKLFDKFSPKVIIVPGIVLVGIAMFLFKGI
TPDTSIVQIIVMHSVLMVGLMFVMTAQTYGLNQLTPDLYPHGTALFNTLQQVAGAIGTAI
FISKMSSGTTSYMESSANPMDPVEKLNGLTSGFQGAFALGLVFIVVAFIVSLFLKEEKKG
VLQNEN
>fig|198094.1.peg.1030 Glyoxalase, Glyoxalase/Bleomycin resistance protein/Dioxygenase superfamily
MFQKLECVSIHTKDIEKSVSFYKEMGMEQNWVIERELEEGAIWTLIGLKFPDEKSSELVI
SNHPDINCIEVEVLVEDVQQTYESLKDNKDVKWIREPFPTESGHVAVMEAPDENVFVLVG
K
>fig|198094.1.peg.1497 Permease of the drug/metabolite transporter (DMT) superfamily
MSVKKDWIAPLALLFVSFIWGATFVVVQNAMSFVGPFTFNGIRFLFAGIILLFVQILFSK
KASKQHIKQSSLAGLIVGFFLCIGYVLQTFGLLYTTSSKAGFLTGLSIVMVPILSFIFLK
QKATIFIVIGIAVATAGLYLLTAGDSFQLNIGDILVLGCAVAFAAHILVNGFFSKKISPL
LLSTSQVLAVGLFSSICAFLFEDWEKLFSVALWTNSSFLFALFLTSLFATSIAFFIQTSA
QKHTSPTRVAIIFAMEPVFAALTGVLVANEQLSISAIIGCLCIFLGMVFVELPSKTKKEA
QAA
>fig|198094.1.peg.1517 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MEVTEKLREKPIKSLFITYLIPAVLGMVLMSVNIVIDAVMISRGVGANGLAGVNVAIPAF
SIFFSISLWIGMGGATLYSIALGENKIERARSIFTQSMTVAVIIVGILAAICLWRIEDLA
YLFGANEVILPYALDYLHVLLTFGMIYVLENILSTFIRNDGNPNLAMAGLVVTAILNIVF
DYIFIFIFGWGVTGAASATILSAAIGFLVLLTHFFRKSSILKWTKFHFEWDTIKQIMIIG
FPSFITESTVAIVTIGFNIAFVQYAGEVGVASYAMVNSIHAMTLLLFFGVGAALQPIASF
HYGANLSERLREGLQFAVKIAVILGGVAIIVGLFFGKYIIGLFDVQSPQLLELTLTGISL
FFIQYVFLGYNIVYGEYFQSVRQTKKSILIIMSRGLLFIIPLLWIMPKLFGINGIWLVMP
VAEVITAIILFTMNRMKHPVPLNMAGEKEVI
>fig|198094.1.peg.1677 Fosmidomycin resistance protein
MQAVSQKNTVETPTIYRILFAISFGHFLNDSMQAVVPALFPILEKTMNLSYMQVGWIAFA
LNMTSSIMQPVFGMYSDKKPSPFLLPLGMFSSMLGMIGLAFAPNFIIVIISVLFIGLGSA
VFHPEGARVAYMAAGTKRGLAQAIYQVGGNTGNSLAPIFTALIFVPLGQIGSLGFTAFAA
VGIVLLIFVSNWYRNELATGAVRRKKRAALEAENAIVSTHIKFVIVLLVFLTFVRSWYGA
GIGNFYQFYLIEHYGLSIKNAQYFVFAFMIAGVLGTFFGGPLADRFGKKTIIVFSMLGSA
PLALLLPHVSLVWVVPLFLCIGFISSSSFSVIVVYAQELVPGKVGMVSGLIVGLAFGLGA
LGSVVLGKLADIYSLQFIMLLCSCLPLIGLTSWLLPSDKKTIE
>fig|198094.1.peg.1752 Permease of the drug/metabolite transporter (DMT) superfamily
MTQLSRTKTAIILTFLVFMWGINWPLSKFALHYTPPVLFAGVRTLIGGFILLLFALPKYK
ELHLKETWHLYVISSLLNIIIFYGLQTVGLQYMPAGLFSAIVFLQPVLLGIFSWIWLEES
MYGLKIFGLILGFIGVGVISSSSLTGHISIIGILLAIGCAIGWALGTVFIKKTGHRVNSI
WMVTLQLIIGGLCLIGFGSEFESWSSIAWSMPFVSVLLFISFFVIAMGWLAYFTLVGAGE
ASKVGAYTFLIPLIAIIVSSIFLHEAITISLFIGLLFIVVSICFVNIKPKTLAVGQRVEV
K
>fig|198094.1.peg.2247 Multidrug resistance ABC transporter ATP-binding and permease protein
MKSFRKLLQYLKPYMFFAIIGPLFMVLEVAMDLIQPTIMQHIIDVGIANRDLNYVIKMGL
LMIGAAALGLVGGLGCMMYSTKAAVNFATDIRKDVFAKIETFSSENRDSFGTGKLLTIVT
NDITSIQSAMTMTLRVLVRGPLLFIGSIIIVFVTARELFPILLVVVPILLLAIIYIASRA
SGTFKKVQEALDKVNTKLQENLSGVRVIKAYVRQKYEINQFGKVNTNLTKINIRAVQLIS
LMMPIIMLVVNGGIVATLWVGGEKVFNGTLQVGAILAFINYLNIILMSLMSISMVFMQIA
RAFPSADRVQQVLNTDVDITTPKNALAPKRIEGQIDFKNVSYSYTKNNEYVLKDISFRIG
KGEKVGVIGSTGSGKSTLAKLLPRLYDVDQGEICIDGINVKAYDLQKLRGSIGFVPQKAL
LFSGSIEENLRYGKEDATKEELEVAASSACATEFINKLEDSYQYHLTQGATNLSGGQKQR
VSIARALVRKPSILVLDDSTSAVDAKSESNIQSALRREYKGTTTLLIASKISSIIDADKI
LVLDNGELVGDGTHEELLEQCEVYQEIYLSQGGNLHKEGGKEHA
>fig|198094.1.peg.2248 Multidrug resistance ABC transporter ATP-binding and permease protein
MRNFQGQFANKGGRNAPKIDKAKNTKGTVMRVWNYMGYQKAALTFVIFLVLVTTLLGLLG
PYLMGVIIDQYIVPKDVSGTARMCLLLIAIYGVTVLLTWLQTFVMVNVALKTIQKIRQDI
FKKIQTLSLRFFDVRSQGDLMSRVTNDIDNLNQALTQSVVQIISSALTFIGVTIAMFALD
WILAIVTLITVPIMFFVTKKLVAYSGKNFAKRQKDLGELNGFIEEAITGADVTTLYGKEK
ETVQKFNKINEQLRVSATKADTFSAFIFPSMNFINNLGMGLVIGTGSVMVLNGMTTVGVI
AAFINYSRQFSRPLSQFATLMNTIQAAVAGGERVFEIMDEVPEIKNKKDAFVIQNLHGHV
ALENVSFGYEENKTILKEVSLKARPGETIALVGPTGSGKTTIINLLTRFYDVQQGQIYID
EKNIKEYDLNSLRSKIGVVLQDTYLFAGSIMDNIRYGRLDASDEEVINAAKAASAHSFIK
HLPNQYETKIATEGSNLSQGQKQLLAIARAILADTDILILDEATSNIDTRTELQIQEGLN
NLMRGRTSFVIAHRLKTIEKADQILVIKDGSILEKGNHESLMEDRGFYFDLYTSQFKI
>fig|198094.1.peg.2459 Permease of the drug/metabolite transporter (DMT) superfamily
MNYKKWDLRIICAHAFTILIWGSAFPAIRMGLESYTPEHLTLLRLLIASVILLLFSFIYK
LRLPDLKDIPAIFIFGALGFTFYHIALNYGEKTVNAGSASLIVSVTPIVTAIFASVFMNE
KMKLNGWIGGVISFIGIAFISFSQGDAIQLNSGALFILLAAISESLFFVFQSSYLKKYGF
LPFTIYTILSSTVCMLIFLPGMYQEILAAPLEVNLSVIYLGVFPTVLPYIALAYIISRAG
ASEATSSLYLTPITACFVAWIWLGEVPTLVSIIGGGITILGIVIVHIPVLRKEKHSNLAN
NQSV
>fig|198094.1.peg.2514 Permease of the drug/metabolite transporter (DMT) superfamily
MVIFNYILVCIIFGTTFLTIKIGIEAGAPPLFSAGIRFFLAGVILMIIFKLKRKEIMPHI
FSRRIIYAGFCLTFMTFATLYWAEQYISSGLAAVLSATGPMMILLLQTKRNKTKLKKEQL
LALIIALIGVVFVSLPGMHQEISFIWSIACFVLIIGELFYGIGSIRSKEILSDLQSVSLF
LINGIQMFYGGVLLLIVSFIVEQPNVTVLASWSVQWPILYLIFIGSIGGHGLYYWLLSKT
NPVFPSTWLYVSPLIAIIVGYIILGEPLNPIMGIGACFILVGVFLANRSTLRTYFKQGRL
FEKEM
>fig|198094.1.peg.2646 Drug resistance transporter, EmrB/QacA family
MVEKNNKLGFVVAGLLLGILMASMDNTIVVTAMGTIVGDLGGLENFVWVVSAYMVAEMAG
MPIFGKLSDMYGRKRFFIFGLIVFMVGSALCGTAENITQLGIYRAIQGIGGGALVPIAFT
IVFDIFPPEKRGKMGGLFGAVFGLSSIFGPLLGAYITDYISWHWVFYINLPLGVLALIFI
TFFYKESRVHRKQKIDWSGAITLVGAVICLMFALELGGQKYDWDSTFILSLFVGFAILII
SFIFIERKVEEPIISFEMFKQRLFGMSTIIALCYGAAFMSATVYIPLFIQGVYGGSATNS
GLLLLPMMLGSVVTAQLGGFLTTKLSYRNIMIISAVIMLIGLFLLSALTPETSRALLTVY
MIIIGFGVGFSFSVLSMAAIHNFGMEQRGSATSTSNFIRSLGMTLGITIFGMIQRTGFQD
QLEEVFKGMSGGMNTNALGDSRAILSESARSQIPPQILDKIIDALSSSIVQTFMWALVPA
GLAFIFIFFMGNERMVMKKQQKNKKGEISKV
>fig|198094.1.peg.2801 Ribosome protection-type tetracycline resistance related proteins
MTTINIEIVAHVDAGKTSLTERILYETNVIKEVGRVDSGSTQTDSMELERQRGITIKASV
VSFFIDDIKVNVIDTPGHADFIAEVERSFRVLDGAILVISAVEGVQAQTKILMQTLQKLN
IPTILFVNKIDRTGANTEKVVKQIKTILSNETFPFYSVQNEGTKEARIIEYKSYDDCIER
LAPYNESLLESFVNNEIVTDTLLREELEKQIQQANLYPIFFGSALTGIGVTELLEDIPAL
LPANNPSQDEELSGIVFKIEREPSGEKIAYVRVFSGTLHVRKYVHIQRDGSLPHKEKIKK
MCIFHNGNAVQTSTVPSGDFCKVWGLNNIKIGDIIGERTDYIKDIHFAEPQMEAAINAVP
KERIHDLYAALMELCEADPLIKVWKDDIHNELYIRLFGEVQKEVIETTLYEKYNLQVTFS
STRVVCMEKPIGIGNSVEVMGEKANPFYATIGFKVERGELNSGITYKLGVELGSLPLAFH
KASEDTVFQTLKQGLYGWEVTDISVTLTHTGYASPVTTASDFRNLTPLVLMDALKQAETY
VYEPVNEFELTVPEHAISTAMYKLAAILATFAEPIFNNDSYQLTGSLPVAKTESFKRMLH
SFTEGEGVFTTKPAGFTKLMAPLPTRKRVDYNPLNRKDYLLHVLKAY
>fig|198094.1.peg.2819 Permease of the drug/metabolite transporter (DMT) superfamily
MKRWQMEWLLVSVALVWGANYTIGKYGVAYMSSIQFNSLRFLVASPVLLLITFLMERSLR
IERKDWLRLVAVGIVGTTMYQTMFMLSVKYTSATNASLLIAMSPIFTGILAVLHKQERFS
MKVQIGSIVAFIGAAFVLLTGHTGGATYEYAWLGNIIGLVAAIAWGWYPILAQPLITKYS
AMRVTSWSTLIGIVPLVIYCLFNVNSLTWPVDTLSWGSLAYSIIFATIFGLAMWYVGISQ
IGSTKVMVYMYLVPLFAVIFAAVTIGEQINMMQLVGGLIIFVGLYVVKKGGIKKPALNLK
KVS
>fig|198094.1.peg.3217 Glyoxalase, Glyoxalase/Bleomycin resistance protein/Dioxygenase superfamily
MITPIFRIFDIEKAKLFYVGFLGFKLDWEHRYEEHMPLYMQISLHDAVMHLSEHHGDASP
GGAIRIKIDDVKDYHSVLLSKEYAYSKPNIEKTPWGTIELTVIDPFSNRIIFYEERV
>fig|198094.1.peg.3344 Glyoxalase, Glyoxalase/Bleomycin resistance protein/Dioxygenase superfamily
MSENHNFYDRKEMKGNGFELIIVVDRIEDVYERCKEKRCTIQEEIQTYPWEMRGFKVVDP
DGYFLRITSK
>fig|198094.1.peg.3367 Multidrug resistance ABC transporter ATP-binding and permease protein
MKEYKRILLPLQKEKILVIAAVCSGIFAAILNLSRPLFMGLIVDNLIQRELKEAYFYITL
FTVTRLLMWVNNLSFDYVSSKASQRILREKRIDVLRHFFLLPFEESEKIKQGELETLVVS
DIPNWVRLYDSILIEYIHAIAQFIGAIIALQHIDIQFILWVTPFLFLSAMVPMLLGKKVR
NIASIAQKNQSTVVEMMSQFVKGAQDLRSLQKEKWAIRLFKGVTAQSYKSEVKKTMMQHC
IGVVGTVIETGAYIVVLIIGAQKIMQGEMEVGSLVAVLATIEMLFFPVRYVGDLLMMSQV
AVASASRVFSFLDKRVANSNVERAMGMTITNVSFQENDEEKCRIYNIDLQIQPGELIIIV
GESGVGKTTLLKLMTGLYKPSNGSITYYGNEAQLTTVWQEPRFFRVTVKENMYFGEERLE
NELEKNAELVNVTPIIRGLPEGLQTVLHKSGEEFSGGERKRLALLRAIVSNPHLIILDEP
TAGLDPNNQEFVWNMIEELGSEVTRIVATHDVEKVILADRVVIMKEGSIVACGSPEKLIN
SHSFFKRCE
>fig|198094.1.peg.4082 Permeases of the drug/metabolite transporter (DMT) superfamily
MNGRSFTFAIFVLIIGLAIFGLVSSVITNPMGVLRNIGIMLAVVGIFYLLYKMFTNSSGS
ANSQSSYKRAAKQSSRKHGKQNVAPLSNSFFKSNTSNDKGKKGNPSSLKRKRKQSHLTVI
EGKKNKKKDRASF
>fig|198094.1.peg.4497 Zwittermicin A resistance protein ZmaR
MKKLSVAEYRKILPILESHTKTTTFAYAVCDQVIDGEVFVNEKLTAGLIRTANGIYYVFG
HTDDQNYNEDLFLFIKKAIEKTEKRFTLFTSSEEWEMMIEERFSNVLRNIPRMKFQSATF
EERKRDCNKNTYEVKRIDRRDIERSSEFTEEYYKEYWGSKETFLNGGFGFCIEQGGMIVA
ECVSIFSGNGFAEIDIVTHKAYQGKGLAQAVAARFIEHCIQNDIIPCWDCYVDNIPSQKL
ANKLSFHNPIEYSLFVRKKTGE
>fig|198094.1.peg.4584 Drug resistance transporter, EmrB/QacA family
MRKKVMMSLMLMTFLSAVEGTIVSTAIPRITSDLSGVELVSWVYAIYMLATAVSTPIYGK
LADLFGRKKVLLIGATIFLVGSALCGVVTSMEQLIFFRALQGIGAGAVMPITMTIIGDLY
SEAKDRAKAQGWMSAVWGVSGVIGPLVGGFLVDSLSWRYIFFLNVPFGIIACLMIAIYYK
ESIKPAKHHIDYLGATVFSLSMIALLYALLTGSSKQNWGDVTIIGLLIFAVVSFIIFLFI
EKKSPEPLIPLALFSNRTLSTINILTLIAGAMIISITMYLPIWSQGVLGKNATEAGLILM
PIPVMWTFGAIFSGNLVGKLKTKQIILLGASILSVATFLLFTLSTNSPSFLIYVAVGLFG
LGMGLVTPIYMVTIQAAVPAHTRGTAVGLNTFINTFSQTLGAAVFGTIFNTMIHARGIKN
LDLVSGGHGGATANVVTESQSALASSVHVIYMSTFVLAVCTLIIAWLLLKPATQTSEQ
>fig|198094.1.peg.4822 Teicoplanin resistance protein vanZ
MQSSTQKYVEWIGWGLFLPYSFVLLFKLLLGRSAFYFGNLTYFFETGDWHSIHGGLINLV
PLKSTINYLSGFDTTHLLDPYNIDIVLMNTLGNVIIFIPFGFLLPLLFKQINNVKMASKI
FIKFILLIESLQLLTFTGVFDIDDIMLNMLGALIGYGSFVGIKYILERVRSVDKVDTI
>fig|198215.1.peg.392 Acriflavine resistance protein E (AcrE)
MNKNRGFTPLAVVLMLSGSLALTGCDDKQAQQGGQQMPAVGVVTVKTEPLQITTELPGRT
SAYRIAEVRPQVSGIILKRNFKEGSDIEAGVSLYQIDPATYQATYDSAKGDLAKAQAAAN
IAQLTVNRYQKLLGTQYISKQGYDQALADAQQANAAVTAAKAAVETARINLAYTKVTSPI
SGRIGKSNVTEGALVQNGQATVLATVQQLDPIYVDVTQSSNDFLRLKQELANGTLKQENG
KAKVSLITSDGIKFPQDGTLEFSDVTVDQTTGSITLRAIFPNPDHTLLPGMFVRARLEEG
LNPNAILVPQQGVTRTPRGDATVLVVGADDKVETRPIVASQAIGDKWLVTEGLKAGDRVV
ISGLQKVRPGVQVKAQEVTADNNQQAASGAQPEQSKS
>fig|198215.1.peg.3097 Outer membrane component of tripartite multidrug resistance system
MINRQLSRLLLCSILGSTTLISGCALVRKDSAPHQQLKPEQIKLADDIHLASSGWPQAQW
WKQLNDPQLDALIQRTLSGSHTLAEAKLREEKAQSQADLLDAGSQLQVAALGMLNRQRVS
ANGFLSPYAMDAPALGMDGPYYTEATVGLFAGLDLDLWGVHRSAVAAAIGAHNAALAETA
AVELSLTTGVAQLYYSMQASYQMLDLLEQTRDVIDYAVKAHQSKVAHGLEAQVPFHGARA
QILAVDKQIAAVKGQITETRESLRALIGAGASDMPEIKPVALPRVQTGIPATLSYELLAR
RPDLQAMRWYVQASLDQVDSARALFYPSFDIKAFFGLDAIHLDTLFKKTSRQFNFIPGLK
LPLFDGGRLNANLEGTRAASNMMIERYNQSVLNAVRDVAVNGTRLQTLNDEREMQAEHVE
ATRFTQRAAEAAYQRGLTSRLQATEARLPVLAEEMSLLMLDSRRVIQSIQLMKSLGGGYQ
AAPVVEKK
>fig|198215.1.peg.3098 Membrane fusion component of tripartite multidrug resistance system
MTFEIPFVALSLAVLFYGIQSNAFYTKFVAILFVVATVLEIGSLFLIYKWSYGEPLIRLI
IAGPILMGCMFLMRTHRLGLVFFAVAIYGQTFPAMLDYPEVVVRLTLWCIVVGLYPTLLM
TLIGVLWFPNRAITQMHQALNDRLDDAISHLTDSLAPLPETRIEREALALQKLNVFCLAD
DANWRTQSAWWQSCVATVTYIYSTLNRYDPTSFADSQAIIEFRQKLASEINKLQHAVAEG
QCWQSDWRLSESEAVAARECNLENICQTLLQLGQMNPNTPPTPAAKPPSMVADAFTNPDY
IRYAVKTLLACLICYTFYSGVDWEGIHTCMLTCVIVANPNVGSSYQKMVLRFGGAFCGAI
LALLFTLLVMPWLDNIVELLFVLAPIFLLGAWIATSSERSSYIGTQMVVTFALATLENVF
GPVYDLVEIRDRALGIIIGTVVSAMIYTFVWPESEARTLPQKLAGALGMLSKVMRIPRQQ
EVTALRTYLQIRIGLHAAFNACEEMCQRVALERQLDSEERALLIERSQTVIRQGRDILHA
WDATWNSAQALDNALQPDRAGQFADALEKYAAGLATALSRSPQITLEETPTSQAILPTLL
KQEQHVCQLFARLPDWTAPALTPATEQAQGATQ
>fig|198215.1.peg.4255 Polymyxin resistance protein PmrD
MQWNGWHKKSCCNKQDNRHVLMLCDAGGAIKMIAEVKSDFAVKVGDLLSPLQNALYCINR
EKLHTVKVLSASSYSPDEWERQCTAAGKTQ
>fig|203119.11.peg.316 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MQKETASIKKMSVFALTWPIFIETLLRTMLGNVDTFMLSTYSDDAVGAVGVVSQISYILI
MLYNVVSSGTLVLISQYLGAKKKKEASVVAVTSIAGSLIFGLFVGLAVFLFRSQILTFLN
LPPELMGYAMTFLGIVGGFSFTQALIATLSAIIRSYGNTRITMYISVGMNILNIIGNSIF
LYGLLGAPKMGVTGVAIATVISQAVGVVAMLIVMLTGLNQKFSFRDLVPLPWEILRDILK
IGLPSAGEGIAYEASQLTITRIITVLGKVALTTRVYTLNIMYFVMVFSVAVGQGTQIVVG
HLVGAGDNEKAYKTCIKSLRYAVVVAIILAGIVSFFSEQLLGIFTDDRAIIEMGSKLLLI
AVILEPGRVFNIVIINSLRAAGDARFPVIMGIISMWGIGVLLSYFLGVACGLGLIGVWIA
FASDEWFRGIAMLLRWRSRVWYKMALVKNQNIEMPA
>fig|203119.11.peg.927 Permease of the drug/metabolite transporter (DMT) superfamily
MRKFNFGYLFILVTVVFFSTYEVVSKTIIGKVDPFQINFLRFFIGGSLLFLFLLIKRDVK
IDRKSLMIVSAAGILNVVFSMNLLQLSLNVAYAKAAVVAVIFSSNPIFVSIFAAVMDKEK
ITLFKAAGMFLGMLGIAVISINGQAFRDINILSPLLALMSAGLYGLYTVVGRRASSKIGS
IKMNAYSFLIGSLILLSVLLIKGLPAFKFDCSAWPQVVYLSVFVTGIAYLIYFMGLVRTG
AGSGSVVFFLKPVLASVFAIVFLGEKITLNLIFGTFLILLGMAVMFYWEKIRQRFV
>fig|203119.11.peg.1119 Vancomycin B-type resistance protein VanW
MLLDFFSKNKTKILIFAASLLLLVIASVSTYVVVVLNRKTFYDGIAVEGIDVSGLTVDEA
REKVEKKLDRIVYENSLLLNYEGMTWRIGLSDISYDFLVDDAIKRAYSIGREGSVLKRLK
TIRNLKSDKKNVLAKVVFSRPLLEEYITSIKKQVDENPKDATVTYQNGNIMFEKEIIGRF
VDVDKNLGLLENKLIKRDFSPFELEVTNVYPKIMYKDISHIEEVISSFSTVFNSANVNRS
HNIKLACERINNTVLLPGETFSMDASLGSRTKENGYKDAPVIVKGRLIEGVGGGVCQVTS
TLYVAVLKAKLEVVERVKHSMPLGYVEPGQDATISEGYIDFKFRNNTDRACLISASVVGN
RIDIKLLGAKRNSNYDVRLKSVVVERISPPEDEIIVDKSLPKGAVKIEREPVQGLKVIVY
RETYENNRLIEREKISEDIYKPVQGLKRVGPYDSNDTEGGEETVKEEAMEEQTI
>fig|203119.11.peg.1534 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MKDISANTSSSGNPLGYAPVLGLIGKFAIPSIISMLVAAAYNITDQIFIGRLVGMLGNGA
TSVAFPVVTFTTAFAQLIGVGTAANFNINMGAKREKEAKHFVGTGITLMPTVGLLIFCIV
FVLKKQILLLCGATENVLPLAMTYLGITAIGLPFQLFTTASSSLIRADGSPTYSMICNVT
GAILNVFLDWLFMFVFGWGIQGAATATVIGQIVSFLLCAIYYFKFRTFQITRRMLGIKWY
YAKRIAKLGTSNFINHTIMMLVNIVLNNSLKIYGAMSIYGSDIPLAVSGIIAKLNSVLSA
FSIGLAQGCQPILGFNMGAKNYSRVKETYKKAVSIAIGISVLAFILFQCFPRQITGIFGS
GDELYGDELYFEFAEKYLKIYMFMVCVFGIQPVTINYFTGTGNVRQGIILSLSRQGFFLI
PLLLILPQFLGLTGVLYAGPIADFMACLLSLTMITLNFKKLDSGREVADK
>fig|203119.11.peg.2540 Vancomycin B-type resistance protein VanW
MTFDDVCNLLKSKYSEKAKDLKVVLNHEGMAAEVDLSEIDLEYKIEEAAQKAFDVGRKGN
IFERLSEIFNTSREGVRLSLEYSYNLGKVNEIIDDFYSKTLISVKEANLSIQDNKVTLTT
GHPGKSIDKEKALEIIDNSIKTCEGGTFDVPVITTMPKAIGVDDIYNQIVVQPVDAKAVV
ENNKVRVVPHELGREISKSELADIIKENENTTDKEILLPVKFIQPKVTTDEVNAKLFRDV
LASSSTSFSTSGQNNYNRGINIGVAASKINGKILAPGEVFSFNDVVGPRTVANGFKIAKE
YVNGKIVDGVGGGVCQVSSTLYSAVLFADLETVERQNHMFTVSYIPLGRDAAVAYNELDF
KFKNNTNWPIKIVSSVKNNTVSFTIYGTKEEPGKTVELKHVQVSSQPSPVKYIDDPNLEE
GKTVVVQSGYTGYTIDTYKIVKINGNVVSNNKIHRSIYRPYETIIKRGTKKVEKVVQTNS
PAPETVLSPTSDPTPDPAASNEVVDETLVE
>fig|203119.11.peg.2908 Vancomycin B-type resistance protein VanW
MGQKNGLKEIFAVATTIFIAVLSVSCSFGERKVENNVYIKDINVGGKSKAEVEEIIKKMS
DSIDVEPKDAILNEDTLEIAPEEPGRKLNVESTLKAVLNAKEGDRIEPVVEEVLPKITRE
DVEKRIVEIGSYSTPLLDESENRVDNIDTASDYLNNEKVLPGEEFSFNETLGKRTAEKGY
KKAPIIKRTESGSIKGYGIGGGICQLSTTLYNAAEKAGLEITERHSHSKKVPYVPQGKDA
MVSYGSSDLKFRNNRQNPIVIKSEISDGKVTVRLYEIRK
>fig|203120.4.peg.537 Permease of the drug/metabolite transporter (DMT) superfamily
MKKQGIICGVLSATLFGISGILASILFRNQNINPEWLVGVRMSLSGIILLIVLFCFSGRR
VFEIWLNKRDVVLIILYGIVGVLLAQSSFFLSVYFGDAATATILQSLGPTIIVILLSLAT
RTLPSRLDIWSILIALTGVFLLITNGNINQLVVNSKALFWGILSAFGLAAYTLIPKPLLE
KQSPLVVVAWGLLVGGTAENFFHPIWYIPSQVSTKDWIIMVFIIIAGTLLPYALYVMSLS
QLKPTTASLLSTIEPMVATLLSVTLLHVHLRMFQVLGILFIISTIFLISLPLERIFKKRL
SDPKIN
>fig|203120.4.peg.947 Multidrug resistance protein B
MENKVSTKNAMAIIAVALVSFSGIMAETAMNVTFPVLTRYFSTSLNSIQWVTTAYLLSVT
IMITTSAYLNKRYNTRYLWLASLIFFATGTLVGGLASNLPVLLIGRVLEGLAAGISMPLM
FNLIVQLVPRSKIGVWMGIGSMVVSLAPSFGPTYGGALIDTLGWRSIFFILLIVPIISLL
LGWRTIDNSKETQANVSFDVLAFGLLSVSLITALILINQLENGTVNILLLGVTIVSLTGF
VIRSLTSKQTFLNIRLLSNSKFLFLLIPVVLYMFANLGINLLLPNYSQKILNTSSFWAGF
SLLPGTLLGGILNPYFGHLYDKHGDKTPLLVGNTIFGISLLVMAYFTKNLGIIAFIIMYM
IFTFGRNMAFSIGMTASIDELSRDKKTDATAILQSAQMFMGALGTTVAALYGAQKSGLAV
GFQHFLWLLFFISLVIFIMFFARQKTGNK
>fig|203122.12.peg.726 Permease of the drug/metabolite transporter (DMT) superfamily
MRVALAYACVVLIWATTPLGINWSNSTLSFAAAVALRMCLALAICWLALVVMRERLVQQR
SDWKAFFAGAIGLYPNMLLVYWSAQFIPSGLMAVILGLYPFTAGLFTYFILKEWVFTPPR
IVALALAVTGLGVIHYEHLALGSDAIYGIMGMLGSTFLFGLSSVWLKASGAAVEPLRQST
GTLLLSTPFFILSWVVTGVNIPAAIDVKSIVGVSYLAVAGSAIGGTLFFYVLKKCSMSSV
SLITLMTPMMALTIGMLFNNETVTQLEFIGCIIILFSLAIYQGALRVVVKQINRLLAVGK
QPVQLP
>fig|203122.12.peg.1022 Permease of the drug/metabolite transporter (DMT) superfamily
MNPQKTGLLSLYFGIFLMSLTGLFAKSIPLDATSITQLRSTVAIVALFIYCMLRGSSLRL
KSFKEAAGIYGLGIFMAIHWVTYFHAMQVSTVAIGMLSLFSYPVITVLLEPLFQKKLPAR
ADLIAGALSFTGVVILTMDDSTGLGGAALTGAAWGIFSALIFSVRNILQKYTYPDVPSGT
LMFHQVVATAVILIPFVDFGSVASLELDKWALIVALGVLCSSMAHTLLALSLKRLPAKSV
AQISCLQPVLGALLAWFVLKETIAPQVLGGGALILAVAAWESYKQSYRPRAVS
>fig|203122.12.peg.1544 Permeases of the drug/metabolite transporter (DMT) superfamily
MTLWIAFTLMAVVMQAVRTAAQKDLSRALSPMATTLTRYLYGIPFVALYLVVLLQTNTEW
ANSFNYAQLNNARFLVFATVAAIVQIIATAFMVKMFTLKNFAIATSFAKTEAIQVALFAS
VFFQDHLNVYGWVSVFIGVVGVLFVSGLKIGKPQSISSATIFYGTLSGALFAWTSLSLRE
ASLSLDLPLVYSAALTLMYMVIIQTAICAIYITFKERKQWQKLMALQKRGLFVGATSALG
SVGWFTAMSLQNPALVKTLGQVEFFITLGITHFYFKERIKWQEMVGIMCIFASILLILYV
>fig|203122.12.peg.2443 Acriflavin resistance protein
MENKQYQQGDSSGGLSGWFVMHPNAAKILLMVIMLAGFVGVNSLPQEVFPPFAPSRVDID
IPVRGGTASDVEELVVKKVEESLEGLAGIERIVANSTDNGARISVELVNGADQQSLLSLI
KSRVDGISGLPISSEPPVFSLPEPVGPVQFINITGDVPLPALLGQAVKFKSELSRLEGIS
YAVIENEPELPLYIDINPDKLQQYQLSLTDVADTVARYSVNVAGGTIQTLGNRYQLRANT
LGNMASDFIDIPIVSAASGVVVRLGDIAEIQLAPHDDYVAGKFNGKPSLMLSVYRDPKVP
FSTASESINALLDAKRAALSPAIELIAWQDESREFTTRISLLVKNGVGGFIIICLLMGIF
VNPQIAIWTAIGIPISILGAMGLMHFAGLDLSLNAVTLLGFIIALGMIVDDALVIGESIQ
YETAQNGHSMHSVVTGVNRVAIPATFGVLTTIAAFFPLTLTEGDMGSKLGGVGMVVICCL
IVSLVESKFVLPSHLRKPSKILQKPAFNKLNALSTGATKKMDGFVERYYKPALDWVVVRP
VRTISAVVGVLVISLAMIPLGLLKMAIIPNIADFALQASFQFHPSVAPSIRETIGDKATE
QLRAVSEEVKQKYNLDYQPVKHISQHYSGSELVVDVELEEAFNAPYDAYDIQQMWRDSLP
YTPGISSLSIDAGSGSSEKIAIELSGENIESLRALSKELREHLASQDDVVDIRDSELANM
IEYRFKPTDLAKSLNISDAEIITQVRAAFYGQEAQRITVGEREARVMVRLEDEYRHSLTG
LNAMLLPIQSADGSKQYIPLSQLVEIEQNVVPSEIRRINKQRTITVYANTKMNTRSPEDV
AEEMGESVLPEMVKAYPGVGFSIEGEAKEANKSLSSILSSAGLAGFILFALMALPLGSFR
YPALILCLIPFGMIGAVWGHIAYGLTFSLMSIFGVIALAGVLINNGLLLVDQYRENIRLG
QDITEAIKQACVRRFRPIVLTSITTLAGLMPLMWEGDPEALWLVPIAISLGVGLLVATAI
TLIIFPAMLLLLDRNKVHEQQEEFTSGIQPKEV
>fig|203122.12.peg.3480 Drug resistance transporter, EmrB/QacA subfamily
MSQANLGCIQVESTHNKWAVALSVSMGGVMSSLDTFILYVATPNLRGVFSATVAEVSWVS
TSYAIASMMCMFLSGWFVDRLGSKRVYQAGLVLFVIGSALCAMATSLEQLILYRVIQGLG
AGILLPVEGVILRRTFPPVQHGLVMGLYGTSIMCGPAFGPMLGGILIDQFSWHFIFIVNI
PIGIISFVMVRHYLIDDPIGADTPKRTFDAPGILWLLFGVVGTVWLLERGDRTYWFEDTQ
NVVLLVVALASWAMLCAHSLTIKQPLLDLKVLKHKTFTAANSLNFLAAFMITGTLFVLPI
YMQELLGFSPTQAGTTMAPRALVMMLAFPLVGWLFNRVPMRLLITTGLVLGIGSGVMMAG
FTFETGWHDMILPQIIQGLGAAFILGPVTTAALISIPKATMPAAAALESTTRLLGSTLGI
AVFASLITHYELRTWELLRHNVTLSSTVLYKRFGGVVEFYYSETSSQLHALEKAYRALNG
RVTEQVLSITYMNLFQLITVGFIAMLIISAFISLKKQQQVA
>fig|203122.12.peg.3486 Permease of the drug/metabolite transporter (DMT) superfamily
MKALTVLPSDKQRLLGIAAACAVVAIWSGWIVSSRWGLNSNIAAIDLTWLRFTTAALVTL
PLAIKYNWRHLPLGKALVVAFGCGFPYVLFAYLGLQFTPSANASVLINGLLPVVTSLLGY
FFLSGKMTKPLLALVAIACISNIIIASSGAQFSVKYLTGIGFLLSATLVLATYMVAVKAW
NISMHEIMVWVPIINALCVTPFWFVFSDGLSALHTIPTTDLLFHIVYQGVIVSVAALFLF
SYAIKCIGALSASLFMAFVPTTTALLAFISINEQPTSGQWIAITLCTLGLVGYNFYSRKE
EKSTSK
>fig|203122.12.peg.3493 Permease of the drug/metabolite transporter (DMT) superfamily
MRQALLRLSVNHTKLLGVLAAFTMMLIWSGWIVSSRQGLTTTLSPLDITWMRFVVASLVT
LPIALSYHWRTFPVRKACFIALSYGAPYAWPAYLGLIITPSANASVIINGGLPVATSLIA
VFFFGARVTKGVILLIGFIFLANILTFMDAELFNRRYFIGVSLLAVATVSLAIYMAAVKA
WEVSVKDIMVWVPLINTAVMTPIWLVFSDGLTSFTSLPVNELLFHVIYQGVIVSVVALFL
FSFAIRAIGAVASSVLMAFVPSVTAVLALLFNNEVPNSLQWLGIACCSIGLIIYSSWDVF
RKKLRAP
>fig|203123.5.peg.94 Drug resistance transporter, EmrB/QacA subfamily
MNQKEGIIDKTTMTTAWVLVFGALAPLLDSTMINIAVHSLVRNLHSSVSTIQWAVTGYVL
ATAIAVTFSSWLLNQFDGKKVFLAGEIIFAFGSVLSALAINAQFLIGARLIQGFAGGIIM
PLLTTLLVQTAGQKVMGQMMATVGLPIIIGPLVGPIIGGIIIKYLSWQWIFWVNVPVAVI
SILLILWKMPSYPAQNKSAKMDFVGIVFLAGATTSMIYGIVKAARKASFANKDTLLFIGL
GLALALLYVFWAMRIKDKAVLPLNLFKYRSFNGSVLGLLIAGTVLNGAMLALPLFFQEVR
GMSVMMAGLALIPQGAGMLVSRTLTGKLTDKFGAKYVVLTSLIITFIGTIPFYWFNHETS
YWIIALVLFVRGIGAGGILMPLMADSYTGMQGALIPAASIGSRTIQNIGSAFGTAIITTL
ITAYSNAKIKGFKQNISSANYHVKAANMSQFVARHLDLIQIHAFQYGFFCISIAALLIAL
PTFLLTNKIEKNQ
>fig|203123.5.peg.97 Drug transport protein
MKNKLFIATLISYLGIYITMPVLSAISTKAHMLPGQIGVMISLGAIAMLVFAPVWGKLSD
KLGRKTVIVAGLMGMGVMFILYTALFRLSISQSKTITILVILLMAVRFLLGIFMTTAPTA
ANAYMADISYPENRAKDMSSLGLATGLAMVLGPIIGGILSSIGTLYLPFYISIIMLILFG
FIFITILPKKDQEKTIPKKLIISKQLLKIRKVFLLSNYLGG
>fig|203123.5.peg.1051 Multidrug resistance ABC transporter ATP-binding and permease protein
MLKRLLIQTHRLNNLLLASIFCGAISTLLQIFIIAAAFYLIIQHQFSWTYALILLFVALA
LGFSRFGEQYLGHFIAFHLLADLRTQLYDHLLSLAPAKLDDKESGKILKLLVKDIEQIEV
FYAHTIAPVVIAVLLSFLQSFLIFLFSPLMGTLALLSYFWIGFVLPLFRKKKIENTSSSL
SKYETENDQLLSETVNGKSLLQQFQKIEQRISLLDKQRDLIGNTIKKGTFSDSAAATATQ
LSLLFFSIAMGYLAFNFSVGNTLCWVIAFTFPFSFGRVLALANLPSSLGNALLSAKNIFK
ILDEKAVSNLSENQEISLIKQSRFVDVNFSYPLRPNKTVLKDASLIGKKSEVIGIIGESG
ERKSALMKLLMKWYQPKKGLIEVYNHDLRKIKKSGLRKQINYVAQNPLILSGTIRENITL
KNNSFSDSKIWESLKKVELDKTVKKMPKELDTKISRLEQRFFFRRIAKTGNCQSIAVPEF
NIDFRRTDKQLGHP
>fig|203123.5.peg.1354 Multidrug resistance ABC transporter ATP-binding and permease protein
MRNPAARMSGNGNGPRPMARVAEHPHNFWGTTVRLFKYLGRNRIGVVFSVLLAIGSVLLS
VSAPKILGRATTIIYKGVVAGLKSEKYQISYQPIIKILIEVSIIYVLSALMSFLQQVIMT
RISQKTIFRLRSEFKAKMARLPIKYYDQHQNGDIMSRVVNDMDNISGTLQQALIQIVTSA
LTFLGVVFFMLTISWSLSFIAFITVPISIFVVRFIAPHAQKLFARQQAVLGIMNGQVEET
FSGHEVIKTFDREIPVIDRFEKQSQKYYQAAWKAQFISVLIFPAMQFLNNLDYLLIAVFG
SIQVANGQLPLGDIQAFLQYTNQFSQPITQIANLSNTIQSTIASAERIFEILDAKEMTND
FKNLPKNIKNPKSLLSFDHVKFGYSDNLLIKDYSLKVDKGQMIAIVGPTGAGKTTIINLL
ERFYDVKDGSIRYKGFDTRTLTRPEARSHFAMVLQETWLFTGTVFDNIKYGNEQATEEQV
VSAAKEAYADGFIRQLSKGYQTILNESASNISQGQRQLLTIARAFLADPEILILDEATSS
VDTRTEILIQRAMEKLQSSRTSFVVAHRLSTIQNADNIVVMNHGSIVETGTHEELLDANG
FYADLYNSQFSNGAI
>fig|203123.5.peg.1355 Multidrug resistance ABC transporter ATP-binding and permease protein
MFFQVAADLILPSITANIVNIGVVKHDISYIWKTGLVMLIVSFFGIVGAICNQLLAATSS
QKLGVKLRSFMFRKVTKMADGDFEKLGQASLITRTTNDVVQMQNATYSMLRMMIRSPMML
IGASVMAYFKSPRLMLVFAAAMPVLALVVILVMTKSVPLFKKIQALTDQINLVFREGLTG
VRVIRAFNQDEFEQNRFKKANINLTQNAINAYVITSLMSPAMTFIISASNIAIVWFGAHL
IAGSLMPVGNLLSFITYATQMLFSFMQLSMIFVVVPRAQASAQRIQQVLDIKDTINDPIK
PKKLDPIDDLKFSHVDFTFSGSSKKVLDDINFEIHKGQTLAIIGGTGSGKSSLINFVPRL
FDVSGGKVLINGDDVRDFSQSDLHKHISFTSQKSFLFEGTVRGNLKYGNSQASEQDMNRA
LEIAQANSFIQEQGGLDAPVEQGGNNFSGGQIQRLSIARAVIKRADIYIFDDTFSALDFK
TDANLRQALSEDKKIKNAIKIIVAQRVSTVADADQILVLEDGKISGLGTHQELLKNNSIY
KEIVDSQLHKNDILAKSGGKIYA
>fig|203124.6.peg.354 Multidrug resistance protein
MSKKTVSQNIKNSIKIYQDSNFQIIIGIISMAILGGPGISPLLPSIAKNWNISPEHIGWV
ISAFFIPITIGTPISGILADRYGRKQILIPALILFAISGTLCSLAPNFQTLIGLRFVQGI
GAAPLESLTLTLISDFYSGKLLTTAMAFKTMSVGLSLVIYPLISSGLTTWGWRYPFLLYL
IAIPLSIWILFSLKNPAIPKQKSFNLKKYLRNIWQSFNNYQVRSLLIVIIVNFIFSLGPC
LTYIPLFADRQLGASYIVIGIILASRGIFLAFASSQLGIFAKYLSELTLIKISFIIYCIA
FIMIPTINNIWLLFIPGILLGLAHGMLVPSTQSLLGQLSPENYRAGFMAVTSSALSFGRT
LGPILAGSMFYIGGMAGVFYSSSIVSLVIFVFISYLVINTQSIKS
>fig|203124.6.peg.3596 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MKQKLTEGKISTLLLKLTLPTVWGILALLGFSIIDTYFVAQLGTKELAAISFTFPVITFL
NSVSIGLGIGVSSCISRAIGKRVQTPVLDRDDYKVKRLTTDSLILSLLVGAILVILGLAT
IEPLFTALGAKAETLPLIRQYMKTSYLGGIFAVVPIVGNSIIRATGNTFVPSVVMTVAGI
VNLVLDPILIFGVGPISGMGLQGAALATVISMVATLAASLFFLHYHQQMICWKLPSFKLL
LRNWQNILSIAIPNIGQNIIIPISVSFITSLIATYGTAAVAAFGIASKIEVFCFIVFLAL
SSSFIPFVGQNWGAKQYNRVYLGGNLGFKFSLFWGAIIAIALAIGGSWLVSIFDSDPEVI
EVATKYLLIMPISYGTLGITLISSATFNALGKPLPSVMMSLIRVLFLYVPLTYLGSWLLG
INGIFYGTCFANLVVGIGAYFYFNKTFKFNN
>fig|203124.6.peg.4212 Glyoxalase/bleomycin resistance protein/dioxygenase superfamily
MEITWKDSDWAYLKAGDDGLALLSPTYEQAGPHFGFVFSDRSEMEMAYKQLQAKEVEVSP
IHEHRDGTASFYGRDLDGNWFEYLYEPVN
>fig|203124.6.peg.4627 Permeases of the drug/metabolite transporter (DMT) superfamily
MSSTSKKLSTLTKSLFSAQIIVMTGLIWGVLALLFFLLFSVPLPGEELPSWYSVGTYIFE
LGAYLIATIISFRNWQSPQMVSGRNVWIGISLGLLFYFIGGLVFGCWELIWELDPDVSLA
DIFYVFSYIFLAWGMTLAITAKKLNLEFWQWVVLALVAAGGVLLAIFVADPSFFGLLSTP
DTTVLEELDTIKIESAQLAPSWVLALDNKLEPFSFWLNLFYIIADVFLLIIATALLLAFW
GGRFSQSWRMIAGATFSLYIADMYFKWADSQTTGEYESGGLLEVFFVFTAILFAIGAVLE
YDISTRSRQSRRSRRSSSS
>fig|203275.8.peg.258 Tetracycline resistance element mobilization regulatory protein rteC
MNMKRRKDDSRTYFLDELREELNRRMKESDLKGGKFKKR
>fig|203275.8.peg.345 Acriflavin resistance protein
MDNPMSAKKSISAFTVIVAFLSVALMGLALVPLLPVKLAPSHTLPGLTVYFSMPNNSARV
IEMTATSKLEAMLARIKGVKNIYSTSGNGWGSVTLELDKHTPIDAARFEASTIVRQTWHD
LPREVSYPYISVRRPDENAARPFMTFTVNSAAVPVVIQQYAENNIKPRLNDIAGLYKIEV
HGATPMEWQLMYDNDRLQALGVTVNDIREAVSQHYTTDFLGMAETRSADGTAAWMRIMLM
SGSRNDAFDATAITVKNCDGALIRLDQLVEVVHTEQEPQSYYRINGLNSIYISLTAEESA
NQLRLSERVQETMDEIRRLLPPGYEIHSSYDATEYIHAELNKIYLRSGLTVLILLLFVLL
ITRNVRYLFLITVSLTINLAIAVIFYYLLGLEIQLYSLAGITISLSLIIDNTIIMTDHLM
HHGNRNVFMPVLAATMTTVGALSIIFFLDEKIRLNLQDFAAVVMVNLCVSLAVALFFVPA
MAEKIRLKKRISRTRILRWFPLRPKRLIVWFNRFYGAMIRLLSRRKWIPFTAIVLTFGLP
VFLIPDKIEKETKFAEQYNRIFDNATYKEKVKPIVNKVLGGTLRLFVDKVYQGSYFTRNE
ELILTITASMPNGTTLAQMNALVEKMEHYLSSFSEIRQFQTHIPNPRRASIRVFFTKAAE
RGGFPYLLKSNVITKALELGGGSWSVYGLQDQGFDNSVREFAGNYGVKFYGYNYDELGAW
ADTLKNTLLLNRRIKEVTINSDFSWYKDDYREFSFDLKKERLAADGFLPGDLFASLQPIF
ARDMWAGSLIIEGEREDIKLASHQGKHYDIWALRHVAHRMGGRMYKLDELADISQGQAPQ
EVAKENQQYRLTLQYDYIGSGTQGRKMLEREVKALSERLPMGYTVEQRDTQWGWGHKDKK
QYGLLGLLIIIIFFTSSVLFNSIRQPLAVIFVIPVSFIGVFLTFYWFRLNFDQGGFASFI
LLSGITVNASIYILNEYNRVRRLRPRLAPIHAYLKAWNAKIIPIFLTVVSTMLGFVPFMA
GTEKEAFWFPLAAGTIGGLAMSILGLWIFLPLMTIRGKKAIK
>fig|203275.8.peg.1110 Tetracycline resistance protein TetQ
MNIINLGILAHIDAGKTSVTENLLFACGATEKRGSVDKGDTITDSMDIEKRRGITIRAST
TSIVWNGVKCNIIDTPGHMDFIAEVERTFKMLDGAVLILSAKEGIQAQTKLLFKTLQKLQ
IPTIIFINKIDRAGVNLERLYLDIKTNLSQDVLFMQTVVDGVVYPICTSTDIRAEHKEFV
CNHDDDILELYLADKEILPADYWNAIIALVAKAKAYPVLHGSAMCNIGINELLDAIISFI
FPPASVPNRLSAYLYKIEHDPKGHKRSFLKIIDGSLRLRTVIKVNDSEKFIKIKNLKTIY
QGKEINVDEVVANDIAIIEDIEELRIGDYLGVKPCLIQGLSHQHPALKSSVRPDKPEERS
KLISALNVLFIEDPSLSFSINSYSDELEISLYGLTQKEIIQTLLEERFSVKTHFDEIKTI
YKERPKKKVNKIIHIEVPPNPYWASIGLTLEPLPIGSGVQIESEISFGYLNHSFQNAVFE
GIRMSCQSGLHGWEVTDLKVTFTYALYYSPISTPADFRQLSPYVFRLALQQSGVDILEPM
LYFELQIPQVASSKAITDLQKMMSEIKGISCNKEWCLIEGKVPLNTSKDYASEVSSYTKG
LGTFMVKPCGYQITKGGYSDNTRMEEKDKLLFMFEKSVSSK
>fig|203275.8.peg.2442 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MSVQKPLSALETEPVGSLLTKYALPAIIAMTAVSLYNMVDSIFIGRGVGAMAISGLAITF
PFMNIAAAFGALVGVGASTIVSVRLGQKNYGAAQQVLGNVVCMNIVIGGVFTLVSLIFID
PILYFFGAGEQTIGYARDYIVIILSGNIITHLYLGLNSVLRSSGHPIQAMMMTVTTVVLN
TALDPLFIFVFGWGIQGAAIATVLSQCVTLMWLLFLFSDKKRLLHFRKDMLKPRIGIVKD
ILAIGMAPFLMHLASCMIVILINNGLKRYGGDLAIGAYGIVNRFAFMFLMIVMGLNQGMQ
PIVGYNYGACRINRVQKAFRLTVFFATLVTTFAFLLAQLKPEWIVRVFTTDEELIRLSVY
GMRISVMVFPLIGAQMVITNFFQSIGMAKKSVFLSLTRQVIVLIPCLLIMPKLFGIAGIW
MSMPVSDTVSALVSIAMIYVQLGKFNAKQ
>fig|203275.8.peg.2815 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MNNAVNILQEGSMMKALTKLGIPIVIAMLIMAIYNVVDTFWVARLGTLPVAAVSVVFPLS
LLFLGIGLMFGVGGGVYISRLLGAKQIVKAGQVASVSVITSVILAALIALVCNAFLPDIL
LFMGANTGMMHLAEAYGRLFVISCVIGALNVSMSNIIVSQGASKTSASAMIIGSVVNVTL
DPLFIYTFGWGVEGAAWATILSRIITTAIYIRFLTKAEVKVSFALFVPTIRMYAGIIKIG
ISMLFLQSLQTLSISLLQRAAVKYGAEAVAAVGIVLKIVTLGTNVVFGFVKGLQPMAGYN
YGAGNFQRLKEAVHCSLILTTSFCVLWSILIMAFTSPVISCFGKDETMQEIVRIALRANT
IMFFTFGFQFVYSTLYMAIGRARQSLLLNIGRQGLFFIPTILLLPSYWGLNGVLYAQPVA
DVFATLMTLLFAVRIHREIGHQSHLTTENL
>fig|204536.4.peg.1198 Acriflavine resistance protein E
MNKKVITAISVVVIIAVAFFILKSIEKKSKSQTDQRPQKPAPAVKVIIPEKQEVPIYYTA
NAVLQAKTSAKLKPQVSGRVEKIFAEEGSFVKAGQPLAVIQPEKEEYQIESQLAVINQLE
ANYLNKKSIYERRKQLYEKELIAKEELDNAKTDMEVALNQLNSAKATLKEYKRQKNETVI
RAPFDGYLDKRYVSIGDYVDSQKDMFYILKLNPIWAVFELPQQYVKNLSLGKEVEIDVDG
IGAVKGKIDYISSSLNENNLIVVKVLLDNKDGLLRENMYGKAKILVDKVEGYKLPEDAVQ
LAGNDNFVYKVVDSKAEKVLVNVLKQEYGYVYVSGDLKQDDKVIVSNLMNVKHGMPVKVI
QQPEVAK
>fig|204536.4.peg.1203 Membrane fusion component of tripartite multidrug resistance system
MNGKGKKVGLIITVLLIVVFLIYAVKWINHRMKYAISDAVFVESDYLSNIGFNRVSGRVV
QLYKKESDEVKAGEVIAKIDDTDYKLQIEALEKEIEALTYQKKQLESQLQRVARETDINE
SISALTVEEISKKLESLKAQKDQIESQIKLAKKDEERYRNLLEKGLVAKRKYEEVHTNLE
VLEKQKLAIEKNISELKVSMEKSKKSVEYAKTQKSITEELQNQINAISSQIESLLKKKQD
LENQLQYTELKAPFNGVVAKKFVSIGDVVKAGQPVYAILKSDSFYVKVLLEETKLEGVKV
GNKAYIKLDAYPDKTFEGVVESIDVASAAKFALVPRDISAGEFTKLAQRIPVKIRITKGD
ISLLRVGLGGEVEIEKSR
>fig|204669.6.peg.497 Polymyxin resistance protein ArnC, glycosyl transferase (EC 2.4.-.-)
MEYVSYSIVIPAYNESDRIQESLTKIVAFLAEQSWTAEVLVVNDGSRDNTAEVVKRFAAQ
HRFIRLIENPGNRGKGYSVRNGMLQAVGDVVLFTDADLSAPITEAPKLFSEIQKGVDVAF
GSRWLVAKMQTERQSIMRQIAGRMYNVIMRIVLGLNFKDTQCGFKAFNRKALETIFTRQH
VERWGFDVELLFLARKFKLKIEEVPVEWAHDDRSKINPLVDGIKMFGEMLSIRWNSIVGR
YTNPHLPKPVVTDATPVVKIAK
>fig|204669.6.peg.594 Multiple antibiotic resistance MarC-related protein
MAADAGVADFDVFDALAPFNSHFLPFGLAVLTRGRFLCEDRSVGTIVFQVGHIMRGAFEA
HIVQFTLVALSSVFFLVDPFAIIPTFLVMTARHDPITRRRMAARACWTAFIVLTAFAFAG
TAIFKIFGITLPAFEIAGGLILLLIGLDMMQAERPTQEGSPETAEGSVKDDVSITPLGIP
MLAGPGAISTVMVLNGTARDWSTTIPVFAAIALTCFASYWILRGAERVSQKMGQTGIRVL
MRIMGLLLMAIAIQFMINGLTNLGVIHAD
>fig|204669.6.peg.1047 Glyoxalase/Bleomycin resistance protein/Dioxygenase family protein
MRVTGFGGLFFKSPDPEKLYQWYETHLGIKRSEWGVSFKWADDPHAADGQTAWSIFKSDT
KYFNPSQASFMMNFRVEGLKDMLAKMRSEGAQVDEKYEETEYGNFGWVMDPDGNRVELWE
PKD
>fig|204669.6.peg.1425 Permease of the drug/metabolite transporter (DMT) superfamily
MSRSLKAHILLIAVTFVWGSTFVLIKAALADVTPLLFNAVRMTLAGLALGLVYWKALRKM
NRAEFIDGMLVALMMYFGYEFQTSGLKLTTPSKSALLTGMSVVLVPLILHFGWRKHVSKW
TIFGVLIACVGLFLLTVPAGTSRGFSLTEMNLGDLLSMGCAVCFAFQIILVGRASERHGF
EPIAFLQVAGAAVLMFATVPIAEHAHVTWSSTVIWAILVTGLLGTAAAFTVQAWAQQFMP
ATNTALIFLLEPVFAWATSFVILHERLNSRSSLGAVLILVGVVLSELLGSQDHPSEEIRV
S
>fig|204669.6.peg.1465 Multidrug resistance protein B
MSSAAVQQQEASATSPWLIAIAVMLATFMEVLDTSIASVALPHIAGSLSATNDEATWVLT
SYLVANAIILPASTWFALRFGRKRFLIICIAIFTVSSFACGAATSLWMILAARAIQGAGG
GALQPLSQAILLESFPPQKRGLAMAVFALGVVVAPVLGPTFGGWLTDTYSWRWAFYINIP
IGILAVFMILRYVVDPPYIKNAKPGRIDAIGLGLLAVWLGALQIILDKGQEVDWWSATWL
RWATLVLLVTFIAFLWWQFTAEKPLVNLRVFTHRNFTLGCIMIGLFGAVIYGMVTLLPLF
YQELMGYTALNAGIAVSPRGVGAIVAMPIIGILTSRIDNRWLIAFGFALFGICSIWFGEV
YLGIGPWTFIWAIILSGFASGCVFVPLSTTTMAGLRNEEIGNASGLYNLLRNIGGSIGIS
IVNMIVARHSQTHRNDLVHNISAQNPNFHNQFGAIANGLKDAGSGGNGAPLWDSTTRAWG
VVNGMVERQARLWSYVDDFRYLALVCFACVPLVFMLKKAVAKKGAVGAAH
>fig|204669.6.peg.2304 Permeases of the drug/metabolite transporter (DMT) superfamily
MSFKRYLILLGVIVFGALGDCFLSRGMKELGSISLGNWHMAFQIFGNPWVVSGVICLLCY
FASYLTSLSWADLTYVLPASAVGYILIALIAKFFLHEQVSFVRWLGILLIVAGVCFVASG
SHVTPRESETPAEAVEVRG
>fig|204669.6.peg.2305 Permeases of the drug/metabolite transporter (DMT) superfamily
MKNVYTWSFIFAVVFASTAGDILQSHAMKKIGDVGKLRRERGIPYVILRVVTSPSFMLGL
MFMAIAFYSLVIALSWGDVSLVVPASASMTFITNAFAAKVFLKEDVDKKRLVAAVLVAAG
VALLAY
>fig|204669.6.peg.2625 Permease of the drug/metabolite transporter (DMT) superfamily
MTSEHSSHPLRGYLYVAAATLCWGISASLGRAAFTGKLLGGLRPIDPLILAQARTTIAFF
LVTPILWTLRGRSSTKLPRREMLQAFLLGVFGLAFSNYAYYLAIQKTTVATAIILQYVAP
VWVLLYMVFTRQQRATASRVWGVVLAVLGCVFAIGVFAGVGHFPFLAIAAGRIKLNTVGV
LAAQVAAVSFAFYSIYGRHLLQVYDRWAVLTNSLLGAALFWIIVNPPWKIIAAHYAPKQY
AFMVLFSITSAAVPFSLYFAGLHHLDATRVIVTAALEPVFSVVIAAIFLGETVTLVQMAG
MAVVLSAISFVQRSDGTAPAIVVDPIE
>fig|204669.6.peg.3097 Multidrug resistance protein B
MEVWVSATTAPPGVLATEAGGVREINPWWVTAAVMMAVFMEVLDTTIVNVSLPHIAGNLS
ASVDESTWVLTSYLVANAIILPMTGWLANHFGRKRILMSSIIGFTLASVACGMAPNLSSL
IFFRVVQGATGGGLQPLSQAIMLEAFPGKKRGKAMAIWALGIVVAPMLGPMLGGWITDSY
SWRWIFYINLPVGLLATMMSQWFIFDPPYIKRSSDVVDYWGIGFLIVGIGSLQVMLDKGQ
EDDWFGSHFITTLAVLTVVGLILFIMRELMAEHPIVDLRVFRVRTYATGVFLMTILGFVL
YGSTVLIPIWLQTLMGYSSLEAGFAVLPRGLGSFLFMPLVGVLMGFVEPRKLLATGLITA
GGSLYFLSLLNTQAGYWDFFWPQLIQGAAMGLLFVPLTTITNDPIAPENMGNATSIFNLM
RNIGGSIGIAMTTTIVARSQQLHYNNLVHNMSSYNPKVQQMMAGARGMFMSKGMDAHSAG
LQAYHSLWGMVMQQAMMLSFIRAFQILSGLFFICLPLILLMRKPKHNEKGGGGMAH
>fig|204669.6.peg.3099 Outer membrane component of tripartite multidrug resistance system
MSFSVNPKSCFWKLTKRLNLALIAFICLGIAVSANSQAPGGGLTASPAESPAAQSPSQSL
SGSPLSGSVVVLKPTGDVLNLSIKDAIQMGLKYNLGVLLSTEGNEAARGAKIRALAELLP
NLSARVGGAVQQVSLAQFGFPATLTGGKLVIGPFAYFDARTYLTQSVFNYTALQNNHAAD
ENLKAANLDYRNTRDLVVLVSGASYLQAVAATSRVDAAQAEFTTAKATYDRAVNLHTAGV
IPAIDVLRAQVQMQSQQQRLLAAKNDFERSKLSLARVIGLPTAQQFALSDKIPYAPLPPV
SFDDELKRAYDNRSDYKAAQARVKAAEDQRKAAVGERIPTVAINGDYGVIGPHFTQANGT
FTAAGGINIPIFQGGRARGDITQADALLKQRNSELENLRGQIEYDLRTAFLDVQTAAEQI
DVAGSTVKLAHDQLEQSQDRFSAGVADNLEVIQAQQAVAVANENYISSLYAHNFAKLSLV
RAVGVAETAVMNFLGGK
>fig|204669.6.peg.3678 Permease of the drug/metabolite transporter (DMT) superfamily
MSSSAETAVTTSVSTGKPQRAALAFSFLSTWIIWGSTYLAIRYAVETIPPLVTAGVRHFT
AGSVLFAYCYFRGFRPTAKHWKGAFLIGAFYFLGGHGTLHWAEQRVSSGLAAVLIATEPL
FIAAIMIFTGKERFSYWTLLGMLCGISGVAYLMGGEALHAPGQMVGILAVLAGSLSWGIG
VCISPNAGLPEDPVASAGMTMFCGSLLLLTTAGVTGEIAAFHPHQVAMRSVLGLLFLIVF
GSIVAFSAYVWLLGQVSPTMVSTHTFVNPAVAVLLGWAMAGEALTARLLVATLAILGSIA
FIRRGTRAAAH
>fig|204669.6.peg.3977 Permease of the drug/metabolite transporter (DMT) superfamily
MTEVQSRHRLQVILAFGLVYVFWGSTYLAIGIADDEKIPAAAICAMRFLIAGTLMLGACA
LMRKKIRVSWEEFGRLAMVGFLLLVCGNTGLTWAEKYVATGFASLIVAITPIWIFCLESF
VYKGDKTSGRGIIGLALGVVGTGVLFWPKLMNPEIRGGMQLLGAVSLLGSSFCWANGTVL
SRRWKSKFTVDPITATAYEMIVAGTVNLCISLALRQHNIRWTHRGVGAILYLVVFGSWVG
FTAYIWLLKHVPTPKVATYAYVNPIVAVFLGWAVLHETIDRYIVAGSVVIVAAVAMVTIA
KVKSAPAVQMVEVETTGD
>fig|204669.6.peg.4464 Permease of the drug/metabolite transporter (DMT) superfamily
MNLSTQTSVNTAPTRGSAGALAITALVLSGCCWGTGFLFGKIALEQMSVTENVAWRFIFG
SLGLLPIIFLRWQPYTRRDWVSLLIASFVGVPIQFLIQFKGLQLTTVSHASLMIGTLPIM
LAMSSVIFLGERLHWQEWFSLAIATFGAVLIALSHGNGVGSPQASVVGDVLVVLSLLAAV
VMVMITKKLIGRHDSLHVTSMMIVLGTLMLIPWAVLTHPMRFDFSTSTWIGVAAQGFIAT
SGAYLLWNWGLAKVPASRAGVFLNMEPLVGALLGVTVLHEHLGWPALLGGAMVVGAAIHF
SKTS
>fig|204773.3.peg.212 Multidrug resistance ABC transporter ATP-binding and permease protein
MLTATIPRQKHKPFENFSPMRRSSASSEPAPLSSGNRNDWATLKTLIPYLWTYKWRVALA
LLFLIAAKFANVGVPLVLKRLIDGLTIDPASPHALLVLPVGILFAYGALRLSTTLFTELR
EYTFAKVTQRAVRTIALQVFRHLHALSLRFHLNRQTGGMTRDIERGTRGISSLVSYTLFS
ILPTLVEITLVLGYLVLHYDIWFSIITAVALVSYIAFTVVVTEWRTHFRRTMNDLDSKAN
TKAIDSLINYETVKYFGNEDYEAKRYDEGLKRYETAAVKSQTSLSVLNTGQSSIIAVAVT
LILWRATQGVISGTMTLGDLVLVNAFMIQLYIPLNFLGVIYREIKQSLADMERLFSLLDQ
HREIADKPNTQALVVQGAEVKFSHVGFSYEAKRQILFDVDFTIAAGTTTAVVGHSGSGKS
TLSRLLFRFYDVNEGAILIDGQDVRDVTQASLRNAIGIVPQDTVLFNDTIEYNIAYGKPG
ASKDDIVAAAKSAYIHDFIESLPDGYATMVGERGLKLSGGEKQRVAIARTLLKHPAILIF
DEATSALDSKAEQAIQAQLKEIAKDRTTMVIAHRLSTIVDAAQILVLDHGRIVERGTHAQ
LLAADGAYAQMWARQQARQDESPASPTDDDAVAESLLHELHTDMLPDA
>fig|204773.3.peg.368 Probable drug resistance transport protein
MSLALENVNVILAGNPVLRDISMHIEPGELVCLVGRNGAGKSTTFRSIMGFQPLKSGAIK
WKRSAINGMQTHKIVELGLGYTPEGSDVFGDLTVEDNIALPTWTRKSGRSAQERIDEAYA
VFPKLKQYLHRGGQQLSGGERKMVSIARALALDPELLLLDEAFEGLSPAIIPTISEGLQS
ILKQGRGVLLAESNFYHLPPFADRLYVIERGEIVFEGTLAQAEADAATMKIIKGA
>fig|204773.3.peg.369 Probable drug resistance transport protein
MSTNDVLLQAQQISRHYGDFIALHNVDLSVSRGEFVSVVGPNGAGKTTLVNVLTGLHQPT
TGNVHFNGSNIAGVGAVDLATRGLARAFQLTSIFPELTVRETIAVSACSYLNMRWNGFGS
LFGSRKVNDIVVRTADAFGLAPWLDTKGSSLPHGRRKLLDVASAFALHPKVMLLDEPTAG
VSTADKHGVMETLLRAAKHMGIEAIMLVEHDMDLVSRYSTRIIAMQAGKKIADLPRDEFF
ANEEIISIVVGKGAH
>fig|204773.3.peg.990 Glyoxalase/bleomycin resistance protein/dioxygenase
MQPRISVITLGVDDLEKSLQFYRDGLGLQTQGIIGKEFEYGAVVFFDLQAGLKLALWPRK
SMTHDSGIAVAPVSATEFTIGHNVSSKDEVDAVMLQAQDAGAIIVKQAQTTFWGGYAGYF
QDPDRHLWEVVWNPAWAAPD
>fig|204773.3.peg.1367 Permeases of the drug/metabolite transporter (DMT) superfamily
MTQKITPSTALLLTIAPLMWAGNAIVGRSINALVPPLTLNFFRWSIAAIILLPFASWIFR
RNSALWTHWRRFALLGLLGVGLYNSLQYLALKTSSPINVTLVAASMPVWMLMIGSMFFGV
RVSAKQALGAVMSIAGVLLVLSRGELQQLLALRLVPGDILMILAAIIWSFYSWLLTLPKD
PAQIRANWIAFLLAQVAFGAVWSGAFSAAEWTFADPHIVWGWSLIAALIFVAIGPAIIAL
RCWGLGVQRVGPTVAGFFSNLTPLFAALMSAAFLGETPHLYHGLAFLLIVGGIVVSSRH
>fig|204773.3.peg.1378 Multiple antibiotic resistance (MarC)-related protein
MLILFFKAAILIPITLVPILNPFGNAAIFASLAGDIDRDAEKRLARQVAINCFVMLLGTM
FIGSHVLMFFGISLPIVRIGGGILVAATGWRLLNDKGQDDIRTQVASKPREVWSEDDFKV
RSFYPISFPLTVGPGTIAASITLGASAPSRLSNLFVSIGSAALGAAMTALVIFLCYRYAN
KMVRLLGRLGTMVVLRLSAFILLCIGIEIFWQGMLGLLAEAGITLH
>fig|204773.3.peg.2545 Multidrug resistance transporter, Bcr/CflA family
MPDTPKPSIRPAATVAIASSALAIMLAALSMLGPFSIDTYLPAFPNIQTSLGASALEVQQ
TLTAYLFSFAVMILWHGALSDAFGRRNIILVSLAVFAVATLGCAAAHSIEYLWAFRMLQG
ISAGAGVVIGRAIIRDLYAGAEAEKLLSLVTMIFSIAPAIAPMLGGWIVKRMDWRAIFLA
LFAYAVLLLLYCYKRLPESLPPEKRHPFNPQFLYQSYKRVFRSPLFHLKAGAVAFNFAGM
FLYVAAAPVFLVEHLGLGPDQFGWQFVPTVAGIFCGALSANRLAGNIPLDRQVLIGFALL
VGASVFNVVYHALYPPMLPWSVAPLFFYTFGMSMVAPGVTLMVLDLFPHIRGIVASCQSF
VLMLLGALVAGIIAPVLSHSPVSLAAGQLLCAAIALSLWLGGRSYRRALDMRKKANAWET
VE
>fig|204773.3.peg.2962 Polymyxin resistance protein PmrL, sucrose-6 phosphate hydrolase
MLKMGMSAPAIQQAMSNGMRSVYWLALTSPLIWGGMVCFGASAGLWLLVLGKLEVSMAYP
LISLGVVLTTLAGIFILGESVSIYKVLGVSLVIAGVLVLSVKS
>fig|205914.5.peg.27 Tetracycline resistance protein tetA(P), putative
MRHYEKIITSCVSTSATRMLIGAVSTIYMLVSGINLYEVGLIKSTQAILIFVLGFAVGIL
SDRIERKWLHITALIFSTFWLYFFYLAGLYKSFNLFLLAEILNAISLCVYQNNTNAYLVD
QFYHEQPKGELSLALGKLGKWEFSLMAFSALLGGVLYSTLSENLFLLTTIIMSTVTVASF
ILLPKVSRRATHKTLPFIQKQDFLILIRKFSRYKQAIFLFVVLSLYFQIIIQYWQAVVYA
INKSEQNGLILGGMLFSMFMVQSWAGKAIEVKYPFSRLTLALSFLSSMVLSFFAERWQSV
FFYTIAICLALFVVRYTVIQTDTELHRHLLSRFRAKYDMLLNSLVRILTAVVLLIIGYIS
NLYGIQAIQIIGLIIAIIFTLFALITSQNVK
>fig|205914.5.peg.1331 Permeases of the drug/metabolite transporter (DMT) superfamily
MEHSMLTEQSKKHTALLSFLPVLLLIAIDFFTMSLQAQAKAISHLSLAVLVTQLLCILVF
AKGEICNGQRFRLVKVNLYFLIYWGVWLFISLFSNYHYVLTDIVCLCGIALTLAIWQQPQ
DLQMRKSLLVLGTLVGVLGIVTYCLMFIDLPLLYFSQYNPVAQALLGIILANLLLVIAKN
RLQGFIILLPFLMLITLLLNAIIVLGILFFAISQQVVFSNEFSWGLYFILHLVITCIIAI
HLFYKWKFEYYVLLIMSFIVMSFPLWVSFAYVF
>fig|205921.3.peg.1069 Multidrug resistance protein B
MTKKGWRIMPAIITTAILGFSGILIETSMNVTFPLLMKEFGVNPAVIQWVTTGNLLAVAV
TVPLSAFMIKNLSERQIFTLANVLFLSGVLIDSFAPNLPILLVGRVLQGVGTGLALPLLF
HIILTQIPMERRGLMMGVAAMVTLLAPAVGPTYGGVISGMLGWKMIFMLLAPILIISTFI
GLASIPKRQVRINDKLNFPAFVSLGIGLATLLLAIEKMSIFYLLVAIVSFVIFYYLNKQL
EFLNLNVFKDKDFSILLYGVLAFQMIPLALSFLLPNLLQLVLHQTSTKAGLFMFPGAIAV
VFLSPFAGYLLDKIGAFKPIMIGISLSLIGLIGTAIFIPAKSVVVLLAFDILTKIGMGIG
ASNMVTTALTKLKPAQSADGNSILNTLQQFAGAFATAVASQIFTIGQVAIPKNGAIIGSQ
FAVLFVIVVVILAIVGLTYLRKRKAI
>fig|205921.3.peg.1249 Multiple antibiotic resistance protein MarC
MISKFILAFMAFFAIMNPISNLPAFMALVADDDQKISRRIAAKGVLLAFVIIVIFVLSGH
LLFNLFGITLAALKISGGILVGIIGYKMINGIHSPTNKNLEEHKDDPMNVAVSPLAMPLL
AGPGTIATAMGLSSGGLSGKLITILAFAILCVIMYVILISANEITKFLGKNAMTIITKMM
GLILMTIGIEMLITGIKIGFHLT
>fig|205922.3.peg.264 Tabtoxin resistance protein
MNPAQLRRVNAESFAHYRQGLIELLLDAVGYGASVGFMADLDATQARAYFDEVQDNLNKG
NVLLWVVVKDEQVQASVQLGLCQKANGLNRAEVQKLLVREHARRRGLGQQLMQALEQTAR
QYKRGMLYLDTEAGSPAEDFYKALGYTRAGEIPDYACDPNGTYRPTALYYKVLQGAN
>fig|205922.3.peg.643 Bicyclomycin resistance protein
MNPSLILLITCSTVFLAQLGMSIYLPALPQIAKHLQVDATQVAWGLSLYLIGMALPMLLW
GSLAQRIGRKPVLLAALGIYGLANLALPLGATLESFLLLRLLQGIGASGISVMARVLIRD
SFRGDLLAKALSWISISFVVALGIGQYAGSLIQVTLGWQAIFYLLGAVSLLMAAIVSRLS
FPKLVEAPTTASPWEVYRTILIHRAFLLPALAGGLGYGVIIAFNSAAPLILQGPFNWSAT
AYGLLGWPISAAYFLGALAVNRFVLRTGQHRLMTLGVSLVMAGTGVMLAGSLLASSMAWL
LWLPYCVAVFGQSLNYPISLSRANDGAPIAGAYAMALSGFIHQLMAALIGAVASLLASPQ
AWPLSMLCCVLAFGAVLCTRLTPDHQPA
>fig|205922.3.peg.789 Melittin resistance protein PqaB
MSRAASSLLLLAALLFFFALGSHQLQGSTEARVAGIAMEMHLDNDWVTPRLFGEPFLEKP
PLSLWLDAGALRVFGVSPWAVRLASAVAGLLSVMLLYAMLRRFERPKAIAWTAGILLATM
ASYWSNVRGVGEDALLALGVTTALLAFFQAQRASNPGNSLLFVVGIAIATLSKGVLGLAM
PGVVIFAFLLADNLMDKRFKLTDWLRPGLLTLVGLIPLMIWLAVLYQRGGVQAVSEVLLT
NSVGRFSGSFVEAGHYEPFYYYLAKLPQAFLPWNILVYLGLWHFRKELKANRYLLFFSLW
IIAQFILLTLASSKRTVYLMSMTPAAAVIAAEYAGVLFDRLKDHRNGFVGRIARHRQTVA
AGILAVVIASYLGAAQWALPNADKHLSFLPLTEHIQALQASGNQVALFQANERVGGASVF
YTQSVLKGLDTDAQLREFLSASPSNIAVISGDSEPAAPLKVHKTMMVGRQAYYFVGY
>fig|205922.3.peg.1000 Inner membrane component of tripartite multidrug resistance system
MAYRSKVALVYLLGFALDLLNMFAASIAYPDIAAQLRASVTQLAWITNAYMLGLTLIIPM
SVWLAAKVGERRLILGSLLVFGIASGLIAQASSIESLIGWRLLQGLGGGLLLPVGQALAY
REFPATQRAHFTGVVLLVALMVPALSPAAGGLIVEALSWRWIFLLNMPVALFAFGLGLRW
LKADQAASERPKLDARGLLLAVAALSLLLMAVSLASAPATRHLAGGVLLLSVITLWIYLR
DGWNKPGAVLDLQLIKNPSLRLAMLIYLFVPGIFTGTNMIAVLYLHDLGFGAAQTGALML
AWAAASGVAIMLGKRSFNRIGPKPLLIAGMLLQCLGIVVLMQIDQPASGPLILAYALMGL
GGSLCSVTAQTLAFVGITPEKMGHSSALWNINRQLGFCLGAALLSSLLDALGANGFKYCF
LAAALLTLLPMAAVLRFDSTKVLALLRSTHLQEKST
>fig|205922.3.peg.2452 Vancomycin B-type resistance protein VanW
MRRPFKFKEDNGPRRSPRMKPLSLYHPTLYWLRVWQKRLFRHIAWHCSSKRYARPATTSE
RLPYRYLKHTSKLIRKLGESDLALQHNKVINLKLAVAAIDGVTIAPGEYFSFCRLVGRPT
RERGYVEGMELSFGEARTGIGGGICQLSNLIHWMAIHSPLVVIERANHSFDPFPDDGRVL
PFGSGAAIFYNYIDLVLHNPTDRSFQLKLKVGETQLEGELLCDRERAYRYHVFEVGHRFV
REGERVYRENEIWREVREKGQVGALVERERLYGNRVVVKYEVLEGMIEGG
>fig|205922.3.peg.2749 Permease of the drug/metabolite transporter (DMT) superfamily
MSCHEPVRPAASDMPVYLNLALVTMIWGGTWVAGRFLAGSLSPVFAASLRFLLASVALLG
FLRLARIALARPTPRQWLQLALLGFFGIFFYNLCFFYGLRYINASRASLIVALNPAVIGL
ASWLLFKERLSRLKVIGIVICIGGAGVVIVSRHPQLLSETPDAWIGDLLILGCVLSWGVY
SLFSRSLNQSIGPVQTVTFSILLGTLMLWALALSRGEVDVAALAALGSRQWLSLAYLGVL
GSALAYIGYYDGIRKIGATRSGVFIALNPLTAVLAGAILLGEQLTLAMCLGGALILTGIW
LCNKPLAPAGKKRIL
>fig|205922.3.peg.2816 Acriflavin resistance plasma membrane protein
MNLSGPFIKRPVATMLLSLAIMLLGGVSFGLLPVSPLPQMDFPVIVVQASLPGASPEVMA
STVATPLERSFGAIAGVNTMSSRSSQGSTRVILQFDLDRDINGAAREVQAAINASRNLLP
SGMRSMPTYKKVNPSQAPIMVLSLTSDVLEKGQLYDLASTILSQSLSQVQGVGEVQIGGS
SLPAVRIELEPQALNQYGVALDDVRKTIAEANVRRPKGSVEDDQRLWQIQANDQLEKAKD
YESLIIHYNGGAALRLKDVAKVSDGVEDRYNSGFFNDDAAVLLVINRQAGANIIETVNEI
KAQLPALQAVLPASVKLNLAMDRSPVIKATLHEAEMTLLIAVALVILVVFLFLGNFRASL
IPTLAVPVSLVGTFAVMYLYGFSLNNLSLMALILATGLVVDDAIVVLENISRHIDEGVKP
MKAAYLGAKEVGFTLLSMNVSLVAVFLSILFMGGIIESLFREFSITLAAAIVVSLLVSLT
LTPMLCARWLKPHKPGEENRLQRWSRRTNDWMVGKYATSLDWVLRHRRLTLLSLIITVGV
NVALYVVVPKTFMPQQDTGQLIGFVRGDDGLSFSVMQPKMETFRRAVLKDAAVESVAGFI
GGTNGTNNAFMLVRLKPIKERNISAQKVIERLRKEMPKVAGAQLMLMADQDLQFGGGREQ
TTSQYSYILQSGDLGELREWYPKVVTALRALPELTAIDAREGAGAQQVTLIVDRDQAKRL
GVDMEMVTAVLNNAYSQRQISTIYDSLNQYQVVMEVNPKYAQDPVTLKQVQVITADGARI
PLSTFAHYENSLEDDRVSHEGQFASESISFDMAEGVTVEQGSAAIERAIARLGLPEDVIV
KMAGTADAFAATQKSQPFMILGALLAVYLVLGVLYESYIHPLTILSTLPSAGVGALLSIY
VLGGEFSLISLLGLFLLIGVVKKNAILMIDLALQLERHQGMAPLESIRSACLQRLRPILM
TTLAAILGALPLLLGRAEGAEMRQPLGLTIIGGLIFSQVLTLYTTPVVYLYLDKLRHRFN
KWRGVRTDAALETPL
>fig|205922.3.peg.3184 Multidrug resistance efflux pump
MKTLLTRLTTLAVVLLAIVLGWFAWEHYTRAPWTRDARVRADVVTLSADVSGRIVTLAVQ
DNQHVDKGQLLLEIDPARYSLAVEHAKRSVEVSKATLGQSQAAIVASEALLKQRQSEERR
RRTLKQGFAISGEEWEKSSTDVAVAQADLLRNQANLGLAEANVQLAIAALTQAELDLQRT
RVEAPVSGYVTNLLTRQGDYAVAGSALLALVDSSSFYVSGYFEETKLPRIEEGDRVRIEL
MSGEKFGGTVQSIAFAIADRENAPGSRLLANINPSYTWVKLAQRVPVRIGIDPDYSGKDR
LRAGTTATVTVLENPERQAQKSPATE
>fig|205922.3.peg.3467 Membrane fusion component of tripartite multidrug resistance system
MTSMPTVEPDLAVPVSAPKPPLLKRLLLPTAGLAALVLAGLYAVHWWGTGRFLEETDDAY
IGGDVTVIGPKVAGYIEEVLVSDNQKVKAGDVLIRLDARDYRANLAKAEGAVAAEEALLA
NLDATEQLQQAVIGQARAGIDAASAETARSRDDNARYKRLVTTNAVSVESAQRADATFKT
AQALSAKAQAELLAAQRQLTVIETQKQQARAALQQARAERDLAQLNLGYTELRAPVDGVI
GNRRARVGAYAQAGSQQLSVVPASGLWVDANFKEDQLARMKPGQRVSIRADVLSGQEFHG
RLDSLAPASGSQFSVLPPENATGNFTKIVQRVPVRILLDPADGVLGHLRPGLSVTAEVDT
RAQPETTAVASAP
>fig|205922.3.peg.3468 Multidrug resistance protein B
MSTALTAAAQPFNAAEMATATKVFAFATMCIGMFIALLDIQIVSASLRDIGGGLSAGTDE
TAWVQTSYLIAEIIVIPLSGWLSRVFSTRWLFCASAVGFTLASLLCGIAWNIQSMIAFRA
LQGFLGGSMIPLVFTTAFFFFTGKQRVIAAATIGAVASLAPTLGPVIGGWITDISSWHWL
FYINLVPGIFVAVAVPMLVKIDQPELSLLKGADYLSMVFLALFLGCLEYTLEEGPRWNWF
SDQTILTTAWISGLAGLAFVGRTLHVANPIVDLRALKDRNFALGCFFSFVTGIGLFATIY
LTPLFLGRVRGYGALDIGLAVFSTGVFQIMAIPLYAFLANRIDLRWIMMAGLALFALSMW
EFSPINHDWGAGELLLPQALRGIAQQLAVPPAVTLTLGGLAPARLRHASGLFNLMRNLGG
AIGIAACATILNDRTNLHFTRLAEHLNSSNEAVNQWLAQVGGNFAALGQSGDVGLTASLR
QLWLLTYREAQTQTYGDTFLMIMVCFGIATAMVPLMRKVQPPAAPSADAH
>fig|205922.3.peg.3993 Undecaprenyl phosphate-alpha-4-amino-4-deoxy-L-arabinose arabinosyl transferase (EC 2.4.2.43) @ Melittin resistance protein PqaB @ Polymyxin resistance protein PmrK
MTSENNPLRHTALFPSTTAVERWAIPGLILAFVMFYLLPLMSHGLWIPDETRYGQISQEM
LLSGNWVAPHFMGIRYFEKPIAGYWMIAIGQAIFGDNLFGVRIASALSTGVSVWLTYLLA
RRLWNNPRINAASALLYMSFGLIAGQAGYANLDPQFTLWVNLSMVAVWFAIDNRTPRARL
GGWALLGVACGMGLMTKGFLALLLPVLIALPYMLWQRRFGELVRYGLVAVVVCALVSLPW
VLAVHYREPDFWRFFFWHEHIRRFAAGDDAQHARPWWFYLPLLFASTLPWALLLPSTLLR
MWREKREAKMAYLALWFLLPLAFFSLSSGKLPTYIMPCLLPVALLMGQTVVKWLDQRSGR
FLRLNGVFNTVLASVALVALLYLQATKEIYENTEMFSLSLAYIVVVGWIIANALQVLRPL
TLWAMPALGIGLLVALLPAAMPAQIVNSKMPDQFIAEHQRELSETASLLSNDLGAASALA
WRLKRPQVDLFNTIGELKYGLEDPAMEARKVTMDGVGQWMTEARKKGAVGVVLRVNSTQE
EQEVELLPVDGKHYRRGNLHIFIFAQKQP
>fig|205922.3.peg.4073 Polymyxin resistance protein PmrL, sucrose-6 phosphate hydrolase
MSLWLLLLACLLTCLGQVAQKCAVENWRGADLSWSRKWRSPWLWLALFALGSGLLVWLLV
LQRLPVSVAYPMLSLNFVIITLIARFVFKEPVDVQHWFGVLLVIGGVALLGQQS
>fig|205922.3.peg.4074 Polymyxin resistance protein PmrM
MNRRRGILFALASVLLVSVAQLSMRWSMTRLPRPDQWLSVPSVDSVALAVVLAAIFAYAL
SMLCWLAALRDLPLGRAYSLLSISYALVYLLAASLPLFNESFSFSKSLGVALVMLGVITI
NTRPARAPELRSSP
>fig|205922.3.peg.4076 Melittin resistance protein PqaB
MIKLSCTIRRQSLIAGLLAFVLFIAGVYGQAPIGFDSRFVLFAQEMLRHGPSVFPTTYGE
PYADYSALSTLFIWLLSLPFGTVNSLTAWLPSAVAGAVIVTLMYRLLAPSSVRWAIVSIA
LLMLTSTFITETRAVSQDLMLAAVAFSVFYLGYAHDHFAAGRRWPLVFILLLLGFGIRGP
IGLVVPTGMLCSYYLLDRQWSRLLLFGVLASLLLAACVGLLLWLAEVSGGPAFRQDVIRM
QFMGRMDGSEGVSGSLYYFTSSLGNYALAYPLALLALAAAWLSKPSQRGPALRLVQYCAA
AGLIVMLGLSIPQAKKARYLLPMLPMAAIIAAYPFQVLHGRVFAWLRVGMQGLWLLIPAL
LIVLLWVAQRRFPESLTDLTPVMIVLGLLQLAASSRLWLPRWRTEVLAFSAVLAVWSAYA
LVFEPVERQLYDTRSFSQAAMVRIHEQPAPLVLHGMGKDAKAIKFMVNVEQDLQPLFTET
TQALEALKAPAWLMMDRSDFQALQGTPLGALQPTLSGPFDKNDYVLLWLTP
>fig|205922.3.peg.4086 Multidrug resistance protein B
MIVSLTIVVSRAITSPLLTLFLSKKLGLNQQDVGLLLGIAVFIATLLALYGGYIIDRLEK
RRLLILAMLSSAIGFVLLTFAKDLYLTTATLVITETASALFLIGSKAILSENLPMGQRAK
AFSLRYTLTNIGYATGPMLGVVIAGVYPIAPFLIAAGIAFGSIFLMIGIPKDASPIAAIG
QPQSFLKTLITLKNDRTLIMFTCGCLLSTVVHGRFTLYLSQYLLVVEDSQRALQTMAALL
ACNAIAVILLQYQIGRFLNREKLRYWIAAGTSLFILGLIGFSLADSLVSWCIAMFIFTLG
EMIIYPSEFLFVDTLAPEELRGSYYGAQNLAALGGALSPVICGFLLMHTPAPTMFYALSA
LTAMGGFLCFMSGRRVALLHK
>fig|207559.3.peg.118 Permeases of the drug/metabolite transporter (DMT) superfamily
MSTQSPENRHGSASGTERGKTADTGGCAPALRGSAAQAAGETAHQLDMKALLRVMAGAVM
ISFSAVFVNVLETSPSASAFYRVLFGGMALLAVALWRRERLSTSPLVLATIAGAGVFFML
DLECWHRSILYIGPGLATILGNFQVFFMAFAGAVFFREALSLRLVVALPLAVCGLWLLVG
VDVDNLPEGTVMGVIMGLLTAVWYTGYILLLRRSQRMACRMPVMMNMALVSLCTAAACGV
STLLQGASFAIPDTVNGMYLLGYGVLCQGVGWLLLSSGLPGLPAAVAGLVMLTQPTLSFV
WDVLLFDRPTGPLGVAGAVMAIVAIWMGLSGQNAAQRRRALKLAGRVSTAPEK
>fig|207559.3.peg.341 Permeases of the drug/metabolite transporter (DMT) superfamily
MQNTMSFSLRSPLNGLRFSGASAGYLSALVAAVVMSLTGIIIKHISDEYALPPAQLAFWR
NALVFLTLLPVLTLLRVPVRVHGKADNRLLVAYGFMLASMNLDWTIAVIETGASVATVLS
YCSAAYSGILGWLLLGERMSRSLALAVVICLSGCALVCGVLTPEVWSGMSTLGLVTGFAS
GLLYAGYGMMGRLAACRGEVPYR
>fig|207559.3.peg.446 Acriflavin resistance protein
MKLPEISVRRPVTTVMVFAAITLLGCVAFFRLNLDLLPDIEPPAVSVITPYPGASATDVE
SEVTKYLEDQLSTTPNLDRLESKSKDNIAIVNCIFNWGTDLDVAVNDIREKIDLAKPDLA
DGAEDPFIFKFSSSMVPVLIMTVTAEESSPDLYRIVDKQIADPLKRVPGVGAVVYIGGQE
RQINVHFDREAIDAYHISVQQIRNVLAAENLNLPVGTVKIGRNELQIRVAGRYRDAAEIA
NTVIGSNGDALVRLRDVATVTDAFEEPQEWARSGKLPAIALIIQKQSGTNTVNVIEAIKD
RLKTLKTEVPADIEIHGILDNSDHIYAMINSLTEAAVVGGLLVIVVCFLFLRRFRTSLVV
SMAIPFSIIVAFIGLFVMDYTINVISMMSLAIAVGMVVDDAIVVLENIVRHVDDGKPPQL
AAVEGTSEVGMAVAASTLTIVAVFAPLLLVKGIAGIIFGQLAFMILITILASLFISLTLT
PMAASRLLRSRDQRKLNPVFVWSERLLNGIEAGYSHVLGWGLRHRNILLSLIVIVFIGSL
ALIPLVGTEFFPEVDSGEVEVVLEMAQGTRVEVTAGTTEEMLNAVNAIPEMEASYALAGQ
TKKGFLTALGFEEGTGIGRIGGRLIDKKERSRHAKEVASELREQVIKLPGVENFSASAVS
VIQKAFLGGGRPISIDILGHDIETTDKAAAKIQRIVETTPGAVDVSVSRKRPRPEVRICL
DRDKAASLGLNVALVADALRTNYYGFDDTKFREAGDDFDIELRLKKDQRETIREIGETPI
TTLTGQTIKLRNVASVRETFGPVEIDRKNRTRVTKVQAGVQGRVLGDVVRDVREKMASLD
LPPGVSIEWGGEVEEQRKAFRDLTLLLILGIVLVYMVMAGEFEDFVDPFIIMFSVPFAFA
GVIWAFVATATPLNLMSFIGVIMLMGIVVKNAIVLVDYTKQLRAGGMTLNEAVVTGGKTR
LRPVLMTSLTTIFGMVPLALSRGEGSEIWNALGITVIGGLSVSGLVTLILVPLMYSLVHR
GKAK
>fig|207559.3.peg.967 Acriflavin resistance plasma membrane protein
MKSVVRFTLRQTVLLNLLFVLLMVVGVFATFSLPVERYPNVDMGKVVVVGFLPGASPQEV
EALVTTKIEDALDGLENVEFVRATSYRQRSDVIVKFLDDTDYDAQYDELRFRVLSVQNDL
PDAMDPPQFIKIDMDTWMPVMSVNLVGDRSNRALTLMAEELKIYLERLPGVKEVTIEGEY
TREYHVELDPHRMSRYGVTFDEVAAALAAGNVSVPAGDFSSHGKEYALLVDERFRSRDDI
AGTIIRRDGDGSFVRVGDVMSGAFVSYREPEVIASVNGRDSVAVNVIKLDNGNALDIGKA
VEAVLAEYAPVLEREGVEAVITRDQRSHIDQAMSTLGSNLLLGIVLVCAVIWLFMGFRNA
MVTSVGIPFAFLVTMVLMKLTGNSLNEITLFSFVLVAGIIVDDAVVVVENIYRHVQAGSP
LREAVVNGTAEVALPIVSATATTVAAFLPMLIMTGSTGQFFALIPKAISFALVASLVECL
FILPLHFLDWPGRSRLASGDADHTREKPFMIALRNLAERLLRFSMRFRWLTLGAVLAAFS
VAVFIFGVSMSGVMPLMRIKFFPDNYTTFYISVEAPEATPISETSRVIRGFAQFMDSLGA
GMTRSASGVAGYYLDDDYQTVHGSNLGMVTVELPVTGQQHFADYPRNDPQAHLDDVRSRI
AQHTPAGWRVRVRAEKDGPPVGKDVNVRVLGSDPASVSGLAAAMQTFLEQRADIAPHLMD
LGDDTGQPSYVFRFRPREERTAEYGLDTRTVAGLAGSVLDGRFVGEFRLADEDVDLRLKI
DNVFLERPEDALDVPVLEHSSGPVRLGDLCTVSSYREVGQLNRYQRQRAVTLTANIRPDA
AISPQFVIHAVQEHYRKIENDFPGATLDFSGEFASTQRSFQSLMMAFVLAVLIIYVILAT
QFQSYVQPLIILSAVVFALTGVVFGTFFTRTLFTVNSFVATVGVTGVVVNDSLVLVDFMN
KLYRDGLDRTAAAIEGMRIRLRPILLTTLTTMLGLLPMAVGIPSYSLVWGSMASTFVTGL
CTATFLTLFVVPVQWHLLMGYQEWRSRRFGRAMHE
>fig|207559.3.peg.1510 Permeases of the drug/metabolite transporter (DMT) superfamily
MSYRMILAALAVVHIVWGGGFIVLKVVQEHLALEHILLGRVILASLLYLLLWKRIPSPCY
RKGDWKVLLLLALCEPFLLFTFETLGLRYTSASQGGMIVACVPLTVALGAFAVYREKIGR
RCLAGIVCAVCGVVVVSALATAGDQAPAPLLGNFFIFCAVLASTCYALSVKHLCARYHYM
YLAGVQVFGATVLFVPGALMQPLPPAHVLFSPQVAGSLLYLGLGITFLVYFVINYALTRI
KAAVVIQFANLIPVSTLVFAYIFLGERLSPTQYAGVGLVLAGVLLAGASGSGELNTGKTQ
GEAHAQKACAAEGAAGD
>fig|207559.3.peg.2778 Melittin resistance protein PqaB
MTQTENTPDAGQHDLHSQTVTPDASTEAAPAAPQRTVCERILDILAFQPLIPLTILLALQ
TVFMLDARALWYSDEVRYANVFEHVVNAGKWIVLHLNGVPYPDKPPVYFWLLEGIRQGMQ
AAGIAGDAPQGIGPRLFFSGAAVSALFYIWATYALARRVAAADKRTALGAGLVLLSVFYF
IGVSHYSRMDLLFAALITLSHICLFTGWKKEKSTFWIVCGFAFAALATLTKGPLGLAFPL
VTSVLFLLWRGKPRRLAGADVAAGAGVMLFILLAWVMGAYLTEQPDFLYNIFHDQIYRRA
THTWHHSQPWWHYMATLPAAWMPWTLLLPVLPFGFLLSKKGARAVAASRTPEKEGMAYLW
IAFLNGFAILSAVSIKIIIYLLPLFAPLAVLTAGGILSLSRARAKWLMRLMALLLLALAA
ALVTLQLGQMFGWEWLTKAVRWPLALEGLWILAAVSAAGAAIMWVAAPAAGGAGALLLAV
LFTTVWIQPLGLITAPSMDNVMSPRMQGELIGSYIEKGYTPVTYKVYSGTYTFYAGADLL
ELDEWADVDAAVSAHRKTVVAMRTKHWDTWENKPADMREVSRQWIVDQEYVVAVRETSSP
DQTEVSAGTEVSAQTEVPAESGQTGEHADLPADSATAPVQLPAANATDSTATQQSAITPS
ADMPADDASQADTAAEEGHETSPADAPAQGNATTI
>fig|207559.3.peg.2782 Permeases of the drug/metabolite transporter (DMT) superfamily
MLWFVLALATAFFSAGEAVLFKRFFGDRPPYEMIVWPMAWSLPLFAGYLLLSDAPEVQQG
FWSVMAVMLPLNMAAFLIQTWAIRLSPISLTVPFLSFTPAFMLGTGYVILGEAIPAQGVA
GIACIVAGSWLLNRAPAASGRTCGAGAALLEPFRAVYREKGSMLMLLAAFIWSLTAVLSK
KLALLGTPMYTAAMFFAIHNTLMLLLIFGFTRVSPRCLRERPLAGAALGVCMFGQIVFHY
LAITLVAAAYMIAVKRLNGIISVVFGRLVFGERVTLWRTAGACVMGAGAAMIALAG
>fig|207559.3.peg.3218 Permease of the drug/metabolite transporter (DMT) superfamily
MPQSRSAAAAPFALFIAVTLWGSSFVATKIGLRQLEPLSIVWLRQLVATLAILPFWLPAW
LRHRHAATVRRSDTGLLLLLAFFQPCLYFVCESYALQLTTASQAGVVSAMMPLMVAVVAG
AMLGEQVTRRMWGGFALSVTGVVWLTLASAPEESAPSPMLGNMLELAAMACGVGYTIACR
KLGSTFSPVIITGVQILAGFLFFLPGAFMLPAGFTSMAAQALTTPGSDAAISLFAVGYLG
LFVTLGAFALYNFGVSALSASKASAWINLVPVVSIVLGHLVLGETFSPYQAGGALLVLGG
LYLCQRTPAPPRHGIMQVQKPQRAGALEKE
>fig|207559.3.peg.3718 Permeases of the drug/metabolite transporter (DMT) superfamily
MQSALGYVYVALAALMWAFIGPLAQICFNEGTTPMEVAFWRCLTGALFFMAHAAVTGRWR
AGLRDAPVFTAFGLVGIALFFGSYQISVREGGAALASIMLYTAPAWVALLARICFAEALT
PHRLAALALAMSGTMLVSLSGGAGSGSVTAGVLWGLVAGFSYSLHYVFGKNYLHRYSSVT
LYSYCLPAGALALLPWVTFSQHSALGWFALIMEGFLCTWLAYLAYCAGLKRLAASRAAIV
ANLEPVAAAVLAYWWWNEILPPVGLAGSALVLSGVFVVVREKNTAATA
>fig|207949.3.peg.631 Permease of the drug/metabolite transporter (DMT) superfamily
MSIDSKAKGYVFGLTAVLIWSGFVLASRQGGLSELNHFDVIALRYGTCALLLLPLWWFKY
RFNVFQTKYIAIALVGGLAYALCTFQGFQLAPASHGALLLPGTMPLFIFILAVIVGQIRV
EAIKLFGIVLISSGVALLFTQQLMMDGDNNSVLKGDVLFLLGALCWGVFSILIKHWNIPP
WHAVISLALLTCLVYLPWYVMFSPKNIDVAGANSILLQMFYQGFLATIVQLYFYGRAVAV
LGASGMGSLMALVPVIAGVSAIFVFDEPVTLYLIVGLCVVTIGAWLTQLEKIQWKRKFAS
>fig|207949.3.peg.1214 Permease of the drug/metabolite transporter (DMT) superfamily
MSSVQGVPVKYQLMLIFAMAVWGSTFVAMKLVVTGMPAMVAVFIRMCLAVAAFAVLIKYV
RKGVVYRKGDWRYLVLMALFEPCLYFLFESQALQYTSAGQAGMITSLFPILIAVSAFFAF
GERLYRRQWLGLFIAVVGVIWMTLAGEESDQAPNPLLGNLLELAAMGAAVGYTLLVKHLT
SRYPALFLTAMQACVGVVFFLPFALDSQWPDSIGVDMWLLLIYLGVGATLGAYGLFNYAL
THVDATVAAGYVNLIPAFAVLFSVVFLGDEINLWQWLAIALVFVGVYLSRDSKVDAQAKD
NIPAA
>fig|207949.3.peg.1511 Permease of the drug/metabolite transporter (DMT) superfamily
MNKTAHFWGWVLLFVCFVWGVEFSLVHMSLDSMGAHTFNGIRFLIAFITLAAWFIYSKHG
FWRRLDKWLVIHGVVLGFLLFTGFATQTIGLQYTTASNAGFITGLNVVMVPIIAWLWLRQ
TQHWYVWLGVALATIGTLLLTGGLSGFGEGELWVLICALGFATHIVYISRFAQTIDALSL
TQVQMITVTVLSFLSAFWWEAESLAGVTQVLLSEGSFVPWVALILGGTLGTAFAYLAQTL
GQQSLEAWRVALIYSTEPLFAALGGFVLLDERLAMLAWIGALFIIAGMLIAELVDDDVVE
ELLDEPNADVK
>fig|207949.3.peg.1629 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MARDLTQGSIGRWLYRLTAPMVVGILSIFLFNLVDTYFISLLGTQPLAAVSFTFPINMLV
MNVAIGLSIATGAVVARALGQKNHLQAQSWVTSSLYLTICIGIGIAILGILFHPFIFKLM
GATDELIPIISEYMVWWFSGSTLLMVMIVVNASIRASGNTKLPSLAMMASAGINVILDPI
LIFGLGPIPALGVQGAAIASVLSWLAAFVFMFRYLQQNRLVEYRLPEGLMRLWQKLFTLA
VPAAITNMLGPIANSVLIAWVAGFGTAAVAAFGVGMRIEPLAMIVVMAFTSSLPPFVGQN
HGAGEVDRIGLALRKSLTFILFWQTAVYLLLILLAEPLSRQFSEEKAVQEIIQTFLFIVP
LSYIGVGFTLLTTATINALHKPKISMKIHILRLFVFYLPFAWVGQAFYGLEGLFIGCALG
NVAIGISVLVMIRHVKKSDQWQQRLLTIQS
>fig|207949.3.peg.1671 Permease of the drug/metabolite transporter (DMT) superfamily
MLPVIAVYAAVVLIWSTTPLAIRLSVDSVDFVQGSALRMWISLALCLLLLPLFRLKLSFN
KLAMQRYMASALGICFAMLCVYWSAQTLPSGLIAVLWGLTPILVSLQSRCLIAGTRLDGL
RLLSMAIAVLGLYVIFAQQIALSPTMAVALAVLLLAVNFHSLSAVLLQKLQLKQQSSEDE
RMHPLVQTTGGLLVSAPIYAIVWLLMSGPLPEVMSWTSIGAIAYLSIIGSAVGFIGYFYL
LTKMSAADASLITLMTPVIALFLGTSIANETLSDRTLMGAGIILFALFIYHLKNIRLVLV
RLAQKD
>fig|208964.1.peg.240 Permeases of the drug/metabolite transporter (DMT) superfamily
MNASTSPLPASDQTLRGILLICAAVFLFASHDGLSKFLSGFYPIVMVVWARYLVHTLLMV
AVFVPRNGLAVIRSRRPLMQLARALCLIGTSLFFTTGLRYLPLAEATAVNFLAPLLVTAL
SVPLLKEKVSLGQWLAVLTGFIGVLFIVRPGGALFTPAALFPLGSALCFGLYQLLTRMLA
NSDSPTTSNFLAGIFNTLIMSLLVPFFWQTPSLLHGLMMIALGGCGMGGHLLLTQAFRHA
PPATLAPFSYGQIIFAGLLGLLVFGHVPDAWALLGILVICASGLVVAWRRGR
>fig|208964.1.peg.1239 Outer membrane component of tripartite multidrug resistance system
MPLASHLRCVALALGISTALGCANRNQPAPRAESLDPGLSRVAGTRGDALPAQWWTLYQD
PGLNHLVAAALRHNRDLAAADAHARALLGHLRGAQGERWPRTEVGYGYQYGRDGDDQTLA
EATDEDLHSQWKHTVRLDLSYQLDLWGEVRARIAAAKADAEAAQAARDLLRVSVASQTTL
AYVRACALARRAEVQRRSVGLLDASLALSERQLAAGLSSELQRRRLLALRERTRAALPML
EARRRAALYELALLSGRSPRQLDAPAATCAGIPQLRRALPTGDGWSLLARRPDVRAAERR
LAAADARRALAEAELYPRISFAVGAETSAATLAGLGGSGALAYAAGPLLSWRFPNRESAR
GRLDSAAAERDAALARFDGAVLGALREVERALALYAGERQRRADLQRALDEQRHAYRLAR
SNYRAGALDALELLDSQRSLVADRARLVDAEMRVAERQVELFRALGGGWQAASSPSHQEN
GQ
>fig|208964.1.peg.1266 Permeases of the drug/metabolite transporter (DMT) superfamily
MRATTCTPRAMPGATRLLAVQLGMVLAWSSGFVGYRYAMEQAPVFLTSFWRFAVCLALLL
PFAWAGLRRLSARQWRRQALIGALAYAGYIAPIAKAIELGVSPGVAALMADLLPLLVALL
ALVLPGQRTRPGQWPGIALGVAGVLWAGHAALALGRAPGWAYGLPLLGMLALALATLLQK
RWDDAPGSLAVVLFVQIGAALPAFAGLALAEGSLRPPLSGGFLFGLAWLVLLPTFGGYGL
YWLGLRHLSAQGGSAALYLSPALTLLWAHWMFAEPLTPMLLGGLLLSLAGLGWLYRAERR
>fig|208964.1.peg.2101 Permease of the drug/metabolite transporter (DMT) superfamily
MASLVTAVLFLVVCISWGTTWLGIKIAVESVPPLTAAGLRFLIAFPLFLLFARLRHETIF
FPRRLLAFFVFVTLGYFSVPYYLLNYGEQYVASGLTALLFSSMPVFILIFSAIFLRERIY
LSQILGIAIGFGSLFMIIRSQGLHLDYTELLGVLAILLAAIMHALSYVITKRQGADIGVI
TFNTLPIGIAGLGLFMAGLVMEHPNLSAVTSRSWAALIYLGLVASVGGFIVYFFLLKRLS
PVVLSFVFIIFPVFAVIIGAWYEGVAISRELIGFTVLLLAGFAITKLPIEKLLGRR
>fig|208964.1.peg.2628 Permeases of the drug/metabolite transporter (DMT) superfamily
MAMAGSQPQRRNSPTQGAAMLALSALFFALMGGLIREASSTVNNETVVFFRNLVGVLFFL
PLALTRGIGPLRTRRPLSHLLRTTYGLGGMYCYFYALAHLPLTDAMLFSYAAPVFTPLIA
HLWIKEPLTRRMMVATLVGFLGVLLVARPSGAVVAPIALVGIASSLMAACAFVSIREMSD
SEPAYRIVFYFALFGTLFSAVPLAWAWQPLNGQELLLLLGAGLFASLGQLTMSQAYALAS
PGVIGPIAYMAIVFAGVIAWLRWDELPSHTSLLGAALIFAASLIPLLGNRPAERPR
>fig|208964.1.peg.3222 Permeases of the drug/metabolite transporter (DMT) superfamily
MNRRSALAALHGGALLFGLTGVFGKLASASPGVIVFGRALFAVLALGLFARLAGQAWRAL
GPAQWLRLALCGLLLAGHWVSFFIAVKTAGVAIATLGFASFPAFTVILEGLLFRERIHLA
EGLLVVLVSLGLVLVTPNFDLASGATLGLLWAILSGLLFALLSLANRSNSGQVGPVQAAL
WQNLVVALCLLPFAVSELPALPALDWLWLALLGVFCTGLAHSLFVASLAVVKARTAALVF
ALEPVYGIAFAWLLFHETPGPRMFLGGALIILAIVLSARLGARGRKTAVGDERGDPERA
>fig|208964.1.peg.3304 Fusaric acid resistance protein fusE
MRASLRVVVTLLVVAAAVLAGIWLWRYYMLSPWTRDARVRADVVVVAPDVSGWVTDLEVK
DNQVVKVGDVLMRIDQERYQANLEQARAVAETRHQQYLLRQNEAARRSRLGIGAISAEDK
ENAQINAAIARSEYQEALAQVKIAELNLKRSELRAARNGQVTNLRLAQGNYATAGQAVMA
LVDQQSFYVVAYFEETKLPGIRVGMRAQVRLMSGDQPIDGTVESISSGITDRNSTPDGQL
LANVEPTFNWVRLAQRIPVRIRLDQVPADVHLSAGMTASVTVQGD
>fig|208964.1.peg.3605 Permease of the drug/metabolite transporter (DMT) superfamily
MADPPRPVERAMRSQALRADVLMLITAMIWGVSFVAQRLGMDAIGPFLYTGLRFVLGALV
LVPLLMLRSRRDGAQPFNRGQLLAGVILGVALTTGINLQQVGLLFTSVTNSGFITGLYVI
VVPLLGLLFGQRTGAGTWLGASLAVLGMALLSIGPGFQVASGDWLQLAGAVVWGAHVLLV
GLFASRYDPIRLAFLQFATCAAVSLLLALVFEEIHWDAIVQAGPALLYGGLLGVGTGFTL
QVVAQKHAIASHAAIILSLEAVFAAIAGALFLAETLHLRGYFGCALMLAGMLVAQLWPRK
LAAEARPA
>fig|208964.1.peg.3893 Outer membrane component of tripartite multidrug resistance system
MVGSFVGFLVVFSAISGCVSTGDIAPEAATLDANALATDHAIQAAAREAGWPQAQWWKVY
ADPQLDAWIEKALDGNPGLAVAHARVRQAKSMAGLVESIESPQIEGKGSLVRHRWPDDYF
YGPGDLARTTSWNNSTEIGLNYKLDLWGRDRSDSERAVDLAHMAAAEARQAQLELEGNIV
RAYVQLSLQYAEMDIAKAMLQQQRDILALAQRRLRGGIGTHFEVSQAEVPLPETERRIEV
IDEEIQLTRNLLAALAGKGPGEGRTIRRPSLNLAAQPSLPSALPAELLGRRPDVVARRWQ
VAALAKGVDVARADFYPNVDLMASVGFSAVGGGMLEFFRSAKYTYSAGPAVTLPIFDGGR
LRSQLGEAAAGYDAAVEQYNQTLVDALKNISDQLIRLHSVDIQKDFAAQSVASAQKTYDI
ATLAYQRGLTDYLNVLNAQTRLFQQQLVQEQVQAARLAAHASLLTALGGGVGAGADTPAQ
RKLAPENVPVRAVSSR
>fig|208964.1.peg.4831 Permeases of the drug/metabolite transporter (DMT) superfamily
MVLDLLKSGVLLAVLASFTFSVMNALVKEASATLPAAEIVFFRSAIGTLLIYLLMRQAGV
ALSRQGVPMLLVRGVMGALYLVCYFYAIAHIPLADASILAHMSPFFVILFSALFLGERIP
RAVYWLLLVVVLGALMIVKPFSYSSYSVYAVVGLLSAVFAAGASVAIRQLSARHHTYEIV
FYFLAVATLVAIPLMWNDFVVPATLREWGLLLAIGVVSLLGQVFLTRAFSHESATIVAVT
RYIGIVFNAGWGWLFWSEVPDALTIAGGVLIVVACIALSRTKKG
>fig|208964.1.peg.5155 Outer membrane component of tripartite multidrug resistance system
MPFPLLHPWPQRLALASAILLAAGCVTSEGLEPNARLQPAGALQAGRSLDGVALSPAAWP
RQDWWTGLGDRQLDQLIGEALQGTPDLQIAEARARQAAATAQAQDAARQPTLDAKASYSG
IRAPTSVAPAPLGGRYSAIKYLSLGFNYDFDLWGGERAAWEAALGQANAARIDSQAARIG
LSASIARAYSDLAHAFTVRDLAEEELKRSQRMTELSQKRMSAGLDSKVQLQQTQTQLATA
RQQLSAAEQDIASARIALAVLLGKGPDRGLELQRPQPLNPASLSLPSVLPAELLGRRADI
VAARWRVEAARRNIDSAKTEFYPNLNLGAMAGLAALHTSDVLQAPSRFFQVAPAISLPIF
DGGRRRANLAERDADYDLAVGQYNKTLVQALGEVSDDLGKLRSLEQQVIDQRQARDIARS
NFDLAMRRYGEGVGSYLDALSVQQQLLVAERQLASLESQQIDLSVQLVQALGGGFQPDSR
SAALATAKAPAE
>fig|208964.1.peg.5483 Multiple antibiotic resistance protein MarC
MDMFGVAVLIFLVTDPFGNIAVFLAALKGVAPGRRLRVAFRELAFALGLLLLFLTLGEHI
LSGLGLSREATGIAGGIILFVIAMRLIFPSPQGLLGEVPDGEPLLVPLATPAVAGPSALA
MLITLRTTFDGPLWELYLAVVLAWAATALILLQAAFLQRFLGPRGLTAIERLAGMLLIML
SVDMLLDNLRSVLHIAA
>fig|209261.1.peg.951 Permease of the drug/metabolite transporter (DMT) superfamily
MRKVSISILFMLVSLTWGTTWLAMRIAVETIPPVFATGMRFMFAAPFLIIIAWLRKKNLL
FPPGQRLFQFVICIFYFSIPFSLMIYGETYVNSGLAAIIFANMPVAVLIASVLFLNEKAK
LMQIAGLTIAITALTGILLEETNTSTESHWQGITALISAVLIHAIIYTQCKKRSCTVSVI
TFNALPCLLAGLILSATGWFFERPQVSTFSVHSILATLYLGAFAGVFGILCYFALQQKAN
AFQASLVFLIFPLIAVSLEDYIYGYAISTHSMLLIIPLAIGIFLTLVARNIPVTSRCRDN
SSQK
>fig|209261.1.peg.1347 Multiple antibiotic resistance protein MarB
MKMLFPALPGLLLIASGYGIAEQTLLPVAQNSRDVMLLPCVGDPPNDLHPVSVNSDKSDE
LGVPYYNDQHL
>fig|211586.9.peg.640 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MKDRHGLLSAPIGRVLLNMSLPNLIGIMTILGFSLADTFFISQLGTEALAAISFTFPVTL
IISSIAIGVGAGVSTNLGRLIGSGNAPQAKVFLHDALLLTFILIASLSALGSIFIEPLFS
LLGANETSLPLIHDYMMYWYVGAPLLVLLMVGNQGLRSTGDTRSPAMIMTLAAIINLILD
PLLIFGIGPFPRLEIQGAAIATLFSWLVALSLSGYLLIIKHRMLERAAFDIDRMRANWSK
LAHIAQPAALMNLINPLANAVIMAMLAHIDHSAVAAFGAGTRLESVLLIVVMALSSSLMP
FIAQNLGAGQPQRAKQALLLSLKFILVFQTLLYIPLAFFAQPLASLFSTDPQVLEWLSFY
ILVLPCAYGPLGIVIIFATALNAYHRPMSSLVINLCRLVLLMLPLAALGSYIDGVKGLLL
ALPITNLLMGIACYYLAQRICEPVKATTADTL
>fig|211586.9.peg.1360 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MTAISHSATDQRLLQEPIAKLFWRYTIPTIASMLVTGVYVTIDGIFVGHYLGETGLAGMM
LAYPVGAILYAIGAMIGMGSAALVSINLGQGNVAKARKLLGNAFSLCLLAGAFFALVGGV
FSRDILIALGAEGEILENANEYLFWYFALCHFPIISMAFTTLLRNDGRPSMVTFVLILGG
VLNTFLDWLFIVVFPFGLAGAAIATMLSQAVTGLLCLQHFFGARTQLKINLEQMKLKLDN
CINIARVGLPSFLMNLYLSIVLTLHNTAFLWVGGPLHVAAYGVVSYTEAFFYLIFEGIAL
GTQPIYSFNAGAGRFDRVKQARNIAFSMTLLTAALGLVLIYSRPEWLVYLFAGDNPSLTP
VAIEGMRWYFWGLPMEGLILVGASFFQAINCSKQASILTGAKLILIAAIIYCFAWAFGVI
GVWVSLATCSTMLVIWMFIAMQRLKVNA
>fig|211586.9.peg.1724 Acriflavin resistance protein
MNLTRLAIKLPVTTSMFFFAILLFGLASSRLLPLEMFPGIDIPQIVVQVPYKGSTPAEVE
RDITKVLEESLATMGGIDELESESSQEGAEIEINMKWGENVATKSLEAREKIDAVRHLLP
RDVERVFIRQFSTADMPVLTIRISSDRELSGAFDLLDKQLKRPLERVEGVSKVSLYGVEQ
KQIEVRINANRLAASGFSATELQARLARENFVLSAGTLRESNLVYQVSPKGEFRNLEDIK
ALVLVPGLTLGDVADVQFSLPERSEGRHLDQHYAVGLDVFKESGANLVEVSDRVLKVIEQ
AKQDQQFQGIRLFIMEDQASGVKSSLTDLLLSGLVGALLSFIILYLFLRNFKMTMIVVSS
VPISIGMTLAAMYLLGYSLNILSMMGLLLAVGMLIDNAVVVTESVLQEKQGNSVNSNPQD
NENAVMTGVDKVSLAVLAGTLTTAIVFLPNIFGVKVQLTIFLEHVAIAICISLAASLLVA
KTLIPLMLTKFHFDIEPDNTTGKLQNFYNRSLNWVLIRPWRSGLISIAILASTALPISMV
KQDQEDSQSKERIYINYQVEGRHNLNVTEAMVNQMEDYLYKNKEQFHIDTVYSYYAPDDA
SSVILLKKDLPMPLDELKQKIRSGFPKYSIAKPQFGWGDDNSGVRVTLTGRSTSELIHLS
EQVLPLLKNIKGLVDVRSEVNGAQQEVVIRINRQMAARLDLKLNEVASSISMALRGTPLR
SFRHDPSGELRIEMAYEKEWQKSLDKLKQLPVVRIDQRLYTLDNLASIEIQPRFDTIKHY
NRQTSLSIGANLDNLTTEEAQTKIKQVMENVSFPDGYNYSLRGGFERQEEDQSIMVINML
LAIAMIYIVMAALFESLLLPTAIITSILFSITGVFWALLLTGTPMSVMAMIGILILMGVV
VNNGIVLVDQINQMTPELDKLSDTIREVCITRLRPVLMTVGTTVLGLVPLAMDDTQIGGG
GPPYYPMAIAIIGGLSFSTLTSLYLVPLCYQLLYRMRYRAVLQLGESHRFAQKLLPWTAR
>fig|211586.9.peg.1725 Acriflavin resistance protein
MSIISTSVKRPVTVWMFMLAIMLFGMVGFSRLAVKLLPDLSYPTLTIRTMYDGAAPVEVE
QLVSKPIEEAVGVVKGLRKISSISRSGMSDVVLEFEWGTTMDMASLDVREKLDTIALPLD
VKKPLLLRFNPNLDPIMRLALSVPNASEAELKQMRTYAEEELKRRLEALSGVAAVRLSGG
LEQEVHIQLNQEKLSQLNLNADDIKRRINEENINLSAGKVIQGDREYLVRTLNQFNSLDE
LGQVIVYRDAQTLVRLFEVATITDAYKERSDITRIGSQESIELAIYKEGDANTVAVAKKL
RDELVKINKDPQQNKLEVIYDQSEFIESAVSEVTSSALMGSVLAMLVIYLFLRNIIPTLI
ISISIPFSVIATFNMMYFADISLNIMSLGGIALAIGLLVDNAIVVLENIDRCRSEGMSKL
DAAVTGTKEVAGAIFASTMTTLAVFVPLVFVDGIAGALFSDQALTVTFALLASLLVALTS
IPMLASREGFKILPELMKKTPKEKPTTKLGKLKHYSATVFSFPIVLLFNYLPSALLTFVL
IIGRFFSWLLGLIMRPLSSGFNFVYHSTESIYHKLLAIALRKQLATLLLTTGITGACISL
LPRLGMELIPPMNQGEFYVEILLPPGTAVGETDRILQQLALSIKDRPEVKHAYSQAGSGG
LMTSDTARGGENWGRLQVELVDHSAYHQVTQVLRDTARRIPALEAKIEQPELFSFKTPLE
IELTGYDLALLKRSADSLVNALSASDRFADINTSLRDGQPELSIRFDHARLAALGMDAPT
VANRIAQRVGGTVASQYTVRDRKIDILVRSQLDERDQISDIDTLIINPDSSQPIALSAVA
EVSLQLGPSAINRISQQRVALVSANLAYGDLSDAVADAQQILAAQVLPTSVQARFGGQNE
EMEHSFQSLKIALILAVFLVYLVMASQFESLLHPLLILVAVPMALAGSVLGLYITQTHLS
VVVFIGLIMLAGIVVNNAIVLVDRINQLRSEGVEKLEAIRVAAKSRLRPIMMTTLTTVLG
LLPMALGLGDGAEVRAPMAITVIFGLSLSTLLTLIVIPVLYAMFDRKKFDHTNIVSTAEQ
DATTLTVETRP
>fig|211586.9.peg.2114 Multidrug resistance transporter, Bcr/CflA family
MKTSSNIFVNMKFFIFLLYLALLSMLGFIATDMYLPAFKAIESSLNSSPSQVAMSLTCFL
AGLALGQLIYGPLVSKLGKRYALLIGLAVFALSSVAIANSDSVMMLNIARFFQAIGACSA
GVIWQAIVVEQYDAEKAQGIFSNIMPLVALSPALAPILGAYILNEFGWRAIFISLCVIAF
LLVLMTLYFVPGKSKHQDIKPSAVSYGQILKNTRYLGNVVIFGACSGAFFAYLTVWPIVM
EQHGYQATEIGLSFIPQTIMFIVGGYASKLLIKRIGADKTLNVLLSIFGICVVSIVLFTL
LFKTITIFPLLISFSILAAANGAIYPIVVNSALQQFTQHASKAAGLQNFLQITIAFGASS
LVAMWANFGEVAIGWGILCCSLLVILGYVLKTEQTWGDFAHHFTAPDPARVGIVANAKQN
QAD
>fig|211586.9.peg.2128 Multidrug resistance protein D
MMSGEKPSLISAKASTPSAGSATRLLFMLVFMVACGQMAQTIFVPALPLIAQGLAVDASK
LQAVMACYLLAYGLFQFIYGPLSDRYGRKLPLLIGIGIFIIGALLATQATSFNQLICASL
LQGLGTASAGALCRSIPRDHYFGDNLLKFNSYVSMAVVFLPLVAPFLGSLASAYFGWQAV
YWVLFGFGVFVWLLLCFGFKESLPKDKREQQPVLASYRHVLRHRSFRAYLFSLIATFAGI
AAFEAIAGVLYGQYLQLTPFMVSCYFVAPIPGYLLGALIAGRQKQAQRSVFQGVALLGAG
ALFMLIPGLFQLVVGWSLLVGSILFFSGAGMLFPTLTSAALEPFPRQAGIAGALLGGLQN
FGAGLAALTMSLVPMGGQLSIGLLSAVMVLLVIVALHYARDQNDTHQTLLPQKT
>fig|211586.9.peg.3151 Acriflavin resistance protein
MLSQFFIKRPIFAAVLSLLFFITGAIAVWQLPITEYPEVVPPTVVVTANYPGANPKVIAE
TVASPLEQEINGVEDMLYMSSQATSDGRMTLTITFAIGTDVDRAQTQVQSRVDRAMPRLP
QEVQRLGIVTEKSSPDLTMVVHLLSPDNRYDMLYLSNYAALNVKDELARIKGVGAVRLFG
AGEYSLRIWLDPNKVSALGMSPSDIIAAVREQNQQAAAGSLGAQPSGNADFQLLINVKGR
LTELSEFEDIIIKVGQNGEVIRLKDVARVELGAISYALRSLLDNKDAVAIPVFQASGSNA
IQISDDVRAEMARLAKSFPEGLQYEIVYDPTVFVRGSIEAVVKTLLEAVLLVVLVVVLFL
QTWRASIIPLVAVPVSLVGTFAFMHLMGFSLNALSLFGLVLAIGIVVDDAIVVVENVERN
IASGLSPIAATQKAMKEVTGPIVATTLVLAAVFIPTAFMSGLTGQFYKQFALTITISTFI
SAINSLTLSPALSALLLKGHDAPKDALTRLMDKLFGGWLFTPFNRLFNRASEGYGYLVRK
VIRFGGIIGLVYLGMVALTGVQFVNTPTGYVPGQDKQYLVAFAQLPDAASLERTDVVIKK
MSDIALNHPGVAHSIAFPGLSINGFTNSPNSGVVFVALDDFELRKSPELSANAIAGQLNQ
QFAGIQDAFIAIFPPPPVQGLGTIGGFRLQIQDRANLGYEALYQVTQQVMYKAWADPQLA
GIFSSYQVNVPQLELDIDRTKAKQQAVSLDQIFQTLQTYMGSTYVNDFNRFGRTYQVNMQ
ADEAFRQSPQQISQLKVPNVNGDMIPLGSFINVSQSAGPDRVMHYNGFTTAEINGGPAPG
VSSGQAQAAIEKILAETLPIGMTYEWTELTYQQILAGNTGLLVFPLVIVLVFMVLAAQYE
SLSLPLAIILIIPMTLLSALSGVLLYGGDNNIFTQIGLIVLVGLATKNAILIVEFAKEKQ
DHGMEVMESILEAARLRLRPILMTSIAFIMGVVPMVFSTGAGAEMRQAMGVAVFAGMIGV
TIFGLILTPLFYYSLVKRGRRKRTLEV
>fig|211586.9.peg.3603 Acriflavin resistance protein
MRLPEVCIRHPIFASVLSIMAVLLGLIAFQKLDIQYFPEHTTHSASVNASIAGASADFMS
SNVADKLIAAASGIDKVDTMSTDCSEGRCSLTIKFNDDTSDIEYTNLMNKLRSSIEGIND
FPQSMIDKPTVTDDTSATDSASNIITFVNSGGMEKQAMYDYISQQLVPQLKQVQGVGAVW
GPYGGSQKAVRVWLNPEQMKALNIKAADVVGTLGSYNASFTSGAIKGKSRDFSINPLNQV
ETLEDVKDLVIKVSEGKIIRIADVAQVVMGEESLSPSMLSISRHSAMSLQILPLSNANPV
KVASNIKAEIARMQKHLPQGLEMHLAYNQADFIEAAIHEGFAALIEAVILVSLIVVLFLG
SLRAASIPIITIPVCVVGVFAVMSALGFSINVLTILAIILAIGLVVDDAIVVVENCYRHI
ENGETPFNAAIKGCQEIIFPIIAMTLTLAAVYLPIGLMSGLTADLFRQFSFTLAAAVMIS
GVVALTLSPMMSAYLINTTEQHPRWFSRVEVQLQQLNHLYINELNKWFVRKRLMFGVAVV
LVGLAGIAYWQLPKILLPAEDSGFIDVTANGPTGVGRQYHLDHNRELNSVIDGHPAVGAN
LSYIEGEPINHVLLKPWGERSEGIDEVIEDLIAKSKQSVSAYNMSFSIRSADNLNIANNL
RLELTTLDRNKDELSQTAAKVQKLLEDYPGLTNVGNSVLRDQLRYDLSIDRNAIILSGVS
YGDVTNALSTFLGSVKAADLHATDGFTYPIQVQVNLDKLSDFKVLNKLYVTSESGQALPL
SQFVSIKQTTAESNIKTFMGLDSAELTADLMPGYSTDEIKAYLDEQLPSLLNDAQGFKYN
GVVKELMDSQAGTQSLFLLALVFIYLILAAQFESFVDPLIILLTVPLCIVGALLTLAVFG
QSINIYSQIGLLTLVGLVTKHGILLVEFANKQQAQGMSAIEAALSSAKWRLRPILMTSLT
MILSAIPLALATGPGSLGLANIGLVLVGGLLAGTFFSLFVVPVAYVAMSELKARDVVAHL
RSA
>fig|211586.9.peg.4056 Permease of the drug/metabolite transporter (DMT) superfamily
MPFVIALLAPVFWGTTYALVSLYLQDMSPYWVAVWRALPAGVLLLMLRPRLPTLAWSKLS
LLAFCNIGAFFTLLFIGAYRLPGAVAGTLGATLPLIFLILAWLIDKKRPGMKWLLLGLMG
LGGVILLLNPSADLDPIGVLCMLSATTLIAFSSRWMQRWDVGDFLVLTAWQLLLGGLMLI
PLAWLMAGPPQIPSMDVVPSLIWLATANTAVAYWAWLWSMRNLGPEIMGMVALVNPVVAV
SLGVLIVGETLDMRQWAGILVILLSLLLMKLPQKLRWNPLKARG
>fig|211586.9.peg.4078 Drug resistance transporter Bcr/CflA subfamily precursor
MRRNLLPILMSLVLLSPLAIDIYLPSMPTMAAEFAVSASEVQSTLVLFLFAMGVGQILIG
PLADRYGRRPVALFGVLLYGASSLLAAAAIEFHWLQIARVLQGLAACSTSIVVFSAVRDC
YSPKEGAKIYSYLNGAICVIPALAPTLGGLLAMQFGWRSTFVFMTLYAILMMLLVGYRLP
ETRPANTVSTGPLYRWSRYKPVLSNTHFLFYAFACMSAMAAILSYVSYSPVWLIGHLGVS
ELAFSGLFGLNALVNIVACFAAPVVIRKLGNRPTAILALALLVLSAVFIIAAQAFGPSAG
MAAAFAFMLPMMLLCIGFAFLLGPATSMALSAFGERAGTATAMLGFIQMSGASVIAGLVQ
QTNLTAPYAVALVMGFFSIGLLSMMAISRFDHWHQEQLAAEH
>fig|212042.5.peg.158 Bicyclomycin resistance protein
MVMLVLRETVVLFLVIMSITICDISYDMYAPGLPQIGAFFGVAQTIVQLTVSMNLLGGAL
SGLIYGPLSDHYGRRSVMLWGIAIFVIASIGCCFAWSIGVLIVLRFLQGLGAGVAGVVGF
AIVNDIYVGEAAAKNLSIVNMVVSLSPAVGPIMGSYIVSLGYGWRLLFVLVSMISVLLLL
ALIFGLTETIQNRREKLSLSSILAEYGALFRNYRFLCFALVQSLTIMWVWASMANLPFVF
IEGMHLPVEYYGYLVAMSVVSYIAGTIVNRRLIGKLGMMRMIVLGLLSVMIPDVIVIICH
YAFPAFLTPLFIEMIWLPSSFGIAFITSNSVAIAFGEVRDKGAASAFISFGQTIFGACGI
YIVGKFYNGTIVPVSVLPIVCCLLGMTIIWLLTKREGMFPREKTV
>fig|212042.5.peg.434 Multidrug resistance protein D
MVDSACRFCLLDHKRLYNINNMNVIADYFLKNNRFTLFLLLFIAILGVHSYWMLPQERTP
TIKIPVISVRAVVNGISAERAEKLLAIPMEKELRAVSGIKKVLSEVRDGHVSVALKFNHD
ANMRIAMEDVRNQLDVIRPKLPRQLTSLTVQEMDLGSMPILHLAIVGDIEAVVLSKVARE
LKSKIEPLRDVLSVETEGLHEYVLELNFSPELVNYHGIQIQDIQRALSSSYAFVEYGMLE
SDVGSHKVKLEGELDSYKKIMDLVLKAGEDQFVTVRDVATVRFARKDNHELVRVNGKPAV
VLKVAKREGSNITEVVKRVEHICDSAARFLPKDVSLLFLQDQSEEVKSALRELENTLVFS
VILVSVVMMIFMGIRTAILIAVAIPVSVLFSITVVYLMGYTINIVILFTLIMVIGMLVDD
AIVVSEYADRKMAHGFSRLEAYRLAATAMFWPVATSTMIRLSVFIPLLFWPGFTGEFMKY
IPVVSISALVGSWITALIFTPVLGAMFGRGSATSPGELARVNAIEDIDIENLGKGARFYT
KVLGVVLDHPIKFVSIVSGVLIFSTVAYFTLGPGGEFFPDIEPDQATITVKSDSNLSLKE
KDFLMKEVEGRISEVAGIKYLYTRLSDSKASTSSEVLGVIHVEFVNWYLRAKSSKVLRNI
ETLLKDMKGVFFDIAQYSMKPSVGKQLEISLRADDPALVQKAARVLQKEMSASQGFRGVS
SDNPVSGMEWVMMVDRKKADVAAVSVSMIGQYIKMLTDGLLVGTYYPKDSTDGVDIIARF
QEKHRSLKYLDNFLINTMYGPRPVSSFISRKARSSTGTINRIDGLRAITISSDIAPGYSI
ADRVRYIKEVLDREPRVEVAFLGDMEDQAESKTFLIKSFFLILLMIALVLIAEFNSWYYV
MVVMTAVFLSTTCVFLGFLLTSKVFGIVMGGVGIIVLAGVVVNNNILLIDAFCANIKSGL
SYRDAIIKSALSRFRPIFLTVITGVLGLMPMVLRLSVDFIGRNILYDSPTSQLWFELSTT
TSMGLLFATAVTLLFTPAVLMCGGRQKSSHKVL
>fig|212717.8.peg.101 Permease of the drug/metabolite transporter (DMT) superfamily
MKKQNLWADISLLIVAIIWGSGFVATKNALDSISPFFITTLRFSISTLAIGIIFFKRIKN
IDISHLKAGFIIGFFLFSAFSTQTIGLLYTTASKQAFLTGTNVVMVPFFYWFISKEKPNL
YNITATFLCLIGISLLTLDGSMHINKGDLLTLICAIFFACHVVATGYFTKKYDPIILTFT
QFFVTTILSFLSMIILEGVPSAIPKEGIFPVFYLGIFSTFIAFLIQTIAQRYTSPSHTAI
VLCLESVFGTILSCILLGDKFTYKIFIGCVLIFLAIITAETKWEFLRDINKNVQAQEE
>fig|212717.8.peg.327 Vancomycin B-type resistance protein VanW
MAKRKKRKKNSSKKITICLIIAAVLIGLTSVKAGYSYNNIKHYENLFYPGITVGNEDISG
KTLEEGRKIIKEKYANKLLNKKITVKIPEGEYSITFDKIEGKYDIDNSLKKAYDYGKDSN
AFSKYRIIKKAEKKPFELMFSYNEKKVIDFINDVEKKVNKDATNAKLIKKGENFNIIPES
VGKKLNKEKLQKDILTNINGDISKDLVVNGEVKNVQAKVTSDKLTSVNSLIASFGTNYAN
ISSQQRANNIRLSTESINGTVLMPGEVFSFNGAVGERTADRGYQAASVIIGNQVEDGLGG
GICQTSSTLYNAALKANLKSVERAHHTLPSSYVPLGRDATVDWENIDYKFRNDYSFPIYI
EGLTQNGEVRFNIYSHSSVKNRRYEITTDVYENLPTDTKTIQDANLSKGTTEVVQKPYQG
FKVKVYRNIYENEKFINKELISNDFYRPIQGIIKVGTKK
>fig|212717.8.peg.388 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MKNTISTAEMMEKESISKVLLKLSVPAIIAMLINAIYNIVDTMFVGMLDNTSAIAAVSIV
YPLFMFIGAIGVMFGAGGASYLSRLLGEKKKEEADKTLTSTIIMGCIFSLIFTVIATVFL
DEFLLMYGATETIMPYAKEYGYVIVLGSIFTIGTAIMSNTIRAEGNSRYSMIATCVGAVV
NIILDPILMFNFNMGIKGAAIATVIAQLTSFIFLLRYYYSNRNYINFKINLFKPTFNMFF
EILKIGIPIFVTQVLASFALGFMNLGAKPYGDAAVAAMGIVFRVMSIGFYIVFGIGQGFQ
PVAGYNYGAKNFTRLEESIKISIRWSTIAAIITSLLFIIFAKECMLIFTRDREVIDIGIK
AFRAASLLFPLFGYVNTYAVLFQALGKAVGAFILSISRQGIFYIPLMYVLPKFMGLNGVM
FCQTAADGLAFLETIIMAIWLKKQFKKEVSQESTLGDVKEIS
>fig|212717.8.peg.961 Permease of the drug/metabolite transporter (DMT) superfamily
MKDVKKAHFLAIILMILWGMSYLSIKVVVHEIHPVLSAFYRFLIAAIILFIYLKVRYPEE
KVLKEDKIKMALGGFFGVAMYFLFENYAVYFTTASNVAIIISSIPIFTLISQRIIFKEKI
NVVKAIGASLSIIGIGIILLSKGKVSLFSKGTIGDLMGIGAALCWVAYTVVISKLKGNYR
SIVITTYQTIWGCIFLSPSIFIFQHSIMPSTKAIANLLYLSFFCTCIGYAIYIYCQNKLG
ATVITTYINLQPIVSIISAKILLNENINSKQILGSAIIIIGLFLASKSEKINKQIIEALK
G
>fig|212717.8.peg.1846 Vancomycin B-type resistance protein VanW
MKKLSIWHILIFILIFFSLGFYIFLLYTVKNLNDKIYPGVSVNNIDLSGKTKKEAASIIE
KSLTNNIKGAFKLKSSNKTYVVSFEDLNLKHDLNSTVEEAFSYGKNFSSFKKFSLLMNSK
PVNISSKVLYNKNKLQNSIFSIEKEINKNAIDAKINGITSGVLSFTPGVEGHRLNKEDLL
EEINGNLSTLQNPNSIVEIKLKVDTYPPKINDKNLRKINSLVSSFSTTYENSSKERKNNI
KLATNSIDGTLLLPGDVFSFNEVVGNPTTEKGYKESNIIVNNKLEKGVGGGLCQVSTTLY
NSIIRSNIKSLERKNHSIIPSYVEPGLDSTVSYGNIDYKFKNTLTYPIYIEGIANNEKVT
FNIYSNSSLNKIKYDLISEVHDKIPFKTVYEKDDNLPLNSEKISQNGSFGCRVNVFLVAY
ENGKEISKELIYKDIYNPGNKIVKRKKL
>fig|212717.8.peg.1869 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MNKKAIKEVLSIALPAVGEMFLYVMIWFFDTAMVGKYGGQVAVSTVGLCSEMMAGIINIF
IILGICVGSISLISRSLGGNNFDLAEEYTSISFFIGIMLSFLISTMAYTFAPKLLHFAGA
KDQVLSLGIVYLRITSIGLFFNMLMNVLNSVLRGTKNTKTPLFASAIVNVVNIFLDWAMI
FGKAGFPELGVKGAAIATSIAHFTGFLFIVIYTFKYSPLKPRLIHIKNMSLPKLKNLIKL
SIPSSLQEAAYSIARIWGIFVMMGLGEASFAANQIATTVESISYMPGTGFGVACTALVGH
KIGEGKFKEANEYAKTCAFLSLIFMSLCSATFLIFPKFIVSLFINKNEVEVIKLGMLCIM
VAAAEQPFMALYLVFGGALKGAGDTKTPFYISLIAAWAIRVPFMLYFIGHLKVSVHYNWW
ITAGQWAFQGIAIYLVFKKRFSHPKKLQDNYLVNG
>fig|212717.8.peg.2518 Permease of the drug/metabolite transporter (DMT) superfamily
MINTKVLATITAISYSVIFGLSFLFTKKALIFATPFQLIAFRFLLAFIFMSILIFSKILK
INYENKDIKGLFFLVLMQPIGYFIFETYGLKLSTSSQAGILTALIPIISSIVAVYILKEI
PSKKQWFFIILSVIGVIFIVIMDKNSDSGNSLLGTFLLLGAIICGSFYHVLSRKVSSTFT
PIETTYFMMGVGAVTFNFISIITHIKDNDFSNYFHLLYNKDFLIPLLFLGILSSVIAFLF
VNFSLCYLEASKCAVFSNLSTVISILAGVLFLDEKIYWYHIIGSITILIGVYFTNYLNSN
NKNTSSEKDVDLDESNKERAISK
>fig|216432.7.peg.504 Permease of the drug/metabolite transporter (DMT) superfamily
MNNRILALLAAFAASAIYGANHTIAKDLMPTVIQPFGFILLRVSGAALLFWVASLFLPRE
KIDRKDWLRFVACALFGMAINMLSFFKGLSLSTPINSSVVITLSPVLLLVLSAIFLKERV
TLLKSIGIGLGLAGALLLILFGMKEQPNAPNIPLGNLLFVLNASSYSVYLILVKPIANKY
RPVTLMKWFFLFAVIINLPIGLSEFTQVEWTALSLGSIWRMLFVIIGTTFLTYLFNIYAL
KILSPSTIGAFMYLQPLLATLIAVLVGSDILTTLRIFAAALIFTGVYISSRKPKKRLQSN
NIQH
>fig|216432.7.peg.1384 Probable multidrug resistance protein
MKFFKFYADSFKGLSREMWYLSIIMFINRAGAMVIPFLSLYLTKSEGYSLPQVGWIMSAF
GIGSVIGAWVGGQLTDTIGHYKTMVLSLILGGLGFIGLQYLHTFWTLVIGVGVVMIFVDS
FRPAAFTAINAYSKPENKTRSVTLLRLAINLGFSMGPALGGLIITSLSYSGLFWVDGVTC
VIAGFLLIKLLDPKTAREEHQEVVQHPLSPYKDFTYLWFILAIILFSLAFVQYFSVMPLF
YTNIYALSEDEIGLLLALNGLVIFLLEMPLIKYLETKAVSVLTYIIWGTILTAFSFLILN
VFSWIGVLIIGMLLMTVGEMIAFPFTNKFALDRAKGGKMGAYMALYSISFSISHIFGHNT
GMNLVSNFGYTATWFTMAALLGIAVLIFLSIKLKQR
>fig|216432.7.peg.2319 Tetracycline resistance element mobilization regulatory protein rteC
MEAALNKLLNQFINIIEEHYSINQINLPIISIAIDCCEKHIIDIRKVFGTYNFDSTNAEV
KFFKYQKPVIYGHLKYYLHIQSYLIYKGSGSITQQRQLVDNNIKKLKKGLKPFAEFVTYC
KQGRSELDEYYYLRKNKSLWPITYRSACIYDPDFSTSHDELRAEIVAYDLIMKFYEKELE
TLRIKELNAYVVDSSNENKFNLEWTSNKIDLVELIYALQTSRAIQNGKISITTLANVFGT
VFNTDLSNIHRTYVELKSRKKDRCKFMKYLMVALENRVITEES
>fig|216596.11.peg.323 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MNDMSDTSGSFRKRQRLAPEDLASPELLRLLLRLGLPAMFGLSINAAHHTINMIFVGMIG
DDQIAAIMIVLPVLMLVAAFGEGIGVGVATEVGRTLGAGNRSRAGAIASISLAAGVVFGA
ASAIAILAFPDLLLFGATPALQPLAQHYLMIIAVSVPLTMAQIILDFLAIAEGNARFSMW
TLVACFALNMILDPIMIFGFGLGLQGVAIATILSQLVALCIYAAYHARRLGTVRLTFGWR
WRDIGYLRPVLAVGAPTTLTSLATAGAIAAVVSLAGTYHGEAGIAGVGIALRLLAVGTLP
VIGISLGAQSILSFAWGRGDTTRMLSAARILTVVTSAVSGAYGLGALVFSEELASFFTDD
ATVIGIAGQAIIATHLPLLLFGLRQTVLILFQAQGRPKAAVAIGLAQNGYLLFPLLALLP
PFFGFSGLLAAMFLASALTGLLSAGCLARTLSALRQRAADHLTSIRPYPNFCP
>fig|216596.11.peg.747 Permeases of the drug/metabolite transporter (DMT) superfamily
MTTKTGVANAGNLIMTGVVLMLLGDLLFALNDAMGKWLVASFAVGQVLVIRSVGAFIVLG
PMILRQGPMALFRVEQKGLQFIRVLMATCDVALFYAAVAYLPLADVMTFYMAGPIYIAAL
SHFFLGEKIGWRRWLAVLIGFAGVVIALRPSTAMLSLPSLFGLAGSLAFALSLVMSRYLR
STSDTTLVTWQTIAALVTGIVLSIGHWQPATLIDWSGMLLLGIVATCAHLLITRSLKLAP
ASLLAPLQYTLLLWAIVLGYLFFNDIPDTQIIVGAAIIVVAGLFIFHRKNLKETVPVEAV
PPDGH
>fig|216596.11.peg.1683 Drug resistance transporter, EmrB/QacA family
MSNAAQRSNRVLIVATIMLATFMVAIEATIVATAMPRIVGELGGFSYYSWVFSAFLLAQS
TTTVIYGKLSDIFGRKPVLIGGILIFLVGSLLCGLAWSMMSLVLFRLLQGLGAGAIQPVT
MTIIGDLFKLEERGRVQGAMATVWATSAVVGPLAGGIIVDNISWAWIFWINLPIGVISII
AFMVFLKEDVAHKQAKIDYLGSVLFSISIVALLVMLTETDASAWILLSLFAVFVVTGLLF
LAQEKRAPEPIISIPLWSRRLIATSNTATLLAGMALIGLSTILPLYVQGVLGRSPLVAGF
TLTMLVVGWPLAVMLSSRFYKAFGIRRTLRVGSLMFPFGACFLLFLTPDSSPVVAGAGSF
FMGFGMGLISLTSIVLVQDSVEWSMRGSATASIIFSRSLGNTLGATVLGAILNAGINHYA
SGDAAAGLHEALNQPTGLSALAADPAIRSVFNAALHWSFWGVVVVAVLTFFTTWLIPVGH
GQKGEGAAVPSEAASH
>fig|216596.11.peg.1833 Permease of the drug/metabolite transporter (DMT) superfamily
MSQAAPTLSEASPSNRFALAALLLGGAAIGGSPIFVRLSEVGPMATAFWRVALALIPIVI
VSLMKKERGPKPQSLSDYAMLVLPGVMLALDLAAWHLSLTMTSVANATLLANLAPVFVTL
IAFVFFSARISRVFVIGLAVALSGVVILKGGPAAIGNGDLRGDGIAMIAAFFYACYILAI
GRLRSRFDTIRIMLWSTACAAVCIFPIGLIYEGHMLPATVYGWSIVFGLAFISHAGGQVA
ITYALAYLPPAFSSLTLLLQPVVAAILAWALLNEAIGTMQALGGAVVLAGIMIARTSRVQ
V
>fig|216596.11.peg.2655 Permease of the drug/metabolite transporter (DMT) superfamily
MTTIAFTNDKSPSQVLGYAGGTITVLIWATWFLVTRHSAATPLGSIDIGLIRFGIPALVL
SPVWLKTGLLPKGLPLHLLAIMVSGSGAVFFLLTTLAIHSTPAASSGILLGGSMPLAAAL
IGIALFRERPDGTRIAGLIAIVAGVLILLTRSLADASLPWTSFVLLPAGAVLWASYTHAF
RRSGLTAVQASALIAVWSFLIMGTLALVFGVSLPQATLPEIGLQVLSQGVLSGLVAMVAY
GTAVRTLGGTQAAAFTALTPVLATLGGGLLLGEAIGMTEISAAVITGIGVALSTGIATPR
R
>fig|216596.11.peg.2689 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MTDLSEGNAFLTGWLPGVFIKTAAPIVAITTVSGLFTVVDAYFLGAYVGPDALSAVSLIF
PGLMLLVALQSLVSNGMASILARRLGAGDRQGARRVFASAHALAFAVTLILNLVYWTLGR
QIIDAGAAGNAAVADGARLFMGAMTACAPVGFFLSLHLDGLRCEGKIGFMTLVTLSASLL
NILANWLFMAVMHWGVLGSAAGSIASQFVCLAAVLAYRWRRPAILRPSRGLALAEWRGIV
AFGAPMSLGFIGISLASAAILLNVSLWSTHDYVATVAAYGIITRIMTFTYLPLLGLSIAL
QTIVGNNHGAGLGLRVGRSLQIAMLAALVYCTLVEITVELLAGRLGAVFVADPAIIAEVR
RILPWTIGAYFLFGQMLILSSYFQSIGDAPRAAIFGLSRPYLLTLPLTFLLPFVFGEQGI
WMVPVFAEAGMFILAFLVLSQNAKRRGWRYGLLPA
>fig|216596.11.peg.2823 Permeases of the drug/metabolite transporter (DMT) superfamily
MFPTALSDHRKGLLLTAIGGLALSVDIPLMRLADGELWSILAARSIATLGVTLLVATALR
IAKGRWPVLVPGWPGLVTGLLYGLTTVVFLLAVFNTSTANVVFIVAFNPMFAALLSWIFL
KERPAPATLIAMAAMIFGVGLIVRDGLSGGHLFGDTMALLTAFIIAAAITISRASRREMG
FVSLLSTVLPAAIGLISVMPAGGFSIEHPAWILFNGAVMMPLAFWCLATGPRYLSAPEVG
MFYLLETVLAPIWVWLIFAETPAPMTLVGGGILVAAIAAHSVWIVRRKSIAQMAG
>fig|216596.11.peg.4136 Multidrug resistance efflux pump
MALALFVFSIFMERRTPSTSQAQVQAYIVGIAPEVTGRVVEVGVTDNSRVEADQLLFRID
PERYELAVSEAEASLASVGQSMGASTAAVDAAQAKLVTAQVDRDNLREQAARAAELEKRG
VYSKARADSTRSAFGQSEAAVIGAEAELAKAKEQLGPSGNDNPQLRAALAALEKARLDLV
RTTVQAPSAGVVTNLQLTIGKVVSAGQSAMTFIDVGTIWITAAFKENSLEKVAVGNRAEV
LFDALPGRLFPAQVESVGFGVSQGSTDPNTGLPTIRSDSGWVQEPQRFPVRLIIEEAQRP
KGGVRYGSQATVVIYTGDNPVTNAWGSLWIRIMSVLTYVR
>fig|216596.11.peg.4294 Permease of the drug/metabolite transporter (DMT) superfamily
MAMNVLAVHRDTVGTEQAAGNSLAAAYSVGVLCWLLSAGVYIAAKWVSSEMPPWALCFWR
VLIAFAILMPIVRRHFGDMVALVRARALELLAIGGVGLAICQGMIFVGLEHADATTAGII
IALIPIITMILARLMLAEPMGRWQVIGSILAFLGIVVIIIKGSPAALMRLDFNPGELWIV
AGAFCFSLYTVLLRRAKFDLNRLALLVLLLGAAVLTALPFYLSELFSDERSTLNGNGLIA
LAYVAIPGGAVMYYLFNRSIEALGAARAGVLLYIQTIFIAVLAYLILGEQLQRYHLEGAA
LIIAGLLLIILLKPKIKAEAATA
>fig|216596.11.peg.4298 Acriflavin resistance protein
MNTTSEHDRDLAAKLRSLSIEPAAFKTEPPEPRVRRRVIPGAMLALAATASLAVVLLYRP
DTLARIETVLAGLIGKDEAAISVDGTDVPAAGPIRALPSNNPADRALPSREVTGSGYVVA
PDIATIFSKYEGRIAAVEVEAGDRVVSGQVLVRLDDAGARFALQGAEITRQSAELALTAK
TIELAQARSSLTRTERLAGRDAMSAQTLEEARTAFDTAENAAQQARQDVAKADLDIDRAR
EQVEALTVRAPISGTVTRLTAHVGDTVLSREDSVRENESLLAIADMTTMVIDADVAEANI
ALMRPGLRGESVLDGFPDRPFAVEVSKIAPMISREKGTVTLRLSLSSPPSDMRPAMAARI
RLLVGEAGDSTDHQQGAER
>fig|216596.11.peg.4681 Permease of the drug/metabolite transporter (DMT) superfamily
MSRQVQGYVYLALAMLTVGSTVVASKLIASGLPPFGATALRFAIAFPVLLLLMWATGARL
PRFSRHDRLILVIQAGAGSVGYTTLLISGLSLTSAADAGVIIGTLPVVSAAISILLLRER
PQRALLLAVALATSGVLSIAFTPDAAGGSLTGNALIFLAVVCEGLFILLNKRLKTEIAPL
ALSTLMAGIGFIVAAIPAIFEAPFADGISASAVAAVVYYALVPTVGGFLLWYAGAERVSG
TEAALFTALAPVSAVMLAFIILGEPVGLSQIAGIGCVLAAVLGLAFAGSRTVKLAGGR
>fig|216596.11.peg.5082 Permeases of the drug/metabolite transporter (DMT) superfamily
MQATAYICLVIATLCWGGNSVAGKLALGHISPMMLTFLRWFLAVAMIAVISVPQLRKDWP
VVRKNLPLLLFYGVIGYTLFNAMLYSAVQYTTAINVAIEQAGIPMLIFLLNFMFFRTGIS
LAQCLGFGMTLIGVALTAAHGDLATLLQLSLNRGDGLMLIAIAAYSVYTIFLRWKPPLDW
RTLMAVPALGAMLTSLPLLLWEAGRGAARWPDQAGWVITLYTAIFPSLVAQILYIKGVVA
IGANRAGLFINLVPVFGTLLSVALIGERLQSFHVIALVLTLGGIAIAEKGRPKASSPTVT
ASPVD
>fig|216596.11.peg.5507 Membrane fusion component of tripartite multidrug resistance system
MAMSSNQKSNVARIVSENAGTEEVKAEVAGVEAPTAEAREVPSAPAQSAPASVAAPAAPK
KRRSPVLPIVVLALLAGGGWYGYEWWTNGRFMVSTDDAYIEGDIATISPKVTGYVAKVNV
VANQEVKAGDVLATLDNGDYQNALDLAQAQIVTEQLSLQRIDAQIEGANASLVQAQAQKV
ALEAAVRGAEITQKRQSDLQAKSVGTAADLDNANIALDQAKANLAGGDANITAAQANITI
LQAQRKEAEGSVRSLEISRDKAVRDLSFTVLKAPYDGIVGNRSVQEGDLVSPGQRLMALV
PVRQLYIDANFKETQIQHLVPGSKVNVQVDAYSDHPIVGTVESISPASGSVFSLLPPENA
TGNFTKVIQRVPVRIALPQDALDSGRLRAGLSVVVDVDTRTAPSK
>fig|216596.11.peg.7355 Permease of the drug/metabolite transporter (DMT) superfamily
MQVGPVPVLVSVFYRFAVAAVILAAILAVMRQLKLPALRDQPFILAQALCLFSLNFICFY
NAAASIPSGLISVIFSLATIYNAVNARLFFGDRITGRTLLAAALGATGLLLLFGQDVVVD
FDMGTLKGIGLAALGTLFFSLGNMASRRNSAVGISPLTANAWGMTYGAIVLLFLIAVTQT
PIVAPPDITYLAAMLYLAAIGSVIGFTTYLMLVSRIGSSRAAYATVLFPIVALSLSTVFE
GYHWSGLGLIGLALTLLGNVVIFARPLARRPPRSDARLPAEVR
>fig|216596.11.peg.7368 Inner membrane component of tripartite multidrug resistance system
MSERLESARPDETPAIVWLGFMAMCVGMFMAILDVQVVATSLPTIQSALDIDPDQMSWIQ
TAYLIAEVVAIPLTGFLTRLLTMRWLFVTAISLFVAASAGCAMSGSFGELVAWRVLQGFS
GGTLIPSVFSAVFILFRNERQALATTIAGVLAVLAPTVGPIVGGWLTETYSWHWLFLINI
LPGIASAILAARSLPRQATDPSELRHLDGLSLLLMATALTSLELSLKEAPTSGWISAYVL
SLLAVCLASGGVFIWRTLRRNRPIVDLGNFGDRNFLVGSVLSFVLGIGLFGSVYLMPVFL
AFIRGHDALQIGMTMLVTGVAQLITAPIAVALEKRMDARLLSAAGFALFAIGVGMSAFQD
PRSDYDAMFWPQVVRGVAIMFCLLPPTRLALGTLPPDRIPDASGLFNLMRNLGGAIGIAL
IDTIIYTRSEPLGQGLWTRLQAGDVEAATFVGAPLQTISGHSGSFDADTTALLDPLIQTA
ASVQAINEAWMVIAVLTGCALLSVPFARRPKST
>fig|217.1.peg.130 Bacteriocin resistance protein, putative
MKSLFFFLQFISLSFAHTFFDNNFFFFEKPLQSWVEIKSKNLIKQQYDYSCGAASLATLF
TYYLNTKVDENDVLDYIFEKKNLEKKKQQKIEISFLDLANFSESKGFKALALGLDFDTLL
QIKIPVILYLMTRKSPHFSVFIGTDKKFIYLADPSLGNIKIRIQKFKEMFAQRDTKKHSG
SILAILPKDEGSKTRLKEPPKNHEEIFQEAIKNQIIHPF
>fig|217.1.peg.195 Tetracycline resistance protein tetA(P), putative
MQIALIANMPLKRNILVYYASILTAISAQALPHAILTPLLLAKGLSLAEIMWVQATYSMA
MLLAEYPSGVLADLMARKRLFLLSKLVLMCSFSIIWLCEGLTWMLLAWALYGLASALDSG
TIDASLINAIKEQKANLSRFFAIDKQLRFAGMILGSVLGSFLYVRYGASVYIMGLLLLAL
CMIIVFLGFKEGEVLVHSKSLELLKRHIKEGFLELGQKPHLKKLMICSLVLQVFFQTHFQ
LWQAYFLAKDIATSHLFYFYVGFQILGVLIHFIPATSAVSKKSWILLAGLPLILGLLSSV
PIVFIALYALVVAIFSWIAYCVDYHFSLCVSKQKISSLISLKSSISRLASVAILILSSAE
LAFVSVGYVVVWHFLLALVAVAFLLKWTNLQSIGNKPS
>fig|217.1.peg.507 Permease of the drug/metabolite transporter (DMT) superfamily
MLLNRIQRIQTLQKPHHPRNLTNRNFLHFTPPVFLKNHPTSIPTPHQKMHPKNPSLMPNP
RPLKPQTSPKVKNSKAQKHHLKRNINITQKSRFMPFPLLFFLALLAEAFIVYASVLVKIV
DLPPILLGFYRVFLAIPIFFLFALRKGNLSKIPIKDIALMLLAGVFFGLDLVFFNTALHH
TSVTNVNLICSLVVFVLAPIGVFFFKEHLHKSFLLGAGVAVIGIFVLIKGKSDTSIATPY
GDFLALLSNVSYSIFLALIYGLRKKYTAMALMVYVCIGSSLLLGIIAEIKEGFMLPNSAN
AWIYVGLIVLFGQILGQGFFGYIMGKINTQVSSLIMLFSPITAAILGFLILKESIGIFEI
LGMFIILFGVYIAKR
>fig|217.1.peg.977 Acriflavin resistance plasma membrane protein
MNSWIKFCLKNPVGVFVCAIFLLLFGYIALSKIPYQLLPQVTHPVVSVYTIWKGATPYEI
EKEITQRQEKTLKNTPNLLAMTSTSKEGMAIINLEFAISTDMKTALLNISSRLDEVRGYP
ADVEKPIIKPTGENIPISVYLFAKSINPHLDINTAKNFINDEILKYYERIEGVGEVYVSG
GRKKQIFITLDTQKLAFFHITMDEVIASIKKQNVNISAGSMDFFQRSYRISTNGEYTSLD
AIRNTVVKTIDHKNILLRDLASVSEGYEKLTSYNVHNGSNVISLQIRPTASANILDLTNR
VEKLTHRLNEDFLKKRGIVMEWGRDQRQYIKSSISLMRENIFVGILLAIGVLFLFLRNLM
SLVVISLVIPLSIMGSLIFLQAWGRTFNVISLAGISFAVSMIIDSAIVVLENILRQAKIQ
KNFFLACVVGTREVGGALFASSVTTIAIFVPIIFVKDDAGRLFVDIALASSSIILLSLLV
CFFMIPTFLYVLLKRSDFGRKKGKVDAFLVHLGRVLSFWIMQSVRFCVRNKKRQIITVVG
FVGICGIFSYAAFPKTDYLPRGNQNFIFANLSIPPGLSLKEKKRILDALQADFYPFLLEN
HNSHAKIPAIKDFFISTGERVSFYLVSADKKKIPELMDYAQEKIDSIPNVRGSILQQEIF
SGASSSSIDINITGGNLDSISKTAGKLIASIKKNLPKVSISVVPARESNNQEINLYPDKS
ALALNGLNVESFGIMVGVILNGKKVGEYRKDEGILDMILDSKKSLKNDGKTSPEDIFYSQ
IYTPNGGVLPLNTLATIKHEYGVSRIRHFEQQRNILLILNIRDNTPVETLAQILQEKVIA
PIAAESENDITLSGSAGKLQKLKTELLHGFLLAIVITYLILCALYGNFLYPFIIILTVPL
ATTGGLIGLYLVNHFIAKQNLDVLTMLGFIILVGSVVNNAILIVYQTLNNLKKMQPRRAV
FLATKTRLAPIYMSMLTSVLALFPLVIFAGDGSEIYRGLGAILIGGMIFSTFITVLIIPA
LLLLCIKAKQKA
>fig|217.1.peg.1456 Multidrug resistance protein
MSIETKRTYHELLLFFTESKLFKAALFSISATTVLGATIIAPSLPALEKHFSDIGPSAEI
LSKLILTIPSLLMVFFSPIAGFLFERFRRLNIIFFALMIWSLAGISGFFLNNIYLVLTSR
AILGIAASFLMTGIGVLLADYYSGARREKALMLQNFFMAFGAGIFLTLGGFLASMSWRYP
FLVYSLGFVILIFGIFELFEPIKFHHKTHANPTKFTFSKFIPMYLLGMFIMICFYIAPTQ
MPFFMTDYLHIDQTRVGVSLAVVSVAMAIGSLFYMQLRKLFSLYEIFFLALSFFALGFAC
ISLVHNYLSVLIGFCFLGASLGISLINTNAWLFHIAEEGERSRAYGFLASSVFLGQATSP
LITQTFVSHLGIVKMIAIFTLMLFSVSFLFLFMSWRSQDRKF
>fig|218491.3.peg.1636 Polymyxin resistance protein PmrM
MTNKGYFWVVASLVLASAAQVLMKSGMLALPSISMTHWPSLSTLMAGWPVVAVLVGIICY
GLSMVCWFMVLRYLPLSRAYPLISLSYAVVYLAAVFLPWLNEPMSLRKNLGVLIILLGVW
LVSRDAQATK
>fig|218491.3.peg.1771 Multidrug resistance protein B
MKTENNQKQTPVPHRHWILIACMLAMFTAAIEVTIVATALPTIIADLGGFSLLGWVFAGY
LLTQSISIPIYGRLADLYGRKKIFFFGMIVFLLGSILCGFSTQMGWLIVFRTLQGLGAGA
ITPIAFTIVADVYSSTERPKIQGYLSSVWGFSAIIGPLLGAFIVQHFNWALVFWVNVPIG
LFSIFLLARYLPTINVVRQHQLDWTGAFYLVVSVASLLMALLQAEVFGYWVIPLLALSVV
GGILLVRQEKRTQEPLFPLALWRNRVIIAGNLGGLVVGAAMMGVSAFLPTFIQGVMGKTP
LEAGSILAMMSIGWPLASTLSGRLMLWTSYRFTAMCGGIVLIIGSLTLLTVQPDSNLMWA
RLAAFLIGSGMGLSSTTFLVSIQNSVDYSIRGIATASAMFTRMLGSALGTAILGATLNIN
LHWRLPEVSDPLQTLMDPAKRILLSVNQLDTLASQVASSIHGVFIVSALIAAITLLSARM
IPASQRPGQT
>fig|218491.3.peg.2237 Chloramphenicol resistance protein
MLAMPLVTQTFNHKALMRIAIVMAFIQFTNALEYMALTPVFTFMADEFSVPVSFSGYVSG
MYTLGAVLSGIIAFYWIDLFNKKQFLIKNMVLLGALTFLSTLTTHFGTLLVLRFCAGLVG
GTTMGVGTSILINCAPANLRGKILATVITSFSMVSIVGMPAILFLCTHYGWHTALWLISS
LCLLSLPLIVFIIPKDTVQSGVKAKLSIDAQTLLFASCSALVQFSPMLIIPILTPLMLQY
MGAQQTLLPLLFLSGGIAGYLSTKITGVLTSHLSALMLATISTLFFVASLLIPAMGYHNA
VLFITLFLGASYSRLVSASSVAVQYPENEQRASFSSLQTAMMFLITTLAFFLSSLLLPDQ
GITTQNLNRLLVVSALAASGFPVMVIILQKKLAKRTLQPDRPIID
>fig|218491.3.peg.2564 Daunorubicin resistance ATP-binding protein drrA
MTYALELAQLTKTYAGGVKALRGIDLNVEAGDFYALLGPNGAGKSTTIGIISSLVNKTAG
KVRVFGYDLELDKVNAKRQLGLVPQEFNFNPFETVLQIVVNQAGYYGVKRQDALPRAEKY
LKQLDLWGKRDEKAMMLSGGMKRRLMIARALMHEPKLLILDEPTAGVDIELRRSMWGFLK
ELNAQGTTIILTTHYLEEAEMLCRNIGIIQRGELVENTSMKQLLAQLKSETFIFDLAAKS
PLPQIEGYAFRLTDTSTLEVDVMREQGLNALFSQLSAQGITILSMRNKANRLEELFVSLV
NGDGVNGKGEKA
>fig|218491.3.peg.3000 Multidrug resistance-like ATP-binding protein Mdl
MRLFAQLSWYFRREWRRYLGAVALLIAIAILQLLPPKLVGVIVDGVTQHGMSMAEMMQWI
GVMLLTAVMVYLLRYVWRVFLFGASYQLAVELRADFYRQLSRQHPAFYQRHRTGDLMARA
TNDVDRVVFAAGEGVLTLVDSMVMGCAVLIVMCTQISWELTLLALLPMPVMAIFIKRYGT
QLHNRFKFAQAAFSSLNDQAQESLTSIRMIKAFGLENYQSARFAQVAADAGAKNMHVARV
DARFDPTIYIAVGLSNLLAIGGGSWMVINGSITLGLLTSFVMYLGLMIWPMLALAWMFNI
VERGSAAYGRIRQLLAEELVVKDGEESLPAKRGILEVNISAFRYPDNTRDALQHVQFTLA
PGNMLGLCGPTGSGKSTLLALILRHFDSQSGEIRYHDRPLDAIRLDELRNRFAVVGQMPF
LFSDTVAQNIALGRPDATQQEIEQAARLASVHDDILRLPKGYQTEVGERGVMLSGGQKQR
IAIARALLLDAEILVLDDALSAVDGRTEHQILQNLKTWGEKRTLIISAHRLSALTEANEI
VVLQQGQTAQRGTHRALAAEPGWYRDMYRYQQLEAALDDVPQLEGTKNE
>fig|218491.3.peg.3511 Acriflavin resistance periplasmic protein
MAVGMMRPLLLMSALSLPLWGQAATTGDIRVQLSAQRYTVLSSEIAGKVTDIAVKEGEHF
KQGDTLVTFDCTVLREKLNYSNAAENAARKKLAIADRLDKLNSISLSDVDQARSSVSMAQ
AESGVNRAMLQRCVIKAPFSGRVTETKVKRWESVAEGKELLAIYDDSAFELEMIVPSRWL
VWLKQGSAFQVTLDETGLSYPAEISRLSSAIDPVSQSVKAFGRITQSTAGLLPGMSGVAQ
IASPDAAGSVSP
>fig|218491.3.peg.4068 Membrane fusion component of tripartite multidrug resistance system
MTQSPSSSRSTRKWILQAILVIVVVWIAYRFWLAYQPEPIRLQGQIEAQQYSVSSKVPGR
IADVRIEKGQQLDVGDLVFTLLTPELDAKLEQAKAGEAAAGAVALEAKTGAREQQIAAAK
DQWQKAKAGSELSNKTYLRVQNLYQEGVLPLQKRDEAKASWDAARYTEGMAWQEYQMALE
GTRKETLVAAEEKARMAAGSVAEVEAYLAEARVVSPHSGEVSNVLLRNGEIAPQGFPVVT
LLDMSDIWIQLAVREDLLERFAMGTEFEARIPALNNQTFRFKVSYVSVMGDFATWRATDT
RQGFDMRTFEVEARPVQPISGLRVGMSALVEM
>fig|218491.3.peg.4155 Multidrug resistance transporter, Bcr/CflA family
MTHVQTRSEKTSGLLFIAILSALMAFTSLSTDIYLPAMPIMAKDLQGDAELTITGFLMGF
CIAQLVWGPLSDHLGRRTPLFIGMVLFIIGSVGCALSTDISQMVFWRVFQALGACTGPML
ARAMIRDLFSRTRAAQMLSTLIIVMAIAPIAGPLLGGQLIKVTSWHAIFWLLAIIGIMML
ISLRWLPETLPEDRRVKASLPSAFRNYYALLTNANFMRFTLCLTFYYVSAYAFITGSAFV
YITYFGVEPQHYGCLFALNIVGVMGMSMVNRRLVQRYPLETLLKFAVLIATVASFILAIG
AKLNIGGMPLIVISVFVFFSMNGIIAATSTAAALDAVPNIAGSASALIGALQYGSGIISS
LLLALLSDGTPWTMAWIIALFTTASAITALTTRVTKSSS
>fig|218491.3.peg.4156 Multidrug resistance protein B
MAINSLGEPEKNKPGITITLALSILSASLGTSIANIALPTLTAVFSAPFAQVQAVVIAYL
AAMALSVVIAGRLGDRYGLKPVFIAGLVLFAVASLLCALAPHLWQLIGARTLQGIGAAFL
MTLGMALLRQTAGEKHVGRAMGVLGTVSALGTALGPSVGGFILTTAGWRSLFWVQIPLVA
IVLFLAFTLLPTASVKEKVLAQRVSPIRNPTLLSNLTINAAVTSVMMTTLIVGPYYLGPG
LGLKETLVGIVMAIGPATAIFCGIPSGRLVDTWGFGRALTAGLSLVVTGTLMLAILPPLL
GVTGYILSVIVLTPGYQLFQAANNTATLADVPGNQRGTVSGLLNLSRNIGLIAGASVMGQ
AFALGVGTEDFTHATPASLANGMQLTFFLSGGMILAVLAFTHLPRWKRVTR
>fig|218491.3.peg.4458 Bicyclomycin resistance protein
MNDNKMTSGELRATWGLGAVFSLRMLGMFMVLPVLTTYGMALQGASEALIGIAIGIYGLM
QAIFQIPFGLVSDRIGRKPLIVGGLLIFAFGSAIAALSDSIWGIILGRALQGAGAISAAV
MALLSDLTREQNRTKAMAFIGVSFGVTFAIAMVVGPIVTHAFGLQALFWGIAVLSLAGIA
ITLTLIPSAPEHVLNRESAMVRGSFRKVLGNSRLLKLNIGIMCLHILLMSSFVALPRAME
SAGLAPQEHWKVYLVTMLVSFAGVVPFIIYAEVKRRMKQVFIGCIVVLIAGEIVLWASDN
HLWQIIIGVQLFFLAFNVMEALLPSLISKESPAGYKGTAMGVYSTTQFIGVAIGGSLGGG
LFELYGASTVFMAGAAIAAIWLFVSFTMQEPPYLSSLRIALSDLALQDSELEQKIRTQPG
VAEVVIVPDEFSVYVKIDNKKTNRQQLEQVVGQA
>fig|218491.5.peg.2966 Outer membrane component of tripartite multidrug resistance system
MTQARAGLGAATAALLPSGNVSGQATRAYQSVETAQGRLLNSVPGYNRYGNAYETDLNAS
WEIDVFGGLRRDRQAALADYQASEAGVTATRLAVAAQTADIYIALRGLQTRLKIANRQVN
TQQELLEKVQLLHSKGLAAEYQVRQTEGSLSQVQATVPVLQTGIDAAMNALDVMLGTPPG
TYRNQLASSGPIPQPPQLISTGTPADLLRRRPDIIVAERHLAASNARIGVAISEYYPKFS
LNALLGSATSVSSGNLFSNGASQSAGVLGLRWRLFDFGRINAQIDQAKGQEAEALAAYRL
SVLSATEDVENALSALLNRETQTTTLTAGETALASARQSSFIAYQKGTASLIDVLHNDET
LLQTSDARAQAQTESARAAVATFRALGGGWQPPETAAKML
>fig|218491.5.peg.4545 Antiseptic resistance protein QacA
MQSPKKWLILAIVSSALFLIVIDMTVLYTALPTLTHDLHASASEKLWIVNIYALVASGLL
LGMGTLGDKLGHKPLFISGLVVFGAASLFAAYSPTPSMLIAARALLAVGAAMMMPATLSI
IRLTFTDEQERALAIGIWAAVASGGAAFGPVMGGILLEYFWWGSVFLINVPVVLLALIMG
ITMIPHRPGNASHRWDFIGSLLIMVGLIGITYAIKELGKRAPSYEDALIALLIGVTFITL
FVQRQRNSKHPLVDFSLFRLRPFSAAVAAAIVAAAALIGMELAFTQRLQLVVGLSPLQAG
LFILPLSLASFISGPLTGKILPHVNSGTMLAAGLLISGLGMGSYLLLHNASIIIQVISLT
VIGAGVGSTMTAASSTIMQVAPAEKAGMAASIEEVSYELGGATGVTLMGSLLSFAYSATF
MLPAGFSAPDTAYDSLDEALIFAESLPENMQRILTAQAHSAFDSGFSAVLATATLILLLT
SAFVWTTRNNKQQRNQAADA
>fig|219305.4.peg.1697 Permease of the drug/metabolite transporter (DMT) superfamily
MPQVVGEFDMAPVVVDTVPGNRATSSYPCGRVSGVKPDTTPDRAALRSWLPGFLALAAIW
GSSFLFIKVGVRELHPVHLTLYRVAAGALTLLVALPLLRDRLPREPRTWAHQFVVAALGV
AVPFTLFGYGEQRIESMLAGIWNATTPLIVLPMAVLVFRTERLTTRKAVGLGLGFAGVLV
VLGVWAGVGGAHFAGQLMCFGAAACYGFAIPYQKRFVAGSAHSGLSLSAAQLVLATAQLA
VVGPLVAGAPPVPTDLSGGALASVLALGALGTGLAFVINLRNIRVAGASTASTVTYLIPI
FAVLLGALALGERLTWHQPVGALIVLAGVAVTQGLLGRRRRPGAVGVAPPAPPAAPVGTR
>fig|219305.4.peg.1701 Vancomycin B-type resistance protein VanW
MTLYGETRPPADDRPTIKVTAVSWPGDEPDPAAAAAPGPPDTAPARRHRRLRVLLAAGIS
TAVLGAAGGVGAYAYAGDVPRGTTVLGTELGGRSRTDAIRALRAELERAGTPSTPLRVTV
GEKSLEFEPADVGLAVNVEATVDAAAKAQAHPVSRLVGSRAVAPVVTVDAARLDAALRKA
AGDQTREWTVPAIIFTGTTPKAVRPRSGLALDPQRSAQAVRDGWLSGQPVTVPLVENTPA
TSAEEVDRLLDELAHPAVAAPVTLSTDKGSVTIPPAAIARSLRFTADDAGKLTPRVDVKR
LRAALGDKLDTIEVAPRDARMTVTGGKPKPVNGRPGQQLDTEALSRDLLAVLPRADDRKV
TGRLKETQPKLTAEKLAGLGISERVSRFTTHFTGGLSSPRSQNIVQIAKEVDGTVVLPGE
TFSLNGHTGERGYAQGYRDAPVILDGKLVPGVGGGTSQFTTTLFNATYYAGLEDVEHKPH
SYWFSRYPPVIESTIFWPNLDFKFRNNTKYGVLIDTSTTASSVTVSIWSTKIYDSVKTEY
GPRRDVTKPKTVRLKPGPSCIPSNGIDGFTQDAFRVIKKDGKVVKREKFTWRYLAEPRFV
CGGSAD
>fig|219305.4.peg.2002 Permease of the drug/metabolite transporter (DMT) superfamily
MAIVYVLWGSTYLGIRVAVESLPALASAGLRFGAAAVVLALVLRVRRGAGALRVDRRQLG
SAALVGVLLLAGGNGLVVLAESGPPGTAVPSGIAALLVATVPLLVVLLRTVSGDRPRLWT
FAGVTLGFLGLILLVLPTGGSGAVPLAGALTVVAGATCWSAGSFLAGRLRMPTDPFVATV
YEMVAGAVALAVLAAARGELRDFDPGQVTGRSWLALAYLMVAGSLVAFTAYVWLLHHAPI
SLVSTYAYVNPVVAVALGALLAAEPITAQVLIGGAVIIAGVALVVSTERLGRPTGAAARP
ARR
>fig|219305.4.peg.3607 Glyoxalase/bleomycin resistance protein/dioxygenase
MMPELAGVQHVALTVTDAARSADWYAEVLGLRIVVRFEEGGGERYKIILADRAARILVGV
VEHRGAPPERFDERRPGLDHLAFAVDGRAELDAWAAHLDALGVPYSPVAPATLDPRNSVL
VFRDPDHIQLEFFAVPAEN
>fig|219305.4.peg.3718 Multiple resistance and ph regulation protein f
MTVALATVLTVLLSVTALLALARMYRGPSLLDRVIASDVLLNTMVGAVGTEAAINRHATT
LPVLVVLSLLGFVGAVALVRFAVGEES
>fig|219305.4.peg.3729 Tetracycline resistance protein
MATDLTAPAPSRADVAPIQRRTLRLLFVTQIIGGVGVTIGISVGALLAARVAGTAVAGLA
QSAGVVGAALLAVPVTRIMTGYGRRPGLVTAYLVGAVGGVLVVLAAATRQVPLLFLGMLL
FGGGSAASLQARYTAVDLAEPARRGRQLSLVVWATTVGAVAAPNFAALADRTTRGWGLPS
LAGPFAFSAVAFTLTAAVLLVLLRPDPLLTARRLTAAEAPAAADVVPDAAGPTVTGRRGA
GMRATWRVVRERPAARLGIAAVAVGHLVMVAVMSMTPVRLGEYHDDSVVLGVVGVVLSLH
IAGMYALSPVVGWLTDRLGRRQVIIGGLAVLLAACAVAGSAGHHTPGLSVGLVLLGLGWS
GTMVAGSTLLSESVPAAVRPSVQGLSDLTMGLAGAAAGALSGFVMQVAGYPTLALLAAIA
TVPLLALALRVVPTRVPDEED
>fig|219305.4.peg.5363 Glyoxalase/bleomycin resistance protein/dioxygenase
MHDPLGGSFRVSAGTDVVVPGPGRPSWYEYMTTAPADADRFHADALGLRASAPPDAGDDS
YALLLAAGRPVAGRLALPPPLAALLPTGWMVYFAVADPDAVAGRASGLGGRLLVPPRDVA
TGRVAALADPAGAVFTVIRPAPAPE
>fig|219305.4.peg.5800 Glyoxalase/bleomycin resistance protein/dioxygenase
MSTVRVRELDHLVLNVEDVERSLAFYCGVLGLGPVRVDEWRAGRIRFPSVRVSPDTIIDL
VQRHRGESNVDHICLVVDPLDWHDVIASGVFTVLEGPVSRSGARGQAVSLYVQDPDRNTV
ELRWYPADAEPTTPPTP
>fig|221109.1.peg.72 Membrane component of multidrug resistance system
MKDRSTYLDATNLPKVPIIFVMVMGSFIAILNQTLLNVALPVMIVDMNMSANQAQSLTTI
FMLVNGILIPITAFLMEKFTTRQLFLTAMSLFALGTLVCGLAFGYPSLLVGRVIQAAGAG
IMMPLLMNVILSLFPINKRGSAMGYIGLAMMFAPAIGPTLSGLVVQNYSWRVLFFIVLPI
AIIDIILAFFFLRNVTKQSNPKVNYISILMSTVAFGGLLLGFSLAGEMGWKHVEVIAPLM
IGAIVMVFFIRMQLKLKNPILEFRVFKFSMFSLTTVISVVITMSMFAAMILVPIYLQNLR
GFSPLASGLMLLPGALISAFMSPITGKLFDRIGARPLAITGLGITAITTFLFSDLSNETG
YYYLMFVYSLRMVGISMIMMPIMTAGLNQLPQRLYSHGTAMANTLRQMSGAIGTAFLVTV
MSSQTVKHMDEMTQTVVSEEQLKVIENLATIEGINDSFMIATLFAIFGFILSFFIKRRYP
PEESVETVSKEQKRKQPFRNVASGTNQLR
>fig|221109.1.peg.492 Multidrug resistance protein
MNQIHRPTVVALLLAGSFIAILNQTLMITAIPPIIIEMGITANSAQWLTTVFMLVNGIMI
PVSAFLIERFTTRQLFMSSMGIFAIGTLVAGVAPVFEMLLVGRVIQSIGAGVMLPLMTTV
FLLIFPINRRGSVMGLIGLVISFAPAIGPALSGWVTGHFSWRYLFFIIFPIAVIDMIIAY
FALKNVTEVKKTKLDIPSVILSSFGFGGILYGVTNAGNYGWGASITLITLAIGVISLTLF
ILRQLKLTHPMLEFRVFKYAIFPFSVFIGSITFMGLIGTETLIPLFMQNMREFSAFQAGM
AMLPGALVTGFLAPIIGRMFDRYGGKWIVLPGVVIITLATVPFIFIDTETTFAFITTLYA
VRMLGLALIMMPIQTAALNQLPNNLIPHGAAMDGTMRMTAASVGTAVLVTVMTSVESMAE
NQVARPDILGVNVSFSVIAVLGLCTIIAYFFIKFDPSPAKIAKMEEDKSN
>fig|221109.1.peg.983 Tunicamycin resistance
MIIWINGTFGVGKTETAKILHKRIPNSYLYDPEEVGFLIRKQLPVELCEEDFQDHEEWRM
WNYHLLKKITTETEKIVIVPMTLTNEQYYQEIIGRLKKEGIQLHHFTLVAEPQTIIDRLK
KRGDEDNKFIVNRIEKM
>fig|221109.1.peg.1041 Multidrug resistance protein
MSESHVGGSTEKMSRVPILVVLLSGAFVAILNQTLLGTALPHIMSDLELEANTAQWLQSA
FMLVNGIMIPITAFLIGTFTTRSLFLAAMSSFAIGTLICGIAPNFELLLTGRILQAAGAG
IIMPLMQTIMMLIYPREQRGSAMGMFGLIISFAPAIGPSLSGYIVEHSPWRTLFFMVLPI
AIINIGIAYFLLKNVTKRTFPQLDKLSIILSTLGFGGLLYGFSIAGSAGWLSNQVIISMI
VGIIALAWFILRQLNLKTPILEFRVFQYKIFTITTILGMVTFMTMIGAAVILPLYMQDML
GFSAFESGLALLAGAVLQGIMNPVTGRLFDRYGSRYLAIIGLGLIVVTTFMFGMLTAETS
FTYIATIHAIRMLGVAMAMMPVTTAGLNSLPDEFIAHGTAVNNTLRQVSGAIGTALPITI
MSTAAIPSEGLQGLIHGVNVSFIVTAIISIVGLILAFFIHDEKKKRISSR
>fig|221109.1.peg.1196 Antibiotic resistance protein
MNLEKIWTKSFISISLVQLLIFLSFYALLTTLPIYVMDQLGGNEAEGGLVVTVMLLAAII
IRFFSAKLLDKIGKKRGLIISVALFMITSFLYLLVETYTSLLALRFLHGFSFGIITTATG
AIAADIIPASRKGAGLGYFAMAMNVAVVLGPFIGLTLIQYVSFHTLFFILGVLMIVALIN
SMMVQVEEQIVEVNDNRQRLSIHDFIETRALPIAIIASLVSLSYASVMSFISVYASSIGL
ASTASFFFLVFAAVMLITRPSIGRSFDLKGPRFVLLPCLMIFSVGLIALSITNSSWMLLL
AAGLIGLGYGSILPGFQTIAIQLSPDSRSSHATSTFFILYDLGIAIGSFVWGLIVSEIGF
SNLYLVAAAIVVIALFLFEFYYRRPSKKEVNIADVQ
>fig|221109.1.peg.1411 Multidrug resistance ABC transporter ATP-binding and permease protein
METFKKLKRFYWPYKKYFIWSILFMLVVTSITVVYPIMLQITIDDVVVQSRYELIPWICG
LFLGLMVIKGFSTFSFQYLGDLFGMTSVYKLRESLYDKLQTLAFKYYDNAKTGDIMSRLT
ADVEGFRFFLSVGFAELLRIISLILISLSIMFYYSVPLALVTMAAMPFLAIVVFQFDKRV
HPAFRNVRKSFGQLNTRVQENISGMNTVKSLSREDFEIGRFSNSNDNYRQKYLFTSKLWA
RFFPMMEFIGNVSAVVLLAYGGYLVINETMNPGELVAFFSLVWYIMGPLMNLGFIINQFS
QAKASGERLLEILEAKEDIVEKESAIETTIKGHVEFNDVTLTYIKDDDEALKNISFDAPP
GKTIGLIGATGSGKTSITQLITRFYEPEQGEVLLDGRPVSDYKLKTLRSQIGFVLQEPFL
FSTTIRENISYGNPEVTEDQIVQAAKMAQAHDFIMELPNGYDTLLGERGMGLSGGQKQRI
AIARAICIDPSILILDDATSAVDMQTEFKIQKALREVMKNRTSFIIAHRISSLKHADEIL
VLEDGEIVERGTHDDLVNNNGPYERIFNIQYQDREEILSAVK
>fig|221109.1.peg.1412 Multidrug resistance ABC transporter ATP-binding and permease protein
MAKNKDNLKSESKHLQRFHYTIDQAIEKPFNWQQMWRLLQFLKPYSKTYLPGAVLAMMVS
TAIRLAIPILIGKVAFDVAIANKDTTLLTYLVIGIAVLYSISFVANTFRIKWVNILGQNV
IYDLRQKLFSHVQRLSHRFFDSRSAGSILVRILNDINSLQELFTNGIINLLMDLLMLSGI
LVILFVLSPPLALAVIIIIPLMFLISTTLRRKIRRSWQVVRLHQSRMNSHLNEGIQGMRI
TQSFSQEKENAEFFDGVNSGFFQSFRDAAKKSAMFRPLVDICDAAGTIILISYGAYLILN
GTITVGTFVSFAFFLGMFWEPISRLGQMYNQLLMAMASSERIFEFLDERPNVAEKNNALQ
MEEMRGEIEFDKVEFSYNKDRIALKKLSIHIHAGETIALVGHTGSGKSTIANLISRFYDP
TSGAVKIDGSDLRDVTIDSLRQKISVVLQDTFIFSGTIMENIRFGRPNATDEEVIDAAKV
VGADDFIQRLADGYQTEVEERGNILSAGERQLLSFARALLANPSIIILDEATASIDTESE
VKIQQALKRLLKGRTSIIIAHRLSTIREADNIFVLEQGEVLEQGNHQSLIQQKGKYYELV
KSQFTMLDAM
>fig|221109.1.peg.1709 Multidrug resistance protein
MGKNHTSTAILSLGSIPFITTLGNSTLIPILPEMKEALGISNIQVSLTITLFSIAAAICI
PVAGYLSDRFSRKAIIVPSLVIFGAGGLLAGIGAAFFSSAFIWLLIGRIIQGIGAAGTFP
IAMALIGDLFKGSEQSKMLGIYEASNELGKVLSPIIGAAFALITWYFVFFTFPVISFLCA
ILVFFFIKERRNRQTPPPFYQYVKGLFLVFKQEGRWLFTVYLAGGTCLLTIFGILFYLSD
KLETENHIIGVWKGLILAIPLLILVATSYRTGSRIGKNFVKMKRLAVFGFLLMTLSYLSL
IWIEPLVWFIFALCFSSIGAGLVLPCVNTMIAGAVGKEKRGFITSLYGSVRYIGVALGPL
LFGWLMDWSRTGLFLSVACFTFFVALLVLFLLHVNGMDGRDKRTKITYNYY
>fig|221109.1.peg.2135 Daunorubicin resistance
MISVQNLRKSYKKNVVIDQLSVDINSGDIVGLVGENGAGKSSFLRILATLSKADKGTITW
NDVSYEKETKKLRRDIGFVPQEISIWEDFTVEENMKFFEKLSWVNRSESELKQLCLDMKL
SKWKEPVHTLSGGMKRKLNMAISFIHDPKLLLLDEPTVGIDLKSKKEIGEYLYKQSKEHH
KTIIYTSHDMDEIISLCDWVICIGKDSFYENLLKSRGKEIFTI
>fig|221109.1.peg.3060 Multidrug resistance protein
MWLANFFISGSMTMVVPFISLYIESMGDFSEGYVQTWSGLTFAVTFITAFIFSPIWGRIG
DRYGRKKIMIASAFGIGFSVFLMGFADTVWQLFLLRLFMGIVTGFIPMSQAFIATQTPKE
VAGKVLGTLQTGTITGSLMGPLLGGALADAFGYTSTFKWVAITIFISGLLVLFGVKELKM
KFSNNENDTKKYSRKEVLQHILQKPVLFVVMLLSALVQIAHFSIQPILSLFVAEIHGPVN
LAFFAGIAFSAAGLGNLLMARRWGIIGDNHGYVKILIILLFAAGFVYLPGIFVTNIWQLV
ILRFLLGLSIGGIVPLRIAYIRQEAPLSMQGEVLGYNTSLRFLGNIIGPALGGTIAASFG
FSAVFIITSMLLILSGMIMLYVWYRHEYESTSSHSYSSK
>fig|221109.1.peg.3265 Broad-specificity multidrug efflux pump YkkD
MNWIILILAGLSEVVGVNGIQKVSAGKKKSGFAFLIIGFAVSLTLLSIAMSTIPLGVAYA
VWTGMGTVGSVVIGMIFYNDSADRKRIFFLSLIVVAVIGLRIVSN
>fig|221988.1.peg.741 Fosmidomycin resistance protein
MQNKFAVYLAAIGHLVTDMAQGALPALLPLFIKNYGLTYQEAGGLIFANTVLASIAQPFF
GYLADKRSMPWLIPLGMMLSGCCIAAMGFVHSYPGLFFFAMIAGIGSALFHPEGARLVNR
MSGGEKGKAMGIFAVGGNAGFAIGPMFAGLAYLFGAQTLSIFALINTIIALIIFLQLPKL
TVENVVNKAKNTASTTLQNDWRSFAKLSVIIFVRATNFTVLNAFIPIYWIHILHQQETDA
NFALTIFLSMGVAITFIGGLLSDRLGYVRIIRYAYLIFLPTILIFTQSENLWLSFILLIP
LGLGVFTQYSPIVVLGQTYLAKSVGFAAGITLGLGITMGGIFSPIVGWIADHYGLQIALQ
TLSVLSLLGLIFSYRLKITDTEKPEKK
>fig|221988.1.peg.1644 Permease of the drug/metabolite transporter (DMT) superfamily
MLFQIIATLIWASAFIAAKYTYEMMDPVLMVQCRFFIASIIMLPGFFAAYKRVPKERLKI
MWLLALINFPLMFLLQFIGLYFTSAASAVTMLGMIPLLTVLIGFLFFKRRINKIDLLLSL
VALAGIILTVVGGGEDNLINPWGCLLVLGSAVSFCFCLYLSKDVMQEMAPKDYTNVLVIL
GSILCLPFTCVLVRDWSIVPSVKGMISLFYLGIGCTWLAVVLWFKGVQKTPTYISSILTT
LEPIFGVILAILILDERLSTVSAMGILLTLGAAAVSVLIPVLMKKSP
>fig|221988.1.peg.1645 Permease of the drug/metabolite transporter (DMT) superfamily
MFYLIAAVLIWASAFIAAKFSYTMFDPALTVMLRLILSALLVLPTFFRSYRKIPKQYRLQ
LWGLGLLNFPVVLLLQFTGVHYTSVASAVTMLGTEPLVVTLLGHIFFHKPARLLDWLLGI
VALTGIVFVVYGSESGGEVTLLGCTLVLLGSIAFSFSIHLAQSVMKAVEAKAYTDVIIMT
GAISCVPFSLLLVQDWQIHLNIEGISAILYLSVGCTWLAYRLWSKGLRVSSANTASILTT
LEPVFGVLLAILLLGEHLTLTTLFGICLVISAAGISVLSSMLINYIKNKVTIL
>fig|222891.5.peg.51 Bicyclomycin resistance protein
MNRFLHVVLITFVVFVADVAVEIYVPALPSIGVFFSATAMAVKASISSNILGLALSSLFW
GTVSDLWGRKLALLLGSLVFVVSSVLCIFSASIDALVFFRFLQGIGQGVAVVVGFASVKD
FYSGEKCAQVISKLSSVVAVSPTFAPILGTVILFYFSWHYIFLFLASLGLVCLLLLVFFF
QDTLKERNPASLRGLLNSYIRIATNKSYVLYSAITVITFMWLWNVISSAPFLLLEDMGVT
IQEYGYLVAINVMGFLLGTILNSKYIPKVGLKKLVAFGLALPLLSEVLLILLHYTTGFSP
LILECIWFFSAMGLAFVIGNSTTLALDQVGESNNGKATALLVCSEMALGSLSVYLNAPFY
DGTIVPLSLFTIVSVLASMIVFYYAVRNPGNTVKPAR
>fig|222891.5.peg.146 Multidrug resistance protein D
MDLQMLDFLLERNKAVLVLWFILIAAGLYSCFVISKEQTPNMEIPYILVNAVLTGVSAED
STRFLSKELEDSLRSIEHLKSITSQSVENASSILMEFEVGFDSAKALASIRDKLDQVVSK
LPKDTLRPTVEQVSTALIPAVVVTVSSNLGVEATQMVATKLRDRLNTLANVLSTKIIGKR
KKIVEIMIDPKTFSRYNIGLHNIVNTLHQNNTLILSGSFPSNEYLVSTNGLVTHLNKLKE
LPISLNNGNILTLKDIADVNGVFEREKALSRIGGMDTVVIEVSKAGGKNLLETVKQVQEE
VSKMQATLPEGFSLSTEFDTSTEVKEVLTDLKNSIALTVVMVVAIMVVYIGWKMALMTAF
TVPGSIFIAILLLYVGGFTMNIVVLFSLIMSVGMIVDAAIIVNEYADRKMLMGSSAREAY
TLSARKMFWPVLSSTATTLIVLVPLLFWPGLAGEFMKFLPITLIFTLSASVLMSVVFTPV
IGSMIGTPSTSDPVEISKIFAIDQADPSAMGKISGKYCRLLEKLLDHPKAVVAGISVFLV
LSIGGYYIFGKGLQFLPNVEPKSSTILIKAVENLTLAQKRTIVETAEKTICETPEIKTCY
TKIGTLGNDVIGSVQVEFAHWKKRRKIAAINDDIERRMQSIKGIQFELFTQKDGPIQEKP
IKIVISGTSYGEVAQAAASIEEMLSKINGTKSISDDTSVQKLAWEAVIDRNKAARYGVDV
ATVGQYIALATSGITVGEYRGNDHEEKLDIVLTLPEEGKSVSSILGMMIPSQKGMIQLSS
LMKVKPIAKTTTVKRFNSEPTIHVYSDVQPGFLSHNIVKSLRKEIEKHKELSQLKISFKG
EQQDQSETTRFLVVAFLVSTLCMVLILLLQFNSFCQVLIILTAVALSTGGVTFGLLITHQ
PFIVVMSGIGIISLAGIVVNNNILLIDAYNDYMSESTDKKRSIIRAAISRFRPILLTSGT
TVLGLLPMVFCITINLVDFTISYGAPATQWWQSLATTVAGGLSFTTLLTLILTPALLMLS
PTPKLNTRT
>fig|223926.6.peg.1156 MFS family multidrug transport protein, bicyclomycin resistance protein
MTEKAQSAPQSQISFLLFLVLGAIGALTPLAIDMYLPAMPTIAKDLGVAPGAVQITLTAY
TAGFAIGQLIHGPLADSFGRRPVLILGVLFFGLAAVVSATTNGIDALTYVRTAQGFAGAA
AAVIIQAVVRDMFDREDFARAMSFVTLVITIAPLVAPMIGGHLAIWFGWRSIFWVLAIFA
VVVILLVFWKIPETLKPENRQPLRFRTTLKNYARLCSSSEALGLMLSGAFSFSGMFAFLT
AGSFVYIDLYGVRPDQFGYLFGLNIVAMIIMTSINGRLVKKVGSHAMLRFGLFVQLLAGI
GLFVSWLMDFGLWGIVPFVVLFIGTLSTIGSNAMALLLSGYPSMAGTASSLAGTLRFGIG
SLVGALVASLPGNVAWPMIIVMFACSVLSALFYWTLGRKA
>fig|223926.6.peg.1682 Permease of the drug/metabolite transporter (DMT) superfamily
MNILLAMIPAFFWGTTYAVTQFTLPDWPPVLLGALRALPAGLLLLAIKPSLPKKHEWKVL
LVLGTINIAFFFGLIFVMALTLPSAISGVGMISVPVFAMLFGWAVYKRQPSAIQGISGAV
LIALAWFLFDPSSISLNPIGLGAMLAAIMCIVIGSSVTKSLGTKMHWWTVLTWQLILGGV
LLSIAAAVLATINPQPYVHAVQNIDMTNTLGLLWVIVLNTALGYGMYVWLLQRMSVVDFT
FGGIANPIAGIVSGLLLLGENFTPLQYSLMVGMIVMSLLPQILTSLRARKEAITV
>fig|223926.6.peg.1901 Multidrug resistance efflux pump
MTADQKFKHWMRTLIVLFIVLFLYIIIADRHAPLTTEGRVQGYVVQVAPEVSGKVTDVLI
ENNQSVQKGDVLFTIDDRKYKIALEQAELSLQSAYEKEATLYSQREAALANIARAQATFD
NAHREYTRLLTLSKQKVISQSTLDNAFAQNQVSRAALKAERQNLKVIEAQLGDQKGQSTA
VRIAKNGIEKAQLDLANTAVLAPSDGVVTNLQLEVGTMANTNMPLLTFVPTGSLWVAADF
REKSVANVDKTFHALVTFDANPGSVYDFDLASRDYGVAAAQQTPNGALTKVEVNNRWVRD
AQRTRVNLTSSEELPPALFVGSRATIVLYPDNSIFWQLMAQAQIHLASWFHFIY
>fig|223926.6.peg.2350 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MQNSIYKQFWKYTIPTVAAMLVNGLYQVVDGIFIGRYVGADGLAGINVAWPVIGSILGIG
MMVGVGTGALTSIKQGEQDQQGAKRVLTTGLLFLLALMPIVATILFFFADDFIRWQGAQE
RVYELGLQYLQILIVACIFSLGSIAVPFLLRNDNSPNLATILMVIGAIINIVLDYVFIAW
MNWELTGAAIATALAQMVVTVLGVGYFFSSKAKLRLTFRELKVQLDAIPKIVLIGTSSFF
MYAYGSTMVALHNALFAQYGSPLLIGAYAILGYIVTVYYLVAEGIANGMQPLVSYNHGAR
NQDNIRKLLQIAMGTSVLGGVVFVVLMNLFPYQLVSVFNDADQQLIESAVMGIRLHMFAL
FMDGFLVVAGAYYQSVNKGSKAMFVTVGNMLIQLPFLFIMPKLLGVTGIWIAFPLSNIAL
SLVVMSMLWRDIKKLMVDSPVEPSIQAS
>fig|223926.6.peg.2719 Permease of the drug/metabolite transporter (DMT) superfamily
MGYEWLALCAAFLWAVSSLISVIPAQHLGAFSYSRWRMGCTAVILSTMAWITGGWLSVSW
EHITPMMASGLIGIFIGDTALFACLNRMGPRQAGLLFSCHAVFSTILGYFLFSESMTAIE
LLGSALVFSGVVMAIFFGRRGQTNNVLEEIKGNIWVGVSLGLTAAICQALGGIIAKPVMQ
TSVDPIAASAIRMISAFVAHCLLLIVGVKVARSTQRITWRVFGITALNGFLAMAVGMTLI
LYALREGNVGMVALLSSTTPIMLLPLLWVYTKRRPNRFAWLGAALAVIGAGILVQ
>fig|223926.6.peg.2746 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MFNMLEKNKPENHATDKHGLLSAPIPETLRKMTVPMTMGMIAILMFNLVDTFFISLLGTH
ALAAISYTFPVTFAVNCITMGIGMGLSTNIGRLLGQGHAPQAARFTTHGLLLAVLLVAIA
SSIGFATIAPLFRFLGATDDLIPLIEQYMQVWYLTIPLLVIPMAGNSAIRATGDTKTPAK
IMMLAGLINGMLDPLLIFGYGPFPELGIQGAAIASAFSWLGALCGSFYVLVKREKLLAQP
QWASLKQDWQQTLKIGTPAALSNAMNPLSGAILMMLLSSHGTAAVAAYGAAQRIESILIL
VLMSLTSALTPFMAQNLGAKNPQRAFSGLFLSMRFAVVFQGFIFLMMVPLSIPLAALFSQ
EETVKNLLWHYLLVVPFSYGFQGIVMMLVSGLNAMHKPLRAFQWSFMRLFVFTLPAAWVG
SQVYSIEGLFIGIALGNTLGGLLGYMFALRERKLTLIEQNSAS
>fig|223926.6.peg.2902 Multidrug resistance transporter, Bcr/CflA family
MSSHISNSKKQMALLTLLVLFSPLAIDIYLPALPLIASTFQVDNALAQDTITWFLFAMGV
GQLFAGPLADKLGRRTVALGGITIYAMSALLAWSAQNIEWMLMSRLLQGLGACATSVAAF
ATVRDIFGPEKSGKMISYLNGAICFIPALAPILGSWLTQQFDWRANFSFMAGFAVVSGTL
MFLMMKETNPATEKQAVFKVSRYWSVLSTPSFIFHASLCLMAMAVILAYVTSAPSVLMTG
MGLSMNEFTFWFGINAVINIAGCMLAPKFMERFGTHNTLVVGISTLALAGVVMLVMNGQN
TALSFMLPIFMSSVGFALILGGAAGKALEPFGDKAGTAAALLGLFQMSGSGLLVGTLQRL
PFDPQTLIAIHMWVLLPALVILFSKAGKSWHARFANA
>fig|223926.6.peg.2950 Multidrug resistance protein
MLGFVATDMYLPAFKAMEIDFATGPEQIALSLTVFLVGMAFGQLMWGLASDKFGHRNTLA
AGLVLFTIASFGLAFCDEVWQLLTLRFVQAIGVCAPAVIWQAMVIKRYSSSSQQIFATIM
PLVALSPALAPQLGVVLADSFGWHSIFIALTLVGVVLVAATMAQKNEQAEIKQTSMSADI
KALLGSKTYLGNVFMFATASAAFFAYLTGMPEIMAQLGYEAKDIGLSFIPQTIAFMAGGY
LGKVGVRKFGDEKVLRQLIGLFSVAALLIFVASQWELTSIWPILAPFCLIAVANGALYPI
VVNRALASAHQSPATAAGLQNSLQITVSSLSSALVAAMASQAQMVTGVAIVICMGGLWMG
YILSNRELSKHFTTPDNARVVSEDEL
>fig|223926.6.peg.3057 Multidrug resistance protein A
MYWSWQYSDSHPSTEDAYVRAKILSVAPQVKGQVVSVDVKDFQSVNKGDLLLKIDSRPYL
LAVKQAKAAYQLAVQQHDVADKQVTEAVAGLDAARSNLTEAQVEYKRTDSLVKRKLASDQ
DLDTAKNKLANAQASLEQARATVEKAIANRGEEGAEAAVVQQAAAQLAQAELNLSYTDIT
SPVDGIAGEINTHVGSVVSVGQTLFPVILKDSYWVRANFKETDLTHIKPGMHADVVIDMY
PDVVWKATVEQLSPASGTSFSLMPPENATGNWVKIKQRFPVRLALEVPADAPQLRVGASS
EVTIDLQSSVQ
>fig|223926.6.peg.3079 Permease of the drug/metabolite transporter (DMT) superfamily
MLIRAIPFVFVILWASGFVGARFGLQYAEPATLLSIRMAFNVLLFLVLVAVLRRRLPTGT
DFWHSCVVGALIHGFYLGGTYFAIALGMPAGLSSLLVGIQPILTAALLVAFVREEFKPSQ
WLGLALGFVGIAMVLMGKMEWQSEQHKVLAIGLCLLALVGITLGTLYQKKHCQQVDMVGG
ATVQYLAALIMFLPVAMQFETMQVQWELEFILTVLWLVVVLSCVAILLLLYMVRNGASSS
VASVFYLVPPTTAIQAWLAFGESFDWMGISGFVLAATAVYLVVKKPDLTIKKAIKTEYT
>fig|223926.6.peg.3126 Multidrug resistance protein D
MYVPSIGHMAGEFLVSASSLQAVMACYLIPYGLSQFAYGTLSDRLGRKPIIIVGLLIYIL
GTLVALFAHQFEWFLAGSFIQGLGIGCGGAMSRTLTRDCFEGAELHRANSLISMCVIFSP
LMAPVLGGYLTEAFGWRSSYLFLALFGIAVVITMMTSMMETLPKEKRKFEPVAKSYKHVL
SDRRFQGFLICLVATFAGVGVFEAAAGVLLGGVLALPATTVSLLFILPIPGYLVGAGLSS
YIAQRRSERRALNVGLVSIFIGSAVVLIPGLFGVTTALTLIGGATIYFLGAGILFPAATT
GAIAPFPYHAGTAGATLGGMQNLGAGIATLLASLFPAHNQMPLGVLMMAMSIVAMLGLLW
VHRAHDHSNEMPQVI
>fig|223926.6.peg.3196 Permease of the drug/metabolite transporter (DMT) superfamily
MDFLAIALVVFSAVLHAGWNILGKSHSGSGVAFTMAASLSACGVLTPYLIWYLTTLGWTS
LPVEFWGMLAFSGIAQIVYLVGLIMAYKHADVGVIYPIARALPVMMVGGFSVALGHALSS
QQWLGFVLITFGCILVPLTHVRQVSLVAYLNVGVFWALIAAIGTTGYSVVDKEALTLLTQ
QASTIFNDQYSAIFYLGAQFWAMGLPVLLWCLITRNDQELQAAWRIRKSASMAGIMMAST
YGLVLFAMTMTDNVSLVVALRQISIVFGLLMGIWLLAEKWYLTRGIGVAFILAGIVLSLE
GA
>fig|223926.6.peg.3265 Permease of the drug/metabolite transporter (DMT) superfamily
MKVTSVGAAMLLLIVGNLIAVLSDSLIKSVANEVPMFQFVFFRQISAVMFLLPVCLLAKQ
TNFMEGFKWHAVRAHVWLLGAVFMVMAISSLPLATANAIFYAAPLIMLPLAAIFFGEQLS
KQSVAAAVMGFAGVLVIIRPDQIDWAAISAFVVALTLAINNLLIRKLPKNQSVMQTLLMT
NLAGIPVALLLVLIEDQPWQWGAFPVAAGSSLFIMIYAATCVLAYRSIDSNKIASAEYSG
LIGAVVVGFIWFGEIPDIFMAIGTVMIVVPLIWLSKRERRKQKEHAQLQAQKEHEQQQAH
VA
>fig|223926.6.peg.3308 Acriflavin resistance protein
MINLAEFAIRQRKFVLFFIVLSVIAGIYSYFDLGKLEDPSFTVKTAVVVTLYPGASAEEV
EHQVTDTVETKLQEMAELDRLRSLSRPGLSMVFVDLKESLNSKALPQEWDLLRRKVDDVK
LQLPSSAQISVVQDEFSEVYGMLFSIHSTDAAPEELRRYAEELQRQIKAVDGIKKIELHG
VQPRVVHIDMPDERLAQYGLSIAQVWNQLSTQNSTFEAGKFDAGTERIRIAQTSEFQSLE
DIRNLIINGGTGEFGSGLIRLGDIADITMGYQTPALAENRYNGEPAVTLAVSPVQGINVV
SLGDTIQDIIANYQASLPLGVDISTVAYQPEEVQKSIDDFVGNLLESVAIVFVVLLVFMG
FKSATIVGASLLLTILLTLVYMNIASIDLHRVSLGTFILALGMLVDNAIVITDMMIAKLN
KGIERTRAAIDSVKETAVPLLGATVIAIMGASPVLFSKTDSAEFASSVFYIVASSLLLSW
IVAMTFTVLMAWMFIKPKANNEETKPSRYKQLVFWTVDNPRKALAALVPLILVTAVAIPY
VAVNFIPQSDRSIVFLDYWLPNGAKIEQTSADMRKVEEWLVAQPEVESISSYVGTSAPRF
SVTVEPEPLDPAYGQILINTKDYESISHLVTRGDDWLKEAFPDAEPRFRALKLATKDKFA
VEVRFSGPDETVLHQLAAEAKTIFASNPDAKYIRDDWRQESKVLKPILNQDKMRQAGINR
ADVAFALKRASDGMPLGQMNLNDELIPIQLRGTSQNMASLETLPVRSLLGFNSVPLGQVV
DGFELVTEESMIWRRDRVKTITVQAGVSRDSTPANVRNAIKDQVEAIQLPAGYSMEWGGE
YYDEDKAVTDIMKQQPKAMLIMVIILVAMFNGFKQPIIILATLPLAASGAVFALLGFDKP
FGFMALIGAITLTGMIIKNGIVLMDQIELERTNGKSLSDAIKEATVNRTMAISMGALTTA
LGMIPLLSDLLFDQMAATIIGGLAAATILSLFVMPALYRLVYKEKAPSTQTNAELEEASS
>fig|223926.6.peg.3346 Permease of the drug/metabolite transporter (DMT) superfamily
MVYLLPFFTVMIWGGNSIVNKMAASTIEPSAMSFYRWFVAMVLLTPFCLPAVIKQRHVIR
PYLTKLAFLALLGMVLNQSLGYYAGLTTTASNMALITSLVPLISVFLSVPLLGKSVSMLS
IVGGVISLGGLAFMLGHGDVTYFLHQDMTQGDSLMLLAALVYAAYCVLLKRWKMPFNSLT
LVYMQGFFSVIMLTPLWLSSEQLLPSQEALPLIAYAGIAASIFAPLMWVKAIDLIGADSS
AMFMNLMPVVSVALASTLLGEEIHVYHIIGGLMVISGVILSQIKVRKKQDLVVSESLTTT
TR
>fig|223926.6.peg.3463 Multidrug resistance protein D
MRKTPLLLAMMIIATGQVGVSIYLPSLPLIGHDLNLPQPSIQSLVTLFLVGFGVSQLFYG
PLSDAIGRRPVFILGQSICLIGTVICIVFGDNISALEAGRLLQGLGAGSASVLGRSVLRD
SYDGMQLTKALSYISVTASVMPIVAPLFGGWIAYHFSWQAVFVFVLLYLLAIFILGYLVL
PETLPYPKRKFEVRQVMVNYFYLLTNKQVIGSASYNWLSYLSGLVTLSLYPFLMQQELGL
TAADYGSLMIIPSAGLLMGSLVLNLINNRYKAQQILLMSFAIVALSGCLLLVTPFTVASL
LVAFTCLSFAQGMSFPVSISLLLSPHKQQAGAVSALSGSIQMCLAGLFGGYLVEKWVTDQ
HQLGIFYLFIALISCIVLVVSQYRRAPRQTAQPEASS
>fig|223926.6.peg.3509 Permease of the drug/metabolite transporter (DMT) superfamily
MLYSLSSIFLLIVVGIPKLSYFSPKYLIVGGAMFVCYEIFLALALGYSNSRAQAIEVSIV
NYLWPALTVLFAVLGSNKKPNWLLYPAVTLAFIGVAWTVSGDNGLSPTQIISNVSSNPLV
YFMAFTGAVIWAVYCNLTQRQQSKHNAITLFFIATAVSLWVKYAFADEPTMTFSWSALGY
LFASAALMAGGYGLWNIAIVGGNMVFLATLSYFTPIFSALFSSLILGVTLSNSFWQGVVM
VTVGSLLCWLVTKEKREAAG
>fig|223926.6.peg.3552 Permease of the drug/metabolite transporter (DMT) superfamily
MFNSERKATVILVATTMIAALGWIFSKETIQGLPPFGFIGLRFTIASLCLLPLCFRPLKA
ARLKDVLAASGVGLLLGGAVMTWIYAISISDTLGEGAFIMSLSMLFVPIVAWVMFQQRPQ
RIFWISLPIAVIGLACLSLAGGWKQSASQLWFLGAALILALHFNVNSKYSQKLPVLLLTC
VQLFSAGCLGLLVSFLMESRPEQVDSSIWWWFALSTLLATSLRYVMQTMGQKFVQAGNAA
LIMILEPVWTVVLSILWYGEVLTANKLVGCLLILFSLVIYRTGGRFRFPKRA
>fig|223926.6.peg.4143 Permease of the drug/metabolite transporter (DMT) superfamily
MILGYAAILVTVLLWSGFFISLKGGAISALQPADIALVRFLVPSLILLPFVMKHKAALKV
VPNKYLTGIVLGSGLPYLLVAGTAMHFAPVAHGSALIPGTLPLFVSAIAVLFYQQSLSHH
RIIGLSTVLLGIFVFLLSNIGEEYNWSQLQGHAMFLVGSLMWAVFTISARVANLNAYVCA
GFVAIVSLLMLIIAVGFGWIDSYLAVTPISSWPWEELFSHAMLQGVGAGLIASFTFIYAI
KIIGAEASAAFGSLTPVVATLLAVPIFGEQPDSLTWIALILVTCGSVVASQIFMKHELTQ
TYRPPLHR
>fig|223926.6.peg.4155 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MPSTSTNAQPTLAKQLFTMTWPMLFGVLSLMSFQLVDSAFIGQLGVLPLAAQGFTLPLQM
VIIGIQVGLGIATTAVISKALGANDARYAKQLGGLVLMIGSIGVAVFGLLIWLLRYPILS
LLSAPETVMPIIDSYWPWWLLSSWAGAVLYFYYSICRANGNTMLPGTMMMVTSGVNLVLD
PLFIFTLDLGINGAALATLVAFGFGILVVAPRVKRNHWATTQWQDLNVMKSVTSIGNIMG
PAMVSQLLPPLSSMLATKLLASFGTAAVAAWALGSRYEFFAIVSVLALTMSMPPMVGRLL
GAKNYRDIQSLVGIAVKFILGFQLLIAAITFLLANPLALLMTSDTQVEQVLHMHLMIVPI
SLGSLGVCMLMVSICNALGKSYTALTISALRLFVFFLPCLWLGAQLDGIRGLLFGACVGN
IMAGISAYLTYRKTIHKLAIKQATA
>fig|223926.6.peg.4452 Permease of the drug/metabolite transporter (DMT) superfamily
MNHVHKPIVFMLMSTLSLSVTGLLAKQLSEALSVTMFSFLRFFLPAVILLLVLIPKGIKL
PKSTELKPTLLRALCIGLSQLCFIASLQTLTLVESVVLFATGPLFMPVIEKLVWHGKIRA
SIVFGIVMAFSGVVLLAGTEGEFTLRYDLLLGLAGGLFNSGSQLTLYKVSKSNMSPLEIN
FWAFSFAALFILPLALINDGSGLLGAHSFSLSVEPSVLWLLVMSMLIINTQVFRAKAYQL
ASSGSQLAPLIFTNLLFTAVWQSLFFADVMSRTQIAGMGLIVLATVLNGCWDVLVKHHQS
KALQTRTS
>fig|223926.6.peg.4497 Permease of the drug/metabolite transporter (DMT) superfamily
MSTFLLTAITMLAFAANSLLCRLALAEGLIDAGSFTLVRLISGAITLIALLVVRGQWKTD
RPTSRFRFFAGVALFGYAALFSFAYLQLATGTGALLLFGAVQLTLLVIYWWQGERFQFLE
IIGIGLSIVGFVWLMLPSTTRPDISSALLMLISGVCWAAFTALGKQAPSPSSGITWGFIA
ASMIGILLSPLMLSSIHLSLSGILLAITSGAIASGLGYTLWYQVMRKLSLLQAAVSQLSV
PAIALLLGTVVLHESLSLHTLLTSGIILGGIALVFLSRSKKTSKQLASR
>fig|223926.6.peg.4499 Outer membrane component of tripartite multidrug resistance system
MMLPKLTKPSLAILSLLGLSACTTVGPDYVHPPQTPLPSDWSVQKAAKDTQQSEQQLQQW
WQQFNDPTLNRLVELANEQNLDIEAAGLRIVQARSLLGISTGLQYPQVQTVSGNLARAYV
NDQGVNNAALSFDAAWEMDIWGKYARGIESAEAGYYASIASYHDIMVTITAEVARNYINY
RTFQERILLSRRNIEIQERVVHITQVQFDSGNVTELDVQQAKNQLYTTKAAQPSLEVAMK
QSRTALALLLGVLPEEVEKLLQSDGLTQQIADYEAQFKSTGRKSALSGTDEHSIVPRPPL
LDTQVDANLVMRRPDLQVSEMQARAQSAQIGVAETALYPSFSLFGSIGIDSTVPDGSSFS
FSDSLTMVVGPTFSWNIFQYGRVKNNIRFEDARFQETLTNYNKKVLQAVNEVTNAIEAYD
LYLQQKDLRLQSVNSSIRAFNISMTQYENGQISFERLLNSVEKMTRAEDSYAQIKGNVAN
QVIALYKALGGGWQAQTGKPFLEESIAKQMQDRTDWDGYLDEENRTLPPLPIETPTENGD
KNKTEDL
>fig|223926.6.peg.4501 Fusaric acid resistance protein fusE
MKKLFVIALNLVILGGAAWLGYQKFEEYFNNPWTRDGQVRANVIKVAPRVSGPIVNVSVQ
DNQEVKTGDLLFEIDPTTYEVALSQAEVALEKSIVSSRGKKIEYDRLKDIRAKDRGAVSH
KDLIRREIAYEESLLQIKSAEEQLKSARLNLSFTKVYATVDGFVSNLDIRNGTQAVANQP
LLALIDKNSFWVFGFFRENQLAQIEPGSRARVTLMSHPDTPIDATVDSIGWGIAPKDGTV
GYNLLPNVNPVFQWIRLAQRIPVRISIQELPEDVDLRFGLSASIMVMKDSSAENEQ
>fig|223926.6.peg.4566 Multidrug resistance protein D
MNRPINFRTILLACLIISVGQLSMGLVMPSLPWIAKDFSVSLDQAQLLVSIYLLGFGPSQ
FIYGPMSDALGRKKVLLAGLLIAMSGLLMIIFWSHTFTGMVLGRFLQGLGTGCCAVLARA
STRDQFSGNELPVAMSYIAMAASITPLIAPVIGGFINFHFGWSMVFISLLGYVSLAWIII
AFRFKETITRRSAIPSPAKMLVQYRDLLSSRYFMSFASISWLNFSLMITTVSVMPFIMQD
QIGMTSDEYAMWALIPALGMLGGTTICNRIRPVIGNKKMLLCTPVLHISAALWLFFCPVE
PLYLMIGQLLMILGNGIALPCAQALVMQPYKEQAGAAAAMSGGGQMVVSSLVSMTLVQLG
LSEAWHLSLVVVLFTAITLTNILRGFNTEEAQQHREVAEKAS
>fig|224308.1.peg.189 Chloramphenicol resistance protein
MSNTWKIYILAIVSFLVGTSEYIISGILDQIAHTLGITLAAAGQLITIFSLVYALSTPVL
MALTASMDRRKLMMYALGLFVFGNVLAFVLPGYGWFIAARIIMAMGAGVVVVTALTIAAK
IASEGKQGSAIATVVMGFTASLIIGVPLGRMIAVALGWKSVFGAIALLGLIAMVVIFFTL
PYTEGDKPVPLLQQLALFKKRKVAMGLSITFFWLGGYSVAYTYLSPYLLNISGINGKLLS
GVLLIFGIASLVGSKFGGYSTDKWGVPFTLVGGMTLHIVTLILLSLVTHSYIGVLVILIL
WSFAAWSTGPTQQFHLATIEPEMSGVLLSMNQSMMQFAMAVGAGIGGVFVENVSLASITW
VGALGVMIAIIASLLIFNSQPKQALKDINQ
>fig|224308.1.peg.255 Permeases of the drug/metabolite transporter (DMT) superfamily
MRAEEQSKIREAAAGTIFLLIGTVCFASKSIWIKWAYQMGAEPDAVLLYRQLLAVPLFWL
IFLIYRPPMPDGKKKGDLWKACGAGVFCFFLSPLLDFIGLNHVSAMVERILLMSYPLFVF
GFTACRDRKMSSIQDLFAVLAVMFGLFLALGGWNAELFQANMIGAVFILLSSAVYAGYLV
LSGHLVHQIGGIRLNAYGMTAAGAAMMLYTGIKSAAGMNTPMAAYPLSMYGLFAVIAVVT
TVIPFVLMLEGIKRIGAQRAAAISMAGPILTIFYGALFLGERLGLIQVIGCGGVFFVITG
MEYRKLKTGKKE
>fig|224308.1.peg.315 TmrB protein, responsible for tunicamycin resistance
MIIWINGAFGSGKTQTAFELHRRLNPSYVYDPQKMGFALRSMVPQEIAKDDFQSYPLWRA
FNYSLLASLTDTYRGILIVPMTIVHPEYFNEIIGRLRQEGRIVHHFTLMASKETLLKRLR
TRAEGKNSWAAKQIDRCVEGLSSPIFEDHIQTDNLSIQDVAENIAARAELPLDPDTRGSL
RRFADRLMVKLNHIRIK
>fig|224308.1.peg.721 Permeases of the drug/metabolite transporter (DMT) superfamily
MKKRLSLDRRFLPYIKKAGGVLVKKQMGAYVSLAAAMAIVGSSVVVGKLMVERIPVFLSS
GLRFLIASVVLLMLLFCIEKGFPALTKKDVFVLLVQSFTGVFLFSICLLYGVQYTTGTES
GILTSTTPMLIGILSFFLLREKIEKKTLIGILLAVCGVMAINLFGAGSQDGTPHALFGNM
LIIAAVIGEALFTLMAKLLSPHISALAISTFVSLFGFLFFLPFALFEASSFDYSVPTVLD
WSYVLYYALFVTVLAFYLWYSGVTKVPAGVSGIFTSVLPVSAVILSGVILKEPFEFVHFI
GIACVIGGIFVTVIKKKQPDAYPAAEEKTL
>fig|224308.1.peg.821 Multidrug resistance ABC transporter ATP-binding and permease protein
MQKALSFLKPYSLLAGIALILMLTELAVELMQPLLIAKIIDDGILKQDLRHVWIWGTVMI
GLTVLSFAAGMLNSFYAAHVSQSFSYDTRKGLFQKIQSFSYSTFGQFSSSSYITRLTNDV
TQVQNMIFMSLRFMLRAPLMIAGGIVLSLAVNVKLGFFLLVTIPILILFLLWVLRKGGAL
FRSVQKRLDQVNTIMQENLIAIKLIKALLRGSHEVKRFIKANTRLMEKTVSAFQLVEFTM
PVLMLLMNLCILLILWAGSYSITSGSTQVGDVVAIINYATRITGALSMFPFLIMIFTRAK
ASGDRIGEVLETEGDEREEGTISDRLSGRIEFQHVSFRYPEMDREALRNVSFSAKPRETI
AILGATGSGKSTLFQLIPRLYQPDSGRIYIDEKPVQDIPAEGLRRQIGYVPQEVLLFSGT
IKENIAWGKENASLDEIMDAAKLAQIHETILKLPNGYDTVLGQRGVNLSGGQKQRISIAR
ALIRKPAILLLDDSTSALDLQTEAKLLEAISTYHCTTLIITQKITTAMKADQILLLEDGE
LIEKGTHSELLSESQLYKRIYESQFGREGSESC
>fig|224308.1.peg.822 Multidrug resistance ABC transporter ATP-binding and permease protein
MLKDIRKPFQYPKLPIDKKEGAKKRAKAKDTKGTLRRIWSYLAERKGLLILVMLMVVISA
IFGLLGPFVIGKAIDHFIVGKTVSGLIPVLLLLLAIYIIQSLSLWFQNYWMITISQGTVF
RMRSELFTHLHELPIPFFDKQRHGELMSRVTNDIENVSSTLNTSVIQILSSVITFVGTIA
VMLYMSPLLTLITLTIIPVMAASLKWITNRTGKLFKEQQKNLGDLNGYIEESVSGAKVIK
AYSREKQITAEFLEKNAALKTSGFWAQTISGFIPKVMNSLNNLSFTMIAAIGGLFALKGW
ISIGSIVVFAEYSRQFTRPLNDLANQFNTMLSAIAGAERVFDVLDEKEEREDEKNAVHQP
IQTGSIEFRDVSFGYDKGQQTLKHLQFTVPAGQSIAFVGPTGAGKTTVTNLLARFYEPND
GKILIDGTDIKTLTRASLRKNMGFVLQDSFLFQGTIRENIRYGRLDASDQEVEAAAKTAN
AHSFIERLPKGYDTVLTQNGSGISQGQKQLISIARAVLADPVLLILDEATSNIDTVTEVN
IQEALARLMEGRTSVIIAHRLNTIQRADQIVVLKNGEMIEKGSHDELIRQKGFYSDLYES
QFEK
>fig|224308.1.peg.840 Drug resistance transporter, EmrB/QacA family
MSEALTEQKSQKWAISLFTIGVFMAALDNGIISAALTTINESFSVSPSWGSWGITLYTLG
LSVSVPIVGKLSDRYGRKKLFLIEVCLFGLGSLLVALSQSFPLFLISRLIQALGGGGIFI
IGSSHILATLPKEKQGKALGLLGAMNGMAAVLGPNIGSFLLDWTGSWHWLFLINLPIAVL
LVVFGACFIAETKAPEAKRLDAAGIFLLSLSILAVMYGMTNLDGANLLHSLGNPEVYGCI
IFGILCFAALISYEKRVEMRGGDPILAYSLLRNHMFQRTLIIGLLSGGLLAAVIFIPSYV
EQYLGVPAAKAGYWMTPLALASGIGAWLGGALTDKKGPVKTVILSGIISCAGFALFPLWV
TEKWEFVIASVAAGIGFGFLLGAPLNVLVSEAAKTNKGTALGTLSLVRQIGLTLAPTLYA
GFITAGFDQIGDEINSRLSDSGYSEKAMQMIPEIDSSEVSSLQEQIERIPVPEVKTAISD
AIHASVASGYDHLYAAAAVVSLLVIAAISIPAFRRQKR
>fig|224308.1.peg.901 Membrane component of multidrug resistance system
MATGKEKNAKNPMSLLIVLMAGLFLAILNQTLLNVAMPHLMTEFGVSATTIQWLTTGYML
VNGVLIPLSAFLITRFGQRSLFLVAMFCFTLGTLVCGIAPNFSTMLIGRLIQAVGGGILQ
PLVMTTILLIFPPESRGKGMGIFGLAMMFAPAVGPTLSGWIIEHYTWRIMFYGLVPIGAI
VIIVAFFIFKNMVEPQKIKLDTLGAILSIVGFASLLYGVSEAGSDGWTDPIVLSTVIIGA
IAIVAFVVQQLRHDDPMLDFRVFKYDIFSLSSVINIIITVALYTGMFLLPIYLQNLVGFT
ALQSGLLLLPGAIVMLIMSPISGILFDKFGPRPLAIIGLLVTVVTTYQYTQLTIDTPYTH
IMLIYSIRAFGMSLLMMPVMTAGMNQLPARLNSHGTAMSNTLRQISGSIGTSLITTIYTN
RTTFHYSQIADKTSTADPNFLHAFQNAVSNLMVNMNVSYDTAKTYVYSHIYKHASLDSNV
MGINDAFMWATLFCVAGLILSIFLRDVRKDKLRKKKKEELSLLPAPKEAKES
>fig|224308.1.peg.1119 Multidrug resistance protein B
MFFASSLIFPFYILFVKNIGSSYTQFGFSYGLFGLSGALIYPLLGRLSERFDSRYFLLLN
SWGMAVLLLYVPHIGSVVQVYIVQVLLGLFGAMQKHGEKVLIANFTDSGERGKKIGNYHF
WTAVFSAAAIMLGGFLADFFTVQMIFYASSILYFLSGLMMMKTG
>fig|224308.1.peg.1686 Multidrug resistance protein
MVAGFIRSSLSGVSLCFWLFGVLFYLSDTLENKYAIDGVAKGGLLAIPLLFLSTSSFIAG
KKIGKDKGRMKFCVVTGMILLTLSFIALWWNHSFYFLFVFLSFGGIGIGMALPALDALIT
EGIESEQCGTISSFYNSMRFIGVALGPPVFAALMSNANWIIFILSAFCSIVSLFLVLFTV
DAKKSEEEKNLGTV
>fig|224308.1.peg.1733 Multidrug resistance protein EbrB
MRGLLYLALAIVSEVFGSTMLKLSEGFTQAWPIAGVIVGFLSAFTFLSFSLKTIDLSSAY
ATWSGVGTALTAIVGFLLFGETISLKGVFGLTLVIAGVVVLNQSKAHAEDKKQTACE
>fig|224308.1.peg.1734 Small multidrug resistance protein
MLIGYIFLTIAICSESIGAAMLKVSDGFKKWKPSALVVIGYSLAFYMLSLTLNHIPLSLS
YATWSGAGTVLTTVIGVKWFKEDLNAKGLIGILLLLSGVVLLNWP
>fig|224308.1.peg.1880 Permease of the drug/metabolite transporter (DMT) superfamily
MVKVMLGIISVTLIWGYTWVAMKVGIHDIPPLLFSGLRLFIGAVPLFLILFIQRKKLSIQ
KEHLKSYIIMSLLMGLGYMGILTYGMQFVDSGKTSVLVYTMPIFVTVISHFSLNEKMNVY
KTMGLVCGLFGLLFIFGKEMLNIDQSALFGELCVLVAALSWGIANVFSKLQFKHIDIIHM
NAWHLMMGAVMLLVFSFIFEAVPSAEWTYQAVWSLLFNGLLSTGFTFVVWFWVLNQIQAS
KASMALMFVPVLALFFGWLQLHEQITINIILGALLICCGIFMNTFTFSRRKV
>fig|224308.1.peg.2378 Multidrug resistance protein B
MKKWKDIHPISWTIIIGTIFGRMATSMSIPFLAIYLTAVQGASASYAGLVIAASSSVGIL
ASFYGGYISDKFGRKNMMLVSIFGWMLVFAGFAAASNLWVFFVVNALNGLCKSLFEPASK
ALLSDMTEEKTRLLVFNLRYAAINIGVVFGPVLGLYFGSSQSTTPFLVPAVIYGLYGIVL
ALQFKKHPSLSAPAQSRNMSVREAFMVTQKDYLFTIALVGITLCTFGYSQFSSTFPQYMA
QNPLIGNGTKLYGLMLTLNAIVVLATQFPIVHFAKRFSPLCSLMLGNVMVSISMAIFTVS
HGVPSIVMIVITFTIGEVLLFSMMDLYVDQIAKPGLKGTYFGAIGFPQLGNVIGPWVGGI
CIDLFGAGRPIYIFSVLSGITLLGLPFLAFAYRQMKMETTKHRSRLEKPL
>fig|224308.1.peg.2406 Transcriptional activator BmrR for multidrug resistance transporter
MKESYYSIGEVSKLANVSIKALRYYDKIDLFKPAYVDPDTSYRYYTDSQLIHLDLIKSLK
YIGTPLEEMKKAQGLRDGRTVCFLYRAGEANQGEIRLFISPGANHFIGEKADETADGISR
RLGEVFVLDEEEIRIIQTEAEGIGPENVLNASYSKLKKFIESADGFTNNSYGATFSFQPY
TSIDEMTYRHIFTPVLTNKQISSITPDMEITTIPKGRYACIAYNFSPEHYFLNLQKLIKY
IADRQLTVVSDVYELIIPIHYSPKKQEEYRVEMKIRIAE
>fig|224308.1.peg.3116 Multidrug resistance protein
MKTKHYWVISLLAVLAVGPGLMSNTALSSVQGLVQKTVGTSVFTSVNPILIGNMAFALLV
PAGPLLRKKFGARPVYLASLPVFILGSLLIACSGDIALMAAGRFLQGAATGVMLMIMIPM
LVLSFPIERRNYALLVLIGGFYGSVIIGTILGTIATSCGHWRWLFFIFGTLSLIGVAVSY
FFLHDEHHGAADQEQPLDRAGILLSVFLAAASAVSFIFLQKWGLSSGYVWIGFGVTLCLL
IGLLIVEYKVKNPFISIKLMLLPKPVLGLLIIAAGTITVAVSLSAFQGLLRQMYDISQEH
LILLSLTLLIGVAIAAILSALLYDKVGPGMLGIIGGLILVFVNFQWLHIQDRSSLYMFAA
LFIMLAAGTGLTVAAGLMGAAMGGPLPDLVKRMTAVQFLRLFVYMGVPILIGFFTKKDAA
RQSGSVQDSMMTAYHDLFFISFILSVLLVCLSFCMNATGMGHKLAHKPHDKAKTAPEKPA
VSAQGLSKATVKSYKVINDTEYRNALRNLQK
>fig|224308.1.peg.3391 Multiple antibiotic resistance protein MarC
MMFSFIVHVFISLFAVSNPIGNVPIFLTLTEGYTAAERKAIARKAAILSFFILAAFLVFG
HLIFKLFDINIHALRVAGGIFIFGIAYNLLNAKESHVQSLHHDEHKESKEKADISVTPLS
IPIIAGPGTIATVMSLSAGHSGIGHYAAVMIGIAAVIALTFLFFHYSAFISSKLGKTEMN
VITRLMGLILAVVAVGMIGAGLKGMFPVLTS
>fig|224308.1.peg.3527 Drug resistance transporter, EmrB/QacA family
MSSRKEWALIVSLLLGAILVPINSTMIAVALSSISHTYNESIASITWVVTVYLIVMAVTQ
PIAGKLGDMYGNKTMYLWGVGLFLIASLGCALSPSLLLLIVFRALQAVGGALLTPNSIAI
IRHVVSEKRLPKVFGFFGLGAGLGAALGPFIGSILIDSFSWHSIFWVNIPFLAIALFTAL
TMFPQYKENKSDAPLDIIGSLLLAGSIVSIILLTKNEAPWGYTVYSVLILLFVPLFFRRE
KRTQHPIIDFALFKSSTFTNANLSVLLSNLMMYAVLLIMPLFMTNQFGLNTSNSGMALSV
FSIFMSASNWVGAQLHHKWGAKKIIFLSFAMMAGANLLFLLLSSSHSVLFLMLSLILGGL
ASGVGLTSMQVSSLATVDPGMSGVASGIFSTFRYFGSIISSALIGLISGYHTLFMILFAV
SIIGVFVSLGIKSDETARIEKNSA
>fig|224308.1.peg.3763 Methylenomycin A resistance protein
MKNSGSIQESTSSTGISVLIVLALGFLMATLDVTVVNVAMADMKNTLSMSLSGVTWVVDG
YILTFASLLLAGGALADRFGSKTIYILGLAVFVMASCLCAASINGQMLIAGRLIQGIGAA
LFMPSSLSLLAASYLDERARARMFGLWAALVSAASALGPFIGGVLVQLAGWQSIFLINVP
IGAAALISAYRILSRVPGKSSRVNIIGHLLGMMALGFLSYALIQGPSAGWRSPVILVAFT
AAVLAFVLFLLREISAKTPILPASLYKNGRFSAAQFIGFLLNFALFGGMFMLSLFLQEAG
GASSFMAGVELLPMMAVFVIGNLLFARLANRFEAGQLMFVSMAVSCIIALLLFVLISPDF
PYWQLAVLMSVMNLCTGITVPAMTTVIMQAAGQRHTNIAGAALNANRQIGALVGVAITGV
IIHLSATWYAGAGFAFLMMGAAYSLAALLVWLFLAAHNGTAASEKM
>fig|224308.1.peg.3998 Tetracycline resistance protein
MSIFYSFSALRGLAMGIFSPIWILYLISKDYDFLQIGLMGAVLEIAKLIFEVPSGVFADR
YGIKISIASSFFFSILTWAFFPFIDSAAICILAMIIWALSDSLISGSFETWMSRVAGEDR
FGKEMMKNTQLLITFLIIGSIASGYLYSLNIYFPFLLVMVIYLLLFIWMSVFIKVPSVSE
TNHGDQNQHDSIKIIKESLKIIFNKKRVLLIVIAGFFTATAYDTISRYWQPFLSDLGFSE
KSLGYIFPLGGFTALVLLTLTIRFEKKIEKNPYLALTSLDSMGMVMTFLLSRAFRPLGIP
CTAFLLAIEDIHHPIVTSYLNKFFPDSYKNTLFSLNSGVGAIGEILSGVIFGIISAAFGL
SAMFVVVAVFLLIPIILYTIVPKIKDNDMKVQIEKSQQV
>fig|224308.1.peg.4084 Tetracycline resistance leader peptide
MKCNKMNRVQLKEGSVSMTL
>fig|224308.1.peg.4087 Permease of the drug/metabolite transporter (DMT) superfamily
MKHLNIYIMLLGFSIFTGATFNLAKYTVGYFSPSSSAAWRFGLAAAVMLIILIFTEGIKK
SQLRKNAVSYIVLGIIGIFGFNALFFVGLKYTSPVNGALIMGLNPLLTAILARIILKDNM
TKKQVLGIFFAFIGVLLVITQGSIETIKTLSISGGDLIIFTGNVCWALYGVLGRRFVKDG
TPLSTTTYTMVIGAVSLIVVSLFTSKPVSLSNIPIGVWGAIAFMAFFTSVLGYLWWNQGI
KEIGASKTSLFFNLVPVVTMIISFAVGTPIKVFQVIGAVLVILGVLTASGVIRIPKYNTK
EQSAI
>fig|224324.1.peg.394 Multiple antibiotic resistance protein MarC
MIITWMEEFGVLFVKAFLSLLAIMNPFSSVPVVISLMNEYSKEEIRVIALKASVYAFFIL
TFFLISGDLLFRFMGITLPAFKVGGGILLFLIALNLVQGEVTKEKGKAHEIEAALRRDNI
ALIPLAMPLLAGPGSITTVLVLRGYLNTLEGKVALFCAIFLSSFTAFVVYSLSTFFYRVL
GRTGINLITRISGILLLAISVQFVVDGLKNLLKH
>fig|224324.1.peg.860 Melittin resistance protein PqaB
MFYILIILLATFSMIPNINEFAFRFEETTRAVVAFEMYHSGNYFQPTILGDPYYNKPPLF
NWFIIISSKFFGWDIVTARAVSVFFTLANAFLIYFFSSKVLKNKEKALLSSVFFITFADV
LFWYGWLAEIDVTLSFFVTLLFIQIYKLWEEGKPIYYYTSALLTGLIFMIKGFPAFAFYG
LSLISLSIFKRDFKVLLNFHAFASYFLALIASFWWLPFSENPEFYFRRLWEESFSRVESS
KDLEKFLIHLITYPLLNVKQLLPASLFVIPLIFTKRISLPRELKFLLFLVIFNYIPYIIS
ATSRGRYVLPLFPILAVIFAHLIHEYLSKNWKKVLLFSLIFVIILRFIYGIFFLPYVNHR
KGEPKLQAKVAYELTKTGKVACDCPKIKDFCLYIGFLRGEPLLRPKYTKAWDYLVDCKER
KDLSLIKKFYVNKKEVYLYGRFASGFAINTFNRSRGSKVFEGMSGARR
>fig|224325.1.peg.263 Permease of the drug/metabolite transporter (DMT) superfamily
MKKWIVLALTVTFWGLAFTAIKYSVRFLSPIAIASLRFAIANTLFAVIIILGKRIKWKDL
PKVFALGIFGVSVYHVFLNLGEVYISSGVASVVISLAPIFVLILSAIFLRERITYSKVVG
IIIAFLGVVVISEPSYANIYGIALVMVSTVAAAIYTTFGKSLLSKYNPITLTSNAMVLGS
IPLYPFLPDSIRSLGGDLNLIGSIVFLGIFSTFFGYLGWYYFLEKEEASRASVFLLAIPV
VSLLAGNILLAEPLTLRTVAGSGLVLLGIYIVVRKR
>fig|224325.1.peg.505 Permease of the drug/metabolite transporter (DMT) superfamily
MNSKTHLLLALTMLIWAGSFIFIKIGLKELDPFNLAFYRFLLASPLLMAWVFWKRGLAKP
SGSEWLHLSVLALSGVTLLYAFQFLALKYTTATNASILINTSAVFVALWGLVKGEANPRK
LAGVFLSFAGVVLIVSKGTLEFFSSKTIFGDVLMIVDGFLWAVYTVLGSKMLLKYDHETL
TAYAFALGTIFLIPFALMSGFANPVTFNPETVAALLYLSILCSVFAYVVWYYALTNADST
SVAVYVYLVPLFTAIFAFYALNEKPDFFTAIGGIITIAGVYLTTAKQHQ
>fig|224325.1.peg.781 Permease of the drug/metabolite transporter (DMT) superfamily
MGEDRRSLRVDYDDNFLRNNICSLKVSFIKQQGGAEGVKRLYADLGLALVALIWGSTFPV
VKIALDSMSPFAFNTVRFFIACLFFLPFLKGWDFKDGFKIGIASFLGYTFQTVGLDYTTA
TNAGFITSTYVVLAPIISWLVYKDVFDKRDVSGVLLAFVGFYFLSGYSGFNIGDILMLFC
ALFFGAEIAMISHYSRLSNPTMLAFWQSFAIFILSAPFAVFTTTKFEINTTVILCLLITA
FFATFVAKMLQNWLQSYTKSSDAAVILSLEGVFAHLFSVAVLAEILTPVQYFGAFLILLA
VIIVSLRV
>fig|224325.1.peg.1315 Multidrug resistance protein
MLRLILSGFFAYASLSCVIPIIPSYASSLGASVFLSAFAAGVFALFPAIAMTPFGMLSEV
YGRRRFLVAGAVTSLLASLLYLQSSTAELLVFSRTLHGLGSALYIPSINALVADISEESR
RGEAMGKLQTALMLGFFAGPLAGGFVSDFFGVKAVFLLALVFSAAALVPVVGVRERSKGG
EIGKQFIFPRKLAPLFAVMFVGMATGSSLALFAIPFYAPELNISQQQAGLLVAVLFLFSA
IIRVPAGILADRAGRNVTALLGMVVTGLGLFSAFKPDFPFLFLASLLCGAGNGIVNTAVF
AAASDYENRGYAMGVANTVLNAGIFAGTTLAGFMAGFLSFQSMMLILAAATLLFSPISLS
KGFGSISEVER
>fig|224325.1.peg.2244 Multidrug resistance protein
MSDDDQSVLKAWIAFLPVSAGLFMVLLDVSVLNVALPRIAEDFGAKMSDLQWIMNAYTLT
MVVLLVLAGRIGDMVRRDRFFILGMVIFVLGSFLCAQSWNTQSMIAFRTLQAIGGTILSG
NVLAIAAELFPPGRRGEVMGLNAILTASSFTLGPIIGGWLTTHLSWHWVFYINIPIGIVA
IAAAWFTLPPLGGREKVPIDWVGAVLLSIGLGALTLGIIEGQNWGWWDEKTLSCFIIALP
YLLAFSLWELRTPYPMLDLSLFKIRNFSVGVVATAILFFGVSASLFVFPYFLQGLKFLSA
EEAGYWLVAIPIMNTFVAPVAGRLSDRMNPKYLMSLGPLFFAIGLINITSIDVDIKYWDF
FAKIAPMGIGMGMLMSPSFNVILSSVPLEKVGMANGTVRSVNTLGQAMGIAVGGVLLTTR
MSDWIPGYANQIPDPGTMKILIEYAKYNPAPLVEMVEGFVDSMHFVFSTMIVFPILTSLI
IALFLHGDEHVRRARAARKGVVA
>fig|224326.1.peg.524 Acriflavine resistance protein
MLVKRIVGKPITMLILFSLLLMISLYTFSRLKVDLLPGIDIPQISIHTVYPGASPREVEE
SVSRVLESGLSSVKNLKNIYSVSSKESSTVSLEFYHGTDLDLVLNEIRDALELVKSSLPS
KSQTPRIFRYNLKNIPVMEIVINSVRPVSELKRYADEIIKPGLERLDGVAIVTVNGGSKK
RVLIEVSQNRLESYGLSLSRISSIIASQNLELSAGNILENNLEYLVEVSGKFKSIEEIGN
VVIAYKIPDISSGINLSPIEIKLKDIANIKTDFEDLSEYVEYNGLPSISLSVQKRSDSNS
IAVSNVVMNEIEKLKLSMPKDMKLEIASDSTDFIKASISTVVNSAYFGAMLAIFVIFFFL
RSFRATIIIGISIPIAIVLTFCLMYFVNISLNIMSLAGLALGIGMVVDCSIVVIDNIYKY
RQKGAKLISSSILGAQEMMLPITSSTFTSICVFGPFLIFKSELGVYGDFFKDFTFTIVIS
LGVSLLVAIFLVPVLSSHYVGLYTSFQKNIKNAFIRKIDAFFASIYYFLEFLYINLLNIV
LNHKLIFGLIVFFSFIGSLLLGLLLDVTTFTRGKENSITINLNFPHKTNLEYAKFYSNRF
LEIVKSEAKGYKSIIATLRADRITFNVLFPLKEESRDNLTQSVDYDSIKYKIMNRIGNLY
PEFNIEPSISGNALGGGDSIKIKISANDFEYIKDYGKILVSMLKKEIPELVNPRLSISDF
QLQIGVEIDRALVYNYGIDMNTILNELKANINGVVAGQYVEKGLNYDIVLKLDRMDVKNL
KDLEKIFITNSSGVKIPFSSIATFEKTNKAESIYRENQALTIYLNAGISPDDNLTQVTAK
VVDFINNKVPHKEGITLKVEGEYNEFSNIMNQFKIIIMMAIIVVFGIMASQFESFLKPFI
IIFTIPLTAIGVVLIHFLAGEKLSIFAAIGMLMLVGVVVNTGIVLVDYTGLLIKRGFGLR
EAIIESCRSRLRPILMSSLTSIIGLIPMAFSSGSGNELLKPIAFTFIGGMTASTFLTLFF
IPMLFEIFPTCFKFQI
>fig|224326.1.peg.857 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MSTDKSKTRELILNGNLYKVLFLISFPIVITNIIQAFYDLTDMFYVGKLGAMPLSALSLA
GPVNFFIIAIAMGMATGSISLMSKCIGEGNFSRFSRYAGQLIVLNFVLSLFVTICAFFFI
DHLLDLLGVKGELKELSRVYFYVTIFAIPIMFLSISITYILNAQGETILSMTIVLFANIV
NFILDPILIFSFNMGITGAAWATLFSKLLTVVFYLFLTYRLNYGLKIHLKDLVIDIRSIK
EIVNLGLPSTFGQIMVSLSFFIFNYIVIEISPKFLAAYGLTNTIISFLFLPAMGIGTGII
SIVGQNLGAKKVNRVEEVLKKGFFISLAILLIINSIVIFNKQFILRLFTNDLEVLNYANN
YLLLTTIGTFGYGLQQVFFGGLIGSGRTKIAMIVIFIRLWLIRLPVVFIFQYFGIMENSL
GYAFIISNYLAIIILIAFTCTRYWVKPILIKKYK
>fig|224911.1.peg.932 Multidrug resistance protein A
MADQVIKFQPEQKIDSGKPTKKAGTDPRRRIIAGLRRYRRFLLMVVLPIVAAIGGLTLYL
NGGRYVGTDDAYVGAQKVLVTPDISGKIEKVVVREGQLVKQGDELFEIDPVPFRLAVDEA
RAQLAQAQSTYDNLRANIKIYGDMLSLAQQGVDLKQRDVERKQALVKNSYGSQLDLDNAA
NALVTSGSIAQYVKQQISAAKTQLLGDTDLPLEKFPPYAQAKSKLDNAERNLDHAVVRAP
MGGVATQVEQIQLGRYVTAGTPVFSIIDVAHPWVDANPKESDLTYVTEGQPVTLEVDAFP
NHVFKGKIGSLSPGTGAQFAILPPQNATGNFVKVVQRVPIRIYFDETDKYVRKLKAGMSV
YATIDTGHRRSLAGLFGLSATAGQDKD
>fig|224911.1.peg.935 Permease of the drug/metabolite transporter (DMT) superfamily
MSSPQAIPSAGRPLSAGAIALMLMLCLTWGFNQIAVKLVLPDIPPMLQAMIRSMGALPVL
FIIGTLRGVKFFEKDGTWKPGLIAGLMFGIEFVLIFQGLRLTPASRAVVFLYTAPFFVAL
GSYQVLGERLGGTQWLGLAVSFAGVALAIGVPQPDVDAKVLLGDLMIVGGAALWAATTLV
AKGTRLRFAAPEKALGYQVATSIPILGLAAWLFGESITHTPAPLSLALMAFQAIWVVGTT
FTLWFALVKAYSASKLSAFTFITPLFGVVGSYFIMHDTLSLTFGAAAVLVIAGLFLVNRP
SQTAAAPRDALLNVTKT
>fig|224911.1.peg.3407 Permease of the drug/metabolite transporter (DMT) superfamily
MTKAKTRLAYMGAGVAVVIWGATPAATAIVARELSPGLIGLARLLLSATILIPIAVSLKP
ELPSDRGGWIALLISALVGFAGSFVLQGVGIARTSTSHAALVLALAPIFTATVHFLLSRC
WPRPLWWLGSAIALMGVAILIPGRNPAGSVAAPTLFGDLLVLAGTVTVSVGYVAGARLSA
RIGLFAATCWSLLLAGLITLPAFPALASALGQLSFAVWGALGFLAVFCTLIGFAVWFWAL
EHGGVTSIAPLQFGQPLVSLVIAVAFLSEDIFPATLLALSLVILGVHLSRRAA
>fig|224911.1.peg.4275 Permease of the drug/metabolite transporter (DMT) superfamily
MLDSTRPVLRPRIAPAGLMFLAITSIGWGFNWPVTKFLLAELPPLTLRGVTGVLGAGLLA
ALALVRGDSLKVAREIWPRLLTAAVLNVTGWMVLMGLALLWLPASEAALIAYTMPVWASI
IAWPVLGERPTVLRTLGLVMAFVGLASIMGGNGIAASTEKLPGIIMALFGALGFALGTVF
SKKYPIRLPPITAAAWQIGIGCLPISIVGLLIETSHLELVTPVGWWLLVYSTVVQFCIAY
VSWFAALARLPASVAAIGTMAVPVIGVVASAIALHEPLGPGQIAALVFTLGAVVLATR
>fig|224911.1.peg.4311 Permease of the drug/metabolite transporter (DMT) superfamily
MPPNDNRIDARDWSLLAVLSILWGGSFFFNSAGLRELPPLTLVFLRVALGAAVLLPLLHV
QGISFPKGTLGWKPFFVIGLLNNVIPFSLIVIGQTIIPSGLASILNATTPLFTVTVMAMA
GEEALQMRRVAGVVLGVVGVVILRGWGIETRPGQGFGILLCLGGACSYGFAALAARRLLK
DSAPLGTATFQLMASTVMMAVVAAVMEQPWHLPAPGLTTWLAVLGLAGLSTALAYIVFFQ
ILRRSGATNVMLVTLLIPVTAILLGWLVLGEPISMREIAGAIVIGSALLVIDGRALRMLQ
RVA
>fig|224911.1.peg.6257 Multidrug resistance protein B
MSTTVPSTGAAGDHRAISAAALIAIYMQAVNISIPNAALPHIQATLSMANDEVGWVFSSY
IAASAVTMSITQWLAGRYGRKAVYQAALAIFTFGLVLDTLATTSIQFVLARILQGAASGP
LAPLSLAILLEVTPARHARMSLASTVCSLLGISTGPAIGGWLSEYYGWASIFYVSLPMTA
FIFMTMASLLSEKRAERSQPFDFFGLTTFSVGMIGLQMLLDRGERLEWFASTEIWAEAVA
SVLGFYLFSVHVLTTREHFLRTALFRDRNLVLSTVISFALGFVLLPTLALTSPMLEELLN
YPVDTTGYMTIPRGVALVGALVLTSLVPGQVDYRPFLMGGMALVVYANWLMLGYSPAMDW
RPVVEAGMLQGAGLGMLLPALARAAFGTLDPKLRPEGGALINLSRLYGSTIGIAVVQLFF
YANTQAVHVALAKHLTPFRVAAHGAGPIGKPSLAALNGMVTHQAATVAVIDQFEILMFAM
LVVIPLVFFLRKPRPAG
>fig|224911.1.peg.6258 Multidrug resistance protein A
MRLNFAPIAGWLGDRSFRGSEGAVPLFGADLGRRLRRPLMLALPTVVAVFGAFMYLAQEQ
YVSTDDAFVRAAKVTINARVSGQAVEIAVRDNERVRRGQVLFRIDPEPYQIAVDQAEARL
GSARLQIDSLKATHRQQQAELQSARESASFDEREFDRKKMLVASDFTPRAVYERAETDLK
VARHRMASIEQQIANTVVALNGDPDIDADRHPTVRAARAQLDRARLDLSYATVIAPDDGI
VTKVDDLQIGGFVNAGAPTFSLMSSRDIWIEANFRETGLTHMRPGQEATIDVDAYPDRKF
RAHIVSMSPGTGSDFSVLPPENATGNWVKVVQRLPVRLELDDLDPTRPLFSGISVTARVD
TGHRRSWPHLLQGALATEVK
>fig|224911.1.peg.6622 Multidrug resistance protein A
MAVSRDQAARVLRQDTVETNSANGEPVTETSAVLAEQLRSHVAEEAKRRSDAPGKPVTDK
PATPGSDAPAASGTPKSGKRKFVLVGVGLVLALAAAGYAGYYTLVGRFYIATDDAYVRAN
NTMLGARVAGHISSILAGDNTTVRAGDVIFRIDDGDYKIAVDAAATRIATQQATIDRIGR
QIAALESQVAQAKAQLVSAEAGLKRADLDYERQQALSSKGFASRATFESSEAGRDQGAAA
VKAAQAAYDVAVSNVDVTKAQQAEAQAQLAELKTSLAKAERDLAFTAVRAPVNGTFSNRL
VSAGDFVAVGQRLGNVVPLDDVYIDANFKETQLKRIRPGQPVTIKVDAYGMRKFSGVVDS
IAAGAGSVFTLLPPDNATGNFTKIVQRVPVRIRVPKSVAKQNLLRAGMSVYATVDTNKGA
ADADSEVDLDDPTMIHPQ
>fig|224911.1.peg.8172 Permease of the drug/metabolite transporter (DMT) superfamily
MSTQAQQTTSGQTTLAFEIGLLLLLALIWGSSFTLIKVAIPSIPPFTMVAARVTIAAILL
LLIARAQGHALPRRGSVWAAFLVQGLLQSALPFTLISWGETHIASGLAGVLNATPPMFVL
AIALTTGRGRQTVSGRKIIGVALGLAGVAVTMGADALSGIGTTAPLAQAAVLCASLCYAV
APIWGQRFSGLPAIVTAAGAMSCAAVLMLPAAAVLERPWTLAPPPAQAIAAVIALAVICT
AFAMVIYFRLIHTLGPLGTTSGSYLRAGFAVALGTAWLGERFSWSSLAGMALILAGVVAV
TVPAPARTGKTATGAPSRN
>fig|224914.1.peg.187 Permease of the drug/metabolite transporter (DMT) superfamily
MKRRMKLMESAPFLLIATGTLLGLILPLGKIAAQAGIPPEMWTFLFSASAGVILFAVLCL
RKKRLGFSGGRLRYYICTALISYALPNFLILSAIPHLGAGFTGIMYTLSPVITLLLSMGF
GLRRPNALGIGGIAIGFVGAAMVAMTRGEVGKPTDLLWIAAALLIPVLLAIGNIYRTLDW
PKNSEPTELAAGSHLASAFILFICITLFTGRFPLESFALAPFAALAQSLAAAGMFALFFR
LQAVGGPVYLSQIGYVAAALGLVSGTLFLGEHYPPLTWIGAAVIAAGVAMTTRAQKG
>fig|224914.1.peg.402 Multiple antibiotic resistance protein MarC
METGMIVGKLLPLLFNMMGPIGLMPIFAAMTVQMDKPTRNSVAARAAIFAALGILIAIFI
GDPILQSWGISKPALILAAGVILTLSSIRAVLMPPAAPSQPAAAGDPKALAIRPLAFPTI
VSPQGVGVLIIFVAFLSSLSSTITILTVAGVIVLLDYGAMRIAHWFMATVGMVPLLVLGA
VFGVLQVALGIEMMLSGLLLVLNS
>fig|224914.1.peg.925 Multidrug resistance protein A
MFRFPAGQTEPPNEIVVHAEIVHRRPKIFRCTAPEDTVAETNTSPSPAQDQSPKHPMLRR
ILLIVGPVVAIAIGLWIYFSGGQYVSEDDSYVGAAAVAITPQVSGQVIRVAVGPNQPVKE
GDLLFEIDPQPFQIELDQAKANLAQASEKLAGLVLTYKQQLASVAQAKDDVTFAQEQSPT
SRCPICREALRRQAARSIGC
>fig|224914.1.peg.2340 Multidrug resistance protein
MADGMKHKTAIQQGVSLAPDGLPRPRIYWAWATLMVGLTLAVIDGTIANVALPTIAADFS
AGPAASIWIVNGYQLAIVITMLPLAALGEIYGYRRVYVAGVALFTIASIGCVFSRSLEAL
TLARIIQGLGAAGLMSVNTALLRYTVPQAKFGTAIGLNALFVAVSSTIGPSLAGVMLSSL
SWPWLFVINIPLGIAAVLMGLRSLPDNDRSARKFDVVSAILCAVTFGLLITTIDSAGNKI
GSLAVMLQALCCLLAGIWLTRRSFHMSDPLLPLDLLRIPVFTLSICTSIMSFLAQMMAFI
SLPFLFQTVFGFRPIEVGFLMMPWPIALALVAPLSGKLSDKYSPAILGLLGLITFSVGLA
LVGLLPGHPTIPDICWRMAICGIGFGLFQAPNNRMMITSTPRARSGAASGMLGTARLLGQ
SVGAALVAFLLSQWGVEGTPYILFLASGFALFASVISISRLRH
>fig|224914.1.peg.2575 Multidrug resistance protein 1
MNHRHDMSTTQAAAGDASQMETPHPNGSFTQSNADENHEQYWKQNLVICLLGSFTTLIAM
SLLLPFLPLYVEQLGVISHAAIVQWSGIAYGATFLAAAFVAPLWGRLGDRYGRKLMLIRA
SLGMVTCVWQLVALRLFVGIAGGYSSGSMILVATQTPKDKTGWALGALSAGIMAGIMAGN
LAGPLLGGALPPLIGIRATFWLAGGVIFLTFLATTFLIREERKPPKPTREEKTQSIWAAI
PDKGPVVAMLVTGILLLFANMSIEPILTIYVMQLMDDQTKVTLVSGVVMAAAALGSILSS
SRLGQLADRIGHTRVIIGALAVSALLLVPQAFVTDAWQLIGLRFLMGLALGGLLPCITSV
IRHNVPDRVAGGILGYSVSAQYVGQVAGPVAGGFVGGHFGMRAVFLGTCLMMAAGAIYNW
AVLRNSKTR
>fig|224914.1.peg.2656 Drug resistance transporter, Bcr/CflA family
MNRIIPLVLAIALFMEQMDSNVISTSLPAIAADIGTSPIALKLALTAYLVALAVFIPVSG
WMADRFGAKNVFRAAIAVFVVGSIACAASNSLPAFVIARFLQGMGGAMMTPVGRLVLIRS
TPRNELVSAMAWLTIPAMVGPLVGPPVGGFITTFLTWHWIFLINVPIGMIGIWFATHFLP
DNEERIIKRLDWPGFFLSGFAMSGVVFGLSVVSLPALPPVIGFATLAVGMLCTVLYVLHA
RRTPDPLLNLRLFDNQVFRSAVFGGSIFRFGIGAIPFLLPLMFQLGFGLTPFQSGMMTFV
SAIGAISMKFGAKRIFTRISFRRALMGGSLISAAFIAVNGTFTPATPYWIIIGFLLVGGF
ARSLFFTGVNALAFAEIPNEKTSQATPLTAVAQQVSIAIGVALAGGILEISTMLRGAPLA
LVDFHIGFFVVACVSVLAFFWFARLAPDAGKELATPSVIRHHGKPVTTA
>fig|224914.1.peg.2854 Multidrug resistance protein B
MPRCCIGSISWYTFIAIGFGALVVVLVQGKNYWWFEAPWIGVCLAISILSLAIAAAIELN
RDQPLMNLHWLASPEILRFTLILLVFRMVLAEQTSGALGLFQVFGLQDAQSKGLYTLILL
ASFAGGITCGALLKVERVPVIFGFALLCIAVGAFLDSHATNLTRPHNVYVSQGLIAFGGA
LFLPPAMLAGITKAMKQGPAYMTSFIVVFLFTQNIGGLIGSALFSTFISIREKYHSAHLV
EQLVMSDPLVAQRVQALSGTYAKVLADQGLTKAEGPVLLGQQVTKEATILSYNDAFLAIS
VIAAIALCCQVTYRVYEAFRARRSALAVMS
>fig|224914.1.peg.2855 Multidrug resistance protein B
MSIIYIAASMLLWSTRGLSMYFISANTQQIQGSLGASLTETTWLVAAYMAPFASLTILLL
KIRTQFGLRRFAEVAIAVFLVASLLHLLVYDVWSAIPVRFIAGAAAVPISSVGFLYMLEA
FPPDKKRTWGLSLALTCSGAAGPFARIISPMLFDIGQWQQLYMLEIGLALACFAVVYVLP
LTQIPRAKVLHWLDFVVYIYRNRLRRPCCGACPGQELLVVRGALDRCLSGDINPVACHRC
GHRA
>fig|224914.1.peg.3161 Polymyxin resistance protein ArnC, glycosyl transferase (EC 2.4.-.-)
MNAKTLCIIVPVYNEAEGLSDLLDRLHSAADNIASQFTLNIEFIFIDDGSSDGSFALLKA
HDFGSRPVRLLRFSRNFGKEAALSAGIDAAEGADAAILMDADLQHPPEMIADFVRIWQEE
DADSVYAYKASRLASEGPVKAALSRAFFWVINRDQRYKIPPGAGGFRLVNRRFMAALRSL
PESDRFMKGLYGWVGFNQVGLPLQPPPRMRGTSYYNPLQLLLMSLGAMTSFSTTPLRLMA
LAGIVVAGLSAAYGLYVLSEYFFFPGVPVGLTSILALTAFFGGIQLMFLGLLGEYIGKSV
LEAKKRPIYILAEDIRRKESDDADRG
>fig|226185.1.peg.598 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MEQTQQNHFTALFYKNVLLGILSMAAQSIFILADTFFIANGIGTEALAGLNIVLPLVNII
NGLGWMFGVGGATLFSTTVAQKEIKKANQYFSLTIGLVFVIGRLFTLVSLIFSDQIIRGL
QGTGVLFGLAKEYYMIYLSCSLLFILNNCLITFLRNDHNPRLATIAFVSGGIVNIILDYV
FIYQFGWGMAGAAIATVMSPLTSLILITLHKWSPQRVLRFEKFKVKFQDVREIMSIGFSS
FLNEFSSAFVMFLFNIVLLNLVGHVAISAYAIVANLNIIVIAIFTGIGQGAQPLLSRYYG
LGETKVLRKFVKLSFITYLVAGFLFFLISQVFTGQIIEVFNSEGNDQLAQIARTAIRLYA
ISFLFTGLNFMGIYYFSAVRKPKMALMISSLRGFFLIVPVLFILVKLLGLTGVWLAMPVV
EFVTFGLMLVGYLAYRNYLKKREAVT
>fig|226185.1.peg.715 Drug resistance transporter, EmrB/QacA family
MAKETNVKLVTVSVFVATFMTAIEGTIVSTAMPTIVGSLHGMEIMNWVFSIYLLTNAMLT
PIYGKLADKIGRKPVFMIGIIIFILGSSLCGFAQDMLTLIIARAIQGVGAGAILPVALTI
IADMYTLDKRAKILGLNSAAWGIASIFGPLAGGFIVDTVGWHWIFFINVPIGLVLLGLIS
IFLVEPKRERTKMPMDILGSVTLMVVLLTLLLGFQMISDNGFTLVTFGCLSLSVLFFVAF
VMIEKRAQDPVIDLHLFNQPTFVLVNLIAALISGFLMGIDVYIPMWMQGVLGKSAGIGGL
VLAPMSLLWMAGSFIASSFMEKYAMKKVLTIGLSILLVGAIFLVVMPMAVPFWLFFVVSS
VLGVGFGITITTTTVTAQSTVEPEKMGVATSFNTLVRTIGQTVMVSIFGVILNAGMFAKL
EASALNVDADVMNQLVNPHTANLIPAALLKPLRGILYAGLHNVYLVGAGLVVVALLLNIF
AKAQRAKV
>fig|226185.1.peg.1276 Drug resistance transporter, EmrB/QacA family protein
MEKIKSYQEDSEVQKNRWWILVSVAMFTFMSTLDSSIVNIALPTISKEMSVPMNQAEWVV
SIYLMVVCACLLLFGKIGDSFGKIKVYRIGTVIFTIGSLLCGFNQSLSFLLFARVVQSIG
ASMTMATNSGIITEVFPLNERGRALGAVGAFVSLGAIAGPGIGGLILSNFSWSYIFWINV
PVGLVTILIGEKFLPKDITKTKEKIDFSGFACIAIAIMTFFGGIFLGQESGFGSLQSYLL
FIIAVIALGLFIMVERKRKSPLIKFAIFKNKIFTLSLLSAVLIFASNFFVNVVIPFYLQD
ARKLSASYAGLLMMVFPLLMVVGAPLSGYLTDKIGPGILTFGGLLLLCCTSLMYMFLDMN
SPIWYYVIATAIMGLGNALFQSPNNTMVMSSVEKQDLGVAGSMNSFARNLGMVIGIALST
TILYRGMSEAYGERVTTYLANRPDIFIVGMRETFFVAFLLCVAAFILTILRFRKTTK
>fig|226185.1.peg.1697 Drug resistance transporter, EmrB/QacA family protein
MLERTVFMIDRKKVILYTCCMSLFVVTMDVTVVNVALPSIQSDFHTNLSTLQWVTDGYTL
MVASLLLLSGSTADRIGRKRVLQLGLACFGLASFLCGISQTPGQLIAFRMLQGIGGSMLN
PVAMSIITQVFTEKLERAKAIGLWGSVTGISLGMGPIIGGLIVSYFSWRYVFFVNVPIIA
AAIILTQKFVPESKVEKTVKNDFVGQALMILFLFSSIYSIIGLPRKGLFAPDILSTGIIG
CLAIVIFFIYEYNIDNPLINPRFFLSIPFTSASFLAIFGFIIYNGYLFLNTLYLQEMRGF
SPLEAGLSTIPLAFVSFLVAPRAGEMVGRIGTKRPIMLCGISMLAVSFLQLFVTKTTPMI
ILFIIYIFLGIGFGMLNSPITITAIEGMPLSQSGTAAAIAVTCKQIGNSLGVALPSLLIT
KPITSSLTRTPFTNVWLLFGCCAIAIIFLSYLSNSPLAKKSLRRVRFYF
>fig|226185.1.peg.1807 Drug resistance transporter, Bcr/CflA family protein
MKNTRNTVPSLLIIILLVGFPQISESIFTPILPALSSAFNIHDSVAQLTMSIYFVAFAVG
VLFWGILSDTIGRRPAMLLGILCYLIGNIGLFLSPTFPWLLFFRLIQAFGASVGSVITQS
MMRESFNDLQRGKIFAQTSAALSLSPAIGPLVGGLVQTYFGYQHVFSTLIVMAVLLLFYS
FYRLPETFHLGNTLTKAPFWSVAKRLSFDSKVWCYGLLIGGINGLLFSYYAEAPFIFINH
FGFSSVQYGFLGLVLAVSSILAAVLINWLLGYWSAEKIAFAGLLLSIFAACCLLIMTQFE
TIIGLILFIFLFFLGINITLPNALSMALKGYESVIGTASGIFSFVYYLFVSFFTYLISYF
HNGTIWVLPLYFLSFACLLAFSYYVIVYRKTLK
>fig|226185.1.peg.2722 Multidrug resistance ABC transporter ATP-binding and permease protein
MKHAFSSMKRIGRYIKPYRVTFYLVILFTILTVAFNAALPYLTGLPTTEISRNIAAGESI
NFDYVIQCLIWILVVGTGYCVAQFLSGFLMTNVVQQSMRDLRRDIEEKINRLPVSYFDKN
QQGNILSRVTNDVDAVSNAMQQSFINIVSAVLGIVMAVVMMFLINPLMAIFSVIMIPLSL
IISRTIVKISQKYFQGMQNSLGDLNGYVQENMTGFSVLKLYGREKETLEGFKQVNHRLNG
FGFKASFISGLMLPLVQMTAYGTYIGVAVLGSYYVVAGVIVVGQLQAFIQYIWQISQPMG
NITQLSAALQSASASTMRIFEILDEPEEELNEQDVPLPEPILGSVEFENVSFSYDPEKPL
IRNLNFKVDAGQMVAIVGPTGAGKTTLINLLMRFYDVTEGAIKIDGIDTKKMNRSDVRSV
FGMVLQDAWLYKGTIADNIRFGKLDATDYEVVDAAKTANVDHFIRTMPDGYEMEINSEGD
NVSLGQKQLLTIARAVISDPKILILDEATSSVDTRLEALIQKAMDRVMEGRTSFVIAHRL
STIREADLILVMKQGEIIEKGTHHELLEQGGFYEKLYNSQFAEEGDYEE
>fig|226186.1.peg.110 Tetracycline resistance element mobilization regulatory protein rteC
MNSEIEYENFIKNIDLVIYDKIDIDNWNISIDLIFEVVEFLQKSLEELRTIIIEHPFESK
EEEIYFFKYIKPEVLGRLLYFTDVYNAEMRKPNGSIEVVKKHYNDRLDELTSYFESNLDF
YQYYRSKATHLDNHYFVRGHIDFKLCPNCTPYDRDPEFSTCYDHKAAQILANDMLSIYLN
KRLHYVDKQIIIEESRAFLSEHPFRWTAPKIALVELGYSIYAACVLNNGKADIKEIMTYL
EASFKVDLGDYYRTYITIKDRKKDRTSFLSNLIKCLLKKMDEDDNL
>fig|226186.1.peg.696 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MSKNDPHILGKESIGKLLLQYSIPAIIGMTITSIYNIIDSIFIGHGVGAMAIAGLAVSFP
LMNLVVAFCTLVSAGGSTIASIRLGQKDMKGATEILSHTLMLCITNSFFFGILSFIFLDD
ILTFFGASPDTLPYARSFMQVILLGTPITYTMIGLNNVMRATGYPKKAMLTSMVTVVANI
ILAPIFIFHFEWGMRGAATATVISQLIGMVWVVSHFCKKDSTVHFEGKVWKMKGRIVESI
FAIGMSPFLMNVCACAIVIVINNSLQEHGGDMAIGAYGIINRLLTLYVMIVLGLTMGMQP
IVGYNFGAQKIDRVKQTLKLGIISGVVITSSGFLICEFFPHAVSAVFTDSDELIGLAVDG
LRLTVLMFPFVGAQIVIGNFFQSIGKVKISIFLSLTRQLLYLLPCLLLFPHWWGLKGIWI
SLPVSDSLAFITAVISLMIYIKKVSKEHPIADKVAE
>fig|226186.1.peg.1108 Multiple antibiotic resistance protein MarC
MQNLILQNAIWYVFCDIIIDNKLYVIMDIFVYLTLCFTSLFTLMDPLGVMPVFLQMTDGM
DTKERRYIALKACTIAFIILVLFTLSGRFLFHFFGISTNGFRIVGGIIIFKIGYDMLQAH
FTHVKLNETERKEYSKDITITPLAIPMLCGPGAISSGITLMEDASEYTFKIVLLGVIALV
CILSFFILCASTQLLKILGETGNNVMMRLMGLILMVIAVECFISGIRPVLIEILKQAHAC
S
>fig|226186.1.peg.1248 Inner membrane component of tripartite multidrug resistance system
MKELGVPVRSWVPDWLGFCCIFIVILPVTMLNGSYTGSMLEVSNTLGTNSEDITMGYYAA
SAGMAIAYPIIPKVLAAVSVKFLLLIDLLLQFFLSWICARSQNADILIACSFAIGFLKGF
LMLWFIRYAQKIFSAKNIRSEFYSYFYPLVYGGGQASMLVTAQLAYHYNWKYMYYFMMLL
ILVSVLFVIICFRHNRPIKSVPLSDLHIREMFIISVGLLMLIYVINYGKVLDWMASAKLC
AYIVISPILIALFIWIQHHSKNPYVSLAPLFQPKAIIGYFYMMLVMFFSTSTTLLTNYLS
IILKVDSTHTYSLYIFLLPGYVIGAFICFWWFRWQRWRFRFLIAGGMSCFVIFFGVLYFG
IAPNSTYEMLYLPIFFRGLGMLTLIIAFALFAVEDLNPKFLLSNAFFLIIFRSVLAPIMA
TSFYSNMLYRLQQKYIYSLSETITTADPLAASRYTQSLNNALAQGHRYDEAVQIATHSLY
GTLQEQSLLLALKEILGYLLVISVIIAVISRFIPFHKTIRVTFAKTGDDMV
>fig|226186.1.peg.1249 Membrane fusion component of tripartite multidrug resistance system
MRARNIILNMVCVCLAVSGLWWTITYFWRYINYEVTNDAFVDQYVAPLNIRASGYIKDIR
FKEHQYVRQGDTLLVLDNREYQIKVKEAEAALLDAHGLQDVLHSGIETSHTNIAVQDANI
AEAKAKLWQLEQDYHRFERLLKEESVPEQQYEQTKAAYEAAEARYQALVAQKQAALSQYA
ETSKKTTGVQAGILRKEADLDLAKLNLSYTVLTAPYDGYMGRRTLEPGQYVQTGQTISYL
VRNKDKWITANYKETQIANIYIGQQVRVKVDALPGKIFNGEVTAISEATGSKYSLVPTDN
SAGNFVKVQQRIPVRIELENISSEEMAQLRAGMMVETEALRK
>fig|226186.1.peg.1250 Outer membrane component of tripartite multidrug resistance system
MFLKTYRVYLMGPLCLMFAGQPAKAQTDSLFLSVDQLFERGVQHSLQLQADALKEAMAQE
RTRTARTSSLPDLQVGLKGGFVGQPVVWERGLSGPTYPDIPDWSQNYAIDFSQPLYQGGK
IRRTIHKAEMEKQVAELQTLTDQAEIKLGLLNQYMNLFSLFKQHEILMRNIEESELRLRD
IRRMKKEGVITNNDVLRSEMQLTNDRLSLQETENSIVLVSQQLDILLGQDENLLLKPDTT
LLHQAVALEAYDDYITLAYTNDPAMKLLRKQTELARNEIRLAQSLSLPSISLYASNTLAR
PVSRTLTDMYNNNWNVGLSVSYPLSSIYKNSHKIKESKLMVSLRKNDEEQKMQRIRMDVR
TAFLRHQEALQRVEALQLSVRQAQENYRIMQNRYLNQLAILTDLLDANSVRLNVELQLVT
ARTRVIYTYYQLQKACGRL
>fig|226186.1.peg.1427 Tetracycline resistance element mobilization regulatory protein rteC
MENFVRNSKLNIEKEIKRIEQQPIALLERIKQIIDVIQTSLTLLKRAVAEYQFQNPEEEI
QFFKVWKPQISGLLMFYIRLYQIEKNRVGKSLSAQCKYLKMELENIQKSFLNNSFYDYYR
AGQTELDNQYFIRENYDILSDVHCHLLDRDSSFTTLHDSSVAMILANSHLIEYVSDEIDS
LSDKLHLKFTSIVDSKLLQWTDSKVALVEFIYAIYAGKCFNNGNTSLKDIAFCCEILFNI
EIGDFYRIFLEIRNRKKSRTQFLDKLKDKIQKMMEELDR
>fig|226186.1.peg.1966 AcrB/AcrD family multidrug resistance protein
MNLRTFIERPVLSAVISITIVVVGIIGLFSLPVEQYPDIAPPTIMVSTTYYGASAETLQK
SVIAPLEEAINGVEDMTYMTSTATNAGTVSITVYFKQGTDPDMAAVNVQNRVSRATGQLP
AEVTQVGVTTSKRQTSILQMFSLSSPDDSYDENFLSNYISINIKPQILRISGVGDLMIMG
GEYSMRVWMKPDVMAQYKLIPSDITGVLAEQNIESATGSFGENSNETYQYTMKYKGRLIT
PEEFGDIVIRSTDNGEVLKLKDIAEVQLGQDSYAYHGGMDGHPGVSCMVFQTAGSNATEV
NQNIDELLEEVRKDLPKGVELTQIMSSNDFLFASIHEVVKTLIEAIILVILVVYVFLQDF
RSTLIPLVGVIVSLIGTFAFMALAGFSINLLTLFALVLVIGTVVDDAIIVVEAVQARFDV
GYRSSYMASIDAMKGISNAVITSSLVFMAVFIPVSFMGGTSGTFYTQFGLTMAVAVGISA
INALTLSPALCALLLKPYINEDGTQKNNFAASFRKAFNSAFDILIEKYKNVVLIFIKRRW
LAWSLLVCSVVLLVFLMNTTKTSLVPDEDQGVVFVNVSTAAGSSLTTTDEVMERIEKRLM
DIPQIKHVQKVAGYGLLAGQGSSFGMLILKLKPWDERPNDEDNVQAVIGQVYGRTADIKD
ASVFAISPGMIPGYGMGNALELHMQDKMGGDINEFFTTTQQYLGVLNQRPEIAMAYSTFD
VRYPQWTVEVDAAKCKRAGITPDAVLSTLSGYYGGQYVSNFNRFSKVYRVMIQADPQFRL
DETSLDNAFVRMSNGEMAPLSQFVTLTRSYGAESLSRFNMYNSIAVNAMPADGYSTGDAI
KAVQETAVQSLPKGYGYDYGGITREENQQSGTTMIIFGICFLMIYLILSALYESFIIPFA
VLLSVPCGLMGSFLFAWMFGLENNIYLQTGLIMLIGLLAKTAILLTEYAAERRKAGMGLI
ASAVSAAKARLRPILMTALTMIFGLFPLMLSSGVGANGNRSLGTGVVGGMTIGTLALLFI
VPTLFIAFQWLQERLRPVQSRPTEDWQIEEEIKVSEEEKSKAGKK
>fig|226186.1.peg.2101 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MKDSIDFGSMDISTLFRKLLVPTVLGMVFSAIFVITDGIFVGKGIGSDALAAVNITAPLF
MIATGIGLMFGVGGSVVASIYLSQGKRKAANINITQALVFSTFIVLVMSALCFCFVGPLG
CLLGSSDRLLPLVIEYMIWYLPFLVFYELLSTGMFFIRLDGSPNYAMMCNAIAAIFNIIF
DYIFIFEFGWGMMGAAFATSLGTVVGGLMTVIYLTRFSRNIHLHRIKLSLKSLMLTLRNG
GYMIKLGTSAFISEASIACMMFLGNYVFIHHLGEDGVAAFSIACYFFPIIFMVYNAIAQS
AQPIISYNFGAGQPDRVRKALHLAIRTALICGISFFIITFLCRQNIVSLFIDRSCPAFDI
AVNGIPYFGVGFIFFAANMIGIGYYQSIRRGQRATIITLLRGVVFMLIGFFVLPLVLGVP
GIWLAVSLAELLTTLYIIGIYFKDRFMVHRL
>fig|226186.1.peg.2377 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MNNKYEERLGTERMLPLVFKMALPAVAAQFVNLLYSIVDRIYIGHIPGIGTDALAGVGVT
TSLIILISSFSAIVGGGGAPLAAIALGQGDRVRAGKILGNGFVLLILFTLLTSVIAYTFM
EPILLFTGASENTLEYAVDYLSIYLLGTIFVEISTGLNSFINAQGRPAIAMFSVLIGALL
NIILDPIFIFWFDMGVKGAALATVLSQACSAVWVVSFLFSRRASLPLEKRYMGLDRKIIL
SILALGVSPFIMASTESLVGFVLNSSLKEFGDIYISALTILQSSMQFASVPLTGFAQGFV
PIISYNFGHGDKQRVKDCFRIVLVTMFSFNLILMLFMILFPSTVASAFTSDERLIETVRW
TMPVFLGGMTIFGLQRACQNMFVALGQARISIFIALLRKAILLIPLALILPNFMGVTGVY
AAEAISDATAAICCTLLFFGQFPKILGRIKGNTLRVE
>fig|226186.1.peg.2792 Inner membrane component of tripartite multidrug resistance system
MPSCPRNYPFYNWVPKPIGIIILLFFFLPILSVGGVYSVNSTEMMSGLGIISEHIQFANF
VTSIGMAAFAPFLYELVCIRREKLMCIAGFALMYVFSYVCAKTDSIFLLALCSLLTGFLR
MVLMMVNLFTLIKYAFGMEATRNITPGMEPKDATGWNKLDIEKCISQPVVYLFFMILGQM
GTALTAWLAFEYEWKYVYYFMMGILLLSILILFITMPNHGFAGRFPINFRKFGNVTAFCI
SLTCITYVLVYGKVLDWYDDPSICWATAISILFAGIFLYMDVTRRSSYFILGALRLRTIR
MGALLYLLLMIINSSAMFVNVYAGVGMHLDNLQNASLANWCMVGYFIGALISIVLGSKGV
HLKYLFALGFFFLALSAGFMYFEVQTAGLYERMKYPVIIRTIGMMILYALTAAYANQRMP
FKYLSTWICIMLTVRMVLGPGIGGAIYSNVLQERQQHYITRYAQNVDLVNPEASASYTNT
VQGMQYQGKSETEAHNMAAMSVKGRIQVQATLSAVKEMAGWTIYAGVICMIFVLVVPYPK
RKLLT
>fig|226186.1.peg.2794 Outer membrane component of tripartite multidrug resistance system
MDSPILSQPIKFVPEYRAIIMKRLLFIFTFFCLLAIHGGAQNILTLENCLRIGIENNLSL
QGKRKAMQKSKYGISENRVKLLPQINGFANFNDNIDPPVSVTDGSSYGVPYNITRTLQYS
ANAGIELQMPLYNQTLYTSISIAEIVDEMSRLSYEKAREDLILQISKMYYLGQVTAEQIA
LIKANITRLEELRDITQAFFDNGMAMEVDLKRVNINLENLKVQYDNAQAMMTQQLNMLKY
IMDYPAEKEIGLLPVNTDSIATVALTGLSENLYELQLLQSQVQLAERQKRLISNGYIPSL
NLTGNWRFAAYTDEAYHWFHSGPSNHWFRSYGVGLTLRIPIFDGLDKKYKIRKAMIDIET
MKLSRLDTRKNLQTQYLNAVNDLMNNQRNFKKQKDNYLLAEEVYTVTTDRYREGITSMTE
VLQDEMRMSEAQNNYISAHYNYRVTNLMLLKLTGQISSLFK
>fig|226186.1.peg.2939 Multidrug resistance protein
MITVNKKWIRLIGIVGCTVWMASCKQAPDAGVKSSYAVMQIEPTDKELSSSYSATIRGRQ
DIDIYPQVSGTIEKLCVTEGQKVRRGQLLFIIDQVPYRAALKTATANVEAARAATSTAEL
TYKSNKELYAQKVVSEFSLKTAENSYLTAKAQLAQAEAQEISARNNLSYTEVKSPSDGVV
GALPYRAGALVSANIPYPLTTVSDNSDMYVYFSMTENQLLALTRQYGDMDEALKNMPEVE
LILNDNSVYQKKGTIESISGVIDRQTGTVVARVVFPNESRLLHSGASGTVVVPSIYKNCI
AIPQTATVRMQDKTIVYKVVDGKAVSTLITVAGINDGREYVVLDGLKAGDEIVSEGAGLV
REGTQVK
>fig|226186.1.peg.3289 Permease of the drug/metabolite transporter (DMT) superfamily
MNKVNGFLYGLLSSASFGLIPLFTIPAMQAGMQFESILFYRFLFACMALGGILLINGQSF
RISRRDIPSLLLLAILYLMSAVFLFWGYKFMASGVATTIHFMYPVLTTLVMMLFFKEKKS
GWRIAAIASAVIGVYFLSGGNTETGSFSFFGLFIVLLSALGYALYLVTMSQLKIGRMKGL
LLTFYVFLFGGIFLLIGTSSISHLQPIREWHTAGNLILLALIPTVVSNLALVRAVKSIGS
TLTSVLGAMEPVTAVCVGIFLFGEAFTTSIGVGIALIIVAVMVIILKR
>fig|226186.1.peg.3336 Outer membrane protein oprM, multidrug resistance protein
MKKQILYMLCATALLSSCHIYKSYDRPEDITASGLYRDPAADNDTLASDTTNFGNLPWRE
VFTDPQLQSLIEQGLKQNTDLLSAALNVKAAEASLMSARLAYAPSIGLSPQGTISSFDKN
AATKTYSLPVTASWQVDLFGQLLNSKRNAQVTLKQTKAYRQAVQTQVIANIANMYYTLLM
LDRQLEITQATAEVLKRNAETVQALSERSTYTSAALAQSKAAYAQVVASIPDIEQSIRET
ENALSTFLGEAPHAIKRGVLEAQALPEELSAGIPLQLLSNRPDVKAAEMSLASCYYNTNS
ARAAFYPQITLSGSAGWTNSAGSAIINPGKLLASAIGSLTQPLFYRGTNIARLKAAKAQE
EQAKLSFQQTLYNAGSEVSNALSLYQNTSKKAESRQMQVESAKKASEDTKELFNLGTSTY
LEVLSAQQSYLSAQISQVSDCFDKMQAVVSLYQALGGGRED
>fig|226186.1.peg.3902 Membrane fusion component of tripartite multidrug resistance system
MAPIKSQNSNMLLAFLTLLGVIAIVAVVGFFMLRKGPEIIQGQAEVTEYRVSSKVPGRIL
EFRVKEGQSVNAGDTLAILEAPDVVAKMEQARAAEAAAQAQNEKAIKGAREEQIQAAYEM
WQKAQAGVTIAEKSYKRVKNLYEQGVMPAQKLDEVTAQRDAAIATEKAAKAQYTMAKNGA
EREDKMAAEALVNRAKGAVAEVESYIKETYLIAPAAGEVSEIFPKVGELVGTGAPIMNIA
ELNDMWVTFNVREDLLKNLTMGAEFEAVVPALDNKTVKLKVYYLKDLGTYAAWKATKTTG
QFDLKTFEVKASPMEKVENLRPGMSVIINK
>fig|226186.1.peg.4049 Permease of the drug/metabolite transporter (DMT) superfamily
MGNNKNLHGHLFALTANVMWGLMSPIGKSALQEFSAISVTTFRMVGAAAAFWILSIFCKQ
EHVDHRDMLKIFFASLFALVFNQGIFIFGLSMTSPIDASIVTTTLPIVTMIVAAIYLKEP
ITNKKVLGIFVGAMGALILIMSSQAASSGNGSLIGDLLCLVAQISFSIYLTVFKGLSQRY
SAVTINKWMFIYASMCYIPFSYQDISVIQWTSIPMVAILQVLYVVLGGSFLAYLCIMTAQ
KLLRPTVVSMYNYMQPIVATIAAILMGIGSFGWEKGIAITLVFLGVYIVTQSKSKADFEK
AGKEL
>fig|226186.1.peg.4502 Probable multiple antibiotic resistance protein marC
MSLSSLLIIFSSSFMALFPVINPLGNGFVVNGFFADLDPSQRKTAIQKLTINFIMIGVGT
LLIGHLFLLIFGLAIPVIQLGGGILICKTAIELLGDSNSSDKEGTSQNVDSFKWKSIEQK
IFYPITFPISIGPGSISVIFTLMASASVKGKLLHTGINYLVIALVIICMAGILYVFLSQG
QRIIQKLGPVGNQIINKLVAFFTFCIGIQISVTGISQIFHLNIL
>fig|226186.1.peg.4571 Quinolone resistance protein
MIKRNAAKPVRVAPPMMEEQEVSTSTLQELLEKEETVSNLIFSKGREEGISKSYKSFKNC
TFRNQTFSECKFRSSQLADIRFENCDLSNISFAESSLYRVEFIACKLLGTNLSETTMNHV
LLHDCNASYINLAMSKMNQVRFSHCHFRNGSFNDCRFSSVAFDSCDLVEADFSHAPLRGI
DLRTSRIGGITLNISDLKGAVITSLQAMDLLPLLGVIIED
>fig|226186.1.peg.4740 Tetracycline resistance element regulator RteB - Bacteroides thetaiotaomicron
MTRATSSVSFALRNDAENKERIFRTLKQANRK
>fig|226900.1.peg.182 Multidrug resistance protein B
MMAGSMVFPFYILLLRNVGNSFSQFGWAYGLFALTSALVYPLVGKISDQVGDKKLLIIYA
WSMAILMLCFPIATEVWHVYILQIVMGILGAVQRNTEKTSLARKVAQEKAGYEIGKYHVW
TSIGGAVAVIATGYLVDFFTIGTIFYIASILYVVSGIVLSSKKI
>fig|226900.1.peg.205 Permease of the drug/metabolite transporter (DMT) superfamily
MRRGQMIIGALACLIASMSWGAMFPVADHALEYIDPFYFSLIRYGAVAIMLIVLLLVKEG
KQAFCLEGRGKLLVFFGTMAFTVYNVLIFLGQMLMGKSGVMVASIMEALMPMISICILWG
YKHIKPKKYMITSMVIAFVGAVFVITKGDMSFFVTLKDNMFPLAFIFIGVVGWVIYTMGG
QTCSDWSTLRYSTLTCVFGTTVTGIITVIITSLGYISVPSMGTISIVKYDLLFMMTLPGI
VALLAWNYGVKILSSINGILFINFVPITTLAIMMMQGYQITMFDIIGTVLVIAALIRNNV
CQRKEENINKRVLQEEQLRQAV
>fig|226900.1.peg.236 Multidrug resistance protein B
MDRNVWIRFIGETLNGIAMMMLMPFFALYLKDKVDSLLEVGVIMALSPIAASFGSLIGGR
IADIYGRKPIMIFSMASNALLMLGFLFIEGFIPYAILSIFLGLSNSLFHPAASAMVADVT
APEKRTEAYGLLRMGHNIGAAIGPIMGASVVVLSKNLVFIIASSTMLFYALLVLLLIQET
MPKRTDKEEHKEKEAGTVWKIVMRDKVLMIYLLAGIIISMGFSQTEGMLPLHFDNEMKHI
FGTNNPYPYLMALNGLLVVLFQFQISKWATDKPVGKTMLYGACLFGIGLFFIGWLPKWFG
EFNTNATIILITLLFVYALYTLGEMIMSPVQMTFVANLAPEHLRGTYMGAASLQWITGSA
FGPLLGGFLLDRLLGHFLFTILAVGCVVAGIVYVSLDRLVEQRQKDTLTKQSS
>fig|226900.1.peg.272 Permease of the drug/metabolite transporter (DMT) superfamily
MKEICMLLVAVILWGTAIAPTKWALESIQPFTLLFIRLFFAGGICMIFSFKELQKSVVHK
KVPWKRMSLLAFTGVAGYFMFTSYGISLTSGLHVSIIDAALPLVTILFSALFLKEEIRLN
YWIGIILGAIGVLFITIPSKSANQEVSLIGDILILLSTFLFAFYTVLLKRPKQEQYLSNE
VFTTLTLIIGAVILLPFALVEIFYYGLPKVETWKTVLSVIYLVIGATILAYWFWNKALER
VSASVSGLYLNALPLISIITSIILLNESLTWRVIMGASLVLIGVGWADKQKLCNLLKGNK
VENRDC
>fig|226900.1.peg.405 Permease of the drug/metabolite transporter (DMT) superfamily
MKTEKFFTHPIGVFIAAIVATFLWGSAFPFIKLSYVELGIQPQEVGEQILFAGYRFFLSG
FMLLLFFKVLGKDMSFKKGTGKQLIQIGLFQTFLQYICFYIGMSYSSGIEGAIISGTSSF
FQILLAHFLYKDDALNMRKIIGVSIGFCGVVLVNMPSDGSLSFHFGIGSLLLLSAAMLYS
YGNILAKEGSKTLDVGYMTAYQMMFGSIGLLCIGALQVGVMPFTFSLHALLMLIYLSFLS
AAGFCIWNTIMKYNKVGKVSMYMFFIPVFGVLLSSMILGEAIHSFVLLGLACVAAGIIVV
NRTPAKQKIEKEKQVA
>fig|226900.1.peg.462 Daunorubicin resistance ATP-binding protein drrA
MKSVIEVQGLRKEFTAYSSRPGLKGAFRDLLNRNYKIVPAVNDVSFTVKQGEMVGYIGEN
GAGKSTTIKMLTGILTPTSGQITVNGMNPHNQREEFVRTIGVVFGQRSQLWWDIAVQESF
RLLKKVYGVSDAQYKEHMEHVIETLDIGPLLDKPVRKLSLGQRMRCELAAALIHNPPLLF
LDEPTIGLDVLVKLKIREFLKEMNERYKTTILLTTHDITDIEALCERVIMLDEGNIMYDG
SLNNLRTQWGAEKEIHFQFVAPVSYQALSMVMPDNHVVWSKAKEENAWVAKIPNEEVIIS
MLISKVVQAFQIKDLKINEVSTEEIIRNIYEEGITHG
>fig|226900.1.peg.463 Daunorubicin resistance transmembrane protein
MGKYIEMIRIRFLMMLAYRTNYYSGILIYTINIGAYYFLWQAIYSGKENIESLSISQMTT
YIAIAWMARAFYFNNIDREIAMEIQEGRVAVELIRPYNYLGMKVMQGLGEGIFRFAFFSI
PGMVIVTLLFSLQITTNFQTWLYFFLSLIFSFIINTQINLMTGMLTFFLFNNSGIMYAKR
VVIDLFSGLLLPISFYPLWAQKAMMFLPFQAISYIPSMIFSEGIQGSKLYEALVFQVIWA
IVLIIPIVLMWRTARKRLIVQGG
>fig|226900.1.peg.511 Permease of the drug/metabolite transporter (DMT) superfamily
MNNGRRIGLIMIITGATLWGLSGPMIQWLFQHTNVSSIDFLTIRLLLAGIFILSFLLIKK
QNIFQIWKHPRYSIQLIIFSILGMLGAQYAFIETVHISNAVTATLFQFLGPVLITMYVAF
EQRKFPASMQLFAIIAALIGTYFIITNGSIENIVLSKEAIIFGLLTAIGFAFYTLHPASL
IKECGTTVVIGWGMLIGGIALLIYNRSFGWNQFSQTLTLKTFSMLILIIISGTLSFLLYI
GSLKYLAATETSILSSIEPLVAAIVSITWLNESFGTYQLLGGVCIVLSVIFLTMPQKETE
PTYTTEQI
>fig|226900.1.peg.592 Bicyclomycin resistance protein
MKYFIYFIVIVAFLDTFSQLPIMSTFAQSLGGTPLIIGLVVGMYSFANMIGNIIAGAAVD
KFGAKKILYISMGITSFIVLLYTVVQSGEQLLVVRFMHGFSDGFLIPAAFTFLSKQTNAK
RQGKAMALSGAAVGTAAIVGPAFSGIMKATAGVEWVFITISILMALGTIVSLFFLPNNVS
RKDTSRTQMMNKEDMVELLKSEPLLQAYIGAFTLMFSQGIVTYMLPVKVEALALKASTTG
MMLSVFGITAILFFLLPTNRIYDRFNRSKLMLIGIAVMAFALSLLGLFATKGMLFIVMMI
YGIGFAILFPSINALLVENTTDDNRGKAFGLFYAFFSLGVVAGSFTVGAIGASPSVSFII
GTAFLLTFAGMIYVRSKVKKTMMG
>fig|226900.1.peg.638 Acriflavin resistance plasma membrane protein
MDRLTKFSLKNRAAIIIMIFLISILGVYSGSKLPMEFLPSIDNPAITVTTLSQGLDAETM
TKDVTDPLEKQFRNLEHVDTITSSTYEGLSRIDIAYTSKANMKDAAREVEKAVNTIKLPK
DVTKPVVSQLNTSMIPLAQITIQKQNGFSKADEKQIEKEIVPQLENIDGVANVMFFGKST
SELSIVLDPNQLKNKNVTSQQVLTVLQGKETSTPAGAITVNQEEYNLRVIGDIKNVNDIK
NITVAPQVKLQDIAQIEIKQHYDTISHINGEEGTGLIIMKEPSKNAVAIGKEIDKKVKEI
DKEYKDQFSIKLLASTHEQVENAVTSMGKEVILGAIAATLIILIFLRNFRTTLIAVVSIP
LSILLTLFLLHQSNITLNILTLGGLAVAVGRLVDDSIVVIENIFRRLQKDSFSKDIILDA
TKEVAVAITSSTLTTVAVFLPIGLVSGAIGKLMLPMVLAVVYSILSSLIVALTVVPLMAF
LLLKKTKHRKPSSSSRYVATLKWALSHKFIILLTAFLLFVGSIAAYILLPKANIKSEDDT
MLSINMTFPAHYNAESQKQKAFDFEKKLLSNSDITDVILRMGSSAEDAQWGQTTKNNLAS
IFVVFKKGSDIDQYIKELKKENKTFEPAELDYIKTSYSSSGGGNNLQFNVTATNEADLKE
AATIVETKLKSMDDLSKVKTNLEDSKKEWQIHIDQTKAEQLGLTPEIAAQQVAFLMKKSP
IGEITINNEKATIMIEHKKENINKQEDILNTNILSPINGPIPLKDIATISEKQTQTEIFH
KDGKETIQITAEASNEDLSKVNTAVNKAMTDLDLPGGAKVNIAGATESMQENFTDLFKIM
GIAIGIVYLIMVITFGQARAPFAILFSLPLAAFGGILGLIISRTPVDVNSLIGALMLIGM
VVTNAIVLIERVQQNREHGMETREALLEAGSTRLRPIIMTAITTIVAMLPLLFGQSQAGS
MVSKSLAVVVIGGLAVSTALTLVVVPVMYELLDKIGRKRRSRRKISTSTETLDI
>fig|226900.1.peg.756 Modulator of drug activity B
MKNIFIINGHEKYGTKEGRLNRTLVDYMVTVLGENHHVKTTTIQDGYNIKEEQDKFLWAD
VVIYQTPIYWFSVPGLFKTYMDEVYEYGLFFKGADEYGTGGLLKKKEYMFSTTWNAPEKA
FGDKTKFFEGESLESALSHLHRVQKFLGMSPLKSFACYDVVKNPDIEKFLVNLKDHLDGV
IK
>fig|226900.1.peg.758 Multidrug resistance protein B
MGFWSMHRNIKIRIITSFLTRTVSTMIFPFMAIYFSIKLGSAVAGALLLINVIVSLVIGL
YGGYVGDLLGRKKVMIIGQSIQVISIACMGVANSDYVDSPWLTFIFMLVNSLGSGLMNPA
TEAMLIDVSTPENRKVMYSINYWAINLSIAIGAIFGGLLFENYRLQLFIVLTLVAIITLY
VMAVYMEEVYVARKTVEKKNVLKGMADSYKVVMKDKAFLIFCAASICTLSLEFQINNYLG
VRLQKEFETVHFFFGNGVTFDLTGIRMLSWISAENTILVVLCSALLIKMLKSFNDLKILY
VGLFIYTIGFTILGTSNSLWILLIAGLFQTVGEMMYVPVRQSIMADMVPNEARGSYMAIN
GMVFQVAKMNGALDVMLGSFIASWGMSALYFIVGMSSILLFMKAIGKEKYEDERNVSQIG
>fig|226900.1.peg.768 Multidrug resistance ABC transporter ATP-binding and permease protein
MLSVLLKLKWFFREHWKRYSIAIGALLIVNIVEVIPPKVLGVTIDNIKTGTLSNEAIIQS
ILILIGVTIVGYGLTFVWQHQLFGGAFVLEKTMRSKFMGHLLKMTPTFYQKNRTGDLMAR
ATNDLKAIAMTAGFGILTLVDSSLYMLTIVFMMGFTISWELTFAALIPLPIMAYAMNIYG
KKLHERFTVAQDAFGDMNDKVLESIAGVRVIRAYVQENADEERFHHLGDDVYEKNMKVAK
IDALFQPTVKMLVGLSYLIGLVYGAYLVFQSKVTLGELVSFNVYLGMMIWPMFAIGELIN
VMQRGNASLDRVNETLAYEPDVKNPKHPKLVQEPDYIQFDDVSFSYPSSTEENLKKVSFT
LKQGETLGVVGKTGSGKTTLVRQLLRQYPLGDGDIAVSDVTLDKMTNENVLGWIGYVPQE
HILFSKTARENILFGNREATEEELEKAIEIAAFKKDLEFLPEGLETLVGEKGVSLSGGQK
QRISIARAVIQNPEILILDDSLSAVDARTEAAIIENIRTERSGKTTIITTHRLSAVQHAD
WILVMDEGAVIEEGTHDQLIQKGGWYAEQFERQQGESESADSGVKI
>fig|226900.1.peg.769 Multidrug resistance ABC transporter ATP-binding and permease protein
MYKAKALTKEEVFAFYKPEINRLLLLGGGYFALLVVVSLFAYGKQFFLQKAANKIIQIMR
EDVFSHIQTLPIRYFDHLPAGKIVSRVTNDTEAIRDLYVTVLATFVSSIIYIIGIFAALF
LLDVKLASLCLLIIPILIVWAILYRKYASVYNHKMRSRLSDINGTVNESIQGMPIIQAFR
QERETKKEFEELNGDYFKYQNKILNLNAATSHNLVAVLRNIAFTGVIWYFGGASLSATGI
ISLGVLYAFVDYLTRLFSPITNMVNQLANLEQARVASERVFELLEEKGEPVEEERMPRLK
GNVKFDNVSFSYNGKDEVLKNISFEAKQGETVALVGHTGSGKSSIMNVLFQFYEFEKGKL
TIDGHDVKEMPKQATREHMGIVLQDPFLFSGTVASNVSLENEKISKERIIKALHDVGAER
FANNINEEITEKGSTLSTGERQLISFARALAFDPAILILDEATSSIDTETEAMIQQALEV
VKKGRTTFIIAHRLSTIKSADQIIVLDRGTILEKGSHDELMKKRGRYYDMYKTQMEGNQS
A
>fig|226900.1.peg.876 Teicoplanin resistance protein vanZ
MHTEVLMSYLYTYFFTIMFCILFQIGFYFKAKRNISIRHFLWVYVFLFYLSLVYKVTQIA
TVWDISRYETWIRVSQINLTLFDTAGSTTYLLNIVLFMPFGFLLPMIWPYFRKIKNTVCA
GFFFSLAIELNQLLNNRITDIDDLFTNTLGAIIGYLLYRALKMIFKREGEKLDTSSSLVI
KYEAIFCLVCSFVGAMLIYHPALFGRPVIIQ
>fig|226900.1.peg.936 Teicoplanin resistance protein vanZ
MSEFDEYIKSILAYSELSDIEQDELFLEMYDHLNSLKEEYMEQGMNEKEAIYKAIQSFGE
SKVIGVEINKSVYEVPRPLKVLSKILCIPYIIICFIVFLGTFISTSTFDSVRSLTGGGTV
YHPIEFWQQFLHISDLETLLQLFGITLWQVKDFIAHPGPWGNSTYWLSVLQHIILVVPFG
FFVPVLINKVTNYKKARKWYVMTFLVWEILHLLTLSDVFDVWQIAINMLGASVGYLLFIS
IMQLDNKFRVMRKKIFEN
>fig|226900.1.peg.1123 Permease of the drug/metabolite transporter (DMT) superfamily
MKQEKSIALPLAISIIAISFAAVFVKMSSAPSSILSMYRLWIIVLIMLPIVWKKREEFNR
IQMKDWGFLIGSGFFLALHFLLWFESLKHTTVASSTIILALQPIVSLVGGFFLFKERTTY
SAIATMGIAILGVMCIGWGDLGLSKQAIYGDILSFLSVIAVVGYLFIGQTTVKKVSHWIY
SFTVFAFAGLFMGIYNVILQVPFTGYTRWDWTVFLLLAIVPTVSHVINTWLLNYVNATPI
SMSILGEPVGASILAFCLLGEKLNAMQIIGSMLVLFGVSVFLLQQQKRTAKNVVNEPVYT
QEL
>fig|226900.1.peg.1272 Gentamicin resistance protein
MDSYKHYIKEALPNLSIHSYKQNEEGWDNVAVIVNDELLFRFPRKQEYAMRIPLEKELCA
ILTQSLQEIEVPQYHLIYKNESDEVPLCSYYTLIHGEPLKTETVATLEDPKLKAIITQLA
TFLAVLHSIPLHQVTTLCFPIEKTCTYWKELQTKLNQYLTTSLTSLQKLALNRLFENFFA
CLATSTFQNTIIHADFTHHHILFNKHNKSISGVIDFGDAQIGDPAFDFAGLYYDFGHEFT
TSVYEQYSTLISHHDPLLIHRITTFYQYSPLLHNIIYNFESENELEFITGTEQLKTILQG
>fig|226900.1.peg.1568 Tetracycline resistance determinant tetV
MKIATRNIILMMIGKMTSLLGAGIYTFAMGLYVLKTTGSGMGFAITLVCGSLPRMICGPI
AGAVADRVNRKWLVIGTDLLSSLTMLSMFILATIFGPSLLFIYISAALLSICASFYSVAL
TSSIPSLVDEGRIQKASALNQTAASLSNILGPIIGGVVYGFFSIKSFFLLNSITFFLAVI
LQLFIVFDLYKKEVAESTEHFLTSIKEGFLYVKRQREIYGLMKIALWVNFFACGLTVALP
YIIVHTLHLSSKQLGTVEGMLAVGMLMGAIALSVRKEVNNPFRSIYTGLFLFAGLSLCTA
FPLLVIIPKVASFIYYIAFMMLTGIAIMIVNIPMQVHMQKTTDPSYLGRVFGLLETIATA
IAPLGMIVYGLLLDMLPTSIVMMTIGGGLLLVVLVGVKQHMAKKQVDVSA
>fig|226900.1.peg.1621 ABC-type multidrug transport system (daunorubicin resistance), ATPase component
MMNTLEIKNLTKKFGNFIAVDNMSLSIKEGEIFGFLGSNGAGKSTTINMIAGLLRSNEGE
ISILGKNIKKHNRFAKMNIGIVPQDIAIYEELTAYENVKFFAGLYGLRGAELKARVEEAL
KFVGLSDKQKSYPKNFSGGMKRRLNIACAIAHRPKLIIMDEPTVGIDPQSRNYILQSVRK
LNEMGSTIIYTSHYMEEVEEICTKIAIVDHGKVIAEGTKEQLKAIITDTKDIWIEVKSVE
NLDVEKLKEINGVKAVQIEENVIKVNSDAGLNNLNKIIQHCINHDIEIRSLEEQAPNLET
VFLTLTGRNLRDK
>fig|226900.1.peg.1644 Drug resistance transporter, EmrB/QacA family
MEQSKGIKIVFLMCLGIFLCMIDTTIMNIALPAIQSSVNTSLEKMSWVLNVYTMTIAVLA
IPLGRIADIFGKAKMYILGLVIFGGGSVLCAFANTGDFLIFSRFIQSIGAAILFPTSMVI
GVSAMPLAKRHVALAILGVTQGLSAAMGPVIGGIITQHLGWRWVFFVNVPVCIIGIVLCC
IMLQIKNEERIISKIDWIGLLLSSTAIFSFTLILVKGNTWGWQSNIALSCYAISTISLIL
FVLVERKIHNPMVNLKLFQDRMFVGASIVVILSNLFLIGVTVLLPTFLTKLQGRTEIEAA
FLVTPISAMIFFVSPVAATLIKKLGKVTIILSGFLIMGLSYYWLQMIDVHSTNIEIIIPC
MILGVGYGLVVGPITVLSASSFEGELLTASQSVVSMLRQVGIVLAVAIFVSNLTHNLTVN
KEKVYRYAEEKVRTIHVNSTEQTEILQMTKEKIENQSLESNINKKQNAMTMGLSKEKKEE
LIRDKTDEILRKVPVEYRDVKREEVMRQVTKEVEKQEESIKKEVLTFSNDVNHYAKNQMA
MSFTDLYKASVPIILICAFVSLLFWEGKALSKKRKGRIVEEA
>fig|226900.1.peg.1714 Quinolone resistance protein
MKIDRPKISPELSSKNFQDIFYEEDPTLEVCEIIDSTFENESVDRVRLYDAVIKNCKFTN
TDFSNIDITDVCLENCDLSNVNLSNSSVHRVEFKNSKLIGVNFTESSLGNVKFENSILNL
AAFGNSKLEKIIFNETSLNNADFFDCKLKKVEFQLCSLDEANFDQTSLKGIDISSSTFDT
LTVSVNDLRGCKVSTYQAVQFATLLGLIIKD
>fig|226900.1.peg.1941 Multidrug resistance protein B
MAFVNMYTVLGNYLSSPTYNLTAEQILYFRLAGLFGMLLSPLAGRLTKRFEVRKVLQGGL
LIAIFSLSSIGFVSYLSLLVMMSVCFVIGIAISVPSLVSLVGQLGGEIRNDTFYWFCSFS
IYN
>fig|226900.1.peg.2224 Permease of the drug/metabolite transporter (DMT) superfamily
MKSPILSYFILFFGVFALSTSAIFVKLADAPATIIAFYRLFFATLILLPLLLFNKNSRNE
LKTLTKKQWTFGFISGLFLAAHYVLWFESLQYTSVASSTVIVTLQPLFSMIGGYFLFKER
FTKGAVIGCLIAISGSIIIGWQDFQISGEALYGDILAFIAAGIITAYFFISQHVRKDLSL
IPYSVISYGSSAGFLGIFAFTQQESFIHYFTQTWLCFIGLAFIATILGQTIFNWLLKWMS
ATVISMSILGETIGTCILAYFILHETISLQQGLGITVIFIGLVLFLLQPSSNKKA
>fig|226900.1.peg.2391 Glyoxalase/bleomycin resistance protein/dioxygenase superfamily
MITHISDIKLQTVSIEGVKQVYKDILSFPIKKETASFIQFEVTPYTTISFQEVYEPIAPA
HFAFEIPYSKFHETAKWLKDSGLLIVKWQNGNVIGEENGLFNLYFKDGDGNLLEIIAHSY
VKEDVLVPHSPLNILYVREIGLPVKSVPVFTEWLKSNLNMKTMEDGDIFNFVIGGTAYIV
ATWWQRPWIPIAMKALSPKVYVSFGTPDVAFLQRIQNNFKKNSVSFECKRNEVSFIEQGY
TFSIVHTSEFHSDIPKQLNLPLSI
>fig|226900.1.peg.2532 Teicoplanin resistance protein vanZ
MINGSLFIILGVICYLIVRGILIGTKNKKHVIWWKEIVSFLFVVYICMVVAVTLFPLPIG
FPSNVENLNRSVNIIPFASIIKDINQIGSAYDGDALFMIGLIVRNVGGNILLLMPLGFLA
PILWDKYKKFKNTILLGFSISASIELLQLIESLFSGVGRITDIDDVICNVLGSIFGYCIY
NIFLKAINKFNIRVLGKTNSKGVELVDK
>fig|226900.1.peg.2557 Quaternary ammonium compound-resistance protein, C-terminal
MITTIISSVVAFATTNIDDIFILLVLFSQVRTEVIRKEGRAVREKATRKKLYIVIGQYLG
FSMIIFLSIIGSLSSFFIPVSWIGLLGFVPIYMGVKGLLSLRSYKSNEVIDNVTVSLFKV
ASITLANGADNISIYIPMFASQTLETNIVTLVIFFSMIAIWCFISYKLIKAPILAKVLEE
NCHIIVPIVLIGLGMFILFRSGTIGLFS
>fig|226900.1.peg.2737 Zwittermicin A resistance protein ZmaR
MIYEANIHTRKKLVSMFEDFNNVVLLSYLQGHMGTAWVNDLENPKVAQVTVGIFTFYAGD
PNTKETEELLRNIPERILVIVNSEEWKQRLETFHERKIDKFLRYKFKRNPEVFNRSKLKS
FISALPKEYELRRIDEHIANSPTLHKISEDFTSQFHSVEDYINRGIGYSILYNGEVVCGA
SSYSIYNDGIEIEVATDHNHRREGLATVVSAALILDCLENGKYPNWDAANTTSAKLAEKL
GYEFDKAYDTYFVDNR
>fig|226900.1.peg.3004 Zwittermicin A resistance protein ZmaR
MICELSKDDFYRCNRLVNEQGQLEVRAVIAGVNPGRIFVDNVTSPNSGLIWLGNNDGFFF
IGDAENEEFNKEVNRFINHVIVPEARKVGLDCFEGIGNHSKWNKTIERIFQHRKLKSWNQ
RVYMLGKEDYENHHEPKFEQRYTVLKMSKALYENNNNTFKNIDFLQSKILEFWSSPDSFF
NEGIGYCIVYDDLIVSVCFSGFVFENIHCIDIETIEGHQGRKLAQKIAHSFVKDCLENDI
IPYWDCMELNKPSVAVVENVGFTNVFNYVGYYFLFE
>fig|226900.1.peg.3015 Bicyclomycin resistance protein
MSNFKNKAIDKDISSGLIILLATACGIIVANLYYAQPLIGLISNEIGLSNSSAGLIVTLT
QIGYVVGLLFLVPLGDIVENKKLILILLFLSAFALISMVFVKSATLLLIASFFIGLGSVA
AQVLVPLVSYLSSENARGRVVGNVMSGLLLGIMLARPISSLVADMWGWNAIFALSATVII
VLAFVLSKVLPTRKPKAKTNYIALLNSMWQLLRTTPILRRRAIYHACVFGAFSLFWTTVP
LLLFSPAFHFSQTAIALYALVGITGAIAAPIGGRLADLGWTRPATGIALTVVIISLILPL
FIQSSSSFGIAVLVIAAILLDMGVSANLVLSQRLIFSLSPEIRSRLNGLFMAIFFLGGAV
GSFIGGWAYALGGWNLTLWIGIAFPTIALLYFAREE
>fig|226900.1.peg.3044 Permease of the drug/metabolite transporter (DMT) superfamily
MKPIKANLMILLVTMTWGTSYLFMKIGLETVPSFSLVALRFGIAFFVCAAVFFKQFRSIH
FVTLKYGFILGFLLFVVSASVILGLKTTSASNAGFLASLTVIFIPLLSIVLFKDRLSYRL
IISSLVAMTGIGLLTLNNQLTLNSGDLLCILAALFYAFHIIVTGRAAKVANTLQLGILQL
GFAGGFGVLSALIFEEPQLPSTKESWIAVLVLSIFCSAFAYIIQAMAQKYTTPTHTGLIF
SLEPVFSALFAYLFMNEVLSLKGYIGALLILSGVILAEIKVKRKSTLLL
>fig|226900.1.peg.3240 Chloramphenicol resistance protein
MNSYTASSSEVQTNRRSIFALLALAISAFGIGTTEFVSVGLLPSISEDLHVSVTTAGLTV
SLYALGVAFGAPVLTSLTANMSRKTLLMWIMIIFIIGNGIAAVATSFTVLLIARIISALS
HGVFMSIGSTIAAALVPENKRASAIAIMFTGVTVATITGAPIGTFIGQQFGWRTSFLAIV
VIGIIALIANSILIPSNMKKGASVSFRDQFKLITNGRLLLVFIITALGYGGTFVTFTYLS
PLLQEVTGFKANTVTIILLVYGIAIAIGNVIGGKLSNHNPIRALFYMFFIQAIILFVLTF
TAPFKVAGLITIILMGLFAFMNVPGLQVYVVMLAERFVPSAVDVASAINIAAFNAGIALG
AYLGGIVTNSLGLIHTAWVGGIMVVGAVILTAWSMTLEKRDQVK
>fig|226900.1.peg.3281 Daunorubicin resistance transmembrane protein
MKSKTGVLLGRLMRNIMRSPDTIITVAITPIMMMLLFVYVFGGAIKTGTENYVNYLLPGI
LLMAIASGVAYTSVRLFTDVKSGLMARFITMPIKRSSILWAHVLTSLVANVLTIVVVILV
ALLMGFRSSANILDWLAVAGILGMFTLALTWLAIIPGLKARSMEGATAYSYPLVFLPFIS
SAFVPTETMPKIVRAFAENQPVTSIVNAIRALLYKGTVGNDIWIALAWCVGIMIISYFFA
SKAFKRQLG
>fig|226900.1.peg.3282 Daunorubicin resistance ABC transporter ATPase subunit
MSHAAISVKGLKKSFKDKEVLKGVDFEVQRGEIFALLGSNGAGKTTTVNILSTLMKQDSG
EVSICGFDVQSQSDHVRQSISLTGQFAALDGMLTGRENLIMIAKLRGVSNPAQVADNLLA
RFSLTDAANQRADQYSGGMKRRLDIAMSLIGAPAVIFLDEPTTGLDPEARIEVWDTVKEL
AGSGTTILLTTQYLEEAEQLADRIAILHGGKIITTGTLAELKEMFPPAKVEYIEKQPTLE
EIFLSIIGKKEEM
>fig|226900.1.peg.3378 Vancomycin B-type resistance protein VanW
MVGVLCVAIMSGCGAKVSDVALVSDIGGHTVEAKAEVQDTISLVDGRTGTEVKKLDLSSL
GYFEDEAKFKKSVTKVVGEVGKSVDKKMVPSRIAPDGSWQEGKPSYELMEKELVDKLLNV
GMWDATYQLPIVEKKPVATLSDAQGNGTVIGRYETNLGGSTGGRIENIRLSAASINGVVL
AKGDRFSFNSLIGDTTPDKGYQLGKEIVDGKLVDGYGGGVCQTSSTLYNAADQAGLKMVE
RTTHSKTVGYVPQGRDATIAYPYLDLVFENTNDAPVKLYMGIQGGKLVAEVHKMR
>fig|226900.1.peg.3503 Permease of the drug/metabolite transporter (DMT) superfamily
MLRYSLLVLLGACSYGILAIFVKLAYAEGFSLGEVIGSQYLFGWIILLAITLLFSRHRVP
LKQALLLFVAGTSASFTGIFYYASLKTVPASIAIILLFQFVWVGIIIEAVATKTLPSREK
VISVIFLLVGTFLSSGLLEQSAGAFDTTGIILGLLSAVTFATYIFVSGKVAVEVPSLPRG
VLLMTGALTLVMIVFPPTFIFNGAISQGLWKYGLGLGTFSIVIPSIAFTIGIPKIGSGLA
TILGAAELPVTTIMSVFVLKEAVLSSQWFGVSLILIGIAIPQIAYAMRGRYRKHHTHKKV
AA
>fig|226900.1.peg.3518 Multidrug resistance ABC transporter ATP-binding and permease protein
MKPYKGLLSLAFIFLVGATVTEMMGPFLIKQFLDEHLVPRDFERSALVTLFVIYIVAHLL
KVLFTYLNLLYFQNIAFKIVQDMRVEVYEHVQKLSLSFFDRTPIGTLVSRITNDTEAIKD
FYVSVLSTFVKNVVFLVGILVAMFLLDVKLALFSLVLIPIMFAIMVLYRRKSAAFYLEVR
NQLSVLNAKLNESIQGMNIVQVFRQEKRMRKEFEEVNNKHYSAGRRTLKLDALLLRPATD
LVHIVAIALVLGLFGIDALKSPVEVGVLYAFVNYIHRFFQPVNEMMMKLSFFQQALVSSS
RVFHLMDEKDLAPVQKGNENPQIVDGDIEFKNVTFSYDGKRDVLKNVSFHVKQGQTVAFV
GHTGSGKSTIMNLLMRFYNIKSGNIVIDGVDLEKFEEREIRKKIGLVLQDAFLFAGNVKQ
NIRMYNEEITDEEVKEAARFVQANTFIEKLPKQYETEVVERGAAFSSGQRQLIAFARTIA
TNPKVLVLDEATANIDTETEEAIQTALQQMRKGRTTIAIAHRLSTIQDADQIFVMHDGEI
VERGTHQELLSEQGLYYNMYLLQNKVSLQKAL
>fig|226900.1.peg.3519 Multidrug resistance ABC transporter ATP-binding and permease protein
MFMNLAWFFKQEKRAYITGIILLFGVALLELVAPKVIGIVVDEINDGTLTTDKLLKWVVL
LVIVGITMYILRYIWRIMIFGSSLKLARQLRKNLYEHFTKMSPSFYQSNRTGDLMAHATN
DIQAIQQTAGAGVLTLVDSLAVGGCVLVAMGFTISWKLTLLSLIPMPIVAISTNYYGTLL
HKRFHKAQQSFSEINDKVQESMSGMKVIRSLGQEKEDLQAFRRKSEDVVHKNVLVARIDS
LFDPTISLIVGFSFLIAVCYGSVLVVRGELTVGDLVTFTTYLGTLVWPMLAFGWLFNIME
RGRASYDRVEKILSQKSDVVNSENAVHTIASGNVSFAVDSFSYKKNELLHLNDIHFDLKK
GETLGVVGRTGAGKTTLLKCLIREYDHFNGELKIGERDIRDITLHGVRSAISYVPQDHFL
FSASIGENIAFGKADATYNEITQAAEIACIHNDILQFSEGYETVVGERGVSLSGGQKQRI
SIARALLTNAEILILDDCLSAVDAKTEETILSALKRERAGKTTIITAHRLSAIQHANLIL
VVDEGRIVQRGTHEELMKEKGWYKEMYESQQLEALVEKGGV
>fig|226900.1.peg.4469 Permease of the drug/metabolite transporter (DMT) superfamily
MNKNQMLLGSFLCLLAVTAWGFMFPVMARALQFIDPFFFTTLRYGSAAIIFLILLLITEG
KTSLRLEKRTLSLFFYGTVGFAGYGFLVFYGQQLAGPSGAIHAAMIQSLMPLIALSLQWI
TQNRRPQNYTFLCMFVALLGVMLVISKGNIELLFGAASHLSTNILMLCGVTCWVIYTNGA
ARFQSWSPLRYTTLTCLFGSISLIVIVTFLTYTNIVTMPSLRTVVSVRFELFYMSIIAGV
IAVFCWNMGNRYISSINGILFMNLVPILALIGSIFRGYTVDKIEIAGAALTIIALLCNNL
WQRKVNIKIPTSVR
>fig|226900.1.peg.4581 Permease of the drug/metabolite transporter (DMT) superfamily
MRRWGIELLILSVVIIWGINYTIAKYGLLEFTAIEFTALRMMAAAPLLLLLTFCIEKSVY
MERTDIPRLIIVSVVGIVLYQTLFMETVKYTSATNASLLISISPIFTTAFAIFLKQEKFS
SRKLIGSMTAFVGAALVLVAGHSLTSSFYGNGIGLITSICWGLYPVLAGPLIKKYSALRV
TAWSALVGAIPLLLLSGPHVFVMPFHITHGMTLFALLYSIFFVTVFGLVMWYVGVQKIGA
SHTMVYMYITPLVAVLFAAVWANEYVSFQQIIGGIIIFVGLWFVKSEKVKVHSIAGEPIS
K
>fig|226900.1.peg.4872 Glyoxalase/bleomycin resistance protein/dioxygenase superfamily
MIKELDHVMIKVQNLEESITFYSEQLRLQIIWEYDNYVGFHNGIVIHDSKNSENLTSFFK
VDSVEETVKILKESNVKIILEPTPIPTGYTAAFQDISNNIIHIVDNINLS
>fig|226900.1.peg.4954 Pristinamycin resistance protein VgaB
MTILFARNIEKSFGDRTLFTLPSLEIQAQDRIGIVGVNGAGKSTLLQILSKEIEADRGIV
THHSSIAIILQLSEELPETASSLAKGKWSISNVTDAMSGGERMRLKIAHALEQNAGILFA
DEPTSHLDMVGTEQLEKALSSYKGALVLISHDREFLDNICTKIIEIEDGIIQEYKGNYSN
YRKQKERERIQKQAEYEQYIQEKNRLEQSILQRKQRASNMEKIPTRFSSSESRLYRLSGA
HGQEQVSKAAKALETRLEKLEKKEKPKDLSQAQFDVQYHTPIHSKVAVQFNKATKKIGDR
ILFKNMNGTIAPGAKLAVLGANGSGKTTLFNMLLTNERGMQLSKSCKIGYFEQTLSILKT
DKTILENVLEETNYTEAFVRTILARLLFRREDVHKPVHVLSGGERMKVALAKVFLGNYNM
LLLDEPTNYLDLATQEELETMLQEYPGTILFISHDRAFIRSVADHILQVDESEPRVFHGN
YEQYTKRTTGDSVNVTEQELLRLQTKLTEVIGRNSIPNHHNDISSLEQEYETLLVKIRKC
KEAL
>fig|226900.1.peg.5204 Multidrug resistance protein B
MTSEVNKRTFFTKSTLIIIPLLIICAFAFHYFFLKSDNVFSSTGDALSQFSFFTFLLQHA
FKDGNLFWSWDYGLGGDLFGEFSYYYSTAPFFWLTLLLPKLNFDQIFEMKLYMSILKSTL
AMLFMYGSLRYHNKTIFSSFISAIIYGGCVTFIRHSLLWDFMADAIVFLPLVIWGLDKYI
LERKKGLFLFATALMLASNFYFAFITSIFIYIYAFFQYFATQQNKTIKTFIIYYIRIAFL
YALSLGLSAVCFIPSVNGVFSSDRLATKFTIPLFFEGTFYKNLMESIFFINNTEDYQLAF
PVFILFLITSALLIRNKLVTNKLTFTGFMLVLYMLPYTYSVFNGFSAMQYRWFYLFAFVV
AQTVAYILDWMLLNKQKVNSLIGPLLATTLFIYAFYRKVNINAQPLQTIDKILICTTVLS
IITILLWRYLSKVALQCFIVLNVLVNVIFINYFYSDFALSKHFNQAGVTKESLHGPGLDN
KDEIDAIRYIQNQDKDFYRIINPNNNYKNTPMLQGYHGTSTYQSLVNYHVHDFMKNKYNV
FQGYDSPSMFFQLDKRLFLENMLGVKYYVLSEGANKTEIPYGYKHLQQVGPYNIYKNEFA
LPLGYVYEAGISDEEFSKLNFAEKDQLLLDAVVVNDVGSLPLKQFNTKQLDSKQIKINPN
KMKWENIEKEKDILTVHENGRIIVPIDNNDMLGDLLVEIKIRNINKVSFGVTVNNKSMIK
GNEDGAYAYPLERFVYNLGKDAKPTELIISIPTPGQYELKDLQINSTNYQTVPKKVNTLK
ENSLQNIYYEGNSLKGDINSTKDGLLYLSVPYSKGWSIKVDGKETEFTKANSAFIGVPIS
KGQHVVEMKYVTPYFKMGLVISIISFIICISLLVLGDTKRYSKLKSRFKKRY
>fig|227882.1.peg.1994 Permease of the drug/metabolite transporter (DMT) superfamily
MSSIAVPGALAPRRAWLTDLPVLLVAVVWGASYLAAKDITTARTVIAVLVLRFGVVLPVL
VIAGRRSLRALSAAQWRGAALLGLILSGIFLLETYGVVHTSATNAGLIISLTMIFTPLAE
AAVTRARPPRAFLAAAGVSVLGVVLLTQGGGFTRPSLGDLLMLLAALARTVHVLAMSRVK
SVQGADALPLTTVQLGAAVAVFAVLSTGTDATVWGTAAGFGAREWGGLLFLAAFCTLFAF
CVQMWAVRRTSPSRVSLLLGTEPLWAAAAGITLGGERLGALGLMGGVLVLAGTAWGRRAA
G
>fig|227882.1.peg.5649 Drug resistance transporter EmrB/QacA subfamily precursor
MTETLTSPTTRSPVAPPVLGGLGLFTVLLGAALPLIDFFIVNVALPTIGRDLHASETVLE
LVVAGYGVSYAVLLVLGGRLGDLFGRREFFLGGMAAFGLTSLACGLAPSAWTLVAARVAQ
GAAAAAMLPQVLATIQSATEGPRRAKAMGLYGATAGLSMVAGQILGGVLVAADIAGTGWR
SVFLVNVPVVVVGLFLAARAVPETRSQRPEPVDGPGTVLLAVSLLTLLVPLTEGRAAGWP
LWTWPALAAFPFAAWAFYAVERRADRQGRTPLVPPSLFALTSLRRGLVMIVPFSIGFSGF
MFVIAVALQRGAGLGPVPAGLALAPMAVVFFAVSLCGPRLVARYGTRVVTAGGLIQAVGV
TLIVLAALRSWPDLGVLELLPGAAVAGAGQALQLPVLFRIILSEVPPTRAGVGGGVMITT
QQSGLALGVATLGSLFLALVPGWGMRDALVTTLLVQLAGVALTTALSLRLPRSIS
>fig|227882.1.peg.5651 Drug resistance transporter EmrB/QacA subfamily precursor
MPELSPRRRLLVLAICCLSLLIVSLDNTVLNVALPSMQKELHASVAGLQWTIDAYTLVLA
SLLMLAGSTADRIGRRRVFRTGLVLFTIGSVLCSLAPNLESLVAFRMVQAVGGSMLNPVA
MSIITNTFTEPRERARAIGVWGGVVGISMAAGPIVGGLLVDSVGWRSIFWINLPVGLVAL
LLTWRYVPESRAPKARRPDPVGQLLVIALLGSLTYAIIEAPSSGAAEILAFGGTALAALI
ALLWYEPRRAEPLIDLRFFRSVPFSGATVVAISAFAALSGFLFLSTLYLQNVRGLSALHA
GLWMLPMAVMCFVCAPLSGRLVGSRGPRFSLLTAGIAMTASGVLFAAFEAETSDVTLVIG
YVLFGVGFGFVNAPITNTAVSGMPRAQAGVAAAIASTSRQIGGTLGVAVVGAVLASGVRT
GPYRQVFESAARPGWWIIAGCGLSVLVLGALSSGAWARATARRTAQRLESTEVRDEAGVN
A
>fig|228405.5.peg.473 Permease of the drug/metabolite transporter (DMT) superfamily
MLPMSPVAQLRRMRLYPPLQSGGGGRRRSRLTEGGSQAVPPPHSSPAALTRRAPCPLSQN
PDRPEPIMAIRDFILLCAVCLVWGLNLVVTRWAVADMAIPPIFFAALRFLGVAVCLVPFL
FPRPPNLRTLFFVSIMIGSVHFSLLFIGLQHADASAAAVTGQLGVPFSTLMSMLFLGEVI
RWRRAIGITLAFLGVIIIALDPANFSVSFGLLYIIASAFIGSAGGIVMKRMPQISGLRMQ
AWVGLFSFAPLFALSFAIEENQLATYIDGGWMVWAASAFAILGVSVFGHSAFYTLLKKYD
VSLLSPLTLMTPIWGVIFGIALLNEPLTPRLILGAIVSLSGVLVIALRPNEKMPEAALGK
KAGAGDS
>fig|228405.5.peg.696 Probable multidrug resistance protein norM
MLPSRIARKIIIGISCPPFAFEASRPAAQKSGTDLEKTKGRAVMTATSRLPAWARPKDIA
DLIRLSVPIAVSRMAMMLMGLTDAIVLGQYAPGELAYVLSAWLPISISLGFGVGILLGIQ
VLTSELLGTGREAGSGRVFRRGLWWAVVMGAVLTAVLLPISDPFFHWVFVTIAPASDAPS
AVTPEIVASSTASVTRILALGLAGHMISQACSYYLEALRRPLLVTVVMYVGVVINLFANL
ALVAGWWGFPQMGAEGVAWATTGTRWLITIVLLIFVATLTPAFRRSPPAEKGESRRQLAV
GVGTAISNIAEYGGFNITFIIATWVSIAANAVYGYSVQVIGVCFMFYLGIATATSVRVAE
AIGRGSQEEVRNAGRLGVAATFVMGIILGVLLVLLSGPISRLLVREDAVIGGIAIAPAIA
ALLWLAAAVTVFDGLQATASFALRAQGMVWLPSAIHISSFFLVMIPVCYWLAITLGRGAA
GVLEGAFIAVFVAGMAQFILLEWKAARPDVERAA
>fig|228405.5.peg.2319 Multidrug resistance protein B
MTVAPGIPSQSGPGTARKPLPDDIPAMAGPSVRAQFERFGGIYRWILLFTMLTGSMATML
AATTINVALPAIIGAFGLGQDQAQWMSTAFLASSTIAMLANAWAMTTFGPRATYTFGMVV
FVFGSLLGAVSNTLELLIVSRGLQGISAGLLQPMSMFLIFQTFPDSRRGTAMGVFSIGVV
LAPAFGPALGGIAVDLASWRLVFVATLPLALVALGIAPFLMPKGDRNRSTPRPPLDWVGL
SLLAVAVIGLLAAFAGGNRDGWDSDQTYLRFAIAILAAIAFFFWELRHPFPALNPKVFTY
RQFWSAGLIISATGIAIYASTYLIPLFVQLVQGYSPTAAGVMMIPAGIAMMIGFPIAGRL
TDRVDPRWLLGFGITTFAASAWLLSHVSAMTPYWVLVGWILLSRIGISFCMPPSNTTAVR
AVPPHLLASATGGVSFLMQVGGAFGVNILAIILQRRTIFHGEHLSTAMNETNAEMMYQHA
LQAQTLEMTGMTQVQAFQSAFGLLNQKVAMEASVYAFRDCFFIIFVWFVIVLGALALMPK
PKMIQPAR
>fig|228405.5.peg.2958 Permeases of the drug/metabolite transporter (DMT) superfamily
MQVMSSGLDCTLAPDMRAPHPILLVCFGVVFGCGIDALMKSVMQGSTSVLTATTWRYVLG
SVIMIALSLQARRSMPTLPAIRFHALRSLAQVISAFCFFYSLTQIALAEAVVMGFTAALM
IAPIARVILGEKMSPVTIGASLIGFCGAALAATAESSGAPVEGNRLYGTVAVLASAVLYA
LNIVLLRLRTREEDSLTLVTFMNIFPALFLLPFMLVFTDPMPAEGAWSMLIGAAVFGIGI
WWLMTMAYGRAKAQTLAPFEYTGLIWSALLGYFFFQEIPGWRVWAGAGIIIAACLVVAFE
THFIARREAKMPASDILT
>fig|228405.5.peg.3043 Permease of the drug/metabolite transporter (DMT) superfamily
MALDAAGRTTMTEASLPGAKIARPAIVWILFATLTTLWAGAYGLTRVAVGKGTLEGLPPE
WVLPGRLTGGAIVLLTLMLVMGKRLPPFSDLRRWGVIGAMGVVGSLVPFFLITVAQQTVD
SSLAALYTAAAPVFVVLGATLFFADERMTRNTGLGVLLGFAGVLALFGPDAVRHFGSASV
TAQLLLLLATLSFSASTLIARAAPKMDAIPLAAGFVTVSAVVSWPLALTVHPSEVEADWH
HWAAVAGLGLGPSGIAQALYMALVARAGATFQSLTGYSVPVVGAAFGWLFFRETQSWNAA
LAFALILGGVWLARQGGRGRVG
>fig|228405.5.peg.3118 Multidrug resistance protein 2
MSLLGRRGPHQMDDTETPLHPLSPFQRGMLMLATIAMGAGMSINFVVVAPLTRKAGLGEV
EVAAILTLSTLLYAVMIPRWGRIADRVGRKRVMVFSLIAMGVTNMAFLFALEAGLAGVIT
GTSLMLTLIFVRLWFGLLTPGLQPASMAAMTDATTIRDRAAGLGMLGAGMSIGSILGPAG
AAALAPFGALAPLWGTIVFCILIGILLGFSLPRTVKRPRNAARPKPLSMFDARVRPHLLF
LLSYFIGVGMVQQTLGWFIEDRYALAGDDPAAVGQTAVLYTGIVFSCMAVSTIAVQFGYI
SRLKPDPRKILWVGLALVAVGYTAADVFHAFPVLCAAFLLIGAGSALAIPSANALGSLSV
SREEQGAAAALMSAAPPAGFIFGPLMGAGLYQVNHALPLIASAVLVGSLAVYAMLVTARR
PLAEG
>fig|228405.5.peg.3334 Permease of the drug/metabolite transporter (DMT) superfamily
MTQTPPATAPLPVSLPPARSWIGPLMVLGGGVAIGFAPIGLRIGLQEYGGELGPQAIAMW
RYIFATPILFGLVLLIHRRLPRPPNRFIILAGTFFAIDIALWHWALTMTSVSNATFIVNL
GNVGVGIVAWLFLKERPGMHWFVAASLAICGAAALSLGGAALHTGGLKGDLFALAAAGFV
AGYMMFSKLGRRNLSGIEAIFWLSVVESLVAFLIVLLAGERVLPMTANGFIVPVFLAIVA
HVMGQGLIVSGLGWTNTAVAGILVLAQPVVAAAIAWKLFEEPLTALQAAGAATILVAVWL
AQRQTVPPAG
>fig|228410.1.peg.2100 Permease of the drug/metabolite transporter (DMT) superfamily
MTNTRNENLGYVYGLIAVTAFALTLPAMRAALSALDPVFVALGRGAGAAVLAAVFLWFTR
QRLPTREEAKGLIIVAAGAVIGFPLLAAWAMLYVDASHGGVVLGILPLATAVAAALFSNE
RPSMKFWLFALIGAGLVVGYSLSRAGGTLHPADLALFGSIVCAGVSYAEGARLSKSLGGP
QVISWALVFSFPILIIPAIHYAPVSLNLPLESWLGFIYLTVISQYLGFFPWYHGLALGGI
AKVGQTQLLQPFLTIIASVLLLGEHADLMTWLVATLVVAVVAVGKHAQVKHNDPESATIA
DTSPHS
>fig|229193.1.peg.267 Permease of the drug/metabolite transporter (DMT) superfamily
MNRLPTLYGIIAILLWSMSVALTRGLAEALGPFGAGSAIYSVSGILVWLVAGKPRVRGQH
PAYLYGCGLLFVVYMVAFALAIGMANDRQQTLEIGLINYLWPSLTLLLAVPLLKLRARWW
LWPGAALALFGVIWVVSGGEGLDVKTLAVNISSNPLAYSLALIAAFTWAGYSNLVRLYSQ
GPGALPLFLIACALCLWLMFFMWTPGKLHFTPRAIFELLLMGANTALAYQCWDRAYQCWD
SAMKKGNATLVAALSYFTPLLSILIASVWLNTLPSAAFWPGVAMVVAGSLLCWSASRNPL
RT
>fig|232721.5.peg.348 Permease of the drug/metabolite transporter (DMT) superfamily
MNTASIRSIAMVLLAAMLWGTTGTAQSLAPAGLSPYWVGALRLVIASAFFALLAWPAWRA
RRGGGLRWGPVLLAGACVATYNLSFFAGVKSAGVALGTALAIGSGPIWAGLLQTVAQRRL
PAPVWWLGTLLGVAGGAAMALDGGSTVRAPWTGIALCLLAGLAYAMYALTNKRLVAQAGA
AVVNLAVFGMAGLLSLPVALLLGGAPTVAPGALGIVLYLGLVATGVAYLLFSTALRHISG
ATGVTLALAEPVTAFALAVAVVGESPSAMAYGGLAAVLAGLLLVIWAELRTTRPAVGAAA
A
>fig|232721.5.peg.389 Permease of the drug/metabolite transporter (DMT) superfamily
MRSERQGLLALLLVVAVWGTTFPAMKMMSAHLDALQIIWARFAIALLVLAPLWRGLRRTE
LRWGLLLGALLFLAFWLQIEGLARTSSNRNAFVTGLNVLVVPLLAMAVLGRRYGAALWAA
CAMALAGMVLMFHENEPWNLGDTLTLASTLFYAIYILTLEECARRTAAQPLRATRMAAVQ
ALVMFAAASVLLLARHGEVATTLQALADLPAHALTALAYLGVVASVLVVTLQAWGQQRVD
AMRSAIVFGLEPVFAAATAWVLIGERLGAAGLAGAALIVAALVVSQLPPPRALARPSTP
>fig|232721.5.peg.404 Multiple antibiotic resistance protein MarC
MDLKPLITLLAIVNPLAIVPFFIHYTSGFNAAQRRRTVQVAAFSAFCVIAACALVGLQIL
DFFNISLQSFQVGGGMLLLISAMNMLNAQPAEAKPHTHELEQGAEKAAAGSSIAVVPLTI
PLLTGPAAMSTVVIYADRAQSIWQHLALVGYGVVVGAATALCFALAEPIERVLGKTGINV
MTRLMGLILAALAVEVMADGLSKLFPVLAARS
>fig|232721.5.peg.409 Outer membrane component of tripartite multidrug resistance system
MKNHLSPSSAPALTPPTAPRGSALLYGATLAVALLALPLLSGCADMAGIDSHARMRDPVS
LGLAAAPSSGADAAVQPQTAVSADWWRSFGDAQLDALITQALQGNPGLQQAAARIARAEA
FADTARAAQSPQVNGSLDATRQRYSANGPYPPGQAGAIRSVETARLSGSWELDFFGKHRA
ALAAALGEAQAARADAEAARLLLASRVAQGYFQLARLQAQRAVAERTLQQRTEMLQLVQR
RVQAGLDTQLELRQSEGTLPEARQQIEALREQEALARNALGALIADPQTAQTLTPQALAA
IHFSETPAAVPADLLGRRPDVAAARWRVEAATQDMGVARAQFYPNVSLTAFVGLASVGLD
RFIEAGSREWGVGPALRLPIFDAGRLRANLRGKAADRDAAVESYNAALLEAVRDAADQLA
SSSSIARQITEQRQAGESAQAAYGIARRRYEAGLGTYLQVLTAESQVLAQRRLAVDLAAR
RLDNQVGVMRALGGGYAATPPPMAQAPQAAPTVAAAR
>fig|232721.5.peg.1181 Permease of the drug/metabolite transporter (DMT) superfamily
MSTSLSRADWAKALVVVVVWGLNFVVMKWGLATLSPLVLCALRFLAASLPFLLFVRPPRH
LSWGVMAAYGLVQGVGQFGLLFTGMQLGMPAGMSSVVLQTQAFITMLMAAALLGETPHRW
QWLGLCIAIGGLVFIGAAHGDGASGMTLAGFLLTVGAAAMWAGSNLLTRVAARQGPYEPV
SFIVWSSVFPIVPLLLLACVVDGTEAVVQQLRGLGGRELGVVAYLALLSTLLGYGLWTRL
LQRYAASTVAPLSLLVPVVGLLSAMLLLGERPTAWQWMGTLGVLAGMVINQFGGLWAKRR
RGVASI
>fig|232721.5.peg.2086 Permease of the drug/metabolite transporter (DMT) superfamily
MTAPHTSAEALSPHAPAWVGEFVLLSSLWGASFLFMRLGAAEFGPLPMAGLRVLMAALFL
WPFLLHRGEWPALRRHWRPVLFAGLINSAIPFALFAWAVMHIATGLTSILNATVPLFGAL
VAWLWLGDRISRLRWAGLALGFVGVALLAWRAPAGVGASGSQAGWAIAACLLASTCYAVA
ASYARRYLVGIPPLATATGSQVGAALGLALPMWWAWPAQTPSLRAWAAIAAIAVLCTGIA
YILYFRLIANAGPSRALAVTFLAPVFAVFYGAVFLGEAVTPWMLGCGVIIACGTALSTGL
VGGAVRPGTKTP
>fig|232721.5.peg.2952 Membrane fusion component of tripartite multidrug resistance system
MAMPKKAKITSAVLLLAVAAGCVIYLNRPESSASTQSTDDAYVQADFTLVAPQVSGVIGK
VLVEENQPVKAGDLLAAIDDRDFIVAVDAAKAQVAAAEASVAGLAARVAQQETAIRQAQA
AVAVDDAELKLAEANQKRYRNLAADGSGSIQAQQQAEAQLAIRLASRDKNRAGLQAARQQ
TDILKADLEKAKAALSQAQAAQAAAELKLSYTQITAPINGMIGQKSVRVGAFVNAGKPLL
AVIPLDALYITANFRETQLARVRAGQSVDIKVDALPGAVLKGTVESLGPASGVSYSAVAP
HNATGNFTKIVQRLPVRIRIDPDQLDAANLRVGMSVTPKIRIGE
>fig|232721.5.peg.2954 Outer membrane component of tripartite multidrug resistance system
MTSQPLLTQLLRQAGTALCTISLVGCAVGPDFVKPDDRLATVQLSPRADYAQPNETSAAN
FPSSWWTLFNDPVLAGLQSRAQAGNLNLQIASERIEQSRAQLGIASSLLLPSVGVSAGYS
REAISEHGKFAALGAPTSASDFWQLGFEASWELDLWGRARRSREGAAAAFEATVYEREAA
RVALSAEVARAYLQLRGAQAQLDITRQNLEVADRTLRLAESRERNGVATRFETSSARAQL
ATVEALVPELVQRRNTLMNALALLLGEEPRALDAQLLEAMPLPSLPSNVPVGLPSELAHR
RPDIQRAEAQLHAATAAIGVAKADFYPRIGLRGRVGVEAFEFNDLDSWDSRFFSVGPTVY
LPIFQGGRLKQRVALNEARQRTAAIAYRQTVLQAWHEVDNALDAWAAQQNRHAELRVSYE
QNKQALHAAERGYQEGAADYLNVLAAQRGVLASQTSLNASATNAALTLVNLYKSLGGGWD
PDALTSGRQAGGDAPLTTTTSPASLQSKVDQ
>fig|232721.5.peg.3126 Multidrug resistance transporter, Bcr/CflA family
MSVPSAAIGPQQAPAVPVPVPPGLAILVLALLLSIQPVTTDLYLPALPALTRSLNAPVAA
GQLTLSALLLAFGCSQLAWGPLSDRFGRRPVLLTGLALYTLAAVGAALAPSMAVLIAWRT
AQGVAMGAVVMCARAIVRDLYTPLAGARAMSKALTGLGLVACLCAPLGGLLTEWFNWRAA
LLALTGYAMGTLALVALRMPETLHQRNPHALRPAMLAGTAAQVLRTPAFWAFSLLTTASY
GGLFTFLAASSFVYLDVLGISRTQYGLALLSTAVAYLLGTLLCRRLLARQGLKRTVAIAG
ALSASGGLLMLLAAALGWHSVAALLPPFYLYMVGHGIHQPCGQSGAVGPFPQAAGMASAL
NGFMMMLAGFAIGQWLGGALDGSVWPLVQGVALWSLLLAAIAWTLVQRHAPQEVTHAR
>fig|232721.5.peg.3151 Multidrug resistance transporter, Bcr/CflA family
MRASPSPSAGAPPLWLLVLITLSGTLAMHMFVPALPDAARALGVGPAAVQATISIYIVGL
ALGQLVYGPLSDALGRRPLLLGGLALYAAGSIAAMLAPTAPALIAAWFIQALGGCAGLAL
GRAMVRDTNGPVEAVRALALLNLMMMVGPGMAPLAGSGLVALGGWRAVFVALALAGVATL
LLSWRKVPETGTPTGRVSPGRLARAYAALLRSPTFLAYAVGGGCATTAVYAFIAAAPFII
TEQLGHPLRDVGIALGVVMVGMAIGNALTRRLALSMRLGRLLVWGNAVSVACALVFLALE
LLGYLTLEATVGLMLLFVLGAGMASPAALSKVLTVDARHVGAAAGLYGFAQMALGALFTL
LVGWGSNPALASSCVLLGAALVGQGCLQFALRREKRARGERVRGERARGERARGE
>fig|232721.5.peg.4052 Permease of the drug/metabolite transporter (DMT) superfamily
MPALSRRQLVVLALLTLVWGLNWPVMKMGVAHFPPLTFRMASLWLGLPILAAVIGVRKLP
FTIARTHWGRVALLALTNMVLWHVLMILAIPQLSSGRAAILGYTMPIFSAVLGALVFGDR
LAGRAWMGVGAALVGVVLLLWHEVGALGGRPLGVTLMLVSAASWAMGTQLLRRLTVPVPL
LTLSFWMVAITCVVLTVLAVAFERERWVAPDAQAWAAILYNGLLALGFAQTAWFFLVRTL
PPVASTLSVMMIPVLGVFSGALWLGEVLHWQDWTAVGLMAVAIGTVLWPARAVQAQEFK
>fig|234267.9.peg.427 Multidrug resistance ABC transporter ATP-binding and permease protein
MHRSHTKGYGYHTSARRRHPVYRHRSRLEEVEEEVLGKAYDGRLMRRLLGYMRPYRLLVA
LSLVFLLLQSALQVLGPLLTKTAVDRYIAPTGGQIPEFLARFLPADAWDGLTRIGLVYLT
VLAANFVCEFIQMYVMQYTGQLAMFDLRRELMEHLQGLDLAFYDRNPVGRLVTRVTTDVD
VLNELFASGLVTILGDILVLVFILAIMFSFSPTLTAIMLTAMPFVILTTVIFRRSVSQSY
RRIRVAIAKINSFLQEHITGIAVLQLFNREERSCKEFEQVNREHMEAFKDAITAYGWFYP
VVEFLSMMALAGILTYGGFRVQAGRLSLGVVAAFLQYGLRFFRPIQDLSEKYNILQSAMA
SSERVFKLLDTEAAVLPPESAQPAPAGIAPIEFDHVWFAYKDEDWVLRDVSFTIAPGETI
AVVGHTGAGKTTLISLLLRFYDVQRGSIKVGGVDVRLYGPLDLRRMFGVVLQDPYLFTGT
LEENIRLGTENIRAEEVEAAAEQVNLMDFIRTLPEGFGHTIRERGSGLSTGQKQLISFAR
ALAHNPRYLILDEATSSVDTETEFRVREALNRMVAGRTSIVIAHRLSTIQRADRILVMHK
GHLRESGTHQELLAQRGIYWKLYQLQYKDQERVAAD
>fig|234267.9.peg.623 Drug resistance transporter EmrB/QacA subfamily
MIIDNRYHVNCGLQNAFDRYIIGNQSSAASCPYQNRTGPPGHSPPDPYRDVASGRAAAGR
QTIQGTGRFPGDRQCRLAGPSQSGPGQQAPEPLHQRQPLHVGGYRETLCGPRPAGAGRRC
RALRHLVRRSAGFPAGTGEPDAPRGAHQRPLEVGHRRLHLSPGNLQTQRQSLSDAGRPGD
CCRAVRLYPLRSPGGAPHRLPRHGGRPPGGAHGDRRRPGGRGARDPAFLGGVAQPLAARP
ARSFCERQPRGSAANRSTQGPGVTASVGEWSMGSIARPPCDEAAIRAGACEPQATVNGSW
ILAATILGSSMAFIDGTVVNVALPALQSALRATLADVQWVVESYALFLAALLLTGGSLGD
RYGRRKIFVIGVVLFSIASAWCGMAPNIRQLVLARAVQGIGGALLVPGSLALISANFYQA
ERGRAIGTWSGFTSITAAIGPVLGGWLTEHGSWRWVFFINLPLGIAVVALSLTKVPESRS
GTESRRFDWQGGLLAALGLGGIVFGLIESAPLACVAGAIALIVLLYWEGRAPSPMIPLRL
FGSRDFSGANLLTLFLYAALSGVLFFFPLNLIQVQGYTPTQAGAALLPFILLMFLLSRWS
GGLLDRYGAKLPLVVGPIIAATGFALFARPGIGGSYWTTFFPAVLTLGFGMAVSVAPLTT
TVMNAVDESYAGAASGINNSVSRVAGLLAVAVFGALLSGVFQNTLERRLDAGTVPPPVRA
ELEAQRSKLAAAVTADPRGRRAVQEAFVEGYRVVLWVAAGLALASSLSAAVMIKASGSAS
PRRS
>fig|234267.9.peg.736 Permease of the drug/metabolite transporter (DMT) superfamily
MISWCMAPTPSPSIRRRPDIVPLLLAFAAIYFVWGSTFLAIRFAVETLPPLITMGTRHLM
AGGLLFLWLRFRGEPLPEPRLWRPALFSGAFCFLGCHGLLAWAEKTVPSGLAALLSATLP
VWMILLARMLGQGSELTLKVMGGITLGFLGVAVLVPFHSGARDGIPWTSLAIIVCEIFWA
IGAIFSRGVKGTVPPATFAAMQMLCGGVLLWTLGLILGEGSQLHPESFTTRSVVSLAYLI
VFGSLITFTAYVWLLQVCSPALVSTHSYINPVVAIFCGWALGGEPLTARTLAGTAIILAS
VALVSVRKS
>fig|234267.9.peg.765 Permease of the drug/metabolite transporter (DMT) superfamily
MSRHPLFKAYIALVAVCFFWGTTYLGIRMALESFPPMVLVCVRYMISGSLMLLFARVRGL
YLPKGKELAWACFSGLLTLGIGNGALVYSETMVPSGIAGLIVTISPFWMVGAEALLPGGA
RLHAPTIGGMAIGLAGAAMLFTPDPGTHGVDHKLVIGFLVLTFGMAGWSFGSIIQRRKTG
KAHPVVAGGVQQLAAGLAMIPITLASGDLTIHWKTRGVTAILYLVTFGSLVGYSAYVYAM
DRLPVAIVSIYPYVNAVVAVALGWLFYREPFGIRETLSMIVIFAGVAVVKRYSQKPPEKV
LSAARR
>fig|234267.9.peg.1715 Polymyxin resistance protein ArnC, glycosyl transferase (EC 2.4.-.-)
MNGRFPSLSVFFPAYNDAPSLPGLLAKTFHALEEHVADYEVIVVNDGSYDDTGKVLEELR
QKYHPYLRVVTHEQNRGYGGALRTGFESATREFVFYTDGDGQYDAGELPKLLELMTPDTG
LVNGYKLERHDPAHRIWIGSTYNFCARLLFGIRIRDIDCDFRLIRKSRLQEIRLTSTSGT
ICVELVRKLELTGCGVVETGVRHYPRLHGKSQFFRLKSLATTLGELIRLWVRVVLLRGKK
Y
>fig|234267.9.peg.1768 Glyoxalase/Bleomycin resistance protein/Dioxygenase family protein
MLRARREFVALPHGRGSLACNISYTDVRRWEECLLVRLNAAAAFLRIETLYNPPMHRIPW
STIGLGSLLLISVCSKGGQEVQSQQPENAKPPVKTEQRGRILGIGGVFFKSANRDQMREW
YSKHLGLTDKGGGAMLPWREHDDPKKEHVTVWSIFPASSNYFDPGHAQFMVNYIVDDLDA
LLDRLKKEGVKIDDKRMDESYGRFAWIYDADGNKIELWQPIAKP
>fig|234267.9.peg.1800 Multidrug resistance ABC transporter ATP-binding and permease protein
MLTKCWLLGFSGEGLPRMTNIAEDRAGDESEKSPFDRRVFRALFDIAKQYKRQFIVVSLF
SFLYTGLDLLQPLVYRRAINAVAGMFVNQVPAAAPGLGNLAAQTPEQTLHTLLVSVVLLF
FIAVISYYFYQRASYYGARVASYMESKLIVQTFGHVLRLPLSFFNHQASAGLARRIDQCD
QVAPVVHAVSQQIAPEAVRLVAICAIMLTQNWEMSLMAVCLLPPYVWLARRAALRLQSNL
DPYYQMWEDISAHIADAIGAVKTVKLSGAEAREQDKLREKSIAAYDVYLRRIRTSQKYYL
SQVALSNLSKSLLLGYGGWLVLRHMLTPGDVVMFAAYLDRLYSPIDSLNGLAVSLQENLT
SLRRAVDLRDSGRPEPGGAALPEGQGHVEFRNVHFGYTPEREVLHGINLTLQPGKITALA
GPSGAGKTTTADLLLKLFEPSSGEIFLDGQPLSTAGCASIRAAIGVVASDGTVFRGTLAD
NIRYKRPEASLEETHRVALAAGLGRALERLPEGLNTQVGERGVGLSLGERQRLQIARMLI
DRPRLLVLDEATANLDYATELDVRSALEQMSPKPTMLVIAHRYTMMKNADYVYVLKEGEV
VEEGPPAALLKGQGWFADLARESGEVPSFV
>fig|234267.9.peg.2272 Nisin-resistance protein
MFKARLYSIGTLIVSCAACAAQSTVADATRSDPIEYLHRALDEMHARSLRRDRIDWPLLR
KETLARAAGAEITVDTYDAIRFALASLEDHHSSFHPTPALEDLEKKRKATRRPAPAPIPQ
SPPSSPFTGRYEPEGRLVTSGGKTFAFVVVTKCFPETDGQFIAYETKLQRILADLDKSHP
TGWIVDLRGNVGGNMWPMLAGIGPLLGEGDHLGEFFTLDSHSTWKYRDGVAAEIENGKEQ
RYPAVAGVPYKLAGTPKVAVLIDRRTGSSGEAIAIAFRGRPQTRFFGEHTEGVSTANDVV
KLSDGASMWLTIGVDADRTGKQYMEGFDPDEVVGAGDKILSDGQDPVLQAALRWLSRS
>fig|234267.9.peg.2369 Permease of the drug/metabolite transporter (DMT) superfamily
MPRRRPVRRDAPGFGPEIVDQCRSHRRRHRRQRDCSNGALQGGYPLRKQRAHGPTGGRAG
ERRGPRTRLGKPARQRRTGRGQNQGDRLAAGRDAARTGAHPAICARGGFAPRYSVAPGLF
FHRCQHPARHGHPRARHGRRRTRRRRPYPAGMVQPRWTRSWPQTHPAHSPAPDPRPRGQR
EVNRRKADLALLFNAFIWGSTFILVKSSLSYISPLLFLAIRFSLATAALGLLFRGTWKWR
RRATPAMIGAGCLAGVFLFAGYALQTIGLRLTTAPKSAFLTGLATVMVPLLGALVYRIRP
QLSEVFGVLIATFGMALMTIEGPIDSIGRGDLLTLGGAIAFAAHIVTLGHYSEKIGYELL
SITQVGAAAVSSLTMFWWAETPRFHWNPVVLWAILITGLFCTALAFTIQAWAQRYTTATR
TALIYALEPVVAWTTSFLVVGEGLSGRAAAGAGLILGGVLLVEMKPLKPREHQSR
>fig|234267.9.peg.2504 Inner membrane component of tripartite multidrug resistance system
MPIDESQGWHPGHSPWTVALTVTIATFMEVMDTSIANVSLPHIAGGLSAGVDESTWILTS
YLVSNAIVLPISAWLSNRFGRKRFYMTSVAIFTVSSLLCGLAPSLSLLIFFRILQGVGGG
GLGPSEQAILTDTFPAAKRGMAFAVYGMAVVLAPAIGPTLGGWITDQYSWRWIFFINVPF
GILSLFLTNHMVQDPPDMERAKQDAKKAPVDFLGLVLIATGLGAFQIMLDKGQRDDWFAS
PFITACVIVTVGALGAFVIWEWNHRHPIVELGLLKNRSFAVACMLMLVTFAVMLGSTLLI
PQFAQLELGYTARQAGELLSPGGFTILILMPMIGYLVSRVDARYLIGIGYLIFAASLFHM
TNLYLGVDFRTAVMWRVYQAAGMAFLFVPTNTIAYTDMTPGASNQVSALTNLMRNMGGSV
GISAVTTLLARRQQTHQVFLVRNVTSADPHLKQMLTQFANRFSLRTDSHHAMQQAYGAIY
RQVQSQAAVLAYIDVITIMGALCLAAILLLFFAKKSKPGQAAVAH
>fig|234267.9.peg.2505 Membrane fusion component of tripartite multidrug resistance system
MVDDRTPYASHQEIEQLRDELRRLKEEQEKQKNGRHEDGQPKDEKKEESGEENEKPEEPK
KPHPVRKFILIALVLVLAIGGLLWWLHARNFESTDDAIVDGHTSGLAARVAGTVIAVYVE
ENQFVKAGQVVVDLDPRDYEAAVASARGQLQQAQAQQQAELPSVPVTRVTSQTNIANAGS
SIASAEAGVAAAQRNYEAALDRVREAQATAAKAQSDVDRYRPLAEKDEVPREQFDQVVAT
ATSSAAAVAANQAGAQAALKQVDQARAQLAQARQTAGEVANNAPRQIAIQQANVRSRAGS
AQMSRAQLEQALLNLSYCKIQTPVSGIVARRVAEIGQHVAPGQEVLLVTRLDDLWVTANF
RETQIRRMVAGQSARIHVDALAQDFDGYVESMPAASGSITSLLPPENATGNFIKVVQRLP
VRIRFKQGQNGLDRLRPGMSVEPKVRVR
>fig|234267.9.peg.2506 Outer membrane component of tripartite multidrug resistance system
MRWHTLFFLIILSTPSAGQIGAPQSPGQLPRAQPVPLSGKPQIGSVVPQQTPTPGATNSV
NTINPSVQVQGAYQGSVPAGTSTSTPLALSLEDAVKRGIQYNLGSVTASDATRQARALRL
AALAELLPDLTGNVRETVQQIDLAITGLRLNLPLPGFRFPAIVGPFNYFDTRANFTESLS
VTGVRNWQASRENLSSSEFNIQDSRDLVAFAVAGTYLQILASAARILTANAQIETSRAVY
TQAVDRNRSGLIAHIDVSRSLVELQTQQQRLTSLTNDFEKQKLTLARLIGLPMAQPFTLS
DAIPYREMPPVDIAALIHTAISARHDVQAAAAQVKAAELSRKAAVAEHLPFLDVAADYGI
TGINPSQSHGTFAVTGSVRFPIYRSGRIRADIEQADAALSQRRAEYEDTKARAEQDVRNA
VLDLNAASQQVRVAESNRGLAAETLQQSRDRFRAGVTDTVELVQAQESVATAEQDFISAL
FAFNLARVALARATAQTEQGVTRLLRER
>fig|234267.9.peg.3505 Permease of the drug/metabolite transporter (DMT) superfamily
MGGEKKQAPPRVVYGWLALLLMLWSSNFIFARFALRELPLGVVLGFRYVFSAALMLPVIA
LGGGQSRVKHPWNWHDLPGLLTIGLLGLVGNQALFVVGISMTSVAHAGVITALSPVLVLL
GSAALGHERISGARIVGLLTAACGVVVLQFSRGAAGAATLKGDAVMLASVVVFAGFNLAA
KPYAERAGTVRVNAIAYFAAGLLALPLALWSLSRGAHGSLLAWCGVAYMAAGSSVAGYLI
YAYALRHLAASRVSVVVYLQPIVVTLLAIVALGERPGAGFLPAVGLVLAGVWVVERRG
>fig|234267.9.peg.3637 Polymyxin resistance protein ArnC, glycosyl transferase (EC 2.4.-.-)
MQSSYSGKSKMAAAPHTGEAGRIIAAPTGPLIVAAANAGDDAPELSVVVPTLNESENIVD
FLAAVRRTLDASLPGRYEVIVVDDDSADGTGTIAASLMCGFPELRVVRRQNEGGLAVAVI
RGWQVARGKMLGTINADFQHPPDVLGRLLEREAGADLLVATRHSDGGGLGDWGLTRRITS
WGAAQIGKWLLPEVYARVSDPLSGCYLVRRSAIAGAVLRPLGYKSLMEILVRGNVREIHE
CGYEMRKRERGQSKVHVLHPLQYLRHVMRLRAAARERGR
>fig|234267.9.peg.3861 Multiple antibiotic resistance protein MarC
MIAEEAFGELTKTTLLIVGALFPIVNPIGNTPIFLSLTHGLSSQGRTVLARMIAINGLIL
ILASIFIGTHILAFFGISLPVVQVGGGMVVIATGWTLLRQPNDDGSGDSGARDECHEADY
KRQAFYPLTLPLTVGPGSISVAITVGANRPEGAEWRWPLIGGMLLGSALIAVSIYLSYRF
AERLAQTLGDSAMNVMIRLSSFILLCIGVQILWNGLSALLRTVVH
>fig|234267.9.peg.5700 Daunorubicin resistance ATP-binding protein drrA
MQPHEPIIETRDLTRRFGQLTAVDHLNLSVARGEIFGLVGPDGAGKTTTLRMLCGLMEPS
EGSARVAGHDASRESQAVKDQIGYMAQRFGLYQDLTVEENMVFYADLFDITGPRRDELTA
QLLRMTRMEPFRARQAGRLSGGMKQKLALMCTLLHRPQVLFLDEPTNGVDPVSRRDFWTI
LYQLLKDGITIFMTTAYLDEAERCNRIGLMNKGRLIRCSTPEVMKAETGSATLEGAFIKT
IHEVEGVARS
>fig|234267.9.peg.5701 Daunorubicin resistance ATP-binding protein drrA
MNSVEIHDLVKTFGSFVAVDHVSMEVEKGEIFGFLGPNGAGKSTTIRMLCGLLTPTSGRA
LVNGFDVASQPEEIRRTIGYMSQKFSLYDDLTVEENIDFFTGIYGVPQARRTERKDYVLE
MANLTDRRAAMTRTLSGGWKQRLALGCAILHEPAVLFLDEPTSGVDPLARGAFWHLIHDL
SEAGHTVFVSTHYMDEAEYCHRLALMYRGKVIALGTPAELKSGLKDQSLLNLESSDPLAT
MRALEGVAGVHDVAVFGGGLHITVDNAETGAARIRERLAASGIEVRKLEPIQPSMEDVFV
AMIEAEERKAA
>fig|234267.9.peg.6014 Membrane fusion component of tripartite multidrug resistance system
MADTLVETPKTETPPPRIVRKPKRHRGALIAMLVLLPLLVGGYFLWKYLGTYESTDDAQI
DGHIHAISARISGHISQVLVEDQQIVKAGDVLVVIDPRDYDVAVAKAEADVADARAALTG
SQTEIPITSTNTASTLQTAQSTLADSRAGLLSAQRQLSAAESRLAAAEAQVTEAQANYKK
AADDERRYKQLVDKEEISQQLYEQAAQAAAAAKATVDTRIASVNEARHNVAVAEAAIQQA
QAKVPQAEASIQSALTAPQQVAISRSKAKSSEAKLAQQAALLAQARLNQSYTTIVAPAAG
IIGKKTVEVGQNVSPGQQLMAIVQLDDVWVIANFKETQLRRMQPGQRVRFSVDAYSREYQ
GRITGIGGASGSRFSLLPPENATGNYVKVVQRIPVRIDLDPGQNADHHLRPGMSVDPKVF
LR
>fig|234267.9.peg.6015 Outer membrane component of tripartite multidrug resistance system
MPRTSLPRAKKLLKMDDSQPGDRRALPHFEIGMGPARIGCHVQCTHRRAVSSTPLFVCLA
LLFSSVLAAQENSPFQGSVPTGNATTTPLGLKLDDAIQRGLRANLGLLERGTASQAARAE
RIRALSALYPQVTGSVGETVQQLNLKTLGFGTLGIPGLSGLPSIAGPFSYSTAQANVSAT
VFDWSKRKNLSSARDTEEASKLSIQDARDLVVQAVAYAYLQIIADNSRVESIQAQVTTAE
AIYNRAVDQKKAGVAPAIDVLRAQVEFKTQQQRLLVEQNQFAKDKLTLGRVIGLPPGQPF
YIADATPFTPFSGLTLDQALRTAVAQRADYQSARKLFLAADDALKAARAEWYPTVDLNGY
YGVTGPTPGNSHGVFLVTGALNFNIFNGGRIHGDIEQARAAKQQRADELADLGGQIEVQV
RTAFLDIQSAADQVAVAQSNVELAAQTLQQARDRFASGVADTIEVVQAQESVATASDNLI
SASYAHNLAKASLARALGLAEQGIKKLIEVK
>fig|234267.9.peg.6125 Permeases of the drug/metabolite transporter (DMT) superfamily
MILLDLSSHSGTEATRLRWKTWICVVVVVFSNAFGDFFMKRGLPESARLATPLDYIATLF
QPWVALGVGLLILWQLSRMALLSWADLSYVLPVTSVGYVVVALIGKLLLSEAITPRRWAG
IVLIMAGVALVSIGSPSTVEAAVDADRVVGK
>fig|234267.9.peg.6126 Polymyxin resistance protein PmrL, sucrose-6 phosphate hydrolase
MKWLLVAMMVGATTAGEVLQAAGMRRHGEIRDFRPGALGRAAAMLARNRFVIGSAVCMAI
SFFAFMKLLSVTELSFAVPVSAVSYVMETVLAKYVLKEQVSRRRWAGALLVIGGVVLVST
>fig|234267.9.peg.6633 Chloramphenicol resistance protein
MSLTRDGRLLFCTRFLRLFSYGALSVVLVFYLTGLGLSQQQTGLLFTLTLLGDTAISLAL
TTQADRIGRRKMLIAGAALMAGAGLAFALTRNPLLLVIAGTIGVISPSGNEVGPFLPIEQ
AALSQVIPSRDRTSVFAWYALTGAVATAAGSLFAGFFTQSLQSARMTPIASQRAILYLYA
AMGLLLGILFTRLSATSEIARDPDRPAIATLLGIGASRPVVLRLSALFALDAFGGGFVVQ
SFAAWWFYLRFGVQPATLGGIFFGANLFAGISALLASRIAARIGLVRTMVFTHLPSNILL
ILVPLMPTLPLAILVLLLRFSISQMDVPTRQSYTMAVVAPEERSAAAGITGVARTTGAAF
APLFAGLLFAHPATISVPFFLAGTLKILYDILLYRAFVNLPPMDGLR
>fig|234267.9.peg.7509 Membrane fusion component of tripartite multidrug resistance system
MANVVDDLPKAESRKVEAAPTVAAPRKSPVKYIVLGMVAIGAAVGAWAWFHFRDQVSSDD
AQVDAHIVAIAPKISGNVTEVLVRDNQQVKAGEVLVRIDPRDYQARVNAARAALLQAESQ
VVTSRTMVPMTNESTQSGVSGAAAQVSDAMAELDRARLNYEQAASSDIAEAEAKVRSKQA
SNDRAQADLARMKPLLDKAEISRLQYDAYQAQARVAESELNAAQEQLKSAQNNANMRKAA
VAAAQSRVNMAQSQVQASMANRKQVDVRRAETGTASAGVEAARANLAAAELMLSYTTIVA
PSDGVVTRKSVEPGQIVQPGQSLMTLIQLQDVWVTANFKETQLAQVRAGQKAEIHVDMYG
KSVAGHVDSIAGATGSRLSLLPAENATGNFVKVVQRIPVKILVDNTNGLVLRPGMNVDAT
IFVN
>fig|234267.9.peg.7511 Outer membrane component of tripartite multidrug resistance system
MKLRIAIAVALAGSAFGQQPAPLKLTLHDAVQLALKQNPQVILANLDVQQSQEDRNLARS
ALLPQVHGAASETVSRVNLEAAIGFRFPGFSQHVGPYRYEQAGVNLQAPVFDLTLWRRYR
ASVVGIETSRIQELGVREESVLLVVSQYLGSQRAAADVQAAQSRVDLAQALYDQAADLQK
NGVGTGIDTLRANVQLQNEKQRQIVARTQLETSLFGLARLLNIDPRTRVELADQVSFFDT
PTIDVNQTLEQAWQVRPELRQVLSQEQRAELDLQGATDARLPRVAVNGFWSQQGLNSSTA
IPVYTYQATVEVPIFTGGRIQADRAKAEITIRQLKQQEQEVRNRIALEVKNAIAQLASAR
NEVDVANLGIQLARQEVDQSRDRFQAGVTNNVEVIQAQDSFARASDNQIAALYRYNQSRA
DLAHSIGQMEALYAR
>fig|234826.3.peg.243 Bicyclomycin resistance protein
MLLSSLAFILAVLSVVLVDITNAMYANYLTQVGAFFGAEQTVTQFTVSCEMLGYSTSGLI
YGPMSDRHGRRPVMLFGMAVFLITGLWCYFANSITVLIIARFFHGVGAGVSAVVGYAIIC
DTYSSEECSKRISLMYMCAVTGSAFIAPGMSSYMIEHGYGWRTVFVVSIVLSAALLSWLV
CKLPETISERRAGCNPITIVSGYVALLRNRRFLAYCFIKVLTMTYTLASVGTLPFVFIEG
MGLQAKYYGYVAAIGGVSFIAGTMANVKLVGRFGMRRMIAVGLVLTVASDVAAIMADYYF
ALTPVLVEAIWIPSSFCISLIASNGAVLAFREVSNKGAASAFIIFCQTVFGVVGMYVVGK
FYNGTIVPICLLTFTCCGISSVILCVCTPRSEA
>fig|235279.1.peg.167 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MSAVSVNDKVDMRKDSIYKLFFYFFIPNLCAMLALSTYSTIDGIFVGKKLGENALAAIGL
CWPIFPALIAFELLFGLGAASIASYFLGKGQDNRARLMFSSVFYFATLSSVIIGVILFFC
VEKVALALGANELVLPYVVEYLQVIFLSAVIMVLHPLLDIFVINDKRPILAMMAMIIGSA
SNIVLNYIFLFVLELGMFGSALATAMGHGLGMMILLSHFVRKRGRIYFVWRFSLNAVFAS
AKNGVPQSISELSVAFVMIMFNHTLKALAESEEMKVSYLAIYSIVMYVGVVCFTILLSCA
QGVQPVASYNYGAGEMKRVRGIYAFGVGFATALGILVYAVFMSIDSMLVKLFLKSGQEMI
LEPTLEAMKVYFIGYIFLGFNIVSAIFFQSIQRPKSSFLITLSYNLIFVSILLFVLSYYY
GVFGVWLSYPLSLVCSSIVVIGVIFYESRYGVLGKKVS
>fig|235279.1.peg.684 Multidrug resistance protein (msbA)
MRTILEFFKKFFPYIKGHKLSFAIAIIASLVVGLCTAGTAYLIDPLLDTLSGKVPRANPF
FSFDELAQNNTLTFAMMFMIIGTYLGKSLGTYVQAYFMNFIGQDIVRQVRDRMLRHMLSL
EMVFFNKMRNGELMARITNDIGIIRSAVSNYITEFIRESITIIGLVAIVIYQSPKYALIG
LVIVPLALIPINLIIKKLKKYSRNIMEKNADITAKLHEIFNNIEVIKASNGERLELKKFK
LQNLTFLKISMKAVRVGELITPLMELLGAIMLALVVYMAIIDISKGELSVAQFSSFAGAL
LFIYTPLKRLVNLYGQMQSAIVASDRIFEILNQTQQIRDGGIQLQAPINEIIFKDVHFRY
NEETHALKGISMCFAKNKITALVGKSGSGKSSIINLLLRLYEADSGEVLINSQNIKNYTQ
KSVRNNMAVVTQRIFIFNDSILHNVAYGSKIDEKKVIEALKFAHAWDFVQEMPQGIHTIL
DEFGSNLSGGQRQRIAIARAIYKNPEVLILDEATSALDSQTEEAIKESIEHLRHNKIIII
VAHRPSTIELADEVLHLQLGQIIKQETRSKK
>fig|235279.1.peg.1464 Drug resistance transporter, EmrB/QacA subfamily
MNLILFTILLAVFVVPSSISGTAIALPYIAEDIGSDTTLLQWVVNSFNLFFACFTLIWGA
ISDRLGAKTCLIAGVATYLLGSILSFLAPSLLWLDVGRALAGIGGASVFACGSAILIRTF
EDKERVKAFAFFGTTAGLGITLGPTLSGFLIDLFAWRAIFVFHFLTLGVVLLLSPMLPKD
PQKQQKAFKFDKMGALLFIAFMSSFMLFITKIHAFKEPQTLGILAFCLIVGIVFGVHQRS
LHYKNITPNPTLHIPQPLLDFEVLKNASFFGFSLVAVIAGFSFVVLLTYFPTFLSINFGF
SASFSGLFMLSLTTPMLFCPILAGKMLNKGVDSKALALAMSLMMSLGIFALLIILHTLSG
VTLQLMTLLVLFVIGCGMGLHAGAIDGLALGSVESAKSGLGAGVLNSLRLGSEAVGVSLY
GALMVVFITANLSYLLDSEDSVYPIVESIASGNLSAVENPLISANAPSIYLQSFSYTLGI
LGLISLALSLGVWRLLGRVK
>fig|235909.3.peg.1858 Multidrug resistance protein B
MNWKRSVRVLWLCNFMVSAGMTMVIPFLSLFLWQMGVTEHHALSIWTGLVFSVTFLSAAV
MAPIWGVFADKYGQRANLIRAGIGMGLITGCMAFAASPMTLLALRFLVGFFSGFITVSFS
YLARVVPRDHSGEALGTLQTGSIAGNIIGPLIGGALSDLFGFRPVFLVTGLCILLTLLPV
IFWLEKDPVVPQTKENKASFKEVFRHRPLIVLFIATFLVQIAVLGVNSMMTIFVQSLIGH
SSNLAFLSGLASSITGIATIIGAPYLGKLGDRIGQEKTLPILLVLSGLFALPQVWTDNIY
ELYVWRFLQGLVVGGVWPSIQALINAQSPRRIQGRVFGVTASSRFLGNLTGPTAAGAIAG
FFSISSIFVLSGLLLIATGALVGYATHDRAWREEMKEKIAAWTHRLHSRY
>fig|235909.3.peg.3243 Drug resistance transporter, EmrB/QacA family
MEKALTVPASTIRHRPLLITGLIIAMLFAALDGTIVGTAMPRIVGELHGLGIMTWLTTAY
MLTSTTVVPIAGKLADLLGRRIVYVSGLVIFMAGSALCGMANDMTELIIYRGIQGLGGGI
MMPMAMIVIGDVFTGKERAKWQGVFGGLYGLASVLGPQIGGFIVDHLNWRWVFYINLPVG
ILATVLIAMGLSKYKAEGPVKFDIAGMATLTAGVVSLLLGLTFGGDRYPWGSWQIVSLFA
AAVVFFALFVWAEKRAEEPIIPLRLFRNRTFTLLNGIGFFMSVGMFGAIMFVPFFMQGIV
GVSATQSGTIMTPMMITMIIGSVLGGRLVYRIGVKPQLIIGMAVMASAFGLLGTMDVETS
KWTATMYMIILGLGTGLVMPILTLALQESFPKSELGVVTSSSQFFRSIGGTFGMTVLGAI
MNHRSSALLDERLMPKLEALPAQAKGLVDRFAGMIHDDPQGLYSVLLSPEAMAKIPALLR
DMFVPVLKQSLVDSLQSVFLFGLVFIAVGLLLVFGLKRITLSDRTEAMKQLKQAEEKA
>fig|235909.3.peg.3319 Permeases of the drug/metabolite transporter (DMT) superfamily
MRKSFIYALLVAIMVAWGLNVTALKILVEHFSPVALTALRILTAGLVVLLFLWGIGKLQK
VSWNEAKQIGLAALFSVVAHHFFLALGLARTTAVNAGLVLGMVPLVTALLAIVFLGQRPT
LFRLLGIALGFFGVVFVVANGDGGLGHLSIGDVYIFLAVLAQGISFIMIKKATVEARVMT
GWMLVFGSLWLFVLSLVLEPSGLSSLKEGTLPLWLIFLASAVVATALGHMFYNQAVQHLG
PAESAVFINLNPLFSLLGAHWLLGEPISWMQLAGFLFIVAGVMFGSGGMDDVIARFRRAK
AVEGGRKAGM
>fig|237727.3.peg.984 Tetracycline resistance protein, class A
MSEHAAQPHANTTTLFFVALIVFIDMVGIGLIVPVLPGLLEEVTGETLDQTAQIGGWLLF
AYAVMQFTFAPIIGGLSDRFGRRPVLLFTLFMLGVDYAIMAWAPTLFWLFVGRILSGIMG
ASWAAANSAIADVAEPEERGKFFGIMGAAGAAGFVIGPGIGGLLGSIDVRLPFIAASLLA
IGGAIAGYWLLKETLPSGRRRGFSITRANPLGTLIQMARHPVVFGFLTVIFFMQMAAQSH
QSVWAYHTELVFGWSTLQIGLSVALYGVMVAVTQGGLTGMIIARIGAARTVLIGFIISLP
ANLMFAFAPAGYFMIIGIVIGSLGAMAFPAIQQMMSERIADDAQGELQGAVASTMSITSI
IGPLIMTRAFGTFADSEGLYFPGAPYLLAALFGATALGIAAWNISRIKAAPDPAET
>fig|237727.3.peg.1712 Glyoxalase/bleomycin resistance protein/dioxygenase
MSNANGPRVTGLGGVFYVAADPEATRAWYREKLGVDGEYGPQFAWADEPKTNPYSLISNF
KDDEYIKPGKGGFMINLRVHDLDGFVEGLKAKDVHVLDTADEGYGKFAWILDPNGVKIEL
WEQVAEELP
>fig|237727.3.peg.2091 Drug resistance transporter, Bcr/CflA family
MRKEQWSSGEPQGKGAAMATAAPISAPTKRLGETEMIWMMALLMALQAFGIDAILPALDE
LAVSLSVQGNDRQFVVGVYLLTAGIGALIPGALADRFGRRPILLGSIAVYIVLSIASALV
TTYEALIAVRAAQGFFGAGIVALPPAIIRDRVGGDKMARMMSLIFVIFLMVPAIAPSIGE
VILLIGDWRMIFGAMALQGLIIGAWVYFRLPESLTEENRQEIRPRVIGGNMLRAVSMPSI
IGYVIGSSLVFGALFGFINSSQQLISESFGAPDLFPIIFGICAGSMAFASWSNSRIVERF
GARRVSHTALLTFIFVASLQVYFAFQPNETLWQFVPLMAINMMLLGFIGSNFGSIAMNPF
FDIAGAASSVHGFIRLTVAALLGAAVGYAYDGTPQPLALSLLAAGLACLALVLFSEKGKL
FGPPEPEMGLGAKEA
>fig|237727.3.peg.2536 Permease of the drug/metabolite transporter (DMT) superfamily
MGHPRGSRGRAGQGHRQLVSAATPQVLNWRVIVPFVLTGTIWGSTWLVITGQIDGVPAAW
SVFYRFLLATPALFLVAFFMKRRLKLTGPEHRLALLVGIFQFSGNFLFVYHAELYVTSGI
VALMFGLMMVPNALLARAFLGEKVQGGFMLGSAIAIVGVSFLLIHEWTSNPNAGVIGGNV
GLGIILALLGILAASVANVIQANPTGRAVPMVSLLAWAMLYGTIFDLGFALLTAGPPPLP
TNPNYWAGIVYLALIGSVITFPLHYNLVREIGAGRTAYNAILTISVAMLLSTVFEDYRWT
SLTITGMGLAVIGMVLALRSKQRR
>fig|237727.3.peg.3231 Multidrug resistance protein
MADADPSRDSIPRTENASASGAISNGRMALLFTVMLVTAAGNTAMQSVMPSIGTALEVSD
VWISLAFSWSALLWVVCAPIWARRSDRRGRKAMMSLGLVGFVASMVICGMVLWAGLAGWL
GAFATLILFAAARSLYGGFGSAAPPAVQAYVASRTPRAERTNALSLIASSFGLGTVIGPA
LAPLMVLPFMGLGLTGPFIGFALLGIVVLVLLHLQLPNDQPQFAARGMATSYSGPSETLS
EEELEDEAETGGVTGEMVGEPPRLKWTDPRIRAWIIAQLLGGHAQAMVLGITGFLVLDRL
ALRDTPAEGAGPVGLVLMAGAIASLLAQWGIIPRFNLGPRAATLAGVLTAALGTALLAAG
TQLHVIALGYAIASLGFGLFRPGTTAGTSLAVTRAEQGQASGVVASLAGFSYIYAPALGV
WLYGYSDWGAFGLIIALCLAVAVHGWRGLQADEDLTTERR
>fig|240015.3.peg.272 Permease of the drug/metabolite transporter (DMT) superfamily
MIKSALADISPLLFNLIRMTIASACLLAIYGRRLRRLRWATLGAGALTGLCLAAGYQFQT
AGLRLTTPSKSAFLTGLVVVLVPLLAGIPGLRPPGASLPKWNAWLGVVAAFVGIVLLTAP
QGSGWSILMLREINPGDLLTLACALGFSLHVIALAHFSPRFDFEQLAILQIVFCTLAMGV
TTPLLEKCWVHWTPRVVIALVVAAVLATAAAFTVQAWAQQILPATHTALILALEPVFAWV
TAFLVLRTGLHGREIVGALLILAGIGVTELMPSRMQPTMPEMPSI
>fig|240015.3.peg.566 Glyoxalase/bleomycin resistance protein/dioxygenase
MLSSSRLTAFLTVPDAALARNFYRDTLGLTLTHEDRFALAFDANGTPLRVAIFPDFKPQP
FTVLGWQVPDAVVMSRQMQSAGIAFERFDGLAQDEHGLWNAPGGSRVGWFRDPFGNLLSI
HDAAAAMAI
>fig|240015.3.peg.1259 Multidrug resistance protein B
MPAKQIRPVLGIFAVLLGASLATFFGRLLSVGTADLRGPLGLSADASSWLGTAYNMGMMF
IGPFSVYLGGVLGPRRVLLWCACIFTLATFFMPFAGHLSWLITLLAIAGLTAGSFYPLTL
SFILRNLPQKYMLYGIAAYAIDIVVTTHVADSYEAWVMRDLSWCWLFWSITAATPFMVWL
VQSGIPTQPIPRSAPRQPRISWRGFLYASLGAALVFGALDQGQRLDWWHSGTFAAMALSG
SFLILAAVVRHFCQPHPLVNFPFLRRRNTLLLGLTVMVFRFVLLASVVLVPGYLSAIKGY
RPDQVGPVLLWLAIPQFLAGIFAVYLLGKVDTRLVLAAGFSLIALGSLMDSHLTTAWAGN
TFTVSQLVLAMGEGLAFNSMVGAIILDILNSGSLNKPADVLTFAGFFQTIRLFGGEVGAT
FIRHFLHVREVFHYNLLASGVQGGSAPLLARERALLPVMQSRALTQNALAGRSVELLVVS
VRQQAFTLSLADSFTLIATVAAGCLLIAASLRALKLGFPQIIATPGAGKSTT
>fig|240015.3.peg.1260 Acriflavine resistance protein a precursor
MKKWSFVIPVAVLATAAFLILAIRGHWTSWQSDAVVQKTDDAYVTANQIPLSTRISGTVK
AVDVHDYQGVRAGEPLIVLDDADYQAVVSEAQAAIAAAQAELAANQAAKHAADAQVQSAA
SGIAQAQAAARAAQDAIAAAQAQADDAASEYRRVHALYANQAATQEQYDHALAARESTQA
ALQAKQAQAAQAQAAIASGETARAAALEQRAGLNAKDRALEAQIAAKKAQLIVAQVNLSY
ATISAPASGRIGKLQVHPGQLIGAGVEVVDFVPHDPWVEANYQETQLRRIRVSDRADVHI
DAFPGRTFHGHVQEIAPASGAATALLPPDNATGNFTKVVQRIPVKIVLDDLPPGDLLRPG
LSAEVAIHTNDVQRAAQTAATSN
>fig|240015.3.peg.1290 Acriflavin resistance periplasmic protein
MSGSLHFNNFINCKQEAFIVMTERNRRSMSRISSALLTPIVGAALLPLLVAGCSGKKQAA
ANPHAMGPFPVTVMAVQQKNVPIYGDWIGNLAGYVTANIQPQVSGYLIRQDYKEGSPVHK
GQVLFQIDPRPFQATLDQAKGQLAQVQAQLQLANINVNRDSPLAKAHAIAQSTLDNDLQQ
QAAEKAALESAKASVETAQINLGFTKVRSLIDGIAGLAATQVGALVSPTTTLTTVSQVNP
IKVYFSISEQEYLALSTSVRAMGKADLLDSGNAVPLQLTLANGQVYPHEGRIIFVDRAVN
PQTGTILIAGSFANPRGLLRPGQFGHIKAETHIAENALLIPQQALNQLQGNYVVAVVGSD
HKIHMTPVQLGPEVGNMQVINKGLQPGDLVVIQGIEKLRDGMPVVPHQVSAPAPDTDGAQ
STEGN
>fig|240015.3.peg.1350 Multidrug resistance protein B
MLAQMDATVVNVSLSQLAADLHASLQWIQWVTSGYLLALALTLPLNGWLVERLGAKRVYL
LCFTGFTLSSALCAMSWSANSLIGFRILQGMSGGLMAPMAQLMIAKAAGKQMARVAGYAI
VPVLLGPVAGPVLAGTVLQYATWHWLFLINVPIGVLGIVLAILFLPRDGHEERSSRKLDI
GGLLLLSPALVLLLYGMEHLNEHAGLAAFGLSLALLAGFFYKARRDGERALLDLKLFRRR
VFATAAITQFTGNGLLFAVQMLVPVYLMRGAGESPSMTGWLMAPMGMGMMITSPLVGRLT
QRYGIRGTSSRGAMLALVSTLMLIYLSIERLNPWLVGMVLFLRGMGTSAVGIPSMSAAYA
SVPRAELPMATTSMNIVQRLGGPTLTTLCAGFLGWRLGGAQIGAGRPGAFPESFALLCGL
QLLLWLATLRLPRDMEEAEESKKTAAAA
>fig|240015.3.peg.1899 Inner membrane component of tripartite multidrug resistance system
MSQSSVAPRPAAAASDQDFHYEHWTPRFNPWVITFTVTLATFMEALDSSIANVALPHIAG
SLGASQDEATWVLTSYLVSNAIVLPISGWISNRIGRKRFYMACVAAFTLFSFFCGLAPTL
TWLVIFRVIQGAAGGGLQPSERAILADTFAPEKRSLAFSLYGMAVVLAPAIGPTIGGWIT
DNYTWRWIFFLNIPVGILSLLLTSRIVEDPPYLKRQLARLKESVDGIGLGLLALCIGAAQ
IVFDKGQQDDWFGSHFIVGCTIVAVVCLVLFLYRESTVEHPIVDLKLYRTRNFAMTQIVM
LLIGAALYSTTVMIPQFLQVLMGYTATQAGLALSIGGVVLMILFPIMGFLGQKMDPRLMI
TLGFAVLTFGIWRISDLNLNISFGTALSWRAVMVLGMPMLFVPISVMSYVGIPQEKNNEV
SGLTALARNIGGSVGISFVTTLITRRTQVHENYLAAQVNPSSAQYQSLAQGMQGFLAQAG
AGTGNAAHAAAAQIYNIMKQQAAALAYVDTVHVLVLLTACLIPIGYLMKKPRYRKRS
>fig|240015.3.peg.1922 Permease of the drug/metabolite transporter (DMT) superfamily
MTRVLGYGACALAGCLWGTGFYFGKIALTELPVGHMVLYRFLFACVGLLPVVRWPRFTRR
AWAWLLTASFVGIPVQFLVQFYGLSMTTVSHASLMVGTMPVILAVGAWLFAGEKLDWKGW
LALAGSTTGVALIVLGGRHGAAGGKGPSLAGDLLVVLAMVFALGWILVNQKLMREGHSPL
SVTVWGLLTGTAMLAVWVVWRQGMPPVHGLSGQVWFALAASGLACTAATTLLWNWGMHRV
PASRAGVFLNIEPALGSILGVELLGDRLGPGAWLGGALIITAAVVLTMTGHVEPDSVLE
>fig|240015.3.peg.2125 Permease of the drug/metabolite transporter (DMT) superfamily
MPSSSSHAGPARLAVLLAFGSVYFFWGATYTAMSIGVHLLPAPILAGTRMLIGAALMLLF
CKLRGKKIFYSRGVMARLGLLGVMLLFMGNVGLVWSEKYLASGLAALIVAIVPLYVAVIE
AVTGGEQLRRRGLFGLFLGFLALIALLWPSFHEALLPRHGSSMQIIAAIIVLLGALSFAS
GSVLSRHMQLPVPPLVAAGWEMGAAGLANVVLATATWQWPHATWNWHSLAAIGYLILFGS
LLGFSCYIWLIHHVPVAKVATYAYVNPVVAVILGVLVLHEHMQPTEYFGMVAVIASVALV
TSSQMKSGKPAAAPAPVENEA
>fig|240015.3.peg.2816 Inner membrane component of tripartite multidrug resistance system
MAATATLLPETLAPKKLAARAAINPWVIALTVTLATFMELLDTSIANVSLPYIAGGLGRS
YDEVTWILTTYLVANAVVLPMSAWLSRVFGRKTYYMACVALFTVTSFFCGIAPSLNVILI
ARILQGIGGGGLAPVEQAILVDTFPANKRASAFALYTVAIVTAPAIGPVLGGWITDNFSW
RWVFFINIPIGLLSLFLTNRFVHDPPQFQEERRSARIAGKLRIDGVGIALIGIGSAALEV
TLDRGQIDDWFGSTFICWALSIAITCLVAAIVWELRQKDPIIDLHLLRSRNFAIASFLYF
LFGFGLFGSTTMIPQLLQSLYGYRATDAGLVLGPGAFVITMLAPVGAQLVQRGIVAARTL
LFFALITVGLSFLYYSHFNLATDYDHYAWARALQGLGYAFFFVPLSVITYSQLRPDQNNR
ASSITNFFRNWGGSFGVAFITTMTERRQNFHQAVLGASLTGPSLWLQQAVHRMAGYLAAR
GLSPGDALHYANAIYYQRLEDQARLLAFMDCFHVMGILTLIAAPLVLLTRSFRAGGKAPE
GH
>fig|240015.3.peg.3307 Membrane fusion component of tripartite multidrug resistance system
MADQNPEQKNTPADEQQLDKPENLRPKSRKRFILFGVIAIVLIGGGLYWWHSTFYENTDD
AQIDGNIIQISSRISGHVLNVEVQQNQSVKKGEILVELDPTDYETAVKQDEADLASAEAN
YEAATVNVPITHVSTSSTLSSADATVLSARDSVAQAERQLQAARAQVLSAQANYTKAKLD
LKRYTSLVQKDVISRQQYDAAVATATADQAAVQQAEADVQAYQAAVSVAHAKVAQAQASY
RNAQTGPRQVAIQKAKADQAAAQVKLAEAKLQQAKLNLSYCIIRAPESGIVTTKSVEVGQ
NVSIGQNMATLVSLDNVWVTANFKETQLDNMKVGQPVTISVDAYGGKQFDGKVTEIGGAT
GSMLSLFPPENATGNYVKVVQRIPVRIDFTNPSQDKDHMLRPGMSVEPKVRIK
>fig|240016.6.peg.509 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MTPEKNPALNGAVLPTFFYYAVPSMVGLIALTTTSLVDGIFVGNYVGADALAAVTLLVPL
LTVLYALALMFAIGGSVGAGTHMGAKDPGTASSVFSQTLIATVATTTLFTLASIVFEPWL
FRLLNIPTELVPMVGEYFGILRWTLIIQLTTMVLYYFVRADGHPILATISLLVGSLGNIG
LDVFFVCQWGWGLAGAAWSTAIAQVAQAAVLCIYFFSRRRTLHFIWRQTRWSHLFKACYN
GVSEFINEISAGIIIWLLNFLLIGRLGVDGVAAFSVVSYYIYLSLMLTYGVADALHLLVS
QNFGAGNHQRIRQFLSTALIGSSGIGLSLAVSLLLFGDQLTGWFLSGEDAAIVEEASRLA
FAIWPLFLVNGVNVILSCYLTAIHRPTPSAIVAILRGLILPACFLLGLAHLFDQAALRDS
SSQWSFLWALPLAEWITFAVAIAFCYRHRPDRFEPAFPIQPVED
>fig|240016.6.peg.637 Permease of the drug/metabolite transporter (DMT) superfamily
MAPSSSSAGTASSPTLSASPSLTEAAARPPLLLILLAFAAVYLIWGSTYLGIRLATDTMP
PFLMAGSRFVLAGAFLYGVLRWRGEAKPPTVAWKDAAIIGGLLLLGGNGGVSWAQQYVPT
GVSALIVASVPLWIVVTDWLRPGGTRPRATVMIGLALGFFGVVLMVLGKDSKGHPVVIPL
GAAVLVLSTITWALGSIYSRHAKLPGSALMGISMQMMAGGGLQLLVGTLLGELPRLRFDL
ISATSAWAFVYLTLIGSLVGFTAYVWLMRTCSPALVSTYAYVNPLVAVALGSLVLKEPVP
HAMATAGGLILAAVVLITLTSKRRAKGGDATQAGGDSLRSSG
>fig|240016.6.peg.2365 Permease of the drug/metabolite transporter (DMT) superfamily
MSRSFKSSLVTFLIVAGSSLFFCSKAVFVKLAYRYGLDAVTTLALRMAMAFPFFLIGGIW
ASSGKQVHPLTSRDWARLALLGFCGWYFSSVINFMGLEHVSVGLERMILYTYPSIVLLGS
VIVLRKPLRWGVAGAMLLSYLGILIGYYGEASAKTGGETWLGALLVFGSAISYAIFVLMS
GEMIARIGPIRFTSCVVGFSCLYVLIHFVLTHPPGAILKLPPGAYGCGVALAIAGTVIPS
YLFGIGLKRAGAQAFAVIGMIGPLGTVGLAWMLLGEAINPVQVLGLALTLAGGAMVAVRK
>fig|240016.6.peg.2401 Outer membrane component of tripartite multidrug resistance system
MNCLPPQAVAPLLLLAFAGGLVGCVGSNPDRAQSELKVPGKWKGAARSGFPQRPLNTAAL
PKWWERFHDPVLNQLVSTALQNSTDIRTAVSKVRESRARRGVQAAGLFPTVDAGFSARGE
RTDNRNTGVSSSENYGASIDMTWEVDLFGKQRQNIKAATEDLREAGENLYAAQVSLAAEV
ADTYVSLRQAEAQLAVVERTLASRTETTQIARWKEEAKITGSVDTQQAISTLEQARAQVP
SLKQTISQTQNQLSLLASLPPGALDKLLARSDKMPSPPARIAIGIPADTLRQRPDIRAAE
RRVDAAVARTKSAVAERYPDLSLSGSIGVDALKAGRIFSPENVAASIAGSLAAPIFDAGR
IRQDINIQSELESQALIGWEATVLTSLSEVENALIGIQRTAERLVILEQALKAARQAEEL
STQQYEAGLVDLLVVLEAQRTLLSLEDQEVTTRANQASAHIQLYKALGGGWSS
>fig|240016.6.peg.3293 Glyoxalase/bleomycin resistance protein/dioxygenase
MSTPYRPEGFSAITPYLIAPDAARLIQFLVEAFDAKEKILVHDDAGKVRHAGFQIGDSHI
ELADGNPQWKPMAAGLHLYVQDTDAAYLKAIAAGGTSLYEPTDMHYGERSGGVMDPAGNH
WYIATLLPS
>fig|240016.6.peg.3327 Acriflavin resistance protein
MQWLAAISVKRPVFATVLVLVFVVVGALGYTRLPVDRFPKVDFPTVSVVTRLDGATPKEI
ETEITDKIEEAVNTVSGIDELRSVSTEGISQVLVAFNLDKKVDVAAQEVRDRVNRILPNL
PEDVDTPIVEKLDPDAEPIMSISLVAEKPVREISELADKVVRRQLESVAGVGQVTLLGAR
KRQINIWMDPVRLKAFDLAAVDVERALRQQNVQIPSGNVKGNGVEAGLRVLGKAQSVDDI
GRIVVREKDGGLVRLADVARVEDGAEDLQTVARRNGQPTVTLSIRKQSGENTIAVVDAVK
ERLEEIRPTLPEGYKIEIVRDNSLIIRTSTHAVKEHLVLGSIFAALIVLFFLGNGRATLI
SALAIPTSIIASFGVMWVGNVTLNSISLVALALAVGIVIDDAIIVVENIFRHLHEKNESP
HDAAINGTKEIGLAVMATTLSLLAVFIPVAFLSGIVGKFLSSFGLTMAFAIAVSLLVSFT
LAPSMSARMLKITKPNWIERGMTYLVNIFYTPLEGLYMWMLRLSMRHRWIVVLACVGALY
SVGPMMGKVQKALLPPAEEAEFLVNLRTAEGTTLEATDLVAERVARDIRTIPGVEYTLLT
IGDNDQRTPNKAGIYVRLIDPAKRNDSQEQIMDRVRQQIVPKYPKELRMTVLQVPPFSTG
QSSATVQFIIAGSDLDRINQAAENALKEIPNIPGIRDVDSTLVSGKPEIVASVDRAKAGQ
LGVNIADLSSTLRLLVGGADVSTYNEGGEQYDIHLRSEAPYRNSQEALSLLSVPSGRGGT
VSLSNVVKLERREGPAEINRADRRRQVTIMANPAPGVGESQIADAIETIVKKQNLPPDYE
VGPTGRSKELKKAGLAFVTAFGMAFIFMYLILAAQFESWLHPFTILLALPLTLPFAILSL
LLFNQSLNIFSVLGILVLFGMVKKNGILQIDHTNQLRERGMNRLEAILQANKDRLRPILM
TTLAFVAGMVPLMFSKGVGAAFNNATAGVIIGGQMMSLLLTLLATPVFYSLFDDVIGWRK
RRADRREAKRAAREAAAHPAPQPAH
>fig|240016.6.peg.3750 Multiple antibiotic resistance (MarC)-related proteins
MRPTDWISALVLLLIVLDPLGNVPVFSSLLRQVEPARRKRVILRECGIALVVLFLFLAFG
GGFLKLVGLSQSSLGIAGSIILFMIALRMVFESTEKVFGGLPQGEPFIVPMAIPMLAGPS
ALATVILFTTREGISTLGAVGAISIAMGVTCIVLLLGERIIRLVGERGLAAMERLMGLLL
TAIAVEMFLRGVKEFMK
>fig|240016.6.peg.4282 Glyoxalase/bleomycin resistance protein/dioxygenase
MLPSAILETALSVADLNLSREFYARLFGHPILASDERLCAFDVQGRQVLLLFPKDSDPEG
TTMPFGGHIPAHGSHGRSHVGFAIPAESLDEWRQHLHHLSITVESEFTWPRGGRSLYFRD
PDGHLLELLTPGVWPTY
>fig|240016.6.peg.4587 Acriflavin resistance protein
MISWFARNHVAANLLMLAVVAAGAWTLFSGKIPLEVFPDVPSRMLSVSVPYPGSTPEEVE
EMIVLKIEEAIQQVQGIKHINSTASSSGANISIEVEEGSDPRQVLEDVKIRVDAVPQFPE
EAEKPVVQLDDWFMSVITVVISAEMADRDLRRLGEQVRDEVGALPGISHVSLGGIRPLEI
SMEIPEATLRKYGLTLESISRAIQSAAIDLPAGVVQTESGDVAIRTRGRAYSGDDYAKVV
VLTREDGTKLTLGDIAMIEDGFNENPLIARLNGKKCVVVNVMREGSQNAIKIADDVKGYI
EAARSKLPDGVTIEYWNDRSKIVKGRIDLLLGNAQSSLILVFLCIGLFLRLDSVIWVALG
LPVAFLGAFALMPWLGITINTATLFGFILVLGIVVDDAIVISEHVDKLQRQGLPPLQAAI
EGTRRMAVPITFGVLTTVMAFLPMVFEKGDWARMFQPIALVFVTVMLIALVETKIILPAH
LAHPFMEPVMKHLAPFYNFTDGCLQWVITRLYRPSIRWSLDHRYTVLAIFFGGLLLLCGF
FFGGRILFVKFPRIDSERIEARLTMLDGTPFEVTDRHIARIYEIGEQLRREYVGPDGRPV
IRHILATTGTTRLTGSTGGSGGVSHLGEVNMECYGPEERSLKIRTPDIANEWRRRIGQIV
GAEELNFRAEILRSGDPIDVQLSGTNPQELLALSSQIKDKLGQYRGVFDIADSLDSGRNE
IQLRLKPEARQFGVTVNDLARQVRQAFYGFEVQRIQRGRNEVKVMVRSPRNERRNLATLD
TMRVRLADGLELPFSSVAEIKVDKSFTSIRRVDRRRALNVTADVDKSSTDVAVVRAGLSE
YLNELMAAHPHVHWSFEGEARSERESASAGWMALITVGLGLYAMMAIPFKSYTQPLIVLL
VIPFGVVGAVLGHLFHGMPVSMMSLFGMLAVSGVIVNDTLVLVDEINSQRDETGDLEMAA
REGGAARFRAILLTQITTFFGLVPLIFDNSPQSTHNQFLLPVSVAMGYGSLFATVITLYL
VPLSYLAVDDLLGLFRKQPRKAATIASPDDNGAVVRA
>fig|240016.6.peg.4818 Polymyxin resistance protein ArnC, glycosyl transferase (EC 2.4.-.-)
MPDIQPQISVVVPLYNEEENVAELQRQLSQALAGHSYELVFVDDGSTDATSAHVQKSDQV
RLICFRKNSGQSAAMYAGIMAARGEVIVLIDGDLQNDPADIPALVGKLQEGSYDLVCGYR
AKRKDTAFKRLQSRIANAVRSRFIGDGVRDTGCSLKAMRRECRRALLPFNGMHRFIPALI
RHSGYKITEVPVNHRPRIHGVSKYTFANRAWRATKDMVGVSWLLSRMVKIDAEER
>fig|240016.6.peg.5115 Inner membrane component of tripartite multidrug resistance system
MGGGVLLANAQSVIFESFPPERRSLAQAVFGLGVITGPAIGPILGGYLTDTLGWRWIFFI
NLPVGIVSVILAITFLPQDDASQKKTGESVDWLGIVLLTIGLGSLQTLLEEGQQDDWFAS
RFITGLAVTSAVAATLFVWRQLTVSHPVVDLRVLRHRSVAAGSLYSVVLGAGLYGVIFAV
PVFAQNYLHFNAMQTGNLLGPGAITSAVVMIMLARVTKFVDPRILVAMGGLLTALVAFQL
SHITTQSGANELFWPLVMRVGSSVLMFLPLALLPPDNASGNFTKVVQRVPVKITFDPTTL
SGIRQQVRPGLSAIVSIAVK
>fig|240016.6.peg.6450 Membrane fusion component of tripartite multidrug resistance system
MSSRVISLNELPKRGFSPAPNVEHNGAAAPQTTTPAESEPRPPQSTGHRSRKPLLIGLPI
LLVVATTVGFWLHYAAQFVETDNAFIEADVHPVSSRVAGNIQSVLVEDNQKVEAGQPLAQ
LDPRDYEMKLQSARTALEQAAAQVPQAEAALAQAQAISAQTEAQVNASAAQLEKYRLDFD
RAQKLRNLTGKAISDQDFDATKAAYVAAQASHASTQAARQAGEAGVKTAEANLAVARAGQ
HHAQAAVSDAELQLSYTTVRAPAAGTVGKRTLQVGQQIQPGQALLAVVSPDHWLVANFKE
NQLATMKAGQPVEIKIDAIKGQRFEGRVESFAPGTGAKFSLLPPDNATGNFTKIVQRVPV
KITFDHNANTEANHDRITPGLSAIATVKVK
>fig|240016.6.peg.6451 Inner membrane component of tripartite multidrug resistance system
MNATATLPQTGARDSTNPGTSLRNWIAVLGALLGAFMAVLDIQISNSSLQNITGGIGATL
EEGSWISIAYLVPEIIVIPLCGWLAQVFGLRRYLMWNSVLFLVFSMCCGFAWNLESMIAF
RAFQGFTGGALIPMASTMVMIMLPAEKQPVGFALFGLSAMFAPAIGPSIGGWITENYSWP
WIFYLNLVPGIILISAIGYGLNSTPAKLDLLKKGDWWGIAFMAVGLGSLTVFLEEGTRKD
WFGSEFITTLAIIAAITLPVFVILSLIKRKRTPAVNLRLFSRRNFLLGCIVNLVVGLCLY
GMMYLLPLYLAQIQGYNALEIGRTLMWVGLPQLVVMPFIPKIMQWVDKRVVVAFGLGMFG
LSALLMSSMSADTGHDQLIMPQIIRAIGLTCTIVPLSLITTGGIESEQAASASGLFNMLR
NLGGSIGIALLSALLTNREHFHSHHLGEAISTYNPLTNERLTAMAQNFMNQGLDAVTAQS
RALGLLDLGVRKQAYIMAYNDSFHIASLLLFAMIPLIFLTRKATGPAPAGAH
>fig|240292.3.peg.727 Multidrug resistance protein
MPQKSAALRFVILLGFVSLCADATYEGARSITGAYLQVLGASGTVVGLVAGFGELIGYGL
RLVIGYLSDQSRKYWGITTLGYILNTAVVPLLALTGRWEAAAGLMMAERTGKAVRTPPRD
ALLSHGASQIGRGFGFGLHEAMDQTGAVMGPLAVAAMVYFQGEYRHAFTILIVPAVLGLV
VLLVLQFLYPNPSDFEEETEEQKQQEGLPRIFWIYLGAVAVIAAGYADFPLIAFHFQKSG
IATGETIPLFYALAMGVDAIAALIFGYVFDRLGISILIIAAFISCLFAPLVFLGDTNLAL
LGIAFWGIGMGAQESILKAAIAGMVPKHKRATAYGIFSTGYGLSWFLGSALMGILYDHSI
TTLIVFSSATQLLAIPFFTWVKLKADDSPKTITNQAS
>fig|240292.3.peg.824 Permease of the drug/metabolite transporter (DMT) superfamily
MIKFRGRSRLIHRVSGQVYLWLAIFIFGASSAVTRKLTEIGARHFIDGRNPISLCNVLFV
GNLCALMVMLLIYNRQWNKATLAQLSKKDWLGLTAVAILSGALAPGLIFQALSLTGVNNV
ILVGRLEPTLALALSVWLLKERIGFGEFIGAIAAFTGVILTIILQPPGSDMMNMGGWQLG
LGELLVALGSITLAISTIIGKKYLTHIPLGIYSIFRTALGTVIFFFIALLLYGRDHFADV
FSPFLWQWMFLYGGVIVVVGQSFWIIGLKSSTVSTASLVASFTPIAGIMAAYFILGEVPT
MAQYLGGSLIMLGIFLSQVSKSRQTSHKSPIASTPTEQKVEMDIGFKGI
>fig|240292.3.peg.2142 Melittin resistance protein PqaB
MRPITQKKLLLVLLVAALALWLTFLGNLPLRDWDEGTIAQVARDIWQAPVGSMRWLYPTL
AGEAYHNKPPLMHLLIAWAYSIGGINEWTTRFPGAFITALGVPLLYLLGRSLFNRSLPAL
FAALVYLTMLPVVRHGRLAMLDGTLITFFLFVLFCLLKARQNQKYALGVGIGLGLIALTK
GMMVLLLGGIAGLFLLADRQLTLLTSPYLWTGLFLGSAPAIAWYLAQWQHYGGSFLQINL
QSQTFNRVFQPVEGHSGPPWYYVLEILKYGFPWLLFLPGGLYLAAKKRDTSWGCLILVGT
IVYLASISVMRTKLPWYVMPIYPFLALAIGAKLADVWQYHHVKSTTLVVFFVILAIAGLG
GCVYFATTETQPVLIAMSLVLAVSMATVAWLVNQGDRNFIPVLFTGMYLVLIMFVSSQSW
IWELNEAFPVKPVAALIRQHVLPGTKIYTSFAYNRPSLDFYCDCQVLTEPSISQQMAKRN
DYLLLDNTTLEKINLSGNEILGTVENFTLIAPSKN
>fig|240292.3.peg.2550 Melittin resistance protein PqaB
MQEGSFIWGHLERQHRAVDKWIDRLWLVVLLIAALLLFSVNLGGLPLQDWDEGTIAQIAR
EITQESANSIRWLYPTLRGQPYHDTPPLMHIVIAGAYHLGGVNEWTTRLPGAILTALSVP
LLYCLGREIFRQRWAAIYSALIYLTMLPVVRYGRLAMLEGAVVSFLLVMMLCVLRSRRDL
RYCLGIGLSLGLICLTQGLSGFLLGAVVLVFLFWDTPRLLTSYYLWIAIAIGILPVAGWY
SAQLLHYGNDFVQNGLLLQSLQQAGIVNHKNAQPSWFYIVELLKWTWPWLIFLPQTTKLL
WENRNLSWARLILVWSIVYLLLISLMSVKLAWYIFPIYPSLALAFGAQLAEIENLPLLSS
YPRAWVAGLSILAVVASAASIHFSWGIAAKTDLQLIFAAVALTMIMGAILAERGDGQFLK
ILFWGSYISLLLLMKSNYWVWELWQAYPVKPVAAMIEKVNPAAKKIYTSFPYHRPSLDFY
SDRHIIPASAEELKHHWHYDRQPYLLISSSDFQRLQLDSVQILDKTEGWQLITKETNRL
>fig|240292.3.peg.5031 Multiple antibiotic resistance protein MarC
MDTSILIQTFIAVFVLADAIGNIPIVLALTKGMEPEDRNRVIDKASIVAIAVLLLFAFGG
QYILTYLEISMASLRVAGGLLLLLIALQMLRGELETPTIEEGRDVAITPLALPLLAGPGT
LTTVMLFMSKSQSPHLAVVLGILAAMFVTWLILRLANPIEKRIGLEGGVIVTQLLGFLLA
ALAVEIGSTGIRELFLQ
>fig|243090.1.peg.181 Drug transporters
MLASGTELKIANLFSRRSDAFSIRRMPANQALAAAAFVTMTFGGASMLLADDAKSKPIVI
EGAQTTLVTDLTLAAPIAGRVMSVTATEGQQVSKSDVLVQLDDRRAKAELAAAESAAKAA
ELRSTSDVDQRYAERTREVRMRELEQSIDANKRYQNSVTATEIDRLQLVIDQAGLSIEQA
RKELEVAEAQADEKLSLVEMAKLRLSEHRVDSPVVGNVAETMVSVGEWVEAGAPLLRVVS
LDPIRVSGFVDGRVHGGELKGRPVEFEWTQSIGGEDQSIVLSGEVTFVSLEVHPVNSQVR
MWATLRNPDQLARPGVRGTMRILPAVGEAKTPAE
>fig|243090.1.peg.2374 Drug transporters
MRFRRLRLKQRPCQRSWGVAQRRRVATTDTRSAIGLMTPASVSFRSDWLIKATNALNVRV
SSPLPGRVRNWAAGACPWPWSFRCEKLVEDIVFSCLRCHVGRREAVARVSLAKSRIGCVL
ALHFLSQRVIAFRSTTSRRDPRTFHLFYFAGPGGWPLSSLSQESMTESPRRIERDAYGYR
AMVAVAIPLAATVGCFSITLFTDRTLLMWYGPTSSAASMAAGNLYWAIACIPVTAMGFIT
PLAAMAMGRKRGRGAVALRVWSLLWQCLWFTLACVPAFALIGWMSPNLFEAFGHDVELAK
QEARYFQTLLLVAPASMLEAGLTAFFVGRRVTRPILQTNIASSVLNVGLDYWFIFGGLGL
PAMGVFGAALATTIAMWFKVAVFAVMLMRLNSFGRHFRAAWRPSRHVMTEIIVPGSAIGL
QQLIRSGLFSFVLLVIGAASVTGLAATSAALTMYQLLSIPAIGLGTAVTVVTGQALAAKG
IGLASDTIRRGMGLGVVVALTLAIALAAFPETLLQIPLGGISDEERAEIQPLAIRLMWFA
AIYALVDVASLLLAASAKGIGKSFVILVATAVPGVLVVAGGWLLAPDGWLRAGSLVRENQ
IVIHWWSALVLWSTAQAFVLAGSLFWSTNALLPVRVGQAPPSQPDA
>fig|243090.1.peg.3638 Drug transporters
MAEPTKHSHSGELKIGLVCALLAHTMWGLFPIYWRQIGNADSTELVCHRIVWSFVTLGLV
LPVMLWRGRWGGFRVVYQQLRSRKVWAVYSIAAVMIAINWLAFIWAVNNNRVLEASLGYY
INPLLNVVLGVVVLGERLRWPQWMAVGFAAVGVSVMAIGNGGLPWVSMAMATSFAIYGLV
KKKASLPVLLGLMLEVTLLVVPAAIYLGMRLADGVSTMQTGTTIEFGMLLGAGLITIAPL
AFFAAAVQRVDLSLMGILQYIGPTLQFLVGYVLFGETLDLPRKIGFVFVWTGLLIFLLAS
QFKRRRPTLVAEAS
>fig|243090.15.peg.998 Permease of the drug/metabolite transporter (DMT) superfamily
MVTIFDDTFGGEPLIGIVFAMLVVLSIPIGILLTTFSFAKDHKREHWPIAAVSSALLVMI
GLASYNGAWPLAKLLTADFVRGTAFTNNPRFWWMMAREVRDAGFYLLCIAAIVAFGNLLI
YAVHRFCGNIPRPSDSTQS
>fig|243090.15.peg.1089 AcrA/AcrE family multidrug resistance protein
MHNQFLEMISIIRSMLNRSIPILIFVVIPCAFLGCDTMSGSRPAQIISGSHPSSHSKQHT
TTGQANSHHNESHHGSSEPEVTNAHHATGEHHAQHKIVVTSPVARDVTLTRQYVCQIHSR
RHIEVCALEGGYLKDIHVNEGQAVTKGQTMFHILPTIYEAKLDADMAEAQLAQVEFDNTK
SLVQQNIVSTQELKLAEAKLAKAVANVKLAQAEMNFANIKAPFDGIVDRLQEQEGSLVEE
GAMLTTMSDNSVMWVYFNVPESRYLEYQEAMNAGQNQDALDVQLRLANHKIFDQPGKIGA
IEADFDSETGNIAFRADFPNPNGLLRHGQTGTVLINQVAKNAVVIPQRATFEILAKKYAF
VIDVDDIVHQREIVIQNEKDDIFLISEGLQPGEKIVLEGILQVRDGEKVEYEYRDPDTVL
GNLKYHAE
>fig|243090.15.peg.2640 Probable multidrug resistance efflux pump
MGAAIYGYTFLGERQRPQRSKPAKSPVTIVATDDIRFHSGPVVIDVNGVVVPLRELRLAS
EVAGRVVELSENVRAGRKVKQGEVLIRLDATEYELEVKRLQALAQQEAAEENSVQVGIEN
TLQLQSLAQKQLEIARQERERINALVAQRAASASEVDTARRAELAADASLVELENRRREL
TAQLQLVTEKRSLTEVLLERARLDLSRCEIKSPIDGRVVSSEVEEQSFLPTGTTFITIED
TSAVEVRASLTADQMFWIWNSRSVLSTLAASDPAQAEKAVTDADRFNSAVSATISSVIGS
ESHQWSAVFERLDGVGIDLNTRTYPCLFRVESPESSLEGSASRQLTRGMFVDVSIETQPN
QVLVRVAESAVRPGNRLWLNVDGKLRIVPVTIVSRTGDDVVVQIQPELDHLCTLASTRII
VSPISDPVEGMPVGGQPPSPSGEGAGPGKTGQSDSPPIGDTTSNPIQANSSLRVDG
>fig|243090.15.peg.4571 Multidrug resistance efflux pump
MSWILGGVYCGIIWLVFAKLKLMRLSLPLAIILASVGPGLIVVLLFCAQYFHPYTKQAIV
IAQIDPITAQLSTNGRVKEVFVSPNVPIQAGDVLFTVDPIPYENAVEVAKAGLEQAKQNV
QLSESTVELSRATLVRAKADLTYATNDRDRYQKLRESGGASQDELERAVTLFQQSDAALT
QAEQSLKQAGISVGVAKAKQTQAETTLANAEYDLQQTTVKAPADGYVTNLQVHPGMLLGP
ATGPVMSFIRDTDERQKGVVVAVFVEKNFLRIRTDQYAELAMDAYPGEILTGRVLNSINV
SGKGQLVAGGMVPTDLADGKPTQFAVRIQLDDVDSYPLPGGAQGQAAVYTGDVQIAGIPI
MFLIRANSWMNYLF
>fig|243090.15.peg.5396 Acriflavin resistance protein
MTSLSKMVPEGGPIAWMARNSIAANLLMLLLLGGGIWSAFAIQKEVFPQFQLDIVEVAVG
YPGAAPEEVEQGILRPIEEAVRGVEGIREVTSEAREGRGELLIELVGGEDRMKVLQDVDQ
AVSRIRTFPDQIEQPEVRLQSRQQEVMQVAIYGPIDVWALRKLAEQLRDQLQSKEQITQV
ELRRVPAYVTHVEIPRQRLREYGLTLPDVAEIIRTSSQDVAAGSVQTTAGEILLRVKARK
QWAEEFAGIEIVAGRDGPMVTLGDIATIRDGFEEVGFHSQFSQTPSVELDIYRVGSQSPM
DVAEAVQETMEEFETALPPGVKWRIDSNNAEEFRRRLMLVAENAAMAVVIVLVILSLFLE
FRLAFWVMMGMAVSFIGGVLLLPAAGVSINMISLFGFLVVLGIVVDDAVVVGENVYEKRQ
TLKDHEAAAVEGTKEVSGPVTFSILTNIVAFVPLLFIPGETGKFWGPLPVVVIIVLALSL
VESLFILPAHLAHARDAGRDPNSIGARLHHLQQRFSQGFNRLVEFFYRPVLILSLRHRYV
TASLALALFVVIGGYATSAHMGLILMPEVSADEIEAGVRMPVGTTQAQAAKIADTVTKAS
IKMFEEHNLYEVAEGIKTNVRGQSFIDVEIVMKPPDQRDMTANEVIDLWREHIGDLPGVN
QVTFEAERGPGGHRRDISIDLSHSDIDVLEQAATAFVDRVKLYSNARDVNDNYNKGKTQY
DFRLRPEGRSLGLTDEELGEQLRGAFFGSLALRLIRGTNETEVRVKLPEEQREDIHSLED
LIIRTPSGAEVPLLDVAEVEETLAFRSINRRDGRRTISVSMDVEPKRAATQVIEALQNSE
LPKLREDFPGITWSFEGSDAEMRQATASLWGSFGLALAVIYSLLAIAFKGYVQPLIVLVA
IPFGVVGAIIGHIMLGYDLSLVSLMGVIALSGVVINDSLIMIDYANRHRKNQSAFDAISQ
AGLRRFRPILLTTLTTFGGLMPLIFEDSLQAQYIIPMAISLGFGILFATAIILVLVPCLY
LILEDIQKTFTPDTE
>fig|243160.4.peg.22 Outer membrane component of tripartite multidrug resistance system
MKTFPLSACRTAVAVAVAALALAGCANYFGLKNDKAIAPAAQFESARSLPAQGGQWPSLD
WANQFGDPQLPKLIDEALEGNPTIAQAQARIAKASSYIESSRSTLLPKADAKYSWTRELY
SGNALFPPPYGGQWYSENNALASASWELDLWGKNRARLNAAVSQEKAAEADLQQARVTLA
TSVARTYNQLAQLYALRDIAGREISNRQTVDKITDGRVGAGLDTNVERQTARGNIATSQS
TLSDLDGQITNVRYQLAALLGKGPDRGLQIAAPVLSAGGAVALPENLPADLVSRRPDLVA
ARWQVEAAMHDVKEAKAEFFPDINLAAGFGFDAFGWGRFLNFASRQAQFGPAIHLPIFDG
GALRAQLKGRYADFDLSVANYNQTLINALNDVATQVASIRSVDTQMGDAQRALDASTRAY
ELAVIRYKAGLSPQLQVLNADSNRLAAEQTVTNLKMRRRDLQIGLVKALGGGFDAAGTRL
AAPAPASAPAAPAQHASN
>fig|243160.4.peg.601 Permeases of the drug/metabolite transporter (DMT) superfamily
MAILMGLLSALCWGSTDFLAGHAARRVGVTKSLFYSQSFGFLILTASLALHPSSLRITAI
DMGFAVGILAAVCNLIAMAALLRALAIGKASVVAPIVSLYGAVTTILSLATGQSITRLAI
AGLVLCIVGASLASISKAADGKTESPASIGFALLSAAMFGLGFWLQGAFAVKSLGVVSAL
WIYYLTAVVILFATLARARNLSAPPGSIVLLILSISVFSLVGFFSLAYGSTTGHVAIVTV
LSSLASGVTALLGFFVRGERPSALQWAGIATIIVGVVMLKITPQALAA
>fig|243160.4.peg.793 Permeases of the drug/metabolite transporter (DMT) superfamily
MQENERRSAGWPTLAILVGASVWGLIWYPLRLLAALGVTGTVASAATSIVACAFVLIVRR
KSIATVRRHWLLPALGVAAGVTNLGFVWGTIHGEVLRVMLLFYLTPAWTAICAHFILRER
LTAAGAALAALSLGGAVLMLWSPRLGVPLPSNPAEWAGLAAGMSFAMSNVLVVKASRELP
RMKPEMRTATLFAGAAAMGVAAAFVEGLPPLPAGGELGRAALLVVGIGVTVAANNMLVQH
GLARVQANRASIIMLFEIVVTALTAWLFANEVPSAREWAGGLCIVVVTLLSSRVHRARPA
EDEPLEPRDGARAMV
>fig|243160.4.peg.1258 Albicidin resistance protein
MRLKIGELAKKVGLSVRALHHYDAIGLLSPSQRTDGGARLYGRDDLIRLHRIEALKRFGY
SLPAIQASLDGPPAGAPLQILRRQIAALDAQAARAQRLSRHLQHLVAMVAAGGETAAIDW
LNVLELMNMYQKHLDDNELDTLLASGPDTVAPMDPSWVGLVDEVRDAMRRALPADSDAAQ
ALAWRWSRLMNRMTRNDPALAGKLMGIQLGEPRAQHIVGITPAMLTWIGEACAHARCTLF
AKYLNPAQIAEVRRRQLADTHMHAWLALVAELRAHMEAGVDAGAAPVQAIVARWQQLFRD
SFCGEEEGLEAKVRDALMREPDLQLGGGFDEALLVYLNKAHIAGRDIASGDDGPKPSALM
VAKQRAAHQLLDRPLVLDDPIALSILGAAEEQALRADLDRFRYPASLGMRSSVVVRSRLA
DDMRAEAIGRGVRQYVVLGAGLDTSAYRHPEAPGRLFEVDLPATQRWKQARLREAGIALP
RSLRFVPVDFEHVSLADGLARAGFDPGAPALFSWLGVTMYLDEAAVVETLRFIAGCAKGS
AVLFEYVTPLSGLPPMMRIAMEQLTAQLAARGEPWKCFFEPAALAEMLIGLGFGSIGAWS
PDELNRRYLADRADGLHIGATPARLILATV
>fig|243160.4.peg.1676 Bicyclomycin resistance protein
MPHVARRRPDGRLILLLGALAACGPIATDMYLPSLPAIAGGFGVTAAAAQRTLTSFMAGF
SIGMLLYGPLSDTYGRRPVLLGGIALFTLASVGCFVAGSIDMLIAVRFLQAFGAGAASVL
ARAIARDAHEPADAAKVLSMVAIVTAIGPLLAPLIGGQVLRFSGWRGVFVVLALFGAVCA
TAAYLRVPETWPREKRASSAVLNSFAAYGRILVDPVAWGHMLCGGMAFASMFAYITATPF
VYIDYFHVSPQHYGLLFGLNVIGIMLGNFLNARLVGRVGSLKIIAGASLLSGAASFAVAF
FALTGLGGLWSIVASLFFVVGILSANCTTDLMLRYPHNAGAAAAVFGAMQLALGALANGA
PFAMGVTIGATGLLCLGGRMLVLRWHGRPVKGALGRVDAA
>fig|243160.4.peg.2029 Multiple antibiotic resistance (MarC) -related proteins
MESNFLSATVLLILITDPLGNIPLVIAALRDVPRERRVKVILREVAIAFVILLFFMVVGD
RFLRMMSLTDLSLRIGGGIVLFLIALRMIFPHPDGALGSDPRAGGEPFIVPLAIPALAGP
SALATVMLLTSQAPGKTLEWAGALTVTMLVCAVTLVLAERIQQWLGERTVIAFERLMGLV
LVAISVEMMMAGIRAFVHQL
>fig|243160.4.peg.2712 Permease of the drug/metabolite transporter (DMT) superfamily
MTPFDRFLAFVARHPPRLPQSRSGRVALALVFIYFAWGSTYLALHVALESFPPLLLSGLR
NLLAGVGLFVFAMRRRPVRPTLVEIRNAALVGTMLVTMSSGLIALGMRTVSSGSAAVMVA
TVPLFATVIASVAGRRVTGGEWGAVALGMVGIVVLNSGGPSSPGSTLGSITVLAGALFWA
GGAHLAARLALPHDLFLSTALQIGLGGAASTCIAWVLGERIGHVAWVPGAAFVYLMLAGT
MAAYVAYGYLIRHTSPIIASSCMYVNPVVAVALGALLLGEPVTAATVIATIAILGSVGLS
FVFDPARRRAQ
>fig|243160.4.peg.3389 Outer membrane component of tripartite multidrug resistance system
MTQTATHAATRTTTLPVRRPARRLAALALAWALAGCVPSGLKPTLAPRTPGDDALAHTTG
GATHGAWPSPDWVRQLGDPQLDALVDEALRQNPTLQAAQARIGVAQSQLQQFESLTGLTA
TAGASLSKAHVPRSGGTLNTTLNGLPVSVPLVGESVVSSSSLFVGLNYQLDLWGKNAAAT
RGLLSMRDAARVEAEQARLTLSVAIVTLYGELDRAYALRELLQQKRRASEQVEAVLRERA
ARGIDNGYDADDAALKRGKLLEQIALTDEQIQLQRLQLGVLSGRGPERGLSLARPKLAPL
ADAPLPARLPARLPAGLLGRRPDIVAARLRVEAAYAAIDGTRASFYPDVNLAALGGLFAL
TPASLFRHDALGGSIGPALSLPIFDRSRLKAKLGGDVANADMALALYNQTVDAALGEVAR
QLTSLATLDTLLKAQQQALRAAQRMVALAQDRHRRGMGMRKDIDVAQLTLLDERAHVVEL
QARRRTLRVGLIGALGGGFDARPASGAPPAQAGQPFAAASRPVAAHDAQPD
>fig|243160.4.peg.3427 Permease of the drug/metabolite transporter (DMT) superfamily
MTQRLLAAAWRRPVWLLWVPPAFWAGNVVLGRAFSTSFPPVSLAVGRWLVALVALAPFVW
RDVLRERRLLLRHWKLIWACGALGIAGYNALAYVALRTVPAASVAFLNSTLPLMVPLAAA
MLGVERITSRAIVGIVVSFGGVAWIVARGHWEDLVALRFDHGELIVILATANYAIYSVLL
RRKPAAIGPLAFLAATMAAGLAVLAPFWALELAGGARIPFDPKAIGAVLYIGVFASLIAF
ILWGHCVQVLGATVTGVSFHLVALFTAVLAALTLGEPVRSYHLVGIALILFGFFVATRAA
PGVRSAPNARSL
>fig|243160.4.peg.3582 Tetracycline resistance protein
MDLHERTLDAPGAPAAAAHGAGSRLSREVWIILLTLAVDAVGLGVATPVLPDLLRAVGER
PAHVPVMLGSLITCFYFMQFVFGPIVGALSDAWGRRPILLIALGGGALSYAIGATARSYG
GLLAAHMLAGIAASSAAVATAYLADVTPPALRARRFALASSVLGLGLIAGPAFGGVLGAL
GPRVPFVAAGAIAALNFVSAACFLRESLPARRRVPVSWARANLFGSLRLVREDRVFRDLL
AAVCLGMLAYGIYLSCFVLANAARLGWGPRENGLALAGLGLGITLTQTLLLPRLVARLGE
HRTALVGFGAFVLAYGLYSRADSVALVAAALAVHALSLISDPSVRSLISVHAGPQRQGEY
QGALVCLTGLASSIAPLVGGNLFAFFTRAGASTYFPGAPFLAAAVLYALAMLAVWRAMAG
AARRRSASH
>fig|243160.4.peg.3703 Multiple antibiotic resistance protein MarC
MARPRERPPITLVRPSRFPMIVDRLISEILFGFTGLMGIINPFGIAFLFLERTESLTEAQ
RAALARKVAINAFIVLLAAFFVGISLEALRIGGGLAVAVAGWQMLNEPDVPTGGDTAAQP
VEPRNAMARAFFPLTIPLTTGPGSIATAIALNANRTHKLSEFVLSSIVSVAVSALAALVI
WQTYSRAAFLARYLGTEGTKVAMRVSAFLLLCVGVQIMLTGFSEFLRPIADQVK
>fig|243160.4.peg.3704 Multiple antibiotic resistance protein MarC
MDARKRAAARPSRPRRWSRKRSRFFAGGAGAFLYHTDWSVCGPRLDRARRHRAIGGAPPM
TRPSCPAGALEAVETASRDERRVLQRARLKGALRRASDHVAHYQPLLRCGGRASGDVLKT
LADRARVRAVTRVGIGRAVARRESCAAGCQMPDAGCKARAERHEAQRAGPHARSLRSDRL
AGAGAPRSARRRVGCAASAKRPPASGG
>fig|243160.4.peg.4101 Bicyclomycin resistance protein
MHPLRSILPLALFTAVGLLATDLYLPAVPSLPQQLGGSIESAQATLAAFSAALAVSQLVW
GAAADRFGHRRTLAFAVLLQLVAGAACALAPSMGALIGARLAQGFGVGAAMVIVPALVRQ
SFGDGGAVRALAWLGIVESAVPGLAPLVGAALLVVADWRTSFWIIVALSAIAAPLVFRVI
PTARAMRACAPANVGAHAGGYRRLLRSPVYLGYALGHALCFAALLAFVASAPQVVEIWLG
AGPSTFSLMQACGVAAFMLSAARSGKWSDALGLDRIIALGALLQFAASAAFLLLAYADWR
STPLVVASWMLFCGSLGLRGPASMARALAAEPAVAGRAAGLLMFFGLGGAALATQAVAPF
LRLGLAPVAWMCAGFTLASGAVVLWGIAIRGRHRAAATEIA
>fig|243160.4.peg.4140 Methylenomycin A resistance protein
MDTHLPHPALSRAALVRIVSTVSAGFVITQLDVTIVNVALARIGIDLHTSVAGLQWIVDA
YTLALAGLMLSAGALGDRFGARRPFAAGLALFAVASFVCGIAANAATLIAARALQGLAAA
AMLPNSLALLNHACAHDPRLRARAVGWWTASGAISIAAGPVIGGVLIAQFGWRSIFFVNL
PLCAAGLAATRLWIDSDDTRAAAASSASSASSASSAADGAHHSHPAADRRASGPNACAPA
PKRAAGAGTRGLDLPGQCLAVVALTLFTGAVIDWHPALVAIALAAGAAFVFVESRSAHPM
MPLALFRRRTFSVAVLFGVCMNLSYYGIIFVLSLYLQRVRHNTPLEAGLAFLPLTGGFLL
SNVASGWATAHYGPRRPMIAGALIGATGFALLSAVRADTPIAMLVVPFLLIPGGMGLAVP
AMTTTVLASVERARAATASAVLNTARQAGGAIGVAAFGALASGARPPDIVSGLHASAYVS
AALFVFASAMAAFVHGAPQPAAGKPANANAR
>fig|243160.4.peg.4597 Antibiotic transport protein
MLTSVAPPSATSEAVSHRNTAVLVVFTALTNLADGVTKVALPLMATALTHSPARISGVSL
TLTLPWLLVALHVGVLVDRFDRRTLLWLANAARMAAMALLIALLPSGRVTLPVLYASGLT
LGLAEVVALTSAAALIPDAVAPSSRERANAWIAGAETVCNEFCGPLTGGMLVAAGTAIAL
GAVAVGYFGGGVALFFLIGRFRVAHAPHGRPPPVRLQIAEGLGCLWHQPLLRLMAVALTV
LCMCWGAWLALMPLFATTVLGLDSRGYGVTVSALGVGGFVGALSVTLLNRRFGRRTVMLT
DLLGTFAMMAVPVLSTNLWAVAASAFAGGLGGTLWTVNARTISQHLVPGPLLGRYNAAAR
LFSWGAMPIGAGFAGAIAELLGMRAAFAALAVAALLLIVPFLRVASAQALRIGPERRH
>fig|243160.4.peg.4696 Bicyclomycin resistance protein
MSDRGWLSLLMLVVCLPRMTIDAYLPSLPAMADALHGTDAQMQLTLTMYMAGYALSMLLS
GPLSDRYGRRPVLLAGMLVYLGASVACATATSVQGIVVARIGQALGGCCGTVIGRVIVRE
RFGTAMQAAMLSRISAGMALSPVVAPLAGHVVAQWLGWRGVFALLAFGGGAAALMVHRFL
PETRVRAAASERGAGLAKTYLSLLRDRRFVRYSLAIGFVYCTYFPFIAESSALFQRTLRA
SGAVYAAIFGITVLGYLIGSSVFRRASGRFGIDAIIASAAFVNLVGAAALWIGTSVAPPS
VWSIALPMFVVMVSVGVSIPACQFAVLQPFAKLAGTASGLFFFIQMAMTAGCGGMLSRLS
DGSARPMAVVTAASSAAFMAVVMLVRTRGVNGRRG
>fig|243160.4.peg.5238 Outer membrane component of tripartite multidrug resistance system
MSLPIFEGGALVANLRLSQAQQAQAALGYRRAVLLALRDVDNALAAYRTDQTRRDALRDA
AAAERTTFELARDSYRHGLVSFIDVLDAERELSQARQQYVQGSLQLTTDLVSLYKALGGG
WQPVPAAQTPAPAALDAPTQDTPLGATAPARR
>fig|243164.3.peg.772 Permease of the drug/metabolite transporter (DMT) superfamily
MPRHILIALIFTILFWSSAFAAIRVSLADYSPSHLALLRFLVASLALVIYALITRMRLPD
KRDLPAIFLLGLIGISLYHFALNYGEKTVTAGAASLIIASAPIFSVLLARFFYKDKLTPA
GWLGILLSFGGIAVITLGEGQTLSFEPHAFWVLLAALFTSIYIVFQRPLLKKYSGFEFST
YAIWAGTLLLMVGAPGLLKEISEAPASSTLAVVYLGIFPTAISYLLYSYALSKARISQVI
SFLYLNPVFAIGIAFLWLGEIPAPISLLGGLLALAGVILVNRYGHYR
>fig|243230.1.peg.194 Vancomycin B-type resistance protein VanW
MTKFVSAPLICGLALLGALSAAHAQTGIPALPPIAQPLPVPAPAPVTPPAPTVPVPQEPA
PVPQPPMPQPSVPQTPAPQKPVTPRPAPAPSRAPLLIQARANVPALVAGKKTTVPVLKTL
TIPAERAAQLRQRGEVSASLQADLDTFLKSLAAPRDARFEQQDDGQWAVVQPNGLKVDAQ
ATRAAVAKVLRDPRGVSANVVVTGQVAPQRTLDFFASRGITTFLATGFTSYYGSSPERVK
NIHVGAQNFKDRLFEGDVFSFNKFIGPVSERNGYVPGLVIAGDQTASGVGGGICQVSTTV
FRTLYGAGLGIVQRQNHSYQVFYYDPQGLDATIYQPQLDLKFANTTGGPIWFQTEWDDQE
ATLTITAFGQARDYQVQVDAPKTLKTVAPPKDRLIPDASLPAGQRKQVDWAAPGATIEVT
RRFTRGGKTFKQDTLRSVYRPWPNIFRVGTKK
>fig|243230.1.peg.210 Vancomycin B-type resistance protein VanW
MKRFLLPLLLTWPGAALAAQPAPQLALAQDLQLTFKGELKKIDDGQLVTAPVTKSWTLPA
KWVARSREYNKLSSYLTPYLDRVEKETFVRGRPAKFEQVGNKWVATDQPEWKLDRPATEA
KLLEAIRTGATTLPVVFSEKVPQRSVALLAERGVMRNLASARSSFTGSPDFRVKNIVVGS
SKLDYQWVAPGEDFDFNKSMGDINAANGFVPGYIISGGTLALEDGGGICQVSTTIFRALW
EAGLPIVERNQHSYRVHYYDPVGYEATVYAPSKNLRMKNDTDAYIFIQASWNTATQKLRF
DVFGPDTGRKTQISAPVVTDVKPAASPTFTPDKRVVLGQQRLLDQPMEGMTSVITRTVTF
RDGTSQQDSIKSVYKPWGAVYGVHPSDPRLKQTEAQAKK
>fig|243230.1.peg.294 Glyoxalase/bleomycin resistance protein/dioxygenase superfamily
MPLLNGLDHVQLEAPAGCEVAAREFFAGVLGLPELQKPEALRKNGGCWFGLPDGRQVHVG
VVADYVPRRKGHFALRCDDVGAVARHLAAHGVACTPDKEAGVPRLFLQDPWGGRLEIVQG
AHPSRPLS
>fig|243230.1.peg.694 Permease of the drug/metabolite transporter (DMT) superfamily
MLTPMTSAAPVQGRLDPLSLGAIVVTLVFWASAFTGIRIGLEHFSPGHLALYRFLVASVT
LLLVMAVTRLPVPAPRDLWQIGVLSVAGISLYHVLLNMGERSVPAGTASLIIAAGPVITA
LLAARFLGESLNPLGWLGTAVSLGGVALIVLGQGQGLGFSAGALLVLGAAFFTSLYFVFQ
KGVLARVGSLRFTVWSLILGTVPLLVFLPGFGTELRAAPLPAHLAVLYLGVFPSALAYLT
WTFAISRVGAGVTSSFLYVSPVFALLMAWALLGEVPGAVTLLGGVIALAGVLLVNTRGRP
Q
>fig|243230.1.peg.1406 Multidrug resistance protein-related protein
MTGAAGLRARVPLRPGTLRRVLAGVLLLSCAEFVRSGLYAGYLPQAASKLLGLPKADAVV
FGASAFTAHFIADTAMRGPAGAALLRFGLRPVVLAGAALSLLALVLMSVTHTGWVLLLAA
ALHGIGFSPLWPAVMSLTTDSAQPTHQGRVLTAVSMSVMPFVGLSVLTLGALADAPRSAV
FGLCLGLLTASLLLSLLLPQRLRTAPAPTQNPAAPTDRRQGVKVAAQALAPLIPAAFLQT
LTMTLLGPLMFTLYKELGLTYWGLVALLGLGGAVAFGSMPLTGKLADQGRARLTVTLGFA
SLALALGGIALRPAVWALYPLAMLAGLGYAFIAPGWAALVAQRLPEAQRPAAWGTLMTVE
NLGTSLGPLLGGFAYRTLGVPGPFIAGSGLALLATLGYVLFRRAFDTPAGGPLDPEVASA
PPSETPQL
>fig|243230.1.peg.1601 Antibiotic resistance protein
MTPMRSPIIWINGPFGVGKTHTAHTLHERLPGSFVFEPEEMGQALRKLTPGFSGDPQEHP
MWIPLMLDALQYASREAAGPLIVPVSISDTARHRRLMSGLKDRGLSVHHFTLIAPLNVVL
ERLRRDGQPQVNVGTVEDRLNELRGEQFQTHIDTAGLGTQQVAEQIAAQVGLTLAPPPQG
ALHWLRGALGRRREN
>fig|243230.1.peg.1801 Vancomycin B-type resistance protein VanW
MSAQADKLAPGLRVGGVDVGGMTPDAALIAVREQTQAKEPKIEVQATGTGKSWTLSAGKL
GYQVDPQASLAAARKLSDARPWTERALGVLGQMNLTQPKAQDVPLVTKVDPAVAQATIGK
LTADLATQPVNATVGFDPKTRRYAVLTPDTPGRKANAEAAAKAFAADPSQRVLKVPLTEW
PAQYTAAELSKHAELGNKLMRGVTVKLDGSDRAGSLGPLQVANLYWVKPEGIVLDDKTLK
GAFESLSYQLDQPAQNARYAWRDGVWGKVGEKPGRVTDPQKGLEAFRKGLLDPTKTTITF
PSVQQQPAIKLADLPSPAKLQLIASGSSTYYGSSAERRTNVANAAAKIDGTVVAPGENFS
FLQSLGGISPENGFVGGLIISGGRTVDGLGGGVCQVSTTAFRALYQAGLPVVERNQHSYR
VKYYEPEVGFEAAVYDPGVDLKMKNDTGAPILIRTVNNNNASRLEIQVWGTKPQRTVSVS
PAVILSRSPHPAPQYVFNPNLPAGASKQVDWAQDGYNLYQWFVQF
>fig|243230.1.peg.1884 Kanamycin resistance protein-related protein
MLSPTPPMTPDVSLKPVLDFTPAEWRTLYSFFRDRELAAWNDAKPIRMPEWLFRRVMQEE
EKTGERAGFGVMDAAGRLIGNAELYDFRPSPPLTATTATLGIMIGFPALWGQGYGRAGVR
ALLHWAFAVHNPALQRVRLTTFGHNRRAQRAFAACGFREVGRRTYPERVDVHMEITREEW
QSGAGADA
>fig|243230.1.peg.2351 Drug transport protein
MVGPSLLMKTSNLPSGKLEVYTFGMTATSPAPEPDASTKGRTKIILFLTIFIAMLGLSVL
FPIIGPLGRQLGLTPAQIGWFSTSYSLMQFIFSPIWGNRSEHHGRRPTLLMGLVGFSVSF
GLFGLFAQLGMNGGLALGTLFALLVGTRIIGGIFSSATLPTAQAMMADISSEDDRAASMG
LIGAAFGLGVVFGPAIGGLLSGISLVAPVYFSAGLGLFTAALAYFMVPETRHPGQTRTAT
VDRRSLLSRGGIPLFLAASALTTLASVGMEQTISFYVQDVMKLDPGETAKTVGKMLAIFG
ILAALVQGGAIRPLSKKLPPTPLILVGLVIMAAGMFLLPQMATYWPITAALALIGVGSAI
LSPTLSAALSLSVGKDGQGAVAGLNSSALALGRMVGPLLGTNLYQHVGHGAPYIASGSIL
AVLFVVMLIARPQVQPQTPAA
>fig|243230.1.peg.2523 Multiple antibiotic resistance (MarC)-related proteins
MDWSEVITLSYRTFLTMLVIMDPVGLAPMFIALARDRPAFEKKRLALKATLVAGGIIFVF
GLFGRALLEHLGISLSAFRIAGGILLFMVALDMVSARQSATRETPEEEREAQEREDISVF
PLAIPLIAGPGTLASIMIQTNAAHGNPILMFAVFLVTGIVLALCYLALRLSNQIAKALGL
TGVNVVTRVLGVLLGALAVQYIADGTLELMRGGLPLN
>fig|243230.1.peg.2573 Permease of the drug/metabolite transporter (DMT) superfamily
MTSHLRGILLLLLVTAIWGSTFAVVKELGALLAPPVLLAWRFSIGALVLLPLAALRRTPA
PTVTVTQADGTSLWSDGMVLGLWLIAGYGTQTIALQTTTANRAAFFTALSVVLVPVWLTL
VQRRRMPAVLWAALPLAVAGLALLSWEGGAWVSGDAWALACAVTYAGFILALEKLASRHA
ALPFTLAQVLSVALVAWGWALLSGAPLWPPQAAWAPLFYLGVVATAGTTLLQTLGQRHVS
AAEASLIYALEPVSAALFSFALIGERVGARGALGGALVVLATVLSSRAGETEPVARVLDS
SQDD
>fig|243230.1.peg.2616 Permeases of the drug/metabolite transporter (DMT) superfamily
MWAMNPVFSGLFSALTYGVSDFLAGLASRHDSPLRVVALSHTLSAVALVLLAVGLGQPMP
GQTALLWGAGAGLLGMGAVVAFYRALALGPMGAVSVGAGALSAVVPVGAGLLAGESLGRL
GSLGALGVLLGTALLSFRPGGAGKEGNSGVGLGLLAGLGFGMFFLLLGQAQSPGVLWVLA
AARATSALLSLMIAASTVGLRPRAPALILAAFPGDMLGSLFYLIAVQGGGLALGALFSSL
YPAFTTLMAVAVLRERLRAAQWVGVGFALVGAVLLSQR
>fig|243231.1.peg.263 Multidrug resistance transporter, Bcr/CflA family
MEITSTAPAFQPADMTRRELARLVLILGALTAFSSMSIDMYLPAFPQIARDLGVPLGTVQ
LSISAFLFGSAAGQLVYGPLADRWGRRTPLLGGLALYVAAAFGCAAVHTGEGLLFWRVVM
ALGGGAGMVISRAVVRDLYDTAEAARMFSLLMLVMGAAPILAPIAGGQLLLITGWRGIFG
FLGIFGILSLAAAAACLPESLPPERRSTRGVAEMAAIYGHLLRNRRYLRYAIALGCVAGV
NFSYISGSPFVFIELNGVSPQQFGLFFGANAFGLIGASQVNRRLLRRFSAQRILNVAFTV
NAAAALLLTVAGFTGVGGFPAQVVLLFVCLCMTGFLYPNVTALAMAPFDKAAGSASALLG
TIQYTLGASAGALVGMLHNGTAVPMTAAMAACGLLGWCAAVAGIPRAQVDH
>fig|243231.1.peg.541 Permease of the drug/metabolite transporter (DMT) superfamily
MIQAQTAAPPHAKVTAILLFTTLMWGGSFLFNKIGMREVPPVHFFFFRFALAALLMGGVC
LPRLARLNRHIAVRGAVVGLALAAVNLTFVLGVSGTTISRAGYLNNLFVLFIPLLTFALW
RERVDRVTFGGIALAVVGLWALASGGAEGFNQGDLLSTVCALFIAIHIIAVSRVLRDEDV
YLVTFVQFVTVAAVGLVLCLVLPWPEFTIGRAGAWSLAYCALFPTVICFTLQNAYQRFTT
PTRAGLIYTLDPVWSMLFGVFILGERLTPRELAGCVLILMAVAGPLLARLYLEQRHRRLY
RLDGAEGT
>fig|243231.1.peg.1143 Permeases of the drug/metabolite transporter (DMT) superfamily
MFKTVIIMLMAVSAGTIGDILLAKGMKELGDLSAMNLRGILNVAGQALTSPKLIFGTAML
AIFFFLWLAVLSWEDLSVALPMQALNYVLVAFLSQWFLGETVSPLRWTGTIMVCVGVMLI
TKSGTP
>fig|243231.1.peg.1470 Membrane fusion component of tripartite multidrug resistance system
MTTEQELPDRGENREAPSAQTAPQGKGSGGKRRRAGIFLLILFVVGAVIGLRWLVHGITY
ISTDNAFVESHIHAVSSRVPGTVAAVYVTDNQAVKKGDLLAELDPSDYRTRVSEATAALA
MARNETSGDYAQVEAARAAVDHARARLAQADLDLTRGTALLAKEVIPREQFDRLETAKRV
AVAQVREAEEQMRKAQAEIGLSGSGSREARVALRDAQLATASLNLSYTKILAPADGYVTR
KSVEPGNTVQAGQPLMAVVDLDDVWITANYKESQLTHMKPGQKVTFTVDAYPGRTFSGRI
DSIMAGTGAAFSLLPPENATGNYVKVVQRVPVKIAVDRASDPGHLLRVGMSVVPSVDVER
SLGDILHGLWPF
>fig|243231.1.peg.1471 Outer membrane component of tripartite multidrug resistance system
MKPLPIRSIPFLILALCAATPAMASALSLKECLSLAAAGNYSLAVTASDRLIAQEAITQA
RSGFLPRVDFQGGYTLQAKPQAVNFGERGSIETQDGTYGFFNLSVTQTIYDFGRTSSRRQ
RASLLHEATAQQYAAAEKDVFLQVVEAYFGILEARRLLGTAEEEVAQRTDHLRIATNLFE
QGVVTRNDLLQAQVRLAESSQKRLVAANRLENRWMYLNHLTGRPLDQRDELEEGTESAMP
DTAGAEERAFANRPELTALARSADAADAEVSEARSGYYPELYAKAGVDYVENSKVREQAI
YAATVGLKINLFEGFATESRHRQSVERLTRSRDALRLAREQVRLELATALNDARVAEQRI
KSVETAIRQGEENLRINRDRYQAQVGTATDVLDAQTLLTQIKTDYHRAVFDFQVAKARVS
KAMGEL
>fig|243231.1.peg.2537 Polymyxin resistance protein ArnC, glycosyl transferase (EC 2.4.-.-)
MKISFVIPVHNEQDNLLPLFDEITRMADAERYEYEIIFVDDGSRDNSLQVLKSLARGCPA
VRYLSLAANRGQSAALGVGFAHAAGDVIITMDADGQNDPADVPAMMARYGEGCDMVTGWR
RNRRDTLSKRVGSRIGNGIRNRLTGESIHDTGCSLKVMRADMVKRIKMFKGMHRFLPTLM
RMEGARVVEMEVNHRPRRHGTSNYTNWRRAREGFFDLLAVRWMQRRYQPATIGEKHV
>fig|243231.1.peg.2541 Polymyxin resistance protein PmrJ, predicted deacetylase
MERPTIAIKVDADTFVGTRDGIPRILDILGRFGVKATFYFSLGPDNTGKAVRRIITRRGF
LRTSLRLNAPALLGPRTLLSGLLIPPPIIGNRLADTIRLTARLGHEVGIHGWDHVKWHDL
LPWIPKKMIALELGRACALFEEVMGRRARTAAAPGWTVSADSLEIQDSMLLSFCSDCRGR
TPFYPVVDGRRFGTLQVPTTLPTLDELLGGGIATEREAVDRLMGLVGPGLNVHTVQAEIE
GKRYAPHLASLLDRLTGTGARFVTLGEAADEAKRATVPVCRLTMEEIPGRPGRVAVQGEE
WSEPGPAAGEP
>fig|243231.1.peg.2647 Acriflavin resistance protein
MILSDLSIKRPIFATVMMLVLVTLGAFSYRLLSVEMYPNVEMPVISIVTKYPGASPETVE
REVSKRIEEAVNQIAGVKHVVSTSRESVSTVVVEFRLEERTNEVAQEARAKVNSVRGQLP
AGIEDPIIQKLDFNALPVAALAIQSKTLSQRELTTLVDKRVRKRFESVAGVGKVEMVGGA
KREVNVQVDPVRLESLGLGANDVVRGLQNENVNTPLGRITREGAEYPLRIDGKPDLVGGY
RSMVVAQKGGRPITLGEVAAISDGVEERRTLALVNGVPAIGIDIYKQSGANQVQVVDNVR
KVMEKIRKELPPEVSLTLVRDSSIMTRQSLADVEETLIIGGILTVIIVFLFINSWRSTVI
TGVTLPISVISSFIIMNAMGMTLNVMTLMALSLSIGLLIDDAIVVRENIVRHLEMGKDHM
EASRFGTSEIGLAVFATTLSILAVFVPVAFMRGIVGRFFFPFGITVSFAVLVSLFVSFTL
DPMLSSRWHDPAVHAHGKRRGLARWLESFNDWFDRAADRYRLAIAWALDHRRTVIATAAL
TFFLGIAVMGTLESSFMSEEDTSEFQVSFKAAPNASITESEGRLKAMLAAIGDIPEISHT
YSTIGAGDGGTVRDGLLYVKLREKKERERGQFEIERVVRQRLQQIAGITFSIEKVGNVGG
AAKPLNVNLKGDDIGLLKSYAAQLKEKMYAIPGIVDVSATLEHDTPEYRLRVDREKALSA
GVTSNDVVTALSRLVGGEAVTTYEDEDGDAVDVRVRLPEVLRQNPAQVRDLKISVPDSDG
GTKLIPLASVSTESVAATPSEVNRRDLSRLVTVSANLDGLPIGTAVKKVEEVSKTIAMAP
GYSIGFSGEAEDMAESFGYMGESLLLAVVFVFLILAAQFESFFEPLAIMLSLPLSIVGMA
GMLKLTGDTINIMALIGLIMLMGLVTKNAILLVDYAKVLRRRDGLPRREAVIEAGRTRLR
PIVMTTLAMIFGMLPLFLGIGAGGEGRAPMARAVVGGLITSSLLTLIVVPVMYTYMDDLA
VRLRRWWLGNAEGALAVGPASDGLVASILKKARGISLKKFFGVFACLITLGTGAFSAEAA
DIRVLTLDQALAMADERNRDIAKAREFFRQVEGRYVEERSAALPQFTITGSASWLDDRSQ
KALAGGFIPTRQDVRAAGVELSQALYTWGKVSAAIRAADLGFRTADEQLRTARQDARRDV
AVAFYDILLAREQLAISRQNLEQKERHLDEAQRKYAAGVATDYDVLAAGVSVENARPEVI
RAENLTRLATDRLRYFLALDQEIEVEGALSFEPATVPSHAEALAVARRQRPELEELRRRI
DMAGELVAVADAEDKPRLDLKAGYGWRQLETGDGRGDGAAWNVGLYLSFPVFDGLKARGK
VAQAESERRSLRIEEAKLMDSVSLEIRDAVNNVREAREIVSALEGTVAQAERLLTMAEQG
FELGVKIRLEVDDAELNLRQARGNLAKARRDYLVARVNLERVMGVLGEEGADQNKM
>fig|243231.1.peg.2660 Permease of the drug/metabolite transporter (DMT) superfamily
MALESLHTTRQDRVSHSLVGPRLAGAAFVAASAVGFGALGIFGKVAFASGASTAVVLFLR
FLVAGVLMAALMPVLRLSWPRGRDLWILVGMGAIGYVGQAFCYFTSLRYASAGLTALLLY
LYPALVTLASAALGRQRLTPLKVAAVAASLIGILLTVADGLTGSLSGIAFGAGAAVIYTG
YILVGEQVSRRTGAIPAATVIMLAAATVYGCAVIWQGPHWPTGLAGWGAVVGIALFSTVV
AMVGFFAGMQRLGAADAATLSTLEPVVTLVLAALILGESLGGVQLAGAALVLGAVVALAR
AK
>fig|243231.1.peg.3385 Permease of the drug/metabolite transporter (DMT) superfamily
MNKAKAIVALLLTTFFWGITFTIVKDAVAQVDVFVFLAQRFLMAVVLLVPFCACRRVPLT
MQTVRHGLFLGLFLFGSYAFQTMALRFTTASNTGFLTGLSVVLVPMLGALLFRQAVSQGI
KWGVALAVPGLFLLCTNGAFVLNIGDMLAAICAVCVSLHLILTGKFARDNDVWWLTAMQL
STVALLSFLVAEVGGHRTMAWHPEILWALLICAVFATVFAFLVQTSMQRFLSPAHTALIF
CLEPVFAALYAFWAADERLGTLGYLGALLILAGMVISELAPSGESPEASTAT
>fig|243232.1.peg.731 MATE family drug/sodium antiporter
MKNVEILLDDPKKAVIEVSKPIIVATFIESIYSLVDSIWVSGLGADALAAVGASFPILIS
IYAVSWGLSIGISSGIARRVGAKNKEEADKVANHAIILALIAGILYIIAVYPNLDTLFSL
MGTYGDCKSLAIKYSSILVLGTVIFTICDALYGIFRGEGNTKIVMIASVIGTLTNIILDP
IFIYMLNLGISGASYATLIAIIISLLILAYELFIKKSCYVTVKLSKFKPDLKIIADLIRV
GIPSALIEITVAVSFFIMTSIIMMVGDSRGLAVYTGALRITEFGFIPMLGLASGATSVIG
ATYGARSFEKLKTAYFYTIKIGVLMEIIIVALIMLLSPILAYLFTYTKTSMGIHEELVKA
LRIVPLYLLFTPFILTTSAMFQGIGKGEKSLIISIFRSLICHISYAYLFAVILGLGMFGI
YSGLVVGEFTAGIFAFLFGVLAIKALIKSK
>fig|243232.1.peg.1004 Multiple antibiotic resistance protein MarC
MVGYSGEHFIFNVVKYMDILNFYIYGFVSLFITIDPIGLIPIVHSLTYPYPKEQRIRIIK
KAIISSTVVLLLFALFGNYIFGYFGITIDAFRVAGGILLFKIAWDMLHAEIPKTKHKPDE
RLDLEDIDSIVYVPLAIPLISGPGAITTTMILISKTQSILEKGVVVLSILSAMLVSGIIL
SLTDFIIRRVNIYGINAFVRIMGLLLVAISVQIIFTGIVGLYNSISVQ
>fig|243232.1.peg.1354 Multidrug resistance protein
MVRKVAEQNLQKNNENDRELSKNVYLLGFTSFLNDMSSEMIMPILPMLITSVGGGSLSIG
LVGGLREFISNILMVLIGYCSDKVRKRKIFVVLGYLTSSMFKLLLGLSKSWLGAVIFSSL
ERMGKGIRTAPRDAIISESMPKTLGKGFGIQRAFDTAGAILGSTLSLLFILYLQYSFNQI
ILIAAVIGFLTLIPLYFVKEKPSPSNNKITFRVGIKNLPKELKLFILISAIFTLSNFSYM
FYILRAQEFLMIVDEKMAIIIPIALYILYNIFYATFSIPFGILSDKIGRKSVLTIGYIVY
GIVSLGFAYFISQKSLILLFALYGIAYALFAGNQKAYVSDLSSEDIRATALGLFYTVVGL
TSLPASLIAGYLWKISPEMTFLYGSVLAIISGLLLLFI
>fig|243232.1.peg.1724 Multiple antibiotic resistance protein MarC
MDLQYFILAFSSIFSILNPFGAVPVFITLTESYPKKERDLVAKKTVIYALAILLAFALFG
EWILKFFGISLDAFKIAGGILLLLISLDMVRGQQEAKIHRKEIEAAYEIDEIALMPLATP
LLAGPGSITACMVAMAEASDIGDKFLVILAILLSLGITYLTLLSAESVLDRIGRLGIRIL
TRMMGLILTAIAVQMIVNGIRGALL
>fig|243265.1.peg.177 CpmF protein involved in carbapenem resistance
MKYIYLFLSIIMSSKAYSFDNMKLSFVEGGDFYVGSVFGAQNYESHSNVTLNSFYIMKNE
VTYSEYKEVYEWAILNGYDFDDGCNGSHYEDCLPPEQDEGRHPVTSIKWLDTILFSNALS
EKLKLTPVYFQKGNKIIRKKDKNLEIFINTNANGYRLPTLNEWHVAARGGEPALRLGRYG
YYHSGSNDSKKVAWYPEFNTSNFGTQVVGKLSPNDLDLYDMSGNVSEWVYDSYELGTVKL
YYFCGGSYLSHANSLSSCDNHSSGYIMPDVGFRLVRSYLNEK
>fig|243265.1.peg.178 CpmG protein involved in carbapenem resistance
MKNKFYLIFILLFSFEAFSHCGNKVNLKDGINLIDLNGDGKKDVIFYAKFENNTSHPSNT
LTVFIKNKNGKFNIVPLPNDTGFTWFDFKLSASEIKIQDYELGVKNGVYYIIFFRKKNND
DDIFGEYPVEFIKYDIKYNNEVPGISNYYWDYTKSYLTKKKYKNVSDAMTEYNMECSL
>fig|243265.1.peg.1331 Multidrug resistance protein B
MKNFSLSNYTSIPACIWGLFLGTFVTRSTSMMVWPFISIILYTKFHFTASMIGLVLSLSI
AISSILSFYAGYFSDKVGRAKIIIIGCLISSLAYLILWLSEHQSGFIIGTLLANISWALV
NNPIKAVIGDIIEEKQVRENAMYLRYLFLNAGAVVGPYLGVKLSLDINSISFLIVSLSYV
IFMIPVYLFGKKIKIKLTNNDDFKGTMKVLLNDRVFLMLVINNILMMFIFGHFDSTLPQL
ITSLGFNGYAEFIASLIMLHAVTIVVMQLPFSILTQKMALETKINVGSVLLILSEFMFFI
SFKYYDVYLLWYVAAFIMSISQTILFPCVNVFIDRLAPNDLRGAYFGAASLYSIGFSISP
LVGGTVIQLFNGGVLFQLLAILSVLMLVIFCRMFKLRDKHEINIRRSLKS
>fig|243265.1.peg.1433 Multidrug resistance protein 2
MRMLVGATSTIFILNHGLTLVDIGLMKTIQSFIYFLFDIPSSYLADKFGRKFAIILSTTF
GGVWLIITGIADSKYLFYIAEIFNSISLTILGGVFYSYLIDNSLNDNDTHKILGESNKLQ
FLFMAIFSIIGSLITDFDDRLVWLIAGSGCIILSVSLSWFLPKSITKNRQPNLSFLKEIK
TSIAMLKDNKNYLFITSISLSSSLLYFQIILQYWQPLINYIIEELGVSIFFGIVFSAILL
SQSISGWIISKNEDNNKNHLYSIVILLVCSLTCIYGVYEKNHITTISTIIMFGANQVMTT
SLRSNYHQIIPSELRSTFDSFISTITRLIAVIVIPLIALITENFGWIYFPILISLIISIN
ILCYFFIKKHHKRKPTWNPKS
>fig|243265.1.peg.3357 Probable multidrug resistance protein norM
MAKFSNWRELKQLLFFSFPIIVSQIARTAMSFVDIVMSGHYATADLAAVTLGSSIWFPIF
VLGYGTIIMLAADVAKQKAQHDDEGIKDSLKNYLFLAVILSIPIIILLMLVSWLLSFIGI
DEHILEITQGYVIALACGVPSVMIFNVFRSFLQGLEDTKIAMYLSAGALLLNIPLNYILI
YGKLGLPEMGGIGAGITTAIINNLIAVCLIIYFLLKKEYRRYRPDFSLPKYNSLIRTFYI
GMPSGLALFVEMVFLDVIAITAAPLGAQVIAAHNIMLNITSIIYTITGGIAAAVTVRVGS
YIGKRDKISLTGTIKISIALILSISAVIGVLIYYFAGSFISLYTNDNGVIIIALNIIFLL
CLFQFFDSCQAALSGILRGFHDTRSVFYAPLFGYWLVGLPLGFILALTDWVTERMGIIGF
WYGLVLGLFVNAILLFIILKVRQRGMISRLISY
>fig|243265.1.peg.3899 Bicyclomycin resistance protein
MKNKSLLFIVLMAFLSMGGLVSSDIFLPALSKMGNYYHVSESSIQSTITIFLFGIAFSQL
IYGPLSDCLGRKTVLISGMIIWLISTIGIFYSTHISELLLLRLFQGIGACAGITLSRAII
SDLMEKEEAANLYLIIFPFVGMSPAIAPMIGGMLSEYYGWRSCFLFLTLFITVTLILCLL
VLKESLPINKRQKLSIKNVLVSTYQVIINKEFLYYAAIPCFAYTAYFSYLIESPFILTAM
GLPEKYVGYTYIMLSLSYVLGNLIAKKLSRRQGVRKTISHGYLIFVVGGIAFTIQMFFSS
YPLITSVLTISVLTFGNGFLLPLGTASAIATHSQAAGTASGVMGTLQLGSAGLASLFIGY
ISHHEPIKVASIITVVSLVGSIIYITGNRGGKENK
>fig|243265.1.peg.4055 Bicyclomycin resistance protein
MPPLILRLLPIILIIGMVPSFIEVDITLPAFPQMLNFFSAAESAVQFTLIVNFLGLCIFT
PIFGPLSESYGRRKIILIGATLFFIGSIGCSTVVDLNQLYLFRFIQGAGCSAIWIVGFII
CSDIYKDEESVQVFGILNAAISMALIIAPIAGSLIVAHYNWRFTYHLVALLSFLSLMAVF
IVPETNRNTVKLSVNKVIKNYCQLIFNTRFLIYSFTPGLLVSACIAYVSVVPFLYIDKMG
MSYYIFAVHQAILGICLSVAGFYSGALNRKIGSANCIYLSIIICLIGCGSLMIFSHIYPE
SAILFTLSMAVICIGSAFQYSMVFSRSLALHPELVGSASSLLTFFRLIFFSFSVLISGWA
FTGKLFNSAIVVSSIIAMGLLFSLFVLIDLRNNVVNRRINDESHVS
>fig|243274.1.peg.283 Multidrug resistance ABC transporter ATP-binding and permease protein
MKTLARYLKPYWIFAVLAPLFMVVEVICDLSQPTLLARIVDEGIARGDFSLVLKTGILML
IVALIGAVGGIGCTVFASYASQNFGADLRRDLFRKVLSFSISNVNRFHTSSLITRLTNDV
TQLQNLVMMLLRIVVRAPLLFVGGIVMAVSINVKLSSVLIFLIPPIVLLFVWLTKKGNPL
FRKIQESTDEVNRVVRENLLGVRVVRAFRREEYENENFRKANESLRRSIISAFSLIVFAL
PLFIFIVNMGMIAVLWFGGVLVRNNQMEIGSIMAYTNYLMQIMFSLMMIGNILNFIVRAS
ASAKRVLEVLNEKPAIEEADNALALPNVEGSVSFENVEFRYFENTDPVLSGVNFSVKPGS
LVAVLGETGSGKSTLMNLIPRLIDPERGRVEVDELDVRTVKLKDLRGHISAVPQETVLFS
GTIKENLKWGREDATDDEIVEAAKIAQIHDFIISLPEGYDSRVERGGRNFSGGQKQRLSI
ARALVKKPKVLILDDCTSSVDPITEKRILDGLKRYTKGCTTFIITQKIPTALLADKILVL
HEGKVAGFGTHKELLEHCKPYREIYESQFGNGVMNDA
>fig|243274.1.peg.284 Multidrug resistance ABC transporter ATP-binding and permease protein
MPEIRRRPHGPILEKPALKNPTATLRRLLGYLRPHTFTLIMVFVFVTVSSILGVLSPYLI
GKTIDVVFVPRRFDLLPRYMLILGTIYALTSLLFWLQGKIMLTLSQDVVFRLRKELFEKL
QRVPVGFFDRTPHGDIISRVINDVDNINNVLGNSIIQFFSGIVTLAGAVIMMFRVNVILS
LVTLSIVPLTVLITQIVSSQTRKYFYENQRVLGQLNGIIEEDISGLTVIKLFTREEKEME
KFDRVNESLRKVGTKAQIFSGVLPPLMNMVNNLGFALISGFGGWLALKDIITVGTIATFI
GYSRQFTRPLNELSNQFNMIQMALASAERIFEILDLEEEKDDPDAVELREVRGEIEFKNV
WFSYDKKKPVLKDITFHIKPGQKVALVGPTGSGKTTIVNLLMRFYDVDRGQILVDGIDIR
KIKRSSLRSSIGIVLQDTILFSTTVKENLKYGNPGATDEEIKEAAKLTHSDHFIKHLPEG
YETVLTDNGEDLSQGQRQLLAITRAFLANPKILILDEATSNVDTKTEKSIQAAMWKLMEG
KTSIIIAHRLNTIKNADLIIVLRDGEIVEMGKHDELIQKRGFYYELFTSQYGLVVEKE
>fig|243274.1.peg.580 Permease of the drug/metabolite transporter (DMT) superfamily
MILERFFAWLVVVFWGISFLATKVVVQVLDPFFAGFLRFIFAFFFLFLISGGRPKLFNKN
IVMAGFWGVFSYFAFENSALMFTEPTNAAIIVSSAPVFFLLFSHLVQKKKTTSKMYLGVI
LSFLGVALVVLNGRFVLKLNPLGDLLAFGAALSWVFYTHHIESLGSLSFRENAGIMFWGV
VFFLPFSAGKFQQIREMNSIVVISLLYLGLVCSGLAYFLWNKAIERLGSRTTTNMIYYIP
VVTAVAEHLLKLKLPSALLVGGVVLVVIGLLIFEREVHYETEDSTRGMRKDRTEETRPSA
D
>fig|243274.1.peg.721 Permease of the drug/metabolite transporter (DMT) superfamily
MWRENKALAFLVLTAVLQGSTFPLQKLVLGGVSPFVYNTVRFGSAALLSLFVFGPGRFVK
GFLLGLVLCGAYIFQLWGLKFTSAVKSGFIVSSFVFLVPLFAFLLEREKLRKIHFISFTS
GFLGLYLLTGGVSQITLGNLFQFFCAVLFALHVVLITRFSRSEEEKNMLFWQFVTVGAVN
FLFGLGERWHLNLEAISVGIYSGVFATTLGILWQMRYQKEVGNNTTALVYMTQPFVSLVL
SFLLLGERMSFLQLLGGILVLVALFTGTTLRPRESN
>fig|243274.1.peg.1007 Permease of the drug/metabolite transporter (DMT) superfamily
MDLRVLLSGLAYSTIFGLSFLFTKNALDYVTPLTFLSFRFIVAFLSYLLLLITGAVKLGK
KPYWKLWKLVLFQPVLYFLFETYGLQRVNSSEAGMIIALIPIVVNLLAPFILKEKGDLLH
YLLVGMGFLGVSLIVGFNITPGNIVGKVFMLLAVLSGAMYSVFSRKFSKEFTPTEITFFM
MMTGAVFFTLLSLSTGDFRPVFNVDVVIGALYLGVLSSTVAFFLLNYAIRKLSPIFTTLF
SNFTTVVSVIAGVVFRNETVGIQQIAGMGLIISSLIIMSLRRSYKRLSRAQKL
>fig|243274.1.peg.1705 Permease of the drug/metabolite transporter (DMT) superfamily
MVKALFSLLFVAFIWGSTFPIQKIVLVGVSPTFYIAVRFFIAALVSYFLFGKGNVKYGSI
LGTLLGIAYTTQTWGLTITTSTKSGFITSMYIVFVPVFAYLLEREIPTIFQIVSFFAASL
GLYMISGGIKDFNFGDFLTLICAVSFALHVVLITMFSKRVKEVDLLFPQFLVVGILNLIL
NFFWKNWNFTLPALGSAVFTALAATILAIYLQAKYQKALGNNVSAIVFLGEPVFAAVVSY
FMLGETMAGKQLLGAALLLISMLFSSLERVKIVRDANQKGRDECEDSL
>fig|243275.1.peg.330 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MTDKREHLISGNMFKLMLELSIPGIIGMFVISLYSFVDAIFVGRYVSSVALGAVSLAYTF
TLINNGIAVLVGIGSASVLSRAVGRSDQETVDSIMGNVLLLTLLFSLGTMTIGLIFAPQL
LILIGAEGEMLRLGVSYLRIVYIGSVFVNFGQAANMVMRGEGRMGLAMLLMGISAVLNII
LDAVFVIVLKKGLEGTAIATVISQVVLAICNFCYFAFFSKNVKFKHFKLQKSIVKETLSI
GFSAMLMQVFALLQQAVMYSTLKRYGGEDQVILMGAFFRYMMLSFIPLWGISQGYQPFAG
TNFGAQKFERVKKGTFLFYGFGLFLSLIFWLVFLIIPEQVLGLFLKNKELISLGRTNAML
AMSLFPLSAIMIINLTLFQALGKAKYAGILVIARQFLLYIPAVLILPVFFGTRGVWISTP
IIDTLVTVLSAFIVIKLFKKDLSPKDKPLSA
>fig|243275.1.peg.347 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MDSKELRRFNILTKPIFPLLVKTSIPTIIGMLISVIYNLTDTFFVGRLNNRAMIAAIGIV
FSFVSIIQAIGFWFGYGSGNAMSKKIGEQDYAEAETISSVGIVFAIIIGILIAIGASIFI
LPLSKFIGGSASQDVLTFTVQYLRIIIISIPFSLYALTVYNQLRLCGNVRDGMVGLLSGM
LSNMVLDPVLMFIFKQGFIGAGYATLIGQIIGCIVLTLLAKRHESISFNLKKVQYSKERM
YHILAGGMPNFSRQAITSAALVLLNVKAAQYGESMIAALTVSSRVAALAYMIMIGWGQGF
QPICAMNYGAKQYSRVKKAFITTVLIGTIFLTAASIILFLFAEQCIGVMSKDDEVIFAGI
KILRMQCFSLPLLSFFAVSSMFMQNIGHYFSSLLISISRQGFFYLPLLYILPALYGKTGI
YLLQPFSDVLSFLFAVAVVYRWYSSGAFSSALNAG
>fig|243275.1.peg.669 Permease of the drug/metabolite transporter (DMT) superfamily
MNKNIIAIIYAVAAAAFYALNVPCSKILLQNISPVFMAGLLYIGAGLGVGILYLFNFKKE
QKSERLDKNYLPYTIGMIFLDIVAPILLMLGVKYGTSSNASLLGNFEIVATALIALIIFK
EKVTWRLWIAIFFITASSIILSFENIEGLNFSIGSLFVLGATICWGLENNCTRRMSDKST
YQIVTIKGLCSGFGSIIVAFVSGETDFTLKYIPFALLLGFVSYGLSIFTYIRAQKYLGAA
KTSAYYSIAPFIGTFLAFVLLKEKISTKYISALFVMIIGTAFAVYDTLIRKHLHGHRHTF
THTHNGITHTHTISHSHLHNHFISDSKHGHHHSIEELENELKNEIGK
>fig|243275.1.peg.804 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MENEKQKEFILNGNLWKVIFDLSWPAVIAMILLGANNVLDGIFVGHFAEEGAFAGISVAL
PPIITIIGLGILIGSGAGTLLSIAIGAEDKNIQKKILGNVNFLTLIISVIVMTLGFLFSE
QTLFLMGGRGNALIHGSKYYRTILWGTPIWIYAIALNNLIRSEGKMKTAAAIMGISLIVN
GCANYTLMVIFNFGIKGAAIGTNIGMAVQAIISTLYFAKKNPDSPVSVFTIRIDGEIISK
IISMGLASFIMQFMGTIQMLLVLNVLNHYGSQDDIAFYGIITRIFSFILQTIGGFMIALS
PIIGINFGADKTERLISAFKRFVFAALILIAPLWILILIFPQTSVSLMMKNPHLSIHNIS
YFRIYMALLPVMPLVFFALAFFPAVNKGKISSILGILQQIVFYIPIMLILPIFIGIAGIY
YGTFLIEILSAIPISILIIREFRLLRSGITKWQKN
>fig|243275.1.peg.1869 Permease of the drug/metabolite transporter (DMT) superfamily
MSFKLKSGSRIRILSRLALLSATLLWGSTFVAVSSTNDFFKPNFLLACRFLPACLILCAV
FFKRLKQLDKRYVKAGMILGLIMFAGYSLQAIAITTAGGLPGRSSFLVATYCVLVPFVNA
VVLKKRPDKFNLFAAFLCFAGILAISMPDLISESQKGINWGDVLSLISSFIFAVYIVLLP
KFMEELDVPLITLTQFAFAGTYALIFSLLFEDNSNTVWNYQSVFTLVYLTVLCTALCVLL
QAVGQKNTPPTTAALIFSLESVFSIFLSIMLTDEKFTPALALGCSFIFIAIIISETKLSF
LKKKSVEVNC
>fig|243275.1.peg.2452 Permease of the drug/metabolite transporter (DMT) superfamily
MFQHRTIFCLYKFRLVFFFVFLYNADLSYNTPFQKGKLVPGLFEAFCICRFTDDAKEFIL
TNTKINVLSRLALLIVAIVWGSSLVVVSETTDFFKPNFLLGLRFSIACFLLCLVFYKKLK
LIDKDYLINGGIVGFFLFIAYSSQTFGVTTAGGLPGRSAFLSASYCVIVPFLGWLVNRIR
PDRYNASAAVLCILGIGLVSFKDLVLSSSVGITLGDFYALLSGLLFASHIVSITRLSKRK
DPILMTIIQFGAAAILSWLVTLIFEDNSAIVWSYSSVGSVLYLAAICTGLALLLQNIGQK
HTDASSAAIILGLESIFGIIFSVIFKGESLDVYSVFGFILIFIAIIISETKLSFLKKEKA
>fig|243276.1.peg.983 Multiple antibiotic resistance protein MarC
MLCMLEMDSARQRFVRDVEHIRHEDMHEMGICARRGFTCSDTHPHRKRHSQKKCCTRAVP
TQGNGDCRTRGSSRILTPRMSTWTHIWSTAFTLLFIIDPIGNIPVVLSVLRTVPAERHTR
IIFRELLLGLVLMLSFLFCGKVFLSLFQLETGVMKMAGSVILFLVGIKMVFPDQHALPST
TEEEPFIVPIATPMIAGPSAFTTLVIMGETKGTSRLATCAALLVAWTLACLIMISAPCLY
RLLKEKGITALERITGILLLILSIQMCVEGARGIIATS
>fig|243277.1.peg.1393 Outer membrane component of tripartite multidrug resistance system
MKNSVQTVGLLHKAAPYFTASLLSAFVLTGCSVPDHYPDLATMWEANELSSTNTFSHQAE
MDWPSANWWQRYQDAQLNHLIEEALQHSPSLEMAMARLKGAQGFARQAGAIRSFDLGLAA
SATESKVSERYQSATPPDGWNDYGTLTLNFQYDFDFWGKNRAAVVAATSELAAAEAESVA
ARLMISTSIANAYAELARLYANQETVHAALQVRNKTVELLEKRYANGLETLGSVSQAKAV
AASVEAELLGIQESIQLQKNALAALVGQGPDRAASIEEPHITLTSRYGLPSEAGVGLLGH
RADITAARWRAEAAAQQVGIAQAQFYPDVTLSAFIGYQAFGLDHLFDSGNDAGAIGPAIY
LPLFTGGRLEGQLTSAEARYQEAVAQYNGTLVQALYEVADVVTSSQALQARINKTEQAVQ
QAEQALHIATNRYQGGLATYLDVLVAEESLLNNQRALVNLQSRAFSLDLALIHALGGGFE
TTES
>fig|243277.1.peg.2832 Permease of the drug/metabolite transporter (DMT) superfamily
MSLVNLLQLLCLAAIWGGSFLFMRIAAHSFGPAYLIEARVGFAALSLFLVAQLLRRSLPI
RQHWPHFLILGLINTAVPFLLFAYAALTLNVSTLSILNSTAPIWGAVIGFLWHGTPLSRK
AVAGLLLGVSGVAVIVGWDMVAIGHHAALPMVCAALAAASYGLATNYTKQAPQLSAFENA
HGSMWAACLWVAPLMWFVPLRETPSSLEWGAVILLGVICTGLAYLIYFRLVKAIGAASTL
SVTFLIPVFGILWGYWILDEPIGLNTLFGTLLVLAGTMLVTGFSLRNARLSRQPQPH
>fig|243277.1.peg.3688 Permease of the drug/metabolite transporter (DMT) superfamily
MPNHVLPVLFMLLSTFSLSLTGLLTQYLSHIIPITLLGFLRFIIPALFLLVAMKLTHFRW
PQRNMWFSLLIRAVCIAGSQLCFIYALQSLSLVESVVLFSTGPLFIPLLEKWLWGGQLAW
RTVLSVCIIFVGVVMLAGNTGSIEWRPELLAGLSAGLFNAGSQLSLYRAAQSDMRSIEIH
GWTFLVAALLLSPLLLLVPWSSDVGASLGMSWDISGAVTFAALLLSAILVVNTQVFRAKA
YRLAKSGSQLAPLIFTNLLFSALWQVLFFDVDYTLAQQVGLAVIIVTTVINGILPRLTER
KTRLKSA
>fig|243365.1.peg.122 Probable multidrug resistance protein
MSHSSLAVRQSNPATAAAILLILFNPLGVDLYLSALPALQRHFQADVSASISVFVFCLGL
GQLLFGPLADRAGRRPVALGGLLAYALGSALASLSDSMGSFMLARMLQGLGASASSVCAF
TIIRDCFSGNAASQRYSLLNGALNIVPALAPALGGVLTELYGWQSCFLFLAVSALAALAL
LSRLMPETRPERLEDAAGPGFLQVLRHPALLRNGACSSTALGLIVSYVTLAPTVLIERGG
LSAATFGLLFGANALLIMAASFVGLGLIGRLGPRRVLKTGLAIMLAAGALLPALAHQAGA
WHYMLPVAVLSVGFAFTLGPAAGLAMAPFAESAGRAAALLGCAQMLFASALSALLAALPV
AGELALGGAVIALSLLCLALQWRAPARG
>fig|243365.1.peg.219 Permease of the drug/metabolite transporter (DMT) superfamily
MRVAAPAFGPLPLIALRVGLAACLLLPLLLWRGLWPLWRDNWLPVAAVGVFFTAFPFSLI
AWAQLSLPAGMASVLNATTPLMTALWAWPLAGERLSPRRMAGLGLGLAGVLALLAGHGAR
FEVRSLAPVLAMLGATASYGWAGHMARRWLPGMPPLVTACGGLASGALLMLPLAWLSWPA
LPPPPQAWTALLLLAAFCTALAYLIFYRLINRLGATRASGVTYLVPVFGVLWGALFLGEA
IGAGMVLGAALILAGVLALNARR
>fig|243365.1.peg.719 Methylenomycin A resistance protein
MPHAQSVRTGLPTLLALSAGMFMAVLDTNIVNLALPALLRSLDASLSQLTWIVDAYALGF
AGLMLSAGWLADRFGPRRMLAWGLALFVLASLLCGLAPGARTLILFRLLQGMAAALFIPS
SLGLLRHAFPHPAERARAVGLYGGLSASAAAAGPVLGGLLLAPLGWRGAFLINVPIGLAA
LLAIPFVVPHRQAMPTRGADLPGQAAGMLTLLLASYALIEGPRLGAPVLFALLLAVAGCG
RLFWQLENANPQAMVPPELFRNPVFAAANWVGFAIGVAYFGTLLLLSLYLQQGLGLDALH
AGLAMLPLAGCLIIGNVAAGRLLPRLGARRQIRGGLLLSAAGYLLLALADGHALAWSLLA
MLPLALGTALAIAPMTATVLESAPPHLSGTASAVLNAVRQTGALVGAAGAALAVGYGADL
RHALAIGLSVAALASLSGALIAGWIPRAGQQAAPEPAPAAR
>fig|243365.1.peg.768 Outer membrane component of tripartite multidrug resistance system
METDKVNKKSWPQTAGVLLISAVLSGCASFGPDAAPDQMVGADQLKLAVAGQQNVRADWW
RQLNDPELDRLVEATLKDAPSLKLAAARLRQARAAVGIVESKDGPQLDAMANAVQIHADP
LKALPHNDKDYINAYTAALVGSWEFDFWGKNHAAVSAALGQQQAVAYEGQQTRLLLTQAV
VAQYTQLQRSLAQSRLLSQRLAIAQSRQKLTQARVNAGLLPGDNQRGNEVSIERLQQQQS
ALDNDIARSRHALAALTGQGPQQQDSLNPGKLDAAPQPALDKLDANLLGRRPDIAAQRAR
VESMTASVKEARAEFYPNVKLTVFAGQSSLKMDQLWKSESSLWGFMPAISLPIFHSGQLQ
SNLSKQQAGYDMAVQQYNQTVLDALRDAADAVSGWQNSQRQLQQSERALQSSRKANDSMA
ARLRAGLVNKLSLLDSQDALLSQQSANIDAQAANRLAWASLNTALGGGFDNQAASR
>fig|243365.1.peg.771 Multidrug resistance transporter, Bcr/CflA family
MSRTSRNHFGLAALLAALSTLGPFSIDTFLPAMRAIGDTLSASPLEMQQALTVYLFCYAL
MMLWHGSISDAVGRRPVVLATTLLFGLASVGCALSNTLGQLLLFRALQGLCGGAGLVVGR
AIIRDRLEGAAAQRLMSQVTMLFSLSPAVAPVVGGWLFGAFGWHSIFAFMALIGFALFAL
CWFGLPETHPKAARQPLHPRPLLASYWRVGRTVNFQLLTAAVSFNFAGFFLYVPSAPVFL
MQHLRLGPTEFLWLFGPAVSGIMFGAYLSGRMAGHFSSREVVSRAYWLMFAAALANLVYN
LLAPEQALPWAVLPLALYTTGMSLAAPSITLNLMDQFPELRGTASSLQGFCQTMVSSLVA
GVIAPLAWASPLRLALVMNLLLLLGFICRMGYRFRQLGKDENKPAV
>fig|243365.1.peg.1135 Permease of the drug/metabolite transporter (DMT) superfamily
MPYLALTLAMFLWSSAFIVLKYVFQFYHPLAVLFARMAIATLCLLPLAMGGRIRWRYRQG
DWPWLLAMGLCEPCLYFLFEANALMHTSASQAGVITATLPMMMAAGAAAFLHERQPRQVW
LGIALSFAGVIWLSMDSQAGPGAPNPLLGNALEFCAMVCASGYVLIAKRLSARYSPLALT
GVQTLAGCAWFGLAMLTPWGAWPDALLLVPSLWVLYLGAAITLGAYGLYTWAVSRIPVAR
AGAFNNLIPVFTVAMAWLLLGETPQPWQGAAGALVFAGVWLSQRRPT
>fig|243365.1.peg.1160 Polymyxin resistance protein ArnC, glycosyl transferase (EC 2.4.-.-)
MTDARNFVPPYLLELHAAERPADPLVSCLIPAYNESENIVPMLETLHRLLSAHGYRHELV
VVDDGSRDDTVPKALEAAKRLPVTLIQLSRNFGKEIALTAGIDNIGGDVAVLIDGDFQHP
PEMVPVFLAKWREGYDMVYSVRANRDGETLAKRAFTRVFYALLNSGAPLKIPENTQDFRV
LDKSILEALRRMPERNRFMKGLYNWVGFTQLAMETQTRERRAGKSSFNFRSLFNLGLTGL
TAFSNMPLRIWTLVGCVISLLSIGYAIWELVHTLLFGNPVSGWPTLAVAVTFLGGVQLLS
IGILGEYVGRIFNEVKGRPTYLISRIAKPRDERDE
>fig|243365.1.peg.1179 Probable multidrug resistance protein
MDLRSPVVRRVLLSSFLLSLSRAVISPLLVLALGKQLQLSVQATGTLLALVLLGSALFGL
YGGYWLDRLPRGPALRGAALLMAAGSVLLPYGHGYATVVTALAAGELAMVVYSIAVKAIL
SDVVAERWRSKAFSMRYTLANVAWALGPMLCAGMLFWHETAPYWLGGLLALAGLAAQPRL
PQRRHDPAALPDGFAATLRTLAGDRVLVWFTVSSLLAYVVYGRFSGYLPLFLLTRMDEAE
AMRWMSALISCNAVVVVLLQYPLGRLLKPNRLMRAIVGGFLLIGAGMLWLGNVDSLPLMC
AAIALFTLGEIVLVPAEYLYIDAIAPDALKGSYYGAQNLASLGGALGPAMVGALLSRGPS
WVVFAALALLCVAGAGLALYSERLRLRGLRLANRIDASALPGSLS
>fig|243365.1.peg.1361 Permease of the drug/metabolite transporter (DMT) superfamily
MLNNPMPLALGAILLWASLATLGALTRTLPPFFVVGVSLCVGSLLSAHRIRDWKVPPLTL
LTGIYGLFGYHFLLFFAFRQAPALEANLLNYLWPLLIVMLSPLLRPGTRLTRRHIIGGVM
GFIGAGLIVTGGKLALSQQYLTGYLLAISAAMVWSTFSLLLGRLPAFSGSAMGGFCLASG
LLSLLCHALFESPAHPSASQWATLALLGLGPMGGAFFLWERALRLGDPRQIGSLSYSTPL
LSTLLLSASGQGQLNSLAAVAILLILGGALLGTLPGRRHAQTQAT
>fig|243365.1.peg.2455 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MDLLPVSTLFWRYAIPSIAGMLVTGLYAVIDGVFVGHYVGSHGLAAINLAYPLVMLQVGL
GAMISMGAATRIAIQQGAGDMRAARGTLLTALALLLLLSALIPALGLPNIDLLLAWLKAD
VQPQVAEQARDYLLLMLAGAGLTMGPMLLTYLVRNDGRPKLSTALMTLGALLNIGLDYLF
VGVMGKGLAGAAIGTLLAEAVVLILALAYFLSPRASLRIRADRLRPDWRGLWPILALGAP
SLLMELNLALLLYAHNHQLLVWGNDLSVAAYAVAGYSESLFTLVIHGLAVGMQPLLGHAI
GAGQAERARDALRHGVKVGLIIGVAAWAAVQLFPAWIAGWYSDGSAALVEEGSRALRLHL
LAMPLDGLVIVGTTALQAMALTRLALGVTVGKTALLLPALGLLPLAMGLDGVWLAMPLVN
LLLGTAVALLLWRQFGQLRGRSLAAQA
>fig|243365.1.peg.2550 Probable mitomycin resistance protein
MHPSRCPPPDAATDLLQLPNVGPRAAADLRLLGFNHPADLRGRDPHQLYLRLCDATGERH
DPCVLDVLMSVCHYMDTGEARAWPSFTAERKRRWTV
>fig|243365.1.peg.2729 Probable multiple antibiotic resistance protein marC
MQLLSTFITKFLFVMAALLPIMNPPGLVPIFISMTARNTPQQRRYLARRIAIYCALLLVG
SMFVGGYVLSFFGVSLPVVQMSGGLLITFAAWRMLNDTPAESSQPSAEQARVDSQAELKQ
RAFYPLTFPLTVGPGSVSVAITIGATLTGSGKGLVRFVISPIAGLSAVLVGSTLVYLCYA
NADKLLRYLGQTGSVVFLRLSAFILLCLGVQIMWDGFGELASQWLRDNAGLLH
>fig|243365.1.peg.3243 Transmembrane multidrug resistance efflux protein
MQPSVNNESLFSQGRTAACIGGIALISLLAFESIAVAAAMPAVAAALGGLDFYAIAFGGT
LATSVAGMTLGGEICDRYGAARSAWLGLAAFIAGLLAAGAASDMYTLVLGRLMQGLGSGL
LGVAIYVGMSRAVPPALHPKLFAMFAGAWVVPALIGPGIAAGLVHIFGWRAVFLAVAALA
PVAGALLLPALSRQEAPAGAAKPMRWRRLGWSLLAASGALALHGGSHLPQTQYILPMLAA
GFALAFFAARRLLPAGSLRAAEGLPSVVAMRGLIAAAFFASEAFVPLILTTRYHWSLGSA
GLALTASAVMWSLGSATQTRLRGDAARRRGLTLGFAAMGAGLCFALGAASLSLHAGWVVA
GWAVTGLGIGLSFPMLSVLTMKLSRPDEQGSNASALQLSDALSSSIALALAGLLIHALSR
PSAPPDALPILAMSALLALIGAWVSPRAFASAAPARAEAGAGQLS
>fig|243365.1.peg.3479 Permease of the drug/metabolite transporter (DMT) superfamily
MAMLFPLLAVLIWAANTIVSKAAAQVLDPAAISIYRWLLAALVLTPFCLPVLRRRMGELK
PWLGKLLVLAMLGMVMFQCLAYYAAHSTSATNMGVITALVPLLGLLLNAAVFRQKVAALA
WLGVAVSLSGVVYLLGKGDPASLLANGVNTGDALILAGAASYALYGILLRRWAPPFGAWL
NLYLQASLAVLLLLPLTLTAQSMAIPAKGIGLVLFAGIGSSLVAAYFWMRGIQKLGSERT
AIFMNLLPLFTALLASALLGETIHHYHWLGGGLILLGVALGQGLLRLGGAKRPAFVNK
>fig|243365.1.peg.3736 Probable multidrug resistance protein
MPQAALLRRLSRPYRGLPPSVYIQVVCSFINNVGGISKLFLPLYLRESYQLPYNQIGMLM
AFYGAGMLAGSLKGGSLTDRFDSRALGVLALAVSGLCMVLLALRIPVWLFMPVLVLSGMA
DGGFRPINQRLALEPCAPQQRPVAQGMMRVAFNLGVAIAGVSSGFLAAYGYQWVYAANAA
GTLLGACWMACSYARRVESTRPQRRRADDEDALAGPWRDASFLRSILALVLITLAFDQMY
VTLALFLREHYQLGPQWVGYLFTLNGLMVVALQIPISRRILRWGLARSTQLGVLLTGCSF
LWLNAGHGVPWAVLMMMTLTFGELLLSPSYAHLVMHRSEGRLRGSYLGLYNAAWNGRTLV
APALGTALYGQFGGQMLWWLCALAACLGVAIQHGALKAMLAPAAERG
>fig|243365.1.peg.4365 Probable multiple antibiotic resistance protein marC
MFKTLSLQFLFGGLLSLITITNPLSKIPLFITLTREMSDSHRDSQARRACVFAAAIMAVS
LLAGNLIMAAFGISYGALRIAGGFVVAVLGYRMLFLSQDPGQAPRQSGEREDYAFFPLAM
PGISGPGTIAVVIGISTEIAELSTLPAKALAFAMTFAAIGLTCVGMWLTLKSSLLISERL
GRGGREVMTRLMGFLLICIGVQFVGSGIRTFMAGS
>fig|244592.3.peg.585 Multidrug resistance efflux pump
MFEKKFLVVFVAVLFLILIGNEISRHFFAYTSDAYITSDYASMSPAVAGTLAELHVTNDT
EVRKGDPLFTLDQTPYKLAAESAAANVAVSEQALQVAKDGVEEAKTNVTATKAILDDAEA
TQRRLSTLQESGVVTEQRLDDATRDLAEAQANYERALAARTGAQDQLKQKAAELRQATAE
KAVADYNLEQTVVRAPFDGQVVPFNTKTGQYLDAGDVVLILVSRTGYRIVANVHEQHVQF
IKPGQPVYYMVSTAPWVFFEGSVRGISKGIARSTLETQALPYVDPETDWIRLSQRFPVEI
NLSVHPDDRQAFMGADARVLILNTDPPPPTGSSHGSGQ
>fig|244592.3.peg.1525 Permease of the drug/metabolite transporter (DMT) superfamily
MVGRASLPGHLIEELRKLPIKLSSIPVLVHFIAAQDKPAHPTFARFSGVGNRKHMVPGRH
SPGWSSLMKLQHWILLICLGAIWGGSFIFAKVAVAEIPALTLVFFRVASACLALWLVLWA
QGTLEQFPLKMAASFLAMGLLNNVIPFSLLFAGQTVIGAGLASILNATTPVFTVLVAGVL
FRQETLGIHKIAGIALGIAGVATMLSGSLSGIVSDPLWAQAACLGAALSYAFAATFAKRF
KGLPPLISATGQLSGSTLIMAPIALFASRSWSVADPSVIAWLNVLALGIFATALAYLMYF
RLLAEAGATNASLVTLLVPASALFFGWLLLGEELSAIQLAGFALLLSGLVVLDGRLFARF
KPVSTSAK
>fig|244592.3.peg.1799 Outer membrane component of tripartite multidrug resistance system
MVGPDFERPEAPVLDSWGKGANLSVDHRTGFTTRSAASVPWWHVFKDEALNGLIAEAYRQ
NVELQAAGVRVYQARAQLGIARGELFPQVQQLKGNSENIRFSTQDPIIRDLERAGLVDSH
ISRVSAGFDAAWEIDIWGKIRRDVQSAKANLNANLASYDDALVTLTGDIAATYVTIRELQ
QLAASSRKNAALQKKSLNLTQLRLENGVASQLDVHEATVLYNNTLAAIPGYEAELAQAYN
AMSVLLSEPPGKMKARFSGRSGFPRVPAEVAIGVPADMLRRRPDIRQAEYIAGAQSAQIG
VAKADLFPAFTISGAIGVRADDFSNLFTGGATTALFNPGFSWNFLNYGRIRNNVRVQDAK
FQEALLTYENTVLSAYAEVENALTGFLRSKQQALYLRRSLRAARSSVGEVEAQYEDGTAS
YNRVVDAQKSLLVAEERLIAAEANVLTNLVAVYKGLGGGWAPENVRGLISDETRAQMADR
TRWGQLLDNPVGPSGKS
>fig|244592.3.peg.1807 Multidrug resistance transporter, Bcr/CflA family
MTAAPATLMSARRTALLGAGLVAVGPISMALYTPAMPALVEFFGTTDGAVKLTLTSYFAG
FAATQLVCGPLTDAFGRKPVTILFLGIYLISSVLATFSPTVEFMVAARALQGVGAAIGIS
VSRAIVRDQFTGQASARIMNTIAMMLALGPAISPTIGGFVLELFGWREVFWCMVIYGVAL
MVAVTVFQVETNPSPGKHHLNPRQLAINYTTLLKDPRFLAPAILIGCGLGNIYALATVLP
FVLIYEVGLSPSVFGLTMILQSGSFILGTVITGQLLKVTDAHKLVPFGLAMLVVASVLMC
AMTLTQEPSVASVMAPVGLFVFALAFVLPASFTDSMAPFPHIAGAASSMLGFLQFGGGVA
ASLIVAMVGDPVLGLAFVLPAMPVAGVVCYLLLRGQDTQHAAAE
>fig|244592.3.peg.2796 Probable phosphinothricin acetyltransferase (antibiotic resistance) protein
MPLRDAEPGDIPAILALYNQAVRETTAAWTSQEETLDERITWFETRQNAGWPVIVATSPE
DKLIGFASYGAFRPREGYRKTLEHTVYVDPDFQGQGIGAKLLQQLIDKAQAQEVHVLVGV
VDGDNTASIALHKKLGFEIAGRLPEAGTKFGRWLDLVFLTKIVTPGLDSPDV
>fig|244592.3.peg.3619 Permease of the drug/metabolite transporter (DMT) superfamily
MQARDFLLWSLLAALWGSSFLAIGVAVKDINPATLVFARMAIAAPVLGCVLLLRGGGFNL
GVRGWIIAAIVGLSGNVLPFLLISYAEQEVNTGLAALIMGIAPIITLVAAPLVHFEDSLT
RLKVFGALAGFAGVAVLAAPDLSEGRIGSLLPELCLVVAACCYAFTALFSRRFPYPEPLK
MAAASVFVGLLALGGYMALFASEPGLPAAPVPALAAVLYLGLGPTALAALIYFYLIPRIG
AARLQQVNYAVPVIGTLLGIAVLGEQPGWTAWPALGLIVFGVYLVTRPDKTEPAPARPMG
EPAE
>fig|244592.3.peg.4855 Bicyclomycin resistance protein
MASDLTAHTTREPKRIAFVVMLMGISTLSPFAMNIYLPSVDGMMSAFSATAAEIQLTLAF
YFIAIAVAQIFLGPISDQFGRRPVIVAGMVLFVIGSVLCLMAPTVEALIAARIVQAIGGG
AGLVLARAIVRDVYGRDKAASMIGYVAMGMAVAPTIGPAIGGFLDAHYGWRGGFVLMLIF
GIGVTICAWLFLPETNQHKKAVSLKQIGQGYADLFKEKMFWVFCGASTFMAWLYFAYLGG
APFVAAGVFNMAPAEIGLYLMVVSIGYIIGNFITGRIAARAGIARMIALGVITGVFGVSL
LVVGTLTDSLTGPLFFMPMFFIGLGNGLGIPSAISGAVSIRPDLAGTASGMLSFLQVGAG
ALVSSAVAYMFSADIAGGGEMPMILVMVVGGVFGLACVLAVFLGERQDTQYEDR
>fig|244592.3.peg.5109 Drug resistance transporter, Bcr/CflA subfamily
MNLTVLSPAGSPPRQISLILLSAISIVSLNMHIPSLTAMSADFGVSYADISLSISLYMVL
TACLQIVAGPLSDRYGRRPVLLAAVTIFLAASAGCALAEDFWVFMVFRLVQGAIATAAVI
SRAIVRDSAAPQNAAVRLGEIGMAMALAPMLAPMLGGLLESGFGWRSTFWAFALAAAALW
LLSWKDVGETNASRHSSFGDQLKGYPALAADPAFWSYTLCMAFSVGVFFVYITGIPLVAT
GYFGMSPVGTGVVMGLPPVGFMLGNWIVIRLGQKVPLSLLMMTGRLVTLVALLIAALLLS
LGRADALSFFPWMIAIGIGNGLTMPSANAGVMSVNPKLAGTASGLSGAITILMGAGAAAA
TGVALDAIPGPATLLSILIGFSGVALVLAHAARGAEQRVSNAI
>fig|244592.3.peg.5277 Permease of the drug/metabolite transporter (DMT) superfamily
MSERTTGILEMTFAMTLIGTLGIFVVFSGESPVTVAFWRCLFGAIGLALICSLKGAFAFK
ISPKQFLLAVLGGIALTTNWVMLFYAIGHASISLTTAIYNTQPFMLVCFGVLFFGEHLTL
RKLCWLGLAFCGVVVIAQSKPELAYANGNFAVGVALSIGAAFLWAVAVVVTKKLSGIPSH
LIALIQVSAGAILLAPFASVSDLPSQSTAWASLLTLGFVHTAMMYTILYSAVQKLPTDLQ
GALTFLYPSVAYVTDYLVLGQKLGTVQILGVAVIMLAAAGMTLGWRLPFFRKEKSYHQA
>fig|245012.3.peg.208 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MSKTMRETLTAGRSIDLTSGPVARSMWLFALPLMTGNLLQQFYNVADTLIVGRFLGAGAL
AAVGSSYTVMTFLTSVILGLCMGSGVLFSMLCGAGETERMKNSFVQSFFFIALVTGLVEG
LALLLIDPMLAVFQIPADILKDTKAYLQIIFIGLVFTFVYNYFAALLRALGNSLVPLMFL
AVSALGNIVLDLVLILEFHMGTAGAAWATITAQFLSALGIGIYVWVKMPHLLPGRRHFYR
DSEILKKITRYSLLTCVQQSVMNFGILMVQGLINSYGVTVMAAFAAAVKIDSFAYMPVQD
FGNAFSTFIAQNHGAGRKERIRLGLRAAVLSSGAFCLVISFVVVAFGGRLMTIFISPEET
QIIRIGAQYLHVEGACYVGIGCLFLLYGLYRGLGHAGVSVILTVISLGTRVALAYLLSPI
PSVGLLGIWWAVPIGWFLADIAGFAYFWKLDRKEKREAIS
>fig|245012.3.peg.223 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MTYLYNMTAGIIRSLGDSRTPVYFLLLSSVINIVLDLFTIIVLKMGPAGAAWATVISQGV
SGVLCLLYMKKHFEILRLQKDERKIDGQIMKILCKMGIPMGLQYSITAIGSVILQASVNT
LGSMAVAAVAAGSKVSLFFCCPFDALGGTMATYAGQNVGAKKLERIRQGVKSASVIGCIY
SAAAFLVLLLFSGKIALLFMDAGETETISRVSLFLTANSAFYIPLVFVNVVRFAIQGMGY
STFAILAGVFEMAARGLVGLFLVPVFGYIAACFGSPLAWVFADIFLIPAFSHCLRRMKKN
FEENEEKYTAGQLSK
>fig|245012.3.peg.486 Multidrug resistance protein
MGSSVLMPLYVQSVMGYSAVISGLVTLPGSLATTLVSPFAGRIYDKMGIKRLFVIGSAIM
LFSNIGMYFLTMSTPLWTAAVLNVIRNVSIGSLMMPLLTWGTSSIQIKKVADASSLLTSF
RTIAGSIGSAVFVGIMTAVSEGSAAAYGEGALMHGMNIAFLCMAAGSVILLLISVFGVRK
ENICNREGTETNG
>fig|245012.3.peg.508 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MSQAVKAKKKTCSMLTDHPGKALLLFAFPMILGNLFQQFYNIMDSVVVGQFVSENALASV
GASYAITNVFIAVAIGGGTGSSVIISQFLGAGQITKMKTAVSTTLLNFLVISVFLGVFGL
AYSDRILALMNVPGNIFEDAALYLSIYFLGLPFLFMYNVQASVFNSLGDSRTPLWLLIFS
SLLNIVLDLLFVIQFGMAVRGVAVATLIAQGLSAVLSFCLLMRKLRGYEHRREEFRFYDR
GMMLSMVKVAIPSILQQSIVQMGILLVQSVVNTFGSSAIAGYSAGTRIESISIVPMLAIG
NAMSTFTAQNIGAGNEKRVREGYRTCYFALAAFAAALCVLTQSFGSLFISAFLDAEVSEE
AFSVAMSYADFISFFYILIGLKATTDGLLRGAGDVTVFTVSNLANLTIRVFVASFFAPRY
GLEFVWYAVPLGWATNYAISFGWYLTGHWKRIRLIEGGEKRPYRA
>fig|245012.3.peg.533 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MWGICGYFSISSSQQAVRESGLQYTHIVFLFSFGLFAEANATKLLQAKGNTVLPMLAQIA
GAVLNILLDPILIYGLFGLPAMGIRGAAVATVLGQWLAMFIVILPVFRRFPVFSGRVLPA
DCIRIYRAGLPAIAMQSLNTLYIVGLNLVLKQFSESAVLVLGIYYKLQTFFFIPLMGLQQ
VILPLISFYHGAEQPQRERQVLGCSIKLSLAVMLTALGAFMIRPRRPSFHLHSRTGCPLH
RLHRASDHLPQFPVRRPGNDVYRIFSERRARENQPAGDCASPGRSPGPPGLAVPL
>fig|245012.3.peg.543 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MKHETKALQSGNPLEYKPIPQLLLAFSVPAIISCLINSIYNIVDQIFIGQGVGYLGNAAT
TIAFPVMTIILAFGTLIGAGSSANAAISLGERRNRRAEIILNNAFALALVSGIILMAVGL
LFLRPILSLFGATEASMPYAVDYTSIILLGTPFNLIGIVLSNLARTDGHPRLSMYGMMIG
AGLNTILDPIYIFIFHWGVKGAAIATITSQIISAIILTAYFLRANKNPQHMRLRLRSMRF
AGPIVSRSLTLGVSSGITQSVACIMQVVLNNSLVHYGNLEAAGGGDIALSAMGIVSKISM
ILASLAIGFGIGAQPILGFNRGAGKYDRIKTTYKICSIMASVCLITGWVLCQLFPEQIIS
LFGHESAAFTDFAVKCMRIYLFGIFCAGFQIVSTNYFQATGQPLKAAILSSLRQLVLLIP
LILILPLFWGLDGILFAGPVADISSTIIVSLFVIPEMKKLNQKISEMRTAAQ
>fig|245012.3.peg.664 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MGVRGAALATIISQFFSAVWIVRFLTGKRTILRLRLSCLRPQWKRIRAIVGLGMSGFTMA
ITNCTVQIVCNATLQTFGGDLYVGVMTVINSLREVASMPVQGVTNSAQPVMGFNYGAKEY
GRVKKAIVFTSLFSIAYTTLAWAFLHGFPEFFIRIFNQDQALIEAGVPALRLYFFGFFMM
SLQFAGQAVFVALGMSRQAIFFSIFRKVVIVVPLTLLLPSVFGMGTNGVFLAEPISNFIG
GAACFGTMLLLVWTELTRRERAKTV
>fig|245012.3.peg.825 Acriflavin resistance protein
MPAQVAQSVYLMISGSEATTLDQDGEEISVNVEYPDGWYETVDQVKGIVVSGAAGNSVAL
ADIADIYFKDSPQSITRKDKEYQVTISGDFVNGTQEEQMDAIETQIYDEEVAPRLTENVT
RAQNAMDESMAEEFASLGGAIAMAIFLVFVVMAAQFESPKFSLMVMTTIPFSLIGAFGLL
FLADASISMASLLGFLMLFGTVVNSGILYVDTADQYRAEMDRDTALVEAGATRLRPILMT
TLTTVVSMIPMAMAYGDSGETMQGLALVNVGGLVASTVLSLLMLPIYYTLMNRKPKYDEL
DVD
>fig|245012.3.peg.1500 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MQKGEQKMKIENDLGRDDVRLLVMRIAIPSMLAQFVSVLYSVVDRMYIGNIPEIGETALA
GVGVCGPIVTLITAFGSLVGVGGAPLMSIRLGEKDEKGASQILANCFLLLSAISLIIMAA
ALLLKNRLLVWFGASEAIFPYANDYITIYLLGTIFALLSIGMNQFIICQGFAKVAMKSVM
LGAVVNIVLDPVFIFGFDMGVKGGALATVISQMASAAFVLAFLFGKRVPIRITFGNYQWR
IMRKVIFLGLSPFLIVAFDNVLVIAMNASLQHYGGPEGDMLLTCNTIVQSFMLMVTMPLG
GITGGTQSILGYNFGARRSDRVLAAQQWIVTLALIFTAVMFIIAQAVPQYFVRIFTREPE
YVELTVWAIRVFTLGIIPLSIQYGIVDGYTGMGIAPIAISLSAFRKTLYLLGVFLIPMIF
GVRAVFYTEPFSDFLGTAVSIAVYLLTMKKILRRRENGAL
>fig|245012.3.peg.1525 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MAVPALKLFSSAYLIRWFSFATQSYMSAVEKPVPAMIISVCTAVVFPLLIIAVLWPMGLN
GLWLNVPATSLLAAILAFFILNRFERKEMREAAR
>fig|245012.3.peg.1528 Acriflavin resistance protein
MEDLKNVPITTSSGEIIMLQDVANITEAKEEQGGISRYDGQETISISITKNQSNTAMEVS
NAVKETIETLTADDSDLTIEIVNDSADTILDSLKDVAVTMILAVVISMIIIFLFFGDVKA
SLIVGSSIPTSILLSLIAITSAGFSLNVITMSALTLGVGMMVDNSIVVLESCFRVTKENW
DKGIVGYAKSALQGTNVVFASIIGGTATTCVVFIPLASLQGMSGQMFGPLGFTVVFCMIA
SLLSAVTVVPLCYVVYKPREKEGAVLSRPVERLQDLYRRIMKRLLRHKAMVMSVSVAMLV
ATVYLASGMETELITADDTAQISIDIEARPGILDEKADTALEEIEQIVSS
>fig|245012.3.peg.1529 Acriflavin resistance protein
MGITKFVLKRPVTIVMALLCLLVFGISSVFNATLEQMPEMETPMLIISTRYDGAGPEDIC
ELVTEPIEDEVSTLEGVKSVSSTSSDGSSMVMLEYDYGTDMDEAYSDLTKKMNSIERQLP
DDAEEPTVMEMSMDASTTMMLSISHRTQSNLYDYVDQKIVPELEKITSVASVEATGGSSE
YIKVELISEKMAQYKVTMSQITSAIEAANLSSPSGDTVVGNLELSVTT
>fig|245012.3.peg.1554 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MNYKELFSKTPPTKLFFTAAIPGSIGMLASALYQTIDGVLVGRILSGNAFAALNLAMPLV
IINFSLADLIGVGSAVPISVRLGEKKEAEANNIFTSACLMIVITGLILGLAIFLAAPALI
GLMGAEGELAKLAVQYLRVYCLCSPVTTIVFAMDNYLKICGRVRSSMALNIVISVLSAVL
EFIFLFVFRFGIWAAALATCTSMFLCALAALYPFFSRKMQLRFVRPRLNRTMIKTIVTCG
SPNFLNNVAGRITSIIMNMILLRVGGATAVSVYGILMFADGFVQPLLYGMCDSLQPAVGY
NWGAGALKRVKDIEKRCFTAG
>fig|245012.3.peg.1559 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MLAISCCILADTFFVSQRLGTDGLAALNLAIPIYDVIHGTGLMLGMGGATRFSICKSRGE
DREANLMFTNTLFLAGACSVFFVLSGLLFSERLAVLLGADEAVLEMNKYVNLKVLMLFSP
AFLMNDIFLCFVRNDKNPGMSMAATIGGSFSNIILDYVFMFPLGMGIFGAALATGLAPVI
GIAIMSPHWLKRSKGFHAVKTGLLPNR
>fig|245012.3.peg.1560 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MNASLGFPSLLAQLSSGVVMIVFNKIILELEGNTGVAAYGVIANIALVVVAVYSGVGQGI
QPLVSREYGYGRKEREVQLLRWAAAVVLALSVLIYGGLFGLAEPIVGIFNSENSVRMGQI
AVIGLKLYFISVPFVGLNIVLTTYFSAVEQAVPAQVISLLRGLVLLIPMAFFMAEAGGLT
GVWLAVPVTEFLSVVLGGWLYFRMEKGGAKRAKNRLPEDI
>fig|245012.3.peg.1774 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MENFNGIAGIGIGIGMMTVVGQCLGAGRPDEARYYIKKLSYAAEAAVFVSCILIFLLSGP
ITRLAGLEAESASLCLFMVGWITVVKPLVWTAAFIPGYGLRAAGDVKFSMLLSCLSMWTC
RVTLCIFLIRVCGFGPMAVWIGMFTDWAVRGFFFVRRFRSGKWLEHEVAD
>fig|245012.3.peg.1775 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MNQKESAPSGAGHLYSNRQLFALMVPLICEQLFTSFMGTVDSMMVSNVSEAAISAVSLVD
SINILVIQAFYALAAGGAIICANYMGQKREEQAKRCADQLLFIVLAISLAVLAVCQLFRG
PILGLIFGSVEKEVMDSAMVYFFYTSLSFPFIALFDSGSAIFRAQNNSRLPMAVTVATNL
LNIFGNAVLIWGAGLGVAGAAISTLVSRIIAAVCVLLFLRRKSGQIIIGNFIFLRPDGRL
IKNILRIGIPSGVENGMFQFGKLAIQSTVPLWEQRPLPPRP
>fig|245012.3.peg.1875 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MKENTSGSRSLNNGLNNNSDNRSHNNTLLTERLPRLFLLFVLPAVISMVISGTQSMIDGI
FLGRFAGVNAMASVNIAGPYMQIITGCTMVICIGTFSYLGRTLGENTNPQKAKDIFRTAV
VSLAACALILMAAGLFLSRPLALLLGANEVLLDETALYIRTVAVFIPAICFMMHFGFTAR
LLEKPHLYLIATLCCVSCNVIMDYLAVK
>fig|245012.3.peg.2179 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MTEMKKQVDLLNGKIISALTELAIPIMGTAAVQMAYNLTDMAWIGRVGATAVASVGAAGM
YTWLS
>fig|245012.3.peg.2284 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MEERENTMGSRPVFPLLMSMSVPPMISMLIQSLYNIVDSIFVARISDKALTAVSLAYPLQ
NLIIAVAVGYGVGINACIARSLGAKRQEETNQTAAHGALGTALHCILFILVGVFLTEPFL
RLFTDDPEIFSMGCSYTYIVVCFSFGSLFHIYIEKMFQATGNMVMPMILQGVGALINIIL
DPIMIFGLFGFPAMGVTGAAAATVAGQILACILAVTLFNLKEKNIRVSFRAFHFDRRIFF
RIYSIGIPSCIMLSLPSLLVGILNSLLVGLSSVAVAVFGLYFKLQSFVYMPENGIIQGMR
PIISYNYGAGHLDRMRETVRCSMISCGAILAAGTLLFLAVPDYIMMMFGAEGEMMEMGMS
CLRIISLGFIFSAAGTVFSGCFEAIGRGLHSLAVSLVRQLVVIPPLAFLLAETMGVTGVW
IAFPAAEILAALLGLVLYRGQMRKVKLELLGSLKKEERR
>fig|245012.3.peg.2560 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MERDLTKGNIVFTLAGFSLPLILSGVLQQLYNWADAFIVGNIEGELALAAVGATGTITNL
FVMVITGLTLGLSILAAQKYGRGERESLRRILSTFSIVLGVLFLLTAAAGLWLSDGILRL
LHTPEDIFDISEGYLRIILTGIPFSTIYNVYSAVLRGLGDSRAPFLSVLVSAAANVILDL
AFVGGLRMGAPGAAAATVISQALMTVFIVCYAGRKYEILRFSREEKLVDKKILVQGFQLG
LPPAIQSSVNSCGNLLLQNFMNSFGTQTVAAITTAYRVDSILLLPIINLGSGISTVTAQN
MGAGNRARAKKVLFAGSVMMLCVSICLTFLILSAGGPLIALFGVTEESTAIGASFFRSIA
GFYTVYGFAMAFRGFLEGCGDVLYSSIAGIAALASRILISYLCVSVWGNMVIAYAEGISW
ILLLALYLVRFLWKQRKPCGRREETER
>fig|245012.3.peg.2713 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MQTPNLYFRIYFLGATFNLVYNMGAGILRAVGDSMRPLYYLCVSSVVNIVLDLLFVSQLH
MGVDGVAWATIISQLISAILTVRALMTSDDIYRLELKKLKIDFRMMKRILNMGIPSGIQQ
SIISLSNVIVQANVNVYGAMAMAGFGAYNKVDGFVVLPMQSFCMAATTFTGQNIGARRMD
RVKKGLFQGMVICSIYTVGVSVLLFFKAHSILEIFSSDPGVISYGLKTMIVMVPFYLLLS
AHQILMGTMRGAGKSMQTMLISVGNMCVLRVIYINLFVPLFPSFDAVMWCYPITWATTVL
MDLAYMKWGRWLGQAGDRKKKRH
>fig|245012.3.peg.2714 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MKKQKKNSVLMTEGVIWKQLIAFSIPLLIGNLFQQLYNTVDSVVVGQFIGSEALAAVGSS
NSLINLIIGMFMGISVGAGVIISQYYGAKSAEKMSWAVHTSMALSLVGGVVLTVVGEAFS
PVILRWMKTPEEVLANSQSVFQDLFSGGHLQSGLQYGSGNSEGGGRFYETSLLPVRVIGS
KHCPGSSLCEPASHGSGRRGMGYDYLPAYLSHTDGAGADDLRRYLPSGA
>fig|245012.3.peg.2761 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MAYPLTTICLSIALLIGIGSASRFSLELGAGRKESAAQAVGTAVCMMVLFGVIYVVLIEL
FLHPLLTVFGATKDVMPYAESYTRITAVGMPLLILTNGISNLARADGSPKYSMTCMLVGA
VINTILDPIFIFVLHQGVAGAALATVIGQVFSCLMALNYLRRFSHVELRRSHFRLRLPVC
LKIASLGMSNSLNQLAITFVQIVLNNSLTYYGAHSVYGSEIPLASCGIVMKTNAILLAVI
IGISQGSQPIIGFNYGARQYERVRGIYRLAITCNLIISGIGFLLFQLFPRQIIALFGTGD
ALYFEFAIKFLRIFLFMVIINGVQLISANFFAAIGKPVKGVVLSLTRQVFFLVPLILILP
LVWGIEGIMFAGPIADFAAFITTMILIRREMGHIRAAQAELEAA
>fig|246194.3.peg.77 Vancomycin B-type resistance protein VanW
MKKSYIILTVLIALVIMFLAGIVGFSYYTYIKPYQGKIAYGVTVEGEPVGGMTFKEFKRY
LEGLNNELQNQPVVLTLGNKTWTYKKGDLGISLNTAEMYRKAYELGRKGSLLKQIMERRQ
LNKAAVDIKYLVRLEERKLLAKLDQINKEIYVEPKNAEFRLLPNETFAIIPHKTGIALDS
EQAVKDVRANLLENPLKVSFKLKEVLPDKTTEDIKKMRLTGLLASFTTSFDVRKVNRSYN
IGVAAGKLNGILIAPGEVFSFNKTVGPRSAKEGYKNAPVILRDQLVEALGGGVCQVSTTL
YNAVLLANLPIVERHNHSLPVAYVPPGRDATVTDGGKDFKFKNNLPCYLYIKSYVNGNRI
TFKIFGDASLKKHVVIKSWVTKTIPYKTIIIKDSSLPEGKKVVKQEGALGKYAKAQRIVY
QNGRVVKVENLRDSYYKPMNEIILVGTKKVPNSSAKESSVTENVY
>fig|246194.3.peg.256 Drug resistance transporter, EmrB/QacA family protein
MEYRWRVMWVVALGTFMAPLDASVVNIALLSIIKDFKASLATGEWVILIYLLFISTLLLT
YGRLGDLYGKKLVYVTGFVVFTVGSLLCGLSPTLGFLIGARVIQSLGAGMMMAMAPAIVT
EVFPSQERGKALGINGMMVAAALAFGPSAGGFLTHFFGWRSVFFINLPIGLIGSILAFKI
IKNDFTREKHSFDFLGAFLSFLGLGSLLILLTFFEKYGFTHPLMIGALVISILAFLLFLY
TEKKVSEPMVDLGLFKNRDFSFSNLSAFLSYVALYQVVFLMPIYLQQLRHFTPEKAGMVM
SVHPLLTMIVAPLSGSLSDKIGSKVLAPLGMTVMALGLFALSRLNSETTVGIIILSLMLI
GLGSAIFQSPNNSTIMGSVPKNRLGTASGFLATMRNVGMVMGVAVAGAVFTGRRTYYLTY
YLQNHYTKELATVKAFVLAFREAFLVGAFIALLSAAASLVRSRGRKEKLLQK
>fig|246194.3.peg.914 Permease of the drug/metabolite transporter (DMT) superfamily
MGDNERIKGLVLAILATSLWGINGTVTRYLLINNLDPVVLVQIRLTVSALLLFILLFILK
INVKISRDDIISLLILGIFGLSLVQMTYFYTISLTNVATAVFLQYLSPVFVALYGVFFKA
EEITGSKLTAIGMSLLGSFLIVTQNGEIQLPFMGLLSGLLSALSQSFYIIYGKKVLNRFS
PITVLAYGWLFGAVFWWLLIPPNKALMHQVFTLRDVFGISYVIIFATVIPFLLYFESLKY
LNSTTMSVVSLVEPVVAVIVAYLVLGEKLTPLSTLGAVLILFAIYKITRS
>fig|246194.3.peg.1031 Permease of the drug/metabolite transporter (DMT) superfamily
MELKTKQLLADISLIVVTAFWGTTFVIIKNILANIEPFSFLSFRFLLSTFFLLPLLLQKE
GFSPKGVFFGSIAGFFLWLGYILQTIGLKYTSAANSGFITGLAVVMVPVLSSILNKKPVT
PGVIFGTGLSFLGLFIMSFDFKAGFNTGDLLTLAGALFFSMQIVSVERFSPNFSATSLTL
GQIATVGVLSLPAALWLEEPFKPYPNEVFYAIVFTAIFATVLAFLVQSKAQQFTSASHVA
LIFTLEPVFALLFAVLFGGESLVAKQGIGAFFILAGMLTAEFLDQYWPKAKDEKKANL
>fig|246194.3.peg.1047 Fosmidomycin resistance protein
MGEVILLEKAVKSAKPNLGVLLLLSMGHLVTDMAQGALPALLPILKQAFALNYAKTSLLV
LMSNIASSVIQPFFGYIADRRPARWLLPLGCLLAGVGVAVTGRMPWFSLLLIVVTIASVG
VAAYHPEGSRVANLASGVRKGRGMAVFSVGGNLGFGLGSIYMAWLLSKGGLKATVFFLLP
SLLIAVLFLFSWPRLTSLRDEVVEKKAKGNGQGSGQEIKAESKKRTIAAFFLLLLYIVFR
TWMHAGLYTYVPLYYTDYLKGDPHLAGYIVSVFLLAGAVGTLLGGPLTDILGAPKVMAGS
MALLIPLIFFFSRTNNGFVYFVLLALVGATLISTFSTTVVLGQQLIPHRKGLASGFTMGF
GVGMGGVGVTLLGVLADHLGVPAVFHVLNILAVGGFVLALILIRYFPWSSKTME
>fig|246194.3.peg.1488 Fosmidomycin resistance protein
MNYNYNKIRYAIAFGHFWIDFYANVLASTMYLLARDLHLSLTRQGILVAVVSFAGSVMQP
YLGYLVDKKGKSTHLLFSLLLMGLLTTATGLFQNFYPVLILFTLGALGSALYHPLGSVLT
TSISEKKNTAVSFYVTWGNIGYSIAPVILVPVVEALGRKGLLLFSLPMFLALIFLYLSKS
HQLPLPHEERKETLPSFRATIKSAFTGLLLLNLIVWGRAWIQVALGNYSIQYFLHQGLSA
NQSSILLSAYLLAGTAGVVAGGFVSEKHGERFTLLATFLLSGATLIMMFFTPPPFSYLGM
LITGFLLNMSFPATIVMGQNLIPENAGMVSGMMMGLAFGLGGMGAMLTGTVADYTSLAFS
LKLLVVIPFIISALTLVYFQKISLPKPKIK
>fig|246194.3.peg.2430 Inner membrane component of tripartite multidrug resistance system
MEHQRHNFGENKWLTMFVVVIGTFMAILDTSIVNIAIPKMMQVFAVGTEEIQWVLTGYML
VMGVVIPVTGYLGDTYGYKRLYIAALFFFTLGSALCGFAWSNNSMIAARVVQAIGGGMMM
PASMTIIFNTFPKEERGMALGIWGISVMVAPAIGPTLSGYLVEYFNWRLIFTINIPIGLF
GMVMALLFLKESVRRPHATFDLPGFITSSVGFFALLLALSKGTDWGWSSAKILFLFWLSA
LSLTLFTYFELKSPEPLLDLSVLKNPTFAMSLVITMINTMGLFGGLFLFPIFFENLRGYP
PMDTGLIMLPAALASGLVMPIAGRLFDRFGAKPVVLFGLTLAIISSYGLSLTHINTELWW
LQTLLIIRAMGIGFSMMPVNTAGMNALPNYQVGRASAINNTLRQVSSSLGVAIITTITQQ
RVAFHTARMVEGLNQASPVFQNTVNFLKSGLSFMGVSPLVSVKGAMGVIAMRLYQVAYAK
AITDAILVTAFIMVFGVILTFFLKEERKNQEEKEKLPVAEF
>fig|246194.3.peg.2433 Permease of the drug/metabolite transporter (DMT) superfamily
MNKSYLYLGITVVLFSTYEVVGRALAGLVNPFQLNFLRFFFGGFVLLPVALSNIKRKNVK
LTGSDFLFAFLIGLLNVVLSMSFLQIGINMTKASLAAAIFSSNPLFVVLFAYLILDEKLN
FQKILGLFIGIVGVVIVFYKDLELGISHVYGILMLILAAVTYGLYTVLGKRFSQKTDSVI
MNSFSFILGSVFLLPIILLKHYPLFSLQPKAILPMAYLTFFVTGLAYYTYFLGLTNISAG
NGSMVFFIKPVLASFFAWAILGEKITFEFIAGTMVILLGIYIVQWAGQVNDGATCEKLRT
LEK
>fig|246195.3.peg.500 Drug resistance transporter
MMTEPATQQPSRYLPCLLTLAIFMQMLDTTILNTALPSIARSLHESPLSMQSAIVAYALT
VALLMPLSGYLCDRYGTRKVFANAMLLFVVGSVLCAAAPSLTFLVLGRMIQGMGGAMLSP
VPRVVVMRAYPRNQIVSMLNLIVMPALIGPIIGPLLGGYLVEYAHWSWIFLINLPIGILA
ILATHRVMPDFTGAANPRLDIVGFLLFAGGALGISLAMETVLHPAGKLFSSLTALLGIVS
FYGYWHYARGNPDALYAANLFKVRTYRVGLSGNLVSRLGMSSVPFLLPLLLQVVFGYSAS
AAGWMLMPIAFAAMFGKMVTLPLISYFGYRRLLIINTRLIGILIMSLALPQPHTSPWLLM
PLLAGIGLSNSVQFTSMNTISLADLRIYQTGSGNSLLAVDQQLSISMGITLGAAVLTGFR
SSQWIGDDLHLAFRLTFIVIGCITFTSSWVFARLHPYDGQNLLPSEKD
>fig|246195.3.peg.851 Multiple antibiotic resistance (MarC)-related protein
MSLTAAILTLFLIINPLGNVPVFLSILKNLSPKRQRIVLLRELCIAYAIMVVFLFGGSSI
LHGLNISREAVSISGAIVLFIIALRMIFPLRSGSVMGADDTEGEEEPLIVPIAIPFVAGP
SLLATLIMMVESDPSLTTRWFFAMTISWFISLLIFLCAPFFFKILRKRGLKAVERLMGMI
LISISVQMMLNVYMALQATGA
>fig|246197.19.peg.93 Drug resistance transporter EmrB/QacA subfamily
MLARCGASPGARPLAAPERAQSCRRTETAGAAKGLCRWPSGRNVPTFPLAPLTREPPRHM
APSAAPATANAPPAFPAFTRSQKVFTLLGAVLGLLLAALDQTIVATAGPAIQADLRIPAS
LYPWLTTSYFVASTTMVPVWGKLSDLLGRRAVLAAGILIFLAGSFLCGVARSTVALILFR
AVQGLGSAALFTAALAVVADLFEPRERGKYQGLFGAMFGLSSVVGPLAGGFITDHLGWHW
VFFINLPVGAVALALVLSRMPRLKPQRVSRGGLDLVGAFTLAVALVPLLLALSLGQTDGG
DWAWTSWRILGLFALSAVGLVAFLWAERRAPEPLLDLTLFRLRAFSAGNAAVFIVGGAFL
SGIVFLPLFMVNVVGLSATRSGLTVMPLTLGVVAGNVLSGQLVSRVGRYKALLLGSLVLL
MAGFAVMAFTLTPDSTQAEVTAKMVLVGLGLGPSIPLYTMAIQNAVPPDQIGVGTAAATF
FRQLGMTLGVALLGTVFASTLSSELEARMAQATSALPDSVKAEVTRAAPGVSGEGGPTGQ
VFRADEVKARVRAEFDAERRRAETTAAPEARAKVDADERQALAAVDAADRALKMAFTRGV
SAVYHVALFIAGAALLVTLFLPEQHLRRKRRRIESRASAPEQ
>fig|246197.19.peg.179 Permease of the drug/metabolite transporter (DMT) superfamily
MTRAPGWSRVRPPAMSRTAGFLIVALSGVCFGALGLFGRLAYAAGTDVATLLFLRFSIAG
AVLASVMVLRRQRWPRGGVLVVLMLLGAAGYFSQSGVYFFALQHAPAGLVALLLYSFPAL
VALVQRVVFKEHLGRVKWLAVVLSVGGTVLTADLSQGGATLPGVLLGLLSALFYTVYVVA
SGRVSGRAGPLASSTVILCSAGFSFGVAMLVRGPAFPGSVTGWAAVVGLALVATVAAVLL
FFVGIQRIGPVNTSLVSNLEPLTAVVLGALFLDERLTPRQVLGGVLILGAAVMLARADVP
RASPEPPAGGGAPGAVPG
>fig|246197.19.peg.1413 Drug resistance transporter, EmrB/QacA family
MARRPARATSRKARSCSEVMRIPQKAYAEDAVSAWGPGAYREVMDGSGVTAEPMVSARPG
VARRTATGAVLLALVVSAFEGTVVTSAMPTITRELGGQHLYSWVFSAFLFASTVGVLVSG
KLADRLGRKPVFFSGMGLFLVGSALCGLADSVPGLIAFRVIQGLGAGALQPTTLTISADL
YTLRERVAVQGLFTGAWGAGNVVGPLIGGWLVMHASWRWVFLVNVPVGLFAAALLYLSYR
DPPRRPEVRMDRWGPVLAGSSAALLLFSLEPGAASLRWACALAAVGAGWLLVWQQRTTVS
PLLPAELLRDRAVLSGIVGGIAGGSLLYSMAAWVPLWMTEQGGHTPLAAGLALLPMLLGW
SVGSTFGVKLLVRGGMRLSAGVGFAVAALGAGWLSLAAARGWGVPAALMGLAVLGLGLGP
AASTSLIGPQSRAPWHHRGIVTSALYATRLLGGSLAVALLALASGHFALQFGIAAGLTAV
AALGLALLAPGRTEPAASGA
>fig|246197.19.peg.1493 Membrane component of multidrug resistance system
MSGFGLALQRLPPPMHSAAEPTVPRFWPFMFTLFVGSFMSVLSSSTITIAIPELQRHFGA
ELSSVQWTLTGFMLAMGTSAPLTGYLGGRFSFKWVYVASLVAFLVASVLCGVAWDTRSLV
AFRFVQGAFCGAIMPVTMTLIYQLLPRERQALAASLWTLSSMLAPAFGPTLAGWLMTLGN
WRWLFFMNVPLGLAAVAMAVRAVPYYRLEVPKAFDFPGLLTVITGTLALLIALSQGRAWG
WTDSKTVSLAVLGTVSLVYFVVRQLRTHAPLLDLRVLANGRYVVTLLISSIITISLYSGA
FLIPLFLQEIQGVTPLKTGLILLPASLSMALLMPLVGRMYGKLGPSTLMTAGVLLIAGGT
YALSRLTPDVSHTYVLMWMLVRNVGISLSIMPASNAGMEQLSRELSGHASSISNWLRNVF
GAFSIAIFTSLLSSFAAREAQVLAREGMTERRDIELLSFVTGINQVYLVATVIALVAVPL
SLMVRKYVSGLEASRGAR
>fig|246197.19.peg.1938 Multidrug resistance protein D
MSPRPPFLLAILLLSFPQIVETIYSPALPLIATAYRVTPAETGQTLSLWFAAFAFGVVAW
GRLSDLWGRRPALLAGLALYAAGAAWAMVASDFSHLLAARLISAFGAAVGSIVTQTALRD
SHAGPELGRVFAVLGLALAISPAVGLFAGQLLAAKAGHSGVFAALGLLAAFMLGLSLWRW
PETRPATLSVAPFWPTFRVMLRDPGIWRCTLLIAAFNAAIFAWYQLGPFLFAGLENPWLS
FGQSGFLLAAGALAGALMNRALLRRGWTAEALIALGVLLLGAGTALVILLTALLPQSLAF
LSGVTLISSAYAVAIPNVLGIALRAYADRFGTAGAVLSLFYYNLLGAGLVIAGYGQRLDF
ALAVCALLAAIVSVRPMRCRGALSEESPPGGKSRIPCSSSGGGRS
>fig|246197.19.peg.2958 Permease of the drug/metabolite transporter (DMT) superfamily
MPGSKRRLARATPRAYSPAAVSTPTTAVVPAPSRGISASDLAIVGVVIAWGTNYTVVKEA
METLPPLAFMSLRFTIAALAMGALLLGVEGWKPLPRPVFLKLLGLGLVGNTVYQVCFIVG
LANTSVANSGMLTAVTPVLVATLGAVFGVDRLTRPLIAALALGVVGMLLVLGGRGASEHG
ASLIGDGLIVGASLCWAIYTVGIRTVGPEVSALRITAISMLTGAPGVVLVGVPELLRLET
ENIRAGAWAGVVYSALVPLVLAYFTWGRTVQKVGSSRAGLYNTGIPVVAALTAWAVRGEQ
PTWMQVLGAGLVLSGVLLSRRKS
>fig|246197.19.peg.4119 Drug resistance transporter, EmrB/QacA family
MPGHPASSSAEAGGDAPRGSRLASIAVASALFMEFVDSTALSTALPRLSLAFGTDPIHLK
LALTSYILALAVLAPASGWVADRFGPRRVFMLAMSVFLLGSVLCGFSQSLTQLVIFRTLQ
GLGGALMTPVGRIIVVSSAPRERLVAALSWFTMPALVGPLVGPPLAGLILGVADWPWIFF
INVPVGILGMLAVARFVPPLHQPDPGPFDTRGFVLVAVAITTLIGAAETVGIGLMPLSLQ
LGLAAVAFLSLGAYVWHALRVERPVLNLRLLRIDTFRASMIGGTLTRMGLGASPFLLPLL
FQVGLGWTPVEAGLVTIGGGVGALACKSVAPYIIRRFGFRQTLIFANLTSAVLTAMPAFF
RNSTPIPLIVGVLMVSGFMRSMQFTAINTVAYADIPPDTVSNASTLSVVTMQMALGLGIS
FGGLMLHLARGAGEAPLTPDRFVLPFIAVGIMSSLAGPLYRRLSPNAGAHIGGRRVG
>fig|246197.19.peg.4331 Drug resistance transporter, EmrB/QacA family
MKPPGPAPTHVGVGPSFVSESVCARTLSDHPGREAACCWRPPPAAVKEGLSRVGVFMRTT
HRPLTTLALALSLFMAALEATVVSTAMPTVVGELGGIQHYAWVFTAYMLSSTITVPIYGK
LADLYGRKPVLVFGIVLFLVGSIASGLSTSMAMLIGFRTLQGLGAGAMQPVALTVIGDIY
TLEERAKVQGAFSAVWGIAGLIGPITGGFLVKYLTWHWVFFINVPVGVGCLVLLLSYFHE
RVERKPQKLDYAGAALLTGWVVALLVGVQGVGVNLWGLPVAAVLLAAFVAVERKVAEPII
PMSIFKVPAIVISSIAGALFSAAMFGATTYVPLFVQGVLGGTPTEAGGMITPMIVGWPLA
ALVAGKLLLKTGFRPLIVGGLGLTVVGTSLMALLLGPQAPRLLPEVAMGLFGIGMGFAST
ALLIAVQTSVGWELRGVATASNMFFRTIGGAIGVGLMGGVMVSQLLKDPTVPISAANALM
SPDHGQDLPADLLATLSGALGTGLSINFWLICAFTVAAFAAGLFFPKVSRTTTVSSTEVV
APH
>fig|246197.19.peg.4462 Permease of the drug/metabolite transporter (DMT) superfamily
MPSARTVREPQAEVGCAPAGAGVRAGVTRSHTVRYFAMVAAGATLWGCWALFFRPAGLAG
PQNAFLVLLAMSLPAPFLFRRDALRDRRATLAMLVVALADAANTALFFAAMERGPVSIAV
LTHYLAPLLLALLAPWVLGEERSTRALIGGPVTLVGLALLIGRPDGDFSGLTALLGAGSA
CFYAIIVLAAKQAARAYSPMAVTSLHAPISAGVLLLCFGDRVLPPTVDGGTLLVLVGGIV
CGLIGNILFHTGLRHVPTAATAALTYLEPLTASLVGWAFFSETLTPVALGGGLLVLVAGA
WVAAERRATLQAVPLRAAAR
>fig|246197.19.peg.4466 Vancomycin B-type resistance protein VanW
MVSDPGVSFPGAALAECSDMPSPPIAPRLLELSAHALLWRRSKQWMLQANRLVRWSATPE
RWPRPLLAPTHEKGVLLGSHTVNLERSDSDADPVLEAGKQHNVRLAAPAFDGLLLAPDRP
LSFWRTLGRLTERKGYRHGLALSGGCLTPSIGGGICLLANALFEFGARQGWHILERWGHT
MEAVPPPPGALWGMDATVAWPYVDLVMAPREGAVRLGARVSDGKLRLSIHGAEAPRTRSR
LWSEDESLLELAEGTLRINRVVRRVEDTSSGAVLEERTIAENRRRLLNPEARKRTCLTCG
ETACHARVEVPRSEVRAP
>fig|246197.19.peg.4793 Polymyxin resistance protein ArnC, glycosyl transferase (EC 2.4.-.-)
MVISRYHRHATICDPCNWIKTGFSASEPPTSQVRPPRSLVAQYPSISLFFPAWNEEDYVE
RAVSRALEVLPALTDDFEIIVVNDASTDRTREVCEALAQKVPQLRVIHHPVNLKLGGAMR
TGLAASTKDIVVYSDVDLPWDMRELERALHLMSYLEADMICAFRFDRTSEGAKRIIYSFV
YNMLIRSLFDIQIKDVNFSFKVMHRRVLEAMELHSQGSFIDAELVVKAIRQGFRVFQMGV
DYFPRTRGVSTLASPSVITKMVRELVKLYPKMRAPQPPVHPVRLPPSVQQLHAVPPGRTA
RG
>fig|246197.19.peg.5288 Permease of the drug/metabolite transporter (DMT) superfamily
MRRRRLRGRPGCVKKPAAVAAVTSPGEPGVILSGGPRDMSTSTSDMLGGGTEPSSRSQRL
RADGALALITSFWGITFVVVKDALGHGDPFSFLTLRFIVGAVVLSVLAGRQVLIARNLRI
GSMLGTFLFLGFSLQTVGLTTTTPSRSAFITGLCVLLVPLLSMVLYRKAPKFTSLLGVGV
AAVGLYFFTQPDGGLGSGGLSSGDVLSLGGAVAYACHILMTERHAPKQGVMGLVAVQLWT
VALLSALCLPFVERRVAWHPSFVGAVLVCGVFASAVAISLQTWGQARTTAVRAALIYSLE
SVFAALYSVLLGYETLGPREWLGGALILSGVLMSEVGAAAWVWWRARAPAR
>fig|246197.19.peg.5308 Permease of the drug/metabolite transporter (DMT) superfamily
MGAPSARPLTSTSPQSLGPVYAGLMLQVLISAGTYLAGKRAMSELAPLTVVLWRFVLSGS
VFMLLLCFLPGPRLPPRNEWGRVLMLGLLAGPVNQVFFFYGLSQSTAAHAALLYALTPLG
VYLLSLGRGHERASFRAMGGIVTAFAGVVVLLLGRGLADASGSLMGDLLILGAVMSWVVY
TTEGKPFVAIHGPIRATSWSMVASTLMMMLMAPFFAKPEAVLAASSAARYSIVYLGLLTS
VVAYLLWYFALSRVPASKVAVFSNLQPAATALAAWVILDEALHWEIAVGGVLVLLGVRLT
QAAHVRPPAVAPAAPERPPVSSSVG
>fig|246197.19.peg.5977 Glyoxalase/bleomycin resistance protein/dioxygenase
MKKPAVGSVGWMDLTVKDAVAVRDFYKDVAGWSATGLDMGGYEDFVMMPPGGGETPAGGI
CHARGKNADIPSGWMMYITVADLEQSLERVTAMGGRVLGTIRGSAKTGRFCFIEDPSGTA
CALYQSGSD
>fig|246197.19.peg.6668 Multidrug resistance transporter, Bcr/CflA family
MYSHGVPFQQPCFWVRGTFTVRRPEAGYSPGLGPRPRESMTTPSTQSIEKGTLGLELLLG
TLTAFAPLSIDMYLPALPRIAEDLQSTAPAIQLTLASCFAGLALGQLFTGPLIDRFGRTR
PLYAGLALYVLGSLGCALAPSASMLVAMRFVQALGGSVALVVPRAVVRDLWSGANAARTM
SRLMLVMGVAPILAPLLGGMVLQYSGWRAIFVVLAAVGAVALAFVLKSLPETAPPHVGAQ
SMRSRMGALMKDPDFVGPALAGGFAQAGMFAYIAGSPFVFISLYGIPEEHFGWFFGVNAM
GLIAVAQLNRKLVTHLPLHRLLRLALSLCVVAAVAVLAVAWTGFMGLWGIAVTLFFFVSA
MGLVGPNAAAIALERHATRAGMASAALGALQFTAAAGASWAVSTFNNGTAMPMAGVMTAM
ALLAWLAAFFGLRARTRQQEAGEGAQAHGPRIVSSSSAP
>fig|246200.3.peg.1512 Bicyclomycin resistance protein
MQSPPAPSHRSPPALATLILLSGLSALGMNIFLPSLPNMTEYFQTDYRLMQLSVALYLAV
NAAMQVVIGPLADKAGRRPVILWGLVLFLFVTLGCIYAPTVEVFLFFRMCQAVIAVAIVL
SRAAVRDMYQQDEAASMLGWVTMGMAVVPMIGPALGGVLDQYFGWQANFWILFVLGVAAL
ILTYVDFGETALKSGKTLIQQFREYPALLTSPRFWGYSLASGLSSGAFFAYLGGAPFVST
EVFGMEPARMGLFFGAPALGYFAGNFVSGAFSVRVGVDRMVLWGCLMNALGVTLSLVTLL
AGFGSEYSFFGFMTLVGLGNGMAIPNATAGALSVRPHLAGSASGLNGAIMLGGGAALSAW
AGALLSPETGAMPLLLLMLATALLGVVAIFSVIWRARRLGL
>fig|246200.3.peg.1776 Permease of the drug/metabolite transporter (DMT) superfamily
MTQSPDITAKSWAMVATLGFVWGGTFLINELALEGITPFWLAAGRVCFGALLSTLVWRAM
GGRLFSAPLSGSERLSLVIIALLSSAVPFSLIAWGQQYVTAGFTGVSMASIALMVLPLAH
FFVPGERMTWRRALGFAIGFAGVALLMGAQAFESSGAALELPGRLACLAATACYAVASIL
MRRLPAVDPMGLSTVLLLIGVVAVLPMAWIAEGPPPSTDLRTLGLIVFLGMVPTAAANLL
RVTLIRSAGPVFMSLTNYQVPIWSVLLGAALLGEPLPPVLLWSLLLILGGVGLSQYGALR
RLFTRQ
>fig|246200.3.peg.1840 Antibiotic efflux protein
MAAPLVIRNRNFRLLFTAGALTNLGDGVLVLAVPWLAALMTRDAVAIAAVAAAARLPWLL
FALPAGVIIDRSDRRKLIARADLMRAGIVLAILLLALGDPAPGAIWALAGLAFLLGSAEV
LRDNAAQTILPALVDPDDLEAANGQLWSTEQLTGQFIGPPLAGVLISAGIAVPFGLDVAV
LVLAAGLVWLISLPPQVPSRARFAQALAEGIAFMRGDALLLRLAVVLGLANFIAMATITV
QVLFAQEVLGLGAAHYGMVLSAGAVGAICGSLLAPRAMRLIGTQACLFLSIAVWGAGYAS
IGLSNSGWVMGLALTAIMAAAMLWNVITVSWRQRRIPPAMLGRVNSIYRFFGWGSMPLGA
LAGGALVVLAEQQMSREMALRAPFLLAGLCCLALLIYALARLRLE
>fig|246200.3.peg.2378 Permease of the drug/metabolite transporter (DMT) superfamily
MSDQKTLSPRAWAELLLLGLIWGASFLAIRVALDEVPVVTAVLHRTFWAALLLWLVVWAS
RIALPRDPRVWGAFLVMGLLNNVIPFGLMAWGQLYIETGLTSILNASTAIFGVLVAAAVF
ADERLTPRRLLGVSIGFAGVVITIGFEHLTRFDPRSTAQLAVLAGTLSYAFAGAWARARL
GGLAPQLAAAGMLTGSSLILLPAALLIDGPVTLSLQPVTWAAIGYYALVATAGAYLLYYR
VLAMAGAGNLMLVTLVIPPVAIGLGAWIRDEALPANAFGGLALLALGLMLLNRRPRRRD
>fig|246200.3.peg.2834 Bicyclomycin resistance protein
MGWSGARDRDSADLPSKPPDPLMRHASNPPHLITLVLLTALSVLTLNMFLPSLAHMGQDF
EVDYGLINLAIAGYLGVSAILQLIIGPLSDRFGRRPVLLIAMAIFLVASIGCVLAGSIWV
FLGFRLLQAAVVAGPISSSASIRDQYPPNEAASKLGYVAMAMALAPMLGPMLGGALDMLF
GWRAGFVLYSILGAVMLALLWVDFGETNTERSVTFKAQWQQYPHLFRSRRFWGYALCASF
SIGGFYAFITGAPLVAAAWFDLSPALLGLGIGIITGGFMVGNFVTGRIAARTRLTTMILL
GRIIASTGPAIGLILFLTGAGSVWVFFGSAVLVGFGNGLTNANAVAGLMSVRPRLAASAA
GLSGALTVALGAVLTTVTGIVVSAENAPFAVLGLMSGSSFLGLLAVLYVRWVDLREPLPD
T
>fig|246200.3.peg.2871 Drug/metabolite exporter family protein
MCRTRPSCGRMEEKRPVDAAGAVALIGIAALLAFNQVVIKVTGGGFGPLFQAGLRSALGL
VFVLIWMRLLRKPIVFPRAALMGALITGLLFTVEFMALFAALDLTSVSRVSILFYSMPVW
LALGGHFLLPGERLSGMRVLGLMLAMGGVVLALLERDAAHVSLLGDALAVFAAMCWAAIA
LGVRLTPLGRVPAEMQLMSQLVISAPLLLVLAPLTGETLRTPGLLHWAGLLFQAVGVVGL
GFLIWFRLLAVYRANGVASFSFLSPVLAVILGWLLLGEQVGPLVWLALGLVAAGIVLINR
R
>fig|246200.3.peg.4191 Permease of the drug/metabolite transporter (DMT) superfamily
MDLRAIAMGLAFAFMWSSAFSSARIIVADASPLFSLACRFLISGLLGVIIARAMGQTWRL
TRNQWKATIVFGICQNALYLGLNFYAMQTVEASVAAIIASTMPLLVALASWGLFGERLPA
LGIAGLLAGFLGVALIMGARIGAGVDLFGVLLCGLGALALAAATLALRGATSGGNFMMVV
GLQMLVGSAVLFLATPIFETVHVTPTLPLALAFAYTTLVPGLTATFVWVLLLNRIGAIRA
ATFHFLNPVFGVAIAAALLGERLGALDAIGVAITTAGILAVQLSRQASARKP
>fig|246200.7.peg.100 Permease of the drug/metabolite transporter (DMT) superfamily
MVLAILLSLLALVLFDMMGLIIKYLSPRYGAAELSAYRNFFGVFPSVIALWSSPGWHRAG
RPWRIRQWRLGLMRGVYVTFAQFLFYYSLGKLAFATASTITYANAVFMTALAVPLLGERV
GLMRWAAVLLGFAGVLLVMKPGSDSFTPDALAPLGAAFLYALTGVSARQMDSAVPSALIN
LYSVVAALVGALALALLSGGFTPLAQWSDLGWIAAMGGFGGTAVLCLVASYRMTEQSNLA
PFSYFGIPIAFVAGWLVFDETPWADLFPGAFFIAGGGLMIVWRERIRSRAGRRISN
>fig|246200.7.peg.1464 Permeases of the drug/metabolite transporter (DMT) superfamily
MSLWIPVTLAAALFQTVRFMLQKSLATVKLSASGATFARFLYSAPLALAGLLIATTAGGY
DLPALGARFWIFVAIGGTAQILATICVVALFKQRNFAVGITFKKTEVIQTAIVGFVILGE
GVSFGALGAILLGLVAVLLLSKTPGGSGAWWRHLTNRASQLGLGSGVLFAFSAVSYRAAS
LELGDLTPWFRALVTLAAVVSFQLVSMALWLWWRDRAQLAAVWATRNTGAFVGLTSLGGS
FCWFLAFTLQNAAYVKALGQVELIFSLMASTLFFREKITTREIAGIGLLGLSILALVLAI
>fig|246200.7.peg.1547 Acriflavin resistance protein
MSEGSQNTPLGIAGGLTRGFIGSALTPLMILAALAMGLVALISLPREEEPQISVPLVDIH
IQAPGLKAEDAVKLVTEPMETIVKAIGDVDHVYSQTGDDYAMVTARFLVGTPADTAILRV
HDKVRANMDRIPVGIGEPLIVGRGIDDVAIVSLTLSPRDGAGDVSANDLTRIARELQVQL
AKIGDVGLTYLVGEAPEAIRIAPDPERLALYGVTLQQLAAKVEGANRALATGLVRDGGEQ
IALVAGETLHAPAEIANLLLTTRDNRPVYVRDVADVRFVPDTSERIVANVTRDDSGGFRR
SPAVTLALAKRAGANAVVVAEEILHRVHLLEHDLIPDSVEVTVTRDYGETANEKANELLF
HLGLATVSIVVLVLFSIGWRESIVVAVVIPVTILLTLFAAWVMGYTLNRVSLFALIFSIG
ILVDDAIVVIENIARHWAMPDSASRTQKAIRAVAEVGNPTIVATLTVVAALLPMLFVSGL
MGPYMSPIPANASAAMIFSFFVAVIITPWLMVKIAGRAPAHAHDAAAQHGGALGRLYRAV
ARPLLRTKSGSGLFLLVAAVLSFGSLGALYTRDVTVKLLPFDNKSELSVVIDLPEGASVE
DTDAVAQQVARRVLELPEVISAQTHAGDAAPFNFNGLVRHYYLRARPELGDVQINLLPKD
ARTRTSHDIALDIRERLSTLDLPEGTVLKTVEPPPGPPVIATLLAEVYGPDADSRRAAAT
RIREAFESVPFVVDVDDSFGTQARRLRATVSTDQLEFFGVQERDVFSTLAILNAGQTVGY
SHRGEGRRPIPIEVARDSADRVVDERFLSTPVPANVLPGARGVVELGDVVELREERASYP
VFRHNGRAAEMVMAELAGDFEAPLYGMLAVAEALDAMDWPEGGKPQIRLNGQPEDESVIT
LLWDGEWEVTWITFRDMGAAFGVALLGIYILVVAQFGSFRLPLVVLTPVPLTFLGIIIGH
WLFNAPFSAPSMIGFIALAGIIVRNSILLVDFIRHANPERDKIETLIEAGAIRFKPILLT
AVAAMIGAAVILTDPIFQGLALSLLFGLLSSTLLTVLVIPAIYRVFKT
>fig|246201.1.peg.1787 Permease of the drug/metabolite transporter (DMT) superfamily
MSSGWITSMRLTLAGSLVLIWSAVQLKSQVLDIWRDKKNYLPFLAYAILGIFSVQYFFYL
CVEYSNAATATILQFISPVFILFYNRLVYQKRASKSAILYVLVAMLGVCLMATKGDLSQL
SMTPLALVTGLLSAMGVMFNVILPQPFAKRYGFVPTVGWGMILAGLFSNVLSPVYQLSFT
PDIWSILICLIIAFFGTAFAFFISMKAVSLVSPLVVSVISASEPLSSALLSVLFLGLVVD
WSLLLAMALIILPMIFLSIEEAKESK
>fig|247156.1.peg.887 Permease of the drug/metabolite transporter (DMT) superfamily
MASGLAFASSGPLAKSVLAAGWSPGAVLAVRLTGAAAVMLVAAALADPRGLARSPRHLRT
IGGFGVVAVAGVQATFFLSLQHLQVGVALMIQFLAPVVVIAWDWVVRGRRPTPLTLLGAA
VALGGAALVIDVFHTEGLRPVGLAWAALSMLCNAAFFLLSARTSDSLAPVTLLGAGLGVA
AVTSWALGLSSVLPLHFGTGTAVLAARELPVWAALALLITISTVVAYACGVAGAARIGST
LMSLVLLSEVLFAVALSRILLGEAIAPIQMVGALLVVGGIALARSGGQRRPAASEVPAPG
PQAT
>fig|247156.1.peg.1442 Drug transporter
MTTVSQRTQRPPNLARRTLLIACGATFIALLDLSVVNIAFPSLARDYPDTPVTTLTWVVS
GYGVAFAALLTPAGRFADALGRRRLFLIALAAFALTSLLCGLAPDAATLIAGRVAQGAAA
ALMMPAALGLILAVTPRERIGAAIGAWSAAGSFAAVVGPPLGGALVEAFGWRAVFVVNVP
IALALMLPARGLPETGLRPPGSGLPDPVGTIAVALGLGGLVVGVTEGQRWGWTAPTTLLA
LGVGAALVAVAIARSARLTVTGRAAGAALAVGLWRSRPYALANAASFVFAGAMYSWLMAG
PLFLDAVWGYSVLGSAGAMTAGALTSMITATAAGRITAPAVRRWAGVLGALLFAAAALWM
SSDSFGPDPALWTAWIPAGVLGGGGIGLVLTALGTAAAAALPPEQFAAGIGMNLTARQVG
GALGVAVMAAVLAAHPGDALTGLHTHFAVCAAIAALTAVLTALPSRQEQP
>fig|247156.1.peg.2923 Multidrug resistance protein B
MSSSVETGTRPDPDAMTHREVLEAMTGLLAALFTALLSTTIVATALPTIIGDLQGSQTAY
AWVITTALLANAASTPIWGKLADLFNKKLLVQLSIVIFVAGSILAGVAHSVDVLLAARVV
QGIGMGGLTALVVAIIGSIVAPRERGRYSGLMGAVMAVSMSGGPILGGVIVDSPLGWRWC
FFVCVPLAVIALFLLQRTLRLPTERKDDVSIDWLGAVLLTAGVSVLLIWVSFAGKAGYYD
WVSRESVLYVGGGVLLLAATVWVEARAKAPIIPLKIVTERTTGLAIIASIAVGVGMFGAT
TFLGQYFQTSRAYSPTIAGVLTIPMVAGMLVASVVSGQMITRFGKWKSFVVSGAALMVVG
FSLLATIDHATNLWLVGIYITVIGLGMGMMMQNLVLAVQNTVSVQNIGAASSSVAFFRTF
GGAIGVSVLGSVLATRVSELSAEGFARLGIRPSGEGGSNLDLSGLPAPVLDVIRASYGDA
TGRIFLIAAVATFVALLAAAVLPNRPLRRTIDIDPAQDPMRTGVPAAPEERDGVELEKAR
TS
>fig|247156.1.peg.3258 Multidrug resistance protein B
MTSSTPKPSPETTASVAEMPVSEQDSGWRGLFSRPHRTAVIVMAGGVGLYAMNLYFTAAL
MPTVVGELGGQQYYAWAATAYLITAVTATMIVSRMLAVRGSGGSYVVAYLLFAGGTVVGA
GSPTMEFFVAGRAIQGLGAGLLTGLGYATIRRVLPPQLWTRATGLVSAMFGVGTLLGPAL
GGVFAEGGAWRAAFATLTGIAILLLLVTVRALPTRRPEEATRTPVPVASILALALTAALL
SLRSALSGVWVPVTVAAGLLLLIAFFVIDSRDPDGVLPRLAYTPGNPLKWVYVTVAALCA
GVMVENFIPLFAQQLADATPIVAGLLGAVLSLGWTLAQLFSVAAAERTARILVRTGPVLL
TAGLAAYGLLQADGAGWLHLTVWAVLLFVAGAGIGLAFPHLSVAAMRAGKDEAEGAKAAA
AVSTTQLIAFTLTSALAGNLLALGGDSPLASARWLILGIAVLTAIGVATALVATRTATTR
SRLHQW
>fig|247156.1.peg.4681 Probable multidrug resistance protein norM
MTPFGPDTRRLAALATPIALTQLAQIAVSTTNIALMGTLGVGAVAAGGLALVLFNQIRTM
CVGLVTGTGNQVAAAVSAADKRGDSPAGEVREIVRASFLVATLAGLLGGAVLIGLGWSLQ
WLGQDASVLAEARPLLVALAPGLLPCLWFQVLRQYTVGMQRPQALLLVTLASIALNLVLA
LAFIHGWAGVPALGLTGVGVATSLVFLITFGVFWAMVRHDERLGAMLSVRPWPVRGRTVL
AELRLGTPIALTYGSEAGMFSVLALVMGSLGPAALAAHNVVYQIIYIVFQVAIGLSHGAS
ILVSHAVARDEHAHARHVAWLALRYAGVVAAVTGALYVLAPQLVLRPFLDPADTATLDIA
RALLLIGIVLQFFDAAQNIGTGLLRGLKETGAGFRLSLIGYWLVGLPTALVLALPVGLGA
PGVWWGLTAGLAATAILMVRRYFVLLDGLALPRPRPLPQAVGTA
>fig|247639.3.peg.1038 Permease of the drug/metabolite transporter (DMT) superfamily
MTGPRYMLLSAFAFALMGAMVKIASAEGLPLLQIIFVRAIISVLLCLIAIRRSGSNPLGR
QRGLLLARGVVGFMALTGVFYAFINLPYAQATVLQYLHPVFTAGLAFWFLSERPTPATLI
CIALSLLGLGCVVYPYLQSTNTSVMPIAAVLAGLGGALGSGIAYTLVRKLATTEHPSVIV
LYFPMVCVPATLLLGAGDFIWPSQIGWLTLLGVGCFTQLGQISLTKAMQTDSASRATSLS
YLQIVFAASLGWLLFKEVPATATVIGAAFILFGALISAALQPNPDKKRGAGNA
>fig|247639.3.peg.1525 Acriflavin resistance protein
MKGLISWFVRNPIAANLLMFSLVVGGLLGLIEVRKEEFPNIDVPTITVSVPYLGAAPSEV
ETGVCIRIEEAVQGIEGIEKIKTQAAENRCVVALELTNASYQDRALDDVKAQVNAISTFP
ANTERPVVALVSLRSVVMYIAVSGETDERSLKNLTESLREEILEIPSVSLVDTMYVRPDE
ISVEIPEFTLRRHSLTLGQVAEAIRQSSIDIPGGSIKTESGEIRLRGTAQRYSGRELEDI
PIITNADGTRVLLRDIAVIRDGFEQQDLSAMLDGRPTQLLKVWRLGKDNTLAMARDLSEF
LEVKQRSLPSGLELRIWSNEADELVSRLSTLINNATGGLLLVILTLALFLRLRLALWVTA
GIPVSILGAIAFFPSADLGISTLSLMGFLLSLGILVDDAIVVGERIHTHEGFTPDSREAA
INGTTEVAIPVFFGVLTTMAAFIPIVTVDSMLGSFFGAIGWTVLLCLVFSLIESQLVLPA
HLAHRNRERGKSAIGARWENFQENVSGGLERFAQQRYQPALRLVLKYRYVTLGAAVAALI
IIVGLLASGRIVFQFFPTVSGNEIYASVELPEGYPVERTATALEVIQASADQLIVELNEG
LPEGATAVVNQFKTIGLPISKSTISGSEESGSHIAEMSITLYPHDERGGMTPKQAAKRWR
ELTPDIPDVIEKSFTASAVSLGEDINIQIRGKDLEVMSAAASALTKILSSFDAIYDISDS
YRAGKQELVLRVRPEAESLGLTQADLGSQVRHAFYGAEAQRVQRGRDDMRIMVRYPEADR
RSLDDYNQLYIRLPNGAEVPIESVASTQLSTGNATIRRVDGQRTINVTAYADRTRIAPET
VLRLVEDQHIPRLEAEFPGTTFSLAGEAEERASALTGLARTSLLALIIIYTLLAVPLKSY
LQPLVVMASIPFGLIGAILGHFILGYDLVFFSILGIVALSGVVINASLVLVDFINKRRLN
LEITVAEAVTRAGVARFRPIFLTSVTTFVGLAPLMLNADLATAPFVPLAVSLGFGVIFAT
AVTLLLVPALYLILDDFSGPPDNETNTDHGSKQGEA
>fig|247639.3.peg.1607 Acriflavin resistance protein
MQGPLSWMIKNPIAANLLMLLLIVGGVLTTPSLDKQFFPTAQINQVSVTMPFPGAGPAEV
EEQISVRIEEAIHDLNGIKEIRSTAVQGLGTVMVEATQNYPMQRLTSDIKTRVDAINSFP
ADAERPIVTEITYRHLMTVVQLSGDLDEYELKELGEALRDDLARQPWVSMVDLITARPYE
VSINISETMLRRYGLTFDQVVAAIQGTSLNLPAGAIKTQEGDVRVQTRGQAYGRADFERI
TLLTQTDGTELLLGDVAIIEDGFVDLDLNVTFDENPALGLRVYVTSNPDVLKTNQVVKDW
VAEQQLSLPPGVSLTIWRDISKSFRGRVTTLLENGIGGLLLVAAVLVLFLRPKLAFWVGS
GIAVAFLGTLFMLQFTGISLNMISLFAFLLVLGIVVDDAIIVGESIHTHQARGERGHVGA
LLGVRGVFKPVMFAVISTMIFFVPMLLLPGDWSTAARSIPVVVLLALAFSLVECLLILPA
HLAHLGPEKEPKTRVMQRLAGWRQACASGMVWFARYRYRPFLRWALSHHYAAAGVFLVAF
SMSIALYGGGWVRSAFFPKVNSDYVVASVEMPEGGPYSDTVALRDRMVAAAQVLKADWNA
RPEFFVTPAISHVSATTNDNKINIEIGTVSEGVDTEQIALDFRDLVGPVPQAKEIRMDFT
IQDPGKQIKLLFASRNTEDLEGLAPRVRAALLAYPGVFDVSDSFDSPRDEVVLDLKPAAE
ALGVTLASVAKQVRQAFYGAEAQRIPRGREDVKVMVRYPESERRSLANLDEMYIRTPTGK
EVPFGTVATYRIEPGYQKLERLNRMRTLEIGADVRADGASPRAVVDGIVVNKLPLWQQEY
PGLELNLDGELQEEAEFKSSMLMFMGLAMLVIFGLMAIAFKSYWQPFLVLTAIPFGIMGA
IFGHALLDWEVSIFSMMGVIACAGVVVNDNLVLIDRINHLREQGYELWDALLQGAEDRFR
PIILTSLTTFVGLLPIMSETSVQAQFLIPMVTSLAFGVLFATGVTLVLVPALYLVGDDVT
GFLQRLLGGDKVSAATDSSVVTTAH
>fig|247639.3.peg.1700 Permease of the drug/metabolite transporter (DMT) superfamily
MILRSYYWLLLASTLLMASAFVVSKLFIVDGIHPLVLVASRFTLAGALAIIWLSLRRQLE
TPKTLSDVGGVFLVGTLQTAVLFGTGFIAMEHLSAATISLLTLTMPIWVTGMLALMNRKF
PPLLQLIALGVGMAGVALIIGSGVSEAGMGELQWFALALVGAACWASATVFTKTSGLSIT
GWSLNAWQMLVGGGEVLILALAMDLPGIKLVLVSDILLFIWLVVPASILSFGFWFSALKL
GGAAVTSGYLFLIPLFTALISVPVLNASFAPMQLLGGVAVAAAVWLMSRSST
>fig|247639.3.peg.2328 Glyoxalase/bleomycin resistance protein/dioxygenase
MSVEVIASEKAEAADSLWGLALKTADIDATHQRLNEAGVEVSEVRDGRKKDTRVCTVKSH
ALNVPTLLIEHPVK
>fig|247639.3.peg.3295 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MAAAKLMTVTLFRREMRQLLRFAFPLFIAQSAQMGTGVVDTIMAARYGEQDLAAISIGIN
IWLPVYLLILGTVFATATIVAQDFGGGRIEKIRQQLPQSLWVAVFLGLTLSPAIWYAGPI
LDLLGLNPTTRQLALDYAQMVALGMPATAIFQALRYHTQGLGITQPFAFAAVAGFLINVP
LNYAFIFGEWGAPELGAKGCGIATAISMWLSVFLIGAYVLRSKKIRLYLPEWKPVAPDWA
KIREILSVGAPIGLTFFLEMGVFSVIALLVASLGDTAISAHQIAFNVWDLYYIPMLAIGT
AMSTRIGHAIGAGWREGIYRAMIVGGAISAVVAIGTMLILLSFPGAIIGIYTDAPDIQLL
ATRLLTLSAFFILIDGAQIVGSFILRAYKETQFPFIMMVVSYWLVALPLGWWLGIEVPDN
PNDGAAGFWYATITGISVCTVLIGARIWVILRRELPSTAAE
>fig|251221.1.peg.268 Drug resistance transporter, EmrB/QacA family
MKTRRPSFGRYHRKCALVTGDSVVQYQRPIDYTTALDERTKRLVMGAVLIALFLTSLDQT
VVVAALPKIVADLGDLDLLAWTSASYLLVSTTSLPILGKLSDLYGRKNILLIGIAIFLLG
SFLCGLAPSMLMLVVFRGIQGLGAGAITSVALTIPADLYVPAERAQLQGIIAAVFALSSI
VGPLLGGVLTDTLGWHWIFFINLPFGLLALAFIVAFMPRLNSGLTRSIDYWGAVLLMLTV
VPLLVALSLEKEKYAWDSPLVLGLLAAAAVSFGLFVFAELRAKEPILPLSLFRIPIFSLI
CAMSVMVGATFIVAILFLPVFLVNVMGASATEAGVALIPETLGLLVSSFISGLVVQRTGR
YKAAMLVGLVLMSIGIFLLTQLSLTTTIAQVWFSIAIFGLGAGATFPQANLALQNAVPFE
YVGVATAGRLFFAQLGQTVSAALYGALLVAYLNTALVDSLQPVAARLPASLATHLDPGRL
RNGGEQAAAELAALGTEMAPRFTPEVRRRTEAQVRTAVRRSFAEAVARVYQASLPLPLIA
LLLGLLVPELPLKRSNSPDTPPAAVHE
>fig|251221.1.peg.2822 Drug resistance transporter EmrB/QacA subfamily precursor
MTKQVARNTTRDLGAQPDNKWAILLAVSIGTFLVPLDITVVALALPDIESSLRTSFADLQ
WIINGYNLSFTAFLLAAGTLADRFGRRRLFLVGLALFTLTSLTCGLATTPLTLTLARSIQ
GLGGALLLISSLAILSQTFREGPERANAFGVWGLVMGVGASLGPMIGGLLVDLLSWRWIF
LLNVPIGVGLVAFTLSKVDESRDPGAARVDWLGLTTFTSALFSLCFALIQGNELGWTSAA
ILGLLAAAAVLLFAFALIERRQSQPMFDLSLLGNPAFVGTSLLAASNGASFWAMIVYLPL
FFQNVLGYSPLQAGLMLLPLTVPLLVCPPLGGRLAQVLPARLLLSGGMLMVGLGFVWMYG
VNAGSPWTAFLPGFLLAGIGAGLINAEIANVAIAVLPPQRSGMGSGITSTFRHGAHALGI
ALLGSLLTQRVATSLEQSTLPGLVTERSTQLASQIAAGDLIGVVRTLPPELQNAFAAAAQ
NSFIDGFNLIVLLAAATALLGALATFVLVKDQRSQSQLQRQERPSASKS
>fig|252305.5.peg.1593 Multidrug resistance protein B
MPSKTEHPVTPPPDLPGPDAATLRVLLITVATTLFLASTGNTIVTTALPRIVSDLGGLAY
ISWVVTAFLLASTVGAPIAGKLGDMYGRKIVLQVAIGVFLLGGLICGVARSMEVLIAGRF
VQGLGGGALIVVSMAVVADVLPPRERGRVQGALSSVFGFSTVVGPLIGGFLVQTVGWHWI
FFVNFPIGVVAFVILTRTLKSSTEKVPHKMDFVGSALLLILLSSVVLIANLAGSVYAWTS
LTVLFLLALAPMALVGFVSAERRAAEPVMPLDLFRIRNFQAANSVNFLVGMAMFGTIAFI
PMFLQVVKHVGPVSSGLYLVAMMGGLIGTSFAAGRVISSTGRYKVMPTVSTAVLAGAMLL
LTTINPETPLAVITLYLFLVGAGIGPTMSVGIVSIQSAVPREHLGVGTASANMFRLIGGA
IGTSVFGALFTLGLGRHVQPLMPQVQEVRELTSAMVDRLEPAAQAAVLQGFSDALMPVYF
VGAAVAAIACLASTRLVELPLGPVPRDRRGTPAE
>fig|252305.5.peg.2558 Drug/metabolite exporter family protein
MRAMRKDHLDPAGFAALVLFTTVLAGNQIVMKLTNAGLSPIFQAGLRSLLACLVVLAWVR
VRGLGLGPFRRNFWPGLALGLFFSIEFAALYTALDMTSVSRASIIFYTMPMHLSLAAHFL
IPGERLTPQKVAGLVCAFAGVVIVLADRSGGEASLLGDVLALVGALGWAAIALTVRITRI
SEAPPEAQQIWQLSVSAVVFLAIAPLFGPVLRDPGPEHIWLMAYQVLLVASLGFLAWFYL
LKRYPAATVASFSFLTPVLAVFMGWALLDETLRWSVLLSLTLVSVGIVLINRKPRARGNG
RARAAATPPT
>fig|257309.1.peg.1871 Sulfonamide resistance protein
MLRSRVTVFGILNLTEDSFFDESRRLDPAGAVTAAIEMLRVGSDVVDVGPAASHPDARPV
SPADEIRRIAPLLDALSDQMHRVSIDSFQPETQRYALKRGVGYLNDIQGFPDPALYPDIA
EADCRLVVMHSAQRDGIATRTGHLRPEDALDEIVRFFEARVSALRRSGVAADRLILDPGM
GFFLSPAPETSLHVLSNLQKLKSALGLPLLVSVSRKSFLGATVGLPVKDLGPASLAAELH
AIGNGADYVRTHAPGDLRSAITFSETLAKFRSRNARDRGLDHA
>fig|257310.1.peg.62 Permease of the drug/metabolite transporter (DMT) superfamily
MGERLVRCCPYQPRRRDPVASHPSSHYVSTAIASPANVGRVYLQLLLVMAAWGVNLVAVK
YLTFHMDVQVVAAVRIVVAFVAVSAILLWRLHGVPRLSLRQFGWLACAGLLVVYAHQILL
VNALRLTPAANATLIMATSPLFSVVLAAFFYRERLTASRIGGAALGLGGVALVVAGGDGV
LASVGRGDVLALCAVIVFVIGGLIIQRVSRALDPLTILWYMYLVGAVTLSAHAAFSPATY
LASSWTLEPWPWLVVLFSSVIASGVSNLLWNAGIARLGMSRAAMFVNWLPIFGLLAAAVF
LGERITALHFAGLACVLSGTWLGLRTAPAPAAGQADARPARARRA
>fig|257310.1.peg.118 Multidrug resistance protein B
MSAPPTQDPEITTTTQESPHSRRDLLRAMAGVSATVVLVAFDSTIVTTTLPRVAAALNGM
ALYAWVGTAYLLATAASILIFGRLGDMYGRKPLMLVSVSLVALGSIACGLAQSMPQLIAF
RTLQGIGGGMMIATAFAAPADLFPDAGQRVRWMALVSATFAMASGIGPVLGGAATQALGW
RAAFFISPLAAVAALFLLARYFPRIRPAQTASRRIDWVGGLLLIVVVGAPLAAIELAFAP
GDGAHPRVALALAVAGIAAVALLVPIERRVRSPIFPLRVLAGLEPRLLNLAAVAVGATMF
ILIFYSPLLLQHELDYSPSEAGLLLTPLVAAISFGSIINGRLFPRQTEPQRLMVFGSCLL
AAGSAMMLAVSAGTSAWWIVAAFFVNGTALGFLLPNLTLFMQMLSERRDVGVASALVQTT
RAMGSAAGTALVGIAISHSSVLDGVRAGLILCVLLSLFSAVVAHRVKMKNVAATPAA
>fig|257310.1.peg.3048 Probable antibiotic-resistance protein
MIVDMRLRPPIPGFARSTLYQAGPKTSHPDFPVEPSVGQCSLPLLISEMDAAGVAVGVVP
GRYSMEPFGIVSNDELATLFADHPGRFVGFMGLDLGWPMQRMLDEIDARVGTPGFRGVAL
EPTISADASFCGMNDKRLYPIYEACVKHGVPVSVTLSAVLQAFTKRPYEHSNPVQAYQVA
IDFPSLDIVIAHAAYPWVMEMIGVCLTCPNVWLSPDLYLTNVFPGAQEYAKAAATYLPRR
TLFGTGYPAKPFKPMIDAYAAWGWPQDVVAAILGGNAARLLRLADQ
>fig|257310.1.peg.3064 Inner membrane component of tripartite multidrug resistance system
MKLPTADEAVFSIKCYLGAMLALYLAYSIGLPRPFWAMTTAYVVAQPWSGAVRSKAVYRL
GGTFFGSAMTIYTVPRLANYPVLMTLAMVLWVGLCLYIAVLDRTPRSYLFMLAGYTAAMI
GFPSVTDPALVFDTALARVEEISLGIICATLVHSVVLPRGIGRAMMGRLDATVRDARSWI
QDVLNQRGAAQHARDRRALANDITQLRLLSTHVPFDTGNIRWTANALRAMQEHITALTPA
VSAVEDRLQALQAQGRALPPPAARVLADISAWMDDSAHATREQAVQLRAALTRLAPAIDR
QSGWHDALLASLVARLRELVDSYDACLVLRQDIHAGLGGAPTGRTRRLTRGAALHRDHGL
ALLSALAAALAISVCCLFWIGTAWTNGATAAMMAAIFSCFFAAQDNPVPGIMQFLTYTIY
SIPLSALYLLGIMPALHSFEMLALAIFPVAFVTGVYIARPTTTGKAMAVFFGLSGTLALQ
DTHAADLVSFVDTIVAQIIGVAVAAIIAAVFRTVSAEWSARRIQAANWKELAALAGAGRA
PARLDFTARMLDRIGLLQPRLALSKRRDDQLADDALQDLRVGKDIAELQRARRHLPMADP
AIQPVLRTLAGLFRKRPGRLGGERPAELLQTIDRALYSVSNTPVAHAARERAVVALVGLR
RAFFPEAAAYRPGRDVESPAS
>fig|257310.1.peg.3067 Outer membrane component of tripartite multidrug resistance system
MSIRSLLPLIPALALAGCAAVGPDYRLPEQAAAKRPAAAAPFVQAREQAVYRQDELPPHW
WRLYQDRQLDSLVEQALAANADLRVAAANLERAQAVTRQAQARQQPTVDVSAAPAFGHAS
GVQELQPGLRPQDSWSYSGGLGVSYQLDLFGQIRRAIEAAQDDAQAAQAAYDAARVTVAA
ETARAYADLCAAGMQLDSARHSVQVQQQSVDAVQRLLAAGRGTTLDVARARSQLEQLQAE
LPPFQAGQRTALYRLAALTGHAPAELPQSLLACVRPPRLAQAIPVGDGAALLRRRPDIRQ
AERSLAAATARIGVATADLYPKISLGLSGASAGPAALFGEPGTFSWSVGPLISWTLPDTG
AAQARIAQAEASTKGALARFDATVLNALRETESALVTYARQLDRDAALRAAREQGAQAAA
QARQLFRLGKTDYLTVLDAERTLAGNESALAASQAQLAGDQIAVFLALGGGWE
>fig|257310.1.peg.3565 Multidrug resistance ABC transporter ATP-binding and permease protein
MKKPQNLAGAGRREVPAEWRDAIHSHLDAGETVLAWLETDLDARLRFETGMVLATDRRIL
ACAPGRREWSSWPYSPDLRLALHDHAGAASLELDAGARRLASWRFTLGRNPAAQRLLEQF
ESLQALRLAGAAPTAGESPRPCPTCQAPIPADREDCPECSQEPAAPPATWALLRLWRFAR
PYRGALLAGFLLTLLGTAATLVPPYLTMPLMDDVLIPFQNGAPIDYAKVRLYLAGLLASA
VLAWGLGWARTYILAWVSERIGADLRTTTYEHLQQLSLEYFGGKRTGDLMARIGSETDRI
CVFLSLHLLDFATDVLMIAMTAAILVSINPWLALATLVPLPFIMWMIHVVRDRLRHGFEK
VDRIWSEITNVLADTIPGIRVVKAFAQERREVQRFREANNRNLEVNDRVNTVWSLFSPTV
TLLTEIGLLIVWIFGIWQVSQKHITVGVLAAFLAYIGRFYTRLDSMSRIVSVTQKAAAGA
KRIFDILDHVSSVPEPHKPVHLPRVNGHIELRDVGFRYGNRSVIRGLDLSIAPGEMIGLV
GHSGSGKSTLINLICRFYDVSEGAVLVDGVDIRSLRIADYRRNIGLVLQEPFLFFGTIAD
NISYGKPDATRAEIIAAARAAHAHEFILRLPHGYDSLVGERGQALSGGERQRISIARALL
IDPRILIMDEATSSVDTTTEKEIQKALDNLVRGRTTIAIAHRLSTLRRADRLVVLDRGQI
VEEGAHEALMAREGAYYRLYQAQQTRQAEGGDDGSDAIAAIA
>fig|257310.1.peg.3706 Permease of the drug/metabolite transporter (DMT) superfamily
MNRAAFDRVGLGLMLLTIFVWAGSWIAMKLVVPYIGPFDFIAVRYLSGAVVLFSILVATG
RPLGMPPWKLTLLAAATQITGFQGFVQTALISGGVGKVSLMAYTMPFWVVLFAWALQGER
PTARHWGGIALAAVGLVCFLDPWAGLGDLAPVALGLCSGLCWGLGTVLSKRMFERHAPDI
MTFTAWQMLLGGVVILPFAWLVPQIPAQWGGWRLWLGMSYIVLVATALGWILWLLVVRRV
PASIAGLSSLGVPVVAVLLAWAILGERPTLTEMAGMALILFGLWVVSRAARPAPRAVS
>fig|257310.1.peg.4251 Polymyxin resistance protein ArnC, glycosyl transferase (EC 2.4.-.-)
MFMYTEFRSQLLAGAGTSAAGQSARMAVLAGDGATGVQVSCVVPGLNEAANLRVLVPALR
ACLEQWCASWEIIVVDDGSTDDTAELMAQWSAVEGIRYVQLSRNFGKEAALTAGLEAADG
DAVICLDADMQHPPELIGDMLAAWRNGAEMVYAVRRQRDDEPWFKRVGARAFYRLLSTAR
GVEVPPHAGDFRLMDRRVVEALVALPERTRFMKGLYAWVGFKSQAVPYTPQARRHGASHF
SAWKLFRLACDGLTAFTTWPLRLVSLIGVLFALLSLSYGGYLVADYLISGNAVSGWTTIV
TALLFFAGINLISLGVVGEYVARIFDEVKGRPLFIARQRRGRAKRAAKARSQ
>fig|257310.1.peg.4422 Multidrug resistance protein B
MSADPATAAAPPPLANPDAARAARMIPFIVGCALFMQMLDSTVVATALPAMAAALGSTPV
RLNVAITSYLLAVAVFVPISGWAADRFGARRVLIAAIALFTLSSVGCALSQNLGQLVVAR
IVQGMAGAMMVPVGRIILLRTVPKQDLLKAMSFLSIPALLGPVIGPPVGGFMVTYMSWHW
IFLINIPIGILGIALVLRFVSEIREENAPRLDLPGFLLSGICLAALVSAFEALGHGLLPP
LELGALIAAGLLCGVLYVWHSRRVEHPILDLSLLRTPTFAISVLGGNLCRFAVGAVPFLL
AMLLQVGFGLSPFAAGMITFASAAGALLMKFVATPIVTRYGFRRVLTINAILTGLFIVAC
AAFTPVTPAWAMIAVLLAGGFFRSLQFTAVNTLTYADIGPERMSRASSFAAMAQQLGISL
GVGVAAVTLNVSMAARGAASLAIGDVVVGFMVVGALCMLSVLSFRRLAPSAGAQLQNVKV
PRDGK
>fig|257310.1.peg.4672 Probable antibiotic-resistance protein
MKIIDFRLRPPAMGFLNARIYTRPDIRNRFTRQLGFEPAPSAEEKSLELMFEEMAAAGIE
QGVCVGRNSSVLGSVSNADVAAVAKAYPDKFHPVGSIEAATRKEAMAQMQEILDLGIRIV
NLEPGVWATPMHVDDRRLYPLYAFCEDNGIPVIMMTGGNAGPDITYTNPEHIDRVLGDFP
DLTVVSSHGNWPWVQEIIHVAFRRPNLYLSPDMYLYNLPGHADFIQAANSFLADRMLFGT
AYPMCPLKEYTEWFLTLPIKPDAMEKILHGNAERLLAQAGR
>fig|257311.1.peg.4335 Inner membrane component of tripartite multidrug resistance system
MSHQQALTVINGMIDTQAYTLSALDVFYASAAIFLLLTGLVWLARPKSAKSAGGGAAEAA
AGAH
>fig|257311.1.peg.4414 Acriflavin resistance protein
MTLTLAAVYAPIGLMGGLTGSLFKEFAFTLAAAVGVSGVIALTLSPVMSSFLLNSRVSEG
WMARKAEHFFQRLGDAYGRVLDVSLRHRWVTGLIAAVVLASLPVLYGSAQRELAPVEDQA
MILTAVKSPQHANIDYVEKFGQKWDAVMQEIPEQNGRWLINGSDGVANSIGGVNLVTWQA
RKRSADEIQGDLQNRVNAIEGSNTFAFQLPSLPGSTGGLPVQMVLMSAADYRVVYDAMET
LKQAARASGLFMVVDSDLDYNNPVVRVDIDRAKANSLGVTMKAIGDTLAVLVGENYVNRF
GMDGRSYDVIPQSPRGMRLTPQSLGQFYVKSASGAQVPLATLVKISMGVEPNRLTQFDQL
NSATFQAIPMPGVTMGDAVQFLTEQARLLLPGSSHDWQSDARQYSQEGSALVVTFLFAII
VIYLVLAAQYESLRDPLIILISVPMSICGALIPLALGMATINIYTQIGLVTLIGLISKHG
ILMVEFANEMQAHAGLDRRAAMERAARIRLRPILMTTAAMVVGLVPLLFASGAGAHSRFS
LGLVIVVGMLVGTLFTLFVLPTMYTLLARDHRAAGQSARARELARLDAQAGAASPAHETA
S
>fig|257363.1.peg.141 Multidrug resistance protein B
MPNNDLKKLPLSKKQLLAFFGMIVGMFMSVLDIQIVASSLSVIASGLAASSNELSWIQTS
YLIAEVIIIPITGFLARLLSTRICYFIASLGFTMMSVLCSLANNIESMIIFRALQGFCGG
AMIPLVFSTVFIIFPASQRPTVTILIGLIVTVAPTLGPTLGGYITEILSWHFMFLLNVIP
GIFVCTVVFLYVDFDKPNYQLLKNFDFLGILLMSLTLGLLQYVLEEGNKAGWLDNKLILF
LSITVALGFILLIIRELTFINPILDLNTFLYKDFTFGCIYSFILGIGLYGTVYILPLFLF
TIAKYDTLQIGATMMVTGVAQFLSAPLAGRMLGLGIDSRLMLTIGLGGFALGCHLNSFLT
TDSKFAAFVLPQFIRGFSLMFCFIPINNIALCNMPKEKIANASGLYNLTRNLGGAVGLAI
ISTILSNDTKIFMQYLSENISYTSIMALTKLDYYTELLSWKVLNPEQGAYLLLADKLNND
AFVIAINNIFNMIGLLFIFIMLLIPFTSNIELTGNVNVH
>fig|257363.1.peg.226 Multidrug resistance protein A
MFSVLQQVIYKYKYHSFIKYVIIIVLIVFTYFGYRIYVWANTQSTDNAYIDADISNVSTE
VSGVLTKLFVTNNTRVNKGDLIGEIDDRDYKARLAALDASIQACIKNIEIIEKKISIGQM
RLEQVTEKLKLTKISFDIISIDLTRVQALSNAKFVSSKTLDDSKNGYQKVKTEYKQAQLD
LDISKHNLQLLELEKAAAQEKLKELIENKKVTLRSLQNTKIIAMVPGIFSNSNLAIGNYI
VKGKVLFSIVQDNTMYIKANFKETQIKNFKSGMKVKIVFDALPAKVIYGKIRNIAPATGA
KFSLIPPDNATGNFTKIVQRVPVLIDFAPTNDTLVPGMSARVSIRTDQST
>fig|257363.1.peg.566 MFS-type bicyclomycin resistance protein
MKIIVKIPVWMLLSLFILSPTTETIYTSGLPSLTKYFSIDGCITQITSTLYFLGFAVGIL
SLGRLSDIYGRRPIVLLGLFIYIVSSIISIFSVNIEMLMIARFIQAFGVSVGSVIGQSMA
RDSYQGAELSYVYAILSPWLLFIPSLGSYIGGYIIEYSSWHYVFVFFSLIGTILLALYYK
ILPETNYYIDFSQSSKYFEVFNIIIKDKILWLYAFIIGAFNGIYYGFFIEAPFILIDKMK
VLPSFYGKLAFLLSFSAIFGGFLGGYLIKKRQVHDKKVMSIGFIFSLCGCILFVVNAFIL
EFILVSNGLAISMIFVPMMIHIIGHSLLIPITLRYALEDYAKVTGTAGSIFGAIYYIVIA
AVTYCVSKIHGETISNFSLLCLVSSISSVISFYYICILYKKKSIVANEK
>fig|257363.1.peg.662 Bicyclomycin resistance protein
MKLLITVIIMEILAGSEIDLFIPSFPEIQDTFNLSTFMTELLLGVNLIAYCITSLIVGNL
GDKYGRRPIIILGLLIFNLGSLFCVFANNYETILFGRFFQGCGIASVAVLVYVVLADIYS
IQEQQKLMGVLNGTIALSMAVAPVIGSYVNLFWGWHANFILLLSVGLISLILGIFFIPKG
QVNKKTRISLKEYIPIFKSPKAIYYILTMIFLAQGYWIFIGIAPILYMQDLGVTLEYFGL
YQGAMAALFSIMSFSSGYCFKKFGIKNCFYFGVIFIILFLLGNSILIVYNINNPLTITIV
TLLLSLGVIYPINILWPLLLEAVADGKARMTAIFTAARLILTAFGLQLVGFLYNGTFTPI
GITISIVTLFGLVTLNQLFKYDKIFEIYEIV
>fig|258594.1.peg.1913 Drug resistance transporter, EmrB/QacA family
MTVDHPPATSHVPQTAAKTRPSALALTILLLGGFITVFDLFVVNIAIPSMQADLGVSFAE
IGFVIAGYELAFGVLLIAGGRLGDRHGRRRLFALGMAGFAITSFLCGIAPDATSLIVARL
LQGATGAILFPQVYALLRVMYDDAGRRRAFGLLGMTLGLAAIVGQVFGGLIVESDLFGLG
WRIIFLINLPIGIIALLSARIIPESRSSDAMGVDWPGIGLATAGLLLLLLPLLEGPNLDW
PLWTWASMAVSVVLLTAFLVWEHLVARRGGDPAIDLTLFRNTGFSVGSVVVLLIYSTATS
LFLCFALLVQSGLGLTPFAAGTLFAPASVGFVVASLVAPKLVARFGNIAIAGGTLVYAAG
IGWLIVTAAGLGDGAGIFALLPPLVLFGFGQGLSMTPLLNLVIGYVEESHAGMAAGFIST
MQQVGGAFGVSVVGIFFVGILGKDAGEGVSQAGRYADAFSGAMIYNLAAVIVAAALIALI
VRKSPARQ
>fig|258594.1.peg.3679 Multidrug resistance protein B
MTASQAKQPITPLVGVPRSLAAVTFGLASFMAVVDITVANVSVPTISGNLGVSPEEGEWT
ITFFAISNAICIPLTGWLGRRFGQARLFAGSVAAFTLASILCGLAPTFETLLIARVLQGA
VAGPIVPLSQALLVAVFPPEKRTFAVAMWAMTNMAGPVAGPMLGGWITDQFSWPWIFLIN
APVGAFVVVSAGVLLRGKDTPTVRLPVDVVGLALLAIAVGCLQVTFDRGRTLGWFASPLI
CATATISVVGLVLLVVWELGEAHPIVDLRLFEFRNFAIGTLSVAVGFGLYFAALVLVPLW
LQTDLGYSSTWAGVATAPMGVFGIVLAPFLGRWVATHGPRLYASIAFAAWALVALWRSTM
TTGVTIADVALIHLAQGIGIAFFLTPVVSLSLAGLPPDKLASASGLQTAIRMMAGSLCAS
IAQTFWDERARFHRNHLVDAVTELSGRAATALNQLRSAGLTEQQSWTVINQQIDVQARML
SLNDFFYVSAFAFAAALGIIWLARGPKQST
>fig|258594.1.peg.4084 Membrane fusion component of tripartite multidrug resistance system
MASEPADGNKRSRESGSHDQEQAPPPTDHDDTQGKLAPSMLSNPWLRWGLITAAILLLLG
GTGYGWYWWTTGSYFQSTNDAYLKADQVSIAPNVSGYLVGVPVVQNQTIAAGDQLAKIDD
RSYRVRVEQAKAQLDQARAGKARAEAELNRQYAQIEQANAQLGQSEVSLAFAENQVARYR
PLAASGAEATERYDQIRNQRDQARAQVALNNAQVESARRMVPSIEAQIAEAQAAIEQAEA
QLHQAQIDLDNTVVVSPIAGRVGDLTARVGQFVQPGMRMMTVVPLHDLYLEANYKETQIG
LMRVGQPATIEVDALPNEKLHGEVLSFSPGTGSEFSLLPPQNATGNFTKVVQRVPVRIRI
DAGPEARKVLVPGLSIVVDVDTRNAKADIDRQRGELQDSRKAAQ
>fig|258594.1.peg.4086 Outer membrane component of tripartite multidrug resistance system
MAGDPRSHATELIERALADSPSIQIVEARVRQARASAREQYANLLPSGSVAGAYLHNRIP
LGDARRGLENVAGGQAIAGQIPDGTNLDLYDANFDASWEIDIFGGRQRAAEQAVAQADAA
VARFADAHVQLAAQVAQSYVGLRDAQHRLDLTLQSVKLQQEAIDLTAQRLGGGTTSDLDL
ERLRTQLASTEAMADPLRATIDQNRGQLAVLVGLEPGTLDSQLRRPRPVPVPPRPLRIGD
PAGMLRRRPDIREAERNLAATNAQIGQAVAGYFPRVTLLGNVGSLSTSTAVFGTAGSLIG
NVGPTLQWNVLDFGRTLARIRQAEAGSDAAIAQYQNTVLTALQDAESSLSRFGHQRNQVT
KLARASASADKAAELMRQRNRAGTVSVIDLLDVERQRLQTVQSLAQAQAQLMNDYIALQK
SLGLGWSDDPVFEVASSKAPDQ
>fig|259536.4.peg.422 Multidrug resistance transporter, Bcr/CflA family
MSAPKFPLPNKPVAADRVRSADLPVAWIMMLGLIVAVGPLSIDMYLPALPSMADDFGVST
AFMANSVPAYFVGLVFGQLFYGPFSDRVGRVKPLYIGMVLYVIASIICATTNNEYVLFTG
RTLQALGACVGAVVTRAAIRDRLTAKQTAKAFSIMILVMGLAPILAPSLGAVFLQFFSWH
SIFWFLAAFGTLNLLLTKFFFFETLSEENRNVRPAKEILSQYWELLKDPTFNYPAIGGGL
LMGAMFVYISSASELIMDTYGLSATHFGWLFGMNAAGFVALTQLNQWLTNRFRILSILRF
GAMMQVISAGALFTLGIVFGTDAWLPLVLACIFFCIAGLGLTQPNSSAIALAFQQRRAGM
ASALQGSLMFSVGIFGGLLLNLFPVNPVLKIGIAMFSLMSLGCYLIWQIDRNLNLDNAD
>fig|259536.4.peg.689 Permease of the drug/metabolite transporter (DMT) superfamily
MTPIHIALAVLVTFIWGVNFTFIAWALESFPPLMLTALRFFFTAVPLVLFLKPPKFNRTL
FIYAIGTFVMQYAFVFTAMHLGASAGLTALLLQVQIFITVLLAYVILGEAVSRMQIIGML
VGVLGLGVIALNLGGDMPLVGFICILIAAIGWSFGNIASKQASTQQSTSNISTASPVDSN
NRTSALSALSLVVWGGLIACVILTLSSLLFETEAWHLTTFTHASFKSWLSLGFIVYVSTL
IGFGLWAHLLSQNIASKVVPFALLVPVFGMATSVLLIGEVVTWWKVLAMVLILSGLILAN
VKIGLGRRSAHA
>fig|259564.8.peg.598 Permease of the drug/metabolite transporter (DMT) superfamily
MFGSVFSWVFYTTIIDKFRSKDMVILSRDITMFGTIFLFPFALLEARDMRVDIVSQSDLV
VAIVILMYLAILGSALGFLLWNKAIDLAGSSTTTNGLYFVPPIAIFGDSIILGNLPNLYV
LVSAVLVFVGVYLSEKA
>fig|259564.8.peg.2212 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MSEDELAVESIGKLFRKFALPAVVGFIIGGVQITIDGYFIGNGVGTLGLASVTLVYPLLI
GMIATAMLIGTGGASLVAIELGKGNRKRAHRIASDMLPLMFVLGTFFAILGLFFTEPLLR
MVGATGTVFVMANDYLRIMFIGSICLIAGIGLDPLVRNDGRPNFAMKMMVVGAMTNVVLD
YLFVMCWGMGMQGAAIATIIAFAVSMIAFVSYFFSRYAQLRLYLSDISPDIKIIAGILKT
GFPAFVMQASLGVLVLSYNYMLLRYGSEIAVSSYGVIEYSFAIFFMIFEGISAGVQPIIG
FNHGAKLYDRVYVATKMAILSCFLVGLSGFILLYTFPETIIQLFNRNDPELLATAVEGMR
IFIFGIIVEGVIISVAVYYQSVNKIKPSLFIHFGKIFIFILPLLFILPRYYGLTGVWMAA
PVGIYLMLIVVGVMFLKEIKILKHPPTEVNE
>fig|261594.1.peg.2143 Multidrug resistance protein
MKRVLAVFFTIMFMIGTDTFLISPLLPTLQQVYHISTELSGWMVSSYALGYAAFALIAGP
ISDSINRKKVMVIGMSFFALSTFLCGIAPSFLWMLIFRFLAGVSAAFVSPQVWASIPLLI
EKEQIVKAIGIATAGLSLSQILGLPVGSYLAMIHYTTPFFIIGILSALLVILIYGVLPEI
QPVHIRENKTNILKRYKQLLSDSKVSLSYFAYFVFQTGNFAAFSFFGVWLSIQFGLQIHE
IGTAMLVLGLGNLTGNIFGHRIVNKIGYNLSFYGGIIFIAVLYALLPHVNNIIIVELLFF
VLFFVTGILFVLMMRHLQNISIVARGTGAALANASMYIGQMIGAAIAGMLFAASHNFIFV
GSFTALLYILALFLFRKSEKLTENRETGIAS
>fig|262543.4.peg.428 Quinolone resistance protein
MKKQIIQLPELPQQLTSETFADVEIDDPYLYQTLYEKETLPVELTERLDVNQVCFRNVSF
AGLVFERASFENVRFEQCDLTGCQFQDSRFHRVVFEDCRLTGIHFESNTIDHVTIKDCQA
NYAQVIRTALRHVTLEQTSMRESHFFEMKPIDFRLHEVDLSESQWVETALKGLDLRQADL
SGITIDPRFLPGAIVTESQAITFARLLGLVIPSHG
>fig|262543.4.peg.511 Permease of the drug/metabolite transporter (DMT) superfamily
MNRSKATLFVLIGAISYGVLSTIVKLAYGAGFDSAAVSGSQFFFGWLMIFVLALLSKNLR
LHPKTALTLMAIGISSGTTGYLYYQSLQTVSASVAIILLFQFTWIGVVIDSILAKRLPSR
SHFLSAVLLIGGAVLASAAYTSALDVRGTLFGLGAAVSFSIFLLASGRVANHVPVIKKSF
YMMTGGLLFVMIMYPPTTFLTATNFEQGLIWYALPLGLFALILPPLLFAAGAPHLSPASV
SLLGAAELPTAVICSVLILGEHLSGSQWIGIIIILIGIFYPIYVSSLKQSTTSVPRQNDL
S
>fig|262543.4.peg.900 Permeases of the drug/metabolite transporter (DMT) superfamily
MIRQRIGSTFALVVLLFAFVGFGYKLANDPGSLFSQLLFFAITAGIIFLLFKFLTRNSVN
SSTNSQYRKSVAQSKKMYAKNNPSPRRTDFKKKPVKTTKTAASSKVRPLRDRSKAPHLTV
IEGKKGKKKKRAF
>fig|262543.4.peg.963 Drug resistance transporter, EmrB/QacA family
MRKNVTIALLLATFLAAIEGTIVATATPVMASELNGAKLVSWIFAGFLLFMAVSTPIYGK
MADLYGRKRVLLFGIGVFTVASLACGLAQSMEMLILFRAAQGIGAGAVLPIAMTIIGDLY
TYEERGKIQGVLSAVWGISGVAGPLVGGFLVETLSWRYIFLLNVPFALISFIMIVLFYKE
NVTETSRKIDYRGAILFATGMSALLYGLLSGSESESFAETLILISFAVSVILLFWFYRVE
KKASDPLLPPAVIRHPVILVINLAVFFSAWVLVSMSAYIPIFAQGVLGKSPTEAGFMLMP
LSLFWTLTAIVGGRTIGIASPRYRTMTGMGLLVIGMAILIGIGRESSDVFIYLAVSLIGI
GFGLAQPVFMVVLQTSVDWSLRGSATAVNSFLSTTGQTLGVAIFGTLFNVSIIQAFSDSK
LLSGYSIDPFFQSGTASRYGADVQSAAEQALANGLHLVFIGGLVCAILAFFMTFRLPKVR
PEDPTN
>fig|262543.4.peg.1119 Multidrug resistance protein B
MFTALKQLDRNIWIRFVGETITGVMMFMIAPFLVLYYSEQLDSYFLVGLIMATGPITSLF
GSFLGGYLADLYGRKPLMVISIVGDVIALIGFSFADSFWPLLLMNALLGLTNSLFHPAAS
AMVADVTPPERLNESFGLLRMGHNVGAAFGPLIGSAVLFIDRSLIFYAAAAVFFLYALVL
LVFIQETKPEQIEHTHDEPKLSAFTVLRKDHVFVIFIAAGVFISMGFALVESMLPVFLKE
ALPGLPNDKNPFPYLMGLNGIMVVLFQFPVAARLSGKAFGKVMLLGASIFGLGMILLAFI
PSYLFSLGTGYIVLVTILLVIYALYTLGEMIMSPVQMTFIALIAPEHLRGTYNGAASIQW
LIGGVTAPLLGSLFLDSGNGQYALAGVGVACCLSGLVYLALDRSIQRAKRLSQSA
>fig|262543.4.peg.2345 Multidrug resistance protein B
MQRLKQLHPLTVGVLLGTFFARLGTFITMPFFAIYLSVVLKFSPVDVGWILSISAIASLV
MSFVGGTLSDRYGRRTMMLSGTFGFVLVFIGLAQVETFWAFFILSALNGIFRSIFEPSAR
ALISDTTEEENRLFVFNIRYTCINIAAAIGPGIALLLSAGNTSITFYITAFVYFGYGVAI
FILFRRHPITESHGGKKVSFGATVRLLKTDVAFTFALAGIIFGVFGYSQFNSTLPQFLTT
TTLLSGGTSLFALLITINAITVLVVQYPIMKFGVKTSPLVSITVGIATVAVGLFVMGTAG
TVWLMIGAMFIFTCGEVMMFTMTDILTDSFATPELRGSYFGAMGLTSIGQSVGPVIGGQL
LLYFGPERPLPIFGILALLTVLGIPLLLLSQRVHRQTKPEEEKEVVSL
>fig|262543.4.peg.2850 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MHPSGEATNLNENLCPCFEKKEALLMMNKNTARLGEAPINKLLIGLSLPAMIGMLVTALY
NIVDTIFVAQGIGTVAVAAVGIAFPVQLVLMAISNSVGIGGAAIASQRLGQKNLAGASRA
YANVLMTVFVVSMLAIITAFIFVEPLLRVFGATPEITPYSIDFLRVLLLGSPFFMLTMAS
SAMLRAEGRASYQMRVMLTTVAINIVLTPLFIFGLDWGIQGAALGTVVAQIVGSVLIFRF
FFTKSKKTSLVLDREAFRFDPKLVGRIGQIGSSSFIMQVSQSILFITVNHMLVRYGGTTE
LATFAVINKFMALVGMPIMGIVQGMQPIVGYNFGSKQFDRMSQAIKLAIRYGLTLSITLW
LLIQLFPRFWVGMFTEDATLLNEGSTAMRILFAISFVYGIQMIVNGMYQSLAKARIALFL
SLSRQTLYTIPLVLILPMFFGVQGVWFAFPIADLMAVLTAVVFAYRDRIMLFKPDEYAAP
EEQEKAAQAK
>fig|262724.1.peg.163 Permeases of the drug/metabolite transporter (DMT) superfamily
MDASLLLPLGFGLLSALTWGAGDFGGGMASRRAHAQAVVLWASGIGLLLFLLLAQVFGEA
PQGRDLPYALLGGASGALGLLAFYRALAQGEMGLAAPVAGVVGAALPVALGALLEGWPGL
FPALGMGLGLLAVWLVSRPEGRARPGNLGLALLAGLGFGGFYAFMDRVEGLFYPAAWAKL
TAFLLVLPAALRARPWPGGREAPWVLLAGLGDAGGNLFFLLAAQAGRLDVAAVLSSFYPV
FTVLLAWLVLKERLSRRRLTGVGLSLLAMALIALG
>fig|262724.1.peg.377 Acriflavin resistance protein B
MRENPLVAFFVERFVFATSIFVGMVLVGLLLGLGLGVELLPRFSVPVIAISTSYPGAGPE
EVAEQVSKPLEDALSTLTGVDVIGSSSTEGFSLVFVQFKQGVDVDQGAVEASQKVAAIRS
TLPKDASAPVVQKFDPSASPILYLALEAPGEDLAEVLRYAERTLKPRLQLVSGVADIRLT
GAPKTAIKVYLDPDRLQALGIPPLQVVQALSASALNLPLGALTEEERRLVYTLRATPRTA
SEVAEVLVDPGRGIRVRDVARVEEAREAPTTLNRVNGRPAVVLAVVKTPDANAVAVAQGV
RRALEETSLPPGYRAEVALDTTRFIQAAVEDTVREAFLAALAVSLVVLVFLGKLNSVFSV
ILAIPITLSGAILLFGVLGFTYNLISLLALTVAVGIVVDDSIVVAENIDRYRRMGLGLKE
AVLKGASEVSAAVAAATLSLLAVFLPISFLPGLIGQIFQQFGLGMAAAIGVSWLEALLFL
TVRLAYFPDPDPPTLKEALRAALLLPKDLAWAYRRGFRTALGLLLGLGAAFLLYRQGPLH
LLLLVLYPALLGLGRYLGRLLLDLAGALARLLHEATEGGVRRLTEGYARALEAALARPYL
VLGLAGLAFLSVFPILPRIPFNFTPRADTGVLTATLLLPKDTPLSVSDRAARALEAYFLA
HPAVERVVTTVGASATGGAQVGDPSRVQLQIVLKPKGERPDIFTLTEVFNREGKEALKDF
PGADLRVLAQTGPEAGDADLQFFVTGPDREALEARVQAIVDRIAEKPYVLNVKSTLEATQ
RERVFVPDPARLSGTGLTPQDVAQTLRLYLSGTQAATARRSGEEYPVVVQADPLRYSGEG
GLLSLPVYAPALQAFLPLGSLGRFEERPSPTLISRRNQAYAAGININLKPEAPGALQVQA
ELEQDLRAAGLLGDGVELVASGLGSFTEELASLAPLAFGLALVLNYLVIASQFNAWRYPL
YLLLPVPLALVGAFWLTYFLGTGLDVISVLGVVMLIGLVTKNAILLLDFASRRMREKPLK
EALVEAARLRLRPILMTTLTVLIISLPLLLGAGEGSEYRRPLGVVILGGMLSSTLLTLFV
VPAAFFAVEGRLARKGGKG
>fig|262724.1.peg.525 Multidrug resistance protein-related protein
MFRFLPWRREGLSALLRLILVVGLLEGVRSGYFAGLLPFYAPEHLGLGPAAFTLAFTLHQ
LAENLSKAAGGLLAERLGYGLTVTLAAATGLLALLLTPRADSAWILWTLGALWGLTFSSL
YPGLMTLASRIARPGMDARALAFTLSLVMPWVGLGLVGVGQVAQRHPLQALHLLLAAQGL
ALLVALSLVRFRIPVPPPSRERYPLYRLLLFVPAAFGQTFAPGLVSLFLLRFAKEELGLE
PLALGGLLVLGGGAAFLLLPFTGRLVDRRGYQAALVLGLFLLALVMARLGTGPHPYELPA
AALLGGLGFSLFLPGWNGLLAKNLPQENRAAIWGSLMTVEGLGLALGPVAGGLLWEAFGL
PAPFLAGSGIFLALSLFYLLLFRVRKLWRR
>fig|262724.1.peg.625 Multidrug resistance protein B
MNFTPDAKEVRYTMVGILLGLFLAALDQTIVSTAMPRIVGELKGAEYYAWVTTSYLLAST
VSAPVFGRLTELFSRKAVLVAAVLLFLLGSALSGLSQNMVELVLFRGVQGLGGGALFALA
LTTLAALFPPRERGRLAGVFGAMFGLSSAVGPWLGGLLTDHFSWRWVFYVNMPVGAVALW
FILRHMPRLSPGKREPFDFLGAFLLAAWAVPLMLAFSWGGSTYPWDSPRILGLFALAAAA
FGLWVLVELRVPHPLFDLAVFRIPTFTYAALASFFYGPAFLGAVAFLPLYLQVVKGVSAS
QSGVTVLPLTFGVILGSVGGGQLAARHGRYKGLVLGSALFLLGIFLLFHFLLRVDTPLWL
AVFLFFLAGLGLGPAQSLLNIAAQNDVPMNRIGSATSAVQFMRQIGATMGVAFLGTVLAS
ALSDHLKAAFPQGAAGAPVLAQGGEGMALDLDREFARLEDLLARALRGDEAAYRALLQDP
MVPKAYLQGLSPGGLPARFAALKEEVRAALAGDEAARRALLQDPALPEDLKAFLRAPRGA
LGPEAVEAALAQAEARALEEATRQAVAGLEAAKARLKEALSFGITEALRRIFLYSALFTL
GALVFVLLLPDRELKGRPAPVE
>fig|262724.1.peg.970 Multidrug resistance ABC transporter ATP-binding and permease protein
MTEDTYSKAFDRALFARILRYVWPYRLQVVLALLFLLVVTLAAAATPLFFKWAIDLALVP
TEPRPLAERFHLLLWISLGFLAVRAVHFAATYGETYLIQWVGQRVLFDLRSDLFAKLMRL
HPGFYDRNPVGRLMTRVTSDVDAINQFITGGLVGVIADLFTLVGLLGFMLFLSPKLTLVV
LLVAPVLLAVTTWVRLGMRSAYREMRLRLARVNAALQENLSGVETIQLFVKEREREEKFD
RLNRDLFRAWVEIIRWFALFFPVVGFLGDFAVASLVYYGGGEVVRGAVSLGLLVAFVDYT
RQLFQPLQDLSDKFNLFQGAMASAERIFGVLDTEEELKDPEDPTPIRGFRGEVEFRDVWL
AYTPKGVEPTEKDWVLKGVSFRVRPGEKVALVGATGAGKTSVVSLIARFYDPQRGCVFLD
GVDVRRYRQEELRRHVGIVLQEPFLFSGTVLDNLRLFDPSVPPERVEEVARFLGAHEFIL
RLPKGYQTVLGERGAGLSTGEKQLLALVRALLASPDILLILDEATASVDSETEKRLQEAL
YKAMEGRTSLIIAHRLSTIRHVDRILVFRKGRLVEEGSHEELLAKGGYYAALYRLQFQEA
>fig|262724.1.peg.971 Multidrug resistance ABC transporter ATP-binding and permease protein
MTGRSAAPLLRRLWPYVGRYRWRYLWAVLAGLVSIFFFVLTPYFLRLAVDAVQAGRGFGV
YALAIVASAALSGLLSYAMRRLAVVASRQVEYDLRRDLLHHLLTLDRDFYHKHRVGDLMN
RLNTDLSAVREMVGPGILMGSRLSFLVLLAFLSMYAVNARLAFYLTLILPGIFLAMRFLL
RLIDRRYREAQEVFDRISTLAQEAFSGIRVVKGYALERRMVAWFQDLNRLYVEKSLALAR
VEGPLHALLGFLMGFAFLTVLWAGGAMVVRGELSVGELVQFNAYLAQLTWPILGLGWVMA
LYQRGLTSLRRLFELLDEKPAIRDEDPLPLALEDLSGEVRFEGVGLKRDGRWLLRGLTLT
IPEGMTLGITGRTGSGKSLLAALVPRLLDPSEGRVYVGGHEARRIPLAVLRKAVGVAPQE
PFLFSETILENIAFGLDEVDRERVEWAARLAGIHEEILAFPKGYETVLGERGITLSGGQR
QRVALARALAKRPKILILDDALSAVDAETEARILQGLKTVLGKQTTLLISHRTAALRHAD
WIIVLDGGRIVEEGTHESLLQAGGLYAEMDRLQKEVEA
>fig|262724.1.peg.1626 Fosmidomycin resistance protein
MLPLLLAWLHTTNDLFSNFLTPLLPKLMDRFGVGLGTAGLLVSAYSLTGSLLQPFAGLVA
DRVDRRLLAALGPVLVALGMGSMGLWPRFEALLFVLALAGVGSALFHASGASLVGEYAPK
ERRGFWLSFFGSAGNLGLSLGPIVALYVAGRWGLEALFWLTPLVLLPALVLLRLPPVRRA
GRPAGFRDFLRVFRGDVARLWGMATLRSLVFLSFSTTLPYWYATKGLPDGYTALSLSIYS
LSATLGILVGGTLSDRLGRKAVLVGTLTLGLPLYLGLLFFPAENPLYLLLLAATGALMNA
GIPVAVALAQELEPGQTATVSGLLMGFTWGFAGLFYAPIGRLIEAFGVLPVLLGLGVLLL
PAWALARGVREPARTMGV
>fig|262724.1.peg.1716 Multidrug resistance protein 2
MSPLALLFLTLFNSVLGLSILFPILGPLGRALGLTEVQVGLFSTGYALMQFLLSPYWGRR
SERGRKPVLLVGILGFAASFLLFGVFALLGERGLVPPGLLFFLLLLARLLGGAFSSATLP
TAQAYVADVTGRENRTAGMALLGAAFGLAVILGPALGAGLAALFGLLAPVFFSAGIALLN
ALFVYLVLPESRPRGQEAGARLSPFDPRVFPLLLLGLALNLSSVALEQTIAFYFQDRLLL
GGVETAQKVGLALVLYGVVAVFVQGVLVRKTGWPPRVLLSLGLPLGILGFVLLVYAKTFW
ALALGLALQGAGQGLALPGVTAALSLAVGEGEQGLVAGLNSSAQALGRMLGPIVGTGLYR
LAPEGPYVLGASLLLLALLFLPALFRRARL
>fig|262724.1.peg.1927 Vancomycin B-type resistance protein VanW
MRPFVLLILLGLALGQSAPLEAVLVLREDVLEEGRLVAYTGTQRYPVASEAELLRLLDRL
ARPPRPPRFIYQDGRWRGVEKKGLAFDREEALKAFREARAQGKKRFLLPVRYTPPSPSLK
DLYALGVREHLATAETGFWGSSPERVHNIRLAASRLDGLLVPPGPFSFNRALGPIALETG
FKEAYVIVGDRTETGVGGGVCQVSTTLFRAFFFAGLPILERHAHSYQVAYYKPPGLDAAV
IQPYKDLKVLNDTPGALWIQASVQEGRLRFHLFGTKDREVAWEGPFITDRKPPLPPREIP
DPTLPPGARKQVDFAAEGAKVVVRRRVRYGDGRVREDQVVSVYRPWGAVYLVGPSPAPEA
PPAPPEEAGAAP
>fig|262724.1.peg.1981 Permease of the drug/metabolite transporter (DMT) superfamily
MRGYVLGLLALNLLTLIWGTTFVVVKGAVEGMAPSLLILLRFGVAALFFLPWLFRLPVGV
FGPGMELAFWLFVGYASQTLGLAHTSASRSAFITALSVVLVPLLLRLAGREVGPAFLAAF
LALAGVGLLSYDPYQPPFNVGDLWTFLTALAYALYIVRLEVHARAFPSLPLTAVQVLGTA
LFALPWVLAEGGAWGPVAWGAVLYLGVVATALTTWLQTWGQRHVPAPQAAILYTLEPVWA
AFFAYLALGERLSPSGLLGALLVLLATLLAIRRSPA
>fig|263358.5.peg.348 Glyoxalase/bleomycin resistance protein/dioxygenase
MLRRCHDAGEGGRAAATAGSRGVAVASVPSGTPCWADLATPGLDRARRFYPELFGWTGRV
DPEPEAGGYTTFQLDGRAVAGVGPPAVPDQVPIWSTYVATDDADLVTGRVERAGGQVVVP
PFEVFDRGRMAVFSDPAGAAFSVWQPMAFSGAEVFDVPGAMCWTELVTPDTDGARIFYEL
VFGWQPEEEPMGQTSYTGWRLGDRMVAGMMPPREEAFAADSPAYWTLYFSVADADATAAR
AAELGGTILVPPRDIPAGRVTALRDPDGALFSLIALTP
>fig|263358.5.peg.535 EmrB/QacA family drug resistance transporter
MTPSRTRPSPSPAETPADPPAQPAPIAGRARTIALVAVLVGLLLDLLDIVIVNVALPTIQ
EEIGASSSDMQWMVGGYTLAFATMLVTGGRLGDIYGRKKIFIIGMVGFAAASLVAGIAAN
PEQLIVARFVQGGMGALMVPQVLSILQVMYPPQERGRAFSALSVVFAVGTVAGPIVGALL
TAVDIAGLTWRTIFLVNLPIAAVCLFITVKLVPESKGESAQRLDVKGAILVGLGMLLLVF
PLIQGPEQGWPAWTLISLVASLLAFAALVAVQRRQTESPLIPISLFSHRSFRGGLAVSLL
FMSGVMPFFLVNTLYLQFGQGFSVIKAGLIGVLWGFAVPLFTAISARHITPKLGRLGLQL
GLVMLIAAMVILITVIHQFDTITPWALAPGLILGGAGMGMTFAPLLTYTLNDVPLHSAGA
ASGVFNTVQQMGAAIGIALSSMVFFIALAVQSPAVGDDLRNTVKEELSARGVPVAAVDAA
ADSARACFDERIKAANPEADVAACRAVASQSGADVADRHDELQFIANRTAYQQTTVRALV
YQIVVFTLAIAASFLLPRRVEHQG
>fig|263358.5.peg.547 Glyoxalase/bleomycin resistance protein/dioxygenase
MSERSFSPVIPFLRYQDPTAAVDWLVNTFGLERFDVTEVDGKVVHAELSWGNSTIQLGGG
GPHDTLGMVSPRELPATSGGIYICVGDAADVDKHYERTVQAGAKLVYELHDTSYGSRDYG
AYDLEGHVWSFGSYLPREASA
>fig|263358.5.peg.561 Glyoxalase/bleomycin resistance protein/dioxygenase
MAGEPSFIEFAVPVPERTRDFYEALFGWKFTMLTHGSYIEMPGAPAGLEAGSHPDTDPPH
IIVYFAVDDLAAAVERVKELGGEVGPLRPPSPDYGAFAECRDNQGVAFGLRELPKAS
>fig|263358.5.peg.569 Glyoxalase/bleomycin resistance protein/dioxygenase
MANDSVPPLNGGTHINLTVRDLDRSTDWYCRALGFTVVRDARPVESGFTFRTLLHSRALT
SIVLGQADRPVEEPFDEHRVGLHHLAFHVPERDDLHTWVAHLDAVGVEHGGVQELFLEAG
HGVWLRDPDNIWLELYWLNADYFMQRMREHHRARRAERVGGQQ
>fig|263358.5.peg.1140 Bicyclomycin resistance protein
MPQTATPSTAPDRVAVPTGRAAIGLLVLLGSLTAIGPLSLDTYLPALPDMTRDLSASQAR
IQLSLTTCLIGVAVGQLVTGPLSDRWGRRRPVIVGLAAYTLLSLLCTLAPSAETFAAARF
FQGFAGGMGTVVARAIVRDLYAGRAAAKYFSRLTLIFGLAPMIAPAFGSLLLNFGDWRVI
FVALTVIGALLATVVAWRLPETLPVARRNTGGLLSIARIARVLITDRIYLGYTLTQGLAF
AGLLGYLSGSSFVLQDVFGLSVGMYSLIFGVNSLAFVAVGQLNARLLDRHGPRQLLITAL
GLGLLAALGLIAGALLQALPLVIVAMLVFLGSLGMVMPNGTALALDRHGAHAGTAAALLG
GIQAVVAAGAAPLVGIGGEGSALPMALVIAGAAAGSLLVVLTLARRR
>fig|263358.5.peg.1357 Glyoxalase/bleomycin resistance protein/dioxygenase
MIGRLRSTVIDCPDPRALAGFYAELLGLPLMEEDSEGNGWVVLGGPPGHQPRLAFQRAPD
LRPPDWPDPERPQQLHLDVTVDDVEAAERAVLALGARRLPGEGDGFRVYADPVGHPFCLC
WD
>fig|263358.5.peg.1520 Glyoxalase/bleomycin resistance protein/dioxygenase
MGMSQPTTHRHHCIDYIEFTVTDLAEAKRFYAEAFGWQFTDYGTAYAGIRGGSGAEVGGL
RQEQQARTGGGPLVLLYSADLEQSVEAVEKAGGTVVAGPYEFPGGRRFHFTDPSGNELGV
WAEA
>fig|263358.5.peg.1642 Glyoxalase/bleomycin resistance protein/dioxygenase
MNWTLEVVVVPVSDLDRAKAFYAERLGFTVDHDTVVNDDIRLVQLTPPGSGCSIVIGKGA
VPQMPPGSLKGLQLVVPDLHKARTQLLERGVEVSEIQVMGENPRPVPDPLDNVGFIHFAD
PDGNAWAVQQISSRA
>fig|263358.5.peg.2119 Tetracycline resistance protein
MNPLSVRQVRRRYLVLHGLRWLPVGLLIPVTILLMQERGLTLTQIGLAIAAQGVVVLALE
LPTGGFADALGRKPVLVVASLVGLVSTGLLVVADSFALLVAVWALQGVFRALDSGPLESW
YVDTTLAADPDARYENGLGQGGTVLGLAMAAGALLSGALVALGPIGPLSALTGPVIAAVG
LQVVYLVALLALLTERRAVTGPAALRASVREAPRMVGEAFGLLRRSRVLLALVAVELFWG
FGMATFEGLLPIRLAEVVADADRAATLLGPASTAAWLASAGGAALTPLLIRRLGAAPGAA
LLRILQGITVVGMALFAGPTGVLIAFVACYAVHGASNPLHMGLLHRQVAGPYRTSLISLN
SMVAMPAGALGGVVLGYIGDRAGVSTAMLVGAVVLAVAAPLYLPAWRAGRQSADDGRDAG
VPDTGPSPGDGESAARPSGDSVPAAGPPGVPVARLAGDGEPAAGQAQRTEVSGKAAV
>fig|263358.5.peg.2422 Multidrug resistance protein B
MTQSPSDRIDGPLLRLLGVMVLGGVMSYFDATIINVSVETLTAHFDATLGTISWVATGYL
LAVAVAIPLAGWAVARFGARRVWLAALTLFLVASALCALAWDVGSLIAFRVFQGFAGGLL
EPIMLTVVATAAGPSRMGRAMGLISIPITLGPVLGPIIGGLILQNLTWQWIFLVNVPIAL
LAIALALLIMRDDRPEPGAAPPLDLIGVALLSPGFAALIYALSQAGTAGFGATRVIVGLA
VGVVLVAAYVAHALRSAQPLIDLRLFRSSGFTSSVLTMFLLGGMLFSLLFLLPLFYQQVR
GQGVLAAGLLLVPLGLGTMVGMPVAGKLADTFGPRRLVPTGALLIALSALVYTQAGPDTS
QVLLTAAQLVTGFGLGLVGAPTMGSVYRTVAPEAVGGATGTLFILNQIGASLGVAVVALI
VQSGLTDGRTPADSFDQAFWWTVAGGVIVALASRFLPGRPQPVTPTPADAETAAA
>fig|263358.5.peg.2763 EmrB/QacA subfamily drug resistance transporter protein
MADRRIMVPLSGVVLAQLLAMVDLNLTAAALPVIAADLGGTDRFAWVVTAAVLASTVTTP
LYGKLSDVYGRRALLVAALAVLTLGSLLCGLAQSMNQLIAARAVQGAGAGGLMISAYAVY
AELLDPRRLVRYQIVTATLVNIGTAFGPLAGGVLTDSFGWRWVFLATVPPSVLALLLVAT
LRLPPVAAGGRVDYAGMLWLGAALTTLVLLAGVAGTQWAFASPGVIALVVAAAVLLALWW
RSAHRAADPVLPPALLRDRVVRSVAVQGWNTGAGMLVVVTFLPIVFVSLGASAADAGMYL
LTLTFGTLVVSLAGTPLLARAARTQWFGVTGTVLLAAGTAWLAFTHPDLGPGGWAGWALA
TMAIGVGIGLGFQVYTLTLLRHAPRVHLGAALAMQSLSRQVGGSLVLAVLSAVFHSRLAA
GGSTSTLDAAQTVFGLTALLLVVGVVAAVRLPVPSLTVAERSPVTTVETG
>fig|263358.5.peg.2817 EmrB/QacA subfamily drug resistance transporter protein
MVENFSGASTARLGARQWLAIGALGASFLVVAADSTIVYAAIPSIQRALDLSTATVQWLM
SAFLISFGGVLLLSSRLAELFGRRRLFTIGLALMTAASMLSAVAWAGEVLIGARVLQGIG
AALIATTALPLLAIALGPGPARVRALGLWTLIGAFGGTTGLLLGGLLTDTVGWRWVFLVN
VPVGIVAALLAPILPADRCGGSGHPLEVAGGVSLVGALTLIGWTVVAAFAPGSSTGPALL
RLAAAAVLLLLFLVIEARTGRRLVRPGLLRSRTRLGGLVVLFAAGTLIDAVLLLVTLYGQ
GALGLSATRFGALMVALTLSSVVGSYVGQVVVVRHGLRLVALTGMSVAGAGLLALAMVNG
PLDTVDFLSVLPVVGVGAGAAFVAAQIAVTLGASDADSAAASGLSDASFSLGGALGLAAV
SAVLVANQTELPVPMGAALPMAFTVTAGLAAIGLVAALLLMGQQRTPVPSQGT
>fig|263358.5.peg.3073 Antibiotic efflux protein
MIAVLHGRFPAGRPPCTGGVEQGREVCDDLPVTGVDEPVATARPAGSEQTGTGSGGLGGR
YWRLWSASAVSNLADGIVKIALPLTAVGYTTSPVLVAGVAAAFSLPWLLFALPAGALVDR
LDRRQVMLAANSLRAALLGTLALAVALDAGSIWLLYLVAFGAGTAETLYDTSAQSILPQL
VPRAALPRANGRLYAVELAANQFVGPPLAGFLVAGGVAYAMLGPAGLWAAAVVALLLVGG
RFRVARQGTSTLRADIAEGVRFLWRHRLLRTLALMVGVSNLTTTATFAVLVLYAVGPNSA
IGLSEPGYGLLLTTLAAGIVLGSLVAARIERLLGRARALGVAMVAIAVVVGVPAVSTNPF
VLGGVFFVGGILLTSWSVITVSLRQQITPDRLLGRVNSGYRLLAWGSMPLGALVGGGLAE
VFGLQAVFVIMGVLALILLVGMFWVTDAAIEAAERAAA
>fig|263358.5.peg.3098 Glyoxalase/bleomycin resistance protein/dioxygenase
MLKCREPEVLARFWCEVLDFVVLDREGEGCIEIGPREGFGGPQPTIFLIRTDEPTIGHAR
LHIDVNATDRDQDAELERLLGLGAELVDIGQPVEASWHVLADPEGNEFCLLKRRLDPV
>fig|263358.5.peg.3608 Glyoxalase/bleomycin resistance protein/dioxygenase
MITNVSLTSVFVKDIDAAKAFYIDVLGFVERTDITIGDGSYRWCTVGHPGQPELEVHLQL
PGPPLSPEVAELFARARDEGSLFALGLAVDDCRKTYDDLRAKGVEFLQEPADRPYGVEAV
ARDNSGNWLVLVEHKEFSPADFD
>fig|263358.5.peg.3820 Glyoxalase/bleomycin resistance protein/dioxygenase
MTPELDLIGMVSTDLARTVAFYRRLGIDIPADAEREPHVEVRLPNGLRLAWDDVATIRSF
DPDWTPPVGGARTALAFRCADPAEVDRWYAELTAAGGHGHRPPWDAVWGQRYAVVHDPDG
NAIDLFAPLPPAES
>fig|263358.5.peg.4308 Glyoxalase/bleomycin resistance protein/dioxygenase
MIHHVQLACPRDSEDRSRAFYVDLLGLTELTKPPTLAARGGCWFSGYGAELHLGVEDDFR
PARKAHPALLRPDLDALATRLTAAGCPVTWSDDLPGLRRFHTTDPHGNRLEFLTPTHPTP
SPR
>fig|263820.1.peg.449 Multidrug resistance protein
MRRIALFVIVLGLMMTGVDTTAVILALPDITTDLHSSLSTTIWVIIMYLLVIAVMTTQLG
RIGDSLGRGKMYNSGFIIFTLGSALAGTSIFADELIFFRAVQAFGGALMQANSGAIVADI
FPVNERGRAYGYTSIGWTTGATLGILVGGLITTYIGWQYIFYINVPIGIMAAVLGIMNIK
DDKRQESHSDIPGFLSLLASLVLIAYGASNITGYGVDKFNILLIITGIAILIFFIFIERR
AEYPIINMKIFKNHIFSFSILASFFQSMGYLSVVFIVIMYLQGIRGLSPLNASLLLVPGY
VLGSVIAPFAGRLSDRIGSRIPATLGLSMMMAGVLIYMSFSVTTPLYFVIIASLVGGLGT
SLFYPANNSAVMANAPRGFYGVSSGILRTFANIGTLISYVLAITIASITVPRYVAFEVFL
GLHNIVGTIAGKFMTGIRSALIMSFIILVIAVILSISRGRENRAEKAVKLKT
>fig|263820.1.peg.597 Multiple antibiotic resistance protein MarC
MNYAYLFISSLVTLFAIMNPIGAVPILIALTDGYTKDERNNVILKSVFTAAGMMLGFMLI
GVYIFQVLRISIYDFEIAGGMLLFKVAFDMLQGRTSPTKITSTEKEESVEREAIGVAPLG
TPLLAGPGTITTAIIFFNGNGNAIMTRFVVIMSVIILIILTYIILKFSIPIFARLGKTGS
IVITRIMGLLLASIGVQLVASGIINVFHI
>fig|263820.1.peg.630 Permease of the drug/metabolite transporter (DMT) superfamily
MDRRIFYLLLLIFVVFIWGLTFPFMKITLYYISPVVLLAFRFIISSILLIPLIKKRNFLL
EKKHLKYGLSAGFMLFLAYYFQTVGLKYTTPSQSGLITGLYVVMLPLISYFYLHIKANRG
DLIAVMLGTAGLIIMSKIDFSGSYLFGDVLTLICAFFYAMQTAYVFKYSRDLDSGVFTFY
QLIVVGVLSAILISYNPDISGLVVPIVIFTLIFTAALAGTFAIYINTRALMYVEPTAAGI
IYVGEPMFAVLSSIIILGEIPNIYTIIGGIIIISGMLVESIDKYLAAKTTF
>fig|263820.1.peg.729 Daunorubicin resistance ATP-binding protein drrA
MIELINLSKTYPDGKVAVDHLNYKIDSGIVSIIGRNGAGKTTLLRMLSTQLRPSSGDALI
DGISIVREPEKVRKKIVSIPQEASPIGILTAYEQVNMFLAARGFSFHEAKNAAIKALKDV
GLDAMHKPTDTLSGGMKRKMFVAIALAANADTVFLDEPTTGLDPLSRFEVWSAIKKLNGN
VILTTHYMEEAEELSKKIYMMESGKIIKSGSVDELISNMRNLVRIESYKPMENSYTIGSL
YIKYVDKSEVYRYIKMDYNVKPVSIEDLFIMRGVTLES
>fig|263820.1.peg.730 Daunorubicin resistance ATP-binding protein DrrB
MNLRFILLMAWYYGIKAIKRGPSYLIASLATPLTLLFLVFVLSHGTLVKYAIVGGLIAFV
GSVGLSSAGDAAFMRLQLRVQDMYVASNIKPFDYMMAFTLSYLVFSVPGIILYIALGMHY
HLFNLYNSIYMLLIMISLILTTTSISFIIAGSINHLRNIWGITGILSILTSILPPTFYPY
YYVPRPFLYLLSLSPTTPAAVLVQGVFHLAPLFKNMIYIIIIETVFYTVLGRFAIRWREN
>fig|263820.1.peg.914 Involved in antibiotic resistance
MINLENKRIDEFNNQKRDLVNDFVDLISSRTFKSTLRIAIIVLLGINGPLTFTDLQRSLR
IGKGSLKNHLDVLETEDFIKGRNVITLNGPRLVYQITDKGREFYNKYIDLFDRFKLL
>fig|263820.1.peg.976 Multidrug resistance ABC transporter ATP-binding and permease protein
MNNYSIRRVLRDLMIYKKRLYLVSMAIIGSSIVAMIGPYIIGLAVDAITHRDLSLILDFG
IIYIIIYIINYAFERLRTYNMTYISQGFIMNLRNREFERLQYVPLGYYTYRKAGEIISRI
TNDGEAMSDFLTFQMPQVLAGVIGIIFSMAIMLYLDWNLALYSFIVIPLLLITVFSISGK
IRNYYNETRIKIARLTGFASESINGISSIKEFGSEQRFIDEFSVKNYENYLANIRANRLG
SIFSSLVDIIQALGIIIVIGVGATQVINHAIQIGLLVSFIVYVQSFFNPLAQLSQFYNSY
QSSKVAIKRIYSIIDEEQDDNKYKYKIEDFGSEIKFENVSFSYGSKPALKNINFSLKRGE
KLAIIGKTGAGKSTLINLLLRFYRPESGEIKIDNININDVDIYSYRSLFGVILQEPLLFN
GSIMDNIKFNGNYTDDDVINLIKRFNLEGIFSEKDLYENVGENGHGLSQGQRQAVSILRA
MIRNPEIVIMDEATSQLDPETEEIIQNAIRSVNKTFIVIAHHLSTILDSDQAILLENGEI
KSTGTPEHVLKINGLLD
>fig|263820.1.peg.977 Multidrug resistance ABC transporter ATP-binding and permease protein
MVLISGILSSYLTILVPVFIGDAIDSVPRYYKIFDYIILILIVSSLSSLFGFILEYYSSK
TGNIFARRIRDMSFKRVLSNSYDKLENQDSGDLLSRITMDVDASRRFVTISISNLFSTTA
LLFIALYELTRIYYLFSIIFLIVMVPTIYLTFKMQRMQRGYWRSLRKKYGNMNSKIGENI
SGMRVVRSFNAEDFEIKSFKDKTQDYFSDYVGIAAVRSFYTPLLAAIISISIGFIIITSG
ISSAAGIPIGSIVAAINIFTLVLRPVRFYGRYISFYENGMASLERLSEIDYSNENYSKKE
PTGYDIIIENLSFFRNNKKIINNISLNIHENEHIALTGGTASGKTTFLNLISGLYKNYDG
SIRLGGIEIRDISPGLLRRIIGIIPQNPFIFSGSIFYNIDFGRGYSLSQVINAARLAKID
DFIETLPDKYNTVIGEHGINLSGGQRQRIALARALIGDPKILVMDDFTSSLDIVTEEELI
NDIRPLLDGKTVVISGYKKKTLELADDVYYMSNGALLPVESGVNE
>fig|263820.1.peg.1080 Multiple antibiotic resistance protein MarC
MPLLVVIDPFGSLAIFVSMTASYNKDTKLSISRDAVLYGGMILIIFAALGEIIIQFFGIS
IEALEIAGGIILLLMGIEMVREGAKPESSSGSKNLGIVPFATPLLAGPGAISLVIILMKG
SLTTKIFTIVSILIVLALVYIFFIFSSKILEILGEKIMTAITRIFGLLLAGFAIQYFLDA
LISLGLIK
>fig|263820.1.peg.1096 Daunorubicin resistance ATP-binding protein drrA
MENIIETKNLTKIYKNLRAVDNLNMTVRSGEIFGLLGQNGAGKTTTIKMLTTIIKPTSGT
AIVDGHDIVKESMKVRDSIGIVPQELTTDEDLSGYENLMLIADFYNIKKSDARAKALELL
KMVDLEDAARRPVSTYSGGMRKRIELIAGLVHSPKVLFLDEPTLGLDVQTRTNLWSYIKA
IKENLGITIILTSHYLEEVDALADHIAIIDHGRLLKVGTSEELKEGLGGDIISMELNSES
EVNLLKDFPAKETSINGSSIRFKVENSDAILPELMDILYRNHIWPRKMTVEKPSLDEAFL
EYTGRKINDETPMDYGKTMNYMRRISR
>fig|263820.1.peg.1097 Daunorubicin resistance ATP-binding protein DrrB
MSGLLPLTGRELKKWYRNPTYLIVSVIQPIFWILLFGSAIDIAKFAFPGAPVSSFFNGAP
DYITFLLGGILTVLSLFTAMFSGINIIWDRRLGVLTRFLASPIHRSSIVFSRMLASVVKI
AVQAAILIGIAAVIPDGLKFPHGFTVFDALILFTAMLLISVIFGSIFSVIAIKMTQVNTI
MGIVNLVNLPLMFASTALFPGAIMQPWLHHVAMYNPISWSADTIRTVIINGDLNAAQMHS
VGLDLLYLFIFAVVMILITYFASEKGIQN
>fig|263820.1.peg.1498 Multi drug ABC transporter permease protein
MGNLYNVYMQYVKNYYRSKSFYLMLTLILVISILMTYFSLKYVNDLPAFLGRNVSFHLKK
ILFYFIWSFVLINIPVFSSVFFGSPAISSEIENKTAYYIFPLPINRYKLYIGKYLSAFTV
TFIIVLIYSSFEVIILHYLFGSIPLSFYYSIGLLAIFIFTILSITFMISSIFNKNTYAYI
TVFIIYYIVFEAGSLIINLLYKITPIYLLNEAADIVEKVYLNINTSSFVTSPSLAPATNT
EIYTSVLIMIIYMIISFVAGIIIFERKEVS
>fig|263820.1.peg.1499 Multi drug ABC transporter ATP binding protein
MEISIRNLTKRYGRILALNKINMHASGPGCIAILGPNGAGKTTMLKLISNIIKPTDGSVL
INNINVSDYPERALKYLGALIEQPEFYYYLNGYEILKFAAKVKGLKNNIDDEIKRLADLT
DMNDYLYRKTGTYSRGMKQRLALAVAMIGDPEIIILDEPTFGLDPKGMAYIRDLIKNLSR
EKLVILSTHLIYEAKEVSNRTLIIDHGEIKYDSINSDNKRKILVTFDGSISNIKSDFIRD
FVIDKNRIIITPREDADNYNIIYDLIKNGVKVNSAQDYDDLEETYISITS
>fig|263820.1.peg.1530 Tetracycline resistance protein
MDKGILPLFVTAMIDFIGFGIIIPIAPFYTRDLGATPFEFSILLVVYSLAQFIASPYLGR
LSDRIGRKNVLVLGLSGEIAGYLIFGLSPVLSLLYIGRAITGATSGNLPVIYSFVSDKTS
SDNRTRAIGMIGAAIGIGFVIGPFIGGSLSIFGYRVPILFAAVLSFINMVLVLRIKEERK
KTNYKKGSILKAFEIAPYIFISITFIALGFVMLQTTLAYYGQALYSWGSLAVGIILGIVG
MEQALFQLLLVFRLTRRIGSIRTVMLGIISFTMAFLILSFRVNEYIAIFSLTLFSLGYSL
FQTPVISIISDIAPVEIRGSTLGITQSAQSLSNIIGPLIAGYTFEFISIYSPYMLAAAFG
ILSLLFISIFIIKSGSALKDIGYT
>fig|264198.3.peg.748 Outer membrane component of tripartite multidrug resistance system
MTQGQPFPPARRFGRSLAVLAATAMAASLAACAFGPDYHAPAPDLPAAYAHAAALQAQEA
APAAPALDSWWKGFDDPALTRIIERALAQNLDLAASVARVDQARAAADYAGAALLPEGSL
SGSVARQRQSLESPLGKIASKSPGFERNNTLYNAGAGASWEIDIAGGLRRGAEAADAEAQ
AAEAEHLGVRVLVAAEAADAYFRVRGAQQRITIAQQQVQTNARLLDLVKLRLADGIGAER
ERAQAEARLAQTRVTIPPLQIELDTQLNRLDVLMGAAPGTYAAELATPGARTGVPQIPLA
QGPAALLERRPDVIAAERRLAASSARIGVATAEYYPKLSLAALLGFESLSASKMFTAATF
QPAAMAGLRWRLFDFGRVDAEVAQARGANAEALATYRKSMLRATEDVENAIVTLTQLQLQ
SQDLTVEVDAQARSRGAAEEAYKGGAVSLFEVLEEDRQLLAARDQQARAGTDNARAAVAA
FRALGGGW
>fig|264198.3.peg.4312 Drug resistance transporter, EmrB/QacA family
MTSTAQSGHGSGQVLPFRESLLAMLGVAFVSMLVALDQTVVGTALPTVVAELQGFEYYAW
VATSYLLLSVITVPIFGRLGDYYGRKPFVLASIVVFSVASALCGMATSMPFLVAARGLQG
IGGGMLVGTAFACIPDLFPDSHVRLRWQVLMSAAFGVANAIGPSLGGILTEWYGWRAVFY
VNLPVGVLSLWFVWRYLPHLRQQSHSGPIRVDWLGALLIGVGLGCMQMSVELLPQRGVDW
LTAGLLAVAVAALVGLWQWERRCANPILPLDMFRNPGVAPLLQLAVLVGFTMFAVLIYAP
LLLQGGFGYSPRDAGLLVTPLVVCITVGSIVNGRIITRIRRPNAMLFAGFGMLAAGCLAL
SQATRGMPHSLLLAIMLVAGFGLGFIMPNLTVFAQQTVGREHLGIATAMLQSLRMVGGMI
GTAMVGTMVSRSYTAGVEQSLAAVNAQGWLTRMADPQVLIDKAAQAGLLTELQQAGHNGA
LLLEQARVSLVTAIHFGLVIAAAAALIGLWRARRVPPVRLVRAGQQPAMAAD
>fig|264198.3.peg.4993 Multidrug resistance protein B
MSVGSRWQSLWQLRLSVRWLRWLSHRQRQTLLMMLLALATGVEFLENIMFVFASSHIMGG
LDADPRSFALAQAAYAVGSMLMILKQQWLSRRFGYRYYLTGALLIFMAGTLGAATSHSLA
QLVGARFVQGFGGGALFTSCRILVAVLFGPADRPRASRIFMTGIFVASALGPAFAAELVD
HGVWQDVFYGALPFAALAALGAWVLLPDAEPRRPAPSPGLGPLLLFGAAVVTLQAALTEA
RFDIFSHPLRLALIAAAGLGLLAVFLWHQWHHETPVLHLRALRNPIYLAGIGMYFVYYMI
NNLSAYVFPIYAEQALRIPLATTGWLNTFAAIVSLVGVIIYLRYGSRLTRKKPLMVTGLM
MMAATAWWFSRMPPDAGPPALAWGLVGKGLFGVMVIIPIAGLTFRSLSGEEFAHGYRSKN
LMRQIASSFASAIGAVLLQNRQFAVHDSLVHALGQRVAETQLWMQSVQAALAARGFDEAQ
ARHGAMAQLAGLVEQQARLIACEDIYRLIAVLALTAAVYMLLQRRLD
>fig|264198.3.peg.5092 Multidrug resistance protein B
MPNPIITISARESHSGANYADRNASYWKRNLAVATFGSFTTLVSLSMLLPFLPLYVEQLG
ITAQNEIVQWSGVAFGVTFLATAVTAPLWGRLADRFGRKPMLVRAAVGMAIVMSMIGLAH
NIYELVALRFAAGLIGGYASAATVMIGTQAPAERAGWALGVLSSGALVGNLVGPLVGGLL
PNLIGIRGTFFAGGAMISVAALLTIFLVREDFRRPAKRTLSHEAIADRHERSSRVPLVAL
LVTATMVLFSNMSIEPIITVYIGQLGVPRAQLSTIAGIVMASSALGSVLTASRLGALADR
LGAWRVIIGCLVATAVVMIPQAFVTNWWTLAILRGLMGMTVAGLLPAIGKLVRQATKEHQ
SGKMLGYLQSAQFAGQVTGPLIGGQIGVHVGMRAVFFVTSAVLLGCAAFDRWAKTR
>fig|264198.3.peg.5258 Outer membrane component of tripartite multidrug resistance system
MNAADFSMRASILAILACLALAGCAVGPDFERPTPSAPDVFHRIQSAQASSKAVDAEFNV
EWWTLLNDPLLNNLESRLVDANLDVAAASARLRQSRSTQQVVGAAQLPRLDGAASYYRER
GSPNGIVSLLGVSPTGSPPQPASGSSPLGVAPVPGSSGSPPFDLYQFGFDASWEIDIWGR
VRRSVEAAGALTEASFEDRNAILLSARAELARDYVELRDLQSLLEITKQNLEIARDTARL
TQVRAREGVTTDLDVANAAAQVASIESLMPTLEARLEAAINAIGLLLAEEPGALRQELAE
RREVPELPERVPVGFPSEIVQRRPDIRRAEAQLHAATASIGMAKADFYPRISLNGSAGFQ
SLQLSSLADWASRQFVVGPSITFPIFEGGRLKGTLHLREAQQQEAAIAYKRTVLDAWREV
DDALVAYDAEQRRRDRLVTVVSENQRALAIAQRRYKAGAVDYLDVLNVQRQLLRSQSNLE
QSRATAATNLITLCKVLGGGWESAYARTPTAN
>fig|264198.3.peg.5816 Bicyclomycin resistance protein
MEMKGSRADERAAPGVLTAQSDPQPKALPGIAAMAAIAAGLSMLGQFAIATYLPAFAIMS
DALHATNAQVQQSLTAYLLPFALMLPWHGAISDAVGRRRMVLLGCALFTIGSLVCAGATG
IDMLHAGRVLQGISAGIGVIVGRAMVRDVFDGMQAQQVMALVAMIFALAPAIAPVCGGWL
LLWTGWRSIFVFLALVSASLLVACWRWVPETLPPARRHPLHPALLARGYGSMLTHWRFVA
LTLANAGVNVGIYVYIFAAPTFVTRHLGLGAQSFGWLFIPIVAGIMLGSLVSHRMAGRIS
PVRSVLLGHAVMLFAGILNIVLTALHAPAMPWALIALPVYGAGMTITQPSLQLLALDCFP
ERRGLASSGYVTVQQLGNFLMSALLVPLLLDSTVKLAVCMAALQLFGLAMFMGGQRDRAV
VVSS
>fig|264198.3.peg.6318 Permease of the drug/metabolite transporter (DMT) superfamily
MPMAICALLIWSTLAVSVVSLSEMSLLLTTGIGLAGGGLIGLPWVPWRSLRPRAVAVGAL
AMFGYHALYFVSLRTADPVAANLLHYLWPLLIILFSPIMLKGVRMEVRHIVAGVLGFAAA
CVCLAPAVSIQGSQIGGLSVALMSAAIWAYYSVWSGRFPEIPTAAVSLYCLLAGIGSLVA
YLALGALPDLDAWQLGGRFGAPTPGQWLMLGYLAIGPLGGAFYLWDHAMKKGNPHQIALI
AYAVPIASTTFVSLFLGRGLEIATALGAALVTLAVAVGGRPSRAKPPYTAETGIQDG
>fig|264201.1.peg.127 Multidrug resistance protein B
MPVKTLSPAALIILTLALGLGTFIQVLDSSIANVSISHIAGDLAVSPNQGTWVITSFAIS
NGIVLAITGWLAARFGRVRLFIWSTSLFSITSWLCGLAWDLNVLILFRTLQGASAGALIP
LSQALLLTNYPEEKKGVALGFWSMIVIVAPILGPIVGGYITDNYGWPWIFYINIPIGFLS
AWMTGLLIQDPPHEGKSKVPLDLTGLLLLTIGISSLQVFLDKGQELDWLNSLTIRVLIVT
CVIAFTIFIPWNYYAKHPVMNFSYFRHRNFTIGTILGAIGFLMFFGSAVLLPLWLETEMG
YTAFWAGFAVMPIGIIPLFLSSTIGKSVSRFDPRIMTTFSFISFGLTFFWFSELTPSVSL
FKLMLPRFFQGIGLSFFFIPLVTISLSPIPNHELAGASGIFNFIRLIAGGGFGTALYVTL
WDRREIFHHSRLTEATTIYDPLTWEFYENLKQSLSLSQPESNLILEDLLSAQSYLLAVND
VFWLTGWVFLACIPLIWLCKKNTTNKTQQVAMD
>fig|264201.15.peg.1902 Permease of the drug/metabolite transporter (DMT) superfamily
MFYVILLYALFASVFTIAKTGLEYSQPFFLVGTRMLLAGCLLLGYQKIVNKEHFSFDKQT
WWRIVQLAAFNIYLTNVFEFWGLKYLTSFKTCFIYSLSPFLSALFCYTLFSEKLTTKKWM
GLLIGFMGFLPILMNQTSSEEATGHLLFFSWAELSVMMAAICSVYGWIVLMQLVKENNLS
PITANGTSMFIGGAFALCHSLLVENWSPIPVTNIPIYLECTFLLILISNLICYNLYGTLL
KKYSATFISFAGFTTPLFTALFGWVFLGEVVTWPFYISFGIVFLGLVLFDKEELQQSYRG
KLLSQPQLSE
>fig|264203.3.peg.208 Permease of the drug/metabolite transporter (DMT) superfamily
MNEAERESQPESKLTSPKVFLPFLLVILIWSTTWIVIRDQLHSVPANWSICYRFFVAGLL
MMLFCRIKGYKLALDRGNQFFCITVGLLLISVDYGFLYAAEKHITSGLVAVVFALIIIPN
SFFARVFLGKKSSPYFILGAVLAGIGLGLLFRSQLAYLPDRTEMKLGLGMSLLAVLATSL
GEILLSTPRGKSQPMPVFLAWSMLWGSLGIGSAAFFLDGAPVIGGIAYLGGLLYLTLFAS
VLAFVLYFYVLHIIGPDMAAYAHVLSPVLAMVISTLYENYIWSSSAIAGSIMVLAGLLLA
MKSQKKSIRSVMVKARID
>fig|264203.3.peg.1774 Permeases of the drug/metabolite transporter (DMT) superfamily
MNRLWNNAWITLSLAAFMWASNFVIGRIIPPSMPPVSLSFWRWTLAACILLPFVWSSLKK
EWRVVLRHWPIILLLGTTGQAGSNTLAYYGLHSTGATVALLIQSATPVVILLFAFFLYGE
KPSPKRIVAMLFAFGGILFVIAAKGNGGAASTIGGTLLLTATMLCQALYATILRHKPPTT
PLVLLFSCFVAASLVLLPFQIPYGVGLPFHDSHSLSAIIYLAIGPSIFAFLFFNRGVHII
GASRASIFLYLMPVFGSLIAVPFLGERLGWMHLTGFLLVGVGFVLSREKVKSILSR
>fig|264203.3.peg.1802 Outer membrane component of tripartite multidrug resistance system
MHLKRPLITSISVAALLLTGCASIPKLGKAPKVKDVHDYATAQSLAGNGSAWPGEGWWKS
YGDPQLDQLMTEALAKAPDMAIAKARILSAAGSKQRAGAGLLPSVNGFVGTGAGHLMRDQ
EIRQVTGRNDEFKDWGDGGSSFLTIRYNIDIWGGYRAKLAAATSEAKAAIVDSHEAALTL
TTSIAAAYANLSRLFEERQVLNRTLAVRSHVLELTQQRLGHGLDNDSTMQDASARLANAQ
ADLTANQESIDLVRHQIAALMGAGPDRGMAITRPQSVKLRAVGLPDNAALDLLGRRPDIV
AARLTAEAAGYRVKVAKTQFYPNVSLNGIVGYQTRALEHMATHGLALGAASAALNLPIFR
GGSLSGQYREAWATYQEAVASYDKTLSQALQQVADAATSQKQLNLQLDQTVQALNHAELS
YNVLANRYKSGLVTYIEVLQGEENVLTLRKAVADLRARAFQLDVSLIQALGGGFTAA
>fig|264462.1.peg.238 Permease of the drug/metabolite transporter (DMT) superfamily
MPARFENLILYAICTLIWGSTWLVITFQIDAASPVTSVFWRFLLSTAILLLFCFWKKQNL
KYSRQDHLLFAGQGVLMFSINYMLTYVAETMVSSGMVALSFTLLVYYNMFGMRLFFKKPI
TQNVIWGSLLGGVGIVFIFLNEILNFDPSSRTIWGLLVGFLATLSASLGNMVAQKSYQKR
IPVVVTNTWGMLYGSLFTLIVALVLQHDLSIPLNARFLGALFYLALFGSVIAFGAYLSLA
GRIGAEKAAYTSVLSPVIALTLSSFFENFHWTPYIILGVVLCLLGNVLTLTKRAG
>fig|264462.1.peg.359 Drug resistance transporter, Bcr/CflA family
MQSSAKPNTPFALLILLLASLTAFGPLSIDMYLPAFPAIAENLNVPLSSVQMSLASFFIG
LATGQIFYGPITDRFGRKKPLYVGLGIYALASLVCAFTKNVEMLILFRFLQALGSCAGVV
ISRAIVRDLFTHQETARVFSLLMLVMGVAPILAPFFGGYISEFFGWRAIFALMVIISTSC
IVMLAIFLPETHQPDQRVHIKDSLKNYVQIIKDRHFMGYALAGGAAQAGLFAYITGSSFV
FINLFEIPAKSFGWVFGSNAIGLIACSQINARLLKRLSYDVILEKIFVVLGVLGVILAMA
GIFNWGFWGLAIPLFLFIAALGMTFPNATAGAMATQRKAAGSASALLGTLQYGIAALSSA
AVSRLHDGTTLPMCAMIGFCGVLALALHRLLVKKAA
>fig|264462.1.peg.419 Multidrug resistance protein
MTATSNKSQLAIIFFTVFLYLVGFGVVIPILPILSRNFGATALETGLLLSVYSLMQFLFA
PFWGRLSDRMGRRPILLFCLVGETLSYIMFAWARSLEWLFVARILAGFFGASLSTASAYI
SDITPKHERSKGMALIGAAFGLGFVVGPALGGGLAVWGQHINPAPHFDTSFASYWVAALC
FANFLFGVKFLKESLSEKSESAAKRKRFSIMWQYLNKKTVGPLMTVFLLSSLAMSSMEAT
LILFMGEKYQWDVKQVSFGFAYIGVIIIFTQGFLVRRLLPKWGERKVLRLGVLLLALGLT
GIAIADSITGMAITMTLLSLGNGLANPSTLGSISLLSDANEQGAAMGVTQSMASLGRILG
PALGGALYGTVAITAPFWASGLMAFLGLAIVIIIYKFIPEHGRVG
>fig|264462.1.peg.1432 Multidrug resistance protein
MKKLSALGHLNTTTFSAIQMMTFTLIPFIAEKATLSLSSVVLSFSVGSFLFLWSSPFWAS
RSDSWGRMKVLSVGMLGLFLSTGILTAVLMAPGTYWMNELAVWGSRLLYGLTAAAIVPVS
QALQIDQHPEQTPLKSMLSNSMSLNVGRALGPLYLLLGGGSNMLLILQSTVVWALVVLGL
NLFGITQSEAPKATQTERISILEWKSALRHISDIFSLAILFTSFVGILNFSLASILKKSF
DLTSVDSSVLMAKLLLVSAILAVLTQALGKVLFKNPWQGAMIVGVATLLGASLILGDLGG
WAQLWLAIVLLSVGLSLIPPCYMALMATRGPELQFGRRAGLAAAANTLGYTFGGGLAALT
FKLDLFGIESVMTALVVVMALNIALLYRRREAVYA
>fig|264462.1.peg.1946 Daunorubicin resistance ABC transporter, permease protein yadH
MTGFVTIFQREIARFLKVLVQTVITPFISSFLYLLIFGVSLGQQMASHQGVSYLSFLIPG
LMMMGLINNAFQNSSSSIVSSKFSGDLEDLRVAPITDQEIIWAMSLGALVRGSIVAVITY
GVGSLFMYYQQGEWLLVAHPLAALFFVVLAGLIFGMIGISIAFWANTFDQLSAFSAFILL
PLTYLGGVFLSIEHLHPFWQTVSKANPLLYLINGLRYGILGVSDVNVWTAAVISLIGFGV
FYAVALVSLRKGSFQRW
>fig|264462.1.peg.2047 Permeases of the drug/metabolite transporter (DMT) superfamily
MGFDTIKRHGAAVFCGPALWKGFKTTTMTLGPLLLLLSALLHAAWNGLAKASKDKESFLF
LTILLSGLLTAASLPISGTGFIFPDNRAFAIAVLSGVFEGFYFLTLSKALRASSLGKSYA
IMRGGAMVLVWMYSTVLLGERAHGLQFLGAVFVLLGILAMNFQDLLKGKRQNLKNDIWAY
ISAIFIAGYHLAYHEALTENTDPKPLFLVAMIVSLPFLLYGIRSAPWQRLKATMTSHPAR
VLLCGSFATASFLIFLYGLKVSAPGFAISLRNSSIFFAVLFSVFLKESLTRTQILGATTI
GLGALLLSL
>fig|264462.1.peg.2230 Permease of the drug/metabolite transporter (DMT) superfamily
MVLTKQESGPRRLTKNRAAVELIFAGVLWGFGFVATVWALEAFSPVETLFFRFVIASVVG
EILYLILKGPNFTSLREEIFRALPAGLLLGGMLLLQTIGLKYTTATKSGFLTSLYVILVP
LFNAWLFKSPSSWKNYALTALALAGTFVLVNANLSGINTGDLWTLGCSVFAAFHIIYIGK
ISNKVGNAFRFNNFQSAWCLLALTPLLLTQERSDWNLLSYKPLLGILCLGLGSSIIAFYL
QIRTQKVLSDSTASMLFLLESPFAALFGFLILSERLSWFQASGAVIIMIASVLQIAVDPG
QKPQETTSPRV
>fig|264462.1.peg.2992 Permeases of the drug/metabolite transporter (DMT) superfamily
MKNMNPRLRGSLEISVASVGFGFLGIFGKWAFQSGLSVGELLSYRFALAAVLLWIFLLLF
RPSWVRLSVRQIVIAALLGIFGYAFFSTLYFTAVDGLSITLAALLLYTYPFWVNVFSHFF
TQDKISGKEALCLVAASSGLVMLLWGHIEVKNIWAVAAGLGAAISYAIYVLLSGRLQKNV
RPITSALYVITFGALALSLFHHPHYSAISNLSDIQATSILGLAFVCTIIPLTLELAALQK
LKSTEVALLMMIEPITAALMGALIFHERLTPVQLLGALVIGAALVTNTLYSRPTPSAD
>fig|264730.3.peg.1729 Glyoxalase/bleomycin resistance protein/dioxygenase
MIDHLDHLVLTTADVDACKDFYVRVMGMAPERFRQGRLAFRFGNQKINVHERGKEFEPKA
HLPVPGALDLCFIASIPLAQVIAHLQEQDWPIVEGPVERTGATGPIRSVYVRDPDLNLIE
ISELA
>fig|264730.3.peg.1864 Permease of the drug/metabolite transporter (DMT) superfamily
MSMNQHLSISPSVTRPAWHQAIPLILLEAALVLTWSSGFIGARFSLDYAPPLLVVFWRCV
VVTLILMPFVTRQLRSIPLATLLKNAGIGLLAMAGYVAGVTQGIALGVPAGLAALFADLL
PMGMALLAAAVLGQRLVWQIWAGLVVGLVGVVLVTYSTLAVGDAPLWAYGLPLLGMLSLA
IATLWQKHSTHMQPMDLLPNLWLQCFISSFAFAIIQGTQGSLAPIPSTGFALSVIWTVGL
ATLGGYGLYWVCLRRASATRVASVLYLSPPVTMLWAWVMFNEPLSWQMASGMAVSGVGVW
MVVRAEARQVAS
>fig|264730.3.peg.4236 Permease of the drug/metabolite transporter (DMT) superfamily
MQYAFPLITVLIWAINTAVTKASAGVIFPAEIGFYRWALAGLLFTPFMLRPVWANRAAIK
PVLGKIFILAVLGTAMYQSLAYFAASLTTATNMGIIQSLVPMMAQGLSIACLGNRLTRGA
LLGAVLSFVGVVVVVSAGNPAGLIDHGVNRGDAMVLVATASYAVYSTLLKKWQLCLPPLQ
LLYVQILLALIVLLPPFILSAKTGLNASNIPMVLYAAIPTSMLAPWLWMTSIMRLGPSRT
TLFFNLMPIATALIAAATLGEQLALYHLFGGALTLCGVILAERWTTPLRSKTS
>fig|264730.3.peg.4286 Permease of the drug/metabolite transporter (DMT) superfamily
MEDKNQSQGVIQLSLAMLISGTIGLFVVESGQSAINAVFFRCLIGGGVLLAYIFYKKMLK
ASYFSKKNVVCLLVIGCSIVINWVTLFNSYTHISIGLATTIYHVQPFLVFFGGALFLRES
LSKHRLVYVCIAFAGVLLIVNPGGESQDSNYLVGCGLALFAAFFYAVATIATKKMDKIPP
HIVALSQMAIGVVVLLPLANFDKLPSTAVQWSLVLTLGVVHSAIMYIMIYSAYQKLPTSK
IAVLGYVYPLMAVAVDYLYFGRALNSLQVLGGVMIIFSGLMGTLNANPFVRKTKAVNI
>fig|264731.4.peg.254 Acriflavin resistance protein
MEHYSITLLIIGILFVMGIYGMYIMPKDEFPHATIRQGVVVAVYPGATSEEVEQQVARPL
ERYLFTYGEVNRVKTTTQSQNGMCIVMVKLNDDVNNKDEVWSKIKHGLNGFKAQLPSGVL
AIVVNDDFGNTSALLIAIESDQRSYRELKQYSDDLSDRLRRIPSVANVKLFGEQKEQISL
YIDRQRMQAYGIGQQMLFSRLQAQGITTMSGAISDDDQQIPIHVEAQENSEEEIANQIIF
SDPVTGKVARVRDVARVVREYEPNASRIEQDGHPCVLLSMEMTPGNNVVQYGEQVDKVLK
EFSLNELPEDVKVTRIADKPKVVAMSVSDFLRDLLISMAIIILVMMVLFPLRSAIVSAIT
IPLSTFVSVAIMYIMGIELNIVTLAALIVVLGMIVDNSIVVIDGYLEYLGKGFKPFDAAI
ESARQYFMPMLLATICICAIFYPFLITMKGMFHDCLEDFPVTITINLMVSLVLAVTVIPF
LETRIIKPGKVSTDGNAITKWVQKTYNKVLDFTFAHPWLTIGGGIGVILLSTLIAPTLKI
RLFPYADRDQFAVEIFLPEGKGMAETEVIADSVQHVLAKDERITGITGFIGCSSPRFMDA
YAPQMAGNNYAQFIVNTKSNKATLDLLAQYQPQLSEAFPNAYVKFKRLDYLEVSELEYRF
YGDNLDSLHVVVERLMERMRKMPELEWVHTDYLQPYPIINVELDPVTSAQLGITRTTAQL
ALSATSSDLRVGQIWEKDYELPIVVKDDADMTFSDIANLGIASPASMVSGGLRSTNSTVP
LRQIAKVQPKWSESRIMHRGGERCITVTAQFAQGVYTAPVEKEIARMMNEEIKLPQGVRA
EVGGEIEYGDEAMPQIIGGITIALIIVYFFLLFNFKKYGVTTVCMAALGLMIPGALIGLG
LMNRALGLTSIFGLITLMGMIMRNEILIFEHAIDLIKKHVAEHGDWKTDRQAYNAAVRQA
AYDAGKRRMVPIFLTTATTAVGVVPMIIAQSSFWMPVGVTIFAGGIGSLIMVVTMLPVIY
WKVSTK
>fig|264731.4.peg.310 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MTDQRLGTEPIRRLFVSMTVPVVLQQLLMLLNNVVDRIWIAHIPDVGQLAFTASGVCVPI
VYMIIALAELTGTGISSRVGLILGQGHHHQAERTLGSMMAFSILLAILTLLLVEVFCPEL
IRIFGGSPQTAAMAECYLRISTPGNAACIISSMLAPFLLVQGYSNEALFVIGSGIVINMI
LDPIFIFLFGWGIAGAAWATTVAEVTSAVVAIVMLARVGNLRIRMKLLSLDWRHIVPCLA
LGTAPMAMMLAETAQMGVYNQTLYHLAGDWGVGTMALVIMLHDFLFFPVRGMAYGSQPIT
SYNLGAGKWQRVWDNVKLLLAFTLVWSMMVCLLMMILTEPVVRLVVGDGPMVDYAVPMVR
LSFVVFFVATVQFASQCTLQAMNRPVLTFWIGISRTLLLLVPFVWLLPRLLTDHADMGVF
LAQPATDVVVGTVTVIILFKLLQNYKNIQNNKV
>fig|264731.4.peg.395 Permease of the drug/metabolite transporter (DMT) superfamily
MTQQSIFQRPVWAALMAFTAAFLWGWAYPFIKLGFAEFEITADMTGSKMLFAGIRFCISG
LIILSIARFTHRSFQFNEAAKPNLIGSALFLLGFTLLNTTLHYAAFYIGLSHSQGSRAAI
LNSLSVFTLVLLACMFFKSDKLTTRKILGCTIGFGGILSLNLGGEGSGQFTLLGDGMIIL
NALCGAFAGLMTRGVNKRVDVFVGTGYSLGIGGALLIIPGLLLGGTLPHVTLLGLFYLLM
LIGISTIGFALYNKLLTCNPVGKIAIWNSLIPVVGAVTSCLCLGEPFLPKYILAATLTTA
GIYIINKGKV
>fig|264731.4.peg.483 Membrane fusion component of tripartite multidrug resistance system
MEKNKITTYIYNAIVILCIVGGAVYAASQFMHFGGGEVTDNARVCQNIVPQNCRVQGFIR
EVRFNEFQEVKKGDTLVVIEDAEFRLRLAQAEADLTRAERGSQGTASSIHTTKTSIGVTE
AGIEAARVQMENAKREDARFQKLLEQDAVTQQQYDNVHTGYLSAKAGYEQALRSRNTQTA
VVAEQGHHLSASEAAIELARAQVEIARLNLSYCYIIATCDGVVGSKDIHVGQLVNPGQTM
VSIVDKHEKWVEANYQESQMPNIKVGDKVRFTADAVPDVEYTGVVERISDATGSAFSLVP
IDNATGNFVKVEQRVTVRVKIDVNDELQKLHGGYNVVCKVEE
>fig|264731.4.peg.484 Drug resistance transporter, EmrB/QacA family protein
MGKLTEFLMKAPPPPAGMGFAMPMMKGWVPRKLQPWIYVLTALCFQFSGGIYLGALDEIR
GTTNFMIEDVMFLLYATLAGMAVWFPMLFRMKFRFTNQQLLCTSAIVMGICNVITMHSQS
MPVLMLACFIAGIAKIQGTFECMSNIQLWITPKRDFAVFFPVLHIILLTAIEGGGWLAAW
MGHHFTWQMMHTFTVGTMSFVLLSQIVLCRPFCPMPNRFSLKGTDWQGALLICVTMLLFS
YIFVYGDHYRWFANRHIRMVGAFALIFAGLTLYRLIHNRYPYVELRLLKCRNVVPILIVT
ILAELAFGAEHTLEEILYTEVVGLEELTKESQYMWALPGMFLGIAFDLYWLKVQKWKVWK
LIGIAFLSISAYALLMYSTLGMAVNIEQYQLSIMLRGFGYGVLAPTLMWALDESVPSLEM
FFMGLFVFNIPHMYLGGAMGYGFYTTIFSHFLNEDMMNYGRQLTLTNLDLSQFDFGAFMG
NSYLHSMMLVAIKQVYGYVIWFALLLASVFLLCDIPAVRTNIRKVPLWPVLAIEYLARKH
KNA
>fig|264731.4.peg.543 Permease of the drug/metabolite transporter (DMT) superfamily
MFKVQNSKLQAHSAIFLANTIFGLGVPVTKLLLDEWVTPMGYMASRSLGACIVFWAIAAF
LPKEKVERKDLITILLGGLLGFVVSQTLTAWSLDYTSPVYFSLIATLTPVAVMLCAALTI
GEKITPMKSIGVLLGIAGAVLMVLMSQSMGSGKNDLIGIVLAILSVLTWAIYLIITRNVA
SKYSPVTQLKYVFLISAIVTVPIAWPELSANALYTPEWGWDGVAEMAFIVIGATALGFFL
IPFAMKYLQATTVSIYTNLQPVIASFVAILLGQDVITWDKPVAGALVLISAYIVTVVTEK
KNS
>fig|264731.4.peg.2063 Multidrug resistance ABC transporter ATP-binding and permease protein
MNYIAWLWHHSRGIRFNTVVRIVTGIGQVALGLLMVWLSRKFIDETIRTGTADDVLRMVL
LLVLTVLGGVALRQVGYWLTTTAGVHQSNALRLRIFSSLFRRQLYTEQELHSGDVTSRLV
KDIETISSVCTDTIPQIAITFIQLCGAFLLMRWFDARLAWALLLLTPMAIVFGKLISRRL
RKMTLDIREDESRIQMQVQESMEHNAVLRSLGSEQWVTDRLESMQQRLKGNVMRRMRFTV
AMRIVMGCVFGLGYLLAFVWGGISLRNGTITFGVMTSFLQLVGMIQHPILQLLNMVPTVI
HCTASIDRLEELSVQDKKEIRDNPCNSVPNKMVRLDDVSFRYANGDSEILQHFTHQFAPG
TKTAIMGQTGIGKTTLFRLILGFIQPTSGRVEVGGNICYVPQGNTLMSGTIRYNLQLAKP
TATDDELRQVLHTACADFVFDLEDGLDTELGERGCGLSEGQAQRIAIARGLLHDGDILLL
DEISSSLDESTEKDLYHRIFTALPQKTMIFITHRSTVCELCDDIVLIENEKKQFASHS
>fig|264731.4.peg.2335 Permease of the drug/metabolite transporter (DMT) superfamily
MKRFLPHLIAFIVVAIWGVTFVCTKLLLLGGLTAAQIFILRFIIAYLLLLGYSLSKGIHW
LSNSWRDELNMMALGVFGGSLYFLTENSAMNYTTTTNTSIIVSLCPLFASAIIGAFYKTE
RLNRWQTAGTVMASLGVIMVVMNGHFVLHLSPLGDALAFGACMCWAFYSLLIIPVSKRYP
TVFITRKVFFYGLLSMIPYIILHPDLNIQLVINKPTLLANLLFLGCVASMLCYVAWNWVL
KRLGAVVATNYVYLNPVTTIVFAWMVLNEQITVWFIIGTVLILYGMYLVNTKRPKLSA
>fig|264732.9.peg.664 Vancomycin B-type resistance protein VanW
METALIRLPDDGQREMENLLRSFYWLVVLVAFFFAWPVLEPALAADPVVAYEDPDTQRAM
IAVRDFSTVLGGEVDWEAATSTVSIRVYGRPALYLDVKAGTLAGVPLQPRPQIKDGVTYA
PLRQVAEALGARVDWREDGIHVYTPAGEQVSIKYIHLLGRYTITFPEKEAGSPSLHNARL
AGQYLNGLVVPPGGVVSFNNVVGPRTGARGFVPGIIFMGDQKVPEIGGGICRTATLLHNA
VLSAGLEVVERHRHGLPVTYVPPGYDATVYYGVLDYRFRNNRPVPIKLEFTSQGSSITMA
IWELG
>fig|264732.9.peg.979 Multidrug resistance protein related protein
MLAKTKENYKWYALSCTTLGALLSVLNSNTLLIALPVIARALHASLETIIWTLMIYMLAV
TVMVPAIGRVADIIGRKKLYVSGFALFTVASLLCGLVQSGGQLVAARFIQSVGGSLMLAN
STAIVTDAFPKGQLGRALGINSMVIGAGAVIGPILGGLLTSWHWRWIFFFNVPLGIIGTL
WAAIQLREIIELPEGQRFDWLGTSLFTIGFTFILLALTFGDMVGWHTPWIVASLVGGSLL
MLLFIYIENHVDQPMLDLSLFRQRLLAAAYASNLLNGIARGAVTFLLIFFFQGIWGIDPL
WAGILLTPFALAMMFVAPVSGILSDRYGSRELSSLGLAVSAIGLYGLTRLQINTPMTVVI
LWMVIMGLGSGFFFSPNTNAIMGAVAAERRGIAAGTRTMMNNAGMVISIALGLAMTASSM
TPEAMQGLFAGTQVGSQGIAVQEFMNGLHRAFWLSFIISIVAAVVALMRGPHEVYYQETG
SGSNKA
>fig|264732.9.peg.1090 Permease of the drug/metabolite transporter (DMT) superfamily
MGINREGYMKKAKDSSGEGRGLFLAVLAAAALGLEGISAKLAYAGGANILSILAIRFLAA
GILFWGSLIVFPLDWKLNLGTMVRLTVLALGGQATTILLLFYAFERIPATVAMLFFYLYP
VIVSLLATVFLKETLTRAKIGALVLAFTGLAIILGVPTGNLEIWGIVTALLAACTNGIYM
VGQTGLLKTIEPRVFNAYATLTIGVAYFILAIVTGTFSLAFNSQAILAIATLSLICTLLA
YTAVAWSLKYIGASRAAIISTLEPVVTAVLGFLILGERLHPIQLLGGALILAGVTVQQVL
TSKDSGEGHGYGIIKQ
>fig|264732.9.peg.1200 Probable multidrug resistance protein
MLQNDAYPAPNPRRWLILFAVMAAGIMGPIDGSVVNVALPTIGRVFNVDLNTVGWVSMAY
LLVLGSLILTYGRLGDMYGFRRVLLTGIVIFTIASGICALAPNIWVLIVFRAVQAIGAGM
FMAMGPAIITSVFPPYERGRALGTNGMIIAVGLALGPTLGGFLVTVAGWEAIFTINIPIG
IISYIMCRQVVPESRDLKPQQFDLIGAAMGFISLSAFLLAGSYGEEWGWTSPATLVLSVV
FLVGGWLFLRWEKRVQEPMLDLTLFHNKVFSAANFAALMNFMSQYALIFLLPFYLQQILN
YTAGHTGLILTASPLVVLMLAPVSGALSDRLGTRWLAFTGQAIVSLALFLMVGLKVTSRA
FDIIWRLCLFGLGTGIFQSPNNSAVMGSVPRHRLGIGSGVLATVRNVGMVLGIAVSSGVF
TWQRSAKLVAWGPGSATAAFMAGMKSAFLVGAILAAAGAIASLVRSDNFPPGEH
>fig|264732.9.peg.1204 Permease of the drug/metabolite transporter (DMT) superfamily
MSLPLPAPKTSTSIKDHLSLLLTVTIWASTFINIKIVLLQVPPNTLAFLRFLVASIVLGL
HLIWRRQPFVKRQDWPLAGLTGLTGITLYNFLQNQGLKYAGATDAAILAAMAPVFIALLA
WLLLRERISRRQVAGIIMAFSGSVLVATNGSPEGLVLNPARLYGDLLVLLTGLSWAVYSI
SLKRLLNRYTPVTVLTCSTIAGTIFLFPLALLESPINWAAVDISCWLNVLYLGLLASALA
YLIWNTVLTRVPAVTAGVYLYLLPVITAIIAALFLREIPGTFTITGGIIVLLGTYLAGK
>fig|264732.9.peg.1524 Fosmidomycin resistance protein
MRKRILYLLSLGHMVTDINQGLLPIFLSVYKDQYGLSYAAAGLVVFLSNISSSVIQPLFG
YWSDRHQLRWLLPAGCLVAGLGMVAAGYAANYYLLVAAVFISGLGVAAYHPEASKSAHYI
SGPMQASSMSIFSVGGNVGFGLGPLIATFILSHGGLRASWIILIPTSVTVALLSHTLPAL
GRAMAGGHQAAPAGNPRAKTSQAPLVAITLLVLVVIMRSWLQSGLTYYIPFYYLNFLHGN
EHFASSMLSIFLIAGAVGTLVGGRLADYWGAKRMIIGSMLVLIPMVVTFPYVQGAWVAIL
LALSGFALVSTFAPAIVLAQNILPEHVGMASGLMMGFAIGTGGLGTFLLGGIADAHGVPF
TIQIMAVIPAIGAALAFFIPDLRQQPSARQVRVEPVPEEKNSRA
>fig|264732.9.peg.1638 Vancomycin B-type resistance protein VanW
MARWKLGVLLFFLLGLALLALARFYFSGRILPGVAVAGRPVGGMDLERARKVITELAAEV
ENRQVSLRLGEQVLASTPGALGLEVDVEATLARAYALGRQGPLVKRLVLLSARKRRVEPV
THLDQQRLQAGLERLGGAWRREPADARIEIVAGGQPRLVPAVTGWQVDAAILKSRLEEAT
TGQTIDIPLNRLEPRLTTAELAARRITRQVASFTTLFDPAEADRTHNIRLAAGTLDGLWL
PPGGEFSFNRTVGPRTPDRGYRDALVVEEGNFVPGTGGGVCQVSSTLYNVALLAGLTITE
RQPHGLPITYVPPGRDATVAYGLIDLKFRNDTPYWYLLKTGVEAGKLTMAFYAADEAPRA
EVTSQVLETIPPLEEIEWEPDWPPGRVELKREGKPGFRTQVIRIIYQDDKKGQPEVVSRD
LYPPQPRIIRKGGQGG
>fig|264732.9.peg.1854 Permease of the drug/metabolite transporter (DMT) superfamily
MAIKEAAIRPITSGCAAGADRRLGYIAIILASLLYGGNVIAGRVIAPLVPPLALAAARGL
LGLPVLLLFALKAGGKPRLADLPYMALMGFLGISIAYGTFSWSMQNSPAVNAAIIFATFP
AVTLVLLAIGWHVKPSRYQVAGIIMAFIGLALVSTRGSLAQLLAMRFQPVDLVLLANVTA
ASLYNILGQRMVERYSPIVTSTYSLFFGTLFLLPAGFWEVSRQGWYLPPSGWLLLIYMGC
IIAGLAVLLTFEAVERIGCGPVAMFNNLNPLFAIALAALFLGEKLSWYHWAGIILVLGGV
CISLRQQPGRQQGQKQGQQ
>fig|264732.9.peg.1943 Multiple antibiotic resistance protein MarC
MSVFFLHAVVSILAILNPIGNLPIFLSLVEGEATADQIATARRATLAAFGFLTLFVLLGN
NILLFFGITLAAFRVAGSIILFSIGYKILQGRNIHSRSLAPDIHEDIMARDDVAITPLAT
PILAGPGSITTVMLLVGSEWRLRTILLTVAAIAVVTLGTYLIFRYATLITRHLGPMEMNI
ISRVMGLLLAVIAVQMGASGLLELFPGLGR
>fig|264732.9.peg.2253 Probable multidrug resistance protein
MYSPTVLIPFFYQKVLGFTPQKAGFLMMAFLAAMAITASFSGWLSDKIGYVLLTTSGLVL
NGLALVALANINLQTPLTLIIIYIAVMGTSLGMFQSPNNSCVTGSVPKNKLGAATGISQL
IKNLGMVIGITFSVAIFSSRMAGMPVEYNQAFVKSMGFVYYLAAVLSFAGAVISSRRSK
>fig|264732.9.peg.2259 Permease of the drug/metabolite transporter (DMT) superfamily
MVYLLVGLNILLLVSGQILWKLGVARDAGFKAVLASFFSPLVLAGLALYVLATVIWLYVL
AREQFSLLYPLQSLAYALGVVVAWLVFKEAVPLTRWIGVLVIMAGVALVAMK
>fig|264732.9.peg.2348 Permease of the drug/metabolite transporter (DMT) superfamily
MQPKHIYALILVALIWGLTFPAMKIGSFYLPPLSFAAWRFFLGALCLLPLAGRRQGKLWH
AGRDFWPLFLLGLLQTAIMGGALHLGISMVKSGITSVVLYSYPFFFTFLAFLLLREPLTG
KQMAGLIIGFAGLILVVDPWKMHPTHAEFIGILVLLGGSIGWGLASVYLKAAFKTRDKLE
VTTYQMFYGSLVLMLVAAFADHGLRFSWTAPGLGIMLYTALLTSALGFVILLTIQARYPA
SQTSVYLFLVPVFGVLFSSLLLGEKLTLNLLLGLALVAAGIITVNLGAPVQAREKTDCVA
SGK
>fig|265072.7.peg.175 Outer membrane component of tripartite multidrug resistance system
MKTPPPLPFPRSRHQHWQIAIAALCLALAGCQSMAPDYERPAAPVAEHFPQAGTGTADAP
SLAWQDYFADTTLQDLIQEALANNRDLRSAIQRVEGARALYGVQRADLFPGLNAQGSFGR
SRTPEDMSLIGRPMVLSEYRVGFGITNWELDFWGRIRSLRDAALETFLAAESAQRASAIS
LVAQVANSYLNLRELDQRILIAEKTIESRQESVRIFQRRFDVGSTSKLDLKQVQALLAQA
QTLRYQLQQSRAIELNALTLLVGKPVDLPPASHAFSETKMLHQLKPGLPSDVLTQRPDII
AAEHILKSANANIGAARAAFFPRVTLTTSLGTASRELDGLFDTGSHAWSFAPSISLPIFD
GWRNRSNLELANVRRDLAVTSYEQTIQTAFREVADALAAQHSIRQQLVSQQEMLDAQAER
ARLAKLRYDHGATSYFEVLDAERSLLEVEQQLVQMQRALFSSQVSLYAALGGGSHSITVP
PPSTTPAARQPSN
>fig|265072.7.peg.374 Multidrug resistance protein, AcrB/AcrD family
MVYAIIQTPPGSTLEVTNKIARQLQGIASKVEGVQSVSSLAGYEVLTEGRGSNAGTCIIN
LKDWSERKQSVHQIIEELEEKTKDFGAVIEFFEPPAVPGYGAASGLALRLLDKTDNTDYH
EFDKINQDFMKALAKRKELTGLFTFYAANYPQYEIQIDNKLAMQKKVSIAKAMDNLDILI
GSTYEQGFIRFNNFFKVYTQAGPEFRRYPTDILNYYVKNEEGEMVPYSAFMKLKKMQGPN
EITRYNLYNSATIRAMPADGYTTDDAIKAVEQVAKATLPHGYDIGWEGLSFDEANRGNEA
IIIFGVVLVFVYMVLAAQYESFILPLVVVLSLPAGVFGSFFMLKALGLANDIYAQVGLVM
LVGLLGKNAVLIVEYAVQKHAQGLSIKDAAIESARVRFRPILMTSFAFIAGLIPLVVATG
AGAVGNRTIGSSALGGMLFGTIFGVILIPGLYYIFAKLSDGKSMIRNEEFEPLTETYHYS
KSDDDQE
>fig|265072.7.peg.449 Multiple antibiotic resistance protein MarC
MTGQPGTARVRHDGQHVAAYRLVDAAPARHRHTVLECILTVIFNNKKRTGTMSILEALKY
ISIVVIGLLPIMNPLTTIPLYMALTQRMTPETRKLQARKACIYAFFILTTFLLLGNGIIA
LFGISMAGIRVAGGLIILILALRMIFSGLDSSSSVDSEPEEIKSANLDYSFSPLAMPSLA
GPGSIAVVMSFGSQIPEGSHLIGDPIVIAGIAITIGIAYLALSSATHIEKMLGEHGMQAV
TKIMGFLLTCVAVQFLASGIRDFYIEFSTI
>fig|265072.7.peg.1404 Polymyxin resistance protein ArnC, glycosyl transferase (EC 2.4.-.-)
MTTDRSQSNPHISVIVPAFNESSAITSTVENIANQLATLSPHWDIVVIDDGSRDKTADIV
RGLPAYLRTTLVRFSRNFGKEYAITAGLEYASGDIVICMDADGQHSPALISEMLEKWRAG
YDMVYAVRQNRHIESGFKRWGSKLFYEIMTLGERITIPRDAGDFRLMNRNVVNALRKLPE
RNRFMKGMYAWVGYKSIGIPYTPLPRSHGVSTFSRLKLIQLAWTGITSFSVIPLRLASAV
GGLLALLAFIYGIWVILEKMFFHESIPGWPTVVASLMFFSGVQLLFIGILGEYIARIYDE
VKGRPPYIVAEVSASYQGKESQL
>fig|265072.7.peg.2382 Permease of the drug/metabolite transporter (DMT) superfamily
MKAGTSTTLRAFAALLLLAVLWGYNWVVMKHALDYAGAFQFGAMRTFYGAVCLMALLVLM
RKPLKPREVPTLIWLGVLQTCGFTGLIIWALVEGGAGKTAVLTYTMPFWVMVLAWPLLGE
KIRGIQWLAVLFSVMGLLFILDPLHLGSDLFSMSLAILGGVFWAISVIVAKKLHQRVPDL
DLMSLTAWQMLFGSLPLVAVAFIVPAPPIDWSINFIGAVLYNAVLCNALAWLLWLYALQH
LPAGIASMTSLLAPVIGVLAAWWQLGEEPERGEVIGMILIGVALLIISLHSMKRREVVNP
AMGQD
>fig|265072.7.peg.2506 Permease of the drug/metabolite transporter (DMT) superfamily
MPPFLAKFFSSRQQALGVLFALVSAIGFSAKAIFVKLAYVEPVDAVTLLALRMAFSVPFF
IVAMFYGQEKAVAMQRRDWLAVLVLGFIGYYLASFLDFLGLQYISAGLERLILFLYPTMV
VLISALLFRERIGRTVMVALLLSYAGIVLVFVHDFSMSGDGLFLGGGLVFASAFAYAVYL
VGAGHTIARIGAMRFTAYAMTVACLACIAQFLLTHPLDALRQSGRVYVLTANMALFSTVL
PAFALAAAMKRIGSMQTSMIGALGPVATIYLAYVFLGEQLSLIQFLGSVLVLVGVMMISL
RKKK
>fig|265072.7.peg.2607 Permease of the drug/metabolite transporter (DMT) superfamily
MSASSRDADAWGGMVSDDQPMTRLLGKSCSIVHHKLAYTMRLMQKPAVSPFTLYLILILP
PLFWAGNFVVGRAVHTDIPPFTLSLGRWVIALLCILPFAWPTMRRDLPLYWQYRWRLLAV
SVVGVAAFNTLVYSGLHHTTATNGILLNSCIPILILLFGAMFYRLRLHSLQLLGLALSFF
GVLTIILHGEWERLLSLAFSSGDLVIFTAMICWALYTLWLRDLPASIHRLGLMGAQIMVA
VIVLLPLFIWEQAHGQHARWGQETWLALAYVGIFPSVIAYTLYTIGVEKAGAARAGLFIH
LMPVFGSLLSVIFLGEHLHLFHAIGIAAILGGLALSNRHQHP
>fig|265072.7.peg.2613 Outer membrane component of tripartite multidrug resistance system
MHRNILKAFSTAVIAVLPGCMSMSGISTTAQPKDTAQLEAGHDISEARHDLPWPGEAWWQ
VFQDPQLDALVNHSLQQHPDIRAARSRTAIAEAQAQAAGALLAPQASANGTLVRERFTSL
QFIPPPWAGHTEWNNKATLNLGYDLDLWGQRAQQWQSALDRTQATAAEAQQVKLSLTTAL
VMQYIALSRAHALHDITHHRLDIAHQQLDIRKRALAAGLGTEIEVTEAESLIPALRAQLE
AGDERITLLRQQLAALAGEGPGYAERLHPPKLSLDADIGLPDALPANLVGRRPDIVAAKW
RIEAARHNIASAKAAFYPNINLLGFVGLQAMGFGKILTESGMVAGVGPALSLPLFDGGLR
RGNLAATTADYDLAVEQYNSILLQSLQEISAQLVTLRSNAIQHAELLDALRLAQRSRKLA
LTHHQAGLANYLQVLEAEHHVLTQHAALVDLEASRLSAYADLMKALGGGAGQPQ
>fig|266117.6.peg.200 Permease of the drug/metabolite transporter (DMT) superfamily
MAWRKGGFFGVLLVALGASLWGTDGVLRVPLLEDMSPLSIVFAEHLFLAAYSVPAVVIGR
RAFRGFGLPQWGALLVIGWGGSALATLLFTAAFAVGNPTVVILLQKTQPLFAIALSALLL
REPLGWRYWPGFAVAMVGAYLVSFADLSPFRQLPGAEALTAALALGAALLWGSSTVLGRL
VLREVPFHTLTGARLLLALPLLAGIVLAQGTLGQAAQGLAGHPGRLALLALLPGLLALLL
YYRGLSSTRASYATLAELTFPATAVVLNWAVLGVGIGASQLAGFLLLWGAVLYLSHLNAR
SPSPEGPALEPGRG
>fig|266117.6.peg.377 Daunorubicin resistance ATP-binding protein drrA
MVEALRMRGVRKRFRRRRGEVVCALEDVSLEIRRGEVVGILGPNGSGKSTLVRVISTLVL
PDSGSVEVFGVDALRHPKRVQRSMNRVSVEASFFKKLSAMENLLYGAKLYGVSDREARPR
IEEIMGHIGFDYKRAAEPMEHLSRGMQQKVALARALLTSPMLMLLDEPTTGLDPRSRRDV
QAFIRRIREAHDSSILLCTHDMGEAEELCDRVGIMVGGRIIALDEPRRLKERYASGGRLP
DLEEVFMAATGYTVEEASAEEGER
>fig|266117.6.peg.551 Multidrug resistance protein B
MSAAGHKNIIFIGVALGMLSAAAAQTIVSPAMPRIVAELGGMNHYSWVATAALLASAVTV
PVVGKLSDMYGRRGFFIWGLVVFMAGSALSGAAQGFWWLVAARAVQGLGMGTIMPLAQTI
IGDIISPRERGRYVGYLGAVFGVASITGPLVGGWITDNFSWRWLFYVNLPLGVAALAFVV
AYLHLPHTPRRHAVDYAGFATLAVGLSAVLLATSWGGTEYPWGSWQIVGLYGLGAAVLAV
FLVNEHRAEEPVLPLRLWKSGVFTFSNIANLAISMGMFGAIYYIPVFAQGVLGVSVTNSG
AITLPLMLAALPVSVLVGRMITRTGRYKLFLLAGVAVMWLGYLILSNLDYGSTQAELTLA
MVVVGLGLGAVMQTFTLVVQNAVTREDLGVATAATQFTRSTGATVGIAVFGTIMTNRMQT
EIPAHLPPAARRHSAALFGDSGGGVGAVLDPSSLSHLPAPVVEGIQQGLAAAMHPVFVAG
LPVLAVAFLATLLVKELPLRTVAFADMDRAVPGGRDDEARRLLLSGVALDWAARRIESAN
GDAPHLLRAAASLVGPDGGRSERERALRASREVIRPAARLLLAGYLLRRRPASGAAAGEN
GREEVVR
>fig|266117.6.peg.670 Permease of the drug/metabolite transporter (DMT) superfamily
MDSAGRRGSAWAELSLLLTAFFFGTNFVAVKHVVEEVPPVLFAAARFTAAGLLLWAVLRL
FEPASRLKRADLPPVAGLGLLGITATQTVFTIGVHHTTAANTAVIYSTAPVWGMLLGFAL
GLERPRLSGVAGVAMCLAGVAAIEGGGLRLAGTSLLGDALILLAAVFWGSYTVLSLPLLR
RYTPLAVAAYPMLLGGLAAFPLAALDLRVEPSALGGSVWFAALYSTLFSSAFGFVGWQKG
VARVGANRVLVYQYLVALSGVAAGMVVLGEGFGPLQALGAAVVLVGVYLARRRA
>fig|266117.6.peg.928 Permeases of the drug/metabolite transporter (DMT) superfamily
MKGSGRPGALLLLFALLVLFWGTAFAAIKIGVSYCPPLLFAGLRALLGGAVMVPLALARD
GVPDLRRGWRAFALLSLLNVVLFFGLQTYAVLLLPSGSAALLVYLQPILVGLLAWPLLGE
RLSAGGVAGLLLGFAGIAVVGAGSLSGGLEALSPAGVALGAASALAWAAGTVCFKMVQDG
VSTLWSVAVQFVAGGGVLTAAGALVEGWGRVAWGAGAFWASLLYASLVGVSLAWIIWFSL
VRAGEASRVSAYIFAVPLTAVAVGVIFLDEPFGPALLLGAALVVAGIYLVNRSGRVAP
>fig|266117.6.peg.1124 Fosmidomycin resistance protein
MDRRAMAALSAGHLFTDVNQGAVAAIIPFLVSQRGISLAAAGALVLASTVSSSVVQPLFG
VLSDRRPLPALMPLGVLVAGLGMALVGVAPGYAAVFACTVLSGVGVAAFHPESARFANYV
SGSRRARGMSLFSVGGNVGFALGPVLTTPLVLLFGLPGTLFLALPAAAMAAILIYELPRL
NAFRPGRGIEAGGGGEAAAEDRWGPFALMAGVVVLRSLIYFGLVAFVASYYVRVLGTSEA
WGNTALAVLTGAGAAGTLALGPLADRFGRRTVIVCSMLVLAPVLFAFAHAGPVSGMVLLA
LAGGAIVGTFGVTVVMGQEYLPRSIGLAAGVTMGLSIGLGGAGAPVLGYFADHYGLHATM
LLISGLPLPALLLALALPGGGRV
>fig|266117.6.peg.1146 Vancomycin B-type resistance protein VanW
MSLKRVAGRDAPRRGGRDDAPWERGSSGRAGTGGARRFVGPFIIALAAVAVLVALDYWMN
AGRIYRGVEVGDVALGGKTPEEAREIVLRRAEGALERVELRGGPEGEISFDARRMGIDYK
VRETVQAAYAVGREGNLLERLGERLRAAYGTVQIEPRVDYRPSVARQRIEEVASRLDRPP
RQAEVNVYGSEVDVVGSREGYRVDVEATMRSVGEAVEDMSGEARLVGRVLEPEYTTAEAE
RAAERARRALDGELVLTYEGRRWTVSPAAIGDSLDITARDGEFRVGVDRDRLRENLSGVY
AAINQEPVEAGYEISGEQITVTPSRTGRAIQDEKLLGAIEEGIFEGRREYRIPVAVDRPE
LTTAEAERLKPTDLLATYQTNYLTYDDSPGRVENLEIASEAVDGTLLAPGEVFSFNELAA
PLDYHDTKVIINGRVDTAEGGGLCQVSSTLYMAANLAGLDVIERHPHYAELPYIRPGFDA
TVWFGALDMKFKNTSPGYILIREWVDRSTGTVNAAIYGRPSGIEVDMRSEKVSETVDEEG
NPVTTWITYQTVRKNGEVVFDGVLHKDVYKYLKPAAPDAPYDERPVN
>fig|266117.6.peg.1151 Permeases of the drug/metabolite transporter (DMT) superfamily
MVAVGSAAVLIRLAEAPALAVAFWRCALGAALLLPFALARRERFPRGRELRVGVASGVAL
GAHFGLWISSLDYTSVAASVVLVSTQPVFVAVLAYLLFGERTSALSLAGILLAIAGTVLI
AADRSAGQAAPLGNALALAGALAVAFYVLIGRSSRTGGLGVLPYSVVVYSSAALVLLAAG
LAWGVRMWGFPPETWLWLWAITLGPQLMGHTVFNWALRYVEASVVSGSILAEPVIAALLA
WAVLAERPGWPTLAGGAVVLLGLALLLRGHRRGAAGP
>fig|266117.6.peg.1956 Drug resistance transporter, EmrB/QacA family
MGLSRRRKILVTLATLIGTFLAALDSTVVGTAMPTVIGDLGGLGLYPWVFASYLLAATVT
GPLFGRLSDAYGRKPVYLAGVSLFLLGSVLCGTAGSMGALIVYRTIQGLGAGAVQPVAVT
IVGDIFELETRARIQGLFGAVWGVSAVVGPAAGGLITDYLSWRWVFYVNVPFGLAAGALL
ALALRESFERRPGRADYPGVFLLTGGLLAVLLAVLGAGSLLADLALLAGGASALALFVLA
EARAPDPIVPLELFRERLFAVASAGNAALGGVLLGVSVYVPLYVQGALGGTALTAGTVVA
PLSIGWPVGSFVGGRMLLRAGYRTTLLVGSAFVVAGSAMCLALDAATPLAYVILSVFVIG
LGMGFSSTSYLVSVQNAVPWHRRGIATSSVVFFRTIGGSLGVAVMGALLDLSLGERYRAA
VERAAGENGALARLLSDPNALLQPALRAKIPEGAYGELASALASALSPAFWAVAVMAVAA
LAVSALFPAGRAEDFVKREPRP
>fig|266117.6.peg.2302 Kanamycin resistance protein-related protein
MAGREKEGADIHAEELDTLRGGEVSLRPPREEDVETVYEWDRDPELAAWNGRAPVSVSLE
AARRDYLLRWEDPGVKTFIIEAEGRPVGLATLYDFRGGGCELGIKIGPEELRGRGYATEA
VRLLVDYAFQRLGLRVVRGSTLAHNRRMRRVFEKCGFERVGEGSILSRYDNRRYAEVFYE
RRRH
>fig|266264.4.peg.4109 Glyoxalase/bleomycin resistance protein/dioxygenase
MEPAHPASPRDAWQFDHLNVSIGADHALRALFEGVMDMHPGYRPPFPFPGLWLYEGDQAM
VHAVDDDSLSASSGEVRMGHIAFRSQARATDVIARLQAAGLRFRVAHVPADGTIQIFVPL
PGGLVVELDVPGDPDIATSHQYSAERRAPDASDI
>fig|266264.4.peg.4941 Permease of the drug/metabolite transporter (DMT) superfamily
MSATVPSTASSRAPATTGFRSFLPLIGAVVIWGGNWPVMKMGLAHISPLWFAACRFGSAA
LISFLVLGALRRLRLPSRQEWPLVIGVGLLQMGAFTALALWALQYVPPGRASVIAYATAI
WVIPLSSLVLGERPSRLQWLATAFSYAGIAVIVAPALGGWELHTVMGLTMLLGASLAWSV
SIIQLRANRAIRLGADMIPWECAVATVPLIALAWLRDGAPDLGAMVDIWPVIAYTGPLAT
ALTFIVVLNVTQSLPPAATSIAMLGVPVIGLVLSTVAWHEQISLDLSIGLALIGMGVVTT
ALAPRLGRLAAR
>fig|266264.4.peg.5001 Multidrug resistance efflux pump
MDALILGVYALAVWLVFFKFKWLPWNTPTMVIVVTIPVVAMTVLVLTLNVVAPSSHDVRV
VGKVLQVVPQVRGRIVELPAEGNRSYKKGDVLLRIDPTPYQASVRQLEGRLMADDAALAE
AEAAARQLSESVRGAAGRVSAVQARLSLARRRVSEHDALLSAGAGSKFDREEASAREHEL
EGDLLSAQAAEEEARQKLSAKSQGEFVAIATARAKRAETEVMLENARWELEQTVYRAPSD
GRVVNLQVRVGTMLVPFPFSPAFSFVEDQQEVLAFYHQNELYNVKTGDLAEIYLPTAPGE
IIKARVDSIVWAQSQGQFAQGGMIPNTGATDVVPNRFAVKLALRDESSGLTLPVGAVGAG
AIYTERMEMFHIIRMVFLRVSSKLNYLVFKLH
>fig|266264.4.peg.5174 Inner membrane component of tripartite multidrug resistance system
MGSWPSARDWVFSIKAFVAAMLALWIAMYLGLPRPYWAMGSVYIVAHPLTGATRSKALYR
VLGTLLGAAAGILMVPPLVNAPPLLMGAVAIWTACLLYVALLHRTPRSYVFMLAAYTLPL
VALPSVDNPAGIFDLAVARSEEICLGILCASVVGAVVFPASVANVLRDKSRQWMADATLW
ASDMLSASPGKQVSRHHSRHRLAADILALDQLISQLSYDAESAQRVRAARELRGRMTMLL
PVMSSLATVVESMQSAGGVPEPLAAQMRAVKAWIQAGAAEGERPELTSTPVQAGWDAALV
AAAEDRLQQMAALWHDCVSLCRRLGEKHIEGEWLPEFLRWDVGRARHYDHGMLLFSTVTV
ALAIFAMGMIWIHTGWADGAGAVALGAISCCFFAALDEPAPMIQSFFNWNVVCLLISMVM
LFAVLPIAHDFEMLVLMFAVPYLIIGLLVAQPRLAMIGMPLAVVTANDIGISGAYSANFQ
SFFNSNLAGIAGIAFALVWTLAVRPFGTRAATRRLVRSGWSDIAENAVSTRPESHSTLRA
RMLDRLAQLVPRLAASESEVSADGFSEVRVELCTLALQREMAELEADEQHAVNRVLRSVS
GYYQSRLKGAIDAPPPALLTRLGKAQQKVRSRIALAALVDLQVALFPPVVVPATVSGKA
>fig|266264.4.peg.5622 Drug resistance transporter, EmrB/QacA family
MSAPQAPSAPHSPPDVPVMQVIFGLMLAIMLGALEQSIVAVVLPEIALQLNGFEDMAWVI
SAYLVASTVVTPIYGKLSDVLGRRSVLTFSIVLFVLASIACAMATTMPMLIVARILQGLG
GGGLISVSQATIADVVPLRERGKYQGYVSGVWAVASMAGPVIGGYLAHFLSWRWIFWINI
PLGLIALIVVRRALRHLPVSGRKHRIDYLGALLFGGGLSGVLVFLTRMGQGHSPLEPQTI
GLLAAGLIGLVLFIWQERRAVDPVIPLKMLAVPTVAICCLTLFLCFFQLIAMSVLLPLRF
QVVGGAGADTAALRLVPLTLAIPFGAYASGRLMSWSGRYKPLQLAGCLVAPIAIVGLAFV
PPQAVVPAALVMIVLGLSIGLQLPSGLVATQNSVPPQQVGIATALTAFSRLLGGAVGVAV
LTTVLIALLRHSGMAVSDLHGGEDVLMSMFRRAMDAGDQGDAAAVREAAEHAFRLLFLMS
AGVSLIAPFFVMRLKEKTLRGSPAGAAASAAAE
>fig|266264.4.peg.5968 Outer membrane component of tripartite multidrug resistance system
MSVSFRATLLTLAAAMFAAGCTVGPDYRGAPQVAGNAIDTGKFPRAGEGTDSQTPRVADW
WHALGDTQLDGLIESALKQSPDIRVARARVRQARAGLAGNKANLFPTVAVDAATLRTRSP
NLSALSGQGSSNAGRGPLSLYIAAFDASWEIDLFGGTRRSIEAASAEADAADAQLADAHV
QLAAEVAQAYITLREQQESLAHLTSSEQLEAEMFELTQQRRARGVASQLEVERLMTQLDN
TRAQMSPVQASIAESLDQLAMLTGRSPGTLDAELSAPKPLPGVPETVAVGDPGALLKSRP
DIRAAERRLASSTAQIGVRKADWFPKLSLLGSLGFAATDPSHLARKENGTWMTLPRLQWN
ILDFGRVAAGVEGAEGGRDEAEASYESVVLKALRDADVALSRYGHQREHVVVLRRVEASA
ERASTLQQQRYRAGTASMLEWLDVERTRVVAQQSRISGDADLLKDFVSLQKSLGLGWQSS
AAPAS
>fig|266779.9.peg.1518 Permeases of the drug/metabolite transporter (DMT) superfamily
MSALIKAAGNVPAGQIVFFRSFFAIFPIVVMLAWQRELGTAFHTKHPMGHVLRAIVGVAS
MGFGFFGLTRLPLPEAVTLSYAQPLLVVVFSAIFLHETVRIYRWSAVLIGFVGVVIIAWP
NLTLFAGDGPGMETEQAIGVIATLVGAAFSAVAMLLVRRLVHTEKTSTIVMWFSVTATVI
SLGTIPFGWVWLSFWQFLFLAGAGICGGIAQIFMTQCYRHAELSTIAPFEYTSMVLAIVV
GYFAFSDIPTIYTLVGGLIVVVAGLLIIWRERRLGLKRVAARRFVPPSP
>fig|266779.9.peg.2208 Permeases of the drug/metabolite transporter (DMT) superfamily
MLQALPLAVTMGAAMVLAEPVGWRRWSAISVGFVGVMIIVRPGLGDFSAWSLLALLTVGF
CAVRDLSTRLIPQDIPSVGVSVATSAGVTLSGAALLPFTGGWQPVEVPSALSIFLAGILV
VVGYQFVIKAMRQGDISFMAPFRYTSLLWAILLGFLVFGDVPDALMLFGSALVVGSGLYA
LYRERIVGHDLPITESTAPAITTSGLDTKPVHDRRI
>fig|266779.9.peg.2500 Probable antibiotic-resistance protein
MRIFDCRLRPPFGEFLTTSYFTDVPRITRMAAEMGLEAPASLAETSMELLFTEMDAAGVG
VGLAAGRISPGLGNVSNASVRELCRLWPDRFVGLAVVDPGKAAEASAEIDRAMRDGFKGA
LIEPGLLGNALAIDDRRIYPFYSHCEDAGIPLFIMAGGNAGPDLSFTNPEHLDRVAADFP
RLKLVSLHGSWPWVLQILHVCLRRQNVYLCPDMYLAGRMPGFEEYVRAANGFLSDRLLFG
SSYPVLALDRAVKSVQQIGFRPEVLERIFFRNAAALLGL
>fig|266779.9.peg.3340 Acriflavin resistance protein
MNVSALFIRRPVLSTVLALLILLLGIQGLFNLSVREYPEVEETVITVTTTYPGASPDLIQ
GFITSPIAAAVSTTENIDYVSSQSRPSTSVVTVQMQLGSDSDAALTEVMSKVQQVRGQLP
SDADDPTIVKGTGMQFAIMYIALQNPNMTPEQLTEYIERVIRPRVSTIQGVAEVQIIGAQ
NYAMRIWIDPIRLAARGVTAGEVVSAVNASNFLSAPGKTKNEYVAYPITTETTLQTPDAF
AALPLKSEGDEVVRLRDVADVELAAESTETIVNFNGRPGTFIGIFPTPSANPLDTADAVI
AEMPAIQATLPEGMNMEVVYDATESISASIEEVFKTIGEAVAIVVIVILLFLGSFRSVLM
PIVTIPLSLIGVCFLLFLAGFSINLLSLLAMVLAIGLVVDDAIVVVENIHRHMEEGMSPF
QAAFTGMKEISSAVVAMTITLAAVFAPLAFTGGLTGSLFREFAFTLAGAVVISGIVALTI
TPMMSARILKSGSHSRFQSFVDRTFTRLENRYERLVSGSLKYRPVTLMIVIALVSLTGFL
FFKTSSELAPEEDVGALFSIVNAPRYATSEYTNLYTTQMRDLTEDLPELRVDFSIVGFGG
STNSAIALWAFKDWADRNRSQKEIQQDIQQRISKVAGVEAFVFAPPTLPGTGGGLPISVV
IQTTGDPSQVYEIAEEIKNKAQQSGRFIVVQNSMAFDAPQVTVSVDRERAAALNIPASEI
GRTLGALVGGGSMAQFDRDSNSYDIITQVPEAYRSNPESLGGYFVRSATGGMVPLSAVVS
IKTNASPAAIEQFNQLNSATISALPRPDVTTGTGLQTIEEVARTTLPEGFFLDYSGQSRL
EKEQGNTILVAFILAVVVIYLVLAAQFESFRDPLIIMMSVPLSIFGAIVPLNLGLGTLNI
YTQVGLITLIGLITKHGILLVEFANQQREVHGLSRREAIVASARVRLRPILMTTAAMALG
VVPLILAQGAGAAARYSMGLVIFSGILIGTMFTLFVVPMFYTFISSRDIHVRGQVPEDAA
PAHA
>fig|266779.9.peg.4090 Acriflavin resistance protein
MDIVRLAIRNARLTLSILLFFIVAGSLAYINIPKEAEPDVPIPIIYVSLAYQGISPEDSE
RLLLRPIETALKSLEGVKEMRSAAYQGGGFVLVEFQAGYDFSNAIEDVRAKVSDAKGELP
EDAEEPTVNEVNVSEFPILVVTLSGNLPERQLTIAAKELRDRIEEVPGVLEGALQGSRDE
LLEVIIDPVKLSSYNIQLDQLISGINASNSLVAAGALQGQEGRYAVKVPALIENSEDIAN
LPIVATRDAVVRARDLASVRSTFTDAETITRLNGHSAIAIEVKKRVGANLVETVDAVKKI
SEEFVTAMPEGVSVTFSQDKSTMIRDMLDELQNHVVIAIILVFIVVLYTLSGRASFLIGL
AVPASFLMGIFALSMLGYTVNMVVLFSLILAVGMLVDDAIIVTEFAERRMNEGMPRAEAF
ELAAKRMAGPVIAATMTRIAAFSPLLFWPGIVGEFMKYLPITLIVTLAASMAYALIFAPT
LGAMFAKAHVEEERKRDGWYIRLVKQAVRFPKTVLLLTIALLVGVQWSYSKWGAGVEFFP
SVEPEYGLMYVHARGNMSLDEMDRLVRPAEEKLLNWPGIESVYTRVGQTRGGGQDIDEDV
IGIIQYEFVDWRERKPASEILNDLRAEMAGMPGAEIEVRVPDAGPPTGQPIQIQLSAADP
QYLNDQAAMVAERIGQIDGVIDISDGLPPPGVDWALEVDRAKAAQFGVSPVAVGTVVQLV
TNGLKLSDYRPAGADDAVDIRLRLPEDRRTLSMLDQLRVETPEGPVPISNFVTRQPERST
GILNRIDAQRTITVTANVASGYQVAEVQAQVTAALQDMNLGATRWKLAGSSEESDAAASF
LTNAFGAAIFLIFVVLLAQFNRFTSVFLVLMTVVMATIGVFLGLLITGQPFGIVMSGIGV
IALAGVVVNNNIVLIDTYDRLRDEGMSKYDAIIETCRERARPVLLTAFSAVLGVLPIAFG
LGLELFHHEVTIGAPSTQWWISLSSAIVYGLTFATVLTLIVTPSALMVFTREKRPAGQKR
GGLISRLFRRRKGEKAADEEKPDADHGGFTAFPKAAE
>fig|266779.9.peg.4652 Permease of the drug/metabolite transporter (DMT) superfamily
MITRFTPILVLVAFLNALCFPLITVGLEHAPHMTFAALRAIVAGMSLALVAALLRRPIPM
DLRMWMALGAMGMGATGFAYFGMFHAAEFVSPGLATILTNTQPLIAAVLAFAFLSERLRP
SQYIGLGIGFLGIVTVAMPRLGIGNGPGELFALSYLILAASGLAVSNVLMKTVRSRIDPL
VAMAAQLLLGAVPLAILALLTEQPSDIHLSADFVIALTLLALPGTALSYWLWFWVLDRIS
LSHANAFTFLTPVLALLLGVTMFDEQIGPPLILGLLLTGIGVVIVERNSRSRIAPTT
>fig|266834.1.peg.595 Multiple antibiotic resistance protein MarC
MLTIKSLAIAGLLGRTMLENFEISLPVLAMTGGIILFLVALRTVLHQSSSLPDQTTEPGQ
PSDLRLALTPLAFPTILAVIVFATLAGGRQAEGRTVAAIVLLILAMDWAAMIFAESILRW
IGTSLQVLAVVLGVTQAALGLQIILHSLSTVSW
>fig|266834.1.peg.1065 Permease of the drug/metabolite transporter (DMT) superfamily
MSARILCQQMFVWHTARMNKNAADIPMTPFLPALAIAGTVITWSFSFAAIGYALREVEPL
PLAAIRFALAAVFAIAWIAWRRPRWFLPRDFVVLAISGLLGIAAYNVLLNLGQAAVSAGA
AGFIVNTQPLFMVLLAVLFLKERFGRWNWVGTIVGFSGVALIASGQPGGLSFGTGSTLIV
LAAACAAAYSILQRPLFARAEPLDVTGARHRCRRSRPHALATGRRLPIDARASGHLADDH
VPGRRSGHYRSKLLDLRTQEFRCRAGRSISLFGSTVLCWTGVAPAR
>fig|266834.1.peg.1221 Glyoxalase/bleomycin resistance protein/dioxygenase
MRKTPIKCQTTPGCPVSGHLKRPLLDQTIPCRLERHPGDWNVALKRMDNVGIVVEDLEGT
IEFFRELGLELEGKATIGGEWAGRVTGLGDQHVEIAMMRTPDGHSRLELSRFLTPPIVAD
HRNAPVNSLGYLRVMFTVDDISETLERLRTRGAQLVGEVVDYEDVYRLCYIRGPGGLLIG
LAQELG
>fig|266834.1.peg.1474 Permeases of the drug/metabolite transporter (DMT) superfamily
MAAAAKRVYHHPMRSKTNGYVFALLAIVIFSIQDGISKHLGAIYPPVFVAMIRYWAFAGF
AAAIAARAPGGFAATAVTRKPLIQLLRGVLLPVQIVVVITSFTIVGLAHSQAILAATPLF
VALLSMPLLGERVGWRRWSAIAVGLLGVLLILRPEDGSFDLNFLLPLAAAVMFAFYVITT
RLASREDSAMTSFFYTGIVGAFAISLVGPFFWATLSGADWVWMVLLCITGTSSHYFLIRA
YDMLDAAAVQPLTYLQLVFASIMGVTIFGETLTTGMIIGSVLVVAAGIFTLWREHVVGRQ
KSRLPPR
>fig|266834.1.peg.3498 Permeases of the drug/metabolite transporter (DMT) superfamily
MSELSLSKAAIDHNRISYGLTLMVLSVLLSPLIDIFSKLAIATVPSAEITAARFLLQIVF
ILPIVLVRGTLFDLTWRKSALHALRGGLLVVTMLSFITTLKVMEVADAIAIFFVEPIILT
ILGSIFLKETIGWRRYTACAVGFLGSLLVIQPSMQEVGLVALLPIVAAFGLAVFLLVTRM
VAQNEDPWSMQFHAGIWGGLFCLALLWFGEGSGSSVFDPVWPDGRAWYYLLGVGVTATIS
GVLGVYAYRAAPASVLAPLQYLEIVSATIFGWLVFGDLPDALKWLGIAIIIGSGLYIIWR
ERQVQKTAGIAPVSPAI
>fig|266834.1.peg.4253 Permeases of the drug/metabolite transporter (DMT) superfamily
MSVDATVAPAAGGLPRNLRAAALGFLAFAVFSGTDVLVKLLAERFEVPQVTFMVTLAALA
MLAVYAGVTGTTASLRPRHPGLALLRAFLLAVDTLLIHYAFSVLPLSEAYLLAFLTPVLV
AVLAFALLAERLSMLAWCGVVVGFLGVAVALRPGIAPLNLGHAAAAGSALVFALSLVLLR
RAKATESDLALVSTLLVVLAAVALAVASIGGGLAPVGPGDLLIAFFAGLFMLGGHLLLVR
AFRMGDASVVAPFQYSQIVWGCLYGALFFAAPIELHTVAGALVIVLSGWLVLK
>fig|266834.1.peg.6040 Multidrug resistance protein B
MTIATATPSRDISMAGGLLVAGIVLATLTEAIASTVLSLGRGDIIGDTYATPDEFAWLDV
GYTTFKLIGFMAASWLMSRFDPRNLVVGSTLAMGMACGIAAMTARLDLLVALRMIQGFSG
GTLLVGGQAIIFLTFPHSRQPLLQAFFAMGSVVAPATIAPALQGLLLDSQSWTWIFFSII
PLALAAAGLLLLADGPVATRAQRRPFDWIGFSLISAALFCFTYVFSQGSRWDWFEEPRIL
WLAVIGTATLLAFLGQQVLAKGQGLFDFTLFETEDFCFAFIVSFVAGAALFGSAFLIPSF
AVSVLAFTPTDAGQLLLPSGALFIGALLIAAFLMQLRRVPPVATVPFGILMIMAAMWMLS
GSTSESGAGDMMAAILLRGAGLGFLFLSITLIAFSNLNSRNLASGIGLFNTGRQLGGLIG
VSALQTLIEHNVSHNLAVLGANVTAGAPAVADRLTTTAALLTAKGMDAAAASRGAASLLG
RAVAGQSTVIAFDTAFNAIGLLFVIAAPVLVGIKIGLARYAKARAEKGRAGVAAKPSGHH
TLPIKRVPAS
>fig|266834.1.peg.6041 Membrane fusion component of tripartite multidrug resistance system
MESLEEKVAIITGARSGNGVAVARPNRKKMIGLALCLGAVVVVVAGWTWARESGAASTDN
AYVRGDVTSLAPKVAGYVTAVEVEDNQAVRAGDVLFRIDDRDYRAKLAQAVANVEAAEAR
LTNVDAEMALQHALIRQAEAQRRSVVAELNLAAKAYDRRRELIRSETISQAHVDESDAAK
SRAEANVLAASATVEAQQQRIAVLAAQREAAVAAVAQAEAARDLAGIDLESTVVRAPVGG
VIGNRQVRVGRLVAPGASLLDIVPLDNVWIVANFKETQLEHIRPGQRASITIDGYKSGAL
EGVVDSFAPGSGSAFSLLPADNATGNFVRVVQRVPVKIRFAGNPLSGRLLPGLSARVEID
LEGGS
>fig|266834.1.peg.6058 Permeases of the drug/metabolite transporter (DMT) superfamily
MTHQPISLSAPRHHRLLWPMMATLLVVGWSSGFVGIRYASEEAGVMLVLFWRTLLSGVIL
LPFALTIGPLLRMRGIAEQMLFGVMSVFLYLGGFALAIEQRVPTGLVALISDLLPLAIAA
LSQPVLGERLSARQWFGTAIAVFGVLIVSFDSLSFGAAPLWAYGLTVGSMLVFALASVLH
KRRRTQHMPVHQSLCIHTLTGSVLFGLCAMMQGDLAPPLTRAFAVGMVWLVLIATFAAYS
IYYTSLRLFPVAQVSAAIYLSPPVTMLWAWALFSEPLTAATFIGLTATLVGVWMTSRS
>fig|266835.1.peg.204 Permeases of the drug/metabolite transporter (DMT) superfamily
MHFIPASIRGPLFMIVSTGSYLVNDTMMKLATAGLPSYEVLFLRGVAAALWGFPLLFLLG
YGKQIPLIFDGHVLRRNLLELAAILCYVVALANMQIADSTALGQITPLLMLVGSSILFGE
RIGGQRMALIGLGFIGALMVAQPTMQGISVYALLALGNAALSAARDLAGRRVSAEVPGMI
VAISAVVVVLIGAGAAHLVSERWVMPEARHLLLMAGAGFFLIFGHFFIFMAYRVGPTSAV
APFYYCFTVWAVISGLLVFGQFPNALAVCGILLVVASGLTIVSLDQRKRRLTVVA
>fig|266835.1.peg.1997 Permeases of the drug/metabolite transporter (DMT) superfamily
MKSSSLAGAVSPMIPVLVCAFGIFLLSGMDAAMKVLVIAVGVYNTVLWRSMLATLIAGAG
WLAGPRSLPTAAVLRLHALRAVVVGIVLMSFFWGLARLPLAEAVGLSFVAPLFALLLAAL
LLGERIQRKAIWASLAGIAGVAIIVAGQFGQKTYAGDALLGTAAVLVSTVFYAYNLILAR
RQAMLAKPIEIMLFQNLCVAVMLGLAAPWLAISLPSNLWLPLAGVTALSLAGQFLMSWAY
ARAEAQYLIPTEYSAFIWAIALGWFFFDEAVTWTTLAGAGLIVASCLIAARSNPRLAEPI
EVAV
>fig|266835.1.peg.2001 Multidrug resistance protein A
MNKVLSAAELQPAQPSAVQIPAPAKSRRKPIVMLGAAIAIGVAGWYGFQWWQAGRFVMST
DDAYVGGNVTPLAPRVAGHIDQILVEDNQHVDAGQLIIRIDDRPFKAAVERARASVQQQQ
SALDNLRAQVSLQNSLIEQAEADLEAKSAAATFTTQDAKRYEVLASTRAGSQQDAQRSLA
ADGQAKASVSASRAGLAAARQQLDVLNTQISEATAAVLAAKADLDTAELDLGFTQIRAPI
DGLVGNRLAQVGTYVSPGSYLLTIVPQSGLWVDANFKEDQLRRMADGQAATVYTDIAPDQ
PLKGHVSSLGPATGAIFSVIPAQNATGNFTKIVQRVPVRITIDPDQARKVALRPGLSTVV
TVDTGAH
>fig|266835.1.peg.2080 Kanamycin resistance protein
MSSRPAETGLPNGLRQLVSGYRWHRQTIGQSQAGVFRLAADGRPALFLKCERSGPFAELA
DEAARLRWLTGQGVACPDVIALESHAGYDWLLMSAVAGEDLASAAIDQADVIGIMASALR
DLHAIDIRSCPFDHRLIRRIAAARARMEGGQVDESDFDEERQGRTDAEVFAELEALRPAT
EDLVVTHGDACLPNVMTAGGGFSGFIDCGRLGVADRHQDLALACWSIRYNLGQVWIEPFL
KRYEPPETEPAKLSWYRLLDEFF
>fig|266835.1.peg.2121 Permeases of the drug/metabolite transporter (DMT) superfamily
MKDLPTSRFPAASLALAMMIAGTVGAFVTEAGLHPVTIVFWRCVFGAMFLGAWCLLRGYL
PDRTLSPSRLALAALAGACMVLSWTAFFAGFAMTSIATTTIVYHVQPFFVVIIGVVFLKE
RISLDQMLWMLGAFLGVVLASGLVVSHAQASAAWALGIALTLVAALLYAVATILAKGLGQ
QRAEVTVLCQTIIGIVMLAPFAGIGQHVPAHSWGWLVSIGVLHTGIAYVLMNSAFPRLTT
PVIGIITFIYPVVAIIIDWAVYGHPLGPAQAAGMALIALATLGVRLGWRFPLRRVSAA
>fig|266835.1.peg.2706 Permeases of the drug/metabolite transporter (DMT) superfamily
MKNRMVRGILSLCLGVLVFSLQDPLVKAVSSGYPVTEVMAIRSIVALPILIILVHADVGL
RAILSKRFGLLTIRAFIQFTSYTVYYLAIAALPLADAVALYFMAPLFIMALAGPYLGERV
SWRTLATVLIGLFGVIVMVRPGAGLFDWAALLSLGSAALYGFSQLMARKIGDTESSTVMA
FYQNGAYLVGAAVVAGTFHLAGINHAVHPSIEFLVRPWIWPTLPDFLKMAACGFVASAGM
ILLSQGYRLAPANRVATFEYTGILWSPLWGFLFFAEVPRSTTVIGAALIIGAGLLALNTA
RRRSAAPVLAAADPV
>fig|266835.1.peg.4097 Permeases of the drug/metabolite transporter (DMT) superfamily
MSSGCAPSASIFKLLSPRKWKNVPNGILLALLAYASYSGSDAVIKSLGGQFTVFEIGFFV
TLFAGFFLFFARPAGERWRDFWRMKRPWAVQARAWAGIASGVLSVYAFTHIPLAEVYALI
FLAPLLVTILSTVILKEKVGPWRWLAVVAGFAGVMLVVRPGFRELNLGHLAAFVNAFLAA
TSVILLRSLAQQEKRTSMLGVLVGYGLLFNGAGAAATSFTLPNAVQLVWLAMAGAFTAGG
QFMQLLAAKYAPANRIAPTHYSQIVWAVILGALFFQEYPDWLTLVGLAIVGGSGLLTMVR
EEVRLGTVRWNPFARTRL
>fig|266835.1.peg.5120 Permeases of the drug/metabolite transporter (DMT) superfamily
MTDAASSPGLVASTFSPREERVGMLLVFLSALMWSFGGTIARFITVGDSWTIIFWRSVWA
AAFLVLFMTWRDGWRGMLRSFRDMGLPGLGVGFCFAIASTAFVVALAYTTVANILLMQAG
VPLLAALLAWALFRERVGVVTWVAIAAVIAGVAIMVSESLDGAVSPIGDGLALLIAFMFS
IATVITRRFASVRMTPATCLGTLLAAGFAASQAAAFTVSAADMGFLFAFGVVNLGIGLAF
FATGARLIPAAIAALLGTFEPILGPIWVWLIHSEVPSGRTIVGGAVVVTALLVHIGFEFK
RQARPRRAGITGVPSPN
>fig|266835.1.peg.6162 Permeases of the drug/metabolite transporter (DMT) superfamily
MTDAAAAKPEATERTLGIILVSSSAAVFGLTGVLTKSIHADPLTITCWRGFVGSILISLY
VLWRHHRSGNRGTLRLGWRGWLLAVEGALASIAFISAFKFTYVANVAVIYATSPFIAALL
AWVLVREPFRLQTMLAAAVSMCGVGIMVWSGFGTGHLFGDGLALLMTAGSALYMIMVRAF
RDTPVVWAGAVSAFLLFILGWFITDPLAVSARDAVLLVTFGASFALSSILWTEGARLIPA
PESGLLGSAEVPFAILFAFLFLAEIPPVASMVGGAIVLCAVFVHAGRDWLAARSHQAASN
IS
>fig|266835.1.peg.6234 Permease of the drug/metabolite transporter (DMT) superfamily
MVQHRDRAPGRLFRHGSSSISALVFAAGAVALWSTNALVGKSLLATHPVSQVQFLQFAGA
ALVFALIRFMSREAAPSVAPRAAVAALAVGIIGLVGTMVLQYIAFASMPVIEANLVAYTW
PLMVAAAVIAFDNPRRPALLGLAAVLGFVGVALVISGGRENNWFQGDLVGYFAAFGSALC
MAFYSVMVGRLATSPDRLLLPSSLVGVALALLWSAGEGVAWPAGMDLALGLYLGAGPMGL
GYYFWSRALKLEGSGKVAVVAYLTPIASTLLLTLSGEQLTTTAIAGAVLVIGSCIAVGLE
RSEAQDYV
>fig|266835.1.peg.6505 Permeases of the drug/metabolite transporter (DMT) superfamily
MSAMTGTLNQTQRMDTTAAIAVALTVVGWASAFPAIRAGLAAFGPLELGALRFAIAAVPA
AIFLAVKRPALPRLDEVWRLVFGGAIFVALYTAMLNFGELTVSAGAAGFIINVSPIFTAI
MAMALLGERFSRWAWAGTAISFAGIGVIAMADGQGLHFNAGALLVLGSALCSAVNTIVQK
PLFARHHPLTISASNMVLGALCLSPFLPSGFAQAAVANTAGLGAVIFLGIVPSLIAYAAW
ATALSRLPAARASNFLYLVSPMSALIGFFWLGEVPTLLGILGGALALGGVIVVNLKR
>fig|266835.1.peg.6645 Streptomycin phosphotransferase, streptomycin-resistance
MDAPALPARWKVSAPELIAETFSSRIWKVVRDDGSPAVVKALKPFDDVADELRGEHFLAW
RRGEGAVRLLGRDGHSMLLEYAGETLLTQVLDEQGDNAATAIAAELMTKLFSPSQHPYPP
ELQPLTERYTSLFRKAATDRGAGHASIYVEAAAIAERLLDNPHDIRPLHGDLHHDNILHG
PRGWLVIDPKGVLGNPGFDAANMFYNPLDRDDLCLDPERIAHMAEVFAKTLGESPAAILD
HAIAYGCLSAAWHHEDDNAVEENRELSIAKAIRAMRANF
>fig|266835.1.peg.7242 Permease of the drug/metabolite transporter (DMT) superfamily
MVISPMTGSSREKLAIVCGFAAIYLIWGSTYLALAVAVQTIPPFALMGTRSIVGGVILLA
YSKAKADDGGSIRSWIRASLCGVLFFVGCHGVLAYAEQRMPSGLAALLLATIPFWIIVGR
SILGRSDKPLVRTILLLLPGLLGVVLVAWRSVAGPAALHLSDILLLLMASASWALGTLIA
EGHNNKGSSVALAGRELITGGAALMFLSLARGEPIGAVEQISLSSFLGWSYLTLAGTVVA
FGSYIWLLKKISPALVATYTFVNPVIAMFLGWAFLGEEVSVTTVIGGFLVVASVACLLVA
NRNSTHKEAASWSTPPKTAAAIAKG
>fig|266940.5.peg.2801 Drug:proton antiporter
MMLPASMALVREAFPDAARRARALGVWAVGGAVSALVGQPLGGLATSIDWRWVFSINVPV
GAAMLLALLAVAPSPTRPARFDAAGQVLSVLGLSALVYGLIEGGHAGFGAGPVVAALAVA
AAALAAFVAVQARGRHPMMPLNLFHARGFRLALPVGFAFMVANYGHVFLVSLFLQQQLDL
SPTHAGLVFIPAALFAIAGNLTSGPVTNRFGARVPVVLGQSCMVVGLLALIPATAQRSPW
LVALCLIPIGVGGSLAMPSVTSVVLEGVPSERAGTASAVFNTFRQVGGAVAIAVFGALIA
DPDTFTGGLRTSLLVAATLLTVTAVLSTRIQPRAHVG
>fig|266940.5.peg.2859 Nisin-resistance protein
MPSAARLCTRRSSRRLSGSELSPGRDAPPAAEARPSSRSSSSGPARTPGSRAEGRHERDR
DVRHGPHDDDRERQSRLRPPRGTGWSNSDPTPRAPTAARGSPGPTPAPAPRWVPQRFGHH
RGRRAPLHRGLPRRPRPRDRLPGPSAAAVRRLRHRWGQPQPRTARGQQYPVPPGGCRPRR
PADGFRTSAAPRRHRRPAHRPRAHRRCVGGLDGFPRPPACSTVLVMPTTDVETYARRALR
AIETRALHLDRANWPEHRAEVLGAARTATHPAQLHPLLRQAVRHAGGAHSGLIEPGRRSL
FDAQDHPLPTARLIGTTAVLSLPACPAGARGADAYVRAAAAALHHVGERAGAAGARGWVV
DLRGNLGGSMWPMLAAVAPLLGGEGRIGAFVDRDGHRTPWRLSRGCVGTARWALRRRALA
RCSDPRPLPGPVLVLTDERTASSGEAVVVAFRGAPGVRSCGRATHGSSTANDVVVLPDGA
TLLITCAALADRTGTVHTGRLHPDHPLQGTARTSGPAPGAASGGADAAGPAPDETLLRAL
ELLP
>fig|266940.5.peg.3527 Bicyclomycin resistance protein
MPTPLAVPTGRPRLGVLPGFLAALSPLSQLGFTPVAVVLGDRLGLSVGQVGLTVGIYAAA
AAVATLVLGPLFDLVSPRRVLPVAVAANVVLSASLLLEPGFAGILVSRVLSGLTNSALML
CASVVVADANRGDGTARERGFSRLQTFTSLGAVAGLGVGATAAGLGAPQVWSWTVVGYGL
VVLALTPAISRRLPAALPGVAGAGPGARVSAVLREVGAALRVPRTALLLVAAAGVGWAIQ
AAHYAVSLLSEQLHPPLWQRVLLAVMIPAGVFLGSSANQVLLGRRSAARVFSRAYPALPV
SCAVLALVVGAGGGWGVVALLTTLVVLGAVLGTLMPLSPAVLVGWHPGLRGSVTAADSVA
KGLGSTVSPVVLGAVAAATSLGAGFLVLAAVAALAAVCARAATPGPPQRG
>fig|266940.5.peg.3627 Drug resistance transporter, EmrB/QacA subfamily
MRPHRTSGDVAGHHDPHPGEAVAGQRMSTTTPTTSTQPAPGVAPKMSHKEILEALSGLLL
GMFVAILSSTVVSNALPRIVNDLHGTESGYTWVVTAALLATTISTPIWGKLADLFSKKLL
VQIALVIFVVASAIAGLSTSMGMLITLRVFQGLGGGGLLALAQVILASMVSPRERGRYSG
YLGATFALATVGGPLIGGVLTEHLSWHWCFYVGVPFAVIAFFVLQFKLKLPEQPRREVSI
DYLGAILLALGISALLIWVSLAGTEFDWASWWTVALVAAGVVFLALAVLAEHRAKEPIVP
LKFFRNPTIALSAAASLFVGVAMFGATIFLSQYFQLARHESPTMAGVMTIPMIAGLFLAS
TVAGQAITRTGKWKAWLVVGGVLLTAGLALMGTIEYDTNYWVVAPYMALIGLGVGMMMQN
LVLAVQNVADARDMGSASSFVAFARSLGGAIGVSALGAVLGHRVTSHLETGLSTAGIDPA
AATSALGSSTGVPDLDAIPAPLRAVVQAAYGSSIADVFLLAAPFALIAFVITLFFKERAL
RSDDGTGQDVAEATTSSPDRVAATTTGTPGAHGAARPDREETTSVPAQPTRTDTGLSLSG
AVRHHDQRPLAGAVVTLADQSGQQVSRTSTGADGSYRLALPTGGTYLLIVAAAHVAPSAT
LVGVGDTSITRDVTLSGRSAITGRVLAHEVTGDVDAGDHHGVRGALVTLTDVTGEVVGST
RTDGGGSYAFDQLMGGSYVLTAQSESHRPLARGVEVPDSGALACDLVLTGGGRLTGTVVA
ASDGRVLKEAAVTLVDSSGEVVGSVLTGADGSYSFEDLAGGHYTLTAAGFAPVATSVDIE
EDTVSAAQITLGSGDAPSTLDLTRFEDTSRVGEDRR
>fig|266940.5.peg.3990 Permease of the drug/metabolite transporter (DMT) superfamily
MTRRAALMFAALGFAWGIPYLLIKVVGEELPPSTLVLARTALAALVLAPIALSRKDVRAG
LPDLLRRWPALAAYTGFEIVGPWLFLARAEQDLPSSTTAVVISAVPVVGVLVAFAGGRAE
RLGRTGWTGLALGTLGVATLVGFDLVPGQFGAVAELAVVVVGYAVGPAVLSRHLGDLPGT
TVVLASLVLAALVYVPVVLLGPGLPAALPSGQVVASLVVLAVVCTAGAFLLLFALIGEMG
PVRATAIVYVNPVVAVLAGAVVLGERITATTLAGFALVLAGSFLATRKPANRPEQPAAPL
TVEV
>fig|266940.5.peg.4605 Drug resistance transporter, Bcr-CflA family protein
MRCTLDEAPEDTLRMTAPPTEPSTQPTQRTRRTAAARPAPRTPSTAGLVVLLGAMAALGA
VTIDLYLPSLPEVAVDLGTTEARTQLTITGVLVGAGLGQLVVGPLSDAYGRRRPAAVGFV
VYVVATLLCAVAPNLPALVAFRVLSGVGASAGAVIGMAVIRDLFVGPAAARLQSRLVLVI
GVAPLFAPTVGGAIAAHTGWRPVLALLAVAGLGVLIAVWRRLPETRPELTDTPAQARAEE
ERAPVTPPRGARVLRTFTGYGALLRDRRFLALAAMPGLALATIMAYVSTSVFVLQDGFGL
SGTGFAVYFAVNGTALVGGSQLNAALVGRFGSARLLRVGVAAAFVFGLALAGVLMARTDE
LLLFAVPLYLLLLVLGLIMPNAVTLALEPYGDSAGAAAALVTALQSGIGGLVGVLVGVLG
GDEHATGLVIGAAVVLNVVLLLSVSRSIRPSVRT
>fig|267377.1.peg.166 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MKTTKGVQNLLGDPKKAIVKISLPMVIAMSFQSLYNVIDAIWVAGLGSDALAAIGLFFPF
MFAIMAISNGVGIGGSSAISRRIGQNNKDAADNIAVHSIVLGIIIGILLIGVIPFLGAIF
SLIGASGITVTMAVEYSTILFGGAVVLLFTNIANAILRGEGDTKRAMYAIILGSVLNIVL
DPIFIYVLNMGVAGAAWATLLSLVITGILFVYWLFIKKDTFLKISFEKFKLDINIIKEIF
SIGLPASISHLTMAFSMFLLTAIVAKAGGNDGIAVFSTGWRIVSMGTIPLVGLATGVTVV
TGAAYGSANPEKLEISYKYALKMGILVETIIAALILIFENQITYLFTYSENSVHILEGLL
VFLKYMFLFYPTLPLGMLTAAMFQGVSKGNNSLFISLLRTIILQIPMAYTFGIIFNQGLT
GVWFGMILGHVIAVSIAYLLGIYTIRQFKTTLTPETVKFK
>fig|267377.1.peg.266 Multiple antibiotic resistance protein MarC
MDVQFIILAFTSLFSILNPFGVIPTYLVLTSQYSKVEKIKIIRKSMLAAFALLMMFALLG
NQIIGFFGISIPAIKITGGVLLFLIALDMIQGNTSKVEKSPKLESHLKSHSEEIEDMDEI
AIVPLTVPLLTGPGSISAVIAMMAQTSDFDGKLSVIIAISLCIIISYFVLKFSKDLEKML
GKIGFKVLTKMMGLVLTAISIQMALDGILMVFG
>fig|267377.1.peg.552 Transporter, drug/metabolite exporter family
MNKVKGTAYTIYSSVAFGIMPFLTKFAYDGGANAVTTLMFRFLIAGLILYVFLKFKKISL
KISRHNFVEILFYGAFLYALNTVFLYEAYNYIPTGIATTLHFIYPVTVTLLMISIFKENL
GINKVLALIFSFLGMYCLLGGNCAGFDIYGVLLAAGSGLVYAGYIVSAGKCKYSKIDSYV
TIFYLSILSSVLLFIYGLFTNTLTLNMAFSSYASIGLISIFCTVLALIAFLEGIKLIGPS
NTAILSTLEPIVSIILGILLLNEVLSFKIGLGSVLVLISVIIVTIEKSKVSDTVKN
>fig|267377.1.peg.670 Permease of the drug/metabolite transporter (DMT) superfamily
MNDRSLGILLMFLTVIFWGISFVSTKIILEFIPPITIGFIRVVIAAVILIFFIRNFTKYS
KEDFVYIVLAGFLGITSYYLFENVALKYTTATNASLIAATVPIFYLIVSDIVEKKIPSKI
KYFGSLIGLFGVFILILNGKFVLELNPLGDILMFGAVCTWVLYTFVIQKLQKHDDLKVTR
DITLIGAVFFIPFTIMELGYNGMFEFTILLNPYIAFSLLYLAIFCSAIAYLFWNMAIRLA
GASTTTNGVYIIPIVAMITDAIILKNIPNIYAIIGAVLVLFGVYISENGGKLKINL
>fig|267377.1.peg.699 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MAYKSEFLGTEDVKKLLVKLSVPAIIGMLIMALYNIVDGFFIGRWVGTAAFTGIALIFPF
QMMIMAFGVTFGIGGSSLLSRKLGEGNLDFARKAGGNAISSVLILSVLITIVGVVFMVPI
LNLLGTSADIFPYAKDYYEIILYGTIFNSYLVAANNLVRAEGMAKVAMFAMVVPAIINII
LDPILIIVFNMGIKGAAIATVLSQIIGVIYILKHQFGKNTSIKYAMNDFLINLKILKETV
FIGASEFAKLIISSILLILGNNLLGIYGGDIAIAIYGVIMRIAMLLLMPVLGIVQGFQPI
VGYNYGKGQLNRVSESIKLALVGTSGLCLLGFILVMIFPEKFIQIFITDPEVISQGVFAT
RIFFMFSFLIGAQMTIGGLYQSLGKAKPAFIISCARQTLFLMPALIILPLFFGLNGIWFS
FPIGDLLGFTLASGIIFKDRKSLNLSS
>fig|267377.1.peg.733 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MKQVKKLENEKINNLMIRYVIPSIAGTVIIGIYGIIDGIFIGRTIGAEGLAGVTFSFPVL
IAISSIGVMIGAGSSAIISISLGKKDYKKASCILKTALTYIILISLIITCFGYLLIDPVI
SFMNLSKNLESYVVGYSKIIILGAIAQIFAISLDPILRNDGFPKKSMIILALMSVFNIIL
DYMLIVVFNFGVMGAAAATVLAQGLGSILYLKHFLSGKSNVKIGKNSPFLEFSLIKRIAK
TGFSPFIMELAFGILMIVHNIQFMRYGSSLDVSAYGIVIYITSFLYMVYLGISEGVQPLI
SYNHGAKKFNRVFEILKKAVFVNAILGICSFLTILKFPNLLIKIFNPHDTNLIATTTIGL
EIHNFAILIMGVSMVLMMYFLATEQPKIAGFLSLGRTLIFILPAIILLPIYLGIKGIWWA
TVFSEYLSFIITIYFITKEFKKIKYEKIRG
>fig|267608.1.peg.614 Permeases of the drug/metabolite transporter (DMT) superfamily
MLLGTIGVFVHQANAGPLTATWFRCAFGLLGLTLWVLLRRQTGFLRLTRATGPWILSAGV
LMVLGWGLFFTAIERTSAGVAIVLFHIQPLWVLVLGAWWLKEPISRRRIGSVCAAMLGLV
LATGIPEHTALFGASEMLRPGDWLGVASCLIGAFCTACVTLIAKRLRDLPAGILAWWQCA
VGTLVLWVWPMEHGWPAWGMAWMWLAGLGLIHTGLAYTLIYVGMARLNTGRIAIFQFAYP
AVAIVIDWLFFDQRLDGAQLFGIALMSVAIRFAERAPKAGVPRGMTGPHSASR
>fig|267608.1.peg.3573 Permeases of the drug/metabolite transporter (DMT) superfamily
MRSRMPLANRASRTFEPTILTRSQHPLQGIAFLIAAVAFFAVFDTLTKYISITVPVVMAL
WFRYLFQMVATGATLLPSRGRSLLRTRRPWLQVVRGLLLLLVSLFSFLSLRRMPVGDVTA
IVMLTPLVVTFVAAVSLGEQVSATRWIFMAGGFFGALMVIRPGGAAFDWGMLLPLGMVVA
NAAFQVVTSRLANVDEAGTTQFYTGAVGALLLTCMLPFGWQALGGKWWWLLILIGIVSSS
GHALLIMAYTRAPVAMLTPYLYMQIGFAMIGGWLVFSHVPDGWSVAGIAIIAMCGAAGTW
VAARERRMAMLVAVDV
>fig|267608.1.peg.3881 Inner membrane component of tripartite multidrug resistance system
MLLAAILSGLNNRVPGLALADVQGALGFAQDDASWLNTAYAAGELAAMPFATWFAVTFSM
RRFHLAMLAGALVLSAILPFVQSLSLLLALRALQGLLSGALIPMLMMSALRFLPPPIRLH
GLALYAMTATFAPNVALWLAALCVDRLEDWRWVYWQAIPLGLVAMGLVAWGVPKMPPALS
RLKQGNWLGMALGVPGLALVVAGLDQGVRLDWFHSPLIVAALGVGIVLTALFLASEWRHP
APFMQLQMLGRRNLGVGFSVFVCLLMTMATAVTLPASLLGRLQGFRMEQMASIGLIVGLP
QLVLGPAVALLLYQRWVDARHVFAAGLACIAAACWLGAGITSEWMVPQFMWAEILQAIGQ
PMAVIALLFLATSVVQPMEGPSVAGIVNTFRAFSSVLGGALIGQLTTVRSHFHADMLLDH
AGHLLPRLPPSDPGALTLAAMVAQQAGVLAAADVYRVFGWLALLLIPIVLKLQYIPAPAQ
TRTPQATPPAGTQTGTAH
>fig|267671.1.peg.58 Drug:Na+ antiporter of the multi antimicrobial extrusion family
MSRKELNTLLPKDLSISIETRHKFYKLTFYNILANITVPLTGIVDTSILGNLNTYVFMAG
AALSGILFDFMFWMFGFLRMGTTGLTAQAVGEKNEKESIFILVRSISLACFFGAMILIFS
PWIREIGFQILEGSSEVKMAGISYFDARIPGSIAVLCNYVFTGWFLGRGKSSVVLIATVV
GNGINVILDVWFIFKLGWEAYGAGLATSISQFGMLLIFIFLFFIELKIQNISKFLFLNNK
NLFSVQGFSSLLHLNKDIFLRTFFLIITFSIFRNFSSEAGTEILATNSILLQLILVSAYL
VDGAAFATESLAGNIYGKKNWKLLKELLYLAFYNSIFFTSIFLGSVFLFPNFIFGMITKS
DKVLSLLIDYRFWLFPVLEVGAIAFILDGFFIGLTKGKILRNSMLISTAFFFFPIVYLGK
IQKDNHLLWLSLVLFMVGRALTLSFQAKKIFENSKLQNVN
>fig|267671.1.peg.474 Acriflavine resistance
MNENRLPSKITTQMIIGAVLLFGVISAFMLNYSLFPVVKNPALSIVVDYPGTDAETVENT
ITIPLENQVSTIGGISEIRSTSEKGKSLIRLDFENDTNIDVKTLEIKERIETIINTFPKE
VRKPRVLNFDPNEMPIAVISLNATDSRSLGELRAFADSIVKKDIEGINGVSKVTVSGGKI
KEILISFDIRKLNSYNIRLADINEAIYFNNRTSTIASVEEKGGLYQVRLKGKFSKLDDLV
DLPISSPDIGKSITLGNVANIQNSYRDEDSTYRVNGNQNIGIYVYKKYDANILSISSEIK
KTVSHLSQDGTKFDLLYNQADNIRNTYFNLICIIAVTIAILFFAAKKKGNIDIPKFIGTI
LSQLILSFLLISFIHFILKKDFDLLCVLSIYLSFAIWIVFYFNFIQNHTIDSIGEKKLLL
FITPSIPILFFPGILLNNTVAVNLIRMAIMTSIGVLNNYIVYKYFYQNLSTNKLDKFPTI
ITIPEKSKTQSVLYEPQKNKRDLILNFLLIIVPIVMIFALIQSSKEVYFNVEDDRIYGYV
ELPADSNFEYTDEIVQKIESKLVANPNVKDVISQVEPSHAFLIINYHKSFFSSDSIIPSL
NQSVGRQNPAFCYFTKESDLGRMKEVSLDIVGQSHSDLNKSVPKIANLITNLPGIHEVIL
NFKQPRNELQLDLNNRDPLLQNSEIGSFLRTVVQGSVISKYNENNNELDIRVRASKEFRD
SEKQLNKFLIKNNSGEFSSIGSSFTQRETLSPIKFFRKNKRPNLSISVRTDSYNPNTLLK
LVQNSSQTLLNNNERIELNHRIEKLSKSNTNFTVYIILILLTCFFFFIIYTESLKTSFIY
FCSLLFFYCIFASIYLIIFKTYDIGFHIGSVIVLISLLLHILSNFPEIKRQNTIPINWDF
YLVAIALFLPLLILSTPELNVFKKVFGLFMISLILSRFLLIHFNFRFANVFEKVLSTNNI
SKISGGKNVRR
>fig|267671.1.peg.475 Acriflavin resistance
MKSVVRFCVSKPITVLMAWFAIIIFGIIGLKNAKITLLPEIVFPKISVITGYPNASPEEI
ENLITKPLTDSIGTVGGIEKVTSESLEGISIITVQFSFHKSVDFAMIELREKIDLIRDQL
PQDASKPIATRFDPAQSAFQEIIIFPKNESDSKSLKSFIEENVKVFLERIEGMAYVQISG
GFEKEVRVEIDPERMTTYGVSIPEIQKSIVSANINVPAGSLPVGNKDLLLRTVGEYKSLE
DIKETIIATNNTGIPIPIGSVASVYRSYRERTGLARYNGKDCIVLYLYKESGRNSVELAD
KVTKELESINTTFADKLSAQLVYDESVFIRDSVWGLVWSLILGAFLAFLILMLLIQSFRA
PLILLIIIPASLLATFLLFYIFHISLNMMSLGGLALGIGMLFDTSNVVFSSIERNLTKRK
SILESSIEGTSEVAGSILSATLTTIIVFLPIIFIKSFIGILFSEMAIAIILSISISLFAS
VTIIPTLYVLFENTNFDSKLIDHPIFAKSADLYQTALITYEKKLIEYLERPKKLFSILLT
GIFFSSIFLFILPREFMPTVDNGEFTINIENVPNSTLNSTTGIAEVIEKILLSNKDIKSV
ISKIGSDNDDFIAKVNGNSGTNIAKIRVILVSNPKHTTTEIIEEVRRRISFTEDIRINFD
ANGDIIGKILDPNGSRLNLEIHGEDLKTLSTIGKNLIDKLKKEQVATDLRNSLETKKNEY
VIEFDPIKASSLKLTNDYISQYVKVASYGSNISKIKYQEDDLNIRLLIKKDSIDNLNKLQ
NLNIKTPTGEFIKLSQLANIQENTSSSSIKRSGNSRINVVQGNLNSNKSIDSIIQNMKLP
LGYRIKIGGESENMEKSFKELLFAFALASILIYMLLSSQFQSLKLSAIMICTIPLMFIGI
FPALFLFGKSFNISAFLGLVLLLGVVVDNASLYYEYLIISLNESKELSKAIIESGKIVFR
PILMNNLTTILGLIPVAFEFQKGAEFQSPMAIVVIIGLLSSFAFSLFLLPILFFYILQKQ
KFKTIK
>fig|267671.1.peg.956 Permease of the drug/metabolite transporter (DMT) superfamily
MFHIRHEIYLILCTLIWGGTFTMTIFGLRDTSPSIFLGLRFGIASMIFLPFAWKEFRKGK
IWYPGAFLLGMFLYLGFACETIGLKTTTATKSSFLIGTLVVITPIFEAILKKRMPGKGNL
LGASVVFTGICLIFAGEIGMEGTLTITNGDWITLGGAIFFSLYIIQMDRVSIQIPIRISV
FYQSFVAGFFALISVIILHFVGIEKIRLNPSARLIPGVLYNALLASVLTTFLQTKFQRYV
SPTRVGIIFSLEPVFSSIIAFLLLGEKSGPVRIVGCTIVFLGLILAESIGKDQNLSMENT
N
>fig|267671.1.peg.2318 Drug/metabolite exporter
MDFMEVSESKWKPFLGTCIVLIGAIFFSAKAIFVKLVYRYDIDSITALTLRMLFAIPFFA
WIAFRSKNTKTSVNLTKKDWGLIFILGFLGFYLASLFDFIGLEYISAGLERLTLFVYPTI
VLIIGSFLFKRKIKKAEVFAIFLTYSGILVAFIGDIQTEGPNATKGVLFVLASAISYSLY
LVGSESLIPKLGSVRFTSYLMLISGLIVVIHFFIVRNPKNLIQPPNVYLYGLALGILTTV
IPAYLTTEGIRMIGSGRAAIIGSTGPISTILLAWIFLEEPITSSGIAGTILVLTGVLWIG
RKKTDLKND
>fig|267671.1.peg.2514 Drug proton antiporter
MTQTQIKHDPFQALRISDFRSFLFGKFTVTLSISIQTTVVGWQMYHLTGSNLHVGFIGLA
EAIPSISMALFSGLVIDSFPRKKIVVSALCLLSICSLLLLTLVIPNINWILRDFGVYPIY
AVIFLSGIARGFLNPATAAFQTQLVDKETFPNAATWSGIAWQTSLVLGPLAGGVLIVLGL
YFAYSVDLILMSLGLIMVLFVKGKPVPSKPESSESIWESLSGGWKFVSTHQIILGAISLD
LFAVLFGGAVALLPSFTEKILGQSPEIFGILRSAQGVGAVLCAFFIAAKPPKKHSGWILL
SCVFGFGICIILFGFSEDYRISFLCLAAAGAFDMVSVVIRHTIVQMHTPDHMRGRVSAVN
HIFIGSSNEIGEFESGVTAEWLGIRRSIVAGGILTLLTVGLVGAITPRLRKMQLKDIL
>fig|267747.1.peg.170 Multidrug resistance ABC transporter ATP-binding and permease protein
MTGKDAQQAPTRNEQAEIARASSQQGHRGSQVTEKPISFGPSLKRLLGQLKPHRITLTIV
VIMATISVAFNVIGPKILGRATDVIFGGIVGKQIGKHIPAARGMTAETFINTLGQASHGG
DRGKIITLLQQYPHVVIGSGIDFHRLGVIIGWALGLYACAALLMFLQGFLLNTAIQRSMY
DLRRQVSAKLDKLPLSYFDGQPHGELMSRMTNDIDNVSQTLLQTLQQLLNALLTIIGALI
MMFWISPLLAVISLVVIPIAGVIAGLIGKRAQGQFAQMWKATGELNSRVEEAYSGHALVK
TFGRSRAVAQEFHERNEELRQATAKAQFVSGLIQPVMFLLGNANYAIIVLIGCLRVAKGQ
MPLGNVQAFIQYSRMFTQPITQIASMANLLQSGVASAERVFQVLDADELSTDAHGSLPAT
KGRVVFDHVRFSYNPDKPLITDLSLVAEPGQTIAVVGPTGAGKTTLVNLLMRFYEIDDGT
ITLDGVDISAVPRAELRSRLGMVLQDTWLFSGTIHDNIAYGCPEASEEDILNAARAAHVD
HFVHTLPDGYDTIIDDDGSNVSVGQKQLITIARAFLAAPDLLILDEATSSVDTRTEMLVQ
EAMANLRKERTSFVIAHRLSTIRDADLILVMEHGDIVEQGGHSELLEHQGHYYELYQAQF
AAASHE
>fig|267748.1.peg.350 Unspecified toxin/drug ABC transporter ATP-binding and permease protein
MLFKYMKIKVQNDLKECGLVVIQSFYKYYFKTWLDINFLKAISKFNQKGLSIYDLNLLAK
QINLKTTSYEIKYSDFQNLKITKPIIVLLKENNYIHFVIVEKKSNHNYLILDPIEGKYFL
DEKSFEKMYLNIVIEVEKLKDLVIVEKVKSNFKLEIKNFYTSWNILLSIFMLIFSFCFTF
LLKIIFEEIFPSKDENLLWQIIILFFWISFLNIVLNLIKKLIISKTINKLSKLNLGIYFQ
KYNTLNLNYSNKITNIDHLKRIEILDSYINFKTNLNYFLIVEFINLIASSIFLIYINWEI
FIISFCVGFLILNTNFLFNKILKNNYVKIQKSNINFSTSIIDKIYSKQELKNSTQNQFLD
NKINEFKIELVKSNFKFLLKSNFKEFLLKTISSLSSILIIYLMSLRVINNSISLGELLLF
LSVFNFFLNPFYSFSDLISEIPLQKENKKILDFILNGQFEKNYSQKPIEKINSISLKNFS
FSYTSEQEIFKNINFYFEKNLQLKGPNGSGKSTLMKIIALSNLEDFSKILVNDLSVDNYD
IDSVRTNILYLYNDFYFFKSTLIDFVTLKNLDYLNTFNSNIIQFNLMEFLDRLNLNLNTP
IESNGINLSSGQKQLILLLRLFVKKFDVILLDEVFENLQSSIFYEISKIIKDYQNQAIFL
EISHNENFLYKGNELYI
>fig|269483.3.peg.31 Permeases of the drug/metabolite transporter (DMT) superfamily
MNGNERFAGIGYGLLAALIWGGFPVVTRLGVTHSALDAYDIAFIRFVVSGTLLLPVLLRS
GLGTLRPASIALMVIGAGAPYILTVAAALGHAPVGYFALTPGSMIALTAILGRQVAHERL
SAAQVAGIVTILAGIALAASDALRGAIGLPALVLFMLGGLLWAVYNVTTKRAGAGALHAT
AVVSVGSAVLYCPLYLAARGGAVLHAPVAAIATQAIYQGVLMSVLALYCFSQAVVALGPA
IGATFAALMPLLATLEAMLLLDERPHAPALAGIAIVTAGMAVSLASRWRTGHAPAIRRLN
SAAHG
>fig|269483.3.peg.193 Permeases of the drug/metabolite transporter (DMT) superfamily
MQLFLLQLVFVLSWSSGFIGAKLGAETAGAFNLLFWRFLLVTLCLAIVLNRQLGRLTWEK
LRYHAVIGFLSQFLYLTCVYIAIQHGLPPGIAAIVAALQPLITAAMTSLEGSERSGARQW
AGLVVGFVGVGIVIGGQYALPAGSVGLVMYLLPLVSALGLSIATIYQRRRALTAARSNED
GLFLPLFVQGCVSLVLFAACGIGTGNLHVPTQPNVWISVVWLTVFSTFVAYLSLWALLKR
MPATRVATLVYLEPPVTLMWAAWMFGDRIEVTTYLGIVVVAVGVWLAGKHVERPARARRA
NMEAAGR
>fig|269483.3.peg.553 Bicyclomycin resistance protein
MSHFSLILVVSLLSAFGLIASDVYLPAMPSMAHAFSIGAWQMPQTVSAYLIALACAQLFY
GPLSDRWGRKPVLTVGILVYILGSIGCASASGFASFLGWRVLEALGAASGLVIGRAIIAD
TCDKHASAKVYSIVYPLVSLSPAIAPAIGGYLAAWFGWRSDFIFVAAFGGVALVLVQLLL
KETRPPVTPGQQRAVPLAGFADVLGDRAFIRYTLVVCAIYCAWFVYLTQSPFIFSGLGLS
EQQSGWLYLPLTAGIISANLLSRRMLDRMSYDAIVAAGVGCFVAGGIAFALCESSQVKGI
IAIVMPMFLVSLSNGSSLSLAVSGAIASEHGRAATASGLVGFFQIGSASLAATVSSSLLG
TGSHVLATAMPFFAIVAAVAIVPRWYAARRTLSMRKAQPR
>fig|269483.3.peg.934 Drug transporter
MPRYRRAALVLAACLGTFLATLDISIVNVALPTLQTALDTDIGGLQWVVNAYALALSAFM
LSAGPLGDRYGHKRVWLASVILFTAGSVVCACAGSIEPLLIGRAIQGLAGALLIPGAMPI
LTHAFPDARERARAIGGWSAFSALALILGPLVGGLLVEHGGWQNIFLVNVPIGIVTVLLG
AWGIPERRHPQHAAFDPLGQVLSVIWLGLLTYGLIGIGEAGAWHVKVLVPLAGAAVAFVA
FVQVETRVERPLLPVWLFRDRRLVRANLASFVLGFSGYSSLFFLSLFLQQAQGRTPAEAG
WQLMPQFVMTAITSMLFGRIAARIPLHALMVAGYGLIGAMLAVMAGFGAGTPYLPVGIVL
AVLGVGMGLAVPATGMTVMELAPAERAGMASATMNALRQTGMSMGIAVLGSMMSVGALHR
MTGAMQAAGSAHADTLARQAVMEHVFAAGRPALLGAYRDAMAYGFSIAVLCSGILSILIA
AMLMMRRETKQQSGRAAACVTSSQPE
>fig|269483.3.peg.1004 Permeases of the drug/metabolite transporter (DMT) superfamily
MNNATLAMPGANAYGKGVAACVAATILMGVMFPVMTDALRTIDPFTFTSLRYLIAGAGFI
ALLRIVEGPGAFSSAGEPVALAWLLGSIGFCGFGSFVFLGQQLAGDEGALTASIMMATQP
MMGLLLNALVRRVAPAPVSVLFVVLSFTGVALVITRGDLIGALHEPQHYAANALIIVGAL
CWVVYTFGAARFTRWSALKYTTFTTWLGLTTIVAVNLVLIVTHRIAAPSLAAVHAVLPHL
VYMGPVAGFGAILLWMTGNRMLGPMNGTLFMDIVPITAFIVSAFTGLVPNHAQIAGAALT
GTALILNNLYLRRRARRIDTAPARVPSASA
>fig|269483.3.peg.1691 Permease of the drug/metabolite transporter (DMT) superfamily
MNAPAPPAALVATRPHAAIYVKLTLVALFWGGTFIAGRILAASMPATTAATGRFAIAALL
LVVLTWKIEGGLPKLSSRQVVTTFGLGATGIFLYNVCFFAALARMPAGRTALFVALNPVA
TAVLLSIVVRGERLSLSRWAGIAVALFGALVVISRGELLRVLTDLGNTFGAGERYMLCAV
LSWAAYTVIGRRALDGLSPLAATTYAALWGLALLIVAHLVGSPAGSTTPLTWQAIASMLY
LGAVGTVVAFVWYSQGIRELGPARAAVFTNLVPVFGVLLSVALLGEPLSPSMLAGGALVI
AGVALTNRARR
>fig|269483.3.peg.2411 Outer membrane component of tripartite multidrug resistance system
MKKLLVALAVSALAAGCAVQPAQHPALQDSVRTLAPDGWDTDVPRADIDAAAWWAQFRDP
VLDRLIATVLNDNLDLQAAAERVKQAQALTVQKRAVLLPELDATAHAADARQNTPPPLGY
VRQAGAGLALSWSPDVFGGERLDLLAAQAELVGQKHAEDAMRLALAADAASAYVDLRWAQ
QELKILQDNAKIRQHALELTRKRQAFGLSTELDVTRAQNQLDALEARIPPTQAQVSHQLN
LIAVYSGRTPESVDRLVLAQAGEIPAPPVGSPGTLPSQALLRRPDVLTAYAQVERRAAQV
GVAKAERYPKFSLNLTDGILAASYLGLPTLTDNLFSAALSATSPIFNAGRITADITQSES
RMRESELGLRQTMLQALREVEDARANLVSSDEASRRLGSALAASDKALGLANQLYKGGAT
DFLDVLSAQEVYLRDSDSLNQVKREHALAAVALYRSLGGGWSRNEAAGGPEVEAVAKN
>fig|269483.3.peg.3014 Outer membrane component of tripartite multidrug resistance system
MHASSFPPVSFRSSVAAALLSAAMLAACSVGDPYRPPVADAARAAPFDAAADAPVASGGT
LPDRWWQLFDDPVLDALVREALAQNRDLAVAAARVARARAVLDEAGAARLPDTTAGFGVD
YGKHAPDQIVASAKGTDARTRWGFAPSFAVSWEVDLWGRVGHLVDAARADSEAVQAASDA
MRVAVAAETTAAYAQACAYGERIDVAERSVAIADRLAALTARQRAHGLVSDLEVARSRAF
ADDTRAELPALAGARRAALVELAVLTGHAPGAIPDAAARCHATPALARPFPVGDGAALLR
RRPDLRESERRLAASNARIGVATAELYPSIVLGGSVNWLSTTGDPSSLGDKYAIAWGVGP
LITWRFPNLAASRAQLAQARADDAAARASFDAQVLRALKETEQALARYGAEWRHKAALDT
ARAEHARAYRLAELNYDAGALDFLGVLDAQRSLVAVDAALAASTQQVALDQVAVFKALGG
GWQR
>fig|269483.3.peg.3193 Permease of the drug/metabolite transporter (DMT) superfamily
MAFPTTPDPCQDINPSNAMNKSPFLFPFCAIALWAGNVVVSKLSASTIDPSAITFYRLLL
AVALMSVFTLRPAWRNRAALVAHLPKLAVLGFLAMALFQSLSYEAAKTTSATNMAIITAL
VPLMTMALSSLLLGDPPSVGMIGGGVLSLAGVVYLIAEGHPTTIAARGVHTGDLLMLAAS
AAYALYGVLLKRWRIGALPAWQSTYVQALAALVFMVPMLLRLPAQAAWPTRASVPLILYA
GVLASVVLPYLWMQGVRLLGPSRCAMFMNLLPVMTAGGAIVLLGESLKLYHLIGGGVALV
GVAIAQRFPFQASASQGVRQ
>fig|269483.3.peg.3764 Membrane fusion component of tripartite multidrug resistance system
MPPPAARLSEHRMSTEQFASSNLQRLAGFIGGEVRPYPGRMNVMLRCLLTSALVIVTSMA
LQVPLLPVSLIVVFFVTQSNVVVTRLTGVLFVVGSTIAVGSTILVLKFTYDYPLLRILLA
GTLVFLSVYMMRVAKIGVVFFIVGLTVIYGQTFVDSTDQAELLVRAELWAWVAVTYAIAL
TLLINTLFLPVEPMRQLCSAMGGQLKAIDTSLAGLEHWALVASAPGAYEIQVGALTLKKL
LRFATMRDAAYRANQALHLARVATVSRLYAATGHLPASSAGLTVDAIPVLRDAIQRLADA
VEADGQFVAPGALIDLGGDGLPGALAEMRDALLEFSGRSAAPQGVQSPAEKERLLVPDAV
TNPVYAQFALKTLMAAMISYLFYIATDWQGIHTMMLTCLIVAQPSLGSSVQRAVLRIGGA
AVGSVLALAMVVWVMPHLDGVVGLLMMVLPVIALAAWVSAGSEHISYAGTQIMFTFSLAV
LEQFGPAINLTEIRDRMIGILFGVAVSAVVHACLWPEAEGEALRQRAAKLLRRIGAQLRS
DGTGPIPVTLWAELSDSEAMSARVALEPGWQMADGEQESLTLRMQTLLARVREILLATDA
FGAERNAQKLPGGIATATTAFQAELAGLLDGYASALAERPLTINAPPCASLAALSDCCAA
ELSTLPTDALRAAYDRLLTRASNLAVQVAGLPAWAPGSVGTVLTSRAS
>fig|269483.3.peg.6041 Outer membrane component of tripartite multidrug resistance system
MKRASALIAAYALASCTIVPRPLVPVPVGHDTFRHAGTPLAHEAALTDWPALFGDPQLSA
LVDAALTHNNDIRAASARIDQAQALLGMHEASLLPSVTVDPSFSRARVSGTVDNALPKRM
MHNWSAPVTASYEIDLWGRVRGDVDIERENVLQAIADRDAVRLRVATDVASDYLTLHYVE
QDLNALTRVIDLRYTALDVISARVRAGAASDLDSLRAAADLDTARADLADSQRTRENLID
ALAILTGVSPTAIAIDPTAVNLRVPDVPSGLPSALLGHRPDVFAAERRVDAASLELGIAR
KAWLPTLSLTAQGGFASRDLRTFLDRNSSLWSFGLSMAETIFDGGKRDAAVAAAQAGVTV
ADANYRSIAIGALREVQDALNNIASEKERIARLDSAARTTEAAARLSVSRYEHGYVSYLE
VIDADRDALNAQRQWIHSRQAYSVATVSLVRALGGGWIPPVPADAR
>fig|269483.3.peg.6042 Membrane fusion component of tripartite multidrug resistance system
MVTQTPQDTPSEPPERGRRLPIVLIAMFAILLVTVLIYEFEVRDLSTDDAYVTGHLHVIS
PRVSGTVERVLVNDNQFVHAGDPLTLLDPRDFDVRVALQRSRVAQAQSDAARARALVEQA
VATRISAQADADKAELDYARANELTRETPRGLSKQEYDAADAARKSARARIVAADAQLRS
TRAAAQAADAVSGQNDAELRDALLQREYTTVIAPSDGYVGKKTVETGEHVAPGQALLTIV
EPHPWVVANFRETQLRHVRVGEPVRLHFDALPDVEFVGHIDSQSPATGSQFSLLPPDNAT
GNFTKVTQRVPVKILLDGRAAIEPRIHPGLSVVVTLQRGRHSP
>fig|269483.3.peg.6043 Inner membrane component of tripartite multidrug resistance system
MSTMLVAGGGTPEASPVPGATVPPFRSIAAIAAVLFGAVISTLTSRITSLGLADLRGALG
IGFDEGAWINTAFIASQMFIGPLAIAAAFLLGTRRVLLAGAVVFLVAESVLPLCPGFGSL
IICQSVAGLASGVFVPLTVGFIVRTLPSRFIPFGIAAYAMNLEMSLNLSATLEGWYSEHL
NWRWLFWQNALMTIPFIVCLLLSLSNEPIKRFASGADYRGMLLGASGFTCLCIALDQGER
LFWLESPLIVTLLCISIVTISTFLVHELVSKQAGLNLGYLVRPNVLLLMLLVGLVRFTVL
NTSFIPSLFLASTYGLRPLQIGDTLRWIAMPQFLFAPCVALLLQRFDSRRLIVIGFVMVA
IAFALGSRLTSVWAEPDFIPSQLLQALGQTMALTSVIFFFGKHVTAEHALTFGAVVQTTR
LLGGQLGTTSIAVVQRIMEATHSNRVGLHVALSDPVTLERLRVGAASLVTHGATFATGDS
GTYVLLDRAVRVQATTLALADNFRVAMTCAMVGALIGMMLRPVRAPRSS
>fig|269483.3.peg.6523 Permeases of the drug/metabolite transporter (DMT) superfamily
MNDNARKTGYLIMATLCWGIAIPFSKMVLPALSPAWLIVLQIAASVAVLACLAAVQRVSL
QGIAPAQIAVVALIGMLEPRGAYYLGFVGMQSTSALHTAVIFALEPLGILAFNIVLFRFR
VDGRLLVAGVVALMGVVVITLGDASADGHASLRGDAFVFAGVMVAALYVSLSTQAVTLPS
ATAMLLIQQAGSLLLALVLLGIDAGGSGPHRLPAWPAVWPALAIGVLQFTLAFLFYFRGA
RDNASYWSVVVLNLIPVVGIAASILILGESASPIYFVGGAITIGAALYTHLRERRSEPGP
ARA
>fig|269796.9.peg.245 Probable multidrug resistance protein norM
MAGNLDVLTLGTVATGAALWVPMMIFLLGLLYGVTPTIGKMLGENASEAVSGVAARGLLV
GLLGGALLGALLFWMSTPLFRLFGVAPELIPEASAYLNWMALAMPGMGLFLAFRFVIEAH
HVGWIVTVVAVLGVAAKIWLNDALVHGHAGLPALGTGGFGAASVALYWGMAVMLAGATFL
HGAVKPLWTHRLSGADLSLAAIGRFLRFGLPIALNFLSDYLIMAVVAVFIATLGAVAIGA
HQITFNILMVLLMMPTGLSMAATILISRSPGGGHTATLGPVMSWTLGIGVAFSIVLAVLL
AAFDAPVIRLYTDDAEVIALALDLLGVVVFILTIDVVAIALGFFLRGLGDPGSPFLILLA
AHWLISLPVGYVLCFTDWVVAPQGPLGWWYGLSTGLLVACCLLGLRLRQRLSRAAQPVCS
PAEATVAGVAE
>fig|269796.9.peg.267 Permease of the drug/metabolite transporter (DMT) superfamily
MSQPSALPAADSLAALHPGFKSSALVWLGVMVALWGFSWPVMKICVGLAPPLWLAAIRFT
SSGLCLFAFLACRGELRLPPRADWPIVASVGGLQMMAFTGLGLVAMQYTDAGRAALLAYT
TPLWAVVTAWIAFGQRPTAAQGVALCVGLSGVAVICSPADMDWGDSTVLLGNALLLLSAM
CWSFVILHVRRHRFTARPIDLAPWQMLLAALPLIVIAASVDGSPLTIAWTPELIGFLIYF
GPIATSACFVISSEYGRRVSAFAMSNITLGVPVIGMLSSIFLLGERVTVPLIIGLTLIVS
GVALAALAVNRKAAAGRADTALRSQAGKANWPTA
>fig|269796.9.peg.387 Permease of the drug/metabolite transporter (DMT) superfamily
MSAPASGFSAPRSPKAPVDWAPWMVLISTIALSFKGISAKYAYDAGMGVGMVLILRFVLA
APFFWVGERLLGAGRPRLPLGWAEIRPCILAGVLFSVATYSDFSSVQLIGAGLSRVILFT
YPAVILIIGAFSRRTWPARRQMLAFAITYLGLLIIIVPSVGLVAVDVMLEGVAMSLLSSV
TYGSFLVYSQSLTGRLGSARFTAISNTVTMLMIVPFALAMGGDLTIPNTTALIWAVVIAT
VCTVLPFFLLFEGIRRWGAEKTGLMTLSGPALTIAMAWVLLDETLTPLQLIGFAVVMAGV
GALQGVDRPLLRLLRRGRRAEA
>fig|269796.9.peg.590 Permease of the drug/metabolite transporter (DMT) superfamily
MSVILFCVVVLCWGFTWFGIHLQLGTIAPEVSILWRFLLAAIVLAFGLAASGRFKPAPLA
HHPWFALLGLCLFSTNFVLMYSATQYIASGIVSVVFCMATVFNAANQWLFLKRVPAVRTV
GGALIGIAGIALLFGESFLHVEASADTALGVALALGGTYVFSLGNLVSLRATASGTDLPN
AVVRAMAWGSVFLALFVLARGVPFAMDWSARYVGSLLYLAIPGSVIGFTAYLSLVSRIGP
DRAAYSAVLFPVVALTVSTLFEGYQWSAWAMAGLPLILIGNLVIFARLPARWRRAAA
>fig|269796.9.peg.731 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MSARHAAQQVNPFLTVPIGRLFVSNALPMAVVMSMGGVLNVVDGIFVGHFIGSDALAAVS
LAFPVAMVLSALTTLTGGGMSSLMARYLGAGDRGAAGRIFAETHGLVLAISVGLVVLWAV
VGAALVDSMAAGNPKVAGLAQDYLQIMILGAPAQLMLGVHADALRNEGRAGLIAALSVLV
NLFNIGANGLGIVVLGLGISGSALGTVAAQALGLALVIGVRGHSKGLLPLSVLRARNWLG
AWSQIIRLGLPLCLSFIGIAMVASVVIVSLRLSAGTDYNALVAAYGVVTRLLGFAFLPQM
AIALATQSITGNNAGAGRTDRARAALRLALGAAFLWCLPVVLAGVFAGTTLGSWFSDDPA
VIDAVAEILRPMMLFYAASGPVLVLALYVHALGQPGRTAALTLVKPWLLTPLLILALSIG
FGVSEMWLAFPMADAIILMLAVMIGRNVLHTAGTRAAHAEEGA
>fig|269796.9.peg.915 Outer membrane component of tripartite multidrug resistance system
MNMAFLVAPSLIALILGGCAPWDGIDRQSAMTDAKTLALSAPSDPIPEVAPWPEGEWWRG
YHDAQLNQLIGEALAGNPSLKVAQARLRRAGALAGLAEAALSPHLDGGASIIDQRFNEGG
LYPDSLAGKVKTENKIALEGAYTLDLWGGREAEYRSALGELRASEIDAQAARLDLAAAIA
QSYARLAAAFDQRDISHEVLRQKQEIQALTARQVRSGLVTEVETRQADAAIAAARADIAG
DEERISLLRRDLAVLTGAGPDRGAAITRPGLSMRAGVGLPSTLPADLIGRRPDIVAHRWR
IEAATRSIDAAKARFYPNVDLTAFLGFKSIGLANFMTAGSFMAGAGPAITLPIFDAGRLR
SQLAEANATLDITVELYNGAVLEALRDIVGSLTSWRANQARLAEKSLAVASLEEAYRLAL
LRYREGLANYLTVLSAETALIAERRQEAEFRNRQYGLSIALAHALGGGFAPQGPPPSRAA
SGDPAPRAPL
>fig|269796.9.peg.1952 Permeases of the drug/metabolite transporter (DMT) superfamily
MLMVCGAFLLVGSSVVASKVVTAAFPPFTATAVRFAIAVGLLIPWMVLSQGWPAWPGRRA
VLALGLQALTGCVLFSVLLLEGLRRSGGVEAGLTLGTLPAVVALLAVPLLGERLDRRIGV
AVLLAAGAGALLHGGKGAGGSGWLGPVLLFGAVVCEALFTLLGKRAVVHLSPVVTATAVS
FASLALSLGPALTEQPLAALSSAPAAAWLGALWLGAPVTVGGFVLFHAGVAGTSGGAAGV
ASALVPLSAAGLSALLLGEALLPTDLMAGALVLGAILLLALPTGKAG
>fig|269796.9.peg.3389 Permease of the drug/metabolite transporter (DMT) superfamily
MDLGYLKSKESGFIAGMILCTAFMGSSFPSGKYLISEEAMPAFYAGGWRFLLAGGLILAF
CAAKDGLGAILPASGGSVIKGALFVLVVGCLQTAGTMGFLNLALTTLSASMASLLLFTNP
LWVAILAHFALGETLSWHKVVALVCGILGVSLCLGGGADHGLGGIVIALAGSLCWALCTL
ISKKHKFDKSVFVFTGWQLTLGALVMLAISKLSGEAYDIDRITGWGIACFIWLVGPASIG
SFGLWFTALSRRGATVTSSYLFLVPLFSAVFSMMVLGEAVSPHSLIGGAIIIVALWLINL
PQTVSAVWRERLGL
>fig|269796.9.peg.3484 Permease of the drug/metabolite transporter (DMT) superfamily
MVDPAVSLVWRFGLASLIMVAWALARGQSLRFSLRDHAWLALQGISLFCANYLLIYTATG
LLRSGLVAVACSTIVAMNIVLGAAFFGQPIRPRVAAGAGLGLVGITLVFSPEFSHLSLGD
EALRGFVFCLIGTAFASLGNLLAGRNQRTGIGVLAGSGLGMGYGALAMALFAALSGKAFL
IDLSLPYLGSLLYLAVFGSVIAFGCYLTLLGRIGADRASYCAVVYPVVALGLSTAFEGYR
WSAAGAAGLALVLAGNLLILRRPGAAAPGAGSLTTSLSPRGGGR
>fig|269797.3.peg.1328 Permeases of the drug/metabolite transporter (DMT) superfamily
MENMMLWLAFAILTAFSESIKDVLNKRLLTQVNEYLLAWSLVLFALPWLVLSLFFTGIPP
LKTEFWSYLIIDSILNIVANLLYIRAIKHGDLSSTVPIINFTPLFLIVTSPLILGERLNI
FGCIGVLLVLTGSYFINFQVRDKGYLYPFHMLLKEKGPRTMLCVALIWSITSTMDKIGVI
NSSSFFWAISLNICIFALMSLFLLHNSKVDSKKINHNLKDFVFLGFFYALGWLAQMTAIS
LISVAYVISIKRSSTLISVILGYLLFKESNIKWRLPGATIMFVGFLVLALS
>fig|269798.12.peg.1245 Drug/metabolite exporter
MTAIPNSIQKQYLGVFLGVCSAACFSTKAIMVKIAYMYGADTVFILFLRLFFSLPLYIIL
AVIYSKNADMKITRIQWIWIVLLGFIGYYISSLFDFMGLSYISASLERLILFIYPTLIVV
LNTLLFGSKLQRKDYLALVLTYIGIFFIYLGNTESTTENLIKGSILVFACALTYAFYIVG
SGRLIPVIGAQRYTAYAMLVSTLSVMIHQGLVNGIPDLTHTSSEILWVGFAMAIIATVIP
SLTLAQSIKLIGTEKSSIIATLGPVFTIALANIILKEPFTLRQGIGTAFIITGVWIVGKK
DS
>fig|269798.12.peg.1339 Multiple antibiotic resistance protein MarC
MSIDWSFALVVFTGLFAIINPIGNAPIFISFVDHLDKHQQKAIALKSVTVGFIILAIFVV
FGYALFNVFNISIQAFRITGGLLVLKVGFDMINSKPKDAATLVKNSEATDTGFAISPLAT
PILVGPGTLSTAVSFVGVGNKIENSIIIICSSAIILTITYFVFISSTTLIAKIGKEALNV
VTKIMGLLIASIGIQMIITSIEELIHNYKL
>fig|269798.12.peg.1787 Multiple antibiotic resistance protein MarC
MDLIFATVAALLPIINPFSTAPMFLSLTQGDTKSYRNAQATQGVIYMLAILLVSLVGGSF
IMNFFGLSMPGMRIAGGILVAGVGMKMLKPNDEIETTEAETKEAENKKDISFTPLAMPSL
SGPGSISVVIGMSSLAKNISDYCYIALGIIFVACVVLLVLRSSVGLVKVLGVNGLHAMTK
IMGFLILCVGIQFIIHGTMDILTGNEMLEFLKKVHQNV
>fig|269798.12.peg.2075 Multidrug resistance transporter, Bcr/CflA family
MRHTQNRHLITLILGMLATVSPFAIDFYLPAFSQIANELGTTTARISLSVSSYFIGMALG
QLLYGPLLDRFGRKPPLYAGLIIFIIASIGCCFSTGVEMLITLRFIQALGGSVAGVAAMA
MVKDFFPPEQNHRIFAMLILTIGLSPLLAPSIGGFVATAFNWKFVFVLLALIALFAITIV
FLFLPEGQEPDKTVTLQLKPMAKTYLSILSDTQFFTYTISGAFAFASLFIYVAGSPIVFI
DLFHVSKQMYGAIFAFLSIGFIGASQLNILLVQKFSSASIFRFAMRLQVAAGMVFSIVAW
NGWMDLYTTILMLFVFLSCVGLINPNASALALAPFTKNIGSAAAMMGCSQIGIAAVASIA
VGMFDAASVLPMVLSMSATACIALALLMWGEKKMAGKIVAADASKGVVVH
>fig|269798.12.peg.2312 Permease of the drug/metabolite transporter (DMT) superfamily
MNRIARAHIFLSILTIISGFNYTIAKIAMPVPIQPSSIIWIRMCCTTIFFFFFILLAKRS
FFIAAEDRLRLFLCAIFGITINQIFFFEGLSRTMPINTSLIMAGIPITVFILSAIFLKEK
MNWMNTLGLTLSAAGAALLLLDSKGKLNGLFIGDLFILINAISYGIFLILARQLMQKYDS
VTVIFWIFLIGACLTFPYSYANYTHTDWAHLPVLVWLAVGFIVVFATIVNYYIGVDVLKD
VSPAVSSMYVYIQPIFTTAIAMYFGSDKMDAQKLFYALAILLGVYLVSKSTGKKTLVDDK
KGPA
>fig|269798.12.peg.3318 Permease of the drug/metabolite transporter (DMT) superfamily
MLLSIVSFSLMHLCVKAIPDIPVVQTIFLRSVFSIVFCCIAIKQAKVSVWGNNKTFLVLR
GLVGMLSLICFFYSIQMLPLGTAVTIGNLVPFFTLFLAFVFLKEKIPHIKWLFFAVSFVG
VLLMKGLDDELPALGIILGLCAAFFTATAHFVVRKLRDTDDTSVIMFYFPFITIPFMLPF
AILQWETPDAREWLFLVLIGITTHVGQLFLTKAYKHEEVKNISYVYYLGIILSFVYGVSF
FGEFISVKSSVGVGLVILGMVLNMLG
>fig|269798.12.peg.3630 Permease of the drug/metabolite transporter (DMT) superfamily
MFFWGLSWPSGKVAASYGSPVTIVLIRYIVVFAGFLPVFFFMKAPLTIHRKGIPSLLAAG
LLLSAYTYLFFYGLKNGLAGAGGVLVTTMNPIMAYSIGLVLNRKKPSRNETIGLVLGLVA
GATLLKIWGSLDELFASGNIYFLLAAFVWAVMSRITSKASTYGSSMSFSLWMYLATVLIM
IPFVNLTDLNNILHNADQYFWWNILFSGIFATSLATSYYFYATTTLGPEKASSFIFLVPV
SAAVSSWVFLNETLLLHTIIGGVLGIAAVYMINRKKEIM
>fig|269799.3.peg.3236 Permeases of the drug/metabolite transporter (DMT) superfamily
MSTLAFTLIVISAVMHALWNLLVKRSRHKTVFIWWMFVASSSLFTLTIPFLPERFRWPDP
ATLLLVTAGAVCFVLYHLLNGRAYRGGDLSVVYPLSQTSMVYVPIWGMSILGERLTMPGI
AGILLVILGAFSVQMERLSLAEFLRPFRNLGSPTVRNALAAGFIYSLGSIAEKVGVRDYT
PLYFTYFLVLIMLGLMSVNLLRPCYRPLIVAEFREHWPLILVSGPVMMASFLTFRYGLNL
SPMSYAVPVRQVSILMGVLIGILFLGESCGRIRLGAALVILAGAIMIRLG
>fig|269799.3.peg.3428 Permeases of the drug/metabolite transporter (DMT) superfamily
MYSGQFLAVISAALFGISPVLCKLVIGEMSPALLAGLLYLGSGIGLHILLLFQGKKSIEE
VKRLSPKKRLALLGSILSGGVVAPLFLAYGIKFGTASEVSLLLNIETVATTLIAWFVFRE
HVGLGVWGGKALILLGSVFVILKNDGSLAFSFAGLLVLLACAFWGIDNNLTRDIEELPAT
VLASIKGFGAGAFNTLLALALSTGTATVPQVAGSLLIGAMSYGMSLVLFVEALRRIGSAR
TSTLFAIGPFVGTFLSVLILGERPPATYWVAASLMLAGIALLQREMHGHPHTHEELSHSH
KHLHDEHHQHEHAEGEGTEPHDHPHLHEPLTHSHVHWPDIHHRHSH
>fig|269800.4.peg.243 Permease of the drug/metabolite transporter (DMT) superfamily
MSLPRSSPPSALPRWRGPLLLALAGVLWGTGGFAGAFLQQLTGIHPIATACYRLLAGGVL
AIVALGVSGQLRGLPRSPAVLRRVAAAGVLLAAFQACYFAAIAVSSVSLATLIAIGSVPV
FVTCAAAVLERRLPRPTLLAAVCCGVLGLVLLSGDPGGDVPPGRVALGVGCALGAGAAFA
ALTLVNRRPVPGLDPLRVTALGCLLGGTLLVPLAAATGMTFTPTLPAVGVLLYLGLAPTA
LAYLAYFGGMRTTPAPVAALAVILEPLTATVLSLLLLGEVLTPTGTVGAVLLFGAILLEY
VRPPRR
>fig|269800.4.peg.2011 Bicyclomycin resistance protein
MSLTALRSRTPVISAVLRAPAPRRPTSAPRPQQRPQRSAALLVFVLSLLTATSALATDLY
LPAFPEIAADLGATESQVQLTLTAIMVGLAVGQLVLGPLSDRWGRRLPLLIGAAVFTLSS
LASAVAPSTEVLSALRLLQGFSAAAGAVISRAVVRDIFHGEDSARFFSRLSLLTGVAPMV
APMLGGQLLLAGSWRLLFVVLALIGVANLVLVYVALPETLPRTPAAGRGTQRGSVLGALL
RLQLDPRFMGPTLVMSLSFAMTFTYISAFSFVSESEFGTTPQQFSLIFGVNSLGMVLGNQ
VNTMLINRMDGPRRLLAGLLGALASVAVLVGLAISEQANVVVVTAALFTMMFFTGLISPN
ATTLAIASQPSSVAGTGSALLGALQFAIGGGLAATTGMGEGGEASLLSMSVVMLVTAAAA
GAVFAGWAFLARRVPAPRTA
>fig|271065.3.peg.1585 Acriflavin resistance protein
MDQVKLDGLFAWFADNPVAANLLMLVILAGGAFGMIDVDKEVFPRFSPHQIEVTAIFPGA
GPAEVEQSVCIPIEEAVHDLSGIKHLHGEIRGDTCTIGVEILPNRDREQMMALLRSRIQS
IRRLPKQLENIDVLPSDRKDDDGVIWVALHGETDAFSLQRFGDRIQQQLATIPGVSRVRN
YGEIGYEISVEVAPEQLRKYRLTLDDVAGAIRQASVELPGGLVKNPDGELLLRVDSRAKD
ADAVGSLIIKTLPDGNRLRLDQIATIKDGLEERLYTWRHNGQTAQGWEIHTEQDSVAVAR
QVKSTIEAMRANLPEGLRLITWWDDSQAYDERIGALLENGLIGFLLVCSVLTLFLRLRVA
LWAGAGIFTSILGAFWLMPMLDISLNMLSLFGFLLAMGVLVDDAIIIGESVHSRQMEGRE
TPLQAAVNGVKAVALPVTLSVLIVLAAFLPGLYLPGWAGQMMRPICLIMILTLVFSLIEA
LLILPSHLVAAVESNANPTRLQKLRTKLNQGMDRFVDRVYRPLLKIALSWRYLTVALFAA
LLILCSGLVASDRVRQSINPDVTKDSFWVSIQLPQSAPYSEAQALATRVENALFALRDEL
DGVAEAGRDANNRDNVTQMYERSVIVGIETIIWEHGAGIWLELSSEGRQRIKVENFIRDW
RQRIGDIGRGKVDFIFKEGDEPYDIELMLGSDQPNILAPAVEQLKQQIKAFPGVYDVIDS
AEPGKPEIHLTLKPDAERLGLSLEQLAEQVRQGYYGAEVYRFMRGRKEVKVMVRYPLHER
RSLDQLKAQPIRLPNETSAPLTNLAEVDLIQGYSRIHREDRQRVLKVQARVDPTLTDANE
LYVLLEKDVFQTLENQFPGLNIQTGQQRQEQKALLAAFSKNTLIALLVIYALIAVPFRSY
SKPIIFLLAAPVAWCGAVLAHWAVGLPLSMESLVGMIAASGIVINDSLVLLYCIRQSGDD
RDPPVEALIIEACASRFRPILLAFLTTFAGFLPTLLETSAQAQFLIPMTLSLSAGLLVGM
LASLILTPVCYTILDRRRSPVVPDAHATLSFD
>fig|271065.3.peg.3148 Outer membrane component of tripartite multidrug resistance system
MTDNLAKQHTVSACLLGGTLLIAGCAWFPESTQRAVMNALPEIGQTISEAQQRLPATDRW
PDPAWWDIFNNPQLQTLIEASLESNPDLKATAARLSQAQSMVDAQAAELYPTVHANITFN
AQRFSANSVQVKFAGENFRHMLINPLILRYHLDFWGRDKAALQAAVGRAVAVENELADAK
LLLSATVAQGYFDLSESAEKLKLIQQIVRHKEALLKLEQTRLELGLVERSAPLTTGIELN
AAREIEAAFRAKVDLQRHLLAALAGRGPDWGQSIAADPSLFPKRLNLPADLPLSLLAHRP
DIAAARLHAEAAAEEIKVAETAFYPDVNLIAFTGLHSVSMTDVMLQGASLAYAVGPSIEF
PIFEGGRLRANLTYQEATYDAAVERYNASLLHAVQEVADALTRWQEIEDRLAKHQHSLEA
AQSNESLAQTLNRAGLNNRSDLLEARIQVLDQRYHLATLENERFKTAVQLFKALGGGYTE
NDKL
>fig|271065.3.peg.3149 Membrane fusion component of tripartite multidrug resistance system
MTTAVPQKIRPREILRKRNRRLKGVTLAILLAGLSYFAYWWYMNRDWVATDDAFVAGHLI
TIKALTEGIVVEVAAENTQAVQAGDLLVRLDGNHAEVALQQAKAELAETVRNIVTLKAQI
DTLNHRVIARQASLATVRHDLKRYESALFEGAVSEQQVQNARDRLRELEAAISEAEAEKS
GIQAQLLETDIDHHPSVEKAKSRVKKAYLDYRRSNIFAPVSGYVSNRRAHVGDHIKSGMP
LMAIVPLDEVWIEANFLETQIASIRPGQSAEIKIDAYGGERLYHGTVQGLNPGTGSVFAV
LPTNNATGNFIHIAERVPVRIGLDPKEIQEHPLQPGLSTLTRINISETGEPLLTSSVSIR
SEFYRTTIFDNELEEAERLIREIIYKNQPNNNRLNE
>fig|272557.1.peg.19 Antibiotic resistance protein
MPSLSPGEESRIHLTTKALSLALTAFLVMYVEAVLYTSVPAIQAELGISPVEASWIFTSY
LVTGSVLIPLMGRLGDAVGRRRTLILILIIFGISLLLGGSVNSFRLLLGLRAAQGVGMTA
LPLIYAIVREEFPPNRAPVIQGILAAMNGIGLLIALPAGGWVTENLDWRLNFVLISPLAL
LSILLNIALLKDTRDLSLDKSLSGMRVSVASVLSFAALVTSLLILITIHTTGESGEYAQG
LLLAIFIVSLLAFRWSERRSSAPLLPISTFNRSVRLGVFCASIIAVTFQLVLFVLPYLLQ
TPHPNGFGLTPTESGVYMMLLIVSYAISSPLAGYLVVRVGMKRIAYAGSLLSAAAYLAVA
VKPLQSPLLEVTLVSLGFVGMAFINNSLINIVVYSADKSYLSTTTSLYTLLRTLGSALGP
LIGGLIFSMCSYSEIKTTQITSFSIDPLSYSLAFAAASSLFLIVLAMVLQIDEPSLLKDL
SPSRVLT
>fig|272557.1.peg.51 Permeases of the drug/metabolite transporter (DMT) superfamily
MSVGVWLYGCGCGMDRRSSELLGVAAALTAALLWSTIGVVQRLAEARGADTETLIVGRTL
GGSLLALALLAIYRAVPTRRSFAVAVLGLAPLYYTYMMSVSIVGAAVASLLLYTAPAWVA
LLGTVFLGETPSVRDVVTIILGLAGAALVSLGGEGKAGELRLLGIVLGVASGFFYALYIV
MARFFQSRGAGVMEVSLAPIALTGPLLGVALKPSLPPNSVEVAASIYFAVFTMVTPYLLN
VYALRRIEAHRVSVMSLIEPLSAVLLAVLLLGEDLTALQALGGVLILAAALGASFK
>fig|272557.1.peg.1758 Multiple antibiotic resistance protein MarC
MADLYTVVSSIILLFIVLDPVGVSPYVASIVARRPEGERERIVRTALASAGAILVAFTLI
GVAVLDILGVSMDEFKVAAGLLLLIYATADLFEIKIGYSEPSGDEVAIFPLATPLLAGPG
SIATVMYIMGSSGIAVALIAILVNLVLAYPILHASLKLVRLLGRHGSLLVAKFTAFLMVG
FAVSIIFDGLRGIVPGVFS
>fig|272557.1.peg.1760 Antibiotic transport-associated protein
MARYHILIFIAWFIVTALLLPYALALDEVLVTETESFLPETAESRMAEEKVKEILAAEGY
GGADSLLGLLGSANALIMVTGLREPLDPSSYQLLKEQGYDELRAEYNLFSWIDIVDKAME
NLEPALEEAVRGGVQAFEGGYSIWNSYLEVSQRLSNLSQSVDGLSLLLTESDKAYSTLAS
SWGELAALRGVLESASTPLIDVCTAIAPVYSTVYLDVVRTEGALEFYTNAYATGLQDVDI
TVVTLLTYVPEAGLEPVDRGFVVYVYTETLSLGGPGAFNNAAAAEITYTIVQARIGDSSL
LQAYHQAWLHAVSETPELKLFMAEDAKVGQIRLKAAVEDIADQVTEATVMALAEEASSIM
PDDIKPIYTIYVESLIEEGCTEEAKERALQTAITQLLKSRGLPEEHASTLASAFARGDYN
SYLQTAALASATLALAEANMTELQPEDLASVLVAFDPEASGAIASGETLEDALSVLLSRI
AGLTPDTARLIIEERIEEAAAEIVLSNTPPQAADLAQALLAPAPPATEEEALQRIRSYLE
QQLASQGMPEDLAVKAAEAAEEAWREGIVDAVIQRLVGEVAHDAAKGVLDELRGVLVEDD
MGGFLIAYLGGGGYEGAKAAAEDVRRLVNEALDGDARVMLAGEEALRKELQEAVVEDLRR
SDAASSIIVVAILAAVIGTILGVIIPFIGIGAGLTAALAILYFLASNDLVDVTSQSRAIV
FTTGLGLGIDYSAYVTKKFRDNIRGSRGAWEAAGKAASNSVRPVLAGAFAAAAGFSSLML
AFEFPFVKSIGATVPIAILSVAVASLTLTPAILALVGWAGILWFPTCPYKAYQPGSRVFK
SLVSAAGKAAPVLLPLLVVAGLAGVYYAATSFEGSFDILISIPRETGVYESMQHLVSEYD
ASRLFPQYIVASSSTLAPDVADAADDLECVREAETDGRLIYVVLDTNPLNTEAVKCVEEL
RGKVREVDPGSLVGGTAAVNLDLRDYLYRAFYNRVIPAAAVLVAAIIAVFYGSIPAALAG
VASILFAAAWSLSIVSILSGWTGIEAPWFAPVLLAAALLGVGMDYISFYVNHAREAYLRG
EHSRYYVEAASTGTGLVIGLAMIMGGAYAGLTLSRVEALQAIGVSLSLGVILAGLLASLL
LIPPVMALLKARFWWPLARGRKSGGAGKVERG
>fig|272557.1.peg.1785 Permease of the drug/metabolite transporter (DMT) superfamily
MSGWEYLVLALAVANVSTASILVRLAGVHGFAAATWRLVLSTILTAAILVAAYAVKKHRK
PVLPGGVDLLLVAASGVALALHFDLWMASLFHMSVAMSVTVVDSYPAVLAIVGFRLFKEK
YTPLQLLGAVIAMVGVAGIAFYSSRGASAPPGGDPIKGFLLAFAGMLAVAAYFSIGKGLR
SKYSTLEYTLPVYGFAAIVSLLLTTLVVRAPLTGYTAETYLYLILLALLPMLGGHTLINL
LLRRLSLLAATVPILGEPVGAAALAWILLGEKVSTLEALLMVVVLAGIGLVLYEENRVKK
EIKQGLASEGP
>fig|272558.1.peg.290 Multidrug resistance ABC transporter ATP-binding and permease protein
MKLEIKSVTKKYKEKTAVHDFSMDLLSGECVGLIGPNGAGKTTLIKMITNILDPTRGDIL
LNGKRISEMKREIGYLPQYPDFYQWMTASETLLFMGQLSGISKKKLTKSIPEILSKVGLR
GEENSKVSTFSGGMKQRLGIAQALLHKPSFIVMDEPVSALDPIGRREVLNIIEEIKKDST
ILLSTHILADAEEICERLVMIKNGEKIEDTTMMELLNRNSKNKIRVEITDESKDWIEVVK
KLNYVQDVEVTGNKVNVEVKNIELHKNMLLANALKHDVNIVKFELDHDTLEELFLKLVVG
E
>fig|272558.1.peg.390 Permease of the drug/metabolite transporter (DMT) superfamily
MNQTISAQLKIMFAMVIVGSSVVAGKMLVESFPVFLASELRFLIAALILVPMLLKKEGIP
TFSKKEVGILFLQALSGVFLFSIFMLYGLMYTTAMEGGIIMSTLPAVVALMAFITLKEKL
TRLTIIGILLAVGGTLAINTSGTLSDVERGVAPLLGNLLIIGAVISEALFIIFGKSISQR
VSPLAISTMVSVFGVVLFLPFAIYEATRFPLTDVSLNDWLIIFYFGVVVTVIAFVLMYQG
IEKVPASTVGVLTGVLPISAVLLSALILKESFSTFHVAGMGLVLAAILLISIDSNVEKKE
VASLKKKKGIS
>fig|272558.1.peg.396 Permease of the drug/metabolite transporter (DMT) superfamily
MRLYVMLLSLSLIWGFSFVFIEHLLGIVGVWGTVVVRCFAGAIILLPILLMRRKLFYRPA
PWKALMIVGIFNAGLPWGLIALSQTEIYSSTAAVLNALTPLFTGLIGFLLYSNALSRQQW
GGIVLGFSGVVVLTGFQLQLLAPEHFVGVGTMILATICYGFASQYVKRHLHDTDVVLITT
FSLLFGGLVGLIGMWITDSLHVVRVPLTIDWLSLISIIGLGCLGSGMAHLLYYDLMKKGG
PEFATTVTYLIPMTAIIWGKLFLDELITKNIVIGMLMILMGVYFTSRKRNVCSKANEDSN
KGELA
>fig|272558.1.peg.1403 Multidrug resistance protein
MTRVTDTLLYVVLGMAPLLMVLGNSMFIPMLPTIQAEWGLSVVQGGWLLTSFTVPAALLI
PISGILSERYGQKRIGLASLVILGTGCVLSSIAVVIETRPFWLLLTGRIIQGLGTGGLTP
ISLMVASELFSGKKRNEALGFLEVSNGIGKIISPIIGGLILLASWYYSFVVLFALALLAF
VGFYTLVNEPKKHETTLSARAYTKKLSQSLQENWKMFVPIFIIGSLGMLILFGYLFAVSN
MIGEVSPFWKGVILAVPFLLFAVASFWTSRWLTPEFASFQKAMMVGTTLMTGAMFLMLWQ
HDRTILFMLVSLFSLGLGMFFPPASAAVAALTNNVSRSVIMPLYSMARFLGVAVGPVIFG
FWLERNISIHTMSFFIISLSFFIMCVLWYSGFLRKTNLSHESS
>fig|272558.1.peg.1741 Permease of the drug/metabolite transporter (DMT) superfamily
MNRWLTYFLVFFVMVLWGLNVVMLKLLVTSFPPVTMTALRIFVAGFVVLLVLLLLKTFRQ
LTATEWKYVILAAIFGVLGHHFFLSIGLTMTSASNAVLILALLPLTTSLLAILLLGDMLT
RWRGFGIFLGLIGVCTIVLFGEGGLAGIRTGDGVIFLAMMIQALSFVYIKKATDTLDAKQ
VTGMMLLIGSLLLFVTSFIIEPNGLASMGDKALWIWWVFVISAVFATGLGHIIYNQAIHQ
LGTGETAIFNNLVPFFGLLFSALFLGEAIALAQIAGLLFIVAGVILGTGHVDAWMQKRKR
RFDQVG
>fig|272558.1.peg.1937 Permease of the drug/metabolite transporter (DMT) superfamily
MRIKFITAVFLGACSYGVLSTLVKLAYENGVPTAVVTSSQFLIGWFLLATLLAFTQKKRR
LTMKEKIQLMLAGIPTGLVGIFYYLSLVTIEASVAIILLFQFVWIGVVLESLINRQFPTK
KTVGSLIILLIGTVLASGSPWFNQGTVHWLGVLFGLLAAVSFALFILANAKVLPQLPTVQ
RSYYMVSGSLMAVLFIFGPQLFYQPLTTYGQLGWYGVLLGFFGVCIPPLLFAYGMPQIGS
GLGSILSSIELPVAVLLSVIVLKETVILSQWIGVFFIFLAIILPNIEWKKEQLAKNPL
>fig|272558.1.peg.2098 ABC transporter (ATP-binding protein) (daunorubicin resistance)
MLETINLCKTFKGQPAVQEVNMYLNSGESVGLLGPNGAGKSTTISMISTLIKPTSGEIKL
NGINIISHPGDIRKILGVVPQELALYQELSAYENLKFFGSTYKMKGKHLENRIQHALEIV
GLKDRQKDLVKTFSGGMKRRINIAAALLHEPKILILDEPTVGIDPQSRNHILETVRTLNE
NEGTTVLYTSHYMEEVEQLCDRLYIMDHGEIIAAGTKEELLSILSTEDTIKVELSKIDET
FVQNVKMIEGVRKVEASHSQLKMIAKKGSHLIRELVHLTDQHQIQMIHFHTETPSLEDVF
LHLTGRTLRD
>fig|272558.1.peg.2116 Chloramphenicol resistance protein
MSNKKTALTIFLLSLGAFVTGTAEFVFSGILEIISLDLGVSIAAAGQLLTMYSLSYAAGA
LILVLLTAKYNRKKVLMYAIFTFLIGNLIAFVSYSYSLLMFSRVVMAMSGGLYIVVATNY
AAQIVSPEKRGSAIAKIITGFTVSLVLGVPIGTFFSAYVDWRYIFLIIALISLFLIISLY
KLLPEIQANKPLPFTTQLQIMKDRRLMTGLGTTIFWILGYTMVFAYISPLLSREAEMPLE
MISVALFVLGTSAFIGSRFGGFAVDKWGPARTISISLIILQHSFRS
>fig|272558.1.peg.2163 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MEQKQQSERLGTEAIPKLLRSLSIPAMIGMFVMALYNVVDTIFISYAVGIEGVAGVTIAF
PIMMIMMSMAGALGIGGASVISRRLGERRGEEANQVFGNILTVILVLSVIGFISAFTLLG
PALQLFGATSVTQGYATDYLFPILLGSIFFFFAFAANNIIRSEGNATFAMVTMIVPAVLN
ILLDVLFIFGLNMGVLGASIATVIAQASVTGLVLRYFLTGKSTLSLHWSDLRMKGSVIKE
VCLVGLPAFVQQSSASLMMIAINSMLLRFGSDFYVGVFGLVQRIMMFVMMPMMGIMQAMQ
PIVGYNYGAKQYSRLRETVMLGFKVATIFSIGIFALLMLFPEALLRVFTADREVIQAGVS
AMHILFCVTFLIGAQIVAGGLYQSLGKPKQALILSLSRQIIFLIPLVLILPHIFGLSGVW
WAFPIADVLSFILTVVLLYRDRNVFFLKTKEERELDLVKTASST
>fig|272558.1.peg.2592 Multidrug resistance protein B
MKGWKRNLYILVVCQFLVVSAMTMIIPFLPLYLQELGVTDPSEVSLWAGIIFAANFLTAF
LFSPLWSRLADRYGRKMMILRSGFGMALIIGLTGFAQGPLSLLCLRLLNGVISGFIPASI
GLVATNTPKEKAGYALGFLQAGAVSGGICGPLIGGIMAQAFGYRMIFFLTGLCIFIAALV
VLLFVNEQFTPNPKEEKTNTWGEFKKITAIRPIFSLYVVVFLIQFAVMGVNPLISLFVEE
LVSGVNVALFAGLAISATGFANMLSSMQLGKLSDKAGAHHVLFFCLLGTVIFMIPQAFVQ
QLWQLIVLRFFVGLSLGGLLPAANALVRMHAPKGMESRTYGFSTSALYLGNMVGPTVGGA
VVATVGIRGLFLISAFTLLLTVWIVKGKVMPASDKQFRYEQNERKIASS
>fig|272558.1.peg.3211 Multidrug resistance protein
MNIGFGMVVPYFAIYLGTYTGLDPVSIGLIVGTTSIGSLVGGFLGGTLSDQFGRKKIMLV
SLVVASAIYAGFMLQDYALLLVCLTLVMGFCTSFFEPCAKALMADFTESKKRMKAFSLRY
IGANIGFAIGPLIGIVAGVTASSRLPFIVVSTILLAYALFLQWLFRAFGVQEISIGEKEH
VNLTGAFKAIQSDRVLLLFLFGGLLATVVHGQFSVILSQYFELEFQSGLAYLMLLWSVHS
GVIVICGIPLVKVMERLSPLRAIVIGSLFFAVGVIGFAFSFNFMTFCLAMIVFTIGEMFL
IPAEYSIVDEITPNHMRGTYYGSLNFTSLGSFIGPWLSGILLVHFGGKFMFIGLALICAL
SLFFFIAGHLKRRAYTVGEAVREAERGL
>fig|272558.1.peg.3496 Transcriptional activator BmrR for multidrug resistance transporter
MKNQFPIGEMAKLHNTSIKTLRYYDEIGLLKPDYIDPNNGYRYYSTEQFEHLNTIHYLKE
LGFSLKEIKKHLEDRDIDGFLTLLEKQKELTEAKIKELERINRRFENRIHDIKWARHIEE
LGIVTIKDMEKRKIVRLKETIRSEPELEITLRQLENKSKMTSSIFIGGVGLTVSMRNIKS
NKFNEYNSIFILIEDDIQNPLVATLQEGKYACIYFRGNHHDSPKYYKALLNYIQTNNLHM
IGDAIERTIIDHYISESKDDYLTEIQIPIKY
>fig|272558.1.peg.3856 Quinolone resistance protein
MKQKIKAPQLPSSLTSATILQLEEGDDQIGSIQLIGDETNGLICPDHLEIRQSSFKQVTL
LNSSFSRSDLSDVVFEKCDLSNVQFQDAIIHKAEFRRCRMTGFNGSGASFRHVRFIDCLL
DYSAFGFSNMKNVAFSHCSLQEADFYQSVLKHTEIQDCQMHGANFAQTDLSDMDLRTCSF
QQLTVSFDKLQGCTVTSEQAIGFAKILGLNIEDH
>fig|272558.1.peg.3880 Multidrug resistance protein
MKTTKKRETLWQQPGYKKLFTSYSISMVGQWFDLVALLVLFGYVWNADPLLLAFIPIAFA
LPQMLFGQFAGVFVKKYHKVKVMAVADGVTSLLTISLLFTGHPLVVLGIISLRATVNVVH
YPAQQSLLRQLIRDDLRLQAITWNGAVSQAAKIIGPMGGGALLTAFSPHTLILLNGIAFL
LSALLLTTLFRNVKVVEKDTSLENQSSFWASWKAGWQVVFKRKVIYFSFAIALLGMSVIQ
MVDIQFPVLFRQIAAAQPQMVAWIMAAIGTGAIAMMAFLGRMKQLRNVGMWLAGAMICIG
IAFLGIGMLQEGFLMMIPIGLGLIAGLGTGTSMVVSNYIIQTEPREQEVSQVAGIYQSLI
SMAILLPPLLGAWLIHLIGVILLFQIVGAVLLIIGGIALCFHPILFTTKQGTKEAGTKLL
IVKE
>fig|272558.1.peg.4045 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MEMSKQLGKKFNLLTLLAYAAPTMALMLFMSIYTMVDGMFIARYVGATALSAVNIFFPIY
GLIIAIALMLGTGANAIIAKKIGENNEEEAKENFTFIVICGAVLGLVITVFGLLLMEPIL
LMLGAGATEELFDFTYTYAKIILCTSPFMILQMLFQNFFVTAGKPNLGLTITVVGGVANI
VLDYVFIVLLQMGIAGAGIATAIGIFIPAAYGFVYFIYNKESGLHFVKPKVDGKVLLNSC
INGSSEMVSNLASSIVTFAFNLLMIKHLGVDGVAAITIMLYVMFILSSISMGYSAGVAPI
ISYNYGSKNSSQLKRVFNYSLLIIVIGSVTMYGVSMMFGAYFIQFMAPEGSAVYHIAIEG
LNIFSISFLFMGFNIFSSMVFTAFSNGKISAAISFLRTLVFVLASLWILPAILGVTGIWL
AIPLAEILSVIVCIFFLTHYRNDYHYA
>fig|272559.3.peg.71 Permease of the drug/metabolite transporter (DMT) superfamily
MMKNKKVEANLSMVVSKTFSGLNMNALKYLLPVWVSPLSGVTLRCVFAAIAFWIIGMFVK
PEISTRKEKIFLFLLGALGIYGFMFLYLMGLSKTTPVSSSIFTSLQPIWVFVIAVVFFKE
KISAMKIAGISLGLGGAILCILAQKSDDLASDALTGNMLCLLSSIAYAVYLVASNRILKS
VGMFTVLKYTFAGAAFSSIVVSAVTGFHAPVFSGPLHWFPLSVLLFVLIFPTVVSYLLVP
IGLKYLKTTVVAIYGYLILIVATIVSLLVGQDRFSWSQTIAIGMICVSVYLVEVAETKEK
PVSNSDKPSSLPPHGS
>fig|272559.3.peg.782 Bicyclomycin resistance protein
MTDRQNSRRFLLLFLGVLSAFGPFIMDMYLPTLPAMADFFHTSSSMVQLGLTTSMIGLAA
GQLIFGPLSDKYGRRPPLLLAMILFLLATVGCIFSHTISQFVTSRFLQGIAGAGGVVISR
SIATDEYSGQQLAGMLAVIGGINGIATVIAPIGGGILAQITSWQGIFICLFFMGVVLLSG
SLHLNESLPAKHRQTVSWQDLYHSFGEVLHNRRYVGYVLQYGFTMGILFVNISSAPFIMQ
QHYGLSPLSFSLCFGINAIAMVISSAISIKLPTMERALYIGSRGMLSVSALLMVFLSLRC
DFWIYELLIFALLSMIGMTFTASNTLAMECERRNAGIASALLGATGFAFGGIVSPLVSLG
DMMTSTGILFLAGSACAYACTRYVLSQSVQPSGVLYH
>fig|272559.3.peg.1185 Tetracycline resistance element mobilization regulatory protein rteC
MKEVVDRILEQVEADISEIDLYGYNIIETSLSMVHRLQTVLNDLRTKIQTYVFLTKEDEI
LFFKTQKPEILGRLLFFYKIYKIETQCPNGSDEAIRNYINRELDNLTYFFNRNLDFYQYY
RSHSTVYDEYYFVRGKADLRLCTDSAQFDKDPNFSTGYDYKVAKIIANEMLRIYLNKRLV
KLGTNNQIEDNLQKCFKYPFRFTGKKAYLIELGYSLVSSGDINNGNVEIKEMMNFLSTIF
HIDLGDYYASYIAMKERKDRTAYLHHLIDSLIKRMNEDDMKC
>fig|272559.3.peg.1195 Permease of the drug/metabolite transporter (DMT) superfamily
MKSLKGIIYAMISSGTFGLIPLFTIPLMGNMEMNESNILFYRFLFSTLMMGAVCLLHKST
LKINMKHLISIIGLGALYALTALFLIYSYHYITSGVATTIHFLYPICVSFLMVVFFKEQK
SKSLFLAASLSLIGVALMCWSGGGSIRLMGIGLAALTILTYGIYIVALNQLDIGKLPAEV
LTFYVLLGGCVIFFIYSLFTAGISSIPSTKAGFYILALAFLSTVISDLTLILAVKYAGST
TTAILGSMEPLVAVVVGVLVFSEHFTLQSLIGLLLILMSVIIVILADQQKKSKRITEQKI
IKPH
>fig|272559.3.peg.1654 Tetracycline resistance element mobilization regulatory protein rteC
MEEYFNGLLKEVDQRMATTAPGMDGKEVIGVCREMVSYLKGKNRELKEYALAHPFAGDAK
EILYFKYYKPALTGRLLYYYRVYQIESGCPACLRVAEPYYRKAMERAERMMERYLPFYQY
YHSGATYRDSYYFLRAKGELSPESGSFVLDEEAEFSTGYDILAARLISVEMLLVHLSRRM
ERAAQGTETEAVPEKEHRWTNTKVAAILLVYGIHVTGSVDEGNAEIGELAALFEKHFHVD
LGNVYHAFGRLRGQQNPTAFLDEMKERLLKKMRDMDSR
>fig|272559.3.peg.1875 Permease of the drug/metabolite transporter (DMT) superfamily
MKTTQRTAGWYHVMAAVTVMIWGTTFVATKVLIKYGLSPVDILFYRFLLAYICIWFFSPR
VLLAKSWQDELRFVGLGLCGGSLYFVAENTALGMTLASNVSLIICTTPILTALLAPFFYK
GDKLKARLIGGSLMALIGVGLVVFNGSFILQLSPAGDILTLIAALMWAFYCLLLRRMNTH
YPTLFITRKVFFYGLVTLLPLFLVYPLQTDIHILFRPVVALNLLFLGVIASMLCYIMWNT
AVKQLGVVCATSYIYVVPLITLLTSAIVIDETITIVALLGSALILSGVYIAERGVNLKK
>fig|272559.3.peg.2680 Multidrug resistance protein B
MGNIMIGTFMAVLDSTVVNTGLPVIMGTLGADINVAEWVLTGYMLSMASILPAAGWLSER
FGYKKIYFLSLLVFTAGSFMCGSSSTIEELIFWRVIEGFGCGMLLPVGMAIVSDVFPPEQ
RGTALGFWSIASAASVSFGPAIGGYLVDYMDWNYIFYVNIPIGILALIVTAIVQKEHVKG
TGVPFDIPGFITSAIFLPVFMYGLSEVNSSTNSMGWSSPVVLGAMWIAVVTFILFLYFEF
TVKTPLINLRLFVDRDFALSNLILFVFGIGMFGSTFLIPLYLQDNLGYSALQAGMFFMPV
GIIQGVASPLSGKLMQRINPKVFIVSGILLMALSFYMNYYLSFLTEKWYIILSLYLRGLG
MGLLFTPLLTLSLVNIRNSDMAQASSITNIVRQMGGSFGVAIFSHLLTQRTAFHTQRYGE
ALNYTGDVYRQTLHSLSRFIEHTGGRTPDTAKEVAEMLILKRIDLEGYISAINDDFFIAF
IVTLLCVVPVLFLRTKKG
>fig|272559.3.peg.2985 Permease of the drug/metabolite transporter (DMT) superfamily
MNIIMNINSKAKGFVCGAVAAATYGMNPLFTLPLYKEGMSVDSVLFYRYGFAVLILGILM
KVQGQSFALKKNEVLPLIVGGLLFSASSLLLFLSYKHMDAGIASTILFVYPVMVALIMFL
FFHEKVSLLTVFCILLALSGIGLLYKGEGGETLSLVGMLLVILSSLSYAVYIVGVNHSTL
KLMSTAKLTFYALLFGLSIYIVRLNFCSDLQAVPSLPAWGNILAMAFLPTVISLVCTAVS
IHTIGSTSTAILGALEPVTALFFGVMIFGERLTPRLMLGILMILVAVTFIVVGKPLMTFL
KEEVAGGMKRKLTR
>fig|272559.3.peg.3009 Bicyclomycin resistance protein
MTKRIGNSRLYILIFIGIVSAFGPFVTDFYLPALPVLSEYFDTTASLVQLSLTFSMVGLA
VGQLIIGPLSDKYGRKLPLMVSLVIFCISTVGCLYSPEIHGFIFARLLQGLSGAGGVVIS
KSIAIDLYQGKELTRFFAMLSSVQGLAPVCAPVLGGILLGAMDWKGIFWILLAIGILLIV
ALSAFKESLEIKKRQKGNVFSTFKYYLPVLRNRQFMRYVLIQAFAMGVMFTYIAASPFIF
QNHFGTSPFAYSLCFGVNALGIMLGSLAVSRFKDATAALRFGVAGFTTMSLPVAAALIFS
PSVWIVEGTLFFLLAFLGLILPGSTTLALDMERKNSGNASALLGFLMFVFGGLLSPLTGI
GNMLYSTGIIIVACCVGTWFFTYKATSSAR
>fig|272562.1.peg.85 Permease, MDR related, probably tetracycline resistance protein
MKSSKLSIIKYYLYTFGVQMRLTRIVNILYLVQCVHISIVQFTLLQSIFSITQFVMEVPS
GMLGDFFKKKNITTYGLILSATAQLLICSRLVVNAENPFVILAFAFAIEGIGRALISGAD
DALFYENIRADGYAAEYDKIRGRYQLISSISVGIVTSLGTILYTINNSIPYIGQCIMTII
SIGSIMTVKEHNVKKTLRKNENGKNSIKVFLTSILQVRNSPHIVFMMCLVCLTFGVINTV
FGIMPDYISEIGFSNTQTGTVFMLLSFIGGIVATQAYRISNKRYGQLVLVTVLCMSSGVS
LVGLRGNKEMIFIGLALLYVIIDVLDPIAMKSFNAYVDDSIRSTFLSMVSFMVSTSTMIL
YPIAGIIVEAFGMLTLLIAISAVVIPLLGVSCIIYKKYSVN
>fig|272562.1.peg.122 Permease, MDR related, probably tetracycline resistance protein
MNTTINNSNLKYNNLILILGLAGFVSAADNWFVSPALQPIASELSISVSTAGIILTSYMI
PYGVMQPVYGFFSDRWSKASVLKIIVGGLAIGTAGSAFVRALPLLCLFRIITGFFAAGII
AVSLGLIGDTIPKLERQIYVGRFMGIVFLGQGLSAGLGGLITKYISWRGAFVFFAVVAAI
SDIILIKGLSSDSKKISFNCKQNNFFLQTKIAICTPAGRKIFPLALISGFLLLGLYSYLG
SFLHDVMHLDYLECGVLIMFYGFACLIGGTKVGKLSKRYGKKNIILLGEGFALITALSLY
FFHYWEIALVATVFLGFGYICIQSTLATLAFDVNPENTGLPSGLIGLGLFGGGGLGSLFS
GWLLSIDGYEAIWIVFASFIVVISLITLKIKLN
>fig|272562.1.peg.818 Teicoplanin resistance protein vanZ
MSITIKFILSVILIKLFNDIVNKKSKQEKNEVPLKYYIMKCVFILYLIVVLDVVGFPSLW
EWKMMMSLSQPIFNPHINLIPFKEMGIEDALNIVLFMPFGFFLPTLWKRYHKFWMTASFG
LAFSLTIELSQLFSRSRVTDIDDLIMNGLGTVLGFMIFYIIRKKNYHTDEKEENNLFVKV
EPFVCIIIVIICNFLF
>fig|272562.1.peg.827 ABC transporter ATP-binding protein (multidrug resistance protein)
MKYSNINKKLGSFLSSSKNIIKTVKLLWKSSSLSFIATLIITVLNGIIVPINMVISKYLI
DSVVNALKNKSPIDSLNKVLFWLVVEFGVIAFSYVIGRVNTYFSTIQSKCLNNSISELLI
KKANELDLSYFENDEFYNKIEKANSQAVGTTIQIVNGLTQIVKNFTTLVGAIVIVFQLSP
IILLLCIMTSIPMFIINIKIYKQKYNIYSKRIEKTRLAHYLQMVMMDYIPVKEIKLNRIG
DWLEKIILSIYKDNLNQDKKIEKKQLLIMSIVDIFNTIISYGYKIYVIFITLTQRLSIGS
MNMYISALTNLEDSVKNTLDNFALLYSNNLYIENLFYVLDLKPLILNNNSGKKEFINEIR
DSIEFRNVSFKYPNSKKYALKNVSFKIEANQNCAIVGLNGCGKTTLIKLLTRLYDPTEGE
IYIDNINIKEFNIESLYKGIGIVFQDFMKYPFDVKKNIGFGNIDNLDNFELIKTAAKKAN
AYTFIQGLSNKFDTKLQKMWSNGVDLSLGQWQKLAISRAFMSNACLLILDEPTASIDAKS
EYELFKDFKELMGEGTSILISHRFSTVKMADKIIVLKDGEIVEQGNHDSLIKSDGLYAEL
YNMQADAYLVNEDKNIDVSKDKLKDIV
>fig|272562.1.peg.857 Vancomycin B-type resistance protein VanW
MKKVVIGAFSSAIIIILIVLSSIYIKVKKWDGLVYRGVTIDRVDVSSKTKKEVQDIVKKK
FDKIVQNRTINMVTDDNKTIPLKYSDINVKYDIDKAVSGAFDYGKSLSIYDRYKLLHNPK
KLEISVGMTYDKNALENSIKNLSNTLNKKAKDATIVKTASGFQITPEADGKKVNEDKLKA
DIEGKITDNNITDYNVKINMDAVKANATQDKLKGINTLISSFNTEYASLSSPQRANNITL
ATKAINGIVLMPGDSFSFNGVVGERTAAKGYQSAPVLIGNKSDMGLGGGICQVSTTLYNT
VLTSGIKATERHHHTLPSHYVPVGYDATVDYGTLDYKFKNTLSFPIYIEGNTDNGHVTFN
IYSDASLLSKTYKVSSENISDSVPKAKVYLETYENGTLISKDMIANDAYSK
>fig|272562.1.peg.994 Teicoplanin resistance protein vanZ
MKKIKNKKKIFKVILFGLFIIYIIALFKIILFKSISFLQIFKGYNKSRSINLIPFKSIIQ
FIDTYKEMGSFRAFANLAGNLIVFMPFGYLVPTLNKRFSRIRSTVIASFGLSLFFEVTQY
VLEIGSSDIDDIILNTLGAVAGYSVLTCLRKISSKVVIQNFCIMCITVIFLITGSIVAFR
EYGVMLNLTKLKEVINGGRDIPKISADAVGHTVQIKENDIKLEKVSIYNKNKGGKSHDKG
ERNIDIVFNKSTKVYFERDDYKDNTMTITNIKVNEKKLYTLKKNSMISVWGNNREGKLFA
NFIIVYLK
>fig|272562.1.peg.1012 Probable cation efflux pump (multidrug resistance protein)
MKLLQLFNDKKFFKAAFGLAIPIIIQNFILSSLNLVDNIIIGGLGETAIAGVGLANQYFF
LLDLALFGTASGASIFTAQYWGKRDTKNIKRVLGICLITTIILSGIFTIGALAFPNIIIG
FFSQDKNVISLGANYLRIICFSYIVTGISFAYSIILRTVGQVKIPMIVSGTALAINTFLN
FSLVYGIGSFHGIGVYGSAIATLIARFIEFFLMLLAIYKLKLPIAAKLHELLDLSTTFVK
RFFKVAVPVMLNESMWGLGVTAYAAVYAHMGTAVIAATNITSTIDRLSMVVFFGFGNAAA
IMIGNRIGQKDEKTAFLYAKRFIILSPFIGIFMGIILYTSSPAILYAYNINSQVHMYSKE
ILHIIGMFLWIKIFNYTNVVGILRSGGDTKFCLMLDMGGMWLVGVPFVALTGIYFKLPIG
IVYYFVFMEEFVKLLVGLPRLLSKKWINNLVSKPSEVSI
>fig|272562.1.peg.1210 Permease of the drug/metabolite transporter (DMT) superfamily
MKKGYMYIALTTIIFSTMEIALKLVSKSFNPIQLNFTRFFIGGLFLVPFALNTLHKRHLS
ISTKDLRFFALLGLLGTVISMSLYQLAVQNTKASVVAVLFSCNPVFVTILAFFLLREAIH
KNNIAALILEVIGTIVIIDPLNTKLSILGLALTIASTLIFAAYGVFGKKKCAKYGGIVVT
CFGFLFGSIEMLVLIGITHITPIANLFSSNGIAIFSNIPLFTGYSLKNLPLMCFICLINT
GAGFACYFKAMEETSAQTTSLVFFFKPILAPILALILLHEIIPVNMIIGILFILAGSISS
ILPELLAQRQTKLEKTA
>fig|272562.1.peg.1237 Permease of the drug/metabolite transporter (DMT) superfamily
MSKSTKVDLVFLFFTAIWGLSFPLTKNVLGYTSIFAFLSLRFTSAAVILIIIFWKKLKLI
NTKIILYGSLIGLMFFGSLAFQVASLRFTTSSNSSFISALSVVIVPLVSAGYYKKKIDFS
CVLGVLFAVVGLFFISGGVNFKLNIGDLFSFLCAICITFQIIFIDIFCSKCDSALLSLIQ
VVFCAIFYNIVLFIIGTKPIVFNTQLTVSIFITGILGTAVAYTGIVFLEKFTSPTHTALI
FCAEPVFATIFAMFIPNNNGSCESITINTFIGCGVILLSMVISELKIGNNIPQKIIKL
>fig|272562.1.peg.1605 Tetracycline resistance protein TetP
MKKIINIGIVAHVDAGKTTITENLLYYSGAIKSVGSVDSGNTQTDSMELERKRGITIKSS
TISFNWNDVKINIIDTPGHVDFISEVERSLSVLDGAIIVISGVEGIQSQTRILFNTLKEL
NIPTIIFVNKLDRIGADFNKVFEEIKKNISNRVVRLQEAYDMGSKDVYIRNLSDICPINN
DAVDVISDLDEVFLERYISGVEPNKEEVQEKLSLYAREGSLYPVFCGAAAIGLGIGDLLD
GICSYLPFAGDECEGNLSGVVFKIERTSTNEKKVYVRLFGGRVSVRDRIQVPSKEIVEKV
KKINSLENGRIIETQSIEAGDIGILYGLTDFQVGDVIGVSNNKIKNISIAKPTLKTTISA
IDKEENQELFKALTLLAEEDPLLELEMNDIDEEIYVNLFGEVQMEILSSILDGLYGIKVE
FSNIQTIYKEKPKGVGMSIMRMQEDLNPFWATVALKIEPKGRGEGLRYISNVSVGSLPKS
FQNAIEEAVVKTSKQGLFGWEVTDAKVTLTCGEFFSPASTPSDFRNVTPMVFMEALYRAQ
TVLLEPLYEFELRIPQDVLSKAIWDLETMRAIFDSPIVIGDEFSIRGLIPVENSKEYKMK
IASYTKGKGMFTTKFYGYKEVSAKFAKARPKTTYDPLNKKEYLLYKLNAIRD
>fig|272562.1.peg.1694 Permease of the drug/metabolite transporter (DMT) superfamily
MNGKQKILPYIAATVSSTIFGLSFLFSKMALKVAGPLSLVALRFLLAFIIMTILVLFRVI
KVDYRNKPIGQLVLLGLAEPVIYFIFETYGVKNISSSMAGLMLALIPIVVTIMGSYFLKE
VPSLKRTSFIVLSVSGVALIGVMGSSGGSGNSPIGILFLLGAVTCAGAYSIISRKTSVHF
KPVEITYFMMFFAAFCFNIMAAIQLLAEGKINEYFSPLKSSTFVISILYLGILSSIVAYF
LTNFTLSKIQASRSSVFSNLSTIVSIIAGVIILKESFHLYHLVGSVLILTGVWGTNKFK
>fig|272562.1.peg.1767 Probable cation efflux pump, multidrug resistance protein (FS)
MALVRKDVVKLAAPIFVEQLFVTLMGMINTMMAGHIGKEAVSAIGMIDSINNIFIAFFSA
LAVGGTVVVAQYIGQNNIKKANESTKQALYSTIIIAFVITIIMAILKGPLLGFLFGSAEK
EVILDANSYFGITLLTYPLITIDLVSNGILRGAGDTKTPMKISILMNVLNVAFTALFIWG
IKINGTVVVKSLGITGAALGIATARTIGGIIILIVMVRGSRIVQLKKLTEFKFDMTLLKP
IFGIGVPASVESLLFNGGKLIMQIFIVGMGTVAMASNTIVNSISNFLNIPGNSLVIAATA
LVGQHMGRDDDKGAEKCLSYITKLSTVLLAIVGILSILFSRHLPSPVYWK
>fig|272562.1.peg.1768 Probable cation efflux pump, multidrug resistance protein (FS)
MVSYLFFFQDIYLPLYTGNNDIIKLSSKVLIANAFAMIIWSSAFTLPAGLKGAGDAKYTM
VTSIIGMWLFRIVLGNFLGNTMKFGLLGIFLGMYTDWLVRGILYIIRFRSGKWKNHVVVK
RVKTSVKA
>fig|272562.1.peg.1812 Quinolone resistance protein
MQRKKKLKIVNPDIYEELEEVLEGEIIVEDDSYIELKSFENVSLENKQAKKVSISQSIFK
NVSFNNTSFKGIDLTDVIFEKCDLSNADFTESVIYRTQFKNCKLMGINLSEGTLNNVTFD
NCMARYSICTLLRCKNVLFKECTFTSTDFYKSQFTNVEFLNSELIEAQMHETSLKGIDLT
SCSIDGIGLNIEDLKGCIVGPEQLMCFANLLGVILK
>fig|272562.1.peg.2536 Multidrug resistance ABC transporter ATP-binding and permease protein
MKKGTLFRLASYVGKYKMYMFISLIFALISNVLIAFMPLIVGKGIDNIKSQGKVDFNNLL
KIIIVLAAVYLISSIFTWLFTAVANILAYNTVRDLRNEALSKISTLPLKYFDVNPHGDIM
SRLTNDMDAISDGLFQGITQFFPAIVTIISSILLMLSLSIKLTGIIILMTPLCFFIASFI
TKRSNKMFKQQQNTVGELNGYIEEIIGNEKIVKLFGYEKRAEKKFSEINSRLYNCGQLAQ
FYSSLTNPSTRFVNNITYVLVGAVGGLLAVLSGLSIGTISSFLTYSTQFSQPINNVTGVA
TQLQAAFASAERVFSILDEIPEKKDNEGAKKFEHCEGNISFNNVSFSYNKKQPLIENFSV
DIKKGSTIAIVGPTGAGKTTMVNLLMRFYDIDGGKITIDGKDINKMKRNDVRGQFGMVLQ
DTWLFEGTIKENIAYGKPDASMEEIESAAKKAYIHNFIKRLSDGYDTRITESGGNLSEGQ
KQLLTIARVMLINPPMLILDEATSSVDTRTEIKIQNAFLKMMEGRTSFVIAHRLSTIKDA
DLILVMKNGHIVERGKHEELVNSEGLYREIYESQFKNAV
>fig|272562.1.peg.3475 Probable cation efflux pump (multidrug resistance protein)
MKSLATDMTEGNVSKHLIKFAIPLILGNLFQLTYNASDSIIVGRFVGKNALAAVGIANPI
MNIVMFFIVGICLGASVLMSEYYGAGNVKKLRREISTTVIAGFIFTVLIIIICVIFTEPI
LGLVKTPKEIIPEAAIYLRIIFISLIFTFFYNIYAAALRSIGDSKNPLLFLMISAVLNVV
MDIVFVVWLKMGVAGSAIATSVAEMMSCVFCIVYVHFKIPILKFSFKDMVIDKGLLRSTV
NYSWATAMQQTCLYVGKFMVQGAVNPLGVNSIAAFNAVNRVDDFAFAPEQSISNAMTTFL
AQNRGANKYKRIKKGFLTGMKLETLYWCILVGIVYLGSTAIMKLFVSGSEVKVISIGSYY
LKLMAFFYLLPSWTNGVQGYFRGMGDMKITLRSTFSQIVGRVAFSYILAPRIGMVGIAFS
CLGGWIVMLAYEVPCLIKYRRNFNNKLSESSI
>fig|272562.1.peg.3489 Multidrug resistance protein B
MSKDKKRIIALAIFLLGIFMGAIDSGIVSPARDVIRSSFGIGESLSVWMVTIYTLAYAVS
MPIVSKLSDRYGRKKVYVISIATFALGSFLCGVSNFYGNYTFFLVARVIQAIGGGGIMPI
ANAFIGVSFPPEKRGTALGFVGGIYGIATILGPTMGSSVLNLAGNNHWGWIFFINLPISL
IILALSVNLKENLGEAKKKMDLKGSIVLSAMILSLMYALTNLNFSDIVKSLRSSVVYPFL
IVFFITLPIFIVIEKKAEDPILNLRYFKEKQILLTLILGFITGVGLMAVIFIPQFAENIL
KLKTGNGGYLVTFMSVFAGVSAPLGGKFIDKYSAKLVTALGMICTVFGTFFLAFYTTSNP
NFISIMIGLVFVGFGMGFTMGTPLNYLMLSFVDEKESASALSTLSLIRSIGVAVSPNIMI
NFISEAGKRVQGNIMSVMPQISVPVFLQGKSAVRTIDISKLSGSGKISNAAISKFQSADV
TNIVKVLKEFAASIIDKMLPGIKAQILRQMGPTSKMAPHIDLNKVFSSWKADYLNKIDQK
RAVIESTFQSTISSGYKNMFIAAGIIALVGFIAALMLENKKMRVKNNI
>fig|272562.1.peg.3563 Probable cation efflux pump (multidrug resistance protein)
MLNVIKNINQRKDMVISIFALSWPSILEQLLETAVQYVSSAMVGQLGAEASAAVGLTTTA
TWLINSPSFAMGIGVLSYISLSIGAKKFRRAKIAAVQSIIITLILGIFMGIGTLAISPFL
PKWLGAAPEIQRNASLYFGIICIPMIFRVAIIVFGAVIRSTGDMKTPMKVNLIMNLINIV
LNFILIYGKQTISIGSFKITTYGGNLGVVGSAIAAATAYTVSGILMFLALYKNKIVSPKG
EKLKLNIPIMRRCVNVGFPVTIERVATSLGQVVFSSLVTRLGTLAFAAHSIAITAEQAFY
IPGYGMEATASTLAGNALGEKNEKKLNQISVTIIGMAITIMTVTGTILFLFPDFMMSLFI
KDPVVIKSGSSVLRLVAISEPVFGALIILEGIFNGVGETKTPVLVSILSMWGVRILSTSI
CIYVFHLGLKSVWICMIADNVFRFTILFIRFLNGAWKKKLNL
>fig|272562.1.peg.3590 Multidrug resistance protein B
MKTKNYFDLKKVLPAVLTIAVGMLLVMMDTTIMNVALPHIQSTFNTNLATSQWAITAYTL
AMAAVIPYSGWLADRFSAKKIFGIAILFFTIASLLVSISTNIEQVIFYRILQGLSGGIVG
PIGIAISFKIIPIEKRGSMMGLLGLPMLLAPTIGPALSGFLIKYYNWHTIFLINIPIGLL
SLILVFLFLPNFKSKHNTKIDLRGAFLSPLAFPLLIYGVHVGSDKGWQSPISIISIALGF
LMLLTFIFLETKTQTPLLEVKVFKISEFRKGIILMWLNQIAVFGSMLLIPLYLQNIRNYS
SLEAGLMMVPQAIASFIGMTVGGRLFDKYGTKSAAIPGFLLTGFSLILLAQITNTTALAY
LIICIILLGLGQGLVNMQVNNHALQSVPLNLINRVTPMTNELLQVINSLSIAFITAFLSN
QIKTAFRKHSLAVSGNIAFHNTFILLTIFIAIGLGLTFFLKNKKSKEAS
>fig|272564.4.peg.581 Acriflavin resistance protein
MNNKKGLLYHIISNWRFTIFFTILTMALGIYSYYIVPKQESPDISAPFAVITTIYPGAAP
EDVEKLVTRVIEDEIREVPGYKTSQSITKNSLSVVVLELHNDVDVKEAWNELGQILDGAQ
GKIPAECFDIEADTKLSETAGMIISLSGAGYTYEQLADYAEQFKSRLAKIDGISRFTVTG
VQNKAARIEVKIAELNKYNISLDELVSLIQAQNLQIPSGSLSDQRVKVNVSSPGLFTSLS
DLENMIIDVSAETGAPIRLQDLADIRWDIEDADYQLKHNGQNAIMLSGFFKENRNILLVG
EDVRAELDRLKAELPPELIVDEVVYQPTDVDKSVAEFFKNLLEGMALVLIVVFLGMGFKN
ALVASTAVPLSIVITFIAMHLLGIQLQEISIAGLILALGILVDDAIVIIDAIQVHIDQGL
EKMEACIRGMKQAMIPVFSATLTIAAAFSPMLFVPGPAGEFLRSLPQTVIIAVSASFLVA
ITVTPVLAYLFFDKLKKEDDKRTPLRRVYGYALQIGMQYKKSTVCAAILLIAIAGYGALQ
LQIEFFPKADKNVFYINLYSENASDISATARLAEQVEGILQENEEIVSYSTALGGGLPKF
YITLPKATPAKDFGQIMVKVDLDKGEFANNEDLALHLQEQLDQHLIGGSANVLLLEKAMP
GDPLEVRVSGADPLQVRDGVALIRRELEGVPGTMKVADDYVAGEYEFVVDVDTERATTMG
ITNYDIQRQINIALSGAEASLFRIAGNEYPILVQSDVKSKEDLENLAIKSSLTGHKILLK
QLGNIHLQATVPTINKYDGVQAVTISGKVQPGFSAVTIENTLKQRLTQSGFDFSGLTVSY
EGEAKDIKDNFGSLGTTAIFALFLIYVILMIQFRSFLQPAIIFITIPLSVIGVVAGLMLF
AQPLSFTALVGVVSLMGLVIRNAILLIEFINLAREEGMSIDEACHFAVNRRYRPIILAAV
TTVIGLVPLAFSGSDLFTPMSVALMSGLLISTLFTLVVVPVLYSLLVREGKGTAPGASAA
GKREMGQSV
>fig|272564.4.peg.2257 Multidrug resistance ABC transporter ATP-binding and permease protein
MSAAEKQTGFGPGRQGPGGGRGFFGGPPGGPGGPGGGEKARDFNKTLRTLTGYLTPHKTT
ISIVVFFALFSTVFTIVGPKLLGKVTTKLAEGLFAWYNQTGLLTDFNYIGKIIGALVVLY
VISSICSYVQGYLMSGVAMDVTYRLRKEIAEKMSRVPLNYYDTRSHGEVLSRITNDVDLI
NQTLNQSLNQIITSAASIVGILIMMLSISWMMTVAALLVIPLSLGIVGVVIKRSQRFFRE
QQHSLGELNGHIEEMYGGHTIVQAFNGEAESVAFFERVNDQLYHSAWKSQFVTSIMMPVM
SFVGNLGYVVVSILGGYLAVKRVVDIGDIQAFIQYMRSFTQPIAQLSSISNTLQSTAAAA
ERVFEFLAEGEETPETAHPVTLDQFSGHVRFEHVSFGYSKDKQIIHDFSADIKAGQRVAI
VGPTGAGKTTIMKLLMRFYEIDSGRILISDHDIYDFSRHDLRSLFGMVLQDTWLYNASIK
ENIRYGTFAATDEEVMEAAKAAHCDEFIRALPGGYDMVLNEESSNISQGQKQLFTIARAI
LADPKILILDEATSSVDTRTEILIQKAMENLMRNRTSFVIAHRLSTIRDADMILVLKDGD
IVEQGNHEELLAQNGFYADLYQSQFEEAEAV
>fig|272564.4.peg.2540 Daunorubicin resistance ABC transporter, permease protein
MSGQVLTRKKSRIYREASTVLAIFAREVTVALKSPGTLIMSLAMPMIMMGMIGGNLMQNM
AGGLGFQFGTFMLVGMLVNMLFMTTTMGVASLVDDHDSNFSEEMLIAPVSRYGIVIGKIF
GSMFGAVLSMVGTLIVGLVMGITLPFTQLLLILALSPLICLSAGALAMILIGLIQNRKTA
NLAVMLITMPQMFLSGAIIPINHSSGVLLVLSRMMPMTYCLDLVRAVVYRGTPEYSSVVM
FNPVVNFAAIVGLTVLCLIIGTFFFARSEKNR
>fig|272564.4.peg.2599 Drug resistance transporter, EmrB/QacA subfamily
MPTIMEELHIEATTAQWLVSGFTLVNAIVIAISAFLMDRFRTKQLFLSIFVLFLAGSLLA
SWGVNFTVLLIGRLLQAICAGIMMPLSMTIILLLFPHEKRGSAMGMYSLVIMVAPAIGPV
LAGVLTDKVGWRIMFLVMAVLAGAIILLASLIMKNYGDVKQTTLDKPSFTMASLGLLALL
YGFSLLGNISMILTASALVLAGVVILFLFVRRQLSLTQPFLQIKVLGNAQYRNGTIILML
IQASLAAATITLPIYIQTVRGMSATVSGMVMMPGAILGAVFGYFAGKLYDAFGARYVGLF
GGFLLLLGSLGMALFDFDTTIGFMTAAYTLRSVGLMLANTPINMWSIKKLPDEILHHGNA
VGITLRQVATTLCTAVMVSVMSFASSVYAAKGEIQSQMYGISMTYWLSVVIGLVALILVA
VKVKNRKKTVAAVTEAVYELDIAMRADPYTVSCDDNLKQVVEKFIGYKTSGLPIIDAQKH
LIGFVSDGDVMRYFTKQDLRFVAEFYSAVIPDTDTLNSKARKLLSMNVMEIASPNAIAVS
HDTPLLEVCEIFSRRKINKLPVTQNDILIGTISRGDIMRALMTRLPLGGED
>fig|272564.4.peg.4245 Permeases of the drug/metabolite transporter (DMT) superfamily
MDMRQTEHELEHKISAYIDALFAGVGASQQLFDLKEEITTNLNEKTLDYKNRGISEDQAF
KEAIVSLGDLSGLVAEMRQIGQDKAKQAVYSTMTARISLAGTIAGSLIILFGFFNVAMLY
FMKLDAVSISGSGIFIVAGGALLTYSLLTRETRQKYAMNKIRAGLYALSVGLLLFGMFSA
AVAGFATGEVFIAIASLMMFFLVGFGVFLFLILTGPDRRKR
>fig|272568.11.peg.1436 Outer membrane component of tripartite multidrug resistance system
MLLAAMVPAACDLAPRYAPPVAPVPASFKERDGWALAVPGDDVPKGPWWRIFHDPVLDAL
EDRVTIANQDLRVAVAQYDEARADARTAQAGYYPTLDFTGSASRSGLSRETANVFNKSTF
NSYSLGLDLQYEVDVWGRVRNTAKAGRARAQASAGDLATVDLSLHAELATDYFTLRGYDA
MQAVLDQTVGNYRHALALTQAQFDVGYAAQPDVSAATAQLDGLLTQAADNRLRRAMLEHA
IAILTGQPPATFAVAARSLDSAPPPIAPGLPVALLQRRPDIAAAERRVAAANADIGVARA
AYFPAFNINAMMGVQAAMPNHLLVAPAQAWSFGPEALLNVFDGGRRAALNAHARAVYDEE
VARYRQTVLDACRDVEDSLVSLRRLAEESATQQQAVIAAQDATHRAGELNTGGLASYYNV
ILARNIELSDRLSEVDIRVRRMTASVALIKALGGGWGG
>fig|272568.11.peg.1696 Outer membrane component of tripartite multidrug resistance system
MPHWHRGLPDAESHPEESPADPQWWTIYRDPVLTALEQQVASANLDLRASAYRLAESLAE
RRIASAAQFPHVEGNASYARERASTNGILGLLGTLERAGAGDVASGAQGFGPVAVPGTVG
NPSFNLPQYGMSASWEVDLWGHVRRQVEAANAAVKATQDMQRDVLVSLMAETAQDYLDLR
GVQAQIAIVGRNIDTARHSVVLTGLRFAQGASTQLDVADSRGQLSEFQSRLPILQSQEVH
LINALSFLVAREPGALRAQLATPAPIPPVPDAVPVGLPSELAERRPDIRMAEEQLHVATA
SIGVAVADFFPRVTLSGSLDVQALQFSGLGSWASRQYGFGPTMTLPLFEGGRLTGQLRLR
RAQQKEAAITLQRTILKAWQEIDDAMADFSAAQQQRDRLKETVAQNETAVRLAQQQYVQG
ASDFLNVLTLQNALLASQNQLVRSTTAVSVSVARLYRALGGGWEARYPVATAQRAAIRQE
GQGGRQG
>fig|272568.11.peg.1799 Outer membrane component of tripartite multidrug resistance system
MLLAATMLAGCTVGPRYQPDRMKLPPGFAEDEHAATPAEIARTNAELKDWWHRFGDAELD
RLVDRAIAGNYDLQIAGQRILAERALRDVQASAWYPQVDANTTDGDSRYSINVDNWPLRP
GDPANRPGASYLSYGVSASWQIDVFGRIRRAVEASEHAVEENVEERRAVLMTMLSSLVSD
YMVLRDTQLRLEISNRNIGVAQEAYDLTRRLYLEGVGNTLQIAQAKAELDAQQAAREPLR
THIAQITHAIDVLMGQVPGTTEAELKVARPLPQVPEFPATVPSIVLGNRPDIRRAERAYA
EATARIGVAVAQMYPNFAIPLNFNPNASAMYQVFEAGALSWQFFMLASLPLMHGGKLTGQ
IRTAQAAAEASRLTYRQTVLGAFREVEDAMAAWHDDVEHTELLHRAAEDSRLASDRARKL
YAAGLVGFLEVLTTERTALAAENAEAVARLERLQDAIDLYTAMGAGWQGVGVTASALPVS
LEKQNVLARAFQD
>fig|272568.11.peg.1809 Membrane fusion component of tripartite multidrug resistance system
MADEDRNGNRGHTDSKQKHGSPVMRGLFIGGGAVVVVFIAVVLAIIFVPTRRVWTDDAYV
TAHYTVVAPRVSGQVVAVNVTDNQSVKAGQVLVELDPRDYRTALDQARATLERDRSLVQD
AASAVTRQPSIIDESVGAAARVRAQLIFARQNAQRYANLAKTGAGSTQENQQSTATLRDM
EANLQSLEARVAAARAQLPILQARHKAAQATVDLDNARVRQAELNLSYTRIRALEDGMIG
ERSVQTGNYVSPGAALMALVPLDQIWIRANYRELALRHMRPGQPVRIHVDAYDVTLNGIV
DSIPPASGAVFAPIAPENATGNFTKIVQRLPVKIILAPNQPLAKLLRLGFSVETTVDTGF
ADVVGAQGHDAAATVTGREGAGP
>fig|272568.11.peg.1810 Inner membrane component of tripartite multidrug resistance system
MSVSPWLAVTLTLRRFSLAVPWLAVLSSSLIPLTGNLTLLYILRIFQGLSGGFTVPLLMT
TALRVLPPPIRLYGLAAYALTATFFPSLSTAFAGLWTDLVDWRFVFWQSIPLCTIAFVLL
WYGMPVEQPRHERFWRFDWQGFLLVLIGMGAFSTMLQMGDWMDWFNSPAICVMALLSGVC
IPLFVLNEWFHPLPLFKFQLLERRNFAYGASTLLTFMIISLSSSALPADFLREAAGYRPE
QTYPITLEIAAIQIVMLPLMAVLLNRKGVDSRIVSLIGMACILTACIGDFFVTSNWNRDQ
FYLWQAFQGVGNAMIVMPLLMMSTNALVPEEGPFASAMVNTPRAVAEAVGIWLIQLVHRE
RGALHSDRITDRLGQDRFQLVQGMNPVLQRPAALTPDGLPAFPGSMTALHAQVTRQTATL
TYSDDWLIIAGIVVCLMVWVCVLPVRTYPPRIVFQSK
>fig|272568.11.peg.2700 Outer membrane component of tripartite multidrug resistance system
MPPACRNWGPRRAIRASGWARRDCSRCWGGAGSGTGQPAFLVGIGGLTQGTDLYQVGFDA
SWELDLFGRVRRSVEQAHAQVAAQVARQGDARLTLQGDVVRAYLQWRAAQALLDLAGEVA
AARARAVVLRAFQRRLGLADGTDVDLARAALVRAQGQAAGFQRQAGQALNRLAILTGQPP
GALDGPLVAVRPLPDPPPRVPVVLPAALARLRPDIRAAEADLHAATAGIGAAVAQLYPDI
TLSGQVGQRTLTLGSLADWGNTFYQFGPAISLPLFQGGRLRAAIRLARARQQEAALAYRQ
RVLDALGEVEDALVALRTDGAARESDRAAMASVTDRLALARTRYRDGTGDALAVLDARAE
LGGAGQDDIQARLAVLLDVVALCKATGGGWPEAGD
>fig|272568.11.peg.2710 Outer membrane component of tripartite multidrug resistance system
MIVRSLRRTVMSGGAMLSLAALSACDLAPTYHPPTYVVPASWHGQAPFATATPADTQLPS
NWWTMLHDPQLDALEDKATAANADLQAAAERFVQARAMVMQARADLLPHFGLAFGASDNK
QSADRLFRYKGATTATDEFYGGLASWEPDFWSEIRNQVRMAKYSAQEKAADFAAARLSLQ
AELANDYVALRGYDAQDAIYRKSIAYYERAVSVTQTQLANQAAPKLDLARAQNRLYVTQA
AEMDILAEREVTEHAIAVLTNSAPSSFHIAPVDTLTFTRAAIPVGVPSDLLQRRPDIAAA
ERQMAQANRSIGVSRAAFYPHISLNANGGFDANGFDLANLANSMWSYGASASMPIFEGGL
RRAALQASWSTYRETRDHYRSSVLSAFREVEDGLSRTDRLWAENDRLKAAVSAALDMQNM
TMTLYKGGLSAYLDAIIAQEAALDAQISQVQVETRYVQAEVGLIRALGGGWNDRLLPTPD
QTMTFSILQYDGLHHPTPAGGIDTPGDTDTRYDDLTGATTLRTGTVPVSGR
>fig|272620.3.peg.1873 Glyoxalase/bleomycin resistance protein/dioxygenase
MGELSMQSVDVGFTHVAFTVRCLASSIDFYTRYTAMTIIHQREPDLPSARKVAWLSDRTR
PFALVLVQSDDPADTPLGPFGHLGVACATQAEIDEKVALARREGVLRREPEQLGDPVGYF
AFFADPDGNTLELSWGQRVGLEVILAGKPGE
>fig|272620.3.peg.2453 polymyxin resistance protein B
MEWWVKKVQDNASASLCRVVLQSGALEMIAEIEACRLRLREGDKLTPLADARYCLNNNPT
QTLKIRNATHYSSERWTNAGK
>fig|272620.3.peg.3717 Acriflavine resistance protein F (AcrF)
MSKFFIHRPVFAWVLAIIMMIAGGLAILQLPIAQYPTIAPPAVAISATYPGADAQTVQDT
VTQVIEQNMNGIDNLMYMSSTSDSAGSVTITLTFKSGTDPDIAQVQVQNKLQLATPLLPQ
EVQQQGISVEKSSSSFLLVAGFISDNPTTTQDDISDYVASNVKDPISRLNGVGDVQLFGA
QYAMRVWLDGNLLNKYNLTPVDVINALQVQNDQIAAGQLGGTPALKGQQLNASIIAQTRL
KDPQEFGKVTLRVNADGSVVHLKDVARIELGGENYNVVARINGKPASGLGIKLATGANAL
DTATAIKAKLAELQPYFPQGMKVVYPYDTTPFVKISIHEVVKTLFEAIILVFLVMYLFLQ
NMRATLIPTIAVPVVLLGTFAVLSMFGYSINTLTMFGMVLAIGLLVDDAIVVVENVERVM
VEEKLSPKEATEKSMSQIQGALVGIAMVLSAVFVPMAFFGGSTGAIYRQFSITIVSAMAL
SVLVALVLTPALCATLLKPASAEHHEKKGFFGWFNARFDRSVNHYTNSVSGILRGTGRYL
VIYLLIVVGMAVLFMRLPTSFLPDEDQGVFLTMIQLPSGATQERTQKVLDTVTDYYLHNE
KANVESVFTVNGFSFSGQGQNSGMAFVSLKPWEARSGDKNSVESIIKRATVAFSQIKDAM
VFPFNMPAIIELGTATGFDFELIDQGGLGHTALTQARNQLLGMVKQHPDQLVRVRPNGLE
DTPQFKLDVDQEKAQALGVSLSDINETISAALGGYYVNDFIDRGRVKKVYVQADAHFRML
PSDINNMYVRSANGEMVPFSAFVTSRWIYGSPRLERYNGLPSMEILGEASPGKSTGEAMA
LMETLASKLPSGIGYDWTGMSYQERLSGNQAPALYAISLIVVFLCLAALYESWSIPFSVM
LVVPLGVIGALLAATLRGLNNDVYFQVGLLTTIGLSAKNAILIVEFAKDLMEKEGKGIIE
ATLEASRMRLRPILMTSLAFILGVMPLVISHGAGSGAQNAVGTGVMGGMLTATLLAIFFV
PVFFVVVRRRFTRHAE
>fig|272620.3.peg.4282 COG0697: Permeases of the drug/metabolite transporter (DMT) superfamily
MGYAMARKSDPLAFGGLALLTLIWSFSWIAMKQVTSYIGAFDFTALRCIFGAVVQWIVML
IRGKALKPTPFGYTLAIALLQTCGMVGLAQWALMSGGAGKVAILSYTMPFWVVVMAALFL
GERMRRWQYIAIGVACVGLILVLQPWQLDFTSLKSALLAILSGVSWGAGAIVAKRMYTRY
PQVDLLALTTWQMLYAAVVMSVVAWLVPQQAVDWQPDVFWALAYSAILATALAWSLWLFV
LRNLPASIAGLSTLAVPVCGVLFSWWLLHENPGKVEGCGIALIVLALAMISIKRRGA
>fig|272621.3.peg.291 Multidrug resistance protein
MGVKMAEKRNKKIILMMATLLLGSFITTLAETLMNNGLPMIMEETHISQMNAQWLNTGYM
LVAGMVMPLATFFMHRFPLRHLFTATMSIFLLGSLVATFAPNFLFLLIGRLVQAMVVGIN
MPLVTNVLTIIIPAKNRGLAIGIAGIIINLGPAIGPTLSGVILEFYSWRMLFIILLPFTV
LTLICT
>fig|272621.3.peg.726 Glycopeptide antibiotics resistance protein
MLFFGPLYSFLAKQYATNINHFALVKLTLLALDKTVFYFLIFAVIRLIWLLFVRRRRSIK
SEAGVWIFAFYLILILMLTTFRDTYFPWQPNLNFSRPLSDVNLIFMKETWKMIYAPSRLD
FFYNSFGNVLCFVPFGILFPIVFSKKESFLKTTISGMFLSIGIETLQFLLMTGVSDIDDV
FFNTCGAILGYLIYILFKKR
>fig|272621.3.peg.1405 Lincomycin-resistance
MENTQMGMKARIDVKHPWLAILPLMIGSFVGMFSETSLNIALPQLMKALQVGQSSIQWLV
TGYMLVIGIILPLSSLFTKWFTTKKLVLFGLAAFIIGSLISGFGINFSMVLMGRMIQGIG
TGIILPLMFTIAMLIFPPNKLGTVNGVLALVIMFAPAIGPTLTGLILAVGSWRDIFFTFV
VFLVIAFVIGLFTLQNVSQITKPKVDFISIILSIIAFSGLIAGASFASELGWLSIQVLAC
LIGGIIALIFYVKRQLKLTVPVLNMRVFEHRNFTLGAVLVMIDFGIILSAMYLLPQYLQN
GLLVAVALTGIIMLPGGIINALVSALAGRMYDNSGAKWPTRIGFTIALIGAIMLSLVTTH
SASWYVILAHVVLMIGAPLAMSPSQTSALNSLKGLESADGSAILNTMQQIVGALATALAT
SFLTLGRNAVNGSAAFKFTNGVHYGMYFTCALAIIGMIISLFVTDDGKE
>fig|272621.3.peg.1778 ABC transporter ATP-binding/membrane spanning protein - multidrug resistance
MNINFKWIIKNLPFWLLILIVITLIAGGFEGVINGIILGQFPNLVGKSGTDLILFLIRST
IIFVATYTAIVLQNIFLNMARKRLRVKLKKTMLINSFALKEDAASGLNHISNDATKIDDQ
YFAVIAGILSTGTAAVISTIYVLQVNLLMGIIFVAFSCLSLIPMLFGKNELGKLGEQWSN
ENSQMMRSASDWFKGLRDILQYQAQKPFFKRVSQDVETSENTLLKQENLQWWIQYANLLF
TVLAIIAPWAIGFYFITTHQFGVTISALLSLTLSANSVVQNFRGLMQYWAQVASTTEIRK
IKVAKYDIFKDIKTENEKPDIKFDNVSLTYKDHPIYQNLNFDLAYGKKVLLQGPSGSGKS
TLLNMVSGLLKPTRGTIKIGGEDPNPAQSVYIAQTPWLFQGTIKDNLCLGESFTDQQLLK
VLNEVGLADELGKDPLNRVIHPEQEDLSGGQKQRLVIARALLRDRPIILLDEITAALDEK
NSDDIREILYNTPKTIIESAHHINFDLIKKYGFESWKISDHQVAKS
>fig|272623.1.peg.133 Multidrug resistance efflux pump
MKESWQRNLIVLWFGTFMTGIGSSLIAPFISLYISTLGHYSKTELNIWSGLVFSSTFIVL
AIVSPLWGRLADQKGRKLMLLRASLGMAISISLMAFVTAAWQLLILRMLLGAFSGFVSNS
MALMASSAPKEKSGAVLSLLTTGSVAGTLIGPIIGGILVNITGYRRVFSVTGIIMFLVFF
LALFFVKEIFKPVEKKNMLSYKQVWEVVTHPAIIWGMFFATLITQMTNQSINPVLSLYVQ
ELMHGQGNITFMAGIVAAAPGIVTLVAAPFLGRLGDKVGQRKILGFGLFFSLIVFSITAM
TTNVWFLIVMRLLVGVSDAAILPSVQAILAKESPQAITGRIFSYNQSAQSIGAFAGPLLG
SAIAGFIDYRYVFVGSAILVVFNLINYFTHTKSLAVKN
>fig|272623.1.peg.246 Drug resistance transporter, EmrB/QacA family
MNKIQEKRSIRAFMLSNVMAGLEGSIVATALPAMMAELHGIKLMSWVVTIYMLLMAVSSP
IWTKLAERFEYKQMFVLGTLLFTIGSLGEGLAINMLMVIVARALMGLGAGVMIQLPFVIY
GMMYQADERRRVIGNTVAAYSFSTIAGPIVGGLIVTLLDWRWVFFINIPIGIYMAFIVWK
NFDLKTDHTKKSIDFAGSASLSIAVIAIMLHFQMMGNAVINLPLLLILLVVSFLFFIGFY
FAEKRAVDPIVPLELFKNPSFIAKNIMFFMQYGFFGFYTNYLPTWGQGVMGATALVGGMV
LIPSAIMLVIGTRNVNHLIQKVGEKKTIYIGFSIMVLGAIFLFSLPEHASIMMLFVATAI
LGTAFGIVNITLQVAVQESVAKHLIGAATAVNALLRTMGTTLVLSGLSIALNRTFTEATA
HNPKLTTTLLNQISDAKALKNIPVNLIAPLRHTLFNGMHLLALISGLLLFIALFVNWLDP
WKKGLE
>fig|272623.1.peg.388 Efflux pump antibiotic resistance protein
MSDRIKALIALGIFTFMSTLDGSIVNIALPTMSKELHVSTSQITWVVTIYLIVISAIVLI
FGRLGDLIGKSRIARIGWGIFILGSALAGLNFGWGLGFLLFARVIQAIGASMFMATGFGI
ISEIFPPESRARALSISAMFVSVGSIAGPALGGLILQVASWNYIFWINVPIGILAWIFGN
HALPKEKTSGKWSDIDFKGGTLMTSVIVLLFLALNFGQALGWTNPLIIIGALLGFILFGI
FILTEKKVAQPLLDLGIFKSKLFSMSIIMALFNFTVAMFSSILLPFYLQDFRNYGPGLAG
MIMMAYPVAMLIASPLAGSAADKMDKEIVTFVGISGIVLSQLGYLLINPHSAPWLVVVIL
LIQGMSMGIFQSPNNALIMETVDRKYLGIAGSVNSLARNMAFVLGTSLATLILFTAMSNQ
LGYKVTTYLHNQPDVFLHGFHVAFYFSTFLVLVTWVLGLFRLLGRKK
>fig|272623.1.peg.599 Glyoxalase/bleomycin resistance protein/dioxygenase superfamily protein
MAFNICVNLYVKEVEKEVDFFRSIGFLEIERHKMENSDSVVISPLSDGNAFLQIWDIEFI
KKVSPEVANDKPSLLFTVYNIEEMNEKLKKITPTTSDLMDANGKKAFNFQSPSGNYYAFM
EI
>fig|272623.1.peg.624 Drug resistance transporter, EmrB/QacA subfamily
MAKSKKNEKEKLPKELTRNAWILVVGAIAPMLDSTMVNIAINKLQSDLHTSLDMIQWAIT
GYVLALAVAVPVCGYVVNHIDGKKVMQWSLLSFGLFSFLSGIAWNIDSFIIFRAVQGFSA
GFITLLMTTLLMQITPPDKLGQLMAVVSTPIILGPIIGPVLGGAIVSGANWHWIFYINIP
VVIIAVLLNHFYLSSFKPFNPKAKLDWFGTLLLAGGSVGLIYGMMKGSTNAKNFFNSQMI
TFVIIGLALFVIYGIYNRIRKNNTVLPLRFFKSKNFTAANIGIFLAGIASNGPMLLLPLF
FQNTKGFTAVEAGLMLIPQGLGMMVTRPLIGKMIDRMGARPVVLVSLAISLLGTLPFIFV
HENTNLIWLGLVLFVRGMGIGGLQMPMMTDIFIGLDKQDIPGASVGQRIIQNVGSSFGSA
VISAVVTAVVTSEIAGQMTTKLHQLAAMHTNLTPTVIAKAKTSVEKAVTLNGYQLGFLVS
SIVLIVIAIPAMFLSQKKVNK
>fig|272623.1.peg.774 Quinolone resistance protein
MTINQRTIFSGCSFKNTTFEFTDNTISEFTDCLFEKCDFSNLNFNKIGIYRSIFKSCKLL
GTDFTESHLQDLQFTENLMTYANFSGSTLKSVRFLENEAKETFFTACNFKNVELLKNQLE
AANFWETALAGIDFSTNQFERMEVTPQLAKNMKISLSQAPFFTSLFGIEII
>fig|272623.1.peg.924 Permease of the drug/metabolite transporter (DMT) superfamily
MNPLDVWYNIKMNVKKQIFKGTLYAVVAGCMWGISGIFGQLFFRDYHGSPLWITSTRLTI
AGIILLAMSFSRDHKRFFDVWKSKKNMPTLFLYVFGGVFSVQYFYYVAIQLSNSATATIL
QYTAPVFIMLYLLIFQRQVPKPKSVLFVILAMIGVFLLITDGNIKHLSISPLALVTGLLA
GVAVVIYSIIPRPLLDKYGALNMTGWGMMLAGIACNIFYPVWRIDFRIEPLSIFYVLTIS
IVGTALAFLLLLRAFQLISPLVVSVATATEPLTSVFLSIPLFGLKLTPLELLGIVMVIVS
VILLSKSEQA
>fig|272623.1.peg.1383 Drug-export protein
MNKNNHFHLLGAVIATGILSFSGVLIETAMNVTFPTLINEFGLSTSKIQWVTTIYLLVIA
ITIPLSSYFNERFSARKLFLVANLIFLVGVLTNCFSPNFAMLLFGRLLQGVGTGIGLPLM
FHLILTKAPLHKRGMMMGIGTLTTSIAPAIGPTYGGIISNSLDWRYIYIFLLPLVVISLV
LGLACLPREGEKTPKKLALRPVIALSIMFFAFISALSAEHLMTFALLFIVGLVGAFLFVQ
FNRKESLIDLGILKNHRFVALIFSLLVYQALLLGLSFVLPSFIQVSAGFSSSVAGLFMFS
GALIGAVLAPISGKVLDQIGARKPITTGLILAALGLALIFVFLPTKSLALLLGAHIVLML
GLGISYSNLMTCSLSTLATDQLSDGNALVNTLQQFIGAVATAVVATTLSIFQGLNGFKVG
TSHGTSIILALFFILIIVSLIVSFPNLKKIRANH
>fig|272623.1.peg.1519 Permease of the drug/metabolite transporter (DMT) superfamily
MTKFKGIIYASLGAAFFGISSIIAGLLFNRCSIEPGWLVTTRMLFSGLLLLAWLAITKHN
IFSVWSSVKSSLRIVAFGIFGVLFAQSSFLLSVYYGNAAIATILQSLGPSIIIIILAIKS
KAIPRRLDIIAIFLSLIGVFLLVTNGNIGELSFSASALVWGLLSALGVCAYTLIPCPLIK
EHPPLSLVAWALLIGGVISNFLHPVTNLPKNFDQTDLLLVSLIVVVGTLLAYSLYINSLK
YTEPHIVGMLGMLEPVTAILISTLFLGVSFLGFQQLGIFVVFLSLFLINFPAKKK
>fig|272623.1.peg.1580 Drug resistance transporter, EmrB/QacA family
MNTELETNTANHKISAKTRFSIVAVALVAFMGILAETSLNVTFPTLEKTFGLPLSTVQWV
TTAYLLVVAIVMPTSSYISQRFQNRTLFFSGLIFFTLGDLLSLISPNFTILMAGRLIQGI
GTGIAIPLMFNLVLTKIPRERVGLWMGFAGMILSIAPALGPTYGGLLTGTLGWRMIFAII
LIIPICLFPLGAWAIEKSEKKRPGKFDFIAFIFLSLAMTSALLALDSLSSAHFSWIWLVV
FILGLIAFIWRSKTSTLNFIDINVFKSPTFTLSVLVYCILQFVNLGINFIIPNFLQVSLG
TTSTLAGFALLPGSLIGSAAQGPIGALYDRKGAKGILYSGNTVFFIALVLLTIFTKNLTL
LGVMGLYVVFTIGRSSSFATTMTNSLAQLPHDKAASGNAWFTTTSQFAASAGTATASLIA
TKSSNLTTGTQHVFMFFLCLALLNFVFYTLILNKKIK
>fig|272623.1.peg.1822 Drug and analog sensitivity
MEFRLAKKSDAKRLLEIYKPYVEKTAITFEYEVPTIAEFEKRIEKIGSRYPYIVAIENDK
IIGYAYAGAYRERAAYDWVVELSIYLDENERQHGAGSALYQKLLTALSVLNYQRAYACIT
YPNPASVAFHKKFGFEQIGLFPKAGYKFEQWYGIVWLERSLQTTDKVTAIKLLTDLSENE
LEKILAN
>fig|272624.3.peg.3 Multidrug resistance efflux pump PmrA
MKEKFATWYKIVTKHIRFFFSYSIPMFFKKAKNYINLPIIVVGLALIIGLFHLFSYLIPF
TDNAFVVTNVTPVAADVSGFITEIYVKNGQKVKKNDPIFSVYRVPYELAYQQAMADYKEG
LKKIDVFQKQIERTVALIKATDAELEKAQFALGLKKNKNVAEAVSVLELKNLGYDVSTLS
NKRNALQQEVAVLQAKIEQQRHTVASLKAKMDNAKVNLDLTIVRAPGDGVIDNMYVSPNT
PIEIHKPVFSFIDTANYYIQANFNETDLRNVRQGDKAYIILRMYYFDKIFHGVVVNSLWA
AERQSTAPKSQIQVVTNQNEWLLLPQRFPLQIKILDPDPDYPLNPGASAYVYISTKR
>fig|272624.3.peg.105 Drug resistance transporter, Bcr/CflA
MKKNALLIVLLTWFLGNMDIHFLTPALPSLVDYFSVTPNTVQLTISLFLLGKALSMILWG
LLSERYGRKPIFIGGLLLFILSNFLIALNHSILPFLVCRFLQGISVGATLLMGRAMINDT
HNEQNATKYFAWLFTLAGLFICFLPFFGGLINSYWNWQIASLIIAAYGLLLLPLCRGLKE
TKPHYVKFPRLGHSIMVVFNHPLFVSYLLISALMMAGESAFNTSASFILIKGENFTSAQY
GTIKTTMAIMHLLGTACCGLIAKYYHSIQLTKLGVRFFIFAAFLMWLFVFSAENIYLTFI
VPMVIYYFGTGFIVASATASAVRPFPQQMALALAITLFCQFNCSAFFSFITSMIGIQQVE
TFMFLLSLVSILSFLALLKLQRMEPC
>fig|272624.3.peg.106 Multidrug resistance protein B
MNKLVQKMMLSGQFLMILALEMTNPFLPLLIAHQSNTPVPSVVIYNTLSLVLPMLANILL
TPIWGLAADRYGYKPMLMRASWALVLTQASMIFVNSVFWILIIRLLQGAFAGFLVAMQTY
ALSITEWQSKSTQLSRLQSSKAIATSTAGFLGGLALSFTNYQGLFGLATLICLGTTVVMH
YKLPSPPKQQIKKRSQTLNHSYTSKSVFFFLCVLIMLTQIAKFLPDPGFTLYLNKYCSNN
LVLIGFLYSLPAMGMLCSSVWCGKQFDYCRSQPSLVNQYLIRYSVFGAILMIIQANVDNF
YLFALIRILWGIVLAALLPALFALCSDRNLLPGYALGLANSFAKLGNLIGLLLGGLFAFY
LPYPAIFMIIAGIYSLFAIFVYGYDRLNVRQMTDFSNSYFNVKS
>fig|272624.3.peg.435 ABC transporter ATP-binding protein Uup, erythromycin resistance
MNHKPIQFKDLSLIYPHKTCFQDFSGEIHFADRIALIGRNGSGKSTLLKMLCGLFLAPAG
EIKIPHDVRFGHLPQVLENCPDLSGGQRLNRVLSKILSYEPNVLLLDEPTNHLDRRNRCS
LMRMLEHYPGTLIIASHDIELINTVTDTLWHIDLGQVTVFRGTYFDYQQILEDKKASIEQ
ELSRIVRQKKESHLALMKEQERNKRARVQGEKKITQRKWPTIRSHTKLGSAITTGNKRLS
HINYKKQQLLEELSSLNYPEVIKPKFRLKGLGHHKPLIRIQDASVAYEAVVILENIHFHL
SGCERAALYGKNASGKSTFVKAILGESQIKRTGEWAVPDCNTIGYIDQHYQHLNFNETVL
DLMRSSMPHAFHTEIRAHLNDFLFRKNEEVEIKVKNLSGGEKARLSMALIAANPPKLLIL
DEITNNVDLETRTHIIQVLREFQGAMLVISHDYDFLESIHIETRYQIHQGKIHHFNEKQL
EVVHHD
>fig|272624.3.peg.733 Permease of the drug/metabolite transporter (DMT) superfamily
MNSQEQRGSFYAILSGFLYGFIGYFGISAIHGDLSASNMLFWRFLISSIFILIVLIPQLK
NINDTYKSMFTAFLSGVLYYGLSTLLYFYASLYIGSGLSMVIFFTYPVIIMVFNYFFYSQ
TIPKIYYLAISVILIGMALLIDVNEIAFDLWGIFLGLASAFFYACYIVSSKNNEISPNVS
TLMVCLGCMTTSLIVACLDHTFKVPTSFPVWLNLFGIGLVATVIPILLMLHSLKYISSEK
ASILSVLEPVFVVIFGVVLLGEELKPWHALGIVLVLAGALITLFSHRINLNQWLGAIYKS
>fig|272624.3.peg.1081 Drug resistance transporter, Bcr/CflA family
MNSDRRFAIGIFYFADVEANALFSNTFVLLVNNDIVISLVRNHSKGYLMHQEHPGQTDTP
KIDPWLIFVILMLMALMQTTTDQYIPSLPAITTALNSTEASIQLTISMFMLGLSLSHIFY
GPLSDKIGRKPPLMFGVGLSILGSLVCFVAPNVSVLILGRFLQGFGIGCCNSVGRSLVRD
LFTDRLLAKIGSYVGVVSIFIMAASPTLGGFIQEMAGWKANFMFLFVFGILVWLLAFCIL
PETNKHLNPEATKIKVMAKNYFTLLRSKIFVGYTMCACFAFAGMVSYLTIAPFLFQNTMG
LSPLEFGRLTFFIAGAICFSGIVNSQLVMRKGISFMVCTGVLFMIVGGLSLLLITILGWS
QIYFIMISMTLFSAGAGFTFINAFAGAFHPFPQMAGTVGALYASMQDLSAALTSGFIAGI
KGYGQYSLAIILLILGLSSLVAWYYLGLQDDAISN
>fig|272624.3.peg.1220 Multidrug resistance protein
MLSVLSYRLSLLPKLSKTCYLLLLFSFLECVAGGIAYYLSLYLGTSTPLTKLQIGQVGSI
VGFGALAGALCSTYITDKLNNKNIIIASFLFLGLGFFCLPQSMSFLLISGCVFIIGFATS
IFLTTNNTLLLQNAPQDQNSLRFIQSMKIVSENLGNSFSILLIMFFAAQYYGQIFEVIGL
FFFLFALNTMKYLNVKQNSLEDSSYEEKETNQQGNNKRLYVTISAVFIVGIIYAQQRIAY
PLFLHEAFSSFTITAILFWLDPIIVSLFQVKITKIVSPLKISHQLAIGGLLLGTGLFALL
IVDSIGGAIMACLTFILGEMLFMPTSFVRCYESAGNKRKGMVAGAWRSAYSSGLIVGPVL
SGFLMEYYSYNACWILAGILGFFLFILFSVKK
>fig|272624.3.peg.1227 Permease of the drug/metabolite transporter (DMT) superfamily
MANLFSFLFLGTLGWGMSLYLMKILLVSLTPTEIVLYRMAIGAASLFILAKLFKLKTDNI
RGLILDGIIVGTFNMTLPFYLTTYAVKTVSSSLASVINGLTPLCTLILGMVFFSSKQKLG
VLNLLSIVLGFIGIIIINSDVSIYQGSAVEFIALLATTISYGVTANYFKYHARTKEPILV
SAVSAFVSAITMLIFKCATESSINSWGIPQGMNQIIALLWLGIIGSGFCLYLYCSLIQNA
GAVFASMITYLMTITGVIMGMIFLHETISHQVMIGCIFIFFSLILVNHAPLLEKILVSIS
RQISLKSARRYELNQ
>fig|272624.3.peg.1303 RND efflux membrane fusion protein, acriflavin resistance protein E
MNKRLTIMGIILLVVFGGIIAFNLIKAYMIKQFFASYAPPAVTVSSAVAQAVDWKPTIDA
VGNFVAINGVDVNSEASGNVVQIHFESGQYVEKDEPLITIDDSIDQALLKFNQSELTLKE
LSYKRQTDLFKRGATPSSSVDEAKANLQQAQAKVEQIQAQIKQKHIGAPFSGRLGIRQVN
LGQYVTPGQTSIVSLQSLDPLYLEFYLPEQYYKRIHLNQPVTFRVEEFPNILFEGVIHAV
NSKVDLTTHNVQVQALLPNCPADAIQDPTKSPLIKARKQVRGDKLIVACSTELNKQNKIR
NFVFIPGMFASIEVDQPAEPNTIIVPSTAISYSLYGNAVYIIEKSKEGKKNKDGTDQLVV
NRVFVTTGEQQGNYTVIKKGIKAGQLVVSTGDLKLQNGTPVVINNSVKLDTDSDPNQLGQ
>fig|272624.3.peg.2285 Glyoxalase/bleomycin resistance protein/dioxygenase
MTQAAFGEFCWNELATSDVKKAKDFYGKVFGWQFREIESKEMTYTLIQCNDKEMAGIWQI
PKDQQSHIPPHWMAYIYVQDVSEALKKAKQHGAQEVKGITQAGEMGRFAIIVDPTGAHVA
LWESFE
>fig|272624.3.peg.2500 Permease of the drug/metabolite transporter (DMT) superfamily
MVIDVKKSNTYFIQGMLFLIFAQIMVGINIVFSKYVLSSIPVLYILALRFTLAAVILLLL
HWLTPAKKLPMYSYFLQLKRRDWFFIFAQALSAGVLFNFLILWGLQYTDANVAGIITSAL
PAIIAIMSWLILGEKISGKKAICVGFATLGLVVIACDKLGDINVSHSFLGDALVLTSLLP
EAMYYILSKMHVNSLPVFLISSLLNGINAILLLFCLSFSTWDSFTIHTLDWLILIILGLS
SGLFYVFWYFGCQTVDGVMASLSTAIMPLATVTIAWIFLGEQLTIGQIIGMGMVILSITV
YAKR
>fig|272624.3.peg.2781 Bicyclomycin resistance protein
MFIRNLQLFIVVASCILVLIGTDILLPSLPNIAHALSVSSNEAKMLISIFMIGQFSTVLI
WGVIADRLGRRKTLFLGMLIFFIGSIFSLKADSIQLLLACRFLQGTGAVVVPVAGWALVQ
DLFPKDEGARIMTWIGTLTAVIPLFAPALGGQLDVLYGWRSNLYCIAFYSFILCVIMLFL
PRTIPVQKTTTADLKETLSIYIRIIKNKTFISYIALFGLLNCGEWCFLTVAPFYYSHAHI
AADTMGILLMITSMGFVCGSLLASRLFNRLGIDKIIALGIQLAVMSSLMLLIGEYFHWSK
YQLYNAITIGVYILSSALLWGATTSRALQCFDDCRGSASAIRSLILLCFAAFGTYSGRLV
NHNSLFPVGLFLLFMAFIAFIVFNNKELKTERHMEGIPI
>fig|272631.1.peg.1262 Probable multidrug resistance pump
MELRPFYPSVNWGYALPDSLWWIAKAWAISAACVVVLVMLSFITRWGRQYWRITRGYFIG
PQSVGVWLMLAVLLFSVVISVRLNVLFSYQSKDLYNALQAAFEGAGAQNDLVKQSGMHGF
WMSLGIFSILAVIFIARVMADIYLTQRFIIAWRMWLTNHLTTDWLDQRAYYREQFIDNTI
DNPDQRIQQDIDIFTAGAGGTPNGPSNGTGSTLLFGAVESVISVISFTAILWNLSGRLAV
FEFEIPRAMFWIVIVYVLLATIITFWIGRPLIGLNFANEKLNAAFRYALVRLRDAAEAVA
FYRGEEAERKQLEQRFTPIIDNYRRYVSRTIRFLGWNASVSQTIVPLPWILQAPRLFAGK
INLGDVGQTATAFGNIHDSLSFFRNNYAAFAAFRAAIIRLHGLVVANARSRELPHVTAKS
TNDGTVHVVAVEVRTSAGEQLIDPLDLQLNCGSSLVITGRSGVGKTTMLRSLAELWPYAS
GTLSRPDGKNETMFLSQLPYVPLGNLRGVVCYPNAPADIPEDTVRDTLTKVALNPLCDRL
DEERDWAKILSPGEQQRIAFARILLTKPKAIFLDESTSALDEGLEFALYQMLRSELPDCI
IVSVSHRRAVELLHAQQLELLGGGQWRLGPVEKEPLHV
>fig|272631.1.peg.1655 Multidrug resistance protein B
MCAAATIGAASLLGLLAGRRAGLAVDFFINVRRYLSARPWRFGLGLVLSTQGHRFDLISV
GLSESGTFLIVFRL
>fig|272843.1.peg.1049 Permease of the drug/metabolite transporter (DMT) superfamily
MTKLSIQRDNLICLSYVALMGFGFPIMRYMSIHFDTLNNNAVRFLSGGSVFILACFFYYR
AELTRVFHQPKLLLSFLLLACFMTANMYFFINGMKYTSALSGSIFGVLAMPLSIFMAAII
YQDERKKVMQIPFAVGSSILILGSLLFVLYGQHSASDSDFLLGSLFLTLAIFIQSIQNLV
VKQVARGTNVVVLSAFTAFLSGMIYLVWALKSEIIFRLAEVSIGALVELSLAGVYGMMTG
MLLAFFIVKTQGIVRFNVIQLLVPISTALVGYVTLGEVMNVYQGIGALCVLLGCILCLRI
RT
>fig|272844.1.peg.223 Multidrug resistance protein
MERDAKVLVIANAVGQLFLQFSWFVMPFYLKVLGYGMDKMGVLFSVQTFIGGLSFLLAGQ
ISLRIGYKRTLILAALLGLLGRILQVIGYNFYILILGFFLVGINMGLRDPNYSALLSEKV
KSEEERHRIFSYSFGLGTLMNAIGVLVAGYAPGYLISLGYRKEIAYRLVIALALLQFLVV
IPALMLVKDVPVKESRIKWRKDLIVRILKFSLPSAIIGLGAGITIPYMSIYFNLRFGRDI
KEISWVFFGQQLVMGLGSFILPELVRKIGAVKVITYFQWSAALLFLIFPSIPTFILASIV
YVIRSILMNIVWPVNDSFMMGFFSTEEKATAAGIRRAFSTFMRGAGNYIGGLLFAVSLSY
PFYATAILYIFATAMFYAFFIKHN
>fig|272844.1.peg.1139 Multidrug resistance protein (multidrug-ef flux transporter)
MNRNFWLFVAGRFISQLGWAIQEVALPLYVLDVTHSAKIMTLFVLADLIPSIITTPIAGV
FGDRYDRKKIMVGFDLIRGVLLFLVIAFNFLTIRCLLVVQVIMAIMNAFFSAGTGAMYPD
LVKPEELERANSIVMSASIISRLVGPAIGGFVYGFGGIKLAILMNAISFFGSGLFEIFIK
YEWKTRNIEGFSDFVRDIKEGLKFIMSNSFISTLIGLVILLNALGAPFASIIYPYAMREI
LKFSSQQFGLVESAFMLGALIGNLIVGAFLGAKAGRYIFRLFLVNGAVELIFILIISPFL
ALPRNSAFMLLLVLGATMGMAGAMINVPLASKLQRAVPSEIRGRVFSTMEMLARIANPLS
LVVVGPLVDTIGAWKTASFLWLGSGVVILYYWIFKGKELTSEEESKLVENFPGVPPED
>fig|272844.1.peg.1385 Multiple antibiotic resistance protein related
MLEVLKTFAVLYVGLFAITNPVGAVPIFMGVVSHLAPDKRHEVAEKVSITVLVTLLTFAL
VGKWIFKFFGSSVDAFAIAGGILLFRMGMEMLSGKLSSVKIDEEDVTLEEVAVIPLAIPL
ISGPGAITTVMLYMTRESPPIVIATIIAIGISVYIILASGNKIIEKLGRVGIKVTTRMMG
LILTSMAIQMIINGIKGAFGI
>fig|272844.1.peg.1459 Multidrug resistance protein
MRPRELAILQGLQEKSGKIRKITMRKNILMFAIGMFFADFAWGLGFPYLGVYMKLIGGTM
FLVGLLSVVYNLTSTIFQYPFGYLSDKTGKRKPFIILGILASGTTYGLVALITSPILLLG
LRAFQGALGASLAPAHSALISELSPRIGSMFGFFGFVENLGFMAGNFAGGYIVKTLGMKM
MFIITSLVSLIGILFLLKIKERGRAKAGGDRLIIVKEGRESDRVELKEIAFKKLMKGRLG
IFYVAVLLAMIASGAVYATVSVYFEEKFGEEFVGYLFGIDSLSAALSALIIGRLIDKYGE
KLFFRLSLVGYIITFMGYALANSVIIMALISILSGLKWTMLTNSSSTYVARRVPTSERGQ
GMGLLNTMMTLGWVIGPLIGGILADNFGFAVMLYSTVPILFLGFLLSFRI
>fig|272942.6.peg.926 Bicyclomycin resistance protein
MAFLNRKTPPHIVTLVLATGVAALSLNIFLPSLPGMARHFGVDYGLMQLAVSAYLAASAV
AQFVIGPISDRYGRRPVLLWVVAIFTLASVVALFAPNAHAFLAARFVQAVVATAFVLARA
AVRDMVPGPGAASMIGYVTMGMSLVPMIGPAVGGLLDGLFGWQANLAVLALSGALLFALV
WADMGETVSGGGLGFGAQMRAYPILLRSPRFWGYALSAAASAGLFYAYLGGAALVGEQAF
GLSPVEVGYFFALPSLGYLIGNWISGRFSLHLGMDRMVLSGTVLATAAIAVALIAKAAGV
LGPITFFTAVGVTGIGNGLSLPSANAGLMSVRADLAGTASGLGATMTIGTGAVLASLTAT
FLGAEVEVARLLWVMFGSSALSVAAILWVMRRPQ
>fig|272942.6.peg.1353 Permease of the drug/metabolite transporter (DMT) superfamily
MSDVFSAPRPRAETAAFALSALAAVFWGSNFEATRVVLQEMPPWTAAAGRFLIAALAILG
WLWLAEGSGLPALRRNWKVFLGLGVVGVAGFNAALFLGMRSSSPVTAALIMGTSPLTTTL
IEAALTRRWPKAGTLAGMAISLVGVALTVGAFSGARLAPGDGLILLGSLAWALYTVGCRR
WVVAASPLETSVWTMLAGALALLGAAFALETPVASVLAASPAAWGATLWMALAGSVLAYL
FWQVGIQIRGPGATSVLFNLVPVSALAIAALFGRTPELSQLAGVALAILGVLLASGRLTV
PRR
>fig|272943.3.peg.158 Permeases of the drug/metabolite transporter (DMT) superfamily
MENLRGIVMMVVSMAGFAMEDMFVKLAAANMPTGQILMLLGLFAAPLFWALARREGKAVL
SREALAGPILWRNGGEMVGTAGFVTALTLGQLSSVSAILQAAPLVVTFGAALFLGERVGW
RRWSAIAVGFVGVIVVIRPGLDGFDTASLWAVLGVAGLAIRDLATRRVAPSTSTMQVGAW
AFLTVAVLGAMMLAVGGGATWPTPGQAALLLGAVSFSFVGYWTLILATRVGDVSAIVPFR
YSRLVFAMLIGFLVFHERPDGWMLAGAALIIGSGLYSFMREQRLRRLSMRAAAE
>fig|272943.3.peg.289 Glyoxalase/bleomycin resistance protein/dioxygenase
MIDQCSLHVTDLERSRCFYDAALGRLGIPTGRAARSGVHWVGDGVEAFSINEIRSGRNAR
QVREAHLAFVARSRPAVDAFHAAALRAGGRNDREPGLRPEYHPNYYAALVLDPDGHRIEA
VCHTPD
>fig|272943.3.peg.399 Permeases of the drug/metabolite transporter (DMT) superfamily
MISQDRTRAAAGFILLYAVVIGFTDNYVRVIADEAGLWQFHLTRSVMALAILAAVAPALG
LRLRPVDWRAVAARSAIHGTAMLIYFGALAFLPVAQVAAGLFTAPIFVLVISRFVYGERI
GPVRVLAVLTGFAGVLLVLGPEAMAGASFAAGLPVLAGLLYGMGNIATRAWCPQESAGTL
LGGFFVALGVLGAAGLAVLALVSLPVPEGPDGFVMRGFVVPSQDFWFWTFVQAAGSLFAV
GMMIRAYQAATASRVSVFEYVILPASAIWGWLLWDERLSPVAAAGMALIALAGIAIAVGS
RPPAATATPA
>fig|272943.3.peg.447 Permeases of the drug/metabolite transporter (DMT) superfamily
MTLASLLLVVLASFIHASWNLLAKTAASVGPVFVFAYNLIACVAYAPWVLYLLIHDGIIW
TWTGIGFVLLSGLIHLAYSLCLQRGYQVADLSVVYPVARGTGPMLSTLGAFLILGETPSG
TGLIGLALVVAGILLIATRGSLAAFTRPGGQAGVRWGTATGGLIASYTVVDAFAVTALGI
APVVLDWFSNLLRFFLLLPLVIADPRRALSAMRGHWGAAIGVGLLSPLSYILVLAALTGG
APLSLVAPMREMSMMVGALLGMLILREAVGRWRLVGCAVLIAGVILLSAG
>fig|272943.3.peg.590 Multidrug resistance efflux pump
MLELLLTSFPAIFRYYQLKRRAEAMTVWNMRTAVFAWAVMAMGLFLVIFYFHPKSYSGLL
PFRTISVVAQTSGPVTEIHVENGQRVAAGDLLFKIEDSSQKARLNQAEAEFDKIAAAEIK
AQDTLRVALASVAAATSTLEKLSVDRDNARQLLTRNVGTQDTLRQTEASVAAADAEREAA
QAQADLARAELSQAIPAQHKAAEAALQVARADLAKTEVRSFSDGLVTQLALSVGSPAATL
ILSPAMLIIPDRPEDLPLRFTAGFNQVARSTLYVGMPAEIACNTNINLSFRDTVLPARIQ
AIQPAIASGQVVPGGRLLEAESGMQRGSLLVYLELIHPEQESITIDGSGCVVQTYTDNLD
GIFGHVIAATGVIKAAGLRLKVWGAMVAGVGLGGGH
>fig|272943.3.peg.631 Permeases of the drug/metabolite transporter (DMT) superfamily
MTAWILSLEGTPEGARIALLLALTSAFAHACFGALQKGRHDPWLSRGAIDSFMLLLSAPV
AVFLVPWPRGVEWLVMAGVMAIHLAYKIAMARAYSRAAYTVVYPVVRGVGPLATLAFAAL
FLGEHYVAIQWLGVAILSAAILALARLNFTASPQIGRMDLKAGLVWAFAGGLMVAIYTTF
DAWAIRLMPDPFTFLAWFFLMTSLDFPLLLGYRLLKARQMPEAAAALALRGFVGALVAFV
SFGGVMLGTRLGKVAEVSSLRETSTLFAAAIGWLLLGERSGPAKILLMGLIALGAILVQL
A
>fig|272943.3.peg.871 Permeases of the drug/metabolite transporter (DMT) superfamily
MSASARSSSEDRIPLAVTSIILTVLALSLGDALVKMTSGSFVIWQIFVVRSLILLPILMG
VALSLGCLRVPQAGIWIAVRSLMLIAMWICYYLALPNLSLSAAAAAYYTLPIFITLFSAV
FVGDSITAKGWAAVVLGFVGVLFILRPSAGDFNLYALLPLLAAMLYAGAMILTRTRCQSE
HPVILSLALNLGFIIAGGIAACLIWQLPADMRQGFLLSEWTAMGWSEWVSMGLLAASILI
GSIGAAIAYQNGPPAMIGAFDFAYVGFAVLWGIVFFNETPDLIASIGMIMIVGGGILSLR
Q
>fig|272943.3.peg.1937 Permeases of the drug/metabolite transporter (DMT) superfamily
MPAQQSLLSATFWMAGAIASFSAMAVSGRMVSGIHDTFEIMAWRSLVGLAVVLLWATLSG
RLGEIRTRHFGGHLVRNLSHFTGQNLWFWALGLIPLAQVIALEFTSPLWVILLSPFLLGE
RITSLRALSTVVGFAGILIVARPDFAALDVGVLAAAGSAVFFAGSIILTKRLTRHDSIVT
IMFWLTLIQAVLGLLCTFADGETTWPTTVSGFWLVMIGLSGLAAHLCLTQALARASAGFV
VTVDFLRLPVFAILGMILFSEPLDAMVILGGGIILAANWISIRAAGRASRPQDAR
>fig|272943.3.peg.2113 Permeases of the drug/metabolite transporter (DMT) superfamily
MTASSDRILPGVALMIAFCVLAPLLDVCAKLASATIPVGQITGARFLVQAALMLPVVALM
GTGWRMSRRMAGLVALRAIFLILSTYSFVAAVTVMPIADALAIAFVEPFILLILGRILFG
DEVGPRRIAASIVGFGGALLVIQPSLVAFGLVALWPLGTAVFFAFYMLVTRQMSRGMHPV
SMQFHTALAGVLLLVPVMAWGHAAGVPSLTLVRPDGMGWALLFGVGFWAAASHMCMTYAL
KFAPSATLAPLHYCEIVAAVGLGYLVFGDFPNLLTWAGIGTIAASGLYIIHRERLSARVL
PTPAPAP
>fig|272943.3.peg.2577 Permeases of the drug/metabolite transporter (DMT) superfamily
MAKSNTRGALLALLAFAIYATHDVVVKVLGRDYTAVQILFFATLLGFPLASMMLMRDRAD
GNLRPRHPWWVLLRTCCIVTTGLCAFYAFSVLPLAQTYAILFTMPLLVTLLAIPLLGETI
GLHRGAAIATGLLGVLIVLRPGAEPLSLGHAAALLAAVTSSLGSVIVRKIGQDERSVVLL
LYPMVANFFVLGAALPFVYRPMPVEHLGMMGIIAAFSFVAMLLTITAYRMAEAVIVAPMQ
YSQMVWAAIFGWLIFGERSDVWTWVGAGVIIASGLYIVGRESRRNVSENRPASQTRLRPE
VGLMPRLLRRRETRDTP
>fig|272943.3.peg.2642 Permeases of the drug/metabolite transporter (DMT) superfamily
MTEQNTRLGIGLMVLTTCIFALQDGISRHLAEHYSVLMVVMIRYWFFAAFVIAVAARQAG
GLAPAIRSRFPVLQVLRGLLLAAEVCVMVVGFVKLGLVASHAVFICYPLLVAALSGPVLG
ETVGWRRWLAIGAGFVGILIILQPGLAVFSPWALVPLAAATLFATYALLTRYVARGDSAA
VSFFWTGTVGAVAMTAVGLWHWEPMAPGDWFWMAALCCTAALGHWCLIRAYEVAEASAVQ
PFAYLQLPFAAMLGFFVFDERPGWNVVLGACVVVSAGLFTLWREQVRARARAGR
>fig|272943.3.peg.2680 Permeases of the drug/metabolite transporter (DMT) superfamily
MSLFVLLAVLGAAFLHASWNAIIKVGTSKVAAMVILSVAEVPIGLAIALTRPWPAAEVWP
WVLAAGCCHFAYKSFLTFAYEHGDLSRVYPIARGAAPMAVALVGAFALSDAVTAGQYAGI
AVLGAGILLMARGVFTSGEERRLLPFALGSAAATACYTMIDGLGARVSGDAVAYVAWVFV
ADGLIFGTGMVAWKGTALLRADARAWASGTAACAASYGAYAISIWAMTVAPIAVVAALRE
TSILFAVLIGWLVFGERMTRDKAMASALIVAGVMLTRL
>fig|272943.3.peg.2904 Permeases of the drug/metabolite transporter (DMT) superfamily
MAQARRLVRPLDAAGLAIMLGLCLVWGFQQVAMKAMAGAADPLLQVAVRSSGSAVLVWAY
SRFWRRDRWLAGLTWREGLLVGALFGVEYLFVGIGLRHVGSGLMSILLYTAPLFVAVSLH
LTLREERLTGRQWIGCLLSFAGVVVIFLRPGEALRGEEGAALLLAGSLCALLAGFCWGMT
TVAVRLTRLSGAPFAQTLFYQLLGGALCAWPVVLAEGRTGWAGGLDLWLLTFYQTVIVCF
ASYLVWFWLLQRYLASRLGAMSLLSPVFAAALGAALLREPLTPGFLLATALIVAGLVTVM
LHDRRERPRLLPPR
>fig|272943.3.peg.2916 Permeases of the drug/metabolite transporter (DMT) superfamily
MSARPAVPSRTRTLEGVLWMLASGVSFVGVTGIVRYLGTDIPAAQGAFLRFAFGALFLLP
TLVPVLRQGVPMSTLKLYGLRGAFHTAAVICWFYAMARIPVAEVTAIGYLNPVLVTVGAA
LFFSERLALRRILAVAVALVGALIVLRPGLRELSAGHLSQLCAATLFAGSYLLARRLSDV
AGAGAIVAMMSATVTLGLLPFALLVWVPVGVDQLLWLALVAVFATAGHYCMTRAFGAAPL
TVTQPVTFLQLLWATLLGALAFGERVDPFVLLGGGIIISAISYITWRESVLKRRASAVAL
ENT
>fig|272943.3.peg.3276 Probable antibiotic-resistance protein
MLIDFSSRPPHPDFSPPAPHLQNYRRVYQASERRSAASDAAQGLDSWLETYERLGARHVV
LKARDLTTTFGFRISNEAVAEFIRAHGPRYVGFAGVDPWQEDAVDHFDHAIRHLGLRGLN
LQCFELKMRPDDERLFPLYEKAIELDVPVNIHCGINFSTHTPMALGRPEYLDNVMVRYPE
LRAVASPPGWPWVQELIGVAWRHPNLSIGLLAVRPKLLAKAHSGYEPLLQYGRTLLKEKI
IFGSAFPMMPVETALAELDALGLDADTRRLWLHDNAARLLGLDTAAT
>fig|272943.3.peg.3688 Permeases of the drug/metabolite transporter (DMT) superfamily
MPSRSLSLLCVILAAVLWGTTGTVQSLLPPEREPLIVAAIRLAVGATLLTLMALRLPESR
RAFRRLPWRPVLVAGLAIGLYNLLFFVAVTQAGVGVGTAIAIGSAPVWVTLYEAAVLRRL
PTGVRAAGQVLSVLGAALLVAGAGAGSASLTGAALAAAAGAAYATYSVATSRVGAQVPSD
TLAAATFGVAMLLAAPALFLLPVSWVADLRAWPALLFLGAVTTGVAYALFTRGLAGLATS
TAVTLSLVEPLTAWILAIVVLGEAVTAQRLLGAALLFAGLAIVTLAPARPAVRATRGENQ
RAGTSRG
>fig|273057.1.peg.498 Multidrug resistance related protein
MGLKQTLKEIYYIVADKRLLYFSLSLGISTFAYSLLTYYFPIIMTNLDITTFTIGIIYSI
ISFLYVVFNIPLGAIVDKIGSKNAVTLSALMAVPLFLLMGTLNPLLFIISLVIFESVIRI
VNSLGAHRFMLNYTNAGKAFGVFSLITSILAAIGIMLGGYLLQHSVSTLLFTIIAVLFGI
SGIIRFLELPKDENKVEVKRSLRLGFKYLKEDKKLLLYLLVSILSSGLSLETYYVTIYFV
KDLLLPLTFVGVLYSSYALIMAFLPLLFSVILSKRSNFKNLSILIFSNSVIFFLVPLFTN
VYILFLLFYAWTVIVAMESIVDYNVAQSVTKPEIRGTQVALISTFVRIFSVFYNAIVGLL
FQITPLYSFYFTGFLGILAIFTIKFAEFIGVLK
>fig|273057.1.peg.551 Multiple antibiotic resistance protein MarC
MSELVSIPEIAFKLYAIMDPLSILPYLIALYEEFNRNSQNKISWRFLVNKLSIAVTVLLL
FFSILGGPLLAFLGISVSALEIGGGIILVYLGVDTLGGFQQLKFLSSRIEEAIITPIATP
LIVGPGTMTGLITLSVSNNLIILILGSLLAALLVYLSLLLGPIIIRILGNTGTVAVGRFM
AIIIAAFGVQLIIDGISQIKLI
>fig|273057.1.peg.897 Fosmidomycin resistance protein
MKIRILTLTSLSHFINDGNSWVLPVTFIFLITYLGISKFLIGILSGAFFFGISALASPLV
SKIADKFTNYSSIMGIGILLWGIGLISFGYSIQLHFLPLVFISVAIAGFASAFYHPIGAA
VLSITYKGNAGIALGINGSMGSLGRAIYPTLTLSLFAILNKDMTLDMLIIGIISIIAALP
SIFLKISITKEEDHKTPSSSNTTSTRGTLFVVILLTIIALLRSIFGQGISQFLPTLLVEN
YGYSYNVNLGEAITIALAAAIVGQPILGFLSDRVGRRLIYAISTFGAALTLLLFLKIPNI
ALLSLFGFFNFSAFPLMLSIVGDFVPRNSASFANSLVWGLGVTGGGVIGPIVVGAVSQVS
NLVFASEIVTIMAFVAGALTALIPKPPKRTKVPLFG
>fig|273057.1.peg.1024 Multidrug resistance protein
MLKNRNEVLKISFSAFFADLGYQAVVASFPIIFVLIFKAPIPLYGFAEALNYGIGTVMAY
AGGLAGDRFGRKRIAILGNVLILFTSLIGLSRDYIQALIFFMIGWWFRNFRSPPRRAMMA
EVTSPEERSEAFGILHSLDIAGALIAIIYLTVLLYLRVSIFFVLLFTSIPLLMSTIVLTM
VNAGKKSEKAKRKEAESKITQKRVFWTLILSTMFFGFSQYSFGFPILTTTEITGKEYLGV
LSYGIFLGASSLFGYLFGRIRMKEFESLAFLGYLIGALGSLGFAYLSSFGVFSLYPLSFL
MGTSVASTETFEPTIISKITKEEAFSTSMGYLSAGRSIGIFLGNVIMGFLYQISYTYAYL
FAAITSLISFALILNLIMRPNAS
>fig|273057.1.peg.1190 Antibiotic ABC transporter ATP binding protein
MIVVSNIVKKYGNKIALDNVSLEVKKREFVSLIGPNGAGKTTLIRILLTLMKPDRGEVQI
LGENPFKSKRIFKEVGYVQEIPNYPPFLTGKQVLELSAKIRGVDKSEVNRVLEFVEMENY
ANNPIVKYSKGMVQRIAIAEALLGNPSILIMDEPNMGIDPIFSLKTRELLNKLKRKDNVS
ILMTSHELEDVKKLSDRIFMIYKGKIVFSGTVEDMVKEFLGIQVVVETDEIEKAEGVLKG
IEYVKGIFNDGNRLIAKLNEDRREELLKDLVTSGVKVKGFYIDLNLEEAYMRALGNV
>fig|273057.1.peg.1389 Multidrug resistance transporter related protein
MERAFLRYVPILAFITIMTMYVEMVILPSLPEIENQFSITSSEASWVLSSETLAGMTLAP
FLGKLADSYGRKKVLISILVVYILSVFLTAISPNYSILLISRSIQGIGLSINPIAYTILR
ERIPDRELPIAQGIIASTFAIGAAVALPIGSYISQYFSWEFAYETAIPLLILSTIIIYVI
LPSSESKGSDRKIDDVGVILLSLSFLILGIGLTEAPTWGWTSLQFFTSLLLSILLFYLFA
LHISKSRNPIIDPYDFKNPNVAVPLISSFITGFGLFLTFQSLVFIFELPSPIGYGMTILQ
TGETMAPIALIILIAGPFFGRLVTKIGYMKVILTSSSVSSFLLLFLAYIISLRISVLELM
GFLSLILFFISGMNVTRVTLLIASSKRERMSTLTGTNTSMRLMGNTLGPIVVGSLEDTFK
TPIFEGYLNNIPIFAFVPSRLAFEYAFLISMATTVLVTILATRIRERPSTTTYA
>fig|273057.1.peg.1734 Multidrug resistance protein
MDPKGTMRTLITLTLMLTLVNYVETMVIPALPKIEDQFSTTATTVAWVTSAYLIVGAIAS
PLFGKLGDRYGKKKVYLLSIGFYSLAVLLAGFSTNIYFLIFARAIQGLGYATFPLAIAII
TDLFPKERVAWAQGILSATLAAGPALGLLVGSYIVQDLGWPYAFHTAFILSIILVIVSAK
YIVEIPQKTKEKIDYLGATFLMLTVVPLLVYLSNGPNVGWTSTSQFLLIVISIIAFPIFL
WVEGRTNEPLMRLDLFRIRNIMVANIAGLISGAGMFLMFTGLVYYLQLPKPYGLGLSIIE
SGLLMAPVALVMMIVGPIVGRLINNIGPKPLLMIGSIISIVGYLLLDTFRYSIYEVVVDV
MITAVGLVNIMIPLVNMVAVSLPEEQRGIGIGMNTLIRTIGSSIGPVISTVFMDTYTTWI
IYDFNNQIVPVAQVPSYSAFHYMYTAAVGIMFLNLIVALFTRNYVIKAGQHA
>fig|273057.1.peg.2022 Multidrug resistance protein
MKGIKIIVARVIYAIHWFYLAPLIPFLAGKLNLSLQIVGLIPLSFFLGSGIMQIPSAFLS
TRIGLRNTLLLGLFIMSISPLLIPLSSNFIELLIFYLMDGVGASMFFSTGGGILASLNRD
SPSLALGLYNASFAVGGLIGLNWYIVFGNYLSFYILSILTFLSLIINVNNSNLKPCWRII
RDNRIVILGISIAGIWGVYYVIGELYPTFAYYYLHLNLIDSSLFTSLLLVSSVIGGSLTF
LADRKIKKFNLLIISSLLGSVPSLLLYTKVYLLGIVITGIFNELAISVLYSIIASLQRDA
NATMGLALVNSLNILIGMNFELLASYSGYYMWIAVNIIGLLLFSLIVLVRQNISI
>fig|273057.1.peg.2459 Permease, multidrug resistance protein
MNTNSILIVLTLGSLMAAVDTTIVLLALPTITSSLHTDLLSSIWVLLAYMIVISVLSTQA
GRIGDLFGKGKIYNLGFVIFTAASALCGISSNIDMLIVFRIIQAIGGSMLVANSSSIVAD
VFPPNRRGKAYGITSLGWNIGALVGIVLGGVLTTFFGWQYIFYINVPIGIVAVLLGVMNI
KDINKVNTKLDMLGAILLGISLALISLSLMFIAASGISTDNIIELALGVALIPFFLLNET
RSKYPILNLKIFKIRLLTYSILANFLQGIGGLSLSFLLIMYLQGVRGLSPLDSSLLLTPG
YVIASILAPFMGRVADRGKPGIVAGIGLMFIFITMILYFFLLTPTTDYYLIVGISAITGI
GSAMFWPSNSTAIMFHAPKEYYGSVSGLSRTLGNIGTILSYVLSIVVATLSIPRSVAFEI
FIGTTTLNGDVSVTFVNGLHFAFLISSIIIVVAMIFSFMSGKTQESAIK
>fig|273057.1.peg.2489 Multidrug resistance protein
MWLKQVMIKYKDTRWMYLIIPYNASTGPLSTLVTLQILSLGGNAINVAYAISLSNAVLIP
ASILWGFMADRMDRKKQILLSLAGVSIPLVFMPFMNSISLVTLNYALITFMSTASATPFN
LLIMESVEKKHWGSLFSRFSLFSSIGVLLGLVISTFLVILLRIDQIEEILGFSVLATLIA
SIKILPKPIITFERTAIIHHKESFLTRMRHLPMMFLHLPNIHHFKMFSMTRLFRKPINYV
PLLYLGIVLFYISSGIFNTVYPAGLYVKGLNKSEVLAVISVGMVFQILGFRISSMLLESK
DEKGLAHISLILRGVSYVVLGIFAQLFLGIPIFISGLIFYPLAAGIAYAIFYSSSTTLIF
KIVGERRQGTGLGVYSTVVGISLFLGSLLSGYITHYISYGIDFITAGIILLFASWIFRYL
EEG
>fig|273057.1.peg.2608 Permease of the drug/metabolite transporter (DMT) superfamily
MKILKYLLPYVTITSFNYYFAKDAITFSSPIFFNLIRYVISSIIFLSISRGKILFNRDVI
QLAVYTTVSSLLWAYGLLYVSPAESAVLSYTMPLFSIPISFIILLERPAVLEIVGVVIGF
SGVILYGLPLVHGLTLFGSIITIVNALFWGLFTVFYRKLKGYDPITVNASQFSIGSIILA
LLLPIHHNIDPNPEFYIGIAYTSTLGGAISFFLWNMMVKAEKIPKVTVLSFSVPILTTLV
EFLLYHVLPFPIQLFGIFLMFLGILISRSRTLLS
>fig|273063.1.peg.2348 Permease of the drug/metabolite transporter (DMT) superfamily
MLVWSSAYPLIKIALQYMSPIILAIIRLLVGGLILLIYGKGIIYGLKEFIGSLLNVAIFM
ILLNLGVLLSPNPALSATLIYTQPVFVAIFSYFIFKEKIGILKIFGIIIAISGAIIASGN
LEVNIGALISLLGGITWAVGTIYYRKYLINEDVIRLNSFFALSSVPVLVPLIPFQFYFKV
SLEGIVVAIIIGITAQALGFIFWFSSVKNLGAFKASSISLLVPALSYFFSYIILGDMPTL
IEMIGSFLVLFGVLLTNLKISNFSSRF
>fig|273068.3.peg.314 Permease of the drug/metabolite transporter (DMT) superfamily
MSKQLQSDIVLTLVTMIWGSTFIIVKNAIQSLPVYNFLFIRFLLAFLLLAAIFYKKLKKI
DKSTLMAASLIGTMLFLGYAFQTMGLLYTTASKSGFITGFSVVLVPILEAILLKRKPTKA
ATVGVVLAFIGLILLTTNIDLSINIGDFLTLLCAFAFAMHIVLISKYASKMDTYLLATVQ
IGMVALLSGIVSLIFEKPFIPTSLDVWGAIIITGVFATAFAFVAQNTMQAYTTATHTALI
FSLEPVFAALAAYLIAGETMSIRAIIGGAFMLAGIILSELPEKEPEKR
>fig|273068.3.peg.1085 Multidrug resistance ABC transporter ATP-binding and permease protein
MEYQQEEIMAKPFDWKIMKRLLTYAKPYWFYILIGVIAILLVTVSNLLRPYLVQQAIDNY
INNPHISKEQAIQGVIRIGSLYIVIITVAFLINYGQVYLIQYTGQKIIFNLRQQIFEHLQ
KLSLSFFDRNPVGRLVTRVTNDTDTLNEMYTSVITNLFNDVFIIAGIVIAMVSYNLKLAF
IALSTTPLILTGMYIYRKLASQAYRLVRVRLARINAFLSEHISGMKIVQLFVTENKKMEE
FKKINKEYYDANMRQLTIFAIFRPSMDVIYSLTLALLIWYGGRDIIAGKIEFGVLYAFVN
YLQQLFQPIFDISEKYDILQSAMASAERIFILLDTKEEVKDPEDPIPLEEVKGKIEFKNV
WFSYNGKEWVLKDVSFEVNPGETVAFVGATGAGKTSIINLLCRFYDIQKGEILIDGIDIR
KVRQQDLRKHIGIVLQDVFLFTGDIKSNIRLNNKNITDNDIYRVAKYVNAHQFIKKLPEG
YNSKVTERGSTLSAGQRQLLAFARALAFNPKILVLDEATANIDTETERLIQDALEKLTKG
RTTLVIAHRLSTIQHADKIIVLHKGRIREIGTHQELLQKKGLYYNLYMLQYKDQLSESKI
S
>fig|273068.3.peg.1086 Multidrug resistance ABC transporter ATP-binding and permease protein
MKSFTTVIPFIKRHKWDYIIGIIFLLGVDLLQMIIPHLLGSVTDLFKSKDLTPKILLNYS
LWIIGISLLVFAFRFIWRIKIMGMSRLLEKDLREDLFSKLLTLSPQYYHEHKTGDLMAHA
TNDINAIRMAAGPGIIMSIDASFLSITIILIMIFTINFKLTLFALLPLPVLALVVNRFGK
IIHARFTKVQEAFASLTDKVQESISGIRVIKAFVQEKEEIENFRQENFRNFLANMNMIKI
WGLFDPAVQFLAALSFTIALLYGGTQVIRGVISLGEFVAFTAYLGMLIWPMMAFGWVINI
FQRGAASMERINVILNEVPEITDKFADPNITTIKGDIEIKNLTFSYKKDLPPVLKNINLK
IPRGKTLAIIGKTGSGKSTLVNLIARLYTVPCDKIFIDGHDINEIPLKVLRENIGFVPQD
NFIFSDTIANNIAFTKEEPLEKIQKFAEMADVHKDIVEFPQQYDTVVGERGVTLSGGQKQ
RIAIARALIKDPKILILDDSLSAVDTNTEERILNNLKEFMKDRTTIIVSHRISTIKNADE
IIVLDEGEIVERGTHEELLNLKGLYYSIYEKQQLEEAIQKEG
>fig|273068.3.peg.1300 Vancomycin B-type resistance protein VanW
MQAKGGSNKNKKRNYFYLVTVLALAVFLSFAFAYFYVLLTSSYIAKGVFIEGINVGGMER
EEALSIIKEKFKVPKFSIVAFYEGQSFEITTEDIGLQYNYEEVVNKAYEVGRNGNVLDRI
REIYTVGREGRNYNLSLSYDEKPLKEFIDRIAEKIDKKPENASIRIVRGVKSITPEKLGF
KVDKEKTLSNIVDELSKAIENKLFGRVEVEVSVKKVLPQVTKSMLDSINGRISTFSTVFN
AEDVNRSDNLVVASRAINGTLLLPGEVFSLNKALGPRVIERGYKEAPVIIDNKLVPALGG
GICQVATTLYNAVLRADITVVERYHHSFPVAYVPPGQDATISGDVLDLKFKNSTQYPIYI
ESYIEGNRLIINLYGHVENPSRWVDIQSEIVEKYEPSVKYIEDPNLHEGEVIEEVKPQTG
YKVNVYRLTYENGKLVKKEFLYRDLYKPVDGVIKKGTKKVPKENNPLKATSPVVPPTDTS
PPPDTSTEESPAN
>fig|273068.3.peg.2136 Permeases of the drug/metabolite transporter (DMT) superfamily
MRRGEVLALSAGALWGTTGLFVRMIVKLGFTTADVAFLRMFFGALLAFSIIAVLRQSFSL
PLWSWKYLLGTGILSLTLFNWSYFQAIKLTTLPIAVALLYTAPAFVVVLARIFYGERITL
RKSIALILTLTGVLLVSGALRSFITGEEISWLGVLYGLLSAVGYGLYTIFAKPLSGHIPP
ERIAAFTFLIATIALVPISSVLAKPSIFFNTHVILLGFLFGAFSTALPYFLYTRALTFME
AGRAAIFTTMEPVVATLIGVFVLKEPFNLFEFLGITCIISAVILLSLSDKVSTPNIDN
>fig|273075.1.peg.149 Multidrug resistance protein B
MPEPAFTYRSILLRKQIQAVSGAQFIRVLARSQIWIFIPVYLTKVRDLPVYFSGILFLLT
AMIALPISVYGGNLVDTIGRRKVSLAVPVLLFALMIITALSILYRSSIVFIVIEFLSIEP
ISVIQWIADNAIVSDVTGIGERTGSFGILRIAGNLGFSADPAIGGFLAGYSYAYIFLFGA
AGAVIELLLYYHLVNETGKLRTGSGKFSMPLSDRYFVVVAIMIGVTYFVSGQWGTTLTLF
LSVIYGISNNMIGILYSINGITVILLQMPIIRMIERINGFWQLALGTIVYGFGFFVLALT
HSFLLLGLDIVFITIGENILAPVTNSIISKIAPEDRRGEYFGSAQLISGFISPLAPVMGT
LLIYRNANDPLMVWSPVLGIAILASISIIIAGNRLMKSIQAHV
>fig|273075.1.peg.156 Multidrug resistance protein
MPDNRWFASYLMSSMASGITNPMIPLFVVVYLHSNVFFVGLASAVSSAASVPALILWGDL
SDAVSKRKIFVLIGFFGAFVSFLPIVFVHSIYQYLAILITFQVLAMASVPVSTIMLLEQN
DRSVWPQIISKFSMVSGIGSVLGLGLGTALITFYYSPSDLPYVYIVSSAVYLIAGIMALR
FIHEPRRILNRNAIQANTFRIIERPRYFPVAVIHYLRLNGKNNGHRLDRNLVLFIAMTAF
LMFGFQIFFVPYPVMVIDFGANNTLIFLMYMFNSAFSTVSFIFSGRIVNRIGGKTSLFLA
VTTRIMVFGLSSLIPNISSRDLAIISAVSIYSFLGGIWSIISVSQTNYVSKNATQQTRGK
AIGLYNSLLGVGQIFGGLVSGEVTTLFGYSIDYIMAAAVITIGMVIILRIYRGERLFLTG
MRPMAKA
>fig|273075.1.peg.221 Permease of the drug/metabolite transporter (DMT) superfamily
MQKNGEPVLFFFMAFFWGLNYIMVKYAYVYDVSSSILLMRVLYALVFSAIIFVRQIRFPR
TPMEHLKVFVLSNLNITAFFALWFFGETGVSASLTSIVIYSYPIMSLVASYALLNDRFGR
GKAMGIALGFAGLIIIFFRSINVSNYIDLIMLILAALSWAMGTVFYRKFLTGYDSAGLNT
LQLLYAMPAVILIAFMTGGINRNLMIPQFNLIMLYMGSLGTAVAYFIFLTLYRRYRVSDI
SAFFFIVPAISVILSVILLHEAVSRIMLIGFAVMSVGIYLSGRLR
>fig|273075.1.peg.410 Multidrug resistance protein B
MVQYKWVALSNTTIGVLMASINGTIMMISLPAIFRGINLNPFLPSSFQYLLWILMGYMVV
TAVLLVTVGRLSDMYGRVRLFNLGFAIFTAGSILLFLTPGHGTSAAMYMIMFRMVQAVGA
SFLFANSAAIITDAFPSNERGKAMGINQIAGLAGSLIGLILGGILATINWRYVFLVSVPV
GALGTIWSYLKLKDQSVRRKDEKIDLPGNVTFAAGLTLILIGITYGLMPYGSSSMGWSSP
WVISAMASGAAMLVAFPFIELHVDQPMFNMHLFKYRGFTFGNFAGFFQSMGMGGVMFMVI
ILLQGIWLPLHGYSYSSVPFWAGIYTIPMMAGFVLFGPIAGALSDRIGARLLTTLGMSVS
AVAFILLTLFPYNFSYPPFAATLFMMGSGMGLFGAPNITAVMNSLPPHYRGTGSGMRATL
QNTGQTASMGIFFSIVLITLTAYLSSSFNTALAAAGASVLIPVFDKIPATSALFSAFLGY
NPMQTILGLLPASFASLISPSSLAILEGTHWFPLALAPAFMKALHASFYAGAGILVVAAL
LSAFRGKRFVYGEETELKEKMQQTTEAKLSSQLEVMRDGKK
>fig|273075.1.peg.509 Multidrug resistance protein related protein
MLLRLVLSIIVNNERFSSLIGDRNVSLIGIIEGIRTFAAFLPIPVFSIYALRFTSSGLLA
GLAMGVYGIAMIFSQIMMGSLSDIIGRKRVSMVSSVLFSLGNLISWHPFSIQILVFSRLL
AGLGAISSPLMALLNERSDMDERTSRMAFVGTLSGLGIVIGVIAGPEISTYIGIDTIFLF
SAILGFISLLPILMLAEDRVTVRRRLKIKWDPSFTFSSFVSSFILFAIFFFLPIYWMSRS
QILPYGSFIAISLVAAGSIGILISIKFGMLSRITAITLTLFAVSSLAMFYFSEYPYAVMS
GFFIFAIGYTIFEISFIPLLIKEHGGDYGSLIGFFNGGRYAGEFAGSLTMGALIKNPIDL
HGLHLLFLAIVFMITLSILLLKIRFSKYGNVFNIHN
>fig|273075.1.peg.605 Multidrug resistance protein related protein
MDSYKIIAITVTSIGSLLAVINSTSLLISLPTIMISLHTTFFFVIWILVIYPLVMTIGAP
LFGRYSDFVGRNRLYALGYLFFISGSIIASLSPDVMILLVARLLQGVGGALLFSNSLAII
ADAFRQDELKWAIGTNSLVIGIATAIGPLVGGILTAINWRYVFAFNVPFGIAGYVMALKL
REIEKRKVKINWKPAIFFSTFIVFIVIYLTFSPPNLWLNPVEVIYLLISVVSFVLFIFLS
RGGDDSLIDISLFRIRSFATQSVATFLNSITRYSALLIAIIMLQGPLGISPLESSIMVIP
YAVSLSLSSYLVGNINTKRFEGHLIYAGLFLSFFGSVVLSLVRNVNVPFYLGLVMVGFGI
GLFYTPSNAILMSTAPPDRRGSAAGIRTVILNLGSVIGMSMVFTIVALYVPETALSSAFL
GIKIPGFEAVKLSFLKGISITFLVSGMASLLAFLAVLGEKLAETNKK
>fig|273075.1.peg.720 ATP-binding protein related resistance protein
MENGNLLEVRNLSKIYPGGSGVRNASIKIRYGSIHALLGNNGAGKSTTMKCITGLLEPDS
IEISFRGTTYPWNSKDLKKHIGYVPELPAFPKVFTVHDCIVSYGRMMGLGKAEAVGRAMP
IVSILGLEEHMKKRVSSLSRGMLQKLDIVIALLSDPDVIIMDEPTAGLDVSAVEELFGII
RSLRDRGKSILISSHQLRDIETISDSVTVMDSGHVIFDGSIKDLYASAGSVEVVAEFSRI
DGKLMETIKRMQGVMDVRMEDVPNRISIAFSGSTDPCGYLRDLAFRDGVSLISCSRSQSD
LRTAFIRMVEYVRGQRKDQ
>fig|273075.1.peg.777 Multidrug resistance protein related protein
MPSGYRHGYQDRKELLAICMDVTSGVAKLHGTPSIRGRGPILLTTSIGSFLTPFLSSAAA
FAVPSIGRYFHLSFIQAAIIPMVLLIPLASMMIFLGKFADAVGRVLIFRMGFMVFMAFSL
VAAFSRSYTMLLASLFMVGFGSAALSTNGTAIVSYIFSRGGRGFALGINAMAVYLGLTFA
PFLGGTLIEAYDWQSVFYFSAGMAVVGYAVSMFSLRSIDMRGRRSREIPQAGLFMASLLS
ITSFAALGYFFGYLRLIYLIVIGLILLGIFVYREIRSDVQVIPRQMVSGNRTFVASNITA
LLNYLSTFSIVFVFSIYLQAILRITPFISGLIILPEPVMMVLLSPVAGRLSDRYGSRVIA
SLGMIIIGASFIYLFVYAGRDIRVIMASLAVIGVGFGLFSAPNTNSVMSSIDPMFSGIGS
GFLGTMRFLGQLFSIIMASSILSSYIPRELVSGIFSGAVVSIDPAYAADFVHGFRIVMIV
SGILSLAGAYTSLLKNRGR
>fig|273075.1.peg.913 Multidrug resistance protein NorA related protein
MDYKPKAYSIIFARSLYALNWFDIAPALKYISIDLNINVIKIGLVTTSFYIGLALFQLVG
GSLAHRIGNLVVSVTGLTILGLAGIFSGLSGNFIELSVSRFMAGAGSALFFSPALGIISD
IVPVDRYGSYVSVYNGAFSFGAGTGIFAFGYLDTVSGWRISLVIGGALLLIADLAMFLMI
RGGNTKVRRPMKELITAVKKPEIWILPVVTVGSAISETIMGQLFVYYLEEYRHFPAITAS
AAGSFFLFVGLPGGFISAYIIRRYSKKIQVASLLAVMGLIFFLVPFEVNIIEILTTLFAF
SVLSIYGFSYLYMEASMINKSAVSFSLSIVNFVQMMISSAIPYLYTYAIYSISIMLAGIC
WA
>fig|273075.1.peg.990 Permease of the drug/metabolite transporter (DMT) superfamily
MKEIKYLIPYVLISSFSYYFAKNGVDQVSPAIFMSMRYFIAGLTLLPFAKHLKFSWSILI
LSIMTSTSTALWAYGLIYVSPAESAILSYSMPVFSLPIAFLMVKEKPSAIEIAGISIGFA
GVILYGMPLMHGFTLFGAILTIANAVFWALFTVYYRKLKEEDPVSINTMQFFIGGAILLA
YIPFDTRFDPGLSFVADVLWMALLGGSVQFILWNVMIKMSSVNKITVLAFSVPIFTMILS
IFIDHEIPNIMEIAGVIVMFTGIFLSRLKGGISVVKETST
>fig|273075.1.peg.1016 Fosmidomycin resistance protein
MDTNIAFSGEAKIRSLVYTSLGHFTNDFNILLFSVLITYYHSDFGISLALLGAVAIIYSI
ISGLLSTPVGRYADKTRRYRFLMMVGFIILGVSIYLFALSFVSARIALPVMIVASILFGF
GQAFYHPLGSSILNLTYGNGSASALGINGAFGSIGRSALPVILVPLIILVGEKYALVILG
TYMILAGIIIYAGLGFIREHEIPEKSRSASSSKNRDMLSRYSGVLAIIVAMVFIRAMFLT
GTTTYISQFVLDRVKSETIMSIVLTVSFLTAVGGQPYFGRLTQRHGGKVTIGLTTGLSTL
FFIFFMLAGTNPIINTVTYALYVFTAFSGFPVLMGYVNQIVPRDISTTAGGMVWGLGNTV
GGGIGIAVISVLLYFHITLAETMWIMTIFGAVSLVLFPFIPSKDAAARLKASST
>fig|273075.1.peg.1044 Multidrug resistance protein B
MRSMMSNHSARTIAISAFAGLLVTYVETMITPALPILVSFFDTNYDHLSWIITAYIISGT
VSSAIFGRLADMYGKKNIFVILAVFYTIAVSFGGFARTLEELIIIRTVQGIGMGMFPVSF
ALINDQVPKHRLALAQGIVSSTFSGGAAIGLVAGAWITQNYGWQWSYHSSIPVAVLLVIV
ASIYLHDESERKPAKIDFIGVGSLGLAIVSFILAISEGEYWGWASPSIIGLFLFSAAMFA
AFVLYERNTPEPFIRMDLLRIRNVLLANMTGLFAMSGMFFLFYTVPALLQDPEPTGFGIS
IVESGLILLPAAVLNMALAPLAAKITTSRGPKTAIIIGLFILLFSYLGLYYNRSSIIAIL
EDSAVMGMGISFIFVGIINILLISVPRDRSGESTGMNVVFRNIGTSLAPAIGGVMETMFV
TYVIVGAIPVKFHGLPITPIMENFPSSEAYDAIYVIGMAFVVIAMILSMFMKNVIVGGEK
R
>fig|273075.1.peg.1051 Multidrug resistance protein related protein
MILASRAFRSAGLIFMALSLPLYLLLNRISIVNVGIIYVGTALANVSVTIAIGMLGDRIG
YKYSLVFGEIPALLASGILAFTRSVPLIVIATVISGSAGAPGGMRGSFSVGITPYLARIW
QEPSIRIERMAQITFVASIASIGGSLLLYLHGFITRIYGDLGAFEILYHVAFILILLSFV
SLTMIRRDRRQKKTTKFLRKETMKFSARVIITNVINGSAIGFSMALISAWFEIRYGVSAS
KIGLVFTISYITTAIGSLLASRIHISRERAVYFGSLTRILQGILLIAMAASPIFIMGSTI
YIVRTVVAGFGTPIRNVVNIQGIKDEDLGTASSIQGAPSRIMQSTSGIAGYLMDYYPPLP
VEIGGLIQIVGGFVYFKLLRRY
>fig|273075.1.peg.1166 Multidrug resistance protein NorA related protein
MSLYLHHIGYSLFTVGVILGSAIVISSILTFFMAMLADHYGRKSLLIVLYLIFAVSAFGF
LVSKEMFILILLSGLGSFTGSGGGPIGSGGAFGAVQTALITEFTEKNRFSRVLSTASAVG
LLASSAGSFLIDVVERIGGDVYRLFYLAGIMGIVGMLITVFLNDNGIRSRKLLPSISWKK
MIRLSIPTIPNGIGAGFVSPIFSLWFHLRFGISSGEIGVIFGISNIFVLIFMIVIPRIIR
SESELNAIVWTRAASSMLLVALAFIPFLQIAALVYILRQGLQMGAVPVRQSFSMGIVDST
ERATASGVTSMTRTGFSAVSPPLAGDLLSISSIYPPLIGGIITAADPLLYYMLFRDSFRR
KS
>fig|273075.1.peg.1380 Multidrug resistance (emrA) protein related
MTIDYSRKYFVLSITTLGSLMAAIDSTIVFLALPAMGHYFSSSVSYLTWIVVAYIISATI
FMIPSADIMRKIGKKQLYLIGFVIFALSSLVIALSSNVIMAIIFRFIEGIGAGFLSAVGI
PILLDAFPPQERGRAVGINSISWAIGTLVGPVLGGYLVLYDWRYVFLINVPIGIIAAILG
LARIPHYPKENAQKYDPIPLIGLIAFLLPLTVGISFINVYFLVASAIIFPFFIMAQRRNP
IIPSVLLKNRNYVRVSISSTLQALSFFGVLYALSLYLQISRGMSSLSASLYLFTYPLASM
IANPVSGFLFDRTGKGAHLLVIGLVMQAFGIFMVAYTMTLIPIYLFIAGFGGSLFWAPST
TMVVDAAGPKFRGIANSSLFTLRNMSLILGISVFPIFVSAFSHVKSSSIIITAFGANLSA
STSYYLITVSLLSVLAIIPIVGFLRSKRESIESKAEIPG
>fig|273075.1.peg.1443 Permease of the drug/metabolite transporter (DMT) superfamily
MFRSKRYQMVAYAITGSALWGLSGTVSSILFSRYGMPFSTLVTIRMVFSGLILLAAGRGF
VGKKDLPMFLVFAIPGLFGVQILYLATISFSNAPVATLLQFLFFPMVAVYDYITIRSLTV
SSLILALIFSVAGIYELTTGFPLGGTALRISLTALILGLATAATAALYTVTSARIVKEYG
GLRTVASGMMVGGLVSLPLGSFSGVPYFHGLGQADVIPVLALTIFVIVFGTSMAFYLYIN
SMRYISPVEAAVSGTFEPVAAAMSSYLLLGIKLSAMQYLGGALIVISILVIVISKNRRG
>fig|273075.1.peg.1467 Permease of the drug/metabolite transporter (DMT) superfamily
MDRKDAIYLALLIFVTFIWGVTFPMIKDVFAYLSPVSFLAVRFAVASLIFLPFVYRKLIQ
TNRNTIKYGVVAGIFLFIAYYLQTVGLKYTEPALSGTITGIYVVFVPIISYLYLKRRVMR
IEVYSSVFAFLGLVLMSYSGLHNLAIESGDILTFIAAIFYAMQLVYISKYASNVDPLVFS
FLQIVVVGVLSLAFMPTDMYPIVFSYYALFVIVFTAIFATFLATYVYVSALSRMNVTKVG
VILIGEPIFADITSIFLFNEPVGPIEILGICIMIVSIGVISYFSD
>fig|273116.1.peg.394 Multidrug resistance protein
MVFGIVEALGYGIGSDFSYIGGRLWDSHSPKKLTILGNSLIPLMSLIGLAGTYIGASALY
IGGWWSRNFRNPPPRVMIIQSSKEEDISRAICLLHGLDITGGTIAGILPLSFTALGLPLS
RVFLFSIAPLVVSNLLVASTRSVHXVKQEEVKIKNVDSAKAEKNVVYGVFLATLSFGFSY
HSIGFPILTAAQSADSTISGLVLFPVFMASSSVGGFLYSRLRISKEVRLLGYLGYTLTGV
GTLLISLVYLYRAPELYYYLSAVVIGLGTSGVETFEPTIISKIIKGSRTGSGVGYLTSFI
SIGLFTSNILMGLLYYEISPLSAYLYAGLAAILGGLIILFAGRKFKYY
>fig|273121.1.peg.255 Permease of the drug/metabolite transporter (DMT) superfamily
MSLKSRELLADVSLLGISVIWGVTFLMVQDAIKEVPVFAFLFWRFLLATVLFFLIGIALK
PSFDLPSIRAGAILGVMFCLAFSLQTFGLEHSLSSVVGFITGLNVVFVPLFLWMLFSQKQ
TPFALLGIALAVVGLWMVSTNGGGIGLGKGELLTLGCAALFALHIVYTGIFSKRHRLFPL
ILAQFSTATLLCLLFSLLFDPFTIPSTLSYPFLKALFITALFATVLAFLVQTYMQRFTTP
AKTAVIFTMEPVSAGIFGYFYAGEPLGSIQILGAGIIVLAMLSVELGSLLYRRKKRLN
>fig|273121.1.peg.383 Acriflavin resistance protein D
MIKYVIAKPVVVIVGIILVALFGVLSLSQMPYQLTPSVTRPIITINTLWTGATPYEMERE
IIERQEKVLKGIDNLISMESRSRNGRADITLEFKIGTSLTEAMLKVSNKLDEVKKYPDGI
DKPIITATGESTSPVVWMVLKTQKENPRHINEYRTFFNESVIQYFERIDGVAEVFFPSGT
DREMHVVIDHNKLASYQLTLQDLISVLDLENANVSAGTMDYGRRSYRVRSVAEYKSPEQI
EQTVVWSDGQRRVRIADLGYVKEGYARPTAYVEHNFESGAVVGIKPTPGTNILELSDEVE
RVFFRLNEGVLAKEGLYLDWMYDQRSYINGAISLVRQNILIGAFLAVVVLWLFLRSFTST
VVIALSMPISILGTFIVMNALGRTLNVVSMAGISFAVGMLVDSAIVVLENIDRHKRLGKG
IFAASYEGTKEVVGALVASVLTTVAIFIPIINMEEEAGQLFRDIALTASSAVLFSMVVSI
LIIPMFSYQLLKLFGVEKPHPKSTLEGVGARIIDTVVAWVKGCTASVGSRLATIFFFTFL
SLAISYALFPKMEYLPEGNQNFVTTVLNPPPGLSYEERQNIGKEVFRLNESYFVQKGYEK
NEKGEMPPIRHMFFLGSENFMYFGTRGAIEDRAGEMIPQFLKTIESLPGMTGVSMQPGIF
ERGMGKGRTIDVDISGVEIESLIQTASAMQRLIKQRLPQGTQVRPLPSLELIYPEINLYP
DSDKLKAAGLNPSTFGVALDVLMDGRAIAEYKEEGREKIDLVLKANKGELKTPEEIYNAL
IYTPSAGILPLSSLSEIKREYGITEIRHFERKRTVTLQVTPPKNMPLEEAMEKIQGEFVE
ELQKQGLIGSNELRLSGTADKLTQTRLALQGGFVLAVVIIYLLMAALYENFIYPLIIIFT
VPLAVAGGVIGLKLVNLFLANQPLDILTMLGFIILVGTVVNNAILIVYQAINNIREEGME
AYEAVILSVRTRLRPIYMSTLTSLFGMLPLVLAPGPGSEVYRGLGAVILGGLTFSTLITV
FVIPSLLLFVIQKERLKIDIEKAEKAGGIA
>fig|273121.1.peg.796 Permease of the drug/metabolite transporter (DMT) superfamily
MSNSSKGALYVALCITLWSLIPIFAKLGQSNLDHHQYLFFSSLLSFLALLGVGYYRRELG
NFWRYSLQTLLFLAFLGFLDFFYYWLLYFGYKEAQGLEVLVFQYSWPIFIVILSPWFLGE
KLSMKHALSLLFGFLGVAVVLSQGKMSEIEFSNFKALFLVLLGAFSFALFSVLSKRVSAK
ALHAVTLYFLSATLYSSLALSLFSSWEMPSWGDWPFILVNGIFLNGISYLFWVEALRLGD
ASKVAPFLFFIPPLSAFWLILFLDEPWVWAYGVGLMLVILSGIINARRKR
>fig|273121.1.peg.861 Permease of the drug/metabolite transporter (DMT) superfamily
MSNRSTLLPYGALILAMFIWGSSFIALKYAFISYDSSWVIFWRLLFATLFLLLFIPKMSL
RSFRPQDLPALLLMALLEPCLYFVFESKAIENTTASQAGMISSMLPVLVALLAAWLLGER
LKSRMMIGFLVAILGALWLSLSSSLSDYAPNPLLGNFLEFLAMLCAAFFTISVKRLSQRY
NAFFLTGFQSLMGALFFGVLTFASPLSEPMGRDELHFGAIGAIVYLGVVVSFGGYGLYNY
ALSKVEASQAAGFTNLIPLFSLILGYLLLGETLNSSQLFGCGLIFLGVVGAFYRQKSRG
>fig|273121.1.peg.1958 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MGLAAVNLCVPLFYLFMSLEVLFGFGGSALASMALGRGDDEEAREIFSSVALFMLFLSSL
LALGLFAYRDSLALWLGAGEKLLPYVKEYLGVIVLAAPIMMVQPLLEAFVRNDRAPYLAM
SSMVVGSLSNIVLNYLFIFIFSWGLFGAALATVLGHLIGLLILGGHFYLKRGNIYFSSLR
LRFSYVFRAFANGVAPALSEAAAGIVVVLFNLKLMEISKEEGVAIFGAVSYIGVMAVTAL
VAASQGLQPIASFNHGAGFYDRVRAVFRFSFGITLVLGFVLYALSWSFAPFLAELFFPLD
APLAKESAEAMRIYYAGYLFLGLNILSAVFFQSIGRSLVSFVISLSYNFVFILFWLELLP
RFFGLQGIWLSYPLAMISGFLLVLWVIARERKIQTKEPLCKTPL
>fig|279010.5.peg.841 Vancomycin B-type resistance protein VanW
MLKIWMTGLLLLAQPAGHSDSLTITQQGKKVAVVNREDFTMPLPGTPMIDDKKYNEFVDR
LERKVHKDPVNAVINDQGRIVPGKVGYSLSRKGFKEQFYAYFYGDGPSTIEVPELNVYPK
VDSELLSHIRTQRIGQYVTYFNSGNKSRTHNISLAAKAIDNHVVFPNETFSFNKVVGMRT
PDKGYMKAPVIVRGELSEGVGGGICQVSSTLFNAVDRAGLEIVQRYSHSRRVPYVPPGRD
ATVSWGGPDLRFQNKYNQPVLIRAKRHGGTMVVTLYSSDVVNHQLRKVPKAPAQIPKEEH
QSGDH
>fig|279010.5.peg.1804 Multidrug resistance protein B
MFAQFKAFSRLHPLIRFLLIGTLVTKAAKSMTTPFLALYLHMKTGADFGTIGLVIGLGYF
SSTVGGVVGGALSDKIGRKKVMLSSIFIWSFVFILFGLVHDFMWFLLLNILSWLCHSCFE
PVSKALMAELSEREMRFRIFSLRYLAINVGAAVGPLLGAYFGLAKTGTPFIITGLVYFGY
AILLSLMMIRLTTVKETKIAPEKVQAGSVLKTLKQDKALRLYIAGGILFLFSYSQMESTL
LQYLNNDFANGVKIFSTLITLNAVTVILLQVPLTRLFERYKSLTTISIGTVFCILGNIGF
SIANGWIVFMLSMFVLTIGEILCFPSMNVLLDELAPDHMKGAYYGMQNLYNIGEFLGPWL
GGMMLALYGGKAVFLIAACSVFLALGAYHVGRRKFLSAQHYGVSPFSY
>fig|279010.5.peg.2644 Tetracycline resistance protein
MKNSKIQTFKHQKKAFWWLSFVAFFSVMNETVFNVALPDIKNQFGVSPAAANWVNTSFII
SFAAGSVVYSRLSDMYGVRKLFVAGLLIYGGGSFMGLLAQAYFPAVIFARFVQGSGASAV
PALILVIITRYVRPEGRGKAFGIVGSLVAMGEGIGPAIGGMIDCTLYSLVVSVYSADGSA
DGDSFLL
>fig|279010.5.peg.2645 Tetracycline resistance protein
MIVHYIHWSFLFILPMAVLMAIPFFFRNMPDEAAAKANLDIIGIGLLTISIVMFAVYISL
YHVFYLLAGIFCLIGAAVHTRHAEHPFIDRSLIKNRRYIGVVLAGCTVLGSVAGGALTDR
FGSRFVFTLGWLLILSTMAAASQVGDRTPWLMTIMLVFIFGGLSFVKTAISNSTAESLEE
KAAGAGMGMLNFACFLSEGIGVALAGGLMAVHGFGYSALPAMNDAWSAVFSRSFAIFTVF
VLAGGLLYLLTCKRKKS
>fig|279010.5.peg.2723 Glyoxalase/bleomycin resistance protein (EC 4.4.1.5)
MKKKTSGIHHITAIVGHPQENVDFYAGVLGLRLVKKTVNFDDPGTYHLYFGNEGGKPGTI
ITFFPWVGARRGVIGDGQVGVTSYVVPKGAMAFWENRLAKFNLPYTKMNRFGEEYLEFDD
PHGLHLEIVEREEGEKNSWKIGEITPDKAIKGFGGATLLSKQPEKTAELLEKVMGLEKVG
EEGDFVRFRSSGDIGNIIDLKLTTIGSGQMGIGTVHHIAWRAIDDNDQLEWQKYVAENGY
RVTPVQDRNYFNAIYFREHGEILFEIATDPPGFAHDESHQTMGEQLMLPAQYEHYREQLE
RRLIPITVKALD
>fig|279010.5.peg.3076 Transcriptional activator BmrR for multidrug resistance transporter
MKEYFSIGETARLNNISIQTLRYYDKIGIFKPQCTDRDNGYRYYHVKQFFYLDIIKYLKS
IKTPLEEIKRIISHTSAPELMQTFLEEQENVIEREMEKLERARQLLQRRKDQLHEQLEIR
AKKEEGLVYVRHIEGQTILKAATPQVNPHDQSDLYYRKLAEVLEERGDMVDNYYGLIYDL
KPYKNSGDIYCNSVYTTIYDGAKIDTEEQNIGMDTIPSGEYVCISFDCSSTNYFSYYQKL
YHFIETHGIQTDGKVYQVSFPNSYNSLKEEDFLTEFRVLKK
>fig|279010.5.peg.3290 Drug resistance transporter, EmrB/QacA family
MAGLKKKRALFLTAVASGTMLNPLNSSMISLALHSIQHEFHLSFATVSWLISSFYLASAV
AQPVTGKIGDLIGRKKMFLSGLVLVAVSAIGAPLAPAFSVLLIMRLFQSIGSGAIYPSGV
GLIRSHIHEKQASALSVLSIFSSAMTAFGPTVGGFLIVLGGWPAIFLVNFPFILFSFLLG
MYMFPKDEKKAGLNVRAVIKRLDLTGILLFAGGIVLLLAFLLSLSTGEPRFAEGMFGLVL
LLMFVWWELRVNSPFIDIRLLIARRTLTSVYAQFIMLNIFNYCLFFGLPSYFQDEMHLSV
QTSGLLMLFMSGTSVLISPFVGKWIDRSGETQPVLIGSCLMAAGAILLTLFFVDAPMLWK
GIILSLLGVSYGLGNVALQAAMFTASPPDIVGTTSGLFQTCRYLGSIFSSVILGLLFGEE
ITAGHFQDLGMVMIAVAIGSILMSFRFIKLMKD
>fig|279010.5.peg.3456 Lincomycin resistance protein lmrB
MSQSDVAIPSSKKIGIPKYLIISVLTILAIGPQYFLNLSYTLSQVVIQNGLHLSPDDMRI
PSILTNLAFALGVPLGRIFSRRFGIRNSYLTLITLFLCGSLIDAFSAGLFSLLIGRVIQG
LCSGMLFLTILPVKLISFPNKVRNLFLFFVISGLFGASAIGAVFGSLSLSADAWRWVFIL
NICSPVLCLVIGFFSLPKQAADEREHHSIDKTGVFMLSLLMVVLTVPLINLQKTGVHSFY
VWPFFLAGFIILALFVITDLRAREPLVPFRSLWSAKAVSGTVMAVASHIAIIVSLAGING
FLENIAEASFESMTRFYLCFFAGILATAVLSTLLYDHFGAGLLGCIGALEMIIVGMEWRS
VQPGVSMESLYLHAVLLGSGVSMVLVSGALGTALAGDIHQASKRSVSLHFIRNFAGAWAA
PVIGWFASMKNAVHYEMIRGHISEADPEIQLELSKMIRDFVSSGLSVGDAKNMAAYTIVA
NARKASALGAYHDLFTILLWLSIIMLAASIGKAATGKGRSLVQKRLRLPDPSASQQKEIG
>fig|279010.5.peg.3509 Multidrug resistance ABC transporter ATP-binding and permease protein
MRSFLGCSNLSVRFYHRPETVLDRVSLSIEQGEKVLILGPSGSGKSTLLSVLSGIIPEHI
EAEVTGEVNRRKSAGVMFQDPDSQFCMLHVDEEIAFSLENRSVPPKDMDRIISELMELVG
LKIDKKTPIETLSGGMKQRLALACLLALEPEVLFFDEPTAQLDPASRQDIFALLRDVSRK
SGQTMVFVEHVLDGCIEWMDRVILFNEKGQIIADGKPEEIVKHFQPEMKAAGIWQPKLYP
AVWEDVTTQDDHPLAVKLSSTLKMKEEEAKNRPSADRDILIRTEDAAIGYRKKIVADGIN
LEIPRGEWISVIGGNGSGKSTFLKSLIRLEAVKKGRIYLEGRELKKWSDRTLYEKAGFVF
QNPELQFIRDTVFDEIAFGARQRSWPEEQVERKTAELLQEFGLDGHQKAHPFTLSLGQKR
RLSVATMLLFDQDLLLLDEPTFGQDEKTAKELIKRLKERQERGTTIVMVTHDMDIVDEHS
DRVIVFHQGKAAYQGTPYQLFSDQDLVRRFSLIPPLHYRFMHERKERVPV
>fig|279010.5.peg.3683 Multidrug resistance protein B
MKKMARLYMLMLNVFIVMLGIGLIIPLMPTFIEEFGASGSTLGLLIAASGITQLLFSPVA
GEMTDKYGRRKMIILGIGAFAVSQLLFALASQMWLLFVSRLLGGAGAAFLVPAMFAYIAD
ITSEKDRSKGMGLISAAMSLGFVIGPGAGGYLAAFGLTFPFYVSAGLAGLATVLSLLVLP
ETLSQEKMLEKRRSVQKREPLAKQMARALRSPYAFLFILVFILNFGIMNFEAVFSLYVDH
KHGFTPGDIAFVITAASLIGVFVQAVALGMLTNRFGEKKLMNMTLIGSAGALAVCSIAGS
YWLVFGATIVFFMLTSILRPAINTLISKMAGDEQGFAAGMNNAFMSLANIVGPTVAGLLF
DVNVEIPYIFGVVVLVLSFLAAVSWGRKQQARTIPEKV
>fig|279010.5.peg.3949 Permease of the drug/metabolite transporter (DMT) superfamily
MLTNVLKYRVHILFIVLCLIGGTTWAFQKAGLSDSLPFWSAGMRFMIASILIAAFLLARR
QFVLSKELLVLSFLNGIMYFSVPFGSVYWASLYLPSGLVSILAASISVFALMINRLVKGT
PATKLQKWGICLALLGITIVFGNQLLIKVDVIEIVAMIVILCAMFGSAFIQIKVQQRIRS
LPILSFNSLSMLSGGAVLLISSLIFESGTRTFSGVSLYALLYLAVVGSILGFWINIYLLK
KWHISKATSHLFISPVIALYIGFLFLDEKLNANIYLGTLFVIFGVMFINLKKEERIAKID
ETKQKLGHHLSK
>fig|279238.18.peg.94 Permeases of the drug/metabolite transporter (DMT) superfamily
MHFLALLTGNVALALGPWFVRLADSGPVSAGLWRLALALPLLAIFALRGREPMWGYQRKD
WAIIVGAGVVFALDLASWHVGIERTRLGNATLFGNSGSVILMVWGLIAMHRRPHLREFAA
VALALGGAGLLLGRSMEIDTRTLAGDLFCILAGLFYVVYILLVQHVRGRFGSWSLLFWSS
LAGCPVLLVTALALGEPVLPGTWWPLVGLMLASQIVGQGLLVYSLRHFPPLVIGLVLLTQ
PAVSVVVGWLSFGEVLALPDAIGMALVGAALVLARLGEGKSA
>fig|279238.18.peg.1750 Outer membrane component of tripartite multidrug resistance system
MAGALVVAALLAGCTTVGPNYAGAPDAAPQAVSRGTFARAGADALAAAPAARWWESLGDP
VLNQLVEQALADAPGIAAANARVAQSRAALAANRTAVLPQLNTSFAAPYINVPGGLLSPN
GESGGRDEINAYNLGFDAAWEIDLFGGTRRKIEAASARAEAAEASAADARVTLSAEIARA
YVGLRARQAMVGLQERQVEIDRELASLARQRFEAGRIPQQPVNGAEAQAFSSEADLAKSR
AEIAVLMDQIAVLTGKEPGTLDALLVAPAPVPLPPAQVAVGDPALLLRSRPDIRAAERQL
AAANADVGSRIADKFPKISFLGLLGLGGQDFGDVFDPGNIVGIALPQIKWSLFDGGRAER
QVEAARGAFAEAEANYRRTVLSALQDAEGSLARFGAQRVAFGKALDAETRARRNVELQQQ
RLAAGTIGKPDRLDAERQALQLAMAATSARAELTTGFVAVEKALGLGWTAPEPAK
>fig|279238.18.peg.1900 Permeases of the drug/metabolite transporter (DMT) superfamily
MQDSHRSALIFALLGFALLSVGDAVVKSMAGMWPGTAIGALRYVFGAVGLGIVLLLREGP
SGFAFPKPRWQVLRGFCVAMSAMSFFSAVHLMPIGEATAISFTSPMITALLAAVLLKEPL
RRETWIASIVAFGGVLLILRPNFGLLGLAALLPMVSATGMALLIIANRKVAGMGSALSMQ
FNVALIGSLFLCIATLSGHFSGVAFFAVQVPAMSVIAKCALIAVSASTAHALIYMATTRA
GAATIAPMTYVQLLMAGVLGWGLFGERPDGVAAAGAVIIVGAGLYLWRAGRAPEEPTMTD
>fig|279238.18.peg.3505 Outer membrane component of tripartite multidrug resistance system
METADTIEAAQTLAARGNTTWPPDQWWRLAGDPQLTALIEEGLSNAPQVAVAVARVRRAE
AEAQRVGAARLPTIGAEAEGGLRRQSGNNGIPAQFLPDGWQDYGQTSLSFGFDLDLWGRN
RAAYAAATSEARAAMVDAAQARLVLSVAITAAYAELGRHYRERDNAAATLANRRLMRDLV
AQRQRNGLDNLASLRRADAEVALAEQDLAAVDENIGIRRNQLAALLGAGPDRGTSITRLP
LAPSTPGGVPAGVTTDLLGRRPDIVAARERVEAAASRVKVARAGFFPSINLRALIGLQAL
GLGNLVASGSLFGSVGPAISLPIFQGGALKAQYGSAEAAYDEAVANYNQTVVTAYQQAAD
AVTQRDAADKRLGATRTALAASEEALGLVRTRYEAGLASYLDVLASERGVQDLRVAVIGL
ETYERGATLAMIRALGGGFDAGTTQPSGQTEQ
>fig|279238.18.peg.4013 Inner membrane component of tripartite multidrug resistance system
MLIGTMAAMIMYTLDTTIANVALPHMTASLGATQDTITWVLTSYVLASAVALPLAGWLVD
RVGIRNMMLASVLLFTAASMLCGAAQSLEQMVLFRVLQGLGGAFLSPLAQTVTLDSSTAA
ERPRMMGIYTQGVMLGPITGPIIGGFLTDNYNWRWVFYVNVPVGVLCFLLLLLYLPKTPT
RERKVDLTGWLLVALTVSSIQLILDRGLTLDWFASAEIVTYAVVAGACAWLGLFHLSGSR
NPLFPTALFHDRNFTVGLAFMFLIGLVMMSVMALLPGLLQQIYGYTPLQSGMLLAPRGVG
MLASITLFGRFMAKVDARILLAFGLSLMGASMWMMTGWSTEMPRTPIIMAGLLQGLGLSF
TFMPMNLISFATLPPQYRTDASSLGNLMRNLGSSIGIAAASVELARNIQVNHAELGAHVT
RSLVPFNLDRITAYGGTAETALRVMDGLVNQQAAMIAYINDFYAMAMACFVAIPLLLLVR
TGAKKG
>fig|279238.18.peg.4014 Membrane fusion component of tripartite multidrug resistance system
MAEADPFPIQESSAARAVGEHERRTRSKRLRTVLMALGPILAIGGGLWYWFGRPGVVETD
NAYIKQDIVSVAGEVTGLVTSVKVKENQHVKAGDVLFTIDPSSFTVATRQADAQIASAQA
RVIALNADVTAKAADLAGARDDLALAQANYAREKALMDRGFNTRARMDAAEHAVATARDR
IVSIQAEVEQARAELAQGSQVPGVNPEIAAAQANRAKAALDVERTVVRAPADGIVTQVTR
LQIGQMVFPGVPMLSIVRDGGARIEANFKETDLNHMRPGQRADIEIDAYPGLKLKGRVES
IGAGTGSEFSVLPAQNATGNWVKVIQRVPVRIAIEDKSPRPLIAGLSSDVTVHVGK
>fig|279714.3.peg.585 Inner membrane component of tripartite multidrug resistance system
MMTLPSWRDWLFSAKTFLAAILALYIGMALGLPRPYWAMSTVYIVSHPLIGATRSKGLYR
VIGTLIGGAAAILFVPRFVNEPIMLSLVISLWTGTLLCLSLRDRTPRNYLFMLSAYTLPM
IALPAVSQPEAVFDIALARSEEIVLGIVCASVVASIVFPSKVAPVLEARIGAWFKDAGAW
AAEALSPAFASSHPATRHRLAADILSLDQYITHLAYDAANADMVHTTRELQSRMSMLLPI
LSSLTATLDAARKLEQGVPAPLTGLMKAIARWILSSPGARGRDEAARFQRQLADARRSGP
DAEWNDLLIAHAVTRLQSLIRLWQDCLDLRDMIARGEADTAWKPAYRRWELGGKARHYDH
GMILFAAASASLAIFLSCLLWIGMGWNDGASAVILGAVSSCFFAAQDEPAPLIRTFFTWA
AVSIPLTAVLLFLIIPAAHEFETLALMLAIPFLAIGTLASHPRFTMAAMLLTVNTASFLG
LQGAYDADFTAFFNSSVAGVCGVLFALCWTLLTRPFGAELAMRRLLRASWKDLAETAAGS
HRGDYANLTSHMLDRLGLLVPRLAASDDDHGDAGFGELRVGFSTLDLQRDEHRLPETAHV
AIDRVLQSVAGHYRECVGHHGQRQPPASLREEIDRALSLTKAELGRAAREAQNALVELRI
TLFPDAARFVALTGVPATGPSAGETP
>fig|279714.3.peg.614 Transcription repressor of tripartite multidrug resistance system
MSDSFKPYESAITAIASQIPGAPLREAILTRLFLHVSGELSDFFDARLKEYGLNYTTWTS
LVVLYSSPQHRLLPSELSVFINTSRTHCTRIADELVDKGWVERVASEADRRQTYLQLTAA
GVAFVEQLQPQRREQYRQLWSSFSPEEQNQLDALLRKMLVLLKS
>fig|279714.3.peg.647 Permease of the drug/metabolite transporter (DMT) superfamily
MDGIESLARLEWRHAYAKNKGMILAALAAIGFSAKAIFVKMGYRYGASAEALLVLRMAFA
LPFFLLLALQSTQADVDQLTWRDWRQLVVLGLLGYYLSSWLDFVGLRFVSAALERLTLYL
YPTLVLFISVLWLGKRYPAKVWWGVVLAYLGVVLAFVQDLRDAELIHQALFGLSWVLASA
VSFALYLVGSGEAIARFGATRFTALATLVACIAVFIHFAVTMPLAALQLPAPVYLIGLAM
GVFSTALPLLCMNMAIRQLGAGKAASVGTLGPVLTMALGWLVLGENLSVLQIVGAGLVIS
GVGLVSSSK
>fig|279714.3.peg.1497 Membrane fusion component of tripartite multidrug resistance system
MTNKTELSPGSPLPTGQAPSHPAASGRGARKGRLILALILLATAAVAGRMWWRSHYFEET
DNAYLAGHVSTISPRIAGVVHQVLVSDNQLVRAGDPLLELDAADQEVKIAQIKAQIAQTD
EQVRQIAEQLEQARAEAQAAQALVARAAAQFQRNDAEAKRVSALHDVQLKSVSKSELEGA
IAARDSAAAEAQAQQFQAKAASAKSGSVAAARAAALAQKKVLAAQLRDAELQLKYTRIVA
PVDGRIGKKSVEVGTRVQAGQQLLAIVQDGVWVNANFKETQLHDLYPGQQATVRIDAFPG
RTFSGKVDSFAPASGAQFALLPPDNATGNFTKIVQRIPVKVLLDPNDVKAMGGRLAPGMS
AFVEVDLRQGAPAGTVR
>fig|279714.3.peg.1498 Inner membrane component of tripartite multidrug resistance system
MAAMAEKTAVAARPMPPPAAVLPLPEPAVDARTWIAIFAAILGVFMAILDIQVTNASLRE
IRGALSATVEEGSWMTTSYLAAEVVVIPLTAFFVRVFGARAYMLGNVVLFLVFSTLCGYA
WNLPSMIVFRALQGFTGGALIPTAMTLILTRLPPSKRTIGLAWLMLSSTMAPAFGPTLGG
VLTNFYGWPSIFFINWAPGVLMLAGLAYGLKREPLQLKLLREADWLAITAMTVGLGSLIV
FLEEGNSKDWFASDLIRACALAALLGIVAWVAILQSRGKPFVNLALFARRTFGVSSLVGA
AAGMGLYGSTFVLPLFLSEIAGYNSLQIGEVIMWMGLPQIVMMPLAAAFAKRFDNRVICS
LGLLLFASSCFMNATMDATTGYDQLVFSQVLRALGQPLIVLTLSNFAIHRIEAANLSSAS
GLYNMSRILGGAVGTAVLATTITWREHFHSARIGESVSLFSDAVQERLGQLGSQFLAGSG
DPVAAQQQALAALDHLVRREAYVLAYTDSFFILGCVLLASIAVMWLADRVVAGGK
>fig|279714.3.peg.1499 Outer membrane component of tripartite multidrug resistance system
MLKKTMICTVLASLLAGCATPALQPPAPTELVPASYQHAGAPAAHDLPRQWWRLYHDATL
NQLVETTLRDNPYTQVAHLRQIAAEAQTRLANADRLPQLNAGVGFSNSRTSTNTALGQIL
GHQTISGDKITAGFDAAWQIDVWNRVGYAVAAAKAGVEAEQAFARMVEQTLSWEVATTYW
QYRLAESDLTLLTDIRQQRAEAESVQAGRFDAGLSSELDLARARLELKNADVEIEDARKR
LSLAEHELATLTVKPVAEFSVPRDAAYRLPDVPAISPGLPASILRQRPDLAQSAQNIRAL
LAQKEIADTAFYPSISLTGNFGFASMELRNLTNSDSRQFTLGPLAISLPILDGGRIRANQ
KIADARYQEALNVHKVQLLIALREVDDALTEVESCRTQAGLLDAALESARRVSLLAKARY
DKGAVNYLEVTQAERDLSTAELKFRRNQLKGLLASTQLVYVLGGGWKDEAAPTR
>fig|279714.3.peg.2091 Multidrug resistance transporter, Bcr/CflA family
MPIVAAGLHPTRLIVLLSALVAFGPLSIDMYLPSLPAIARDLAAPVGLVQFTIGGFLTGF
CLGMLLYGPLSDRFGRRPVLLAGIALYLVASLACAFASSAEQLIALRVLQAVGGGAGSVM
GRTVVRDVFPLDRAAQVLSLMHLVTMIAPLVAPVLGGWLLLAAGWRSLFLALALFGAVCL
ALVALRLPETHPAERRGEVSLASAFSAYGHLLTDTPTLGYMLALGLTFGAMFAYITGSPF
VYIDYFGVAPQHYGWLFGLNIASVIVLTTLNKWLVKRVALDTLLQAQTAVIAAAGLALWL
AGAHSLLAVVLPLLVSVGLTGSIGPNTMARLLQRHSERAGAAMALAVSGQFGLGMLASAL
VAALHDGTPRAMCQVVALFGVAACLGLQLIRLPAATARPQSSTL
>fig|279714.3.peg.2249 Multi antimicrobial extrusion protein (Na(+)/drug antiporter), MATE family of MDR efflux pumps
MVAQIAHVAMGFVDTVMSGRVSTNDLAAVSLGSSVFITVYVTLVGIATALNPLIAHQFGA
GEREPIGETVRQGMWFCLFLGLIGSALMIFGQPWLRDSLTLSNDVEDKVMLFLDGVALGL
PAALMQRALHAFASGLSRPKPIMLVGVVALLLNIPLNYALIHGLYGLPAMGGAGCGWATA
AALWFNFLALLGYVALHRHFRPYAFTRRWSWPDWARYRAMLKLGLPIGLSFFFEVSLFSF
IAFLVAKLGTTVVASHQAVLSVSSIIYMMPQSISTAMSVRVGQAVGAGDYRQARFTAGTG
LLTGLVLAGLTMLLMLTLREDIIRLYTTDPEVIRIGAGLLVFAAVFQLTDATQCISSGAL
RGYKITTAPMIIHVVSFWGLGLSLGMVLGLTDWPLPFLTLPMGIEGFWAALVFSLSVAAF
LLVGYLSRESRRRLVRQHTES
>fig|279714.3.peg.2704 Permease of the drug/metabolite transporter (DMT) superfamily
MPPSLIGLIQVLLSAVAFGTMAILARFAYADGTSTTTLLLLRFVIAGLVLLPWVALQRLP
WPTGRPLLALIVMGAVGYAGMSACYFNALNHASAGTVALLLYLYPVLVLLLSMLLGERLT
TLRLIALLLALSGLAVTIGLEFSARPLGLVLGVGAALIYSCYILIGSRFTAGTHPLAATC
VVILSAAASYALQSTWQGWGPPHSARGWLAIGMMALICTVAAVALFLNGLEKIGATRASL
VSTVEPVVTLLLAWGLLGEPIGLSQALGGLLILGAVLLVSREADPKRTELTELHD
>fig|279808.3.peg.645 Glyoxalase/bleomycin resistance protein (EC 4.4.1.5)
MEPITHIHHISAIVGDAQETYDFYTNVLNLSLIKQTVNYDDTKTYHLYFSNDRAQHDMVL
TFFNWPNQYRGRIGSGQVGHLAFRIPKDSMSHWEMKLNANGIQTRQTDSFNQTTLEFEDI
HGLTLAMVESDEERVNNDIIGFHGVTMLSGNPQATEALLQNDLGLEYIQETDDNVHYQTS
GSVHHQIIGKKFVNPQPVRWGGGIFHHIAWSVPNDEVHVQWRDYLHNKGLHVTDVKERFY
FHAVYMKEPGNLIFEFATAGPGFTIDESVDDLGRQLQLPPFYEERRYEIEGHLMPIKLNE
Y
>fig|279808.3.peg.1736 Erythromycin resistance ATP-binding protein msrA
MEQYTIKFNQINHKLTDLRSLNIGHLYAYQFEKIALIGGNGTGKTTLLNMIAQKTKPESG
TVETVGEIQYFEQLNMDVENDFNTLDGSLMSELHIPMHTTDSMSGGEKAKYKLANVISNY
SPILLLDEPTNHLDKIGKDYLKNILKYYYGTLIIVSHDRALIDQIADTIWDIQEDGTIRV
FKGNYTQYQNQYEQEQLEQQRQYEQYISEKQRLSQASKAKRNQAQQMAQASSKQKNKSIA
PDRLSASKQKGTVEKAAQKQAKHIEKRMEHLEEVEKPQSYHEFNFPQNKIYDIHNNYPII
AQNLTLVKGSQKLLTQVRFQIPYGKNIALVGANGVGKTTLLEAIYHQIEGIDCSPKVQMA
YYRQLAYEDMRDVSLLQYLMDETDSSESFSRAILNNLGLNEALDRSCNVLSGGERTKLSL
AVLFSTKANMLILDEPTNFLDIKTLEALEMFMNKYPGIILFTSHDTRFVKHVSDKKWELT
GQSIHDIT
>fig|279808.3.peg.2434 Drug resistance transporter, EmrB/QacA subfamily
MLDLTMINIAIKQLNNTFNTTIEITQWGITGYVLALALVIPIAGWLVNQFNGKYVFIGAS
ILFGITSVLAGISWNAESFIVFRIIQGMSAGIITTLMFTLLIKTTGQDNIGKVMAVVSTP
MIFGPILGPVIGGFIIHIVSWRWMFFINVLVVIIAILLQIKYLPNFVPFNKSKSIDILGM
ILLGLISISTIYGLTKASDYHSFYNRTTILLLIIGCIMILIYYIHNKVKHDNTILPLSLF
CKGNYTASFIGLFLSNIGIMGPMVIIPLYFQTFKHYTPIEAALALIPQGIGMLITRPYLG
KLIDQYGAKWVVLISVIISMFGSIPLLFITDHTSIIALSIILFLRGCSIGGINLGLTTDT
YMGIKESVLAEAGVGINM